Phosphorylation	O
of	O
Activation	O
Transcription	O
Factor-2	O
at	O
Serine	O
121	O
by	O
Protein	B-DNAMutation
Kinase	I-DNAMutation
C	I-DNAMutation
Controls	O
c-Jun-mediated	O
Activation	O
of	O
Transcription	O
.	O

Activation	B-DNAMutation
transcription	I-DNAMutation
factor-2	I-DNAMutation
ATF-2	B-DNAMutation
is	O
phosphorylated	O
by	O
various	O
protein	O
kinases	O
,	O
such	O
as	O
JNK/p38/ERK	B-DNAMutation
,	O
calmodulin	O
kinase	I-DNAMutation
IV	I-DNAMutation
,	O
protein	B-DNAMutation
kinase	I-DNAMutation
A	I-DNAMutation
,	O
and	O
protein	B-DNAMutation
kinase	I-DNAMutation
C	I-DNAMutation
PKC	B-DNAMutation
,	O
in	O
response	O
to	O
a	O
variety	O
of	O
stimuli	O
.	O

However	O
,	O
the	O
role	O
of	O
the	O
phosphorylation	O
of	O
ATF-2	B-DNAMutation
by	O
PKC	B-DNAMutation
in	O
vivo	O
in	O
the	O
transcriptional	O
control	O
of	O
genes	O
that	O
include	O
the	O
activation	B-DNAMutation
protein-1	I-DNAMutation
(AP-1)/cyclic	B-DNAMutation
AMP-response	I-DNAMutation
element	I-DNAMutation
remains	O
to	O
be	O
defined	O
.	O

Using	O
antibodies	O
against	O
the	O
phosphorylated	O
serine	O
residue	O
(Ser(P))	O
at	O
position	O
121	O
of	O
ATF-2	B-DNAMutation
,	O
we	O
have	O
demonstrated	O
that	O
PKC	B-DNAMutation
phosphorylates	O
ATF-2	B-DNAMutation
at	O
Ser-121	O
and	O
that	O
phosphorylation	O
of	O
Ser-121	O
(	O
to	O
yield	O
ATF-2pS121	O
)	O
becomes	O
detectable	O
at	O
the	O
late	O
stage	O
of	O
the	O
response	O
of	O
HeLa	O
cells	O
to	O
12-O-tetradecanoylphorbol-13-acetate	B-DNAMutation
TPA	B-DNAMutation
and	O
is	O
maintained	O
for	O
more	O
than	O
2	O
h	O
.	O

By	O
contrast	O
,	O
phosphorylation	O
of	O
ATF-2	B-DNAMutation
at	O
threonine	O
residues	O
69	O
and	O
71	O
(	O
Thr-69/71	O
,	O
to	O
yield	O
ATF-2pT69/71	O
)	O
and	O
at	O
Ser-340	O
and	O
Ser-367	O
(	O
to	O
yield	O
ATF-2pS340	O
and	O
ATF-2pS367	O
)	O
is	O
detectable	O
as	O
an	O
immediate	O
early	O
response	O
.	O

Unlike	O
levels	O
of	O
ATF-2pT69/71	O
and	O
ATF-2pS340	O
,	O
the	O
level	O
of	O
ATF-2pS121	O
increases	O
in	O
the	O
nuclei	O
of	O
HeLa	O
cells	O
in	O
response	O
to	O
TPA	B-DNAMutation
.	O

A	O
serine-to-alanine	B-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
121	I-DNAMutation
of	O
ATF-2	B-DNAMutation
represses	O
the	O
c-Jun-dependent	O
transcription	O
of	O
AP-1/cyclic	B-DNAMutation
AMP-response	I-DNAMutation
element	I-DNAMutation
reporter	O
genes	O
and	O
also	O
the	O
p300-mediated	B-DNAMutation
activation	O
of	O
a	O
Gal4-reporter	O
gene	O
in	O
response	O
to	O
TPA	B-DNAMutation
.	O

Our	O
results	O
suggest	O
that	O
the	O
phosphorylation	O
of	O
ATF-2	B-DNAMutation
at	O
Ser-121	O
plays	O
a	O
key	O
role	O
in	O
the	O
c-Jun-mediated	O
activation	O
of	O
transcription	O
that	O
occurs	O
in	O
response	O
to	O
TPA	B-DNAMutation
.	O

Molecular	O
definition	O
of	O
an	O
elusive	O
third	O
HLA-A9	O
molecule	O
:	O
HLA-A9.3	O
.	O

The	O
HLA-A9	O
family	O
has	O
been	O
characterized	O
as	O
possessing	O
two	O
well	O
defined	O
specificities	O
;	O
HLA-A23	B-DNAMutation
and	O
A24	B-DNAMutation
.	O

Serological	O
studies	O
have	O
suggested	O
the	O
presence	O
of	O
a	O
third	O
member	O
of	O
this	O
family	O
HLA-A9.3	O
,	O
however	O
there	O
is	O
doubt	O
surrounding	O
the	O
existence	O
of	O
this	O
specificity	O
.	O

HLA-A23	B-DNAMutation
,	O
A24	B-DNAMutation
,	O
and	O
the	O
putative	O
A9.3	O
proteins	O
were	O
analyzed	O
biochemically	O
by	O
immunoprecipitation	O
and	O
isoelectric	O
focusing	O
.	O

Both	O
HLA-A24	B-DNAMutation
and	O
A9.3	O
have	O
identical	O
isoelectric	O
points	O
whereas	O
A23	B-DNAMutation
is	O
different	O
.	O

We	O
have	O
sequenced	O
cDNA	O
encoding	O
HLA-A23	B-DNAMutation
,	O
A24	B-DNAMutation
,	O
and	O
A9.3	O
.	O

From	O
the	O
observed	O
protein	O
sequences	O
,	O
we	O
found	O
A9.3	O
to	O
differ	O
from	O
A24	B-DNAMutation
by	O
two	O
amino	O
acid	O
substitutions	O
located	O
in	O
the	O
alpha	O
2	O
helix	O
of	O
the	O
class	O
I	O
molecule	O
.	O

These	O
substitutions	O
are	O
expected	O
to	O
significantly	O
change	O
the	O
shape	O
of	O
the	O
peptide	O
binding	O
cleft	O
.	O

Gelsolin	B-DNAMutation
variant	O
(Asn-187)	O
in	O
familial	O
amyloidosis	O
,	O
Finnish	O
type	O
.	O

Familial	O
amyloidosis	O
,	O
Finnish	O
type	O
(FAF)	O
,	O
is	O
an	O
inherited	O
form	O
of	O
systemic	O
amyloidosis	O
clinically	O
characterized	O
by	O
cranial	O
neuropathy	O
and	O
lattice	O
corneal	O
dystrophy	O
.	O

We	O
have	O
demonstrated	O
that	O
the	O
protein	O
subunit	O
isolated	O
from	O
amyloid	O
fibrils	O
shows	O
considerable	O
sequence	O
identity	O
with	O
gelsolin	B-DNAMutation
,	O
an	O
actin-binding	O
protein	O
.	O

We	O
have	O
purified	O
the	O
amyloid	O
subunit	O
from	O
a	O
second	O
case	O
and	O
further	O
analysed	O
different	O
fractions	O
from	O
the	O
previous	O
one	O
.	O

Sequence	O
analysis	O
shows	O
that	O
,	O
in	O
both	O
cases	O
,	O
the	O
amyloid	O
subunit	O
starts	O
at	O
position	O
173	O
of	O
the	O
mature	O
molecule	O
;	O
it	O
has	O
a	O
heterogeneous	O
N-terminus	O
and	O
contains	O
one	O
amino	O
acid	O
substitution	O
,	O
namely	O
asparagine	B-DNAMutation
for	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
,	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
15	I-DNAMutation
(	O
gelsolin	B-DNAMutation
residue	O
187	O
)	O
,	O
that	O
is	O
due	O
to	O
a	O
guanine-to-adenine	B-DNAMutation
transversion	I-DNAMutation
corresponding	I-DNAMutation
to	I-DNAMutation
nucleotide-654	I-DNAMutation
of	O
human	O
plasma	O
gelsolin	B-DNAMutation
cDNA	O
.	O

The	O
substitution	O
maps	O
in	O
a	O
fragment	O
with	O
actin-binding	O
activity	O
and	O
is	O
located	O
in	O
a	O
repetitive	O
motif	O
highly	O
conserved	O
among	O
species	O
.	O

Thus	O
FAF	O
is	O
the	O
first	O
human	O
disease	O
known	O
to	O
be	O
caused	O
by	O
an	O
internal	O
abnormal	O
degradation	O
of	O
a	O
gelsolin	B-DNAMutation
variant	O
.	O

We	O
designate	O
this	O
variant	O
of	O
gelsolin-associated	B-DNAMutation
amyloidosis	O
'Agel	O
Asn-187'	O
.	O

Zfp281	B-DNAMutation
functions	O
as	O
a	O
transcriptional	O
repressor	O
for	O
pluripotency	O
of	O
mouse	O
embryonic	O
stem	O
cells	O
.	O

Embryonic	O
stem	O
cells	O
(ESCs)	O
derived	O
from	O
preimplantation	O
blastocysts	O
have	O
unique	O
self-renewal	O
and	O
multilineage	O
differentiation	O
properties	O
that	O
are	O
controlled	O
by	O
key	O
components	O
of	O
a	O
core	O
regulatory	O
network	O
including	O
Oct4	B-DNAMutation
,	O
Sox2	B-DNAMutation
,	O
and	O
Nanog	B-DNAMutation
.	O

Understanding	O
molecular	O
underpinnings	O
of	O
these	O
properties	O
requires	O
identification	O
and	O
characterization	O
of	O
additional	O
factors	O
that	O
act	O
in	O
conjunction	O
with	O
these	O
key	O
factors	O
in	O
ESCs	O
.	O

We	O
have	O
previously	O
identified	O
Zfp281	B-DNAMutation
,	O
a	O
KrÃ¼ppel-like	O
zinc	O
finger	O
transcription	O
factor	O
,	O
as	O
an	O
interaction	O
partner	O
of	B-DNAMutation
Nanog	I-DNAMutation
.	O

We	O
now	O
present	O
detailed	O
functional	O
analyses	O
of	B-DNAMutation
Zfp281	I-DNAMutation
using	O
a	O
genetically	O
ablated	O
null	O
allele	O
in	O
mouse	O
ESCs	O
.	O

Our	O
data	O
show	O
that	O
while	B-DNAMutation
Zfp281	I-DNAMutation
is	O
dispensable	O
for	O
establishment	O
and	O
maintenance	O
of	O
ESCs	O
,	O
it	O
is	O
required	O
for	O
their	O
proper	O
differentiation	O
in	O
vitro	O
.	O

We	O
performed	O
microarray	O
profiling	O
in	O
combination	O
with	O
previously	O
published	O
datasets	O
of	B-DNAMutation
Zfp281	I-DNAMutation
global	O
target	O
gene	O
occupancy	O
and	O
found	O
that	B-DNAMutation
Zfp281	I-DNAMutation
mainly	O
functions	O
as	O
a	O
repressor	O
to	O
restrict	O
expression	O
of	O
many	O
stem	O
cell	O
pluripotency	O
genes	O
.	O

In	O
particular	O
,	O
we	O
demonstrated	O
that	B-DNAMutation
deletion	I-DNAMutation
of	O
Zfp281	I-DNAMutation
resulted	O
in	O
upregulation	O
of	B-DNAMutation
Nanog	I-DNAMutation
at	O
both	O
the	O
transcript	O
and	O
protein	O
levels	O
with	O
concomitant	O
compromised	O
differentiation	O
of	O
ESCs	O
during	O
embryoid	O
body	O
culture	O
.	O

Chromatin	O
immunoprecipitation	O
experiments	O
demonstrated	O
that	B-DNAMutation
Zfp281	I-DNAMutation
is	O
required	O
for	B-DNAMutation
Nanog	I-DNAMutation
binding	O
to	O
its	O
own	O
promoter	O
,	O
suggesting	O
that	B-DNAMutation
Nanog-associated	I-DNAMutation
repressive	O
complex(es)	O
involving	B-DNAMutation
Zfp281	I-DNAMutation
may	O
fine-tune	B-DNAMutation
Nanog	I-DNAMutation
expression	O
for	O
pluripotency	O
of	O
ESCs	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
C-terminus	O
of	O
adseverin	B-DNAMutation
reveals	O
the	O
actin-binding	O
interface	O
.	O

Adseverin	B-DNAMutation
is	O
a	O
member	O
of	O
the	O
calcium-regulated	O
gelsolin	O
superfamily	O
of	O
actin	O
severing	O
and	O
capping	O
proteins	O
.	O

Adseverin	B-DNAMutation
comprises	O
6	O
homologous	O
domains	O
(A1-A6)	O
,	O
which	O
share	O
60%	O
identity	O
with	O
the	O
6	O
domains	O
from	O
gelsolin	B-DNAMutation
(G1-G6)	O
.	O

Adseverin	B-DNAMutation
is	O
truncated	O
in	O
comparison	O
to	O
gelsolin	B-DNAMutation
,	O
lacking	B-DNAMutation
the	I-DNAMutation
C-terminal	I-DNAMutation
extension	I-DNAMutation
that	O
masks	O
the	O
F-actin	O
binding	O
site	O
in	O
calcium-free	O
gelsolin	O
.	O

Biochemical	O
assays	O
have	O
indicated	O
differences	O
in	O
the	O
interaction	O
of	O
the	O
C-terminal	O
halves	O
of	O
adseverin	B-DNAMutation
and	O
gelsolin	B-DNAMutation
with	O
actin	O
.	O

Gelsolin	B-DNAMutation
contacts	O
actin	O
through	O
a	O
major	O
site	O
on	O
G4	O
and	O
a	O
minor	O
site	O
on	O
G6	O
,	O
whereas	O
adseverin	B-DNAMutation
uses	O
a	O
site	O
on	O
A5	O
.	O

Here	O
,	O
we	O
present	O
the	O
X-ray	O
structure	O
of	O
the	O
activated	O
C-terminal	O
half	O
of	O
adseverin	B-DNAMutation
(A4-A6)	O
.	O

This	O
structure	O
is	O
highly	O
similar	O
to	O
that	O
of	O
the	O
activated	O
form	O
of	O
the	O
C-terminal	O
half	O
of	O
gelsolin	B-DNAMutation
(G4-G6)	O
,	O
both	O
in	O
arrangement	O
of	O
domains	O
and	O
in	O
the	O
3	O
bound	O
calcium	O
ions	O
.	O

Comparative	O
analysis	O
of	O
the	O
actin-binding	O
surfaces	O
observed	O
in	O
the	O
G4-G6/actin	O
structure	O
suggests	O
that	O
adseverin	B-DNAMutation
in	O
this	O
conformation	O
will	O
also	O
be	O
able	O
to	O
interact	O
with	O
actin	O
through	O
A4	O
and	O
A6	O
,	O
whereas	O
the	O
A5	O
surface	O
is	O
obscured	O
.	O

A	O
single	O
residue	O
mutation	O
in	O
A4-A6	O
located	O
at	O
the	O
predicted	O
A4/actin	O
interface	O
completely	O
abrogates	O
actin	O
sequestration	O
.	O

A	O
model	O
of	O
calcium-free	O
adseverin	O
,	O
constructed	O
from	O
the	O
structure	O
of	O
gelsolin	B-DNAMutation
,	O
predicts	O
that	O
in	O
the	O
absence	O
of	O
a	O
gelsolin-like	O
C-terminal	O
extension	O
the	O
interaction	O
between	O
A2	O
and	O
A6	O
provides	O
the	O
steric	O
inhibition	O
to	O
prevent	O
interaction	O
with	O
F-actin	O
.	O

We	O
propose	O
that	O
calcium	O
binding	O
to	O
the	O
N	O
terminus	O
of	O
adseverin	B-DNAMutation
dominates	O
the	O
activation	O
process	O
to	O
expose	O
the	O
F-actin	O
binding	O
site	O
on	O
A2	O
.	O

LNX	B-DNAMutation
functions	O
as	O
a	O
RING	O
type	O
E3	O
ubiquitin	O
ligase	O
that	O
targets	O
the	O
cell	O
fate	O
determinant	O
Numb	B-DNAMutation
for	O
ubiquitin-dependent	O
degradation	O
.	O

LNX	B-DNAMutation
is	O
a	O
RING	O
finger	O
and	O
PDZ	O
domain	O
containing	O
protein	O
that	O
interacts	O
with	O
the	O
cell	O
fate	O
determinant	O
Numb	B-DNAMutation
.	O

To	O
investigate	O
the	O
function	O
of	O
LNX	B-DNAMutation
,	O
we	O
tested	O
its	O
RING	O
finger	O
domain	O
for	O
ubiquitin	O
ligase	O
activity	O
.	O

The	O
isolated	O
RING	O
finger	O
domain	O
was	O
able	O
to	O
function	O
as	O
an	O
E2-dependent	O
,	O
E3	O
ubiquitin	O
ligase	O
in	O
vitro	O
and	O
mutation	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
conserved	I-DNAMutation
cysteine	I-DNAMutation
residue	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
RING	I-DNAMutation
domain	I-DNAMutation
abolished	O
its	O
activity	O
,	O
indicating	O
that	O
LNX	B-DNAMutation
is	O
the	O
first	O
described	O
PDZ	O
domain-containing	O
member	O
of	O
the	O
E3	O
ubiquitin	O
ligase	O
family	O
.	O

We	O
have	O
identified	O
Numb	B-DNAMutation
as	O
a	O
substrate	O
of	O
LNX	B-DNAMutation
E3	O
activity	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

In	O
addition	O
to	O
the	O
RING	O
finger	O
,	O
a	O
region	O
of	O
LNX	B-DNAMutation
,	O
including	O
the	O
Numb	O
PTB	O
domain-binding	O
site	O
and	O
the	O
first	O
PDZ	O
domain	O
,	O
is	O
required	O
for	O
Numb	B-DNAMutation
ubiquitylation	O
.	O

Expression	O
of	O
wild-type	O
but	O
not	O
mutant	O
LNX	B-DNAMutation
causes	O
proteasome-dependent	O
degradation	O
of	O
Numb	B-DNAMutation
and	O
can	O
enhance	O
Notch	O
signalling	O
.	O

These	O
results	O
suggest	O
that	O
the	O
levels	O
of	O
mammalian	O
Numb	B-DNAMutation
protein	O
and	O
therefore	O
,	O
by	O
extension	O
,	O
the	O
processes	O
of	O
asymmetric	O
cell	O
division	O
and	O
cell	O
fate	O
determination	O
may	O
be	O
regulated	O
by	O
ubiquitin-dependent	O
proteolysis	O
.	O

A	O
null	O
deficiency	O
allele	O
of	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
,	O
QOludwigshafen	O
,	O
with	O
altered	O
tertiary	O
structure	O
.	O

The	O
most	O
common	O
deficiency	O
allele	O
of	O
the	O
plasma	O
protease	O
inhibitor	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
(	O
alpha	B-DNAMutation
1AT	I-DNAMutation
)	O
is	O
PI*Z	O
.	O

Some	O
rare	O
deficiency	O
alleles	O
of	O
alpha	B-DNAMutation
1AT	I-DNAMutation
produce	O
low	O
but	O
detectable	O
amounts	O
of	O
plasma	O
alpha	B-DNAMutation
1AT	I-DNAMutation
(	O
1-20%	O
of	O
normal	O
)	O
,	O
which	O
can	O
be	O
differentiated	O
by	O
isoelectric	O
focusing	O
.	O

Others	O
,	O
designated	O
null	O
(QO)	O
alleles	O
,	O
produce	O
no	O
alpha	B-DNAMutation
1AT	I-DNAMutation
detectable	O
by	O
routine	O
quantitative	O
methods	O
.	O

We	O
have	O
previously	O
described	O
a	O
method	O
using	O
DNA	O
polymorphisms	O
,	O
haplotypes	O
,	O
and	O
polyacrylamide	O
isoelectric	O
focusing	O
gels	O
,	O
to	O
differentiate	O
various	O
deficiency	O
alleles	O
.	O

Based	O
on	O
haplotypes	O
,	O
we	O
previously	O
identified	O
,	O
in	O
eight	O
patients	O
,	O
five	O
different	O
null	O
alleles	O
,	O
four	O
of	O
which	O
had	O
been	O
previously	O
sequenced	O
.	O

We	O
have	O
now	O
analyzed	O
all	O
12	O
null	O
alleles	O
in	O
these	O
eight	O
patients	O
,	O
using	O
allele-specific	O
oligonucleotide	O
probes	O
,	O
and	O
have	O
identified	O
six	O
different	O
null	O
alleles	O
.	O

We	O
have	O
cloned	O
and	O
sequenced	O
one	O
of	O
these	O
,	O
PI*QOludwigshafen	O
,	O
which	O
has	O
a	O
base	B-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
II	I-DNAMutation
,	I-DNAMutation
replacing	I-DNAMutation
isoleucine	I-DNAMutation
92	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
normal	I-DNAMutation
sequence	I-DNAMutation
with	I-DNAMutation
an	I-DNAMutation
asparagine	I-DNAMutation
.	O

This	O
substitution	O
of	O
a	O
polar	O
for	O
a	O
nonpolar	O
amino	O
acid	O
occurs	O
in	O
one	O
of	O
the	O
alpha-helices	O
and	O
is	O
predicted	O
to	O
disrupt	O
the	O
tertiary	O
structure	O
.	O

A	O
total	O
of	O
13	O
different	O
alpha	B-DNAMutation
1AT	I-DNAMutation
deficiency	O
alleles	O
,	O
6	O
of	O
them	O
null	O
alleles	O
,	O
have	O
been	O
sequenced	O
to	O
date	O
.	O

Conserved	O
alpha-helix	O
acts	O
as	O
autoinhibitory	O
sequence	O
in	O
AMP-activated	O
protein	O
kinase	O
alpha	O
subunits	O
.	O

AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
AMPK	B-DNAMutation
acts	O
as	O
an	O
energy	O
sensor	O
,	O
being	O
activated	O
by	O
metabolic	O
stresses	O
and	O
regulating	O
cellular	O
metabolism	O
.	O

AMPK	B-DNAMutation
is	O
a	O
heterotrimer	O
consisting	O
of	O
a	O
catalytic	O
alpha	O
subunit	O
and	O
two	O
regulatory	O
subunits	O
,	O
beta	O
and	O
gamma	O
.	O

It	O
had	O
been	O
reported	O
that	O
the	O
mammalian	O
AMPK	O
alpha	O
subunit	O
contained	O
an	O
autoinhibitory	O
domain	O
(	O
alpha1	B-DNAMutation
:	O
residues	O
313-392	O
)	O
and	O
had	O
little	O
kinase	O
activity	O
.	O

We	O
have	O
found	O
that	O
a	O
conserved	O
short	O
segment	O
of	O
the	O
alpha	O
subunit	O
alpha1-(313-335)	B-DNAMutation
,	O
which	O
includes	O
a	O
predicted	O
alpha-helix	O
,	O
is	O
responsible	O
for	O
alpha	O
subunit	O
autoinhibition	O
.	O

The	O
role	O
of	O
the	O
residues	O
in	O
this	O
segment	O
for	O
autoinhibition	O
was	O
further	O
investigated	O
by	O
systematic	O
site-directed	O
mutation	O
.	O

Several	O
hydrophobic	O
and	O
charged	O
residues	O
,	O
in	O
particular	O
Leu-328	O
,	O
were	O
found	O
to	O
be	O
critical	O
for	O
alpha1	B-DNAMutation
autoinhibition	O
.	O

An	O
autoinhibitory	O
structural	O
model	O
of	O
human	O
AMPK	B-DNAMutation
alpha1-(1-335)	I-DNAMutation
was	O
constructed	O
and	O
revealed	O
that	O
Val-298	O
interacts	O
with	O
Leu-328	O
through	O
hydrophobic	O
bonding	O
at	O
a	O
distance	O
of	O
about	O
4	O
A	O
and	O
may	O
stabilize	O
the	O
autoinhibitory	O
conformation	O
.	O

Further	O
mutation	O
analysis	O
showed	O
that	O
V298G	B-DNAMutation
mutation	O
significantly	O
activated	O
the	O
kinase	O
activity	O
.	O

Moreover	O
,	O
the	O
phosphorylation	O
level	O
of	O
acetyl-CoA	O
carboxylase	O
,	O
the	O
AMPK	B-DNAMutation
downstream	O
substrate	O
,	O
was	O
significantly	O
increased	O
in	O
COS7	O
cells	O
overexpressing	O
AMPK	B-DNAMutation
alpha1-(1-394)	I-DNAMutation
with	O
deletion	B-DNAMutation
of	I-DNAMutation
residues	I-DNAMutation
313-335	I-DNAMutation
Deltaalpha394	B-DNAMutation
and	O
a	O
V298G	B-DNAMutation
or	O
L328Q	B-DNAMutation
mutation	O
,	O
and	O
the	O
glucose	O
uptake	O
was	O
also	O
significantly	O
enhanced	O
in	O
HepG2	O
cells	O
transiently	O
transfected	O
with	O
Deltaalpha394	B-DNAMutation
,	O
V298G	B-DNAMutation
,	O
or	O
L328Q	B-DNAMutation
mutants	O
,	O
which	O
indicated	O
that	O
these	O
AMPK	B-DNAMutation
alpha1	I-DNAMutation
mutants	O
are	O
constitutively	O
active	O
in	O
mammalian	O
cells	O
and	O
that	O
interaction	O
between	O
Leu-328	O
and	O
Val-298	O
plays	O
an	O
important	O
role	O
in	O
AMPK	B-DNAMutation
alpha	O
autoinhibitory	O
function	O
.	O

Niemann-Pick	O
type	O
B	O
disease	O
.	O

Identification	O
of	O
a	O
single	O
codon	O
deletion	O
in	O
the	O
acid	B-DNAMutation
sphingomyelinase	I-DNAMutation
gene	O
and	O
genotype/phenotype	O
correlations	O
in	O
type	O
A	O
and	O
B	O
patients	O
.	O

Types	O
A	O
and	O
B	O
Niemann-Pick	O
disease	O
both	O
result	O
from	O
the	O
deficient	O
activity	O
of	O
the	O
lysosomal	O
hydrolase	O
,	O
acid	B-DNAMutation
sphingomyelinase	I-DNAMutation
(	O
E.C	O
.	O

3.1.4.12	O
)	O
.	O

Type	O
A	O
Niemann-Pick	O
disease	O
is	O
a	O
severe	O
neurodegenerative	O
disorder	O
of	O
infancy	O
which	O
leads	O
to	O
death	O
by	O
three	O
years	O
of	O
age	O
,	O
whereas	O
Type	O
B	O
disease	O
has	O
a	O
later	O
age	O
at	O
onset	O
,	O
little	O
or	O
no	O
neurologic	O
involvement	O
,	O
and	O
most	O
patients	O
survive	O
into	O
adulthood	O
.	O

To	O
investigate	O
the	O
molecular	O
basis	O
for	O
the	O
remarkable	O
phenotypic	O
heterogeneity	O
,	O
the	O
nature	O
of	O
the	O
mutations	O
causing	O
Type	O
B	O
Niemann-Pick	O
disease	O
in	O
Ashkenazi	O
Jewish	O
patients	O
was	O
determined	O
.	O

The	O
entire	O
acid	B-DNAMutation
sphingomyelinase	I-DNAMutation
coding	O
region	O
from	O
an	O
Ashkenazi	O
Jewish	O
Type	O
B	O
patient	O
was	O
polymerase	O
chain	O
reaction-amplified	O
,	O
subcloned	O
,	O
and	O
completely	O
sequenced	O
.	O

A	O
three-base	B-DNAMutation
deletion	I-DNAMutation
was	I-DNAMutation
identified	I-DNAMutation
of	I-DNAMutation
nucleotides	I-DNAMutation
1821-1823	I-DNAMutation
in	O
the	O
cDNA	O
which	O
predicted	O
the	O
removal	B-DNAMutation
of	I-DNAMutation
an	I-DNAMutation
arginine	I-DNAMutation
residue	I-DNAMutation
from	I-DNAMutation
position	I-DNAMutation
608	I-DNAMutation
of	O
the	O
acid	B-DNAMutation
sphingomyelinase	I-DNAMutation
polypeptide	O
(	O
delta	B-DNAMutation
R608	I-DNAMutation
)	O
.	O

The	O
other	O
cDNA	O
clones	O
from	O
this	O
patient	O
had	O
the	O
R496L	B-DNAMutation
mutation	O
previously	O
identified	O
in	O
Type	O
A	O
Niemann-Pick	O
disease	O
patients	O
.	O

Both	O
Ashkenazi	O
Jewish	O
Type	O
B	O
patients	O
were	O
heteroallelic	O
for	O
the	O
delta	B-DNAMutation
R608	I-DNAMutation
mutation	O
,	O
whereas	O
this	O
allele	O
was	O
not	O
present	O
in	O
15	O
unrelated	O
non-Jewish	O
Type	O
B	O
patients	O
,	O
with	O
the	O
notable	O
exception	O
of	O
one	O
mildly	O
affected	O
patient	O
of	O
Arabic	O
descent	O
who	O
was	O
homoallelic	O
for	O
the	O
delta	B-DNAMutation
R608	I-DNAMutation
mutation	O
.	O

These	O
results	O
indicate	O
that	O
the	O
delta	B-DNAMutation
R608	I-DNAMutation
mutation	O
predicts	O
the	O
Type	O
B	O
Niemann-Pick	O
disease	O
phenotype	O
,	O
even	O
in	O
the	O
presence	O
of	O
the	O
R496L	B-DNAMutation
Type	O
A	O
allele	O
,	O
thereby	O
providing	O
the	O
first	O
genotype/phenotype	O
correlation	O
for	O
this	O
lysosomal	O
storage	O
disease	O
.	O

Although	O
only	O
two	O
patients	O
have	O
been	O
studied	O
,	O
it	O
appears	O
that	O
the	O
delta	B-DNAMutation
R608	I-DNAMutation
mutation	O
occurs	O
frequently	O
in	O
Type	O
B	O
Niemann-Pick	O
disease	O
patients	O
of	O
Ashkenazi	O
Jewish	O
descent	O
.	O

Two	O
novel	O
mutations	O
in	O
the	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
in	O
Chinese	O
patients	O
with	O
Fabry	O
disease	O
.	O

Fabry	O
disease	O
is	O
an	O
X-linked	O
disorder	O
caused	O
by	O
a	O
deficiency	O
of	O
the	O
lysosomal	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
[	O
EC	O
3.2.1.22	O
]	O
.	O

The	O
molecular	O
diagnosis	O
of	O
Fabry	O
disease	O
is	O
important	O
for	O
genotype/phenotype	O
correlation	O
,	O
pre-natal	O
or	O
early	O
diagnosis	O
,	O
and	O
detection	O
of	O
carrier	O
status	O
.	O

Although	O
more	O
than	O
200	O
genotypes	O
of	O
the	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
have	O
been	O
identified	O
,	O
mutation	O
data	O
on	O
the	O
Chinese	O
population	O
is	O
sparse	O
.	O

We	O
recently	O
identified	O
two	O
unrelated	O
Chinese	O
families	O
with	O
Fabry	O
disease	O
.	O

Mutation	O
analysis	O
was	O
performed	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
sequencing	O
of	O
the	O
seven	O
exons	O
and	O
adjacent	O
introns	O
of	O
the	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
.	O

Two	O
novel	O
mutations	O
were	O
identified	O
:	O
in	O
family	O
I	O
,	O
a	O
C-to-A	B-DNAMutation
transversion	I-DNAMutation
resulted	I-DNAMutation
in	I-DNAMutation
an	I-DNAMutation
early	I-DNAMutation
termination	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
222	I-DNAMutation
Y222X	B-DNAMutation
,	O
while	O
in	O
family	O
II	O
,	O
an	O
A-to-G	B-DNAMutation
transition	I-DNAMutation
resulted	I-DNAMutation
in	I-DNAMutation
a	I-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
alanine	I-DNAMutation
for	I-DNAMutation
threonine	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
410	I-DNAMutation
T410A	B-DNAMutation
.	O

Carrier	O
status	O
was	O
identified	O
in	O
all	O
four	O
females	O
in	O
the	O
two	O
families	O
.	O

The	O
genotype	O
Y222X	B-DNAMutation
is	O
associated	O
with	O
classic	O
Fabry	O
disease	O
,	O
with	O
unexpectedly	O
rapid	O
deterioration	O
of	O
visual	O
acuity	O
,	O
while	O
T410A	B-DNAMutation
is	O
associated	O
with	O
a	O
milder	O
Fabry	O
disease	O
,	O
with	O
ventricular	O
hypertrophy	O
and	O
neuropathic	O
pain	O
.	O

Alterations	O
in	O
the	O
suppressor	O
gene	O
PPP2R1B	B-DNAMutation
in	O
parathyroid	O
hyperplasias	O
and	O
adenomas	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
chromosome	I-DNAMutation
11q23	I-DNAMutation
is	O
a	O
common	O
alteration	O
in	O
parathyroid	O
adenomas	O
and	O
hyperplasias	O
.	O

A	O
new	O
potential	O
suppressor	O
gene	O
PPP2R1B	B-DNAMutation
encoding	O
the	O
beta	O
isoform	O
of	O
the	O
A	O
subunit	O
of	O
the	O
serine/threorine	O
protein	O
phosphatase	O
2A	O
was	O
recently	O
identified	O
and	O
localized	O
to	O
chromosome	O
11q23	O
.	O

We	O
performed	O
polymerase	O
chain	O
reaction-based	O
single-strand	O
conformation	O
polymorphism	O
and	O
direct	O
sequencing	O
on	O
six	O
parathyroid	O
hyperplasias	O
and	O
12	O
adenomas	O
to	O
evaluate	O
the	O
role	O
of	O
PPP2R1B	B-DNAMutation
in	O
the	O
pathogenesis	O
of	O
parathyroid	O
lesions	O
.	O

A	O
previously	O
identified	O
germline	B-DNAMutation
G-A	I-DNAMutation
transition	I-DNAMutation
(GGC-GAC)	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
90	I-DNAMutation
,	I-DNAMutation
changing	I-DNAMutation
glycine	I-DNAMutation
(Gly)	I-DNAMutation
to	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
(Asp)	I-DNAMutation
,	O
was	O
detected	O
in	O
one	O
adenoma	O
.	O

Both	O
the	O
common	O
Gly	O
allele	O
and	O
the	O
variant	O
Asp	O
allele	O
were	O
detected	O
by	O
direct	O
sequencing	O
in	O
the	O
patient's	O
somatic	O
cells	O
.	O

We	O
conclude	O
mutations	O
of	O
PPP2R1B	B-DNAMutation
are	O
not	O
frequent	O
in	O
parathyroid	O
lesions	O
,	O
and	O
that	O
other	O
genes	O
located	O
at	O
11q23	O
may	O
be	O
more	O
closely	O
associated	O
with	O
pathogenesis	O
of	O
parathyroid	O
hyperplasia	O
and	O
adenoma	O
.	O

A	O
novel	O
mutation	O
in	O
medium	B-DNAMutation
chain	I-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
causes	O
sudden	O
neonatal	O
death	O
.	O

Medium	B-DNAMutation
chain	I-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
MCAD	B-DNAMutation
deficiency	O
is	O
the	O
most	O
common	O
known	O
genetic	O
disorder	O
of	O
fatty	O
acid	O
oxidation	O
.	O

Most	O
(	O
approximately	O
80%	O
)	O
cases	O
are	O
homozygous	O
for	O
a	O
single	O
mutation	O
:	O
A	B-DNAMutation
to	I-DNAMutation
G	I-DNAMutation
replacement	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
985	I-DNAMutation
(A985G)	I-DNAMutation
.	O

MCAD	B-DNAMutation
deficiency	O
typically	O
presents	O
in	O
the	O
second	O
year	O
of	O
life	O
as	O
hypoketotic	O
hypoglycemia	O
associated	O
with	O
fasting	O
and	O
may	O
progress	O
to	O
liver	O
failure	O
,	O
coma	O
,	O
and	O
death	O
.	O

Prompt	O
diagnosis	O
and	O
management	O
may	O
prevent	O
long-term	O
sequelae	O
.	O

MCAD	B-DNAMutation
deficiency	O
was	O
verified	O
by	O
analysis	O
of	O
urinary	O
acylglycine	O
and	O
serum	O
acylcarnitine	O
species	O
from	O
two	O
neonates	O
referred	O
for	O
diagnosis	O
.	O

Full-length	O
cDNA	O
and	O
MCAD	B-DNAMutation
exon	O
7	O
and	O
11	O
genomic	O
clones	O
were	O
prepared	O
for	O
sequence	O
analysis	O
.	O

Normal	O
and	O
mutant	O
cDNAs	O
were	O
expressed	O
in	O
bacteria	O
,	O
and	O
enzymatic	O
activity	O
was	O
assayed	O
by	O
the	O
ferricenium	O
hexaflurophosphate	O
method	O
.	O

Four	O
compound	O
heterozygote	O
individuals	O
from	O
two	O
unrelated	O
families	O
with	O
A985G	B-DNAMutation
on	O
one	O
allele	O
and	O
a	O
novel	O
G	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
583	I-DNAMutation
G583A	B-DNAMutation
as	O
the	O
second	O
mutant	O
allele	O
presented	O
with	O
MCAD	B-DNAMutation
deficiency	O
in	O
the	O
first	O
week	O
of	O
life	O
.	O

The	O
expressed	O
G583A	B-DNAMutation
mutant	O
protein	O
lacks	O
enzymatic	O
activity	O
.	O

This	O
novel	O
mutation	O
,	O
G583A	B-DNAMutation
,	O
is	O
associated	O
with	O
severe	O
MCAD	B-DNAMutation
deficiency	O
causing	O
hypoglycemia	O
or	O
sudden	O
,	O
unexpected	O
neonatal	O
death	O
.	O

This	O
previously	O
unrecognized	O
phenotype	O
of	O
MCAD	B-DNAMutation
deficiency	O
may	O
contribute	O
significantly	O
to	O
preventable	O
infant	O
deaths	O
.	O

Identification	O
of	O
a	O
novel	O
point	O
mutation	O
of	O
mouse	O
proto-oncogene	B-DNAMutation
c-kit	I-DNAMutation
through	O
N-ethyl-N-nitrosourea	O
mutagenesis	O
.	O

Manipulation	O
of	O
the	O
mouse	O
genome	O
has	O
emerged	O
as	O
an	O
important	O
approach	O
for	O
studying	O
gene	O
function	O
and	O
establishing	O
human	O
disease	O
models	O
.	O

In	O
this	O
study	O
,	O
the	O
mouse	O
mutants	O
were	O
generated	O
through	O
N-ethyl-N-nitrosourea	O
(ENU)-induced	O
mutagenesis	O
in	O
C57BL/6J	O
mice	O
.	O

The	O
screening	O
for	O
dominant	O
mutations	O
yielded	O
several	O
mice	O
with	O
fur	O
color	O
abnormalities	O
.	O

One	O
of	O
them	O
causes	O
a	O
phenotype	O
similar	O
to	O
that	O
shown	O
by	O
dominant-white	O
spotting	O
(W)	O
allele	O
mutants	O
.	O

This	O
strain	O
was	O
named	O
Wads	O
because	O
the	O
homozygous	O
mutant	O
mice	O
are	O
white	O
color	O
,	O
anemic	O
,	O
deaf	O
,	O
and	O
sterile	O
.	O

The	O
new	O
mutation	O
was	O
mapped	O
to	O
42	O
cM	O
on	O
chromosome	O
five	O
,	O
where	O
proto-oncogene	B-DNAMutation
c-kit	I-DNAMutation
resides	O
.	O

Sequence	O
analysis	O
of	O
c-kit	B-DNAMutation
cDNA	O
from	O
Wads(m/m)	O
revealed	O
a	O
unique	O
T-to-C	O
transition	O
mutation	O
that	O
resulted	O
in	O
Phe-to-Ser	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
856	I-DNAMutation
within	O
a	O
highly	O
conserved	O
tyrosine	O
kinase	O
domain	O
.	O

Compared	O
with	O
other	O
c-kit	B-DNAMutation
mutants	O
,	O
Wads	O
may	O
present	O
a	O
novel	O
loss-of-function	O
or	O
hypomorphic	O
mutation	O
.	O

In	O
addition	O
to	O
the	O
examination	O
of	O
adult	O
phenotypes	O
in	O
hearing	O
loss	O
,	O
anemia	O
,	O
and	O
mast	O
cell	O
deficiency	O
,	O
we	O
also	O
detected	O
some	O
early	O
developmental	O
defects	O
during	O
germ	O
cell	O
differentiation	O
in	O
the	O
testis	O
and	O
ovary	O
of	O
neonatal	O
Wads(m/m)	O
mice	O
.	O

Therefore	O
,	O
the	O
Wads	O
mutant	O
may	O
serve	O
as	O
a	O
new	O
disease	O
model	O
of	O
human	O
piebaldism	O
,	O
anemia	O
,	O
deafness	O
,	O
sterility	O
,	O
and	O
mast	O
cell	O
diseases	O
.	O

A	O
novel	O
mutation	O
in	O
the	O
ferrochelatase	B-DNAMutation
gene	O
associated	O
with	O
erythropoietic	B-DNAMutation
protoporphyria	I-DNAMutation
.	O

Erythropoietic	O
protoporphyria	O
EPP	B-DNAMutation
is	O
a	O
hereditary	O
disorder	O
caused	O
by	O
mutations	O
of	O
the	O
ferrochelatase	B-DNAMutation
gene	O
.	O

We	O
investigated	O
a	O
Japanese	O
patient	O
with	O
a	O
dominant	O
form	O
of	O
erythropoietic	B-DNAMutation
protoporphyria	I-DNAMutation
for	O
a	O
ferrochelatase	B-DNAMutation
mutation	O
.	O

Sequence	O
analysis	O
of	O
the	O
proband's	O
ferrochelatase	B-DNAMutation
cDNA	O
revealed	O
a	O
T	B-DNAMutation
to	I-DNAMutation
C	I-DNAMutation
point	I-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
557	I-DNAMutation
.	O

This	O
mutation	O
resulted	O
in	O
the	O
replacement	B-DNAMutation
of	I-DNAMutation
Ile	I-DNAMutation
by	I-DNAMutation
Thr	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
position	I-DNAMutation
186	I-DNAMutation
,	O
a	O
novel	O
mutation	O
in	O
erythropoietic	B-DNAMutation
protoporphyria	I-DNAMutation
.	O

An	O
increase	O
in	O
ferrochelatase	B-DNAMutation
activity	O
was	O
not	O
observed	O
in	O
the	O
crude	O
extract	O
of	O
E	O
.	O

coli	O
over-expressing	O
the	O
mutant	O
protein	O
compared	O
with	O
the	O
control	O
,	O
whereas	O
a	O
marked	O
increase	O
in	O
activity	O
was	O
observed	O
in	O
that	O
over-expressing	O
the	O
wild	O
type	O
.	O

Prediction	O
of	O
the	O
secondary	O
structure	O
of	O
ferrochelatase	B-DNAMutation
suggested	O
that	O
the	O
Ile186-->Thr	B-DNAMutation
mutation	O
changed	O
the	O
original	O
beta-sheet	O
structure	O
to	O
an	O
alpha	O
helix	O
in	O
the	O
region	O
including	O
amino	O
acid	O
residue	O
of	O
mutation	O
.	O

We	O
conclude	O
that	O
,	O
in	O
the	O
patient	O
,	O
the	O
Ile186-->Thr	B-DNAMutation
mutation	O
had	O
abolished	O
enzyme	O
activity	O
,	O
possibly	O
by	O
disrupting	O
the	O
secondary	O
structure	O
,	O
thereby	O
causing	O
erythropoietic	B-DNAMutation
protoporphyria	I-DNAMutation
.	O

Cdc42Hs	B-DNAMutation
facilitates	O
cytoskeletal	O
reorganization	O
and	O
neurite	O
outgrowth	O
by	O
localizing	O
the	O
58-kD	O
insulin	O
receptor	O
substrate	O
to	O
filamentous	O
actin	O
.	O

Cdc42Hs	B-DNAMutation
is	O
involved	O
in	O
cytoskeletal	O
reorganization	O
and	O
is	O
required	O
for	O
neurite	O
outgrowth	O
in	O
N1E-115	O
cells	O
.	O

To	O
investigate	O
the	O
molecular	O
mechanism	O
by	O
which	O
Cdc42Hs	B-DNAMutation
regulates	O
these	O
processes	O
,	O
a	O
search	O
for	O
novel	O
Cdc42Hs	B-DNAMutation
protein	O
partners	O
was	O
undertaken	O
by	O
yeast	O
two-hybrid	O
assay	O
.	O

Here	O
,	O
we	O
identify	O
the	O
58-kD	O
substrate	O
of	O
the	O
insulin	O
receptor	O
tyrosine	O
kinase	O
IRS-58	B-DNAMutation
as	O
a	O
Cdc42Hs	B-DNAMutation
target	O
.	O

IRS-58	B-DNAMutation
is	O
a	O
brain-enriched	O
protein	O
comprising	O
at	O
least	O
four	O
protein-protein	O
interaction	O
sites	O
:	O
a	O
Cdc42Hs	B-DNAMutation
binding	O
site	O
,	O
an	O
Src	O
homology	O
(SH)3-binding	O
site	O
,	O
an	O
SH3	O
domain	O
,	O
and	O
a	O
tryptophan	O
,	O
tyrptophan	O
(WW)-binding	O
domain	O
.	O

Expression	O
of	O
IRS-58	B-DNAMutation
in	O
Swiss	O
3T3	O
cells	O
leads	O
to	O
reorganization	O
of	O
the	O
filamentous	O
(F)-actin	O
cytoskeleton	O
,	O
involving	O
loss	O
of	O
stress	O
fibers	O
and	O
formation	O
of	O
filopodia	O
and	O
clusters	O
.	O

In	O
N1E-115	O
cells	O
IRS-58	B-DNAMutation
induces	O
neurite	O
outgrowth	O
with	O
high	O
complexity	O
.	O

Expression	O
of	O
a	O
deletion	O
mutant	O
of	O
IRS-58	B-DNAMutation
,	O
which	O
lacks	O
the	O
SH3-	O
and	O
WW-binding	O
domains	O
,	O
induced	O
neurite	O
extension	O
without	O
complexity	O
in	O
N1E-115	O
cells	O
.	O

In	O
Swiss	O
3T3	O
cells	O
and	O
N1E-115	O
cells	O
,	O
IRS-58	B-DNAMutation
colocalizes	O
with	O
F-actin	O
in	O
clusters	O
and	O
filopodia	O
.	O

An	O
IRS-58(1267N)	B-DNAMutation
mutant	O
unable	O
to	O
bind	O
Cdc42Hs	B-DNAMutation
failed	O
to	O
localize	O
with	O
F-actin	O
to	O
induce	O
neurite	O
outgrowth	O
or	O
significant	O
cytoskeletal	O
reorganization	O
.	O

These	O
results	O
suggest	O
that	O
Cdc42Hs	B-DNAMutation
facilitates	O
cytoskeletal	O
reorganization	O
and	O
neurite	O
outgrowth	O
by	O
localizing	O
protein	O
complexes	O
via	O
adaptor	O
proteins	O
such	O
as	O
IRS-58	B-DNAMutation
to	O
F-actin	O
.	O

Cloning	O
,	O
expression	O
,	O
and	O
catalytic	O
mechanism	O
of	O
murine	O
lysophospholipase	B-DNAMutation
I	I-DNAMutation
.	O

A	O
lysophospholipase	O
(	O
LysoPLA	B-DNAMutation
I	I-DNAMutation
)	O
has	O
been	O
purified	O
and	O
characterized	O
from	O
the	O
mouse	O
macrophage-like	O
P388D1	O
cell	O
line	O
(	O
Zhang	O
,	O
Y	O
.	O

Y	O
,	O
and	O
Dennis	O
,	O
E	O
.	O

A	O
.	O

(1988)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

263	O
,	O
9965-9972	O
)	O
.	O

This	O
enzyme	O
has	O
now	O
been	O
sequenced	O
,	O
cloned	O
,	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
cells	O
.	O

The	O
enzyme	O
contains	O
230	O
amino	O
acid	O
residues	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
24.7	O
kDa	O
.	O

It	O
has	O
a	O
high	O
helical	O
content	O
in	O
its	O
predicated	O
secondary	O
structure	O
,	O
which	O
is	O
also	O
indicated	O
in	O
its	O
CD	O
spectrum	O
.	O

The	O
cloned	O
LysoPLA	B-DNAMutation
I	I-DNAMutation
was	O
purified	O
to	O
homogeneity	O
from	O
the	O
transformed	O
E	O
.	O

coli	O
cells	O
by	O
a	O
gel	O
filtration	O
column	O
and	O
an	O
ion	O
exchange	O
column	O
.	O

The	O
specific	O
activity	O
of	O
the	O
purified	O
protein	O
is	O
1	O
.	O

47	O
micromol/min.mg	O
toward	O
1-palmitoyl-sn-glycero-3-phosphorylcholine	O
at	O
pH	O
8.0	O
and	O
40	O
degrees	O
C	O
,	O
corresponding	O
to	O
the	O
reported	O
value	O
of	O
1.3-1.7	O
micromol/min.mg	O
for	O
the	O
protein	O
purified	O
from	O
the	O
P388D1	O
cells	O
.	O

In	O
addition	O
,	O
the	O
cloned	O
protein	O
cross-reacted	O
with	O
an	O
antibody	O
raised	O
against	O
LysoPLA	B-DNAMutation
I	I-DNAMutation
also	O
purified	O
from	O
the	O
P388D1	O
cells	O
.	O

The	O
deduced	O
LysoPLA	O
I	O
sequence	O
contains	O
a	O
well	O
conserved	O
GXSXG	O
motif	O
found	O
in	O
the	O
active	O
site	O
of	O
many	O
serine	O
enzymes	O
,	O
and	O
the	O
activity	O
of	O
the	O
LysoPLA	O
I	O
was	O
irreversibly	O
inhibited	O
by	O
the	O
classical	O
serine	O
protease	O
inhibitor	O
diisopropyl	O
fluorophosphate	O
.	O

Furthermore	O
,	O
site-directed	O
mutagenesis	O
was	O
employed	O
to	O
change	B-DNAMutation
Ser-119	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
GXSXG	I-DNAMutation
motif	I-DNAMutation
to	I-DNAMutation
an	I-DNAMutation
Ala	I-DNAMutation
.	O

The	O
resulting	O
mutant	O
protein	O
lost	O
all	O
of	O
its	O
lysophospholipase	O
activity	O
,	O
even	O
though	O
it	O
had	O
the	O
same	O
overall	O
protein	O
conformation	O
as	O
that	O
of	O
the	O
wild-type	O
LysoPLA	B-DNAMutation
I	I-DNAMutation
.	O

Therefore	O
,	O
LysoPLA	B-DNAMutation
I	I-DNAMutation
has	O
been	O
demonstrated	O
to	O
be	O
a	O
serine	O
enzyme	O
with	O
Ser-119	O
at	O
the	O
active	O
site	O
.	O

Mutation	O
of	O
the	O
Alzheimer's	O
disease	O
amyloid	O
gene	O
in	O
hereditary	O
cerebral	O
hemorrhage	O
,	O
Dutch	O
type	O
.	O

An	O
amyloid	O
protein	O
that	O
precipitates	O
in	O
the	O
cerebral	O
vessel	O
walls	O
of	O
Dutch	O
patients	O
with	O
hereditary	O
cerebral	O
hemorrhage	O
with	O
amyloidosis	O
is	O
similar	O
to	O
the	O
amyloid	O
protein	O
in	O
vessel	O
walls	O
and	O
senile	O
plaques	O
in	O
brains	O
of	O
patients	O
with	O
Alzheimer's	O
disease	O
,	O
Down	O
syndrome	O
,	O
and	O
sporadic	O
cerebral	O
amyloid	O
angiopathy	O
.	O

Cloning	O
and	O
sequencing	O
of	O
the	O
two	O
exons	O
that	O
encode	O
the	O
amyloid	O
protein	O
from	O
two	O
patients	O
with	O
this	O
amyloidosis	O
revealed	O
a	O
cytosine-to-guanine	O
transversion	O
,	O
a	O
mutation	O
that	O
caused	O
a	O
single	O
amino	O
acid	O
substitution	O
(	B-DNAMutation
glutamine	I-DNAMutation
instead	I-DNAMutation
of	I-DNAMutation
glutamic	I-DNAMutation
acid	I-DNAMutation
)	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
22	I-DNAMutation
of	O
the	O
amyloid	O
protein	O
.	O

The	O
mutation	O
may	O
account	O
for	O
the	O
deposition	O
of	O
this	O
amyloid	O
protein	O
in	O
the	O
cerebral	O
vessel	O
walls	O
of	O
these	O
patients	O
,	O
leading	O
to	O
cerebral	O
hemorrhages	O
and	O
premature	O
death	O
.	O

Phosphorylation	O
of	O
adducin	O
by	O
Rho-kinase	O
plays	O
a	O
crucial	O
role	O
in	O
cell	O
motility	O
.	O

Adducin	O
is	O
a	O
membrane	O
skeletal	O
protein	O
that	O
binds	O
to	O
actin	O
filaments	O
(F-actin)	O
and	O
thereby	O
promotes	O
the	O
association	O
of	O
spectrin	O
with	O
F-actin	O
to	O
form	O
a	O
spectrin-actin	O
meshwork	O
beneath	O
plasma	O
membranes	O
such	O
as	O
ruffling	O
membranes	O
.	O

Rho-associated	O
kinase	O
(	O
Rho-	O
kinase	O
)	O
,	O
which	O
is	O
activated	O
by	O
the	O
small	O
guanosine	O
triphosphatase	O
Rho	O
,	O
phosphorylates	O
alpha-adducin	B-DNAMutation
and	O
thereby	O
enhances	O
the	O
F-actin-binding	O
activity	O
of	O
alpha-adducin	B-DNAMutation
in	O
vitro	O
.	O

Here	O
we	O
identified	O
the	O
sites	O
of	O
phosphorylation	O
of	O
alpha-adducin	B-DNAMutation
by	O
Rho-kinase	O
as	O
Thr445	O
and	O
Thr480	O
.	O

We	O
prepared	O
antibody	O
that	O
specifically	O
recognized	O
alpha-adducin	B-DNAMutation
phosphorylated	O
at	O
Thr445	O
,	O
and	O
found	O
by	O
use	O
of	O
this	O
antibody	O
that	O
Rho-kinase	O
phosphorylated	O
alpha-adducin	B-DNAMutation
at	O
Thr445	O
in	O
COS7	O
cells	O
in	O
a	O
Rho-dependent	O
manner	O
.	O

Phosphorylated	O
alpha-adducin	B-DNAMutation
accumulated	O
in	O
the	O
membrane	O
ruffling	O
area	O
of	O
Madin-Darby	O
canine	O
kidney	O
(MDCK)	O
epithelial	O
cells	O
and	O
the	O
leading	O
edge	O
of	O
scattering	O
cells	O
during	O
the	O
action	O
of	O
tetradecanoylphorbol-13-acetate	O
(TPA)	O
or	O
hepatocyte	O
growth	O
factor	O
(HGF)	O
.	O

The	O
microinjection	O
of	O
Botulinum	O
C3	O
ADP-ribosyl-transferase	O
,	O
dominant	O
negative	O
Rho-kinase	O
,	O
or	O
alpha-adducinT445A,T480A	B-DNAMutation
(	O
substitution	B-DNAMutation
of	I-DNAMutation
Thr445	I-DNAMutation
and	O
Thr480	B-DNAMutation
by	I-DNAMutation
Ala	I-DNAMutation
)	O
inhibited	O
the	O
TPA-induced	O
membrane	O
ruffling	O
in	O
MDCK	O
cells	O
and	O
wound-induced	O
migration	O
in	O
NRK49F	O
cells	O
.	O

alpha-AdducinT445D,T480D	B-DNAMutation
(	O
substitution	B-DNAMutation
of	I-DNAMutation
Thr445	I-DNAMutation
and	O
Thr480	B-DNAMutation
by	I-DNAMutation
Asp	I-DNAMutation
)	O
,	O
but	O
not	O
alpha-adducinT445A,T480A	B-DNAMutation
,	O
counteracted	O
the	O
inhibitory	O
effect	O
of	O
the	O
dominant	O
negative	O
Rho-kinase	O
on	O
the	O
TPA-induced	O
membrane	O
ruffling	O
in	O
MDCK	O
cells	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
Rho-kinase	O
phosphorylates	O
alpha-adducin	B-DNAMutation
downstream	O
of	O
Rho	O
in	O
vivo	O
,	O
and	O
that	O
the	O
phosphorylation	O
of	O
adducin	O
by	O
Rho-kinase	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
membrane	O
ruffling	O
and	O
cell	O
motility	O
.	O

An	O
asn	O
to	O
lys	O
polymorphism	O
in	O
the	O
third	O
intracellular	O
loop	O
of	O
the	O
human	O
alpha	B-DNAMutation
2A-adrenergic	I-DNAMutation
receptor	I-DNAMutation
imparts	O
enhanced	O
agonist-promoted	O
Gi	O
coupling	O
.	O

alpha(2A)-Adrenergic	O
receptors	O
(alpha(2A)AR)	O
are	O
presynaptic	O
autoinhibitory	O
receptors	O
of	O
noradrenergic	O
neurons	O
in	O
the	O
central	O
and	O
peripheral	O
sympathetic	O
nervous	O
systems	O
,	O
which	O
act	O
to	O
dynamically	O
regulate	O
neurotransmitter	O
release	O
.	O

Signaling	O
through	O
the	O
G(i)/G(o)	O
family	O
of	O
G-proteins	O
,	O
the	O
receptor	O
subserves	O
numerous	O
homeostatic	O
and	O
central	O
nervous	O
system	O
functions	O
.	O

A	O
single	O
nucleotide	O
polymorphism	O
of	O
this	O
receptor	O
,	O
which	O
results	O
in	O
an	O
Asn	B-DNAMutation
to	I-DNAMutation
Lys	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
251	I-DNAMutation
of	O
the	O
third	O
intracellular	O
loop	O
,	O
was	O
identified	O
in	O
the	O
human	O
population	O
.	O

The	O
frequency	O
of	O
Lys-251	O
was	O
10-fold	O
greater	O
in	O
African-Americans	O
than	O
in	O
Caucasians	O
,	O
but	O
was	O
not	O
associated	O
with	O
essential	O
hypertension	O
.	O

To	O
determine	O
the	O
consequences	O
of	O
this	O
substitution	O
,	O
wild-type	O
and	O
Lys-251	O
receptors	O
were	O
expressed	O
in	O
CHO	O
and	O
COS-7	O
cells	O
.	O

Expression	O
,	O
ligand	O
binding	O
,	O
and	O
basal	O
receptor	O
function	O
were	O
unaffected	O
by	O
the	O
substitution	O
.	O

However	O
,	O
agonist-promoted	O
[(35)S]GTPgammaS	O
binding	O
was	O
approximately	O
40%	O
greater	O
with	O
the	O
Lys-251	O
receptor	O
.	O

This	O
enhanced	O
agonist	O
function	O
was	O
observed	O
with	O
catecholamines	O
,	O
azepines	O
,	O
and	O
imidazolines	O
albeit	O
to	O
different	O
degrees	O
.	O

In	O
studies	O
of	O
agonist-promoted	O
functional	O
coupling	O
to	O
G(i)	O
,	O
the	O
polymorphic	O
receptor	O
displayed	O
enhanced	O
inhibition	O
of	O
adenylyl	O
cyclase	O
(	O
60	O
+/-	O
4	O
.	O

4	O
versus	O
46	O
+/-	O
4.1%	O
inhibition	O
)	O
and	O
markedly	O
enhanced	O
stimulation	O
of	O
MAP	O
kinase	O
(	O
57	O
+/-	O
9	O
versus	O
15-	O
+/-	O
2-fold	O
increase	O
over	O
basal	O
)	O
compared	O
with	O
wild-type	O
alpha(2A)AR	O
.	O

The	O
potency	O
of	O
epinephrine	O
in	O
stimulating	O
inositol	O
phosphate	O
accumulation	O
was	O
increased	O
approximately	O
4	O
fold	O
with	O
the	O
Lys-251	O
receptor	O
.	O

Unlike	O
previously	O
described	O
variants	O
of	O
G-protein-coupled	O
receptors	O
,	O
where	O
the	O
minor	O
species	O
causes	O
either	O
a	O
loss	O
of	O
function	O
or	O
increased	O
non-agonist	O
function	O
,	O
Lys-251	O
alpha(2A)AR	O
represents	O
a	O
new	O
class	O
of	O
polymorphism	O
whose	O
phenotype	O
is	O
a	O
gain	O
of	O
agonist-promoted	O
function	O
.	O

Infantile	O
cerebellar-retinal	O
degeneration	O
associated	O
with	O
a	O
mutation	O
in	O
mitochondrial	O
aconitase	O
,	O
ACO2	B-DNAMutation
.	O

Degeneration	O
of	O
the	O
cerebrum	O
,	O
cerebellum	O
,	O
and	O
retina	O
in	O
infancy	O
is	O
part	O
of	O
the	O
clinical	O
spectrum	O
of	O
lysosomal	O
storage	O
disorders	O
,	O
mitochondrial	O
respiratory	O
chain	O
defects	O
,	O
carbohydrate	O
glycosylation	O
defects	O
,	O
and	O
infantile	O
neuroaxonal	O
dystrophy	O
.	O

We	O
studied	O
eight	O
individuals	O
from	O
two	O
unrelated	O
families	O
who	O
presented	O
at	O
2-6	O
months	O
of	O
age	O
with	O
truncal	O
hypotonia	O
and	O
athetosis	O
,	O
seizure	O
disorder	O
,	O
and	O
ophthalmologic	O
abnormalities	O
.	O

Their	O
course	O
was	O
characterized	O
by	O
failure	O
to	O
acquire	O
developmental	O
milestones	O
and	O
culminated	O
in	O
profound	O
psychomotor	O
retardation	O
and	O
progressive	O
visual	O
loss	O
,	O
including	O
optic	O
nerve	O
and	O
retinal	O
atrophy	O
.	O

Despite	O
their	O
debilitating	O
state	O
,	O
the	O
disease	O
was	O
compatible	O
with	O
survival	O
of	O
up	O
to	O
18	O
years	O
.	O

Laboratory	O
investigations	O
were	O
normal	O
,	O
but	O
the	O
oxidation	O
of	O
glutamate	O
by	O
muscle	O
mitochondria	O
was	O
slightly	O
reduced	O
.	O

Serial	O
brain	O
MRI	B-DNAMutation
displayed	O
progressive	O
,	O
prominent	O
cerebellar	O
atrophy	O
accompanied	O
by	O
thinning	O
of	O
the	O
corpus	O
callosum	O
,	O
dysmyelination	O
,	O
and	O
frontal	O
and	O
temporal	O
cortical	O
atrophy	O
.	O

Homozygosity	O
mapping	O
followed	O
by	O
whole-exome	O
sequencing	O
disclosed	O
a	O
Ser112Arg	B-DNAMutation
mutation	O
in	O
ACO2	B-DNAMutation
,	O
encoding	O
mitochondrial	O
aconitase	O
,	O
a	O
component	O
of	O
the	O
Krebs	O
cycle	O
.	O

Specific	O
aconitase	O
activity	O
in	O
the	O
individuals'	O
lymphoblasts	O
was	O
severely	O
reduced	O
.	O

Under	O
restrictive	O
conditions	O
,	O
the	O
mutant	O
human	O
ACO2	B-DNAMutation
failed	O
to	O
complement	O
a	O
yeast	O
ACO1	B-DNAMutation
deletion	I-DNAMutation
strain	O
,	O
whereas	O
the	O
wild-type	O
human	O
ACO2	B-DNAMutation
succeeded	O
,	O
indicating	O
that	O
this	O
mutation	O
is	O
pathogenic	O
.	O

Thus	O
,	O
a	O
defect	O
in	O
mitochondrial	O
aconitase	O
is	O
associated	O
with	O
an	O
infantile	O
neurodegenerative	O
disorder	O
affecting	O
mainly	O
the	O
cerebellum	O
and	O
retina	O
.	O

In	O
the	O
absence	O
of	O
noninvasive	O
biomarkers	O
,	O
determination	O
of	O
the	O
ACO2	B-DNAMutation
sequence	O
or	O
of	O
aconitase	O
activity	O
in	O
lymphoblasts	O
are	O
warranted	O
in	O
similarly	O
affected	O
individuals	O
,	O
based	O
on	O
clinical	O
and	O
neuroradiologic	O
grounds	O
.	O

Novel	O
mutations	O
in	O
ABCA1	O
gene	O
in	O
Japanese	O
patients	O
with	O
Tangier	O
disease	O
and	O
familial	O
high	O
density	O
lipoprotein	O
deficiency	O
with	O
coronary	O
heart	O
disease	O
.	O

Mutations	O
in	O
the	O
ATP-binding	B-DNAMutation
cassette	I-DNAMutation
transporter	I-DNAMutation
1	I-DNAMutation
ABCA1	B-DNAMutation
gene	O
have	O
been	O
recently	O
identified	O
as	O
the	O
molecular	O
defect	O
in	O
Tangier	O
disease	O
(TD)	O
and	O
familial	O
high	O
density	O
lipoprotein	O
deficiency	O
(FHA)	O
.	O

We	O
here	O
report	O
novel	O
mutations	O
in	O
the	O
ABCA1	O
gene	O
in	O
two	O
sisters	O
from	O
a	O
Japanese	O
family	O
with	O
TD	O
who	O
have	O
been	O
described	O
previously	O
(	O
S	O
.	O

Ohtaki	O
,	O
H	O
.	O

Nakagawa	O
,	O
N	O
.	O

Kida	O
,	O
H	O
.	O

Nakamura	O
,	O
K	O
.	O

Tsuda	O
,	O
S	O
.	O

Yokoyama	O
,	O
T	O
.	O

Yamamura	O
,	O
S	O
.	O

Tajima	O
,	O
A	O
.	O

Yamamoto	O
,	O
Atherosclerosis	O
49	O
(	O
1983	O
)	O
)	O
and	O
a	O
family	O
with	O
FHA	O
.	O

Both	O
probands	O
of	O
TD	O
and	O
FHA	O
developed	O
coronary	O
heart	O
disease	O
.	O

Sequence	O
analysis	O
of	O
the	O
ABCA1	B-DNAMutation
gene	O
from	O
the	O
patients	O
with	O
TD	O
revealed	O
a	O
homozygous	B-DNAMutation
G	I-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
3805	I-DNAMutation
of	O
the	O
cDNA	O
resulting	O
in	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
Asp	I-DNAMutation
1229	I-DNAMutation
with	I-DNAMutation
Asn	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
27	I-DNAMutation
,	O
and	O
a	O
C	B-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
6181	I-DNAMutation
resulting	O
in	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
Arg	I-DNAMutation
2021	I-DNAMutation
with	I-DNAMutation
Trp	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
47	I-DNAMutation
.	O

Sequence	O
analysis	O
of	O
the	O
ABCA1	B-DNAMutation
gene	O
from	O
the	O
FHA	O
patient	O
revealed	O
a	O
homozygous	B-DNAMutation
4	I-DNAMutation
bp	I-DNAMutation
CGCC	I-DNAMutation
deletion	I-DNAMutation
from	I-DNAMutation
nucleotide	I-DNAMutation
3787	I-DNAMutation
to	I-DNAMutation
3790	I-DNAMutation
resulting	O
in	O
premature	B-DNAMutation
termination	I-DNAMutation
by	I-DNAMutation
frameshift	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
1224	I-DNAMutation
.	O

These	O
mutations	O
were	O
confirmed	O
by	O
restriction	O
digestion	O
analysis	O
,	O
and	O
were	O
not	O
found	O
in	O
141	O
control	O
subjects	O
.	O

Our	O
findings	O
indicate	O
that	O
mutations	O
in	O
the	O
ABCA1	B-DNAMutation
gene	O
are	O
associated	O
with	O
TD	O
as	O
well	O
as	O
FHA	O
.	O

Apolipoprotein	O
A-I	O
variants	O
.	O

Naturally	O
occurring	O
substitutions	O
of	O
proline	O
residues	O
affect	O
plasma	O
concentration	O
of	O
apolipoprotein	O
A-I	O
.	O

Six	O
unrelated	O
families	O
with	O
genetically	O
determined	O
structural	O
variants	O
of	O
apo	B-DNAMutation
A-I	I-DNAMutation
were	O
found	O
in	O
the	O
course	O
of	O
an	O
electrophoretic	O
screening	O
program	O
for	O
apo	B-DNAMutation
A-I	I-DNAMutation
variants	O
in	O
dried	O
blood	O
samples	O
of	O
newborns	O
.	O

The	O
following	O
structural	O
variations	O
were	O
identified	O
by	O
the	O
combined	O
use	O
of	O
HPLC	O
,	O
time-of-flight	O
secondary	O
ion	O
mass	O
spectrometry	O
(TOF-SIMS)	O
,	O
and	O
automated	O
gas	O
phase	O
sequencing	O
:	O
Pro3----Arg	B-DNAMutation
(1x)	O
,	O
Pro4----Arg	B-DNAMutation
(1x)	O
,	O
and	O
Pro165----Arg	B-DNAMutation
(4x)	O
.	O

All	O
variant	O
carriers	O
were	O
heterozygous	O
for	O
their	O
mutant	O
of	O
apo	B-DNAMutation
A-I	I-DNAMutation
.	O

Subjects	O
heterozygous	O
for	O
apo	B-DNAMutation
A-I(Pro165----Arg)	I-DNAMutation
(	O
n	O
=	O
12	O
)	O
were	O
found	O
to	O
exhibit	O
lower	O
mean	O
values	O
for	O
apo	B-DNAMutation
A-I	I-DNAMutation
(	O
109	O
+/-	O
16	O
mg/dl	O
)	O
and	O
HDL	O
cholesterol	O
(	O
37	O
+/-	O
9	O
mg/dl	O
)	O
than	O
unaffected	O
family	O
members	O
(	O
n	O
=	O
9	O
)	O
:	O
176	O
+/-	O
41	O
and	O
64	O
+/-	O
18	O
mg/dl	O
,	O
respectively	O
(	O
P	O
less	O
than	O
0.001	O
)	O
.	O

In	O
9	O
of	O
12	O
apo	B-DNAMutation
A-I(Pro165----Arg)	I-DNAMutation
variant	O
carriers	O
the	O
concentrations	O
of	O
apo	B-DNAMutation
A-I	I-DNAMutation
were	O
below	O
the	O
fifth	O
percentile	O
of	O
sex-matched	O
controls	O
.	O

By	O
two-dimensional	O
immunoelectrophoresis	O
as	O
well	O
as	O
by	O
densitometry	O
the	O
relative	O
concentration	O
of	O
the	O
variant	O
apo	B-DNAMutation
A-I	I-DNAMutation
in	O
heterozygous	O
carriers	O
of	O
apo	B-DNAMutation
A-I(Pro165----Arg)	I-DNAMutation
was	O
determined	O
to	O
account	O
for	O
only	O
30%	O
of	O
the	O
total	O
plasma	O
apo	B-DNAMutation
A-I	I-DNAMutation
mass	O
instead	O
of	O
the	O
expected	O
50%	O
.	O

Thus	O
,	O
the	O
observed	O
apo	B-DNAMutation
A-I	I-DNAMutation
deficiency	O
may	O
be	O
largely	O
a	O
consequence	O
of	O
the	O
decreased	O
concentration	O
of	O
the	O
variant	O
apo	B-DNAMutation
A-I	I-DNAMutation
.	O

In	O
the	O
case	O
of	O
the	O
apo	B-DNAMutation
A-I(Pro3----Arg)	I-DNAMutation
mutant	O
,	O
densitometry	O
of	O
HDL	O
apolipoproteins	O
demonstrated	O
a	O
distinctly	O
increased	O
concentration	O
of	O
the	O
variant	O
proapo	O
A-I	O
relative	O
to	O
normal	O
proapo	O
A-I	O
.	O

This	O
phenomenon	O
was	O
not	O
observed	O
in	O
the	O
apo	B-DNAMutation
A-I(Pro4----Arg)	I-DNAMutation
mutant	O
or	O
in	O
other	O
mutants	O
.	O

This	O
suggests	O
that	O
the	O
interspecies	O
conserved	O
proline	O
residue	O
in	O
position	O
3	O
of	O
mature	O
apo	B-DNAMutation
A-I	I-DNAMutation
is	O
functionally	O
important	O
for	O
the	O
regular	O
enzymatic	O
conversion	O
of	O
proapo	O
A-I	O
to	O
mature	O
apo	B-DNAMutation
A-I	I-DNAMutation
.	O

A	O
Crohn's	O
disease	O
variant	O
in	O
Atg16l1	B-DNAMutation
enhances	O
its	O
degradation	O
by	O
caspase	B-DNAMutation
3	I-DNAMutation
.	O

Crohn's	O
disease	O
is	O
a	O
debilitating	O
inflammatory	O
bowel	O
disease	O
(IBD)	O
that	O
can	O
involve	O
the	O
entire	O
digestive	O
tract	O
.	O

A	O
single-nucleotide	O
polymorphism	O
(SNP)	O
encoding	O
a	O
missense	O
variant	O
in	O
the	O
autophagy	O
gene	O
ATG16L1	B-DNAMutation
(	O
rs2241880	B-DNAMutation
,	O
Thr300Ala	B-DNAMutation
)	O
is	O
strongly	O
associated	O
with	O
the	O
incidence	O
of	O
Crohn's	O
disease	O
.	O

Numerous	O
studies	O
have	O
demonstrated	O
the	O
effect	O
of	O
ATG16L1	B-DNAMutation
deletion	O
or	O
deficiency	O
;	O
however	O
,	O
the	O
molecular	O
consequences	O
of	O
the	O
Thr300Ala	B-DNAMutation
T300A	B-DNAMutation
variant	O
remains	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
amino	O
acids	O
296-299	O
constitute	O
a	O
caspase	O
cleavage	O
motif	O
in	O
ATG16L1	B-DNAMutation
and	O
that	O
the	O
T300A	B-DNAMutation
variant	O
(	O
T316A	B-DNAMutation
in	O
mice	O
)	O
significantly	O
increases	O
ATG16L1	B-DNAMutation
sensitization	O
to	O
caspase-3-mediated	B-DNAMutation
processing	O
.	O

We	O
observed	O
that	O
death-receptor	O
activation	O
or	O
starvation-induced	O
metabolic	O
stress	O
in	O
human	O
and	O
murine	O
macrophages	O
increased	O
degradation	O
of	O
the	O
T300A	B-DNAMutation
or	O
T316A	B-DNAMutation
variants	O
of	O
ATG16L1	B-DNAMutation
,	O
respectively	O
,	O
resulting	O
in	O
diminished	O
autophagy	O
.	O

Knock-in	O
mice	O
harbouring	O
the	O
T316A	B-DNAMutation
variant	O
showed	O
defective	O
clearance	O
of	O
the	O
ileal	O
pathogen	O
Yersinia	O
enterocolitica	O
and	O
an	O
elevated	O
inflammatory	O
cytokine	O
response	O
.	O

In	O
turn	O
,	O
deletion	O
of	O
the	O
caspase-3-encoding	B-DNAMutation
gene	O
,	O
Casp3	B-DNAMutation
,	O
or	O
elimination	O
of	O
the	O
caspase	O
cleavage	O
site	O
by	O
site-directed	O
mutagenesis	O
rescued	O
starvation-induced	O
autophagy	O
and	O
pathogen	O
clearance	O
,	O
respectively	O
.	O

These	O
findings	O
demonstrate	O
that	O
caspase	B-DNAMutation
3	I-DNAMutation
activation	O
in	O
the	O
presence	O
of	O
a	O
common	O
risk	O
allele	O
leads	O
to	O
accelerated	O
degradation	O
of	O
ATG16L1	B-DNAMutation
,	O
placing	O
cellular	O
stress	O
,	O
apoptotic	O
stimuli	O
and	O
impaired	O
autophagy	O
in	O
a	O
unified	O
pathway	O
that	O
predisposes	O
to	O
Crohn's	O
disease	O
.	O

Identification	O
of	O
four	O
novel	O
mutations	O
in	O
the	O
COL4A5	B-DNAMutation
gene	O
of	O
patients	O
with	O
Alport	O
syndrome	O
.	O

The	O
type	O
IV	O
collagen	O
alpha	O
5	O
chain	O
COL4A5	B-DNAMutation
genes	O
of	O
patients	O
with	O
Alport	O
syndrome	O
were	O
tested	O
for	O
major	O
gene	O
rearrangements	O
by	O
Southern	O
blot	O
analysis	O
,	O
using	O
COL4A5	B-DNAMutation
cDNA	O
clones	O
as	O
probes	O
.	O

In	O
addition	O
,	O
individual	O
exons	O
were	O
screened	O
for	O
small	O
mutations	O
by	O
single-strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
.	O

Four	O
new	O
COL4A5	B-DNAMutation
mutations	O
were	O
detected	O
.	O

A	O
duplication	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
nine	I-DNAMutation
most	I-DNAMutation
3'	I-DNAMutation
located	I-DNAMutation
nucleotides	I-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
49	I-DNAMutation
and	O
the	B-DNAMutation
first	I-DNAMutation
nucleotide	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
49	I-DNAMutation
was	O
identified	O
in	O
the	O
COL4A5	B-DNAMutation
gene	O
of	O
one	O
patient	O
.	O

Two	O
patients	O
displayed	O
single	O
base	O
substitutions	O
leading	O
to	O
,	O
respectively	O
,	O
a	O
proline	B-DNAMutation
to	I-DNAMutation
threonine	I-DNAMutation
and	I-DNAMutation
an	I-DNAMutation
arginine	I-DNAMutation
to	I-DNAMutation
glutamine	I-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
C-terminal	I-DNAMutation
end	I-DNAMutation
.	O

Both	O
substitutions	O
involve	O
amino	O
acids	O
conserved	O
through	O
evolution	O
.	O

In	O
COL4A5	B-DNAMutation
intron	O
41	O
a	O
mutation	O
changing	O
the	O
splice	O
acceptor	O
site	O
from	O
AG	O
to	O
AA	O
was	O
identified	O
.	O

All	O
mutations	O
cosegregate	O
with	O
the	O
clinical	O
phenotype	O
of	O
Alport	O
syndrome	O
in	O
affected	O
family	O
members	O
.	O

In	O
a	O
control	O
population	O
of	O
50	O
individuals	O
tested	O
by	O
PCR-SSCP	O
these	O
mutations	O
were	O
never	O
identified	O
.	O

Together	O
with	O
two	O
mutations	O
reported	O
previously	O
,	O
a	O
total	O
of	O
six	O
mutations	O
were	O
found	O
in	O
26	O
patients	O
with	O
Alport	O
syndrome	O
(23%)	O
after	O
systematic	O
screening	O
of	O
about	O
30%	O
of	O
the	O
COL4A5	B-DNAMutation
coding	O
region	O
.	O

The	O
clinical	O
features	O
of	O
these	O
six	O
patients	O
are	O
described	O
in	O
detail	O
.	O

Cloning	O
,	O
expression	O
,	O
and	O
catalytic	O
triad	O
of	O
recombinant	O
arylformamidase	B-DNAMutation
.	O

Arylformamidase	B-DNAMutation
AFMID	B-DNAMutation
is	O
the	O
second	O
enzyme	O
of	O
the	O
kynurenine	O
pathway	O
metabolizing	O
tryptophan	O
to	O
nicotinic	O
acid	O
and	O
nicotinamide	O
adenine	O
dinucleotide	O
cofactors	O
.	O

Inhibition	O
of	O
AFMID	B-DNAMutation
by	O
organophosphorus	O
insecticides	O
in	O
developing	O
chicken	O
embryos	O
is	O
correlated	O
with	O
lowered	O
NAD	O
levels	O
and	O
severe	O
teratogenesis	O
.	O

The	O
cDNA	O
sequence	O
previously	O
identified	O
for	O
mouse	O
liver	O
AFMID	B-DNAMutation
(AF399717)	O
(	O
MW	O
34229	O
)	O
was	O
cloned	O
and	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

Residues	O
identified	O
as	O
potential	O
catalytic	O
triad	O
members	O
(	B-DNAMutation
S162	I-DNAMutation
,	I-DNAMutation
D247	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
H279	I-DNAMutation
)	I-DNAMutation
through	I-DNAMutation
sequence	I-DNAMutation
motif	I-DNAMutation
and	I-DNAMutation
homology	I-DNAMutation
modeling	I-DNAMutation
were	I-DNAMutation
mutated	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
to	O
probe	O
their	O
contributions	O
to	O
enzyme	O
activity	O
.	O

The	O
wild-type	O
and	O
mutant	O
AFMIDs	O
were	O
expressed	O
as	O
amino	O
terminal	O
6	O
x	O
His-tagged	O
recombinant	O
proteins	O
to	O
facilitate	O
purification	O
.	O

Three	O
chromatography	O
steps	O
isolated	O
highly	O
purified	O
proteins	O
for	O
enzyme	O
activity	O
comparisons	O
.	O

Expressed	O
AFMID	B-DNAMutation
showed	O
high	O
activity	O
,	O
42+/-1	O
micromol/min/mg	O
protein	O
,	O
for	O
its	O
natural	O
substrate	O
,	O
N-formyl-l-kynurenine	O
.	O

The	O
same	O
K(m)	O
(	O
0.18--0.19	O
mM	O
)	O
was	O
observed	O
for	O
expressed	O
and	O
native	O
cytosolic	O
AFMID	B-DNAMutation
.	O

The	O
single	O
mutants	O
(	O
S162A	B-DNAMutation
,	O
D247A	B-DNAMutation
,	O
and	O
H279A	B-DNAMutation
)	O
lost	O
essentially	O
all	O
(>99%)	O
activity	O
.	O

The	O
predicted	O
catalytic	O
triad	O
of	O
S162	O
,	O
D247	O
,	O
and	O
H279	O
is	O
therefore	O
confirmed	O
by	O
site-directed	O
mutagenesis	O
.	O

Scd1ab-Xyk	O
:	O
a	O
new	O
asebia	O
allele	O
characterized	O
by	O
a	O
CCC	B-DNAMutation
trinucleotide	I-DNAMutation
insertion	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
5	I-DNAMutation
of	O
the	O
stearoyl-CoA	B-DNAMutation
desaturase	I-DNAMutation
1	I-DNAMutation
gene	O
in	O
mouse	O
.	O

We	O
describe	O
here	O
a	O
spontaneous	O
,	O
autosomal	O
recessive	O
mutant	O
mouse	O
suffering	O
from	O
skin	O
and	O
hair	O
defects	O
,	O
which	O
arose	O
in	O
the	O
outbred	O
Kunming	O
strain	O
.	O

By	O
haplotype	O
analysis	O
and	O
direct	O
sequencing	O
of	O
PCR	O
products	O
,	O
we	O
show	O
that	O
this	O
mutation	O
is	O
a	O
new	O
allele	O
of	O
the	O
asebia	O
locus	O
with	O
a	O
naturally	O
occurring	O
mutation	O
in	O
the	O
Scd1	B-DNAMutation
gene	O
(	O
a	B-DNAMutation
CCC	I-DNAMutation
insertion	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
position	I-DNAMutation
835	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
5	I-DNAMutation
)	O
,	O
which	O
codes	O
for	O
stearoyl-CoA	B-DNAMutation
desaturase	I-DNAMutation
1	I-DNAMutation
.	O

This	O
mutation	O
introduces	O
an	O
extra	B-DNAMutation
proline	I-DNAMutation
residue	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
279	I-DNAMutation
in	O
the	O
Scd1	B-DNAMutation
protein	O
.	O

The	O
mutant	O
mice	O
,	O
originally	O
designated	O
km/km	O
but	O
now	O
assigned	O
the	O
name	O
Scd1ab-Xyk	O
(	O
hereafter	O
abbreviated	O
as	O
abXyk/abXyk	O
)	O
,	O
have	O
a	O
similar	O
gross	O
and	O
histological	O
phenotype	O
to	O
that	O
reported	O
for	O
previously	O
characterized	O
allelic	O
asebia	O
mutations	O
(	O
Scd1ab	O
,	O
Scd1abJ	O
,	O
Scd1ab2J	O
,	O
and	O
Scd1tm1Ntam	O
)	O
.	O

Histological	O
analysis	O
showed	O
they	O
were	O
also	O
characterized	O
by	O
hypoplasic	O
sebaceous	O
glands	O
and	O
abnormal	O
hair	O
follicles	O
.	O

In	O
a	O
cross	O
between	O
Kunming-	O
abXyk/abXyk	O
and	O
ABJ/Le-abJ/abJ	O
mice	O
,	O
all	O
the	O
progeny	O
showed	O
the	O
same	O
phenotype	O
,	O
indicating	O
that	O
the	O
two	O
mutations	O
were	O
non-complementing	O
and	O
therefore	O
allelic	O
.	O

Comparisons	O
with	O
the	O
other	O
four	O
allelic	O
mutants	O
indicate	O
that	O
the	O
Scd1ab-Xyk	O
mutation	O
causes	O
the	O
mildest	O
change	O
in	O
Scd1	B-DNAMutation
function	O
.	O

This	O
new	O
mouse	O
mutant	O
is	O
a	O
good	O
model	O
not	O
only	O
for	O
the	O
study	O
of	O
scarring	O
alopecias	O
in	O
humans	O
,	O
which	O
are	O
characterized	O
by	O
hypoplasic	O
sebaceous	O
glands	O
,	O
but	O
also	O
for	O
studying	O
the	O
structure	O
and	O
function	O
of	O
the	O
Scd1	B-DNAMutation
protein	O
.	O

Hereditary	O
isolated	O
glucocorticoid	O
deficiency	O
is	O
associated	O
with	O
abnormalities	O
of	O
the	O
adrenocorticotropin	B-DNAMutation
receptor	I-DNAMutation
gene	O
.	O

Isolated	O
glucocorticoid	O
deficiency	O
(IGD)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
progressive	O
primary	O
adrenal	O
insufficiency	O
,	O
without	O
mineralocorticoid	O
deficiency	O
.	O

The	O
cDNA	O
and	O
gene	O
of	O
the	O
human	O
ACTH	B-DNAMutation
receptor	I-DNAMutation
were	O
recently	O
cloned	O
.	O

The	O
gene	O
encodes	O
a	O
297-amino	O
acid	O
protein	O
that	O
belongs	O
to	O
the	O
G	O
protein-coupled	O
superfamily	O
of	O
membrane	O
receptors	O
.	O

We	O
hypothesized	O
that	O
the	O
ACTH	B-DNAMutation
receptor	I-DNAMutation
gene	O
might	O
be	O
defective	O
in	O
IGD	O
.	O

To	O
examine	O
this	O
,	O
we	O
studied	O
its	O
genomic	O
structure	O
by	O
PCR	O
and	O
direct	O
sequencing	O
in	O
a	O
5-yr-old	O
proband	O
with	O
the	O
disease	O
,	O
his	O
parents	O
,	O
and	O
grandparents	O
.	O

The	O
proband	O
was	O
a	O
compound	O
heterozygote	O
for	O
two	O
different	O
point	O
mutations	O
,	O
one	O
in	O
each	O
allele	O
:	O
(a)	O
a	O
substitution	O
(C-->T)	O
,	O
also	O
found	O
in	O
one	O
allele	O
of	O
the	O
mother	O
and	O
maternal	O
grandmother	O
,	O
which	O
introduced	O
a	O
premature	B-DNAMutation
stop	I-DNAMutation
codon	I-DNAMutation
(TGA)	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
201	I-DNAMutation
of	O
the	O
protein	O
;	O
this	O
mutant	B-DNAMutation
receptor	I-DNAMutation
lacks	I-DNAMutation
its	I-DNAMutation
entire	I-DNAMutation
carboxy-terminal	I-DNAMutation
third	I-DNAMutation
and	O
,	O
if	O
expressed	O
,	O
should	O
be	O
unable	O
to	O
transduce	O
the	O
signal	O
;	O
and	O
(b)	O
a	O
substitution	O
(C-->G)	O
,	O
also	O
found	O
in	O
one	O
of	O
the	O
paternal	O
alleles	O
,	O
which	O
changed	B-DNAMutation
neutral	I-DNAMutation
serine120	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
apolar	I-DNAMutation
third	I-DNAMutation
transmembrane	I-DNAMutation
domain	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
receptor	I-DNAMutation
to	I-DNAMutation
a	I-DNAMutation
positively	I-DNAMutation
charged	I-DNAMutation
arginine	I-DNAMutation
,	O
probably	O
disrupting	O
the	O
ligand-binding	O
site	O
.	O

Standard	O
ovine	O
corticotropin	O
releasing	O
hormone	O
(oCRH)	O
test	O
in	O
the	O
heterozygote	O
parents	O
and	O
maternal	O
grandmother	O
revealed	O
exaggerated	O
and	O
prolonged	O
ACTH	B-DNAMutation
responses	O
,	O
suggestive	O
of	O
subclinical	O
resistance	O
to	O
ACTH	B-DNAMutation
.	O

We	O
conclude	O
that	O
IGD	O
in	O
this	O
family	O
appears	O
to	O
be	O
due	O
to	O
defects	O
of	O
the	O
ACTH	B-DNAMutation
receptor	I-DNAMutation
gene	O
.	O

The	O
oCRH	O
test	O
appears	O
to	O
be	O
useful	O
in	O
ascertaining	O
heterozygosity	O
in	O
this	O
syndrome	O
.	O

A	O
mutation	O
in	O
the	O
gamma	O
actin	O
1	O
ACTG1	B-DNAMutation
gene	O
causes	O
autosomal	O
dominant	O
hearing	O
loss	O
DFNA20/26	B-DNAMutation
.	O

Linkage	O
analysis	O
in	O
a	O
multigenerational	O
family	O
with	O
autosomal	O
dominant	O
hearing	O
loss	O
yielded	O
a	O
chromosomal	O
localisation	O
of	O
the	O
underlying	O
genetic	O
defect	O
in	O
the	O
DFNA20/26	B-DNAMutation
locus	O
at	O
17q25-qter	O
.	O

The	O
6-cM	O
critical	O
region	O
harboured	O
the	O
gamma-1-actin	O
ACTG1	B-DNAMutation
gene	O
,	O
which	O
was	O
considered	O
an	O
attractive	O
candidate	O
gene	O
because	O
actins	O
are	O
important	O
structural	O
elements	O
of	O
the	O
inner	O
ear	O
hair	O
cells	O
.	O

In	O
this	O
study	O
,	O
a	O
Thr278Ile	B-DNAMutation
mutation	O
was	O
identified	O
in	O
helix	O
9	O
of	O
the	O
modelled	O
protein	O
structure	O
.	O

The	O
alteration	B-DNAMutation
of	I-DNAMutation
residue	I-DNAMutation
Thr278	I-DNAMutation
is	O
predicted	O
to	O
have	O
a	O
small	O
but	O
significant	O
effect	O
on	O
the	O
gamma	O
1	O
actin	O
structure	O
owing	O
to	O
its	O
close	O
proximity	O
to	O
a	O
methionine	O
residue	O
at	O
position	O
313	O
in	O
helix	O
11	O
.	O

Met313	O
has	O
no	O
space	O
in	O
the	O
structure	O
to	O
move	O
away	O
.	O

Moreover	O
,	O
the	O
Thr278	O
residue	O
is	O
highly	O
conserved	O
throughout	O
eukaryotic	O
evolution	O
.	O

Using	O
a	O
known	O
actin	O
structure	O
the	O
mutation	O
could	O
be	O
predicted	O
to	O
impair	O
actin	O
polymerisation	O
.	O

These	O
findings	O
strongly	O
suggest	O
that	O
the	O
Thr278Ile	B-DNAMutation
mutation	O
in	O
ACTG1	B-DNAMutation
represents	O
the	O
first	O
disease	O
causing	O
germline	O
mutation	O
in	O
a	O
cytoplasmic	O
actin	O
isoform	O
.	O

ABCA1(Alabama)	B-DNAMutation
:	O
a	O
novel	O
variant	O
associated	O
with	O
HDL	O
deficiency	O
and	O
premature	O
coronary	O
artery	O
disease	O
.	O

The	O
ATP-binding	B-DNAMutation
cassette	I-DNAMutation
transporter	I-DNAMutation
,	O
ABCA1	B-DNAMutation
,	O
is	O
a	O
member	O
of	O
the	O
ABC	O
superfamily	O
of	O
proteins	O
involved	O
in	O
the	O
active	O
transport	O
of	O
substrates	O
across	O
cellular	O
membranes	O
.	O

Recent	O
studies	O
have	O
implicated	O
mutations	O
in	O
ABCA1	B-DNAMutation
as	O
the	O
cause	O
of	O
Tangier	O
disease	O
(TD)	O
and	O
familial	O
hypoalphalipoproteinemia	O
(FHA)	O
.	O

To	O
evaluate	O
the	O
molecular	O
basis	O
of	O
low	O
high	O
density	O
lipoprotein	O
(HDL)	O
in	O
a	O
family	O
with	O
premature	O
coronary	O
artery	O
disease	O
,	O
single	O
strand	O
conformational	O
polymorphism	O
analysis	O
was	O
performed	O
for	O
all	O
coding	O
regions	O
and	O
splice	O
site	O
junctions	O
of	O
ABCA1	B-DNAMutation
with	O
the	O
genomic	O
DNA	O
of	O
the	O
proband	O
.	O

The	O
proband	O
and	O
affected	O
individuals	O
were	O
heterozygotes	O
for	O
C254T	B-DNAMutation
with	O
proline	B-DNAMutation
converted	I-DNAMutation
to	I-DNAMutation
leucine	I-DNAMutation
(P85L)	I-DNAMutation
.	O

This	O
mutation	O
was	O
not	O
identified	O
in	O
over	O
400	O
chromosomes	O
of	O
healthy	O
subjects	O
.	O

In	O
the	O
FHA	O
kindred	O
,	O
family	O
members	O
heterozygous	O
for	O
the	O
ABCA1	B-DNAMutation
variant	O
also	O
exhibited	O
corresponding	O
low	O
levels	O
of	O
HDL	O
cholesterol	O
.	O

These	O
data	O
confirm	O
recent	O
data	O
that	O
a	O
single	O
defective	O
allele	O
in	O
ABCA1	B-DNAMutation
may	O
be	O
associated	O
with	O
reduced	O
HDL	O
cholesterol	O
and	O
FHA	O
.	O

A	O
single	O
base	O
mutation	O
in	O
the	O
PRAT4A	B-DNAMutation
gene	O
reveals	O
differential	O
interaction	O
of	O
PRAT4A	B-DNAMutation
with	O
Toll-like	O
receptors	O
.	O

Toll-like	O
receptors	O
(TLRs)	O
play	O
an	O
essential	O
role	O
in	O
defense	O
responses	O
.	O

Immune	O
cells	O
express	O
multiple	O
TLRs	O
which	O
are	O
simultaneously	O
activated	O
by	O
microbial	O
pathogens	O
.	O

PRotein	B-DNAMutation
Associated	I-DNAMutation
with	I-DNAMutation
Tlr4	I-DNAMutation
A	I-DNAMutation
PRAT4A	B-DNAMutation
is	O
a	O
chaperone-like	O
endoplasmic	O
reticulum	O
(ER)-resident	O
protein	O
required	O
for	O
the	O
proper	O
subcellular	O
distribution	O
of	O
multiple	O
TLRs	O
.	O

PRAT4A(-/-)	B-DNAMutation
mice	O
show	O
impaired	O
expression	O
of	O
TLR2/4	B-DNAMutation
on	O
the	O
cell	O
surface	O
and	O
the	O
lack	O
of	O
ligand-induced	O
TLR9	B-DNAMutation
relocation	O
from	O
the	O
ER	O
to	O
endolysosome	O
.	O

Consequently	O
,	O
TLR	O
responses	O
to	O
whole	O
bacteria	O
as	O
well	O
as	O
to	O
TLR2	B-DNAMutation
,	O
4	O
and	O
9	O
ligands	O
are	O
impaired	O
.	O

We	O
here	O
compare	O
the	O
interaction	O
of	O
these	O
TLRs	O
with	O
PRAT4A	B-DNAMutation
.	O

Association	O
of	O
endogenous	O
PRAT4A	B-DNAMutation
was	O
easily	O
detected	O
only	O
with	O
TLR4	B-DNAMutation
.	O

The	O
TLR4	B-DNAMutation
region	O
responsible	O
for	O
strong	O
interaction	O
with	O
PRAT4A	B-DNAMutation
is	O
very	O
close	O
to	O
the	O
site	O
necessary	O
for	O
interaction	O
with	O
MD-2	B-DNAMutation
.	O

By	O
using	O
transient	O
expression	O
,	O
we	O
were	O
able	O
to	O
detect	O
PRAT4A	B-DNAMutation
interaction	O
with	O
TLR2	B-DNAMutation
and	O
TLR9	B-DNAMutation
.	O

The	O
PRAT4A	B-DNAMutation
single-nucleotide	O
mutant	O
replacing	O
methionine	B-DNAMutation
145	I-DNAMutation
with	I-DNAMutation
lysine	I-DNAMutation
M145K	B-DNAMutation
associates	O
with	O
TLR9	B-DNAMutation
but	O
does	O
not	O
rescue	O
ligand-dependent	O
TLR9	B-DNAMutation
trafficking	O
.	O

By	O
contrast	O
,	O
the	O
M145K	B-DNAMutation
mutant	O
weakly	O
,	O
if	O
at	O
all	O
,	O
associates	O
with	O
TLR2	B-DNAMutation
and	O
TLR4	B-DNAMutation
.	O

The	O
M145K	B-DNAMutation
mutant	O
appreciably	O
rescues	O
cell-surface	O
TLR2	B-DNAMutation
expression	O
and	O
its	O
responses	O
in	O
PRAT4A(-/-)	B-DNAMutation
bone	O
marrow-derived	O
dendritic	O
cells	O
,	O
whereas	O
little	O
if	O
any	O
rescue	O
of	O
cell-surface	O
TLR4/MD-2	B-DNAMutation
expression	O
and	O
its	O
responses	O
occurs	O
.	O

These	O
results	O
demonstrate	O
that	O
PRAT4A	B-DNAMutation
differentially	O
interacts	O
with	O
each	O
TLR	O
and	O
suggest	O
that	O
a	O
single-nucleotide	O
change	O
in	O
the	O
PRAT4A	B-DNAMutation
gene	O
influences	O
not	O
only	O
the	O
strength	O
of	O
TLR	O
responses	O
but	O
can	O
also	O
alter	O
the	O
relative	O
activity	O
of	O
each	O
TLR	O
.	O

Mutations	O
in	O
the	O
gene	O
for	O
X-linked	O
adrenoleukodystrophy	O
in	O
patients	O
with	O
different	O
clinical	O
phenotypes	O
.	O

Recently	O
,	O
the	O
gene	O
for	O
the	O
most	O
common	O
peroxisomal	O
disorder	O
,	O
X-linked	O
adrenoleukodystrophy	O
(X-ALD)	O
,	O
has	O
been	O
described	O
encoding	O
a	O
peroxisomal	O
membrane	O
transporter	O
protein	O
.	O

We	O
analyzed	O
the	O
entire	O
protein-coding	O
sequence	O
of	O
this	O
gene	O
by	O
reverse-transcription	O
PCR	O
,	O
SSCP	O
,	O
and	O
DNA	O
sequencing	O
in	O
five	O
patients	O
with	O
different	O
clinical	O
expression	O
of	O
X-ALD	O
and	O
in	O
their	O
female	O
relatives	O
;	O
these	O
clinical	O
expressions	O
were	O
cerebral	O
childhood	O
ALD	O
,	O
adrenomyeloneuropathy	O
(AMN)	O
,	O
and	O
"Addison	O
disease	O
only"	O
(ADO)	O
phenotype	O
.	O

In	O
the	O
three	O
patients	O
exhibiting	O
the	O
classical	O
picture	O
of	O
severe	O
childhood	O
ALD	O
we	O
identified	O
in	B-DNAMutation
the	I-DNAMutation
5'	I-DNAMutation
portion	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
X-ALD	I-DNAMutation
gene	I-DNAMutation
a	I-DNAMutation
38-bp	I-DNAMutation
deletion	I-DNAMutation
that	I-DNAMutation
causes	I-DNAMutation
a	I-DNAMutation
frameshift	I-DNAMutation
mutation	I-DNAMutation
,	O
a	O
3-bp	B-DNAMutation
deletion	I-DNAMutation
leading	I-DNAMutation
to	I-DNAMutation
a	I-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
an	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
ATP-binding	I-DNAMutation
domain	I-DNAMutation
of	O
the	O
ALD	O
protein	O
,	O
and	O
a	O
missense	O
mutation	O
.	O

In	O
the	O
patient	O
with	O
the	O
clinical	O
phenotype	O
of	O
AMN	O
,	O
a	O
nonsense	B-DNAMutation
mutation	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
212	I-DNAMutation
,	O
along	O
with	O
a	O
second	O
site	O
mutation	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
178	I-DNAMutation
,	O
was	O
observed	O
.	O

Analysis	O
of	O
the	O
patient	O
with	O
the	O
ADO	O
phenotype	O
revealed	O
a	O
further	O
missense	O
mutation	O
at	O
a	O
highly	O
conserved	O
position	O
in	O
the	O
ALDP/PMP70	B-DNAMutation
comparison	O
.	O

The	O
disruptive	O
nature	O
of	O
two	O
mutations	O
(	O
i.e.	O
,	O
the	O
frameshift	O
and	O
the	O
nonsense	O
mutation	O
)	O
in	O
patients	O
with	O
biochemically	O
proved	O
childhood	O
ALD	O
and	O
AMN	O
further	O
strongly	O
supports	O
the	O
hypothesis	O
that	O
alterations	O
in	O
this	O
gene	O
play	O
a	O
crucial	O
role	O
in	O
the	O
pathogenesis	O
of	O
X-ALD	O
.	O

Since	O
the	O
current	O
biochemical	O
techniques	O
for	O
X-ALD	O
carrier	O
detection	O
in	O
affected	O
families	O
lack	O
sufficient	O
reliability	O
,	O
our	O
procedure	O
described	O
for	O
systematic	O
mutation	O
scanning	O
is	O
also	O
capable	O
of	O
improving	O
genetic	O
counseling	O
and	O
prenatal	O
diagnosis	O
.	O

Identification	O
of	O
two	O
amino	O
acids	O
in	O
the	O
C-terminal	O
domain	O
of	O
mouse	O
CRY2	B-DNAMutation
essential	O
for	O
PER2	B-DNAMutation
interaction	O
.	O

BACKGROUND	O
:	O
Cryptochromes	O
(CRYs)	O
are	O
a	O
class	O
of	O
flavoprotein	O
blue-light	O
signaling	O
receptors	O
found	O
in	O
plants	O
and	O
animals	O
,	O
and	O
they	O
control	O
plant	O
development	O
and	O
the	O
entrainment	O
of	O
circadian	O
rhythms	O
.	O

They	O
also	O
act	O
as	O
integral	O
parts	O
of	O
the	O
central	O
circadian	O
oscillator	O
in	O
humans	O
and	O
other	O
animals	O
.	O

In	O
mammals	O
,	O
the	O
CLOCK-BMAL1	O
heterodimer	O
activates	O
transcription	O
of	O
the	O
Per	O
and	O
Cry	O
genes	O
as	O
well	O
as	O
clock-regulated	O
genes	O
.	O

The	O
PER2	B-DNAMutation
proteins	O
interact	O
with	O
CRY	O
and	O
CKIÎµ	O
,	O
and	O
the	O
resulting	O
ternary	O
complexes	O
translocate	O
into	O
the	O
nucleus	O
,	O
where	O
they	O
negatively	O
regulate	O
the	O
transcription	O
of	O
Per	O
and	O
Cry	O
core	O
clock	O
genes	O
and	O
other	O
clock-regulated	O
output	O
genes	O
.	O

Recent	O
studies	O
have	O
indicated	O
that	O
the	O
extended	O
C-termini	O
of	O
the	O
mammalian	O
CRYs	O
,	O
as	O
compared	O
to	O
photolyase	O
proteins	O
,	O
interact	O
with	O
PER	O
proteins	O
.	O

RESULTS	O
:	O
We	O
identified	O
a	O
region	O
on	B-DNAMutation
mCRY2	I-DNAMutation
(	O
between	O
residues	O
493	O
and	O
512	O
)	O
responsible	O
for	O
direct	O
physical	O
interaction	O
with	B-DNAMutation
mPER2	I-DNAMutation
by	O
mammalian	O
two-hybrid	O
and	O
co-immunoprecipitation	O
assays	O
.	O

Moreover	O
,	O
using	O
oligonucleotide-based	O
degenerate	O
PCR	O
,	O
we	O
discovered	O
that	B-DNAMutation
mutation	I-DNAMutation
of	I-DNAMutation
Arg-501	I-DNAMutation
and	I-DNAMutation
Lys-503	I-DNAMutation
of	B-DNAMutation
mCRY2	I-DNAMutation
within	O
this	O
C-terminal	O
region	O
totally	O
abolishes	O
interaction	O
with	B-DNAMutation
PER2	I-DNAMutation
.	O

CONCLUSIONS	O
:	O
Our	O
results	O
identify	B-DNAMutation
mCRY2	I-DNAMutation
amino	O
acid	O
residues	O
that	O
interact	O
with	O
the	B-DNAMutation
mPER2	I-DNAMutation
binding	O
region	O
and	O
suggest	O
the	O
potential	O
for	O
rational	O
drug	O
design	O
to	O
inhibit	O
CRYs	O
for	O
specific	O
therapeutic	O
approaches	O
.	O

Mutations	O
of	O
the	O
PRKAR1A	B-DNAMutation
gene	O
in	O
Cushing's	O
syndrome	O
due	O
to	O
sporadic	O
primary	O
pigmented	O
nodular	O
adrenocortical	O
disease	O
.	O

Primary	O
pigmented	O
nodular	O
adrenocortical	O
disease	O
(PPNAD)	O
is	O
a	O
cause	O
of	O
ACTH-independent	B-DNAMutation
Cushing's	O
syndrome	O
.	O

This	O
condition	O
can	O
be	O
difficult	O
to	O
diagnose	O
because	O
hypercortisolism	O
may	O
be	O
periodic	O
and	O
adrenal	O
imaging	O
may	O
not	O
demonstrate	O
an	O
adrenal	O
tumor	O
.	O

PPNAD	O
can	O
be	O
part	O
of	O
the	O
Carney	O
complex	O
(CNC)	O
,	O
an	O
autosomal	O
dominant	O
multiple	O
neoplasia	O
syndrome	O
.	O

Germline	O
mutations	O
of	O
the	O
regulatory	O
subunit	O
R1A	O
of	O
PKA	O
PRKAR1A	B-DNAMutation
have	O
been	O
observed	O
in	O
about	O
45%	O
of	O
CNC	O
kindreds	O
.	O

To	O
improve	O
our	O
understanding	O
of	O
sporadic	O
PPNAD	O
and	O
develop	O
a	O
potential	O
diagnostic	O
tool	O
,	O
we	O
investigated	O
the	O
genetics	O
of	O
patients	O
with	O
sporadic	O
and	O
isolated	O
PPNAD	O
.	O

Patients	O
undergoing	O
surgery	O
for	O
bilateral	O
ACTH-independent	B-DNAMutation
Cushing's	O
syndrome	O
in	O
whom	O
pathological	O
examination	O
revealed	O
PPNAD	O
were	O
subjected	O
to	O
endocrinological	O
investigations	O
and	O
a	O
systematic	O
search	O
for	O
other	O
manifestations	O
of	O
CNC	O
.	O

The	O
PRKAR1A	B-DNAMutation
gene	O
was	O
sequenced	O
using	O
DNA	O
from	O
frozen	O
adrenal	O
tissues	O
and	O
leukocytes	O
from	O
three	O
patients	O
with	O
sporadic	O
isolated	O
PPNAD	O
and	O
using	O
leukocyte	O
DNA	O
from	O
two	O
additional	O
patients	O
.	O

Different	O
inactivating	O
germline	O
mutations	O
of	O
the	O
PRKAR1A	B-DNAMutation
gene	O
were	O
found	O
in	O
the	O
five	O
patients	O
.	O

For	O
three	O
cases	O
,	O
study	O
of	O
the	O
parents'	O
DNA	O
demonstrated	O
a	O
de	O
novo	O
mutation	O
.	O

One	O
patient	O
presented	O
with	O
an	O
unusual	O
2.5-cm	O
macronodule	O
of	O
the	O
right	O
adrenal	O
mimicking	O
an	O
adrenal	O
adenoma	O
.	O

A	O
somatic	B-DNAMutation
16-bp	I-DNAMutation
deletion	I-DNAMutation
of	O
PRKAR1A	B-DNAMutation
gene	O
was	O
also	O
found	O
in	O
this	O
macronodule	O
.	O

Inactivating	O
germline	O
mutations	O
of	O
PRKAR1A	B-DNAMutation
are	O
frequent	O
in	O
sporadic	O
and	O
isolated	O
cases	O
of	O
PPNAD	O
.	O

The	O
wild-type	O
allele	O
can	O
be	O
inactivated	O
by	O
somatic	O
mutations	O
,	O
consistent	O
with	O
the	O
hypothesis	O
of	O
the	O
gene	O
being	O
a	O
tumor	O
suppressor	O
gene	O
.	O

Thus	O
,	O
genetic	O
analysis	O
can	O
be	O
of	O
help	O
to	O
the	O
clinician	O
in	O
the	O
diagnosis	O
of	O
this	O
difficult	O
form	O
of	O
adrenal	O
Cushing's	O
syndrome	O
.	O

A	O
single	O
histidine	O
residue	O
determines	O
the	O
pH	O
sensitivity	O
of	O
the	O
pacemaker	O
channel	O
HCN2	B-DNAMutation
.	O

Hyperpolarization-activated	O
cyclic	O
nucleotide-gated	O
(HCN)	O
cation	O
channels	O
control	O
the	O
rhythmic	O
activity	O
of	O
heart	O
and	O
neuronal	O
networks	O
.	O

The	O
activation	O
of	O
these	O
channels	O
is	O
regulated	O
in	O
a	O
complex	O
manner	O
by	O
hormones	O
and	O
neurotransmitters	O
.	O

In	O
addition	O
it	O
was	O
suggested	O
that	O
the	O
channels	O
may	O
be	O
controlled	O
by	O
the	O
pH	O
of	O
the	O
cytosol	O
.	O

Here	O
we	O
demonstrate	O
that	O
HCN2	B-DNAMutation
,	O
a	O
member	O
of	O
the	O
HCN	O
channel	O
family	O
,	O
is	O
directly	O
modulated	O
by	O
the	O
intracellular	O
pH	O
in	O
the	O
physiological	O
range	O
.	O

Protons	O
inhibit	O
HCN2	B-DNAMutation
channels	O
by	O
shifting	O
the	O
voltage	O
dependence	O
of	O
channel	O
activation	O
to	O
more	O
negative	O
voltages	O
.	O

By	O
using	O
site-directed	O
mutagenesis	O
,	O
we	O
have	O
identified	O
a	O
single	O
histidine	O
residue	O
(His-321)	O
localized	O
at	O
the	O
boundary	O
between	O
the	O
voltage-sensing	O
S4	O
helix	O
and	O
the	O
cytoplasmic	O
S4-S5	O
linker	O
of	O
the	O
channel	O
that	O
is	O
a	O
major	O
determinant	O
of	O
pH	O
sensitivity	O
.	O

Replacement	B-DNAMutation
of	I-DNAMutation
His-321	I-DNAMutation
by	I-DNAMutation
either	I-DNAMutation
arginine	I-DNAMutation
,	I-DNAMutation
glutamine	I-DNAMutation
,	I-DNAMutation
or	I-DNAMutation
glutamate	I-DNAMutation
results	O
in	O
channels	O
that	O
are	O
no	O
longer	O
sensitive	O
to	O
shifts	O
in	O
intracellular	O
pH	O
.	O

In	O
contrast	O
,	O
cAMP-mediated	B-DNAMutation
modulation	O
is	O
completely	O
intact	O
in	O
mutant	O
channels	O
indicating	O
that	O
His-321	O
is	O
not	O
involved	O
in	O
the	O
molecular	O
mechanism	O
that	O
controls	O
modulation	O
of	O
HCN	O
channel	O
activity	O
by	O
cyclic	O
nucleotides	O
.	O

Because	O
His-321	O
is	O
conserved	O
in	O
all	O
four	O
HCN	O
channels	O
known	O
so	O
far	O
,	O
regulation	O
by	O
intracellular	O
pH	O
is	O
likely	O
to	O
constitute	O
a	O
general	O
feature	O
of	O
both	O
cardiac	O
and	O
neuronal	O
pacemaker	O
channels	O
.	O

Point	O
mutations	O
in	O
the	O
steroid-binding	O
domain	O
of	O
the	O
androgen	B-DNAMutation
receptor	I-DNAMutation
gene	O
of	O
five	O
Japanese	O
patients	O
with	O
androgen	O
insensitivity	O
syndrome	O
.	O

We	O
analyzed	O
the	O
androgen	B-DNAMutation
receptor	I-DNAMutation
(AR)	O
gene	O
in	O
five	O
Japanese	O
patients	O
diagnosed	O
with	O
androgen	O
insensitivity	O
syndrome	O
(AIS)	O
.	O

All	O
AR	O
genes	O
from	O
the	O
five	O
patients	O
had	O
single-nucleotide	O
substitutions	O
,	O
which	O
introduced	B-DNAMutation
a	I-DNAMutation
premature	I-DNAMutation
termination	I-DNAMutation
codon	I-DNAMutation
in	I-DNAMutation
three	I-DNAMutation
patients	I-DNAMutation
(	I-DNAMutation
Gln640	I-DNAMutation
,	I-DNAMutation
Arg752	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Gln640	I-DNAMutation
and	I-DNAMutation
Trp751	I-DNAMutation
)	O
,	O
and	O
a	O
single	O
amino	O
acid	O
substitution	O
in	O
two	O
patients	O
(	O
Arg831	B-DNAMutation
to	I-DNAMutation
Gln	I-DNAMutation
,	O
and	O
Leu812	B-DNAMutation
to	I-DNAMutation
Phe	I-DNAMutation
)	O
.	O

All	O
the	O
mutations	O
occurred	O
in	O
the	O
steroid-binding	O
domain	O
,	O
comprising	O
exons	O
D	O
through	O
G	O
.	O

The	O
three	O
patients	O
with	O
the	O
premature	O
termination	O
codon(s)	O
and	O
the	O
one	O
patient	O
with	O
Arg831Gln	B-DNAMutation
were	O
clinically	O
diagnosed	O
as	O
having	O
complete	O
AIS	O
,	O
while	O
the	O
patient	O
with	O
Leu812Phe	B-DNAMutation
had	O
a	O
partial	O
form	O
of	O
AIS	O
.	O

Pubic	O
skin	O
fibroblasts	O
from	O
four	O
of	O
the	O
five	O
patients	O
did	O
not	O
show	O
detectable	O
androgen	O
binding	O
.	O

These	O
data	O
on	O
mutations	O
that	O
have	O
not	O
been	O
reported	O
previously	O
,	O
provide	O
valuable	O
information	O
for	O
the	O
further	O
characterization	O
of	O
structural	O
and	O
functional	O
relationships	O
in	O
the	O
steroid-binding	O
domain	O
of	O
the	O
AR	O
protein	O
.	O

Single-nucleotide	O
polymorphism	O
haplotypes	O
in	O
the	O
both	O
proximal	O
promoter	O
and	O
exon	O
3	O
of	O
the	O
APM1	B-DNAMutation
gene	O
modulate	O
adipocyte-secreted	O
adiponectin	B-DNAMutation
hormone	O
levels	O
and	O
contribute	O
to	O
the	O
genetic	O
risk	O
for	O
type	O
2	O
diabetes	O
in	O
French	O
Caucasians	O
.	O

Adiponectin	B-DNAMutation
ACRP30	B-DNAMutation
,	O
an	O
adipocyte-secreted	O
protein	O
encoded	O
by	O
the	O
APM1	B-DNAMutation
gene	O
,	O
is	O
known	O
to	O
modulate	O
insulin	B-DNAMutation
sensitivity	O
and	O
glucose	O
homeostasis	O
,	O
those	O
effects	O
protecting	O
obese	O
mice	O
from	O
diabetes	O
.	O

Plasma	O
adiponectin	B-DNAMutation
levels	O
correlate	O
well	O
with	O
insulin	B-DNAMutation
sensitivity	O
in	O
humans	O
,	O
and	O
are	O
decreased	O
in	O
both	O
type	O
2	O
diabetes	O
(T2D)	O
and	O
obesity	O
.	O

We	O
screened	O
for	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
the	O
APM1	B-DNAMutation
gene	O
coding	O
and	O
5'	O
sequences	O
in	O
40	O
French	O
Caucasians	O
:	O
12	O
SNPs	O
and	O
4	O
rare	O
non-synonymous	O
mutations	O
of	O
exon	O
3	O
were	O
detected	O
.	O

The	O
10	O
most	O
frequent	O
SNPs	O
were	O
genotyped	O
in	O
1373	O
T2D	O
and	O
obese	O
French	O
Caucasian	O
subjects	O
and	O
in	O
all	O
subjects	O
available	O
from	O
148	O
T2D	O
multiplex	O
families	O
.	O

The	O
screening	O
for	O
rare	O
mutations	O
of	O
exon	O
3	O
was	O
extended	O
to	O
1246	O
T2D	O
and	O
obese	O
French	O
subjects	O
and	O
to	O
the	O
members	O
of	O
the	O
148	O
T2D	O
multiplex	O
families	O
.	O

A	O
haplotype	O
including	O
SNPs	B-DNAMutation
-11391	I-DNAMutation
and	O
-11377	B-DNAMutation
,	O
both	O
located	O
in	O
the	O
5'	O
sequences	O
,	O
was	O
associated	O
with	O
adiponectin	B-DNAMutation
levels	O
(P<0.0001)	O
and	O
with	O
T2D	O
(P=0.004)	O
.	O

The	O
presence	O
of	O
at	O
least	O
one	O
non-synonymous	O
mutation	O
in	O
exon	O
3	O
showed	O
evidence	O
of	O
association	O
with	O
adiponectin	B-DNAMutation
levels	O
(P=0.0009)	O
and	O
with	O
T2D	O
(P=0.005)	O
.	O

We	O
failed	O
to	O
detect	O
an	O
association	O
with	O
insulin	B-DNAMutation
resistance	O
indexes	O
.	O

Although	O
family-based	O
association	O
analysis	O
with	O
T2D	O
did	O
not	O
reach	O
significance	O
,	O
our	O
results	O
suggest	O
that	O
an	O
at-risk	O
haplotype	O
of	O
common	O
variants	O
located	O
in	O
the	O
promoter	O
and	O
rare	O
mutations	O
in	O
exon	O
3	O
contribute	O
to	O
the	O
variation	O
of	O
the	O
adipocyte-secreted	O
adiponectin	B-DNAMutation
hormone	O
level	O
,	O
and	O
may	O
be	O
part	O
of	O
the	O
genetic	O
determinants	O
for	O
T2D	O
in	O
the	O
French	O
Caucasian	O
population	O
.	O

Nucleotide	O
sequence	O
of	O
cDNA	O
encoding	O
human	O
alpha	B-DNAMutation
2-macroglobulin	I-DNAMutation
and	O
assignment	O
of	O
the	O
chromosomal	O
locus	O
.	O

Six	O
alpha	B-DNAMutation
2-macroglobulin	I-DNAMutation
(	O
alpha	O
2M	O
)	O
cDNA	O
clones	O
were	O
isolated	O
from	O
a	O
human	O
liver	O
cDNA	O
library	O
by	O
using	O
synthetic	O
oligonucleotides	O
as	O
hybridization	O
probes	O
.	O

One	O
of	O
these	O
,	O
p	O
alpha	O
2M1	O
,	O
carries	O
a	O
4.6	O
kilobase-pair	O
insert	O
,	O
which	O
was	O
sequenced	O
.	O

The	O
insert	B-DNAMutation
contains	I-DNAMutation
the	I-DNAMutation
coding	I-DNAMutation
sequences	I-DNAMutation
for	I-DNAMutation
the	I-DNAMutation
mature	I-DNAMutation
alpha	I-DNAMutation
2M	I-DNAMutation
polypeptide	I-DNAMutation
(	I-DNAMutation
1451	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
)	O
and	O
for	O
a	O
23-amino	B-DNAMutation
acid	I-DNAMutation
signal	I-DNAMutation
peptide	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
NH2	I-DNAMutation
terminus	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
precursor	I-DNAMutation
pro-alpha	I-DNAMutation
2M	I-DNAMutation
.	O

At	B-DNAMutation
the	I-DNAMutation
3'	I-DNAMutation
end	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
insert	I-DNAMutation
a	I-DNAMutation
poly(A)	I-DNAMutation
addition	I-DNAMutation
signal	I-DNAMutation
A-A-T-A-A-A	I-DNAMutation
and	I-DNAMutation
part	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
poly(A)	I-DNAMutation
tail	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
messenger	I-DNAMutation
RNA	I-DNAMutation
were	I-DNAMutation
found	I-DNAMutation
.	O

The	O
protein	O
sequence	O
deduced	O
from	O
the	O
nucleotide	O
sequence	O
agrees	O
with	O
the	O
published	O
alpha	O
2M	O
amino	O
acid	O
sequence	O
for	O
all	O
except	O
three	O
residues	O
.	O

The	O
alpha	O
2M	O
locus	O
was	O
assigned	O
to	O
human	O
chromosome	O
12	O
by	O
Southern	O
blot	O
analysis	O
with	O
DNA	O
from	O
a	O
panel	O
of	O
mouse/human	O
somatic	O
cell	O
hybrids	O
,	O
using	O
alpha	O
2M	O
cDNA	O
as	O
a	O
hybridization	O
probe	O
.	O

Genotype-phenotype	O
correlations	O
in	O
children	O
with	O
congenital	O
hyperinsulinism	O
due	O
to	O
recessive	O
mutations	O
of	O
the	O
adenosine	O
triphosphate-sensitive	O
potassium	O
channel	O
genes	O
.	O

Congenital	O
hyperinsulinism	O
(HI)	O
is	O
most	O
commonly	O
caused	O
by	O
recessive	O
mutations	O
of	O
the	O
pancreatic	O
beta-cell	O
ATP-sensitive	O
potassium	O
channel	O
(K(ATP))	O
,	O
encoded	O
by	O
two	O
genes	O
on	O
chromosome	O
11p	O
,	O
SUR1	B-DNAMutation
and	O
Kir6.2	B-DNAMutation
.	O

The	O
two	O
mutations	O
that	O
have	O
been	O
best	O
studied	O
,	O
SUR1	B-DNAMutation
g3992-9a	O
and	O
SUR1	B-DNAMutation
delF1388	B-DNAMutation
,	O
are	O
null	O
mutations	O
yielding	O
nonfunctional	O
channels	O
and	O
are	O
characterized	O
by	O
nonresponsiveness	O
to	O
diazoxide	O
,	O
a	O
channel	O
agonist	O
,	O
and	O
absence	O
of	O
acute	O
insulin	O
responses	O
(AIRs)	O
to	O
tolbutamide	O
,	O
a	O
channel	O
antagonist	O
,	O
or	O
leucine	O
.	O

To	O
examine	O
phenotypes	O
of	O
other	O
K(ATP)	O
mutations	O
,	O
we	O
measured	O
AIRs	O
to	O
calcium	O
,	O
leucine	O
,	O
glucose	O
,	O
and	O
tolbutamide	O
in	O
infants	O
with	O
recessive	O
SUR1	B-DNAMutation
or	O
Kir6.2	B-DNAMutation
mutations	O
expressed	O
as	O
diffuse	O
HI	O
(	O
n	O
=	O
8	O
)	O
or	O
focal	O
HI	O
(	O
n	O
=	O
14	O
)	O
.	O

Of	O
the	O
24	O
total	O
mutations	O
,	O
at	O
least	O
seven	O
showed	O
evidence	O
of	O
residual	O
K(ATP)	O
channel	O
function	O
.	O

This	O
included	O
positive	O
AIR	O
to	O
both	O
tolbutamide	O
and	O
leucine	O
in	O
diffuse	O
HI	O
cases	O
or	O
positive	O
AIR	O
to	O
leucine	O
in	O
focal	O
HI	O
cases	O
.	O

One	O
patient	O
with	O
partial	O
K(ATP)	O
function	O
also	O
responded	O
to	O
treatment	O
with	O
the	O
channel	O
agonist	O
,	O
diazoxide	O
.	O

Six	O
of	O
the	O
seven	O
patients	O
with	O
partial	O
defects	O
had	O
amino	O
acid	O
substitutions	O
or	O
insertions	O
;	O
whereas	O
,	O
the	O
other	O
patient	O
was	O
compound	O
heterozygous	O
for	O
two	O
premature	O
stop	O
codons	O
.	O

These	O
results	O
indicate	O
that	O
some	O
K(ATP)	O
mutations	O
can	O
yield	O
partially	O
functioning	O
channels	O
,	O
including	O
cases	O
of	O
hyperinsulinism	O
that	O
are	O
fully	O
responsive	O
to	O
diazoxide	O
therapy	O
.	O

Cdk2-dependent	B-DNAMutation
phosphorylation	O
of	O
p27	O
facilitates	O
its	O
Myc-induced	O
release	O
from	O
cyclin	O
E/cdk2	B-DNAMutation
complexes	O
.	O

Activation	O
of	O
Myc	O
triggers	O
a	O
rapid	O
induction	O
of	O
cyclin	O
E/cdk2	B-DNAMutation
kinase	O
activity	O
and	O
degradation	O
of	O
p27	O
.	O

Overt	O
degradation	O
of	O
p27	O
is	O
preceded	O
by	O
a	O
specific	O
dissociation	O
of	O
p27	O
from	O
cyclin	O
E/cdk2	B-DNAMutation
,	O
but	O
not	O
from	O
cyclin	O
D/cdk4	B-DNAMutation
complexes	O
.	O

We	O
now	O
show	O
that	O
cyclin	O
E/cdk2	B-DNAMutation
phosphorylates	O
p27	O
at	O
a	O
carboxy-terminal	O
threonine	O
residue	O
T187	B-DNAMutation
in	I-DNAMutation
vitro	I-DNAMutation
;	I-DNAMutation
mutation	I-DNAMutation
of	I-DNAMutation
this	I-DNAMutation
residue	I-DNAMutation
to	I-DNAMutation
valine	I-DNAMutation
stabilises	O
cyclin	O
E/cdk2	B-DNAMutation
complexes	O
.	O

This	O
reaction	O
is	O
not	O
significantly	O
inhibited	O
by	O
high	O
concentrations	O
of	O
p27	O
,	O
suggesting	O
that	O
cdk2	B-DNAMutation
bound	O
to	O
p27	O
is	O
catalytically	O
active	O
.	O

In	O
vivo	O
,	O
p27	O
bound	O
to	O
cyclins	O
E	O
and	O
A	O
,	O
but	O
not	O
to	O
D-type	O
cyclins	O
is	O
phosphorylated	O
.	O

Myc-induced	O
release	O
of	O
p27	O
from	O
cdk2	B-DNAMutation
requires	O
cdk2	B-DNAMutation
kinase	O
activity	O
and	O
is	O
delayed	O
in	O
a	O
T187V	B-DNAMutation
mutant	O
of	O
p27	O
.	O

After	O
induction	O
of	O
Myc	O
,	O
p27	O
phosphorylated	O
at	O
threonine	O
187	O
transiently	O
accumulates	O
in	O
a	O
non	O
cdk2	B-DNAMutation
bound	O
form	O
.	O

Our	O
data	O
suggest	O
a	O
mechanism	O
in	O
which	O
p27	O
is	O
released	O
from	O
cyclin	O
E/cdk2	B-DNAMutation
upon	O
phosphorylation	O
;	O
in	O
Myc-transformed	O
cells	O
,	O
release	O
is	O
efficient	O
as	O
phosphorylated	O
p27	O
is	O
transiently	O
bound	O
in	O
a	O
non-cdk2	B-DNAMutation
containing	O
complex	O
and	O
subsequently	O
degraded	O
.	O

A	O
new	O
point	O
mutation	O
in	O
the	O
beta-hexosaminidase	B-DNAMutation
alpha	I-DNAMutation
subunit	I-DNAMutation
gene	O
responsible	O
for	O
infantile	O
Tay-Sachs	O
disease	O
in	O
a	O
non-Jewish	O
Caucasian	O
patient	O
(	O
a	O
Kpn	O
mutant	O
)	O
.	O

The	O
abnormality	O
in	O
the	O
gene	O
coding	O
for	O
the	O
beta-hexosaminidase	B-DNAMutation
alpha	I-DNAMutation
subunit	I-DNAMutation
was	O
analyzed	O
in	O
a	O
non-Jewish	O
patient	O
with	O
clinically	O
typical	O
infantile	O
Tay-Sachs	O
disease	O
.	O

The	O
family	O
was	O
Catholic	O
,	O
and	O
the	O
father	O
and	O
the	O
mother	O
were	O
of	O
Irish	O
and	O
German	O
descent	O
,	O
respectively	O
.	O

A	O
hitherto	O
undescribed	O
single	B-DNAMutation
nucleotide	I-DNAMutation
transversion	I-DNAMutation
was	I-DNAMutation
found	I-DNAMutation
within	I-DNAMutation
exon	I-DNAMutation
11	I-DNAMutation
(	O
G1260----C	B-DNAMutation
;	O
Trp420----Cys	B-DNAMutation
)	O
.	O

The	O
coding	O
sequence	O
was	O
otherwise	O
entirely	O
normal	O
.	O

Expression	O
in	O
the	O
COS	O
I	O
cell	O
system	O
confirmed	O
that	O
the	O
mutant	O
gene	O
does	O
not	O
produce	O
functional	O
enzyme	O
protein	O
.	O

The	O
mutation	O
can	O
be	O
identified	O
rapidly	O
and	O
reliably	O
because	O
it	O
abolishes	O
one	O
of	O
the	O
two	O
KpnI	O
sites	O
in	O
the	O
coding	O
sequence	O
.	O

The	O
patient	O
was	O
a	O
compound	O
heterozygote	O
with	O
one	O
allele	O
carrying	O
this	O
mutation	O
.	O

The	O
nature	O
of	O
the	O
abnormality	O
in	O
the	O
other	O
allele	O
remains	O
unidentified	O
.	O

Examination	O
of	O
genomic	O
DNA	O
from	O
the	O
parents	O
demonstrated	O
that	O
this	O
"Kpn	O
mutation"	O
was	O
inherited	O
from	O
the	O
maternal	O
side	O
of	O
the	O
family	O
.	O

Site-directed	O
mutagenesis	O
of	O
alpha	O
2A-adrenergic	O
receptors	O
:	O
identification	O
of	O
amino	O
acids	O
involved	O
in	O
ligand	O
binding	O
and	O
receptor	O
activation	O
by	O
agonists	O
.	O

Molecular	O
cloning	O
of	O
the	O
alpha	O
2A-adrenergic	O
receptor	O
has	O
shown	O
that	O
this	O
receptor	O
is	O
a	O
member	O
of	O
the	O
gene	O
superfamily	O
of	O
guanine	O
nucleotide-binding	O
protein	O
(	O
G	O
protein)-coupled	O
receptors	O
.	O

The	O
alpha	O
2A-adrenergic	O
receptor	O
expressed	O
in	O
Chinese	O
hamster	O
ovary	O
(CHO)	O
cells	O
attenuates	O
and	O
potentiates	O
forskolin-stimulated	O
cAMP	O
production	O
through	O
independent	O
signaling	O
pathways	O
.	O

To	O
examine	O
the	O
role	O
of	O
three	O
conserved	O
aspartic	O
acid	O
and	O
two	O
conserved	O
serine	O
residues	O
in	O
alpha	O
2A-adrenergic	O
receptor	O
function	O
,	O
we	O
substituted	B-DNAMutation
asparagine	I-DNAMutation
for	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
or	O
alanine	B-DNAMutation
for	I-DNAMutation
serine	I-DNAMutation
and	O
characterized	O
the	O
mutant	O
receptors	O
in	O
stably	O
transfected	O
CHO	O
cells	O
.	O

Asn113	B-DNAMutation
mutant	I-DNAMutation
alpha	O
2-adrenergic	O
receptors	O
display	O
no	O
[3H]	O
yohimbine	O
specific	O
binding	O
,	O
at	O
concentrations	O
up	O
to	O
1000	O
nM	O
.	O

In	O
transfected	O
cells	O
expressing	O
the	O
Asn113	B-DNAMutation
mutant	I-DNAMutation
receptor	O
,	O
agonists	O
,	O
at	O
concentrations	O
up	O
to	O
0.1	O
mM	O
,	O
produce	O
small	O
decreases	O
(	O
approximately	O
10%	O
of	O
wild-type	O
values	O
)	O
in	O
forskolin-stimulated	O
cAMP	O
and	O
potentiate	O
forskolin-stimulated	O
cAMP	O
concentrations	O
in	O
a	O
dose-dependent	O
manner	O
,	O
with	O
EC50	O
values	O
approximately	O
500-fold	O
higher	O
than	O
those	O
for	O
the	O
wild-type	O
receptor	O
.	O

These	O
findings	O
suggest	O
that	O
Asp113	O
may	O
be	O
involved	O
in	O
high	O
affinity	O
binding	O
of	O
agonists	O
and	O
antagonists	O
,	O
as	O
has	O
been	O
previously	O
reported	O
for	O
beta	O
2-adrenergic	O
and	O
m1	O
muscarinic	O
acetylcholine	O
receptors	O
.	O

Asn79	B-DNAMutation
mutant	I-DNAMutation
alpha	O
2-adrenergic	O
receptors	O
display	O
high	O
affinity	O
agonist	O
binding	O
that	O
is	O
insensitive	O
to	O
guanine	O
nucleotides	O
,	O
suggesting	O
an	O
altered	O
receptor-G	O
protein	O
coupling	O
.	O

Furthermore	O
,	O
agonist	O
binding	O
to	O
Asn79	B-DNAMutation
mutant	I-DNAMutation
receptors	O
elicits	O
no	O
change	O
in	O
forskolin-stimulated	O
cAMP	O
concentrations	O
,	O
similar	O
to	O
earlier	O
findings	O
that	O
the	O
corresponding	O
residue	O
in	O
beta	O
2-adrenergic	O
and	O
muscarinic	O
receptors	O
is	O
required	O
for	O
effector	O
stimulation	O
.	O

Asp130	B-DNAMutation
appears	I-DNAMutation
to	I-DNAMutation
influence	I-DNAMutation
receptor-G	I-DNAMutation
protein	I-DNAMutation
coupling	I-DNAMutation
.	I-DNAMutation
Mutation	I-DNAMutation
of	I-DNAMutation
this	I-DNAMutation
residue	I-DNAMutation
eliminates	O
high	O
affinity	O
,	O
guanine	O
nucleotide-sensitive	O
,	O
agonist	O
binding	O
and	O
produces	O
a	O
rightward	O
shift	O
in	O
the	O
dose-response	O
curves	O
for	O
agonist-mediated	O
inhibition	O
of	O
forskolin-stimulated	O
cAMP	O
production	O
,	O
compared	O
with	O
the	O
wild-type	O
receptor	O
.	O

Moreover	O
,	O
agonist	O
potentiation	O
of	O
forskolin-stimulated	O
cAMP	O
levels	O
is	O
abolished	O
if	O
Asp130	B-DNAMutation
is	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
Asn	I-DNAMutation
,	O
supporting	O
the	O
hypothesis	O
that	O
inhibition	O
and	O
potentiation	O
of	O
forskolin-stimulated	O
cAMP	O
production	O
in	O
CHO	O
cells	O
proceed	O
through	O
distinct	O
signaling	O
pathways	O
.	O

Characterization	O
of	O
Ala204	B-DNAMutation
mutant	I-DNAMutation
alpha	O
2A-adrenergic	O
receptors	O
suggests	O
a	O
possible	O
role	O
for	O
Ser204	O
in	O
hydrogen	O
bond	O
interactions	O
with	O
the	O
para-hydroxyl	O
group	O
of	O
the	O
phenyl	O
ring	O
of	O
the	O
catecholamines	O
,	O
as	O
has	O
been	O
previously	O
described	O
for	O
the	O
corresponding	O
serine	O
in	O
beta	O
2-adrenergic	O
receptors.(ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
NCU-G1	B-DNAMutation
is	O
a	O
highly	O
glycosylated	O
integral	O
membrane	O
protein	O
of	O
the	O
lysosome	O
.	O

Until	O
recently	O
,	O
a	O
modest	O
number	O
of	O
approx	O
.	O

40	O
lysosomal	O
membrane	O
proteins	O
had	O
been	O
identified	O
and	O
even	O
fewer	O
were	O
characterized	O
in	O
their	O
function	O
.	O

In	O
a	O
proteomic	O
study	O
,	O
using	O
lysosomal	O
membranes	O
from	O
human	O
placenta	O
we	O
identified	O
several	O
candidate	O
lysosomal	O
membrane	O
proteins	O
and	O
proved	O
the	O
lysosomal	O
localization	O
of	O
two	O
of	O
them	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
the	O
lysosomal	O
localization	O
of	O
the	O
mouse	O
orthologue	O
of	O
the	O
human	O
C1orf85	B-DNAMutation
protein	O
,	O
which	O
has	O
been	O
termed	O
kidney-predominant	O
protein	O
NCU-G1	B-DNAMutation
(	O
GenBank	O
accession	O
number	O
:	O
AB027141	O
)	O
.	O

NCU-G1	B-DNAMutation
encodes	O
a	O
404	O
amino	O
acid	O
protein	O
with	O
a	O
calculated	O
molecular	O
mass	O
of	O
39	O
kDa	O
.	O

The	O
bioinformatics	O
analysis	O
of	O
its	O
amino	O
acid	O
sequence	O
suggests	O
it	O
is	O
a	O
type	O
I	O
transmembrane	O
protein	O
containing	O
a	O
single	O
tyrosine-based	O
consensus	O
lysosomal	O
sorting	O
motif	O
at	O
position	O
400	O
within	O
the	O
12-residue	O
C-terminal	O
tail	O
.	O

Its	O
lysosomal	O
localization	O
was	O
confirmed	O
using	O
immunofluorescence	O
with	O
a	O
C-terminally	O
His-tagged	O
NCU-G1	B-DNAMutation
and	O
the	O
lysosomal	O
marker	O
LAMP-1	B-DNAMutation
(	O
lysosome-associated	B-DNAMutation
membrane	I-DNAMutation
protein-1	I-DNAMutation
)	O
as	O
a	O
reference	O
,	O
and	O
by	O
subcellular	O
fractionation	O
of	O
mouse	O
liver	O
after	O
a	O
tyloxapol-induced	O
density	O
shift	O
of	O
the	O
lysosomal	O
fraction	O
using	O
an	O
anti-NCU-G1	B-DNAMutation
antiserum	O
.	O

In	O
transiently	O
transfected	O
HT1080	O
and	O
HeLa	O
cells	O
,	O
the	O
His-tagged	O
NCU-G1	B-DNAMutation
was	O
detected	O
in	O
two	O
molecular	O
forms	O
with	O
apparent	O
protein	O
sizes	O
of	O
70	O
and	O
80	O
kDa	O
,	O
and	O
in	O
mouse	O
liver	O
the	O
endogenous	O
wild-type	O
NCU-G1	B-DNAMutation
was	O
detected	O
as	O
a	O
75	O
kDa	O
protein	O
.	O

The	O
remarkable	O
difference	O
between	O
the	O
apparent	O
and	O
the	O
calculated	O
molecular	O
masses	O
of	O
NCU-G1	B-DNAMutation
was	O
shown	O
,	O
by	O
digesting	O
the	O
protein	O
with	O
N-glycosidase	O
F	O
,	O
to	O
be	O
due	O
to	O
an	O
extensive	O
glycosylation	O
.	O

The	O
lysosomal	O
localization	O
was	O
impaired	O
by	O
mutational	O
replacement	B-DNAMutation
of	I-DNAMutation
an	I-DNAMutation
alanine	I-DNAMutation
residue	I-DNAMutation
for	I-DNAMutation
the	I-DNAMutation
tyrosine	I-DNAMutation
residue	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
putative	I-DNAMutation
sorting	I-DNAMutation
motif	I-DNAMutation
.	O

Mitochondrial	O
ADCK3	B-DNAMutation
employs	O
an	O
atypical	O
protein	O
kinase-like	O
fold	O
to	O
enable	O
coenzyme	O
Q	O
biosynthesis	O
.	O

The	O
ancient	O
UbiB	O
protein	O
kinase-like	O
family	O
is	O
involved	O
in	O
isoprenoid	O
lipid	O
biosynthesis	O
and	O
is	O
implicated	O
in	O
human	O
diseases	O
,	O
but	O
demonstration	O
of	O
UbiB	O
kinase	O
activity	O
has	O
remained	O
elusive	O
for	O
unknown	O
reasons	O
.	O

Here	O
,	O
we	O
quantitatively	O
define	O
UbiB-specific	O
sequence	O
motifs	O
and	O
reveal	O
their	O
positions	O
within	O
the	O
crystal	O
structure	O
of	O
a	O
UbiB	O
protein	O
,	O
ADCK3	B-DNAMutation
.	O

We	O
find	O
that	O
multiple	O
UbiB-specific	O
features	O
are	O
poised	O
to	O
inhibit	O
protein	O
kinase	O
activity	O
,	O
including	O
an	O
N-terminal	O
domain	O
that	O
occupies	O
the	O
typical	O
substrate	O
binding	O
pocket	O
and	O
a	O
unique	O
A-rich	O
loop	O
that	O
limits	O
ATP	O
binding	O
by	O
establishing	O
an	O
unusual	O
selectivity	O
for	O
ADP	O
.	O

A	O
single	B-DNAMutation
alanine-to-glycine	I-DNAMutation
mutation	I-DNAMutation
of	I-DNAMutation
this	I-DNAMutation
loop	I-DNAMutation
flips	O
this	O
coenzyme	O
selectivity	O
and	O
enables	O
autophosphorylation	O
but	O
inhibits	O
coenzyme	O
Q	O
biosynthesis	O
in	O
vivo	O
,	O
demonstrating	O
functional	O
relevance	O
for	O
this	O
unique	O
feature	O
.	O

Our	O
work	O
provides	O
mechanistic	O
insight	O
into	O
UbiB	O
enzyme	O
activity	O
and	O
establishes	O
a	O
molecular	O
foundation	O
for	O
further	O
investigation	O
of	O
how	O
UbiB	O
family	O
proteins	O
affect	O
diseases	O
and	O
diverse	O
biological	O
pathways	O
.	O

Clinical	O
and	O
molecular	O
characterization	O
of	O
a	O
dominant	O
form	O
of	O
congenital	O
hyperinsulinism	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
high-affinity	O
sulfonylurea	O
receptor	O
.	O

Recessive	O
mutations	O
of	O
sulfonylurea	B-DNAMutation
receptor	I-DNAMutation
1	I-DNAMutation
SUR1	B-DNAMutation
and	O
potassium	O
inward	O
rectifier	O
6.2	O
Kir6.2	B-DNAMutation
,	O
the	O
two	O
adjacent	O
genes	O
on	O
chromosome	O
11p	O
that	O
comprise	O
the	O
beta-cell	O
plasma	O
membrane	O
ATP-sensitive	O
K(+)	O
(K(ATP))	O
channels	O
,	O
are	O
responsible	O
for	O
the	O
most	O
common	O
form	O
of	O
congenital	O
hyperinsulinism	O
in	O
children	O
.	O

The	O
present	O
study	O
was	O
undertaken	O
to	O
identify	O
the	O
genetic	O
defect	O
in	O
a	O
family	O
with	O
dominantly	O
inherited	O
hyperinsulinism	O
affecting	O
five	O
individuals	O
in	O
three	O
generations	O
.	O

Clinical	O
tests	O
were	O
carried	O
out	O
in	O
three	O
of	O
the	O
patients	O
using	O
acute	O
insulin	O
responses	O
(AIRs)	O
to	O
intravenous	O
stimuli	O
to	O
localize	O
the	O
site	O
of	O
defect	O
in	O
insulin	B-DNAMutation
regulation	O
.	O

The	O
affected	O
individuals	O
showed	O
abnormal	O
positive	O
calcium	O
AIR	O
,	O
normal	O
negative	O
leucine	O
AIR	O
,	O
subnormal	O
positive	O
glucose	O
AIR	O
,	O
and	O
impaired	O
tolbutamide	O
AIR	O
.	O

This	O
AIR	O
pattern	O
suggested	O
a	O
K(ATP)	O
channel	O
defect	O
because	O
it	O
resembled	O
that	O
seen	O
in	O
children	O
with	O
recessive	O
hyperinsulinism	O
due	O
to	O
two	O
common	O
SUR1	B-DNAMutation
mutations	O
,	O
g3992-9a	B-DNAMutation
and	O
delPhe1388	B-DNAMutation
.	O

Genetic	O
linkage	O
to	O
the	O
K(ATP)	O
locus	O
was	O
established	O
using	O
intragenic	O
polymorphisms	O
.	O

Mutation	O
analysis	O
identified	O
a	O
novel	O
trinucleotide	B-DNAMutation
deletion	I-DNAMutation
in	I-DNAMutation
SUR1	I-DNAMutation
exon	I-DNAMutation
34	I-DNAMutation
that	I-DNAMutation
results	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
loss	I-DNAMutation
of	I-DNAMutation
serine	I-DNAMutation
1387	I-DNAMutation
.	O

Studies	O
of	O
delSer1387	B-DNAMutation
in	O
COSm6	O
cells	O
confirmed	O
that	O
the	O
expressed	O
mutant	O
protein	O
assembles	O
with	O
Kir6.2	B-DNAMutation
and	O
trafficks	O
to	O
the	O
plasma	O
membrane	O
,	O
but	O
it	O
had	O
no	O
(86)Rb	O
efflux	O
ion	O
transport	O
activity	O
.	O

These	O
results	O
indicate	O
that	O
hyperinsulinism	O
in	O
this	O
family	O
is	O
caused	O
by	O
a	O
SUR1	B-DNAMutation
mutation	O
that	O
is	O
expressed	O
dominantly	O
rather	O
than	O
recessively	O
.	O

Morphologic	O
and	O
molecular	O
characterization	O
of	O
two	O
novel	O
Krt71	B-DNAMutation
Krt2-6g	B-DNAMutation
mutations	O
:	O
Krt71rco12	O
and	O
Krt71rco13	O
.	O

We	O
have	O
analyzed	O
two	O
novel	O
mouse	O
mutant	O
strains	O
,	O
Rco12	O
and	O
Rco13	O
,	O
displaying	O
a	O
wavy	O
pelage	O
and	O
curly	O
vibrissae	O
that	O
have	O
been	O
identified	O
in	O
an	O
ENU	O
screen	O
for	O
dominant	O
mutations	O
affecting	O
the	O
pelage	O
.	O

The	O
mutations	O
were	O
mapped	O
to	O
mouse	O
Chromosome	O
15	O
and	O
identified	O
as	O
missense	O
point	O
mutations	O
in	O
the	O
first	O
exon	O
of	O
the	O
Krt71	B-DNAMutation
(	O
formerly	O
called	O
Krt2-6g	B-DNAMutation
)	O
gene	O
causing	O
alterations	B-DNAMutation
of	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
residue	I-DNAMutation
143	I-DNAMutation
from	I-DNAMutation
alanine	I-DNAMutation
to	I-DNAMutation
glycine	I-DNAMutation
(Rco12)	O
and	O
residue	B-DNAMutation
146	I-DNAMutation
from	I-DNAMutation
isoleucine	I-DNAMutation
to	I-DNAMutation
phenylalanine	I-DNAMutation
.	O

The	O
morphologic	O
analyses	O
demonstrated	O
that	O
both	O
mutations	O
cause	O
identical	O
phenotypes	O
leading	O
to	O
the	O
formation	O
of	O
filamentous	O
aggregates	O
in	O
Henle's	O
and	O
Huxley's	O
layers	O
of	O
the	O
inner	O
root	O
sheath	O
(IRS)	O
of	O
the	O
hair	O
follicle	O
that	O
leads	O
to	O
the	O
bending	O
of	O
the	O
hair	O
shaft	O
.	O

Both	O
novel	O
mutations	O
are	O
located	O
in	O
the	O
immediate	O
vicinity	O
of	O
previously	O
identified	O
mutations	O
in	O
murine	O
Krt71	B-DNAMutation
that	O
cause	O
similar	O
phenotypes	O
and	O
alter	O
the	O
helix	O
initiation	O
motif	O
of	O
the	O
keratin	O
.	O

The	O
characterization	O
of	O
these	O
mutants	O
demonstrates	O
the	O
importance	O
of	O
this	O
Krt71	O
domain	O
for	O
the	O
formation	O
of	O
linear	O
IRS	O
intermediate	O
filaments	O
.	O

Canavan	O
disease	O
:	O
mutations	O
among	O
Jewish	O
and	O
non-Jewish	O
patients	O
.	O

Canavan	O
disease	O
is	O
an	O
autosomal	O
recessive	O
leukodystrophy	O
caused	O
by	O
the	O
deficiency	O
of	O
aspartoacylase	B-DNAMutation
ASPA	B-DNAMutation
.	O

Sixty-four	O
probands	O
were	O
analyzed	O
for	O
mutations	O
in	O
the	O
ASPA	B-DNAMutation
gene	O
.	O

Three	O
point	O
mutations--693C-->A	B-DNAMutation
,	O
854A-->C	B-DNAMutation
,	O
and	O
914C-->A--were	B-DNAMutation
identified	O
in	O
the	O
coding	O
sequence	O
.	O

The	O
693C-->A	B-DNAMutation
and	O
914C-->A	B-DNAMutation
base	O
changes	O
,	O
resulting	O
in	O
nonsense	B-DNAMutation
tyr231-->ter	I-DNAMutation
and	O
missense	B-DNAMutation
ala305-->glu	I-DNAMutation
mutations	O
,	O
respectively	O
,	O
lead	O
to	O
complete	O
loss	O
of	O
ASPA	B-DNAMutation
activity	O
in	O
in	O
vitro	O
expression	O
studies	O
.	O

The	O
854A-->C	B-DNAMutation
transversion	I-DNAMutation
converted	I-DNAMutation
glu	I-DNAMutation
to	I-DNAMutation
ala	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
285	I-DNAMutation
.	O

The	O
glu285-->ala	B-DNAMutation
mutant	O
ASPA	B-DNAMutation
has	O
2.5%	O
of	O
the	O
activity	O
expressed	O
by	O
the	O
wild-type	O
enzyme	O
.	O

A	O
fourth	O
mutation	O
,	O
433	B-DNAMutation
--2(A-->G)	I-DNAMutation
transition	I-DNAMutation
,	O
was	O
identified	O
at	O
the	O
splice-acceptor	O
site	O
in	O
intron	O
2	O
.	O

The	O
splice-site	O
mutation	O
would	O
lead	O
to	O
skipping	O
of	O
exon	O
3	O
,	O
accompanied	O
by	O
a	O
frameshift	O
,	O
and	O
thus	O
would	O
produce	O
aberrant	O
ASPA	B-DNAMutation
.	O

Of	O
the	O
128	O
unrelated	O
Canavan	O
chromosomes	O
analyzed	O
,	O
88	O
were	O
from	O
probands	O
of	O
Ashkenazi	O
Jewish	O
descent	O
.	O

The	O
glu285-->ala	B-DNAMutation
mutation	O
was	O
predominant	O
(82.9%)	O
in	O
this	O
population	O
,	O
followed	O
by	O
the	O
tyr231-->ter	B-DNAMutation
(14.8%)	O
and	O
433	B-DNAMutation
--2(A-->G)	I-DNAMutation
(1.1%)	O
mutations	O
.	O

The	O
three	O
mutations	O
account	O
for	O
98.8%	O
of	O
the	O
Canavan	O
chromosomes	O
of	O
Ashkenazi	O
Jewish	O
origin	O
.	O

The	O
ala305-->glu	B-DNAMutation
mutation	O
was	O
found	O
exclusively	O
in	O
non-Jewish	O
probands	O
of	O
European	O
descent	O
and	O
constituted	O
60%	O
of	O
the	O
40	O
mutant	O
chromosomes	O
.	O

Predominant	O
occurrence	O
of	O
certain	O
mutations	O
among	O
Ashkenazi	O
Jewish	O
and	O
non-Jewish	O
patients	O
with	O
Canavan	O
disease	O
would	O
suggest	O
a	O
founding-father	O
effect	O
in	O
propagation	O
of	O
these	O
mutant	O
chromosomes	O
.	O

Increased	O
shedding	O
of	O
angiotensin-converting	O
enzyme	O
by	O
a	O
mutation	O
identified	O
in	O
the	O
stalk	O
region	O
.	O

Angiotensin-converting	O
enzyme	O
ACE	B-DNAMutation
,	O
an	O
enzyme	O
that	O
plays	O
a	O
major	O
role	O
in	O
vasoactive	O
peptide	O
metabolism	O
,	O
is	O
a	O
type	O
1	O
ectoprotein	O
,	O
which	O
is	O
released	O
from	O
the	O
plasma	O
membrane	O
by	O
a	O
proteolytic	O
cleavage	O
occurring	O
in	O
the	O
stalk	O
sequence	O
adjacent	O
to	O
the	O
membrane	O
anchor	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
discovered	O
the	O
molecular	O
mechanism	O
underlying	O
the	O
marked	O
increase	O
of	O
plasma	O
ACE	B-DNAMutation
levels	O
observed	O
in	O
three	O
unrelated	O
individuals	O
.	O

We	O
have	O
identified	O
a	O
Pro(1199)	B-DNAMutation
-->	I-DNAMutation
Leu	I-DNAMutation
mutation	O
in	O
the	O
juxtamembrane	O
stalk	O
region	O
.	O

In	O
vitro	O
analysis	O
revealed	O
that	O
the	O
shedding	O
of	O
[Leu(1199)]ACE	B-DNAMutation
was	O
enhanced	O
compared	O
with	O
wild-type	O
ACE	B-DNAMutation
.	O

The	O
solubilization	O
process	O
of	O
[Leu(1199)]ACE	B-DNAMutation
was	O
stimulated	O
by	O
phorbol	O
esters	O
and	O
inhibited	O
by	O
compound	O
3	O
,	O
an	O
inhibitor	O
of	O
ACE-secretase	B-DNAMutation
.	O

The	O
results	O
of	O
Western	O
blot	O
analysis	O
were	O
consistent	O
with	O
a	O
cleavage	O
at	O
the	O
major	O
described	O
site	O
(Arg(1203)/Ser(1204))	O
.	O

Two-dimensional	O
structural	O
analysis	O
of	O
ACE	B-DNAMutation
showed	O
that	O
the	O
mutated	O
residue	O
was	O
critical	O
for	O
the	O
positioning	O
of	O
a	O
specific	O
loop	O
containing	O
the	O
cleavage	O
site	O
.	O

We	O
therefore	O
propose	O
that	O
a	O
local	O
conformational	O
modification	O
caused	O
by	O
the	O
Pro(1199)	B-DNAMutation
-->	I-DNAMutation
Leu	I-DNAMutation
mutation	O
leads	O
to	O
more	O
accessibility	O
at	O
the	O
stalk	O
region	O
for	O
ACE	B-DNAMutation
secretase	O
and	O
is	O
responsible	O
for	O
the	O
enhancement	O
of	O
the	O
cleavage-secretion	O
process	O
.	O

Our	O
results	O
show	O
that	O
different	O
molecular	O
mechanisms	O
are	O
responsible	O
for	O
the	O
common	O
genetic	O
variation	O
of	O
plasma	O
ACE	B-DNAMutation
and	O
for	O
its	O
more	O
rare	O
familial	O
elevation	O
.	O

Methionine	O
residue	O
35	O
is	O
important	O
in	O
amyloid	O
beta-peptide-associated	O
free	O
radical	O
oxidative	O
stress	O
.	O

Amyloid	O
beta-peptide	O
(Abeta)	O
,	O
the	O
central	O
constituent	O
of	O
senile	O
plaques	O
in	O
Alzheimer's	O
disease	O
(AD)	O
brain	O
,	O
has	O
been	O
shown	O
to	O
be	O
a	O
source	O
of	O
free	O
radical	O
oxidative	O
stress	O
that	O
may	O
lead	O
to	O
neurodegeneration	O
.	O

In	O
the	O
current	O
study	O
Abeta(1-40)	O
,	O
found	O
in	O
AD	O
brain	O
,	O
and	O
the	O
amyloid	O
fragment	O
Abeta(25-35)	O
were	O
used	O
in	O
conjunction	O
with	O
electron	O
paramagnetic	O
resonance	O
spin	B-DNAMutation
trapping	O
techniques	O
to	O
demonstrate	O
that	O
these	O
peptides	O
mediate	O
free	O
radical	O
production	O
.	O

The	O
methionine	O
residue	O
in	O
these	O
peptides	O
is	O
believed	O
to	O
play	O
an	O
important	O
role	O
in	O
their	O
neurotoxicity	O
.	O

Substitution	B-DNAMutation
of	I-DNAMutation
methionine	I-DNAMutation
by	I-DNAMutation
structurally	I-DNAMutation
similar	I-DNAMutation
norleucine	I-DNAMutation
in	O
both	O
Abeta(1-40)	O
and	O
Abeta(25-35)	O
,	O
and	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
methionine	I-DNAMutation
by	I-DNAMutation
valine	I-DNAMutation
,	O
or	O
the	O
removal	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
methionine	I-DNAMutation
in	O
Abeta(25-35)	O
,	O
abrogates	O
free	O
radical	O
production	O
and	O
protein	O
oxidation	O
of	O
and	O
toxicity	O
to	O
hippocampal	O
neurons	O
.	O

These	O
results	O
are	O
discussed	O
with	O
relevance	O
to	O
the	O
hypothesis	O
that	O
neurodegeneration	O
in	O
Alzheimer's	O
disease	O
may	O
be	O
due	O
in	O
part	O
to	O
Abeta-associated	O
free	O
radical	O
oxidative	O
stress	O
that	O
involves	O
methionine	O
,	O
and	O
to	O
the	O
use	O
of	O
spin	B-DNAMutation
trapping	O
methods	O
to	O
infer	O
mechanistic	O
information	O
about	O
Abeta	O
.	O

Regulation	O
of	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
by	O
a	O
pseudosubstrate	O
sequence	O
on	O
the	O
gamma	O
subunit	O
.	O

The	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
AMPK	B-DNAMutation
system	O
monitors	O
cellular	O
energy	O
status	O
by	O
sensing	O
AMP	O
and	O
ATP	O
,	O
and	O
is	O
a	O
key	O
regulator	O
of	O
energy	O
balance	O
at	O
the	O
cellular	O
and	O
whole-body	O
levels	O
.	O

AMPK	B-DNAMutation
exists	O
as	O
heterotrimeric	O
alphabetagamma	O
complexes	O
,	O
and	O
the	O
gamma	O
subunits	O
contain	O
two	O
tandem	O
domains	O
that	O
bind	O
the	O
regulatory	O
nucleotides	O
.	O

There	O
is	O
a	O
sequence	O
in	O
the	O
first	O
of	O
these	O
domains	O
that	O
is	O
conserved	O
in	O
gamma	O
subunit	O
homologues	O
in	O
all	O
eukaryotes	O
,	O
and	O
which	O
resembles	O
the	O
sequence	O
around	O
sites	O
phosphorylated	O
on	O
target	O
proteins	O
of	O
AMPK	B-DNAMutation
,	O
except	O
that	O
it	O
has	O
a	O
non-phosphorylatable	B-DNAMutation
residue	I-DNAMutation
in	I-DNAMutation
place	I-DNAMutation
of	I-DNAMutation
serine	I-DNAMutation
.	O

We	O
propose	O
that	O
in	O
the	O
absence	O
of	O
AMP	O
this	O
pseudosubstrate	O
sequence	O
binds	O
to	O
the	O
active	O
site	O
groove	O
on	O
the	O
alpha	O
subunit	O
,	O
preventing	O
phosphorylation	O
by	O
the	O
upstream	O
kinase	O
,	O
LKB1	B-DNAMutation
,	O
and	O
access	O
to	O
downstream	O
targets	O
.	O

Binding	O
of	O
AMP	O
causes	O
a	O
conformational	O
change	O
that	O
prevents	O
this	O
interaction	O
and	O
relieves	O
the	O
inhibition	O
.	O

We	O
present	O
several	O
lines	O
of	O
evidence	O
supporting	O
this	O
hypothesis	O
.	O

A	O
27	O
base-pair	O
deletion	O
of	O
the	O
anti-mÃ¼llerian	O
type	O
II	O
receptor	O
gene	O
is	O
the	O
most	O
common	O
cause	O
of	O
the	O
persistent	O
mÃ¼llerian	O
duct	O
syndrome	O
.	O

The	O
persistent	O
mÃ¼llerian	O
duct	O
syndrome	O
,	O
characterized	O
by	O
the	O
lack	O
of	O
regression	O
of	O
mÃ¼llerian	O
derivatives	O
,	O
uterus	O
and	O
tubes	O
in	O
otherwise	O
normally	O
masculinized	O
males	O
,	O
is	O
a	O
genetically	O
transmitted	O
disorder	O
implicating	O
either	O
anti-mÃ¼llerian	O
hormone	O
(AMH)	O
,	O
a	O
member	O
of	O
the	O
transforming	O
growth	O
factor-beta	O
superfamily	O
,	O
or	O
its	O
type	O
II	O
receptor	O
,	O
a	O
serine/threonine	O
kinase	O
homologous	O
to	O
the	O
receptors	O
of	O
other	O
members	O
of	O
the	O
transforming	O
growth	O
factor-beta	O
superfamily	O
.	O

We	O
have	O
now	O
performed	O
molecular	O
studies	O
in	O
a	O
total	O
of	O
38	O
families	O
.	O

The	O
basis	O
of	O
the	O
condition	O
,	O
namely	O
16	O
AMH	O
and	O
16	O
AMH	O
receptor	O
mutations	O
,	O
was	O
identified	O
in	O
32	O
families	O
.	O

The	O
type	O
of	O
genetic	O
defect	O
could	O
be	O
predicted	O
from	O
the	O
level	O
of	O
serum	O
AMH	O
which	O
is	O
very	O
low	O
or	O
undetectable	O
in	O
patients	O
with	O
AMH	O
mutations	O
and	O
at	O
the	O
upper	O
limit	O
of	O
normal	O
in	O
receptor	O
mutations	O
.	O

Whereas	O
AMH	O
mutations	O
are	O
extremely	O
diverse	O
,	O
patients	O
from	O
10	O
out	O
of	O
16	O
families	O
with	O
receptor	O
mutations	O
had	B-DNAMutation
a	I-DNAMutation
27	I-DNAMutation
bp	I-DNAMutation
deletion	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
10	O
on	O
at	O
least	O
one	O
allele	O
.	O

This	O
deletion	O
is	O
thus	O
implicated	O
in	O
approximately	O
25%	O
of	O
patients	O
with	O
persistent	O
mÃ¼llerian	O
duct	O
syndrome	O
.	O

All	O
AMH	O
and	O
AMH	O
receptor	O
mutations	O
were	O
consistent	O
with	O
an	O
autosomal	O
recessive	O
mode	O
of	O
transmission	O
.	O

New	O
insight	O
into	O
the	O
molecular	O
basis	O
of	O
3beta-hydroxysteroid	O
dehydrogenase	O
deficiency	O
:	O
identification	O
of	O
eight	O
mutations	O
in	O
the	O
HSD3B2	B-DNAMutation
gene	O
eleven	O
patients	O
from	O
seven	O
new	O
families	O
and	O
comparison	O
of	O
the	O
functional	O
properties	O
of	O
twenty-five	O
mutant	O
enzymes	O
.	O

Classical	O
3beta-hydroxysteroid	O
dehydrogenase/delta5-delta4	O
isomerase	O
(3betaHSD)	O
deficiency	O
is	O
a	O
form	O
of	O
congenital	O
adrenal	O
hyperplasia	O
that	O
impairs	O
steroidogenesis	O
in	O
both	O
the	O
adrenals	O
and	O
gonads	O
resulting	O
from	O
mutations	O
in	O
the	O
HSD3B2	O
gene	O
and	O
causing	O
various	O
degrees	O
of	O
salt-wasting	O
in	O
both	O
sexes	O
and	O
incomplete	O
masculinization	O
of	O
the	O
external	O
genitalia	O
in	O
genetic	O
males	O
.	O

To	O
identify	O
the	O
molecular	O
lesion(s)	O
in	O
the	O
HSD3B2	B-DNAMutation
gene	O
in	O
the	O
11	O
patients	O
from	O
the	O
seven	O
new	O
families	O
suffering	O
from	O
classical	O
3betaHSD	O
deficiency	O
,	O
the	O
complete	O
nucleotide	O
sequence	O
of	O
the	O
whole	O
coding	O
region	O
and	O
exon-intron	O
splicing	O
boundaries	O
of	O
this	O
gene	O
was	O
determined	O
by	O
direct	O
sequencing	O
.	O

Five	O
of	O
these	O
families	O
were	O
referred	O
to	O
Morel's	O
molecular	O
diagnostics	O
laboratory	O
in	O
France	O
,	O
whereas	O
the	O
two	O
other	O
families	O
were	O
investigated	O
by	O
Peter's	O
group	O
in	O
Germany	O
.	O

Functional	O
characterization	O
studies	O
were	O
performed	O
by	O
Simard's	O
group	O
in	O
Canada	O
.	O

Following	O
transient	O
expression	O
in	O
293	O
cells	O
of	O
each	O
of	O
the	O
mutant	O
recombinant	O
proteins	O
generated	O
by	O
site-directed	O
mutagenesis	O
,	O
the	O
effect	O
of	O
the	O
25	O
mutations	O
on	O
enzyme	O
activity	O
was	O
assessed	O
by	O
incubating	O
intact	O
cells	O
in	O
culture	O
with	O
10	O
nM	O
[14C]-DHEA	O
as	O
substrate	O
.	O

The	O
stability	O
of	O
the	O
mutant	O
proteins	O
has	O
been	O
investigated	O
using	O
a	O
combination	O
of	O
Northern	O
and	O
Western	O
blot	O
analyses	O
,	O
as	O
well	O
as	O
an	O
in	O
vitro	O
transcription/translation	O
assay	O
using	O
rabbit	O
reticulocyte	O
lysates	O
.	O

The	O
present	O
report	O
describes	O
the	O
identification	O
of	O
8	O
mutations	O
,	O
in	O
seven	O
new	O
families	O
with	O
individuals	O
suffering	O
from	O
classical	O
3betaHSD	O
deficiency	O
,	O
thus	O
increasing	O
the	O
number	O
of	O
known	O
HSD3B2	O
mutations	O
involved	O
in	O
this	O
autosomal	O
recessive	O
disorder	O
to	O
31	O
(	O
1	O
splicing	O
,	O
1	O
in-frame	O
deletion	O
,	O
3	O
nonsense	O
,	O
4	O
frameshift	O
and	O
22	O
missense	O
mutations	O
)	O
.	O

In	O
addition	O
to	O
the	O
mutations	O
reported	O
here	O
in	O
these	O
new	O
families	O
,	O
we	O
have	O
also	O
investigated	O
for	O
the	O
first	O
time	O
the	O
functional	O
significance	O
of	O
previously	O
reported	O
missense	O
mutations	O
and	O
or	O
sequence	O
variants	O
namely	O
,	O
A82T	B-DNAMutation
,	O
A167V	B-DNAMutation
,	O
L173R	B-DNAMutation
,	O
L205P	B-DNAMutation
,	O
S213G	B-DNAMutation
and	O
K216E	B-DNAMutation
,	O
P222H	B-DNAMutation
,	O
T259M	B-DNAMutation
,	O
and	O
T259R	B-DNAMutation
,	O
which	O
have	O
not	O
previously	O
been	O
functionally	O
characterized	O
.	O

Furthermore	O
,	O
their	O
effects	O
have	O
been	O
compared	O
with	O
those	O
of	O
the	O
10	O
previously	O
reported	O
mutant	O
enzymes	O
to	O
provide	O
a	O
more	O
consistent	O
and	O
comprehensive	O
study	O
.	O

The	O
present	O
results	O
are	O
in	O
accordance	O
with	O
the	O
prediction	O
that	O
no	O
functional	O
3betaHSD	B-DNAMutation
type	O
2	O
isoenzyme	O
is	O
expressed	O
in	O
the	O
adrenals	O
and	O
gonads	O
of	O
the	O
patients	O
suffering	O
from	O
a	O
severe	O
salt-wasting	O
form	O
of	O
CAH	O
due	O
to	O
classical	O
3betaHSD	O
deficiency	O
.	O

Whereas	O
the	O
nonsalt-losing	O
form	O
also	O
results	O
from	O
missense	O
mutation(s)	O
in	O
the	O
HSD3B2	B-DNAMutation
gene	O
,	O
which	O
cause	O
an	O
incomplete	O
loss	O
in	O
enzyme	O
activity	O
,	O
thus	O
leaving	O
sufficient	O
enzymatic	O
activity	O
to	O
prevent	O
salt	O
wasting	O
.	O

The	O
functional	O
data	O
described	O
in	O
the	O
present	O
study	O
concerning	O
the	O
sequence	O
variants	O
A167V	B-DNAMutation
,	O
S213G	B-DNAMutation
,	O
K216E	B-DNAMutation
and	O
L236S	B-DNAMutation
,	O
which	O
were	O
detected	O
with	O
premature	O
pubarche	O
or	O
hyperandrogenic	O
adolescent	O
girls	O
suspected	O
to	O
be	O
affected	O
from	O
nonclassical	O
3betaHSD	B-DNAMutation
deficiency	O
,	O
coupled	O
with	O
the	O
previous	O
studies	O
reporting	O
that	O
no	O
mutations	O
were	O
found	O
in	O
both	O
HSD3B1	B-DNAMutation
and/or	O
HSD3B2	B-DNAMutation
genes	O
in	O
such	O
patients	O
strongly	O
support	O
the	O
conclusion	O
that	O
this	O
disorder	O
does	O
not	O
result	O
from	O
a	O
mutant	O
3betaHSD	B-DNAMutation
isoenzyme	O
.	O

The	O
present	O
study	O
provides	O
biochemical	O
evidence	O
supporting	O
the	O
involvement	O
of	O
a	O
new	O
molecular	O
mechanism	O
in	O
classical	O
3betaHSD	O
deficiency	O
involving	O
protein	O
instability	O
and	O
further	O
illustrates	O
the	O
complexity	O
of	O
the	O
genotype-phenotype	O
relationships	O
of	O
this	O
disease	O
,	O
in	O
addition	O
to	O
providing	O
further	O
valuable	O
information	O
concerning	O
the	O
structure-function	O
relationships	O
of	O
the	O
3betaHSD	O
superfamily	O
.	O

A	O
system	O
for	O
studying	O
the	O
effect(s)	O
of	O
familial	O
Alzheimer	O
disease	O
mutations	O
on	O
the	O
processing	O
of	O
the	O
beta-amyloid	O
peptide	O
precursor	O
.	O

Three	O
different	O
point	O
mutations	O
have	O
been	O
observed	O
in	O
some	O
familial	O
Alzheimer's	O
disease	O
pedigrees	O
at	O
a	O
unique	O
valine	O
,	O
Val717	O
,	O
near	O
the	O
carboxyl	O
end	O
of	O
the	O
beta	O
Amyloid	O
Peptide	O
Precursor	O
(	O
beta	O
APP	O
)	O
.	O

The	O
effects	O
of	O
these	O
mutations	O
on	O
the	O
processing	O
and	O
cellular	O
functions	O
of	O
beta	O
APP	O
can	O
best	O
be	O
determined	O
in	O
the	O
absence	O
of	O
the	O
normal	O
form(s)	O
of	O
the	O
protein	O
.	O

We	O
have	O
used	O
targeted	O
mRNA	O
degradation	O
by	O
a	O
trans-acting	O
hammerhead	O
ribozyme	O
to	O
cleave	O
and	O
inactivate	O
beta	O
APP	O
expression	O
in	O
vitro	O
.	O

The	O
consensus	O
ribozyme	O
cleavage	O
site	O
,	O
5'GUC	O
decreases	O
X3	O
,	O
matches	O
the	O
Val717	B-DNAMutation
nucleotide	I-DNAMutation
sequence	I-DNAMutation
in	O
beta	O
APP	O
mRNA	O
.	O

Introduction	O
of	O
FAD	O
point	O
mutations	O
which	O
change	O
Val717	O
decrease	O
the	O
rate	O
of	O
ribozyme	O
cleavage	O
by	O
more	O
than	O
three	O
orders	O
of	O
magnitude	O
.	O

Thus	O
,	O
ribozyme	O
targeting	O
of	O
this	O
site	O
should	O
allow	O
the	O
study	O
of	O
protein	O
processing	O
in	O
vivo	O
.	O

Furthermore	O
,	O
a	O
ribozyme	O
targeted	O
to	O
mutant	O
beta	O
APP	O
mRNA	O
Val717-->Ile	B-DNAMutation
cleaved	O
the	O
mutant	O
sequence	O
300-fold	O
faster	O
than	O
the	O
normal	O
sequence	O
.	O

This	O
suggests	O
that	O
ribozymes	O
might	O
lower	O
mutant	O
beta	O
APP	O
mRNA	O
levels	O
in	O
FAD	O
cells	O
.	O

Investigation	O
of	O
the	O
human	O
serotonin	O
receptor	O
gene	O
HTR3B	B-DNAMutation
in	O
bipolar	O
affective	O
and	O
schizophrenic	O
patients	O
.	O

The	O
neurotransmitter	O
serotonin	O
(	O
5-hydroxytryptamine	O
,	O
5-HT	O
)	O
mediates	O
a	O
multitude	O
of	O
central	O
nervous	O
functions	O
by	O
activating	O
5-HT	O
receptor	O
subtypes	O
.	O

A	O
dysfunction	O
of	O
serotonergic	O
neurotransmission	O
is	O
considered	O
to	O
play	O
a	O
major	O
role	O
in	O
the	O
pathophysiology	O
of	O
complex	O
neuropsychiatric	O
disorders	O
.	O

In	O
our	O
study	O
,	O
a	O
mutation	O
screen	O
of	O
the	O
serotonin	O
receptor	O
gene	O
HTR3B	B-DNAMutation
was	O
carried	O
out	O
to	O
explore	O
a	O
putative	O
contribution	O
to	O
the	O
etiology	O
of	O
bipolar	O
affective	O
disorder	O
(BPAD)	O
and	O
schizophrenia	O
(SZ)	O
.	O

Screening	O
of	O
49	O
patients	O
suffering	O
from	O
BPAD	O
,	O
78	O
patients	O
with	O
SZ	O
and	O
62	O
control	O
individuals	O
revealed	O
eleven	O
sequence	O
variations	O
including	O
a	O
3	B-DNAMutation
bp	I-DNAMutation
deletion	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
5'UTR	I-DNAMutation
(	O
5'	O
untranslated	O
region	O
)	O
,	O
four	O
exonic	O
and	O
five	O
intronic	O
SNPs	O
as	O
well	O
as	O
a	O
point	O
mutation	O
in	O
the	O
3'UTR	O
of	O
HTR3B	B-DNAMutation
.	O

Four	O
of	O
these	O
sequence	O
variations	O
have	O
not	O
been	O
described	O
previously	O
.	O

Statistical	O
computation	O
rated	O
most	O
variants	O
as	O
probably	O
non-disease	O
related	O
polymorphisms	O
.	O

However	O
,	O
IVS6	B-DNAMutation
+	I-DNAMutation
31C	I-DNAMutation
>	I-DNAMutation
T	I-DNAMutation
,	O
IVS6	B-DNAMutation
+	I-DNAMutation
40C	I-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
,	O
and	O
1386T	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
were	O
solely	O
detected	O
in	O
bipolar	O
affective	O
patients	O
and	O
in	O
none	O
of	O
the	O
controls	O
.	O

Interestingly	O
,	O
we	O
observed	O
a	O
significant	O
underrepresentation	O
of	O
the	O
3	B-DNAMutation
bp	I-DNAMutation
deletion	I-DNAMutation
-100_-102delAAG	I-DNAMutation
in	O
an	O
extended	O
sample	O
of	O
162	O
bipolar	O
affected	O
patients	O
compared	O
to	O
controls	O
(	O
allele-wise	O
:	O
8%	O
vs	O
.	O

15%	O
,	O
P	O
=	O
0.006	O
,	O
OR	O
=	O
0.49	O
,	O
95%	O
CI	O
:	O
0.3-0.82	O
;	O
genotype-wise	O
:	O
15,5%	O
vs	O
.	O

29,0%	O
,	O
P	O
=	O
0.005	O
,	O
OR	O
=	O
0.45	O
,	O
95%	O
CI	O
:	O
0.26-0.77	O
)	O
.	O

We	O
suggest	O
that	O
this	O
deletion	O
may	O
influence	O
translational	O
efficiency	O
,	O
thereby	O
possibly	O
affecting	O
the	O
development	O
of	O
bipolar	O
affective	O
disease	O
.	O

NEPH1	B-DNAMutation
defines	O
a	O
novel	O
family	O
of	O
podocin	O
interacting	O
proteins	O
.	O

Mutations	O
of	O
NPHS1	B-DNAMutation
or	O
NPHS2	B-DNAMutation
,	O
the	O
genes	O
encoding	O
for	O
the	O
glomerular	O
podocyte	O
proteins	O
nephrin	B-DNAMutation
and	O
podocin	B-DNAMutation
,	O
cause	O
steroid-resistant	O
proteinuria	O
.	O

In	O
addition	O
,	O
mice	O
lacking	O
NEPH1	B-DNAMutation
develop	O
a	O
nephrotic	O
syndrome	O
that	O
resembles	O
NPHS	O
mutations	O
,	O
suggesting	O
that	O
all	O
three	O
proteins	O
are	O
essential	O
for	O
the	O
integrity	O
of	O
glomerular	O
podocytes	O
.	O

Podocin	B-DNAMutation
interacts	O
with	O
the	O
C-terminal	O
domain	O
of	O
nephrin	B-DNAMutation
and	O
facilitates	O
nephrin-dependent	B-DNAMutation
signaling	O
.	O

NEPH1	B-DNAMutation
,	O
a	O
member	O
of	O
the	O
immunoglobulin	O
superfamily	O
,	O
is	O
structurally	O
related	O
to	O
nephrin	B-DNAMutation
.	O

We	O
report	O
now	O
that	O
NEPH1	B-DNAMutation
belongs	O
to	O
a	O
family	O
of	O
three	O
closely	O
related	O
proteins	O
that	O
interact	O
with	O
the	O
C-terminal	O
domain	O
of	O
podocin	B-DNAMutation
.	O

All	O
three	O
NEPH	O
proteins	O
share	O
a	O
conserved	O
podocin-binding	O
motif	O
;	O
mutation	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
centrally	I-DNAMutation
located	I-DNAMutation
tyrosine	I-DNAMutation
residue	I-DNAMutation
dramatically	O
lowers	O
the	O
affinity	O
of	O
NEPH1	B-DNAMutation
for	O
podocin	B-DNAMutation
.	O

NEPH1	B-DNAMutation
triggers	O
AP-1	O
activation	O
similarly	O
to	O
nephrin	B-DNAMutation
but	O
requires	O
the	O
presence	O
of	O
Tec	O
family	O
kinases	O
for	O
efficient	O
transactivation	O
.	O

We	O
conclude	O
that	O
NEPH1	B-DNAMutation
defines	O
a	O
new	O
family	O
of	O
podocin-binding	B-DNAMutation
molecules	O
that	O
are	O
potential	O
candidates	O
for	O
hereditary	O
nephrotic	O
syndromes	O
not	O
linked	O
to	O
either	O
NPHS1	B-DNAMutation
or	O
NPHS2	B-DNAMutation
.	O

U	O
box	O
proteins	O
as	O
a	O
new	O
family	O
of	O
ubiquitin-protein	O
ligases	O
.	O

The	O
U	O
box	O
is	O
a	O
domain	O
of	O
approximately	O
70	O
amino	O
acids	O
that	O
is	O
present	O
in	O
proteins	O
from	O
yeast	O
to	O
humans	O
.	O

The	O
prototype	O
U	O
box	O
protein	O
,	O
yeast	O
Ufd2	B-DNAMutation
,	O
was	O
identified	O
as	O
a	O
ubiquitin	O
chain	O
assembly	O
factor	O
that	O
cooperates	O
with	O
a	O
ubiquitin-activating	O
enzyme	O
(E1)	O
,	O
a	O
ubiquitin-conjugating	O
enzyme	O
(E2)	O
,	O
and	O
a	O
ubiquitin-protein	O
ligase	O
(E3)	O
to	O
catalyze	O
ubiquitin	O
chain	O
formation	O
on	O
artificial	O
substrates	O
.	O

E3	O
enzymes	O
are	O
thought	O
to	O
determine	O
the	O
substrate	O
specificity	O
of	O
ubiquitination	O
and	O
have	O
been	O
classified	O
into	O
two	O
families	O
,	O
the	O
HECT	O
and	O
RING	O
finger	O
families	O
.	O

Six	O
mammalian	O
U	O
box	O
proteins	O
have	O
now	O
been	O
shown	O
to	O
mediate	O
polyubiquitination	O
in	O
the	O
presence	O
of	O
E1	O
and	O
E2	O
and	O
in	O
the	O
absence	O
of	O
E3	O
.	O

These	O
U	O
box	O
proteins	O
exhibited	O
different	O
specificities	O
for	O
E2	O
enzymes	O
in	O
this	O
reaction	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
U	I-DNAMutation
box	I-DNAMutation
or	O
mutation	O
of	O
conserved	O
amino	O
acids	O
within	O
it	O
abolished	O
ubiquitination	O
activity	O
.	O

Some	O
U	O
box	O
proteins	O
catalyzed	O
polyubiquitination	O
by	O
targeting	O
lysine	O
residues	O
of	O
ubiquitin	O
other	O
than	O
lysine	O
48	O
,	O
which	O
is	O
utilized	O
by	O
HECT	O
and	O
RING	O
finger	O
E3	O
enzymes	O
for	O
polyubiquitination	O
that	O
serves	O
as	O
a	O
signal	O
for	O
proteolysis	O
by	O
the	O
26	O
S	O
proteasome	O
.	O

These	O
data	O
suggest	O
that	O
U	O
box	O
proteins	O
constitute	O
a	O
third	O
family	O
of	O
E3	O
enzymes	O
and	O
that	O
E4	O
activity	O
may	O
reflect	O
a	O
specialized	O
type	O
of	O
E3	O
activity	O
.	O

H2AX	B-DNAMutation
haploinsufficiency	O
modifies	O
genomic	O
stability	O
and	O
tumor	O
susceptibility	O
.	O

Histone	O
H2AX	B-DNAMutation
becomes	O
phosphorylated	O
in	O
chromatin	O
domains	O
flanking	O
sites	O
of	O
DNA	O
double-strand	O
breakage	O
associated	O
with	O
gamma-irradiation	O
,	O
meiotic	O
recombination	O
,	O
DNA	O
replication	O
,	O
and	O
antigen	O
receptor	O
rearrangements	O
.	O

Here	O
,	O
we	O
show	O
that	O
loss	O
of	O
a	O
single	O
H2AX	B-DNAMutation
allele	O
compromises	O
genomic	O
integrity	O
and	O
enhances	O
the	O
susceptibility	O
to	O
cancer	O
in	O
the	O
absence	O
of	O
p53	B-DNAMutation
.	O

In	O
comparison	O
with	O
heterozygotes	O
,	O
tumors	O
arise	O
earlier	O
in	O
the	O
H2AX	B-DNAMutation
homozygous	O
null	O
background	O
,	O
and	O
H2AX(-/-)	B-DNAMutation
p53(-/-)	I-DNAMutation
lymphomas	O
harbor	O
an	O
increased	O
frequency	O
of	O
clonal	O
nonreciprocal	O
translocations	O
and	O
amplifications	O
.	O

These	O
include	O
complex	O
rearrangements	O
that	O
juxtapose	O
the	O
c-myc	B-DNAMutation
oncogene	O
to	O
antigen	O
receptor	O
loci	O
.	O

Restoration	O
of	O
the	O
H2AX	B-DNAMutation
null	O
allele	O
with	O
wild-type	O
H2AX	B-DNAMutation
restores	O
genomic	O
stability	O
and	O
radiation	O
resistance	O
,	O
but	O
this	O
effect	O
is	O
abolished	O
by	O
substitution	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
conserved	I-DNAMutation
serine	I-DNAMutation
phosphorylation	I-DNAMutation
sites	I-DNAMutation
in	I-DNAMutation
H2AX	I-DNAMutation
with	I-DNAMutation
alanine	I-DNAMutation
or	I-DNAMutation
glutamic	I-DNAMutation
acid	I-DNAMutation
residues	I-DNAMutation
.	O

Our	O
results	O
establish	O
H2AX	B-DNAMutation
as	O
genomic	O
caretaker	O
that	O
requires	O
the	O
function	O
of	O
both	O
gene	O
alleles	O
for	O
optimal	O
protection	O
against	O
tumorigenesis	O
.	O

Polymorphisms	O
of	O
human	O
Ah	B-DNAMutation
receptor	I-DNAMutation
gene	O
are	O
not	O
involved	O
in	O
lung	O
cancer	O
.	O

The	O
Ah	B-DNAMutation
receptor	I-DNAMutation
Ahr	B-DNAMutation
is	O
a	O
ligand-dependent	O
transcription	O
factor	O
that	O
positively	O
regulates	O
inducible	O
expression	O
of	O
the	O
CYP1A1	B-DNAMutation
gene	O
.	O

Based	O
on	O
the	O
sequence	O
information	O
of	O
the	O
human	O
Ahr	B-DNAMutation
and	O
the	O
intron-exon	O
junctions	O
of	O
the	O
mouse	O
counterpart	O
,	O
an	O
analysis	O
of	O
single-strand	O
conformational	O
polymorphism	O
(SSCP)	O
was	O
carried	O
out	O
to	O
detect	O
subtle	O
base	O
differences	O
in	O
the	O
coding	O
region	O
of	O
the	O
gene	O
among	O
individuals	O
.	O

We	O
found	O
that	O
the	O
Ahr	B-DNAMutation
protein	O
has	O
at	O
least	O
two	O
forms	O
of	O
variants	O
in	O
a	O
Japanese	O
gene	O
pool	O
,	O
and	O
that	O
these	O
variants	O
can	O
be	O
ascribed	O
to	O
one	O
amino	O
acid	O
replacement	O
of	O
Arg	B-DNAMutation
by	I-DNAMutation
Lys	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
554	I-DNAMutation
.	O

The	O
frequencies	O
of	O
Arg-coded	O
and	O
Lys-coded	O
alleles	O
were	O
0.57	O
and	O
0.43	O
,	O
respectively	O
.	O

We	O
found	O
,	O
however	O
,	O
that	O
this	O
germ	O
line	O
polymorphism	O
of	O
the	O
Ahr	B-DNAMutation
gene	O
did	O
not	O
show	O
a	O
significant	O
association	O
with	O
aryl	B-DNAMutation
hydrocarbon	I-DNAMutation
hydroxylase	I-DNAMutation
AHH	B-DNAMutation
inducibility	O
nor	O
with	O
lung	O
cancer	O
incidence	O
.	O

Molecular	O
basis	O
and	O
PCR-DNA	O
typing	O
of	O
the	O
Fya/fyb	O
blood	O
group	O
polymorphism	O
.	O

The	O
Duffy	O
blood	O
group	O
antigens	O
are	O
carried	O
by	O
the	O
erythrocyte	O
membrane	O
glycoprotein	O
gpD	B-DNAMutation
,	O
which	O
has	O
a	O
molecular	O
weight	O
of	O
35-45	O
kDa	O
and	O
which	O
has	O
been	O
recently	O
cloned	O
.	O

In	O
this	O
report	O
,	O
we	O
have	O
determined	O
,	O
at	O
the	O
nucleic	O
acid	O
level	O
,	O
the	O
molecular	O
basis	O
for	O
the	O
blood	O
group	O
Fya/Fyb	O
polymorphism	O
.	O

The	O
gpD	B-DNAMutation
cDNAs	O
isolated	O
by	O
reverse	O
transcription/polymerase	O
chain	O
reaction	O
(RT-PCR)	O
from	O
Fy(a+b-)	O
and	O
Fy(a-b+)	O
donors	O
differed	O
by	O
only	O
one	O
base	O
substitution	O
G131A	B-DNAMutation
changing	O
Gly	B-DNAMutation
to	I-DNAMutation
Asp	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
44	I-DNAMutation
of	O
the	O
gpD	B-DNAMutation
protein	O
.	O

When	O
expressed	O
in	O
simian	O
Cos-7	O
cells	O
,	O
the	O
Gy(a+b-)	O
and	O
Fy(a-b+)	O
gpD	B-DNAMutation
cDNA	O
produce	O
cell	O
surface	O
proteins	O
that	O
react	O
with	O
the	O
anti-Fya	O
and	O
anti-Fyb	O
antisera	O
,	O
respectively	O
,	O
demonstrating	O
that	O
they	O
represent	O
the	O
FY*A	O
and	O
FY*B	O
alleles	O
of	O
the	O
Duffy	O
blood	O
group	O
locus	O
.	O

The	O
G131A	B-DNAMutation
nucleotide	O
substitution	O
has	O
been	O
correlated	O
with	O
a	O
BanI	O
restriction	O
site	O
polymorphism	O
,	O
which	O
has	O
allowed	O
us	O
to	O
develop	O
a	O
method	O
for	O
the	O
DNA	O
typing	O
of	O
the	O
main	O
Duffy	O
blood	O
group	O
antigens	O
,	O
by	O
means	O
of	O
PCR/restriction	O
fragment	O
length	O
polymorphisms	O
.	O

APECED-causing	B-DNAMutation
mutations	O
in	O
AIRE	B-DNAMutation
reveal	O
the	O
functional	O
domains	O
of	O
the	O
protein	O
.	O

A	O
defective	O
form	O
of	O
the	O
AIRE	B-DNAMutation
protein	O
causes	O
autoimmune	O
destruction	O
of	O
target	O
organs	O
by	O
disturbing	O
the	O
immunological	O
tolerance	O
of	O
patients	O
with	O
a	O
rare	O
monogenic	O
disease	O
,	O
autoimmune	O
polyendocrinopathy	O
(APE)-candidiasis	O
(C)-ectodermal	O
dystrophy	O
(ED)	O
,	O
APECED	B-DNAMutation
.	O

Recently	O
,	O
experiments	O
on	O
knockout	O
mice	O
revealed	O
that	O
AIRE	B-DNAMutation
controls	O
autoimmunity	O
by	O
regulating	O
the	O
transcription	O
of	O
peripheral	O
tissue-restricted	O
antigens	O
in	O
thymic	O
medullary	O
epithelial	O
cells	O
.	O

Thus	O
,	O
AIRE	B-DNAMutation
provides	O
a	O
unique	O
model	O
for	O
molecular	O
studies	O
of	O
organ-specific	O
autoimmunity	O
.	O

In	O
order	O
to	O
analyze	O
the	O
molecular	O
and	O
cellular	O
consequences	O
of	O
16	O
disease-causing	O
mutations	O
in	O
vitro	O
,	O
we	O
studied	O
the	O
subcellular	O
localization	O
,	O
transactivation	O
capacity	O
,	O
homomultimerization	O
,	O
and	O
complex	O
formation	O
of	O
several	O
mutant	O
AIRE	B-DNAMutation
polypeptides	O
.	O

Most	O
of	O
the	O
mutations	O
altered	O
the	O
nucleus-cytoplasm	O
distribution	O
of	O
AIRE	B-DNAMutation
and	O
disturbed	O
its	O
association	O
with	O
nuclear	O
dots	O
and	O
cytoplasmic	O
filaments	O
.	O

While	O
the	O
PHD	O
zinc	O
fingers	O
were	O
necessary	O
for	O
the	O
transactivation	O
capacity	O
of	O
AIRE	B-DNAMutation
,	O
other	O
regions	O
of	O
AIRE	B-DNAMutation
also	O
modulated	O
this	O
function	O
.	O

Consequently	O
,	O
most	O
of	O
the	O
mutations	O
decreased	O
transactivation	O
.	O

The	O
HSR	O
domain	O
was	O
responsible	O
for	O
the	O
homomultimerization	O
activity	O
of	O
AIRE	B-DNAMutation
;	O
all	O
the	O
missense	O
mutations	O
of	O
the	O
HSR	B-DNAMutation
and	O
the	O
SAND	O
domains	O
decreased	O
this	O
activity	O
,	O
but	O
those	O
in	O
other	O
domains	O
did	O
not	O
.	O

The	O
AIRE	B-DNAMutation
protein	O
was	O
present	O
in	O
soluble	O
high-molecular-weight	O
complexes	O
.	O

Mutations	B-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
HSR	I-DNAMutation
domain	I-DNAMutation
and	O
deletion	B-DNAMutation
of	I-DNAMutation
PHD	I-DNAMutation
zinc	I-DNAMutation
fingers	I-DNAMutation
disturbed	O
the	O
formation	O
of	O
these	O
complexes	O
.	O

In	O
conclusion	O
,	O
we	O
propose	O
an	O
in	O
vitro	O
model	O
in	O
which	O
AIRE	B-DNAMutation
transactivates	O
transcription	O
through	O
heteromeric	O
molecular	O
interactions	O
that	O
are	O
regulated	O
by	O
homomultimerization	O
and	O
conditional	O
localization	O
of	O
AIRE	B-DNAMutation
in	O
the	O
nucleus	O
or	O
in	O
the	O
cytoplasm	O
.	O

Direct	O
identification	O
of	O
tyrosine	O
474	O
as	O
a	O
regulatory	O
phosphorylation	O
site	O
for	O
the	O
Akt	O
protein	O
kinase	O
.	O

Understanding	O
the	O
regulation	O
of	O
Akt	O
has	O
been	O
of	O
major	O
interest	O
for	O
elucidating	O
the	O
control	O
of	O
normal	O
cellular	O
physiology	O
as	O
well	O
as	O
malignant	O
transformation	O
.	O

The	O
paradigm	O
for	O
activation	O
of	O
Akt	O
involves	O
phosphatidylinositol	O
3-kinase-dependent	O
membrane	O
localization	O
followed	O
by	O
activating	O
phosphorylation	O
of	O
Thr-308	O
and	O
Ser-473	O
.	O

Many	O
of	O
the	O
activating	O
signals	O
for	O
Akt	O
involve	O
the	O
stimulation	O
of	O
receptor	O
and	O
non-receptor	O
tyrosine	O
kinases	O
,	O
and	O
the	O
most	O
potent	O
activator	O
known	O
is	O
the	O
tyrosine	O
phosphatase	O
inhibitor	O
pervanadate	O
,	O
highlighting	O
a	O
possible	O
role	O
for	O
tyrosine	O
phosphorylation	O
in	O
the	O
regulation	O
of	O
the	O
enzyme	O
.	O

In	O
this	O
study	O
we	O
show	O
that	O
activation	O
of	O
Akt	O
by	O
pervanadate	O
or	O
serum	O
is	O
associated	O
with	O
tyrosine	O
phosphorylation	O
of	O
Akt	O
.	O

In	O
addition	O
,	O
in	O
SKOV3	O
ovarian	O
carcinoma	O
cells	O
that	O
exhibit	O
high	O
basal	O
levels	O
of	O
Akt	O
activity	O
,	O
Akt	O
was	O
tyrosine-phosphorylated	O
in	O
the	O
basal	O
state	O
,	O
and	O
this	O
phosphorylation	O
was	O
further	O
enhanced	O
by	O
both	O
pervanadate	O
and	O
insulin-like	B-DNAMutation
growth	I-DNAMutation
factor-1	I-DNAMutation
.	O

We	O
have	O
used	O
NH(2)-terminal	O
sequencing	O
and	O
phosphate	O
release	O
analysis	O
to	O
directly	O
identify	O
Tyr-474	O
as	O
the	O
site	O
of	O
tyrosine	O
phosphorylation	O
.	O

Substitution	B-DNAMutation
of	I-DNAMutation
Tyr-474	I-DNAMutation
with	I-DNAMutation
phenylalanine	I-DNAMutation
abolished	O
tyrosine	O
phosphorylation	O
of	O
Akt	O
and	O
resulted	O
in	O
up	O
to	O
55%	O
inhibition	O
of	O
Akt	O
activation	O
,	O
indicating	O
phosphorylation	O
at	O
Tyr-474	O
is	O
required	O
for	O
full	O
activation	O
of	O
the	O
kinase	O
.	O

Our	O
data	O
identifies	O
a	O
novel	O
regulatory	O
mechanism	O
for	O
this	O
pleiotropic	O
enzyme	O
that	O
may	O
be	O
applicable	O
to	O
the	O
AGC	O
family	O
of	O
protein	O
kinases	O
given	O
the	O
conserved	O
nature	O
of	O
the	O
COOH-terminal	O
hydrophobic	O
motif	O
containing	O
Tyr-474	O
.	O

Uneven	O
X	O
inactivation	O
in	O
a	O
female	O
monozygotic	O
twin	O
pair	O
with	O
Fabry	O
disease	O
and	O
discordant	O
expression	O
of	O
a	O
novel	O
mutation	O
in	O
the	O
alpha-galactosidase	O
A	O
gene	O
.	O

We	O
describe	O
two	O
female	O
monozygotic	O
(MZ)	O
twins	O
heterozygous	O
for	O
Fabry	O
disease	O
,	O
an	O
X	O
linked	O
disorder	O
resulting	O
from	O
the	O
deficient	O
activity	O
of	O
alpha-galactosidase	O
A	O
.	O

While	O
one	O
of	O
the	O
twins	O
was	O
clinically	O
affected	O
,	O
the	O
other	O
was	O
asymptomatic	O
.	O

Enzymatic	O
assay	O
of	O
alpha-galactosidase	O
in	O
blood	O
leucocytes	O
,	O
skin	O
fibroblasts	O
,	O
Epstein-Barr	O
virus	O
transformed	O
lymphoid	O
cell	O
lines	O
,	O
and	O
hair	O
follicles	O
of	O
the	O
twins	O
and	O
their	O
parents	O
confirmed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
indicated	O
that	O
Fabry	O
disease	O
had	O
occurred	O
as	O
a	O
result	O
of	O
a	O
de	O
novo	O
mutation	O
.	O

The	O
son	O
of	O
the	O
unaffected	O
twin	O
sister	O
was	O
shown	O
to	O
be	O
hemizygous	O
.	O

Molecular	O
analysis	O
of	O
the	O
alpha-galactosidase	O
A	O
gene	O
permitted	O
the	O
identification	O
of	O
an	O
as	O
yet	O
undescribed	O
point	B-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
10182	I-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
5	I-DNAMutation
which	O
causes	O
an	O
Asp	B-DNAMutation
to	I-DNAMutation
Asn	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
231	I-DNAMutation
.	O

Single	O
strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
again	O
showed	O
the	O
heterozygous	O
status	O
of	O
the	O
twins	O
and	O
a	O
normal	O
pattern	O
in	O
their	O
parents	O
.	O

The	O
basis	O
for	O
the	O
discordant	O
expression	O
of	O
this	O
d	O
novo	O
mutation	O
in	O
the	O
twins	O
was	O
investigated	O
by	O
studying	O
their	O
X	O
inactivation	O
status	O
.	O

Analysis	O
of	O
the	O
inactive	O
X	O
specific	O
methylation	O
at	O
the	O
androgen	O
receptor	O
gene	O
showed	O
unbalanced	O
inactivation	O
in	O
the	O
twins'	O
fibroblasts	O
and	O
in	O
opposite	O
directions	O
.	O

While	O
the	O
maternally	O
derived	O
X	O
chromosome	O
was	O
preferentially	O
active	O
in	O
the	O
asymptomatic	O
twin	O
,	O
the	O
paternal	O
X	O
chromosome	O
was	O
active	O
in	O
the	O
other	O
,	O
affected	O
twin	O
and	O
was	O
found	O
in	O
her	O
hemizygotic	O
nephew	O
.	O

These	O
data	O
suggest	O
that	O
the	O
paternal	O
X	O
chromosome	O
carries	O
the	O
de	O
novo	O
alpha-galactosidase	O
A	O
mutation	O
and	O
that	O
uneven	O
X	O
inactivation	O
is	O
the	O
underlying	O
mechanism	O
for	O
disease	O
expression	O
in	O
this	O
novel	O
female	O
MZ	O
twin	O
pair	O
.	O

This	O
is	O
the	O
first	O
documented	O
case	O
of	O
female	O
twins	O
discordant	O
for	O
Fabry	O
disease	O
.	O

A	O
novel	O
polymorphism	O
in	O
the	O
gene	O
coding	O
for	O
the	O
beta(1)-adrenergic	B-DNAMutation
receptor	I-DNAMutation
associated	O
with	O
survival	O
in	O
patients	O
with	O
heart	O
failure	O
.	O

AIMS	O
:	O
The	O
adrenergic	O
nervous	O
system	O
is	O
of	O
major	O
importance	O
in	O
congestive	O
heart	O
failure	O
.	O

No	O
genetic	O
polymorphism	O
has	O
previously	O
been	O
identified	O
in	O
the	O
beta(1)-adrenergic	B-DNAMutation
receptor	I-DNAMutation
gene	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
find	O
possible	O
mutations	O
in	O
this	O
gene	O
and	O
to	O
relate	O
such	O
findings	O
to	O
morbidity	O
and	O
prognosis	O
in	O
heart	O
failure	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Genomic	O
DNA	O
was	O
extracted	O
from	O
blood	O
leukocytes	O
from	O
patients	O
with	O
congestive	O
heart	O
failure	O
(n=184)	O
and	O
from	O
age-matched	O
controls	O
(n=77)	O
.	O

The	O
part	O
of	O
the	O
beta(1)-adrenergic	B-DNAMutation
receptor	I-DNAMutation
gene	O
corresponding	O
to	O
nucleotide	O
1-255	O
was	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
analysed	O
by	O
automated	O
sequencing	O
.	O

The	O
patients	O
were	O
investigated	O
by	O
echocardiography	O
and	O
followed	O
regarding	O
symptoms	O
and	O
survival	O
for	O
5	O
years	O
.	O

A	O
missense	B-DNAMutation
mutation	I-DNAMutation
was	I-DNAMutation
identified	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
position	I-DNAMutation
145	I-DNAMutation
in	O
the	O
beta(1)-adrenergic	B-DNAMutation
receptor	I-DNAMutation
gene	O
,	O
which	O
predicted	O
an	O
amino	B-DNAMutation
acid	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
49	I-DNAMutation
Ser49Gly	B-DNAMutation
.	O

The	O
allele	O
frequency	O
of	O
the	O
Gly49	O
variant	O
was	O
0.13	O
in	O
controls	O
and	O
0.18	O
in	O
patients	O
(P=0.19)	O
.	O

At	O
the	O
time	O
of	O
the	O
5-years	O
follow-up	O
,	O
62%	O
of	O
the	O
patients	O
with	O
the	O
wild	O
type	O
gene	O
and	O
39%	O
of	O
the	O
patients	O
with	O
the	O
Ser49Gly	B-DNAMutation
variant	O
had	O
died	O
or	O
had	O
experienced	O
hospitalization	O
(P=0.005)	O
.	O

Patients	O
without	O
the	O
mutation	O
had	O
significantly	O
poorer	O
survival	O
compared	O
to	O
those	O
with	O
the	O
mutation	O
,	O
risk	O
ratio	O
2.34	O
(	O
95%	O
CI	O
1.30-4.20	O
)	O
,	O
P=0.003	O
.	O

In	O
a	O
mulivariate	O
analysis	O
,	O
the	O
risk	O
ratio	O
was	O
2.03	O
(	O
95%	O
CI	O
0.99-4.16	O
)	O
P=0.05	O
.	O

CONCLUSION	O
:	O
A	O
novel	O
missense	O
mution	O
in	O
the	O
beta(1)-adrenergic	B-DNAMutation
receptor	I-DNAMutation
gene	O
was	O
associated	O
with	O
a	O
decreased	O
mortality	O
risk	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
.	O

These	O
data	O
suggest	O
that	O
the	O
beta(1)-receptor	O
Ser49Gly	B-DNAMutation
variant	O
might	O
be	O
associated	O
with	O
altered	O
receptor	O
function	O
,	O
resulting	O
in	O
myocardial	O
protection	O
in	O
patients	O
with	O
heart	O
failure	O
.	O

Glutamine	O
methylation	O
in	O
histone	O
H2A	O
is	O
an	O
RNA-polymerase-I-dedicated	O
modification	O
.	O

Nucleosomes	O
are	O
decorated	O
with	O
numerous	O
post-translational	O
modifications	O
capable	O
of	O
influencing	O
many	O
DNA	O
processes	O
.	O

Here	O
we	O
describe	O
a	O
new	O
class	O
of	O
histone	O
modification	O
,	O
methylation	B-DNAMutation
of	I-DNAMutation
glutamine	I-DNAMutation
,	I-DNAMutation
occurring	I-DNAMutation
on	I-DNAMutation
yeast	I-DNAMutation
histone	I-DNAMutation
H2A	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
105	I-DNAMutation
(Q105)	I-DNAMutation
and	O
human	O
H2A	O
at	O
Q104	O
.	O

We	O
identify	O
Nop1	B-DNAMutation
as	O
the	O
methyltransferase	O
in	O
yeast	O
and	O
demonstrate	O
that	O
fibrillarin	O
is	O
the	O
orthologue	O
enzyme	O
in	O
human	O
cells	O
.	O

Glutamine	O
methylation	O
of	O
H2A	O
is	O
restricted	O
to	O
the	O
nucleolus	O
.	O

Global	O
analysis	O
in	O
yeast	O
,	O
using	O
an	O
H2AQ105me-specific	O
antibody	O
,	O
shows	O
that	O
this	O
modification	O
is	O
exclusively	O
enriched	O
over	O
the	O
35S	O
ribosomal	O
DNA	O
transcriptional	O
unit	O
.	O

We	O
show	O
that	O
the	O
Q105	O
residue	O
is	O
part	O
of	O
the	O
binding	O
site	O
for	O
the	O
histone	O
chaperone	O
FACT	O
(	O
facilitator	O
of	O
chromatin	O
transcription	O
)	O
complex	O
.	O

Methylation	B-DNAMutation
of	I-DNAMutation
Q105	I-DNAMutation
or	I-DNAMutation
its	I-DNAMutation
substitution	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
disrupts	O
binding	O
to	O
FACT	O
in	O
vitro	O
.	O

A	O
yeast	O
strain	O
mutated	O
at	O
Q105	O
shows	O
reduced	O
histone	O
incorporation	O
and	O
increased	O
transcription	O
at	O
the	O
ribosomal	O
DNA	O
locus	O
.	O

These	O
features	O
are	O
phenocopied	O
by	O
mutations	O
in	O
FACT	O
complex	O
components	O
.	O

Together	O
these	O
data	O
identify	O
glutamine	O
methylation	O
of	O
H2A	O
as	O
the	O
first	O
histone	O
epigenetic	O
mark	O
dedicated	O
to	O
a	O
specific	O
RNA	O
polymerase	O
and	O
define	O
its	O
function	O
as	O
a	O
regulator	O
of	O
FACT	O
interaction	O
with	O
nucleosomes	O
.	O

A	O
missense	O
mutation	O
in	O
SLC33A1	B-DNAMutation
,	O
which	O
encodes	O
the	O
acetyl-CoA	O
transporter	O
,	O
causes	O
autosomal-dominant	O
spastic	O
paraplegia	O
SPG42	B-DNAMutation
.	O

Hereditary	O
spastic	O
paraplegias	O
(HSPs)	O
,	O
characterized	O
by	O
progressive	O
and	O
bilateral	O
spasticity	O
of	O
the	O
legs	O
,	O
are	O
usually	O
caused	O
by	O
developmental	O
failure	O
or	O
degeneration	O
of	O
motor	O
axons	O
in	O
the	O
corticospinal	O
tract	O
.	O

There	O
are	O
considerable	O
interfamilial	O
and	O
intrafamilial	O
variations	O
in	O
age	O
at	O
onset	O
and	O
severity	O
of	O
spasticity	O
.	O

Genetic	O
studies	O
also	O
showed	O
that	O
there	O
are	O
dozens	O
of	O
genetic	O
loci	O
,	O
on	O
multiple	O
chromosomes	O
,	O
that	O
are	O
responsible	O
for	O
HSPs	O
.	O

Through	O
linkage	O
study	O
of	O
a	O
pedigree	O
of	O
HSP	O
with	O
autosomal-dominant	O
inheritance	O
,	O
we	O
mapped	O
the	O
causative	O
gene	O
to	O
3q24-q26	O
.	O

Screening	O
of	O
candidate	O
genes	O
revealed	O
that	O
the	O
HSP	O
is	O
caused	O
by	O
a	O
missense	O
mutation	O
in	O
the	O
gene	O
for	O
acetyl-CoA	O
transporter	O
SLC33A1	B-DNAMutation
.	O

It	O
is	O
predicted	O
that	O
the	O
missense	O
mutation	O
,	O
causing	O
the	O
change	O
of	O
the	O
highly	O
conserved	O
serine	B-DNAMutation
to	I-DNAMutation
arginine	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
codon	I-DNAMutation
113	I-DNAMutation
(	O
p	B-DNAMutation
.	I-DNAMutation
S113R	I-DNAMutation
)	O
,	O
disrupts	O
the	O
second	O
transmembrane	O
domain	O
in	O
the	O
transporter	O
and	O
reverses	O
the	O
orientation	O
of	O
all	O
of	O
the	O
descending	O
domains	O
.	O

Knockdown	B-DNAMutation
of	O
Slc33a1	B-DNAMutation
in	O
zebrafish	O
caused	O
a	O
curve-shaped	O
tail	O
and	O
defective	O
axon	O
outgrowth	O
from	O
the	O
spinal	O
cord	O
.	O

Although	O
the	O
wild-type	O
human	O
SLC33A1	B-DNAMutation
was	O
able	O
to	O
rescue	O
the	O
phenotype	O
caused	O
by	O
Slc33a1	B-DNAMutation
knockdown	O
in	O
zebrafish	O
,	O
the	O
mutant	O
SLC33A1	B-DNAMutation
p.S113R	B-DNAMutation
was	O
not	O
,	O
suggesting	O
that	O
S113R	B-DNAMutation
mutation	O
renders	O
SLC33A1	B-DNAMutation
nonfunctional	O
and	O
one	O
that	O
wild-type	O
allele	O
is	O
not	O
sufficient	O
for	O
sustaining	O
the	O
outgrowth	O
and	O
maintenance	O
of	O
long	O
motor	O
axons	O
in	O
human	O
heterozygotes	O
.	O

Thus	O
,	O
our	O
study	O
illustrated	O
a	O
critical	O
role	O
of	O
acetyl-CoA	O
transporter	O
in	O
motor-neuron	O
development	O
and	O
function	O
.	O

Identification	O
of	O
a	O
point	O
mutation	O
resulting	O
in	O
a	O
heat-labile	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
ADA	B-DNAMutation
in	O
two	O
unrelated	O
children	O
with	O
partial	O
ADA	B-DNAMutation
deficiency	O
.	O

We	O
have	O
determined	O
the	O
mutation	O
in	O
a	O
child	O
with	O
partial	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
ADA	B-DNAMutation
deficiency	O
who	O
is	O
phenotypically	O
homozygous	O
for	O
a	O
mutant	O
ADA	B-DNAMutation
gene	O
encoding	O
a	O
heat-labile	O
enzyme	O
(	O
Am	O
.	O

J	O
.	O

Hum	O
.	O

Genet	O
.	O

38	O
:	O
13-25	O
)	O
.	O

Sequencing	O
of	O
cDNA	O
demonstrated	O
a	O
C	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
transversion	I-DNAMutation
that	I-DNAMutation
results	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
replacement	I-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
proline	I-DNAMutation
by	I-DNAMutation
a	I-DNAMutation
glutamine	I-DNAMutation
residue	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
297	I-DNAMutation
.	O

As	O
this	O
mutation	O
generated	O
a	O
new	O
recognition	O
site	O
in	O
exon	O
10	O
of	O
genomic	O
DNA	O
for	O
the	O
enzyme	O
Alu	O
I	O
,	O
Southern	O
blot	O
analysis	O
was	O
used	O
to	O
establish	O
that	O
this	O
child	O
was	O
indeed	O
homozygous	O
for	O
the	O
mutation	O
.	O

The	O
abnormal	O
restriction	O
fragment	O
generated	O
by	O
this	O
mutation	O
was	O
also	O
found	O
in	O
a	O
second	O
partially	O
ADA-deficient	B-DNAMutation
patient	O
who	O
phenotypically	O
is	O
a	O
genetic	O
compound	O
and	O
also	O
expresses	O
a	O
heat-labile	O
ADA	B-DNAMutation
(	O
in	O
addition	O
to	O
a	O
more	O
acidic	O
than	O
normal	O
ADA	B-DNAMutation
)	O
(	O
Am	O
.	O

J	O
.	O

Hum	O
.	O

Genet	O
.	O

38	O
:	O
13-25	O
)	O
.	O

Sequencing	O
of	O
cDNA	O
clones	O
from	O
the	O
second	O
patient	O
established	O
the	O
identical	O
codon	B-DNAMutation
297	I-DNAMutation
mutation	I-DNAMutation
.	O

Transfection	O
of	O
the	O
mutant	O
cDNA	O
into	O
heterologous	O
cells	O
resulted	O
in	O
expression	O
of	O
a	O
heat-labile	O
ADA	B-DNAMutation
of	O
normal	O
electrophoretic	O
mobility	O
and	O
isoelectric	O
point	O
,	O
properties	O
exhibited	O
by	O
the	O
ADA	B-DNAMutation
in	O
the	O
patients'	O
cells	O
.	O

Three	O
common	O
polymorphisms	O
in	O
the	O
CYBA	B-DNAMutation
gene	O
form	O
a	O
haplotype	O
associated	O
with	O
decreased	O
ROS	O
generation	O
.	O

NOX	O
enzymes	O
are	O
reactive	O
oxygen	O
species	O
(ROS)-generating	O
NADPH	O
oxidases	O
.	O

Several	O
members	O
of	O
the	O
NOX	O
family	O
depend	O
on	O
the	O
p22(phox)	B-DNAMutation
subunit	O
,	O
encoded	O
by	O
the	O
CYBA	B-DNAMutation
gene	O
.	O

CYBA	B-DNAMutation
is	O
highly	O
polymorphic	O
,	O
and	O
has	O
been	O
widely	O
studied	O
as	O
a	O
potential	O
risk	O
factor	O
for	O
various	O
diseases	O
,	O
with	O
conflicting	O
results	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
Epstein-Barr	O
(EBV)-transformed	O
B-lymphocytes	O
from	O
50	O
healthy	O
unrelated	O
individuals	O
to	O
analyze	O
their	O
CYBA	B-DNAMutation
mRNA	O
sequence	O
and	O
NOX2-dependent	B-DNAMutation
ROS	O
generation	O
.	O

Seven	O
single-nucleotide	O
polymorphisms	O
(SNPs)	O
were	O
identified	O
(	O
five	O
previously	O
described	O
,	O
two	O
novel	O
)	O
.	O

The	O
combination	O
of	O
these	O
SNPs	O
yielded	O
11	O
distinct	O
haplotypes	O
,	O
which	O
could	O
be	O
grouped	O
into	O
seven	O
haplogroups	O
(A-G)	O
.	O

Haplogroup	O
C	O
(	O
c.214T>C	B-DNAMutation
,	O
c.521T>C	B-DNAMutation
,	O
and	O
c.(*)24G>A	B-DNAMutation
)	O
showed	O
a	O
significantly	O
lower	O
ROS	O
generation	O
,	O
as	O
compared	O
to	O
the	O
most	O
frequent	O
haplogroup	O
,	O
A	O
.	O

CYBA	B-DNAMutation
variants	O
from	O
the	O
seven	O
haplogroups	O
were	O
transduced	O
into	O
p22(phox)-deficient	B-DNAMutation
B-lymphocytes	O
.	O

The	O
haplogroup	O
C	O
variant	O
showed	O
significantly	O
lower	O
ROS	O
production	O
.	O

c.214T>C	B-DNAMutation
and	O
c.521T>C	B-DNAMutation
lead	O
to	O
nonsynonymous	O
codon	O
changes	O
,	O
while	O
c.(*)24G>A	B-DNAMutation
lies	O
within	O
the	O
3'UTR	O
.	O

Using	O
a	O
luciferase/3'UTR	O
construct	O
,	O
we	O
showed	O
that	O
the	O
(*)24A	O
allele	O
led	O
to	O
decreased	O
reporter	O
gene	O
activity	O
.	O

These	O
results	O
help	O
to	O
unravel	O
the	O
complex	O
nature	O
of	O
how	O
genetic	O
variations	O
in	O
CYBA	B-DNAMutation
influence	O
NOX2	B-DNAMutation
activity	O
,	O
and	O
indicate	O
that	O
haplotypes	O
,	O
rather	O
than	O
individual	O
SNPs	O
,	O
define	O
the	O
effect	O
on	O
ROS	O
generation	O
.	O

Identification	O
of	O
a	O
novel	O
phosphorylation	O
site	O
,	O
Ser-170	O
,	O
as	O
a	O
regulator	O
of	O
bad	B-DNAMutation
pro-apoptotic	O
activity	O
.	O

Bad	B-DNAMutation
is	O
a	O
pro-apoptotic	O
member	O
of	O
the	O
Bcl-2	O
family	O
of	O
proteins	O
that	O
is	O
thought	O
to	O
exert	O
a	O
death-promoting	O
effect	O
by	O
heterodimerization	O
with	O
Bcl-X(L)	B-DNAMutation
,	O
nullifying	O
its	O
anti-apoptotic	O
activity	O
.	O

Growth	O
factors	O
may	O
promote	O
cell	O
survival	O
at	O
least	O
partially	O
through	O
phosphorylation	O
of	O
Bad	B-DNAMutation
at	O
one	O
or	O
more	O
of	O
Ser-112	O
,	O
-136	O
,	O
or	O
-155	O
.	O

Our	O
previous	O
work	O
showed	O
that	O
Bad	B-DNAMutation
is	O
also	O
phosphorylated	O
in	O
response	O
to	O
cytokines	O
at	O
another	O
site	O
,	O
which	O
we	O
now	O
identify	O
as	O
Ser-170	O
.	O

The	O
functional	O
role	O
of	O
this	O
novel	O
phosphorylation	O
site	O
was	O
assessed	O
by	O
site-directed	O
mutagenesis	O
and	O
analysis	O
of	O
the	O
pro-apoptotic	O
function	O
of	O
Bad	B-DNAMutation
in	O
transiently	O
transfected	O
HEK293	O
and	O
COS-7	O
cells	O
or	O
by	O
stable	O
expression	O
in	O
the	O
cytokine-dependent	O
cell	O
line	O
,	O
MC/9	O
.	O

In	O
general	O
,	O
mutation	O
of	O
Ser-170	B-DNAMutation
to	I-DNAMutation
Ala	I-DNAMutation
results	O
in	O
a	O
protein	O
with	O
increased	O
ability	O
to	O
induce	O
apoptosis	O
,	O
similar	O
to	O
the	O
S112A	B-DNAMutation
mutant	O
.	O

Mutation	O
of	O
Ser-170	B-DNAMutation
to	I-DNAMutation
Asp	I-DNAMutation
,	O
mimicking	O
a	O
constitutively	O
phosphorylated	O
site	O
,	O
results	O
in	O
a	O
protein	O
that	O
is	O
virtually	O
unable	O
to	O
induce	O
apoptosis	O
.	O

Similarly	O
,	O
the	O
S112A/S170D	B-DNAMutation
double	O
mutant	O
does	O
not	O
cause	O
apoptosis	O
in	O
HEK293	O
and	O
MC/9	O
cell	O
lines	O
.	O

These	O
data	O
strongly	O
suggest	O
that	O
phosphorylation	O
of	O
Bad	B-DNAMutation
at	O
Ser-170	O
is	O
a	O
critical	O
event	O
in	O
blocking	O
the	O
pro-apoptotic	O
activity	O
of	O
Bad	B-DNAMutation
.	O

An	O
alpha-1	B-DNAMutation
antitrypsin	I-DNAMutation
genetic	O
variant	O
from	O
India	O
.	O

The	O
highly	O
polymorphic	O
human	O
alpha-1	B-DNAMutation
antitrypsin	I-DNAMutation
AAT	B-DNAMutation
gene	O
codes	O
for	O
the	O
most	O
abundant	O
circulating	O
plasma	O
serine	O
protease	O
inhibitor	O
.	O

Previously	O
,	O
genetic	O
variants	O
of	O
the	O
AAT	B-DNAMutation
gene	O
were	O
reported	O
from	O
different	O
regions	O
of	O
the	O
world	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
AAT	B-DNAMutation
gene	O
was	O
characterized	O
in	O
an	O
Indian	O
sample	O
.	O

The	O
AAT	B-DNAMutation
gene	O
was	O
isolated	O
and	O
cloned	O
from	O
a	O
liver	O
biopsy	O
sample	O
through	O
RT-PCR	O
and	O
the	O
full-length	O
gene	O
was	O
sequenced	O
.	O

Nucleotide	O
sequence	O
comparison	O
with	O
the	O
human	O
genome	O
and	O
the	O
AAT	B-DNAMutation
sequences	O
available	O
in	O
the	O
GenBank	O
(NCBI)	O
demonstrated	O
four	O
unique	O
variations--(i)	O
an	O
A	B-DNAMutation
to	I-DNAMutation
G	I-DNAMutation
variation	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
286	I-DNAMutation
(Thr96Ala)	I-DNAMutation
,	O
(ii)	O
an	O
A	B-DNAMutation
to	I-DNAMutation
G	I-DNAMutation
variation	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
839	I-DNAMutation
(Asp280Gly)	I-DNAMutation
,	O
(iii)	O
a	O
T	B-DNAMutation
to	I-DNAMutation
C	I-DNAMutation
variation	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1182	I-DNAMutation
that	I-DNAMutation
did	I-DNAMutation
not	I-DNAMutation
result	I-DNAMutation
in	I-DNAMutation
any	I-DNAMutation
change	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
protein	I-DNAMutation
sequence	I-DNAMutation
(	I-DNAMutation
TTT	I-DNAMutation
to	I-DNAMutation
TTC	I-DNAMutation
both	I-DNAMutation
code	I-DNAMutation
for	I-DNAMutation
Phe	I-DNAMutation
)	O
and	O
(iv)	O
an	O
A	B-DNAMutation
to	I-DNAMutation
C	I-DNAMutation
variation	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1200	I-DNAMutation
(Glu400Asp)	I-DNAMutation
that	O
resulted	O
in	O
replacement	O
by	O
an	O
amino	O
acid	O
of	O
similar	O
nature	O
.	O

Other	O
variations	O
found	O
were	O
T	B-DNAMutation
to	I-DNAMutation
C	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
710	I-DNAMutation
(Val273Ala)	I-DNAMutation
and	O
T	B-DNAMutation
to	I-DNAMutation
C	I-DNAMutation
position	I-DNAMutation
863	I-DNAMutation
(Val288Glu)	I-DNAMutation
,	O
which	O
were	O
also	O
reported	O
earlier	O
.	O

In	O
conclusion	O
,	O
this	O
study	O
reports	O
the	O
entire	O
1257	O
bp	O
nucleotide	O
sequence	O
of	O
protein	O
coding	O
region	O
of	O
the	O
human	O
AAT	B-DNAMutation
gene	O
from	O
an	O
Indian	O
sample	O
.	O

This	O
preliminary	O
finding	O
is	O
significant	O
,	O
as	O
it	O
reports	O
for	O
the	O
first	O
time	O
the	O
AAT	B-DNAMutation
gene	O
sequence	O
in	O
the	O
Indian	O
sample	O
.	O

Tyrosine	B-DNAMutation
706	I-DNAMutation
and	I-DNAMutation
807	I-DNAMutation
phosphorylation	I-DNAMutation
site	I-DNAMutation
mutants	I-DNAMutation
in	O
the	O
murine	O
colony-stimulating	B-DNAMutation
factor-1	I-DNAMutation
receptor	I-DNAMutation
are	O
unaffected	O
in	O
their	O
ability	O
to	O
bind	O
or	O
phosphorylate	O
phosphatidylinositol-3	O
kinase	O
but	O
show	O
differential	O
defects	O
in	O
their	O
ability	O
to	O
induce	O
early	O
response	O
gene	O
transcription	O
.	O

The	O
receptor	O
for	O
colony-stimulating	O
factor-1	O
(CSF-1)	O
is	O
a	O
receptor	O
protein-tyrosine	O
kinase	O
.	O

To	O
study	O
the	O
possible	O
function	O
of	O
CSF-1	O
receptor	O
autophosphorylation	O
,	O
two	O
autophosphorylation	O
sites	O
,	O
Tyr-706	B-DNAMutation
,	I-DNAMutation
located	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
kinase	I-DNAMutation
insert	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Tyr-807	I-DNAMutation
,	I-DNAMutation
a	I-DNAMutation
residue	I-DNAMutation
conserved	I-DNAMutation
in	I-DNAMutation
all	I-DNAMutation
protein-tyrosine	I-DNAMutation
kinases	I-DNAMutation
,	I-DNAMutation
were	I-DNAMutation
changed	I-DNAMutation
independently	O
to	O
either	O
phenylalanine	O
or	O
glycine	O
.	O

Wild-type	O
and	O
mutant	O
receptors	O
were	O
stably	O
expressed	O
in	O
Rat-2	O
cells	O
.	O

In	O
response	O
to	O
CSF-1	O
,	O
cells	O
expressing	O
Phe-	B-DNAMutation
or	I-DNAMutation
Gly-706	I-DNAMutation
mutant	I-DNAMutation
receptors	O
showed	O
increased	O
growth	O
rate	O
and	O
altered	O
cell	O
morphology	O
.	O

Both	O
the	O
Phe-	B-DNAMutation
and	I-DNAMutation
Gly-706	I-DNAMutation
mutant	I-DNAMutation
receptors	O
associated	O
with	O
and	O
phosphorylated	O
phosphatidylinositol-3	O
kinase	O
at	O
levels	O
comparable	O
with	O
those	O
of	O
wild-type	O
receptors	O
.	O

However	O
,	O
these	O
mutant	O
receptors	O
differed	O
subtly	O
from	O
each	O
other	O
and	O
from	O
the	O
wild-type	O
receptor	O
in	O
their	O
ability	O
to	O
induce	O
different	O
aspects	O
of	O
the	O
response	O
to	O
CSF-1	O
.	O

The	O
Phe-706	B-DNAMutation
mutant	I-DNAMutation
receptor	O
was	O
most	O
strongly	O
affected	O
in	O
its	O
ability	O
to	O
increase	O
growth	O
rate	O
or	O
elevate	O
the	O
levels	O
of	O
c-fos	B-DNAMutation
and	O
NGF1A	B-DNAMutation
mRNAs	O
,	O
whereas	O
the	O
Gly-706	B-DNAMutation
mutant	I-DNAMutation
receptor	O
was	O
most	O
markedly	O
affected	O
in	O
its	O
ability	O
to	O
induce	O
a	O
change	O
in	O
cell	O
morphology	O
or	O
increase	O
the	O
levels	O
of	O
c-jun	B-DNAMutation
and	O
NGF1A	B-DNAMutation
mRNAs	O
.	O

These	O
findings	O
indicate	O
that	O
Tyr-706	O
itself	O
,	O
or	O
this	O
region	O
of	O
the	O
receptor	O
,	O
may	O
be	O
important	O
for	O
interaction	O
of	O
the	O
CSF-1	B-DNAMutation
receptor	I-DNAMutation
with	O
different	O
signalling	O
pathways	O
.	O

Gly-807	B-DNAMutation
mutant	I-DNAMutation
receptors	O
lacked	O
protein-tyrosine	O
kinase	O
activity	O
,	O
failed	O
to	O
respond	O
to	O
CSF-1	O
,	O
and	O
were	O
defective	O
in	O
biosynthetic	O
processing	O
.	O

Phe-807	B-DNAMutation
mutant	I-DNAMutation
receptors	O
had	O
40	O
to	O
60%	O
reduced	O
protein-tyrosine	O
kinase	O
activity	O
in	O
vitro	O
.	O

Although	O
cells	O
expressing	O
Phe-807	O
receptors	O
were	O
able	O
to	O
respond	O
to	O
CSF-1	O
,	O
the	O
changes	O
in	O
growth	O
rate	O
and	O
cell	O
morphology	O
were	O
significantly	O
less	O
than	O
seen	O
with	O
wild-type	O
receptors	O
,	O
and	O
the	O
induction	O
of	O
early	O
response	O
genes	O
was	O
also	O
slightly	O
lower	O
than	O
for	O
the	O
wild-type	O
receptor	O
.	O

In	O
contrast	O
,	O
Phe-807	O
receptors	O
were	O
equivalent	O
to	O
wild-type	O
receptors	O
when	O
tested	O
for	O
their	O
ability	O
to	O
interact	O
with	O
phosphatidylinositol-3	O
kinase	O
.	O

These	O
findings	O
indicate	O
that	O
phosphorylation	O
of	O
Tyr-807	O
may	O
be	O
important	O
for	O
full	O
activation	O
of	O
the	O
receptor	O
.	O

Molecular	O
characterization	O
of	O
germline	O
mutations	O
in	O
the	O
BRCA1	B-DNAMutation
and	O
BRCA2	B-DNAMutation
genes	O
from	O
breast	O
cancer	O
families	O
in	O
Taiwan	O
.	O

A	O
total	O
of	O
18	O
families	O
with	O
multiple	O
cases	O
of	O
breast	O
cancer	O
were	O
identified	O
from	O
southern	O
Taiwan	O
,	O
and	O
5	O
of	O
these	O
families	O
were	O
found	O
to	O
carry	O
cancer-associated	O
germline	O
mutations	O
in	O
the	O
BRCA1	B-DNAMutation
and	O
BRCA2	B-DNAMutation
genes	O
.	O

One	O
novel	O
cryptic	O
splicing	O
mutation	O
of	O
the	O
BRCA1	B-DNAMutation
gene	O
,	O
found	O
in	O
two	O
unrelated	O
families	O
,	O
was	O
shown	O
to	O
be	O
a	O
deletion	B-DNAMutation
of	I-DNAMutation
10	I-DNAMutation
bp	I-DNAMutation
near	I-DNAMutation
the	I-DNAMutation
branch	I-DNAMutation
site	I-DNAMutation
in	I-DNAMutation
intron	I-DNAMutation
7	I-DNAMutation
.	O

This	O
mutation	O
causes	O
an	O
insertion	B-DNAMutation
of	I-DNAMutation
59	I-DNAMutation
nucleotides	I-DNAMutation
derived	I-DNAMutation
from	I-DNAMutation
intron	I-DNAMutation
7	I-DNAMutation
and	I-DNAMutation
results	I-DNAMutation
in	I-DNAMutation
a	I-DNAMutation
frameshift	I-DNAMutation
,	O
leading	O
to	O
premature	O
translational	O
termination	O
of	O
BRCA1	B-DNAMutation
mRNA	O
in	O
exon	O
8	O
.	O

Deletions	B-DNAMutation
of	I-DNAMutation
2670delC	I-DNAMutation
,	O
3073delT	B-DNAMutation
and	O
6696-7delTC	B-DNAMutation
in	O
the	O
BRCA2	B-DNAMutation
gene	O
were	O
found	O
in	O
three	O
other	O
breast	O
cancer	O
families	O
.	O

All	O
three	O
deletions	O
are	O
predicted	O
to	O
generate	O
frameshifts	O
and	O
to	O
result	O
in	O
the	O
premature	O
termination	O
of	O
BRCA2	B-DNAMutation
protein	O
translation	O
.	O

Several	O
genetic	O
polymorphisms	O
in	O
both	O
BRCA1	B-DNAMutation
and	O
BRCA2	B-DNAMutation
genes	O
were	O
also	O
detected	O
in	O
this	O
investigation	O
.	O

Characterization	O
of	O
mammalian	O
orthologues	O
of	O
the	O
Drosophila	O
osa	O
gene	O
:	O
cDNA	O
cloning	O
,	O
expression	O
,	O
chromosomal	O
localization	O
,	O
and	O
direct	O
physical	O
interaction	O
with	O
Brahma	O
chromatin-remodeling	O
complex	O
.	O

The	O
osa	O
gene	O
of	O
Drosophila	O
melanogaster	O
encodes	O
a	O
nuclear	O
protein	O
that	O
is	O
a	O
component	O
of	O
the	O
Brahma	O
chromatin-remodeling	O
complex	O
.	O

Osa	O
is	O
required	O
for	O
embryonic	O
segmentation	O
,	O
development	O
of	O
the	O
notum	O
and	O
wing	O
margin	O
,	O
and	O
photoreceptor	O
differentiation	O
.	O

In	O
these	O
tissues	O
,	O
osa	O
mutations	O
have	O
effects	O
opposite	O
to	O
those	O
caused	O
by	O
wingless	O
(wg)	O
mutations	O
,	O
suggesting	O
that	O
osa	O
functions	O
as	O
an	O
antagonist	O
of	O
wg	O
signaling	O
.	O

Here	O
we	O
describe	O
the	O
cloning	O
and	O
characterization	O
of	O
mammalian	O
orthologues	O
of	O
osa	O
.	O

Three	O
evolutionarily	O
conserved	O
domains	O
were	O
identified	O
in	O
Osa	O
family	O
members	O
:	O
the	O
N-terminal	O
Bright	O
domain	O
and	O
C-terminally	O
located	O
Osa	O
homology	O
domains	O
1	O
and	O
2	O
.	O

RNase	O
protection	O
analysis	O
indicates	O
a	O
widespread	O
expression	O
of	O
the	O
Osa1	B-DNAMutation
gene	O
during	O
mouse	O
development	O
,	O
in	O
adult	O
tissues	O
,	O
and	O
in	O
cultured	O
cell	O
lines	O
.	O

The	O
Osa1	B-DNAMutation
gene	O
was	O
localized	O
to	O
mouse	O
chromosome	O
4	O
,	O
within	O
the	O
region	O
syntenic	O
to	O
chromosomal	O
position	O
1p35-p36	O
of	O
its	O
human	O
counterpart	O
.	O

We	O
present	O
evidence	O
that	O
the	O
OSA1	B-DNAMutation
product	O
is	O
localized	O
in	O
the	O
nucleus	O
and	O
associates	O
with	O
human	O
Brahma	O
complex	O
,	O
which	O
suggests	O
evolutionarily	O
conserved	O
function	O
for	O
Osa	O
in	O
gene	O
regulation	O
between	O
mammals	O
and	O
Drosophila	O
.	O

Association	O
study	O
of	O
human	O
MTH1	O
gene	O
polymorphisms	O
with	O
type	O
1	O
diabetes	O
mellitus	O
.	O

Reactive	O
oxygen	O
species	O
are	O
considered	O
to	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
diabetes	O
mellitus	O
and	O
its	O
complications	O
.	O

Human	O
MTH1	B-DNAMutation
(	O
mutT	B-DNAMutation
homologue	I-DNAMutation
1	I-DNAMutation
)	O
has	O
8-oxo-7,8-dihydrodeoxyguanosine	O
triphosphatase	O
activity	O
,	O
which	O
repairs	O
oxidized	O
forms	O
of	O
dGTP	O
.	O

This	O
enzyme	O
is	O
known	O
to	O
have	O
a	O
thermolabile	O
Met83	O
variant	O
.	O

We	O
examined	O
whether	O
Val83Met	B-DNAMutation
polymorphism	O
of	O
human	O
MTH1	O
gene	O
is	O
associated	O
with	O
type	O
1	O
diabetes	O
mellitus	O
.	O

We	O
recruited	O
156	O
type	O
1	O
diabetic	O
patients	O
(	O
59	O
males	O
and	O
97	O
females	O
)	O
.	O

The	O
polymorphism	O
was	O
analyzed	O
by	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
with	O
Nsi	O
I	O
.	O

The	O
Met/Met	B-DNAMutation
genotype	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
83	I-DNAMutation
was	O
very	O
rare	O
in	O
both	O
control	O
and	O
patient	O
groups	O
.	O

Val/Met	B-DNAMutation
genotype	I-DNAMutation
tended	O
to	O
be	O
more	O
frequent	O
in	O
the	O
whole	O
type	O
1	O
diabetic	O
patients	O
than	O
in	O
controls	O
.	O

When	O
subjects	O
were	O
divided	O
into	O
subgroups	O
according	O
to	O
gender	O
,	O
there	O
were	O
no	O
differences	O
in	O
the	O
genotype	O
and	O
allele	O
frequencies	O
between	O
patients	O
and	O
controls	O
in	O
males	O
.	O

On	O
the	O
other	O
hand	O
,	O
in	O
female	O
type	O
1	O
diabetic	O
patients	O
,	O
the	O
Val/Met	B-DNAMutation
genotype	I-DNAMutation
was	O
more	O
frequent	O
than	O
in	O
female	O
controls	O
(	O
corrected	O
P	O
=	O
0.102	O
)	O
.	O

The	O
Met	O
allele	O
was	O
significantly	O
more	O
frequent	O
in	O
female	O
type	O
1	O
diabetic	O
patients	O
than	O
in	O
female	O
controls	O
(	O
corrected	O
P	O
=	O
0.022	O
)	O
.	O

Our	O
results	O
suggested	O
that	O
the	O
Met	O
allele	O
at	O
codon	O
83	O
of	O
MTH1	B-DNAMutation
gene	O
might	O
be	O
involved	O
in	O
the	O
development	O
of	O
type	O
1	O
diabetes	O
mellitus	O
in	O
the	O
Japanese	O
female	O
population	O
.	O

Introduction	O
of	O
histidine	O
analogs	O
leads	O
to	O
enhanced	O
proton	O
transfer	O
in	O
carbonic	O
anhydrase	O
V	O
.	O

The	O
rate-limiting	O
step	O
in	O
the	O
catalysis	O
of	O
the	O
hydration	O
of	O
CO2	O
by	O
carbonic	O
anhydrase	O
involves	O
transfer	O
of	O
protons	O
between	O
zinc-bound	O
water	O
and	O
solution	O
.	O

This	O
proton	O
transfer	O
can	O
be	O
enhanced	O
by	O
proton	O
shuttle	O
residues	O
within	O
the	O
active-site	O
cavity	O
of	O
the	O
enzyme	O
.	O

We	O
have	O
used	O
chemical	O
modulation	O
to	O
provide	O
novel	O
internal	O
proton	O
transfer	O
groups	O
that	O
enhance	O
catalysis	O
by	O
murine	O
carbonic	O
anhydrase	O
V	O
(	O
mCA	B-DNAMutation
V	I-DNAMutation
)	O
.	O

This	O
approach	O
involves	O
the	O
site-directed	O
mutation	O
of	O
a	O
targeted	O
residue	O
to	O
a	O
cysteine	O
which	O
is	O
then	O
subsequently	O
reacted	O
with	O
an	O
imidazole	O
analog	O
containing	O
an	O
appropriately	O
positioned	O
leaving	O
group	O
.	O

Compounds	O
examined	O
include	O
4-bromoethylimidazole	O
(4-BEI)	O
,	O
2-chloromethylimidazole	O
(2-CMI)	O
,	O
4-chloromethylimidazole	O
(4-CMI)	O
,	O
and	O
a	O
triazole	O
analog	O
.	O

Two	O
sites	O
in	O
mCA	B-DNAMutation
V	I-DNAMutation
,	O
Lys	O
91	O
and	O
Tyr	O
131	O
,	O
located	O
on	O
the	O
rim	O
of	O
the	O
active-site	O
cavity	O
have	O
been	O
targeted	O
for	O
the	O
introduction	O
of	O
these	O
imidazole	O
analogs	O
.	O

Modification	O
of	O
the	O
introduced	B-DNAMutation
Cys	I-DNAMutation
131	I-DNAMutation
with	O
4-BEI	O
and	O
4-CMI	O
resulted	O
in	O
enhancements	O
of	O
up	O
to	O
threefold	O
in	O
catalytic	O
activity	O
.	O

The	O
pH	O
profiles	O
indicate	O
the	O
presence	O
of	O
a	O
new	O
proton	O
shuttle	O
residue	O
of	O
pKa	O
near	O
5.8	O
,	O
consistent	O
with	O
the	O
introduction	O
of	O
a	O
functional	O
proton	O
transfer	O
group	O
into	O
the	O
active	O
site	O
.	O

This	O
is	O
the	O
first	O
example	O
of	O
incorporation	O
by	O
chemical	O
modification	O
of	O
an	O
unnatural	O
amino	O
acid	O
analog	O
of	O
histidine	O
that	O
can	O
act	O
as	O
a	O
proton	O
shuttle	O
in	O
an	O
enzyme	O
.	O

Identification	O
of	O
a	O
gene	O
responsible	O
for	O
familial	O
Wolff-Parkinson-White	O
syndrome	O
.	O

BACKGROUND	O
:	O
The	O
Wolff-Parkinson-White	O
syndrome	O
,	O
with	O
a	O
prevalence	O
in	O
Western	O
countries	O
of	O
1.5	O
to	O
3.1	O
per	O
1000	O
persons	O
,	O
causes	O
considerable	O
morbidity	O
and	O
may	O
cause	O
sudden	O
death	O
.	O

We	O
identified	O
two	O
families	O
in	O
which	O
the	O
Wolff-Parkinson-White	O
syndrome	O
segregated	O
as	O
an	O
autosomal	O
dominant	O
disorder	O
.	O

METHODS	O
:	O
We	O
studied	O
70	O
members	O
of	O
the	O
two	O
families	O
(	O
57	O
in	O
Family	O
1	O
and	O
13	O
in	O
Family	O
2	O
)	O
.	O

The	O
subjects	O
underwent	O
12-lead	O
electrocardiography	O
and	O
two-dimensional	O
echocardiography	O
.	O

Genotyping	O
mapped	O
the	O
gene	O
responsible	O
to	O
7q34-q36	O
,	O
a	O
locus	O
previously	O
identified	O
to	O
be	O
responsible	O
for	O
an	O
inherited	O
form	O
of	O
Wolff-Parkinson-White	O
syndrome	O
.	O

Candidate	O
genes	O
were	O
identified	O
,	O
sequenced	O
,	O
and	O
analyzed	O
in	O
normal	O
and	O
affected	O
family	O
members	O
to	O
identify	O
the	O
disease-causing	O
gene	O
.	O

RESULTS	O
:	O
A	O
total	O
of	O
31	O
members	O
(	O
23	O
from	O
Family	O
1	O
and	O
8	O
from	O
Family	O
2	O
)	O
had	O
the	O
Wolff-Parkinson-White	O
syndrome	O
.	O

Affected	O
members	O
of	O
both	O
families	O
had	O
ventricular	O
preexcitation	O
with	O
conduction	O
abnormalities	O
and	O
cardiac	O
hypertrophy	O
.	O

The	O
maximal	O
combined	O
two-point	O
lod	O
score	O
was	O
9.82	O
at	O
a	O
distance	O
of	O
5	O
cM	O
from	O
marker	B-DNAMutation
D7S636	I-DNAMutation
,	O
which	O
confirmed	O
the	O
linkage	O
of	O
the	O
gene	O
in	O
both	O
families	O
to	O
7q34-q36	O
.	O

Haplotype	O
analysis	O
indicated	O
that	O
there	O
were	O
no	O
alleles	O
in	O
common	O
in	O
the	O
two	O
families	O
at	O
this	O
locus	O
,	O
suggesting	O
that	O
the	O
two	O
families	O
do	O
not	O
have	O
a	O
common	O
founder	O
.	O

We	O
identified	O
a	O
missense	O
mutation	O
in	O
the	O
gene	O
that	O
encodes	O
the	O
gamma2	O
regulatory	O
subunit	O
of	O
AMP-activated	O
protein	O
kinase	O
PRKAG2	B-DNAMutation
.	O

The	O
mutation	O
results	O
in	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
glutamine	I-DNAMutation
for	I-DNAMutation
arginine	I-DNAMutation
at	I-DNAMutation
residue	I-DNAMutation
302	I-DNAMutation
in	O
the	O
protein	O
.	O

CONCLUSIONS	O
:	O
The	O
identification	O
of	O
this	O
genetic	O
defect	O
has	O
important	O
implications	O
for	O
elucidating	O
the	O
pathogenesis	O
of	O
ventricular	O
preexcitation	O
.	O

Further	O
understanding	O
of	O
how	O
this	O
molecular	O
defect	O
leads	O
to	O
supraventricular	O
arrhythmias	O
could	O
influence	O
the	O
development	O
of	O
specific	O
therapies	O
for	O
other	O
forms	O
of	O
supraventricular	O
arrhythmia	O
.	O

X-linked	O
cerebellar	O
ataxia	O
and	O
sideroblastic	O
anaemia	O
associated	O
with	O
a	O
missense	O
mutation	O
in	O
the	O
ABC7	B-DNAMutation
gene	O
predicting	O
V411L	B-DNAMutation
.	O

Two	O
brothers	O
with	O
X-linked	B-DNAMutation
ataxia	I-DNAMutation
XLA	B-DNAMutation
were	O
found	O
to	O
have	O
hypochromic	O
red	O
cells	O
and	O
increased	O
erythrocyte	O
protoporphyrin	O
despite	O
normal	O
iron	O
stores	O
.	O

The	O
mother	O
was	O
unaffected	O
by	O
ataxia	O
and	O
had	O
normal	O
iron	O
stores	O
but	O
showed	O
evidence	O
of	O
some	O
red	O
cell	O
hypochromia	O
with	O
heavy	O
basophilic	O
stippling	O
that	O
stained	O
positive	O
for	O
iron	O
.	O

Bone	O
marrow	O
biopsy	O
confirmed	O
the	O
presence	O
of	O
ring	O
sideroblasts	O
in	O
one	O
of	O
the	O
brothers	O
.	O

The	O
absence	O
of	O
mutations	O
in	O
the	O
ALAS2	B-DNAMutation
gene	O
and	O
the	O
predominance	O
of	O
zinc	O
over	O
free	O
protoporphyrin	O
led	O
to	O
a	O
search	O
using	O
a	O
combination	O
of	O
DNA	O
and	O
cDNA	O
analysis	O
for	O
the	O
presence	O
of	O
mutations	O
in	O
the	O
ABC7	B-DNAMutation
gene	O
.	O

ABC7	B-DNAMutation
encodes	O
a	O
mitochondrial	O
half-type	O
ATP	O
Binding	O
Cassette	O
transporter	O
involved	O
in	O
iron	O
homeostasis	O
.	O

The	O
published	O
cDNA	O
sequence	O
was	O
used	O
to	O
search	O
databases	O
for	O
the	O
genomic	O
sequence	O
of	O
which	O
12	O
exons	O
spanning	O
23.4	O
kb	O
were	O
mapped	O
leaving	O
the	O
most	O
5'	O
nucleotides	O
unaccounted	O
for	O
.	O

The	O
identified	O
exons	O
and	O
their	O
exon-intron	O
boundaries	O
were	O
amplified	O
from	O
DNA	O
while	O
the	O
most	O
5'	O
sequence	O
including	O
the	O
initiation	O
codon	O
was	O
amplified	O
from	O
cDNA	O
of	O
peripheral	O
blood	O
cells	O
.	O

Direct	O
sequencing	O
revealed	O
hemizygosity	O
in	O
the	O
brothers	O
and	O
heterozygosity	O
in	O
the	O
mother	O
for	O
a	O
G-->C	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1299	I-DNAMutation
of	O
the	O
published	O
cDNA	O
.	O

This	O
predicts	O
a	O
V411L	B-DNAMutation
substitution	O
at	O
the	O
beginning	O
of	O
the	O
last	O
of	O
six	O
putative	O
transmembrane	O
regions	O
of	O
the	O
protein	O
.	O

Restriction	O
enzyme	O
digestion	O
confirmed	O
the	O
presence	O
of	O
this	O
mutation	O
in	O
the	O
three	O
family	O
members	O
but	O
could	O
not	O
detect	O
it	O
in	O
200	O
normal	O
alleles	O
.	O

An	O
uncle	O
affected	O
by	O
ataxia	O
also	O
carried	O
this	O
mutation	O
.	O

This	O
study	O
supports	O
the	O
recently	O
hypothesized	O
involvement	O
of	O
the	O
ABC7	B-DNAMutation
gene	O
in	O
XLSA/A	B-DNAMutation
and	O
highlights	O
a	O
protein	O
structure	O
region	O
of	O
importance	O
to	O
this	O
syndrome	O
.	O

Disruption	O
of	O
a	O
GATA	O
motif	O
in	O
the	O
Duffy	O
gene	O
promoter	O
abolishes	O
erythroid	O
gene	O
expression	O
in	O
Duffy-negative	O
individuals	O
.	O

The	O
mRNA	O
for	O
the	O
Duffy	O
blood	O
group	O
antigen	O
,	O
the	O
erythrocyte	O
receptor	O
for	O
the	O
Plasmodium	O
vivax	O
malaria	O
parasite	O
,	O
has	O
recently	O
been	O
cloned	O
and	O
shown	O
to	O
encode	O
a	O
widely	O
expressed	O
chemokine	O
receptor	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
Duffy	O
antigen/chemokine	O
receptor	O
gene	O
(DARC)	O
is	O
composed	O
of	O
a	O
single	O
exon	O
and	O
that	O
most	O
Duffy-negative	O
blacks	O
carry	O
a	O
silent	O
FY*B	O
allele	O
with	O
a	O
single	B-DNAMutation
T	I-DNAMutation
to	I-DNAMutation
C	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
-46	I-DNAMutation
.	O

This	O
mutation	O
impairs	O
the	O
promoter	O
activity	O
in	O
erythroid	O
cells	O
by	O
disrupting	O
a	O
binding	O
site	O
for	O
the	O
GATA1	O
erythroid	O
transcription	O
factor	O
.	O

With	O
the	O
recent	O
characterization	O
of	O
the	O
FY*A	O
and	O
FY*B	O
alleles	O
,	O
these	O
findings	O
provide	O
the	O
molecular	O
basis	O
of	O
the	O
Duffy	O
blood	O
group	O
system	O
and	O
an	O
explanation	O
for	O
the	O
erythroid-specific	O
repression	O
of	O
the	O
DARC	O
gene	O
in	O
Duffy-negative	O
individuals	O
.	O

Automethylation	O
of	O
CARM1	B-DNAMutation
allows	O
coupling	O
of	O
transcription	O
and	O
mRNA	O
splicing	O
.	O

Coactivator-associated	B-DNAMutation
arginine	I-DNAMutation
methyltransferase	I-DNAMutation
1	I-DNAMutation
CARM1	B-DNAMutation
,	O
the	O
histone	O
arginine	O
methyltransferase	O
and	O
coactivator	O
for	O
many	O
transcription	O
factors	O
,	O
is	O
subject	O
to	O
multiple	O
post-translational	O
modifications	O
(PTMs)	O
.	O

To	O
unbiasedly	O
investigate	O
novel	O
CARM1	B-DNAMutation
PTMs	O
we	O
employed	O
high-resolution	O
top-down	O
mass	O
spectrometry	O
.	O

Surprisingly	O
,	O
mouse	O
CARM1	B-DNAMutation
expressed	O
in	O
insect	O
and	O
mammalian	O
expression	O
systems	O
was	O
completely	O
dimethylated	O
at	O
a	O
single	O
site	O
in	O
the	O
C-terminal	O
domain	O
(CTD)	O
.	O

We	O
demonstrate	O
that	O
dimethylation	O
of	O
CARM1	B-DNAMutation
occurs	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
and	O
proceeds	O
via	O
an	O
automethylation	O
mechanism	O
.	O

To	O
probe	O
function	O
of	O
automethylation	O
,	O
we	O
mutated	O
arginine	B-DNAMutation
551	I-DNAMutation
to	I-DNAMutation
lysine	I-DNAMutation
to	O
create	O
an	O
automethylation-deficient	O
CARM1	B-DNAMutation
.	O

Although	O
mutation	O
of	O
CARM1's	B-DNAMutation
automethylation	O
site	O
did	O
not	O
affect	O
its	O
enzymatic	O
activity	O
,	O
it	O
did	O
impair	O
both	O
CARM1-activated	B-DNAMutation
transcription	O
and	O
pre-mRNA	O
splicing	O
.	O

These	O
results	O
strongly	O
imply	O
that	O
automethylation	O
of	O
CARM1	B-DNAMutation
provides	O
a	O
direct	O
link	O
to	O
couple	O
transcription	O
and	O
pre-mRNA	O
splicing	O
in	O
a	O
manner	O
differing	O
from	O
the	O
other	O
steroid	O
receptor	O
coactivators	O
.	O

Furthermore	O
,	O
our	O
study	O
identifies	O
a	O
self-regulatory	O
signaling	O
mechanism	O
from	O
CARM1's	B-DNAMutation
catalytic	O
domain	O
to	O
its	O
CTD	O
.	O

Three	O
new	O
adenosine	O
deaminase	O
mutations	O
that	O
define	O
a	O
splicing	O
enhancer	O
and	O
cause	O
severe	O
and	O
partial	O
phenotypes	O
:	O
implications	O
for	O
evolution	O
of	O
a	O
CpG	O
hotspot	O
and	O
expression	O
of	O
a	O
transduced	O
ADA	O
cDNA	O
.	O

We	O
report	O
three	O
novel	O
adenosine	O
deaminase	O
(ADA)	O
mutations	O
with	O
interesting	O
implications	O
.	O

A	O
Somali	O
child	O
with	O
severe	O
combined	O
immunodeficiency	O
disease	O
(SCID)	O
had	O
reduced	O
ADA	O
mRNA	O
in	O
T	O
cells	O
and	O
was	O
homozygous	O
for	O
the	O
nonsense	B-DNAMutation
mutation	I-DNAMutation
Q3X	I-DNAMutation
.	O

Unexpectedly	O
,	O
her	O
healthy	O
father	O
was	O
a	O
compound	O
ADA	O
heterozygote	O
whose	O
second	O
allele	O
carried	O
a	O
'partial'	O
mutation	O
,	O
R142Q	B-DNAMutation
,	O
due	O
to	O
a	O
G-->A	B-DNAMutation
transition	I-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
CpG	I-DNAMutation
dinucleotide	I-DNAMutation
.	O

A	B-DNAMutation
C-->T	I-DNAMutation
transition	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
same	I-DNAMutation
CpG	I-DNAMutation
produced	O
a	O
nonsense	O
mutation	O
,	O
R142X	B-DNAMutation
,	O
in	O
two	O
homozygous	O
Canadian	O
Mennonite	O
infants	O
with	O
SCID	O
.	O

The	O
severe	O
and	O
healthy	O
phenotypes	O
associated	O
with	O
R142X	B-DNAMutation
and	O
R142Q	B-DNAMutation
,	O
the	O
high	O
frequency	O
of	O
'partial'	O
ADA	O
mutations	O
arising	O
from	O
CpGs	O
in	O
healthy	O
individuals	O
of	O
African	O
descent	O
and	O
the	O
presence	O
of	O
CAA	O
(glutamine)	O
at	O
codon	O
142	O
in	O
murine	O
ADA	O
,	O
suggest	O
selection	O
for	O
replacement	B-DNAMutation
of	I-DNAMutation
this	I-DNAMutation
CpG	I-DNAMutation
hotspot	I-DNAMutation
by	I-DNAMutation
CpA	I-DNAMutation
during	O
ADA	O
evolution	O
.	O

R142X	B-DNAMutation
,	O
located	O
within	O
a	O
purine-rich	O
segment	O
at	O
nt	O
62/116	O
of	O
exon	O
5	O
,	O
caused	B-DNAMutation
skipping	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
exon	I-DNAMutation
,	O
possibly	O
by	O
disrupting	O
a	O
splicing	O
enhancer	O
.	O

Absence	B-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
5	I-DNAMutation
in	O
T	O
cell	O
ADA	O
mRNA	O
and	O
low	O
ADA	O
activity	O
in	O
T	O
cells	O
and	O
erythrocytes	O
obtained	O
at	O
age	O
18-22	O
months	O
from	O
one	O
of	O
the	O
Mennonite	O
children	O
,	O
indicate	O
limited	O
expression	O
of	O
a	O
normal	O
ADA	O
cDNA	O
from	O
retrovirally	O
transduced	O
CD34+	O
umbilical	O
cord	O
leukocytes	O
infused	O
shortly	O
after	O
birth	O
in	O
an	O
attempt	O
at	O
stem	O
cell	O
gene	O
therapy	O
.	O

Mutant	O
human	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
alleles	O
and	O
their	O
expression	O
by	O
transfection	O
into	O
fibroblasts	O
.	O

Adenosine	B-DNAMutation
deaminase	I-DNAMutation
(ADA)	O
deficiency	O
in	O
humans	O
is	O
one	O
cause	O
of	O
severe	O
combined	O
immunodeficiency	O
disease	O
.	O

Single	O
base	O
mutations	O
affecting	O
the	O
ADA	O
protein	O
have	O
been	O
identified	O
for	O
both	O
alleles	O
of	O
the	O
ADA-deficient	B-DNAMutation
cell	O
line	O
GM2606	O
and	O
for	O
one	O
allele	O
of	O
the	O
ADA-deficient	B-DNAMutation
cell	O
line	O
GM2825A	O
.	O

One	O
allele	O
of	O
GM2606	O
has	O
a	O
mutation	O
altering	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
101	I-DNAMutation
from	I-DNAMutation
Arg	I-DNAMutation
to	I-DNAMutation
Trp	I-DNAMutation
,	O
and	O
the	O
other	O
allele	O
has	O
a	O
mutation	O
altering	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
211	I-DNAMutation
from	I-DNAMutation
Arg	I-DNAMutation
to	I-DNAMutation
His	I-DNAMutation
.	O

As	O
previously	O
reported	O
,	O
one	O
ADA	B-DNAMutation
allele	O
of	O
GM2825A	O
has	O
a	O
single	O
base	O
mutation	O
changing	O
Ala-329	B-DNAMutation
to	I-DNAMutation
Val-329	I-DNAMutation
,	O
and	O
the	O
other	O
allele	O
has	O
a	O
mutation	B-DNAMutation
which	I-DNAMutation
eliminates	I-DNAMutation
exon	I-DNAMutation
4	I-DNAMutation
from	O
the	O
mature	O
mRNA	O
.	O

Sequence	O
analysis	O
of	O
polymerase	O
chain	O
reaction-amplified	O
GM2825A	O
DNA	O
showed	O
a	O
single	B-DNAMutation
base	I-DNAMutation
change	I-DNAMutation
of	I-DNAMutation
A	I-DNAMutation
to	I-DNAMutation
G	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
invariant	I-DNAMutation
bases	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
3'	I-DNAMutation
splice	I-DNAMutation
site	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
3	I-DNAMutation
that	O
can	O
account	O
for	O
the	O
mis-splicing	O
of	O
exon	O
4	O
.	O

To	O
test	O
the	O
effect	O
on	O
ADA	O
catalytic	O
activity	O
of	O
these	O
mutations	O
and	O
the	O
mutations	O
previously	O
found	O
in	O
the	O
ADA-deficient	O
line	O
GM2756	O
,	O
expression	O
vectors	O
containing	O
normal	O
and	O
mutant	O
ADA-coding	O
sequences	O
under	O
transcriptional	O
regulation	O
of	O
the	O
Rous	O
sarcoma	O
virus	O
long	O
terminal	O
repeat	O
were	O
constructed	O
and	O
transfected	O
into	O
human	O
fibroblasts	O
.	O

All	O
transfected	O
cells	O
had	O
levels	O
of	O
ADA	B-DNAMutation
mRNA	O
15-25	O
times	O
higher	O
than	O
the	O
endogenous	O
ADA	B-DNAMutation
message	O
.	O

Yet	O
,	O
cells	O
transfected	O
with	O
the	O
normal	O
ADA-coding	B-DNAMutation
sequences	O
had	O
ADA	B-DNAMutation
enzymatic	O
levels	O
40	O
times	O
higher	O
than	O
cells	O
transfected	O
with	O
any	O
of	O
the	O
mutant	O
ADA	B-DNAMutation
sequences	O
.	O

This	O
analysis	O
demonstrates	O
that	O
while	O
the	O
mutant	O
ADA-coding	B-DNAMutation
sequences	O
are	O
transcribed	O
,	O
they	O
do	O
not	O
encode	O
a	O
functional	O
ADA	B-DNAMutation
protein	O
.	O

A	O
naturally	O
occurring	O
Tyr143His	B-DNAMutation
alpha	O
IIb	O
mutation	O
abolishes	O
alpha	O
IIb	O
beta	O
3	O
function	O
for	O
soluble	O
ligands	O
but	O
retains	O
its	O
ability	O
for	O
mediating	O
cell	O
adhesion	O
and	O
clot	O
retraction	O
:	O
comparison	O
with	O
other	O
mutations	O
causing	O
ligand-binding	O
defects	O
.	O

The	O
molecular	O
basis	O
for	O
the	O
interaction	O
between	O
a	O
prototypic	O
non-I-domain	O
integrin	O
,	O
alpha(IIb)beta(3)	O
,	O
and	O
its	O
ligands	O
remains	O
to	O
be	O
determined	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
characterized	O
a	O
novel	O
missense	O
mutation	O
Tyr143His	B-DNAMutation
in	O
alpha(IIb)	O
associated	O
with	O
a	O
variant	O
of	O
Glanzmann	O
thrombasthenia	O
.	O

Osaka-12	O
platelets	O
expressed	O
a	O
substantial	O
amount	O
of	O
alpha(IIb)beta(3)	O
(	O
36%-41%	O
of	O
control	O
)	O
but	O
failed	O
to	O
bind	O
soluble	O
ligands	O
,	O
including	O
a	O
high-affinity	O
alpha(IIb)beta(3)-specific	O
peptidomimetic	O
antagonist	O
.	O

Sequence	O
analysis	O
revealed	O
that	O
Osaka-12	O
is	O
a	O
compound	O
heterozygote	O
for	O
a	O
single	B-DNAMutation
(521)T>C	I-DNAMutation
substitution	I-DNAMutation
leading	I-DNAMutation
to	I-DNAMutation
a	I-DNAMutation
Tyr143His	I-DNAMutation
substitution	O
in	O
alpha(IIb)	O
and	O
for	O
the	O
null	O
expression	O
of	O
alpha(IIb)	O
mRNA	O
from	O
the	O
maternal	O
allele	O
.	O

Given	O
that	O
Tyr143	O
is	O
located	O
in	O
the	O
W3	O
4-1	O
loop	O
of	O
the	O
beta-propeller	O
domain	O
of	O
alpha(IIb)	O
,	O
we	O
examined	O
the	O
effects	O
of	O
Tyr143His	B-DNAMutation
or	O
Tyr143Ala	B-DNAMutation
substitution	O
on	O
the	O
expression	O
and	O
function	O
of	O
alpha(IIb)beta(3)	O
and	O
compared	O
them	O
with	O
KO	O
(	O
Arg-Thr	B-DNAMutation
insertion	I-DNAMutation
between	I-DNAMutation
160	I-DNAMutation
and	I-DNAMutation
161	I-DNAMutation
residues	I-DNAMutation
of	O
alpha(IIb)	O
)	O
and	O
with	O
the	O
Asp163Ala	B-DNAMutation
mutation	O
located	O
in	O
the	O
same	O
loop	O
by	O
using	O
293	O
cells	O
.	O

Each	O
of	O
them	O
abolished	O
the	O
binding	O
function	O
of	O
alpha(IIb)beta(3)	O
for	O
soluble	O
ligands	O
without	O
disturbing	O
alpha(IIb)beta(3)	O
expression	O
.	O

Because	O
immobilized	O
fibrinogen	O
and	O
fibrin	O
are	O
higher	O
affinity/avidity	O
ligands	O
for	O
alpha(IIb)beta(3)	O
,	O
we	O
performed	O
cell	O
adhesion	O
and	O
clot	O
retraction	O
assays	O
.	O

In	O
sharp	O
contrast	O
to	O
KO	O
mutation	O
and	O
Asp163Ala	B-DNAMutation
alpha(IIb)beta(3)	O
,	O
Tyr143His	B-DNAMutation
alpha(IIb)beta(3)-expressing	O
cells	O
still	O
had	O
some	O
ability	O
for	O
cell	O
adhesion	O
and	O
clot	O
retraction	O
.	O

Thus	O
,	O
the	O
functional	O
defect	O
induced	O
by	O
Tyr143His	B-DNAMutation
alpha(IIb)	O
is	O
likely	O
caused	O
by	O
its	O
allosteric	O
effect	O
rather	O
than	O
by	O
a	O
defect	O
in	O
the	O
ligand-binding	O
site	O
itself	O
.	O

These	O
detailed	O
structure-function	O
analyses	O
provide	O
better	O
understanding	O
of	O
the	O
ligand-binding	O
sites	O
in	O
integrins	O
.	O

Cloning	O
,	O
chromosomal	O
localization	O
,	O
and	O
functional	O
analysis	O
of	O
the	O
murine	O
estrogen	B-DNAMutation
receptor	I-DNAMutation
beta	I-DNAMutation
.	O

Estrogen	B-DNAMutation
receptor	I-DNAMutation
beta	I-DNAMutation
(	O
ER	B-DNAMutation
beta	I-DNAMutation
)	O
is	O
a	O
novel	O
steroid	O
receptor	O
that	O
is	O
expressed	O
in	O
rat	O
prostate	O
and	O
ovary	O
.	O

We	O
have	O
cloned	O
the	O
mouse	O
homolog	O
of	O
ER	B-DNAMutation
beta	I-DNAMutation
and	O
mapped	O
the	O
gene	O
,	O
designated	O
Estrb	B-DNAMutation
,	O
to	O
the	O
central	O
region	O
of	O
chromosome	O
12	O
.	O

The	O
cDNA	O
encodes	O
a	O
protein	O
of	O
485	O
amino	O
acids	O
that	O
shares	O
,	O
respectively	O
,	O
97%	O
and	O
60%	O
identity	O
with	O
the	O
DNA-	O
and	O
ligand-binding	O
domains	O
of	O
mouse	O
(m)	O
ER	B-DNAMutation
alpha	I-DNAMutation
.	O

Mouse	O
ER	B-DNAMutation
beta	I-DNAMutation
bind	O
to	O
an	O
inverted	O
repeat	O
spaced	O
by	O
three	O
nucleotides	O
in	O
a	O
gel	O
mobility	O
shift	O
assay	O
and	O
transactivates	O
promoters	O
containing	O
synthetic	O
or	O
natural	O
estrogen	O
response	O
elements	O
in	O
an	O
estradiol	O
(E2)-dependent	O
manner	O
.	O

Scatchard	O
analysis	O
indicates	O
that	O
mER	B-DNAMutation
beta	I-DNAMutation
has	O
slightly	O
lower	O
affinity	O
for	O
E2	O
[	O
dissociation	O
constant	O
(Kd)	O
=	O
0.5	O
nM	O
]	O
when	O
compared	O
with	O
mER	B-DNAMutation
alpha	I-DNAMutation
(	O
Kd	O
=	O
0.2	O
nM	O
)	O
.	O

Antiestrogens	O
,	O
including	O
4-hydroxytamoxifen	O
(OHT)	O
,	O
ICI	O
182,780	O
,	O
and	O
a	O
novel	O
compound	O
,	O
EM-800	O
,	O
inhibit	O
E2-dependent	O
transactivation	O
efficiently	O
.	O

However	O
,	O
while	O
OHT	O
displays	O
partial	O
agonistic	O
activity	O
with	O
ER	B-DNAMutation
alpha	I-DNAMutation
on	O
a	O
basal	O
promoter	O
linked	O
to	O
estrogen	O
response	O
elements	O
in	O
Cos-1	O
cells	O
,	O
this	O
effect	O
is	O
not	O
observed	O
with	O
mER	B-DNAMutation
beta	I-DNAMutation
.	O

Cotransfection	O
of	O
mER	B-DNAMutation
beta	I-DNAMutation
and	O
H-RasV12	O
causes	O
enhanced	O
activation	O
in	O
the	O
presence	O
of	O
E2	O
.	O

Mutagenesis	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
serine	I-DNAMutation
residue	I-DNAMutation
(	I-DNAMutation
position	I-DNAMutation
60	I-DNAMutation
)	O
,	O
located	O
within	O
a	O
mitogen-activated	O
protein	O
kinase	O
consensus	O
phosphorylation	O
site	O
abolishes	O
the	O
stimulatory	O
effect	O
of	O
Ras	O
,	O
suggesting	O
that	O
the	O
activity	O
of	O
mER	B-DNAMutation
beta	I-DNAMutation
is	O
also	O
regulated	O
by	O
the	O
mitogen-activated	O
protein	O
kinase	O
pathway	O
.	O

Surprisingly	O
,	O
the	O
coactivator	O
SRC-1	B-DNAMutation
up-regulates	O
mER	B-DNAMutation
beta	I-DNAMutation
transactivation	O
both	O
in	O
the	O
absence	O
and	O
presence	O
of	O
E2	O
,	O
and	O
in	O
vitro	O
interaction	O
between	O
SRC-1	B-DNAMutation
and	O
the	O
ER	O
beta	O
ligand-binding	O
domain	O
is	O
enhanced	O
by	O
E2	O
.	O

Moreover	O
,	O
the	O
ligand-independent	O
stimulatory	O
effect	O
of	O
SRC-1	B-DNAMutation
on	O
ER	B-DNAMutation
beta	I-DNAMutation
transcriptional	O
activity	O
is	O
abolished	O
by	O
ICI	O
182,780	O
,	O
but	O
not	O
by	O
OHT	O
.	O

Our	O
results	O
demonstrate	O
that	O
while	O
ER	B-DNAMutation
beta	I-DNAMutation
shares	O
many	O
of	O
the	O
functional	O
characteristics	O
of	O
ER	B-DNAMutation
alpha	I-DNAMutation
,	O
the	O
molecular	O
mechanisms	O
regulating	O
the	O
transcriptional	O
activity	O
of	O
mER	B-DNAMutation
beta	I-DNAMutation
may	O
be	O
distinct	O
from	O
those	O
of	O
ER	B-DNAMutation
alpha	I-DNAMutation
.	O

A	O
polymorphism	O
in	O
the	O
beta1	O
adrenergic	O
receptor	O
is	O
associated	O
with	O
resting	O
heart	O
rate	O
.	O

Resting	O
heart	O
rate	O
is	O
significantly	O
associated	O
with	O
cardiovascular	O
morbidity	O
and	O
mortality	O
.	O

However	O
,	O
the	O
extent	O
to	O
which	O
resting	O
heart	O
rate	O
is	O
genetically	O
determined	O
is	O
poorly	O
understood	O
,	O
and	O
no	O
genes	O
have	O
been	O
found	O
that	O
contribute	O
to	O
variation	O
in	O
resting	O
heart	O
rate	O
.	O

Because	O
signaling	O
through	O
the	O
beta1	O
adrenergic	O
receptor	O
is	O
a	O
key	O
determinant	O
of	O
cardiac	O
function	O
,	O
we	O
tested	O
whether	O
polymorphisms	O
in	O
this	O
receptor	O
are	O
associated	O
with	O
resting	O
heart	O
rate	O
.	O

A	O
cohort	O
of	O
>1,000	O
individuals	O
of	O
Chinese	O
and	O
Japanese	O
descent	O
,	O
from	O
nuclear	O
families	O
,	O
was	O
genotyped	O
for	O
two	O
polymorphisms	O
,	O
resulting	O
in	O
a	O
serine/glycine	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
49	I-DNAMutation
Ser49Gly	B-DNAMutation
and	O
an	O
arginine/glycine	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
residue	I-DNAMutation
389	I-DNAMutation
Arg389Gly	B-DNAMutation
,	O
in	O
the	O
beta1	O
adrenergic	O
receptor	O
.	O

For	O
comparison	O
,	O
polymorphisms	O
in	O
the	O
beta2	B-DNAMutation
and	O
beta3	B-DNAMutation
adrenergic	I-DNAMutation
receptors	I-DNAMutation
were	O
also	O
evaluated	O
.	O

The	O
Ser49Gly	B-DNAMutation
polymorphism	O
was	O
significantly	O
associated	O
(P=.0004)	O
with	O
resting	O
heart	O
rate	O
,	O
independent	O
of	O
other	O
variables	O
,	O
such	O
as	O
body-mass	O
index	O
,	O
age	O
,	O
sex	O
,	O
ethnicity	O
,	O
exercise	O
,	O
smoking	O
,	O
alcohol	O
intake	O
,	O
hypertension	O
status	O
,	O
and	O
treatment	O
with	O
beta	O
blockers	O
.	O

The	O
data	O
support	O
an	O
additive	O
model	O
in	O
which	O
individuals	O
heterozygous	O
for	O
the	O
Ser49Gly	B-DNAMutation
polymorphism	O
had	O
mean	O
heart	O
rates	O
intermediate	O
to	O
those	O
of	O
either	O
type	O
of	O
homozygote	O
,	O
with	O
Ser	O
homozygotes	O
having	O
the	O
highest	O
mean	O
heart	O
rate	O
and	O
with	O
Gly	O
homozygotes	O
having	O
the	O
lowest	O
.	O

Neither	O
the	O
Arg389Gly	B-DNAMutation
polymorphism	O
in	O
the	O
beta1	O
adrenergic	O
receptor	O
nor	O
polymorphisms	O
in	O
the	O
beta2	B-DNAMutation
and	O
beta3	B-DNAMutation
adrenergic	I-DNAMutation
receptors	I-DNAMutation
were	O
associated	O
with	O
resting	O
heart	O
rate	O
.	O

The	O
heritability	O
of	O
heart	O
rate	O
was	O
39.7%	O
+/-	O
7.1%	O
(P<10-7)	O
.	O

Novel	O
amyloid	O
precursor	O
protein	O
mutation	O
in	O
an	O
Iowa	O
family	O
with	O
dementia	O
and	O
severe	O
cerebral	O
amyloid	O
angiopathy	O
.	O

Several	O
mutations	O
in	O
the	O
amyloid	O
precursor	O
protein	O
(APP)	O
gene	O
have	O
been	O
found	O
to	O
associate	O
with	O
pathologic	O
deposition	O
of	O
the	O
beta-amyloid	B-DNAMutation
peptide	I-DNAMutation
(Abeta)	O
in	O
neuritic	O
plaques	O
or	O
in	O
the	O
walls	O
of	O
cerebral	O
vessels	O
.	O

We	O
report	O
a	O
mutation	O
at	O
a	O
novel	O
site	O
in	O
APP	O
in	O
a	O
three-generation	O
Iowa	O
family	O
with	O
autosomal	O
dominant	O
dementia	O
beginning	O
in	O
the	O
sixth	O
or	O
seventh	O
decade	O
of	O
life	O
.	O

The	O
proband	O
and	O
an	O
affected	O
brother	O
had	O
progressive	O
aphasic	O
dementia	O
,	O
leukoencephalopathy	O
,	O
and	O
occipital	O
calcifications	O
.	O

Neuropathological	O
examination	O
of	O
the	O
proband	O
revealed	O
severe	O
cerebral	O
amyloid	O
angiopathy	O
,	O
widespread	O
neurofibrillary	O
tangles	O
,	O
and	O
unusually	O
extensive	O
distribution	O
of	O
Abeta40	O
in	O
plaques	O
.	O

The	O
affected	O
brothers	O
shared	O
a	O
missense	O
mutation	O
in	O
APP	O
,	O
resulting	O
in	O
substitution	O
of	O
asparagine	B-DNAMutation
for	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
694	I-DNAMutation
.	O

This	O
site	O
corresponds	O
to	O
residue	O
23	O
of	O
Abeta	B-DNAMutation
,	O
thus	O
differing	O
from	O
familial	O
Alzheimer's	O
disease	O
mutations	O
,	O
which	O
occur	O
outside	O
the	O
Abeta	B-DNAMutation
sequence	O
.	O

Restriction	O
enzyme	O
analysis	O
of	O
DNA	O
from	O
94	O
unrelated	O
patients	O
with	O
sporadic	O
cerebral	O
amyloid	O
angiopathy-related	O
hemorrhage	O
found	O
no	O
other	O
instances	O
of	O
this	O
mutation	O
.	O

These	O
results	O
suggest	O
a	O
novel	O
site	O
within	O
Abeta	B-DNAMutation
that	O
may	O
promote	O
its	O
deposition	O
and	O
toxicity	O
.	O

A	O
gene	O
encoding	O
a	O
putative	O
GTPase	O
regulator	O
is	O
mutated	O
in	O
familial	O
amyotrophic	B-DNAMutation
lateral	I-DNAMutation
sclerosis	I-DNAMutation
2	I-DNAMutation
.	O

Amyotrophic	B-DNAMutation
lateral	I-DNAMutation
sclerosis	I-DNAMutation
2	I-DNAMutation
ALS2	B-DNAMutation
is	O
an	O
autosomal	O
recessive	O
form	O
of	O
juvenile	O
ALS	O
and	O
has	O
been	O
mapped	O
to	O
human	O
chromosome	O
2q33	O
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
two	O
independent	O
deletion	O
mutations	O
linked	O
to	O
ALS2	B-DNAMutation
in	O
the	O
coding	O
exons	O
of	O
the	O
new	O
gene	O
ALS2	B-DNAMutation
.	O

These	O
deletion	O
mutations	O
result	O
in	O
frameshifts	O
that	O
generate	O
premature	O
stop	O
codons	O
.	O

ALS2	B-DNAMutation
is	O
expressed	O
in	O
various	O
tissues	O
and	O
cells	O
,	O
including	O
neurons	O
throughout	O
the	O
brain	O
and	O
spinal	O
cord	O
,	O
and	O
encodes	O
a	O
protein	O
containing	O
multiple	O
domains	O
that	O
have	O
homology	O
to	O
RanGEF	O
as	O
well	O
as	O
RhoGEF	O
.	O

Deletion	O
mutations	O
are	O
predicted	O
to	O
cause	O
a	O
loss	O
of	O
protein	O
function	O
,	O
providing	O
strong	O
evidence	O
that	O
ALS2	B-DNAMutation
is	O
the	O
causative	O
gene	O
underlying	O
this	O
form	O
of	O
ALS	O
.	O

Skeletal	O
defects	O
in	O
ringelschwanz	O
mutant	O
mice	O
reveal	O
that	O
Lrp6	O
is	O
required	O
for	O
proper	O
somitogenesis	O
and	O
osteogenesis	O
.	O

Here	O
,	O
we	O
present	O
evidence	O
that	O
Lrp6	O
,	O
a	O
coreceptor	O
for	O
Wnt	O
ligands	O
,	O
is	O
required	O
for	O
the	O
normal	O
formation	O
of	O
somites	O
and	O
bones	O
.	O

By	O
positional	O
cloning	O
,	O
we	O
demonstrate	O
that	O
a	O
novel	O
spontaneous	O
mutation	O
ringelschwanz	O
(rs)	O
in	O
the	O
mouse	O
is	O
caused	O
by	O
a	O
point	O
mutation	O
in	O
Lrp6	O
,	O
leading	B-DNAMutation
to	I-DNAMutation
an	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
tryptophan	I-DNAMutation
for	I-DNAMutation
the	I-DNAMutation
evolutionarily	I-DNAMutation
conserved	I-DNAMutation
residue	I-DNAMutation
arginine	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
886	I-DNAMutation
R886W	B-DNAMutation
.	O

We	O
show	O
that	O
rs	O
is	O
a	O
hypomorphic	O
Lrp6	O
allele	O
by	O
a	O
genetic	O
complementation	O
test	O
with	O
Lrp6-null	O
mice	O
,	O
and	O
that	O
the	O
mutated	O
protein	O
cannot	O
efficiently	O
transduce	O
signals	O
through	O
the	O
Wnt/beta-catenin	B-DNAMutation
pathway	O
.	O

Homozygous	O
rs	O
mice	O
,	O
many	O
of	O
which	O
are	O
remarkably	O
viable	O
,	O
exhibit	O
a	O
combination	O
of	O
multiple	O
Wnt-deficient	O
phenotypes	O
,	O
including	O
dysmorphologies	O
of	O
the	O
axial	O
skeleton	O
,	O
digits	O
and	O
the	O
neural	O
tube	O
.	O

The	O
establishment	O
of	O
the	O
anteroposterior	O
somite	O
compartments	O
,	O
the	O
epithelialization	O
of	O
nascent	O
somites	O
,	O
and	O
the	O
formation	O
of	O
segment	O
borders	O
are	O
disturbed	O
in	O
rs	O
mutants	O
,	O
leading	O
to	O
a	O
characteristic	O
form	O
of	O
vertebral	O
malformations	O
,	O
similar	O
to	O
dysmorphologies	O
in	O
individuals	O
suffering	O
from	O
spondylocostal	O
dysostosis	O
.	O

Marker	O
expression	O
study	O
suggests	O
that	O
Lrp6	O
is	O
required	O
for	O
the	O
crosstalk	O
between	O
the	O
Wnt	O
and	O
notch-delta	O
signaling	O
pathways	O
during	O
somitogenesis	O
.	O

Furthermore	O
,	O
the	O
Lrp6	O
dysfunction	O
in	O
rs	O
leads	O
to	O
delayed	O
ossification	O
at	O
birth	O
and	O
to	O
a	O
low	O
bone	O
mass	O
phenotype	O
in	O
adults	O
.	O

Together	O
,	O
we	O
propose	O
that	O
Lrp6	B-DNAMutation
is	O
one	O
of	O
the	O
key	O
genetic	O
components	O
for	O
the	O
pathogenesis	O
of	O
vertebral	O
segmentation	O
defects	O
and	O
of	O
osteoporosis	O
in	O
humans	O
.	O

Hot	O
spot	O
mutations	O
in	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
deficiency	O
.	O

We	O
have	O
previously	O
characterized	O
mutant	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
(	I-DNAMutation
ADA	I-DNAMutation
;	I-DNAMutation
adenosine	I-DNAMutation
aminohydrolase	I-DNAMutation
,	O
EC	O
3.5.4.4	O
)	O
enzymes	O
in	O
seven	O
children	O
with	O
partial	O
ADA	B-DNAMutation
deficiency	O
.	O

Six	O
children	O
shared	O
common	O
origins	O
,	O
suggesting	O
a	O
common	O
progenitor	O
.	O

However	O
,	O
we	O
found	O
evidence	O
for	O
multiple	O
phenotypically	O
different	O
mutant	O
enzymes	O
.	O

We	O
hypothesized	O
that	O
many	O
of	O
the	O
mutations	O
would	O
be	O
at	O
CpG	O
dinucleotides	O
,	O
hot	B-DNAMutation
spots	I-DNAMutation
at	I-DNAMutation
which	I-DNAMutation
spontaneous	I-DNAMutation
deamination	I-DNAMutation
of	I-DNAMutation
5-methylcytosine	I-DNAMutation
results	I-DNAMutation
in	I-DNAMutation
C	I-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
or	O
G	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
transitions	O
.	O

Digestion	O
of	O
DNA	O
from	O
these	O
children	O
with	O
Msp	O
I	O
and	O
Taq	O
I	O
,	O
enzymes	O
recognizing	O
CpG	O
dinucleotides	O
,	O
identified	O
three	O
different	O
mutations	O
,	O
each	O
correlating	O
with	O
expression	O
of	O
a	O
different	O
mutant	O
enzyme	O
.	O

Sequencing	O
of	O
cDNA	O
clones	O
and	O
genomic	O
DNA	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
confirmed	O
the	O
presence	O
of	O
C	B-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
or	O
G	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
transitions	I-DNAMutation
at	I-DNAMutation
CpG	I-DNAMutation
dinucleotides	I-DNAMutation
(	O
C226	B-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
,	O
G446	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
,	O
and	O
C821	B-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
,	O
resulting	O
in	O
Arg76	B-DNAMutation
to	I-DNAMutation
Trp	I-DNAMutation
,	O
Arg149	B-DNAMutation
to	I-DNAMutation
Gln	I-DNAMutation
,	O
and	O
Pro274	B-DNAMutation
to	I-DNAMutation
Leu	I-DNAMutation
)	O
.	O

A	O
"null"	O
mutation	O
,	O
also	O
found	O
in	O
two	O
ADA-deficient	B-DNAMutation
severe	O
combined	O
immunodeficient	O
children	O
,	O
was	O
serendipitously	O
detected	O
as	O
gain	O
of	O
a	O
site	O
for	O
Msp	O
I	O
.	O

Simultaneous	O
loss	O
of	O
a	O
site	O
for	O
Bal	O
I	O
defined	O
the	O
precise	O
base	O
substitution	O
(	O
T320	B-DNAMutation
to	I-DNAMutation
C	I-DNAMutation
,	O
Leu107	B-DNAMutation
to	I-DNAMutation
Pro	I-DNAMutation
)	O
,	O
confirmed	O
by	O
sequence	O
analysis	O
.	O

To	O
determine	O
the	O
true	O
frequency	O
of	O
hot	O
spot	O
mutation	O
in	O
these	O
children	O
,	O
consecutively	O
ascertained	O
through	O
a	O
newborn	O
screening	O
program	O
,	O
we	O
sequenced	O
cDNA	O
from	O
the	O
remaining	O
alleles	O
.	O

Two	O
others	O
were	O
hot	O
spot	O
mutations	O
(	O
C631	B-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
and	O
G643	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
,	O
resulting	O
in	O
Arg211	B-DNAMutation
to	I-DNAMutation
Cys	I-DNAMutation
and	O
Ala215	B-DNAMutation
to	I-DNAMutation
Thr	I-DNAMutation
)	O
,	O
each	O
again	O
resulting	O
in	O
expression	O
of	O
a	O
phenotypically	O
different	O
mutant	O
enzyme	O
.	O

Only	O
one	O
additional	O
mutation	O
(	O
previously	O
identified	O
by	O
us	O
)	O
is	O
not	O
in	O
a	O
hot	O
spot	O
.	O

These	O
seven	O
mutations	O
account	O
for	O
all	O
14	O
chromosomes	O
in	O
these	O
children	O
.	O

There	O
is	O
thus	O
a	O
very	O
high	O
frequency	O
of	O
hot	O
spot	O
mutations	O
in	O
partial	O
ADA	B-DNAMutation
deficiency	O
.	O

Most	O
of	O
these	O
children	O
carry	O
two	O
different	O
mutant	O
alleles	O
.	O

We	O
were	O
able	O
to	O
correlate	O
genotype	O
and	O
phenotype	O
and	O
to	O
dissect	O
the	O
activity	O
of	O
individual	O
mutant	O
alleles	O
.	O

Tyrosine	O
769	O
of	O
the	O
keratinocyte	B-DNAMutation
growth	I-DNAMutation
factor	I-DNAMutation
receptor	I-DNAMutation
is	O
required	O
for	O
receptor	O
signaling	O
but	O
not	O
endocytosis	O
.	O

Keratinocyte	B-DNAMutation
growth	I-DNAMutation
factor	I-DNAMutation
receptor	I-DNAMutation
KGFR	B-DNAMutation
is	O
a	O
receptor	O
tyrosine	O
kinase	O
expressed	O
on	O
epithelial	O
cells	O
which	O
belongs	O
to	O
the	O
family	O
of	O
fibroblast	O
growth	O
factor	O
receptors	O
(FGFRs)	O
.	O

Following	O
ligand	O
binding	O
,	O
KGFR	B-DNAMutation
is	O
rapidly	O
autophosphorylated	O
on	O
specific	O
tyrosine	O
residues	O
in	O
the	O
intracellular	O
domain	O
,	O
recruits	O
substrate	O
proteins	O
,	O
and	O
is	O
rapidly	O
internalized	O
by	O
clathrin-mediated	O
endocytosis	O
.	O

The	O
role	O
of	O
different	O
autophosphorylation	O
sites	O
in	O
FGFRs	O
,	O
and	O
in	O
particular	O
the	O
role	O
of	O
the	O
tyrosine	O
766	O
in	O
FGFR1	O
,	O
first	O
identified	O
as	O
PLCgamma	O
binding	O
site	O
,	O
has	O
been	O
extensively	O
studied	O
.	O

We	O
analyzed	O
here	O
the	O
possible	O
role	O
of	O
the	O
tyrosine	O
769	O
in	O
KGFR	B-DNAMutation
,	O
corresponding	O
to	O
tyrosine	O
766	O
in	O
FGFR1	O
,	O
in	O
the	O
regulation	O
of	O
KGFR	B-DNAMutation
signal	O
transduction	O
and	O
MAPK	O
activation	O
as	O
well	O
as	O
in	O
the	O
control	O
of	O
the	O
endocytic	O
process	O
of	O
KGFR	B-DNAMutation
.	O

A	O
mutant	O
KGFR	B-DNAMutation
in	O
which	O
tyrosine	B-DNAMutation
769	I-DNAMutation
was	I-DNAMutation
substituted	I-DNAMutation
by	I-DNAMutation
phenylalanine	I-DNAMutation
was	O
generated	O
and	O
transfected	O
in	O
NIH3T3	O
and	O
HeLa	O
cells	O
.	O

Our	O
results	O
indicate	O
that	O
tyrosine	O
769	O
is	O
required	O
for	O
the	O
binding	O
to	O
KGFR	B-DNAMutation
and	O
tyrosine	O
phosphorylation	O
of	O
PLCgamma	O
as	O
well	O
as	O
for	O
the	O
full	O
activation	O
of	O
MAPKs	O
and	O
for	O
cell	O
proliferation	O
through	O
the	O
regulation	O
of	O
FRS2	B-DNAMutation
tyrosine	O
phosphorylation	O
,	O
suggesting	O
that	O
this	O
residue	O
represents	O
a	O
key	O
regulator	O
of	O
KGFR	B-DNAMutation
signal	O
transduction	O
.	O

Our	O
data	O
also	O
show	O
that	O
tyrosine	O
769	O
is	O
not	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
endocytic	O
process	O
of	O
KGFR	B-DNAMutation
.	O

Mutagenesis	O
identifies	O
new	O
signals	O
for	O
beta-amyloid	B-DNAMutation
precursor	I-DNAMutation
protein	I-DNAMutation
endocytosis	O
,	O
turnover	O
,	O
and	O
the	O
generation	O
of	O
secreted	O
fragments	O
,	O
including	O
Abeta42	O
.	O

It	O
has	O
long	O
been	O
assumed	O
that	O
the	O
C-terminal	O
motif	O
,	O
NPXY	O
,	O
is	O
the	O
internalization	O
signal	O
for	O
beta-amyloid	B-DNAMutation
precursor	I-DNAMutation
protein	I-DNAMutation
(APP)	O
and	O
that	O
the	O
NPXY	O
tyrosine	O
(	O
Tyr743	O
by	O
APP751	O
numbering	O
,	O
Tyr682	O
in	O
APP695	O
)	O
is	O
required	O
for	O
APP	O
endocytosis	O
.	O

To	O
evaluate	O
this	O
tenet	O
and	O
to	O
identify	O
the	O
specific	O
amino	O
acids	O
subserving	O
APP	O
endocytosis	O
,	O
we	O
mutated	B-DNAMutation
all	I-DNAMutation
tyrosines	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
APP	I-DNAMutation
cytoplasmic	I-DNAMutation
domain	I-DNAMutation
and	O
amino	B-DNAMutation
acids	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
sequence	I-DNAMutation
GYENPTY	I-DNAMutation
(	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
737-743	I-DNAMutation
)	O
.	O

Stable	O
cell	O
lines	O
expressing	O
these	O
mutations	O
were	O
assessed	O
for	O
APP	O
endocytosis	O
,	O
secretion	O
,	O
and	O
turnover	O
.	O

Normal	O
APP	O
endocytosis	O
was	O
observed	O
for	O
cells	O
expressing	O
Y709A	B-DNAMutation
,	O
G737A	B-DNAMutation
,	O
and	O
Y743A	B-DNAMutation
mutations	O
.	O

However	O
,	O
Y738A	B-DNAMutation
,	O
N740A	B-DNAMutation
,	O
and	O
P741A	B-DNAMutation
or	O
the	O
double	O
mutation	O
of	O
Y738A/P741A	B-DNAMutation
significantly	O
impaired	O
APP	O
internalization	O
to	O
a	O
level	O
similar	O
to	O
that	O
observed	O
for	O
cells	O
lacking	B-DNAMutation
nearly	I-DNAMutation
the	I-DNAMutation
entire	I-DNAMutation
APP	I-DNAMutation
cytoplasmic	I-DNAMutation
domain	I-DNAMutation
DeltaC	B-DNAMutation
,	O
arguing	O
that	O
the	O
dominant	O
signal	O
for	O
APP	O
endocytosis	O
is	O
the	O
tetrapeptide	O
YENP	O
.	O

Although	O
not	O
an	O
APP	O
internalization	O
signal	O
,	O
Tyr743	O
regulates	O
rapid	O
APP	O
turnover	O
because	O
half-life	O
increased	O
by	O
50%	O
with	O
the	O
Y743A	B-DNAMutation
mutation	O
alone	O
.	O

Secretion	O
of	O
the	O
APP-derived	O
proteolytic	O
fragment	O
,	O
Abeta	B-DNAMutation
,	O
was	O
tightly	O
correlated	O
with	O
APP	O
internalization	O
,	O
such	O
that	O
Abeta	B-DNAMutation
secretion	O
was	O
unchanged	O
for	O
cells	O
having	O
normal	O
APP	O
endocytosis	O
but	O
significantly	O
decreased	O
for	O
endocytosis-deficient	O
cell	O
lines	O
.	O

Remarkably	O
,	O
secretion	O
of	O
the	O
Abeta42	O
isoform	O
was	O
also	O
reduced	O
in	O
parallel	O
with	O
endocytosis	O
from	O
internalization-deficient	O
cell	O
lines	O
,	O
suggesting	O
an	O
important	O
role	O
for	O
APP	O
endocytosis	O
in	O
the	O
secretion	O
of	O
this	O
highly	O
pathogenic	O
Abeta	B-DNAMutation
species	O
.	O

The	O
effect	O
of	O
elimination	O
of	O
intersubunit	O
disulfide	O
bonds	O
on	O
the	O
activity	O
,	O
assembly	O
,	O
and	O
secretion	O
of	O
recombinant	O
human	B-DNAMutation
acetylcholinesterase	I-DNAMutation
.	O

Expression	O
of	O
acetylcholinesterase	B-DNAMutation
Cys-580----Ala	B-DNAMutation
mutant	O
.	O

Site-directed	O
mutagenesis	O
was	O
used	O
to	O
study	O
the	O
cysteine	O
residue	O
involved	O
in	O
the	O
assembly	O
of	O
human	B-DNAMutation
acetylcholinesterase	I-DNAMutation
(HuAChE)	O
catalytic	O
subunits	O
.	O

Substitution	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
cysteine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
580	I-DNAMutation
by	I-DNAMutation
alanine	I-DNAMutation
resulted	O
in	O
impairment	O
of	O
interchain	O
disulfide	O
bridge	O
formation	O
;	O
the	O
mutagenized	O
enzyme	O
C580A	B-DNAMutation
was	O
secreted	O
from	O
recombinant	O
cells	O
in	O
the	O
monomeric	O
form	O
and	O
failed	O
to	O
assemble	O
into	O
dimers	O
.	O

The	O
mutant	O
monomeric	O
HuAChE	O
did	O
not	O
differ	O
from	O
the	O
native	O
oligomeric	O
enzyme	O
neither	O
in	O
rate	O
of	O
catalysis	O
nor	O
in	O
affinity	O
to	O
acetylthiocholine	O
.	O

Mutant	O
monomers	O
were	O
also	O
shown	O
to	O
retain	O
the	O
acetylcholinesterase	B-DNAMutation
characteristic	O
sensitivity	O
to	O
high	O
substrate	O
concentrations	O
.	O

The	O
mutation	O
did	O
not	O
seem	O
to	O
affect	O
the	O
efficiencies	O
of	O
either	O
synthesis	O
or	O
secretion	O
of	O
recombinant	O
HuAChE	O
polypeptides	O
,	O
as	O
was	O
demonstrated	O
in	O
cell	O
lines	O
derived	O
from	O
human	O
embryonic	O
kidney	O
(	O
293	O
cells	O
)	O
as	O
well	O
as	O
from	O
a	O
human	O
neuroblastoma	O
(SK-N-SH)	O
.	O

Furthermore	O
,	O
the	O
mutation	O
did	O
not	O
lead	O
to	O
an	O
increase	O
in	O
accumulation	O
of	O
intracellular	O
HuAChE	O
polypeptides	O
,	O
suggesting	O
that	O
export	O
of	O
acetylcholinesterase	B-DNAMutation
from	O
cells	O
may	O
not	O
be	O
coupled	O
to	O
subunit	O
assembly	O
.	O

Molecular	O
characterisation	O
of	O
three	O
alpha-1-antitrypsin	B-DNAMutation
deficiency	O
variants	O
:	O
proteinase	O
inhibitor	O
(Pi)	O
nullcardiff	O
Asp256----Val	B-DNAMutation
;	O
PiMmalton	O
Phe51----deletion	B-DNAMutation
and	O
PiI	O
Arg39----Cys	B-DNAMutation
.	O

Three	O
mutations	O
causing	O
alpha-1-antitrypsin	B-DNAMutation
deficiency	O
have	O
been	O
identified	O
by	O
gene	O
amplification	O
and	O
direct	O
DNA	O
sequencing	O
.	O

In	O
the	O
Pi	O
(proteinase-inhibitor)	O
nullcardiff	O
gene	O
,	O
the	O
codon	B-DNAMutation
for	I-DNAMutation
aspartate	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
256	I-DNAMutation
has	I-DNAMutation
mutated	I-DNAMutation
to	I-DNAMutation
encode	I-DNAMutation
valine	I-DNAMutation
.	O

In	O
PiMmalton	O
and	O
Pi	O
I	O
,	O
the	O
respective	O
mutations	O
are	O
the	O
deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
codon	I-DNAMutation
for	I-DNAMutation
a	I-DNAMutation
phenylalanine	I-DNAMutation
residue	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
51	I-DNAMutation
or	I-DNAMutation
52	I-DNAMutation
,	O
and	O
a	O
single	B-DNAMutation
base	I-DNAMutation
substitution	I-DNAMutation
resulting	I-DNAMutation
in	I-DNAMutation
arginine	I-DNAMutation
being	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
cysteine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
39	I-DNAMutation
.	O

Examination	O
of	O
the	O
protein	O
tertiary	O
structure	O
suggests	O
that	O
all	O
of	O
these	O
mutations	O
are	O
likely	O
to	O
result	O
in	O
folding	O
abnormalities	O
that	O
may	O
explain	O
the	O
deficiency	O
states	O
.	O

Palmitoylation	O
of	O
multiple	O
Src-family	O
kinases	O
at	O
a	O
homologous	O
N-terminal	O
motif	O
.	O

We	O
have	O
recently	O
identified	O
a	O
novel	O
N-terminal	O
cysteine-containing	O
motif	O
which	O
specifies	O
the	O
palmitoylation	O
of	O
several	O
G-protein	O
alpha-subunits	O
[	O
Parenti	O
,	O
ViganÃ³	O
,	O
Newman	O
,	O
Milligan	O
and	O
Magee	O
(1993)	O
Biochem	O
.	O

J	O
.	O

291	O
,	O
349-353	O
]	O
.	O

A	O
related	O
motif	O
occurs	O
at	O
the	O
N-terminus	O
of	O
members	O
of	O
the	O
Src	O
family	O
of	O
protein	O
tyrosine	O
kinases	O
except	O
for	O
Src	O
itself	O
and	O
Blk	O
.	O

We	O
have	O
investigated	O
whether	O
the	O
Src	O
,	O
Fyn	O
,	O
Yes	O
and	O
Lck	O
gene	O
products	O
are	O
palmitoylated	O
.	O

Src	O
was	O
not	O
labelled	O
with	O
[3H]palmitate	O
when	O
endogenously	O
expressed	O
in	O
COS	O
cells	O
.	O

In	O
contrast	O
,	O
endogenous	O
Yes	O
immunoprecipitated	O
from	O
COS	O
cells	O
was	O
palmitoylated	O
.	O

Fyn	O
was	O
palmitoylated	O
in	O
insect	O
cells	O
infected	O
with	O
a	O
recombinant	O
baculovirus	O
and	O
the	O
palmitoylation	O
was	O
independent	O
of	O
protein	O
synthesis	O
,	O
suggesting	O
a	O
dynamic	O
turnover	O
of	O
this	O
lipid	O
.	O

Fatty	O
acid	O
analysis	O
indicated	O
that	O
most	O
of	O
the	O
label	O
was	O
incorporated	O
as	O
palmitate	O
.	O

Lck	O
was	O
palmitoylated	O
when	O
expressed	O
by	O
transfection	O
in	O
COS	O
cells	O
.	O

All	O
of	O
these	O
protein	O
tyrosine	O
kinases	O
were	O
also	O
detectably	O
myristoylated	O
in	O
each	O
of	O
the	O
systems	O
tested	O
.	O

Experiments	O
performed	O
with	O
mutants	O
of	O
Lck	O
expressed	O
by	O
transfection	O
in	O
COS	O
cells	O
indicated	O
that	O
cysteines	O
at	O
positions	O
3	O
and	O
5	O
were	O
both	O
palmitoylation	O
sites	O
and	O
that	O
myristoylation	O
was	O
required	O
for	O
palmitoylation	O
.	O

To	O
confirm	O
that	O
palmitoylation	O
was	O
occurring	O
on	O
cysteines	O
in	O
the	O
N-terminal	O
region	O
of	O
Fyn	O
,	O
site-directed	O
mutagenesis	O
was	O
used	O
to	B-DNAMutation
replace	I-DNAMutation
the	I-DNAMutation
cysteines	I-DNAMutation
at	I-DNAMutation
positions	I-DNAMutation
3	I-DNAMutation
and	I-DNAMutation
6	I-DNAMutation
with	I-DNAMutation
alanine	I-DNAMutation
.	O

The	O
resulting	O
protein	O
was	O
not	O
palmitoylated	O
but	O
was	O
still	O
myristoylated	O
when	O
expressed	O
in	O
COS	O
cells	O
.	O

A	B-DNAMutation
glycine	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
mutant	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2	O
was	O
also	O
not	O
palmitoylated	O
,	O
showing	O
that	O
myristoylation	O
is	O
a	O
prerequisite	O
for	O
palmitoylation	O
.	O

Our	O
data	O
indicate	O
that	O
Src	O
family	O
members	O
containing	O
the	O
N-terminal	O
cysteine	O
motif	O
are	O
indeed	O
palmitoylated	O
.	O

By	O
analogy	O
with	O
Ras	O
,	O
it	O
is	O
possible	O
that	O
palmitoylation	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
localization	O
and	O
function	O
of	O
Src	O
family	O
protein	O
tyrosine	O
kinases	O
.	O

A	O
polymorphism	O
in	O
the	O
human	O
agouti-related	O
protein	O
is	O
associated	O
with	O
late-onset	O
obesity	O
.	O

The	O
mouse	O
agouti-related	B-DNAMutation
protein	I-DNAMutation
AGRP	B-DNAMutation
is	O
a	O
powerful	O
appetite	O
effector	O
that	O
results	O
in	O
hyperphagia	O
and	O
the	O
development	O
of	O
obesity	O
when	O
administered	O
intracerebroventricularly	O
or	O
when	O
overexpressed	O
in	O
transgenic	O
mice	O
.	O

Animal	O
studies	O
have	O
also	O
shown	O
that	O
exogenous	O
administration	O
of	O
AGRP	O
predisposes	O
toward	O
hedonic	O
intake	O
of	O
high	O
fat	O
and	O
high	O
sucrose	O
diets	O
.	O

The	O
human	O
ortholog	O
hAGRP	B-DNAMutation
maps	O
on	O
chromosome	O
16q22	O
and	O
has	O
similar	O
physiological	O
properties	O
,	O
as	O
tested	O
in	O
animal	O
models	O
.	O

A	O
polymorphism	O
was	O
identified	O
in	O
the	O
third	O
exon	O
of	O
hAGRP	B-DNAMutation
,	O
c.199G-->A	B-DNAMutation
,	O
that	O
resulted	O
in	O
a	O
nonconservative	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
substitution	I-DNAMutation
,	I-DNAMutation
Ala(67)Thr	I-DNAMutation
.	O

Computational	O
analysis	O
of	O
the	O
protein	O
showed	O
significant	O
differences	O
in	O
the	O
coils	O
of	O
the	O
two	O
polymorphic	O
isoforms	O
of	O
the	O
protein	O
.	O

Human	O
studies	O
showed	O
no	O
genotype	O
effects	O
in	O
individuals	O
with	O
a	O
mean	O
age	O
of	O
25	O
yr	O
.	O

However	O
,	O
the	O
G/G	O
genotype	O
was	O
significantly	O
associated	O
with	O
fatness	O
and	O
abdominal	O
adiposity	O
in	O
the	O
parental	O
population	O
with	O
a	O
mean	O
age	O
of	O
53	O
yr	O
.	O

The	O
c.199G-->A	B-DNAMutation
polymorphism	O
in	O
hAGRP	B-DNAMutation
could	O
,	O
therefore	O
,	O
play	O
a	O
role	O
in	O
the	O
development	O
of	O
human	O
obesity	O
in	O
an	O
age-dependent	O
fashion	O
.	O

CK2	B-DNAMutation
phosphorylates	O
the	O
angiotensin-converting	O
enzyme	O
and	O
regulates	O
its	O
retention	O
in	O
the	O
endothelial	O
cell	O
plasma	O
membrane	O
.	O

Soluble	O
angiotensin-converting	O
enzyme	O
ACE	B-DNAMutation
is	O
derived	O
from	O
the	O
membrane-bound	O
form	O
by	O
proteolytic	O
cleavage	O
of	O
its	O
C-terminal	O
domain	O
.	O

Because	O
intracellular	O
events	O
might	O
be	O
involved	O
in	O
the	O
regulation	O
of	O
the	O
cleavage	O
process	O
,	O
we	O
determined	O
whether	O
the	O
cytoplasmic	O
tail	O
of	O
ACE	B-DNAMutation
is	O
phosphorylated	O
and	O
whether	O
this	O
process	O
regulates	O
secretion	O
.	O

Immunoprecipitation	O
of	O
ACE	B-DNAMutation
(	O
180	O
kDa	O
)	O
from	O
(32)P-labeled	O
endothelial	O
cells	O
revealed	O
that	O
ACE	B-DNAMutation
is	O
phosphorylated	O
.	O

Phosphorylation	O
was	O
not	O
observed	O
in	O
endothelial	O
cells	O
overexpressing	O
a	O
mutant	O
form	O
of	O
ACE	B-DNAMutation
(	O
ACEDeltaS	B-DNAMutation
,	I-DNAMutation
all	I-DNAMutation
five	I-DNAMutation
cytoplasmic	I-DNAMutation
serine	I-DNAMutation
residues	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
alanine	I-DNAMutation
)	O
.	O

CK2	B-DNAMutation
coprecipitated	O
with	O
ACE	B-DNAMutation
from	O
endothelial	O
cells	O
,	O
and	O
CK2	B-DNAMutation
phosphorylated	O
both	O
ACE	B-DNAMutation
and	O
a	O
peptide	O
corresponding	O
to	O
the	O
cytoplasmic	O
tail	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
serine(1270)	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
CK2	I-DNAMutation
consensus	I-DNAMutation
sequence	I-DNAMutation
almost	O
abolished	O
ACE	B-DNAMutation
phosphorylation	O
.	O

In	O
ACE-overexpressing	B-DNAMutation
endothelial	O
cells	O
,	O
ACE	B-DNAMutation
was	O
mostly	O
localized	O
to	O
the	O
plasma	O
membrane	O
.	O

However	O
,	O
no	O
ACE	B-DNAMutation
was	O
detected	O
in	O
the	O
plasma	O
membrane	O
of	O
ACEDeltaS-overexpressing	O
cells	O
,	O
although	O
a	O
precursor	O
ACE	B-DNAMutation
(	O
170	O
kDa	O
)	O
was	O
prominent	O
in	O
the	O
endoplasmic	O
reticulum	O
and	O
the	O
cell	O
supernatant	O
contained	O
substantial	O
amounts	O
of	O
the	O
soluble	O
protein	O
(	O
175	O
kDa	O
)	O
.	O

A	O
correlation	O
between	O
ACE-phosphorylation	B-DNAMutation
and	O
secretion	O
was	O
confirmed	O
in	O
endothelial	O
cells	O
treated	O
with	O
the	O
CK2-inhibitor	B-DNAMutation
,	O
5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole	O
,	O
which	O
time-dependently	O
decreased	O
the	O
phosphorylation	O
of	O
ACE	B-DNAMutation
and	O
increased	O
its	O
shedding	O
.	O

These	O
results	O
indicate	O
that	O
the	O
CK2-mediated	B-DNAMutation
phosphorylation	O
of	O
ACE	B-DNAMutation
regulates	O
its	O
retention	O
in	O
the	O
plasma	O
membrane	O
and	O
may	O
determine	O
plasma	O
ACE	B-DNAMutation
levels	O
.	O

The	O
'Arctic'	O
APP	O
mutation	O
E693G	B-DNAMutation
causes	O
Alzheimer's	O
disease	O
by	O
enhanced	O
Abeta	O
protofibril	O
formation	O
.	O

Several	O
pathogenic	O
Alzheimer's	O
disease	O
(AD)	O
mutations	O
have	O
been	O
described	O
,	O
all	O
of	O
which	O
cause	O
increased	O
amyloid	O
beta-protein	O
(Abeta)	O
levels	O
.	O

Here	O
we	O
present	O
studies	O
of	O
a	O
pathogenic	O
amyloid	O
precursor	O
protein	O
(APP)	O
mutation	B-DNAMutation
,	I-DNAMutation
located	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
Abeta	I-DNAMutation
sequence	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
693	I-DNAMutation
E693G	B-DNAMutation
,	O
that	O
causes	O
AD	O
in	O
a	O
Swedish	O
family	O
.	O

Carriers	O
of	O
this	O
'Arctic'	O
mutation	O
showed	O
decreased	O
Abeta42	O
and	O
Abeta40	O
levels	O
in	O
plasma	O
.	O

Additionally	O
,	O
low	O
levels	O
of	O
Abeta42	O
were	O
detected	O
in	O
conditioned	O
media	O
from	O
cells	O
transfected	O
with	O
APPE693G	O
.	O

Fibrillization	O
studies	O
demonstrated	O
no	O
difference	O
in	O
fibrillization	O
rate	O
,	O
but	O
Abeta	O
with	O
the	O
Arctic	O
mutation	O
formed	O
protofibrils	O
at	O
a	O
much	O
higher	O
rate	O
and	O
in	O
larger	O
quantities	O
than	O
wild-type	O
(wt)	O
Abeta	O
.	O

The	O
finding	O
of	O
increased	O
protofibril	O
formation	O
and	O
decreased	O
Abeta	O
plasma	O
levels	O
in	O
the	O
Arctic	O
AD	O
may	O
reflect	O
an	O
alternative	O
pathogenic	O
mechanism	O
for	O
AD	O
involving	O
rapid	O
Abeta	O
protofibril	O
formation	O
leading	O
to	O
accelerated	O
buildup	O
of	O
insoluble	O
Abeta	O
intra-	O
and/or	O
extracellularly	O
.	O

Mutations	O
in	O
DCPS	O
and	O
EDC3	O
in	O
autosomal	O
recessive	O
intellectual	O
disability	O
indicate	O
a	O
crucial	O
role	O
for	O
mRNA	O
decapping	O
in	O
neurodevelopment	O
.	O

There	O
are	O
two	O
known	O
mRNA	O
degradation	O
pathways	O
,	O
3'	O
to	O
5'	O
and	O
5'	O
to	O
3'	O
.	O

We	O
identified	O
likely	O
pathogenic	O
variants	O
in	O
two	O
genes	O
involved	O
in	O
these	O
two	O
pathways	O
in	O
individuals	O
with	O
intellectual	O
disability	O
.	O

In	O
a	O
large	O
family	O
with	O
multiple	O
branches	O
,	O
we	O
identified	O
biallelic	O
variants	O
in	O
DCPS	O
in	O
three	O
affected	O
individuals	O
;	O
a	O
splice	O
site	O
variant	O
c.636+1G>A	B-DNAMutation
that	O
results	O
in	O
an	O
in-frame	B-DNAMutation
insertion	I-DNAMutation
of	I-DNAMutation
45	I-DNAMutation
nucleotides	I-DNAMutation
and	O
a	O
missense	O
variant	O
(	O
c.947C>T	B-DNAMutation
;	O
p.Thr316Met	B-DNAMutation
)	O
.	O

DCPS	O
decaps	O
the	O
cap	O
structure	O
generated	O
by	O
3'	O
to	O
5'	O
exonucleolytic	O
degradation	O
of	O
mRNA	O
.	O

In	O
vitro	O
decapping	O
assays	O
showed	O
an	O
ablation	O
of	O
decapping	O
function	O
for	O
both	O
variants	O
in	O
DCPS	O
.	O

In	O
another	O
family	O
,	O
we	O
identified	O
a	O
homozygous	O
mutation	O
(	O
c.161T>C	B-DNAMutation
;	O
p.Phe54Ser	B-DNAMutation
)	O
in	O
EDC3	O
in	O
two	O
affected	O
children	O
.	O

EDC3	O
stimulates	O
DCP2	O
,	O
which	O
decaps	O
mRNAs	O
at	O
the	O
beginning	O
of	O
the	O
5'	O
to	O
3'	O
degradation	O
pathway	O
.	O

In	O
vitro	O
decapping	O
assays	O
showed	O
that	O
altered	O
EDC3	O
is	O
unable	O
to	O
enhance	O
DCP2	O
decapping	O
at	O
low	O
concentrations	O
and	O
even	O
inhibits	O
DCP2	O
decapping	O
at	O
high	O
concentration	O
.	O

We	O
show	O
that	O
individuals	O
with	O
biallelic	O
mutations	O
in	O
these	O
genes	O
of	O
seemingly	O
central	O
functions	O
are	O
viable	O
and	O
that	O
these	O
possibly	O
lead	O
to	O
impairment	O
of	O
neurological	O
functions	O
linking	O
mRNA	O
decapping	O
to	O
normal	O
cognition	O
.	O

Our	O
results	O
further	O
affirm	O
an	O
emerging	O
theme	O
linking	O
aberrant	O
mRNA	O
metabolism	O
to	O
neurological	O
defects	O
.	O

Congenital	O
myasthenia-related	O
AChR	O
delta	O
subunit	O
mutation	O
interferes	O
with	O
intersubunit	O
communication	O
essential	O
for	O
channel	O
gating	O
.	O

Congenital	O
myasthenias	O
(CMs)	O
arise	O
from	O
defects	O
in	O
neuromuscular	O
junction-associated	O
proteins	O
.	O

Deciphering	O
the	O
molecular	O
bases	O
of	O
the	O
CMs	O
is	O
required	O
for	O
therapy	O
and	O
illuminates	O
structure-function	O
relationships	O
in	O
these	O
proteins	O
.	O

Here	O
,	O
we	O
analyze	O
the	O
effects	O
of	O
a	O
mutation	O
in	O
1	O
of	O
4	O
homologous	O
subunits	O
in	O
the	O
AChR	O
from	O
a	O
CM	O
patient	O
,	O
a	O
Leu	B-DNAMutation
to	I-DNAMutation
Pro	I-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
42	I-DNAMutation
of	O
the	O
delta	O
subunit	O
.	O

The	O
mutation	O
is	O
located	O
in	O
a	O
region	O
of	O
contact	O
between	O
subunits	O
required	O
for	O
rapid	O
opening	O
of	O
the	O
AChR	O
channel	O
and	O
impedes	O
the	O
rate	O
of	O
channel	O
opening	O
.	O

Substitutions	B-DNAMutation
of	I-DNAMutation
Gly	I-DNAMutation
,	I-DNAMutation
Lys	I-DNAMutation
,	I-DNAMutation
or	I-DNAMutation
Asp	I-DNAMutation
for	I-DNAMutation
deltaL42	I-DNAMutation
,	I-DNAMutation
or	I-DNAMutation
substitutions	I-DNAMutation
of	I-DNAMutation
Pro	I-DNAMutation
along	O
the	O
local	O
protein	O
chain	O
,	O
also	O
slowed	O
channel	O
opening	O
.	O

Substitution	B-DNAMutation
of	I-DNAMutation
Pro	I-DNAMutation
for	I-DNAMutation
Leu	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
epsilon	I-DNAMutation
subunit	I-DNAMutation
slowed	O
opening	O
,	O
whereas	O
this	O
substitution	O
had	O
no	O
effect	O
in	O
the	O
beta	O
subunit	O
and	O
actually	O
sped	O
opening	O
in	O
the	O
alpha	O
subunit	O
.	O

Analyses	O
of	O
energetic	O
coupling	O
between	O
residues	O
at	O
the	O
subunit	O
interface	O
showed	O
that	O
deltaL42	O
is	O
functionally	O
linked	O
to	O
alphaT127	O
,	O
a	O
key	O
residue	O
in	O
the	O
adjacent	O
alpha	O
subunit	O
required	O
for	O
rapid	O
channel	O
opening	O
.	O

Thus	O
,	O
deltaL42	O
is	O
part	O
of	O
an	O
intersubunit	O
network	O
that	O
enables	O
ACh	O
binding	O
to	O
rapidly	O
open	O
the	O
AChR	O
channel	O
,	O
which	O
may	O
be	O
compromised	O
in	O
patients	O
with	O
CM	O
.	O

SHP-1	B-DNAMutation
binds	O
and	O
negatively	O
modulates	O
the	O
c-Kit	O
receptor	O
by	O
interaction	O
with	O
tyrosine	O
569	O
in	O
the	O
c-Kit	O
juxtamembrane	O
domain	O
.	O

The	O
SH2	O
domain-containing	O
SHP-1	B-DNAMutation
tyrosine	O
phosphatase	O
has	O
been	O
shown	O
to	O
negatively	O
regulate	O
a	O
broad	O
spectrum	O
of	O
growth	O
factor-	O
and	O
cytokine-driven	O
mitogenic	O
signaling	O
pathways	O
.	O

Included	O
among	O
these	O
is	O
the	O
cascade	O
of	O
intracellular	O
events	O
evoked	O
by	O
stem	O
cell	O
factor	O
binding	O
to	O
c-Kit	O
,	O
a	O
tyrosine	O
kinase	O
receptor	O
which	O
associates	O
with	O
and	O
is	O
dephosphorylated	O
by	O
SHP-1	B-DNAMutation
.	O

Using	O
a	O
series	O
of	O
glutathione	O
S-transferase	O
(GST)	O
fusion	O
proteins	O
containing	O
either	O
tyrosine-phosphorylated	O
segments	O
of	O
the	O
c-Kit	O
cytosolic	O
region	O
or	O
the	O
SH2	O
domains	O
of	O
SHP-1	B-DNAMutation
,	O
we	O
have	O
shown	O
that	O
SHP-1	B-DNAMutation
interacts	O
with	O
c-Kit	O
by	O
binding	O
selectively	O
to	O
the	O
phosphorylated	O
c-Kit	O
juxtamembrane	O
region	O
and	O
that	O
the	O
association	O
of	O
c-Kit	O
with	O
the	O
larger	O
of	O
the	O
two	O
SHP-1	B-DNAMutation
isoforms	O
may	O
be	O
mediated	O
through	O
either	O
the	O
N-terminal	O
or	O
C-terminal	O
SHP-1	O
SH2	O
domain	O
.	O

The	O
results	O
of	O
binding	O
assays	O
with	O
mutagenized	O
GST-Kit	O
juxtamembrane	O
fusion	O
proteins	O
and	O
competitive	O
inhibition	O
assays	O
with	O
phosphopeptides	O
encompassing	O
each	O
c-Kit	O
juxtamembrane	O
region	O
identified	O
the	O
tyrosine	O
residue	O
at	O
position	O
569	O
as	O
the	O
major	O
site	O
for	O
binding	O
of	O
SHP-1	B-DNAMutation
to	O
c-Kit	O
and	O
suggested	O
that	O
tyrosine	O
567	O
contributes	O
to	O
,	O
but	O
is	O
not	O
required	O
for	O
,	O
this	O
interaction	O
.	O

By	O
analysis	O
of	O
Ba/F3	O
cells	O
retrovirally	O
transduced	O
to	O
express	O
c-Kit	O
receptors	O
,	O
phenylalanine	B-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
c-Kit	I-DNAMutation
tyrosine	I-DNAMutation
residue	I-DNAMutation
569	I-DNAMutation
was	O
shown	O
to	O
be	O
associated	O
with	O
disruption	O
of	O
c-Kit-SHP-1	B-DNAMutation
binding	O
and	O
induction	O
of	O
hyperproliferative	O
responses	O
to	O
stem	O
cell	O
factor	O
.	O

Although	O
phenylalanine	B-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
c-Kit	I-DNAMutation
tyrosine	I-DNAMutation
residue	I-DNAMutation
567	I-DNAMutation
in	O
the	O
Ba/F3-c-Kit	O
cells	O
did	O
not	O
alter	O
SHP-1	B-DNAMutation
binding	O
to	O
c-Kit	O
,	O
the	O
capacity	O
of	O
a	O
second	O
c-Kit-binding	O
tyrosine	O
phosphatase	O
,	O
SHP-2	B-DNAMutation
,	O
to	O
associate	O
with	O
c-Kit	O
was	O
markedly	O
reduced	O
,	O
and	O
the	O
cells	O
again	O
showed	O
hyperproliferative	O
responses	O
to	O
stem	O
cell	O
factor	O
.	O

These	O
data	O
therefore	O
identify	O
SHP-1	B-DNAMutation
binding	O
to	O
tyrosine	O
569	O
on	O
c-Kit	O
as	O
an	O
interaction	O
pivotal	O
to	O
SHP-1	B-DNAMutation
inhibitory	O
effects	O
on	O
c-Kit	O
signaling	O
,	O
but	O
they	O
indicate	O
as	O
well	O
that	O
cytosolic	O
protein	O
tyrosine	O
phosphatases	O
other	O
than	O
SHP-1	B-DNAMutation
may	O
also	O
negatively	O
regulate	O
the	O
coupling	O
of	O
c-Kit	O
engagement	O
to	O
proliferation	O
.	O

Circadian	O
mutant	O
Overtime	O
reveals	O
F-box	O
protein	O
FBXL3	B-DNAMutation
regulation	O
of	O
cryptochrome	O
and	O
period	O
gene	O
expression	O
.	O

Using	O
a	O
forward	O
genetics	O
ENU	O
mutagenesis	O
screen	O
for	O
recessive	O
mutations	O
that	O
affect	O
circadian	O
rhythmicity	O
in	O
the	O
mouse	O
,	O
we	O
isolated	O
a	O
long	O
period	O
(	O
approximately	O
26	O
hr	O
)	O
circadian	O
mutant	O
named	O
Overtime	B-DNAMutation
Ovtm	B-DNAMutation
.	O

Positional	O
cloning	O
and	O
genetic	O
complementation	O
reveal	O
that	O
Ovtm	B-DNAMutation
is	O
encoded	O
by	O
the	O
F-box	O
protein	O
FBXL3	B-DNAMutation
,	O
a	O
component	O
of	O
the	O
SKP1-CUL1-F-box-protein	O
(SCF)	O
E3	O
ubiquitin	O
ligase	O
complex	O
.	O

The	O
Ovtm	B-DNAMutation
mutation	O
causes	O
an	O
isoleucine	O
to	O
threonine	O
I364T	B-DNAMutation
substitution	O
leading	O
to	O
a	O
loss	O
of	O
function	O
in	O
FBXL3	B-DNAMutation
,	O
which	O
interacts	O
specifically	O
with	O
the	O
CRYPTOCHROME	O
(CRY)	O
proteins	O
.	O

In	O
Ovtm	B-DNAMutation
mice	O
,	O
expression	O
of	O
the	O
PERIOD	O
proteins	O
PER1	B-DNAMutation
and	O
PER2	B-DNAMutation
is	O
reduced	O
;	O
however	O
,	O
the	O
CRY	O
proteins	O
CRY1	B-DNAMutation
and	O
CRY2	B-DNAMutation
are	O
unchanged	O
.	O

The	O
loss	O
of	O
FBXL3	B-DNAMutation
function	O
leads	O
to	O
a	O
stabilization	O
of	O
the	O
CRY	O
proteins	O
,	O
which	O
in	O
turn	O
leads	O
to	O
a	O
global	O
transcriptional	O
repression	O
of	O
the	O
Per	O
and	O
Cry	O
genes	O
.	O

Thus	O
,	O
Fbxl3(Ovtm)	B-DNAMutation
defines	O
a	O
molecular	O
link	O
between	O
CRY	O
turnover	O
and	O
CLOCK/BMAL1-dependent	B-DNAMutation
circadian	O
transcription	O
to	O
modulate	O
circadian	O
period	O
.	O

Characterization	O
of	O
phosphotyrosine	O
binding	O
motifs	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
B	B-DNAMutation
and	I-DNAMutation
T	I-DNAMutation
lymphocyte	I-DNAMutation
attenuator	I-DNAMutation
required	O
for	O
association	O
with	O
protein	O
tyrosine	O
phosphatases	O
SHP-1	B-DNAMutation
and	O
SHP-2	B-DNAMutation
.	O

B	O
and	O
T	O
lymphocytes	O
express	O
receptors	O
providing	O
positive	O
and	O
negative	O
co-stimulatory	O
signals	O
.	O

We	O
recently	O
identified	O
a	O
novel	O
co-stimulatory	O
molecule	O
,	O
B	B-DNAMutation
and	I-DNAMutation
T	I-DNAMutation
lymphocyte	I-DNAMutation
attenuator	I-DNAMutation
BTLA	B-DNAMutation
,	O
which	O
exerts	O
inhibitory	O
effects	O
on	O
B	O
and	O
T	O
lymphocytes	O
.	O

The	O
cytoplasmic	O
domain	O
of	O
murine	O
and	O
human	O
BTLA	B-DNAMutation
share	O
three	O
conserved	O
tyrosine-based	O
signaling	O
motifs	O
,	O
a	O
Grb-2	B-DNAMutation
recognition	O
consensus	O
,	O
and	O
two	O
immunoreceptor	O
tyrosine-based	O
inhibitory	O
motifs	O
(ITIMs)	O
.	O

Phosphorylation	O
of	O
the	O
cytoplasmic	O
domain	O
of	O
BTLA	B-DNAMutation
induced	O
the	O
association	O
with	O
the	O
protein	O
tyrosine	O
phosphatases	O
SHP-1	B-DNAMutation
and	O
SHP-2	B-DNAMutation
.	O

Association	O
of	O
SHP-1	B-DNAMutation
and	O
SHP-2	B-DNAMutation
to	O
other	O
receptors	O
can	O
involve	O
recruitment	O
to	O
either	O
a	O
single	O
receptor	O
ITIM	O
or	O
to	O
two	O
receptor	O
ITIMs	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
requirements	O
of	O
BTLA	B-DNAMutation
interaction	O
with	O
SHP-1	B-DNAMutation
and	O
SHP-2	B-DNAMutation
in	O
a	O
series	O
of	O
murine	O
and	O
human	O
BTLA	B-DNAMutation
mutants	O
.	O

For	O
human	O
BTLA	B-DNAMutation
,	O
mutations	B-DNAMutation
of	I-DNAMutation
either	I-DNAMutation
Y257	I-DNAMutation
or	I-DNAMutation
Y282	I-DNAMutation
,	I-DNAMutation
but	I-DNAMutation
not	I-DNAMutation
Y226	I-DNAMutation
,	O
abrogated	O
association	O
with	O
both	O
SHP-1	B-DNAMutation
and	O
SHP-2	B-DNAMutation
.	O

For	O
murine	O
BTLA	B-DNAMutation
,	O
mutation	B-DNAMutation
of	I-DNAMutation
either	I-DNAMutation
Y274	I-DNAMutation
or	I-DNAMutation
Y299	I-DNAMutation
,	I-DNAMutation
but	I-DNAMutation
not	I-DNAMutation
Y245	I-DNAMutation
,	O
also	O
abrogated	O
association	O
with	O
both	O
SHP-1	B-DNAMutation
and	O
SHP-2	B-DNAMutation
.	O

These	O
results	O
indicate	O
that	O
for	O
both	O
murine	O
and	O
human	O
BTLA	B-DNAMutation
,	O
association	O
with	O
SHP-1	B-DNAMutation
or	O
SHP-2	B-DNAMutation
requires	O
both	O
of	O
conserved	O
ITIM	O
motifs	O
and	O
does	O
not	O
involve	O
the	O
conserved	O
Grb-2	B-DNAMutation
consensus	O
.	O

Thus	O
,	O
similar	O
to	O
the	O
bisphosphoryl	O
tyrosine-based	O
activation	O
motif	O
(BTAM)	O
by	O
which	O
the	O
Grb-2	B-DNAMutation
associated	O
binder	O
Gab1	B-DNAMutation
,	O
PDGF	O
receptor	O
,	O
and	O
PECAM-1	B-DNAMutation
recruit	O
SHP-2	B-DNAMutation
,	O
BTLA	B-DNAMutation
also	O
relies	O
on	O
dual	O
ITIMs	O
for	O
its	O
association	O
with	O
the	O
phosphatases	O
SHP-1	B-DNAMutation
and	O
SHP-2	B-DNAMutation
.	O

Intragenic	O
single	O
nucleotide	O
polymorphism	O
haplotype	O
analysis	O
of	O
SUR1	B-DNAMutation
mutations	O
in	O
familial	O
hyperinsulinism	O
.	O

Familial	O
hyperinsulinism	O
(	O
HI	O
;	O
MIM#	O
256450	O
)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
of	O
pancreatic	O
beta-cell	O
function	O
,	O
characterized	O
by	O
inadequate	O
suppression	O
of	O
insulin	B-DNAMutation
secretion	O
despite	O
severe	O
recurrent	O
fasting	O
hypoglycemia	O
.	O

Subtotal	O
pancreatectomy	O
is	O
frequently	O
required	O
to	O
prevent	O
permanent	O
neurologic	O
sequelae	O
.	O

The	O
incidence	O
of	O
HI	O
in	O
the	O
Caucasian	O
population	O
is	O
estimated	O
at	O
1:50,000	O
,	O
however	O
an	O
apparent	O
increased	O
incidence	O
among	O
Ashkenazi	O
Jews	O
and	O
Saudi	O
Arabian	O
Arabs	O
has	O
been	O
reported	O
.	O

A	O
locus	O
for	O
HI	O
was	O
assigned	O
by	O
linkage	O
analyses	O
to	O
human	O
chromosome	O
11p15.1	O
.	O

The	O
sulfonylurea	O
receptor	O
(	O
MIM#	O
600509	O
,	O
SUR1	B-DNAMutation
)	O
and	O
the	O
potassium	B-DNAMutation
channel	I-DNAMutation
,	I-DNAMutation
inwardly	I-DNAMutation
rectifying	I-DNAMutation
,	I-DNAMutation
subfamily	I-DNAMutation
J	I-DNAMutation
member	I-DNAMutation
11	I-DNAMutation
(	O
MIM#	O
600937	O
,	O
KIR6.2	B-DNAMutation
)	O
genes	O
,	O
2	O
components	O
of	O
the	O
beta-cell	O
K(ATP)	O
channel	O
,	O
are	O
clustered	O
in	O
this	O
chromosomal	O
region	O
,	O
and	O
mutations	O
in	O
these	O
genes	O
have	O
been	O
implicated	O
in	O
HI	O
.	O

We	O
previously	O
demonstrated	O
that	O
two	O
mutations	O
in	O
the	O
SUR1	B-DNAMutation
gene	O
are	O
present	O
on	O
approximately	O
88%	O
of	O
HI-associated	O
chromosomes	O
in	O
Ashkenazi	O
Jewish	O
patients	O
.	O

Haplotype	O
analysis	O
with	O
microsatellite	O
markers	O
flanking	O
the	O
gene	O
revealed	O
that	O
one	O
mutation	O
delF1388	B-DNAMutation
,	O
reported	O
only	O
in	O
Ashkenazi	O
probands	O
,	O
occurred	O
on	O
two	O
related	O
extended	O
haplotypes	O
.	O

By	O
contrast	O
,	O
the	O
second	O
,	O
more	O
common	O
mutation	O
3992-9g-->a	B-DNAMutation
was	O
associated	O
with	O
nine	O
different	O
intergenic	O
haplotypes	O
and	O
has	O
been	O
reported	O
in	O
non-Jewish	O
HI	O
patients	O
as	O
well	O
.	O

In	O
this	O
study	O
,	O
we	O
evaluated	O
disease-associated	O
chromosomes	O
from	O
41	O
Ashkenazi	O
Jewish	O
and	O
2	O
non-Jewish	O
HI	O
patients	O
carrying	O
the	O
3992-9g-->a	B-DNAMutation
mutation	I-DNAMutation
by	O
assessing	O
haplotypes	O
defined	O
by	O
nine	O
common	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
,	O
six	O
in	O
the	O
SUR1	B-DNAMutation
gene	O
,	O
and	O
three	O
in	O
the	O
KIR6.2	B-DNAMutation
gene	O
.	O

Our	O
results	O
indicate	O
that	O
all	B-DNAMutation
54	I-DNAMutation
chromosomes	I-DNAMutation
carrying	I-DNAMutation
the	I-DNAMutation
3992-9g-->a	I-DNAMutation
mutation	I-DNAMutation
in	O
the	O
Jewish	O
patients	O
appear	O
to	O
have	O
originated	O
from	O
one	O
founder	O
mutation	O
,	O
whereas	O
the	O
same	O
mutation	O
on	O
chromosomes	O
from	O
non-Jewish	O
patients	O
originated	O
independently	O
.	O

Furthermore	O
,	O
our	O
findings	O
have	O
implications	O
concerning	O
the	O
HI-associated	O
chromosomes	O
on	O
which	O
no	O
mutation	O
has	O
been	O
identified	O
.	O

Deficiency	O
of	O
dolichyl-P-Man:Man7GlcNAc2-PP-dolichyl	O
mannosyltransferase	O
causes	O
congenital	O
disorder	O
of	O
glycosylation	O
type	O
Ig	O
.	O

Deficiency	O
of	O
the	O
endoplasmic	O
reticulum	O
enzyme	O
dolichyl-phosphate	O
mannose	O
(Dol-P-Man):Man(7)GlcNAc(2)-PP-dolichyl	O
mannosyltransferase	O
leads	O
to	O
a	O
new	O
type	O
of	O
congenital	O
disorder	O
of	O
glycosylation	O
,	O
designated	O
type	O
Ig	O
.	O

The	O
patient	O
1	O
presented	O
with	O
a	O
multisystemic	O
disorder	O
with	O
microcephaly	O
,	O
developmental	O
retardation	O
,	O
convulsions	O
and	O
dysmorphic	O
signs	O
.	O

The	O
isoelectric	O
focusing	O
pattern	O
of	O
the	O
patient's	O
serum	O
transferrin	B-DNAMutation
showed	O
the	O
partial	O
loss	O
of	O
complete	O
N-glycan	O
side	O
chains	O
.	O

In	O
skin	O
fibroblasts	O
from	O
the	O
patient	O
,	O
the	O
activity	O
of	O
Dol-P-Man:Man(7)GlcNAc(2)-PP-Dol	O
mannosyltransferase	O
was	O
severely	O
reduced	O
leading	O
to	O
the	O
accumulation	O
of	O
Man(7)GlcNAc(2)-PP-Dol	O
,	O
which	O
was	O
transferred	O
to	O
newly	O
synthesized	O
glycoproteins	O
.	O

Sequencing	O
of	O
the	O
Dol-P-Man:Man(7)GlcNAc(2)-PP-Dol	O
mannosyltransferase	O
cDNA	O
revealed	O
a	O
compound	O
heterozygosity	O
for	O
two	O
point	O
mutations	O
,	O
leading	O
to	O
the	O
exchange	B-DNAMutation
of	I-DNAMutation
leucine(158)	I-DNAMutation
for	I-DNAMutation
a	I-DNAMutation
proline	I-DNAMutation
residue	I-DNAMutation
and	O
a	B-DNAMutation
premature	I-DNAMutation
translation	I-DNAMutation
stop	I-DNAMutation
with	I-DNAMutation
loss	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
C-terminal	I-DNAMutation
74	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
.	O

The	O
parents	O
were	O
heterozygous	O
for	O
one	O
of	O
the	O
two	O
mutations	O
.	O

Retroviral	O
expression	O
of	O
the	O
wild-type	O
Dol-P-Man:Man(7)GlcNAc(2)-PP-Dol	O
mannosyltransferase	O
cDNA	O
in	O
patient's	O
fibroblasts	O
normalized	O
the	O
mannosyltransferase	O
activity	O
.	O

[	O
A	O
new	O
mutation	O
in	O
COL1A1	O
gene	O
in	O
a	O
family	O
with	O
osteogenesis	O
imperfecta	O
]	O
.	O

OBJECTIVE	O
:	O
Osteogenesis	O
imperfecta	O
(OI)	O
is	O
a	O
congenital	O
disease	O
of	O
connective	O
tissue	O
of	O
increased	O
bone	O
fragility	O
and	O
low	O
bone	O
mass	O
,	O
most	O
often	O
caused	O
by	O
single	O
amino	O
acid	O
substitution	O
of	O
glycine	O
residues	O
in	O
the	O
collagen	O
,	O
type	O
I	O
,	O
alpha	O
1	O
protein	O
(COL1A1)	O
gene	O
or	O
the	O
collagen	O
,	O
type	O
I	O
,	O
alpha	O
2	O
protein	O
(COL1A2)	O
gene	O
,	O
encoding	O
type	O
I	O
procollagen	O
chains	O
.	O

We	O
describe	O
here	O
the	O
clinical	O
,	O
biochemical	O
,	O
and	O
molecular	O
characterization	O
of	O
a	O
family	O
with	O
type	O
I	O
OI	O
in	O
China	O
and	O
would	O
like	O
to	O
explore	O
whether	O
the	O
biochemical	O
characterization	O
of	O
OI	O
in	O
China	O
is	O
different	O
from	O
that	O
in	O
other	O
countries	O
.	O

METHODS	O
:	O
Through	O
clinical	O
research	O
,	O
we	O
study	O
the	O
clinical	O
characteristic	O
of	O
the	O
OI	O
household	O
.	O

Genomic	O
DNA	O
was	O
isolated	O
from	O
peripheral	O
blood	O
lymphocytes	O
of	O
the	O
proband	O
and	O
his	O
family	O
members	O
by	O
saturation	O
hydroxybenzene-chloroform	O
methods	O
;	O
amplification	O
of	O
target	O
COL1A1	O
gene	O
by	O
Polymerase	O
chain	O
reaction	O
with	O
23	O
pairs	O
of	O
different	O
primers	O
;	O
purification	O
;	O
direct	O
sequencing	O
of	O
the	O
Polymerase	O
chain	O
reaction	O
product	O
.	O

According	O
to	O
the	O
mutation	O
site	O
,	O
we	O
took	O
restriction	O
enzyme	O
analysis	O
to	O
50	O
normal	O
control	O
people	O
.	O

RESULTS	O
:	O
We	O
found	O
a	O
G	B-DNAMutation
and	I-DNAMutation
A	I-DNAMutation
heterozygosis	I-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
exon	I-DNAMutation
48	I-DNAMutation
causing	O
an	O
a1	O
(I)	O
p	B-DNAMutation
.	I-DNAMutation
G1157D	I-DNAMutation
substitution	O
in	O
the	O
proband	O
and	O
his	O
sister	O
who	O
is	O
also	O
a	O
sufferer	O
of	O
OI	O
.	O

At	O
the	O
same	O
time	O
,	O
other	O
normal	O
people	O
in	O
the	O
family	O
and	O
other	O
normal	O
control	O
people	O
do	O
not	O
have	O
this	O
change	O
.	O

CONCLUSION	O
:	O
This	O
is	O
the	O
first	O
delineation	O
of	O
an	O
aspartic	O
acid	O
substitution	O
in	O
new	O
site	O
of	O
the	O
a1	O
(I)	O
chain	O
causing	O
nonlethal	O
osteogenesis	O
imperfecta	O
.	O

Only	O
nine	O
aspartic	O
acid	O
substitution	O
in	O
type	O
I	O
collagen	O
has	O
been	O
fully	O
reported	O
in	O
the	O
world	O
.	O

Now	O
we	O
revealed	O
a	O
new	O
nosogenesis	O
of	O
OI	O
.	O

Since	O
only	O
few	O
of	O
nucleotide	O
changes	O
in	O
type	O
I	O
collagen	O
glycine	O
codons	O
would	O
result	O
in	O
an	O
aspartic	O
acid	O
substitution	O
,	O
these	O
are	O
predicted	O
to	O
be	O
infrequent	O
.	O

Furthermore	O
,	O
it	O
is	O
possible	O
to	O
suggest	O
that	O
nosogenesis	O
of	O
OI	O
in	O
china	O
is	O
different	O
from	O
other	O
countries	O
.	O

Phosphorylation	O
of	O
the	O
MADS-Box	O
transcription	O
factor	O
MEF2C	B-DNAMutation
enhances	O
its	O
DNA	O
binding	O
activity	O
.	O

Members	O
of	O
the	O
myocyte	O
enhancer	O
factor-2	O
(MEF2)	O
family	O
of	O
transcription	O
factors	O
activate	O
muscle	O
gene	O
expression	O
by	O
binding	O
an	O
A/T-rich	O
DNA	O
sequence	O
in	O
the	O
control	O
regions	O
of	O
muscle-specific	B-DNAMutation
genes	O
.	O

There	O
are	O
four	O
MEF2	O
factors	O
in	O
vertebrates	O
,	O
MEF2A-D	O
,	O
which	O
share	O
homology	O
in	O
an	O
amino-terminal	O
MADS	O
domain	O
and	O
an	O
adjacent	O
region	O
known	O
as	O
the	O
MEF2	O
domain	O
,	O
that	O
together	O
mediate	O
DNA	O
binding	O
and	O
dimerization	O
.	O

We	O
show	O
that	O
serine	O
59	O
located	O
between	O
the	O
MADS	O
and	O
MEF2	O
domains	O
of	O
MEF2C	B-DNAMutation
is	O
phosphorylated	O
in	O
vivo	O
and	O
can	O
be	O
phosphorylated	O
in	O
vitro	O
by	O
casein	B-DNAMutation
kinase-II	I-DNAMutation
CKII	B-DNAMutation
.	O

Phosphorylation	O
of	O
this	O
site	O
enhanced	O
the	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
of	O
MEF2C	B-DNAMutation
by	O
increasing	O
its	O
DNA	O
binding	O
activity	O
5-fold	O
.	O

In	O
vivo	O
32P	O
labeling	O
experiments	O
showed	O
that	O
serine	O
59	O
is	O
the	O
only	O
phosphorylation	O
site	O
in	O
the	O
MADS	O
and	O
MEF2	O
domains	O
.	O

Mutagenesis	B-DNAMutation
of	I-DNAMutation
this	I-DNAMutation
serine	I-DNAMutation
to	I-DNAMutation
an	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
resulted	O
in	O
an	O
increase	O
in	O
DNA	O
binding	O
and	O
transcriptional	O
activity	O
of	O
MEF2C	B-DNAMutation
comparable	O
to	O
that	O
observed	O
when	O
this	O
site	O
was	O
phosphorylated	O
,	O
suggesting	O
that	O
phosphorylation	O
augments	O
DNA	O
binding	O
activity	O
by	O
introducing	O
negative	O
charge	O
.	O

This	O
phosphorylation	O
site	O
,	O
which	O
corresponds	O
to	O
a	O
CKII	O
recognition	O
site	O
,	O
is	O
conserved	O
in	O
all	O
known	O
MEF2	O
factors	O
in	O
organisms	O
ranging	O
from	O
flies	O
to	O
humans	O
,	O
consistent	O
with	O
its	O
importance	O
for	O
the	O
functions	O
of	O
MEF2C	B-DNAMutation
.	O

Genetic	O
variants	O
in	O
C5	O
and	O
poor	O
response	O
to	O
eculizumab	O
.	O

BACKGROUND	O
:	O
Eculizumab	O
is	O
a	O
humanized	O
monoclonal	O
antibody	O
that	O
targets	O
complement	O
protein	O
C5	O
and	O
inhibits	O
terminal	O
complement-mediated	O
hemolysis	O
associated	O
with	O
paroxysmal	O
nocturnal	O
hemoglobinuria	O
(PNH)	O
.	O

The	O
molecular	O
basis	O
for	O
the	O
poor	O
response	O
to	O
eculizumab	O
in	O
a	O
small	O
population	O
of	O
Japanese	O
patients	O
is	O
unclear	O
.	O

METHODS	O
:	O
We	O
assessed	O
the	O
sequences	O
of	O
the	O
gene	O
encoding	O
C5	O
in	O
patients	O
with	O
PNH	O
who	O
had	O
either	O
a	O
good	O
or	O
poor	O
response	O
to	O
eculizumab	O
.	O

We	O
also	O
evaluated	O
the	O
functional	O
properties	O
of	O
C5	O
as	O
it	O
was	O
encoded	O
in	O
these	O
patients	O
.	O

RESULTS	O
:	O
Of	O
345	O
Japanese	O
patients	O
with	O
PNH	O
who	O
received	O
eculizumab	O
,	O
11	O
patients	O
had	O
a	O
poor	O
response	O
.	O

All	O
11	O
had	O
a	O
single	O
missense	O
C5	O
heterozygous	O
mutation	O
,	B-DNAMutation
c.2654G	I-DNAMutation
â	I-DNAMutation
A	O
,	O
which	O
predicts	O
the	O
polymorphism	B-DNAMutation
p.Arg885His	I-DNAMutation
.	O

The	O
prevalence	O
of	O
this	O
mutation	O
among	O
the	O
patients	O
with	O
PNH	O
(3.2%)	O
was	O
similar	O
to	O
that	O
among	O
healthy	O
Japanese	O
persons	O
(3.5%)	O
.	O

This	O
polymorphism	O
was	O
also	O
identified	O
in	O
a	O
Han	O
Chinese	O
population	O
.	O

A	O
patient	O
in	O
Argentina	O
of	O
Asian	O
ancestry	O
who	O
had	O
a	O
poor	O
response	O
had	O
a	O
very	O
similar	O
mutation	B-DNAMutation
,	I-DNAMutation
c.2653C	I-DNAMutation
â	O
T	O
,	O
which	O
predicts	B-DNAMutation
p.Arg885Cys	I-DNAMutation
.	O

Nonmutant	O
and	O
mutant	O
C5	O
both	O
caused	O
hemolysis	O
in	O
vitro	O
,	O
but	O
only	O
nonmutant	O
C5	O
bound	O
to	O
and	O
was	O
blocked	O
by	O
eculizumab	O
.	O

In	O
vitro	O
hemolysis	O
due	O
to	O
nonmutant	O
and	O
mutant	O
C5	O
was	O
completely	O
blocked	O
with	O
the	O
use	O
of	O
N19-8	O
,	O
a	O
monoclonal	O
antibody	O
that	O
binds	O
to	O
a	O
different	O
site	O
on	O
C5	O
than	O
does	O
eculizumab	O
.	O

CONCLUSIONS	O
:	O
The	O
functional	O
capacity	O
of	O
C5	O
variants	O
with	O
mutations	B-DNAMutation
at	I-DNAMutation
Arg885	I-DNAMutation
,	O
together	O
with	O
their	O
failure	O
to	O
undergo	O
blockade	O
by	O
eculizumab	O
,	O
account	O
for	O
the	O
poor	O
response	O
to	O
this	O
agent	O
in	O
patients	O
who	O
carry	O
these	O
mutations	O
.	O

(	O
Funded	O
by	O
Alexion	O
Pharmaceuticals	O
and	O
the	O
Ministry	O
of	O
Health	O
,	O
Labor	O
,	O
and	O
Welfare	O
of	O
Japan.	O
)	O
.	O

A	O
gain-of-function	O
mutation	O
in	O
adenylate	O
cyclase	O
3	O
protects	O
mice	O
from	O
diet-induced	O
obesity	O
.	O

In	O
a	O
screen	O
for	O
genes	O
that	O
affect	O
the	O
metabolic	O
response	O
to	O
high-fat	O
diet	O
(HFD)	O
,	O
we	O
selected	O
one	O
line	O
of	O
N-ethyl-N-nitrosourea	O
(ENU)-mutagenized	O
mice	O
,	O
Jll	O
,	O
with	O
dominantly	O
inherited	O
resistance	O
to	O
diet-induced	O
obesity	O
(DIO)	O
.	O

Mutant	O
animals	O
had	O
dramatically	O
reduced	O
body	O
weight	O
and	O
fat	O
mass	O
,	O
and	O
low	O
basal	O
insulin	O
and	O
glucose	O
levels	O
relative	O
to	O
unaffected	O
controls	O
.	O

Both	O
white	O
adipose	O
tissue	O
(WAT)	O
and	O
brown	O
adipose	O
tissue	O
(BAT)	O
depots	O
were	O
smaller	O
in	O
mutant	O
animals	O
.	O

Mutant	O
animals	O
fed	O
a	O
HFD	O
gained	O
only	O
slightly	O
more	O
weight	O
than	O
animals	O
fed	O
regular	O
chow	O
,	O
and	O
were	O
protected	O
from	O
hepatic	O
lipid	O
accumulation	O
.	O

The	O
phenotype	O
was	O
genetically	O
linked	O
to	O
a	O
5.7-Mb	O
interval	O
on	O
chromosome	O
12	O
,	O
and	O
sequencing	O
of	O
the	O
entire	O
interval	O
identified	O
a	O
single	O
coding	O
mutation	O
,	O
predicted	O
to	O
cause	O
a	O
methionine-to-isoleucine	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
279	I-DNAMutation
of	O
the	O
Adcy3	B-DNAMutation
protein	O
(	O
Adcy3M279I	O
,	O
henceforth	O
referred	O
to	O
as	O
Adcy3Jll	O
)	O
.	O

The	O
mutant	O
protein	O
is	O
hyperactive	O
,	O
possibly	O
constitutively	O
so	O
,	O
producing	O
elevated	O
levels	O
of	O
cyclic	O
AMP	O
in	O
a	O
cell-based	O
assay	O
.	O

These	O
mice	O
demonstrate	O
that	O
increased	O
Adcy3	B-DNAMutation
activity	O
robustly	O
protect	O
animals	O
from	O
diet-induced	O
metabolic	O
derangements	O
.	O

Foxp3	B-DNAMutation
protein	O
stability	O
is	O
regulated	O
by	O
cyclin-dependent	B-DNAMutation
kinase	I-DNAMutation
2	I-DNAMutation
.	O

Foxp3	B-DNAMutation
is	O
a	O
transcription	O
factor	O
required	O
for	O
the	O
development	O
of	O
regulatory	O
T	O
cells	O
(Treg)	O
.	O

Mice	O
and	O
humans	O
with	O
a	O
loss	O
of	O
Foxp3	B-DNAMutation
function	O
suffer	O
from	O
uncontrolled	O
autoimmunity	O
and	O
inflammatory	O
disease	O
.	O

Expression	O
of	O
Foxp3	B-DNAMutation
is	O
necessary	O
for	O
the	O
anti-inflammatory	O
capacity	O
of	O
Treg	O
,	O
but	O
whether	O
Foxp3	B-DNAMutation
activity	O
is	O
further	O
subject	O
to	O
regulation	O
by	O
extracellular	O
signals	O
is	O
unclear	O
.	O

The	O
primary	O
structure	O
of	O
Foxp3	B-DNAMutation
contains	O
four	O
cyclin-dependent	O
kinase	O
(CDK)	O
motifs	O
(Ser/Thr-Pro)	O
within	O
the	O
N-terminal	O
repressor	O
domain	O
,	O
and	O
we	O
show	O
that	O
CDK2	B-DNAMutation
can	O
partner	O
with	O
cyclin	O
E	O
to	O
phosphorylate	O
Foxp3	B-DNAMutation
at	O
these	O
sites	O
.	O

Consistent	O
with	O
our	O
previous	O
demonstration	O
that	O
CDK2	B-DNAMutation
negatively	O
regulates	O
Treg	O
function	O
,	O
we	O
find	O
that	O
mutation	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
serine	I-DNAMutation
or	I-DNAMutation
threonine	I-DNAMutation
at	I-DNAMutation
each	I-DNAMutation
CDK	I-DNAMutation
motif	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
(S/TâA)	O
results	O
in	O
enhanced	O
Foxp3	B-DNAMutation
protein	O
stability	O
in	O
CD4(+)	O
T	O
cells	O
.	O

T	O
cells	O
expressing	O
the	O
S/TâA	O
mutant	O
of	B-DNAMutation
Foxp3	I-DNAMutation
showed	O
enhanced	O
induction	O
(	O
e.g	B-DNAMutation
.	I-DNAMutation
CD25	I-DNAMutation
)	O
and	O
repression	O
(	O
e.g	O
.	O

IL2	O
)	O
of	O
canonical	B-DNAMutation
Foxp3-responsive	O
genes	O
,	O
exhibited	O
an	O
increased	O
capacity	O
to	O
suppress	O
conventional	O
T	O
cell	O
proliferation	O
in	O
vitro	O
,	O
and	O
were	O
highly	O
effective	O
at	O
ameliorating	O
colitis	O
in	O
an	O
in	O
vivo	O
model	O
of	O
inflammatory	O
bowel	O
disease	O
.	O

These	O
results	O
indicate	O
that	B-DNAMutation
CDK2	O
negatively	O
regulates	O
the	O
stability	O
and	O
activity	B-DNAMutation
of	I-DNAMutation
Foxp3	O
and	O
implicate	O
CDK-coupled	O
receptor	O
signal	O
transduction	O
in	O
the	O
control	O
of	O
regulatory	O
T	O
cell	O
function	O
and	O
stability	O
.	O

Role	O
of	O
the	O
human	O
and	O
murine	O
cyclin	O
T	O
proteins	O
in	O
regulating	O
HIV-1	O
tat-activation	O
.	O

Human	O
cyclin	B-DNAMutation
T1	I-DNAMutation
markedly	O
stimulates	O
tat-activation	O
in	O
rodent	O
cells	O
which	O
are	O
normally	O
poorly	O
responsive	O
to	O
the	O
effects	O
of	O
Tat	O
.	O

This	O
result	O
suggests	O
that	O
there	O
are	O
likely	O
to	O
be	O
critical	O
differences	O
in	O
the	O
murine	O
and	O
human	O
cyclin	B-DNAMutation
T1	I-DNAMutation
proteins	O
.	O

Here	O
,	O
we	O
analyzed	O
the	O
role	O
of	O
the	O
murine	O
and	O
human	O
cyclin	B-DNAMutation
T1	I-DNAMutation
proteins	O
in	O
addition	O
to	O
the	O
human	O
cyclin	B-DNAMutation
T2a	I-DNAMutation
and	O
T2b	O
proteins	O
on	O
regulating	O
tat-activation	O
.	O

Only	O
the	O
human	O
cyclin	B-DNAMutation
T1	I-DNAMutation
protein	O
efficiently	O
formed	O
a	O
complex	O
with	O
Tat	O
bound	O
to	O
TAR	B-DNAMutation
RNA	O
.	O

This	O
difference	O
in	O
function	O
was	O
due	O
to	O
the	O
presence	O
of	O
a	O
cysteine	O
residue	O
in	O
human	O
cyclin	B-DNAMutation
T1	I-DNAMutation
at	O
position	O
261	O
rather	O
than	O
a	O
tyrosine	O
or	O
asparagine	O
residue	O
which	O
are	O
found	O
in	O
the	O
murine	O
cyclin	B-DNAMutation
T1	I-DNAMutation
protein	O
and	O
the	O
human	O
cyclin	B-DNAMutation
T2a	I-DNAMutation
and	O
T2b	O
proteins	O
,	O
respectively	O
.	O

A	O
mouse	O
cyclin	B-DNAMutation
T1	I-DNAMutation
protein	O
containing	O
a	O
substitution	O
of	O
tyrosine	B-DNAMutation
residue	I-DNAMutation
261	I-DNAMutation
with	I-DNAMutation
a	I-DNAMutation
cysteine	I-DNAMutation
residue	I-DNAMutation
,	O
was	O
able	O
to	O
interact	O
with	O
Tat	O
and	O
stimulate	O
tat-transactivation	O
in	O
rodent	O
cells	O
.	O

Likewise	O
,	O
substitution	O
of	O
a	O
cysteine	B-DNAMutation
residue	I-DNAMutation
for	I-DNAMutation
an	I-DNAMutation
asparagine	I-DNAMutation
residue	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
260	I-DNAMutation
of	O
the	O
cyclin	B-DNAMutation
T2a	I-DNAMutation
and	O
T2b	O
proteins	O
also	O
resulted	O
in	O
their	O
ability	O
to	O
interact	O
with	O
Tat	O
and	O
stimulate	O
tat-activation	O
in	O
rodent	O
cells	O
.	O

The	O
data	O
indicate	O
that	O
a	O
specific	O
residue	O
in	O
the	O
cyclin	O
T	O
proteins	O
is	O
required	O
for	O
their	O
in	O
vitro	O
interaction	O
with	O
Tat	O
and	O
their	O
ability	O
to	O
stimulate	O
in	O
vivo	O
tat-activation	O
.	O

A	O
missense	O
mutation	O
in	O
ALDH1A3	B-DNAMutation
causes	O
isolated	O
microphthalmia/anophthalmia	O
in	O
nine	O
individuals	O
from	O
an	O
inbred	O
Muslim	O
kindred	O
.	O

Nine	O
affected	O
individuals	O
with	O
isolated	O
anophthalmia/microphthalmia	O
from	O
a	O
large	O
Muslim-inbred	O
kindred	O
were	O
investigated	O
.	O

Assuming	O
autosomal-recessive	O
mode	O
of	O
inheritance	O
,	O
whole-genome	O
linkage	O
analysis	O
,	O
on	O
DNA	O
samples	O
from	O
four	O
affected	O
individuals	O
,	O
was	O
undertaken	O
.	O

Homozygosity	O
mapping	O
techniques	O
were	O
employed	O
and	O
a	O
1.5-Mbp	O
region	O
,	O
homozygous	O
in	O
all	O
affected	O
individuals	O
,	O
was	O
delineated	O
.	O

The	O
region	O
contained	O
nine	O
genes	O
,	O
one	O
of	O
which	O
,	O
aldehyde	O
dehydrogenase	O
1	O
ALDH1A3	B-DNAMutation
,	O
was	O
a	O
clear	O
candidate	O
.	O

This	O
gene	O
seems	O
to	O
encode	O
a	O
key	O
enzyme	O
in	O
the	O
formation	O
of	O
a	O
retinoic-acid	O
gradient	O
along	O
the	O
dorsoventral	O
axis	O
during	O
an	O
early	O
eye	O
development	O
and	O
the	O
development	O
of	O
the	O
olfactory	O
system	O
.	O

Sanger	O
sequence	O
analysis	O
revealed	O
a	O
missense	O
mutation	O
,	O
causing	O
a	O
substitution	B-DNAMutation
of	I-DNAMutation
valine	I-DNAMutation
(Val)	I-DNAMutation
to	I-DNAMutation
methionine	I-DNAMutation
(Met)	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
71	I-DNAMutation
.	O

Analyzing	O
the	O
p.Val71Met	B-DNAMutation
missense	O
mutation	O
using	O
standard	O
open	O
access	O
software	O
(	O
MutationTaster	O
online	O
,	O
PolyPhen	O
,	O
SIFT/PROVEAN	O
)	O
predicts	O
this	O
variant	O
to	O
be	O
damaging	O
.	O

Enzymatic	O
activity	O
,	O
studied	O
in	O
vitro	O
,	O
showed	O
no	O
changes	O
between	O
the	O
mutated	O
and	O
the	O
wild-type	O
ALDH1A3	B-DNAMutation
protein	O
.	O

Molecular	O
characterization	O
of	O
six	O
unrelated	O
Italian	O
patients	O
affected	O
by	O
pyrimidine	O
5'-nucleotidase	O
deficiency	O
.	O

Pyrimidine	O
5'-nucleotidase	O
deficiency	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
haemolytic	O
anaemia	O
,	O
marked	O
basophilic	O
stippling	O
and	O
accumulation	O
of	O
pyrimidine	O
nucleotides	O
within	O
the	O
erythrocytes	O
.	O

The	O
gene	O
encoding	O
for	O
this	O
enzyme	O
P5'N-1	B-DNAMutation
has	O
been	O
cloned	O
recently	O
,	O
and	O
seven	O
mutations	O
have	O
so	O
far	O
been	O
identified	O
in	O
11	O
unrelated	O
families	O
.	O

We	O
describe	O
the	O
haematological	O
and	O
molecular	O
characteristics	O
of	O
six	O
unrelated	O
Italian	O
patients	O
affected	O
by	O
pyrimidine	O
5'-nucleotidase	O
deficiency	O
(	O
one	O
from	O
northern	O
and	O
five	O
from	O
southern	O
Italy	O
)	O
.	O

The	O
sequence	O
of	O
the	O
complete	O
P5'N-1	B-DNAMutation
gene	O
showed	O
the	O
presence	O
of	O
four	O
different	O
new	O
mutations	O
:	O
a	O
missense	B-DNAMutation
mutation	I-DNAMutation
AAT-AGT	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
190	I-DNAMutation
(Asn-Ser)	I-DNAMutation
,	O
one	B-DNAMutation
splicing	I-DNAMutation
mutation	I-DNAMutation
(	I-DNAMutation
IVS9-1	I-DNAMutation
g-c	I-DNAMutation
)	O
and	O
two	B-DNAMutation
frameshift	I-DNAMutation
mutations	I-DNAMutation
,	I-DNAMutation
DelG576	I-DNAMutation
and	I-DNAMutation
InsGG743	I-DNAMutation
.	O

Although	O
the	O
molecular	O
defect	O
was	O
homozygous	O
in	O
all	O
patients	O
but	O
one	O
,	O
parents'	O
consanguinity	O
could	O
be	O
confirmed	O
in	O
only	O
one	O
case	O
.	O

InsGG743	B-DNAMutation
was	O
detected	O
in	O
two	O
cases	O
,	O
and	O
DelG576	B-DNAMutation
was	O
found	O
in	O
three	O
patients	O
originating	O
from	O
southern	O
Italy	O
,	O
suggesting	O
a	O
possible	O
geographical	O
distribution	O
of	O
the	O
genetic	O
defect	O
.	O

Haematological	O
data	O
showed	O
the	O
presence	O
of	O
peripheral	O
spherocytosis	O
in	O
all	O
cases	O
,	O
although	O
only	O
one	O
had	O
a	O
concomitant	O
membrane	O
defect	O
.	O

An	O
increase	O
in	O
serum	O
ferritin	O
levels	O
was	O
observed	O
in	O
the	O
splenectomized	O
patients	O
,	O
suggesting	O
that	O
the	O
iron	O
status	O
of	O
these	O
subjects	O
should	O
be	O
monitored	O
and	O
that	O
they	O
should	O
be	O
investigated	O
for	O
potential	O
additional	O
risk	O
factors	O
for	O
iron	O
accumulation	O
.	O

p202	B-DNAMutation
,	O
an	O
interferon-inducible	O
modulator	O
of	O
transcription	O
,	O
inhibits	O
transcriptional	O
activation	O
by	O
the	O
p53	B-DNAMutation
tumor	O
suppressor	O
protein	O
,	O
and	O
a	O
segment	O
from	O
the	O
p53-binding	B-DNAMutation
protein	I-DNAMutation
1	I-DNAMutation
that	O
binds	O
to	O
p202	B-DNAMutation
overcomes	O
this	O
inhibition	O
.	O

p202	B-DNAMutation
,	O
an	O
interferon-inducible	O
murine	O
protein	O
,	O
is	O
a	O
member	O
of	O
the	O
"200	O
family"	O
of	O
proteins	O
and	O
is	O
primarily	O
nuclear	O
.	O

p202	B-DNAMutation
is	O
a	O
modulator	O
of	O
transcription	O
;	O
it	O
binds	O
several	O
transcription	O
factors	O
,	O
including	O
NF-kappaB	B-DNAMutation
p50	I-DNAMutation
and	O
p65	B-DNAMutation
,	O
AP-1	O
c-Fos	O
and	O
c-Jun	O
,	O
and	O
E2F1	B-DNAMutation
,	O
and	O
inhibits	O
their	O
transcriptional	O
activity	O
.	O

p202	B-DNAMutation
also	O
binds	O
pRb	B-DNAMutation
,	O
the	O
retinoblastoma	O
protein	O
,	O
and	O
if	O
overexpressed	O
it	O
retards	O
cell	O
proliferation	O
.	O

Here	O
we	O
report	O
that	O
using	O
the	O
yeast	O
two-hybrid	O
assay	O
we	O
found	O
that	O
p202	O
bound	O
the	O
murine	O
homolog	O
of	O
the	O
human	O
p53-binding	B-DNAMutation
protein	I-DNAMutation
1	I-DNAMutation
53BP1	B-DNAMutation
,	O
a	O
protein	O
shown	O
to	O
interact	O
with	O
the	O
DNA	O
binding	O
domain	O
of	O
the	O
p53	O
tumor	O
suppressor	O
protein	O
.	O

p202	B-DNAMutation
bound	O
a	O
98amino	O
acid	O
segment	O
from	O
53BP1	B-DNAMutation
.	O

This	O
binding	O
was	O
inhibited	O
by	O
the	O
replacement	O
in	O
p202	B-DNAMutation
of	O
a	O
histidine	O
(	O
from	O
the	O
M(F/L)HATVA(T/S)	O
sequence	O
that	O
is	O
conserved	O
among	O
all	O
of	O
the	O
200	O
family	O
proteins	O
)	O
by	O
phenylalanine	O
.	O

We	O
also	O
report	O
that	O
overexpression	O
of	O
p202	B-DNAMutation
inhibited	O
the	O
p53-dependent	B-DNAMutation
expression	O
of	O
reporter	O
genes	O
containing	O
p53-activable	B-DNAMutation
segments	O
from	O
the	O
mdm2	B-DNAMutation
and	O
p21	B-DNAMutation
genes	O
,	O
whereas	O
a	O
decrease	O
in	O
the	O
p202	B-DNAMutation
level	O
(	O
in	O
consequence	O
of	O
the	O
expression	O
of	O
202	O
antisense	O
RNA	O
)	O
resulted	O
in	O
an	O
increase	O
in	O
the	O
p53-dependent	B-DNAMutation
expression	O
of	O
these	O
reporters	O
.	O

Expression	O
of	O
the	O
53BP1	O
segment	O
binding	O
to	O
p202	O
overcame	O
the	O
inhibition	O
by	O
overexpressed	O
p202	O
of	O
the	O
transcription	O
of	O
reporters	O
mediated	O
by	O
the	O
p53	O
or	O
the	O
AP-1	O
transcription	O
factors	O
and	O
of	O
the	O
proliferation	O
of	O
yeast	O
.	O

Insulin	O
stimulates	O
phosphorylation	O
of	O
the	O
forkhead	O
transcription	O
factor	O
FKHR	O
on	O
serine	O
253	O
through	O
a	O
Wortmannin-sensitive	O
pathway	O
.	O

In	O
the	O
nematode	O
Caenorhabditis	O
elegans	O
,	O
mutations	O
of	O
the	O
insulin/insulin-like	O
growth	O
factor-1	O
receptor	O
homologue	O
Daf-2	B-DNAMutation
gene	O
cause	O
developmental	O
arrest	O
at	O
the	O
dauer	O
stage	O
.	O

The	O
effect	O
of	O
Daf-2	B-DNAMutation
mutations	O
is	O
counteracted	O
by	O
mutations	O
in	O
the	O
Daf-16	B-DNAMutation
gene	O
,	O
suggesting	O
that	O
Daf-16	B-DNAMutation
is	O
required	O
for	O
signaling	O
by	O
Daf-2	B-DNAMutation
.	O

Daf-16	B-DNAMutation
encodes	O
a	O
forkhead	O
transcription	O
factor	O
.	O

Based	O
on	O
sequence	O
similarity	O
,	O
the	O
FKHR	B-DNAMutation
genes	O
are	O
the	O
likeliest	O
mammalian	O
Daf-16	O
homologues	O
.	O

FKHR	O
proteins	O
contain	O
potential	O
sites	O
for	O
phosphorylation	O
by	O
the	O
serine/threonine	O
kinase	O
Akt	O
.	O

Because	O
Akt	O
is	O
phosphorylated	O
in	O
response	O
to	O
insulin	O
and	O
has	O
been	O
implicated	O
in	O
a	O
variety	O
of	O
insulin	O
effects	O
,	O
we	O
investigated	O
whether	O
insulin	O
affects	O
phosphorylation	O
of	O
FKHR	O
.	O

Insulin	O
stimulated	O
phosphorylation	O
of	O
endogenous	O
FKHR	O
and	O
of	O
a	O
recombinant	O
c-Myc/FKHR	O
fusion	O
protein	O
transiently	O
expressed	O
in	O
murine	O
SV40-transformed	O
hepatocytes	O
.	O

The	O
effect	O
of	O
insulin	O
was	O
inhibited	O
by	O
wortmannin	O
treatment	O
,	O
suggesting	O
that	O
PI	O
3-kinase	O
activity	O
is	O
required	O
for	O
FKHR	O
phosphorylation	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
serine	I-DNAMutation
253	I-DNAMutation
,	O
located	O
in	O
a	O
consensus	O
Akt	O
phosphorylation	O
site	O
at	O
the	O
carboxyl-terminal	O
end	O
of	O
the	O
forkhead	O
domain	O
,	O
abolished	O
the	O
effect	O
of	O
insulin	O
on	O
FKHR	O
phosphorylation	O
.	O

In	O
contrast	O
,	O
mutation	B-DNAMutation
of	I-DNAMutation
two	I-DNAMutation
additional	I-DNAMutation
Akt	I-DNAMutation
phosphorylation	I-DNAMutation
sites	I-DNAMutation
,	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
threonine	I-DNAMutation
24	I-DNAMutation
or	I-DNAMutation
serine	I-DNAMutation
316	I-DNAMutation
,	O
did	O
not	O
abolish	O
insulin-induced	O
phosphorylation	O
.	O

These	O
data	O
indicate	O
that	O
FKHR	O
may	O
represent	O
a	O
distal	O
effector	O
of	O
insulin	O
action	O
.	O

Alpha-cardiac	B-DNAMutation
actin	I-DNAMutation
mutations	O
produce	O
atrial	O
septal	O
defects	O
.	O

Atrial	O
septal	O
defect	O
(ASD)	O
is	O
one	O
of	O
the	O
most	O
frequent	O
congenital	O
heart	O
defects	O
(CHDs)	O
with	O
a	O
variable	O
phenotypic	O
effect	O
depending	O
on	O
the	O
size	O
of	O
the	O
septal	O
shunt	O
.	O

We	O
identified	O
two	O
pedigrees	O
comprising	O
20	O
members	O
segregating	O
isolated	O
autosomal	O
dominant	O
secundum	O
ASD	O
.	O

By	O
genetic	O
mapping	O
,	O
we	O
identified	O
the	O
gene-encoding	O
alpha-cardiac	B-DNAMutation
actin	I-DNAMutation
ACTC1	B-DNAMutation
,	O
which	O
is	O
essential	O
for	O
cardiac	O
contraction	O
,	O
as	O
the	O
likely	O
candidate	O
.	O

A	O
mutation	O
screen	O
of	O
the	O
coding	O
regions	O
of	O
ACTC1	B-DNAMutation
revealed	O
a	O
founder	O
mutation	O
predicting	O
an	O
M123V	B-DNAMutation
substitution	O
in	O
affected	O
individuals	O
of	O
both	O
pedigrees	O
.	O

Functional	O
analysis	O
of	O
ACTC1	B-DNAMutation
with	O
an	O
M123V	B-DNAMutation
substitution	O
shows	O
a	O
reduced	O
affinity	O
for	O
myosin	B-DNAMutation
,	O
but	O
with	O
retained	O
actomyosin	O
motor	O
properties	O
.	O

We	O
also	O
screened	O
408	O
sporadic	O
patients	O
with	O
CHDs	O
and	O
identified	O
a	O
case	O
with	O
ASD	O
and	O
a	O
17-bp	O
deletion	O
in	O
ACTC1	B-DNAMutation
predicting	O
a	O
non-functional	O
protein	O
.	O

Morpholino	O
(MO)	O
knockdown	O
of	O
ACTC1	B-DNAMutation
in	O
chick	O
embryos	O
produces	O
delayed	O
looping	O
and	O
reduced	O
atrial	O
septa	O
,	O
supporting	O
a	O
developmental	O
role	O
for	O
this	O
protein	O
.	O

The	O
combined	O
results	O
indicate	O
,	O
for	O
the	O
first	O
time	O
,	O
that	O
ACTC1	B-DNAMutation
mutations	O
or	O
reduced	O
ACTC1	B-DNAMutation
levels	O
may	O
lead	O
to	O
ASD	O
without	O
signs	O
of	O
cardiomyopathy	O
.	O

Three	O
mammalian	O
cytochromes	O
b561	O
are	O
ascorbate-dependent	O
ferrireductases	O
.	O

Cytochromes	O
b(561)	O
are	O
a	O
family	O
of	O
transmembrane	O
proteins	O
found	O
in	O
most	O
eukaryotic	O
cells	O
.	O

Three	O
evolutionarily	O
closely	O
related	O
mammalian	O
cytochromes	O
b(561)	O
(	O
chromaffin	O
granule	O
cytochrome	O
b	O
,	O
duodenal	O
cytochrome	O
b	O
,	O
and	O
lysosomal	O
cytochrome	O
b	O
)	O
were	O
expressed	O
in	O
a	O
Saccharomyces	O
cerevisiaeDeltafre1Deltafre2	O
mutant	O
,	O
which	O
lacks	O
almost	O
all	O
of	O
its	O
plasma	O
membrane	O
ferrireductase	O
activity	O
,	O
to	O
study	O
their	O
ability	O
to	O
reduce	O
ferric	O
iron	O
(Fe(3+))	O
.	O

The	O
expression	O
of	O
each	O
of	O
these	O
cytochromes	O
b(561)	O
was	O
able	O
to	O
rescue	O
the	O
growth	O
defect	O
of	O
the	O
Deltafre1Deltafre2	O
mutant	O
cells	O
in	O
iron-deficient	O
conditions	O
,	O
suggesting	O
their	O
involvement	O
in	O
iron	O
metabolism	O
.	O

Plasma	O
membrane	O
ferrireductase	O
activities	O
were	O
measured	O
using	O
intact	O
yeast	O
cells	O
.	O

Each	O
cytochrome	O
b(561)	O
showed	O
significant	O
FeCN	O
and	O
Fe(3+)-EDTA	O
reductase	O
activities	O
that	O
were	O
dependent	O
on	O
the	O
presence	O
of	O
intracellular	O
ascorbate	O
.	O

Site-directed	O
mutagenesis	O
of	O
lysosomal	O
cytochrome	O
b	O
was	O
conducted	O
to	O
identify	O
amino	O
acids	O
that	O
are	O
indispensable	O
for	O
its	O
activity	O
.	O

Among	O
more	O
than	O
20	O
conserved	O
or	O
partially	O
conserved	O
amino	O
acids	O
that	O
were	O
investigated	O
,	O
mutations	B-DNAMutation
of	I-DNAMutation
four	I-DNAMutation
His	I-DNAMutation
residues	I-DNAMutation
(	I-DNAMutation
H47	I-DNAMutation
,	I-DNAMutation
H83	I-DNAMutation
,	I-DNAMutation
H117	I-DNAMutation
and	I-DNAMutation
H156	I-DNAMutation
)	I-DNAMutation
,	I-DNAMutation
one	I-DNAMutation
Tyr	I-DNAMutation
(Y66)	I-DNAMutation
and	I-DNAMutation
one	I-DNAMutation
Arg	I-DNAMutation
(R67)	O
completely	O
abrogated	O
the	O
FeCN	O
reductase	O
activity	O
,	O
whereas	O
mutations	B-DNAMutation
of	I-DNAMutation
Arg	I-DNAMutation
(R149)	I-DNAMutation
,	I-DNAMutation
Phe	I-DNAMutation
(F44)	I-DNAMutation
,	I-DNAMutation
Ser	I-DNAMutation
(S115)	I-DNAMutation
,	I-DNAMutation
Trp	I-DNAMutation
(W119)	I-DNAMutation
,	I-DNAMutation
Glu	I-DNAMutation
(E196)	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Gln	I-DNAMutation
(Q131)	I-DNAMutation
affected	O
the	O
ferrireductase	O
activity	O
to	O
some	O
degree	O
.	O

These	O
mutations	O
may	O
affect	O
the	O
heme	O
coordination	O
,	O
ascorbate	O
binding	O
,	O
and/or	O
ferric	O
substrate	O
binding	O
.	O

Possible	O
roles	O
of	O
these	O
residues	O
in	O
lysosomal	O
cytochrome	O
b	O
are	O
discussed	O
.	O

This	O
study	O
demonstrates	O
the	O
ascorbate-dependent	O
transmembrane	O
ferrireductase	O
activities	O
of	O
members	O
of	O
the	O
mammalian	O
cytochrome	O
b(561)	O
family	O
of	O
proteins	O
.	O

Identification	O
of	O
a	O
DOCK180-related	O
guanine	O
nucleotide	O
exchange	O
factor	O
that	O
is	O
capable	O
of	O
mediating	O
a	O
positive	O
feedback	O
activation	O
of	O
Cdc42	B-DNAMutation
.	O

Cdc42	B-DNAMutation
,	O
a	O
member	O
of	O
the	O
Rho	O
subfamily	O
of	O
small	O
GTPases	O
,	O
influences	O
a	O
wide	O
range	O
of	O
activities	O
including	O
the	O
establishment	O
of	O
cell	O
polarity	O
,	O
migration	O
,	O
and	O
the	O
regulation	O
of	O
cell	O
growth	O
and	O
differentiation	O
.	O

Here	O
we	O
describe	O
the	O
identification	O
of	O
an	O
approximately	O
220-kDa	O
protein	O
that	O
formed	O
a	O
stable	O
complex	O
with	O
activated	O
forms	O
of	O
Cdc42	B-DNAMutation
and	O
thereby	O
showed	O
characteristics	O
of	O
a	O
downstream	O
target/effector	O
for	O
this	O
GTPase	O
.	O

However	O
,	O
molecular	O
cloning	O
of	O
the	O
cDNA	O
encoding	O
this	O
protein	O
p220	B-DNAMutation
revealed	O
that	O
it	O
was	O
highly	O
related	O
to	O
Zizimin-1	B-DNAMutation
and	O
identical	O
in	O
sequence	O
to	O
a	O
gene	O
product	O
in	O
the	O
data	O
base	O
designated	O
DOCK11	B-DNAMutation
,	O
which	O
are	O
members	O
of	O
the	O
DOCK180	O
family	O
of	O
guanine	O
nucleotide	O
exchange	O
factors	O
(GEFs)	O
for	O
Cdc42	B-DNAMutation
and	O
Rac	O
.	O

Biochemical	O
characterization	O
shows	O
that	O
p220	B-DNAMutation
is	O
a	O
specific	O
GEF	O
for	O
Cdc42	B-DNAMutation
,	O
with	O
the	O
GEF	O
activity	O
originating	O
from	O
its	O
DHR2	O
(	O
for	O
DOCK	O
homology	O
region	O
2	O
)	O
domain	O
.	O

Nucleotide-depleted	O
Cdc42	B-DNAMutation
forms	O
a	O
stable	O
complex	O
with	O
the	O
DHR2	O
domain	O
,	O
whereas	O
the	O
binding	O
of	O
activated	O
Cdc42	B-DNAMutation
requires	O
both	O
the	O
DHR2	O
domain	O
and	O
residues	O
66-126	O
within	O
the	O
amino-terminal	O
portion	O
of	O
p220	B-DNAMutation
.	O

Moreover	O
,	O
the	O
full-length	O
protein	O
shows	O
markedly	O
higher	O
GEF	O
activity	O
than	O
the	O
isolated	O
DHR2	O
domain	O
,	O
whereas	O
removal	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
amino-terminal	I-DNAMutation
126	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
necessary	O
for	O
binding-activated	O
Cdc42	B-DNAMutation
dramatically	O
diminishes	O
the	O
activity	O
.	O

These	O
and	O
other	O
results	O
point	O
to	O
activated	O
Cdc42	B-DNAMutation
providing	O
a	O
positive	O
feedback	O
regulation	O
of	O
the	O
GEF	O
activity	O
of	O
p220	B-DNAMutation
.	O

Thus	O
,	O
we	O
refer	O
to	O
p220/DOCK11	B-DNAMutation
as	O
activated	O
Cdc42-associated	B-DNAMutation
GEF	O
,	O
befitting	O
its	O
functional	O
activity	O
.	O

Substitutions	B-DNAMutation
for	I-DNAMutation
glycine	I-DNAMutation
alpha	I-DNAMutation
1-637	I-DNAMutation
and	I-DNAMutation
glycine	I-DNAMutation
alpha	I-DNAMutation
2-694	I-DNAMutation
of	O
type	B-DNAMutation
I	I-DNAMutation
procollagen	I-DNAMutation
in	O
lethal	O
osteogenesis	O
imperfecta	O
.	O

The	O
conformational	O
strain	O
on	O
the	O
triple	O
helix	O
introduced	O
by	O
a	O
glycine	O
substitution	O
can	O
be	O
transmitted	O
along	O
the	O
helix	O
.	O

Two	O
substitutions	O
for	O
glycine	O
in	O
the	O
triple-helical	O
domain	O
were	O
found	O
in	O
type	B-DNAMutation
I	I-DNAMutation
procollagen	I-DNAMutation
synthesized	O
by	O
skin	O
fibroblasts	O
from	O
two	O
probands	O
with	O
lethal	O
osteogenesis	O
imperfecta	O
.	O

One	O
was	O
a	O
substitution	B-DNAMutation
of	I-DNAMutation
valine	I-DNAMutation
for	I-DNAMutation
glycine	I-DNAMutation
alpha	I-DNAMutation
1-637	I-DNAMutation
,	O
and	O
the	O
other	O
was	O
a	O
substitution	B-DNAMutation
of	I-DNAMutation
arginine	I-DNAMutation
for	I-DNAMutation
glycine	I-DNAMutation
alpha	I-DNAMutation
2-694	I-DNAMutation
.	O

The	O
effects	O
of	O
the	O
mutations	O
on	O
the	O
zipper-like	O
folding	O
of	O
the	O
collagen	O
triple	O
helix	O
were	O
similar	O
,	O
since	O
there	O
was	O
post-translational	O
overmodification	O
of	O
the	O
collagenase	O
A	O
fragments	O
(	O
amino	O
acids	O
1-775	O
)	O
but	O
not	O
of	O
more	O
COOH-terminal	O
fragments	O
of	O
the	O
protein	O
.	O

The	O
mutations	O
differed	O
markedly	O
,	O
however	O
,	O
on	O
their	O
effects	O
on	O
thermal	O
unfolding	O
of	O
the	O
triple	O
helix	O
.	O

The	O
collagenase	O
A	O
fragment	O
from	O
the	O
collagen	O
containing	O
the	O
arginine	B-DNAMutation
alpha	I-DNAMutation
2-694	I-DNAMutation
substitution	I-DNAMutation
was	O
cleaved	O
at	O
about	O
amino	O
acid	O
700	O
when	O
incubated	O
with	O
trypsin	O
at	O
30-35	O
degrees	O
C	O
.	O

Therefore	O
,	O
there	O
was	O
micro-unfolding	O
of	O
the	O
triple	O
helix	O
at	O
a	O
site	O
close	O
to	O
the	O
glycine	O
substitution	O
.	O

Surprisingly	O
,	O
however	O
,	O
the	O
collagenase	O
A	O
fragment	O
with	O
the	O
valine	B-DNAMutation
alpha	I-DNAMutation
1-637	I-DNAMutation
substitution	I-DNAMutation
was	O
also	O
cleaved	O
at	O
about	O
amino	O
acid	O
700	O
under	O
the	O
same	O
conditions	O
.	O

The	O
results	O
,	O
therefore	O
,	O
demonstrated	O
that	O
although	O
most	O
glycine	O
substitutions	O
delay	O
folding	O
of	O
the	O
triple	O
helix	O
in	O
regions	O
that	O
are	O
NH2-terminal	O
to	O
the	O
site	O
of	O
the	O
substitution	O
,	O
the	O
effects	O
on	O
unfolding	O
can	O
be	O
transmitted	O
to	O
regions	O
that	O
are	O
COOH-terminal	O
to	O
the	O
site	O
of	O
the	O
glycine	O
substitution	O
.	O

A	O
novel	O
nonstop	O
mutation	O
in	O
the	O
stop	O
codon	O
and	O
a	O
novel	O
missense	O
mutation	O
in	O
the	O
type	B-DNAMutation
II	I-DNAMutation
3beta-hydroxysteroid	I-DNAMutation
dehydrogenase	I-DNAMutation
3beta-HSD	B-DNAMutation
gene	O
causing	O
,	O
respectively	O
,	O
nonclassic	O
and	O
classic	O
3beta-HSD	B-DNAMutation
deficiency	O
congenital	O
adrenal	O
hyperplasia	O
.	O

We	O
investigated	O
two	O
novel	O
point	O
mutations	O
in	O
the	O
human	O
type	B-DNAMutation
II	I-DNAMutation
3beta-hydroxysteroid	I-DNAMutation
dehydrogenase	I-DNAMutation
3beta-HSD	B-DNAMutation
gene	O
causing	O
a	O
mild	O
and	O
a	O
severe	O
form	O
of	O
3beta-HSD	B-DNAMutation
deficiency	O
congenital	O
adrenal	O
hyperplasia	O
.	O

The	O
first	O
is	O
a	O
nonstop	B-DNAMutation
mutation	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
normal	I-DNAMutation
stop	I-DNAMutation
codon	I-DNAMutation
373	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
gene	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
IV	I-DNAMutation
[	I-DNAMutation
TGA	I-DNAMutation
(Stop)	I-DNAMutation
-->	I-DNAMutation
TGC	I-DNAMutation
(Cys)	I-DNAMutation
=	O
Stop373C	B-DNAMutation
)	O
identified	O
from	O
one	O
allele	O
of	O
a	O
female	O
child	O
with	O
premature	O
pubarche	O
whose	O
second	O
allele	O
had	O
an	O
E142K	B-DNAMutation
mutation	O
.	O

The	O
Stop373C	B-DNAMutation
mutation	O
predictably	O
results	O
in	O
an	O
open	O
reading	O
frame	O
and	O
a	O
mutant-type	O
(MT)	O
II	B-DNAMutation
3beta-HSD	I-DNAMutation
protein	O
containing	O
467	O
amino	O
acid	O
residues	O
,	O
compared	O
with	O
the	O
372	O
amino	O
acid	O
residues	O
of	O
wild-type	O
(WT)	O
protein	O
.	O

The	O
second	O
is	O
a	O
homozygous	O
missense	O
mutation	B-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
222	I-DNAMutation
[	I-DNAMutation
CCA	I-DNAMutation
(Pro)	I-DNAMutation
-->	I-DNAMutation
ACT	I-DNAMutation
(Thr)	I-DNAMutation
=	O
P222T	B-DNAMutation
]	O
in	O
the	O
gene	O
identified	O
from	O
a	O
female	O
neonate	O
with	O
salt-wasting	O
disorder	O
.	O

The	O
pcDNA	O
vectors	O
containing	O
the	O
constructs	O
of	O
WT	O
II	B-DNAMutation
3beta-HSD	I-DNAMutation
cDNA	O
,	O
WT	O
cDNA	O
with	O
the	O
open	O
reading	O
frame	O
(	O
WT	O
cDNA(+)	O
)	O
,	O
MT	B-DNAMutation
Stop373C	I-DNAMutation
with	O
the	O
open	O
reading	O
frame	O
Stop373C(+)	B-DNAMutation
and	O
MT	O
P222T	B-DNAMutation
cDNA	O
were	O
transfected	O
in	O
COS-I	O
and	O
293T	O
cells	O
and	O
expressed	O
a	O
similar	O
amount	O
of	O
3beta-HSD	B-DNAMutation
mRNA	O
.	O

The	O
enzyme	O
activity	O
in	O
intact	O
cells	O
using	O
pregnenolone	O
and	O
dehydroepiandrosterone	O
as	O
substrate	O
in	O
the	O
medium	O
(	O
1	O
micromol/liter	O
)	O
was	O
identical	O
between	O
the	O
WT	O
cDNA	O
and	O
the	O
WT	O
cDNA(+)	O
,	O
but	O
was	O
decreased	O
to	O
27%	O
of	O
the	O
WT	O
enzymes	O
at	O
6	O
h	O
by	O
MT	O
Stop373C(+)	B-DNAMutation
enzyme	O
,	O
and	O
was	O
undetectable	O
by	O
P222T	B-DNAMutation
enzyme	O
.	O

In	O
the	O
homogenates	O
of	O
the	O
cells	O
,	O
both	O
MT	O
Stop373C(+)	B-DNAMutation
and	O
P222T	B-DNAMutation
enzyme	O
activities	O
and	O
enzymes	O
were	O
undetectable	O
despite	O
clear	O
detection	O
of	O
WT	O
enzyme	O
activities	O
and	O
WT	O
enzymes	O
.	O

LH	O
response	O
to	O
an	O
LHRH	B-DNAMutation
analog	O
stimulation	O
in	O
the	O
pubertal	O
female	O
with	O
the	O
Stop373C/E142K	B-DNAMutation
genotypes	O
and	O
in	O
a	O
pubertal	O
female	O
with	O
compound	O
273/318	O
frameshift	O
genotypes	O
were	O
comparable	O
to	O
and	O
higher	O
than	O
control	O
females	O
,	O
respectively	O
.	O

In	O
conclusion	O
,	O
a	O
structurally	O
lengthy	O
MT	O
II	B-DNAMutation
3beta-HSD	I-DNAMutation
enzyme	O
due	O
to	O
a	O
nonstop	O
mutation	O
was	O
relatively	O
detrimental	O
in	O
intact	O
cells	O
causing	O
the	O
nonclassic	O
phenotype	O
of	O
3beta-HSD	B-DNAMutation
deficiency	O
.	O

A	O
missense	O
P222T	B-DNAMutation
mutation	O
was	O
seriously	O
detrimental	O
,	O
causing	O
the	O
classic	O
phenotype	O
of	O
3beta-HSD	B-DNAMutation
deficiency	O
.	O

The	O
undetectable	O
Stop373C	B-DNAMutation
and	O
P222T	B-DNAMutation
enzymes	O
on	O
Western	O
blottings	O
,	O
together	O
with	O
the	O
respective	O
in	O
vivo	O
and	O
in	O
vitro	O
data	O
,	O
suggest	O
that	O
a	O
relative	O
instability	O
of	O
Stop373C	B-DNAMutation
enzyme	O
and	O
a	O
profound	O
instability	O
of	O
the	O
P222T	B-DNAMutation
enzyme	O
are	O
likely	O
the	O
detrimental	O
molecular	O
mechanisms	O
.	O

The	O
increased	O
LH	O
in	O
the	O
female	O
with	O
the	O
frameshift	O
genotype	O
and	O
the	O
appropriate	O
LH	O
response	O
in	O
the	O
female	O
with	O
the	O
nonstop	O
genotype	O
correlated	O
with	O
predictably	O
severe	O
and	O
mild	O
ovarian	O
type	O
II	B-DNAMutation
3beta-HSD	I-DNAMutation
deficiency	O
,	O
respectively	O
.	O

[	O
HLA-A29	O
sub-types	O
and	O
"Birdshot"	O
choroido-retinopathy	O
susceptibility	O
:	O
a	O
possible	O
"resistance	O
motif"	O
in	O
the	O
HLA-A29.1	O
molecule	O
]	O
.	O

The	O
Birdshot	O
choroidoretinopathy	O
(BSCR)	O
is	O
an	O
ocular	O
disease	O
strongly	O
associated	O
with	O
HLA-A29	O
.	O

The	O
HLA-A29	O
specificity	O
can	O
be	O
split	O
using	O
immunoelectrofocusing	O
in	O
two	O
subtypes	O
A29.1	O
and	O
A29.2	O
.	O

BSCR	O
susceptibility	O
is	O
exclusively	O
linked	O
to	O
the	O
HLA-A29.2	O
molecule	O
.	O

The	O
sequence	O
of	O
HLA-A29.2	O
was	O
established	O
(	O
EMBL	O
X60108	O
and	O
found	O
to	O
be	O
identical	O
between	O
patients	O
and	O
healthy	O
individuals	O
.	O

A	O
single	O
difference	O
was	O
found	O
H----D	B-DNAMutation
102	I-DNAMutation
)	O
in	O
the	O
extra	O
cellular	O
domains	O
between	O
HLA-A29.2	O
and	O
HLA-A29.1	O
.	O

The	O
HLA-A29	O
sub-types	O
shares	O
the	O
consensus	O
HLA	O
class	O
I	O
sequence	O
(D102)	O
.	O

The	O
mutation	O
exhibited	O
by	O
HLA-A29.1	O
(H102)	O
is	O
unique	O
to	O
that	O
molecule	O
.	O

The	O
ancestral	O
type	O
is	O
thus	O
HLA-A29.2	O
that	O
confers	O
the	O
susceptibility	O
to	O
BSCR	O
whereas	O
HLA-A29.1	O
has	O
arisen	O
from	O
a	O
more	O
recent	O
mutation	O
conferring	O
resistance	O
to	O
BSCR	O
.	O

Another	O
single	O
amino-acid	O
difference	O
between	O
HLA-A29.1	O
and	O
HLA-A29.2	O
was	O
found	O
in	O
the	O
intracytoplasmic	O
part	O
of	O
the	O
molecule	O
,	O
HLA-A29.2	O
exhibiting	O
the	O
HLA-A	B-DNAMutation
consensus	O
sequence	O
whereas	O
A29.1	O
shares	O
with	O
AW33.1	O
the	O
mutation	O
S----F321	O
.	O

In	O
addition	O
,	O
the	O
A29	O
specificity	O
was	O
assigned	O
to	O
L	O
and	O
Q	O
amino-acids	O
at	O
position	O
62-63	O
,	O
which	O
can	O
interact	O
with	O
peptides	O
into	O
the	O
binding	O
groove	O
.	O

No	O
specific	O
T	O
or	O
B	O
epitope	O
of	O
susceptibility	O
could	O
be	O
considered	O
involving	O
the	O
region	O
of	O
the	O
mutation	O
discriminating	O
HLA-A29.2	O
from	O
HLA-A29.1	O
.	O

The	O
HLA-A29.1	O
mutation	O
is	O
unable	O
to	O
interact	O
with	O
the	O
T	O
cell	O
receptor	O
and	O
did	O
not	O
seem	O
to	O
induce	O
significant	O
structural	O
changes	O
in	O
the	O
peptide-binding	O
groove	O
.	O

Conversely	O
,	O
its	O
position	O
suggests	O
that	O
the	O
A29.1	O
mutation	O
might	O
interfere	O
with	O
the	O
binding	O
of	O
an	O
accessory	O
molecule	O
,	O
the	O
CD8	B-DNAMutation
molecule	O
being	O
the	O
most	O
likely	O
candidate	O
for	O
that	O
role	O
.	O

Mutation	O
of	O
the	O
acetylcholine	O
receptor	O
alpha	O
subunit	O
causes	O
a	O
slow-channel	O
myasthenic	O
syndrome	O
by	O
enhancing	O
agonist	O
binding	O
affinity	O
.	O

In	O
five	O
members	O
of	O
a	O
family	O
and	O
another	O
unrelated	O
person	O
affected	O
by	O
a	O
slow-channel	O
congenital	O
myasthenic	O
syndrome	O
(SCCMS)	O
,	O
molecular	O
genetic	O
analysis	O
of	O
acetylcholine	O
receptor	O
(AChR)	O
subunit	O
genes	O
revealed	O
a	O
heterozygous	O
G	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
457	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
alpha	I-DNAMutation
subunit	I-DNAMutation
,	O
converting	B-DNAMutation
codon	I-DNAMutation
153	I-DNAMutation
from	I-DNAMutation
glycine	I-DNAMutation
to	I-DNAMutation
serine	I-DNAMutation
(	I-DNAMutation
alpha	I-DNAMutation
G153S	I-DNAMutation
)	O
.	O

Electrophysiologic	O
analysis	O
of	O
SCCMS	O
end	O
plates	O
revealed	O
prolonged	O
decay	O
of	O
miniature	O
end	O
plate	O
currents	O
and	O
prolonged	O
activation	O
episodes	O
of	O
single	O
AChR	O
channels	O
.	O

Engineered	O
mutant	O
AChR	O
expressed	O
in	O
HEK	B-DNAMutation
fibroblasts	O
exhibited	O
prolonged	O
activation	O
episodes	O
strikingly	O
similar	O
to	O
those	O
observed	O
at	O
the	O
SCCMS	O
end	O
plates	O
.	O

Single-channel	O
kinetic	O
analysis	O
of	O
engineered	O
alpha	O
G153S	B-DNAMutation
AChR	O
revealed	O
a	O
markedly	O
decreased	O
rate	O
of	O
ACh	O
dissociation	O
,	O
which	O
causes	O
the	O
mutant	O
AChR	O
to	O
open	O
repeatedly	O
during	O
ACh	O
occupancy	O
.	O

In	O
addition	O
,	O
ACh	O
binding	O
measurements	O
combined	O
with	O
the	O
kinetic	O
analysis	O
indicated	O
increased	O
desensitization	O
of	O
the	O
mutant	O
AChR	O
.	O

Thus	O
,	O
ACh	O
binding	O
affinity	O
can	O
dictate	O
the	O
time	O
course	O
of	O
the	O
synaptic	O
response	O
,	O
and	O
alpha	O
G153	O
contributes	O
to	O
the	O
low	O
binding	O
affinity	O
for	O
ACh	O
needed	O
to	O
speed	O
the	O
decay	O
of	O
the	O
synaptic	O
response	O
.	O

A	O
novel	O
missense	O
mutation	O
of	O
AIRE	B-DNAMutation
gene	O
in	O
a	O
patient	O
with	O
autoimmune	O
polyendocrinopathy	O
,	O
candidiasis	O
and	O
ectodermal	O
dystrophy	O
(APECED)	O
,	O
accompanied	O
with	O
progressive	O
muscular	O
atrophy	O
:	O
case	O
report	O
and	O
review	O
of	O
the	O
literature	O
in	O
Japan	O
.	O

Autoimmune	O
polyendocrinopathy	O
,	O
candidiasis	O
,	O
and	O
ectodermal	O
dystrophy	O
(APECED)	O
also	O
known	O
as	O
autoimmune	O
polyglandular	O
syndrome	O
type	O
I	O
,	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
that	O
results	O
in	O
several	O
autoimmune	O
diseases	O
due	O
to	O
mutations	O
in	O
the	O
AIRE	B-DNAMutation
(	O
autoimmune	O
regulator	O
)	O
gene	O
.	O

A	O
39-year-old	O
female	O
patient	O
developed	O
chronic	O
mucocutaneous	O
candidiasis	O
at	O
3	O
yrs	O
,	O
idiopathic	O
hypoparathyroidism	O
at	O
11	O
yrs	O
,	O
chronic	O
hepatitis	O
at	O
23	O
yrs	O
,	O
Addison's	O
disease	O
and	O
diabetes	O
mellitus	O
type	O
I	O
at	O
27	O
yrs	O
.	O

In	O
addition	O
,	O
the	O
patient	O
developed	O
progressive	O
muscular	O
atrophy	O
of	O
unknown	O
etiology	O
at	O
the	O
beginning	O
of	O
the	O
third	O
decade	O
,	O
and	O
is	O
bedridden	O
at	O
the	O
present	O
time	O
.	O

Her	O
grandparents	O
,	O
parents	O
,	O
brother	O
and	O
daughter	O
did	O
not	O
develop	O
any	O
features	O
of	O
APECED	O
,	O
but	O
her	O
father	O
died	O
of	O
hepatoma	O
.	O

Direct	O
sequencing	O
of	O
the	O
AIRE	B-DNAMutation
gene	O
revealed	O
a	O
novel	O
missense	O
mutation	O
at	O
exon	O
1	O
R15C	B-DNAMutation
,	O
which	O
was	O
identified	O
to	O
be	O
of	O
maternal	O
origin	O
.	O

The	O
other	O
mutation	O
was	O
not	O
found	O
despite	O
repeated	O
sequencing	O
of	O
the	O
whole	O
coding	O
regions	O
.	O

The	O
R15C	B-DNAMutation
mutation	O
was	O
not	O
detected	O
in	O
patients	O
with	O
idiopathic	O
hypoparathyroidism	O
(	O
N=	O
10	O
)	O
,	O
idiopathic	O
Addison's	O
disease	O
(	O
N	O
=	O
3	O
)	O
,	O
and	O
normal	O
subjects	O
(	O
N	O
=	O
55	O
)	O
.	O

Although	O
we	O
could	O
not	O
analyze	O
the	O
father's	O
gene	O
,	O
these	O
results	O
suggest	O
that	O
the	O
patient	O
is	O
probably	O
a	O
compound	O
heterozygote	O
of	O
the	O
AIRE	B-DNAMutation
gene	O
,	O
in	O
which	O
the	O
other	O
abnormal	O
allele	O
could	O
not	O
be	O
identified	O
by	O
the	O
present	O
analytical	O
method	O
.	O

These	O
data	O
are	O
compatible	O
with	O
the	O
recent	O
review	O
that	O
only	O
one	O
defective	O
allele	O
was	O
detectable	O
in	O
some	O
patients	O
with	O
clinically	O
evident	O
APECED	O
.	O

We	O
found	O
only	O
six	O
Japanese	O
patients	O
compatible	O
with	O
diagnosis	O
of	O
APECED	O
,	O
indicating	O
that	O
this	O
autoimmune	O
disease	O
is	O
extremely	O
rare	O
in	O
our	O
country	O
.	O

Molecular	O
genetic	O
analysis	O
of	O
the	O
gene	O
encoding	O
the	O
trifunctional	O
enzyme	O
MTHFD	B-DNAMutation
(	O
methylenetetrahydrofolate-dehydrogenase	B-DNAMutation
,	O
methenyltetrahydrofolate-cyclohydrolase	O
,	O
formyltetrahydrofolate	O
synthetase	O
)	O
in	O
patients	O
with	O
neural	O
tube	O
defects	O
.	O

It	O
is	O
now	O
well	O
recognized	O
that	O
periconceptional	O
folic	O
acid	O
or	O
folic	O
acid	O
containing	O
multivitamin	O
supplementation	O
reduces	O
the	O
risk	O
of	O
neural	O
tube	O
defects	O
(NTDs)	O
.	O

Recently	O
we	O
were	O
able	O
to	O
show	O
that	O
homozygosity	O
for	O
a	O
thermolabile	O
variant	O
of	O
the	O
enzyme	O
methylenetetrahydrofolate	O
reductase	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
spina	O
bifida	O
in	O
patients	O
recruited	O
from	O
the	O
Dutch	O
population	O
.	O

However	O
,	O
this	O
genetic	O
risk	O
factor	O
could	O
not	O
account	O
for	O
all	O
folic	O
acid	O
preventable	O
NTDs	O
.	O

In	O
an	O
attempt	O
to	O
identify	O
additional	O
folate	O
related	O
enzymes	O
that	O
contribute	O
to	O
NTD	B-DNAMutation
etiology	O
we	O
now	O
studied	O
the	O
methylenetetrahydrofolate	B-DNAMutation
dehydrogenase	I-DNAMutation
gene	O
on	O
chromosome	O
14q24	O
which	O
encodes	O
a	O
single	O
protein	O
with	O
three	O
catalytic	O
properties	O
important	O
in	O
the	O
folate	O
metabolism	O
.	O

The	O
cDNA	O
sequence	O
of	O
38	O
familial	O
and	O
79	O
sporadic	O
patients	O
was	O
screened	O
for	O
the	O
presence	O
of	O
mutations	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
followed	O
by	O
sequencing	O
.	O

Two	O
amino	O
acid	O
substitutions	O
were	O
identified	O
.	O

The	O
first	O
one	O
R293H	B-DNAMutation
was	O
detected	O
in	O
a	O
patient	O
with	O
familial	O
spina	O
bifida	O
and	O
not	O
in	O
300	O
control	O
individuals	O
.	O

The	O
mutation	O
was	O
inherited	O
from	O
the	O
unaffected	O
maternal	O
grandmother	O
and	O
was	O
also	O
present	O
in	O
two	O
younger	O
brothers	O
of	O
the	O
index	O
patient	O
,	O
one	O
of	O
them	O
displaying	O
spina	O
bifida	O
occulta	O
and	O
the	O
other	O
being	O
unaffected	O
.	O

The	O
second	O
change	O
turned	O
out	O
to	O
be	O
an	O
amino	O
acid	O
polymorphism	O
R653Q	B-DNAMutation
that	O
was	O
present	O
in	O
both	O
patients	O
and	O
controls	O
with	O
similar	O
frequencies	O
.	O

Our	O
results	O
so	O
far	O
provide	O
no	O
evidence	O
for	O
a	O
major	O
role	O
of	O
the	O
methylenetetrahydrofolate-dehydrogenase	B-DNAMutation
MTHFD	B-DNAMutation
gene	O
in	O
NTD	B-DNAMutation
etiology	O
.	O

However	O
,	O
the	O
identification	O
of	O
a	O
mutation	O
in	O
one	O
family	O
suggests	O
that	O
this	O
gene	O
can	O
act	O
as	O
a	O
risk	O
factor	O
for	O
human	O
NTD	B-DNAMutation
.	O

Molecular	O
bases	O
of	O
dominant	O
negative	O
and	O
loss	O
of	O
function	O
mutations	O
at	O
the	O
murine	O
c-kit/white	B-DNAMutation
spotting	O
locus	O
:	O
W37	O
,	O
Wv	O
,	O
W41	O
and	O
W	O
.	O

The	O
proto-oncogene	B-DNAMutation
c-kit	I-DNAMutation
encodes	O
a	O
transmembrane	O
tyrosine	O
protein	O
kinase	O
receptor	O
for	O
an	O
unknown	O
ligand	O
and	O
is	O
allelic	O
with	O
the	O
murine	O
white-spotting	O
locus	O
(W)	O
.	O

Mutations	O
at	O
the	O
W	O
locus	O
affect	O
various	O
aspects	O
of	O
hematopoiesis	O
,	O
the	O
proliferation	O
and	O
migration	O
of	O
primordial	O
germ	O
cells	O
and	O
melanoblasts	O
during	O
development	O
.	O

The	O
original	O
W	O
mutation	O
and	O
W37	O
are	O
severe	O
lethal	O
mutations	O
when	O
homozygous	O
.	O

In	O
the	O
heterozygous	O
state	O
the	O
W	O
mutation	O
has	O
a	O
weak	O
phenotype	O
while	O
W37	O
has	O
dominant	O
characteristics	O
.	O

Wv	O
and	O
W41	O
are	O
weak	O
W	O
mutations	O
with	O
dominant	O
characteristics	O
.	O

We	O
have	O
characterized	O
the	O
molecular	O
basis	O
of	O
these	O
four	O
W	O
mutations	O
and	O
determined	O
their	O
effects	O
on	O
mast	O
cell	O
differentiation	O
by	O
using	O
a	O
fibroblast/mast	O
cell	O
co-culture	O
assay	O
.	O

We	O
show	O
that	O
W37	O
,	O
Wv	O
and	O
W41	O
are	O
the	O
result	O
of	O
missense	O
mutations	O
in	O
the	O
kinase	O
domain	O
of	O
the	O
c-kit	B-DNAMutation
coding	O
sequence	O
(	O
W37	B-DNAMutation
E----K	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
582	I-DNAMutation
;	O
Wv	B-DNAMutation
T----M	I-DNAMutation
position	I-DNAMutation
660	I-DNAMutation
and	O
W41	B-DNAMutation
V----M	I-DNAMutation
position	I-DNAMutation
831	I-DNAMutation
)	O
,	O
which	O
affect	O
the	O
c-kit	B-DNAMutation
associated	O
tyrosine	O
kinase	O
to	O
varying	O
degrees	O
.	O

The	O
c-kit	B-DNAMutation
protein	O
products	O
in	O
homozygous	O
mutant	O
mast	O
cells	O
are	O
expressed	O
normally	O
,	O
although	O
the	O
160	O
kd	O
cell	O
membrane	O
form	O
of	O
the	O
c-kitW37	O
protein	O
displays	O
accelerated	O
turnover	O
characteristics	O
.	O

The	O
W	O
mutation	O
is	O
the	O
result	O
of	O
a	O
78	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
deletion	I-DNAMutation
which	I-DNAMutation
includes	I-DNAMutation
the	I-DNAMutation
transmembrane	I-DNAMutation
domain	I-DNAMutation
of	O
the	O
c-kit	B-DNAMutation
protein	O
.	O

A	O
125	O
kd	O
c-kit	B-DNAMutation
protein	O
was	O
detected	O
in	O
homozygous	O
W/W	O
mast	O
cells	O
which	O
lacks	O
kinase	O
activity	O
and	O
is	O
not	O
expressed	O
on	O
the	O
cell	O
surface.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Deletion	B-DNAMutation
of	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
Asp487-Ser488-Phe489	I-DNAMutation
in	O
human	O
cytochrome	B-DNAMutation
P450c17	I-DNAMutation
causes	O
severe	O
17	O
alpha-hydroxylase	O
deficiency	O
.	O

17	O
alpha-Hydroxylase	O
deficiency	O
blocks	O
the	O
biosynthesis	O
of	O
cortisol	O
and	O
sex	O
steroids	O
,	O
resulting	O
in	O
mineralocorticoid	O
excess	O
,	O
hypertension	O
,	O
sexual	O
infantilism	O
,	O
and	O
female	O
phenotype	O
in	O
both	O
genetic	O
sexes	O
.	O

The	O
disease	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
cytochrome	B-DNAMutation
P450c17	I-DNAMutation
,	O
which	O
is	O
the	O
single	O
enzyme	O
that	O
mediates	O
both	O
17	O
alpha-hydroxylase	O
and	O
17,20-lyase	O
activities	O
.	O

We	O
report	O
a	O
14-yr-old	O
patient	O
from	O
Thailand	O
with	O
a	O
classical	O
clinical	O
presentation	O
of	O
this	O
rare	O
disorder	O
.	O

Analysis	O
of	O
her	O
P450c17	B-DNAMutation
gene	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
and	O
sequencing	O
showed	O
a	O
nine-base	O
deletion	O
,	O
eliminating	B-DNAMutation
codons	I-DNAMutation
487-489	I-DNAMutation
(Asp-Ser-Phe)	I-DNAMutation
near	O
the	O
carboxy-terminus	O
of	O
P450c17	B-DNAMutation
.	O

This	O
deletion	O
creates	O
a	O
BclI	O
site	O
in	O
the	O
mutant	O
DNA	O
,	O
permitting	O
accurate	O
demonstration	O
that	O
the	O
patient	O
was	O
homozygous	O
for	O
this	O
lesion	O
,	O
whereas	O
one	O
parent	O
and	O
two	O
siblings	O
were	O
heterozygous	O
.	O

By	O
use	O
of	O
site-directed	O
mutagenesis	O
,	O
we	O
created	O
a	O
vector	O
that	O
could	O
express	O
this	O
mutated	O
form	O
of	O
P450c17	B-DNAMutation
when	O
transfected	O
into	O
non-steroidogenic	O
COS-1	O
cells	O
.	O

Such	O
transfected	O
cells	O
produced	O
immunodetectable	O
P450c17	B-DNAMutation
protein	O
,	O
but	O
had	O
no	O
17	O
alpha-hydroxylase	O
or	O
17,20-lyase	O
activity	O
,	O
whereas	O
cells	O
similarly	O
transfected	O
with	O
a	O
vector	O
expressing	O
normal	O
human	O
P450c17	B-DNAMutation
could	O
17	O
alpha-hydroxylate	O
either	O
pregnenolone	O
or	O
progesterone	O
and	O
convert	O
17	O
alpha-hydroxypregnenolone	O
to	O
dehydroepiandrosterone	O
,	O
showing	O
the	O
presence	O
of	O
both	O
activities	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
the	O
molecular	O
genetic	O
basis	O
of	O
17	O
alpha-hydroxylase	O
deficiency	O
in	O
a	O
Southeast	O
Asian	O
patient	O
.	O

Molecular	O
abnormality	O
of	O
an	O
inactive	O
aldehyde	O
dehydrogenase	O
variant	O
commonly	O
found	O
in	O
Orientals	O
.	O

Usual	O
human	O
livers	O
contain	O
two	O
major	O
aldehyde	O
dehydrogenase	O
[	O
(	O
ALDH	O
)	O
aldehyde:NAD+	O
oxidoreductase	O
]	O
isozymes--i.e.	O
,	O
a	O
cytosolic	O
ALDH1	B-DNAMutation
component	O
and	O
a	O
mitochondrial	O
ALDH2	B-DNAMutation
component--whereas	O
approximately	O
equal	O
to	O
50%	O
of	O
Orientals	O
are	O
"atypical"	O
and	O
have	O
only	O
the	O
ALDH1	B-DNAMutation
isozyme	O
and	O
are	O
missing	O
the	O
ALDH2	B-DNAMutation
isozyme	O
.	O

We	O
previously	O
demonstrated	O
that	O
atypical	O
livers	O
contain	O
an	O
enzymatically	O
inactive	O
but	O
immunologically	O
crossreactive	O
material	O
(CRM)	O
corresponding	O
to	O
the	O
ALDH2	B-DNAMutation
component	O
.	O

The	O
enzymatically	O
active	O
ALDH2	B-DNAMutation
obtained	O
from	O
a	O
usual	O
liver	O
and	O
the	O
CRM	O
obtained	O
from	O
an	O
atypical	O
liver	O
were	O
reduced	O
,	O
S-carboxymethylated	O
,	O
and	O
digested	O
by	O
trypsin	O
.	O

Separation	O
of	O
their	O
digests	O
by	O
high-performance	O
reverse-phase	O
chromatography	O
and	O
by	O
two-dimensional	O
paper	O
chromatography	O
and	O
electrophoresis	O
revealed	O
that	O
ALDH2	B-DNAMutation
contained	O
a	O
peptide	O
sequence	O
of	O
-Glu-Leu-Gly-Glu-Ala-Gly-Leu-Gln-Ala-Asn-Val-Gln-Val-Lys-	O
and	O
that	O
the	B-DNAMutation
glutamine	I-DNAMutation
adjacent	I-DNAMutation
to	I-DNAMutation
lysine	I-DNAMutation
was	I-DNAMutation
substituted	I-DNAMutation
by	I-DNAMutation
lysine	I-DNAMutation
in	O
CRM	O
.	O

All	O
other	O
tryptic	O
peptides	O
,	O
including	O
eight	O
peptides	O
containing	O
S-carboxymethylcysteine	O
,	O
were	O
common	O
in	O
ALDH2	B-DNAMutation
and	O
CRM	O
.	O

It	O
is	O
concluded	O
that	O
a	O
point	O
mutation	O
in	O
the	O
human	O
ALDH2	B-DNAMutation
locus	O
produced	O
the	O
glutamine	B-DNAMutation
leads	I-DNAMutation
to	I-DNAMutation
lysine	I-DNAMutation
substitution	I-DNAMutation
and	O
enzyme	O
inactivation	O
.	O

Molecular	O
survey	O
of	O
a	O
prevalent	O
mutation	O
,	O
985A-to-G	B-DNAMutation
transition	O
,	O
and	O
identification	O
of	O
five	O
infrequent	O
mutations	O
in	O
the	O
medium-chain	B-DNAMutation
Acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
MCAD	B-DNAMutation
gene	O
in	O
55	O
patients	O
with	O
MCAD	B-DNAMutation
deficiency	O
.	O

Medium-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
MCAD	B-DNAMutation
deficiency	O
is	O
an	O
inborn	O
error	O
of	O
fatty-acid	O
oxidation	O
that	O
is	O
characterized	O
by	O
fasting	O
intolerance	O
and	O
recurrent	O
episodes	O
of	O
hypoglycemic	O
coma	O
which	O
can	O
be	O
fatal	O
.	O

Its	O
incidence	O
is	O
one	O
of	O
the	O
highest	O
among	O
genetic	O
metabolic	O
disorders	O
.	O

Using	O
a	O
modified	O
PCR	O
and	O
NcoI	O
digestion	O
method	O
,	O
we	O
have	O
surveyed	O
46	O
additional	O
,	O
unrelated	O
MCAD-deficient	B-DNAMutation
patients	O
for	O
a	O
prevalent	O
mutation	O
,	O
an	O
985A-to-G	B-DNAMutation
transition	O
985A----G	B-DNAMutation
,	O
that	O
we	O
previously	O
identified	O
in	O
nine	O
MCAD-deficient	B-DNAMutation
patients	O
.	O

Among	O
the	O
total	O
of	O
55	O
studied	O
,	O
44	O
were	O
homozygous	O
and	O
10	O
were	O
heterozygous	O
for	O
the	O
985G	O
allele	O
,	O
whereas	O
one	O
did	O
not	O
carry	O
this	O
mutant	O
allele	O
,	O
indicating	O
that	O
the	O
prevalence	O
of	O
the	O
985G	O
allele	O
is	O
89.1%	O
.	O

Furthermore	O
,	O
we	O
identified	O
five	O
other	O
types	O
of	O
mutation	O
:	O
one	O
each	O
in	O
three	O
of	O
the	O
compound	O
heterozygotes	O
and	O
two	O
in	O
the	O
single	O
non-985G	O
patient	O
.	O

An	O
RFLP	O
study	O
of	O
12	O
985G-homozygotes	O
showed	O
that	O
all	O
24	O
alleles	O
fell	O
into	O
a	O
single	O
haplotype	O
.	O

A	O
questionnaire	O
regarding	O
the	O
ethnic	O
and	O
national	O
origin	O
of	O
their	O
patients	O
was	O
sent	O
to	O
all	O
referring	O
investigators	O
.	O

All	O
41	O
patients	O
for	O
whom	O
this	O
information	O
was	O
provided	O
were	O
Caucasians	O
.	O

Of	O
29	O
patients	O
whose	O
country	O
of	O
origin	O
was	O
specified	O
,	O
19	O
and	O
five	O
were	O
from	O
the	O
British	O
Isles	O
and	O
Germany	O
,	O
respectively	O
.	O

These	O
data	O
suggest	O
that	O
985A----G	B-DNAMutation
may	O
have	O
occurred	O
in	O
a	O
single	O
person	O
in	O
an	O
ancient	O
Germanic	O
tribe	O
.	O

Novel	O
mutations	O
in	O
the	O
BCHE	O
gene	O
in	O
patients	O
with	O
no	O
butyrylcholinesterase	O
activity	O
.	O

BACKGROUND	O
:	O
Butyrylcholinesterase	O
(BCHE)	O
deficiency	O
is	O
characterized	O
by	O
prolonged	O
apnea	O
after	O
the	O
use	O
of	O
certain	O
muscle	O
relaxants	O
with	O
the	O
genetic	O
defect	O
lying	O
in	O
the	O
BCHE	O
gene	O
.	O

METHODS	O
:	O
Two	O
Chinese	O
patients	O
with	O
no	O
serum	O
BCHE	O
activity	O
were	O
studied	O
.	O

The	O
BCHE	O
genes	O
were	O
screened	O
for	O
mutations	O
by	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Of	O
the	O
four	O
mutations	O
detected	O
,	O
two	O
novel	O
mutations	O
were	O
identified	O
in	O
the	O
two	O
patients	O
,	O
i.e.	O
,	O
F474L	B-DNAMutation
,	O
and	O
an	O
insertion	B-DNAMutation
of	I-DNAMutation
an	I-DNAMutation
adenine	I-DNAMutation
between	I-DNAMutation
nucleotide	I-DNAMutation
positions	I-DNAMutation
395	I-DNAMutation
and	I-DNAMutation
396	I-DNAMutation
.	O

This	O
information	O
was	O
used	O
to	O
screen	O
the	O
immediate	O
families	O
of	O
the	O
patients	O
for	O
carrier	O
status	O
.	O

CONCLUSIONS	O
:	O
We	O
established	O
the	O
molecular	O
basis	O
of	O
butyrylcholinesterase	O
deficiency	O
in	O
two	O
Chinese	O
patients	O
.	O

The	O
developed	O
mutation	O
detection	O
assay	O
provides	O
a	O
reliable	O
method	O
for	O
identifying	O
mutant	O
BCHE	O
carriers	O
.	O

Molecular	O
basis	O
of	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
deficiency	O
and	O
emphysema	O
associated	O
with	O
the	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
Mmineral	O
springs	O
allele	O
.	O

The	O
Mmineral	O
springs	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
(	O
alpha	B-DNAMutation
1AT	I-DNAMutation
)	O
allele	O
,	O
causing	O
alpha	B-DNAMutation
1AT	I-DNAMutation
deficiency	O
and	O
emphysema	O
,	O
is	O
unique	O
among	O
the	O
alpha	B-DNAMutation
1AT-deficiency	I-DNAMutation
alleles	O
in	O
that	O
it	O
was	O
observed	O
in	O
a	O
black	O
family	O
,	O
whereas	O
most	O
mutations	O
causing	O
alpha	B-DNAMutation
1AT	I-DNAMutation
deficiency	O
are	O
confined	O
to	O
Caucasian	O
populations	O
of	O
European	O
descent	O
.	O

Immobilized	O
pH	O
gradient	O
analysis	O
of	O
serum	O
demonstrated	O
that	O
alpha	B-DNAMutation
1AT	I-DNAMutation
Mmineral	O
springs	O
migrated	O
cathodal	O
to	O
the	O
normal	O
M2	O
allele	O
.	O

Evaluation	O
of	O
Mmineral	O
springs	O
alpha	B-DNAMutation
1AT	I-DNAMutation
as	O
an	O
inhibitor	O
of	O
neutrophil	O
elastase	O
,	O
its	O
natural	O
substrate	O
,	O
demonstrated	O
markedly	O
lower	O
than	O
normal	O
function	O
.	O

Characterization	O
of	O
the	O
alpha	B-DNAMutation
1AT	I-DNAMutation
Mmineral	O
springs	O
gene	O
demonstrated	O
that	O
it	O
differed	O
from	O
the	O
common	O
normal	O
M1(Ala213)	B-DNAMutation
allele	I-DNAMutation
by	I-DNAMutation
a	I-DNAMutation
single-base	I-DNAMutation
substitution	I-DNAMutation
causing	I-DNAMutation
the	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
substitution	I-DNAMutation
Gly-67	I-DNAMutation
(GGG)----Glu-67	I-DNAMutation
(GAG)	I-DNAMutation
.	O

Capitalizing	O
on	O
the	O
fact	O
that	O
this	O
mutation	O
creates	O
a	O
polymorphism	O
for	O
the	O
restriction	O
endonuclease	O
AvaII	O
,	O
family	O
analysis	O
demonstrated	O
that	O
the	O
Mmineral	O
springs	O
alpha	B-DNAMutation
1AT	I-DNAMutation
allele	O
was	O
transmitted	O
in	O
an	O
autosomal-codominant	O
fashion	O
.	O

Evaluation	O
of	O
genomic	O
DNA	O
showed	O
that	O
the	O
index	O
case	O
was	O
homozygous	O
for	O
the	O
alpha	B-DNAMutation
1AT	I-DNAMutation
Mmineral	O
springs	O
allele	O
.	O

Cytoplasmic	O
blot	O
analysis	O
of	O
blood	O
monocytes	O
of	O
the	O
Mmineral	O
springs	O
homozygote	O
demonstrated	O
levels	O
of	O
alpha	B-DNAMutation
1AT	I-DNAMutation
mRNA	O
transcripts	O
comparable	O
to	O
those	O
in	O
cells	O
of	O
a	O
normal	O
M1	O
(Val213)	O
homozygote	O
control	O
.	O

Evaluation	O
of	O
in	O
vitro	O
translation	O
of	O
Mmineral	O
springs	O
alpha	B-DNAMutation
1AT	I-DNAMutation
mRNA	O
transcripts	O
demonstrated	O
a	O
normal	O
capacity	O
to	O
direct	O
the	O
translation	O
of	O
alpha	B-DNAMutation
1AT	I-DNAMutation
.	O

Evaluation	O
of	O
secretion	O
of	O
alpha	B-DNAMutation
1AT	I-DNAMutation
by	O
the	O
blood	O
monocytes	O
by	O
pulse-chase	O
labeling	O
with	O
[35S]methionine	O
,	O
however	O
,	O
demonstrated	O
less	O
secretion	O
by	O
the	O
Mmineral	O
springs	O
cells	O
than	O
normal	O
cells	O
.	O

To	O
characterize	O
the	O
posttranslational	O
events	O
causing	O
the	O
alpha	O
1AT-secretory	O
defect	O
associated	O
with	O
the	O
alpha	O
1AT	O
Mmineral	O
springs	O
gene	O
,	O
retroviral	O
gene	O
transfer	O
was	O
used	O
to	O
establish	O
polyclonal	O
populations	O
of	O
murine	O
fibroblasts	O
containing	O
either	O
a	O
normal	O
human	O
M1	O
alpha	B-DNAMutation
1AT	I-DNAMutation
cDNA	O
or	O
an	O
Mmineral	O
springs	O
alpha	B-DNAMutation
1AT	I-DNAMutation
cDNA	O
and	O
expressing	O
comparable	O
levels	O
of	O
human	O
alpha	B-DNAMutation
1AT	I-DNAMutation
mRNA	O
transcripts	O
.	O

Pulse-chase	O
labeling	O
of	O
these	O
cells	O
with	O
[35S]methionine	O
demonstrated	O
less	O
secretion	O
of	O
human	O
alpha	B-DNAMutation
1AT	I-DNAMutation
from	O
the	O
Mmineral	O
springs	O
cells	O
than	O
from	O
the	O
M1	O
cells	O
,	O
and	O
evaluation	O
of	O
cell	O
lysates	O
also	O
demonstrated	O
lower	O
amounts	O
of	O
intracellular	O
human	O
alpha	B-DNAMutation
1AT	I-DNAMutation
in	O
the	O
Mmineral	O
springs	O
cells	O
than	O
in	O
the	O
normal	O
M1	O
control	O
cells	O
.	O

Thus	O
,	O
the	O
Gly-67	B-DNAMutation
-->	I-DNAMutation
Glu	I-DNAMutation
mutation	O
that	O
characterizes	O
Mmineral	O
springs	O
causes	O
reduced	O
alpha	B-DNAMutation
1AT	I-DNAMutation
secretion	O
on	O
the	O
basis	O
of	O
aberrant	O
posttranslational	O
alpha	B-DNAMutation
1AT	I-DNAMutation
biosynthesis	O
by	O
a	O
mechanism	O
distinct	O
from	O
that	O
associated	O
with	O
the	O
alpha	B-DNAMutation
1AT	I-DNAMutation
Z	O
allele	O
,	O
whereby	O
intracellular	O
aggregation	O
of	O
the	O
mutant	O
protein	O
is	O
etiologic	O
of	O
the	O
alpha	B-DNAMutation
1AT-secretory	I-DNAMutation
defect	O
.	O

Furthermore	O
,	O
for	O
the	O
alpha	B-DNAMutation
1AT	I-DNAMutation
protein	O
that	O
does	O
reach	O
the	O
circulation	O
,	O
this	O
mutation	O
markedly	O
affects	O
the	O
ability	O
of	O
the	O
molecule	O
to	O
inhibit	O
neutrophil	O
elastase	O
;	O
i.e.	O
,	O
the	O
alpha	B-DNAMutation
1AT	I-DNAMutation
Mmineral	O
springs	O
allele	O
predisposes	O
to	O
emphysema	O
on	O
the	O
basis	O
of	O
serum	O
apha	O
1AT	O
deficiency	O
coupled	O
with	O
alpha	O
AT	O
dysfunction	O
.	O

Structural	O
basis	O
for	O
defects	O
of	O
Keap1	O
activity	O
provoked	O
by	O
its	O
point	O
mutations	O
in	O
lung	O
cancer	O
.	O

Nrf2	O
regulates	O
the	O
cellular	O
oxidative	O
stress	O
response	O
,	O
whereas	O
Keap1	O
represses	O
Nrf2	O
through	O
its	O
molecular	O
interaction	O
.	O

To	O
elucidate	O
the	O
molecular	O
mechanism	O
of	O
the	O
Keap1	O
and	O
Nrf2	O
interaction	O
,	O
we	O
resolved	O
the	O
six-bladed	O
beta	O
propeller	O
crystal	O
structure	O
of	O
the	O
Kelch/DGR	O
and	O
CTR	O
domains	O
of	O
mouse	O
Keap1	B-DNAMutation
and	O
revealed	O
that	O
extensive	O
inter-	O
and	O
intrablade	O
hydrogen	O
bonds	O
maintain	O
the	O
structural	O
integrity	O
and	O
proper	O
association	O
of	O
Keap1	B-DNAMutation
with	O
Nrf2	B-DNAMutation
.	O

A	O
peptide	O
containing	O
the	O
ETGE	O
motif	O
of	O
Nrf2	O
binds	O
the	O
beta	O
propeller	O
of	O
Keap1	O
at	O
the	O
entrance	O
of	O
the	O
central	O
cavity	O
on	O
the	O
bottom	O
side	O
via	O
electrostatic	O
interactions	O
with	O
conserved	O
arginine	O
residues	O
.	O

We	O
found	O
a	O
somatic	O
mutation	O
and	O
a	O
gene	O
variation	O
in	O
human	O
lung	O
cancer	O
cells	O
that	O
change	B-DNAMutation
glycine	I-DNAMutation
to	I-DNAMutation
cysteine	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
DGR	I-DNAMutation
domain	I-DNAMutation
,	O
introducing	O
local	O
conformational	O
changes	O
that	O
reduce	O
Keap1's	O
affinity	O
for	O
Nrf2	O
.	O

These	O
results	O
provide	O
a	O
structural	O
basis	O
for	O
the	O
loss	O
of	O
Keap1	O
function	O
and	O
gain	O
of	O
Nrf2	O
function	O
.	O

XB130	B-DNAMutation
,	O
a	O
novel	O
adaptor	O
protein	O
for	O
signal	O
transduction	O
.	O

Adaptor	O
proteins	O
are	O
important	O
mediators	O
in	O
signal	O
transduction	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
report	O
the	O
cloning	O
and	O
characterization	O
of	O
a	O
novel	O
adaptor	O
protein	O
,	O
XB130	B-DNAMutation
.	O

This	O
gene	O
is	O
located	O
on	O
human	O
chromosome	O
10q25.3	O
and	O
encodes	O
a	O
protein	O
of	O
818	O
amino	O
acids	O
.	O

It	O
contains	O
several	O
Src	O
homology	O
(SH)2-	O
and	O
SH3-binding	O
motifs	O
,	O
two	O
pleckstrin	O
homology	O
domains	O
,	O
a	O
coiled-coil	O
region	O
,	O
and	O
a	O
number	O
of	O
potential	O
tyrosine	O
or	O
serine/threonine	O
phosphorylation	O
sites	O
.	O

Endogenous	O
XB130	B-DNAMutation
interacts	O
with	O
c-Src	B-DNAMutation
tyrosine	I-DNAMutation
kinase	I-DNAMutation
.	O

Their	O
co-expression	O
in	O
COS-7	O
cells	O
resulted	O
in	O
activation	O
of	O
c-Src	B-DNAMutation
and	O
elevated	O
tyrosine	O
phosphorylation	O
of	O
multiple	O
proteins	O
,	O
including	O
XB130	B-DNAMutation
itself	O
.	O

XB130	B-DNAMutation
expression	O
in	O
HEK293	O
cells	O
enhanced	O
serum	O
response	O
element-	O
and	O
AP-1-dependent	O
transcriptional	O
activation	O
mediated	O
by	O
c-Src	B-DNAMutation
.	O

XB130DeltaN	B-DNAMutation
,	O
an	O
N-terminal	B-DNAMutation
deletion	I-DNAMutation
mutant	I-DNAMutation
lacking	I-DNAMutation
a	I-DNAMutation
putative	I-DNAMutation
SH3-binding	I-DNAMutation
motif	I-DNAMutation
and	I-DNAMutation
several	I-DNAMutation
putative	I-DNAMutation
SH2-binding	I-DNAMutation
sites	I-DNAMutation
,	O
reduced	O
its	O
ability	O
to	O
mediate	O
Src	O
signal	O
transduction	O
.	O

Down-regulation	O
of	O
endogenous	O
XB130	B-DNAMutation
with	O
siRNA	O
reduced	O
c-Src	B-DNAMutation
activity	O
,	O
IL-8	B-DNAMutation
production	O
,	O
EGF-induced	O
phosphorylation	O
of	O
Akt	B-DNAMutation
and	O
GSK3beta	B-DNAMutation
,	O
and	O
altered	O
cell	O
cycles	O
in	O
human	O
lung	O
epithelial	O
cells	O
.	O

These	O
data	O
suggest	O
that	O
XB130	B-DNAMutation
as	O
an	O
adaptor	O
may	O
play	O
an	O
important	O
role	O
in	O
the	O
regulation	O
of	O
signal	O
transduction	O
and	O
cellular	O
functions	O
.	O

Homeodomain-interacting	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
2	I-DNAMutation
HIPK2	B-DNAMutation
targets	O
beta-catenin	B-DNAMutation
for	O
phosphorylation	O
and	O
proteasomal	O
degradation	O
.	O

The	O
regulation	O
of	O
intracellular	O
beta-catenin	B-DNAMutation
levels	O
is	O
central	O
in	O
the	O
Wnt/beta-catenin	B-DNAMutation
signaling	O
cascade	O
and	O
the	O
activation	O
of	O
the	O
Wnt	O
target	O
genes	O
.	O

Here	O
,	O
we	O
show	O
that	O
homeodomain-interacting	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
2	I-DNAMutation
HIPK2	B-DNAMutation
acts	O
as	O
a	O
negative	O
regulator	O
of	O
the	O
Wnt/beta-catenin	B-DNAMutation
pathway	O
.	O

Knock-down	B-DNAMutation
of	O
endogenous	O
HIPK2	B-DNAMutation
increases	O
the	O
stability	O
of	O
beta-catenin	B-DNAMutation
and	O
results	O
in	O
the	O
accumulation	O
of	O
beta-catenin	B-DNAMutation
in	O
the	O
nucleus	O
,	O
consequently	O
enhancing	O
the	O
expression	O
of	O
Wnt	O
target	O
genes	O
and	O
cell	O
proliferation	O
both	O
in	O
vivo	O
and	O
in	O
cultured	O
cells	O
.	O

HIPK2	B-DNAMutation
inhibits	O
TCF/LEF-mediated	O
target	O
gene	O
activation	O
via	O
degradation	O
of	O
beta-catenin	B-DNAMutation
.	O

HIPK2	B-DNAMutation
phosphorylates	O
beta-catenin	B-DNAMutation
at	O
its	O
Ser33	O
and	O
Ser37	O
residues	O
without	O
the	O
aid	O
of	O
a	O
priming	O
kinase	O
.	O

Substitutions	B-DNAMutation
of	I-DNAMutation
Ser33	I-DNAMutation
and	I-DNAMutation
Ser37	I-DNAMutation
for	I-DNAMutation
alanines	I-DNAMutation
abolished	O
the	O
degradation	O
of	O
beta-catenin	B-DNAMutation
associated	O
with	O
HIPK2	B-DNAMutation
.	O

In	O
ex	O
vivo	O
mouse	O
model	O
,	O
HIPK2	B-DNAMutation
knock-down	B-DNAMutation
resulted	O
in	O
accumulation	O
of	O
beta-catenin	B-DNAMutation
,	O
thereby	O
potentiated	O
beta-catenin-mediated	B-DNAMutation
cell	O
proliferation	O
and	O
tumor	O
formation	O
.	O

Furthermore	O
,	O
the	O
axis	O
duplication	O
induced	O
by	O
the	O
ectopic	O
expression	O
of	O
beta-catenin	O
was	O
blocked	O
by	O
co-injection	O
of	O
HIPK2	B-DNAMutation
mRNAs	O
into	O
Xenopus	O
embryos	O
.	O

Taken	O
together	O
,	O
HIPK2	B-DNAMutation
appears	O
to	O
function	O
as	O
a	O
novel	O
negative	O
regulator	O
of	O
beta-catenin	B-DNAMutation
through	O
its	O
phosphorylation	O
and	O
proteasomal	O
degradation	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
Arg-115	I-DNAMutation
of	O
human	O
class	O
III	O
alcohol	O
dehydrogenase	O
:	O
a	O
binding	O
site	O
required	O
for	O
formaldehyde	O
dehydrogenase	O
activity	O
and	O
fatty	O
acid	O
activation	O
.	O

The	O
origin	O
of	O
the	O
fatty	O
acid	O
activation	O
and	O
formaldehyde	O
dehydrogenase	O
activity	O
that	O
distinguishes	O
human	O
class	O
III	O
alcohol	O
dehydrogenase	O
(	O
alcohol:NAD+	O
oxidoreductase	O
,	O
EC	O
1.1.1.1	O
)	O
from	O
all	O
other	O
alcohol	O
dehydrogenases	O
has	O
been	O
examined	O
by	O
site-directed	O
mutagenesis	B-DNAMutation
of	I-DNAMutation
its	I-DNAMutation
Arg-115	I-DNAMutation
residue	I-DNAMutation
.	O

The	O
Ala-	B-DNAMutation
and	I-DNAMutation
Asp-115	I-DNAMutation
mutant	I-DNAMutation
proteins	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
and	O
purified	O
by	O
affinity	O
chromatography	O
and	O
ion-exchange	O
HPLC	O
.	O

The	O
activities	O
of	O
the	O
recombinant	O
native	O
and	O
mutant	O
enzymes	O
toward	O
ethanol	O
are	O
essentially	O
identical	O
,	O
but	O
mutagenesis	O
greatly	O
decreases	O
the	O
kcat/Km	O
values	O
for	O
glutathione-dependent	O
formaldehyde	O
oxidation	O
.	O

The	O
catalytic	O
efficiency	O
for	O
the	O
Asp	O
variant	O
is	O
<	O
0.1%	O
that	O
of	O
the	O
unmutated	O
enzyme	O
,	O
due	O
to	O
both	O
a	O
higher	O
Km	O
and	O
a	O
lower	O
kcat	O
value	O
.	O

As	O
with	O
the	O
native	O
enzyme	O
,	O
neither	O
mutant	O
can	O
oxidize	O
methanol	O
,	O
be	O
saturated	O
by	O
ethanol	O
,	O
or	O
be	O
inhibited	O
by	O
4-methylpyrazole	O
;	O
i.e.	O
,	O
they	O
retain	O
these	O
class	O
III	O
characteristics	O
.	O

In	O
contrast	O
,	O
however	O
,	O
their	O
activation	O
by	O
fatty	O
acids	O
,	O
another	O
characteristic	O
unique	O
to	O
class	O
III	O
alcohol	O
dehydrogenase	O
,	O
is	O
markedly	O
attenuated	O
.	O

The	O
Ala	O
mutant	O
is	O
activated	O
only	O
slightly	O
,	O
but	O
the	O
Asp	O
mutant	O
is	O
not	O
activated	O
at	O
all	O
.	O

The	O
results	O
strongly	O
indicate	O
that	O
Arg-115	O
in	O
class	O
III	O
alcohol	O
dehydrogenase	O
is	O
a	O
component	O
of	O
the	O
binding	O
site	O
for	O
activating	O
fatty	O
acids	O
and	O
is	O
critical	O
for	O
the	O
binding	O
of	O
S-hydroxymethylglutathione	O
in	O
glutathione-dependent	O
formaldehyde	O
dehydrogenase	O
activity	O
.	O

Mutation	O
in	O
Npps	B-DNAMutation
in	O
a	O
mouse	O
model	O
of	O
ossification	O
of	O
the	O
posterior	O
longitudinal	O
ligament	O
of	O
the	O
spine	O
.	O

Ossification	O
of	O
the	O
posterior	O
longitudinal	O
ligament	O
of	O
the	O
spine	O
OPLL	B-DNAMutation
is	O
a	O
common	O
form	O
of	O
human	O
myelopathy	O
caused	O
by	O
a	O
compression	O
of	O
the	O
spinal	O
cord	O
by	O
ectopic	O
ossification	O
of	O
spinal	O
ligaments	O
.	O

To	O
elucidate	O
the	O
genetic	O
basis	O
for	O
OPLL	O
,	O
we	O
have	O
been	O
studying	O
the	O
ttw	O
(	O
tiptoe	O
walking	O
;	O
previously	O
designated	O
twy	O
)	O
mouse	O
,	O
a	O
naturally	O
occurring	O
mutant	O
which	O
exhibits	O
ossification	O
of	O
the	O
spinal	O
ligaments	O
very	O
similar	O
to	O
human	O
OPLL	B-DNAMutation
(	O
refs	O
3,4	O
)	O
.	O

Using	O
a	O
positional	O
candidate-gene	O
approach	O
,	O
we	O
determined	O
the	O
ttw	O
phenotype	O
is	O
caused	O
by	O
a	O
nonsense	O
mutation	O
(	O
glycine	B-DNAMutation
568	I-DNAMutation
to	I-DNAMutation
stop	I-DNAMutation
)	O
in	O
the	O
Npps	B-DNAMutation
gene	O
which	O
encodes	O
nucleotide	O
pyrophosphatase	O
.	O

This	O
enzyme	O
regulates	O
soft-tissue	O
calcification	O
and	O
bone	O
mineralization	O
by	O
producing	O
inorganic	O
pyrophosphate	O
,	O
a	O
major	O
inhibitor	O
of	O
calcification	O
.	O

The	O
accelerated	O
bone	O
formation	O
characteristic	O
of	O
ttw	O
mice	O
is	O
likely	O
to	O
result	O
from	O
dysfunction	O
of	O
NPPS	B-DNAMutation
caused	O
by	O
predicted	O
truncation	O
of	O
the	O
gene	O
product	O
,	O
resulting	O
in	O
the	O
loss	O
of	O
more	O
than	O
one-third	O
of	O
the	O
native	O
protein	O
.	O

Our	O
results	O
may	O
lead	O
to	O
novel	O
insights	O
into	O
the	O
mechanism	O
of	O
ectopic	O
ossification	O
and	O
the	O
aetiology	O
of	O
human	O
OPLL	B-DNAMutation
.	O

Biochemical	O
and	O
molecular	O
characterization	O
of	O
18	O
patients	O
with	O
pyridoxine-dependent	O
epilepsy	O
and	O
mutations	O
of	O
the	O
antiquitin	O
ALDH7A1	B-DNAMutation
gene	O
.	O

Patients	O
with	O
pyridoxine	O
dependent	O
epilepsy	O
(PDE)	O
present	O
with	O
early-onset	O
seizures	O
resistant	O
to	O
common	O
anticonvulsants	O
.	O

According	O
to	O
the	O
benefit	O
of	O
pyridoxine	O
(	O
vitamin	O
B(6)	O
)	O
and	O
recurrence	O
of	O
seizures	O
on	O
pyridoxine	O
withdrawal	O
,	O
patients	O
so	O
far	O
have	O
been	O
classified	O
as	O
having	O
definite	O
,	O
probable	O
,	O
or	O
possible	O
PDE	O
.	O

Recently	O
,	O
PDE	O
has	O
been	O
shown	O
to	O
be	O
caused	O
by	O
a	O
defect	O
of	O
alpha-amino	B-DNAMutation
adipic	I-DNAMutation
semialdehyde	I-DNAMutation
(AASA)	I-DNAMutation
dehydrogenase	I-DNAMutation
(antiquitin)	O
in	O
the	O
cerebral	O
lysine	O
degradation	O
pathway	O
.	O

The	O
accumulating	O
compound	O
piperideine-6-carboxylic	O
acid	O
(P6C)	O
was	O
shown	O
to	O
inactivate	O
pyridoxalphosphate	O
(PLP)	O
by	O
a	O
Knoevenagel	O
condensation	O
.	O

Pipecolic	O
acid	O
(PA)	O
and	O
AASA	O
are	O
markedly	O
elevated	O
in	O
urine	O
,	O
plasma	O
,	O
and	O
cerebrospinal	O
fluid	O
(CSF)	O
and	O
thus	O
can	O
be	O
used	O
as	O
biomarkers	O
of	O
the	O
disease	O
.	O

We	O
have	O
investigated	O
18	O
patients	O
with	O
neonatal	O
seizure	O
onset	O
,	O
who	O
have	O
been	O
classified	O
as	O
having	O
definite	O
(11)	O
,	O
probable	O
(four)	O
,	O
or	O
possible	O
(three)	O
PDE	O
.	O

All	O
patients	O
had	O
elevated	O
PA	O
and	O
AASA	O
in	O
plasma	O
(	O
and	O
urine	O
)	O
while	O
on	O
treatment	O
with	O
individual	O
dosages	O
of	O
pyridoxine	O
.	O

Within	O
this	O
cohort	O
,	O
molecular	O
analysis	O
identified	O
10	O
novel	O
mutations	O
(	O
six	O
missense	O
mutations	O
,	O
one	O
nonsense	O
mutation	O
,	O
two	O
splice	O
site	O
mutations	O
)	O
within	O
highly	O
conserved	O
regions	O
of	O
the	O
antiquitin	O
gene	O
.	O

Seven	O
mutations	O
were	O
located	O
in	O
exonic	O
sequences	O
and	O
two	O
in	O
introns	O
7	O
and	O
17	O
.	O

Furthermore	O
,	O
a	O
novel	B-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
7	I-DNAMutation
was	O
identified	O
.	O

Two	O
of	O
the	O
36	O
alleles	O
investigated	O
require	O
further	O
investigation	O
.	O

A	O
known	O
mutation	O
p.Glu399Gln	B-DNAMutation
was	O
found	O
with	O
marked	O
prevalence	O
,	O
accounting	O
for	O
12	O
out	O
of	O
36	O
alleles	O
(33%)	O
within	O
our	O
cohort	O
.	O

Pyridoxine	O
withdrawal	O
is	O
no	O
longer	O
needed	O
to	O
establish	O
the	O
diagnosis	O
of	O
"definite"	O
PDE	O
.	O

Administration	O
of	O
pyridoxine	O
in	O
PDE	O
may	O
not	O
only	O
correct	O
secondary	O
PLP	O
deficiency	O
,	O
but	O
may	O
also	O
lead	O
to	O
a	O
reduction	O
of	O
AASA	O
(	O
and	O
P6C	O
)	O
as	O
presumably	O
toxic	O
compounds	O
.	O

Tangier	O
disease	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
gene	O
encoding	O
ATP-binding	O
cassette	O
transporter	O
1	O
.	O

Tangier	O
disease	O
(TD)	O
was	O
first	O
discovered	O
nearly	O
40	O
years	O
ago	O
in	O
two	O
siblings	O
living	O
on	O
Tangier	O
Island	O
.	O

This	O
autosomal	O
co-dominant	O
condition	O
is	O
characterized	O
in	O
the	O
homozygous	O
state	O
by	O
the	O
absence	O
of	O
HDL-cholesterol	O
(HDL-C)	O
from	O
plasma	O
,	O
hepatosplenomegaly	O
,	O
peripheral	O
neuropathy	O
and	O
frequently	O
premature	O
coronary	O
artery	O
disease	O
(CAD)	O
.	O

In	O
heterozygotes	O
,	O
HDL-C	O
levels	O
are	O
about	O
one-half	O
those	O
of	O
normal	O
individuals	O
.	O

Impaired	O
cholesterol	O
efflux	O
from	O
macrophages	O
leads	O
to	O
the	O
presence	O
of	O
foam	O
cells	O
throughout	O
the	O
body	O
,	O
which	O
may	O
explain	O
the	O
increased	O
risk	O
of	O
coronary	O
heart	O
disease	O
in	O
some	O
TD	O
families	O
.	O

We	O
report	O
here	O
refining	O
of	O
our	O
previous	O
linkage	O
of	O
the	O
TD	O
gene	O
to	O
a	O
1-cM	O
region	O
between	O
markers	O
D9S271	O
and	O
D9S1866	O
on	O
chromosome	O
9q31	O
,	O
in	O
which	O
we	O
found	O
the	O
gene	O
encoding	O
human	O
ATP	O
cassette-binding	O
transporter	O
1	O
ABC1	B-DNAMutation
.	O

We	O
also	O
found	O
a	O
change	O
in	O
ABC1	B-DNAMutation
expression	O
level	O
on	O
cholesterol	O
loading	O
of	O
phorbol	O
ester-treated	O
THP1	B-DNAMutation
macrophages	O
,	O
substantiating	O
the	O
role	O
of	O
ABC1	B-DNAMutation
in	O
cholesterol	O
efflux	O
.	O

We	O
cloned	O
the	O
full-length	O
cDNA	O
and	O
sequenced	O
the	O
gene	O
in	O
two	O
unrelated	O
families	O
with	O
four	O
TD	O
homozygotes	O
.	O

In	O
the	O
first	O
pedigree	O
,	O
a	O
1-bp	B-DNAMutation
deletion	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
13	I-DNAMutation
,	O
resulting	O
in	O
truncation	O
of	O
the	O
predicted	O
protein	O
to	O
approximately	O
one-fourth	O
of	O
its	O
normal	O
size	O
,	O
co-segregated	O
with	O
the	O
disease	O
phenotype	O
.	O

An	O
in-frame	B-DNAMutation
insertion-deletion	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
12	I-DNAMutation
was	O
found	O
in	O
the	O
second	O
family	O
.	O

Our	O
findings	O
indicate	O
that	O
defects	O
in	O
ABC1	B-DNAMutation
,	O
encoding	O
a	O
member	O
of	O
the	O
ABC	O
transporter	O
superfamily	O
,	O
are	O
the	O
cause	O
of	O
TD	O
.	O

Probing	O
the	O
functional	O
role	O
of	O
two	O
conserved	O
active	O
site	O
aspartates	O
in	O
mouse	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
.	O

Two	O
adjacent	O
aspartates	O
,	O
Asp	O
295	O
and	O
Asp	O
296	O
,	O
playing	O
major	O
roles	O
in	O
the	O
reaction	O
catalyzed	O
by	O
mouse	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
mADA	B-DNAMutation
were	O
altered	O
using	O
site-directed	O
mutagenesis	O
.	O

These	O
mutants	O
were	O
expressed	O
and	O
purified	O
from	O
an	O
ADA-deficient	B-DNAMutation
bacterial	O
strain	O
and	O
characterized	O
.	O

Circular	O
dichroism	O
spectroscopy	O
shows	O
the	O
mutants	O
to	O
have	O
unperturbed	O
secondary	O
structure	O
.	O

Their	O
zinc	O
content	O
compares	O
well	O
to	O
that	O
of	O
wild-type	O
enzyme	O
.	O

Changing	O
Asp	B-DNAMutation
295	I-DNAMutation
to	I-DNAMutation
a	I-DNAMutation
glutamate	I-DNAMutation
decreases	O
the	O
kcat	O
but	O
does	O
not	O
alter	O
the	O
Km	O
for	O
adenosine	O
,	O
confirming	O
the	O
importance	O
of	O
this	O
residue	O
in	O
the	O
catalytic	O
process	O
and	O
its	O
minimal	O
role	O
in	O
substrate	O
binding	O
.	O

The	O
crystal	O
structure	O
of	O
the	O
D295E	B-DNAMutation
mutant	O
reveals	O
a	O
displacement	O
of	O
the	O
catalytic	O
water	O
from	O
the	O
active	O
site	O
due	O
to	O
the	O
longer	O
glutamate	O
side	O
chain	O
,	O
resulting	O
in	O
the	O
mutant's	O
inability	O
to	O
turn	O
over	O
the	O
substrate	O
.	O

In	O
contrast	O
,	O
Asp	B-DNAMutation
296	I-DNAMutation
mutants	I-DNAMutation
exhibit	O
markedly	O
increased	O
Km	O
values	O
,	O
establishing	O
this	O
residue's	O
critical	O
role	O
in	O
substrate	O
binding	O
.	O

The	O
Asp	B-DNAMutation
296->Ala	I-DNAMutation
mutation	O
causes	O
a	O
70-fold	O
increase	O
in	O
the	O
Km	O
for	O
adenosine	O
and	O
retains	O
0.001%	O
of	O
the	O
wild-type	O
kcat/Km	O
value	O
,	O
whereas	O
the	O
ASP	B-DNAMutation
296->Asn	I-DNAMutation
mutant	O
has	O
a	O
10-fold	O
higher	O
Km	O
and	O
retains	O
1%	O
of	O
the	O
wild-type	O
kcat/Km	O
value	O
.	O

The	O
structure	O
of	O
the	O
D296A	B-DNAMutation
mutant	O
shows	O
that	O
the	O
impaired	O
binding	O
of	O
substrate	O
is	O
caused	O
by	O
the	O
loss	O
of	O
a	O
single	O
hydrogen	O
bond	O
between	O
a	O
carboxylate	O
oxygen	O
and	O
N7	O
of	O
the	O
purine	O
ring	O
.	O

These	O
results	O
and	O
others	O
discussed	O
below	O
are	O
in	O
agreement	O
with	O
the	O
postulated	O
role	O
of	O
the	O
adjacent	O
aspartates	O
in	O
the	O
catalytic	O
mechanism	O
for	O
mADA	B-DNAMutation
.	O

Targeted	O
next-generation	O
sequencing	O
of	O
a	O
12.5	O
Mb	O
homozygous	O
region	O
reveals	O
ANO10	B-DNAMutation
mutations	O
in	O
patients	O
with	O
autosomal-recessive	O
cerebellar	O
ataxia	O
.	O

Autosomal-recessive	O
cerebellar	O
ataxias	O
comprise	O
a	O
clinically	O
and	O
genetically	O
heterogeneous	O
group	O
of	O
neurodegenerative	O
disorders	O
.	O

In	O
contrast	O
to	O
their	O
dominant	O
counterparts	O
,	O
unraveling	O
the	O
molecular	O
background	O
of	O
these	O
ataxias	O
has	O
proven	O
to	O
be	O
more	O
complicated	O
and	O
the	O
currently	O
known	O
mutations	O
provide	O
incomplete	O
coverage	O
for	O
genotyping	O
of	O
patients	O
.	O

By	O
combining	O
SNP	O
array-based	O
linkage	O
analysis	O
and	O
targeted	O
resequencing	O
of	O
relevant	O
sequences	O
in	O
the	O
linkage	O
interval	O
with	O
the	O
use	O
of	O
next-generation	O
sequencing	O
technology	O
,	O
we	O
identified	O
a	O
mutation	O
in	O
a	O
gene	O
and	O
have	O
shown	O
its	O
association	O
with	O
autosomal-recessive	O
cerebellar	O
ataxia	O
.	O

In	O
a	O
Dutch	O
consanguineous	O
family	O
with	O
three	O
affected	O
siblings	O
a	O
homozygous	O
12.5	O
Mb	O
region	O
on	O
chromosome	O
3	O
was	O
targeted	O
by	O
array-based	O
sequence	O
capture	O
.	O

Prioritization	O
of	O
all	O
detected	O
sequence	O
variants	O
led	O
to	O
four	O
candidate	O
genes	O
,	O
one	O
of	O
which	O
contained	O
a	O
variant	O
with	O
a	O
high	O
base	O
pair	O
conservation	O
score	O
(	O
phyloP	O
score	O
:	O
5.26	O
)	O
.	O

This	O
variant	O
was	O
a	O
leucine-to-arginine	B-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
DUF	I-DNAMutation
590	I-DNAMutation
domain	I-DNAMutation
of	O
a	O
16K	O
transmembrane	O
protein	O
,	O
a	O
putative	O
calcium-activated	O
chloride	O
channel	O
encoded	O
by	O
anoctamin	B-DNAMutation
10	I-DNAMutation
ANO10	B-DNAMutation
.	O

The	O
analysis	O
of	O
ANO10	B-DNAMutation
by	O
Sanger	O
sequencing	O
revealed	O
three	O
additional	O
mutations	O
:	O
a	O
homozygous	O
mutation	O
(	O
c.1150_1151del	B-DNAMutation
[	O
p.Leu384fs	B-DNAMutation
]	O
)	O
in	O
a	O
Serbian	O
family	O
and	O
a	O
compound-heterozygous	O
splice-site	O
mutation	O
c.1476+1G>T	B-DNAMutation
and	O
a	O
frameshift	O
mutation	O
(	O
c.1604del	B-DNAMutation
[	O
p.Leu535X	B-DNAMutation
]	O
)	O
in	O
a	O
French	O
family	O
.	O

This	O
illustrates	O
the	O
power	O
of	O
using	O
initial	O
homozygosity	O
mapping	O
with	O
next-generation	O
sequencing	O
technology	O
to	O
identify	O
genes	O
involved	O
in	O
autosomal-recessive	O
diseases	O
.	O

Moreover	O
,	O
identifying	O
a	O
putative	O
calcium-dependent	O
chloride	O
channel	O
involved	O
in	O
cerebellar	O
ataxia	O
adds	O
another	O
pathway	O
to	O
the	O
list	O
of	O
pathophysiological	O
mechanisms	O
that	O
may	O
cause	O
cerebellar	O
ataxia	O
.	O

Activation	O
of	O
a	O
GST-tagged	O
AKT2/PKBbeta	B-DNAMutation
.	O

The	O
protein	O
kinase	O
AKT	O
is	O
a	O
key	O
regulator	O
for	O
cell	O
growth	O
,	O
cell	O
survival	O
and	O
metabolic	O
insulin	B-DNAMutation
action	O
.	O

However	O
,	O
the	O
mechanism	O
of	O
activation	O
of	O
AKT	O
in	O
vivo	O
,	O
which	O
presumably	O
involves	O
membrane	O
recruitment	O
of	O
the	O
kinase	O
,	O
oligomerization	O
,	O
and	O
multiple	O
phosphorylation	O
events	O
,	O
is	O
not	O
fully	O
understood	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
have	O
expressed	O
and	O
purified	O
dimeric	O
GST-fusion	O
proteins	O
of	O
human	O
protein	O
kinase	O
AKT2	B-DNAMutation
DeltaPH-AKT2	B-DNAMutation
in	O
milligram	O
quantities	O
via	O
the	O
baculovirus	O
expression	O
system	O
.	O

Treatment	O
of	O
virus-infected	O
insect	O
cells	O
with	O
the	O
phosphatase	O
inhibitor	O
okadaic	O
acid	O
(OA)	O
led	O
to	O
phosphorylation	O
of	O
the	O
two	O
regulatory	O
phosphorylation	O
sites	O
,	O
Thr309	O
and	O
Ser474	O
,	O
and	O
to	O
activation	O
of	O
the	O
kinase	O
.	O

Likewise	O
,	O
phosphorylation	O
of	O
Thr309	O
in	O
vitro	O
by	O
recombinant	O
PDK1	B-DNAMutation
or	O
mutation	B-DNAMutation
of	I-DNAMutation
Thr309	I-DNAMutation
and	I-DNAMutation
Ser474	I-DNAMutation
to	I-DNAMutation
acidic	I-DNAMutation
residues	I-DNAMutation
rendered	O
the	O
kinase	O
constitutively	O
active	O
.	O

However	O
,	O
even	O
though	O
the	O
specific	O
activity	O
of	O
our	O
AKT2	B-DNAMutation
was	O
increased	O
15-fold	O
compared	O
to	O
previous	O
reports	O
,	O
GST-mediated	O
dimerization	O
alone	O
did	O
not	O
lead	O
to	O
an	O
activation	O
of	O
the	O
kinase	O
.	O

Whereas	O
both	O
mutagenesis	O
and	O
phosphorylation	O
led	O
to	O
an	O
increase	O
in	O
the	O
turnover	O
number	O
of	O
the	O
enzyme	O
,	O
only	O
the	O
latter	O
resulted	O
in	O
a	O
marked	O
reduction	O
(20-fold)	O
of	O
the	O
apparent	O
Km	O
value	O
for	O
the	O
exogenous	O
substrate	O
Crosstide	O
,	O
indicating	O
that	O
this	O
widely	O
used	O
mutagenesis	O
only	O
partially	O
mimics	O
phosphorylation	O
.	O

Kinetic	O
analysis	O
of	O
GST-AKT2	B-DNAMutation
demonstrates	O
that	O
phosphorylation	O
of	O
Thr309	O
in	O
the	O
activation	O
loop	O
of	O
the	O
kinase	O
is	O
largely	O
responsible	O
for	O
the	O
observed	O
reduction	O
in	O
Km	O
and	O
for	O
a	O
subsequent	O
150-fold	O
increase	O
in	O
the	O
catalytic	O
efficiency	O
(k(cat)/Km)	O
of	O
the	O
enzyme	O
.	O

Highly	O
active	O
AKT2	B-DNAMutation
constructs	O
were	O
used	O
in	O
autophosphorylation	O
reactions	O
in	O
vitro	O
,	O
where	O
inactive	O
AKT2	B-DNAMutation
kinases	O
served	O
as	O
substrates	O
.	O

As	O
a	O
matter	O
of	O
fact	O
,	O
we	O
found	O
evidence	O
for	O
a	O
minor	O
autophosphorylation	O
activity	O
of	O
AKT2	B-DNAMutation
but	O
no	O
significant	O
autophosphorylation	O
of	O
any	O
of	O
the	O
two	O
regulatory	O
sites	O
,	O
Thr309	O
or	O
Ser474	O
.	O

Autophosphorylation	O
of	O
threonine	O
485	O
in	O
the	O
activation	O
loop	O
is	O
essential	O
for	O
attaining	O
eIF2alpha	B-DNAMutation
kinase	O
activity	O
of	O
HRI	O
.	O

In	O
heme	O
deficiency	O
,	O
protein	O
synthesis	O
is	O
inhibited	O
by	O
the	O
activation	O
of	O
the	O
heme-regulated	O
eIF2alpha	O
kinase	O
(HRI)	O
through	O
its	O
multiple	O
autophosphorylation	O
.	O

Autophosphorylation	O
sites	O
in	O
HRI	O
were	O
identified	O
in	O
order	O
to	O
investigate	O
their	O
functions	O
.	O

We	O
found	O
that	O
there	O
were	O
eight	O
major	O
tryptic	O
phosphopeptides	O
of	O
HRI	O
activated	O
in	O
heme	O
deficiency	O
.	O

In	O
this	O
report	O
we	O
focused	O
on	O
the	O
role	O
of	O
autophosphorylation	O
at	O
Thr483	O
and	O
Thr485	O
in	O
the	O
activation	O
loop	O
of	O
HRI	O
.	O

Disruption	O
of	O
the	O
autophosphorylation	O
of	O
Thr485	O
,	O
but	O
not	O
Thr483	O
,	O
resulted	O
in	O
a	O
lower	O
autokinase	O
activity	O
and	O
locked	O
Thr485Ala	B-DNAMutation
HRI	O
in	O
a	O
hypophosphorylated	O
state	O
.	O

Most	O
importantly	O
,	O
autophosphorylation	O
of	O
Thr485	O
,	O
but	O
not	O
Thr483	O
,	O
was	O
essential	O
for	O
attaining	O
eIF2alpha	B-DNAMutation
kinase	O
activity	O
of	O
HRI	O
.	O

In	O
addition	O
,	O
autophosphorylation	O
of	O
Thr485	O
was	O
necessary	O
for	O
arsenite-induced	O
activation	O
of	O
the	O
eIF2alpha	B-DNAMutation
kinase	O
activity	O
of	O
HRI	O
,	O
while	O
autophosphorylation	O
at	O
Thr483	O
was	O
not	O
required	O
for	O
activation	O
by	O
arsenite	O
.	O

The	O
function	O
of	O
Thr490	O
,	O
another	O
conserved	O
Thr	O
residue	O
in	O
the	O
activation	O
loop	O
of	O
HRI	O
,	O
was	O
also	O
investigated	O
.	O

Mutations	O
of	O
Thr490	B-DNAMutation
to	I-DNAMutation
either	I-DNAMutation
Ala	I-DNAMutation
or	I-DNAMutation
Asp	I-DNAMutation
resulted	O
in	O
reduced	O
autokinase	O
activity	O
and	O
loss	O
of	O
eIF2alpha	B-DNAMutation
kinase	O
activity	O
in	O
heme	O
deficiency	O
or	O
upon	O
arsenite	O
treatment	O
.	O

Since	O
Thr490	O
was	O
not	O
identified	O
as	O
an	O
autophosphorylated	O
site	O
,	O
it	O
is	O
likely	O
that	O
Thr490	O
itself	O
might	O
be	O
critical	O
for	O
the	O
catalytic	O
activity	O
of	O
HRI	O
.	O

Importantly	O
,	O
Thr485	O
was	O
very	O
poorly	O
phosphorylated	O
in	O
Thr490	O
mutant	O
HRI	O
.	O

Collectively	O
,	O
our	O
results	O
demonstrate	O
that	O
autophosphorylation	O
of	O
Thr485	O
is	O
essential	O
for	O
the	O
hyperphosphorylation	O
and	O
activation	O
of	O
HRI	O
and	O
is	O
required	O
for	O
the	O
acquisition	O
of	O
the	O
eIF2alpha	B-DNAMutation
kinase	O
activity	O
.	O

A	O
Pro----Leu	B-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
369	I-DNAMutation
of	O
the	O
alpha-1-antitrypsin	B-DNAMutation
deficiency	O
variant	O
PI	O
MHeerlen	O
.	O

The	O
molecular	O
defect	O
has	O
been	O
elucidated	O
in	O
the	O
alpha-1-antitrypsin	B-DNAMutation
(PI)	O
gene	O
of	O
a	O
patient	O
with	O
a	O
serum	O
level	O
of	O
only	O
5	O
mg/100	O
ml	O
and	O
a	O
PI	O
M-like	O
phenotype	O
,	O
designated	O
PI	O
MHeerlen	O
.	O

The	O
restriction	O
fragment	O
patterns	O
obtained	O
by	O
probes	O
covering	O
the	O
whole	O
gene	O
and	O
flanking	O
sequences	O
were	O
normal	O
,	O
suggesting	O
no	O
major	O
rearrangements	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
exons	O
,	O
intron/exon	O
junctions	O
,	O
and	O
a	O
part	O
of	O
the	O
promoter	O
region	O
is	O
similar	O
to	O
that	O
of	O
a	O
PI	O
M1(Ala213)	O
gene	O
except	O
for	O
an	O
C----T	B-DNAMutation
mutation	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
369	I-DNAMutation
,	O
causing	O
a	O
Pro----Leu	B-DNAMutation
substitution	I-DNAMutation
.	O

Haplotype	O
analysis	O
and	O
oligonucleotide	O
hybridization	O
studies	O
demonstrated	O
the	O
homozygous	O
state	O
of	O
the	O
mutation	O
in	O
the	O
index	O
case	O
.	O

It	O
is	O
most	O
likely	O
that	O
the	O
Pro369----Leu	B-DNAMutation
substitution	I-DNAMutation
is	O
responsible	O
for	O
the	O
low	O
serum	O
alpha-1-antitrypsin	B-DNAMutation
concentration	O
of	O
the	O
patient	O
because	O
this	O
mutation	O
is	O
solely	O
confined	O
to	O
the	O
PI	O
MHeerlen	O
allele	O
and	O
no	O
other	O
relevant	O
mutations	O
could	O
be	O
revealed	O
.	O

As	O
proline	O
is	O
important	O
for	O
the	O
secondary	O
and	O
tertiary	O
structure	O
of	O
proteins	O
,	O
the	O
mutation	O
may	O
cause	O
an	O
abnormal	O
processing	O
of	O
the	O
nascent	O
polypeptide	O
.	O

The	O
same	O
mutation	O
was	O
observed	O
in	O
two	O
unrelated	O
subjects	O
known	O
to	O
carry	O
a	O
PI	O
allele	O
giving	O
a	O
low	O
serum	O
alpha-1-antitrypsin	B-DNAMutation
level	O
.	O

Involvement	O
of	O
a	O
novel	O
Tnf	O
receptor	O
homologue	O
in	O
hair	O
follicle	O
induction	O
.	O

Although	O
inductive	O
interactions	O
are	O
known	O
to	O
be	O
essential	O
for	O
specification	O
of	O
cell	O
fate	O
in	O
many	O
vertebrate	O
tissues	O
,	O
the	O
signals	O
and	O
receptors	O
responsible	O
for	O
transmitting	O
this	O
information	O
remain	O
largely	O
unidentified	O
.	O

Mice	O
with	O
mutations	O
in	O
the	O
downless	B-DNAMutation
(dl)	O
gene	O
have	O
defects	O
in	O
hair	O
follicle	O
induction	O
,	O
lack	O
sweat	O
glands	O
and	O
have	O
malformed	O
teeth	O
.	O

These	O
structures	O
originate	O
as	O
ectodermal	O
placodes	O
,	O
which	O
invaginate	O
into	O
the	O
underlying	O
mesenchyme	O
and	O
differentiate	O
to	O
form	O
specific	O
organs	O
.	O

Positional	O
cloning	O
of	O
the	O
dl	O
gene	O
began	O
with	O
identification	O
of	O
the	O
transgenic	O
family	O
OVE1	O
.	O

One	O
branch	O
of	O
the	O
family	O
,	O
dl(OVE1B)	O
,	O
carries	O
an	O
approximately	O
600-kb	B-DNAMutation
deletion	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
dl	I-DNAMutation
locus	I-DNAMutation
caused	O
by	O
transgene	O
integration	O
.	O

The	O
mutated	O
locus	O
has	O
been	O
physically	O
mapped	O
in	O
this	O
family	O
,	O
and	O
a	O
200-kb	O
mouse	O
YAC	O
clone	O
,	O
YAC	O
D9	O
,	O
has	O
been	O
identified	O
and	O
shown	O
to	O
rescue	O
the	O
dl	O
phenotype	O
in	O
the	O
spontaneous	O
dl(Jackson)	O
(	O
dl(J	O
)	O
,	O
recessive	O
)	O
and	O
Dl(sleek)	O
(	O
Dl(slk	O
)	O
,	O
dominant	O
negative	O
)	O
mutants	O
.	O

Here	O
we	O
report	O
the	O
positional	O
cloning	O
of	O
the	O
dl	O
gene	O
,	O
which	O
encodes	O
a	O
novel	O
member	O
of	O
the	O
tumour	O
necrosis	O
factor	O
(Tnf)	O
receptor	O
(Tnfr)	O
family	O
.	O

The	O
mutant	O
phenotype	O
and	O
dl	O
expression	O
pattern	O
suggests	O
that	O
this	O
gene	O
encodes	O
a	O
receptor	O
that	O
specifies	O
hair	O
follicle	O
fate	O
.	O

Its	O
ligand	O
is	O
likely	O
to	O
be	O
the	O
product	O
of	O
the	O
tabby	B-DNAMutation
(Ta)	O
gene	O
,	O
as	O
Ta	O
mutants	O
have	O
a	O
phenotype	O
identical	O
to	O
that	O
of	O
dl	O
mutants	O
and	O
Ta	O
encodes	O
a	O
Tnf-like	O
protein	O
.	O

The	O
interaction	O
between	O
ADAM	B-DNAMutation
22	I-DNAMutation
and	O
14-3-3zeta	B-DNAMutation
:	O
regulation	O
of	O
cell	O
adhesion	O
and	O
spreading	O
.	O

The	O
ADAM	O
family	O
consists	O
of	O
a	O
number	O
of	O
transmembrane	O
proteins	O
that	O
contain	O
disintegrin-like	O
and	O
metalloproteinase-like	O
domains	O
.	O

Therefore	O
,	O
ADAMs	O
potentially	O
have	O
cell	O
adhesion	O
and	O
protease	O
activities	O
.	O

14-3-3	O
proteins	O
are	O
a	O
highly	O
conserved	O
family	O
of	O
cytoplasmic	O
proteins	O
that	O
associate	O
with	O
several	O
intracellular	O
signaling	O
molecules	O
in	O
the	O
regulation	O
of	O
various	O
cellular	O
functions	O
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
a	O
novel	O
interaction	O
between	O
the	O
ADAM	B-DNAMutation
22	I-DNAMutation
cytoplasmic	O
tail	O
and	O
the	O
14-3-3zeta	B-DNAMutation
isoform	O
by	O
a	O
yeast	O
two-hybrid	O
screen	O
.	O

The	O
interaction	O
between	O
the	O
ADAM	B-DNAMutation
22	I-DNAMutation
cytoplasmic	O
tail	O
and	O
14-3-3zeta	B-DNAMutation
was	O
confirmed	O
by	O
an	O
in	O
vitro	O
protein	O
pull-down	O
assay	O
as	O
well	O
as	O
by	O
co-immunoprecipitation	O
,	O
and	O
the	O
binding	O
sites	O
were	O
mapped	O
to	O
the	O
28	O
amino	O
acid	O
residues	O
of	O
the	O
C-terminus	O
of	O
the	O
ADAM	B-DNAMutation
22	I-DNAMutation
cytoplasmic	O
tail	O
.	O

Furthermore	O
,	O
we	O
found	O
that	O
overexpression	O
of	O
the	O
ADAM	B-DNAMutation
22	I-DNAMutation
cytoplasmic	O
tail	O
in	O
human	O
SGH44	O
cells	O
inhibited	O
cell	O
adhesion	O
and	O
spreading	O
and	O
that	O
deletion	B-DNAMutation
or	I-DNAMutation
mutation	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
binding	I-DNAMutation
site	I-DNAMutation
for	O
14-3-3zeta	B-DNAMutation
within	O
the	O
ADAM	B-DNAMutation
22	I-DNAMutation
cytoplasmic	O
tail	O
abolished	O
the	O
ability	O
of	O
the	O
overexpressed	O
cytoplasmic	O
tail	O
to	O
alter	O
cell	O
adhesion	O
and	O
spreading	O
.	O

Taken	O
together	O
,	O
these	O
results	O
for	O
the	O
first	O
time	O
demonstrate	O
an	O
association	O
between	O
ADAM	B-DNAMutation
22	I-DNAMutation
and	O
a	O
14-3-3	O
protein	O
and	O
suggest	O
a	O
potential	O
role	O
for	O
the	O
14-3-3zeta/ADAM	B-DNAMutation
22	I-DNAMutation
association	O
in	O
the	O
regulation	O
of	O
cell	O
adhesion	O
and	O
related	O
signaling	O
events	O
.	O

Human	O
p32	B-DNAMutation
protein	O
relieves	O
a	O
post-transcriptional	O
block	O
to	O
HIV	O
replication	O
in	O
murine	O
cells	O
.	O

In	O
the	O
mouse	O
,	O
replication	O
of	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
(HIV)	O
is	O
blocked	O
at	O
the	O
levels	O
of	O
entry	O
,	O
transcription	O
and	O
assembly	O
.	O

For	O
the	O
latter	O
effect	O
,	O
the	O
amounts	O
of	O
unspliced	O
viral	O
genomic	O
RNA	O
could	O
have	O
an	O
important	O
function	O
.	O

Indeed	O
,	O
in	O
murine	O
cells	O
,	O
HIV	O
transcripts	O
are	O
spliced	O
excessively	O
,	O
a	O
process	O
that	O
is	O
not	O
inhibited	O
by	O
the	O
murine	O
splicing	O
inhibitor	O
p32	B-DNAMutation
(mp32)	O
.	O

In	O
marked	O
contrast	O
,	O
its	O
human	O
counterpart	O
,	O
hp32	B-DNAMutation
,	O
not	O
only	O
blocks	O
this	O
splicing	O
but	O
promotes	O
the	O
accumulation	O
of	O
viral	O
genomic	O
transcripts	O
and	O
structural	O
proteins	O
,	O
resulting	O
in	O
the	O
assembly	O
and	O
release	O
of	O
infectious	O
virions	O
.	O

A	O
single	O
substitution	O
in	O
hp32	B-DNAMutation
of	O
Gly	B-DNAMutation
35	I-DNAMutation
to	I-DNAMutation
Asp	I-DNAMutation
35	I-DNAMutation
,	O
which	O
is	O
found	O
in	O
mp32	O
,	O
abrogates	O
this	O
activity	O
.	O

Thus	O
,	O
hp32	B-DNAMutation
overcomes	O
an	O
important	O
post-transcriptional	O
block	O
to	O
HIV	O
replication	O
in	O
murine	O
cells	O
.	O

Structural	O
determinants	O
of	O
phosphoinositide	O
selectivity	O
in	O
splice	O
variants	O
of	O
Grp1	O
family	O
PH	O
domains	O
.	O

The	O
pleckstrin	O
homology	O
(PH)	O
domains	O
of	O
the	O
homologous	O
proteins	O
Grp1	O
(	O
general	O
receptor	O
for	O
phosphoinositides	O
)	O
,	O
ARNO	O
(	O
Arf	O
nucleotide	O
binding	O
site	O
opener	O
)	O
,	O
and	O
Cytohesin-1	O
bind	O
phosphatidylinositol	O
(PtdIns)	O
3,4,5-trisphosphate	O
with	O
unusually	O
high	O
selectivity	O
.	O

Remarkably	O
,	O
splice	O
variants	O
that	O
differ	O
only	O
by	O
the	O
insertion	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
single	I-DNAMutation
glycine	I-DNAMutation
residue	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
beta1/beta2	I-DNAMutation
loop	I-DNAMutation
exhibit	O
dual	O
specificity	O
for	O
PtdIns(3,4,5)P(3)	O
and	O
PtdIns(4,5)P(2)	O
.	O

The	O
structural	O
basis	O
for	O
this	O
dramatic	O
specificity	O
switch	O
is	O
not	O
apparent	O
from	O
the	O
known	O
modes	O
of	O
phosphoinositide	O
recognition	O
.	O

Here	O
,	O
we	O
report	O
crystal	O
structures	O
for	O
dual	O
specificity	O
variants	O
of	O
the	O
Grp1	O
and	O
ARNO	O
PH	O
domains	O
in	O
either	O
the	O
unliganded	O
form	O
or	O
in	O
complex	O
with	O
the	O
head	O
groups	O
of	O
PtdIns(4,5)P(2)	O
and	O
PtdIns(3,4,5)P(3)	O
.	O

Loss	O
of	O
contacts	O
with	O
the	O
beta1/beta2	O
loop	O
with	O
no	O
significant	O
change	O
in	O
head	O
group	O
orientation	O
accounts	O
for	O
the	O
significant	O
decrease	O
in	O
PtdIns(3,4,5)P(3)	O
affinity	O
observed	O
for	O
the	O
dual	O
specificity	O
variants	O
.	O

Conversely	O
,	O
a	O
small	O
increase	O
rather	O
than	O
decrease	O
in	O
affinity	O
for	O
PtdIns(4,5)P(2)	O
is	O
explained	O
by	O
a	O
novel	O
binding	O
mode	O
,	O
in	O
which	O
the	O
glycine	O
insertion	O
alleviates	O
unfavorable	O
interactions	O
with	O
the	O
beta1/beta2	O
loop	O
.	O

These	O
observations	O
are	O
supported	O
by	O
a	O
systematic	O
mutational	O
analysis	O
of	O
the	O
determinants	O
of	O
phosphoinositide	O
recognition	O
.	O

CK2Î±	O
phosphorylates	B-DNAMutation
DBC1	I-DNAMutation
and	O
is	O
involved	O
in	O
the	O
progression	O
of	O
gastric	O
carcinoma	O
and	O
predicts	O
poor	O
survival	O
of	O
gastric	O
carcinoma	O
patients	O
.	O

CK2Î±	O
has	O
diverse	O
effects	O
on	O
the	O
tumorigenesis	O
owing	O
to	O
its	O
kinase	O
activity	O
,	O
which	O
phosphorylates	O
various	O
proteins	O
involved	O
in	O
tumorigenesis	O
.	O

We	O
,	O
therefore	O
,	O
investigated	O
the	O
expression	O
and	O
role	O
of	O
CK2Î±	O
in	O
the	O
phosphorylation	O
of	O
deleted	O
in	O
breast	O
cancer	O
1	I-DNAMutation
(DBC1)	I-DNAMutation
in	O
gastric	O
carcinomas	O
.	O

We	O
used	O
187	O
gastric	O
carcinomas	O
and	O
human	O
gastric	O
cancer	O
cells	O
to	O
investigate	O
the	O
roles	O
and	O
relationship	O
between	O
CK2Î±	O
and	I-DNAMutation
DBC1	O
in	O
gastric	O
carcinomas	O
.	O

Positive	O
expression	O
of	O
CK2Î±	O
and	O
phospho-DBC1	B-DNAMutation
predicted	O
shorter	O
overall	O
survival	O
and	O
relapse-free	O
survival	O
by	O
univariate	O
analysis	O
.	O

Especially	O
,	O
CK2Î±	O
expression	O
was	O
an	O
independent	O
prognostic	O
indicator	O
for	O
gastric	O
carcinoma	O
patients	O
.	O

In	O
gastric	O
carcinoma	O
cells	O
,	O
CK2Î±	O
was	O
bound	B-DNAMutation
to	O
DBC1	O
and	O
phosphorylated	B-DNAMutation
DBC1	O
.	O

The	O
phosphorylation	B-DNAMutation
of	O
DBC1	O
by	O
CK2Î±	O
was	O
evidenced	O
by	O
co-immunoprecipitation	O
of	O
CK2Î±	B-DNAMutation
and	O
DBC1	O
in	O
a	O
GST	O
pull-down	O
assay	O
,	O
an	O
in	O
vitro	O
kinase	O
assay	O
,	O
and	O
immunofluorescence	O
staining	O
.	O

Inhibition	O
of	O
both	O
CK2Î±	I-DNAMutation
and	O
DBC1	O
decreased	O
proliferation	O
and	O
invasive	O
activity	O
of	O
cancer	O
cells	O
.	O

Decreased	O
migration	O
and	O
invasive	O
activity	O
was	O
associated	O
with	O
a	O
downregulation	B-DNAMutation
of	I-DNAMutation
MMP2	O
,	O
MMP9	O
and	O
the	O
epithelial-mesenchymal	O
transition	B-DNAMutation
.	I-DNAMutation
A	I-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
phosphorylation	I-DNAMutation
site	I-DNAMutation
of	O
DBC1	O
also	O
downregulated	O
the	O
signals	O
related	O
with	O
the	O
epithelial-mesenchymal	O
transition	O
.	O

Our	O
study	O
demonstrated	O
that	O
CK2Î±	O
is	O
an	O
independent	O
prognostic	O
indicator	O
for	O
gastric	O
carcinoma	O
patients	O
and	O
is	O
involved	O
in	O
tumorigenesis	O
by	O
regulating	O
the	O
phosphorylation	B-DNAMutation
of	O
DBC1	O
.	O

In	O
addition	O
,	O
the	O
blocking	O
of	B-DNAMutation
CK2Î±	I-DNAMutation
and	O
DBC1	O
inhibited	O
the	O
proliferation	O
and	O
invasive	O
potential	O
of	O
gastric	O
cancer	O
cells	O
.	O

Therefore	O
,	O
our	O
study	O
suggests	B-DNAMutation
that	I-DNAMutation
CK2Î±-DBC1	O
pathway	O
might	O
be	O
a	O
new	O
therapeutic	O
target	O
for	O
the	O
treatment	O
of	O
gastric	O
carcinoma	O
.	O

Distinction	O
of	O
sperm-binding	O
site	O
and	O
reactive	O
site	O
for	O
trypsin	O
inhibition	O
on	O
p12	O
secreted	O
from	O
the	O
accessory	O
sex	O
glands	O
of	O
male	O
mice	O
.	O

Six	O
variants	O
of	O
P12	O
,	O
a	O
Kazal-type	O
trypsin	O
inhibitor	O
in	O
the	O
secretion	O
of	O
male	O
mouse	O
accessory	O
sexual	O
glands	O
,	O
were	O
made	O
using	O
single-site	O
mutations	O
including	O
R19L	B-DNAMutation
,	O
Y21V	B-DNAMutation
,	O
D22G	B-DNAMutation
,	O
R43G	B-DNAMutation
,	O
K44S	B-DNAMutation
,	O
and	O
R45T	B-DNAMutation
,	O
based	O
on	O
one-letter-code	O
mutation	O
of	O
amino	O
acids	O
.	O

The	O
other	O
two	O
variants	O
,	O
Nd10	B-DNAMutation
and	O
Cd8	B-DNAMutation
,	O
were	O
made	O
using	O
the	O
deletion	B-DNAMutation
of	I-DNAMutation
10	I-DNAMutation
and	I-DNAMutation
8	I-DNAMutation
residues	I-DNAMutation
from	I-DNAMutation
the	I-DNAMutation
N-	I-DNAMutation
and	I-DNAMutation
C-terminals	I-DNAMutation
,	I-DNAMutation
respectively	I-DNAMutation
.	O

Their	O
CD	O
profiles	O
revealed	O
maintenance	O
of	O
the	O
P12	O
conformation	O
in	O
the	O
seven	O
variants	O
,	O
excluding	O
Cd8	B-DNAMutation
,	O
which	O
became	O
unfolded	O
.	O

Only	O
R19L	B-DNAMutation
entirely	O
lost	O
the	O
ability	O
while	O
the	O
other	O
variants	O
were	O
as	O
strong	O
as	O
P12	O
in	O
inhibiting	O
the	O
trypsin	O
digestion	O
of	O
N-benzoyl-Phe-Val-Arg	O
7-amido-4-methylcoumarin	O
.	O

The	O
immunocytochemical	O
results	O
demonstrated	O
that	O
D22G	B-DNAMutation
and	O
Cd8	B-DNAMutation
failed	O
to	O
bind	O
to	O
sperm	O
,	O
Y21V	B-DNAMutation
very	O
weakly	O
did	O
so	O
,	O
and	O
the	O
other	O
variants	O
retained	O
their	O
sperm-binding	O
abilities	O
.	O

Concomitantly	O
,	O
the	O
immunocytochemical	O
stainability	O
of	O
each	O
ligand	O
was	O
parallel	O
to	O
its	O
inhibitory	O
effect	O
on	O
125I-P12-sperm	O
binding	O
,	O
and	O
a	O
synthetic	O
oligopeptide	O
corresponding	O
to	O
residues	O
18-24	O
of	O
P12	O
was	O
able	O
to	O
inhibit	O
P12-sperm	O
binding	O
.	O

The	O
data	O
together	O
concluded	O
that	O
R19	O
was	O
essential	O
for	O
protease	O
inhibition	O
and	O
D22	O
and/or	O
Y21	O
mainly	O
being	O
responsible	O
for	O
the	O
binding	O
of	O
P12	O
to	O
sperm	O
.	O

The	O
steric	O
arrangement	O
of	O
R19	O
,	O
Y21	O
,	O
and	O
D22	O
on	O
the	O
tertiary	O
structure	O
of	O
P12	O
is	O
discussed	O
.	O

Diagnosis	O
of	O
ABCB11	B-DNAMutation
gene	O
mutations	O
in	O
children	O
with	O
intrahepatic	O
cholestasis	O
using	O
high	O
resolution	O
melting	O
analysis	O
and	O
direct	O
sequencing	O
.	O

Intrahepatic	O
cholestasis	O
represents	O
a	O
heterogeneous	O
group	O
of	O
disorders	O
that	O
begin	O
during	O
childhood	O
,	O
most	O
commonly	O
manifesting	O
as	O
neonatal	O
cholestasis	O
,	O
and	O
lead	O
to	O
ongoing	O
liver	O
dysfunction	O
in	O
children	O
and	O
adults	O
.	O

For	O
children	O
,	O
inherited	O
pathogenic	O
factors	O
of	O
cholestasis	O
have	O
gained	O
increasing	O
attention	O
owing	O
to	O
the	O
rapid	O
development	O
of	O
molecular	O
biology	O
technology	O
.	O

However	O
,	O
these	O
methods	O
have	O
their	O
advantages	O
and	O
disadvantages	O
in	O
terms	O
of	O
simplicity	O
,	O
sensitivity	O
,	O
specificity	O
,	O
time	O
required	O
and	O
expense	O
.	O

In	O
the	O
present	O
study	O
,	O
an	O
effective	O
,	O
sensitive	O
and	O
economical	O
method	O
is	O
recommended	O
,	O
termed	O
high-resolution	O
melting	O
(HRM)	O
analysis	O
and	O
direct	O
sequencing	O
,	O
based	O
on	O
general	O
polymerase	O
chain	O
reaction	O
,	O
to	O
detect	O
mutations	O
in	O
diseaseâcausing	O
genes	O
.	O

As	O
one	O
type	O
of	O
inherited	O
intrahepatic	O
cholestasis	B-DNAMutation
,	I-DNAMutation
progressive	I-DNAMutation
familial	I-DNAMutation
intrahepatic	I-DNAMutation
cholestasis	I-DNAMutation
type	I-DNAMutation
2	B-DNAMutation
(PFIC2)	I-DNAMutation
is	O
caused	O
by	O
pathogenic	O
mutations	O
in	O
the	B-DNAMutation
ABCB11	I-DNAMutation
gene	O
,	O
HRM	O
was	O
used	O
to	O
detect	O
mutations	O
in	O
the	B-DNAMutation
ABCB11	I-DNAMutation
gene	O
in	O
the	O
present	O
study	O
,	O
and	O
the	O
diagnosis	O
for	B-DNAMutation
PFIC2	I-DNAMutation
was	O
made	O
by	O
comprehensive	O
analysis	O
of	O
genetic	O
findings	O
and	O
clinical	O
features	O
.	O

Furthermore	O
,	O
the	O
characteristics	O
of	O
mutations	O
and	O
single	O
nucleotide	O
polymorphisms	O
(SNPs)	O
in	O
the	B-DNAMutation
ABCB11	I-DNAMutation
gene	O
were	O
elucidated	O
.	O

A	O
total	O
of	O
14	O
types	O
of	O
mutations/polymorphisms	O
were	O
identified	O
in	O
20	O
patients	O
from	O
mainland	O
China	O
,	O
including	O
six	O
missense	O
mutations	B-DNAMutation
(	I-DNAMutation
p.Y337H	I-DNAMutation
,	I-DNAMutation
p.Y472C	I-DNAMutation
,	I-DNAMutation
p.R696W	I-DNAMutation
,	I-DNAMutation
p.Q931P	I-DNAMutation
,	I-DNAMutation
p.D1131V	I-DNAMutation
and	B-DNAMutation
p.H1198R	I-DNAMutation
)	O
,	O
one	B-DNAMutation
nonsense	I-DNAMutation
mutation	I-DNAMutation
(p.R928X)	I-DNAMutation
and	O
seven	O
SNPs	B-DNAMutation
(	I-DNAMutation
p.D36D/rs3815675	I-DNAMutation
,	O
p.F90F/rs4148777	I-DNAMutation
,	O
p.Y269Y/rs2287616	I-DNAMutation
,	O
p.I416I/rs183390670	I-DNAMutation
,	O
p.V444A/rs2287622	I-DNAMutation
,	O
p.A865V/rs118109635	I-DNAMutation
and	O
p.A1028A/rs497692	I-DNAMutation
)	O
.	O

Five	O
mutations	O
were	O
novel	O
.	O

The	O
majority	O
of	O
the	O
mutations	O
were	O
different	O
from	O
those	O
detected	O
in	O
other	O
population	O
groups	O
.	O

A	O
total	O
of	O
4/20	O
patients	O
(1/5)	O
were	O
diagnosed	O
to	O
be	B-DNAMutation
PFIC2	I-DNAMutation
by	O
combining	O
genetic	O
findings	O
with	O
the	O
clinical	O
features	O
.	O

Polymorphisms	B-DNAMutation
V444A	I-DNAMutation
and	B-DNAMutation
A1028A	I-DNAMutation
,	O
with	O
an	O
allele	O
frequency	O
of	O
74.5	O
and	O
67.2%	O
,	O
respectively	O
,	O
were	O
highly	O
prevalent	O
in	O
the	O
mainland	O
Chinese	O
subjects	O
.	O

No	O
differences	O
were	O
found	O
between	O
the	O
patients	O
with	O
cholestasis	O
and	O
the	O
control	O
subjects	O
.	O

Efficient	O
genetic	O
screening	O
facilitates	O
the	O
clinical	O
diagnosis	O
of	O
genetic	O
disorders	O
.	O

The	O
present	O
study	O
demonstrated	O
that	O
HRM	O
analysis	O
was	O
efficient	O
and	O
effective	O
in	O
detecting	O
mutations	O
and	O
expanded	O
the	O
known	O
spectrum	O
of	B-DNAMutation
ABCB11	I-DNAMutation
gene	O
mutations	O
.	O

Characterization	O
of	O
amyloid	O
fibril	O
beta-peptide	O
in	O
familial	O
Alzheimer's	O
disease	O
with	O
APP717	O
mutations	O
.	O

Amyloid	O
fibrils	O
were	O
isolated	O
from	O
the	O
brain	O
tissue	O
of	O
two	O
individuals	O
who	O
died	O
with	O
familial	O
Alzheimer's	O
disease	O
,	O
one	B-DNAMutation
with	I-DNAMutation
the	I-DNAMutation
phenylalanine	I-DNAMutation
717	I-DNAMutation
mutation	I-DNAMutation
in	O
amyloid	B-DNAMutation
precursor	I-DNAMutation
protein	I-DNAMutation
(APP)	I-DNAMutation
and	O
one	B-DNAMutation
with	I-DNAMutation
the	I-DNAMutation
isoleucine	I-DNAMutation
717	I-DNAMutation
APP	I-DNAMutation
mutation	I-DNAMutation
.	O

After	O
solubilization	O
in	O
guanidine	O
hydrochloride	O
and	O
fractionation	O
by	O
sieve	O
chromatography	O
,	O
low	O
molecular	O
weight	O
fractions	O
were	O
treated	O
with	O
cyanogen	O
bromide	O
to	O
generate	O
the	O
beta-peptide	O
fragment	O
starting	O
after	O
the	O
methionine	O
at	O
position	O
35	O
.	O

Amino	O
acid	O
sequence	O
analysis	O
of	O
all	O
resultant	O
peptides	O
identified	O
the	O
peptide	O
Val-Gly-Gly-Val-Val-Ile-Ala	O
which	O
represents	O
residues	O
36-42	O
of	O
the	O
beta-amyloid	B-DNAMutation
peptide	I-DNAMutation
.	O

No	O
sequence	O
beyond	O
position	O
42	O
was	O
found	O
.	O

These	O
findings	O
show	O
that	O
the	O
amino	O
acid	O
substitution	O
at	O
position	O
717	O
is	O
not	O
incorporated	O
into	O
the	O
amyloid	O
deposits	O
and	O
suggests	O
that	O
the	O
mutation	O
may	O
have	O
metabolic	O
affects	O
which	O
determine	O
pathogenesis	O
.	O

A	O
gain-of-function	O
polymorphism	O
in	O
a	O
G-protein	O
coupling	O
domain	O
of	O
the	O
human	O
beta1-adrenergic	B-DNAMutation
receptor	I-DNAMutation
.	O

The	O
beta1-adrenergic	B-DNAMutation
receptor	I-DNAMutation
beta1AR	B-DNAMutation
is	O
a	O
key	O
cell	O
surface	O
signaling	O
protein	O
expressed	O
in	O
the	O
heart	O
and	O
other	O
organs	O
that	O
mediates	O
the	O
actions	O
of	O
catecholamines	O
of	O
the	O
sympathetic	O
nervous	O
system	O
.	O

A	O
polymorphism	O
in	O
the	O
intracellular	O
cytoplasmic	O
tail	O
near	O
the	O
seventh	O
transmembrane-spanning	O
segment	O
of	O
the	O
human	O
beta1AR	B-DNAMutation
has	O
been	O
identified	O
in	O
a	O
cohort	O
of	O
normal	O
individuals	O
.	O

At	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
position	I-DNAMutation
389	I-DNAMutation
,	I-DNAMutation
Gly	I-DNAMutation
or	I-DNAMutation
Arg	I-DNAMutation
can	I-DNAMutation
be	I-DNAMutation
found	I-DNAMutation
(	O
allele	O
frequencies	O
0.26	O
and	O
0	O
.	O

74	O
,	O
respectively	O
)	O
,	O
the	O
former	O
previously	O
considered	O
as	O
the	O
human	O
wild-type	O
beta1AR	B-DNAMutation
.	O

Using	O
site-directed	O
mutagenesis	O
to	O
mimic	O
the	O
two	O
variants	O
,	O
CHW-1102	O
cells	O
were	O
permanently	O
transfected	O
to	O
express	O
the	O
Gly-389	O
and	O
Arg-389	O
receptors	O
.	O

In	O
functional	O
studies	O
with	O
matched	O
expression	O
,	O
the	O
Arg-389	O
receptors	O
had	O
slightly	O
higher	O
basal	O
levels	O
of	O
adenylyl	O
cyclase	O
activities	O
(	O
10.7	O
+/-	O
1.2	O
versus	O
6.1	O
+/-	O
0.4	O
pmol/min/mg	O
)	O
.	O

However	O
,	O
maximal	O
isoproterenol-stimulated	O
levels	O
were	O
markedly	O
higher	O
for	O
the	O
Arg-389	O
as	O
compared	O
to	O
the	O
Gly-389	O
receptor	O
(	O
63.3	O
+/-	O
6.1	O
versus	O
20.9	O
+/-	O
2.0	O
pmol/min/mg	O
)	O
.	O

Agonist-promoted	O
[35S]guanosine	O
5'-O-(thiotriphosphate)	O
binding	O
was	O
also	O
increased	O
with	O
the	O
Arg-389	O
receptor	O
consistent	O
with	O
enhanced	O
coupling	O
to	O
Gs	O
and	O
increased	O
adenylyl	O
cyclase	O
activation	O
.	O

In	O
agonist	O
competition	O
studies	O
carried	O
out	O
in	O
the	O
absence	O
of	O
guanosine	O
5'-(beta	O
,	O
gamma-imido)triphosphate	O
,	O
high	O
affinity	O
binding	O
could	O
not	O
be	O
resolved	O
with	O
the	O
Gly-389	O
receptor	O
,	O
whereas	O
Arg-389	O
displayed	O
an	O
accumulation	O
of	O
the	O
agonist	O
high	O
affinity	O
receptor	O
complex	O
(	O
RH	O
=	O
26%	O
)	O
.	O

Taken	O
together	O
,	O
these	O
data	O
indicate	O
that	O
this	O
polymorphic	O
variation	O
of	O
the	O
human	O
beta1AR	B-DNAMutation
results	O
in	O
alterations	O
of	O
receptor-Gs	O
interaction	O
with	O
functional	O
signal	O
transduction	O
consequences	O
,	O
consistent	O
with	O
its	O
localization	O
in	O
a	O
putative	O
G-protein	O
binding	O
domain	O
.	O

The	O
genetic	O
variation	O
of	O
beta1AR	B-DNAMutation
at	O
this	O
locus	O
may	O
be	O
the	O
basis	O
of	O
interindividual	O
differences	O
in	O
pathophysiologic	O
characteristics	O
or	O
in	O
the	O
response	O
to	O
therapeutic	O
betaAR	O
agonists	O
and	O
antagonists	O
in	O
cardiovascular	O
and	O
other	O
diseases	O
.	O

The	O
LXXLL	O
motif	O
of	O
murine	O
forkhead	O
transcription	O
factor	O
FoxO1	B-DNAMutation
mediates	O
Sirt1-dependent	B-DNAMutation
transcriptional	O
activity	O
.	O

The	O
forkhead	O
transcription	O
factor	O
FoxO1	B-DNAMutation
has	O
been	O
identified	O
as	O
a	O
negative	O
regulator	O
of	O
insulin/IGF-1	B-DNAMutation
signaling	O
.	O

Its	O
function	O
is	O
inhibited	O
by	O
phosphorylation	O
and	O
nuclear	O
exclusion	O
through	O
a	O
PI3K-dependent	B-DNAMutation
pathway	O
.	O

However	O
,	O
the	O
structure/function	O
relationship	O
of	O
FoxO1	B-DNAMutation
has	O
not	O
been	O
elucidated	O
completely	O
.	O

In	O
this	O
study	O
,	O
we	O
carried	O
out	O
mutation	O
analysis	O
of	O
the	O
FoxO1	O
coactivator-interacting	O
LXXLL	O
motif	O
(	O
amino	O
acids	O
459-463	O
)	O
.	O

Expression	O
of	O
a	O
3A/LXXAA	O
mutant	O
,	O
in	O
which	O
3	O
Akt	O
phosphorylation	O
sites	O
(	B-DNAMutation
T24	I-DNAMutation
,	I-DNAMutation
S253	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
S316	I-DNAMutation
)	I-DNAMutation
and	I-DNAMutation
2	I-DNAMutation
leucine	I-DNAMutation
residues	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
LXXLL	I-DNAMutation
motif	I-DNAMutation
(	I-DNAMutation
L462	I-DNAMutation
and	I-DNAMutation
L463	I-DNAMutation
)	I-DNAMutation
were	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
alanine	I-DNAMutation
,	O
decreased	O
both	O
Igfbp-1	O
and	O
G6Pase	O
promoter	O
activity	O
and	O
endogenous	O
Igfbp-1	O
and	O
G6Pase	O
gene	O
expression	O
in	O
simian	O
virus	O
40-transformed	O
(SV40-transformed)	O
hepatocytes	O
.	O

Importantly	O
,	O
mutagenesis	O
of	O
the	O
LXXLL	O
motif	O
eliminated	O
FoxO1	B-DNAMutation
interaction	O
with	O
the	O
nicotinamide	O
adenine	O
dinucleotide-dependent	O
(NAD-dependent)	O
deacetylase	O
sirtuin	B-DNAMutation
1	I-DNAMutation
Sirt1	B-DNAMutation
,	O
sustained	O
the	O
acetylated	O
state	O
of	O
FoxO1	B-DNAMutation
,	O
and	O
made	O
FoxO1	B-DNAMutation
nicotinamide	O
and	O
resveratrol	O
insensitive	O
,	O
supporting	O
a	O
role	O
for	O
this	O
motif	O
in	O
Sirt1	B-DNAMutation
binding	O
.	O

Furthermore	O
,	O
intravenous	O
administration	O
of	O
adenovirus	O
encoding	O
3A/LXXAA	O
FoxO1	B-DNAMutation
into	O
Lepr	B-DNAMutation
db/db	O
mice	O
decreased	O
fasting	O
blood	O
glucose	O
levels	O
and	O
improved	O
glucose	O
tolerance	O
and	O
was	O
accompanied	O
by	O
reduced	O
G6Pase	B-DNAMutation
and	O
Igfbp-1	B-DNAMutation
gene	O
expression	O
and	O
increased	O
hepatic	O
glycogen	O
content	O
.	O

In	O
conclusion	O
,	O
the	O
LXXLL	O
motif	O
of	O
FoxO1	B-DNAMutation
may	O
have	O
an	O
important	O
role	O
for	O
its	O
transcriptional	O
activity	O
and	O
Sirt1	B-DNAMutation
binding	O
and	O
should	O
be	O
a	O
target	O
site	O
for	O
regulation	O
of	O
gene	O
expression	O
of	O
FoxO1	B-DNAMutation
target	O
genes	O
and	O
glucose	O
metabolism	O
in	O
vivo	O
.	O

The	O
peroxisome	O
proliferator-induced	O
cytosolic	O
type	O
I	O
acyl-CoA	O
thioesterase	O
(CTE-I)	O
is	O
a	O
serine-histidine-aspartic	O
acid	O
alpha	O
/beta	O
hydrolase	O
.	O

Long-chain	O
acyl-CoA	O
thioesterases	O
hydrolyze	O
long-chain	O
acyl-CoAs	O
to	O
the	O
corresponding	O
free	O
fatty	O
acid	O
and	O
CoASH	O
and	O
may	O
therefore	O
play	O
important	O
roles	O
in	O
regulation	O
of	O
lipid	O
metabolism	O
.	O

We	O
have	O
recently	O
cloned	O
four	O
members	O
of	O
a	O
highly	O
conserved	O
acyl-CoA	O
thioesterase	O
multigene	O
family	O
expressed	O
in	O
cytosol	O
(CTE-I)	O
,	O
mitochondria	O
(MTE-I)	O
,	O
and	O
peroxisomes	O
(	O
PTE-Ia	O
and	O
-Ib	O
)	O
,	O
all	O
of	O
which	O
are	O
regulated	O
via	O
the	O
peroxisome	O
proliferator-activated	O
receptor	O
alpha	O
(	O
Hunt	O
,	O
M	O
.	O

C.	O
,	O
Nousiainen	O
,	O
S	O
.	O

E	O
.	O

B.	O
,	O
Huttunen	O
,	O
M	O
.	O

K.	O
,	O
Orii	O
,	O
K	O
.	O

E.	O
,	O
Svensson	O
,	O
L	O
.	O

T.	O
,	O
and	O
Alexson	O
,	O
S	O
.	O

E	O
.	O

H	O
.	O

(1999)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

274	O
,	O
34317-34326	O
)	O
.	O

Sequence	O
comparison	O
revealed	O
the	O
presence	O
of	O
putative	O
active-site	O
serine	O
motifs	O
(GXSXG)	O
in	O
all	O
four	O
acyl-CoA	O
thioesterases	O
.	O

In	O
the	O
present	O
study	O
we	O
have	O
expressed	O
CTE-I	O
in	O
Escherichia	O
coli	O
and	O
characterized	O
the	O
recombinant	O
protein	O
with	O
respect	O
to	O
sensitivity	O
to	O
various	O
amino	O
acid	O
reactive	O
compounds	O
.	O

The	O
recombinant	O
CTE-I	O
was	O
inhibited	O
by	O
phenylmethylsulfonyl	O
fluoride	O
and	O
diethyl	O
pyrocarbonate	O
,	O
suggesting	O
the	O
involvement	O
of	O
serine	O
and	O
histidine	O
residues	O
for	O
the	O
activity	O
.	O

Extensive	O
sequence	O
analysis	O
pinpointed	O
Ser(232)	O
,	O
Asp(324)	O
,	O
and	O
His(358)	O
as	O
the	O
likely	O
components	O
of	O
a	O
catalytic	O
triad	O
,	O
and	O
site-directed	O
mutagenesis	O
verified	O
the	O
importance	O
of	O
these	O
residues	O
for	O
the	O
catalytic	O
activity	O
.	O

A	O
S232C	B-DNAMutation
mutant	O
retained	O
about	O
2%	O
of	O
the	O
wild	O
type	O
activity	O
and	O
incubation	O
with	O
(14)C-palmitoyl-CoA	O
strongly	O
labeled	O
this	O
mutant	O
protein	O
,	O
in	O
contrast	O
to	O
wild-type	O
enzyme	O
,	O
indicating	O
that	O
deacylation	O
of	O
the	O
acyl-enzyme	O
intermediate	O
becomes	O
rate-limiting	O
in	O
this	O
mutant	O
protein	O
.	O

These	O
data	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
structure/function	O
of	O
acyl-CoA	O
thioesterases	O
versus	O
acyltransferases	O
.	O

Furthermore	O
,	O
kinetic	O
characterization	O
of	O
recombinant	O
CTE-I	O
showed	O
that	O
this	O
enzyme	O
appears	O
to	O
be	O
a	O
true	O
acyl-CoA	O
thioesterase	O
being	O
highly	O
specific	O
for	O
C(12)-C(20)	O
acyl-CoAs	O
.	O

In	O
vitro	O
studies	O
of	O
amyloid	O
beta-protein	O
fibril	O
assembly	O
and	O
toxicity	O
provide	O
clues	O
to	O
the	O
aetiology	O
of	O
Flemish	O
variant	O
Ala692-->Gly	B-DNAMutation
Alzheimer's	O
disease	O
.	O

In	O
a	O
Flemish	O
kindred	O
,	O
an	O
Ala(692)-->Gly	B-DNAMutation
amino	O
acid	O
substitution	O
in	O
the	O
amyloid	O
beta-protein	O
precursor	O
(AbetaPP)	O
causes	O
a	O
form	O
of	O
early-onset	O
Alzheimer's	O
disease	O
(AD)	O
which	O
displays	O
prominent	O
amyloid	O
angiopathy	O
and	O
unusually	O
large	O
senile	O
plaque	O
cores	O
.	O

The	O
mechanistic	O
basis	O
of	O
this	O
Flemish	O
form	O
of	O
AD	O
is	O
unknown	O
.	O

Previous	O
in	O
vitro	O
studies	O
of	O
amyloid	O
beta-protein	O
(Abeta)	O
production	O
in	O
HEK-293	O
cells	O
transfected	O
with	O
cDNA	O
encoding	O
Flemish	O
AbetaPP	O
have	O
shown	O
that	O
full-length	O
[Abeta(1-40)]	O
and	O
truncated	O
[	O
Abeta(5-40	O
)	O
and	O
Abeta(11-40)	O
]	O
forms	O
of	O
Abeta	O
are	O
produced	O
.	O

In	O
an	O
effort	O
to	O
determine	O
how	O
these	O
peptides	O
might	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
the	O
Flemish	O
disease	O
,	O
comparative	O
biophysical	O
and	O
neurotoxicity	O
studies	O
were	O
performed	O
on	O
wild-type	O
and	O
Flemish	O
Abeta(1-40)	O
,	O
Abeta(5-40)	O
and	O
Abeta(11-40)	O
.	O

The	O
results	O
revealed	O
that	O
the	O
Flemish	O
amino	O
acid	O
substitution	O
increased	O
the	O
solubility	O
of	O
each	O
form	O
of	O
peptide	O
,	O
decreased	O
the	O
rate	O
of	O
formation	O
of	O
thioflavin-T-positive	O
assemblies	O
,	O
and	O
increased	O
the	O
SDS-stability	O
of	O
peptide	O
oligomers	O
.	O

Although	O
the	O
kinetics	O
of	O
peptide	O
assembly	O
were	O
altered	O
by	O
the	O
Ala(21)-->Gly	B-DNAMutation
substitution	O
,	O
all	O
three	O
Flemish	O
variants	O
formed	O
fibrils	O
,	O
as	O
did	O
the	O
wild-type	O
peptides	O
.	O

Importantly	O
,	O
toxicity	O
studies	O
using	O
cultured	O
primary	O
rat	O
cortical	O
cells	O
showed	O
that	O
the	O
Flemish	O
assemblies	O
were	O
as	O
potent	O
a	O
neurotoxin	O
as	O
were	O
the	O
wild-type	O
assemblies	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
a	O
pathogenetic	O
process	O
in	O
which	O
conformational	O
changes	O
in	O
Abeta	O
induced	O
by	O
the	O
Ala(21)-->Gly	B-DNAMutation
substitution	O
would	O
facilitate	O
peptide	O
adherence	O
to	O
the	O
vascular	O
endothelium	O
,	O
creating	O
nidi	O
for	O
amyloid	O
growth	O
.	O

Increased	O
peptide	O
solubility	O
and	O
assembly	O
stability	O
would	O
favour	O
formation	O
of	O
larger	O
deposits	O
and	O
inhibit	O
their	O
elimination	O
.	O

In	O
addition	O
,	O
increased	O
concentrations	O
of	O
neurotoxic	O
assemblies	O
would	O
accelerate	O
neuronal	O
injury	O
and	O
death	O
.	O

Roles	O
of	O
tyrosine	O
589	O
and	O
591	O
in	O
STAT5	B-DNAMutation
activation	O
and	O
transformation	O
mediated	O
by	O
FLT3-ITD	B-DNAMutation
.	O

Acquired	O
mutations	O
in	O
the	O
FLT3	B-DNAMutation
receptor	O
tyrosine	O
kinase	O
are	O
common	O
in	O
acute	O
myeloid	O
leukemia	O
and	O
result	O
in	O
constitutive	O
activation	O
.	O

The	O
most	O
frequent	O
mechanism	O
of	O
activation	O
is	O
disruption	O
of	O
the	O
juxtamembrane	O
autoregulatory	O
domain	O
by	O
internal	O
tandem	O
duplications	O
(ITDs)	O
.	O

FLT3-ITDs	B-DNAMutation
confer	O
factor-independent	O
growth	O
to	O
hematopoietic	O
cells	O
and	O
induce	O
a	O
myeloproliferative	O
syndrome	O
in	O
murine	O
bone	O
marrow	O
transplant	O
models	O
.	O

We	O
and	O
others	O
have	O
observed	O
that	O
FLT3-ITD	B-DNAMutation
activates	O
STAT5	B-DNAMutation
and	O
its	O
downstream	O
effectors	O
,	O
whereas	O
ligand-stimulated	O
wild-type	O
FLT3	B-DNAMutation
FLT3WT	B-DNAMutation
does	O
not	O
.	O

In	O
vitro	O
mapping	O
of	O
tyrosine	O
phosphorylation	O
sites	O
in	O
FLT3-ITD	B-DNAMutation
identified	O
2	O
candidate	O
STAT5	B-DNAMutation
docking	O
sites	O
within	O
the	O
juxtamembrane	O
domain	O
that	O
are	O
disrupted	O
by	O
the	O
ITD	O
.	O

Tyrosine	B-DNAMutation
to	I-DNAMutation
phenylalanine	I-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
residues	I-DNAMutation
589	I-DNAMutation
and	I-DNAMutation
591	I-DNAMutation
in	O
the	O
context	O
of	O
the	O
FLT3-ITD	B-DNAMutation
did	O
not	O
affect	O
tyrosine	O
kinase	O
activity	O
,	O
but	O
abrogated	O
STAT5	B-DNAMutation
activation	O
.	O

Furthermore	O
,	O
FLT3-ITD-Y589/591F	B-DNAMutation
was	O
incapable	O
of	O
inducing	O
a	O
myeloproliferative	O
phenotype	O
when	O
transduced	O
into	O
primary	O
murine	O
bone	O
marrow	O
cells	O
,	O
whereas	O
FLT3-ITD	B-DNAMutation
induced	O
myeloproliferative	O
disease	O
with	O
a	O
median	O
latency	O
of	O
50	O
days	O
.	O

Thus	O
,	O
the	O
conformational	O
change	O
in	O
the	O
FLT3	O
juxtamembrane	O
domain	O
induced	O
by	O
the	O
ITD	O
activates	O
the	O
kinase	O
through	O
dysregulation	O
of	O
autoinhibition	O
and	O
results	O
in	O
qualitative	O
differences	O
in	O
signal	O
transduction	O
through	O
STAT5	B-DNAMutation
that	O
are	O
essential	O
for	O
the	O
transforming	O
potential	O
of	O
FLT3-ITD	B-DNAMutation
in	O
vivo	O
.	O

Neuregulin	B-DNAMutation
1	I-DNAMutation
regulates	O
excitability	O
of	O
fast-spiking	O
neurons	O
through	O
Kv1.1	B-DNAMutation
and	O
acts	O
in	O
epilepsy	O
.	O

Dysfunction	O
of	O
fast-spiking	O
,	O
parvalbumin-positive	B-DNAMutation
(FS-PV)	O
interneurons	O
is	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
epilepsy	O
.	O

ErbB4	B-DNAMutation
,	O
a	O
key	O
Neuregulin	B-DNAMutation
1	I-DNAMutation
NRG1	B-DNAMutation
receptor	O
,	O
is	O
mainly	O
expressed	O
in	O
this	O
type	O
of	O
interneurons	O
,	O
and	O
recent	O
studies	O
suggest	O
that	O
parvalbumin	B-DNAMutation
interneurons	O
are	O
a	O
major	O
target	O
of	O
NRG1-ErbB4	B-DNAMutation
signaling	O
in	O
adult	O
brain	O
.	O

Thus	O
,	O
we	O
hypothesized	O
that	O
downregulation	O
of	O
NRG1-ErbB4	B-DNAMutation
signaling	O
in	O
FS-PV	O
interneurons	O
is	O
involved	O
in	O
epilepsy	O
.	O

We	O
found	O
that	O
NRG1	B-DNAMutation
,	O
through	O
its	O
receptor	O
ErbB4	B-DNAMutation
,	O
increased	O
the	O
intrinsic	O
excitability	O
of	O
FS-PV	O
interneurons	O
.	O

This	O
effect	O
was	O
mediated	O
by	O
increasing	O
the	O
near-threshold	O
responsiveness	O
and	O
decreasing	O
the	O
voltage	O
threshold	O
for	O
action	O
potentials	O
through	O
Kv1.1	B-DNAMutation
,	O
a	O
voltage-gated	O
potassium	O
channel	O
.	O

Furthermore	O
,	O
mice	O
with	O
specific	O
deletion	B-DNAMutation
of	I-DNAMutation
ErbB4	B-DNAMutation
in	O
parvalbumin	O
interneurons	O
were	O
more	O
susceptible	O
to	O
pentylenetetrazole-	O
and	O
pilocarpine-induced	O
models	O
of	O
epilepsy	O
.	O

Exogenous	O
NRG1	B-DNAMutation
delayed	O
the	O
onset	O
of	O
seizures	O
and	O
decreased	O
their	O
incidence	O
and	O
stage	O
.	O

Moreover	O
,	O
expression	O
of	O
ErbB4	B-DNAMutation
,	O
but	O
not	O
ErbB2	B-DNAMutation
,	O
was	O
downregulated	O
in	O
human	O
epileptogenic	O
tissue	O
.	O

Together	O
,	O
our	O
findings	O
suggest	O
that	O
NRG1-ErbB4	B-DNAMutation
signaling	O
contributes	O
to	O
human	O
epilepsy	O
through	O
regulating	O
the	O
excitability	O
of	O
FS-PV	O
interneurons	O
.	O

ErbB4	B-DNAMutation
may	O
be	O
a	O
new	O
target	O
for	O
anticonvulsant	O
drugs	O
in	O
epilepsy	O
.	O

SUMO-1	B-DNAMutation
modification	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
C-terminal	I-DNAMutation
KVEKVD	I-DNAMutation
of	O
Axin	B-DNAMutation
is	O
required	O
for	O
JNK	O
activation	O
but	O
has	O
no	O
effect	O
on	O
Wnt	O
signaling	O
.	O

Axin	B-DNAMutation
is	O
a	O
multifunctional	O
protein	O
,	O
regulating	O
Wnt	O
signaling	O
and	O
the	O
c-Jun	O
N-terminal/stress-activated	O
protein	O
kinase	O
(JNK/SAPK)	O
pathway	O
as	O
well	O
as	O
tumorigenesis	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
found	O
that	O
Axin	B-DNAMutation
interacts	O
with	O
three	O
SUMO-1	B-DNAMutation
(	O
small	O
ubiquitin-related	O
modifier	O
)	O
conjugating	O
enzymes	O
3	O
(E3)	O
,	O
PIAS1	B-DNAMutation
,	O
PIASxbeta	B-DNAMutation
,	O
and	O
PIASy	B-DNAMutation
.	O

The	O
extreme	O
C-terminal	O
six	O
amino	O
acid	O
residues	O
of	O
Axin	B-DNAMutation
are	O
critical	O
for	O
the	O
Axin/E3	B-DNAMutation
interaction	O
as	O
deletion	O
of	O
the	O
six	O
residues	O
AxinDeltaC6	B-DNAMutation
completely	O
abolished	O
the	O
ability	O
of	O
Axin	B-DNAMutation
to	O
interact	O
with	O
E3	O
enzymes	O
.	O

AxinDeltaC6	B-DNAMutation
also	O
failed	O
to	O
activate	O
JNK	O
,	O
although	O
it	O
was	O
intact	O
in	O
both	O
its	O
interaction	O
with	O
MEKK1	B-DNAMutation
and	O
homodimerization	O
.	O

Consistent	O
with	O
the	O
presence	O
of	O
a	O
doublet	O
of	O
the	O
KV(E/D)	O
sumoylation	O
consensus	O
motif	O
at	O
the	O
C-terminal	O
end	O
(KVEKVD)	O
,	O
we	O
found	O
that	O
Axin	B-DNAMutation
is	O
heavily	O
sumoylated	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
C-terminal	I-DNAMutation
six	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
drastically	O
reduced	O
sumoylation	O
,	O
indicating	O
that	O
the	O
C-terminal	O
six	O
amino	O
acids	O
stretch	O
is	O
the	O
main	O
sumoylation	O
site	O
for	O
Axin	B-DNAMutation
.	O

Sumoylation-defective	O
mutants	O
failed	O
to	O
activate	O
JNK	O
but	O
effectively	O
destabilized	O
beta-catenin	B-DNAMutation
and	O
attenuated	O
LEF1	B-DNAMutation
transcriptional	O
activity	O
.	O

In	O
addition	O
,	O
we	O
show	O
that	O
dominant	O
negative	O
Axin	B-DNAMutation
mutants	O
blocked	O
PIAS-mediated	O
JNK	O
activation	O
,	O
in	O
accordance	O
with	O
the	O
requirement	O
of	O
sumoylation	O
for	O
Axin-mediated	B-DNAMutation
JNK	O
activation	O
.	O

Taken	O
together	O
,	O
we	O
demonstrate	O
that	O
sumoylation	O
plays	O
a	O
role	O
for	O
Axin	B-DNAMutation
to	O
function	O
in	O
the	O
JNK	O
pathway	O
.	O

USF2/FIP	B-DNAMutation
associates	O
with	O
the	O
b-Zip	O
transcription	O
factor	O
,	O
c-Maf	B-DNAMutation
,	O
via	O
its	O
bHLH	O
domain	O
and	O
inhibits	O
c-Maf	B-DNAMutation
DNA	O
binding	O
activity	O
.	O

In	I-DNAMutation
screening	O
for	O
proteins	O
that	O
interact	O
with	O
the	O
basic	O
zipper	O
(bZip)	O
transcription	O
factor	O
,	O
c-Maf	B-DNAMutation
,	O
we	O
isolated	O
USF2/FIP	B-DNAMutation
.	O

USF2	B-DNAMutation
is	O
a	O
member	O
of	O
the	O
bHLH-Zip	O
protein	O
family	O
,	O
possessing	O
a	O
basic	O
(b)	O
DNA	O
binding	O
region	O
,	O
a	O
helix-loop-helix	O
(HLH)	O
motif	O
,	O
and	O
a	O
leucine	O
zipper	O
(Zip)	O
structure	O
.	O

Mutants	O
of	O
USF2	B-DNAMutation
that	O
lacked	O
a	O
Zip	O
formed	O
heterodimers	O
with	O
c-Maf	B-DNAMutation
,	O
but	O
did	O
not	O
homodimerize	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
USF2	I-DNAMutation
basic	I-DNAMutation
region	I-DNAMutation
or	I-DNAMutation
mutation	I-DNAMutation
of	I-DNAMutation
its	I-DNAMutation
helices	I-DNAMutation
abrogated	O
its	O
binding	O
to	O
c-Maf	B-DNAMutation
,	O
but	O
had	O
no	O
effect	O
on	O
homodimerization	O
.	O

A	O
functional	O
c-Maf	B-DNAMutation
bZip	O
motif	O
was	O
necessary	O
for	O
both	O
homodimerization	O
and	O
heterodimerization	O
with	O
USF2	B-DNAMutation
.	O

These	O
data	O
suggest	O
a	O
tetrameric	O
configuration	O
for	O
Maf-USF2	B-DNAMutation
complexes	O
.	O

In	O
the	O
presence	O
of	O
USF2	B-DNAMutation
,	O
the	O
DNA	O
binding	O
activity	O
of	O
c-Maf	B-DNAMutation
was	O
markedly	O
reduced	O
.	O

Therefore	O
,	O
USF2	B-DNAMutation
and	O
c-Maf	B-DNAMutation
may	O
interact	O
to	O
regulate	O
gene	O
expression	O
.	O

Multisite	O
phosphorylation	O
of	O
doublecortin	B-DNAMutation
by	O
cyclin-dependent	B-DNAMutation
kinase	I-DNAMutation
5	I-DNAMutation
.	O

Doublecortin	B-DNAMutation
DCX	B-DNAMutation
is	O
a	O
40	O
kDa	O
microtubule-associated	O
protein	O
required	O
for	O
normal	O
neural	O
migration	O
and	O
cortical	O
layering	O
during	O
development	O
.	O

Mutations	O
in	O
the	O
human	O
DCX	B-DNAMutation
gene	O
cause	O
a	O
disruption	O
of	O
cortical	O
neuronal	O
migration	O
.	O

Defects	O
in	O
cdk5	B-DNAMutation
(	O
cyclin-dependent	B-DNAMutation
kinase	I-DNAMutation
5	I-DNAMutation
)	O
also	O
cause	O
defects	O
in	O
neural	O
migration	O
and	O
cortical	O
layering	O
.	O

DCX	B-DNAMutation
is	O
a	O
substrate	O
for	O
cdk5	B-DNAMutation
in	O
vitro	O
and	O
in	O
vivo	O
and	O
the	O
major	O
site	O
of	O
in	O
vitro	O
phosphorylation	O
is	O
Ser-297	O
.	O

We	O
used	O
a	O
highly	O
developed	O
MS	O
strategy	O
to	O
identify	O
the	O
cdk5	B-DNAMutation
phosphorylation	O
sites	O
and	O
determine	O
the	O
major	O
and	O
minor	O
sites	O
.	O

Several	O
phosphopeptides	O
were	O
identified	O
from	O
a	O
tryptic	O
digest	O
of	O
32P-labelled	O
,	O
cdk5-phosphorylated	B-DNAMutation
DCX	B-DNAMutation
using	O
a	O
combination	O
of	O
off-line	O
HPLC	O
and	O
matrix-assisted	O
laser-desorption	O
ionization-MS	O
with	O
alkaline	O
phosphatase	O
treatment	O
.	O

Tandem	O
MS/MS	O
enabled	O
the	O
identification	O
of	O
seven	O
phosphorylation	O
sites	O
for	O
cdk5	B-DNAMutation
.	O

Monitoring	O
of	O
32P	O
label	O
indicated	O
that	O
there	O
was	O
one	O
major	O
site	O
,	O
Ser-28	O
,	O
at	O
the	O
N-terminus	O
,	O
and	O
a	O
major	O
site	O
,	O
Ser-339	O
,	O
in	O
the	O
serine/proline-rich	O
domain	O
at	O
the	O
C-terminus	O
.	O

Five	O
other	O
sites	O
,	O
Ser-287	O
,	O
Thr-289	O
,	O
Ser-297	O
,	O
Thr-326	O
and	O
Ser-332	O
,	O
were	O
also	O
found	O
in	O
the	O
tail	O
.	O

Site-directed	O
mutagenesis	O
largely	O
supported	O
these	O
findings	O
.	O

Single	B-DNAMutation
mutation	I-DNAMutation
of	I-DNAMutation
Ser-28	I-DNAMutation
reduced	O
but	O
did	O
not	O
abolish	O
phosphorylation	O
.	O

Double	O
,	O
rather	O
than	O
single	O
,	O
mutation	B-DNAMutation
for	I-DNAMutation
Ser-332	I-DNAMutation
and	I-DNAMutation
Ser-339	I-DNAMutation
was	O
required	O
to	O
reduce	O
overall	O
phosphorylation	O
,	O
suggesting	O
an	O
interaction	O
between	O
these	O
sites	O
.	O

Truncations	O
of	O
the	O
tail	O
produced	O
a	O
significant	O
reduction	O
in	O
cdk5	B-DNAMutation
phosphorylation	O
of	O
DCX	B-DNAMutation
.	O

These	O
results	O
do	O
not	O
support	O
Ser-297	O
as	O
the	O
major	O
cdk5	B-DNAMutation
phosphorylation	O
site	O
in	O
DCX	B-DNAMutation
,	O
but	O
indicate	O
that	O
DCX	B-DNAMutation
is	O
subject	O
to	O
complex	O
multisite	O
phosphorylation	O
.	O

This	O
illustrates	O
the	O
importance	O
of	O
a	O
well-developed	O
MS	O
strategy	O
to	O
identify	O
phosphorylation	O
sites	O
.	O

Two	O
splice	O
variants	O
of	O
protein	O
kinase	O
B	O
gamma	O
have	O
different	O
regulatory	O
capacity	O
depending	O
on	O
the	O
presence	B-DNAMutation
or	I-DNAMutation
absence	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
regulatory	I-DNAMutation
phosphorylation	I-DNAMutation
site	I-DNAMutation
serine	I-DNAMutation
472	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
carboxyl-terminal	I-DNAMutation
hydrophobic	I-DNAMutation
domain	I-DNAMutation
.	O

We	O
have	O
reported	O
previously	O
the	O
cloning	O
and	O
characterization	O
of	O
human	O
and	O
mouse	O
protein	B-DNAMutation
kinase	I-DNAMutation
B	I-DNAMutation
gamma	I-DNAMutation
(	O
PKB	B-DNAMutation
gamma	I-DNAMutation
)	O
,	O
the	O
third	O
member	O
of	O
the	O
PKB	O
family	O
of	O
second	O
messenger-regulated	O
serine/threonine	O
kinases	O
(	O
Brodbeck	O
,	O
D.	O
,	O
Cron	O
,	O
P.	O
,	O
and	O
Hemmings	O
,	O
B	O
.	O

A	O
.	O

(1999)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

274	O
,	O
9133--9136	O
)	O
.	O

Here	O
we	O
report	O
the	O
isolation	O
of	O
human	O
and	O
mouse	O
PKB	B-DNAMutation
gamma	I-DNAMutation
1	I-DNAMutation
,	O
a	O
splice	B-DNAMutation
variant	I-DNAMutation
lacking	I-DNAMutation
the	I-DNAMutation
second	I-DNAMutation
regulatory	I-DNAMutation
phosphorylation	I-DNAMutation
site	I-DNAMutation
Ser-472	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
hydrophobic	I-DNAMutation
C-terminal	I-DNAMutation
domain	I-DNAMutation
.	O

Expression	O
of	O
PKB	B-DNAMutation
gamma	I-DNAMutation
1	I-DNAMutation
is	O
low	O
compared	O
with	O
PKB	B-DNAMutation
gamma	I-DNAMutation
,	O
and	O
it	O
is	O
regulated	O
in	O
different	O
human	O
tissues	O
.	O

We	O
show	O
that	O
PKB	B-DNAMutation
gamma	I-DNAMutation
and	O
PKB	B-DNAMutation
gamma	I-DNAMutation
1	I-DNAMutation
differ	O
in	O
their	O
response	O
to	O
stimulation	O
by	O
insulin	B-DNAMutation
,	O
pervanadate	O
,	O
peroxide	O
,	O
or	O
okadaic	O
acid	O
.	O

Activation	O
of	O
PKB	B-DNAMutation
gamma	I-DNAMutation
1	I-DNAMutation
requires	O
phosphorylation	O
at	O
a	O
single	O
regulatory	O
site	O
Thr-305	O
.	O

Interestingly	O
,	O
this	O
site	O
is	O
phosphorylated	O
to	O
a	O
higher	O
extent	O
in	O
PKB	B-DNAMutation
gamma	I-DNAMutation
compared	O
with	O
PKB	B-DNAMutation
gamma	I-DNAMutation
1	I-DNAMutation
upon	O
maximal	O
stimulation	O
by	O
pervanadate	O
,	O
and	O
this	O
is	O
reflected	O
in	O
the	O
respective	O
specific	O
kinase	O
activities	O
.	O

Furthermore	O
,	O
upon	O
insulin	B-DNAMutation
stimulation	O
of	O
transfected	O
cells	O
,	O
PKB	B-DNAMutation
gamma	I-DNAMutation
1	I-DNAMutation
translocates	O
to	O
the	O
plasma	O
membrane	O
to	O
a	O
lesser	O
extent	O
than	O
PKB	B-DNAMutation
gamma	I-DNAMutation
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
phosphorylation	O
of	O
the	O
hydrophobic	O
motif	O
at	O
the	O
extreme	O
C	O
terminus	O
of	O
PKB	B-DNAMutation
gamma	I-DNAMutation
may	O
facilitate	O
translocation	O
of	O
the	O
kinase	O
to	O
the	O
membrane	O
and/or	O
its	O
phosphorylation	O
on	O
the	O
activation	O
loop	O
site	O
by	O
phosphoinositide-dependent	O
protein	O
kinase-1	O
.	O

Genetic	O
variation	O
in	O
the	O
beta	O
3-adrenergic	O
receptor	O
and	O
an	O
increased	O
capacity	O
to	O
gain	O
weight	O
in	O
patients	O
with	O
morbid	O
obesity	O
.	O

BACKGROUND	O
:	O
The	O
beta	O
3-adrenergic	O
receptor	O
,	O
located	O
mainly	O
in	O
adipose	O
tissue	O
,	O
is	O
involved	O
in	O
the	O
regulation	O
of	O
lipolysis	O
and	O
thermogenesis	O
.	O

The	O
potential	O
relevance	O
of	O
this	O
receptor	O
to	O
obesity	O
in	O
humans	O
led	O
us	O
to	O
screen	O
obese	O
French	O
patients	O
for	O
a	O
recently	O
identified	O
mutation	O
in	O
the	O
gene	O
for	O
the	O
receptor	O
.	O

METHODS	O
:	O
We	O
used	O
the	O
polymerase	O
chain	O
reaction	O
to	O
amplify	O
a	O
region	O
of	O
the	O
gene	O
for	O
the	O
beta	O
3-adrenergic	O
receptor	O
encoding	O
amino	O
acid	O
residues	O
27	O
to	O
110	O
in	O
genomic	O
DNA	O
extracted	O
from	O
leukocytes	O
from	O
185	O
patients	O
with	O
morbid	O
obesity	O
(	O
body-mass	O
index	O
[	O
the	O
weight	O
in	O
kilograms	O
divided	O
by	O
the	O
square	O
of	O
the	O
height	O
in	O
meters	O
]	O
,	O
>	O
40	O
)	O
and	O
94	O
normal	O
subjects	O
.	O

A	O
mutation	O
resulting	O
in	O
the	O
replacement	B-DNAMutation
of	I-DNAMutation
tryptophan	I-DNAMutation
by	I-DNAMutation
arginine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
64	I-DNAMutation
Trp64Arg	B-DNAMutation
was	O
detected	O
by	O
an	O
analysis	O
of	O
restriction-fragment-length	O
polymorphisms	O
with	O
the	O
use	O
of	O
the	O
endonuclease	O
BstNl	O
,	O
which	O
discriminates	O
between	O
the	O
normal	O
and	O
mutant	O
sequences	O
.	O

RESULTS	O
:	O
The	O
frequency	O
of	O
the	O
Trp64Arg	B-DNAMutation
allele	O
was	O
similar	O
in	O
the	O
morbidly	O
obese	O
patients	O
and	O
the	O
normal	O
subjects	O
(	O
0.08	O
and	O
0.10	O
,	O
respectively	O
)	O
.	O

However	O
,	O
the	O
patients	O
with	O
morbid	O
obesity	O
who	O
were	O
heterozygous	O
for	O
the	O
Trp64Arg	B-DNAMutation
mutation	O
had	O
an	O
increased	O
capacity	O
to	O
gain	O
weight	O
;	O
the	O
mean	O
weight	O
in	O
the	O
14	O
heterozygous	O
patients	O
was	O
140	O
kg	O
,	O
as	O
compared	O
with	O
126	O
kg	O
in	O
the	O
171	O
patients	O
without	O
the	O
mutation	O
(	O
P	O
=	O
0.03	O
)	O
.	O

There	O
were	O
no	O
homozygotes	O
in	O
this	O
sample	O
.	O

The	O
cumulative	O
25-year	O
change	O
in	O
weight	O
(	O
from	O
the	O
age	O
of	O
20	O
years	O
)	O
was	O
67	O
kg	O
in	O
the	O
Trp64Arg	B-DNAMutation
heterozygotes	O
,	O
as	O
compared	O
with	O
51	O
kg	O
in	O
those	O
without	O
the	O
mutation	O
.	O

The	O
maximal	O
weight	O
differential	O
(	O
the	O
maximal	O
lifetime	O
weight	O
minus	O
the	O
weight	O
at	O
20	O
years	O
of	O
age	O
)	O
in	O
the	O
Trp64Arg	B-DNAMutation
heterozygotes	O
was	O
74	O
kg	O
,	O
as	O
compared	O
with	O
59	O
kg	O
in	O
the	O
patients	O
without	O
the	O
mutation	O
(	O
P	O
=	O
0.02	O
)	O
.	O

CONCLUSIONS	O
:	O
People	O
with	O
the	O
Trp64Arg	B-DNAMutation
mutation	O
of	O
the	O
gene	O
for	O
the	O
beta	O
3-adrenergic	O
receptor	O
may	O
have	O
an	O
increased	O
capacity	O
to	O
gain	O
weight	O
.	O

Regulation	O
of	O
B-cell	O
development	O
by	O
BCAP	B-DNAMutation
and	O
CD19	B-DNAMutation
through	O
their	O
binding	O
to	O
phosphoinositide	O
3-kinase	O
.	O

Despite	O
the	O
importance	O
of	O
phosphoinositide	O
3-kinase	O
(PI3K)	O
in	O
B-cell	O
development	O
,	O
its	O
activation	O
mechanism	O
still	O
remains	O
elusive	O
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
deletion	B-DNAMutation
of	I-DNAMutation
both	O
BCAP	B-DNAMutation
and	O
CD19	B-DNAMutation
leads	O
to	O
an	O
almost	O
complete	O
block	O
of	O
BCR-mediated	B-DNAMutation
Akt	O
activation	O
and	O
to	O
severe	O
defects	O
in	O
generation	O
of	O
immature	O
and	O
mature	O
B	O
cells	O
.	O

The	O
YXXM	O
motifs	O
in	O
BCAP	B-DNAMutation
and	O
CD19	B-DNAMutation
are	O
crucial	O
for	O
regulating	O
B-cell	O
development	O
in	O
that	O
mutation	O
of	O
these	O
motifs	O
abrogated	O
their	O
ability	O
to	O
induce	O
BCR-mediated	B-DNAMutation
Akt	O
activation	O
as	O
well	O
as	O
to	O
promote	O
B-cell	O
development	O
.	O

Furthermore	O
,	O
the	O
developmental	O
defect	O
in	O
CD19(-/-)BCAP(-/-)	O
B	O
cells	O
was	O
partly	O
relieved	O
by	O
introducing	O
a	O
constitutively	O
active	O
form	O
of	O
PI3K	O
or	O
PDK1	B-DNAMutation
.	O

Together	O
,	O
our	O
data	O
suggest	O
that	O
BCAP	B-DNAMutation
and	O
CD19	B-DNAMutation
have	O
complementary	O
roles	O
in	O
BCR-mediated	B-DNAMutation
PI3K	O
activation	O
,	O
thereby	O
,	O
at	O
least	O
in	O
part	O
,	O
contributing	O
to	O
B-cell	O
development	O
.	O

Role	O
that	O
phosphorylation	O
of	O
GSK3	O
plays	O
in	O
insulin	O
and	O
Wnt	O
signalling	O
defined	O
by	O
knockin	O
analysis	O
.	O

The	O
inactivation	O
of	O
glycogen	O
synthase	O
kinase	O
(GSK)3	O
has	O
been	O
proposed	O
to	O
play	O
important	O
roles	O
in	O
insulin	O
and	O
Wnt	O
signalling	O
.	O

To	O
define	O
the	O
role	O
that	O
inactivation	O
of	O
GSK3	O
plays	O
,	O
we	O
generated	O
homozygous	O
knockin	O
mice	O
in	O
which	O
the	O
protein	O
kinase	O
B	O
phosphorylation	O
sites	O
on	O
GSK3alpha	B-DNAMutation
(Ser21)	O
and	O
GSK3beta	B-DNAMutation
Ser9	B-DNAMutation
were	I-DNAMutation
changed	I-DNAMutation
to	I-DNAMutation
Ala	I-DNAMutation
.	O

The	O
knockin	O
mice	O
were	O
viable	O
and	O
were	O
not	O
diabetic	O
.	O

Using	O
these	O
mice	O
we	O
show	O
that	O
inactivation	O
of	O
GSK3beta	B-DNAMutation
rather	O
than	O
GSK3alpha	B-DNAMutation
is	O
the	O
major	O
route	O
by	O
which	O
insulin	O
activates	O
muscle	O
glycogen	O
synthase	O
.	O

In	O
contrast	O
,	O
we	O
demonstrate	O
that	O
the	O
activation	O
of	O
muscle	O
glycogen	O
synthase	O
by	O
contraction	O
,	O
the	O
stimulation	O
of	O
muscle	O
glucose	O
uptake	O
by	O
insulin	O
,	O
or	O
the	O
activation	O
of	O
hepatic	O
glycogen	O
synthase	O
by	O
glucose	O
do	O
not	O
require	O
GSK3	O
phosphorylation	O
on	O
Ser21/Ser9	O
.	O

GSK3	O
also	O
becomes	O
inhibited	O
in	O
the	O
Wnt-signalling	O
pathway	O
,	O
by	O
a	O
poorly	O
defined	O
mechanism	O
.	O

In	O
GSK3alpha/GSK3beta	B-DNAMutation
homozygous	O
knockin	O
cells	O
,	O
Wnt3a	B-DNAMutation
induces	O
normal	O
inactivation	O
of	O
GSK3	O
,	O
as	O
judged	O
by	O
the	O
stabilisation	O
of	O
beta-catenin	B-DNAMutation
and	O
stimulation	O
of	O
Wnt-dependent	O
transcription	O
.	O

These	O
results	O
establish	O
the	O
function	O
of	O
Ser21/Ser9	O
phosphorylation	O
in	O
several	O
processes	O
in	O
which	O
GSK3	O
inactivation	O
has	O
previously	O
been	O
implicated	O
.	O

Pharmacological	O
characterization	O
of	O
a	O
recently	O
described	O
human	O
beta	B-DNAMutation
3-adrenergic	I-DNAMutation
receptor	I-DNAMutation
mutant	O
.	O

The	O
beta	B-DNAMutation
3-adrenergic	I-DNAMutation
receptor	I-DNAMutation
is	O
the	O
predominant	O
subtype	O
of	O
beta-adrenergic	O
receptor	O
expressed	O
in	O
adipose	O
tissue	O
.	O

Recently	O
,	O
a	O
naturally	O
occurring	O
mutation	O
in	O
the	O
human	O
beta	O
3-receptor	O
gene	O
has	O
been	O
described	O
which	O
results	O
in	O
substitution	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
tryptophan	I-DNAMutation
residue	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
64	I-DNAMutation
in	O
the	O
first	O
intracellular	O
loop	O
with	O
an	O
arginine	O
residue	O
.	O

The	O
polymorphism	O
,	O
which	O
is	O
prevalent	O
in	O
the	O
human	O
population	O
,	O
has	O
been	O
associated	O
with	O
increases	O
in	O
some	O
parameters	O
of	O
obesity	O
and	O
Type	O
II	O
diabetes	O
.	O

In	O
order	O
to	O
characterize	O
the	O
pharmacological	O
effects	O
of	O
this	O
amino	O
acid	O
substitution	O
,	O
the	O
W64R	B-DNAMutation
mutation	O
was	O
made	O
in	O
the	O
human	O
beta	O
3	O
receptor	O
gene	O
and	O
the	O
resulting	O
mutant	O
receptor	O
expressed	O
in	O
CHO	O
cells	O
.	O

Activation	O
by	O
various	O
agonists	O
showed	O
no	O
significant	O
differences	O
(	O
t-test	O
,	O
P	O
>	O
0.05	O
)	O
between	O
the	O
wild	O
type	O
and	O
mutant	O
receptors	O
.	O

These	O
studies	O
show	O
that	O
,	O
when	O
expressed	O
in	O
a	O
heterologous	O
system	O
,	O
the	O
W64R	B-DNAMutation
mutant	O
receptor	O
is	O
pharmacologically	O
and	O
functionally	O
indistinguishable	O
from	O
the	O
wild	O
type	O
beta	B-DNAMutation
3-adrenergic	I-DNAMutation
receptor	I-DNAMutation
.	O

Mis-sense	B-DNAMutation
mutation	I-DNAMutation
Val----Ile	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
17	I-DNAMutation
of	O
amyloid	O
precursor	O
protein	O
gene	O
in	O
Japanese	O
familial	O
Alzheimer's	O
disease	O
.	O

	O
Ferrochelatase	B-DNAMutation
structural	O
mutant	O
(Fechm1Pas)	O
in	O
the	O
house	O
mouse	O
.	O

The	O
molecular	O
basis	O
of	O
an	O
inherited	O
defect	O
of	O
ferrochelatase	B-DNAMutation
in	O
mouse	O
(	O
Fechm1Pas/Fechm1Pas	O
,	O
described	O
by	O
Tutois	O
et	O
al.	O
,	O
1991	O
,	O
J	O
.	O

Clin	O
.	O

Invest	O
.	O

88:1730-1736	O
)	O
was	O
investigated	O
.	O

cDNA	O
clones	O
encoding	O
ferrochelatase	B-DNAMutation
,	O
isolated	O
by	O
amplification	O
of	O
the	O
mRNA	O
from	O
the	O
liver	O
of	O
a	O
mutant	O
mouse	O
using	O
the	O
polymerase	O
chain	O
reaction	O
,	O
were	O
sequenced	O
by	O
the	O
dideoxynucleotide	O
chain-termination	O
method	O
.	O

All	O
the	O
clones	O
carried	O
a	O
T	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
293	I-DNAMutation
,	O
leading	B-DNAMutation
to	I-DNAMutation
a	I-DNAMutation
methionine	I-DNAMutation
to	I-DNAMutation
lysine	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
98	I-DNAMutation
in	O
the	O
protein	O
(	O
mutation	O
M98K	B-DNAMutation
)	O
.	O

Hybridization	O
with	O
allele-specific	O
oligonucleotides	O
(ASOs)	O
confirmed	O
the	O
mutation	O
at	O
the	O
cDNA	O
and	O
genomic	O
levels	O
.	O

Finally	O
,	O
expression	O
of	O
the	O
mutant	O
ferrochelatase	O
protein	O
in	O
E	O
.	O

coli	O
demonstrated	O
a	O
marked	O
deficiency	O
in	O
activity	O
in	O
agreement	O
with	O
the	O
activity	O
of	O
the	O
deficient	O
enzyme	O
in	O
vivo	O
.	O

This	O
Fechm1Pas/Fechm1Pas	O
mutant	O
mouse	O
represents	O
a	O
useful	O
model	O
for	O
studying	O
the	O
pathophysiological	O
feature	O
of	O
the	O
human	O
disease	O
and	O
the	O
first	O
accessible	O
model	O
for	O
gene	O
therapy	O
in	O
the	O
field	O
of	O
porphyrias	O
.	O

The	O
calsequestrin	O
mutation	O
CASQ2D307H	B-DNAMutation
does	O
not	O
affect	O
protein	O
stability	O
and	O
targeting	O
to	O
the	O
junctional	O
sarcoplasmic	O
reticulum	O
but	O
compromises	O
its	O
dynamic	O
regulation	O
of	O
calcium	O
buffering	O
.	O

Mutations	O
in	O
cardiac	O
ryanodine	O
receptor	O
RYR2	B-DNAMutation
and	O
cardiac	B-DNAMutation
calsequestrin	I-DNAMutation
CASQ2	B-DNAMutation
genes	O
are	O
linked	O
to	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia	O
,	O
a	O
life-threatening	O
genetic	O
disease	O
.	O

They	O
predispose	O
young	O
individuals	O
to	O
cardiac	O
arrhythmia	O
in	O
the	O
absence	O
of	O
structural	O
abnormalities	O
.	O

One	O
such	O
mutation	O
that	O
changes	O
an	O
aspartic	B-DNAMutation
residue	I-DNAMutation
to	I-DNAMutation
histidine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
307	I-DNAMutation
in	O
CASQ2	B-DNAMutation
has	O
been	O
linked	O
to	O
catecholaminergic	O
polymorphic	O
ventricular	O
tachycardia	O
.	O

In	O
this	O
study	O
we	O
made	O
a	O
transgenic	O
mouse	O
model	O
expressing	O
the	O
mutant	O
CASQ2(D307H)	B-DNAMutation
protein	O
in	O
a	O
CASQ2	B-DNAMutation
null	O
background	O
and	O
investigated	O
if	O
the	O
disease	O
is	O
caused	O
by	O
accelerated	O
degradation	O
of	O
the	O
mutant	O
protein	O
.	O

Our	O
data	O
suggest	O
that	O
the	O
mutant	O
protein	O
can	O
be	O
expressed	O
,	O
is	O
relatively	O
stable	O
,	O
and	O
targets	O
appropriately	O
to	O
the	O
junctional	O
sarcoplasmic	O
reticulum	O
.	O

Moreover	O
,	O
it	O
partially	O
normalizes	O
the	O
ultrastructure	O
of	O
the	O
sarcoplasmic	O
reticulum	O
,	O
which	O
was	O
altered	O
in	O
the	O
CASQ2	B-DNAMutation
null	O
background	O
.	O

In	O
addition	O
,	O
overexpression	O
of	O
the	O
mutant	O
protein	O
does	B-DNAMutation
not	O
cause	O
any	O
pathology	O
and/or	O
structural	O
changes	O
in	O
the	O
myocardium	O
.	O

We	O
further	O
demonstrate	O
,	O
using	O
purified	O
protein	O
,	O
that	O
the	O
mutant	O
protein	O
is	O
very	O
stable	O
under	O
chemical	O
and	O
thermal	O
denaturation	O
but	O
shows	O
abnormal	O
Ca(2+)	O
buffering	O
characteristics	O
at	O
high	O
calcium	O
concentrations	O
.	O

In	O
addition	O
,	O
trypsin	O
digestion	O
studies	O
reveal	O
that	O
the	O
mutant	O
protein	O
is	O
more	O
susceptible	O
to	O
protease	O
activity	O
only	O
in	O
the	O
presence	O
of	O
high	O
Ca(2+)	O
.	O

These	O
studies	O
collectively	O
suggest	O
that	O
the	O
D307H	B-DNAMutation
mutation	O
can	O
compromise	O
the	O
dynamic	O
behavior	O
of	O
CASQ2	B-DNAMutation
including	O
supramolecular	O
rearrangement	O
upon	O
Ca(2+)	O
activation	O
.	O

BRCA1	B-DNAMutation
interacts	O
with	O
acetyl-CoA	O
carboxylase	O
through	O
its	O
tandem	O
of	O
BRCT	B-DNAMutation
domains	O
.	O

Germ-line	O
alterations	O
in	O
BRCA1	B-DNAMutation
are	O
associated	O
with	O
an	O
increased	O
susceptibility	O
to	O
breast	O
and	O
ovarian	O
cancer	O
.	O

BRCA1	B-DNAMutation
is	O
a	O
220-kDa	O
protein	O
that	O
contains	O
a	O
tandem	O
of	O
two	O
BRCA1	B-DNAMutation
C-Terminal	O
BRCT	B-DNAMutation
domains	O
.	O

Among	O
missense	O
and	O
nonsense	O
BRCA1	B-DNAMutation
mutations	O
responsible	O
for	O
family	O
breast	O
cancer	O
,	O
some	O
are	O
located	O
into	O
the	O
BRCT	B-DNAMutation
tandem	O
of	O
BRCA1	B-DNAMutation
coding	O
sequence	O
.	O

In	O
an	O
attempt	O
to	O
understand	O
how	O
BRCT	B-DNAMutation
is	O
critical	O
for	O
BRCA1	B-DNAMutation
function	O
,	O
we	O
search	O
for	O
partners	O
of	O
this	O
BRCT	B-DNAMutation
tandem	O
of	O
BRCA1	B-DNAMutation
.	O

Using	O
a	O
glutathione-S-transferase	O
(GST)	O
pull-down	O
assay	O
with	O
murine	O
cells	O
,	O
we	O
isolated	O
only	O
one	O
major	O
BRCA1-interacting	B-DNAMutation
protein	O
,	O
further	O
identified	O
as	O
Acetyl	O
Coenzyme	O
A	O
(CoA)	O
Carboxylase	O
alpha	O
(ACCA)	O
.	O

We	O
showed	O
that	O
this	O
interaction	O
is	O
conserved	O
through	O
murine	O
and	O
human	O
species	O
.	O

We	O
also	O
delineated	O
the	O
minimum	O
interacting	O
region	O
as	O
being	O
the	O
whole	O
tandem	O
of	O
BRCT	B-DNAMutation
domains	O
.	O

We	O
demonstrated	O
that	O
BRCA1	B-DNAMutation
interacts	O
in	O
vitro	O
and	O
in	O
vivo	O
with	O
ACCA	O
.	O

This	O
interaction	O
is	O
completely	O
abolished	O
by	O
five	O
distinct	O
germline	O
BRCA1	B-DNAMutation
deleterious	O
mutations	O
affecting	O
the	O
BRCT	B-DNAMutation
tandem	O
of	O
BRCA1	B-DNAMutation
.	O

Interestingly	O
,	O
ACCA	O
originally	O
known	O
as	O
a	O
rate-limiting	O
enzyme	O
for	O
fatty	O
acids	O
biosynthesis	O
,	O
has	O
been	O
recently	O
shown	O
to	O
be	O
over-expressed	O
in	O
breast	O
cancers	O
and	O
considered	O
as	O
a	O
potential	O
target	O
for	O
anti-neoplastic	O
therapy	O
.	O

Furthermore	O
,	O
our	O
observation	O
is	O
making	O
a	O
bridge	O
between	O
the	O
genetic	O
factors	O
involved	O
in	O
susceptibility	O
to	O
breast	O
and	O
ovarian	O
cancers	O
,	O
and	O
environmental	O
factors	O
such	O
as	O
nutrition	O
considered	O
as	O
key	O
elements	O
in	O
the	O
etiology	O
of	O
those	O
cancers	O
.	O

Polymorphisms	O
of	O
cardiac	O
presynaptic	O
alpha2C	O
adrenergic	O
receptors	O
:	O
Diverse	O
intragenic	O
variability	O
with	O
haplotype-specific	O
functional	O
effects	O
.	O

The	O
presynaptic	O
alpha2C	O
adrenergic	O
receptors	O
(AR)	O
act	O
to	O
inhibit	O
norepinephrine	O
release	O
in	O
cardiac	O
and	O
other	O
presynaptic	O
nerves	O
.	O

We	O
have	O
recently	O
shown	O
that	O
a	O
genetic	O
variant	O
in	O
the	O
alpha2CAR	B-DNAMutation
coding	O
region	O
Del322-325	B-DNAMutation
,	O
which	O
renders	O
the	O
receptor	O
partially	O
uncoupled	O
from	O
Gi	O
,	O
is	O
a	O
risk	O
factor	O
for	O
heart	O
failure	O
.	O

However	O
,	O
variability	O
of	O
heart	O
failure	O
phenotypes	O
and	O
a	O
dominance	O
of	O
Del322-325	B-DNAMutation
in	O
those	O
of	O
African	O
descent	O
led	O
us	O
to	O
hypothesize	O
that	O
other	O
regions	O
of	O
this	O
gene	O
have	O
functional	O
polymorphisms	O
.	O

In	O
a	O
multiethnic	O
population	O
,	O
we	O
found	O
20	O
polymorphisms	O
within	O
4,625	O
bp	O
of	O
contiguous	O
sequence	O
of	O
this	O
intronless	O
gene	O
encompassing	O
the	O
promoter	O
,	O
5'	O
UTR	O
,	O
coding	O
,	O
and	O
3'	O
UTR	O
.	O

These	O
polymorphisms	O
occur	O
in	O
24	O
distinct	O
haplotypes	O
with	O
complex	O
organizations	O
,	O
including	O
multiple	O
5'-upstream	O
polymorphisms	O
in	O
regions	O
known	O
to	O
direct	O
expression	O
,	O
a	O
3'	O
UTR	O
substitution	O
polymorphism	O
within	O
an	O
insertion/deletion	O
sequence	O
,	O
and	O
the	O
radical	O
coding	O
polymorphism	O
that	O
deletes	O
four	O
amino	O
acids	O
.	O

Relatively	O
low	O
linkage	O
disequilibrium	O
between	O
many	O
polymorphisms	O
,	O
few	O
cosmopolitan	O
haplotypes	O
,	O
prevalent	O
ethnic-specific	O
haplotypes	O
,	O
and	O
substantial	O
genetic	O
divergence	O
among	O
haplotypes	O
was	O
noted	O
.	O

The	O
dysfunctional	O
Del322-325	B-DNAMutation
allele	O
was	O
partitioned	O
into	O
multiple	O
haplotypes	O
,	O
with	O
frequencies	O
of	O
48%	O
to	O
2%	O
.	O

The	O
functional	O
implications	O
of	O
the	O
haplotypes	O
were	O
ascertained	O
by	O
whole-gene	O
transfections	O
of	O
human	O
neuronal	O
cells	O
,	O
where	O
haplotype	O
was	O
significantly	O
related	O
(	O
P	O
<	O
0.001	O
)	O
to	O
expression	O
levels	O
of	O
receptor	O
transcript	O
and	O
protein	O
.	O

Expression	O
varied	O
by	O
as	O
much	O
as	O
approximately	O
50%	O
by	O
haplotype	O
,	O
and	O
such	O
studies	O
enabled	O
haplotype	O
clustering	O
by	O
phenotypic	O
,	O
rather	O
than	O
genotypic	O
,	O
similarities	O
.	O

Thus	O
,	O
depending	O
on	O
phenotype	O
,	O
expression-specific	O
haplotypes	O
may	O
amplify	O
,	O
attenuate	O
,	O
or	O
dominate	O
the	O
cardiomyopathic	O
effect	O
attributed	O
to	O
the	O
alpha2CDel322-325	B-DNAMutation
marker	O
.	O

Regulated	O
interaction	O
of	O
the	O
Fanconi	O
anemia	O
protein	O
,	O
FANCD2	B-DNAMutation
,	O
with	O
chromatin	B-DNAMutation
.	O

DNA	O
damage	O
activates	O
the	O
monoubiquitination	O
of	O
the	O
Fanconi	O
anemia	O
(FA)	O
protein	O
,	O
FANCD2	B-DNAMutation
,	O
resulting	O
in	O
the	O
assembly	O
of	O
FANCD2	B-DNAMutation
nuclear	O
foci	O
.	O

In	O
the	O
current	O
study	O
,	O
we	O
characterize	O
structural	O
features	O
of	O
FANCD2	B-DNAMutation
required	O
for	O
this	O
intranuclear	O
translocation	O
.	O

We	O
have	O
previously	O
identified	O
2	O
normal	O
mRNA	O
splice	O
variants	O
of	O
FANCD2	B-DNAMutation
,	O
one	O
containing	O
exon	O
44	O
sequence	O
at	O
the	O
3'	O
end	O
FANCD2-44	B-DNAMutation
and	O
one	O
containing	O
exon	O
43	O
sequence	O
FANCD2-43	B-DNAMutation
.	O

The	O
2	O
predicted	O
FANCD2	B-DNAMutation
proteins	O
differ	O
in	O
their	O
carboxy	O
terminal	O
24	O
amino	O
acids	O
.	O

In	O
stably	O
transfected	O
FANCD2(-/-)	B-DNAMutation
fibroblasts	O
,	O
FANCD2-44	B-DNAMutation
and	O
FANCD2-43	B-DNAMutation
proteins	O
were	O
monoubiquitinated	O
on	O
K561	O
.	O

Only	O
FANCD2-44	B-DNAMutation
corrected	O
the	O
mitomycin	O
C	O
(MMC)	O
sensitivity	O
of	O
the	O
transfected	O
cells	O
.	O

We	O
find	O
that	O
monoubiquitinated	O
FANCD2-44	B-DNAMutation
was	O
translocated	O
from	O
the	O
soluble	O
nuclear	O
compartment	O
into	O
chromatin	B-DNAMutation
.	O

A	O
mutant	O
form	O
of	O
FANCD2-44	B-DNAMutation
FANCD2-K561R	B-DNAMutation
was	O
not	O
monoubiquitinated	O
and	O
failed	O
to	O
bind	O
chromatin	B-DNAMutation
.	O

A	O
truncated	O
FANCD2	B-DNAMutation
protein	O
(Exon44-T)	O
,	O
lacking	B-DNAMutation
the	I-DNAMutation
carboxy	I-DNAMutation
terminal	I-DNAMutation
24	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
encoded	I-DNAMutation
by	I-DNAMutation
exon	I-DNAMutation
44	I-DNAMutation
but	O
retaining	O
K561	O
,	O
and	O
another	O
mutant	O
FANCD2	B-DNAMutation
protein	O
,	O
with	O
a	O
single	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
a	I-DNAMutation
conserved	I-DNAMutation
residue	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
C-terminal	I-DNAMutation
24	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
D1428A	B-DNAMutation
,	O
were	O
monoubiquitinated	O
.	O

Both	O
mutants	O
were	O
targeted	O
to	O
chromatin	B-DNAMutation
but	O
failed	O
to	O
correct	O
MMC	O
sensitivity	O
.	O

Taken	O
together	O
,	O
our	O
results	O
indicate	O
that	O
monoubiquitination	O
of	O
FANCD2	B-DNAMutation
regulates	O
chromatin	B-DNAMutation
binding	O
and	O
that	O
D1428	O
within	O
the	O
carboxy	O
terminal	O
acidic	O
sequence	O
encoded	O
by	O
exon	O
44	O
is	O
independently	O
required	O
for	O
functional	O
complementation	O
of	O
FA-D2	O
cells	O
.	O

We	O
hypothesize	O
that	O
the	O
carboxy	O
terminus	O
of	O
FANCD2-44	B-DNAMutation
plays	O
a	O
critical	O
role	O
in	O
sensing	O
or	O
repairing	O
DNA	O
damage	O
.	O

Fibrinogen	O
Lima	O
:	O
a	O
homozygous	O
dysfibrinogen	O
with	O
an	O
A	O
alpha-arginine-141	B-DNAMutation
to	I-DNAMutation
serine	I-DNAMutation
substitution	I-DNAMutation
associated	O
with	O
extra	O
N-glycosylation	O
at	O
A	O
alpha-asparagine-139	O
.	O

Impaired	O
fibrin	O
gel	O
formation	O
but	O
normal	O
fibrin-facilitated	O
plasminogen	B-DNAMutation
activation	O
catalyzed	O
by	O
tissue-type	O
plasminogen	B-DNAMutation
activator	O
.	O

An	O
A	O
alpha-arginine-141	B-DNAMutation
to	I-DNAMutation
serine	I-DNAMutation
substitution	I-DNAMutation
has	O
been	O
identified	O
in	O
a	O
homozygous	O
dysfibrinogen	O
,	O
fibrinogen	B-DNAMutation
Lima	O
,	O
associated	O
with	O
impaired	O
fibrin	O
polymerization	O
.	O

The	O
point	O
mutation	O
created	O
an	O
asparagine-X-serine-type	O
glycosylation	O
sequence	O
,	O
and	O
indeed	O
,	O
extra	O
,	O
mainly	O
disialylated	O
biantennary	O
oligosaccharides	O
have	O
been	O
isolated	O
from	O
A	O
alpha	O
asparagine-139	O
of	O
the	O
patient's	O
fibrinogen	B-DNAMutation
.	O

This	O
type	O
of	O
glycosylation	O
sequence	O
is	O
unique	O
for	O
human	O
fibrinogen	B-DNAMutation
,	O
because	O
the	O
sequences	O
shown	O
for	O
normal	O
and	O
abnormal	O
fibrinogens	O
are	O
all	O
asparagine-X-threonine	O
types	O
.	O

The	O
terminal	O
sialic	O
acids	O
of	O
the	O
extra	O
oligosaccharides	O
seem	O
to	O
have	O
largely	O
contributed	O
to	O
the	O
impaired	O
fibrin	O
gel	O
formation	O
,	O
as	O
evidenced	O
by	O
its	O
correction	O
to	O
a	O
near	O
normal	O
level	O
by	O
desialylation	O
.	O

Nevertheless	O
,	O
the	O
polymerizing	O
fibrin	O
facilitated	O
tissue-type	O
plasminogen	B-DNAMutation
activator-catalyzed	O
plasmin	O
formation	O
in	O
a	O
normal	O
fashion	O
,	O
indicating	O
that	O
the	O
initial	O
two-stranded	O
fibrin	O
protofibrils	O
had	O
been	O
constructed	O
normally	O
.	O

Thus	O
the	O
impaired	O
fibrin	O
gel	O
formation	O
could	O
be	O
attributed	O
to	O
the	O
delay	O
in	O
their	O
subsequent	O
lateral	O
association	O
,	O
most	O
probably	O
because	O
of	O
the	O
repulsive	O
forces	O
generated	O
by	O
the	O
negative	O
electric	O
charge	O
of	O
the	O
extra	O
sialic	O
acids	O
.	O

The	O
substitution	O
of	O
a	O
basic	O
residue	O
arginine	O
to	O
a	O
noncharged	O
residue	O
serine	O
may	O
also	O
have	O
contributed	O
to	O
the	O
impaired	O
function	O
in	O
a	O
similar	O
manner	O
or	O
by	O
steric	O
hindrance	O
in	O
association	O
with	O
bulky	O
extra	O
oligosaccharide	O
chains	O
.	O

Identification	O
of	O
centaurin-alpha1	O
as	O
a	O
potential	O
in	O
vivo	O
phosphatidylinositol	O
3,4,5-trisphosphate-binding	O
protein	O
that	O
is	O
functionally	O
homologous	O
to	O
the	O
yeast	O
ADP-ribosylation	O
factor	O
(ARF)	O
GTPase-activating	O
protein	O
,	O
Gcs1	B-DNAMutation
.	O

Centaurin-alpha	O
is	O
a	O
46	O
kDa	O
in	O
vitro	O
binding	O
protein	O
for	O
the	O
lipid	O
second	O
messenger	O
PtdIns(3,4,5)P3	O
.	O

In	O
this	O
report	O
we	O
have	O
addressed	O
whether	O
centaurin-alpha1	B-DNAMutation
,	O
a	O
human	O
homologue	O
of	O
centaurin-alpha	O
,	O
binds	O
PtdIns(3,4,5)P3	O
in	O
vivo	O
and	O
furthermore	O
,	O
identified	O
a	O
potential	O
physiological	O
function	O
for	O
centaurin-alpha1	B-DNAMutation
.	O

Using	O
confocal	O
microscopy	O
of	O
live	O
PC12	O
cells	O
,	O
transiently	O
transfected	O
with	O
a	O
chimera	O
of	O
green	O
fluorescent	O
protein	O
(GFP)	O
fused	O
to	O
the	O
N-terminus	O
of	O
centaurin-alpha1	B-DNAMutation
GFP-centaurin-alpha1	B-DNAMutation
,	O
we	O
demonstrated	O
the	O
rapid	O
plasma	O
membrane	O
recruitment	O
of	O
cytosolic	O
GFP-centaurin-alpha1	B-DNAMutation
following	O
stimulation	O
with	O
either	O
nerve	O
growth	O
factor	O
or	O
epidermal	O
growth	O
factor	O
.	O

This	O
recruitment	O
was	O
dependent	O
on	O
the	O
centaurin-alpha1	O
pleckstrin	O
homology	O
domains	O
and	O
was	O
blocked	O
by	O
the	O
PtdIns(4,5)P2	O
3-kinase	O
(	O
PI	O
3-kinase	O
)	O
inhibitors	O
wortmannin	O
(	O
100	O
nM	O
)	O
and	O
LY294002	O
(	O
50	O
microM	O
)	O
,	O
and	O
also	O
by	O
co-expression	O
with	O
a	O
dominant	O
negative	O
p85	O
.	O

Functionally	O
,	O
we	O
demonstrated	O
that	O
centaurin-alpha1	O
could	O
complement	O
a	O
yeast	O
strain	O
deficient	O
in	O
the	O
ADP-ribosylation	O
factor	O
(ARF)	O
GTPase-activating	O
protein	O
Gcs1	B-DNAMutation
;	O
a	O
complementation	O
that	O
was	O
blocked	O
by	O
mutagenesis	B-DNAMutation
of	I-DNAMutation
conserved	I-DNAMutation
cysteine	I-DNAMutation
residues	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
ARF	I-DNAMutation
GTPase-activating	I-DNAMutation
protein	I-DNAMutation
analogous	I-DNAMutation
domain	I-DNAMutation
of	I-DNAMutation
centaurin-alpha1	I-DNAMutation
.	O

Taken	O
together	O
,	O
our	O
data	O
demonstrated	O
that	O
centaurin-alpha1	O
could	O
potentially	O
function	O
as	O
an	O
ARF	O
GTPase-activating	O
protein	O
that	O
,	O
on	O
agonist	O
stimulation	O
,	O
was	O
recruited	O
to	O
the	O
plasma	O
membrane	O
possibly	O
through	O
an	O
ability	O
to	O
interact	O
with	O
PtdIns(3,4,5)P3	O
.	O

HtrA2	B-DNAMutation
promotes	O
cell	O
death	O
through	O
its	O
serine	O
protease	O
activity	O
and	O
its	O
ability	O
to	O
antagonize	O
inhibitor	O
of	O
apoptosis	O
proteins	O
.	O

Inhibitor	O
of	O
apoptosis	O
(IAP)	O
proteins	O
inhibit	O
caspases	O
,	O
a	O
function	O
counteracted	O
by	O
IAP	O
antagonists	O
,	O
insect	O
Grim	O
,	O
HID	B-DNAMutation
,	O
and	O
Reaper	O
and	O
mammalian	O
DIABLO/Smac	O
.	O

We	O
now	O
demonstrate	O
that	O
HtrA2	B-DNAMutation
,	O
a	O
mammalian	O
homologue	O
of	O
the	O
Escherichia	O
coli	O
heat	O
shock-inducible	O
protein	O
HtrA	O
,	O
can	O
bind	O
to	O
MIHA/XIAP	O
,	O
MIHB	O
,	O
and	O
baculoviral	O
OpIAP	O
but	O
not	O
survivin	O
.	O

Although	O
produced	O
as	O
a	O
50-kDa	O
protein	O
,	O
HtrA2	B-DNAMutation
is	O
processed	O
to	O
yield	O
an	O
active	O
serine	O
protease	O
with	O
an	O
N	O
terminus	O
similar	O
to	O
that	O
of	O
Grim	O
,	O
Reaper	O
,	O
HID	B-DNAMutation
,	O
and	O
DIABLO/Smac	O
that	O
mediates	O
its	O
interaction	O
with	O
XIAP	B-DNAMutation
.	O

HtrA2	B-DNAMutation
is	O
largely	O
membrane-associated	O
in	O
healthy	O
cells	O
,	O
with	O
a	O
significant	O
proportion	O
observed	O
within	O
the	O
mitochondria	O
,	O
but	O
in	O
response	O
to	O
UV	O
irradiation	O
,	O
HtrA2	B-DNAMutation
shifts	O
into	O
the	O
cytosol	O
,	O
where	O
it	O
can	O
interact	O
with	O
IAPs	O
.	O

HtrA2	B-DNAMutation
can	O
,	O
like	O
DIABLO/Smac	O
,	O
prevent	O
XIAP	B-DNAMutation
inhibition	O
of	O
active	O
caspase	B-DNAMutation
3	I-DNAMutation
in	O
vitro	O
and	O
is	O
able	O
to	O
counteract	O
XIAP	B-DNAMutation
protection	O
of	O
mammalian	O
NT2	O
cells	O
against	O
UV-induced	O
cell	O
death	O
.	O

The	O
proapoptotic	O
activity	O
of	O
HtrA2	B-DNAMutation
in	O
vivo	O
involves	O
both	O
IAP	O
binding	O
and	O
serine	O
protease	O
activity	O
.	O

Mutations	B-DNAMutation
of	I-DNAMutation
either	I-DNAMutation
the	I-DNAMutation
N-terminal	I-DNAMutation
alanine	I-DNAMutation
of	O
mature	O
HtrA2	B-DNAMutation
essential	O
for	O
IAP	O
interaction	O
or	B-DNAMutation
the	I-DNAMutation
catalytic	I-DNAMutation
serine	I-DNAMutation
residue	I-DNAMutation
reduces	O
the	O
ability	O
of	O
HtrA2	B-DNAMutation
to	O
promote	O
cell	O
death	O
,	O
whereas	O
a	O
complete	O
loss	O
in	O
proapoptotic	O
activity	O
is	O
observed	O
when	O
both	O
sites	O
are	O
mutated	O
.	O

Carboxy-terminus	O
of	O
CXCR7	B-DNAMutation
regulates	O
receptor	O
localization	O
and	O
function	O
.	O

Chemokine	B-DNAMutation
receptor	I-DNAMutation
CXCR7	B-DNAMutation
is	O
essential	O
for	O
normal	O
development	O
,	O
and	O
this	O
receptor	O
promotes	O
initiation	O
and	O
progression	O
of	O
diseases	O
including	O
cancer	O
and	O
autoimmunity	O
.	O

To	O
understand	O
normal	O
and	O
pathologic	O
functions	O
of	O
CXCR7	B-DNAMutation
and	O
advance	O
development	O
of	O
therapeutic	O
agents	O
,	O
there	O
is	O
a	O
need	O
to	O
define	O
structural	O
domains	O
that	O
regulate	O
this	O
receptor	O
.	O

We	O
generated	O
mutants	O
of	O
CXCR7	B-DNAMutation
with	O
deletion	O
of	O
different	O
lengths	O
of	O
the	O
predicted	O
intracellular	O
tail	O
and	O
analyzed	O
effects	O
on	O
CXCR7	B-DNAMutation
signaling	O
and	O
function	O
in	O
cell-based	O
assays	O
.	O

While	O
wild-type	O
CXCR7	B-DNAMutation
predominantly	O
localized	O
to	O
intracellular	O
vesicles	O
,	O
progressive	O
deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
carboxy	I-DNAMutation
terminus	I-DNAMutation
redistributed	O
the	O
receptor	O
to	O
the	O
plasma	O
membrane	O
.	O

Truncating	O
the	O
intracellular	O
tail	O
of	O
CXCR7	B-DNAMutation
did	O
not	O
alter	O
binding	O
to	O
CXCL12	B-DNAMutation
,	O
but	O
mutant	O
receptors	O
had	O
reduced	O
scavenging	O
of	O
this	O
chemokine	O
.	O

Using	O
a	O
firefly	O
luciferase	O
complementation	O
system	O
,	O
we	O
established	O
that	O
deletions	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
carboxy	I-DNAMutation
terminus	I-DNAMutation
decreased	O
basal	O
interactions	O
and	O
eliminated	O
ligand-dependent	O
recruitment	O
of	O
the	O
scaffolding	O
protein	I-DNAMutation
Î²-arrestin-2	I-DNAMutation
to	O
receptors	O
.	I-DNAMutation
Deleting	I-DNAMutation
the	I-DNAMutation
carboxy	I-DNAMutation
terminus	I-DNAMutation
of	B-DNAMutation
CXCR7	I-DNAMutation
impaired	O
constitutive	O
internalization	O
of	O
the	O
receptor	O
and	O
reduced	O
activation	O
of	B-DNAMutation
ERK1/2	I-DNAMutation
by	B-DNAMutation
CXCL12-CXCR7	I-DNAMutation
.	O

Inhibiting	O
dynamin	O
,	O
a	O
molecule	O
required	O
for	O
internalization	O
of	B-DNAMutation
CXCR7	I-DNAMutation
,	O
increased	O
ligand-dependent	O
association	O
of	O
the	O
receptor	O
with	B-DNAMutation
Î²-arrestin-2	I-DNAMutation
and	O
enhanced	O
activation	O
of	B-DNAMutation
ERK1/2	I-DNAMutation
.	O

These	O
studies	O
establish	O
mechanisms	O
of	O
action	O
for	B-DNAMutation
CXCR7	I-DNAMutation
and	O
establish	O
the	O
intracellular	O
tail	O
of	B-DNAMutation
CXCR7	I-DNAMutation
as	O
a	O
critical	O
determinant	O
of	O
receptor	O
trafficking	O
,	O
chemokine	O
scavenging	O
,	O
and	O
signaling	O
.	O

Effect	O
of	O
Walker	O
A	O
mutation	O
K86M	B-DNAMutation
on	O
oligomerization	O
and	O
surface	O
targeting	O
of	O
the	O
multidrug	O
resistance	O
transporter	O
ABCG2	B-DNAMutation
.	O

The	O
ATP	O
binding	O
cassette	O
(ABC)	O
half-transporter	O
ABCG2	B-DNAMutation
MXR/BCRP/ABCP	B-DNAMutation
is	O
associated	O
with	O
mitoxantrone	O
resistance	O
accompanied	O
by	O
cross-resistance	O
to	O
a	O
broad	O
spectrum	O
of	O
cytotoxic	O
drugs	O
.	O

Here	O
we	O
investigate	O
the	O
functional	O
consequences	O
of	O
mutating	O
a	O
highly	O
conserved	O
lysine	O
in	O
the	O
Walker	O
A	O
motif	O
of	O
the	O
nucleotide	O
binding	O
domain	O
(NBD)	O
known	O
to	O
be	O
critical	O
for	O
ATP	O
binding	O
and/or	O
hydrolysis	O
in	O
ABC	O
transporters	O
.	O

The	O
mutant	O
ABCG2-K86M	B-DNAMutation
was	O
inactive	O
as	O
expected	O
but	O
was	O
expressed	O
at	O
similar	O
levels	O
as	O
the	O
wild-type	O
(wt)	O
protein	O
.	O

The	O
mutation	O
did	O
not	O
affect	O
the	O
predicted	O
oligomerization	O
properties	O
of	O
the	O
transporter	O
;	O
hence	O
,	O
co-immunoprecipitation	O
experiments	O
using	O
differentially	O
tagged	O
transporters	O
showed	O
evidence	O
for	O
oligomerization	O
of	O
both	O
ABCG2-wt	B-DNAMutation
and	O
of	O
ABCG2-wt	B-DNAMutation
with	O
ABCG2-K86M	B-DNAMutation
.	O

We	O
also	O
obtained	O
evidence	O
that	O
both	O
ABCG2-wt	B-DNAMutation
and	O
ABCG2-K86M	B-DNAMutation
exist	O
in	O
the	O
cells	O
as	O
disulfide-linked	O
dimers	O
.	O

Moreover	O
,	O
measurement	O
of	O
prazosin-stimulated	O
ATPase	O
activity	O
revealed	O
a	O
dominant-negative	O
effect	O
of	O
ABCG2-K86M	B-DNAMutation
on	O
ABCG2-wt	B-DNAMutation
function	O
in	O
co-transfected	O
HEK293	O
cells	O
.	O

This	O
is	O
consistent	O
with	O
the	O
requirement	O
for	O
at	O
least	O
two	O
active	O
NBDs	O
for	O
transporter	O
activity	O
and	O
suggests	O
that	O
the	O
transporter	O
is	O
a	O
functional	O
dimer	O
.	O

Finally	O
,	O
we	O
analyzed	O
targeting	O
of	O
ABCG2-wt	B-DNAMutation
and	O
ABCG2-K86M	B-DNAMutation
and	O
observed	O
that	O
they	O
localize	O
to	O
two	O
distinct	O
subcellular	O
compartments	O
:	O
ABCG2-wt	B-DNAMutation
targets	O
the	O
cell	O
surface	O
whereas	O
ABCG2-K86M	B-DNAMutation
is	O
targeted	O
to	O
the	O
Golgi	O
apparatus	O
followed	O
by	O
retrieval	O
to	O
the	O
endoplasmic	O
reticulum	O
.	O

This	O
suggests	O
an	O
as	O
yet	O
unknown	O
role	O
of	O
the	O
NBDs	O
in	O
assisting	O
proper	O
surface	O
targeting	O
of	O
ABC	O
transporters	O
.	O

Histidine-13	O
is	O
a	O
crucial	O
residue	O
in	O
the	O
zinc	O
ion-induced	O
aggregation	O
of	O
the	O
A	B-DNAMutation
beta	I-DNAMutation
peptide	O
of	O
Alzheimer's	O
disease	O
.	O

Metal	O
ions	O
such	O
as	O
Zn(2+)	O
and	O
Cu(2+)	O
have	O
been	O
implicated	O
in	O
both	O
the	O
aggregation	O
and	O
neurotoxicity	O
of	O
the	O
beta-amyloid	O
Abeta	B-DNAMutation
peptide	O
that	O
is	O
present	O
in	O
the	O
brains	O
of	O
Alzheimer's	O
sufferers	O
.	O

Zinc	O
ions	O
in	O
particular	O
have	O
been	O
shown	O
to	O
induce	O
rapid	O
aggregation	O
of	O
Abeta	B-DNAMutation
.	O

Rat	O
Abeta	B-DNAMutation
binds	O
zinc	O
ions	O
much	O
less	O
avidly	O
than	O
human	O
Abeta	B-DNAMutation
,	O
and	O
rats	O
do	O
not	O
form	O
cerebral	O
Abeta	B-DNAMutation
amyloid	O
.	O

Rat	O
Abeta	B-DNAMutation
differs	O
from	O
human	O
Abeta	B-DNAMutation
by	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
Gly	I-DNAMutation
for	I-DNAMutation
Arg	I-DNAMutation
,	I-DNAMutation
Phe	I-DNAMutation
for	I-DNAMutation
Tyr	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Arg	I-DNAMutation
for	I-DNAMutation
His	I-DNAMutation
at	I-DNAMutation
positions	I-DNAMutation
5	I-DNAMutation
,	I-DNAMutation
10	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
13	I-DNAMutation
,	O
respectively	O
.	O

Through	O
the	O
use	O
of	O
synthetic	O
peptides	O
corresponding	O
to	O
the	O
first	O
28	O
residues	O
of	O
human	O
Abeta	B-DNAMutation
,	O
rat	O
Abeta	B-DNAMutation
,	O
and	O
single-residue	O
variations	O
,	O
we	O
use	O
circular	O
dichroism	O
spectroscopy	O
,	O
sedimentation	O
assays	O
,	O
and	O
immobilized	O
metal	O
ion	O
affinity	O
chromatography	O
to	O
show	O
that	O
the	O
substitution	O
of	O
Arg	B-DNAMutation
for	I-DNAMutation
His-13	I-DNAMutation
is	O
responsible	O
for	O
the	O
different	O
Zn(2+)-induced	O
aggregation	O
behavior	O
of	O
rat	O
and	O
human	O
Abeta	B-DNAMutation
.	O

The	O
coordination	O
of	O
Zn(2+)	O
to	O
histidine-13	O
is	O
critical	O
to	O
the	O
zinc	O
ion	O
induced	O
aggregation	O
of	O
Abeta	B-DNAMutation
.	O

2-Methylbutyryl-coenzyme	B-DNAMutation
A	I-DNAMutation
dehydrogenase	I-DNAMutation
deficiency	O
:	O
a	O
new	O
inborn	O
error	O
of	O
L-isoleucine	O
metabolism	O
.	O

An	O
4-mo-old	O
male	O
was	O
found	O
to	O
have	O
an	O
isolated	O
increase	O
in	O
2-methylbutyrylglycine	O
(2-MBG)	O
and	O
2-methylbutyrylcamitine	O
(2-MBC)	O
in	O
physiologic	O
fluids	O
.	O

In	O
vitro	O
oxidation	O
studies	O
in	O
cultured	O
fibroblasts	O
using	O
13C-	O
and	O
14C-labeled	O
branched	O
chain	O
amino	O
acids	O
indicated	O
an	O
isolated	O
block	O
in	O
2-methylbutyryl-CoA	O
dehydrogenase	O
(2-MBCDase)	O
.	O

Western	O
blotting	O
revealed	O
absence	O
of	O
2-MBCDase	O
protein	O
in	O
fibroblast	O
extracts	O
;	O
DNA	O
sequencing	O
identified	O
a	O
single	B-DNAMutation
778	I-DNAMutation
C>T	I-DNAMutation
substitution	I-DNAMutation
in	O
the	O
2-MBCDase	O
coding	O
region	O
(	O
778	B-DNAMutation
C>T	I-DNAMutation
)	O
,	O
substituting	B-DNAMutation
phenylalanine	I-DNAMutation
for	I-DNAMutation
leucine	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
222	I-DNAMutation
L222F	B-DNAMutation
and	O
absence	O
of	O
enzyme	O
activity	O
for	O
the	O
2-MBCDase	O
protein	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

Prenatal	O
diagnosis	O
in	O
a	O
subsequent	O
pregnancy	O
suggested	O
an	O
affected	O
female	O
fetus	O
,	O
supporting	O
an	O
autosomal	O
recessive	O
mode	O
of	O
inheritance	O
.	O

These	O
data	O
confirm	O
the	O
first	O
documented	O
case	O
of	O
isolated	O
2-MBCDase	O
deficiency	O
in	O
humans	O
.	O

Cloning	O
and	O
characterization	O
of	O
ADAM28	B-DNAMutation
:	O
evidence	O
for	O
autocatalytic	O
pro-domain	O
removal	O
and	O
for	O
cell	O
surface	O
localization	O
of	O
mature	O
ADAM28	B-DNAMutation
.	O

The	O
metalloprotease	O
disintegrins	O
are	O
a	O
family	O
of	O
membrane-anchored	O
glycoproteins	O
with	O
diverse	O
functions	O
in	O
fertilization	O
,	O
myoblast	O
fusion	O
,	O
neurogenesis	O
and	O
protein	O
ectodomain	O
shedding	O
.	O

Here	O
we	O
report	O
a	O
cDNA	O
sequence	O
,	O
encoding	O
a	O
metalloprotease	O
disintegrin	O
,	O
termed	O
ADAM28	B-DNAMutation
(	O
'a	B-DNAMutation
disintegrin	I-DNAMutation
and	I-DNAMutation
metalloprotease	I-DNAMutation
28'	I-DNAMutation
)	O
,	O
which	O
was	O
cloned	O
from	O
mouse	O
lung	O
.	O

From	O
protein	O
sequence	O
comparisons	O
,	O
ADAM28	B-DNAMutation
is	O
more	O
closely	O
related	O
to	O
snake	O
venom	O
metalloproteases	O
(SVMPs)	O
than	O
to	O
other	O
ADAMs	O
,	O
and	O
hence	O
may	O
cleave	O
similar	O
substrates	O
to	O
SVMPs	O
,	O
perhaps	O
including	O
components	O
of	O
the	O
extracellular	O
matrix	O
.	O

Northern	O
blot	O
analysis	O
of	O
selected	O
mouse	O
tissues	O
revealed	O
that	O
ADAM28	B-DNAMutation
is	O
expressed	O
highly	O
and	O
in	O
alternatively	O
spliced	O
forms	O
in	O
the	O
epididymis	O
,	O
suggesting	O
a	O
possible	O
role	O
in	O
sperm	O
maturation	O
,	O
and	O
at	O
lower	O
levels	O
in	O
lung	O
.	O

The	O
intracellular	O
maturation	O
of	O
ADAM28	B-DNAMutation
expressed	O
in	O
COS-7	O
cells	O
resembles	O
that	O
of	O
other	O
ADAMs	O
,	O
in	O
that	O
ADAM28	B-DNAMutation
is	O
made	O
as	O
a	O
precursor	O
and	O
processed	O
to	O
a	O
mature	O
form	O
in	O
a	O
late	O
Golgi	O
compartment	O
of	O
the	O
secretory	O
pathway	O
.	O

Most	O
or	O
all	O
of	O
the	O
mature	O
,	O
and	O
thus	O
presumably	O
catalytically	O
active	O
,	O
form	O
of	O
ADAM28	B-DNAMutation
in	O
COS-7	O
cells	O
is	O
accessible	O
to	O
cell	O
surface	O
trypsinization	O
,	O
suggesting	O
that	O
ADAM28	B-DNAMutation
functions	O
mainly	O
on	O
the	O
cell	O
surface	O
.	O

A	O
mutation	O
converting	B-DNAMutation
the	I-DNAMutation
catalytic-site	I-DNAMutation
glutamate	I-DNAMutation
residue	I-DNAMutation
into	I-DNAMutation
alanine	I-DNAMutation
abolishes	O
pro-domain	O
removal	O
,	O
even	O
though	O
this	O
mutant	O
form	O
of	O
ADAM28	B-DNAMutation
can	O
be	O
transported	O
to	O
the	O
cell	O
surface	O
in	O
a	O
manner	O
similar	O
to	O
the	O
wild-type	O
protein	O
.	O

This	O
suggests	O
that	O
pro-domain	O
removal	O
and	O
maturation	O
of	O
ADAM28	B-DNAMutation
may	O
be	O
,	O
at	O
least	O
in	O
part	O
,	O
autocatalytic	O
.	O

This	O
is	O
in	O
contrast	O
with	O
several	O
other	O
ADAMs	O
,	O
for	O
which	O
furin-like	O
proprotein	O
convertases	O
are	O
involved	O
in	O
pro-domain	O
removal	O
,	O
and	O
in	O
which	O
a	O
glutamate-to-alanine	B-DNAMutation
mutation	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
catalytic	I-DNAMutation
site	I-DNAMutation
does	O
not	O
alter	O
pro-domain	O
removal	O
.	O

AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
AMPK	B-DNAMutation
cross-talks	O
with	O
canonical	O
Wnt	O
signaling	O
via	O
phosphorylation	O
of	O
beta-catenin	B-DNAMutation
at	O
Ser	O
552	O
.	O

AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
AMPK	B-DNAMutation
is	O
a	O
key	O
regulator	O
of	O
energy	O
metabolism	O
;	O
its	O
activity	O
is	O
regulated	O
by	O
a	O
plethora	O
of	O
physiological	O
conditions	O
,	O
exercises	O
and	O
many	O
anti-diabetic	O
drugs	O
.	O

Recent	O
studies	O
show	O
that	O
AMPK	B-DNAMutation
involves	O
in	O
cell	O
differentiation	O
but	O
the	O
underlying	O
mechanism	O
remains	O
undefined	O
.	O

Wingless	O
Int-1	O
(Wnt)/beta-catenin	B-DNAMutation
signaling	O
pathway	O
regulates	O
the	O
differentiation	O
of	O
mesenchymal	O
stem	O
cells	O
through	O
enhancing	O
beta-catenin/T-cell	B-DNAMutation
transcription	I-DNAMutation
factor	I-DNAMutation
1	I-DNAMutation
(TCF)	O
mediated	O
transcription	O
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
determine	O
whether	O
AMPK	B-DNAMutation
cross-talks	O
with	O
Wnt/beta-catenin	B-DNAMutation
signaling	O
through	O
phosphorylation	O
of	O
beta-catenin	B-DNAMutation
.	O

C3H10T1/2	O
mesenchymal	O
cells	O
were	O
used	O
.	O

Chemical	O
inhibition	O
of	O
AMPK	B-DNAMutation
and	O
the	O
expression	O
of	O
a	O
dominant	O
negative	O
AMPK	B-DNAMutation
decreased	O
phosphorylation	O
of	O
beta-catenin	B-DNAMutation
at	O
Ser	O
552	O
.	O

The	O
beta-catenin/TCF	B-DNAMutation
mediated	O
transcription	O
was	O
correlated	O
with	O
AMPK	B-DNAMutation
activity	O
.	O

In	O
vitro	O
,	O
pure	O
AMPK	B-DNAMutation
phosphorylated	O
beta-catenin	B-DNAMutation
at	O
Ser	O
552	O
and	O
the	O
mutation	B-DNAMutation
of	I-DNAMutation
Ser	I-DNAMutation
552	I-DNAMutation
to	I-DNAMutation
Ala	I-DNAMutation
prevented	O
such	O
phosphorylation	O
,	O
which	O
was	O
further	O
confirmed	O
using	O
[gamma-(32)P]ATP	O
autoradiography	O
.	O

In	O
conclusion	O
,	O
AMPK	B-DNAMutation
phosphorylates	O
beta-catenin	B-DNAMutation
at	O
Ser	O
552	O
,	O
which	O
stabilizes	O
beta-catenin	B-DNAMutation
,	O
enhances	O
beta-catenin/TCF	B-DNAMutation
mediated	O
transcription	O
,	O
expanding	O
AMPK	B-DNAMutation
from	O
regulation	O
of	O
energy	O
metabolism	O
to	O
cell	O
differentiation	O
and	O
development	O
via	O
cross-talking	O
with	O
the	O
Wnt/beta-catenin	B-DNAMutation
signaling	O
pathway	O
.	O

Identification	O
and	O
expression	O
of	O
eight	O
novel	O
mutations	O
among	O
non-Jewish	O
patients	O
with	O
Canavan	O
disease	O
.	O

Canavan	O
disease	O
is	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
that	O
is	O
caused	O
by	O
the	O
deficiency	O
of	O
aspartoacylase	B-DNAMutation
ASPA	B-DNAMutation
.	O

The	O
majority	O
of	O
patients	O
with	O
Canavan	O
disease	O
are	O
from	O
an	O
Ashkenazi	O
Jewish	O
background	O
.	O

Mutations	O
in	O
ASPA	B-DNAMutation
that	O
lead	O
to	O
loss	O
of	O
enzymatic	O
activity	O
have	O
been	O
identified	O
,	O
and	O
E285A	B-DNAMutation
and	O
Y231X	B-DNAMutation
are	O
the	O
two	O
predominant	O
mutations	O
that	O
account	O
for	O
97%	O
of	O
the	O
mutant	O
chromosomes	O
in	O
Ashkenazi	O
Jewish	O
patients	O
.	O

The	O
current	O
study	O
was	O
aimed	O
at	O
finding	O
the	O
molecular	O
basis	O
of	O
Canavan	O
disease	O
in	O
25	O
independent	O
patients	O
of	O
non-Jewish	O
background	O
.	O

Eight	O
novel	O
and	O
three	O
previously	O
characterized	O
mutations	O
accounted	O
for	O
80%	O
(40/50)	O
of	O
mutant	O
chromosomes	O
.	O

The	O
A305E	B-DNAMutation
missense	O
mutation	O
accounted	O
for	O
48%	O
(24/50)	O
of	O
mutant	O
chromosomes	O
in	O
patients	O
of	O
western	O
European	O
descent	O
,	O
while	O
the	O
two	O
predominant	O
Jewish	O
mutations	O
each	O
accounted	O
for	O
a	O
single	O
mutant	O
chromosome	O
.	O

The	O
eight	O
novel	O
mutations	O
identified	O
included	O
1-	O
and	O
4-bp	B-DNAMutation
deletions	I-DNAMutation
(	I-DNAMutation
32	I-DNAMutation
deltaT	I-DNAMutation
and	O
876	B-DNAMutation
deltaAGAA	I-DNAMutation
,	O
respectively	O
)	O
and	O
I16T	B-DNAMutation
,	O
G27R	B-DNAMutation
,	O
D114E	B-DNAMutation
,	O
G123E	B-DNAMutation
,	O
C152Y	B-DNAMutation
,	O
and	O
R168C	B-DNAMutation
missense	O
mutations	O
.	O

The	O
homozygous	O
32	O
deltaT	B-DNAMutation
deletion	I-DNAMutation
was	O
identified	O
in	O
the	O
only	O
known	O
patient	O
of	O
African-American	O
origin	O
with	O
Canavan	O
disease	O
.	O

The	O
heterozygosity	O
for	O
876	B-DNAMutation
deltaAGAA	I-DNAMutation
mutation	O
was	O
identified	O
in	O
three	O
independent	O
patients	O
from	O
England	O
.	O

Six	O
single-base	O
changes	O
leading	O
to	O
missense	O
mutations	O
were	O
identified	O
in	O
patients	O
from	O
Turkey	O
(	O
D114E	B-DNAMutation
,	O
R168C	B-DNAMutation
)	O
,	O
The	O
Netherlands	O
I16T	B-DNAMutation
,	O
Germany	O
G27R	B-DNAMutation
,	O
Ireland	O
C152Y	B-DNAMutation
,	O
and	O
Canada	O
G123E	B-DNAMutation
.	O

A	O
PCR-based	O
protocol	O
is	O
described	O
that	O
was	O
used	O
to	O
introduce	O
mutations	O
in	O
wild-type	O
cDNA	O
.	O

In	O
vitro	O
expression	O
of	O
mutant	O
cDNA	O
clones	O
demonstrated	O
that	O
all	O
of	O
these	O
mutations	O
led	O
to	O
a	O
deficiency	O
of	O
ASPA	B-DNAMutation
and	O
should	O
therefore	O
result	O
in	O
Canavan	O
disease	O
.	O

Evaluation	O
of	O
the	O
chromosome	O
2q37.3	O
gene	O
CENTG2	B-DNAMutation
as	O
an	O
autism	O
susceptibility	O
gene	O
.	O

Autism	O
is	O
a	O
highly	O
heritable	O
neurodevelopmental	O
syndrome	O
with	O
a	O
complex	O
genetic	O
etiology	O
for	O
which	O
no	O
disease	O
genes	O
have	O
yet	O
been	O
definitively	O
identified	O
.	O

We	O
ascertained	O
three	O
subjects	O
with	O
autism	O
spectrum	O
disorders	O
and	O
chromosome	B-DNAMutation
2q37.3	I-DNAMutation
terminal	I-DNAMutation
deletions	I-DNAMutation
,	O
and	O
refined	O
the	O
deletion	O
breakpoint	O
regions	O
using	O
polymorphism	O
mapping	O
and	O
fluorescence	O
in	O
situ	O
hybridization	O
(FISH)	O
probes	O
.	O

We	O
then	O
genotyped	O
polymorphic	O
markers	O
downstream	O
from	O
the	O
breakpoint	O
region	O
in	O
a	O
sample	O
of	O
autism	O
affected	O
sibling	O
pair	O
families	O
.	O

Both	O
the	O
chromosomal	O
breakpoints	O
and	O
linkage	O
analyses	O
focused	O
our	O
attention	O
on	O
the	O
gene	O
centaurin	B-DNAMutation
gamma-2	I-DNAMutation
CENTG2	B-DNAMutation
,	O
an	O
attractive	O
candidate	O
gene	O
based	O
also	O
on	O
its	O
function	O
and	O
pattern	O
of	O
expression	O
.	O

We	O
therefore	O
assessed	O
CENTG2	B-DNAMutation
for	O
its	O
involvement	O
in	O
autism	O
by	O
(1)	O
screening	O
its	O
exons	O
for	O
variants	O
in	O
199	O
autistic	O
and	O
160	O
non-autistic	O
individuals	O
,	O
and	O
(2)	O
genotyping	O
and	O
assessing	O
intra-genic	O
polymorphisms	O
for	O
linkage	O
and	O
linkage	O
disequilibrium	O
(LD)	O
.	O

The	O
exon	O
screen	O
revealed	O
a	O
Ser	B-DNAMutation
-->	I-DNAMutation
Gly	I-DNAMutation
substitution	O
in	O
one	O
proband	O
,	O
an	O
Arg	B-DNAMutation
-->	I-DNAMutation
Gly	I-DNAMutation
substitution	O
in	O
another	O
,	O
and	O
a	O
number	O
of	O
additional	O
variants	O
unique	O
to	O
the	O
autism	O
families	O
.	O

No	O
unique	O
variants	O
were	O
found	O
in	O
the	O
control	O
subjects	O
.	O

The	O
genotyping	O
produced	O
strong	O
evidence	O
for	O
linkage	O
from	O
two	O
intronic	O
polymorphisms	O
,	O
with	O
a	O
maximum	O
two-point	O
HLOD	O
value	O
of	O
3.96	O
and	O
a	O
posterior	O
probability	O
of	O
linkage	O
(PPL)	O
of	O
51%	O
.	O

These	O
results	O
were	O
contradicted	O
,	O
however	O
,	O
by	O
substantially	O
weaker	O
evidence	O
for	O
linkage	O
from	O
multi-point	O
analyses	O
and	O
by	O
no	O
evidence	O
of	O
LD	O
.	O

We	O
conclude	O
,	O
therefore	O
,	O
that	O
2q37.3	O
continues	O
to	O
be	O
a	O
region	O
of	O
interest	O
for	O
autism	O
susceptibility	O
,	O
and	O
that	O
CENTG2	B-DNAMutation
is	O
an	O
intriguing	O
candidate	O
gene	O
that	O
merits	O
further	O
scrutiny	O
for	O
its	O
role	O
in	O
autism	O
.	O

Sialic	O
acid	O
modification	O
of	O
adiponectin	B-DNAMutation
is	O
not	O
required	O
for	O
multimerization	O
or	O
secretion	O
but	O
determines	O
half-life	O
in	O
circulation	O
.	O

Adiponectin	B-DNAMutation
is	O
an	O
adipocyte-secreted	O
,	O
insulin-sensitizing	O
hormone	O
the	O
circulating	O
levels	O
of	O
which	O
are	O
reduced	O
in	O
conditions	O
of	O
insulin	O
resistance	O
and	O
diabetes	O
.	O

Previous	O
work	O
has	O
demonstrated	O
the	O
importance	O
of	O
posttranslational	O
modifications	O
,	O
such	O
as	O
proline	O
hydroxylation	O
and	O
lysine	O
hydroxylation/glycosylation	O
,	O
in	O
adiponectin	B-DNAMutation
oligomerization	O
,	O
secretion	O
,	O
and	O
function	O
.	O

Here	O
we	O
describe	O
the	O
first	O
functional	O
characterization	O
of	O
adiponectin	B-DNAMutation
sialylation	O
.	O

Using	O
a	O
variety	O
of	O
biochemical	O
approaches	O
we	O
demonstrated	O
that	O
sialylation	O
occurs	O
on	O
previously	O
unidentified	O
O-linked	O
glycans	O
on	O
Thr	O
residues	O
of	O
the	O
variable	O
domain	O
in	O
human	O
adiponectin	B-DNAMutation
.	O

Enzymatic	O
removal	O
of	O
sialic	O
acid	O
or	O
its	O
underlying	O
O-linked	O
sugars	O
did	O
not	O
affect	O
adiponectin	B-DNAMutation
multimer	O
composition	O
.	O

Expression	O
of	O
mutant	O
forms	O
of	O
adiponectin	B-DNAMutation
(	O
lacking	O
the	O
modified	O
Thr	O
residues	O
)	O
or	O
of	O
wild-type	O
adiponectin	B-DNAMutation
in	O
cells	O
defective	O
in	O
sialylation	O
did	O
not	O
compromise	O
multimer	O
formation	O
or	O
secretion	O
,	O
arguing	O
against	O
a	O
structural	O
role	O
for	O
this	O
modification	O
.	O

Activity	O
of	O
desialylated	O
adiponectin	B-DNAMutation
was	O
comparable	O
to	O
control	O
adiponectin	B-DNAMutation
in	O
L6	O
myotubes	O
and	O
acute	O
assays	O
in	O
adiponectin(-/-)	B-DNAMutation
mice	O
.	O

In	O
contrast	O
,	O
plasma	O
clearance	O
of	O
desialylated	O
adiponectin	B-DNAMutation
was	O
accelerated	O
compared	O
with	O
that	O
of	O
control	O
adiponectin	B-DNAMutation
,	O
implicating	O
a	O
role	O
for	O
this	O
modification	O
in	O
determining	O
the	O
half-life	O
of	O
circulating	O
adiponectin	B-DNAMutation
.	O

Uptake	O
of	O
desialylated	O
adiponectin	B-DNAMutation
by	O
isolated	O
primary	O
rat	O
hepatocytes	O
was	O
also	O
accelerated	O
,	O
suggesting	O
a	O
role	O
for	O
the	O
hepatic	O
asialoglycoprotein	O
receptor	O
.	O

Finally	O
,	O
after	O
chronic	O
administration	O
in	O
adiponectin(-/-)	B-DNAMutation
mice	O
steady-state	O
levels	O
of	O
desialylated	O
adiponectin	B-DNAMutation
were	O
lower	O
than	O
control	O
adiponectin	B-DNAMutation
and	O
failed	O
to	O
recapitulate	O
the	O
improvements	O
in	O
glucose	O
and	O
insulin	O
tolerance	O
tests	O
observed	O
with	O
control	O
adiponectin	B-DNAMutation
.	O

These	O
data	O
suggest	O
an	O
important	O
role	O
for	O
sialic	O
acid	O
content	O
in	O
the	O
regulation	O
of	O
circulating	O
adiponectin	B-DNAMutation
levels	O
and	O
highlight	O
the	O
importance	O
of	O
understanding	O
mechanisms	O
regulating	O
adiponectin	B-DNAMutation
sialylation/desialylation	O
.	O

Localization	O
of	O
the	O
cAMP-dependent	O
protein	O
kinase	O
to	O
the	O
postsynaptic	O
densities	O
by	O
A-kinase	O
anchoring	O
proteins	O
.	O

Characterization	O
of	O
AKAP	O
79	O
.	O

Postsynaptic	O
densities	O
(PSD)	O
are	O
a	O
network	O
of	O
proteins	O
located	O
on	O
the	O
internal	O
surface	O
of	O
excitatory	O
synapses	O
just	O
inside	O
the	O
postsynaptic	O
membrane	O
.	O

Enzymes	O
associated	O
with	O
the	O
PSD	O
are	O
optimally	O
positioned	O
to	O
respond	O
to	O
signals	O
transduced	O
across	O
the	O
postsynaptic	O
membrane	O
resulting	O
from	O
excitatory	O
synaptic	O
transmission	O
or	O
neurotransmitter	O
release	O
.	O

We	O
present	O
evidence	O
suggesting	O
that	O
type	O
II	O
cAMP-dependent	O
protein	O
kinase	O
(PKA)	O
is	O
anchored	O
to	O
the	O
PSD	O
through	O
interaction	O
of	O
its	O
regulatory	O
subunit	O
(RII)	O
with	O
an	O
A-Kinase	O
Anchor	O
Protein	O
(AKAPs)	O
.	O

A	O
cDNA	O
for	O
the	O
human	O
RII-anchoring	O
protein	O
,	O
AKAP	B-DNAMutation
79	I-DNAMutation
,	O
was	O
isolated	O
by	O
screening	O
an	O
expression	O
library	O
with	O
radiolabeled	O
RII	O
.	O

This	O
cDNA	O
(	O
2621	O
base	O
pairs	O
)	O
encodes	O
a	O
protein	O
of	O
427	O
amino	O
acids	O
with	O
76%	O
identity	O
to	O
bovine	O
brain	O
AKAP	B-DNAMutation
75	I-DNAMutation
and	O
93%	O
identity	O
to	O
a	O
carboxyl-terminal	O
RII-binding	O
fragment	O
of	O
murine	O
brain	O
AKAP	B-DNAMutation
150	I-DNAMutation
.	O

A	O
bacterially	O
expressed	O
92-amino	O
acid	O
fragment	O
,	O
AKAP	O
79	O
(335-427)	O
was	O
able	O
to	O
bind	O
RII	B-DNAMutation
alpha	I-DNAMutation
.	O

Disruption	O
of	O
secondary	O
structure	O
by	O
site-directed	B-DNAMutation
mutagenesis	I-DNAMutation
at	I-DNAMutation
selected	I-DNAMutation
residues	I-DNAMutation
within	I-DNAMutation
a	I-DNAMutation
putative	I-DNAMutation
acidic	I-DNAMutation
amphipathic	I-DNAMutation
helix	I-DNAMutation
located	I-DNAMutation
between	I-DNAMutation
residues	I-DNAMutation
392	I-DNAMutation
and	I-DNAMutation
408	I-DNAMutation
prevented	O
RII	O
binding	O
.	O

Immunological	O
studies	O
demonstrate	O
that	O
AKAP	O
79	O
is	O
predominantly	O
expressed	O
in	O
the	O
cerebral	O
cortex	O
and	O
is	O
a	O
component	O
of	O
fractions	O
enriched	O
for	O
postsynaptic	O
densities	O
.	O

AKAP	O
antisera	O
strongly	O
cross-react	O
with	O
a	O
150-kDa	O
protein	O
in	O
murine	O
PSD	O
believed	O
to	O
be	O
AKAP	B-DNAMutation
150	I-DNAMutation
.	O

Co-localization	O
of	O
the	O
type	O
II	O
PKA	O
in	O
purified	O
PSD	O
fractions	O
was	O
confirmed	O
immunologically	O
by	O
detection	O
of	O
RII	O
and	O
enzymologically	O
by	O
measuring	O
cAMP-stimulated	O
phosphorylation	O
of	O
the	O
heptapeptide	O
substrate	O
Kemptide	O
.	O

Approximately	O
30%	O
of	O
the	O
PSD	O
kinase	O
activity	O
was	O
specifically	O
inhibited	O
by	O
PKI	O
5-24	O
peptide	O
,	O
a	O
highly	O
specific	O
inhibitor	O
of	O
PKA	O
.	O

We	O
propose	O
that	O
AKAP	O
79	O
and	O
AKAP	B-DNAMutation
150	I-DNAMutation
function	O
to	O
anchor	O
the	O
type	O
II	O
PKA	O
to	O
the	O
PSD	O
,	O
presumably	O
for	O
a	O
role	O
in	O
the	O
regulation	O
of	O
postsynaptic	O
events	O
.	O

A	O
novel	O
mutation	O
of	O
CHRNA4	O
responsible	O
for	O
autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
.	O

OBJECTIVE	O
:	O
To	O
identify	O
the	O
mutation	O
responsible	O
for	O
autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
(ADNFLE)	O
in	O
a	O
nonwhite	O
family	O
.	O

BACKGROUND	O
:	O
ADNFLE	O
is	O
newly	O
recognized	O
as	O
an	O
entity	O
of	O
idiopathic	O
partial	O
epilepsy	O
.	O

Recently	O
,	O
two	O
different	O
mutations	O
of	O
the	O
neuronal	O
nicotinic	O
acetylcholine	O
receptor	O
alpha4	O
subunit	O
(CHRNA4)	O
gene	O
were	O
identified	O
in	O
a	O
white	O
family	O
as	O
a	O
cause	O
of	O
ADNFLE	O
.	O

METHODS	O
:	O
Four	O
affected	O
and	O
three	O
unaffected	O
individuals	O
in	O
three	O
generations	O
of	O
a	O
Japanese	O
family	O
with	O
ADNFLE	O
,	O
and	O
100	O
unrelated	O
healthy	O
Japanese	O
volunteers	O
were	O
studied	O
.	O

Clinical	O
features	O
and	O
EEG	O
findings	O
in	O
affected	O
individuals	O
were	O
consistent	O
with	O
those	O
of	O
ADNFLE	O
reported	O
in	O
white	O
families	O
with	O
ADNFLE	O
.	O

Mutations	O
within	O
the	O
CHRNA4	O
gene	O
were	O
screened	O
for	O
using	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
(SSCA)	O
and	O
were	O
determined	O
by	O
direct	O
sequencing	O
.	O

The	O
mutation	O
identified	O
was	O
sought	O
in	O
volunteers	O
by	O
the	O
amplification	O
refractory	O
mutation	O
system	O
.	O

RESULTS	O
:	O
A	O
C-to-T	B-DNAMutation
exchange	I-DNAMutation
(C755T)	I-DNAMutation
was	I-DNAMutation
found	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
5	I-DNAMutation
of	O
the	O
CHRNA4	O
gene	O
on	O
one	O
allele	O
of	O
affected	O
individuals	O
.	O

C755T	B-DNAMutation
segregated	O
in	O
affected	O
individuals	O
and	O
was	O
not	O
found	O
in	O
200	O
alleles	O
obtained	O
from	O
the	O
volunteers	O
.	O

C755T	B-DNAMutation
replaced	I-DNAMutation
serine	I-DNAMutation
252	I-DNAMutation
(Ser252)	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
second	I-DNAMutation
membrane-spanning	I-DNAMutation
domain	I-DNAMutation
(M2)	I-DNAMutation
of	I-DNAMutation
CHRNA4	I-DNAMutation
with	I-DNAMutation
a	I-DNAMutation
leucine	I-DNAMutation
.	O

Ser252	O
is	O
conserved	O
characteristically	O
in	O
the	O
alpha-subunit	O
of	O
acetylcholine	O
receptor	O
and	O
is	O
considered	O
to	O
play	O
an	O
important	O
role	O
in	O
channel	O
function	O
.	O

CONCLUSION	O
:	O
C755T	B-DNAMutation
is	O
a	O
novel	O
missense	O
mutation	O
of	O
the	O
CHRNA4	O
gene	O
causing	O
autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
in	O
this	O
Japanese	O
family	O
.	O

Switch	O
of	O
coenzyme	O
specificity	O
of	O
mouse	O
lung	O
carbonyl	O
reductase	O
by	O
substitution	O
of	O
threonine	B-DNAMutation
38	I-DNAMutation
with	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
.	O

Mouse	O
lung	O
carbonyl	O
reductase	O
,	O
a	O
member	O
of	O
the	O
short-chain	O
dehydrogenase/reductase	O
(SDR)	O
family	O
,	O
exhibits	O
coenzyme	O
specificity	O
for	O
NADP(H)	O
over	O
NAD(H)	O
.	O

Crystal	O
structure	O
of	O
the	O
enzyme-NADPH	B-DNAMutation
complex	O
shows	O
that	O
Thr-38	O
interacts	O
with	O
the	O
2'-phosphate	O
of	O
NADPH	B-DNAMutation
and	O
occupies	O
the	O
position	O
spatially	O
similar	O
to	O
an	O
Asp	O
residue	O
of	O
the	O
NAD(H)-dependent	O
SDRs	O
that	O
hydrogen-bonds	O
to	O
the	O
hydroxyl	O
groups	O
of	O
the	O
adenine	O
ribose	O
of	O
the	O
coenzymes	O
.	O

Using	O
site-directed	O
mutagenesis	O
,	O
we	O
constructed	O
a	O
mutant	O
mouse	O
lung	O
carbonyl	O
reductase	O
in	O
which	O
Thr-38	B-DNAMutation
was	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
Asp	I-DNAMutation
T38D	B-DNAMutation
,	O
and	O
we	O
compared	O
kinetic	O
properties	O
of	O
the	O
mutant	O
and	O
wild-type	O
enzymes	O
in	O
both	O
forward	O
and	O
reverse	O
reactions	O
.	O

The	O
mutation	O
resulted	O
in	O
increases	O
of	O
more	O
than	O
200-fold	O
in	O
the	O
Km	O
values	O
for	O
NADP(H)	O
and	O
decreases	O
of	O
more	O
than	O
7-fold	O
in	O
those	O
for	O
NAD(H)	O
,	O
but	O
few	O
changes	O
in	O
the	O
Km	O
values	O
for	O
substrates	O
or	O
in	O
the	O
kcat	O
values	O
of	O
the	O
reactions	O
.	O

NAD(H)	O
provided	O
maximal	O
protection	O
against	O
thermal	O
and	O
urea	O
denaturation	O
of	O
T38D	B-DNAMutation
,	O
in	O
contrast	O
to	O
the	O
effective	O
protection	O
by	O
NADP(H)	O
for	O
the	O
wild-type	O
enzyme	O
.	O

Thus	O
,	O
the	O
single	O
mutation	O
converted	O
the	O
coenzyme	O
specificity	O
from	O
NADP(H)	O
to	O
NAD(H)	O
.	O

Calculation	O
of	O
free	O
energy	O
changes	O
showed	O
that	O
the	O
2'-phosphate	O
of	O
NADP(H)	O
contributes	O
to	O
its	O
interaction	O
with	O
the	O
wild-type	O
enzyme	O
.	O

Changing	O
Thr-38	B-DNAMutation
to	I-DNAMutation
Asp	I-DNAMutation
destabilized	O
the	O
binding	O
energies	O
of	O
NADP(H)	O
by	O
3.9-4.5	O
kcal/mol	O
and	O
stabilized	O
those	O
of	O
NAD(H)	O
by	O
1.2-1.4	O
kcal/mol	O
.	O

These	O
results	O
indicate	O
a	O
significant	O
role	O
of	O
Thr-38	O
in	O
NADP(H)	O
binding	O
for	O
the	O
mouse	O
lung	O
enzyme	O
and	O
provide	O
further	O
evidence	O
for	O
the	O
key	O
role	O
of	O
Asp	O
at	O
this	O
position	O
in	O
NAD(H)	O
specificity	O
of	O
the	O
SDR	O
family	O
proteins	O
.	O

Identification	O
of	O
human	O
phosphoglucomutase	B-DNAMutation
3	I-DNAMutation
PGM3	B-DNAMutation
as	O
N-acetylglucosamine-phosphate	O
mutase	O
AGM1	B-DNAMutation
.	O

We	O
performed	O
phenotyping	O
of	O
human	O
phosphoglucomutase	B-DNAMutation
3	I-DNAMutation
PGM(3)	B-DNAMutation
and	O
screening	O
for	O
mutations	O
in	O
the	O
human	O
N-acetylglucosamine-phosphate	O
mutase	O
gene	O
AGM(1)	B-DNAMutation
to	O
identify	O
PGM(3)	B-DNAMutation
as	O
AGM(1)	B-DNAMutation
.	O

By	O
sequencing	O
the	O
coding	O
region	O
of	O
AGM(1)	B-DNAMutation
,	O
two	O
alleles	O
containing	O
a	O
G	B-DNAMutation
or	I-DNAMutation
A	I-DNAMutation
base	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
1396	I-DNAMutation
,	O
that	O
can	O
respectively	O
encode	O
aspartic	B-DNAMutation
acid	I-DNAMutation
or	I-DNAMutation
asparagine	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
466	I-DNAMutation
,	O
were	O
identified	O
.	O

Cell	O
extracts	O
of	O
COS7	O
cells	O
after	O
transfection	O
with	O
the	O
pcDNA	O
3.1(+)	O
plasmid	O
containing	O
an	O
AGM(1)	B-DNAMutation
allele	O
with	O
1396G	B-DNAMutation
or	I-DNAMutation
1396A	I-DNAMutation
showed	O
similar	O
electrophoretic	O
patterns	O
to	O
the	O
PGM(3)	B-DNAMutation
1	O
or	O
PGM(3)	B-DNAMutation
2	O
protein	O
,	O
respectively	O
,	O
with	O
the	O
isozyme	O
detection	O
method	O
used	O
for	O
PGM(3)	B-DNAMutation
phenotyping	O
.	O

The	O
genotypes	O
determined	O
by	O
the	O
two	O
alleles	O
of	O
AGM(1)	B-DNAMutation
coincided	O
exactly	O
with	O
the	O
PGM(3)	B-DNAMutation
phenotypes	O
in	O
20	O
individuals	O
.	O

We	O
also	O
investigated	O
the	O
allele	O
frequency	O
of	O
the	O
AGM(1)	B-DNAMutation
nucleotide	O
polymorphism	O
in	O
a	O
Japanese	O
population	O
by	O
DNA	O
sequencing	O
and	O
found	O
that	O
the	O
frequencies	O
of	O
alleles	O
1396G	O
and	O
1396A	O
were	O
similar	O
to	O
previously	O
reported	O
PGM(3)	B-DNAMutation
*1	O
and	O
PGM(3)	B-DNAMutation
*2	O
frequencies	O
.	O

Overall	O
,	O
the	O
facts	O
that	O
the	O
AGM(1)	B-DNAMutation
gene	O
product	O
shows	O
PGM	O
activity	O
,	O
AGM(1)	B-DNAMutation
is	O
polymorphic	O
,	O
the	O
electrophoretic	O
mobility	O
is	O
similar	O
between	O
AGM(1)	B-DNAMutation
allele-specific	O
products	O
and	O
PGM(3)	B-DNAMutation
1	I-DNAMutation
and	I-DNAMutation
2	I-DNAMutation
proteins	O
,	O
PGM(3)	B-DNAMutation
phenotypes	O
and	O
AGM(1)	B-DNAMutation
genotypes	O
completely	O
coincide	O
in	O
20	O
individuals	O
,	O
and	O
AGM(1)	B-DNAMutation
allele	O
frequencies	O
are	O
similar	O
to	O
those	O
of	O
PGM(3)	B-DNAMutation
*1	O
and	O
PGM(3)	B-DNAMutation
*2	O
in	O
Japanese	O
populations	O
,	O
suggest	O
that	O
PGM(3)	B-DNAMutation
is	O
identical	O
to	O
AGM(1)	B-DNAMutation
.	O

Positional	O
cloning	O
of	O
the	O
APECED	B-DNAMutation
gene	O
.	O

Autoimmune	O
polyglandular	O
syndrome	O
type	O
I	O
(	O
APS	B-DNAMutation
1	I-DNAMutation
,	O
also	O
called	O
APECED	B-DNAMutation
)	O
is	O
an	O
autosomal-recessive	O
disorder	O
that	O
maps	O
to	O
human	O
chromosome	O
21q22.3	O
between	O
markers	O
D21S49	B-DNAMutation
and	O
D21S171	B-DNAMutation
by	O
linkage	O
studies	O
.	O

We	O
have	O
isolated	O
a	O
novel	O
gene	O
from	O
this	O
region	O
,	O
AIRE	B-DNAMutation
(	O
autoimmune	B-DNAMutation
regulator	I-DNAMutation
)	O
,	O
which	O
encodes	O
a	O
protein	O
containing	O
motifs	O
suggestive	O
of	O
a	O
transcription	O
factor	O
including	O
two	O
zinc-finger	O
(PHD-finger)	O
motifs	O
,	O
a	O
proline-rich	O
region	O
and	O
three	O
LXXLL	O
motifs	O
.	O

Two	O
mutations	O
,	O
a	O
C-->T	B-DNAMutation
substitution	I-DNAMutation
that	O
changes	O
the	O
Arg	B-DNAMutation
257	I-DNAMutation
(CGA)	I-DNAMutation
to	I-DNAMutation
a	I-DNAMutation
stop	I-DNAMutation
codon	I-DNAMutation
(TGA)	I-DNAMutation
and	O
an	O
A-->G	B-DNAMutation
substitution	I-DNAMutation
that	O
changes	O
the	O
Lys	B-DNAMutation
83	I-DNAMutation
(AAG)	I-DNAMutation
to	I-DNAMutation
a	I-DNAMutation
Glu	I-DNAMutation
codon	I-DNAMutation
(GAG)	I-DNAMutation
,	O
were	O
found	O
in	O
this	O
novel	O
gene	O
in	O
Swiss	O
and	O
Finnish	O
APECED	B-DNAMutation
patients	O
.	O

The	O
Arg257stop	B-DNAMutation
R257X	B-DNAMutation
is	O
the	O
predominant	O
mutation	O
in	O
Finnish	O
APECED	B-DNAMutation
patients	O
,	O
accounting	O
for	O
10/12	O
alleles	O
studied	O
.	O

These	O
results	O
indicate	O
that	O
this	O
gene	O
is	O
responsible	O
for	O
the	O
pathogenesis	O
of	O
APECED	B-DNAMutation
.	O

The	O
identification	O
of	O
the	O
gene	O
defective	O
in	O
APECED	B-DNAMutation
should	O
facilitate	O
the	O
genetic	O
diagnosis	O
and	O
potential	O
treatment	O
of	O
the	O
disease	O
and	O
further	O
enhance	O
our	O
general	O
understanding	O
of	O
the	O
mechanisms	O
underlying	O
autoimmune	O
diseases	O
.	O

Tyrosines	O
868	O
,	O
966	O
,	O
and	O
972	O
in	O
the	O
kinase	O
domain	O
of	O
JAK2	B-DNAMutation
are	O
autophosphorylated	O
and	O
required	O
for	O
maximal	O
JAK2	B-DNAMutation
kinase	O
activity	O
.	O

Janus	B-DNAMutation
kinase	I-DNAMutation
2	I-DNAMutation
JAK2	B-DNAMutation
is	O
activated	O
by	O
a	O
majority	O
of	O
cytokine	O
family	O
receptors	O
including	O
receptors	O
for	O
GH	O
,	O
leptin	O
,	O
and	O
erythropoietin	B-DNAMutation
.	O

To	O
identify	O
novel	O
JAK2-regulatory	O
and/or	O
-binding	O
sites	O
,	O
we	O
set	O
out	O
to	O
identify	O
autophosphorylation	O
sites	O
in	O
the	O
kinase	O
domain	O
of	O
JAK2	B-DNAMutation
.	O

Two-dimensional	O
phosphopeptide	O
mapping	O
of	O
in	O
vitro	O
autophosphorylated	O
JAK2	B-DNAMutation
identified	O
tyrosines	O
868	O
,	O
966	O
,	O
and	O
972	O
as	O
sites	O
of	O
autophosphorylation	O
.	O

Phosphorylated	O
tyrosines	O
868	O
and	O
972	O
were	O
also	O
identified	O
by	O
mass	O
spectrometry	O
analysis	O
of	O
JAK2	B-DNAMutation
activated	O
by	O
an	O
erythropoietin-bound	O
chimeric	O
erythropoietin	O
receptor/leptin	B-DNAMutation
receptor	I-DNAMutation
.	O

Phosphospecific	O
antibodies	O
suggest	O
that	O
the	O
phosphorylation	O
of	O
all	O
three	O
tyrosines	O
increases	O
in	O
response	O
to	O
GH	O
.	O

Compared	O
with	O
wild-type	O
JAK2	B-DNAMutation
,	O
which	O
is	O
constitutively	O
active	O
when	O
overexpressed	O
,	O
JAK2	B-DNAMutation
lacking	B-DNAMutation
tyrosine	I-DNAMutation
868	I-DNAMutation
,	I-DNAMutation
966	I-DNAMutation
,	I-DNAMutation
or	I-DNAMutation
972	I-DNAMutation
has	O
substantially	O
reduced	O
activity	O
.	O

Coexpression	O
with	O
GH	B-DNAMutation
receptor	I-DNAMutation
and	O
protein	O
tyrosine	O
phosphatase1B	O
allowed	O
us	O
to	O
investigate	O
GH-dependent	O
activation	O
of	O
these	O
mutated	O
JAK2s	O
in	O
human	O
embryonic	O
kidney	O
293T	O
cells	O
.	O

All	O
three	O
mutated	O
JAK2s	O
are	O
activated	O
by	O
GH	O
,	O
although	O
to	O
a	O
lesser	O
extent	O
than	O
wild-type	O
JAK2	B-DNAMutation
.	O

The	O
three	O
mutated	O
JAK2s	O
also	O
mediate	O
GH	O
activation	O
of	O
signal	B-DNAMutation
transducer	I-DNAMutation
and	I-DNAMutation
activator	I-DNAMutation
of	I-DNAMutation
transcription	I-DNAMutation
3	I-DNAMutation
Stat3	B-DNAMutation
,	O
signal	B-DNAMutation
transducer	I-DNAMutation
and	I-DNAMutation
activator	I-DNAMutation
of	I-DNAMutation
transcription	I-DNAMutation
5b	I-DNAMutation
Stat5b	B-DNAMutation
and	O
ERK1	B-DNAMutation
,	O
but	O
at	O
reduced	O
levels	O
.	O

Coexpression	O
with	O
Src-homology	O
2B1beta	O
(SH2B1beta)	O
,	O
like	O
coexpression	O
with	O
GH-bound	O
GH	B-DNAMutation
receptor	I-DNAMutation
,	O
partially	O
restores	O
the	O
activity	O
of	O
all	O
three	O
JAK2	B-DNAMutation
mutants	O
.	O

Based	O
on	O
these	O
results	O
and	O
the	O
crystal	O
structure	O
of	O
the	O
JAK2	O
kinase	O
domain	O
,	O
we	O
hypothesize	O
that	O
small	O
changes	O
in	O
the	O
conformation	O
of	O
the	O
regions	O
of	O
JAK2	B-DNAMutation
surrounding	O
tyrosines	O
868	O
,	O
966	O
,	O
and	O
972	O
due	O
to	O
e.g	O
.	O

phosphorylation	O
,	O
binding	O
to	O
a	O
ligand-bound	O
cytokine	O
receptor	O
,	O
and/or	O
binding	O
to	O
Src-homology	O
2B1	O
,	O
may	O
be	O
essential	O
for	O
JAK2	B-DNAMutation
to	O
assume	O
a	O
maximally	O
active	O
conformation	O
.	O

Characterization	O
of	O
the	O
molecular	O
basis	O
of	O
the	O
alpha	O
1-antitrypsin	O
F	O
allele	O
.	O

alpha	O
1-Antitrypsin	O
(	O
alpha	B-DNAMutation
1AT	I-DNAMutation
)	O
,	O
the	O
major	O
serum	O
inhibitor	O
of	O
neutrophil	O
elastase	O
,	O
is	O
a	O
highly	O
polymorphic	O
serum	O
protein	O
associated	O
with	O
characteristic	O
isoelectric-focusing	O
(IEF)	O
patterns	O
for	O
most	O
variants	O
.	O

To	O
characterize	O
the	O
molecular	O
basis	O
of	O
the	O
anodal	O
F	O
variant	O
,	O
the	O
DNA	O
sequence	O
of	O
the	O
coding	O
exons	O
of	O
an	O
FZ	O
individual	O
was	O
determined	O
.	O

The	O
F	O
allele	O
differed	O
from	O
the	O
normal	O
M1(Val213)	B-DNAMutation
alpha	I-DNAMutation
1AT	I-DNAMutation
allele	I-DNAMutation
by	I-DNAMutation
a	I-DNAMutation
single	I-DNAMutation
nucleotide	I-DNAMutation
transversion	I-DNAMutation
of	I-DNAMutation
cytosine	I-DNAMutation
to	I-DNAMutation
thymidine	I-DNAMutation
,	O
which	O
results	O
in	O
the	O
amino	O
acid	O
substitution	O
Arg223	B-DNAMutation
CGT----Cys	I-DNAMutation
TGT	I-DNAMutation
.	O

Inheritance	O
of	O
the	O
F	O
mutation	O
was	O
confirmed	O
by	O
family	O
analysis	O
using	O
allele-specific	O
amplification	O
.	O

In	O
the	O
context	O
that	O
the	O
normal	O
alpha	B-DNAMutation
1AT	I-DNAMutation
molecule	O
has	O
only	O
one	O
cysteine	O
residue	O
,	O
a	O
mutation	O
resulting	O
in	O
the	O
addition	O
of	O
a	O
second	O
cysteine	O
may	O
influence	O
the	O
three-dimensional	O
form	O
of	O
the	O
protein	O
and/or	O
permit	O
interaction	O
with	O
other	O
plasma	O
proteins	O
with	O
free-SH	O
groups	O
and	O
may	O
be	O
responsible	O
for	O
the	O
observation	O
that	O
the	O
major	O
F	O
alpha	B-DNAMutation
1AT	I-DNAMutation
bands	O
often	O
migrate	O
as	O
doublets	O
in	O
IEF	O
gels	O
.	O

The	O
second	O
C2-domain	O
of	O
copine-2	B-DNAMutation
,	O
copine-6	B-DNAMutation
and	O
copine-7	B-DNAMutation
is	O
responsible	O
for	O
their	O
calcium-dependent	O
membrane	O
association	O
.	O

The	O
copine	O
family	O
of	O
proteins	O
contains	O
nine	O
members	O
with	O
a	O
similar	O
domain	O
structure	O
,	O
namely	O
two	O
N-terminal	O
C2-domains	O
(	O
C2A	O
and	O
C2B	B-DNAMutation
)	O
and	O
a	O
C-terminal	O
A-domain	O
.	O

The	O
former	O
are	O
thought	O
to	O
be	O
responsible	O
for	O
binding	O
to	O
the	O
inner	O
face	O
of	O
the	O
plasma	O
membrane	O
following	O
increases	O
in	O
intracellular	O
calcium	O
levels	O
,	O
whereas	O
the	O
A-domain	O
has	O
been	O
suggested	O
to	O
be	O
a	O
protein-binding	O
structure	O
.	O

In	O
this	O
study	O
,	O
we	O
examined	O
the	O
effects	O
of	O
mutagenesis	O
of	O
selected	O
residues	O
in	O
the	O
linker	O
area	O
between	O
the	O
C2-domains	O
and	O
the	O
A-domain	O
,	O
and	O
mutagenesis	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
aspartates	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
C2-domains	I-DNAMutation
,	O
which	O
are	O
predicted	O
to	O
bind	O
calcium	O
and	O
promote	O
membrane	O
association	O
of	O
the	O
copines	O
.	O

We	O
found	O
that	O
Lys282-Lys284	O
of	O
the	O
linker	O
area	O
are	O
important	O
for	O
the	O
folding	O
of	O
the	O
intact	O
protein	O
.	O

We	O
showed	O
that	O
substitution	B-DNAMutation
with	I-DNAMutation
asparagine	I-DNAMutation
,	I-DNAMutation
single	I-DNAMutation
or	I-DNAMutation
multiple	I-DNAMutation
,	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
aspartates	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
C2A-domain	I-DNAMutation
had	O
no	O
effect	O
on	O
the	O
calcium-mediated	O
membrane	O
association	O
of	O
copine-2	B-DNAMutation
,	O
copine-6	B-DNAMutation
,	O
or	O
copine-7	B-DNAMutation
.	O

Similar	O
mutagenesis	O
of	O
a	O
single	O
residue	O
in	O
the	O
C2B-domain	O
of	O
copine-6	B-DNAMutation
(	O
but	O
not	O
copine-2	B-DNAMutation
and	O
copine-7	B-DNAMutation
)	O
was	O
sufficient	O
to	O
eliminate	O
its	O
calcium-mediated	O
membrane	O
binding	O
,	O
and	O
simultaneous	O
substitution	B-DNAMutation
of	I-DNAMutation
all	I-DNAMutation
four	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
asparagines	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
C2B-domain	I-DNAMutation
resulted	O
in	O
constitutive	O
membrane	O
association	O
of	O
copine-2	B-DNAMutation
,	O
copine-6	B-DNAMutation
and	O
copine-7	B-DNAMutation
with	O
the	O
plasma	O
membrane	O
.	O

These	O
data	O
show	O
that	O
the	O
C2B-domains	O
of	O
copine-2	B-DNAMutation
,	O
copine-6	B-DNAMutation
and	O
copine-7	B-DNAMutation
are	O
the	O
domains	O
responsible	O
for	O
the	O
protein	O
calcium-dependent	O
membrane	O
association	O
.	O

A	O
novel	O
mutation	O
in	O
the	O
ABCR	B-DNAMutation
gene	O
in	O
four	O
patients	O
with	O
autosomal	O
recessive	O
Stargardt	O
disease	O
.	O

PURPOSE	O
:	O
To	O
identify	O
additional	O
mutations	O
in	O
the	O
ABCR	B-DNAMutation
gene	O
and	O
describe	O
the	O
clinical	O
features	O
of	O
four	O
affected	O
siblings	O
with	O
autosomal	O
recessive	O
Stargardt	O
disease	O
.	O

METHODS	O
:	O
A	O
cohort	O
of	O
eight	O
siblings	O
was	O
identified	O
for	O
study	O
.	O

Four	O
of	O
these	O
individuals	O
were	O
diagnosed	O
with	O
Stargardt	O
disease	O
based	O
on	O
clinical	O
evaluation	O
and	O
fluorescein	O
angiography	O
.	O

Blood	O
samples	O
were	O
obtained	O
from	O
seven	O
of	O
eight	O
siblings	O
,	O
including	O
all	O
those	O
affected	O
.	O

All	O
50	O
exons	O
of	O
the	O
ABCR	B-DNAMutation
gene	O
were	O
analyzed	O
by	O
single-stranded	O
confirmation	O
polymorphism	O
analysis	O
,	O
followed	O
by	O
direct	O
sequencing	O
of	O
observed	O
variants	O
,	O
to	O
identify	O
mutations	O
in	O
the	O
ABCR	B-DNAMutation
gene	O
.	O

RESULTS	O
:	O
We	O
identified	O
a	O
previously	O
unreported	O
kindred	O
of	O
eight	O
siblings	O
,	O
four	O
of	O
whom	O
had	O
mutations	O
in	O
both	O
of	O
their	O
ABCR	B-DNAMutation
alleles	O
.	O

A	O
previously	O
described	O
G-to-C	B-DNAMutation
transversion	I-DNAMutation
of	I-DNAMutation
nucleotide	I-DNAMutation
2588	I-DNAMutation
,	O
predicting	O
a	O
Gly863Ala	B-DNAMutation
amino	O
acid	O
substitution	O
,	O
and	O
a	O
novel	O
G-to-A	B-DNAMutation
transition	I-DNAMutation
of	I-DNAMutation
nucleotide	I-DNAMutation
161	I-DNAMutation
,	O
resulting	O
in	O
a	O
Cys54Tyr	B-DNAMutation
substitution	O
,	O
were	O
identified	O
.	O

These	O
mutations	O
co-segregated	O
with	O
the	O
affected	O
members	O
of	O
this	O
family	O
.	O

Three	O
of	O
the	O
siblings	O
demonstrated	O
clinical	O
features	O
characteristic	O
of	O
classic	O
Stargardt	O
disease	O
,	O
with	O
bilateral	O
regions	O
of	O
macular	O
atrophy	O
associated	O
with	O
yellow-white	O
"flavimaculatus"	O
flecks	O
in	O
the	O
posterior	O
pole	O
at	O
the	O
level	O
of	O
the	O
retinal	O
pigment	O
epithelium	O
.	O

The	O
fourth	O
affected	O
sibling	O
showed	O
features	O
of	O
early	O
Stargardt	O
disease	O
,	O
with	O
a	O
beaten-bronze	O
appearance	O
to	O
both	O
maculas	O
,	O
as	O
well	O
as	O
perimacular	O
flecks	O
.	O

In	O
all	O
four	O
affected	O
patients	O
,	O
fluorescein	O
angiography	O
showed	O
a	O
characteristic	O
peripheral	O
dark	O
choroid	O
.	O

CONCLUSIONS	O
:	O
We	O
have	O
identified	O
both	O
a	O
previously	O
described	O
and	O
a	O
novel	O
mutation	O
in	O
the	O
ABCR	B-DNAMutation
gene	O
in	O
four	O
patients	O
with	O
autosomal	O
recessive	O
Stargardt	O
disease	O
.	O

In-depth	O
knowledge	O
of	O
the	O
ABCR	B-DNAMutation
mutation	O
spectrum	O
in	O
patients	O
with	O
Stargardt	O
disease	O
will	O
provide	O
for	O
more	O
efficient	O
screening	O
and	O
may	O
provide	O
potential	O
therapies	O
for	O
Stargardt	O
disease	O
and	O
other	O
retinal	O
diseases	O
.	O

Integrin	O
trafficking	O
regulated	O
by	O
Rab21	B-DNAMutation
is	O
necessary	O
for	O
cytokinesis	O
.	O

Adherent	O
cells	O
undergo	O
remarkable	O
changes	O
in	O
shape	O
during	O
cell	O
division	O
.	O

However	O
,	O
the	O
functional	O
interplay	O
between	O
cell	O
adhesion	O
turnover	O
and	O
the	O
mitotic	O
machinery	O
is	O
poorly	O
understood	O
.	O

The	O
endo/exocytic	O
trafficking	O
of	O
integrins	O
is	O
regulated	O
by	O
the	O
small	O
GTPase	O
Rab21	B-DNAMutation
,	O
which	O
associates	O
with	O
several	O
integrin	O
alpha	O
subunits	O
.	O

Here	O
,	O
we	O
show	O
that	O
targeted	O
trafficking	O
of	O
integrins	O
to	O
and	O
from	O
the	O
cleavage	O
furrow	O
is	O
required	O
for	O
successful	O
cytokinesis	O
,	O
and	O
that	O
this	O
is	O
regulated	O
by	O
Rab21	B-DNAMutation
.	O

Rab21	B-DNAMutation
activity	O
,	O
integrin-Rab21	B-DNAMutation
association	O
,	O
and	O
integrin	O
endocytosis	O
are	O
all	O
necessary	O
for	O
normal	O
cytokinesis	O
,	O
which	O
becomes	O
impaired	O
when	O
integrin-mediated	O
adhesion	O
at	O
the	O
cleavage	O
furrow	O
fails	O
.	O

We	O
also	O
describe	O
a	O
chromosomal	O
deletion	B-DNAMutation
and	I-DNAMutation
loss	I-DNAMutation
of	I-DNAMutation
Rab21	B-DNAMutation
gene	O
expression	O
in	O
human	O
cancer	O
,	O
which	O
leads	O
to	O
the	O
accumulation	O
of	O
multinucleate	O
cells	O
.	O

Importantly	O
,	O
reintroduction	O
of	O
Rab21	B-DNAMutation
rescued	O
this	O
phenotype	O
.	O

In	O
conclusion	O
,	O
Rab21-regulated	B-DNAMutation
integrin	O
trafficking	O
is	O
essential	O
for	O
normal	O
cell	O
division	O
,	O
and	O
its	O
defects	O
may	O
contribute	O
to	O
multinucleation	O
and	O
genomic	O
instability	O
,	O
which	O
are	O
hallmarks	O
of	O
cancer	O
.	O

cDNA	O
cloning	O
,	O
expression	O
,	O
mutagenesis	O
of	O
C-terminal	O
isoleucine	O
,	O
genomic	O
structure	O
,	O
and	O
chromosomal	O
localizations	O
of	O
murine	O
12-lipoxygenases	O
.	O

Two	O
types	O
of	O
12-lipoxygenase	O
that	O
catalyze	O
the	O
transformation	O
of	O
arachidonic	O
acid	O
to	O
12(S)-hydroperoxyeicosatetraenoic	O
acid	O
(12-HPETE)	O
have	O
been	O
previously	O
classified	O
into	O
platelet-type	O
and	O
leukocyte-type	O
categories	O
.	O

Here	O
,	O
we	O
document	O
,	O
for	O
the	O
first	O
time	O
,	O
a	O
molecular	O
characterization	O
of	O
both	O
forms	O
within	O
the	O
same	O
species	O
.	O

The	O
amino	O
acid	O
sequence	O
of	O
the	O
murine	O
platelet	O
12-lipoxygenase	O
deduced	O
from	O
its	O
cDNA	O
is	O
58%	O
identical	O
to	O
the	O
murine	O
spleen/leukocyte	O
12-lipoxygenase	O
.	O

Expression	O
constructs	O
carrying	O
the	O
cDNAs	O
for	O
the	O
two	O
12-lipoxygenase	O
forms	O
were	O
introduced	O
into	O
human	O
embryonic	O
kidney	O
293	O
cells	O
.	O

The	O
platelet-type	O
enzyme	O
metabolized	O
arachidonic	O
acid	O
exclusively	O
to	O
12-HPETE	O
,	O
whereas	O
the	O
leukocyte-type	O
enzyme	O
formed	O
both	O
12-HPETE	O
and	O
15-hydro(pero)xyeicosatetraenoic	O
acid	O
in	O
a	O
ratio	O
of	O
approximately	O
3:1	O
.	O

Linoleic	O
acid	O
was	O
metabolized	O
to	O
a	O
similar	O
extent	O
by	O
the	O
latter	O
enzyme	O
to	O
13-hydro(pero)xyoctadecadienoic	O
acid	O
but	O
not	O
by	O
the	O
platelet	O
enzyme	O
.	O

Mutagenesis	O
and	O
deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
highly	I-DNAMutation
conserved	I-DNAMutation
lipoxygenase	I-DNAMutation
C-terminal	I-DNAMutation
isoleucine	I-DNAMutation
(Ile663)	I-DNAMutation
,	O
a	O
residue	O
believed	O
to	O
be	O
involved	O
in	O
the	O
non-heme	O
iron	O
atom	O
coordination	O
of	O
all	O
lipoxygenases	O
,	O
was	O
performed	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
Ile663	I-DNAMutation
and	O
substitution	O
with	O
most	O
amino	O
acids	O
abolished	O
enzyme	O
activity	O
.	O

Only	O
a	O
valine	O
substitution	O
retained	O
significant	O
activity	O
.	O

These	O
findings	O
would	O
tend	O
to	O
indicate	O
a	O
stringent	O
requirement	O
for	O
the	O
proper	O
spatial	O
alignment	O
and	O
folding	O
of	O
the	O
C-terminal	O
chain	O
back	O
into	O
the	O
core	O
of	O
the	O
enzyme	O
to	O
interact	O
with	O
the	O
iron	O
atom	O
by	O
analogy	O
with	O
the	O
recently	O
determined	O
crystal	O
structure	O
of	O
a	O
soybean	O
lipoxygenase	O
(	O
Boyington	O
,	O
J	O
.	O

C.	O
,	O
Gaffney	O
,	O
B	O
.	O

J.	O
,	O
and	O
Amzel	O
,	O
L	O
.	O

M	O
.	O

(1993)	O
Science	O
260	O
,	O
1482-1486	O
)	O
.	O

The	O
platelet-type	O
and	O
leukocyte-type	O
12-lipoxygenase	O
genes	O
were	O
cloned	O
from	O
a	O
murine	O
129	O
Sv	O
genomic	O
library	O
.	O

Both	O
genes	O
are	O
divided	O
into	O
a	O
similar	O
14-exon/13-intron	O
format	O
,	O
with	O
the	O
platelet-type	O
gene	O
being	O
approximately	O
twice	O
the	O
size	O
of	O
the	O
leukocyte-type	O
gene	O
(	O
13	O
versus	O
7.5	O
kilobases	O
)	O
.	O

A	O
segment	O
of	O
a	O
third	O
gene	O
was	O
also	O
isolated	O
and	O
probably	O
represents	O
a	O
pseudogene	O
derivative	O
of	O
either	O
of	O
these	O
12-lipoxygenase	O
genes	O
.	O

All	O
three	O
genes	O
were	O
mapped	O
to	O
the	O
central	O
region	O
of	O
mouse	O
chromosome	O
11	O
in	O
a	O
region	O
of	O
homology	O
with	O
human	O
chromosome	O
17	O
.	O

Antibodies	O
prepared	O
against	O
the	O
two	O
forms	O
of	O
12-lipoxygenase	O
revealed	O
the	O
differential	O
distribution	O
of	O
the	O
two	O
enzymes	O
throughout	O
the	O
mouse	O
.	O

A	O
four	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
deletion	I-DNAMutation
polymorphism	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
third	I-DNAMutation
intracellular	I-DNAMutation
loop	I-DNAMutation
of	O
the	O
human	O
alpha	B-DNAMutation
2C-adrenergic	I-DNAMutation
receptor	I-DNAMutation
confers	O
impaired	O
coupling	O
to	O
multiple	O
effectors	O
.	O

The	O
alpha(2)-adrenergic	O
receptors	O
(alpha(2)ARs)	O
play	O
a	O
critical	O
role	O
in	O
modulating	O
neurotransmitter	O
release	O
in	O
the	O
central	O
and	O
peripheral	O
sympathetic	O
nervous	O
systems	O
.	O

A	O
polymorphism	O
of	O
the	O
alpha(2)AR	O
subtype	O
localized	O
to	O
human	O
chromosome	O
4	O
(	O
the	O
pharmacologic	O
alpha(2C)AR	O
subtype	O
)	O
within	O
an	O
intracellular	O
domain	O
has	O
been	O
identified	O
in	O
normal	O
individuals	O
.	O

The	O
polymorphism	O
(	O
denoted	O
Del322-325	B-DNAMutation
)	O
is	O
because	O
of	O
an	O
in-frame	B-DNAMutation
12-nucleic	I-DNAMutation
acid	I-DNAMutation
deletion	I-DNAMutation
encoding	O
a	O
receptor	O
lacking	B-DNAMutation
Gly-Ala-Gly-Pro	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
third	I-DNAMutation
intracellular	I-DNAMutation
loop	I-DNAMutation
.	O

To	O
delineate	O
the	O
functional	O
consequences	O
of	O
this	O
structural	O
alteration	O
,	O
Chinese	O
hamster	O
ovary	O
cells	O
were	O
permanently	O
transfected	O
with	O
constructs	O
encoding	O
wild-type	O
human	O
alpha(2C)AR	B-DNAMutation
and	O
the	O
polymorphic	O
receptor	O
.	O

The	O
Del322-325	B-DNAMutation
variant	O
had	O
decreased	O
high	O
affinity	O
agonist	O
binding	O
(	O
K(H	O
)	O
=	O
7.3	O
+/-	O
0.95	O
versus	O
3.7	O
+/-	O
0.43	O
nm	O
;	O
%R(H)	O
=	O
31	O
+/-	O
4	O
versus	O
49	O
+/-	O
4	O
)	O
compared	O
with	O
wild-type	O
indicating	O
impaired	O
formation	O
of	O
the	O
agonist-receptor-G	O
protein	O
complex	O
.	O

The	O
polymorphic	O
receptor	O
displayed	O
markedly	O
depressed	O
epinephrine-promoted	O
coupling	O
to	O
G(i)	O
,	O
inhibiting	O
adenylyl	O
cyclase	O
by	O
10	O
+/-	O
4.3%	O
compared	O
with	O
73	O
+/-	O
2.4%	O
for	O
wild-type	O
alpha(2C)AR	O
.	O

This	O
also	O
was	O
so	O
for	O
the	O
endogenous	O
ligand	O
norepinephrine	O
and	O
full	O
and	O
partial	O
synthetic	O
agonists	O
.	O

Depressed	O
agonist-promoted	O
coupling	O
to	O
the	O
stimulation	O
of	O
MAP	O
kinase	O
(	O
approximately	O
71%	O
impaired	O
)	O
and	O
inositol	O
phosphate	O
production	O
(	O
approximately	O
60%	O
impaired	O
)	O
was	O
also	O
found	O
with	O
the	O
polymorphic	O
receptor	O
.	O

The	O
Del322-325	B-DNAMutation
receptor	I-DNAMutation
was	O
approximately	O
10	O
times	O
more	O
frequent	O
in	O
African-Americans	O
compared	O
with	O
Caucasians	O
(	O
allele	O
frequencies	O
0.381	O
versus	O
0.040	O
)	O
.	O

Given	O
this	O
significant	O
loss	O
of	O
function	O
phenotype	O
in	O
several	O
signal	O
transduction	O
cascades	O
and	O
the	O
skewed	O
ethnic	O
prevalence	O
,	O
Del322-325	B-DNAMutation
represents	I-DNAMutation
a	O
pharmacoethnogenetic	O
locus	O
and	O
may	O
also	O
be	O
the	O
basis	O
for	O
interindividual	O
variation	O
in	O
cardiovascular	O
or	O
central	O
nervous	O
system	O
pathophysiology	O
.	O

Phosphorylation	O
of	O
BATF	B-DNAMutation
regulates	O
DNA	O
binding	O
:	O
a	O
novel	O
mechanism	O
for	O
AP-1	O
(	O
activator	O
protein-1	O
)	O
regulation	O
.	O

BATF	B-DNAMutation
is	O
a	O
member	O
of	O
the	O
AP-1	O
(	O
activator	O
protein-1	O
)	O
family	O
of	O
bZIP	O
(	O
basic	O
leucine	O
zipper	O
)	O
transcription	O
factors	O
that	O
form	O
transcriptionally	O
inhibitory	O
,	O
DNA	O
binding	O
heterodimers	O
with	O
Jun	O
proteins	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrate	O
that	O
BATF	B-DNAMutation
is	O
phosphorylated	O
in	O
vivo	O
on	O
multiple	O
serine	O
and	O
threonine	O
residues	O
and	O
at	O
least	O
one	O
tyrosine	O
residue	O
.	O

Reverse-polarity	O
PAGE	O
revealed	O
that	O
serine-43	O
and	O
threonine-48	O
within	O
the	O
DNA	O
binding	O
domain	O
of	O
BATF	B-DNAMutation
are	O
phosphorylated	O
.	O

To	O
model	O
phosphorylation	O
of	O
the	O
BATF	O
DNA	O
binding	O
domain	O
,	O
serine-43	B-DNAMutation
was	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
an	I-DNAMutation
aspartate	I-DNAMutation
residue	I-DNAMutation
.	O

BATF(S43D)	B-DNAMutation
retains	O
the	O
ability	O
to	O
dimerize	O
with	O
Jun	O
proteins	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
and	O
the	O
BATF(S43D):Jun	B-DNAMutation
heterodimer	O
localizes	O
properly	O
to	O
the	O
nucleus	O
of	O
cells	O
.	O

Interestingly	O
,	O
BATF(S43D)	B-DNAMutation
functions	O
like	O
wild-type	O
BATF	B-DNAMutation
to	O
reduce	O
AP-1-mediated	O
gene	O
transcription	O
,	O
despite	O
the	O
observed	O
inability	O
of	O
the	O
BATF(S43D):Jun	B-DNAMutation
heterodimer	O
to	O
bind	O
DNA	O
.	O

These	O
data	O
demonstrate	O
that	O
phosphorylation	O
of	O
serine-43	O
converts	O
BATF	B-DNAMutation
from	O
a	O
DNA	O
binding	O
into	O
a	O
non-DNA	O
binding	O
inhibitor	O
of	O
AP-1	O
activity	O
.	O

Given	O
that	O
40%	O
of	O
mammalian	O
bZIP	O
transcription	O
factors	O
contain	O
a	O
residue	O
analogous	O
to	O
serine-43	O
of	O
BATF	B-DNAMutation
in	O
their	O
DNA	O
binding	O
domains	O
,	O
the	O
phosphorylation	O
event	O
described	O
here	O
represents	O
a	O
mechanism	O
that	O
is	O
potentially	O
applicable	O
to	O
the	O
regulation	O
of	O
many	O
bZIP	O
proteins	O
.	O

Amino-terminal	O
polymorphisms	O
of	O
the	O
human	O
beta	B-DNAMutation
2-adrenergic	I-DNAMutation
receptor	I-DNAMutation
impart	O
distinct	O
agonist-promoted	O
regulatory	O
properties	O
.	O

We	O
have	O
recently	O
delineated	O
three	O
naturally	O
occurring	O
polymorphisms	O
of	O
the	O
human	O
beta	B-DNAMutation
2-adrenergic	I-DNAMutation
receptor	I-DNAMutation
caused	O
by	O
missense	O
mutations	O
encoding	O
for	O
amino	O
acids	O
16	O
and	O
27	O
of	O
the	O
extracellular	O
N-terminus	O
of	O
the	O
receptor	O
.	O

We	O
have	O
studied	O
the	O
functional	O
consequences	O
of	O
these	O
polymorphisms	O
by	O
site-directed	O
mutagenesis	O
and	O
the	O
recombinant	O
expression	O
of	O
these	O
receptors	O
in	O
Chinese	O
hamster	O
fibroblasts	O
.	O

The	O
polymorphisms	O
consist	O
of	O
substitutions	B-DNAMutation
of	I-DNAMutation
Gly	I-DNAMutation
for	I-DNAMutation
Arg	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
16	I-DNAMutation
Arg16-->Gly	B-DNAMutation
,	O
Glu	B-DNAMutation
for	I-DNAMutation
Gln	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
27	I-DNAMutation
Gln27-->Glu	B-DNAMutation
,	O
and	O
a	O
combination	O
of	O
both	O
substitutions	O
.	O

All	O
three	O
mutated	O
receptors	O
displayed	O
normal	O
agonist	O
binding	O
and	O
functional	O
coupling	O
to	O
Gs	O
,	O
resulting	O
in	O
the	O
stimulation	O
of	O
adenylyl	O
cyclase	O
activity	O
.	O

However	O
,	O
these	O
mutations	O
markedly	O
altered	O
the	O
degree	O
of	O
agonist-promoted	O
downregulation	O
of	O
receptor	O
expression	O
.	O

After	O
24-h	O
exposure	O
to	O
10	O
microM	O
isoproterenol	O
,	O
wild-type	O
beta	B-DNAMutation
2AR	I-DNAMutation
underwent	O
a	O
26	O
+/-	O
3%	O
reduction	O
in	O
receptor	O
density	O
.	O

In	O
contrast	O
,	O
Arg16-->Gly	B-DNAMutation
underwent	O
a	O
41	O
+/-	O
3%	O
reduction	O
.	O

Gln27-->Glu	B-DNAMutation
,	O
on	O
the	O
other	O
hand	O
,	O
was	O
found	O
to	O
be	O
completely	O
resistant	O
to	O
downregulation	O
.	O

Arg16-->Gly+Gln27-->Glu	B-DNAMutation
also	O
underwent	O
an	O
increased	O
downregulation	O
compared	O
to	O
wild-type	O
beta	B-DNAMutation
2AR	I-DNAMutation
(	O
39	O
+/-	O
4%	O
)	O
.	O

The	O
rates	O
of	O
new	O
receptor	O
synthesis	O
after	O
irreversible	O
alkylation	O
were	O
not	O
different	O
between	O
these	O
receptors	O
,	O
nor	O
were	O
the	O
rates	O
of	O
agonist-promoted	O
receptor	O
internalization	O
to	O
the	O
intracellular	O
pool	O
.	O

Gln27-->Glu	B-DNAMutation
cellular	O
mRNA	O
minimally	O
increased	O
during	O
agonist	O
exposure	O
,	O
and	O
wild-type	O
beta	B-DNAMutation
2AR	I-DNAMutation
and	O
the	O
other	O
mutated	O
receptor	O
mRNAs	O
did	O
not	O
change	O
,	O
which	O
infer	O
that	O
the	O
aberrant	O
downregulation	O
patterns	O
of	O
these	O
polymorphisms	O
may	O
be	O
due	O
to	O
the	O
altered	O
degradation	O
of	O
receptor	O
protein.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Molecular	O
properties	O
and	O
pharmacogenetics	O
of	O
a	O
polymorphism	O
of	O
adenylyl	B-DNAMutation
cyclase	I-DNAMutation
type	I-DNAMutation
9	I-DNAMutation
in	O
asthma	O
:	O
interaction	O
between	O
beta-agonist	O
and	O
corticosteroid	O
pathways	O
.	O

In	O
asthma	O
,	O
the	O
response	O
to	O
beta-agonists	O
acting	O
at	O
beta2-adrenergic	B-DNAMutation
receptors	I-DNAMutation
beta2AR	B-DNAMutation
displays	O
extensive	O
interindividual	O
variation	O
.	O

One	O
effector	O
for	O
airway	O
beta2AR	B-DNAMutation
,	O
adenylyl	B-DNAMutation
cyclase	I-DNAMutation
type	I-DNAMutation
9	I-DNAMutation
AC9	B-DNAMutation
,	O
was	O
considered	O
a	O
candidate	O
locus	O
for	O
predicting	O
beta-agonist	O
efficacy	O
in	O
the	O
absence	O
and	O
presence	O
of	O
corticosteroid	O
treatment	O
.	O

One	O
non-synonymous	O
AC9	B-DNAMutation
polymorphism	O
has	O
been	O
identified	O
,	O
which	O
results	O
in	O
substitution	O
of	O
Met	B-DNAMutation
for	I-DNAMutation
Ile	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
772	I-DNAMutation
.	O

Under	O
standard	O
culture	O
conditions	O
in	O
stably	O
transfected	O
cells	O
,	O
we	O
found	O
decreased	O
catalytic	O
activity	O
of	O
Met772	O
.	O

However	O
,	O
cells	O
cultured	O
in	O
the	O
presence	O
of	O
glucocorticoid	O
expressing	O
Met772	O
had	O
a	O
significantly	O
increased	O
albuterol-stimulated	O
adenylyl	O
cyclase	O
response	O
(	O
approximately	O
80%	O
)	O
when	O
compared	O
with	O
those	O
expressing	O
Ile772	O
(	O
approximately	O
20%	O
,	O
P=0.02	O
)	O
.	O

An	O
equivalent	O
increase	O
in	O
beta2AR	B-DNAMutation
expression	O
was	O
observed	O
in	O
both	O
lines	O
due	O
to	O
glucocorticoid	O
,	O
but	O
AC9	B-DNAMutation
expression	O
was	O
unaffected	O
.	O

The	O
hypothesis	O
that	O
Met772-AC9	B-DNAMutation
is	O
associated	O
with	O
an	O
improved	O
albuterol	O
bronchodilator	O
response	O
in	O
asthmatics	O
was	O
investigated	O
in	O
436	O
asthmatic	O
children	O
who	O
were	O
followed	O
for	O
4	O
years	O
and	O
randomized	O
to	O
receive	O
placebo	O
or	O
the	O
inhaled	O
corticosteroid	O
budesonide	O
.	O

Met772	O
carriers	O
on	O
budesonide	O
showed	O
a	O
significant	O
improvement	O
in	O
forced	O
expiratory	O
volume	O
in	O
1	O
s	O
(P=0.005)	O
.	O

Moreover	O
,	O
a	O
highly	O
significant	O
interaction	O
(P=0.002)	O
was	O
found	O
for	O
budesonide	O
treatment	O
and	O
the	O
AC9	B-DNAMutation
polymorphism	O
.	O

These	O
in	O
vitro	O
and	O
human	O
association	O
studies	O
are	O
consistent	O
with	O
this	O
AC9	B-DNAMutation
polymorphism	O
altering	O
albuterol	O
responsiveness	O
in	O
the	O
context	O
of	O
concomitant	O
inhaled	O
corticosteroid	O
administration	O
,	O
which	O
is	O
a	O
common	O
asthma	O
regimen	O
.	O

The	O
Met772-AC9	B-DNAMutation
polymorphism	O
represents	O
one	O
of	O
most	O
likely	O
several	O
multi-gene	O
polymorphisms	O
along	O
the	O
receptor-relaxation	O
axis	O
,	O
which	O
together	O
may	O
provide	O
for	O
a	O
composite	O
pharmacogenetic	O
index	O
for	O
asthma	O
therapy	O
.	O

An	O
external	O
determinant	O
in	O
the	O
S5-P	O
linker	O
of	O
the	O
pacemaker	O
(HCN)	O
channel	O
identified	O
by	O
sulfhydryl	O
modification	O
.	O

Hyperpolarization-activated	O
,	O
cyclic	O
nucleotide-gated	O
(HCN)	O
channels	O
underlie	O
spontaneous	O
rhythmic	O
activities	O
in	O
the	O
heart	O
and	O
brain	O
.	O

Sulfhydryl	O
modification	O
of	O
ion	O
channels	O
is	O
a	O
proven	O
approach	O
for	O
studying	O
their	O
structure-function	O
relationships	O
;	O
here	O
we	O
examined	O
the	O
effects	O
of	O
the	O
hydrophilic	O
sulfhydryl-modifying	O
agents	O
methanethiosulfonate	O
ethylammonium	O
(MTSEA(+))	O
and	O
methanethiosulfonate	O
ethylsulfonate	O
(MTSES(-))	O
on	O
wild-type	O
(WT)	O
and	O
engineered	O
HCN1	B-DNAMutation
channels	O
.	O

External	O
application	O
of	O
MTSEA(+)	O
to	O
WT	O
channels	O
irreversibly	O
reduced	O
whole-cell	O
currents	O
(	O
I(MTSEA)/I(Control	O
)	O
=	O
42	O
+/-	O
2%	O
)	O
,	O
slowed	O
activation	O
and	O
deactivation	O
kinetics	O
(	O
approximately	O
7-	O
and	O
approximately	O
3-fold	O
at	O
-140	O
and	O
-20	O
mV	O
,	O
respectively	O
)	O
,	O
and	O
produced	O
hyperpolarizing	O
shifts	O
of	O
steady-state	O
activation	O
(	O
V(12)((MTSEA	O
)	O
)	O
=	O
-125.8	O
+/-	O
9.0	O
mV	O
versus	O
V(12)((Control))	O
=	O
-76.4	O
+/-	O
1.6	O
mV	O
)	O
.	O

Sequence	O
inspection	O
revealed	O
the	O
presence	O
of	O
five	O
endogenous	O
cysteines	O
in	O
the	O
transmembrane	O
domains	O
of	O
HCN1	B-DNAMutation
:	O
three	O
are	O
putatively	O
close	O
to	O
the	O
extracellular	O
milieu	O
(	O
Cys(303	O
)	O
,	O
Cys(318)	O
,	O
and	O
Cys(347)	O
in	O
the	O
S5	O
,	O
S5-P	O
,	O
and	O
P	O
segments	O
,	O
respectively	O
)	O
,	O
whereas	O
the	O
remaining	O
two	O
are	O
likely	O
to	O
be	O
cytoplasmic	O
or	O
buried	O
.	O

To	O
identify	O
the	O
molecular	O
constituent(s)	O
responsible	O
for	O
the	O
effects	O
of	O
MTSEA(+)	O
,	O
we	O
mutated	B-DNAMutation
the	I-DNAMutation
three	I-DNAMutation
"external"	I-DNAMutation
cysteines	I-DNAMutation
individually	I-DNAMutation
to	I-DNAMutation
serine	I-DNAMutation
.	O

C303S	B-DNAMutation
did	O
not	O
yield	O
measurable	O
currents	O
.	O

Whereas	O
C347S	B-DNAMutation
channels	O
remained	O
sensitive	O
to	O
MTSEA(+)	O
,	O
C318S	B-DNAMutation
was	O
not	O
modified	O
(	O
I(MTSEA)/I(Control	O
)	O
=	O
101	O
+/-	O
2%	O
,	O
V(12)((MTSEA))	O
=	O
-78.4	O
+/-	O
1.1	O
mV	O
,	O
and	O
V(12)((Control))	O
=	O
-79.8	O
+/-	O
2.3	O
mV	O
)	O
.	O

Likewise	O
,	O
WT	O
(	O
but	O
not	O
C318S	B-DNAMutation
)	O
channels	O
were	O
sensitive	O
to	O
MTSES(-)	O
.	O

Despite	O
their	O
opposite	O
charges	O
,	O
MTSES(-)	O
produced	O
changes	O
directionally	O
similar	O
to	O
those	O
effected	O
by	O
MTSEA(+)	O
(	O
I(MTSES)/I(Control	O
)	O
=	O
22	O
+/-	O
1.6%	O
and	O
V(12)((MTSES))	O
=	O
-145.9	O
+/-	O
4.9	O
mV	O
)	O
.	O

We	O
conclude	O
that	O
S5-P	O
Cys(318)	O
of	O
HCN1	B-DNAMutation
is	O
externally	O
accessible	O
and	O
that	O
the	O
external	O
pore	O
vestibule	O
and	O
activation	O
gating	O
of	O
HCN	O
channels	O
are	O
allosterically	O
coupled	O
.	O

Modulation	O
of	O
ETS-1	B-DNAMutation
transcriptional	O
activity	O
by	O
huUBC9	B-DNAMutation
,	O
a	O
ubiquitin-conjugating	O
enzyme	O
.	O

Ets	O
transcription	O
factors	O
have	O
Ets	O
DNA	O
binding	O
domains	O
,	O
that	O
have	O
a	O
winged	O
helix-turn-helix	O
structure	O
.	O

ETS-1	B-DNAMutation
,	O
the	O
founding	O
member	O
of	O
the	O
family	O
,	O
is	O
regulated	O
by	O
the	O
Ras	O
and	O
Ca2+	O
signaling	O
pathways	O
and	O
is	O
implicated	O
in	O
various	O
physiological	O
processes	O
leading	O
to	O
cell	O
growth	O
,	O
differentiation	O
and	O
apoptosis	O
.	O

We	O
have	O
identified	O
ETS-1	B-DNAMutation
interacting	O
factors	O
with	O
a	O
yeast	B-DNAMutation
two-hybrid	O
screen	O
.	O

The	O
majority	O
of	O
the	O
positive	O
clones	O
turned	O
out	O
to	O
encode	O
the	O
human	B-DNAMutation
homologue	O
of	O
the	O
yeast	B-DNAMutation
ubiquitin-conjugating	O
enzymes	O
UBC9	B-DNAMutation
and	O
Hus5	B-DNAMutation
.	O

In	O
two	O
different	O
yeast	B-DNAMutation
assays	O
,	O
ETS-1	B-DNAMutation
interacted	O
with	O
huUBC9	B-DNAMutation
.	O

In	O
an	O
in	O
vitro	O
GST	O
'pull-down'	O
assay	O
,	O
ETS-1	B-DNAMutation
and	O
several	O
other	O
Ets	O
family	O
members	O
complexed	O
with	O
huUBC9	B-DNAMutation
.	O

Interestingly	O
,	O
in	O
mammalian	O
cells	O
,	O
coexpression	O
of	O
huUBC9	B-DNAMutation
resulted	O
in	O
a	O
substantial	O
increase	O
in	O
the	O
transcriptional	O
activity	O
of	O
ETS-1	B-DNAMutation
.	O

Coexpressed	O
huUBC9	B-DNAMutation
did	O
not	O
affect	O
the	O
ETS-1	B-DNAMutation
protein	O
level	O
,	O
and	O
moreover	O
,	O
a	O
point	B-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
Cys93	I-DNAMutation
,	O
an	O
amino	O
acid	O
known	O
to	O
be	O
essential	O
for	O
ubiquitination	O
,	O
did	O
not	O
abolish	O
the	O
stimulation	O
of	O
the	O
ETS-1	B-DNAMutation
transcriptional	O
activity	O
.	O

Our	O
results	O
indicate	O
that	O
the	O
modulation	O
of	O
ETS-1	B-DNAMutation
activity	O
by	O
huUBC9	B-DNAMutation
results	O
from	O
processes	O
other	O
than	O
ubiquitination	O
and	O
ETS-1	B-DNAMutation
stabilization	O
.	O

Gly387	O
of	O
murine	O
ornithine	O
decarboxylase	O
is	O
essential	O
for	O
the	O
formation	O
of	O
stable	O
homodimers	O
.	O

In	O
its	O
active	O
form	O
mammalian	O
ornithine	B-DNAMutation
decarboxylase	I-DNAMutation
ODC	B-DNAMutation
is	O
a	O
homodimer	O
composed	O
of	O
two	O
53-kDa	O
subunits	O
while	O
the	O
monomer	O
retains	O
no	O
enzymic	O
activity	O
.	O

In	O
the	O
present	O
study	O
we	O
demonstrate	O
that	O
Gly387	O
of	O
mouse	O
ODC	O
plays	O
an	O
important	O
role	O
in	O
enabling	O
dimer	O
formation	O
.	O

Gly387	B-DNAMutation
of	I-DNAMutation
mouse	I-DNAMutation
ODC	I-DNAMutation
,	I-DNAMutation
an	I-DNAMutation
evolutionary	I-DNAMutation
conserved	I-DNAMutation
residue	I-DNAMutation
,	I-DNAMutation
was	I-DNAMutation
converted	I-DNAMutation
to	I-DNAMutation
all	I-DNAMutation
possible	I-DNAMutation
19	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
using	O
site-directed	O
mutagenesis	O
.	O

With	O
the	O
exception	O
of	O
alanine	O
,	O
all	O
other	O
substitutions	O
of	O
Gly387	O
completely	O
abolished	O
enzymic	O
activity	O
.	O

Cross-linking	O
analysis	O
and	O
fractionation	O
through	O
a	O
Superose-12	O
sizing	O
column	O
have	O
demonstrated	O
that	O
mutant	O
subunits	O
are	O
detected	O
only	O
in	O
their	O
monomeric	O
form	O
.	O

These	O
results	O
strongly	O
suggest	O
that	O
the	O
primary	O
lesion	O
of	O
substitution	B-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
387	I-DNAMutation
of	O
mouse	O
ODC	O
is	O
the	O
inability	O
of	O
mutant	O
subunits	O
to	O
associate	O
with	O
each	O
other	O
to	O
form	O
the	O
active	O
homodimers	O
.	O

In	O
agreement	O
with	O
this	O
conclusion	O
,	O
G387A	B-DNAMutation
,	O
the	O
only	O
mutant	O
that	O
retained	O
partial	O
activity	O
,	O
displayed	O
reduced	O
dimerization	O
.	O

The	O
degradation	O
rate	O
of	O
ODC	O
mutants	O
in	O
which	O
Gly387	B-DNAMutation
was	I-DNAMutation
substituted	I-DNAMutation
by	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
or	I-DNAMutation
alanine	I-DNAMutation
was	O
enhanced	O
compared	O
to	O
the	O
wild-type	O
enzyme	O
,	O
suggesting	O
that	O
monomers	O
may	O
be	O
more	O
susceptible	O
to	O
degradation	O
.	O

Site-specific	O
acetylation	O
by	O
p300	B-DNAMutation
or	O
CREB	B-DNAMutation
binding	O
protein	O
regulates	O
erythroid	O
KrÃ¼ppel-like	O
factor	O
transcriptional	O
activity	O
via	O
its	O
interaction	O
with	O
the	O
SWI-SNF	O
complex	O
.	O

Recruitment	O
of	O
modifiers	O
and	O
remodelers	O
to	O
specific	O
DNA	O
sites	O
within	O
chromatin	O
plays	O
a	O
critical	O
role	O
in	O
controlling	O
gene	O
expression	O
.	O

The	O
study	O
of	O
globin	O
gene	O
regulation	O
provides	O
a	O
convergence	O
point	O
within	O
which	O
to	O
address	O
these	O
issues	O
in	O
the	O
context	O
of	O
tissue-specific	O
and	O
developmentally	O
regulated	O
expression	O
.	O

In	O
this	O
regard	O
,	O
erythroid	O
KrÃ¼ppel-like	O
factor	O
(EKLF)	O
is	O
critical	O
.	O

EKLF	O
is	O
a	O
red	O
cell-specific	O
activator	O
whose	O
presence	O
is	O
crucial	O
for	O
establishment	O
of	O
the	O
correct	O
chromatin	O
structure	O
and	O
high-level	O
transcriptional	O
induction	O
of	O
adult	O
beta-globin	O
.	O

We	O
now	O
find	O
,	O
by	O
metabolic	O
labeling-immunoprecipitation	O
experiments	O
,	O
that	O
EKLF	O
is	O
acetylated	O
in	O
the	O
erythroid	O
cell	O
.	O

EKLF	O
residues	O
acetylated	O
by	B-DNAMutation
CREB	I-DNAMutation
binding	O
protein	B-DNAMutation
(CBP)	I-DNAMutation
in	O
vitro	O
map	O
to	O
Lys-288	O
in	O
its	O
transactivation	O
domain	O
and	O
Lys-302	O
in	O
its	O
zinc	O
finger	O
domain	O
.	O

Although	O
site-specific	O
DNA	O
binding	O
by	O
EKLF	O
is	O
unaffected	O
by	O
the	O
acetylation	O
status	O
of	O
either	O
of	O
these	O
lysines	O
,	O
directed	B-DNAMutation
mutagenesis	I-DNAMutation
of	I-DNAMutation
Lys-288	I-DNAMutation
(	I-DNAMutation
but	I-DNAMutation
not	I-DNAMutation
Lys-302	I-DNAMutation
)	O
decreases	O
the	O
ability	O
of	O
EKLF	O
to	O
transactivate	O
the	O
beta-globin	O
promoter	O
in	O
vivo	O
and	O
renders	O
it	O
unable	O
to	O
be	O
superactivated	O
by	O
coexpressed	B-DNAMutation
p300	I-DNAMutation
or	B-DNAMutation
CBP	O
.	O

In	O
addition	O
,	O
the	O
acetyltransferase	O
function	O
of	B-DNAMutation
CBP	O
or	B-DNAMutation
p300	I-DNAMutation
is	O
required	O
for	O
superactivation	O
of	O
wild-type	O
EKLF	O
.	O

Finally	O
,	O
acetylated	O
EKLF	O
has	O
a	O
higher	O
affinity	O
for	O
the	O
SWI-SNF	O
chromatin	O
remodeling	O
complex	O
and	O
is	O
a	O
more	O
potent	O
transcriptional	O
activator	O
of	O
chromatin-assembled	O
templates	O
in	O
vitro	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
acetylation	O
status	O
of	O
EKLF	O
is	O
critical	O
for	O
its	O
optimal	O
activity	O
and	O
suggest	O
a	O
mechanism	O
by	O
which	O
EKLF	O
acts	O
as	O
an	O
integrator	O
of	O
remodeling	O
and	O
transcriptional	O
components	O
to	O
alter	O
chromatin	O
structure	O
and	O
induce	O
adult	O
beta-globin	O
expression	O
within	O
the	O
beta-like	O
globin	O
cluster	O
.	O

Complete	O
loss-of-function	O
of	O
the	O
heart/muscle-specific	O
adenine	O
nucleotide	O
translocator	O
is	O
associated	O
with	O
mitochondrial	O
myopathy	O
and	O
cardiomyopathy	O
.	O

Multiple	O
mitochondrial	O
DNA	O
deletions	O
are	O
associated	O
with	O
clinically	O
heterogeneous	O
disorders	O
transmitted	O
as	O
mendelian	O
traits	O
.	O

Dominant	O
missense	O
mutations	O
were	O
found	O
in	O
the	O
gene	O
encoding	O
the	O
heart	O
and	O
skeletal	O
muscle-specific	O
isoform	O
of	O
the	O
adenine	O
nucleotide	O
translocator	O
(ANT1)	O
in	O
families	O
with	O
autosomal	O
dominant	O
progressive	O
external	O
opthalmoplegia	O
and	O
in	O
a	O
sporadic	O
patient	O
.	O

We	O
herein	O
report	O
on	O
a	O
sporadic	O
patient	O
who	O
presented	O
with	O
hypertrophic	O
cardiomyopathy	O
,	O
mild	O
myopathy	O
with	O
exercise	O
intolerance	O
and	O
lactic	O
acidosis	O
but	O
no	O
ophthalmoplegia	O
.	O

A	O
muscle	O
biopsy	O
showed	O
the	O
presence	O
of	O
numerous	O
ragged-red	O
fibers	O
,	O
and	O
Southern	O
blot	O
analysis	O
disclosed	O
multiple	O
deletions	O
of	O
muscle	O
mitochondrial	O
DNA	O
.	O

Molecular	O
analysis	O
revealed	O
a	O
C	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
homozygous	I-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
368	I-DNAMutation
of	O
the	O
ANT1	O
gene	O
.	O

The	O
mutation	O
converted	B-DNAMutation
a	I-DNAMutation
highly	I-DNAMutation
conserved	I-DNAMutation
alanine	I-DNAMutation
into	I-DNAMutation
an	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
123	I-DNAMutation
and	O
was	O
absent	O
in	O
500	O
control	O
individuals	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
recessive	O
mutation	O
in	O
the	O
ANT1	O
gene	O
.	O

The	O
clinical	O
and	O
biochemical	O
features	O
are	O
different	O
from	O
those	O
found	O
in	O
dominant	O
ANT1	O
mutations	O
,	O
resembling	O
those	O
described	O
in	O
ANT1	O
knockout	O
mice	O
.	O

No	O
ATP	O
uptake	O
was	O
measured	O
in	O
proteoliposomes	O
reconstituted	O
with	O
protein	O
extracts	O
from	O
the	O
patient's	O
muscle	O
.	O

The	O
equivalent	O
mutation	O
in	O
AAC2	B-DNAMutation
,	O
the	O
yeast	O
ortholog	O
of	O
human	O
ANT1	O
,	O
resulted	O
in	O
a	O
complete	O
loss	O
of	O
transport	O
activity	O
and	O
in	O
the	O
inability	O
to	O
rescue	O
the	O
severe	O
Oxidative	O
Phosphorylation	O
phenotype	O
displayed	O
by	O
WB-12	O
,	O
an	O
AAC1/AAC2	B-DNAMutation
defective	O
strain	O
.	O

Interestingly	O
,	O
exposure	O
to	O
reactive	O
oxygen	O
species	O
(ROS)	O
scavengers	O
dramatically	O
increased	O
the	O
viability	O
of	O
the	O
WB-12	O
transformant	O
,	O
suggesting	O
that	O
increased	O
redox	O
stress	O
is	O
involved	O
in	O
the	O
pathogenesis	O
of	O
the	O
disease	O
and	O
that	O
anti-ROS	O
therapy	O
may	O
be	O
beneficial	O
to	O
patients	O
.	O

Mutations	O
in	O
CGI-58	O
,	O
the	O
gene	O
encoding	O
a	O
new	O
protein	O
of	O
the	O
esterase/lipase/thioesterase	O
subfamily	O
,	O
in	O
Chanarin-Dorfman	O
syndrome	O
.	O

Chanarin-Dorfman	O
syndrome	O
(CDS)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
form	O
of	O
nonbullous	O
congenital	O
ichthyosiform	O
erythroderma	O
(NCIE)	O
that	O
is	O
characterized	O
by	O
the	O
presence	O
of	O
intracellular	O
lipid	O
droplets	O
in	O
most	O
tissues	O
.	O

We	O
previously	O
localized	O
a	O
gene	O
for	O
a	O
subset	O
of	O
NCIE	O
to	O
chromosome	O
3	O
(	O
designated	O
"the	O
NCIE2	O
locus"	O
)	O
,	O
in	O
six	O
families	O
.	O

Lipid	O
droplets	O
were	O
found	O
in	O
five	O
of	O
these	O
six	O
families	O
,	O
suggesting	O
a	O
diagnosis	O
of	O
CDS	O
.	O

Four	O
additional	O
families	O
selected	O
on	O
the	O
basis	O
of	O
a	O
confirmed	O
diagnosis	O
of	O
CDS	O
also	O
showed	O
linkage	O
to	O
the	O
NCIE2	O
locus	O
.	O

Linkage-disequilibrium	O
analysis	O
of	O
these	O
families	O
,	O
all	O
from	O
the	O
Mediterranean	O
basin	O
,	O
allowed	O
us	O
to	O
refine	O
the	O
NCIE2	O
locus	O
to	O
an	O
approximately	O
1.3-Mb	O
region	O
.	O

Candidate	O
genes	O
from	O
the	O
interval	O
were	O
screened	O
,	O
and	O
eight	O
distinct	O
mutations	O
in	O
the	O
recently	O
identified	O
CGI-58	O
gene	O
were	O
found	O
in	O
13	O
patients	O
from	O
these	O
nine	O
families	O
.	O

The	O
spectrum	O
of	O
gene	O
variants	O
included	O
insertion	O
,	O
deletion	O
,	O
splice-site	O
,	O
and	O
point	O
mutations	O
.	O

The	O
CGI-58	O
protein	O
belongs	O
to	O
a	O
large	O
family	O
of	O
proteins	O
characterized	O
by	O
an	O
alpha/beta	O
hydrolase	O
fold	O
.	O

CGI-58	O
contains	O
three	O
sequence	O
motifs	O
that	O
correspond	O
to	O
a	O
catalytic	O
triad	O
found	O
in	O
the	O
esterase/lipase/thioesterase	O
subfamily	O
.	O

Interestingly	O
,	O
CGI-58	O
differs	O
from	O
other	O
members	O
of	O
the	O
esterase/lipase/thioesterase	O
subfamily	O
in	O
that	O
its	O
putative	B-DNAMutation
catalytic	I-DNAMutation
triad	I-DNAMutation
contains	I-DNAMutation
an	I-DNAMutation
asparagine	I-DNAMutation
in	I-DNAMutation
place	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
usual	I-DNAMutation
serine	I-DNAMutation
residue	I-DNAMutation
.	O

Molecular	O
and	O
immunohistochemical	O
analyses	O
of	O
the	O
focal	O
form	O
of	O
congenital	O
hyperinsulinism	O
.	O

Congenital	O
hyperinsulinism	O
is	O
a	O
rare	O
pancreatic	O
endocrine	O
cell	O
disorder	O
that	O
has	O
been	O
categorized	O
histologically	O
into	O
diffuse	O
and	O
focal	O
forms	O
.	O

In	O
focal	O
hyperinsulinism	O
,	O
the	O
pancreas	O
contains	O
a	O
focus	O
of	O
endocrine	O
cell	O
adenomatous	O
hyperplasia	O
,	O
and	O
the	O
patients	O
have	O
been	O
reported	O
to	O
possess	O
paternally	O
inherited	O
mutations	O
of	O
the	O
ABCC8	B-DNAMutation
and	O
KCNJ11	B-DNAMutation
genes	O
,	O
which	O
encode	O
subunits	O
of	O
an	O
ATP-sensitive	B-DNAMutation
potassium	I-DNAMutation
channel	I-DNAMutation
(K(ATP))	I-DNAMutation
.	O

In	O
addition	O
,	O
the	O
hyperplastic	O
endocrine	O
cells	O
show	O
loss	O
of	O
maternal	O
11p15	B-DNAMutation
,	O
where	O
imprinted	O
genes	O
such	O
as	O
p57(kip2)	B-DNAMutation
reside	O
.	O

In	O
order	O
to	O
evaluate	O
whether	O
all	O
cases	O
of	O
focal	O
hyperinsulinism	O
are	O
caused	O
by	O
this	O
mechanism	O
,	O
56	O
pancreatectomy	O
specimens	O
with	O
focal	O
hyperinsulinism	O
were	O
tested	O
for	O
the	O
loss	O
of	O
maternal	O
allele	O
by	O
two	O
methods	O
:	O
immunohistochemistry	O
for	O
p57(kip2)	B-DNAMutation
(n=56)	O
and	O
microsatellite	O
marker	O
analysis	O
(n=27)	O
.	O

Additionally	O
,	O
49	O
patients	O
were	O
analyzed	O
for	O
K(ATP)	B-DNAMutation
mutations	O
.	O

Out	O
of	O
56	O
focal	O
lesions	O
,	O
48	O
demonstrated	O
clear	O
loss	O
of	O
p57(kip2)	B-DNAMutation
expression	O
by	O
immunohistochemistry	O
.	O

The	O
other	O
eight	O
lesions	O
similarly	O
showed	O
no	O
nuclear	O
labeling	O
,	O
but	O
the	O
available	O
tissue	O
was	O
not	O
ideal	O
for	O
definitive	O
interpretation	O
.	O

Five	O
of	O
these	O
eight	O
patients	O
had	O
paternal	O
K(ATP)	B-DNAMutation
mutations	O
,	O
of	O
which	O
four	O
demonstrated	O
loss	O
of	O
maternal	O
11p15	B-DNAMutation
within	O
the	O
lesion	O
by	O
microsatellite	O
marker	O
analysis	O
.	O

All	O
of	O
the	O
other	O
three	O
without	O
a	O
paternal	O
K(ATP)	B-DNAMutation
mutation	O
showed	O
loss	O
of	O
maternal	O
11p15	B-DNAMutation
.	O

K(ATP)	B-DNAMutation
mutation	O
analysis	O
identified	O
32/49	O
cases	O
with	O
paternal	O
mutations	O
.	O

There	O
were	O
seven	O
patients	O
with	O
nonmaternal	O
mutations	O
whose	O
paternal	O
DNA	O
material	O
was	O
not	O
available	O
,	O
and	O
one	O
patient	O
with	O
a	O
mutation	O
that	O
was	O
not	O
present	O
in	O
either	O
parent's	O
DNA	O
.	O

These	O
eight	O
patients	O
showed	O
either	O
loss	O
of	O
p57(kip2)	B-DNAMutation
expression	O
or	O
loss	O
of	O
maternal	O
11p15	B-DNAMutation
region	O
by	O
microsatellite	O
marker	O
analysis	O
,	O
as	O
did	O
the	O
remaining	O
nine	O
patients	O
with	O
no	O
identifiable	O
K(ATP)	B-DNAMutation
coding	O
region	O
mutations	O
.	O

The	O
combined	O
results	O
from	O
the	O
immunohistochemical	O
and	O
molecular	O
methods	O
indicate	O
that	O
maternal	O
11p15	B-DNAMutation
loss	O
together	O
with	O
paternal	O
K(ATP)	B-DNAMutation
mutation	O
is	O
the	O
predominant	O
causative	O
mechanism	O
of	O
focal	O
hyperinsulinism	O
.	O

PALS1	B-DNAMutation
specifies	O
the	O
localization	O
of	O
ezrin	B-DNAMutation
to	O
the	O
apical	O
membrane	O
of	O
gastric	O
parietal	O
cells	O
.	O

The	O
ERM	O
ezrin/radixin/moesin	B-DNAMutation
proteins	O
provide	O
a	O
regulated	O
linkage	O
between	O
membrane	O
proteins	O
and	O
the	O
cortical	O
cytoskeleton	O
and	O
also	O
participate	O
in	O
signal	O
transduction	O
pathways	O
.	O

Ezrin	B-DNAMutation
is	O
localized	O
to	O
the	O
apical	O
membrane	O
of	O
parietal	O
cells	O
and	O
couples	O
the	O
protein	O
kinase	O
A	O
activation	O
cascade	O
to	O
regulated	O
HCl	O
secretion	O
in	O
gastric	O
parietal	O
cells	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
integrity	O
of	O
ezrin	B-DNAMutation
is	O
essential	O
for	O
parietal	O
cell	O
activation	O
and	O
provide	O
the	O
first	O
evidence	O
that	O
ezrin	B-DNAMutation
interacts	O
with	O
PALS1	B-DNAMutation
,	O
an	O
evolutionarily	O
conserved	O
PDZ	O
and	O
SH3	O
domain-containing	O
protein	O
.	O

Our	O
biochemical	O
study	O
verifies	O
that	O
ezrin	B-DNAMutation
binds	O
to	O
PALS1	B-DNAMutation
via	O
its	O
N	O
terminus	O
and	O
is	O
co-localized	O
with	O
PALS1	B-DNAMutation
to	O
the	O
apical	O
membrane	O
of	O
gastric	O
parietal	O
cells	O
.	O

Furthermore	O
,	O
our	O
study	O
shows	O
that	O
PALS1	B-DNAMutation
is	O
essential	O
for	O
the	O
apical	O
localization	O
of	O
ezrin	B-DNAMutation
,	O
as	O
either	O
suppression	O
of	O
PALS1	B-DNAMutation
protein	O
accumulation	O
or	O
deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
PALS1-binding	I-DNAMutation
domain	I-DNAMutation
of	O
ezrin	B-DNAMutation
eliminated	O
the	O
apical	O
localization	O
of	O
ezrin	B-DNAMutation
.	O

Finally	O
,	O
our	O
study	O
demonstrates	O
the	O
essential	O
role	O
of	O
ezrin-PALS1	B-DNAMutation
interaction	O
in	O
the	O
apical	O
membrane	O
remodeling	O
associated	O
with	O
parietal	O
cell	O
secretion	O
.	O

Taken	O
together	O
,	O
these	O
results	O
define	O
a	O
novel	O
molecular	O
mechanism	O
linking	O
ezrin	B-DNAMutation
to	O
the	O
conserved	O
apical	O
polarity	O
complexes	O
and	O
their	O
roles	O
in	O
polarized	O
epithelial	O
secretion	O
of	O
gastric	O
parietal	O
cells	O
.	O

Positive	O
and	O
negative	O
regulation	O
of	O
nuclear	B-DNAMutation
factor-kappaB-mediated	I-DNAMutation
transcription	O
by	O
IkappaB-zeta	B-DNAMutation
,	O
an	O
inducible	O
nuclear	O
protein	O
.	O

IkappaB-zeta	B-DNAMutation
is	O
an	O
inducible	O
nuclear	O
protein	O
that	O
interacts	O
with	O
nuclear	B-DNAMutation
factor-kappaB	I-DNAMutation
(NF-kappaB)	O
via	O
its	O
carboxyl-terminal	O
ankyrin-repeats	O
.	O

Previous	O
studies	O
using	O
an	O
NF-kappaB	O
reporter	O
have	O
shown	O
that	O
IkappaB-zeta	B-DNAMutation
inhibits	O
the	O
activity	O
of	O
NF-kappaB	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
dissected	O
the	O
amino-terminal	O
region	O
of	O
IkappaB-zeta	B-DNAMutation
,	O
which	O
shows	O
no	O
homology	O
to	O
any	O
other	O
proteins	O
.	O

Indirect	O
immunofluorescence	O
studies	O
demonstrated	O
the	O
presence	O
of	O
a	O
bipartite	O
nuclear	O
localization	O
signal	O
spanning	O
amino	O
acids	O
163-178	O
.	O

Using	O
GAL4	B-DNAMutation
fusion	O
proteins	O
,	O
we	O
found	O
that	O
internal	O
fragments	O
containing	O
amino	O
acids	O
329-402	O
possessed	O
intrinsic	O
transcriptional	O
activation	O
activity	O
.	O

Interestingly	O
,	O
the	O
activity	O
was	O
not	O
detected	O
in	O
GAL4	B-DNAMutation
fusion	O
proteins	O
of	O
the	O
full-length	O
IkappaB-zeta	B-DNAMutation
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
GAL4-dependent	B-DNAMutation
transcriptional	O
activity	O
was	O
generated	O
by	O
co-expression	O
of	O
the	O
GAL4-NF-kappaB	B-DNAMutation
p50	I-DNAMutation
subunit	O
fusion	O
protein	O
and	O
the	O
full-length	O
IkappaB-zeta	B-DNAMutation
,	O
neither	O
of	O
which	O
exhibited	O
the	O
activity	O
on	O
their	O
own	O
.	O

A	O
new	O
splicing	O
variant	O
,	O
IkappaB-zeta(D)	B-DNAMutation
,	O
with	O
a	O
deletion	B-DNAMutation
of	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
236-429	I-DNAMutation
,	O
was	O
found	O
to	O
lack	O
transactivation	O
activity	O
.	O

Forced	O
expression	O
of	O
IkappaB-zeta	B-DNAMutation
,	O
but	O
not	O
IkappaB-zeta(D)	B-DNAMutation
,	O
augmented	O
interleukin-6	B-DNAMutation
production	O
,	O
indicating	O
the	O
functional	O
significance	O
of	O
the	O
transactivation	O
activity	O
.	O

In	O
contrast	O
,	O
tumor	B-DNAMutation
necrosis	I-DNAMutation
factor-alpha	I-DNAMutation
production	O
was	O
inhibited	O
by	O
expression	O
of	O
IkappaB-zeta	B-DNAMutation
,	O
highlighting	O
the	O
dual	O
functions	O
of	O
this	O
molecule	O
.	O

These	O
results	O
indicate	O
that	O
IkappaB-zeta	B-DNAMutation
harbors	O
latent	O
transcriptional	O
activation	O
activity	O
,	O
and	O
that	O
the	O
activity	O
is	O
expressed	O
upon	O
interaction	O
with	O
the	O
NF-kappaB	B-DNAMutation
p50	I-DNAMutation
subunit	O
.	O

In	O
addition	O
to	O
the	O
inhibitory	O
activity	O
on	O
NF-kappaB-mediated	O
transcription	O
,	O
the	O
transcriptional	O
activation	O
activity	O
of	O
IkappaB-zeta	B-DNAMutation
should	O
be	O
crucial	O
for	O
the	O
regulation	O
of	O
inflammation	O
.	O

Proteasome-mediated	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
degradation	O
restricts	O
transcriptional	O
signaling	O
by	O
glucocorticoids	O
.	O

Ligand-dependent	O
down-regulation	O
of	O
the	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
(GR)	O
has	O
been	O
shown	O
to	O
limit	O
hormone	O
responsiveness	O
,	O
but	O
the	O
mechanisms	O
involved	O
in	O
this	O
process	O
are	O
poorly	O
understood	O
.	O

The	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
is	O
a	O
phosphoprotein	O
that	O
upon	O
ligand	O
binding	O
becomes	O
hyperphosphorylated	O
,	O
and	O
recent	O
evidence	O
indicates	O
that	O
phosphorylation	O
status	O
of	O
the	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
plays	O
a	O
prominent	O
role	O
in	O
receptor	O
protein	O
turnover	O
.	O

Because	O
phosphorylation	O
is	O
a	O
key	O
signal	O
for	O
ubiquitination	O
and	O
proteasomal	O
catabolism	O
of	O
many	O
proteins	O
,	O
we	O
evaluated	O
whether	O
the	O
ubiquitin-proteasomal	O
pathway	O
had	O
a	O
role	O
in	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
down-regulation	O
and	O
the	O
subsequent	O
transcriptional	O
response	O
to	O
glucocorticoids	O
.	O

Pretreatment	O
of	O
COS-1	O
cells	O
expressing	O
mouse	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
with	O
the	O
proteasome	O
inhibitor	O
MG-132	O
effectively	O
blocks	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
protein	O
down-regulation	O
by	O
the	O
glucocorticoid	O
dexamethasone	O
.	O

Interestingly	O
,	O
both	O
MG-132	O
and	O
a	O
second	O
proteasome	O
inhibitor	O
beta-lactone	O
significantly	O
enhanced	O
hormone	O
response	O
of	O
transfected	O
mouse	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
toward	O
transcriptional	O
activation	O
of	O
glucocorticoid	B-DNAMutation
receptor-mediated	I-DNAMutation
reporter	O
gene	O
expression	O
.	O

The	O
transcriptional	O
activity	O
of	O
the	O
endogenous	O
human	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
in	O
HeLa	O
cells	O
was	O
also	O
enhanced	O
by	O
MG-132	O
.	O

Direct	O
evidence	O
for	O
ubiquitination	O
of	O
the	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
was	O
obtained	O
by	O
immunoprecipitation	O
of	O
cellular	O
extracts	O
from	O
proteasome-impaired	O
cells	O
.	O

Examination	O
of	O
the	O
primary	O
sequence	O
of	O
mouse	O
,	O
human	O
,	O
and	O
rat	O
glucocorticoid	O
receptor	O
has	O
identified	O
a	O
candidate	O
PEST	O
degradation	O
motif	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
Lys-426	I-DNAMutation
within	O
this	O
PEST	O
element	O
both	O
abrogated	O
ligand-dependent	O
down-regulation	O
of	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
protein	O
and	O
simultaneously	O
enhanced	O
glucocorticoid	B-DNAMutation
receptor-induced	I-DNAMutation
transcriptional	O
activation	O
of	O
gene	O
expression	O
.	O

Unlike	O
wild	O
type	O
GR	O
,	O
proteasomal	O
inhibition	O
failed	O
to	O
enhance	O
significantly	O
transcriptional	O
activity	O
of	O
K426A	B-DNAMutation
mutant	O
GR	O
.	O

Together	O
these	O
findings	O
suggest	O
a	O
major	O
role	O
of	O
the	O
ubiquitin-proteasome	O
pathway	O
in	O
regulating	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
protein	O
turnover	O
,	O
thereby	O
providing	O
a	O
mechanism	O
to	O
terminate	O
glucocorticoid	O
responses	O
.	O

Early-onset	O
Alzheimer's	O
disease	O
caused	O
by	O
mutations	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
717	I-DNAMutation
of	O
the	O
beta-amyloid	O
precursor	O
protein	O
gene	O
.	O

A	O
mutation	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
717	I-DNAMutation
of	O
the	O
beta-amyloid	O
precursor	O
protein	O
gene	O
has	O
been	O
found	O
to	O
cosegregate	O
with	O
familial	O
Alzheimer's	O
disease	O
in	O
a	O
single	O
family	O
.	O

This	O
mutation	O
has	O
been	O
reported	O
in	O
a	O
further	O
five	O
out	O
of	O
approximately	O
100	O
families	O
multiply	O
affected	O
by	O
Alzheimer's	O
disease	O
.	O

We	O
have	O
identified	O
another	O
family	O
,	O
F19	O
,	O
in	O
which	O
we	O
have	O
detected	O
linkage	O
between	O
the	O
beta-amyloid	O
precursor	O
protein	O
gene	O
and	O
Alzheimer's	O
disease	O
.	O

Direct	O
sequencing	O
of	O
exon	O
17	O
in	O
affected	O
individuals	O
from	O
this	O
family	O
has	O
revealed	O
a	O
base	O
change	O
producing	O
a	O
Val----Gly	B-DNAMutation
substitution	I-DNAMutation
,	I-DNAMutation
also	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
717	I-DNAMutation
.	O

The	O
occurrence	O
of	O
a	O
second	O
allelic	O
variant	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
717	I-DNAMutation
linked	O
to	O
the	O
Alzheimer's	O
phenotype	O
supports	O
the	O
hypothesis	O
that	O
they	O
are	O
pathogenic	O
mutations	O
.	O

N-Glycosylation	O
during	O
translation	O
is	O
essential	O
for	O
human	O
arylacetamide	B-DNAMutation
deacetylase	I-DNAMutation
enzyme	O
activity	O
.	O

Human	O
arylacetamide	B-DNAMutation
deacetylase	I-DNAMutation
AADAC	B-DNAMutation
can	O
hydrolyze	O
clinical	O
drugs	O
such	O
as	O
flutamide	O
,	O
phenacetin	O
,	O
and	O
rifamycins	O
.	O

AADAC	B-DNAMutation
is	O
a	O
glycoprotein	O
,	O
but	O
the	O
role	O
of	O
glycosylation	O
remains	O
unclear	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
investigated	O
the	O
effect	O
of	O
glycosylation	O
on	O
AADAC	B-DNAMutation
enzyme	O
activity	O
.	O

Immunoblot	O
analysis	O
of	O
mutant	O
AADACs	O
that	O
contained	O
an	O
asparagine	B-DNAMutation
(	I-DNAMutation
N	I-DNAMutation
,	I-DNAMutation
Asn	I-DNAMutation
)	I-DNAMutation
to	I-DNAMutation
glutamine	I-DNAMutation
(	I-DNAMutation
Q	I-DNAMutation
,	I-DNAMutation
Gln	I-DNAMutation
)	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
either	I-DNAMutation
residue	I-DNAMutation
78	I-DNAMutation
or	I-DNAMutation
282	I-DNAMutation
(	O
N78Q	B-DNAMutation
or	O
N282Q	B-DNAMutation
)	O
showed	O
a	O
different	O
migration	O
compared	O
with	O
the	O
wild-type	O
protein	O
.	O

A	O
mutant	O
AADAC	B-DNAMutation
that	O
contained	O
N	B-DNAMutation
to	I-DNAMutation
Q	I-DNAMutation
substitutions	I-DNAMutation
at	I-DNAMutation
both	I-DNAMutation
residue	I-DNAMutation
78	I-DNAMutation
and	I-DNAMutation
282	I-DNAMutation
N78Q/N282Q	B-DNAMutation
showed	O
a	O
similar	O
migration	O
to	O
AADAC	B-DNAMutation
in	O
human	O
liver	O
microsomes	O
(HLM)	O
treated	O
with	O
endoglycosidase	O
H	O
(	O
Endo	O
H	O
)	O
,	O
which	O
produces	O
deglycosylated	O
proteins	O
.	O

This	O
result	O
indicated	O
that	O
AADAC	B-DNAMutation
was	O
glycosylated	O
at	O
both	O
N78	O
and	O
N282	O
.	O

Mutant	O
types	O
of	O
AADAC	B-DNAMutation
with	O
the	O
N282Q	B-DNAMutation
and	O
the	O
N78Q/N282Q	B-DNAMutation
substitutions	O
showed	O
dramatically	O
lower	O
phenacetin	O
hydrolase	O
activity	O
than	O
did	O
the	O
wild-type	O
protein	O
.	O

The	O
treatment	O
of	O
wild-type	O
AADAC-expressing	B-DNAMutation
HuH-7	O
cells	O
with	O
tunicamycin	O
,	O
which	O
produces	O
unglycosylated	O
protein	O
,	O
decreased	O
AADAC	B-DNAMutation
enzyme	O
activity	O
.	O

However	O
,	O
the	O
treatment	O
of	O
the	O
HLM	O
with	O
Endo	O
H	O
caused	O
no	O
decrease	O
of	O
AADAC	B-DNAMutation
activity	O
.	O

Thus	O
,	O
the	O
oligosaccharide	O
chain	O
,	O
per	O
se	O
,	O
was	O
not	O
important	O
for	O
AADAC	B-DNAMutation
activity	O
in	O
the	O
mature	O
form	O
.	O

The	O
mutant	O
types	O
of	O
AADAC	B-DNAMutation
containing	O
the	O
N282Q	B-DNAMutation
and	O
the	O
N78Q/N282Q	B-DNAMutation
substitutions	O
were	O
not	O
detected	O
by	O
immunoblotting	O
analysis	O
after	O
non-reducing	O
SDS-PAGE	O
,	O
suggesting	O
that	O
the	O
glycosylation	O
of	O
AADAC	B-DNAMutation
at	O
N282	O
was	O
important	O
for	O
proper	O
protein	O
folding	O
.	O

Overall	O
,	O
this	O
study	O
found	O
that	O
the	O
translational	O
,	O
but	O
not	O
post-translational	O
,	O
N-glycosylation	O
of	O
AADAC	B-DNAMutation
plays	O
a	O
crucial	O
role	O
in	O
regulating	O
AADAC	B-DNAMutation
enzyme	O
activity	O
.	O

Novel	O
splicing	O
,	O
missense	O
,	O
and	O
deletion	O
mutations	O
in	O
seven	O
adenosine	B-DNAMutation
deaminase-deficient	I-DNAMutation
patients	O
with	O
late/delayed	O
onset	O
of	O
combined	O
immunodeficiency	O
disease	O
.	O

Contribution	O
of	O
genotype	O
to	O
phenotype	O
.	O

We	O
examined	O
the	O
genetic	O
basis	O
for	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
ADA	B-DNAMutation
deficiency	O
in	O
seven	O
patients	O
with	O
late/delayed	O
onset	O
of	O
immunodeficiency	O
,	O
an	O
underdiagnosed	O
and	O
relatively	O
unstudied	O
condition	O
.	O

Deoxyadenosine-mediated	O
metabolic	O
abnormalities	O
were	O
less	O
severe	O
than	O
in	O
the	O
usual	O
,	O
early-onset	O
disorder	O
.	O

Six	O
patients	O
were	O
compound	O
heterozygotes	O
;	O
7	O
of	O
10	O
mutations	O
found	O
were	O
novel	O
,	O
including	O
one	O
deletion	O
(	O
delta	B-DNAMutation
1019-1020	I-DNAMutation
)	O
,	O
three	B-DNAMutation
missense	I-DNAMutation
(	I-DNAMutation
Arg156	I-DNAMutation
>	I-DNAMutation
His	I-DNAMutation
,	O
Arg101	B-DNAMutation
>	I-DNAMutation
Leu	I-DNAMutation
,	O
Val177	B-DNAMutation
>	I-DNAMutation
Met	I-DNAMutation
)	O
,	O
and	O
three	O
splicing	O
defects	O
(	O
IVS	B-DNAMutation
5	I-DNAMutation
,	I-DNAMutation
5'ss	I-DNAMutation
T+6	I-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
;	O
IVS	B-DNAMutation
10	I-DNAMutation
,	I-DNAMutation
5'ss	I-DNAMutation
G+1	I-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
;	O
IVS	B-DNAMutation
10	I-DNAMutation
,	I-DNAMutation
3'ss	I-DNAMutation
G-34	I-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
)	O
.	O

Four	O
of	O
the	O
mutations	O
generated	O
stop	O
signals	O
at	O
codons	O
131	O
,	O
321	O
,	O
334	O
,	O
and	O
348	O
;	O
transcripts	O
of	O
all	O
but	O
the	O
last	O
,	O
due	O
to	O
delta	B-DNAMutation
1019-1020	I-DNAMutation
,	O
were	O
severely	O
reduced	O
.	O

delta	B-DNAMutation
1019-1020	I-DNAMutation
(	O
like	O
delta	B-DNAMutation
955-959	I-DNAMutation
,	O
found	O
in	O
one	O
patient	O
and	O
apparently	O
recurrent	O
)	O
is	O
at	O
a	O
short	O
deletional	O
hot	O
spot	O
.	O

Arg156	B-DNAMutation
>	I-DNAMutation
His	I-DNAMutation
,	O
the	O
product	O
of	O
which	O
had	O
detectable	O
activity	O
,	O
was	O
found	O
in	O
three	O
patients	O
whose	O
second	O
alleles	O
were	O
unlikely	O
to	O
yield	O
active	O
ADA	B-DNAMutation
.	O

The	O
oldest	O
patient	O
diagnosed	O
was	O
homozygous	O
for	O
a	O
single	B-DNAMutation
base	I-DNAMutation
change	I-DNAMutation
in	I-DNAMutation
intron	I-DNAMutation
10	I-DNAMutation
,	O
which	O
activates	O
a	O
cryptic	O
splice	O
acceptor	O
,	O
resulting	O
in	O
a	O
protein	O
with	O
100	O
extra	O
amino	O
acids	O
.	O

We	O
speculate	O
that	O
this	O
"macro	O
ADA,"	B-DNAMutation
as	O
well	O
as	O
the	O
Arg156	B-DNAMutation
>	I-DNAMutation
His	I-DNAMutation
,	O
Arg101	B-DNAMutation
>	I-DNAMutation
Leu	I-DNAMutation
,	O
Ser291	B-DNAMutation
>	I-DNAMutation
Leu	I-DNAMutation
,	O
and	O
delta	B-DNAMutation
1019-1020	I-DNAMutation
products	O
,	O
may	O
contribute	O
to	O
mild	O
phenotype	O
.	O

Tissue-specific	O
variation	O
in	O
splicing	O
efficiency	O
may	O
also	O
ameliorate	O
disease	O
severity	O
in	O
patients	O
with	O
splicing	O
mutations	O
.	O

The	O
TC10-interacting	B-DNAMutation
protein	O
CIP4/2	B-DNAMutation
is	O
required	O
for	O
insulin-stimulated	B-DNAMutation
Glut4	B-DNAMutation
translocation	O
in	O
3T3L1	O
adipocytes	O
.	O

The	O
GTPase	O
TC10	B-DNAMutation
plays	O
a	O
critical	O
role	O
in	O
insulin-stimulated	B-DNAMutation
glucose	O
transport	O
.	O

We	O
report	O
here	O
the	O
identification	O
of	O
the	O
TC10-interacting	B-DNAMutation
protein	O
CIP4/2	B-DNAMutation
(	O
Cdc42-interacting	B-DNAMutation
protein	I-DNAMutation
4/2	I-DNAMutation
)	O
as	O
an	O
effector	O
in	O
this	O
pathway	O
.	O

CIP4/2	B-DNAMutation
localizes	O
to	O
an	O
intracellular	O
compartment	O
under	O
basal	O
conditions	O
and	O
translocates	O
to	O
the	O
plasma	O
membrane	O
on	O
insulin	B-DNAMutation
stimulation	O
.	O

Overexpression	O
of	O
constitutively	O
active	O
TC10	B-DNAMutation
brings	O
CIP4/2	B-DNAMutation
to	O
the	O
plasma	O
membrane	O
,	O
whereas	O
overexpression	O
of	O
an	O
inhibitory	O
form	O
of	O
TC10	B-DNAMutation
blocks	O
the	O
translocation	O
of	O
CIP4/2	B-DNAMutation
produced	O
by	O
insulin	B-DNAMutation
.	O

Overexpression	O
of	O
mutant	O
forms	O
of	O
CIP4/2	B-DNAMutation
containing	O
an	O
N-terminal	B-DNAMutation
deletion	I-DNAMutation
or	O
with	O
diminished	O
TC10	B-DNAMutation
binding	O
inhibits	O
insulin-stimulated	B-DNAMutation
Glut4	B-DNAMutation
translocation	O
.	O

These	O
data	O
suggest	O
that	O
CIP4/2	B-DNAMutation
may	O
play	O
an	O
important	O
role	O
in	O
insulin-stimulated	B-DNAMutation
glucose	O
transport	O
as	O
a	O
downstream	O
effector	O
of	O
TC10	B-DNAMutation
.	O

Functional	O
relevance	O
of	O
a	O
novel	O
SlyX	O
motif	O
in	O
non-conventional	O
secretion	O
of	O
insulin-degrading	O
enzyme	O
.	O

Insulin-degrading	O
enzyme	O
(IDE)	O
is	O
a	O
Zn(2+)	O
metalloprotease	O
with	O
a	O
characteristic	O
inverted	O
catalytic	O
motif	O
.	O

IDE	O
is	O
ubiquitously	O
expressed	O
and	O
degrades	O
peptide	O
substrates	O
including	O
insulin	O
,	O
endorphin	O
,	O
and	O
the	O
amyloid-Î²	O
peptide	O
.	O

Although	O
IDE	O
is	O
mainly	O
expressed	O
in	O
the	O
cytosol	O
,	O
it	O
can	O
also	O
be	O
found	O
on	O
the	O
cell	O
surface	O
and	O
in	O
secreted	O
form	O
in	O
extracellular	O
fluids	O
.	O

As	O
IDE	O
lacks	O
a	O
characteristic	O
signal	O
sequence	O
that	O
targets	O
the	O
protein	O
to	O
the	O
classical	O
secretory	O
pathway	O
,	O
release	O
of	O
the	O
enzyme	O
involves	O
non-conventional	O
mechanisms	O
.	O

However	O
,	O
functional	O
domains	O
of	O
IDE	O
involved	O
in	O
its	O
secretion	O
remain	O
elusive	O
.	O

By	O
bioinformatical	O
,	O
biochemical	O
,	O
and	O
cell	O
biological	O
methods	O
,	O
we	O
identified	O
a	O
novel	O
amino	O
acid	O
motif	O
((853)EKPPHY(858))	O
close	O
to	O
the	O
C	O
terminus	O
of	O
IDE	O
and	O
characterized	O
its	O
function	O
in	O
the	O
non-conventional	O
secretion	O
of	O
the	O
protein	O
.	O

Because	O
of	O
its	O
close	O
homology	O
to	O
an	O
amino	O
acid	O
sequence	O
found	O
in	O
bacterial	O
proteins	O
belonging	O
to	O
the	O
SlyX	O
family	O
,	O
we	O
propose	O
to	O
call	O
it	O
the	O
SlyX	O
motif	O
.	O

Mutagenesis	O
revealed	O
that	B-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
this	I-DNAMutation
motif	I-DNAMutation
strongly	O
decreased	O
the	O
release	O
of	O
IDE	O
,	O
whereas	B-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
potential	I-DNAMutation
microbody-targeting	I-DNAMutation
signal	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
extreme	I-DNAMutation
C	I-DNAMutation
terminus	I-DNAMutation
had	O
little	O
effect	O
on	O
secretion	O
.	O

The	O
combined	O
data	O
indicate	O
that	O
the	O
non-conventional	O
secretion	O
of	O
IDE	O
is	O
regulated	O
by	O
the	O
newly	O
identified	O
SlyX	O
motif	O
.	O

Molecular	O
analysis	O
of	O
the	O
genotype-phenotype	O
relationship	O
in	O
factor	O
VII	O
deficiency	O
.	O

Factor	O
VII	O
(FVII)	O
deficiency	O
is	O
a	O
rare	O
haemorrhagic	O
condition	O
,	O
normally	O
inherited	O
as	O
an	O
autosomal	O
recessive	O
trait	O
,	O
in	O
which	O
clinical	O
presentation	O
is	O
highly	O
variable	O
and	O
correlates	O
poorly	O
with	O
laboratory	O
phenotype	O
.	O

The	O
FVII	O
(F7)	O
gene	O
was	O
sequenced	O
in	O
48	O
unrelated	O
individuals	O
with	O
FVII	O
deficiency	O
,	O
yielding	O
a	O
total	O
of	O
23	O
novel	O
lesions	O
including	O
15	O
missense	O
mutations	O
,	O
2	O
micro-deletions	O
,	O
5	O
splice	O
junction	O
mutations	O
and	O
a	O
single	O
base-pair	O
substitution	O
in	O
the	O
5'	O
untranslated	O
region	O
.	O

Family	O
studies	O
were	O
performed	O
in	O
order	O
to	O
distinguish	O
the	O
contributions	O
of	O
individual	O
mutant	O
F7	O
alleles	O
to	O
the	O
clinical	O
and	O
laboratory	O
phenotypes	O
.	O

Specific	O
missense	O
mutations	O
were	O
evaluated	O
by	O
molecular	O
modelling	O
in	O
the	O
context	O
of	O
the	O
FVIIa-tissue	O
factor	O
crystal	O
structure	O
.	O

Single	O
base-pair	O
substitutions	O
in	O
splice	O
sites	O
and	O
the	O
5'	O
untranslated	O
region	O
were	O
studied	O
by	O
in	O
vitro	O
splicing	O
assay	O
and	O
luciferase	O
reporter	O
gene	O
assay	O
,	O
respectively	O
.	O

All	O
probands	O
were	O
also	O
typed	O
for	O
four	O
previously	O
reported	O
F7	O
polymorphisms	O
.	O

In	O
the	O
majority	O
of	O
cases	O
of	O
FVII	O
deficiency	O
studied	O
here	O
,	O
consideration	O
of	O
both	O
mutational	O
and	O
polymorphism	O
data	O
permitted	O
the	O
derivation	O
of	O
plausible	O
explanations	O
for	O
the	O
FVII	O
activity	O
and	O
antigen	O
levels	O
measured	O
in	O
the	O
laboratory	O
.	O

Inter-familial	O
variation	O
in	O
FVII	O
activity	O
and	O
the	O
antigen	O
levels	O
of	O
heterozygous	O
relatives	O
of	O
probands	O
was	O
found	O
to	O
be	O
significantly	O
higher	O
than	O
intra-familial	O
variation	O
,	O
consistent	O
with	O
the	O
view	O
that	O
the	O
nature	O
of	O
the	O
F7	O
gene	O
lesion(s)	O
segregating	O
in	O
a	O
given	O
family	O
is	O
a	O
prime	O
determinant	O
of	O
laboratory	O
phenotype	O
.	O

Although	O
no	O
relationship	O
could	O
be	O
discerned	O
between	O
laboratory	O
phenotype	O
and	O
polymorphism	O
genotype	O
,	O
the	O
frequencies	O
of	O
the	O
A2	O
and	O
M2	O
polymorphic	O
alleles	O
were	O
significantly	O
higher	O
in	O
the	O
FVII-deficient	O
individuals	O
tested	O
than	O
in	O
controls	O
.	O

This	O
suggests	O
that	O
the	O
presence	O
of	O
these	O
alleles	O
may	O
have	O
served	O
to	O
increase	O
the	O
likelihood	O
of	O
pathological	O
F7	O
gene	O
lesions	O
coming	O
to	O
clinical	O
attention	O
.	O

A	O
leucine-to-phenylalanine	B-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
acetylcholine	I-DNAMutation
receptor	I-DNAMutation
ion	I-DNAMutation
channel	I-DNAMutation
in	O
a	O
family	O
with	O
the	O
slow-channel	O
syndrome	O
.	O

The	O
slow-channel	O
syndrome	O
is	O
one	O
of	O
several	O
congenital	O
myasthenic	O
syndromes	O
that	O
result	O
from	O
inherited	O
abnormalities	O
of	O
the	O
ion	O
channel	O
of	O
the	O
skeletal	O
muscle	O
acetylcholine	O
receptor	O
(AChR)	O
.	O

The	O
ion	O
channel	O
is	O
formed	O
by	O
the	O
second	O
transmembrane	O
domains	O
(M2)	O
of	O
the	O
four	O
AChR	O
subunits	O
.	O

We	O
screened	O
the	O
genomic	O
DNA	O
of	O
one	O
family	O
with	O
the	O
slow-channel	O
syndrome	O
for	O
mutations	O
in	O
the	O
coding	O
sequences	O
for	O
the	O
M2	O
domains	O
of	O
the	O
four	O
AChR	O
subunits	O
and	O
report	O
the	O
identification	O
of	O
a	O
missense	O
mutation	O
that	O
causes	O
a	O
leucine-to-phenylalanine	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
269	I-DNAMutation
of	O
the	O
epsilon	O
subunit	O
in	O
three	O
affected	O
members	O
of	O
a	O
family	O
with	O
the	O
slow-channel	O
syndrome	O
.	O

We	O
propose	O
that	O
this	O
mutation	O
may	O
be	O
responsible	O
for	O
the	O
disease	O
.	O

The	O
beta	O
A4	O
amyloid	O
precursor	O
protein	O
binding	O
to	O
copper	O
.	O

Previously	O
it	O
has	O
been	O
shown	O
that	O
the	O
extracellular	O
domain	O
of	O
transmembrane	O
beta	O
A4	O
amyloid	O
precursor	O
protein	O
(APP)	O
includes	O
binding	O
sites	O
for	O
zinc(II)	O
and	O
for	O
molecules	O
of	O
the	O
extracellular	O
matrix	O
such	O
as	O
collagen	O
,	O
laminin	O
and	O
the	O
heparin	O
sulfate	O
chains	O
of	O
proteoglycans	O
(HSPGs)	O
.	O

Here	O
we	O
report	O
that	O
APP	O
also	O
binds	O
copper	O
ions	O
.	O

A	O
copper	O
type	O
II	O
binding	O
site	O
was	O
located	O
within	O
residues	O
135-155	O
of	O
the	O
cysteine-rich	O
domain	O
of	O
APP695	O
which	O
is	O
present	O
in	O
all	O
eight	O
APP	O
splice	O
isoforms	O
known	O
so	O
far	O
.	O

The	O
two	O
essential	O
histidines	O
in	O
the	O
type	O
II	O
copper	O
binding	O
site	O
of	O
APP	O
are	O
conserved	O
in	O
the	O
related	O
protein	O
APLP2	B-DNAMutation
.	O

Copper(II)	O
binding	O
is	O
shown	O
to	O
inhibit	O
homophilic	O
APP	O
binding	O
.	O

The	O
identification	O
of	O
a	O
copper(II)	O
binding	O
site	O
in	O
APP	O
suggests	O
that	O
APP	O
and	O
APLP2	B-DNAMutation
may	O
be	O
involved	O
in	O
electron	O
transfer	O
and	O
radical	O
reactions	O
.	O

Stabilization	O
of	O
non-productive	O
conformations	O
underpins	O
rapid	O
electron	O
transfer	O
to	O
electron-transferring	O
flavoprotein	O
.	O

Crystal	O
structures	O
of	O
protein	O
complexes	O
with	O
electron-transferring	O
flavoprotein	O
(ETF)	O
have	O
revealed	O
a	O
dual	O
protein-protein	O
interface	O
with	O
one	O
region	O
serving	O
as	O
anchor	O
while	O
the	O
ETF	O
FAD	O
domain	O
samples	O
available	O
space	O
within	O
the	O
complex	O
.	O

We	O
show	O
that	O
mutation	O
of	O
the	O
conserved	B-DNAMutation
Glu-165beta	I-DNAMutation
in	O
human	O
ETF	O
leads	O
to	O
drastically	O
modulated	O
rates	O
of	O
interprotein	O
electron	O
transfer	O
with	O
both	O
medium	B-DNAMutation
chain	I-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
and	O
dimethylglycine	O
dehydrogenase	O
.	O

The	O
crystal	O
structure	O
of	O
free	O
E165betaA	O
ETF	O
is	O
essentially	O
identical	O
to	O
that	O
of	O
wild-type	O
ETF	O
,	O
but	O
the	O
crystal	O
structure	O
of	O
the	O
E165betaA	O
ETF.medium	B-DNAMutation
chain	I-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
complex	O
reveals	O
clear	O
electron	O
density	O
for	O
the	O
FAD	O
domain	O
in	O
a	O
position	O
optimal	O
for	O
fast	O
interprotein	O
electron	O
transfer	O
.	O

Based	O
on	O
our	O
observations	O
,	O
we	O
present	O
a	O
dynamic	O
multistate	O
model	O
for	O
conformational	O
sampling	O
that	O
for	O
the	O
wild-type	O
ETF	O
.	O

medium	B-DNAMutation
chain	I-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
complex	O
involves	O
random	O
motion	O
between	O
three	O
distinct	O
positions	O
for	O
the	O
ETF	O
FAD	O
domain	O
.	O

ETF	O
Glu-165beta	O
plays	O
a	O
key	O
role	O
in	O
stabilizing	O
positions	O
incompatible	O
with	O
fast	O
interprotein	O
electron	O
transfer	O
,	O
thus	O
ensuring	O
high	O
rates	O
of	O
complex	O
dissociation	O
.	O

Chylomicronemia	O
with	O
a	O
mutant	O
GPIHBP1	B-DNAMutation
Q115P	B-DNAMutation
that	O
cannot	O
bind	O
lipoprotein	O
lipase	O
.	O

OBJECTIVE	O
:	O
GPIHBP1	B-DNAMutation
is	O
an	O
endothelial	O
cell	O
protein	O
that	O
binds	O
lipoprotein	O
lipase	O
(LPL)	O
and	O
chylomicrons	O
.	O

Because	O
GPIHBP1	B-DNAMutation
deficiency	O
causes	O
chylomicronemia	O
in	O
mice	O
,	O
we	O
sought	O
to	O
determine	O
whether	O
some	O
cases	O
of	O
chylomicronemia	O
in	O
humans	O
could	O
be	O
attributable	O
to	O
defective	O
GPIHBP1	B-DNAMutation
proteins	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
Patients	O
with	O
severe	O
hypertriglyceridemia	O
(	O
n=60	O
,	O
with	O
plasma	O
triglycerides	O
above	O
the	O
95th	O
percentile	O
for	O
age	O
and	O
gender	O
)	O
were	O
screened	O
for	O
mutations	O
in	O
GPIHBP1	B-DNAMutation
.	O

A	O
homozygous	O
GPIHBP1	B-DNAMutation
mutation	O
c.344A>C	B-DNAMutation
that	O
changed	B-DNAMutation
a	I-DNAMutation
highly	I-DNAMutation
conserved	I-DNAMutation
glutamine	I-DNAMutation
at	I-DNAMutation
residue	I-DNAMutation
115	I-DNAMutation
to	I-DNAMutation
a	I-DNAMutation
proline	I-DNAMutation
p.Q115P	B-DNAMutation
was	O
identified	O
in	O
a	O
33-year-old	O
male	O
with	O
lifelong	O
chylomicronemia	O
.	O

The	O
patient	O
had	O
failure-to-thrive	O
as	O
a	O
child	O
but	O
had	O
no	O
history	O
of	O
pancreatitis	O
.	O

He	O
had	O
no	O
mutations	O
in	O
LPL	O
,	O
APOA5	O
,	O
or	O
APOC2	O
.	O

The	O
Q115P	B-DNAMutation
substitution	O
did	O
not	O
affect	O
the	O
ability	O
of	O
GPIHBP1	B-DNAMutation
to	O
reach	O
the	O
cell	O
surface	O
.	O

However	O
,	O
unlike	O
wild-type	O
GPIHBP1	B-DNAMutation
,	O
GPIHBP1-Q115P	B-DNAMutation
lacked	O
the	O
ability	O
to	O
bind	O
LPL	O
or	O
chylomicrons	O
(	O
d	O
<	O
1.006	O
g/mL	O
lipoproteins	O
from	O
Gpihbp1(-/-)	O
mice	O
)	O
.	O

Mouse	O
GPIHBP1	B-DNAMutation
with	O
the	O
corresponding	O
mutation	O
Q114P	B-DNAMutation
also	O
could	O
not	O
bind	O
LPL	O
.	O

CONCLUSIONS	O
:	O
A	O
homozygous	O
missense	O
mutation	O
in	O
GPIHBP1	B-DNAMutation
(Q115P)	O
was	O
identified	O
in	O
a	O
patient	O
with	O
chylomicronemia	O
.	O

The	O
mutation	O
eliminated	O
the	O
ability	O
of	O
GPIHBP1	B-DNAMutation
to	O
bind	O
LPL	O
and	O
chylomicrons	O
,	O
strongly	O
suggesting	O
that	O
it	O
caused	O
the	O
patient's	O
chylomicronemia	O
.	O

Congenital	O
myasthenic	O
syndrome	O
caused	O
by	O
prolonged	O
acetylcholine	O
receptor	O
channel	O
openings	O
due	O
to	O
a	O
mutation	O
in	O
the	O
M2	O
domain	O
of	O
the	O
epsilon	O
subunit	O
.	O

In	O
a	O
congenital	O
myasthenic	O
syndrome	O
with	O
a	O
severe	O
endplate	O
myopathy	O
,	O
patch-clamp	O
studies	O
revealed	O
markedly	O
prolonged	O
acetylcholine	O
receptor	O
(AChR)	O
channel	O
openings	O
.	O

Molecular	O
genetic	O
analysis	O
of	O
AChR	O
subunit	O
genes	O
demonstrated	O
a	O
heterozygous	O
adenosine-to-cytosine	B-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
790	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
8	I-DNAMutation
of	O
the	O
epsilon-subunit	O
gene	O
,	O
predicting	O
substitution	O
of	O
proline	B-DNAMutation
for	I-DNAMutation
threonine	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
264	I-DNAMutation
and	O
no	O
other	O
mutations	O
in	O
the	O
entire	O
coding	O
sequences	O
of	O
genes	O
encoding	O
the	O
alpha	O
,	O
beta	O
,	O
delta	O
,	O
and	O
epsilon	O
subunits	O
.	O

Genetically	O
engineered	O
mutant	O
AChR	O
expressed	O
in	O
a	O
human	O
embryonic	O
kidney	O
fibroblast	O
cell	O
line	O
also	O
exhibited	O
markedly	O
prolonged	O
openings	O
in	O
the	O
presence	O
of	O
agonist	O
and	O
even	O
opened	O
in	O
its	O
absence	O
.	O

The	O
Thr-264-->Pro	B-DNAMutation
mutation	O
in	O
the	O
epsilon	O
subunit	O
involves	O
a	O
highly	O
conserved	O
residue	O
in	O
the	O
M2	O
domain	O
lining	O
the	O
channel	O
pore	O
and	O
is	O
likely	O
to	O
disrupt	O
the	O
putative	O
M2	O
alpha-helix	O
.	O

Our	O
findings	O
indicate	O
that	O
a	O
single	O
mutation	O
at	O
a	O
critical	O
site	O
can	O
greatly	O
alter	O
AChR	O
channel	O
kinetics	O
,	O
leading	O
to	O
a	O
congenital	O
myasthenic	O
syndrome	O
.	O

This	O
observation	O
raises	O
the	O
possibility	O
that	O
mutations	O
involving	O
subunits	O
of	O
other	O
ligand-gated	O
channels	O
may	O
also	O
exist	O
and	O
be	O
the	O
basis	O
of	O
various	O
other	O
neurologic	O
or	O
psychiatric	O
disorders	O
.	O

The	O
KrÃ¼ppel-like	O
zinc	O
finger	O
protein	O
Glis2	O
functions	O
as	O
a	O
negative	O
modulator	O
of	O
the	O
Wnt/beta-catenin	B-DNAMutation
signaling	O
pathway	O
.	O

To	O
gain	O
insight	O
into	O
the	O
mechanism	O
by	O
which	O
Gli-similar	O
2	O
(Glis2)	O
regulates	O
transcription	O
,	O
we	O
performed	O
yeast-two	O
hybrid	O
cDNA	O
library	O
screening	O
using	O
Glis2	O
as	O
bait	O
.	O

This	O
screening	O
identified	B-DNAMutation
beta-catenin	I-DNAMutation
as	O
a	O
potential	O
Glis2-interacting	O
protein	O
.	O

Mammalian	O
two-hybrid	O
,	O
co-immunoprecipitation	O
,	O
and	O
GST-pulldown	O
analyses	O
supported	O
the	O
interaction	O
between	O
Glis2	O
and	B-DNAMutation
beta-catenin	I-DNAMutation
.	O

Pulldown	O
analyses	O
with	O
several	B-DNAMutation
Glis2	I-DNAMutation
deletion	I-DNAMutation
mutants	O
indicated	O
that	O
the	O
1st	O
zinc	O
finger	O
motif	O
of	O
Glis2	O
is	O
critical	O
for	O
its	O
interaction	O
with	B-DNAMutation
beta-catenin	I-DNAMutation
,	O
while	O
the	O
armadillo	O
repeats	O
of	B-DNAMutation
beta-catenin	I-DNAMutation
are	O
important	O
in	O
its	O
interaction	O
with	O
Glis2	O
.	O

Reporter	O
analyses	O
showed	O
that	O
Glis2	O
represses	O
T-cell	O
factor	O
(TCF)-mediated	O
transcriptional	O
activation	O
.	O

In	O
addition	O
,	O
Glis2	O
represses	O
the	O
expression	O
of	O
the	O
TCF	O
target	O
gene	B-DNAMutation
cyclin	I-DNAMutation
D1	O
.	O

Our	O
results	O
indicate	O
that	O
Glis2	O
interacts	O
with	B-DNAMutation
beta-catenin	I-DNAMutation
and	O
suggest	O
that	O
Glis2	O
functions	O
as	O
a	O
negative	O
modulator	O
of	B-DNAMutation
beta-catenin/TCF-mediated	I-DNAMutation
transcription	O
.	O

ABCA12	B-DNAMutation
is	O
the	O
major	O
harlequin	O
ichthyosis	O
gene	O
.	O

Harlequin	O
ichthyosis	O
(HI)	O
is	O
the	O
most	O
severe	O
form	O
of	O
autosomal-recessive	O
,	O
congenital	O
ichthyosis	O
.	O

Affected	O
infants	O
have	O
markedly	O
impaired	O
barrier	O
function	O
and	O
are	O
more	O
susceptible	O
to	O
infection	O
.	O

Abnormalities	O
in	O
the	O
localization	O
of	O
epidermal	O
lipids	O
as	O
well	O
as	O
abnormal	O
lamellar	O
granule	O
formation	O
are	O
features	O
of	O
HI	O
skin	O
.	O

Previously	O
,	O
we	O
and	O
others	O
have	O
shown	O
that	O
mutations	O
in	O
the	O
ABCA12	B-DNAMutation
gene	O
encoding	O
an	O
adenosine	O
triphosphate-binding	O
cassette	O
(ABC)	O
transporter	O
underlie	O
the	O
skin	O
disease	O
HI	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
sequenced	O
the	O
ABCA12	B-DNAMutation
gene	O
in	O
an	O
additional	O
14	O
patients	O
and	O
show	O
that	O
all	O
contain	O
mutations	O
,	O
with	O
the	O
majority	O
being	O
either	O
nonsense	O
substitution	O
or	O
frameshift	O
mutations	O
.	O

Eleven	O
HI	O
patients	O
had	O
bi-allelic	O
ABCA12	B-DNAMutation
mutations	O
,	O
whereas	O
in	O
the	O
remaining	O
three	O
HI	O
patients	O
in	O
this	O
study	O
,	O
ABCA12	B-DNAMutation
mutations	O
were	O
detected	O
on	O
only	O
one	O
allele	O
by	O
sequencing	O
.	O

In	O
addition	O
,	O
the	O
one	O
patient	O
from	O
the	O
previous	O
study	O
where	O
no	O
sequence	O
mutations	O
were	O
detected	O
was	O
screened	O
for	O
heterozygous	O
deletions	O
.	O

A	O
combination	O
of	O
oligonucleotide	O
arrays	O
,	O
multiplex	O
PCR	O
analysis	O
and	O
single-nucleotide	O
polymorphism	O
genotyping	O
revealed	O
a	O
heterozygous	B-DNAMutation
intragenic	I-DNAMutation
deletion	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
8	I-DNAMutation
.	O

These	O
mutation	O
data	O
establish	O
ABCA12	B-DNAMutation
as	O
the	O
major	O
HI	O
gene	O
.	O

Alpha	B-DNAMutation
1a-adrenoceptor	I-DNAMutation
polymorphism	O
:	O
pharmacological	O
characterization	O
and	O
association	O
with	O
benign	O
prostatic	O
hypertrophy	O
.	O

1	O
.	O

Two	O
restriction	O
fragment	O
length	O
polymorphisms	O
of	O
the	O
human	O
alpha	B-DNAMutation
1a-adrenoceptor	I-DNAMutation
gene	O
digested	O
with	O
PstI	B-DNAMutation
restriction	O
enzyme	O
exist	O
;	O
the	O
nucleotide	O
change	O
causes	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
C	I-DNAMutation
residue	I-DNAMutation
for	I-DNAMutation
T	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
1441	I-DNAMutation
,	O
thereby	O
Arg492	B-DNAMutation
to	I-DNAMutation
Cys492	I-DNAMutation
transition	O
,	O
which	O
might	O
confer	O
an	O
additional	O
putative	O
palmitoylation	O
site	O
in	O
the	O
carboxy-terminal	O
segment	O
of	O
the	O
alpha	B-DNAMutation
1a-adrenoceptor	I-DNAMutation
.	O

In	O
the	O
present	O
study	O
,	O
we	O
compared	O
their	O
pharmacological	O
properties	O
and	O
examined	O
whether	O
this	O
alpha	B-DNAMutation
1a-adrenoceptor	I-DNAMutation
polymorphism	O
is	O
associated	O
with	O
benign	O
prostatic	O
hypertrophy	O
(BPH)	O
.	O

2	O
.	O

The	O
frequency	O
of	O
alpha	B-DNAMutation
1a-adrenoceptor	I-DNAMutation
polymorphism	O
was	O
not	O
differently	O
distributed	O
between	O
patients	O
with	O
benign	O
prostatic	O
hypertrophy	O
(BPH)	O
and	O
normal	O
subjects	O
in	O
Japan	O
;	O
thus	O
,	O
the	O
relative	O
frequencies	O
of	O
the	O
C	O
and	O
T	O
alleles	O
were	O
0.90	O
:	O
0.10	O
in	O
normal	O
male	O
subjects	O
(	O
n	O
=	O
45	O
)	O
and	O
0.87	O
:	O
0.13	O
in	O
BPH	O
patients	O
(	O
n	O
=	O
222	O
)	O
,	O
respectively	O
.	O

However	O
,	O
the	O
frequency	O
distribution	O
of	O
this	O
polymorphism	O
was	O
significantly	O
different	O
between	O
the	O
Japanese	O
and	O
U.S	O
.	O

populations	O
;	O
thus	O
,	O
C	O
and	O
T	O
alleles	O
were	O
0.34	O
and	O
0.66	O
in	O
U.S	O
.	O

populations	O
.	O

3	O
.	O

Utilizing	O
Chinese	O
hamster	O
ovary	O
(CHO)	O
cells	O
stably	O
expressing	O
the	O
two	O
polymorphic	O
alpha	O
1a-adrenoceptors	O
(	O
Arg492	O
and	O
Cys492	O
)	O
,	O
we	O
compared	O
their	O
binding	O
affinity	O
and	O
signal	O
transduction	O
.	O

Radioligand	O
binding	O
studies	O
with	O
2-[beta-(4-hydroxy-3[125I]-iodophenyl	O
)	O
ethylamino-methyl]tetralone	O
([125I]-HEAT)	O
showed	O
no	O
marked	O
difference	O
in	O
the	O
antagonist	O
or	O
agonist	O
binding	O
affinities	O
between	O
the	O
two	O
receptors	O
.	O

Also	O
,	O
both	O
receptors	O
were	O
found	O
to	O
be	O
coupled	O
to	O
the	O
calcium	O
signaling	O
,	O
and	O
the	O
concentration-cytosolic	O
Ca2+	O
concentrations	O
([Ca2+]i)	O
response	O
relationships	O
for	O
noradrenaline	O
were	O
similar	O
for	O
the	O
two	O
polymorphic	O
receptors	O
.	O

Furthermore	O
,	O
the	O
receptor-mediated	O
[Ca2+]i	O
response	O
was	O
markedly	O
desensitized	O
after	O
a	O
2	O
h	O
exposure	O
of	O
phenylephrine	O
(	O
10	O
microM	O
)	O
,	O
and	O
the	O
extent	O
of	O
the	O
desensitization	O
was	O
not	O
significantly	O
different	O
between	O
the	O
two	O
receptors	O
.	O

4	O
.	O

In	O
summary	O
,	O
the	O
results	O
showed	O
that	O
the	O
two	O
alpha	O
1a-adrenoceptors	O
generated	O
by	O
genetic	O
polymorphism	O
have	O
similar	O
pharmacological	O
characteristics	O
,	O
and	O
the	O
receptor-mediated	O
[Ca2+]i	O
response	O
can	O
be	O
desensitized	O
in	O
a	O
similar	O
manner	O
.	O

The	O
study	O
did	O
not	O
provide	O
any	O
evidence	O
to	O
support	O
the	O
hypothesis	O
that	O
alpha	B-DNAMutation
1a-adrenoceptor	I-DNAMutation
gene	I-DNAMutation
polymorphism	O
is	O
associated	O
with	O
BPH	O
.	O

Sequence	O
analysis	O
of	O
bile	B-DNAMutation
salt	I-DNAMutation
export	I-DNAMutation
pump	I-DNAMutation
ABCB11	B-DNAMutation
and	O
multidrug	O
resistance	O
p-glycoprotein	B-DNAMutation
3	I-DNAMutation
(	O
ABCB4	B-DNAMutation
,	O
MDR3	B-DNAMutation
)	O
in	O
patients	O
with	O
intrahepatic	O
cholestasis	O
of	O
pregnancy	O
.	O

Intrahepatic	O
cholestasis	O
of	O
pregnancy	O
(ICP)	O
is	O
a	O
liver	O
disorder	O
associated	O
with	O
increased	O
risk	O
of	O
intrauterine	O
fetal	O
death	O
and	O
prematurity	O
.	O

There	O
is	O
increasing	O
evidence	O
that	O
genetically	O
determined	O
dysfunction	O
in	O
the	O
canalicular	O
ABC	O
transporters	O
bile	B-DNAMutation
salt	I-DNAMutation
export	I-DNAMutation
pump	I-DNAMutation
(	O
BSEP	B-DNAMutation
,	O
ABCB11	B-DNAMutation
)	O
and	O
multidrug	B-DNAMutation
resistance	I-DNAMutation
protein	I-DNAMutation
3	I-DNAMutation
(	O
MDR3	B-DNAMutation
,	O
ABCB4	B-DNAMutation
)	O
might	O
be	O
risk	O
factors	O
for	O
ICP	O
development	O
.	O

This	O
study	O
aimed	O
to	O
(i)	O
.	O

describe	O
the	O
extent	O
of	O
genetic	O
variability	O
in	O
BSEP	B-DNAMutation
and	O
MDR3	B-DNAMutation
in	O
ICP	O
and	O
(ii)	O
.	O

identify	O
new	O
disease-causing	O
mutations	O
.	O

Twenty-one	O
women	O
with	O
ICP	O
and	O
40	O
women	O
with	O
uneventful	O
pregnancies	O
were	O
recruited	O
between	O
April	O
2001	O
and	O
April	O
2003	O
.	O

Sequencing	O
of	O
BSEP	B-DNAMutation
and	O
MDR3	B-DNAMutation
spanned	O
8-10	O
kb	O
per	O
gene	O
and	O
comprised	O
the	O
promoter	O
region	O
and	O
100-350	O
bp	O
of	O
the	O
flanking	O
intronic	O
region	O
around	O
each	O
exon	O
.	O

DNA	O
sequencing	O
of	O
polymerase	O
chain	O
reaction	O
fragments	O
was	O
performed	O
on	O
an	O
ABI3700	O
capillary	O
sequencer	O
.	O

MDR3	B-DNAMutation
promoter	O
activity	O
of	O
promoter	O
constructs	O
carrying	O
different	O
ICP-specific	O
mutations	O
was	O
studied	O
using	O
reporter	O
assays	O
.	O

A	O
total	O
of	O
37	O
and	O
51	O
variant	O
sites	O
were	O
detected	O
in	O
BSEP	B-DNAMutation
and	O
MDR3	B-DNAMutation
,	O
respectively	O
.	O

Three	O
non-synonymous	O
sites	O
in	O
codons	O
for	O
evolutionarily	O
conserved	O
amino	O
acids	O
were	O
specific	O
for	O
the	O
ICP	O
collective	O
(	O
BSEP	B-DNAMutation
,	O
N591S	B-DNAMutation
;	O
MDR3	B-DNAMutation
,	O
S320F	B-DNAMutation
and	O
G762E	B-DNAMutation
)	O
.	O

Furthermore	O
,	O
four	O
ICP-specific	O
splicing	O
mutations	O
were	O
detected	O
in	O
MDR3	B-DNAMutation
[	O
intron	B-DNAMutation
21	I-DNAMutation
,	I-DNAMutation
G(+1)A	I-DNAMutation
;	O
intron	B-DNAMutation
25	I-DNAMutation
,	I-DNAMutation
G(+5)C	I-DNAMutation
and	O
C(-3)G	B-DNAMutation
;	O
and	O
intron	B-DNAMutation
26	I-DNAMutation
,	I-DNAMutation
T(+2)A	I-DNAMutation
]	O
.	O

Activity	O
of	O
the	O
mutated	O
MDR3	B-DNAMutation
promoter	O
was	O
similar	O
to	O
that	O
observed	O
for	O
the	O
wild-type	O
promoter	O
.	O

Our	O
data	O
further	O
support	O
an	O
involvement	O
of	O
MDR3	B-DNAMutation
genetic	O
variation	O
in	O
the	O
pathogenesis	O
of	O
ICP	O
,	O
whereas	O
analysis	O
of	O
BSEP	B-DNAMutation
sequence	O
variation	O
indicates	O
that	O
this	O
gene	O
is	O
probably	O
less	O
important	O
for	O
the	O
development	O
of	O
pregnancy-associated	O
cholestasis	O
.	O

Riboflavin-responsive	O
oxidative	O
phosphorylation	O
complex	O
I	O
deficiency	O
caused	O
by	O
defective	O
ACAD9	B-DNAMutation
:	O
new	O
function	O
for	O
an	O
old	O
gene	O
.	O

Mitochondrial	O
complex	O
I	O
deficiency	O
is	O
the	O
most	O
common	O
oxidative	O
phosphorylation	O
defect	O
.	O

Mutations	O
have	O
been	O
detected	O
in	O
mitochondrial	O
and	O
nuclear	O
genes	O
,	O
but	O
the	O
genetics	O
of	O
many	O
patients	O
remain	O
unresolved	O
and	O
new	O
genes	O
are	O
probably	O
involved	O
.	O

In	O
a	O
consanguineous	O
family	O
,	O
patients	O
presented	O
easy	O
fatigability	O
,	O
exercise	O
intolerance	O
and	O
lactic	O
acidosis	O
in	O
blood	O
from	O
early	O
childhood	O
.	O

In	O
muscle	O
,	O
subsarcolemmal	O
mitochondrial	O
proliferation	O
and	O
a	O
severe	O
complex	O
I	O
deficiency	O
were	O
observed	O
.	O

Exercise	O
intolerance	O
and	O
complex	O
I	O
activity	O
was	O
improved	O
by	O
a	O
supplement	O
of	O
riboflavin	O
at	O
high	O
dosage	O
.	O

Homozygosity	O
mapping	O
revealed	O
a	O
candidate	O
region	O
on	O
chromosome	O
three	O
containing	O
six	O
mitochondria-related	O
genes	O
.	O

Four	O
genes	O
were	O
screened	O
for	O
mutations	O
and	O
a	O
homozygous	O
substitution	O
was	O
identified	O
in	O
ACAD9	B-DNAMutation
(	O
c.1594	B-DNAMutation
C>T	I-DNAMutation
)	O
,	O
changing	B-DNAMutation
the	I-DNAMutation
highly	I-DNAMutation
conserved	I-DNAMutation
arginine-532	I-DNAMutation
into	I-DNAMutation
tryptophan	I-DNAMutation
.	O

This	O
mutation	O
was	O
absent	O
in	O
188	O
ethnically	O
matched	O
controls	O
.	O

Protein	O
modelling	O
suggested	O
a	O
functional	O
effect	O
due	O
to	O
the	O
loss	O
of	O
a	O
stabilizing	O
hydrogen	O
bond	O
in	O
an	O
Î±-helix	O
and	O
a	O
local	O
flexibility	O
change	O
.	O

To	O
test	O
whether	O
the	B-DNAMutation
ACAD9	I-DNAMutation
mutation	O
caused	O
the	O
complex	O
I	O
deficiency	O
,	O
we	O
transduced	O
fibroblasts	O
of	O
patients	O
with	O
wild-type	O
and	O
mutant	B-DNAMutation
ACAD9	I-DNAMutation
.	O

Wild-type	O
,	O
but	O
not	O
mutant	O
,	I-DNAMutation
ACAD9	I-DNAMutation
restored	O
complex	O
I	O
activity	O
.	O

An	O
unrelated	O
patient	O
with	O
the	O
same	O
phenotype	O
was	O
compound	O
heterozygous	O
for	B-DNAMutation
c.380	I-DNAMutation
G>A	I-DNAMutation
and	B-DNAMutation
c.1405	I-DNAMutation
C>T	I-DNAMutation
,	O
changing	B-DNAMutation
arginine-127	I-DNAMutation
into	I-DNAMutation
glutamine	I-DNAMutation
and	B-DNAMutation
arginine-469	I-DNAMutation
into	I-DNAMutation
tryptophan	I-DNAMutation
,	O
respectively	O
.	O

These	O
amino	O
acids	O
were	O
highly	O
conserved	O
and	O
the	O
substitutions	O
were	O
not	O
present	O
in	O
controls	O
,	O
making	O
them	O
very	O
probably	O
pathogenic	O
.	O

Our	O
data	O
support	O
a	O
new	O
function	O
for	B-DNAMutation
ACAD9	I-DNAMutation
in	O
complex	O
I	O
function	O
,	O
making	O
this	O
gene	O
an	O
important	O
new	O
candidate	O
for	O
patients	O
with	O
complex	O
I	O
deficiency	O
,	O
which	O
could	O
be	O
improved	O
by	O
riboflavin	O
treatment	O
.	O

Identification	O
of	O
four	O
new	O
mutations	O
in	O
the	O
short-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
(SCAD)	O
gene	O
in	O
two	O
patients	O
:	O
one	O
of	O
the	O
variant	O
alleles	O
,	O
511C-->T	B-DNAMutation
,	O
is	O
present	O
at	O
an	O
unexpectedly	O
high	O
frequency	O
in	O
the	O
general	O
population	O
,	O
as	O
was	O
the	O
case	O
for	O
625G-->A	B-DNAMutation
,	O
together	O
conferring	O
susceptibility	O
to	O
ethylmalonic	O
aciduria	O
.	O

We	O
have	O
shown	O
previously	O
that	O
a	O
variant	O
allele	O
of	O
the	O
short-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
(	O
SCAD	O
)	O
gene	O
,	O
625G-->A	B-DNAMutation
,	I-DNAMutation
is	O
present	O
in	O
homozygous	O
form	O
in	O
7%	O
of	O
control	O
individuals	O
and	O
in	O
60%	O
of	O
135	O
patients	O
with	O
elevated	O
urinary	O
excretion	O
of	O
ethylmalonic	O
acid	O
(EMA)	O
.	O

We	O
have	O
now	O
characterized	O
three	O
disease-causing	O
mutations	O
(	O
confirmed	O
by	O
lack	O
of	O
enzyme	O
activity	O
after	O
expression	O
in	O
COS-7	O
cells	O
)	O
and	O
a	O
new	O
susceptibility	O
variant	O
in	O
the	O
SCAD	O
gene	O
of	O
two	O
patients	O
with	O
SCAD	O
deficiency	O
,	O
and	O
investigated	O
their	O
frequency	O
in	O
patients	O
with	O
elevated	O
EMA	O
excretion	O
.	O

The	O
first	O
SCAD-deficient	O
patient	O
was	O
a	O
compound	O
heterozygote	O
for	O
two	O
mutations	O
,	O
274G-->T	B-DNAMutation
and	I-DNAMutation
529T-->C	B-DNAMutation
.	I-DNAMutation
These	O
mutations	O
were	O
not	O
present	O
in	O
98	O
normal	O
control	O
alleles	O
,	O
but	O
the	O
529T-->C	B-DNAMutation
mutation	I-DNAMutation
was	O
found	O
in	O
one	O
allele	O
among	O
133	O
patients	O
with	O
elevated	O
EMA	O
excretion	O
.	O

The	O
second	O
patient	O
carried	O
a	O
1147C-->T	B-DNAMutation
mutation	I-DNAMutation
and	I-DNAMutation
the	B-DNAMutation
625G-->A	I-DNAMutation
polymorphism	I-DNAMutation
in	O
one	O
allele	O
,	O
and	O
a	O
single	O
point	O
mutation	O
,	O
511C-->T	B-DNAMutation
,	I-DNAMutation
in	O
the	O
other	O
.	O

The	O
1147C-->T	B-DNAMutation
mutation	I-DNAMutation
was	O
not	O
present	O
in	O
98	O
normal	O
alleles	O
,	O
but	O
was	O
detected	O
in	O
three	O
alleles	O
of	O
133	O
patients	O
with	O
elevated	O
EMA	O
excretion	O
,	O
consistently	O
as	O
a	O
625A-1147T	B-DNAMutation
allele	I-DNAMutation
.	I-DNAMutation
On	O
the	O
other	O
hand	O
,	O
the	O
511C-->T	B-DNAMutation
mutation	I-DNAMutation
was	I-DNAMutation
present	O
in	O
13	O
of	O
130	O
and	O
15	O
of	O
67	O
625G	O
alleles	O
,	O
respectively	O
,	O
of	O
normal	O
controls	O
and	O
patients	O
with	O
elevated	O
EMA	O
excretion	O
,	O
and	O
was	O
never	O
associated	O
with	O
the	O
625A	O
variant	O
allele	O
.	O

This	O
over-representation	O
of	O
the	O
haplotype	O
511T-625G	O
among	O
the	O
common	O
625G	O
alleles	O
in	O
patients	O
compared	O
with	O
controls	O
was	O
significant	O
(	O
P	O
<	O
0.02	O
)	O
,	O
suggesting	O
that	O
the	O
allele	O
511T-625G-like	O
511C-625A-confers	O
susceptibility	O
to	O
ethylmalonic	O
aciduria	O
.	O

Expression	O
of	O
the	O
variant	O
R147W	B-DNAMutation
SCAD	I-DNAMutation
protein	O
,	O
encoded	O
by	O
the	O
511T-625G	B-DNAMutation
allele	I-DNAMutation
,	O
in	O
COS-7	O
cells	O
showed	O
45%	O
activity	O
at	O
37	O
degrees	O
C	O
in	O
comparison	O
with	O
the	O
wild-type	O
protein	O
,	O
comparable	O
levels	O
of	O
activity	O
at	O
26	O
degrees	O
C	O
,	O
and	O
13%	O
activity	O
when	O
incubated	O
at	O
41	O
degrees	O
C	O
.	O

This	O
temperature	O
profile	O
is	O
different	O
from	O
that	O
observed	O
for	O
the	O
variant	O
G185S	B-DNAMutation
SCAD	I-DNAMutation
protein	O
,	O
encoded	O
by	O
the	O
511C-625A	B-DNAMutation
allele	I-DNAMutation
,	I-DNAMutation
where	I-DNAMutation
higher	O
than	O
normal	O
activity	O
was	O
found	O
at	O
26	O
and	O
37	O
degrees	O
C	O
,	O
and	O
58%	O
activity	O
was	O
present	O
at	O
41	O
degrees	O
C	O
.	O

These	O
results	O
corroborate	O
the	O
notion	O
that	O
the	O
511C-625A	B-DNAMutation
variant	I-DNAMutation
allele	I-DNAMutation
is	I-DNAMutation
one	O
of	O
the	O
possible	O
underlying	O
causes	O
of	O
ethylmalonic	O
aciduria	O
,	O
and	O
suggest	O
that	O
the	O
511C-->T	B-DNAMutation
mutation	I-DNAMutation
represents	O
a	O
second	O
susceptibility	O
variation	O
in	O
the	O
SCAD	O
gene	O
.	O

We	O
conclude	O
that	O
ethylmalonic	O
aciduria	O
,	O
a	O
commonly	O
detected	O
biochemical	O
phenotype	O
,	O
is	O
a	O
complex	O
multifactorial/polygenic	O
condition	O
where	O
,	O
in	O
addition	O
to	O
the	O
emerging	O
role	O
of	O
SCAD	O
susceptibility	O
alleles	O
,	O
other	O
genetic	O
and	O
environmental	O
factors	O
are	O
involved	O
.	O

The	O
E3	O
ligase	O
TRAF6	B-DNAMutation
regulates	O
Akt	O
ubiquitination	O
and	O
activation	O
.	O

Akt	O
signaling	O
plays	O
a	O
central	O
role	O
in	O
many	O
biological	O
functions	O
,	O
such	O
as	O
cell	O
proliferation	O
and	O
apoptosis	O
.	O

Because	O
Akt	O
(	O
also	O
known	O
as	O
protein	B-DNAMutation
kinase	I-DNAMutation
B	I-DNAMutation
)	O
resides	O
primarily	O
in	O
the	O
cytosol	O
,	O
it	O
is	O
not	O
known	O
how	O
these	O
signaling	O
molecules	O
are	O
recruited	O
to	O
the	O
plasma	O
membrane	O
and	O
subsequently	O
activated	O
by	O
growth	O
factor	O
stimuli	O
.	O

We	O
found	O
that	O
the	O
protein	O
kinase	O
Akt	O
undergoes	O
lysine-63	O
chain	O
ubiquitination	O
,	O
which	O
is	O
important	O
for	O
Akt	O
membrane	O
localization	O
and	O
phosphorylation	O
.	O

TRAF6	B-DNAMutation
was	O
found	O
to	O
be	O
a	O
direct	O
E3	O
ligase	O
for	O
Akt	O
and	O
was	O
essential	O
for	O
Akt	O
ubiquitination	O
,	O
membrane	O
recruitment	O
,	O
and	O
phosphorylation	O
upon	O
growth-factor	O
stimulation	O
.	O

The	O
human	O
cancer-associated	O
Akt	O
mutant	O
displayed	O
an	O
increase	O
in	O
Akt	O
ubiquitination	O
,	O
in	O
turn	O
contributing	O
to	O
the	O
enhancement	O
of	O
Akt	O
membrane	O
localization	O
and	O
phosphorylation	O
.	O

Thus	O
,	O
Akt	O
ubiquitination	O
is	O
an	O
important	O
step	O
for	O
oncogenic	O
Akt	O
activation	O
.	O

Role	O
of	O
adenine	O
nucleotide	O
translocator	O
1	O
in	O
mtDNA	O
maintenance	O
.	O

Autosomal	O
dominant	O
progressive	O
external	O
ophthalmoplegia	O
is	O
a	O
rare	O
human	O
disease	O
that	O
shows	O
a	O
Mendelian	O
inheritance	O
pattern	O
,	O
but	O
is	O
characterized	O
by	O
large-scale	O
mitochondrial	O
DNA	O
(mtDNA)	O
deletions	O
.	O

We	O
have	O
identified	O
two	O
heterozygous	O
missense	O
mutations	O
in	O
the	O
nuclear	O
gene	O
encoding	O
the	O
heart/skeletal	O
muscle	O
isoform	O
of	O
the	O
adenine	O
nucleotide	O
translocator	O
ANT1	B-DNAMutation
in	O
five	O
families	O
and	O
one	O
sporadic	O
patient	O
.	O

The	O
familial	B-DNAMutation
mutation	I-DNAMutation
substitutes	I-DNAMutation
a	I-DNAMutation
proline	I-DNAMutation
for	I-DNAMutation
a	I-DNAMutation
highly	I-DNAMutation
conserved	I-DNAMutation
alanine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
114	I-DNAMutation
in	O
the	O
ANT1	B-DNAMutation
protein	O
.	O

The	O
analogous	O
mutation	O
in	O
yeast	O
caused	O
a	O
respiratory	O
defect	O
.	O

These	O
results	O
indicate	O
that	O
ANT	O
has	O
a	O
role	O
in	O
mtDNA	O
maintenance	O
and	O
that	O
a	O
mitochondrial	O
disease	O
can	O
be	O
caused	O
by	O
a	O
dominant	O
mechanism	O
.	O

Genetic	O
variants	O
of	O
serum	O
albumin	O
in	O
Americans	O
and	O
Japanese	O
.	O

A	O
collaborative	O
search	O
for	O
albumin	O
genetic	O
variants	O
(alloalbumins)	O
was	O
undertaken	O
by	O
cellulose	O
acetate	O
and	O
agarose	O
electrophoresis	O
at	O
pH	O
8.6	O
of	O
the	O
sera	O
of	O
patients	O
at	O
two	O
major	O
medical	O
centers	O
in	O
the	O
United	O
States	O
and	O
of	O
nearly	O
20,000	O
blood	O
donors	O
in	O
Japan	O
.	O

Seventeen	O
instances	O
of	O
alloalbuminemia	O
were	O
ascertained	O
,	O
and	O
seven	O
different	O
alloalbumin	O
types	O
were	O
characterized	O
by	O
structural	O
study	O
.	O

Two	O
previously	O
unreported	O
alloalbumin	O
types	O
were	O
identified	O
.	O

In	O
one	O
type	O
,	O
which	O
was	O
present	O
in	O
a	O
Caucasian	O
family	O
and	O
designated	O
Iowa	O
City-1	O
,	O
aspartic	B-DNAMutation
acid	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
365	I-DNAMutation
was	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
valine	I-DNAMutation
(	O
365	B-DNAMutation
Asp----Val	I-DNAMutation
)	O
;	O
this	O
is	O
the	O
second	O
reported	O
mutation	O
at	O
this	O
position	O
.	O

The	O
other	O
type	O
present	O
in	O
a	O
Japanese	O
blood	O
donor	O
had	O
the	O
mutation	O
128	B-DNAMutation
His----Arg	I-DNAMutation
.	O

An	O
unexpected	O
finding	O
was	O
the	O
presence	O
in	O
a	O
single	O
Japanese	O
of	O
a	O
Naskapi-type	O
alloalbumin	O
(	O
372	B-DNAMutation
Lys----Glu	I-DNAMutation
)	O
,	O
a	O
variant	O
that	O
had	O
previously	O
been	O
described	O
only	O
for	O
certain	O
Amerindian	O
tribes	O
in	O
whom	O
it	O
occurs	O
with	O
a	O
polymorphic	O
frequency	O
(	O
greater	O
than	O
1%	O
)	O
and	O
in	O
Eti	O
Turks	O
.	O

An	O
arginyl-albumin	O
(	O
-1	B-DNAMutation
Arg	I-DNAMutation
,	O
1	B-DNAMutation
Asp----Val	I-DNAMutation
)	O
occurred	O
in	O
an	O
American	O
family	O
.	O

The	O
other	O
alloalbumin	O
types	O
identified	O
were	O
proalbumins	O
Lille	O
and	O
Christchurch	O
and	O
albumin	O
B	O
that	O
have	O
a	O
cumulative	O
frequency	O
of	O
about	O
1:3500	O
in	O
Caucasians	O
probably	O
because	O
of	O
the	O
hypermutability	O
of	O
CpG	O
dinucleotides	O
at	O
the	O
mutated	O
sites	O
.	O

All	O
of	O
the	O
variants	O
characterized	O
in	O
this	O
study	O
are	O
point	O
mutants	O
,	O
and	O
the	O
sites	O
are	O
spread	O
throughout	O
the	O
albumin	O
gene	O
.	O

However	O
,	O
about	O
one-fourth	O
of	O
all	O
known	O
albumin	O
mutations	O
are	O
clustered	O
in	O
the	O
sequence	O
segment	O
from	O
position	O
354	O
through	O
382	O
.	O

Identification	O
of	O
isobutyryl-CoA	O
dehydrogenase	O
and	O
its	O
deficiency	O
in	O
humans	O
.	O

The	O
acyl-CoA	O
dehydrogenases	O
(ACDs)	O
are	O
a	O
family	O
of	O
related	O
enzymes	O
that	O
catalyze	O
the	O
alpha,beta-dehydrogenation	O
of	O
acyl-CoA	O
esters	O
.	O

Two	O
homologues	O
active	O
in	O
branched	O
chain	O
amino	O
acid	O
metabolism	O
have	O
previously	O
been	O
identified	O
.	O

We	O
have	O
used	O
expression	O
in	O
Escherichia	O
coli	O
to	O
produce	O
a	O
previously	O
uncharacterized	O
ACD-like	O
sequence	O
(ACAD8)	O
and	O
define	O
its	O
substrate	O
specificity	O
.	O

Purified	O
recombinant	O
enzyme	O
had	O
a	O
k(cat)/K(m)	O
of	O
0.8	O
,	O
0.23	O
,	O
and	O
0.04	O
(microM(-1)s(-1))	O
with	O
isobutyryl-CoA	O
,	O
(S)	O
2-methylbutyryl-CoA	O
,	O
and	O
n-propionyl-CoA	O
,	O
respectively	O
,	O
as	O
substrates	O
.	O

Thus	O
,	O
this	O
enzyme	O
is	O
an	O
isobutyryl-CoA	O
dehydrogenase	O
.	O

A	O
single	O
patient	O
has	O
previously	O
been	O
described	O
whose	O
fibroblasts	O
exhibit	O
a	O
specific	O
deficit	O
in	O
the	O
oxidation	O
of	O
valine	O
.	O

Amplified	O
ACAD8	B-DNAMutation
cDNA	O
made	O
from	O
patient	O
fibroblast	O
mRNA	O
was	O
homozygous	O
for	O
a	O
single	O
nucleotide	O
change	O
905G>A	B-DNAMutation
in	O
the	O
ACAD8	B-DNAMutation
coding	O
region	O
compared	O
to	O
the	O
sequence	O
from	O
control	O
cells	O
.	O

This	O
encodes	O
an	O
Arg302Gln	B-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
full-length	I-DNAMutation
protein	I-DNAMutation
(	O
position	B-DNAMutation
280	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
mature	I-DNAMutation
protein	I-DNAMutation
)	O
,	O
a	O
position	O
predicted	O
by	O
molecular	O
modeling	O
to	O
be	O
important	O
in	O
subunit	O
interactions	O
.	O

The	O
mutant	O
enzyme	O
was	O
stable	O
but	O
inactive	O
when	O
expressed	O
in	O
E	O
.	O

coli	O
.	O

It	O
was	O
also	O
stable	O
and	O
appropriately	O
targeted	O
to	O
mitochondria	O
,	O
but	O
inactive	O
when	O
expressed	O
in	O
mammalian	O
cells	O
.	O

These	O
data	O
confirm	O
further	O
the	O
presence	O
of	O
a	O
separated	O
ACD	O
in	O
humans	O
specific	O
to	O
valine	O
catabolism	O
(	O
isobutyryl-CoA	O
dehydrogenase	O
,	O
IBDH	O
)	O
,	O
along	O
with	O
the	O
first	O
enzymatic	O
and	O
molecular	O
confirmation	O
of	O
a	O
deficiency	O
of	O
this	O
enzyme	O
in	O
a	O
patient	O
.	O

Mutations	O
in	O
the	O
muscle	B-DNAMutation
LIM	I-DNAMutation
protein	I-DNAMutation
and	O
alpha-actinin-2	B-DNAMutation
genes	O
in	O
dilated	O
cardiomyopathy	O
and	O
endocardial	O
fibroelastosis	O
.	O

Dilated	O
cardiomyopathy	O
(DCM)	O
is	O
a	O
major	O
cause	O
of	O
morbidity	O
and	O
mortality	O
.	O

Two	O
genes	O
have	O
been	O
identified	O
for	O
the	O
X-linked	O
forms	O
(	O
dystrophin	O
and	O
tafazzin	B-DNAMutation
)	O
,	O
while	O
mutations	O
in	O
multiple	O
genes	O
cause	O
autosomal	O
dominant	O
DCM	O
.	O

Muscle	B-DNAMutation
LIM	I-DNAMutation
protein	I-DNAMutation
MLP	B-DNAMutation
is	O
a	O
member	O
of	O
the	O
cysteine-rich	O
protein	O
(CRP)	O
family	O
and	O
has	O
been	O
implicated	O
in	O
both	O
myogenesis	O
and	O
sarcomere	O
assembly	O
.	O

In	O
the	O
latter	O
role	O
,	O
it	O
binds	O
zyxin	B-DNAMutation
and	O
alpha-actinin	B-DNAMutation
,	O
both	O
of	O
which	O
are	O
involved	O
in	O
actin	O
organization	O
.	O

An	O
MLP-deficient	B-DNAMutation
mouse	O
has	O
been	O
described	O
;	O
these	O
mice	O
develop	O
dilated	O
cardiomyopathy	O
and	O
heart	O
failure	O
.	O

Based	O
upon	O
these	O
data	O
,	O
and	O
the	O
recent	O
descriptions	O
of	O
mutations	O
in	O
MLP	B-DNAMutation
in	O
patients	O
with	O
DCM	O
or	O
hypertrophic	O
cardiomyopathy	O
,	O
we	O
screened	O
patients	O
for	O
mutations	O
in	O
the	O
MLP	B-DNAMutation
and	O
alpha-actinin-2	B-DNAMutation
genes	O
.	O

We	O
identified	O
a	O
patient	O
with	O
DCM	O
and	O
EFE	O
,	O
having	O
a	O
mutation	O
in	O
MLP	B-DNAMutation
with	O
the	O
residue	B-DNAMutation
lysine	I-DNAMutation
69	I-DNAMutation
substituted	I-DNAMutation
by	I-DNAMutation
arginine	I-DNAMutation
K69R	B-DNAMutation
.	O

This	O
is	O
within	O
a	O
highly	O
conserved	O
region	O
adjacent	O
to	O
the	O
first	O
LIM	O
domain	O
involved	O
in	O
alpha-actinin	B-DNAMutation
binding	O
.	O

Analysis	O
in	O
cell	O
culture	O
systems	O
demonstrated	O
that	O
the	O
mutation	O
abolishes	O
the	O
interaction	O
between	O
MLP	B-DNAMutation
and	O
alpha-actinin-2	B-DNAMutation
and	O
the	O
cellular	O
localization	O
of	O
MLP	B-DNAMutation
was	O
altered	O
.	O

In	O
another	O
individual	O
with	O
DCM	O
,	O
a	O
W4R	B-DNAMutation
mutation	O
was	O
identified	O
.	O

However	O
,	O
this	O
mutation	O
did	O
not	O
segregate	O
with	O
disease	O
in	O
this	O
family	O
.	O

In	O
another	O
patient	O
with	O
DCM	O
,	O
a	O
Q9R	B-DNAMutation
mutation	O
was	O
identified	O
in	O
alpha-actinin-2	B-DNAMutation
.	O

This	O
mutation	O
also	O
disrupted	O
the	O
interaction	O
with	O
MLP	B-DNAMutation
and	O
appeared	O
to	O
inhibit	O
alpha-actinin	B-DNAMutation
function	O
in	O
cultured	O
cells	O
,	O
in	O
respect	O
to	O
the	O
nuclear	O
localization	O
of	O
actinin	O
and	O
the	O
initiation	O
of	O
cellular	O
differentiation	O
.	O

Characterization	O
of	O
a	O
di-leucine-based	O
signal	O
in	O
the	O
cytoplasmic	O
tail	O
of	O
the	O
nucleotide-pyrophosphatase	O
NPP1	B-DNAMutation
that	O
mediates	O
basolateral	O
targeting	O
but	O
not	O
endocytosis	O
.	O

Enzymes	O
of	O
the	O
nucleotide	O
pyrophosphatase/phosphodiesterase	O
(NPPase)	O
family	O
are	O
expressed	O
at	O
opposite	O
surfaces	O
in	O
polarized	O
epithelial	O
cells	O
.	O

We	O
investigated	O
the	O
targeting	O
signal	O
of	O
NPP1	B-DNAMutation
,	O
which	O
is	O
exclusively	O
expressed	O
at	O
the	O
basolateral	O
surface	O
.	O

Full-length	O
NPP1	B-DNAMutation
and	O
different	O
constructs	O
and	O
mutants	O
were	O
transfected	O
into	O
the	O
polarized	O
MDCK	O
cell	O
line	O
.	O

Expression	O
of	O
the	O
proteins	O
was	O
analyzed	O
by	O
confocal	O
microscopy	O
and	O
surface	O
biotinylation	O
.	O

The	O
basolateral	O
signal	O
of	O
NPP1	B-DNAMutation
was	O
identified	O
as	O
a	O
di-leucine	O
motif	O
located	O
in	O
the	O
cytoplasmic	O
tail	O
.	O

Mutation	O
of	O
either	O
or	O
both	O
leucines	O
largely	O
redirected	O
NPP1	B-DNAMutation
to	O
the	O
apical	O
surface	O
.	O

Furthermore	O
,	O
addition	O
of	O
the	O
conserved	O
sequence	O
AAASLLAP	O
redirected	O
the	O
apical	O
nucleotide	O
pyrophosphatase/phosphodiesterase	O
NPP3	B-DNAMutation
to	O
the	O
basolateral	O
surface	O
.	O

Full-length	O
NPP1	B-DNAMutation
was	O
not	O
significantly	O
internalized	O
.	O

However	O
,	O
when	O
the	O
cytoplasmic	B-DNAMutation
tail	I-DNAMutation
was	I-DNAMutation
deleted	I-DNAMutation
upstream	I-DNAMutation
the	I-DNAMutation
di-leucine	I-DNAMutation
motif	I-DNAMutation
or	O
when	O
the	O
six	B-DNAMutation
upstream	I-DNAMutation
flanking	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
were	I-DNAMutation
deleted	I-DNAMutation
,	O
the	O
protein	O
was	O
mainly	O
found	O
intracellularly	O
.	O

Endocytosis	O
experiments	O
indicated	O
that	O
these	O
mutants	O
were	O
endocytosed	O
from	O
the	O
basolateral	O
surface	O
.	O

These	O
results	O
identify	O
the	O
basolateral	O
signal	O
of	O
NPP1	B-DNAMutation
as	O
a	O
short	O
sequence	O
including	O
a	O
di-leucine	O
motif	O
that	O
is	O
dominant	O
over	O
apical	O
determinants	O
and	O
point	O
to	O
the	O
importance	O
of	O
surrounding	O
amino	O
acids	O
in	O
determining	O
whether	O
the	O
signal	O
will	O
function	O
as	O
a	O
basolateral	O
signal	O
only	O
or	O
as	O
an	O
endocytotic	O
signal	O
as	O
well	O
.	O

Tyrosine	O
phosphorylation	O
and	O
regulation	O
of	O
the	O
AMPA	O
receptor	O
by	O
SRC	O
family	O
tyrosine	O
kinases	O
.	O

Phosphorylation	O
of	O
AMPA	O
receptors	O
is	O
a	O
major	O
mechanism	O
for	O
the	O
regulation	O
of	O
receptor	O
function	O
and	O
underlies	O
several	O
forms	O
of	O
synaptic	O
plasticity	O
in	O
the	O
CNS	O
.	O

Although	O
serine	O
and	O
threonine	O
phosphorylation	O
of	O
AMPA	O
receptors	O
has	O
been	O
well	O
studied	O
,	O
the	O
potential	O
role	O
of	O
tyrosine	O
phosphorylation	O
of	O
AMPA	O
receptors	O
has	O
not	O
been	O
investigated	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
GluR2	B-DNAMutation
subunit	O
of	O
AMPA	O
receptors	O
is	O
tyrosine	O
phosphorylated	O
in	O
vitro	O
and	O
in	O
vivo	O
by	O
Src	O
family	O
tyrosine	O
kinases	O
on	O
tyrosine	O
876	O
near	O
its	O
C	O
terminus	O
.	O

In	O
addition	O
,	O
GluR	O
agonist	O
treatment	O
of	O
cultured	O
cortical	O
neurons	O
increased	O
phosphorylation	O
of	O
tyrosine	O
876	O
.	O

The	O
association	O
with	O
GluR2-interacting	B-DNAMutation
molecules	O
GRIP1/2	B-DNAMutation
was	O
decreased	O
by	O
tyrosine	O
phosphorylation	O
of	O
GluR2	B-DNAMutation
,	O
whereas	O
PICK1	B-DNAMutation
interaction	O
was	O
not	O
influenced	O
.	O

Moreover	O
,	O
mutation	B-DNAMutation
of	I-DNAMutation
tyrosine	I-DNAMutation
876	I-DNAMutation
eliminated	O
AMPA-	O
and	O
NMDA-induced	O
internalization	O
of	O
the	O
GluR2	B-DNAMutation
subunit	O
.	O

These	O
data	O
indicate	O
that	O
tyrosine	O
phosphorylation	O
of	O
tyrosine	O
876	O
on	O
the	O
GluR2	B-DNAMutation
C	O
terminus	O
by	O
Src	O
family	O
tyrosine	O
kinases	O
is	O
important	O
for	O
the	O
regulation	O
of	O
AMPA	O
receptor	O
function	O
and	O
may	O
be	O
important	O
for	O
synaptic	O
plasticity	O
.	O

Study	O
of	O
the	O
molecular	O
defects	O
in	O
glucose	B-DNAMutation
phosphate	I-DNAMutation
isomerase-deficient	I-DNAMutation
patients	O
affected	O
by	O
chronic	O
hemolytic	O
anemia	O
.	O

We	O
have	O
studied	O
four	O
unrelated	O
Italian	O
patients	O
with	O
chronic	O
hemolytic	O
anemia	O
associated	O
with	O
glucose	B-DNAMutation
phosphate	I-DNAMutation
isomerase	I-DNAMutation
GPI	B-DNAMutation
deficiency	O
.	O

Using	O
intronic	O
primers	O
,	O
we	O
were	O
able	O
to	O
detect	O
the	O
gene	O
alterations	O
on	O
the	O
genomic	O
DNA	O
of	O
the	O
patients	O
.	O

Five	O
different	O
mutations	O
were	O
identified	O
among	O
the	O
eight	O
mutated	O
alleles	O
found	O
:	O
three	O
missense	O
mutations	O
301A,584T,1028G	B-DNAMutation
,	O
one	O
nonsense	O
mutation	O
286T	B-DNAMutation
,	O
and	O
a	O
four	O
nucleotides	O
deletion	O
[	O
Del	B-DNAMutation
1473-IVS16(+2)	I-DNAMutation
]	O
.	O

All	O
of	O
these	O
were	O
new	O
except	O
for	O
mutation	O
1028G	B-DNAMutation
,	O
which	O
was	O
previously	O
identified	O
in	O
a	O
Japanese	O
variant	O
(	O
GPI	B-DNAMutation
Narita	O
)	O
.	O

Two	O
patients	O
were	O
homozygotes	O
(	O
301A/301A	B-DNAMutation
and	O
1028G/1028G	B-DNAMutation
)	O
,	O
whereas	O
the	O
other	O
two	O
were	O
compound	O
heterozygotes	O
sharing	O
a	O
common	O
mutation	O
[	O
286T/584T	B-DNAMutation
and	O
Del	B-DNAMutation
1473-IVS16(+2)/584T	I-DNAMutation
]	O
.	O

The	O
missense	O
mutations	O
were	O
found	O
to	O
involve	O
highly	O
conserved	O
amino	O
acids	O
,	O
suggesting	O
that	O
these	O
residues	O
are	O
crucial	O
for	O
the	O
maintenance	O
of	O
the	O
enzyme	O
function	O
.	O

The	O
mutation	O
286T	B-DNAMutation
results	O
in	O
a	O
truncated	O
protein	O
of	O
95	O
amino	O
acids	O
in	O
comparison	O
with	O
the	O
558	O
of	O
the	O
normal	O
one	O
.	O

The	O
four	B-DNAMutation
nucleotides	I-DNAMutation
deletion	I-DNAMutation
located	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
junction	I-DNAMutation
of	I-DNAMutation
exon/intron	I-DNAMutation
16(5'-TTGGTCGgtgagt-3')	I-DNAMutation
is	O
the	O
first	O
GPI	B-DNAMutation
mutation	O
affecting	O
a	O
splice	O
site	O
.	O

Moreover	O
one	O
difference	O
from	O
the	O
published	O
sequence	O
473T-->G	B-DNAMutation
was	O
found	O
in	O
exon	O
five	O
in	O
all	O
of	O
the	O
eight	O
alleles	O
studied	O
and	O
in	O
30	O
normal	O
subjects	O
.	O

Correlation	O
was	O
made	O
between	O
mutations	O
,	O
biochemical	O
characteristics	O
of	O
the	O
enzyme	O
,	O
and	O
clinical	O
course	O
of	O
the	O
disease	O
.	O

FIC1	B-DNAMutation
and	O
BSEP	B-DNAMutation
defects	O
in	O
Taiwanese	O
patients	O
with	O
chronic	O
intrahepatic	O
cholestasis	O
with	O
low	O
gamma-glutamyltranspeptidase	B-DNAMutation
levels	O
.	O

To	O
elucidate	O
the	O
frequency	O
of	O
FIC1	B-DNAMutation
ATP8B1	B-DNAMutation
and	O
BSEP	B-DNAMutation
ABCB11	B-DNAMutation
mutations	O
in	O
Taiwanese	O
children	O
with	O
chronic	O
intrahepatic	O
cholestasis	O
with	O
low	O
gamma-glutamyltranspeptidase	B-DNAMutation
(GGT)	O
levels	O
,	O
we	O
assessed	O
13	O
unrelated	O
patients	O
with	O
infantile	O
onset	O
chronic	O
intrahepatic	O
cholestasis	O
.	O

Liver	O
complementary	O
DNA	O
sequencing	O
was	O
performed	O
in	O
7	O
infants	O
for	O
mutation	O
analyses	O
of	O
FIC1	B-DNAMutation
and	O
BSEP	B-DNAMutation
genes	O
.	O

Two	O
distinct	O
liver	O
histologic	O
features	O
were	O
found	O
.	O

Group	O
1	O
(	O
n	O
=	O
5	O
)	O
was	O
characterized	O
by	O
bland	O
cholestasis	O
and	O
group	O
2	O
(	O
n	O
=	O
8	O
)	O
by	O
giant	O
cell	O
transformation	O
.	O

Group	O
2	O
patients	O
were	O
associated	O
with	O
higher	O
transaminase	O
levels	O
,	O
alpha-fetoprotein	B-DNAMutation
levels	O
,	O
and	O
early	O
mortality	O
.	O

Novel	O
FIC1	B-DNAMutation
mutations	O
were	O
found	O
in	O
all	O
4	O
patients	O
tested	O
in	O
group	O
1	O
,	O
including	O
a	O
74-bp	O
deletion	O
,	O
a	O
98-bp	O
deletion	O
,	O
a	O
nonsense	O
,	O
and	O
2	O
missense	O
mutations	O
.	O

BSEP	B-DNAMutation
mutations	O
were	O
found	O
in	O
2	O
of	O
the	O
3	O
patients	O
in	O
group	O
2	O
,	O
including	O
2	O
missense	O
mutations	O
and	O
a	O
1-bp	O
deletion	O
.	O

Phenotypic	O
characterization	O
is	O
useful	O
to	O
differentiate	O
FIC1-	B-DNAMutation
from	O
BSEP-related	B-DNAMutation
disease	O
.	O

Characterization	O
of	O
palmitoylation	O
of	O
ATP	B-DNAMutation
binding	I-DNAMutation
cassette	I-DNAMutation
transporter	I-DNAMutation
G1	I-DNAMutation
:	O
effect	O
on	O
protein	O
trafficking	O
and	O
function	O
.	O

ATP-binding	B-DNAMutation
cassette	I-DNAMutation
transporter	I-DNAMutation
G1	I-DNAMutation
ABCG1	B-DNAMutation
mediates	O
cholesterol	O
efflux	O
onto	O
lipidated	O
apolipoprotein	O
A-I	O
and	O
HDL	B-DNAMutation
and	O
plays	O
a	O
role	O
in	O
various	O
important	O
physiological	O
functions	O
.	O

However	O
,	O
the	O
mechanism	O
by	O
which	O
ABCG1	B-DNAMutation
mediates	O
cholesterol	O
translocation	O
is	O
unclear	O
.	O

Protein	O
palmitoylation	O
regulates	O
many	O
functions	O
of	O
proteins	O
such	O
as	O
ABCA1	B-DNAMutation
.	O

Here	O
we	O
investigated	O
if	O
ABCG1	B-DNAMutation
is	O
palmitoylated	O
and	O
the	O
subsequent	O
effects	O
on	O
ABCG1-mediated	B-DNAMutation
cholesterol	O
efflux	O
.	O

We	O
demonstrated	O
that	O
ABCG1	B-DNAMutation
is	O
palmitoylated	O
in	O
both	O
human	O
embryonic	O
kidney	O
293	O
cells	O
and	O
in	O
mouse	O
macrophage	O
,	O
J774	O
.	O

Five	O
cysteine	O
residues	O
located	O
at	O
positions	O
26	O
,	O
150	O
,	O
311	O
,	O
390	O
and	O
402	O
in	O
the	O
NH2-terminal	O
cytoplasmic	O
region	O
of	O
ABCG1	B-DNAMutation
were	O
palmitoylated	O
.	O

Removal	B-DNAMutation
of	I-DNAMutation
palmitoylation	I-DNAMutation
at	I-DNAMutation
Cys311	I-DNAMutation
by	I-DNAMutation
mutating	I-DNAMutation
the	I-DNAMutation
residue	I-DNAMutation
to	I-DNAMutation
Ala	I-DNAMutation
C311A	B-DNAMutation
or	B-DNAMutation
Ser	I-DNAMutation
significantly	O
decreased	O
ABCG1-mediated	B-DNAMutation
cholesterol	O
efflux	O
.	O

On	O
the	O
other	O
hand	O
,	O
removal	B-DNAMutation
of	I-DNAMutation
palmitoylation	I-DNAMutation
at	I-DNAMutation
sites	I-DNAMutation
26	I-DNAMutation
,	I-DNAMutation
150	I-DNAMutation
,	I-DNAMutation
390	I-DNAMutation
and	I-DNAMutation
402	I-DNAMutation
had	O
no	O
significant	O
effect	O
.	O

We	O
further	O
demonstrated	O
that	O
mutations	O
of	O
Cys311	O
affected	O
ABCG1	B-DNAMutation
trafficking	O
from	O
the	O
endoplasmic	O
reticulum	O
.	O

Therefore	O
,	O
our	O
data	O
suggest	O
that	O
palmitoylation	O
plays	O
a	O
critical	O
role	O
in	O
ABCG1-mediated	B-DNAMutation
cholesterol	O
efflux	O
through	O
the	O
regulation	O
of	O
trafficking	O
.	O

Segregation	O
of	O
a	O
missense	O
mutation	O
in	O
the	O
amyloid	O
precursor	O
protein	O
gene	O
with	O
familial	O
Alzheimer's	O
disease	O
.	O

A	O
locus	O
segregating	O
with	O
familial	O
Alzheimer's	O
disease	O
(AD)	O
has	O
been	O
mapped	O
to	O
chromosome	O
21	O
,	O
close	O
to	O
the	O
amyloid	O
precursor	O
protein	O
(APP)	O
gene	O
.	O

Recombinants	O
between	O
the	O
APP	O
gene	O
and	O
the	O
AD	O
locus	O
have	O
been	O
reported	O
which	O
seemed	O
to	O
exclude	O
it	O
as	O
the	O
site	O
of	O
the	O
mutation	O
causing	O
familial	O
AD	O
.	O

But	O
recent	O
genetic	O
analysis	O
of	O
a	O
large	O
number	O
of	O
AD	O
families	O
has	O
demonstrated	O
that	O
the	O
disease	O
is	O
heterogeneous	O
.	O

Families	O
with	O
late-onset	O
AD	O
do	O
not	O
show	O
linkage	O
to	O
chromosome	O
21	O
markers	O
.	O

Some	O
families	O
with	O
early-onset	O
AD	O
show	O
linkage	O
to	O
chromosome	O
21	O
markers	O
,	O
but	O
some	O
do	O
not	O
.	O

This	O
has	O
led	O
to	O
the	O
suggestion	O
that	O
there	O
is	O
non-allelic	O
genetic	O
heterogeneity	O
even	O
within	O
early	O
onset	O
familial	O
AD	O
.	O

To	O
avoid	O
the	O
problems	O
that	O
heterogeneity	O
poses	O
for	O
genetic	O
analysis	O
,	O
we	O
have	O
examined	O
the	O
cosegregation	O
of	O
AD	O
and	O
markers	O
along	O
the	O
long	O
arm	O
of	O
chromosome	O
21	O
in	O
a	O
single	O
family	O
with	O
AD	O
confirmed	O
by	O
autopsy	O
.	O

Here	O
we	O
demonstrate	O
that	O
in	O
this	O
kindred	O
,	O
which	O
shows	O
linkage	O
to	O
chromosome	O
21	O
markers	O
,	O
there	O
is	O
a	O
point	O
mutation	O
in	O
the	O
APP	O
gene	O
.	O

This	O
mutation	O
causes	O
an	O
amino-acid	B-DNAMutation
substitution	I-DNAMutation
(Val----Ile)	I-DNAMutation
close	I-DNAMutation
to	I-DNAMutation
the	I-DNAMutation
carboxy	I-DNAMutation
terminus	I-DNAMutation
of	O
the	O
beta-amyloid	O
peptide	O
.	O

Screening	O
other	O
cases	O
of	O
familial	O
AD	O
revealed	O
a	O
second	O
unrelated	O
family	O
in	O
which	O
this	O
variant	O
occurs	O
.	O

This	O
suggests	O
that	O
some	O
cases	O
of	O
AD	O
could	O
be	O
caused	O
by	O
mutations	O
in	O
the	O
APP	O
gene	O
.	O

Fabry	O
disease	O
:	O
twenty-two	O
novel	O
mutations	O
in	O
the	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
and	O
genotype/phenotype	O
correlations	O
in	O
severely	O
and	O
mildly	O
affected	O
hemizygotes	O
and	O
heterozygotes	O
.	O

BACKGROUND	O
:	O
Fabry	O
disease	O
,	O
an	O
inborn	O
error	O
of	O
glycosphingolipid	O
catabolism	O
,	O
results	O
from	O
mutations	O
in	O
the	O
X-chromosomal	O
gene	O
encoding	O
the	O
lysosomal	O
exoglycosidase	O
,	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
(	O
alpha-Gal	B-DNAMutation
A	I-DNAMutation
;	O
EC	O
3.2.1.22	O
)	O
.	O

The	O
nature	O
of	O
the	O
molecular	O
lesions	O
in	O
the	O
alpha-Gal	B-DNAMutation
A	I-DNAMutation
gene	O
in	O
36	O
unrelated	O
families	O
was	O
determined	O
in	O
order	O
to	O
provide	O
precise	O
heterozygote	O
detection	O
,	O
prenatal	O
diagnosis	O
,	O
and	O
to	O
define	O
genotype/phenotype	O
correlations	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
affected	O
males	O
and/or	O
carrier	O
females	O
from	O
36	O
unrelated	O
families	O
with	O
Fabry	O
disease	O
.	O

The	O
entire	O
alpha-Gal	B-DNAMutation
A	I-DNAMutation
coding	O
region	O
and	O
flanking	O
intronic	O
sequences	O
were	O
analyzed	O
by	O
PCR	O
amplification	O
and	O
solid-phase	O
or	O
cycle	O
sequencing	O
.	O

Markers	O
closely	O
linked	O
to	O
the	O
alpha-Gal	B-DNAMutation
A	I-DNAMutation
gene	O
were	O
analyzed	O
to	O
determine	O
if	O
probands	O
with	O
the	O
same	O
mutations	O
were	O
related	O
.	O

RESULTS	O
:	O
Twenty-two	O
novel	O
mutations	O
were	O
identified	O
including	O
10	O
missense	O
(	O
P40L	B-DNAMutation
,	O
W95S	B-DNAMutation
,	O
S148N	B-DNAMutation
,	O
C172R	B-DNAMutation
,	O
M187V	B-DNAMutation
,	O
N224S	B-DNAMutation
,	O
W226R	B-DNAMutation
,	O
A230T	B-DNAMutation
,	O
D266H	B-DNAMutation
,	O
N320Y	B-DNAMutation
)	O
,	O
three	O
nonsense	O
(	O
Y134X	B-DNAMutation
,	O
C142X	B-DNAMutation
,	O
W204X	B-DNAMutation
in	O
two	O
families	O
)	O
,	O
three	O
splice-site	O
defects	O
(	O
IVS2(+1	B-DNAMutation
)	O
,	O
IVS3(+1)	B-DNAMutation
,	O
IVS4(+1)	B-DNAMutation
)	O
and	O
six	O
small	O
deletions	O
or	O
insertions	O
(	O
26delA	B-DNAMutation
in	O
two	O
families	O
,	O
672ins37	B-DNAMutation
,	O
774delAC	B-DNAMutation
,	O
833insA	B-DNAMutation
,	O
1139delC	B-DNAMutation
,	O
1188insT	B-DNAMutation
)	O
.	O

Of	O
the	O
remaining	O
12	O
families	O
(33.3%)	O
,	O
each	O
had	O
a	O
previously	O
identified	O
mutation	O
,	O
eight	O
of	O
which	O
occurred	O
at	O
CpG	O
dinucleotides	O
including	O
R112C	B-DNAMutation
(	O
two	O
families	O
)	O
,	O
R112H	B-DNAMutation
,	O
R227Q	B-DNAMutation
,	O
R227X	B-DNAMutation
(	O
three	O
families	O
)	O
,	O
and	O
R301Q	B-DNAMutation
.	O

Haplotype	O
analysis	O
of	O
the	O
mutant	O
alleles	O
that	O
occurred	O
in	O
two	O
or	O
three	O
presumably	O
unrelated	O
families	O
revealed	O
that	O
the	O
families	O
with	O
the	O
rare	O
novel	O
alleles	O
(	O
W204X	B-DNAMutation
and	O
26delA	B-DNAMutation
)	O
were	O
probably	O
related	O
,	O
whereas	O
those	O
with	O
mutations	O
involving	O
CpG	O
dinucleotides	O
(	O
R112C	B-DNAMutation
and	O
R227X	B-DNAMutation
)	O
were	O
not	O
,	O
the	O
latter	O
being	O
consistent	O
with	O
their	O
origins	O
as	O
independent	O
mutational	O
events	O
.	O

Genotype/phenotype	O
correlations	O
revealed	O
that	O
certain	O
mutations	O
previously	O
found	O
in	O
mild	O
variant	O
patients	O
also	O
were	O
found	O
in	O
classic	O
patients	O
.	O

In	O
addition	O
,	O
the	O
genotypes	O
and	O
spectrum	O
of	O
phenotypic	O
severity	O
were	O
determined	O
in	O
five	O
heterozygotes	O
with	O
no	O
family	O
history	O
.	O

CONCLUSIONS	O
:	O
These	O
results	O
illustrate	O
the	O
molecular	O
heterogeneity	O
of	O
the	O
lesions	O
causing	O
Fabry	O
disease	O
and	O
emphasize	O
the	O
fact	O
that	O
CpG	O
dinucleotides	O
constitute	O
important	O
hot	O
spots	O
for	O
mutation	O
in	O
the	O
alpha-Gal	B-DNAMutation
A	I-DNAMutation
gene	O
.	O

These	O
studies	O
also	O
permit	O
precise	O
heterozygote	O
detection	O
and	O
prenatal	O
diagnosis	O
in	O
these	O
families	O
,	O
and	O
delineate	O
phenotype-genotype	O
correlations	O
in	O
this	O
disease	O
.	O

Characterization	O
of	O
endoglin	B-DNAMutation
and	O
identification	O
of	O
novel	O
mutations	O
in	O
hereditary	O
hemorrhagic	O
telangiectasia	O
.	O

To	O
identify	O
mutations	O
that	O
cause	O
hereditary	O
hemorrhagic	O
telangiectasia	O
(	O
HHT	O
,	O
or	O
Rendu-Osler-Weber	O
syndrome	O
)	O
,	O
clinical	O
evaluations	O
and	O
genetic	O
studies	O
were	O
performed	O
on	O
32	O
families	O
.	O

Linkage	O
studies	O
in	O
four	O
of	O
eight	O
families	O
indicated	O
an	O
endoglin	B-DNAMutation
ENG	B-DNAMutation
gene	O
mutation	O
.	O

ENG	B-DNAMutation
sequences	O
of	O
affected	O
members	O
of	O
the	O
four	O
linked	O
families	O
and	O
probands	O
from	O
the	O
24	O
small	O
families	O
were	O
screened	O
for	O
mutations	O
,	O
by	O
Southern	O
blot	O
analyses	O
and	O
by	O
cycle	O
sequencing	O
of	O
PCR-amplified	O
DNA	O
.	O

Seven	O
novel	O
mutations	O
were	O
identified	O
in	O
eight	O
families	O
.	O

Two	O
mutations	O
(	O
a	B-DNAMutation
termination	I-DNAMutation
codon	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
4	I-DNAMutation
and	O
a	O
large	O
genomic	B-DNAMutation
deletion	I-DNAMutation
extending	I-DNAMutation
3'	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
8	I-DNAMutation
)	O
did	O
not	O
produce	O
a	O
stable	O
ENG	B-DNAMutation
transcript	O
in	O
lymphocytes	O
.	O

Five	O
other	O
mutations	O
(	O
two	O
donor	O
splice-site	O
mutations	O
and	O
three	O
deletions	O
)	O
produce	O
altered	O
mRNAs	O
that	O
are	O
predicted	O
to	O
encode	O
markedly	O
truncated	O
ENG	B-DNAMutation
proteins	O
.	O

Mutations	O
in	O
other	O
families	O
are	O
predicted	O
to	O
lie	O
in	O
ENG-regulatory	B-DNAMutation
regions	O
or	O
in	O
one	O
of	O
the	O
additional	O
genes	O
that	O
may	O
cause	O
HHT	O
.	O

These	O
data	O
suggest	O
that	O
the	O
molecular	O
mechanism	O
by	O
which	O
ENG	B-DNAMutation
mutations	O
cause	O
HHT	O
is	O
haploinsufficiency	O
.	O

Furthermore	O
,	O
because	O
the	O
clinical	O
manifestation	O
of	O
disease	O
in	O
these	O
eight	O
families	O
was	O
similar	O
,	O
we	O
hypothesize	O
that	O
phenotypic	O
variation	O
of	O
HHT	O
is	O
not	O
related	O
to	O
a	O
particular	O
ENG	B-DNAMutation
mutation	O
.	O

A	O
novel	O
,	O
secreted	O
form	O
of	O
human	O
ADAM	B-DNAMutation
12	I-DNAMutation
(	O
meltrin	B-DNAMutation
alpha	I-DNAMutation
)	O
provokes	O
myogenesis	O
in	O
vivo	O
.	O

The	O
ADAM	O
(	O
A	O
Disintegrin	O
And	O
Metalloprotease	O
)	O
family	O
of	O
cell-surface	O
proteins	O
may	O
have	O
an	O
important	O
role	O
in	O
cellular	O
interactions	O
and	O
in	O
modulating	O
cellular	O
responses	O
.	O

In	O
this	O
report	O
we	O
describe	O
a	O
novel	O
,	O
secreted	O
form	O
of	O
human	O
ADAM	B-DNAMutation
12	I-DNAMutation
(	O
meltrin	B-DNAMutation
alpha	I-DNAMutation
)	O
,	O
designated	O
ADAM	B-DNAMutation
12-S	I-DNAMutation
(	O
S	O
for	O
short	O
)	O
,	O
and	O
a	O
larger	O
,	O
membrane-bound	O
form	O
designated	O
ADAM	B-DNAMutation
12-L	I-DNAMutation
(	O
L	O
for	O
long	O
form	O
)	O
.	O

These	O
two	O
forms	O
arise	O
by	O
alternative	O
splicing	O
of	O
a	O
single	O
gene	O
located	O
on	O
chromosome	O
10q26	O
.	O

Northern	O
blotting	O
demonstrated	O
that	O
mRNAs	O
of	O
both	O
forms	O
are	O
abundant	O
in	O
human	O
term	O
placenta	O
and	O
are	O
also	O
present	O
in	O
some	O
tumor	O
cell	O
lines	O
.	O

The	O
ADAM	B-DNAMutation
12-L	I-DNAMutation
transcript	O
can	O
also	O
be	O
detected	O
in	O
normal	O
human	O
adult	O
skeletal	O
,	O
cardiac	O
,	O
and	O
smooth	O
muscle	O
.	O

Human	O
A204	O
embryonal	O
rhabdomyosarcoma	O
cells	O
that	O
do	O
not	O
differentiate	O
into	O
muscle	O
cells	O
and	O
do	O
not	O
express	O
any	O
form	O
of	O
ADAM	B-DNAMutation
12	I-DNAMutation
were	O
stably	O
transfected	O
with	O
an	O
ADAM	B-DNAMutation
12-S	I-DNAMutation
minigene	O
encoding	O
the	O
disintegrin	O
domain	O
,	O
the	O
cysteine-rich	O
domain	O
,	O
and	O
the	O
unique	O
34	O
amino	O
acid	O
carboxyl	O
terminus	O
.	O

Nude	O
mouse	O
tumors	O
derived	O
from	O
these	O
transfected	O
cells	O
contained	O
ectopic	O
muscle	O
cells	O
of	O
apparent	O
mouse	O
origin	O
as	O
shown	O
by	O
species-specific	O
markers	O
.	O

These	O
results	O
may	O
have	O
potential	O
applications	O
in	O
the	O
development	O
of	O
muscle-directed	O
gene	O
and	O
cell	O
therapies	O
.	O

Aldehyde	O
dehydrogenase	O
from	O
adult	O
human	O
brain	O
that	O
dehydrogenates	O
gamma-aminobutyraldehyde	O
:	O
purification	O
,	O
characterization	O
,	O
cloning	O
and	O
distribution	O
.	O

Enzyme	O
purification	O
and	O
characterization	O
,	O
cDNA	O
cloning	O
and	O
Northern	O
blot	O
analysis	O
were	O
the	O
techniques	O
utilized	O
during	O
this	O
investigation	O
to	O
determine	O
the	O
identity	O
and	O
occurrence	O
of	O
the	O
aldehyde	O
dehydrogenase	O
that	O
metabolizes	O
gamma-aminobutyraldehyde	O
in	O
adult	O
human	O
brain	O
.	O

The	O
purification	O
yielded	O
one	O
major	O
protein	O
which	O
was	O
active	O
with	O
gamma-aminobutyraldehyde	O
.	O

It	O
had	O
the	O
physico-chemical	O
and	O
kinetic	O
properties	O
of	O
the	O
human	O
liver	B-DNAMutation
E3	I-DNAMutation
isoenzyme	I-DNAMutation
of	O
aldehyde	O
dehydrogenase	O
(	O
EC	O
1.2.1.3	O
)	O
,	O
and	O
also	O
interacted	O
with	O
an	O
anti-(liver	B-DNAMutation
E3	I-DNAMutation
isoenzyme	I-DNAMutation
)	O
antibody	O
.	O

Tryptic	O
peptides	O
derived	O
from	O
the	O
purified	O
brain	O
protein	O
matched	O
the	O
amino	O
acid	O
sequence	O
of	O
the	O
liver	B-DNAMutation
E3	I-DNAMutation
isoenzyme	I-DNAMutation
.	O

Employing	O
liver	B-DNAMutation
E3	I-DNAMutation
cDNA	O
,	O
a	O
human	O
cerebellar	O
cDNA	O
library	O
was	O
screened	O
and	O
a	O
2.0	O
kb	O
cDNA	O
fragment	O
was	O
isolated	O
.	O

The	O
cerebellar	O
cDNA	O
yielded	O
a	O
derived	O
primary	O
structure	O
which	O
differed	O
from	O
the	O
liver	O
E3	B-DNAMutation
amino	O
acid	O
sequence	O
by	O
a	O
single	B-DNAMutation
serine-to-cysteine	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
88	I-DNAMutation
(	I-DNAMutation
position	I-DNAMutation
84	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
liver	I-DNAMutation
sequence	I-DNAMutation
)	O
.	O

Thus	O
the	O
gamma-amino-butyraldehyde-metabolizing	O
enzyme	O
from	O
human	O
brain	O
can	O
be	O
identified	O
as	O
E3'	B-DNAMutation
,	O
a	O
variant	O
of	O
the	O
E3	B-DNAMutation
isoenzyme	I-DNAMutation
.	O

The	O
catalytic	O
properties	O
of	O
the	O
brain	O
variant	O
were	O
indistinguishable	O
from	O
those	O
of	O
E3	B-DNAMutation
,	O
and	O
so	O
the	O
functional	O
importance	O
of	O
this	O
variant	O
is	O
at	O
present	O
unknown	O
.	O

The	O
distribution	O
of	O
this	O
enzyme	O
in	O
brain	O
was	O
investigated	O
by	O
Northern	O
blot	O
analysis	O
,	O
which	O
demonstrated	O
the	O
presence	O
of	O
E3'	B-DNAMutation
mRNA	O
in	O
all	O
regions	O
of	O
the	O
human	O
brain	O
.	O

mRNA	O
levels	O
were	O
variable	O
in	O
the	O
different	O
brain	O
areas	O
,	O
with	O
the	O
highest	O
levels	O
in	O
the	O
spinal	O
cord	O
and	O
the	O
lowest	O
in	O
the	O
occipital	O
pole	O
.	O

Novel	O
amyloid	O
precursor	O
protein	O
gene	O
mutation	B-DNAMutation
(	I-DNAMutation
codon	I-DNAMutation
665Asp	I-DNAMutation
)	O
in	O
a	O
patient	O
with	O
late-onset	O
Alzheimer's	O
disease	O
.	O

Amyloid	O
plaques	O
in	O
Alzheimer's	O
disease	O
contain	O
beta-amyloid	O
,	O
encoded	O
by	O
portions	O
of	O
exons	O
16	O
and	O
17	O
of	O
the	O
amyloid	O
precursor	O
protein	O
.	O

The	O
specific	O
association	O
of	O
rare	O
amyloid	O
precursor	O
protein	O
mutations	O
with	O
some	O
kindreds	O
with	O
early-onset	O
familial	O
Alzheimer's	O
disease	O
suggests	O
that	O
specific	O
abnormalities	O
in	O
amyloid	O
precursor	O
protein	O
may	O
contribute	O
to	O
the	O
pathogenesis	O
of	O
Alzheimer's	O
disease	O
.	O

Until	O
now	O
,	O
there	O
has	O
been	O
no	O
evidence	O
suggesting	O
that	O
amyloid	O
precursor	O
protein	O
mutations	O
could	O
be	O
involved	O
in	O
late-onset	O
or	O
sporadic	O
Alzheimer's	O
disease	O
.	O

We	O
used	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
,	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
,	O
and	O
direct	O
DNA	O
sequencing	O
to	O
analyze	O
amyloid	O
precursor	O
protein	O
exons	O
16	O
and	O
17	O
from	O
postmortem	O
cerebellar	O
samples	O
from	O
patients	O
with	O
histologically	O
confirmed	O
Alzheimer's	O
disease	O
and	O
control	O
subjects	O
.	O

We	O
found	O
a	O
novel	O
point	O
mutation	O
,	O
substitution	B-DNAMutation
of	I-DNAMutation
cytosine	I-DNAMutation
for	I-DNAMutation
guanine	I-DNAMutation
,	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
2119	I-DNAMutation
(	O
amyloid	O
precursor	O
protein	O
770	O
messenger	O
RNA	O
transcript	O
)	O
in	O
a	O
patient	O
with	O
late-onset	O
Alzheimer's	O
disease	O
.	O

This	O
substitution	O
deletes	B-DNAMutation
a	I-DNAMutation
BglII	I-DNAMutation
site	I-DNAMutation
and	O
substitutes	B-DNAMutation
aspartate	I-DNAMutation
for	I-DNAMutation
glutamine	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
665	I-DNAMutation
.	O

Denaturing	O
gradient	O
gel	O
electrophoresis	O
analysis	O
showed	O
that	O
this	O
mutation	O
was	O
absent	O
in	O
40	O
control	O
subjects	O
and	O
127	O
dementia	O
patients	O
.	O

Whether	O
this	O
mutation	O
is	O
a	O
rare	O
but	O
normal	O
variant	O
or	O
contributes	O
to	O
the	O
development	O
of	O
Alzheimer's	O
disease	O
is	O
not	O
known	O
.	O

The	O
BglII	O
restriction	O
fragment	O
length	O
polymorphism	O
enables	O
investigators	O
to	O
determine	O
the	O
frequency	O
of	O
this	O
polymorphism	O
in	O
normal	O
subjects	O
and	O
Alzheimer's	O
disease	O
patients	O
.	O

Alterations	O
of	O
the	O
PPP2R1B	B-DNAMutation
gene	O
located	O
at	O
11q23	O
in	O
human	O
colorectal	O
cancers	O
.	O

BACKGROUND/AIMS	O
:	O
In	O
1998	O
the	O
PPP2R1B	B-DNAMutation
gene	O
encoding	O
the	O
A	O
subunit	O
of	O
the	O
serine/threonine	O
protein	O
phosphatase	O
was	O
identified	O
as	O
a	O
putative	O
tumour	O
suppressor	O
gene	O
in	O
lung	O
and	O
colon	O
cancer	O
in	O
the	O
chromosome	O
region	O
11q22-24	O
.	O

The	O
aim	O
of	O
the	O
present	O
study	O
was	O
to	O
determine	O
the	O
type	O
of	O
alterations	O
in	O
primary	O
rectal	O
cancers	O
as	O
well	O
as	O
colon	O
cancers	O
and	O
the	O
correlation	O
between	O
these	O
alterations	O
and	O
clinicopathological	O
data	O
.	O

METHODS	O
:	O
Mutation	O
analyses	O
of	O
the	O
PPP2R1B	B-DNAMutation
gene	O
sequence	O
encoding	O
the	O
binding	O
sites	O
of	O
the	O
catalytic	O
C	O
subunit	O
(	O
Huntington	O
elongation	O
A	O
subunit	O
TOR	O
(HEAT)	O
repeats	O
11-15	O
)	O
and	O
partial	O
binding	O
sites	O
of	O
the	O
regulatory	O
B	O
subunit	O
were	O
carried	O
out	O
on	O
cDNA	O
samples	O
from	O
30	O
primary	O
colorectal	O
cancer	O
specimens	O
and	O
corresponding	O
normal	O
tissues	O
using	O
a	O
combination	O
of	O
the	O
polymerase	O
chain	O
reaction	O
and	O
subsequent	O
direct	O
DNA	O
sequencing	O
.	O

RESULTS	O
:	O
Five	O
missense	O
mutations	O
producing	O
amino	O
acid	O
substitutions	O
were	O
detected	O
in	O
the	O
four	O
colon	O
cancer	O
cases	O
(	O
13.3%	O
;	O
four	O
of	O
30	O
colorectal	O
cancers	O
)	O
:	O
(15)glycine	B-DNAMutation
(GGT)	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
(GCT)	I-DNAMutation
and	O
(499)leucine	B-DNAMutation
(TTA)	I-DNAMutation
to	I-DNAMutation
isoleucine	I-DNAMutation
(ATA)	I-DNAMutation
in	O
the	O
same	O
case	O
,	O
and	O
(498)valine	B-DNAMutation
(GTG)	I-DNAMutation
to	I-DNAMutation
glutamic	I-DNAMutation
acid	I-DNAMutation
(GAG)	I-DNAMutation
,	O
(500)valine	B-DNAMutation
(GTA)	I-DNAMutation
to	I-DNAMutation
glycine	I-DNAMutation
(GGA)	I-DNAMutation
,	O
and	O
(365)serine	B-DNAMutation
(TCT)	I-DNAMutation
to	I-DNAMutation
proline	I-DNAMutation
(CCT)	I-DNAMutation
.	O

Of	O
these	O
five	O
mutations	O
,	O
three	O
(60%)	O
were	O
located	O
in	O
HEAT	O
repeat	O
13	O
and	O
four	O
(80%)	O
showed	O
T	O
to	O
other	O
nucleotide	O
substitutions	O
.	O

In	O
addition	O
,	O
a	O
normal	O
polymorphism	O
,	O
(478)leucine	O
,	O
was	O
found	O
.	O

No	O
correlation	O
was	O
found	O
between	O
these	O
mutations	O
and	O
clinicopathological	O
data	O
.	O

CONCLUSION	O
:	O
Our	O
results	O
suggest	O
that	O
the	O
PPP2R1B	B-DNAMutation
gene	O
is	O
one	O
of	O
the	O
true	O
targets	O
at	O
11q23	O
,	O
and	O
its	O
inactivation	O
is	O
involved	O
in	O
the	O
development	O
of	O
all	O
types	O
of	O
colorectal	O
cancers	O
.	O

Analysis	O
of	O
splice-site	O
mutations	O
of	O
the	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
in	O
Fabry	O
disease	O
.	O

Fabry	O
disease	O
is	O
an	O
X-linked	O
disease	O
caused	O
by	O
a	O
defective	O
lysosomal	O
enzyme	O
,	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
,	O
and	O
characterized	O
by	O
skin	O
lesions	O
and	O
multiorgan	O
involvement	O
,	O
including	O
kidney	O
,	O
heart	O
,	O
and	O
the	O
central	O
nervous	O
system	O
.	O

Currently	O
more	O
than	O
200	O
genotypes	O
have	O
been	O
identified	O
,	O
including	O
several	O
aberrant	O
splicing	O
.	O

However	O
,	O
most	O
of	O
the	O
mutation	O
analyses	O
were	O
performed	O
using	O
genomic	O
sequencing	O
only	O
,	O
and	O
therefore	O
some	O
of	O
the	O
splicing	O
mutations	O
were	O
misclassified	O
as	O
missense	O
mutations	O
.	O

In	O
order	O
to	O
predict	O
the	O
splicing	O
event	O
caused	O
by	O
each	O
mutation	O
,	O
we	O
conducted	O
a	O
literature	O
search	O
for	O
all	O
published	O
mutations	O
located	O
near	O
the	O
splice	O
sites	O
,	O
including	O
exonic	O
point	O
mutations	O
,	O
and	O
performed	O
a	O
splice-site	O
score	O
(SSS)	O
analysis	O
.	O

The	O
literature	O
search	O
identified	O
13	O
donor-site	O
mutations	O
,	O
including	O
four	O
exonic	O
mutations	O
(	O
S65T	B-DNAMutation
,	O
D183S	B-DNAMutation
,	O
K213N	B-DNAMutation
,	O
and	O
M267I	B-DNAMutation
)	O
,	O
located	O
at	O
the	O
end	O
of	O
exons	O
1	O
,	O
3	O
,	O
4	O
,	O
and	O
5	O
,	O
respectively	O
,	O
six	O
acceptor-site	O
mutations	O
,	O
and	O
one	O
new	O
exon	O
creation	O
.	O

All	O
mutated	O
splice	O
sites	O
,	O
except	O
for	O
the	O
one	O
associated	O
with	O
the	O
new	O
exon	O
creation	O
,	O
had	O
a	O
lower	O
SSS	O
than	O
their	O
respective	O
natural	O
sites	O
.	O

Cryptic	O
or	O
newly	O
created	O
sites	O
were	O
identified	O
with	O
SSS	O
from	O
0.09	O
to	O
1.0	O
.	O

The	O
predictions	O
,	O
based	O
on	O
SSS	O
analysis	O
,	O
are	O
in	O
agreement	O
with	O
all	O
six	O
mutations	O
with	O
known	O
cDNA	O
sequence	O
from	O
the	O
literature	O
,	O
including	O
five	O
mutations	O
with	O
exon	O
skipping	O
and	O
one	O
mutation	O
with	O
creation	O
of	O
a	O
new	O
acceptor	O
site	O
.	O

For	O
the	O
S65T	B-DNAMutation
genotype	O
,	O
we	O
performed	O
reverse	O
transcription-polymerase	O
chain	O
reaction	O
(RT-PCR)	O
analysis	O
using	O
RNA	O
isolated	O
from	O
the	O
whole-blood	O
sample	O
.	O

We	O
verified	O
that	O
a	O
weak	O
cryptic	O
site	O
(	O
SSS	O
=	O
0.09	O
)	O
14	B-DNAMutation
nucleotides	I-DNAMutation
downstream	I-DNAMutation
was	I-DNAMutation
activated	I-DNAMutation
and	I-DNAMutation
resulted	I-DNAMutation
in	I-DNAMutation
an	I-DNAMutation
insertion	I-DNAMutation
of	I-DNAMutation
14	I-DNAMutation
bp	I-DNAMutation
and	I-DNAMutation
a	I-DNAMutation
frameshift	I-DNAMutation
stop	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
106	I-DNAMutation
.	O

This	O
change	O
is	O
more	O
consistent	O
with	O
the	O
clinical	O
presentation	O
of	O
the	O
patient	O
,	O
the	O
classical	O
Fabry	O
disease	O
,	O
than	O
the	O
amino	O
acid	O
substitution	O
S65T	B-DNAMutation
,	O
which	O
does	O
not	O
affect	O
the	O
enzyme	O
function	O
.	O

In	O
conclusion	O
,	O
the	O
SSS	O
analysis	O
is	O
very	O
useful	O
for	O
predicting	O
splicing	O
events	O
and	O
genotype/phenotype	O
correlation	O
in	O
Fabry	O
disease	O
.	O

As	O
different	O
mechanisms	O
may	O
be	O
involved	O
in	O
pre-mRNA	O
splicing	O
,	O
it	O
is	O
important	O
to	O
obtain	O
cDNA	O
sequencing	O
for	O
molecular	O
diagnosis	O
.	O

Computational	O
and	O
functional	O
characterization	O
of	O
Angiogenin	B-DNAMutation
mutations	O
,	O
and	O
correlation	O
with	O
amyotrophic	O
lateral	O
sclerosis	O
.	O

The	O
Angiogenin	B-DNAMutation
ANG	B-DNAMutation
gene	O
is	O
frequently	O
mutated	O
in	O
patients	O
suffering	O
from	O
the	O
neurodegenerative	O
disease--amyotrophic	O
lateral	O
sclerosis	O
(ALS)	O
.	O

Most	O
of	O
the	O
ALS-causing	O
mutations	O
in	O
Angiogenin	B-DNAMutation
affect	O
either	O
its	O
ribonucleolytic	O
or	O
nuclear	O
translocation	O
activity	O
.	O

Here	O
we	O
report	O
the	O
functional	O
characterization	O
of	O
two	O
previously	O
uncharacterized	O
missense	O
mutations	O
in	O
Angiogenin--D22G	B-DNAMutation
and	O
L35P	B-DNAMutation
.	O

We	O
predict	O
the	O
nature	O
of	O
loss-of-function(s)	O
in	O
these	O
mutants	O
through	O
our	O
previously	O
established	O
Molecular	O
Dynamics	O
(MD)	O
simulation	O
extended	O
to	O
100	O
ns	O
,	O
and	O
show	O
that	O
the	O
predictions	O
are	O
entirely	O
validated	O
through	O
biochemical	O
studies	O
with	O
wild-type	O
and	O
mutated	O
proteins	O
.	O

Based	O
on	O
our	O
studies	O
,	O
we	O
provide	O
a	O
biological	O
explanation	O
for	O
the	O
loss-of-function	O
of	O
D22G-Angiogenin	B-DNAMutation
leading	O
to	O
ALS	O
,	O
and	O
suggest	O
that	O
the	O
L35P-Angiogenin	B-DNAMutation
mutation	O
would	O
probably	O
cause	O
ALS	O
symptoms	O
in	O
individuals	O
harboring	O
this	O
mutation	O
.	O

Our	O
study	O
thus	O
highlights	O
the	O
strength	O
of	O
MD	O
simulation-based	O
predictions	O
,	O
and	O
suggests	O
that	O
this	O
method	O
can	O
be	O
used	O
for	O
correlating	O
mutations	O
in	O
Angiogenin	B-DNAMutation
or	O
other	O
effector	O
proteins	O
with	O
ALS	O
symptoms	O
.	O

Role	O
of	O
FLASH	B-DNAMutation
in	O
caspase-8-mediated	B-DNAMutation
activation	O
of	O
NF-kappaB	O
:	O
dominant-negative	O
function	O
of	O
FLASH	B-DNAMutation
mutant	O
in	O
NF-kappaB	O
signaling	O
pathway	O
.	O

Caspase-8	O
is	O
the	O
most	O
receptor-proximal	O
,	O
upstream	O
caspase	O
in	O
the	O
caspase	O
cascade	O
and	O
plays	O
a	O
key	O
role	O
in	O
cell	O
death	O
triggered	O
by	O
various	O
death	O
receptors	O
.	O

Here	O
,	O
we	O
addressed	O
the	O
role	O
of	O
endogenous	O
caspase-8	B-DNAMutation
in	O
tumor	B-DNAMutation
necrosis	I-DNAMutation
factor	I-DNAMutation
(TNF)-alpha-induced	I-DNAMutation
activation	O
of	O
NF-kappaB	O
.	O

Direct	O
targeting	O
of	O
caspase-8	B-DNAMutation
with	O
siRNA	O
and	O
antisense	O
(AS)	O
approaches	O
abolished	O
TNF-alpha-induced	B-DNAMutation
activation	O
of	O
NF-kappaB	O
in	O
NIH3T3	O
,	O
HeLa	O
,	O
and	O
HEK293	O
cells	O
as	O
determined	O
with	O
luciferase	O
reporter	O
gene	O
and	O
cell	O
fractionation	O
assays	O
.	O

Reconstitution	O
of	O
caspase-8-deficient	B-DNAMutation
C33A	O
cells	O
with	O
processing-defective	O
(P/D)	O
mutant	O
of	O
caspase-8	B-DNAMutation
sensitized	O
the	O
cells	O
to	O
TNF-alpha	B-DNAMutation
for	O
NF-kappaB	O
activation	O
.	O

In	O
contrast	O
to	O
wild-type	O
caspase-8	B-DNAMutation
,	O
death	O
effector	O
domain	O
mutant	O
replacing	O
Asp73	B-DNAMutation
with	I-DNAMutation
Ala	I-DNAMutation
(	O
caspase-8	B-DNAMutation
(	O
D73A	B-DNAMutation
)	O
)	O
failed	O
to	O
activate	O
NF-kappaB	O
and	O
to	O
bind	O
FLICE-associated	B-DNAMutation
huge	I-DNAMutation
protein	I-DNAMutation
FLASH	B-DNAMutation
in	O
vitro	O
and	O
in	O
vivo	O
.	O

Instead	O
,	O
caspase-8	B-DNAMutation
D73A	B-DNAMutation
mutant	O
bound	O
to	O
caspase-8	B-DNAMutation
and	O
blocked	O
NF-kappaB	O
activation	O
triggered	O
by	O
TNF-alpha	B-DNAMutation
and	O
caspase-8	B-DNAMutation
.	O

In	O
addition	O
,	O
expression	O
of	O
an	O
NF-kappaB-activating	O
domain-deletion	O
mutant	O
of	O
FLASH	B-DNAMutation
or	O
transfection	O
of	O
FLASH	B-DNAMutation
AS	O
oligonucleotides	O
abolished	O
TNF-alpha	B-DNAMutation
and	O
caspase-8	B-DNAMutation
,	O
but	O
not	O
phorbol	O
12-myristate	O
13-acetate	O
,	O
-induced	O
activation	O
of	O
NF-kappaB	O
.	O

Further	O
,	O
immunoprecipitation	O
assays	O
showed	O
that	O
caspase-8	B-DNAMutation
formed	O
triple	O
complex	O
with	O
TRAF2	B-DNAMutation
and	O
FLASH	B-DNAMutation
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
endogenous	O
caspase-8	B-DNAMutation
mediates	O
TNF-alpha-induced	B-DNAMutation
activation	O
of	O
NF-kappaB	O
via	O
FLASH	B-DNAMutation
.	O

The	O
N-terminal	O
region	O
of	O
ABC50	B-DNAMutation
interacts	O
with	O
eukaryotic	O
initiation	O
factor	O
eIF2	B-DNAMutation
and	O
is	O
a	O
target	O
for	O
regulatory	O
phosphorylation	O
by	O
CK2	O
.	O

ABC50	B-DNAMutation
is	O
an	O
ABC	B-DNAMutation
(	O
ATP-binding	B-DNAMutation
cassette	I-DNAMutation
)	O
protein	O
which	O
,	O
unlike	O
most	O
ABC	B-DNAMutation
proteins	O
,	O
lacks	O
membrane-spanning	O
domains	O
.	O

ABC50	B-DNAMutation
interacts	O
with	O
eIF2	B-DNAMutation
(	O
eukaryotic	B-DNAMutation
initiation	I-DNAMutation
factor	I-DNAMutation
2	I-DNAMutation
)	O
,	O
a	O
protein	O
that	O
plays	O
a	O
key	O
role	O
in	O
translation	O
initiation	O
and	O
in	O
its	O
control	O
,	O
and	O
in	O
regulation	O
of	O
ribosomes	O
.	O

Here	O
,	O
we	O
establish	O
that	O
the	O
interaction	O
of	O
ABC50	B-DNAMutation
with	O
eIF2	B-DNAMutation
involves	O
features	O
in	O
the	O
N-terminal	O
domain	O
of	O
ABC50	B-DNAMutation
,	O
the	O
region	O
of	O
ABC50	B-DNAMutation
that	O
differs	O
most	O
markedly	O
from	O
other	O
ABC	B-DNAMutation
proteins	O
.	O

This	O
region	O
also	O
shows	O
no	O
apparent	O
similarity	O
to	O
the	O
eIF2-binding	O
domains	O
of	O
other	O
partners	O
of	O
eIF2	B-DNAMutation
.	O

In	O
contrast	O
,	O
the	O
N-terminus	O
of	O
ABC50	B-DNAMutation
cannot	O
bind	O
to	O
ribosomes	O
by	O
itself	O
,	O
but	O
it	O
can	O
in	O
conjunction	O
with	O
one	O
of	O
the	O
nucleotide-binding	O
domains	O
.	O

We	O
demonstrate	O
that	O
ABC50	B-DNAMutation
is	O
a	O
phosphoprotein	O
and	O
is	O
phosphorylated	O
at	O
two	O
sites	O
by	O
CK2	O
.	O

These	O
sites	O
,	O
Ser-109	B-DNAMutation
and	O
Ser-140	B-DNAMutation
,	O
lie	O
in	O
the	O
N-terminal	O
part	O
of	O
ABC50	B-DNAMutation
but	O
are	O
not	O
required	O
for	O
the	O
binding	O
of	O
ABC50	B-DNAMutation
to	O
eIF2	B-DNAMutation
.	O

Expression	O
of	O
a	O
mutant	O
of	O
ABC50	B-DNAMutation
in	O
which	O
both	B-DNAMutation
sites	I-DNAMutation
are	I-DNAMutation
mutated	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
markedly	O
decreased	O
the	O
association	O
of	O
eIF2	B-DNAMutation
with	O
80S	O
ribosomal	O
and	O
polysomal	O
fractions	O
.	O

Mutations	O
in	O
the	O
tricarboxylic	O
acid	O
cycle	O
enzyme	O
,	O
aconitase	O
2	O
,	O
cause	O
either	O
isolated	O
or	O
syndromic	O
optic	O
neuropathy	O
with	O
encephalopathy	O
and	O
cerebellar	O
atrophy	O
.	O

BACKGROUND	O
:	O
Inherited	O
optic	O
neuropathy	O
has	O
been	O
ascribed	O
to	O
mutations	O
in	O
mitochondrial	O
fusion/fission	O
dynamics	O
genes	O
,	O
nuclear	O
and	O
mitochondrial	O
DNA-encoded	O
respiratory	O
enzyme	O
genes	O
or	O
nuclear	O
genes	O
of	O
poorly	O
known	O
mitochondrial	O
function	O
.	O

However	O
,	O
the	O
disease	O
causing	O
gene	O
remains	O
unknown	O
in	O
many	O
families	O
.	O

METHODS	O
:	O
We	O
used	O
exome	O
sequencing	O
in	O
order	O
to	O
identify	O
the	O
gene	O
responsible	O
for	O
isolated	O
or	O
syndromic	O
optic	O
atrophy	O
in	O
five	O
patients	O
from	O
three	O
independent	O
families	O
.	O

RESULTS	O
:	O
We	O
found	O
homozygous	O
or	O
compound	O
heterozygous	O
missense	O
and	O
frameshift	O
mutations	O
in	O
the	O
gene	O
encoding	O
mitochondrial	O
aconitase	O
ACO2	B-DNAMutation
,	O
a	O
tricarboxylic	O
acid	O
cycle	O
enzyme	O
,	O
catalysing	O
interconversion	O
of	O
citrate	O
into	O
isocitrate	O
.	O

Unlike	O
wild	O
type	O
ACO2	O
,	O
all	O
mutant	O
ACO2	O
proteins	O
failed	O
to	O
complement	O
the	O
respiratory	O
growth	O
of	O
a	O
yeast	O
aco1-deletion	B-DNAMutation
strain	O
.	O

Retrospective	O
studies	O
using	O
patient-derived	O
cultured	O
skin	O
fibroblasts	O
revealed	O
various	O
degrees	O
of	O
deficiency	O
in	O
ACO2	B-DNAMutation
activity	O
,	O
but	O
also	O
in	O
ACO1	B-DNAMutation
cytosolic	O
activity	O
.	O

CONCLUSIONS	O
:	O
Our	O
study	O
shows	O
that	O
autosomal	O
recessive	O
ACO2	B-DNAMutation
mutations	O
can	O
cause	O
either	O
isolated	O
or	O
syndromic	O
optic	O
neuropathy	O
.	O

This	O
observation	O
identifies	O
ACO2	B-DNAMutation
as	O
the	O
second	O
gene	O
responsible	O
for	O
non-syndromic	O
autosomal	O
recessive	O
optic	O
neuropathies	O
and	O
provides	O
evidence	O
for	O
a	O
genetic	O
overlap	O
between	O
isolated	O
and	O
syndromic	O
forms	O
,	O
giving	O
further	O
support	O
to	O
the	O
view	O
that	O
optic	O
atrophy	O
is	O
a	O
hallmark	O
of	O
defective	O
mitochondrial	O
energy	O
supply	O
.	O

ADAM-15/metargidin	B-DNAMutation
mediates	O
homotypic	O
aggregation	O
of	O
human	O
T	O
lymphocytes	O
and	O
heterotypic	O
interactions	O
of	O
T	O
lymphocytes	O
with	O
intestinal	O
epithelial	O
cells	O
.	O

Intestinal	O
epithelial	O
cells	O
(IEC)	O
play	O
an	O
immunoregulatory	O
role	O
in	O
the	O
intestine	O
.	O

This	O
role	O
involves	O
cell-cell	O
interactions	O
with	O
intraepithelial	O
lymphocytes	O
that	O
may	O
also	O
play	O
a	O
role	O
in	O
some	O
enteropathies	O
.	O

The	O
discovery	O
of	O
the	O
RGD	O
motif-containing	O
Protein	O
ADAM-15	B-DNAMutation
(	O
a	B-DNAMutation
disintegrin	I-DNAMutation
and	I-DNAMutation
metalloprotease-15	I-DNAMutation
)	O
raises	O
the	O
question	O
of	O
its	O
involvement	O
in	O
these	O
cell-cell	O
interactions	O
.	O

Cell	O
adhesion	O
assays	O
were	O
performed	O
using	O
the	O
Jurkat	O
E6.1	O
T	O
cell	O
line	O
as	O
a	O
model	O
of	O
T	O
lymphocytes	O
and	O
Caco2-BBE	O
monolayers	O
as	O
a	O
model	O
of	O
intestinal	O
epithelia	O
.	O

Our	O
results	O
show	O
that	O
an	O
anti-ADAM-15	B-DNAMutation
ectodomain	O
antibody	O
inhibited	O
the	O
attachment	O
of	O
Jurkat	O
cells	O
on	O
Caco2-BBE	O
monolayers	O
.	O

Overexpression	O
of	O
ADAM-15	B-DNAMutation
in	O
Caco2-BBE	O
cells	O
enhanced	O
Jurkat	O
cell	O
binding	O
,	O
and	O
overexpression	O
of	O
ADAM-15	B-DNAMutation
in	O
Jurkat	O
cells	O
enhanced	O
their	O
aggregation	O
.	O

Mutagenesis	O
experiments	O
showed	O
that	O
both	O
the	O
mutation	O
of	O
ADAM-15	O
RGD	O
domain	O
or	O
the	O
deletion	B-DNAMutation
of	I-DNAMutation
its	I-DNAMutation
cytoplasmic	I-DNAMutation
tail	I-DNAMutation
decreased	O
these	O
cell-cell	O
interactions	O
.	O

Moreover	O
,	O
wound-healing	O
experiments	O
showed	O
that	O
epithelial	O
ADAM-15-mediated	B-DNAMutation
Jurkat	O
cell	O
adhesion	O
to	O
Caco2-BBE	O
cells	O
enhances	O
the	O
mechanisms	O
of	O
wound	O
repair	O
.	O

We	O
also	O
found	O
that	O
ADAM-15-mediated	B-DNAMutation
aggregation	O
of	O
Jurkat	O
cells	O
increases	O
the	O
expression	O
of	O
tumor	B-DNAMutation
necrosis	I-DNAMutation
factor-alpha	I-DNAMutation
mRNA	O
.	O

These	O
results	O
demonstrate	O
the	O
following	O
:	O
1	O
)	O
ADAM-15	B-DNAMutation
is	O
involved	O
in	O
heterotypic	O
adhesion	O
of	O
intraepithelial	O
lymphocytes	O
to	O
IEC	O
as	O
well	O
as	O
in	O
homotypic	O
aggregation	O
of	O
T	O
cells	O
;	O
2	O
)	O
both	O
the	O
RGD	O
motif	O
and	O
the	O
cytoplasmic	O
tail	O
of	O
ADAM-15	B-DNAMutation
are	O
involved	O
for	O
these	O
cell-cell	O
interactions	O
;	O
and	O
3	O
)	O
ADAM-15-mediated	B-DNAMutation
cell-cell	O
interactions	O
are	O
involved	O
in	O
mechanisms	O
of	O
epithelial	O
restitution	O
and	O
production	O
of	O
pro-inflammatory	O
mediators	O
.	O

Altogether	O
these	O
findings	O
point	O
to	O
ADAM-15	B-DNAMutation
as	O
a	O
possible	O
therapeutic	O
target	O
for	O
prevention	O
of	O
inappropriate	O
T	O
cell	O
activation	O
involved	O
in	O
some	O
pathologies	O
.	O

S/T	O
phosphorylation	O
of	O
DLL1	B-DNAMutation
is	O
required	O
for	O
full	O
ligand	O
activity	O
in	O
vitro	O
but	O
dispensable	O
for	O
DLL1	B-DNAMutation
function	O
in	O
vivo	O
during	O
embryonic	O
patterning	O
and	O
marginal	O
zone	O
B	O
cell	O
development	O
.	O

Interaction	O
of	O
Notch	O
receptors	O
with	O
Delta-	O
and	O
Serrate-type	O
ligands	O
is	O
an	O
evolutionarily	O
conserved	O
mechanism	O
that	O
mediates	O
direct	O
communication	O
between	O
adjacent	O
cells	O
and	O
thereby	O
regulates	O
multiple	O
developmental	O
processes	O
.	O

Posttranslational	O
modifications	O
of	O
both	O
receptors	O
and	O
ligands	O
are	O
pivotal	O
for	O
normal	O
Notch	O
pathway	O
function	O
.	O

We	O
have	O
identified	O
by	O
mass	O
spectrometric	O
analysis	O
two	O
serine	O
and	O
one	O
threonine	O
phosphorylation	O
sites	O
in	O
the	O
intracellular	O
domain	O
of	O
the	O
mouse	O
Notch	O
ligand	O
DLL1	B-DNAMutation
.	O

Phosphorylation	O
requires	O
cell	O
membrane	O
association	O
of	O
DLL1	B-DNAMutation
and	O
occurs	O
sequentially	O
at	O
the	O
two	O
serine	O
residues	O
.	O

Phosphorylation	O
of	O
one	O
serine	O
residue	O
most	O
likely	O
by	O
protein	O
kinase	O
B	O
primes	O
phosphorylation	O
of	O
the	O
other	O
serine	O
.	O

A	O
DLL1	B-DNAMutation
variant	O
,	O
in	O
which	O
all	B-DNAMutation
three	I-DNAMutation
identified	I-DNAMutation
phosphorylated	I-DNAMutation
serine/threonine	I-DNAMutation
residues	I-DNAMutation
are	I-DNAMutation
mutated	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
and	I-DNAMutation
valine	I-DNAMutation
,	O
was	O
more	O
stable	O
than	O
wild-type	O
DLL1	B-DNAMutation
but	O
had	O
reduced	O
relative	O
levels	O
on	O
the	O
cell	O
surface	O
and	O
was	O
more	O
effectively	O
cleaved	O
in	O
the	O
extracellular	O
domain	O
.	O

In	O
addition	O
,	O
the	O
mutant	O
variant	O
activated	O
Notch1	B-DNAMutation
significantly	O
less	O
efficient	O
than	O
wild-type	O
DLL1	B-DNAMutation
in	O
a	O
coculture	O
assay	O
in	O
vitro	O
.	O

Mice	O
,	O
however	O
,	O
whose	O
endogenous	O
DLL1	B-DNAMutation
was	O
replaced	O
with	O
the	O
phosphorylation-deficient	O
triple	O
mutant	O
developed	O
normally	O
,	O
suggesting	O
compensatory	O
mechanisms	O
under	O
physiological	O
conditions	O
in	O
vivo	O
.	O

Mutation	O
analysis	O
of	O
very-long-chain	B-DNAMutation
acyl-coenzyme	I-DNAMutation
A	I-DNAMutation
dehydrogenase	I-DNAMutation
VLCAD	B-DNAMutation
deficiency	O
:	O
identification	O
and	O
characterization	O
of	O
mutant	O
VLCAD	B-DNAMutation
cDNAs	O
from	O
four	O
patients	O
.	O

Very-long-chain	B-DNAMutation
acyl-coenzyme	I-DNAMutation
A	I-DNAMutation
dehydrogenase	I-DNAMutation
VLCAD	B-DNAMutation
deficiency	O
is	O
a	O
newly	O
identified	O
disease	O
.	O

A	O
105-bp	O
deletion	O
in	O
the	O
VLCAD	B-DNAMutation
cDNA	O
in	O
two	O
patients	O
has	O
been	O
reported	O
,	O
and	O
detailed	O
molecular	O
characterization	O
of	O
this	O
disease	O
has	O
remained	O
to	O
be	O
done	O
.	O

We	O
report	O
here	O
five	O
mutations	O
identified	O
in	O
four	O
patients	O
:	O
a	O
135-bp	B-DNAMutation
deletion	I-DNAMutation
encompassing	I-DNAMutation
bases	I-DNAMutation
343-477	I-DNAMutation
,	O
a	B-DNAMutation
C-1837-to-T	I-DNAMutation
transition	O
R613W	B-DNAMutation
,	O
3-bp	B-DNAMutation
deletions	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
nucleotide	I-DNAMutation
positions	I-DNAMutation
388-390	I-DNAMutation
(E130del)	I-DNAMutation
and	O
895-897	B-DNAMutation
(K299del)	I-DNAMutation
,	O
and	O
an	O
A-1144-to-C	O
transversion	O
K382Q	B-DNAMutation
.	O

Sequencing	O
of	O
genomic	O
DNA	O
amplified	O
by	O
PCR	O
revealed	O
a	O
135-bp	B-DNAMutation
deletion	I-DNAMutation
caused	I-DNAMutation
by	I-DNAMutation
exon	I-DNAMutation
skipping	I-DNAMutation
due	I-DNAMutation
to	I-DNAMutation
a	I-DNAMutation
1-bp	I-DNAMutation
deletion	I-DNAMutation
in	I-DNAMutation
a	I-DNAMutation
3'	I-DNAMutation
splice	I-DNAMutation
site	I-DNAMutation
of	I-DNAMutation
an	I-DNAMutation
intron	I-DNAMutation
.	O

In	O
cDNA	O
expression	O
experiments	O
using	O
Chinese	O
hamster	O
ovary	O
(CHO)	O
cells	O
,	O
we	O
found	O
that	O
each	O
of	O
the	O
mRNAs	O
derived	O
from	O
E130del	B-DNAMutation
and	O
K299del	B-DNAMutation
clones	O
were	O
unstable	O
and	O
that	O
translation	O
products	O
from	O
R613W	B-DNAMutation
,	O
E130del	B-DNAMutation
,	O
K299del	B-DNAMutation
,	O
and	O
K382Q	B-DNAMutation
clones	O
were	O
labile	O
.	O

Each	O
of	O
R613W	B-DNAMutation
,	O
E130del	B-DNAMutation
,	O
K299del	B-DNAMutation
,	O
and	O
K382Q	B-DNAMutation
proteins	O
expressed	O
in	O
CHO	O
cells	O
appeared	O
abnormal	O
in	O
dimer	O
assembly	O
,	O
as	O
shown	O
in	O
gel-filtration	O
analysis	O
.	O

VLCAD	B-DNAMutation
activity	O
was	O
not	O
detected	O
in	O
mutants'	O
transfectants	O
.	O

Thus	O
,	O
we	O
verified	O
that	O
all	O
five	O
mutations	O
identified	O
in	O
these	O
four	O
patients	O
were	O
disease-causing	O
alterations	O
.	O

Detection	O
and	O
functional	O
characterization	O
of	O
the	O
novel	O
missense	O
mutation	O
Y254D	B-DNAMutation
in	O
type	O
II	O
3	O
beta-hydroxysteroid	O
dehydrogenase	O
(	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
)	O
gene	O
of	O
a	O
female	O
patient	O
with	O
nonsalt-losing	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
deficiency	O
.	O

Three	O
beta-hydroxysteroid	O
dehydrogenase/delta	O
5-delta	O
4-isomerase	O
(	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
)	O
deficiency	O
is	O
a	O
form	O
of	O
congenital	O
adrenal	O
hyperplasia	O
characterized	O
by	O
severe	O
impairment	O
of	O
steroid	O
biosynthesis	O
in	O
the	O
adrenals	O
and	O
gonads	O
.	O

To	O
better	O
understand	O
the	O
molecular	O
basis	O
of	O
the	O
phenotypic	O
heterogeneity	O
found	O
in	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
deficiency	O
,	O
we	O
analyzed	O
the	O
structure	O
of	O
type	O
I	O
and	O
II	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
genes	O
in	O
a	O
female	O
patient	O
with	O
nonsalt-losing	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
deficiency	O
diagnosed	O
at	O
puberty	O
.	O

We	O
directly	O
sequenced	O
DNA	O
fragments	O
generated	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
the	O
four	O
exons	O
,	O
the	O
exon-intron	O
boundaries	O
,	O
and	O
the	O
5'-flanking	O
regions	O
of	O
each	O
gene	O
.	O

No	O
mutation	O
was	O
detected	O
in	O
the	O
type	O
I	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
gene	O
,	O
which	O
is	O
the	O
predominant	O
species	O
expressed	O
in	O
the	O
placenta	O
and	O
peripheral	O
tissues	O
.	O

We	O
detected	O
a	O
novel	O
missense	O
mutation	O
,	O
Y254D	B-DNAMutation
,	O
in	O
one	O
allele	O
of	O
the	O
patient's	O
type	O
II	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
gene	O
,	O
which	O
is	O
the	O
almost	O
exclusive	O
type	O
expressed	O
in	O
the	O
adrenals	O
and	O
gonads	O
.	O

The	O
influence	O
of	O
the	O
Y254D	B-DNAMutation
mutation	O
on	O
enzymatic	O
activity	O
was	O
assessed	O
by	O
analyzing	O
the	O
recombinant	O
mutant	O
enzyme	O
generated	O
by	O
site-directed	O
mutagenesis	O
after	O
its	O
transient	O
expression	O
in	O
COS-1	O
monkey	B-DNAMutation
kidney	O
cells	O
.	O

Recombinant	O
mutant	O
type	O
II	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
enzyme	O
carrying	O
the	O
Y254D	B-DNAMutation
substitution	O
exhibits	O
no	O
detectable	O
activity	O
with	O
C21	O
delta	O
5-steroid	O
pregnenolone	O
or	O
C19	O
delta	O
5-steroid	O
dehydroepiandrosterone	O
used	O
as	O
substrate	O
.	O

The	O
absence	O
of	O
restriction	O
fragment	O
length	O
polymorphism	O
by	O
Southern	O
blot	O
analysis	O
and	O
the	O
finding	O
that	O
all	O
of	O
the	O
amplified	O
DNA	O
fragments	O
possess	O
the	O
expected	O
length	O
suggest	O
the	O
absence	O
of	O
deletions	O
,	O
duplications	O
,	O
or	O
re-arrangements	O
in	O
the	O
other	O
allele	O
.	O

A	O
putative	B-DNAMutation
second	I-DNAMutation
mutation	I-DNAMutation
could	I-DNAMutation
be	I-DNAMutation
located	I-DNAMutation
farther	I-DNAMutation
than	I-DNAMutation
1427	I-DNAMutation
basepairs	I-DNAMutation
upstream	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
initiation	I-DNAMutation
codon	I-DNAMutation
,	O
thus	O
potentially	O
affecting	O
the	O
normal	O
expression	O
of	O
this	O
gene	O
or	O
within	O
intronic	O
regions	O
,	O
generating	O
an	O
alternative	O
aberrant	O
splicing	O
site	O
.	O

These	O
are	O
possibilities	O
that	O
remain	O
to	O
be	O
elucidated	O
.	O

The	O
present	O
findings	O
,	O
which	O
describe	O
the	O
novel	O
missense	O
mutation	O
Y254D	B-DNAMutation
in	O
the	O
human	O
type	O
II	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
gene	O
,	O
provide	O
useful	O
information	O
on	O
the	O
structure-activity	O
relationships	O
of	O
the	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
superfamily	O
.	O

Cloning	O
,	O
characterisation	O
and	O
identification	O
of	O
several	O
polymorphisms	O
in	O
the	O
promoter	O
region	O
of	O
the	O
human	O
alpha2B-adrenergic	B-DNAMutation
receptor	I-DNAMutation
gene	O
.	O

Screening	O
of	O
a	O
foetal	O
brain	O
genomic	O
DNA	O
library	O
allowed	O
to	O
isolate	O
a	O
10-kb	O
fragment	O
of	O
the	O
gene	O
encoding	O
the	O
human	O
alpha2B-adrenergic	B-DNAMutation
receptor	I-DNAMutation
,	O
that	O
contained	O
5.5	O
kb	O
of	O
the	O
5'-flanking	O
region	O
,	O
the	O
open	O
reading	O
frame	O
and	O
2.9	O
kb	O
of	O
the	O
3'-flanking	O
region	O
.	O

The	O
1-kb	O
fragment	O
upstream	O
from	O
the	O
start	O
codon	O
was	O
rich	O
in	O
GC	O
,	O
lacked	O
consensus	O
TATA	O
or	O
CAAT	O
box	O
,	O
but	O
contained	O
several	O
Sp1-binding	O
sites	O
.	O

Other	O
potential	O
cis-regulatory	O
elements	O
found	O
in	O
the	O
5'-flanking	O
region	O
included	O
AP2	B-DNAMutation
,	O
USF	B-DNAMutation
,	O
Stat-6	B-DNAMutation
,	O
NFkappaB	O
and	O
Olf-1	B-DNAMutation
.	O

A	O
single	O
canonical	O
polyadenylation	O
signal	O
(AATAAA)	O
was	O
found	O
at	O
position	O
+3252/+3257	O
and	O
the	O
polyadenylation	O
site	O
was	O
3274	O
nucleotides	O
downstream	O
from	O
ATG	O
.	O

Transfection	O
experiments	O
with	O
chimeric	O
luciferase	O
constructs	O
containing	O
various	O
truncated	O
fragments	O
of	O
the	O
5'-region	O
showed	O
that	O
the	O
fragment	O
-3160/+3	O
exhibited	O
promoter	O
activity	O
in	O
all	O
tested	O
cell	O
lines	O
and	O
permitted	O
the	O
definition	O
of	O
a	O
minimal	O
200-bp	O
promoter	O
(-603/-411)	O
containing	O
three	O
putative	O
Sp1-binding	O
sites	O
and	O
two	O
initiator	O
elements	O
.	O

Transcriptional	O
activity	O
of	O
this	O
region	O
was	O
inhibited	O
by	O
the	O
addition	O
of	O
mithramycin	O
,	O
a	O
specific	O
inhibitor	O
of	O
Sp1	B-DNAMutation
binding	O
to	O
GC-rich	O
sequences	O
.	O

The	O
search	O
for	O
sequence	O
variants	O
within	O
a	O
fragment	O
covering	O
1.7	O
kb	O
of	O
5'-flanking	O
region	O
and	O
the	O
coding	O
region	O
allowed	O
us	O
to	O
identify	O
five	O
novel	O
single	O
nucleotide	O
polymorphisms	O
.	O

Interestingly	O
,	O
the	O
G/C	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
-98	I-DNAMutation
relative	I-DNAMutation
to	I-DNAMutation
the	I-DNAMutation
start	I-DNAMutation
codon	I-DNAMutation
was	O
common	O
and	O
in	O
complete	O
linkage	O
with	O
a	O
previously	O
identified	O
insertion/deletion	O
polymorphism	O
in	O
the	O
coding	O
region	O
which	O
was	O
showed	O
to	O
affect	O
alpha2B-adrenergic	B-DNAMutation
receptor	I-DNAMutation
function	O
.	O

Based	O
on	O
transfection	O
data	O
and	O
computer-assisted	O
sequence	O
analysis	O
,	O
the	O
-98	B-DNAMutation
G/C	I-DNAMutation
single	I-DNAMutation
nucleotide	I-DNAMutation
polymorphism	I-DNAMutation
was	O
located	O
within	O
a	O
portion	O
of	O
the	O
5'-UTR	O
(-127/+3)	O
affecting	O
luciferase	O
activity	O
and	O
it	O
created	O
additional	O
putative	O
binding	O
site	O
for	O
Sp1	B-DNAMutation
.	O

However	O
,	O
G/C	O
substitution	O
had	O
no	O
significant	O
incidence	O
on	O
promoter	O
activity	O
in	O
BHK-21	O
or	O
HeLa	O
cells	O
.	O

A	O
mutation	O
in	O
the	O
amyloid	B-DNAMutation
precursor	I-DNAMutation
protein	I-DNAMutation
associated	O
with	O
hereditary	O
Alzheimer's	O
disease	O
.	O

Alzheimer's	O
disease	O
is	O
a	O
form	O
of	O
localized	O
amyloidosis	O
characterized	O
by	O
cerebral	O
cortical	O
amyloid	O
plaques	O
,	O
neurofibrillary	O
tangles	O
,	O
and	O
amyloid	O
deposits	O
within	O
the	O
walls	O
of	O
leptomeningeal	O
vessels	O
.	O

Although	O
most	O
cases	O
of	O
Alzheimer's	O
disease	O
are	O
sporadic	O
,	O
kindreds	O
with	O
autosomal-dominant	O
inheritance	O
of	O
the	O
syndrome	O
suggest	O
that	O
a	O
single	O
mutation	O
may	O
be	O
important	O
in	O
pathogenesis	O
.	O

Direct	O
sequencing	O
of	O
DNA	O
from	O
a	O
family	O
with	O
autopsy-proven	O
Alzheimer's	O
disease	O
revealed	O
a	O
single	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
substitution	I-DNAMutation
(	I-DNAMutation
Phe	I-DNAMutation
for	I-DNAMutation
Val	I-DNAMutation
)	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
transmembrane	I-DNAMutation
domain	I-DNAMutation
of	O
the	O
amyloid	B-DNAMutation
precursor	I-DNAMutation
protein	I-DNAMutation
.	O

This	O
mutation	O
correlates	O
with	O
the	O
presence	O
of	O
Alzheimer's	O
disease	O
in	O
all	O
patients	O
in	O
this	O
study	O
,	O
and	O
may	O
be	O
the	O
inherited	O
factor	O
causing	O
both	O
amyloid	O
fibril	O
formation	O
and	O
dementia	O
.	O

Lysine	O
269	O
is	O
essential	O
for	O
cyclin	B-DNAMutation
D1	I-DNAMutation
ubiquitylation	O
by	O
the	O
SCF(Fbx4/alphaB-crystallin)	B-DNAMutation
ligase	O
and	O
subsequent	O
proteasome-dependent	O
degradation	O
.	O

Protein	O
ubiquitylation	O
is	O
a	O
complex	O
enzymatic	O
process	O
that	O
results	O
in	O
the	O
covalent	O
attachment	O
of	O
ubiquitin	O
,	O
through	O
Gly-76	O
of	O
ubiquitin	O
,	O
to	O
an	O
varepsilonNH2	O
group	O
of	O
an	O
internal	O
lysine	O
residue	O
in	O
a	O
given	O
substrate	O
.	O

Although	O
E3	O
ligases	O
frequently	O
use	O
lysines	O
adjacent	O
to	O
the	O
degron	O
within	O
the	O
substrate	O
,	O
many	O
substrates	O
can	O
be	O
targeted	O
to	O
the	O
proteasome	O
through	O
the	O
polyubiquitylation	O
of	O
any	O
lysine	O
.	O

We	O
have	O
assessed	O
the	O
role	O
of	O
lysine	O
residues	O
proximal	O
to	O
the	O
cyclin	B-DNAMutation
D1	I-DNAMutation
phosphodegron	O
for	O
ubiquitylation	O
by	O
the	O
SCF(Fbx4/alphaB-crystallin)	B-DNAMutation
ubiquitin	O
ligase	O
and	O
subsequent	O
proteasome-dependent	O
degradation	O
of	O
cyclin	B-DNAMutation
D1	I-DNAMutation
.	O

The	O
work	O
described	O
herein	O
reveals	O
a	O
requisite	O
role	O
for	O
Lys-269	O
(K269)	O
for	O
the	O
rapid	O
polyubiquitin-mediated	O
degradation	O
of	O
cyclin	B-DNAMutation
D1	I-DNAMutation
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
Lys-269	I-DNAMutation
,	O
which	O
is	O
proximal	O
to	O
the	O
phosphodegron	O
sequence	O
surrounding	O
Thr-286	O
in	O
cyclin	B-DNAMutation
D1	I-DNAMutation
,	O
not	O
only	O
stabilizes	O
cyclin	B-DNAMutation
D1	I-DNAMutation
but	O
also	O
triggers	O
cyclin	B-DNAMutation
D1	I-DNAMutation
accumulation	O
within	O
the	O
nucleus	O
,	O
thereby	O
promoting	O
cell	O
transformation	O
.	O

In	O
addition	O
,	O
D1-K269R	B-DNAMutation
is	O
resistant	O
to	O
genotoxic	O
stress-induced	O
degradation	O
,	O
similar	O
to	O
non-phosphorylatable	O
D1-T286A	B-DNAMutation
,	O
supporting	O
the	O
critical	O
role	O
for	O
the	O
post-translational	O
regulation	O
of	O
cyclin	B-DNAMutation
D1	I-DNAMutation
in	O
response	O
to	O
DNA-damaging	O
agents	O
.	O

Strikingly	O
,	O
although	O
mutation	O
of	O
lysine	B-DNAMutation
269	I-DNAMutation
to	I-DNAMutation
arginine	I-DNAMutation
inhibits	O
cyclin	B-DNAMutation
D1	I-DNAMutation
degradation	O
,	O
it	O
does	O
not	O
inhibit	O
cyclin	B-DNAMutation
D1	I-DNAMutation
ubiquitylation	O
in	O
vivo	O
,	O
showing	O
that	O
ubiquitylation	O
of	O
a	O
specific	O
lysine	O
can	O
influence	O
substrate	O
targeting	O
to	O
the	O
26S	O
proteasome	O
.	O

Multiple	O
autophosphorylation	O
sites	O
are	O
dispensable	O
for	O
murine	O
ATM	B-DNAMutation
activation	O
in	O
vivo	O
.	O

Cellular	O
responses	O
to	O
both	O
physiological	O
and	O
pathological	O
DNA	O
double-strand	O
breaks	O
are	O
initiated	O
through	O
activation	O
of	O
the	O
evolutionarily	O
conserved	O
ataxia	B-DNAMutation
telangiectasia	I-DNAMutation
mutated	I-DNAMutation
ATM	B-DNAMutation
kinase	O
.	O

Upon	O
DNA	O
damage	O
,	O
an	O
activation	O
mechanism	O
involving	O
autophosphorylation	O
has	O
been	O
reported	O
to	O
allow	O
ATM	B-DNAMutation
to	O
phosphorylate	O
downstream	O
targets	O
important	O
for	O
cell	O
cycle	O
checkpoints	O
and	O
DNA	O
repair	O
.	O

In	O
humans	O
,	O
serine	O
residues	O
367	O
,	O
1893	O
,	O
and	O
1981	O
have	O
been	O
shown	O
to	O
be	O
autophosphorylation	O
sites	O
that	O
are	O
individually	O
required	O
for	O
ATM	B-DNAMutation
activation	O
.	O

To	O
test	O
the	O
physiological	O
importance	O
of	O
these	O
sites	O
,	O
we	O
generated	O
a	O
transgenic	O
mouse	O
model	O
in	O
which	O
all	O
three	O
conserved	O
ATM	O
serine	B-DNAMutation
autophosphorylation	I-DNAMutation
sites	I-DNAMutation
(S367/1899/1987)	I-DNAMutation
have	I-DNAMutation
been	I-DNAMutation
replaced	I-DNAMutation
with	I-DNAMutation
alanine	I-DNAMutation
.	O

In	O
this	O
study	O
,	O
we	O
show	O
that	O
ATM-dependent	B-DNAMutation
responses	O
at	O
both	O
cellular	O
and	O
organismal	O
levels	O
are	O
functional	O
in	O
mice	O
that	O
express	O
a	O
triple	O
serine	O
mutant	O
form	O
of	O
ATM	B-DNAMutation
as	O
their	O
sole	O
ATM	B-DNAMutation
species	O
.	O

These	O
results	O
lend	O
further	O
support	O
to	O
the	O
notion	O
that	O
ATM	B-DNAMutation
autophosphorylation	O
correlates	O
with	O
the	O
DNA	O
damage-induced	O
activation	O
of	O
the	O
kinase	O
but	O
is	O
not	O
required	O
for	O
ATM	B-DNAMutation
function	O
in	O
vivo	O
.	O

WWP1-dependent	B-DNAMutation
ubiquitination	O
and	O
degradation	O
of	O
the	O
lung	O
KrÃ¼ppel-like	O
factor	O
,	I-DNAMutation
KLF2	I-DNAMutation
.	O

The	O
zinc-finger	O
transcription	O
factor	O
KrÃ¼ppel-like	O
factor-2	O
plays	O
an	O
important	O
role	O
in	O
pulmonary	O
development	O
,	O
inhibition	O
of	O
adipocyte	O
differentiation	O
,	O
and	O
maintaining	O
quiescence	O
in	O
single-positive	O
T	O
cells	B-DNAMutation
.	I-DNAMutation
KLF2	I-DNAMutation
levels	O
rapidly	O
decrease	O
during	O
adipogenesis	O
and	O
activation	O
of	O
T	O
cells	O
,	O
but	O
the	O
pathways	O
involved	O
remain	O
unclear	O
.	O

Previously	O
,	O
we	O
identified	B-DNAMutation
WWP1	I-DNAMutation
,	O
a	O
HECT-domain	O
E3-ubiquitin	O
ligase	O
,	O
as	O
an	O
interacting	O
partner	O
of	B-DNAMutation
KLF2	I-DNAMutation
.	O

This	O
led	O
us	O
to	O
speculate	O
that	B-DNAMutation
KLF2	I-DNAMutation
may	O
be	O
targeted	O
for	O
ubiquitination	O
.	O

Here	O
,	O
we	O
demonstrate	O
that	B-DNAMutation
WWP1	I-DNAMutation
interacts	O
with	B-DNAMutation
KLF2	I-DNAMutation
in	O
vivo	O
and	O
mediates	O
both	O
poly-ubiquitination	O
and	O
proteasomal	O
degradation	O
of	B-DNAMutation
KLF2	I-DNAMutation
.	O

Deleting	O
the	O
inhibitory	O
domain	O
of	B-DNAMutation
KLF2	I-DNAMutation
abrogated	B-DNAMutation
KLF2-WWP1	I-DNAMutation
interactions	O
and	O
abolished	B-DNAMutation
WWP1-mediated	I-DNAMutation
poly-ubiquitination	O
and	O
down-regulation	O
of	B-DNAMutation
KLF2	I-DNAMutation
.	O

Furthermore	O
,	O
lysine-121	O
in	O
the	O
inhibitory	O
domain	O
of	B-DNAMutation
KLF2	I-DNAMutation
is	O
critical	O
for	O
ubiquitin-conjugation	O
.	O

Finally	O
,	O
the	O
catalytic	O
cysteine	O
of	B-DNAMutation
WWP1	I-DNAMutation
is	O
not	O
required	O
for	B-DNAMutation
KLF2-ubiquitination	I-DNAMutation
.	O

Our	O
experiments	O
demonstrate	O
for	O
the	O
first	O
time	O
that	B-DNAMutation
WWP1	I-DNAMutation
promotes	O
ubiquitination	O
and	O
degradation	O
of	B-DNAMutation
KLF2	I-DNAMutation
and	O
is	O
not	O
involved	O
in	O
the	O
ubiquitin-transfer	O
reaction	O
.	O

Palmitoylation	O
is	O
required	O
for	O
signaling	O
functions	O
and	O
membrane	O
attachment	O
of	O
Gq	O
alpha	O
and	O
Gs	O
alpha	O
.	O

We	O
have	O
identified	O
the	O
palmitoylated	O
cysteine	O
residues	O
of	O
alpha	O
q	O
and	O
alpha	O
s	O
,	O
alpha	O
subunits	O
of	O
two	O
heterotrimeric	O
G	O
proteins	O
.	O

Mutational	O
substitutions	B-DNAMutation
of	I-DNAMutation
serines	I-DNAMutation
for	I-DNAMutation
cysteines	I-DNAMutation
9	I-DNAMutation
and	I-DNAMutation
10	I-DNAMutation
in	I-DNAMutation
alpha	I-DNAMutation
q	I-DNAMutation
and	I-DNAMutation
cysteine	I-DNAMutation
3	I-DNAMutation
in	I-DNAMutation
alpha	I-DNAMutation
s	I-DNAMutation
profoundly	O
alter	O
behavior	O
of	O
the	O
subunits	O
expressed	O
in	O
HEK293	O
cells	O
.	O

Neither	O
mutant	O
alpha	O
subunit	O
incorporates	O
palmitate	O
;	O
both	O
mutant	O
proteins	O
are	O
found	O
in	O
the	O
soluble	O
rather	O
than	O
the	O
particulate	O
fraction	O
;	O
mutant	O
alpha	O
q	O
or	O
alpha	O
s	O
cannot	O
couple	O
a	O
co-expressed	O
receptor	O
to	O
stimulation	O
of	O
phospholipase	O
C	O
or	O
adenylylcyclase	O
,	O
respectively	O
;	O
cysteine	O
substitution	O
prevents	O
a	O
mutationally	O
activated	O
alpha	O
q	O
R183C	B-DNAMutation
from	O
stimulating	O
phospholipase	O
C	O
directly	O
,	O
and	O
reduces	O
but	O
does	O
not	O
abolish	O
the	O
ability	O
of	O
a	O
similarly	O
activated	O
alpha	O
s	O
R201C	B-DNAMutation
to	O
stimulate	O
cAMP	O
synthesis	O
.	O

Substitution	O
of	O
a	O
myristoylation	O
sequence	O
for	O
the	O
palmitoylation	O
sites	O
leads	O
to	O
labeling	O
of	O
alpha	O
q	O
and	O
alpha	O
s	O
by	O
myristate	O
,	O
rather	O
than	O
by	O
palmitate	O
.	O

Myristoylation	O
restores	O
the	O
abilities	O
of	O
both	O
nonpalmitoylated	O
alpha	O
q	O
and	O
alpha	O
s	O
to	O
attach	O
to	O
membranes	O
and	O
,	O
in	O
the	O
case	O
of	O
alpha	O
q	O
,	O
restores	O
its	O
ability	O
to	O
stimulate	O
phospholipase	O
C	O
,	O
whether	O
triggered	O
by	O
the	O
R183C	B-DNAMutation
mutation	O
or	O
by	O
receptor	O
activation	O
.	O

These	O
findings	O
identify	O
palmitoylation	O
as	O
a	O
critical	O
determinant	O
of	O
membrane	O
attachment	O
for	O
alpha	O
q	O
and	O
alpha	O
s	O
and	O
show	O
that	O
this	O
modification	O
is	O
required	O
for	O
normal	O
signaling	O
by	O
these	O
proteins	O
.	O

Novel	O
mutations	O
in	O
ENG	B-DNAMutation
and	O
ACVRL1	B-DNAMutation
identified	O
in	O
a	O
series	O
of	O
200	O
individuals	O
undergoing	O
clinical	O
genetic	O
testing	O
for	O
hereditary	O
hemorrhagic	O
telangiectasia	O
(HHT)	O
:	O
correlation	O
of	O
genotype	O
with	O
phenotype	O
.	O

Hereditary	O
hemorrhagic	O
telangiectasia	O
(	O
HHT	O
;	O
Osler-Weber-Rendu	O
disease	O
)	O
is	O
an	O
autosomal	O
dominant	O
disease	O
characterized	O
by	O
arteriovenous	O
malformations	O
ranging	O
from	O
cutaneous	O
and	O
mucous	O
membrane	O
telangiectasias	O
to	O
more	O
severe	O
pulmonary	O
,	O
gastrointestinal	O
,	O
and	O
cerebral	O
arteriovenous	O
malformations	O
(AVMs)	O
.	O

Acute	O
complications	O
from	O
bleeding	O
or	O
pulmonary	O
shunting	O
may	O
be	O
catastrophic	O
.	O

However	O
,	O
when	O
diagnosed	O
early	O
,	O
the	O
complications	O
can	O
usually	O
be	O
prevented	O
.	O

Mutations	O
in	O
two	O
genes	O
,	O
Endoglin	B-DNAMutation
ENG	B-DNAMutation
and	O
activin	B-DNAMutation
receptor-like	I-DNAMutation
kinase	I-DNAMutation
1	I-DNAMutation
(	O
ACVRL1	B-DNAMutation
or	O
ALK1	B-DNAMutation
)	O
have	O
been	O
associated	O
with	O
HHT	O
.	O

We	O
describe	O
the	O
results	O
of	O
mutation	O
analysis	O
on	O
a	O
consecutive	O
series	O
of	O
200	O
individuals	O
undergoing	O
clinical	O
genetic	O
testing	O
for	O
HHT	O
.	O

The	O
observed	O
sensitivity	O
of	O
mutation	O
detection	O
was	O
similar	O
to	O
that	O
in	O
other	O
series	O
with	O
strict	O
ascertainment	O
criteria	O
.	O

A	O
total	O
of	O
127	O
probands	O
were	O
found	O
,	O
with	O
sequence	O
changes	O
consisting	O
of	O
103	O
unique	O
alterations	O
,	O
68	O
of	O
which	O
were	O
novel	O
.	O

In	O
addition	O
,	O
eight	O
intragenic	O
rearrangements	O
in	O
the	O
ENG	B-DNAMutation
gene	O
and	O
two	O
in	O
the	O
ACVRL1	B-DNAMutation
gene	O
were	O
identified	O
in	O
a	O
subset	O
of	O
coding	O
sequence	O
mutation-negative	O
individuals	O
.	O

Most	O
individuals	O
tested	O
could	O
be	O
categorized	O
by	O
the	O
number	O
of	O
HHT	O
diagnostic	O
criteria	O
present	O
.	O

Surprisingly	O
,	O
almost	O
50%	O
of	O
the	O
cases	O
with	O
a	O
single	O
symptom	O
were	O
found	O
to	O
have	O
a	O
significant	O
sequence	O
alteration	O
;	O
three	O
of	O
these	O
reported	O
only	O
nosebleeds	O
.	O

Genetic	O
testing	O
can	O
confirm	O
the	O
clinical	O
diagnosis	O
in	O
individuals	O
and	O
identify	O
presymptomatic	O
mutation	O
carriers	O
.	O

As	O
many	O
of	O
the	O
complications	O
of	O
HHT	O
disease	O
can	O
be	O
prevented	O
,	O
a	O
confirmed	O
molecular	O
diagnosis	O
provides	O
an	O
opportunity	O
for	O
early	O
detection	O
of	O
AVMs	O
and	O
management	O
of	O
the	O
disease	O
.	O

Novel	O
trinucleotide	B-DNAMutation
deletion	I-DNAMutation
in	O
Fabry's	O
disease	O
.	O

We	O
describe	O
the	O
molecular	O
characterization	O
of	O
a	O
novel	O
,	O
in-frame	B-DNAMutation
deletion	I-DNAMutation
that	I-DNAMutation
is	I-DNAMutation
located	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
7	I-DNAMutation
of	O
the	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
in	O
a	O
patient	O
with	O
Fabry's	O
disease	O
.	O

The	O
3-bp	B-DNAMutation
deletion	I-DNAMutation
we	O
identified	O
,	O
besides	O
the	O
typical	O
severe	O
clinical	O
features	O
,	O
also	O
expresses	O
diffuse	O
facial	O
telangiectasias	O
,	O
which	O
is	O
a	O
new	O
cutaneous	O
marker	O
of	O
Fabry's	O
disease	O
.	O

Mutation	O
analysis	O
of	O
the	O
CHK2	B-DNAMutation
gene	O
in	O
families	O
with	O
hereditary	O
breast	O
cancer	O
.	O

Recently	O
CHK2	B-DNAMutation
was	O
functionally	O
linked	O
to	O
the	O
p53	B-DNAMutation
pathway	O
,	O
and	O
mutations	O
in	O
these	O
two	O
genes	O
seem	O
to	O
result	O
in	O
a	O
similar	O
Li-Fraumeni	O
syndrome	O
(LFS)	O
or	O
Li-Fraumeni-like	O
syndrome	O
(LFL)	O
multi-cancer	O
phenotype	O
frequently	O
including	O
breast	O
cancer	O
.	O

As	O
CHK2	B-DNAMutation
has	O
been	O
found	O
to	O
bind	O
and	O
regulate	O
BRCA1	B-DNAMutation
,	O
the	O
product	O
of	O
one	O
of	O
the	O
2	O
known	O
major	O
susceptibility	O
genes	O
to	O
hereditary	O
breast	O
cancer	O
,	O
it	O
also	O
more	O
directly	O
makes	O
CHK2	B-DNAMutation
a	O
suitable	O
candidate	O
gene	O
for	O
hereditary	O
predisposition	O
to	O
breast	O
cancer	O
.	O

Here	O
we	O
have	O
screened	O
79	O
Finnish	O
hereditary	O
breast	O
cancer	O
families	O
for	O
germline	O
CHK2	B-DNAMutation
alterations	O
.	O

Twenty-one	O
of	O
these	O
families	O
also	O
fulfilled	O
the	O
criteria	O
for	O
LFL	O
or	O
LFS	O
.	O

All	O
families	O
had	O
previously	O
been	O
found	O
negative	O
for	O
germline	O
BRCA1	B-DNAMutation
,	O
BRCA2	B-DNAMutation
and	O
TP53	B-DNAMutation
mutations	O
,	O
together	O
explaining	O
about	O
23%	O
of	O
hereditary	O
predisposition	O
to	O
breast	O
cancer	O
in	O
our	O
country	O
.	O

Only	O
one	O
missense-type	O
mutation	O
,	O
Ile(157)-->Thr(157)	B-DNAMutation
,	O
was	O
detected	O
.	O

The	O
high	O
Ile(157)-->	B-DNAMutation
Thr(157)mutation	I-DNAMutation
frequency	O
(6.5%)	O
observed	O
in	O
healthy	O
controls	O
and	O
the	O
lack	O
of	O
other	O
mutations	O
suggest	O
that	O
CHK2	B-DNAMutation
does	O
not	O
contribute	O
significantly	O
to	O
the	O
hereditary	O
breast	O
cancer	O
or	O
LFL-associated	O
breast	O
cancer	O
risk	O
,	O
at	O
least	O
not	O
in	O
the	O
Finnish	O
population	O
.	O

For	O
Ile(157)-->	B-DNAMutation
Thr(157)our	I-DNAMutation
result	O
deviates	O
from	O
what	O
has	O
been	O
reported	O
previously	O
.	O

Molecular	O
identification	O
and	O
characterization	O
of	O
a	O
and	O
b	O
forms	O
of	O
the	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
.	O

The	I-DNAMutation
human	O
glucocorticoid	B-DNAMutation
receptor	I-DNAMutation
(hGRalpha)	O
is	O
a	O
ligand-activated	O
transcription	O
factor	O
that	O
mediates	O
the	O
physiological	O
effects	O
of	O
corticosteroid	O
hormones	O
and	O
is	O
essential	O
for	O
life	O
.	O

Originally	O
cloned	O
in	O
1986	O
,	O
the	O
transcriptionally	O
active	O
hGRalpha	O
was	O
reported	O
to	O
be	O
a	O
single	O
protein	O
species	O
of	O
777	O
amino	O
acids	O
(	O
molecular	O
mass	O
=	O
94	O
kDa	O
)	O
.	O

Biochemical	O
data	O
,	O
obtained	O
using	O
various	O
mammalian	O
tissues	O
and	O
cell	O
lines	O
,	O
however	O
,	O
have	O
consistently	O
revealed	O
an	O
additional	O
,	O
slightly	O
smaller	O
,	O
second	O
hGR	O
protein	O
(	O
molecular	O
mass	O
=	O
91	O
kDa	O
)	O
that	O
is	O
not	O
recognized	O
by	O
antibodies	O
specific	O
for	O
the	O
transcriptionally	O
inactive	O
and	O
dominant	O
negative	O
,	O
non-hormone-binding	O
hGRbeta	O
isoform	O
.	O

We	O
report	O
here	O
that	O
when	O
a	O
single	O
GR	O
cDNA	O
is	O
transfected	O
in	O
COS-1	O
cells	O
,	O
or	O
transcribed	O
and	O
translated	O
in	O
vitro	O
,	O
two	O
forms	O
of	O
the	O
receptor	O
are	O
observed	O
,	O
similar	O
to	O
those	O
seen	O
in	O
cells	O
that	O
contain	O
endogenous	O
GR	O
.	O

These	O
data	O
suggest	O
that	O
two	O
forms	O
of	O
the	O
hGRalpha	O
are	O
produced	O
by	O
alternative	O
translation	O
of	O
the	O
same	O
gene	O
and	O
are	O
henceforth	O
termed	O
GR-A	O
and	O
GR-B	O
.	O

To	O
test	O
this	O
hypothesis	O
,	O
we	O
have	O
investigated	O
the	O
role	O
of	O
an	O
internal	O
ATG	O
codon	O
corresponding	O
to	O
methionine	O
27	O
(M27)	O
as	O
a	O
potential	O
alternative	O
translation	O
initiation	O
site	O
for	O
the	O
GR	O
.	O

Mutagenesis	B-DNAMutation
of	I-DNAMutation
this	I-DNAMutation
ATG	I-DNAMutation
codon	I-DNAMutation
to	I-DNAMutation
ACG	I-DNAMutation
in	O
human	O
,	O
rat	O
,	O
and	O
mouse	O
GR	O
cDNA	O
results	O
in	O
generation	O
of	O
a	O
single	O
94-kDa	O
protein	O
species	O
,	O
GR-A	O
.	O

Moreover	O
,	O
mutagenesis	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
initial	I-DNAMutation
ATG	I-DNAMutation
codon	I-DNAMutation
to	I-DNAMutation
ACG	I-DNAMutation
(	I-DNAMutation
Met	I-DNAMutation
1	I-DNAMutation
to	I-DNAMutation
Thr	I-DNAMutation
)	O
also	O
resulted	O
in	O
production	O
of	O
single	O
,	O
shorter	O
protein	O
species	O
(	O
91	O
kDa	O
)	O
,	O
GR-B	O
.	O

Mutagenesis	O
of	O
the	O
Kozak	O
translation	O
initiation	O
sequence	O
strongly	O
indicates	O
that	O
a	O
leaky	O
ribosomal	O
scanning	O
mechanism	O
is	O
responsible	O
for	O
generating	O
the	O
GR-A	O
and	O
-B	O
isoforms	O
.	O

Western	O
blot	O
analysis	O
using	O
peptide-specific	O
antibodies	O
show	O
both	O
the	O
A	O
and	O
B	O
receptor	O
forms	O
are	O
present	O
in	O
human	O
cell	O
lines	O
.	O

Both	O
receptors	O
exhibit	O
similar	O
subcellular	O
localization	O
and	O
nuclear	O
translocation	O
after	O
ligand	O
activation	O
.	O

Functional	O
analyses	O
of	O
hGR-A	O
and	O
hGR-B	O
under	O
various	O
glucocorticoid-responsive	O
promoters	O
reveal	O
the	O
shorter	O
hGR-B	O
to	O
be	O
nearly	O
twice	O
as	O
effective	O
as	O
the	O
longer	O
hGR-A	O
species	O
in	O
gene	O
transactivation	O
,	O
but	O
not	O
in	O
transrepression	O
.	O

cDNA	O
sequence	O
for	O
human	B-DNAMutation
erythrocyte	B-DNAMutation
ankyrin	I-DNAMutation
.	O

The	O
cDNA	O
for	O
human	B-DNAMutation
erythrocyte	B-DNAMutation
ankyrin	I-DNAMutation
has	O
been	O
isolated	O
from	O
a	O
series	O
of	O
overlapping	O
clones	O
obtained	O
from	O
a	O
reticulocyte	O
cDNA	O
library	O
.	O

The	O
composite	O
cDNA	O
sequence	O
has	O
a	O
large	O
open	O
reading	O
frame	O
of	O
5636	O
base	O
pairs	O
(bp)	O
with	O
the	O
complete	O
coding	O
sequence	O
for	O
a	O
polypeptide	O
of	O
1879	O
amino	O
acids	O
with	O
a	O
predicted	O
molecular	O
mass	O
of	O
206	O
kDa	O
.	O

The	O
derived	O
amino	O
acid	O
sequence	O
contained	O
194	O
residues	O
that	O
were	O
identical	O
to	O
those	O
obtained	O
by	O
direct	O
amino	O
acid	O
sequencing	O
of	O
11	O
ankyrin	O
proteolytic	O
peptides	O
.	O

The	O
primary	O
sequence	O
contained	O
23	O
highly	O
homologous	O
repeat	O
units	O
of	O
33	O
amino	O
acids	O
within	O
the	O
90-kDa	O
band	O
3	O
binding	O
domain	O
.	O

Two	O
cDNA	O
clones	O
showed	O
evidence	O
of	O
apparent	O
mRNA	O
processing	O
,	O
resulting	O
in	O
the	O
deletions	O
of	O
486	O
bp	O
and	O
135	O
bp	O
,	O
respectively	O
.	O

The	O
486-bp	O
deletion	O
resulted	O
in	O
the	O
removal	O
of	O
a	O
16-kDa	O
highly	O
acidic	O
peptide	O
,	O
and	O
the	O
smaller	O
deletion	O
had	O
the	O
effect	O
of	O
altering	O
the	O
COOH	O
terminus	O
of	O
the	O
molecule	O
.	O

Radiolabeled	O
ankyrin	O
cDNAs	O
recognized	O
two	O
erythroid	O
message	O
sizes	O
by	O
RNA	O
blot	O
analysis	O
,	O
one	O
of	O
which	O
was	O
predominantly	O
associated	O
with	O
early	O
erythroid	O
cell	O
types	O
.	O

An	O
ankyrin	O
message	O
was	O
also	O
observed	O
in	O
RNA	O
from	O
the	O
human	B-DNAMutation
cerebellum	O
by	O
the	O
same	O
method	O
.	O

The	O
ankyrin	O
gene	O
is	O
assigned	O
to	O
chromosome	O
8	O
using	O
genomic	O
DNA	O
from	O
a	O
panel	O
of	O
sorted	O
human	B-DNAMutation
chromosomes	O
.	O

A	O
novel	O
polymorphic	O
allele	O
of	O
human	O
arylacetamide	B-DNAMutation
deacetylase	I-DNAMutation
leads	O
to	O
decreased	O
enzyme	O
activity	O
.	O

Human	O
arylacetamide	B-DNAMutation
deacetylase	I-DNAMutation
AADAC	B-DNAMutation
is	O
responsible	O
for	O
the	O
hydrolysis	O
of	O
clinically	O
used	O
drugs	O
such	O
as	O
flutamide	O
,	O
phenacetin	O
,	O
and	O
rifamycins	O
.	O

Our	O
recent	O
studies	O
suggested	O
that	O
human	O
AADAC	B-DNAMutation
is	O
a	O
relevant	O
enzyme	O
pharmacologically	O
and	O
toxicologically	O
.	O

To	O
date	O
,	O
the	O
genetic	O
polymorphisms	O
that	O
affect	O
enzyme	O
activity	O
in	O
AADAC	B-DNAMutation
have	O
been	O
unknown	O
.	O

In	O
this	O
study	O
,	O
we	O
found	O
single-nucleotide	O
polymorphisms	O
in	O
the	O
human	O
AADAC	B-DNAMutation
gene	O
in	O
a	O
liver	O
sample	O
that	O
showed	O
remarkably	O
low	O
flutamide	O
hydrolase	O
activity	O
.	O

Among	O
them	O
,	O
g.13651G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
V281I	B-DNAMutation
and	O
g.14008T	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
X400Q	B-DNAMutation
were	O
nonsynonymous	O
.	O

The	O
latter	O
would	O
be	O
predicted	O
to	O
cause	O
a	O
C-terminal	B-DNAMutation
one-amino	I-DNAMutation
acid	I-DNAMutation
(glutamine)	I-DNAMutation
extension	I-DNAMutation
.	O

The	O
AADAC*2	B-DNAMutation
allele	O
(	O
g.13651G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
)	O
was	O
found	O
in	O
all	O
populations	O
investigated	O
in	O
this	O
study	O
(	O
European	O
American	O
,	O
African	O
American	O
,	O
Korean	O
,	O
and	O
Japanese	O
)	O
,	O
at	O
allelic	O
frequencies	O
of	O
52.6	O
to	O
63.5%	O
,	O
whereas	O
the	O
AADAC*3	B-DNAMutation
allele	O
(	O
g.13651G	B-DNAMutation
>	I-DNAMutation
A/g.14008T	I-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
)	O
was	O
found	O
in	O
European	O
American	O
(1.3%)	O
and	O
African	O
American	O
(2.0%)	O
samples	O
.	O

COS7	O
cells	O
expressing	O
AADAC.1	B-DNAMutation
(wild-type)	O
exhibited	O
flutamide	O
,	O
phenacetin	O
,	O
and	O
rifampicin	O
hydrolase	O
activities	O
with	O
intrinsic	O
clearance	O
CLint	B-DNAMutation
values	O
of	O
1.31	O
Â±	O
0.06	O
,	O
1.00	O
Â±	O
0.02	O
,	O
and	O
0.39	O
Â±	O
0.02	O
Î¼l	B-DNAMutation
x	I-DNAMutation
min(-1)	I-DNAMutation
x	O
unit(-1)	O
,	O
respectively	B-DNAMutation
.	I-DNAMutation
AADAC.2	O
,	O
which	O
is	O
a	O
protein	O
produced	O
from	O
the	I-DNAMutation
AADAC*2	O
allele	O
,	O
showed	O
moderately	O
lower	O
or	O
similar	B-DNAMutation
CLint	O
values	O
,	O
compared	O
with	B-DNAMutation
AADAC.1	O
,	B-DNAMutation
but	I-DNAMutation
AADAC.3	O
showed	O
substantially	O
lower	B-DNAMutation
CLint	O
values	O
(	O
flutamide	O
hydrolase	O
,	O
0.21	O
Â±	O
0.02	O
Î¼l	I-DNAMutation
x	I-DNAMutation
min(-1)	O
x	O
unit(-1)	O
;	O
phenacetin	O
hydrolase	O
,	O
0.12	O
Â±	O
0.00	B-DNAMutation
Î¼l	I-DNAMutation
x	O
min(-1)	O
x	O
unit(-1)	O
;	O
rifampicin	O
hydrolase	O
,	O
0.03	O
Â±	O
0.01	B-DNAMutation
Î¼l	I-DNAMutation
x	O
min(-1)	O
x	O
unit(-1)	O
,	O
respectively	O
)	O
.	O

Microsomes	O
from	O
a	O
liver	O
sample	O
genotyped	B-DNAMutation
as	B-DNAMutation
AADAC*3/AADAC*3	I-DNAMutation
showed	O
decreased	O
enzyme	O
activities	O
,	O
compared	O
with	O
those	O
genotyped	B-DNAMutation
as	B-DNAMutation
AADAC*1/AADAC*1	I-DNAMutation
,	O
AADAC*1/AADAC*2	I-DNAMutation
,	O
and	B-DNAMutation
AADAC*2/AADAC*2	I-DNAMutation
.	O

In	O
conclusion	O
,	O
we	B-DNAMutation
found	I-DNAMutation
an	O
AADAC	O
allele	O
that	O
yielded	O
decreased	O
enzyme	O
activity	O
.	O

This	O
study	O
should	O
provide	O
useful	O
information	O
on	O
interindividual	O
variations	B-DNAMutation
in	O
AADAC	O
enzyme	O
activity	O
.	O

Pyrimidine-5'-nucleotidase	O
Campinas	O
,	O
a	O
new	O
mutation	O
p.R56G	B-DNAMutation
in	O
the	O
NT5C3	B-DNAMutation
gene	O
associated	O
with	O
pyrimidine-5'-nucleotidase	O
type	O
I	O
deficiency	O
and	O
influence	O
of	O
Gilbert's	O
Syndrome	O
on	O
clinical	O
expression	O
.	O

Pyrimidine-5'-nucleotidase	O
type	O
I	O
(P5'NI)	O
deficiency	O
is	O
an	O
autosomal	O
recessive	O
condition	O
that	O
causes	O
nonspherocytic	O
hemolytic	O
anemia	O
,	O
characterized	O
by	O
marked	O
basophilic	O
stippling	O
and	O
pyrimidine	O
nucleotide	O
accumulation	O
in	O
erythrocytes	O
.	O

We	O
herein	O
present	O
two	O
African	O
descendant	O
patients	O
,	O
father	O
and	O
daughter	O
,	O
with	O
P5'N	O
deficiency	O
,	O
both	O
born	O
from	O
first	O
cousins	O
.	O

Investigation	O
of	O
the	O
promoter	O
polymorphism	O
of	O
the	O
uridine	B-DNAMutation
diphospho	I-DNAMutation
glucuronosyl	I-DNAMutation
transferase	I-DNAMutation
1A	I-DNAMutation
UGT1A	B-DNAMutation
gene	O
revealed	O
that	O
the	O
father	O
was	O
homozygous	O
for	O
the	O
allele	O
(TA7)	O
and	O
the	O
daughter	O
heterozygous	O
(TA6/TA7)	O
.	O

P5'NI	O
gene	O
NT5C3	B-DNAMutation
gene	O
sequencing	O
revealed	O
a	O
further	O
change	B-DNAMutation
in	I-DNAMutation
homozygosity	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
position	I-DNAMutation
56	I-DNAMutation
p.R56G	B-DNAMutation
,	O
located	O
in	O
a	O
highly	O
conserved	O
region	O
.	O

Both	O
patients	O
developed	O
gallstones	O
;	O
however	O
the	O
father	O
,	O
who	O
had	O
undergone	O
surgery	O
for	O
the	O
removal	O
of	O
stones	O
,	O
had	O
extremely	O
severe	O
intrahepatic	O
cholestasis	O
and	O
,	O
liver	O
biopsy	O
revealed	O
fibrosis	O
and	O
siderosis	O
grade	O
III	O
,	O
leading	O
us	O
to	O
believe	O
that	O
the	O
homozygosity	O
of	O
the	O
UGT1A	B-DNAMutation
polymorphism	O
was	O
responsible	O
for	O
the	O
more	O
severe	O
clinical	O
features	O
in	O
the	O
father	O
.	O

Moreover	O
,	O
our	O
results	O
show	O
how	O
the	O
clinical	O
expression	O
of	O
hemolytic	O
anemia	O
is	O
influenced	O
by	O
epistatic	O
factors	O
and	O
we	O
describe	O
a	O
new	O
mutation	O
in	O
the	O
P5'N	O
gene	O
associated	O
with	O
enzyme	O
deficiency	O
,	O
iron	O
overload	O
,	O
and	O
severe	O
gallstone	O
formation	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
description	O
of	O
P5'N	O
deficiency	O
in	O
South	O
Americans	O
.	O

Molecular	O
basis	O
for	O
the	O
p	O
phenotype	O
.	O

Identification	O
of	O
distinct	O
and	O
multiple	O
mutations	O
in	O
the	O
alpha	B-DNAMutation
1,4-galactosyltransferase	I-DNAMutation
gene	O
in	O
Swedish	O
and	O
Japanese	O
individuals	O
.	O

p	O
phenotype	O
individuals	O
lack	O
both	O
P(k)	O
Gb3	B-DNAMutation
and	O
P	O
(Gb4)	O
glycolipid	O
antigens	O
of	O
the	O
P	O
blood	O
group	O
system	O
.	O

To	O
explore	O
the	O
molecular	O
basis	O
for	O
this	O
phenotype	O
,	O
DNA	O
sequences	O
of	O
Gb3	B-DNAMutation
synthase	I-DNAMutation
(	O
alpha1	B-DNAMutation
,	I-DNAMutation
4-galactosyltransferase	I-DNAMutation
;	O
alpha1,4Gal-T	O
)	O
in	O
six	O
p	O
phenotype	O
individuals	O
from	O
Japan	O
and	O
Sweden	O
were	O
analyzed	O
.	O

A	O
missense	O
mutation	O
P251L	B-DNAMutation
and	O
a	O
nonsense	O
mutation	O
W261stop	B-DNAMutation
in	O
three	O
and	O
one	O
Japanese	O
indivuiduals	O
,	O
respectively	O
,	O
and	O
missense	O
mutations	O
M183K	B-DNAMutation
and	O
G187D	B-DNAMutation
in	O
one	O
each	O
of	O
two	O
Swedish	O
p	O
individuals	O
were	O
found	O
,	O
indicating	O
that	O
p	O
individuals	O
from	O
Japan	O
and	O
Sweden	O
have	O
distinct	O
and	O
multiple	O
homozygous	O
point	O
mutations	O
in	O
the	O
coding	O
region	O
.	O

In	O
the	O
function	O
analysis	O
of	O
the	O
mutated	O
alpha1,4Gal-Ts	O
by	O
the	O
transfection	O
of	O
the	O
expression	O
vectors	O
,	O
P251L	B-DNAMutation
and	O
M183K	B-DNAMutation
mutations	O
showed	O
complete	O
loss	O
of	O
enzyme	O
function	O
,	O
and	O
W261stop	B-DNAMutation
and	O
G187D	B-DNAMutation
mutations	O
resulted	O
in	O
the	O
marginal	O
activity	O
.	O

BLAST	O
analysis	O
of	O
homologous	O
sequences	O
of	O
alpha1	O
,	O
4Gal-T	O
revealed	O
that	O
three	O
residues	O
,	O
Met(183)	B-DNAMutation
,	I-DNAMutation
Gly(187)	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Pro(251)	I-DNAMutation
,	I-DNAMutation
at	I-DNAMutation
which	I-DNAMutation
missense	I-DNAMutation
mutations	I-DNAMutation
were	I-DNAMutation
found	I-DNAMutation
,	O
were	O
highly	O
conserved	O
among	O
all	O
species	O
examined	O
,	O
suggesting	O
their	O
importance	O
for	O
the	O
function	O
of	O
alpha1,4Gal-T	O
.	O

Four	O
amino	O
acid	O
changes	O
are	O
associated	O
with	O
the	O
Aldh3a1	O
locus	O
polymorphism	O
in	O
mice	O
which	O
may	O
be	O
responsible	O
for	O
corneal	O
sensitivity	O
to	O
ultraviolet	O
light	O
.	O

We	O
studied	O
the	O
phenotype	O
and	O
the	O
nucleotide	O
sequence	O
for	O
the	O
cDNAs	O
of	O
the	O
Aldh3a1a	O
and	O
Aldh3a1c	O
allelic	O
forms	O
of	O
the	O
dioxin-inducible	O
cytosolic	O
aldehyde	O
dehydrogenase	O
(ALDH3A1)	O
present	O
in	O
inbred	O
mouse	O
strains	O
.	O

This	O
gene	O
is	O
constitutively	O
expressed	O
in	O
cornea	O
,	O
stomach	O
,	O
skin	O
,	O
urinary	O
bladder	O
and	O
lungs	O
.	O

The	O
Aldh3a1a	O
allele	O
is	O
found	O
in	O
most	O
inbred	O
mouse	O
strains	O
and	O
codes	O
for	O
a	O
'high-activity'	O
corneal	O
enzyme	O
compared	O
to	O
the	O
'low-activity'	O
encoded	O
by	O
the	O
Aldh3a1c	O
allele	O
in	O
SWR/J	O
strain	O
.	O

The	O
'low-activity'	O
variant	O
is	O
associated	O
with	O
extensive	O
corneal	O
clouding	O
after	O
a	O
single	O
exposure	O
to	O
ultraviolet	O
light	O
.	O

The	O
ALDH3A1	O
phenotype	O
was	O
examined	O
in	O
tissues	O
from	O
inbred	O
mouse	O
strains	O
carrying	O
the	O
Aldh3a1a	O
allele	O
including	O
,	O
SJL/J	O
,	O
C57BL/6	O
J/Ibg	O
,	O
DBA/2	O
J/Ibg	O
,	O
C3H/Ibg	O
and	O
the	O
Aldh3a1c	O
allele	O
(SWR/J)	O
.	O

Only	O
trace	O
levels	O
of	O
ALDH3A1	O
activity	O
were	O
found	O
in	O
all	O
SWR/J	O
tissues	O
.	O

All	O
other	O
strains	O
had	O
significant	O
levels	O
of	O
ALDH3A1	O
activity	O
in	O
eye	O
,	O
stomach	O
,	O
skin	O
,	O
less	O
in	O
urinary	O
bladder	O
and	O
lungs	O
and	O
only	O
trace	O
amounts	O
in	O
liver	O
.	O

However	O
,	O
no	O
differences	O
were	O
found	O
in	O
corneal	O
and	O
stomach	O
ALDH3A1	O
mRNA	O
levels	O
between	O
the	O
'low-'	O
and	O
'high-activity'	O
variants	O
.	O

A	O
1556-bp	O
ALDH3A1	O
cDNA	O
fragment	O
,	O
containing	O
the	O
entire	O
coding	O
region	O
plus	O
5'	O
and	O
3'	O
untranslated	O
regions	O
,	O
was	O
amplified	O
by	O
reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
from	O
SWR/J	O
and	O
DBA/2	O
J/Ibg	O
mouse	O
strains	O
.	O

Sequence	O
analysis	O
revealed	O
13	O
nucleotide	O
changes	O
in	O
the	O
Aldh3a1c	B-DNAMutation
allele	O
.	O

Four	O
of	O
these	O
changes	O
result	O
in	O
G88R	B-DNAMutation
,	O
I154N	B-DNAMutation
,	O
H305R	B-DNAMutation
and	O
I352V	B-DNAMutation
substitutions	O
,	O
whereas	O
nine	O
changes	O
are	O
silent	O
.	O

The	O
I154N	B-DNAMutation
disrupts	O
a	O
potential	O
alpha	O
helix	O
,	O
which	O
belongs	O
to	O
the	O
Rossmann	O
fold	O
.	O

Replacement	B-DNAMutation
of	I-DNAMutation
Arg	I-DNAMutation
with	I-DNAMutation
the	I-DNAMutation
more	I-DNAMutation
ionizable	I-DNAMutation
His	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
305	I-DNAMutation
of	O
a	O
beta	O
strand	O
might	O
directly	O
affect	O
catalytic	O
activity	O
of	O
the	O
enzyme	O
.	O

It	O
is	O
likely	O
that	O
structural	O
changes	O
associated	O
with	O
these	O
amino	O
acid	O
changes	O
are	O
responsible	O
for	O
the	O
loss	O
of	O
ALDH3A1	O
enzymatic	O
activity	O
in	O
SWR/J	O
mice	O
.	O

Sequences	O
of	O
four	O
splits	O
of	O
HLA-A10	O
group	O
.	O

Implications	O
for	O
serologic	O
cross-reactivities	O
and	O
their	O
evolution	O
.	O

Nucleotide	O
sequences	O
of	O
alleles	O
encoding	O
four	O
serologically	O
defined	O
splits	O
of	O
the	O
HLA-A10	O
group	O
,	O
A26.1	O
,	O
A26.3	O
,	O
A26.4	O
,	O
and	O
A10SA	O
,	O
were	O
determined	O
.	O

It	O
was	O
confirmed	O
that	O
the	O
alleles	O
coding	O
for	O
A26.1	O
and	O
A26.3	O
are	O
identical	O
with	O
A*2602	O
and	O
A*2601	O
,	O
respectively	O
.	O

On	O
the	O
other	O
hand	O
,	O
alleles	O
for	O
A26.4	O
and	O
A10SA	O
are	O
thus	O
far	O
undescribed	O
.	O

A26.4	O
(A*2603)	O
was	O
different	B-DNAMutation
from	I-DNAMutation
the	I-DNAMutation
other	I-DNAMutation
A26	I-DNAMutation
splits	I-DNAMutation
at	I-DNAMutation
three	I-DNAMutation
positions	I-DNAMutation
:	I-DNAMutation
74	I-DNAMutation
histidine	I-DNAMutation
,	I-DNAMutation
76	I-DNAMutation
valine	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
77	I-DNAMutation
aspartate	I-DNAMutation
.	O

A10SA	O
(A*2604)	O
was	O
different	O
from	O
A26.3	O
(A*2601)	O
by	O
a	O
single	O
substitution	B-DNAMutation
of	I-DNAMutation
arginine	I-DNAMutation
by	I-DNAMutation
leucine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
163	I-DNAMutation
.	O

A	O
comparison	O
of	O
amino	O
acid	O
sequences	O
of	O
HLA-A10	O
cross-reacting	O
antigens	O
revealed	O
that	O
all	O
of	O
the	O
A10	O
group	O
antigens	O
share	O
specific	O
amino	O
acids	O
:	O
142	O
isoleucine	O
,	O
144	O
glutamine	O
,	O
145	O
arginine	O
,	O
149	O
threonine	O
,	O
and	O
152	O
glutamate	O
.	O

Moreover	O
,	O
A26.1	O
,	O
A26.3	O
,	O
A10SA	O
,	O
and	O
A43	O
share	O
76	O
alanine	O
and	O
77	O
asparagine	O
,	O
which	O
is	O
consistent	O
with	O
the	O
reported	O
serologic	O
cross-reactivity	O
.	O

The	O
close	O
relationship	O
between	O
the	O
alleles	O
for	O
the	O
A10	O
cross-reacting	O
group	O
was	O
supported	O
by	O
a	O
phylogenetic	O
tree	O
analysis	O
for	O
the	O
HLA-A	O
alleles	O
.	O

Site-directed	O
mutagenesis	B-DNAMutation
of	I-DNAMutation
active	I-DNAMutation
site	I-DNAMutation
glutamate-217	I-DNAMutation
in	O
mouse	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
.	O

Mouse	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
ADA	B-DNAMutation
contains	O
an	O
active	O
site	O
glutamate	O
residue	O
at	O
position-217	O
that	O
is	O
highly	O
conserved	O
in	O
other	O
adenosine	O
and	O
AMP	O
deaminases	O
.	O

Previous	O
research	O
has	O
suggested	O
that	O
proton	O
donation	O
to	O
N-1	O
of	O
the	O
adenosine	O
ring	O
occurs	O
prior	O
to	O
catalysis	O
and	O
supports	O
the	O
mechanism	O
as	O
proceeding	O
via	O
formation	O
of	O
a	O
tetrahedral	O
intermediate	O
at	O
C-6	O
of	O
adenosine	O
.	O

The	O
proposed	O
catalytic	O
mechanism	O
of	O
ADA	B-DNAMutation
based	O
on	O
the	O
recent	O
elucidations	O
of	O
the	O
crystal	O
structure	O
of	O
this	O
enzyme	O
with	O
transition-	O
and	O
ground-state	O
analogs	O
hypothesized	O
that	O
Glu217	O
was	O
involved	O
in	O
this	O
proton	O
donation	O
step	O
[	O
Wilson	O
,	O
D	O
.	O

K.	O
,	O
Rudolph	O
,	O
F	O
.	O

B.	O
,	O
&	O
Quiocho	O
,	O
F	O
.	O

A	O
.	O

(1991)	O
Science	O
252	O
,	O
1278-1284	O
;	O
Wilson	O
,	O
D	O
.	O

K.	O
,	O
&	O
Quiocho	O
,	O
F	O
.	O

A	O
.	O

(1993)	O
Biochemistry	O
32	O
,	O
1689-1693	O
]	O
.	O

Site-directed	O
mutagenesis	O
of	O
the	O
equivalent	O
glutamate	O
in	O
human	O
ADA	B-DNAMutation
resulted	O
in	O
a	O
dramatic	O
loss	O
of	O
enzyme	O
activity	O
[	O
Bhaumik	O
,	O
D.	O
,	O
Medin	O
,	O
J.	O
,	O
Gathy	O
,	O
K.	O
,	O
&	O
Coleman	O
,	O
M	O
.	O

(1993)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

268	O
,	O
5464-5470	O
]	O
.	O

To	O
further	O
study	O
the	O
importance	O
of	O
this	O
residue	O
,	O
site-directed	O
mutagenesis	O
was	O
used	O
to	O
create	O
mouse	O
ADA	B-DNAMutation
mutants	O
.	O

Glu217	B-DNAMutation
was	I-DNAMutation
mutated	I-DNAMutation
to	I-DNAMutation
Asp	I-DNAMutation
,	I-DNAMutation
Gly	I-DNAMutation
,	I-DNAMutation
Gln	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Ser	I-DNAMutation
,	O
and	O
all	O
mutants	O
were	O
successfully	O
expressed	O
and	O
purified	O
.	O

Circular	O
dichroism	O
and	O
zinc	O
analysis	O
showed	O
no	O
significant	O
changes	O
in	O
secondary	O
structure	O
or	O
zinc	O
content	O
,	O
respectively	O
,	O
compared	O
to	O
the	O
native	O
protein	O
.	O

The	O
mutants	O
showed	O
only	O
a	O
slight	O
variation	O
in	O
Km	O
but	O
dramatically	O
reduced	O
kcat	O
,	O
less	O
than	O
0.2%	O
of	O
wild-type	O
activity	O
.	O

UV	O
difference	O
and	O
13C	O
NMR	O
spectra	O
conclusively	O
demonstrated	O
the	O
failure	O
of	O
any	O
of	O
these	O
mutants	O
to	O
hydrate	O
purine	O
riboside	O
,	O
a	O
reaction	O
carried	O
out	O
by	O
the	O
wild-type	O
enzyme	O
that	O
results	O
in	O
formation	O
of	O
an	O
enzyme-inhibitor	O
complex	O
.	O

Surprisingly	O
,	O
Ki	O
values	O
for	O
binding	O
of	O
the	O
inhibitor	O
to	O
the	O
mutants	O
and	O
to	O
wild-type	O
protein	O
are	O
similar	O
,	O
irrespective	O
of	O
whether	O
the	O
inhibitor	O
is	O
hydrated	O
upon	O
binding	O
.	O

These	O
data	O
confirm	O
the	O
importance	O
of	O
Glu217	O
in	O
catalysis	O
as	O
suggested	O
by	O
the	O
crystal	O
structure	O
of	O
mouse	O
ADA	B-DNAMutation
.	O

Autosomal	O
recessive	O
phosphoglucomutase	O
3	O
PGM3	B-DNAMutation
mutations	O
link	O
glycosylation	O
defects	O
to	O
atopy	O
,	O
immune	O
deficiency	O
,	O
autoimmunity	O
,	O
and	O
neurocognitive	O
impairment	O
.	O

BACKGROUND	O
:	O
Identifying	O
genetic	O
syndromes	O
that	O
lead	O
to	O
significant	O
atopic	O
disease	O
can	O
open	O
new	O
pathways	O
for	O
investigation	O
and	O
intervention	O
in	O
allergy	O
.	O

OBJECTIVE	O
:	O
We	O
sought	O
to	O
define	O
a	O
genetic	O
syndrome	O
of	O
severe	O
atopy	O
,	O
increased	O
serum	O
IgE	O
levels	O
,	O
immune	O
deficiency	O
,	O
autoimmunity	O
,	O
and	O
motor	O
and	O
neurocognitive	O
impairment	O
.	O

METHODS	O
:	O
Eight	O
patients	O
from	O
2	O
families	O
with	O
similar	O
syndromic	O
features	O
were	O
studied	O
.	O

Thorough	O
clinical	O
evaluations	O
,	O
including	O
brain	O
magnetic	O
resonance	O
imaging	O
and	O
sensory	O
evoked	O
potentials	O
,	O
were	O
performed	O
.	O

Peripheral	O
lymphocyte	O
flow	O
cytometry	O
,	O
antibody	O
responses	O
,	O
and	O
T-cell	O
cytokine	O
production	O
were	O
measured	O
.	O

Whole-exome	O
sequencing	O
was	O
performed	O
to	O
identify	O
disease-causing	O
mutations	O
.	O

Immunoblotting	O
,	O
quantitative	O
RT-PCR	O
,	O
enzymatic	O
assays	O
,	O
nucleotide	O
sugar	O
,	O
and	O
sugar	O
phosphate	O
analyses	O
,	O
along	O
with	O
matrix-assisted	O
laser	O
desorption/ionization-time-of-flight	O
mass	O
spectrometry	O
of	O
glycans	O
,	O
were	O
used	O
to	O
determine	O
the	O
molecular	O
consequences	O
of	O
the	O
mutations	O
.	O

RESULTS	O
:	O
Marked	O
atopy	O
and	O
autoimmunity	O
were	O
associated	O
with	O
increased	O
T(H)2	O
and	O
T(H)17	O
cytokine	O
production	O
by	O
CD4(+)	O
T	O
cells	O
.	O

Bacterial	O
and	O
viral	O
infection	O
susceptibility	O
were	O
noted	O
along	O
with	O
T-cell	O
lymphopenia	O
,	O
particularly	O
of	O
CD8(+)	O
T	O
cells	O
,	O
and	O
reduced	O
memory	O
B-cell	O
numbers	O
.	O

Apparent	O
brain	O
hypomyelination	O
resulted	O
in	O
markedly	O
delayed	O
evoked	O
potentials	O
and	O
likely	O
contributed	O
to	O
neurologic	O
abnormalities	O
.	O

Disease	O
segregated	O
with	O
novel	O
autosomal	O
recessive	O
mutations	O
in	O
a	O
single	O
gene	O
,	O
phosphoglucomutase	O
3	O
PGM3	B-DNAMutation
.	O

Although	O
PGM3	B-DNAMutation
protein	O
expression	O
was	O
variably	O
diminished	O
,	O
impaired	O
function	O
was	O
demonstrated	O
by	O
decreased	O
enzyme	O
activity	O
and	O
reduced	O
uridine	O
diphosphate-N-acetyl-D-glucosamine	O
,	O
along	O
with	O
decreased	O
O-	O
and	O
N-linked	O
protein	O
glycosylation	O
in	O
patients'	O
cells	O
.	O

These	O
results	O
define	O
a	O
new	O
congenital	O
disorder	O
of	O
glycosylation	O
.	O

CONCLUSIONS	O
:	O
Autosomal	O
recessive	O
hypomorphic	O
PGM3	B-DNAMutation
mutations	O
underlie	O
a	O
disorder	O
of	O
severe	O
atopy	O
,	O
immune	O
deficiency	O
,	O
autoimmunity	O
,	O
intellectual	O
disability	O
,	O
and	O
hypomyelination	O
.	O

Primary	O
structure	O
of	O
c-kit	B-DNAMutation
:	O
relationship	O
with	O
the	O
CSF-1/PDGF	B-DNAMutation
receptor	O
kinase	O
family--oncogenic	O
activation	O
of	O
v-kit	O
involves	O
deletion	B-DNAMutation
of	I-DNAMutation
extracellular	I-DNAMutation
domain	I-DNAMutation
and	I-DNAMutation
C	I-DNAMutation
terminus	I-DNAMutation
.	O

The	O
protein	O
kinase	O
domains	O
of	O
v-kit	O
,	O
the	O
oncogene	O
of	O
the	O
acute	O
transforming	O
feline	O
retrovirus	O
HZ4-FeSV	O
(	O
HZ4-feline	O
sarcoma	O
virus	O
)	O
,	O
CSF-1R	B-DNAMutation
(	I-DNAMutation
macrophage	I-DNAMutation
colony	I-DNAMutation
stimulating	I-DNAMutation
factor	I-DNAMutation
receptor	I-DNAMutation
)	O
and	O
PDGFR	B-DNAMutation
(	O
platelet	B-DNAMutation
derived	I-DNAMutation
growth	I-DNAMutation
factor	I-DNAMutation
receptor	I-DNAMutation
)	O
display	O
extensive	O
homology	O
.	O

Because	O
of	O
the	O
close	O
structural	O
relationship	O
of	O
v-kit	O
,	O
CSF-1R	B-DNAMutation
and	O
PDGFR	B-DNAMutation
we	O
predicted	O
that	O
c-kit	B-DNAMutation
would	O
encode	O
a	O
protein	O
kinase	O
transmembrane	O
receptor	O
(	O
Besmer	O
et	O
al.	O
,	O
1986a	O
;	O
Yarden	O
et	O
al.	O
,	O
1986	O
)	O
.	O

We	O
have	O
now	O
determined	O
the	O
primary	O
structure	O
of	O
murine	O
c-kit	B-DNAMutation
from	O
a	O
DNA	O
clone	O
isolated	O
from	O
a	O
brain	O
cDNA	O
library	O
.	O

The	O
nucleotide	O
sequence	O
of	O
the	O
c-kit	B-DNAMutation
cDNA	O
predicts	O
a	O
975	O
amino	O
acid	O
protein	O
product	O
with	O
a	O
calculated	O
mol	O
.	O

wt	O
of	O
109.001	O
kd	O
.	O

It	O
contains	O
an	O
N-terminal	O
signal	O
peptide	O
,	O
a	O
transmembrane	O
domain	O
(	O
residues	O
519-543	O
)	O
and	O
in	O
the	O
C-terminal	O
half	O
the	O
v-kit	O
homologous	O
sequences	O
(	O
residues	O
558-925	O
)	O
.	O

c-kit	B-DNAMutation
therefore	O
contains	O
the	O
features	O
which	O
are	O
characteristic	O
of	O
a	O
transmembrane	O
receptor	O
kinase	O
.	O

Comparison	O
of	O
c-kit	B-DNAMutation
,	O
CSF-1R	B-DNAMutation
and	O
PDGFR	B-DNAMutation
revealed	O
a	O
unique	O
structural	O
relationship	O
of	O
these	O
receptor	O
kinases	O
suggesting	O
a	O
common	O
evolutionary	O
origin	O
.	O

The	O
outer	O
cellular	O
domain	O
of	O
c-kit	B-DNAMutation
was	O
shown	O
to	O
be	O
related	O
to	O
the	O
immunoglobulin	O
superfamily	O
.	O

The	O
sites	O
of	O
expression	O
of	O
c-kit	B-DNAMutation
in	O
normal	O
tissue	O
predict	O
a	O
function	O
in	O
the	O
brain	O
and	O
in	O
hematopoietic	O
cells	O
.	O

N-terminal	B-DNAMutation
sequences	I-DNAMutation
which	I-DNAMutation
include	I-DNAMutation
the	I-DNAMutation
extracellular	I-DNAMutation
domain	I-DNAMutation
and	O
the	O
transmembrane	B-DNAMutation
domain	I-DNAMutation
as	I-DNAMutation
well	I-DNAMutation
as	I-DNAMutation
50	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
from	I-DNAMutation
the	I-DNAMutation
C-terminus	I-DNAMutation
of	I-DNAMutation
c-kit	I-DNAMutation
are	I-DNAMutation
deleted	I-DNAMutation
in	I-DNAMutation
v-kit	I-DNAMutation
.	O

These	O
structural	O
alterations	O
are	O
likely	O
determinants	O
of	O
the	O
oncogenic	O
activation	O
of	O
v-kit.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Point	O
mutations	O
in	O
the	O
murine	O
fumarylacetoacetate	O
hydrolase	O
gene	O
:	O
Animal	O
models	O
for	O
the	O
human	O
genetic	O
disorder	O
hereditary	O
tyrosinemia	O
type	O
1	O
.	O

Hereditary	O
tyrosinemia	O
type	O
1	O
(HT1)	O
is	O
a	O
severe	O
autosomal	O
recessive	O
metabolic	O
disease	O
associated	O
with	O
point	O
mutations	O
in	O
the	O
human	O
fumarylacetoacetate	B-DNAMutation
hydrolase	I-DNAMutation
FAH	B-DNAMutation
gene	O
that	O
disrupt	O
tyrosine	O
catabolism	O
.	O

An	O
acute	O
form	O
of	O
HT1	O
results	O
in	O
death	O
during	O
the	O
first	O
months	O
of	O
life	O
because	O
of	O
hepatic	O
failure	O
,	O
whereas	O
a	O
chronic	O
form	O
leads	O
to	O
gradual	O
development	O
of	O
liver	O
disease	O
often	O
accompanied	O
by	O
renal	O
dysfunction	O
,	O
childhood	O
rickets	O
,	O
neurological	O
crisis	O
,	O
and	O
hepatocellular	O
carcinoma	O
.	O

Mice	O
homozygous	O
for	O
certain	O
chromosome	B-DNAMutation
7	I-DNAMutation
deletions	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
albino	I-DNAMutation
Tyr	I-DNAMutation
;	O
c	O
locus	O
that	O
also	O
include	O
Fah	O
die	O
perinatally	O
as	O
a	O
result	O
of	O
liver	O
dysfunction	O
and	O
exhibit	O
a	O
complex	O
syndrome	O
characterized	O
by	O
structural	O
abnormalities	O
and	O
alterations	O
in	O
gene	O
expression	O
in	O
the	O
liver	O
and	O
kidney	O
.	O

Here	O
we	O
report	O
that	O
two	O
independent	O
,	O
postnatally	O
lethal	O
mutations	O
induced	O
by	O
N-ethyl-N-nitrosourea	O
and	O
mapped	O
near	O
Tyr	O
are	O
alleles	O
of	O
Fah	O
.	O

The	O
Fah(6287SB)	O
allele	O
is	O
a	O
missense	O
mutation	O
in	O
exon	O
6	O
,	O
and	O
Fah(5961SB)	O
is	O
a	O
splice	B-DNAMutation
mutation	I-DNAMutation
causing	I-DNAMutation
loss	I-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
7	I-DNAMutation
,	O
a	O
subsequent	O
frameshift	O
in	O
the	O
resulting	O
mRNA	O
,	O
and	O
a	O
severe	O
reduction	O
of	O
Fah	O
mRNA	O
levels	O
.	O

Increased	O
levels	O
of	O
the	O
diagnostic	O
metabolite	O
succinylacetone	O
in	O
the	O
urine	O
of	O
the	O
Fah(6287SB)	O
and	O
Fah(5961SB)	O
mutants	O
indicate	O
that	O
these	O
mutations	O
cause	O
a	O
decrease	O
in	O
Fah	O
enzymatic	O
activity	O
.	O

Thus	O
,	O
the	O
neonatal	O
phenotype	O
present	O
in	O
both	O
mutants	O
is	O
due	O
to	O
a	O
deficiency	O
in	O
Fah	O
caused	O
by	O
a	O
point	O
mutation	O
,	O
and	O
we	O
propose	O
Fah(5961SB)	O
and	O
Fah(6287SB)	O
as	O
mouse	O
models	O
for	O
acute	O
and	O
chronic	O
forms	O
of	O
human	O
HT1	O
,	O
respectively	O
.	O

Identification	O
of	O
the	O
glycosaminoglycan-attachment	O
site	O
of	O
mouse	O
invariant-chain	O
proteoglycan	O
core	O
protein	O
by	O
site-directed	O
mutagenesis	O
.	O

The	O
invariant	O
chain	O
(Ii)	O
,	O
a	O
nonpolymorphic	O
glycoprotein	O
that	O
associates	O
with	O
the	O
immunoregulatory	O
Ia	O
proteins	O
encoded	O
by	O
the	O
major	O
histocompatibility	O
complex	O
,	O
has	O
a	O
proteoglycan	O
form	O
(Ii-CS)	O
that	O
bears	O
a	O
chondroitin	O
sulfate	O
glycosaminoglycan	O
.	O

In	O
this	O
proteoglycan	O
form	O
,	O
Ii	O
may	O
remain	O
associated	O
with	O
Ia	O
at	O
the	O
cell	O
surface	O
.	O

Inhibitors	O
that	O
prevent	O
the	O
addition	O
of	O
glycosaminoglycan	O
to	O
Ii	O
have	O
been	O
found	O
to	O
depress	O
antigen-presenting	O
function	O
.	O

Ii	O
does	O
not	O
have	O
multiple	O
candidate	O
glycosaminoglycan-attachment	O
sites	O
,	O
and	O
we	O
used	O
site-directed	O
mutagenesis	O
to	O
replace	B-DNAMutation
a	I-DNAMutation
candidate	I-DNAMutation
serine	I-DNAMutation
glycosaminoglycan-acceptor	I-DNAMutation
site	I-DNAMutation
with	I-DNAMutation
alanine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
201	I-DNAMutation
in	O
the	O
murine	O
Ii	O
protein	O
.	O

Transfection	O
of	O
the	O
normal	O
or	O
altered	O
gene	O
into	O
Ii-negative	O
COS-7	O
cells	O
showed	O
that	O
equivalent	O
amounts	O
of	O
core	O
Ii	O
protein	O
and	O
its	O
acidic	O
,	O
terminally	O
glycosylated	O
forms	O
were	O
synthesized	O
,	O
but	O
the	O
Ala-201	O
mutant	O
Ii	O
did	O
not	O
give	O
rise	O
to	O
Ii-CS	O
.	O

The	O
mutant	O
protein	O
had	O
apparently	O
normal	O
transport	O
through	O
the	O
Golgi	O
compartment	O
and	O
associated	O
stably	O
with	O
Ia	O
molecules	O
.	O

Thus	O
,	O
this	O
mutation	O
directly	O
identifies	O
the	O
site	O
of	O
glycosaminoglycan	O
addition	O
and	O
shows	O
that	O
it	O
can	O
be	O
eliminated	O
without	O
adversely	O
affecting	O
the	O
overall	O
biosynthesis	O
of	O
Ii	O
.	O

Molecular	O
genetics	O
of	O
3beta-hydroxy-Delta5-C27-steroid	O
oxidoreductase	O
deficiency	O
in	O
16	O
patients	O
with	O
loss	O
of	O
bile	O
acid	O
synthesis	O
and	O
liver	O
disease	O
.	O

The	O
3beta-hydroxy-Delta(5)-C(27)-steroid	B-DNAMutation
oxidoreductase	I-DNAMutation
(	O
C(27	B-DNAMutation
)	I-DNAMutation
3beta-HSD	I-DNAMutation
)	O
is	O
a	O
membrane-bound	O
enzyme	O
of	O
the	O
endoplasmic	O
reticulum	O
that	O
catalyzes	O
an	O
early	O
step	O
in	O
the	O
synthesis	O
of	O
bile	O
acids	O
from	O
cholesterol	O
.	O

Subjects	O
with	O
autosomal	O
recessive	O
mutations	O
in	O
the	O
encoding	O
gene	O
,	O
HSD3B7	B-DNAMutation
,	O
on	O
chromosome	O
16p11.2-12	O
fail	O
to	O
synthesize	O
bile	O
acids	O
and	O
develop	O
a	O
form	O
of	O
progressive	O
liver	O
disease	O
characterized	O
by	O
cholestatic	O
jaundice	O
and	O
malabsorption	O
of	O
lipids	O
and	O
lipid-soluble	O
vitamins	O
from	O
the	O
gastrointestinal	O
tract	O
.	O

The	O
gene	O
encoding	O
the	O
human	O
C(27)	B-DNAMutation
3beta-HSD	I-DNAMutation
enzyme	O
was	O
isolated	O
previously	O
,	O
and	O
a	O
2-bp	B-DNAMutation
deletion	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
6	I-DNAMutation
of	O
HSD3B7	B-DNAMutation
was	O
identified	O
in	O
a	O
well	O
characterized	O
subject	O
with	O
this	O
disorder	O
.	O

Here	O
,	O
we	O
report	O
a	O
molecular	O
analysis	O
of	O
15	O
additional	O
patients	O
from	O
13	O
kindreds	O
with	O
C(27)	B-DNAMutation
3beta-HSD	I-DNAMutation
deficiency	O
.	O

Twelve	O
different	O
mutations	O
were	O
identified	O
in	O
the	O
HSD3B7	B-DNAMutation
gene	O
on	O
chromosome	O
16p11.2-12	O
.	O

Ten	O
mutations	O
were	O
studied	O
in	O
detail	O
and	O
shown	O
to	O
cause	O
complete	O
loss	O
of	O
enzyme	O
activity	O
and	O
,	O
in	O
two	O
cases	O
,	O
alterations	O
in	O
the	O
size	O
or	O
amount	O
of	O
the	O
transcribed	O
mRNA	O
.	O

Mutations	O
were	O
inherited	O
in	O
homozygous	O
form	O
in	O
13	O
subjects	O
from	O
10	O
families	O
and	O
compound	O
heterozygous	O
form	O
in	O
four	O
subjects	O
from	O
three	O
families	O
.	O

We	O
conclude	O
that	O
a	O
diverse	O
spectrum	O
of	O
mutations	O
in	O
the	O
HSD3B7	B-DNAMutation
gene	O
underlies	O
this	O
rare	O
form	O
of	O
neonatal	O
cholestasis	O
.	O

Three	O
newly	O
identified	O
A*24	O
alleles	O
:	O
A*2406	O
,	O
A*2413	O
and	O
A*2414	O
.	O

Three	O
previously	O
unknown	O
A24-related	B-DNAMutation
alleles	O
were	O
identified	O
by	O
PCR-SSO	O
typing	O
and	O
confirmed	O
by	O
DNA	O
sequencing	O
in	O
Australian	O
Aboriginal	O
populations	O
(	O
A*2406	O
,	O
2413	O
)	O
and	O
in	O
individuals	O
of	O
South	O
American	O
descent	O
(A*2414)	O
.	O

A*2406	O
and	O
A*2413	O
both	O
have	O
two	O
adjacent	O
(	O
but	O
different	O
)	O
nucleotide	O
substitutions	B-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
156	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
3	I-DNAMutation
compared	O
to	O
A*2402	O
,	O
resulting	O
in	O
a	O
single	O
amino	O
acid	O
replacement	O
in	O
each	O
allele	O
.	O

The	O
South	O
American	O
A*2414	O
is	O
apparently	O
a	O
hybrid	O
between	O
A2	O
and	O
A24	B-DNAMutation
with	O
a	O
segment	O
of	O
the	O
A*24	O
sequence	B-DNAMutation
between	I-DNAMutation
codons	I-DNAMutation
95	I-DNAMutation
and	I-DNAMutation
107	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
3	I-DNAMutation
replaced	I-DNAMutation
with	I-DNAMutation
the	I-DNAMutation
A*02	I-DNAMutation
sequence	I-DNAMutation
.	O

Interallelic	O
sequence	O
exchange	O
is	O
the	O
most	O
likely	O
mechanism	O
in	O
the	O
generation	O
of	O
all	O
three	O
novel	O
alleles	O
.	O

Compared	O
to	O
A*2402	O
,	O
the	O
four	O
amino	O
acid	O
substitutions	O
in	O
the	O
A*2414	O
molecule	O
would	O
be	O
expected	O
to	O
significantly	O
change	O
the	O
shape	O
of	O
the	O
peptide	O
binding	O
cleft	O
,	O
leading	O
to	O
selection	O
of	O
different	O
peptide	O
ligands	O
.	O

The	O
single	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
replacements	I-DNAMutation
in	I-DNAMutation
position	I-DNAMutation
156	I-DNAMutation
of	O
the	O
two	O
Australian	O
Aboriginal	O
A*24	O
alleles	O
may	O
also	O
have	O
significant	O
functional	O
effects	O
.	O

In	O
particular	O
,	O
Trp	B-DNAMutation
replacing	I-DNAMutation
Gln	I-DNAMutation
in	I-DNAMutation
position	I-DNAMutation
156	I-DNAMutation
(A*2406)	O
is	O
predicted	O
to	O
markedly	O
reduce	O
the	O
volume	O
of	O
the	O
peptide	O
binding	O
cleft	O
,	O
influence	O
the	O
interaction	O
of	O
HLA	O
pockets	O
with	O
peptide	O
side	O
chains	O
,	O
and	O
therefore	O
,	O
cause	O
major	O
changes	O
in	O
peptide	O
presentation	O
.	O

These	O
newly	O
defined	O
alleles	O
may	O
reflect	O
the	O
adaptive	O
process	O
of	O
HLA	O
genes	O
to	O
local	O
environments	O
.	O

Defective	O
trafficking	O
and	O
function	O
of	O
KATP	O
channels	O
caused	O
by	O
a	O
sulfonylurea	O
receptor	O
1	O
mutation	O
associated	O
with	O
persistent	O
hyperinsulinemic	O
hypoglycemia	O
of	O
infancy	O
.	O

The	I-DNAMutation
ATP-sensitive	I-DNAMutation
potassium	O
channel	O
(K(ATP))	O
regulates	O
insulin	O
secretion	O
in	O
pancreatic	O
beta	O
cells	O
.	O

Loss	O
of	O
functional	O
K(ATP)	O
channels	O
because	O
of	O
mutations	O
in	O
either	O
the	O
SUR1	O
or	O
Kir6.2	O
channel	O
subunit	O
causes	O
persistent	O
hyperinsulinemic	O
hypoglycemia	O
of	O
infancy	O
(PHHI)	O
.	O

We	O
investigated	O
the	O
molecular	O
mechanism	O
by	O
which	O
a	O
single	B-DNAMutation
phenylalanine	I-DNAMutation
deletion	I-DNAMutation
in	O
SUR1	O
DeltaF1388	B-DNAMutation
causes	O
PHHI	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
coexpression	O
of	O
DeltaF1388	B-DNAMutation
SUR1	O
with	O
Kir6.2	O
results	O
in	O
no	O
channel	O
activity	O
.	O

We	O
demonstrate	O
here	O
that	O
the	O
lack	O
of	O
functional	O
expression	O
is	O
due	O
to	O
failure	O
of	O
the	O
mutant	O
channel	O
to	O
traffic	O
to	O
the	O
cell	O
surface	O
.	O

Trafficking	O
of	O
K(ATP)	O
channels	O
requires	O
that	O
the	O
endoplasmic	O
reticulum-retention	O
signal	O
,	O
RKR	O
,	O
present	O
in	O
both	O
SUR1	O
and	O
Kir6.2	O
,	O
be	O
shielded	O
during	O
channel	O
assembly	O
.	O

To	O
ask	O
whether	O
DeltaF1388	B-DNAMutation
SUR1	O
forms	O
functional	O
channels	O
with	O
Kir6.2	O
,	O
we	O
inactivated	O
the	O
RKR	O
signal	O
in	O
DeltaF1388	B-DNAMutation
SUR1	I-DNAMutation
by	I-DNAMutation
mutation	I-DNAMutation
to	I-DNAMutation
AAA	I-DNAMutation
(	I-DNAMutation
DeltaF1388	I-DNAMutation
SUR1(AAA)	I-DNAMutation
)	O
.	O

Inactivation	O
of	O
similar	O
endoplasmic	O
reticulum-retention	O
signals	O
in	O
the	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
has	O
been	O
shown	O
to	O
partially	O
overcome	O
the	O
trafficking	O
defect	O
of	O
a	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator	O
mutation	O
,	O
DeltaF508	B-DNAMutation
.	O

We	O
found	O
that	O
coexpression	O
of	O
DeltaF1388	B-DNAMutation
SUR1(AAA)	O
with	O
Kir6.2	O
led	O
to	O
partial	O
surface	O
expression	O
of	O
the	O
mutant	O
channel	O
.	O

Moreover	O
,	O
mutant	O
channels	O
were	O
active	O
.	O

Compared	O
with	O
wild-type	O
channels	O
,	O
the	O
mutant	O
channels	O
have	O
reduced	O
ATP	O
sensitivity	O
and	O
do	O
not	O
respond	O
to	O
stimulation	O
by	O
MgADP	O
or	O
diazoxide	O
.	O

The	O
RKR	O
-->	O
AAA	O
mutation	O
alone	O
has	O
no	O
effect	O
on	O
channel	O
properties	O
.	O

Our	O
results	O
establish	O
defective	O
trafficking	O
of	O
K(ATP)	O
channels	O
as	O
a	O
molecular	O
basis	O
of	O
PHHI	O
and	O
show	O
that	O
F1388	O
in	O
SUR1	O
is	O
critical	O
for	O
normal	O
trafficking	O
and	O
function	O
of	O
K(ATP)	O
channels	O
.	O

Antithrombin-III-Stockholm	O
:	O
a	O
codon	B-DNAMutation
392	I-DNAMutation
(Gly----Asp)	I-DNAMutation
mutation	I-DNAMutation
with	O
normal	O
heparin	O
binding	O
and	O
impaired	O
serine	O
protease	O
reactivity	O
.	O

Antithrombin-III-Stockholm	O
is	O
a	O
new	O
structural	O
variant	O
of	O
antithrombin-III	B-DNAMutation
AT-III	B-DNAMutation
with	O
normal	O
heparin	O
affinity	O
but	O
defective	O
serine	O
protease	O
inhibitory	O
activity	O
.	O

The	O
proposita	O
,	O
a	O
white	O
female	O
born	O
in	O
1966	O
,	O
was	O
diagnosed	O
to	O
have	O
developed	O
a	O
pulmonary	O
embolus	O
while	O
on	O
oral	O
contraceptives	O
at	O
age	O
19	O
.	O

The	O
proposita	O
,	O
as	O
well	O
as	O
her	O
father	O
,	O
were	O
diagnosed	O
to	O
have	O
a	O
type	O
2	O
AT-III	B-DNAMutation
deficiency	O
as	O
they	O
had	O
normal	O
levels	O
of	O
immunoreactive	O
AT-III	B-DNAMutation
associated	O
with	O
decreased	O
(	O
approximately	O
60%	O
)	O
functional	O
AT-III	B-DNAMutation
when	O
measured	O
with	O
either	O
alpha-thrombin	O
or	O
factor	O
Xa	O
as	O
the	O
substrate	O
,	O
either	O
in	O
the	O
presence	O
or	O
absence	O
of	O
heparin	O
.	O

There	O
was	O
no	O
evidence	O
of	O
abnormal	O
electrophoretic	O
mobility	O
of	O
AT-III	B-DNAMutation
from	O
the	O
proposita	O
either	O
in	O
the	O
presence	O
or	O
absence	O
of	O
heparin	O
.	O

Genomic	O
DNA	O
was	O
prepared	O
and	O
all	O
seven	O
AT-III	B-DNAMutation
exons	O
were	O
polymerase	O
chain	O
reaction	O
(PCR)-amplified	O
and	O
sequenced	O
in	O
both	O
directions	O
using	O
nested	O
primers	O
.	O

Only	O
exon	O
7	O
provided	O
evidence	O
for	O
the	O
presence	O
of	O
a	O
mutation	O
,	O
with	O
the	O
second	B-DNAMutation
base	I-DNAMutation
of	I-DNAMutation
codon	I-DNAMutation
392	I-DNAMutation
having	I-DNAMutation
a	I-DNAMutation
G----A	I-DNAMutation
substitution	I-DNAMutation
.	O

Such	O
a	O
mutation	O
would	O
cause	O
the	O
substitution	O
of	O
aspartic	O
acid	O
at	O
the	O
site	O
of	O
the	O
normally	O
appearing	O
glycine	O
in	O
the	O
translated	O
product	O
.	O

Furthermore	O
,	O
this	O
mutation	O
caused	O
the	O
destruction	O
of	O
an	O
Hae	O
III	O
restriction	O
site	O
at	O
this	O
point	O
in	O
the	O
AT-III	B-DNAMutation
gene	O
.	O

The	O
absence	O
of	O
this	O
Hae	O
III	O
site	O
was	O
confirmed	O
using	O
restriction	O
fragment	O
length	O
polymorphism	O
analysis	O
of	O
PCR-amplified	O
material	O
from	O
the	O
proposita	O
.	O

Experiments	O
with	O
AT-III	B-DNAMutation
from	O
the	O
proposita	O
together	O
with	O
experiments	O
with	O
cell-free	O
translated	O
AT-III-Stockholm	B-DNAMutation
provided	O
evidence	O
that	O
the	O
mutant	O
AT-III	B-DNAMutation
protein	O
does	O
not	O
efficiently	O
form	O
a	O
stable	O
covalent	O
inhibitory	O
complex	O
with	O
alpha-thrombin	O
,	O
although	O
it	O
exhibits	O
normal	O
heparin	O
affinity	O
.	O

The	O
minimal	O
thrombin-complexing	O
ability	O
of	O
the	O
mutant	O
AT-III	B-DNAMutation
protein	O
that	O
was	O
observed	O
was	O
accelerated	O
by	O
heparin	O
,	O
but	O
to	O
subnormal	O
levels	O
.	O

Medium	B-DNAMutation
chain	I-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
deficiency	O
in	O
Pennsylvania	O
:	O
neonatal	O
screening	O
shows	O
high	O
incidence	O
and	O
unexpected	O
mutation	O
frequencies	O
.	O

Medium	B-DNAMutation
chain	I-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
deficiency	O
(MCAD)	O
is	O
a	O
defect	O
in	O
the	O
mitochondrial	O
oxidation	O
of	O
fatty	O
acids	O
.	O

The	O
disorder	O
typically	O
presents	O
with	O
episodes	O
of	O
vomiting	O
and	O
hypoglycemia	O
,	O
sometimes	O
with	O
changes	O
in	O
mental	O
status	O
and	O
hepatic	O
failure	O
.	O

These	O
Reye's-like	O
features	O
may	O
culminate	O
in	O
coma	O
and	O
death	O
.	O

Stress	O
,	O
intercurrent	O
illness	O
,	O
and	O
reaction	O
to	O
childhood	O
immunization	O
have	O
been	O
shown	O
to	O
precipitate	O
acute	O
metabolic	O
episodes	O
in	O
MCAD	O
patients	O
.	O

All	O
cases	O
are	O
caused	O
by	O
mutations	O
of	O
the	O
single	O
MCAD	O
gene	O
on	O
chromosome	O
1	O
.	O

Most	O
clinically	O
ascertained	O
cases	O
are	O
caused	O
by	O
an	O
A985G	B-DNAMutation
transition	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
11	I-DNAMutation
.	O

Here	O
we	O
report	O
the	O
preliminary	O
findings	O
of	O
MCAD	O
patients	O
detected	O
prospectively	O
through	O
a	O
supplemental	O
newborn	O
screening	O
program	O
in	O
Pennsylvania	O
using	O
tandem	O
mass	O
spectrometry	O
.	O

From	O
the	O
first	O
80,371	O
newborns	O
screened	O
we	O
prospectively	O
found	O
nine	O
babies	O
with	O
MCAD	O
(1/8930)	O
plus	O
two	O
additional	O
newborns	O
screened	O
because	O
of	O
a	O
previously	O
known	O
family	O
history	O
.	O

Molecular	O
analysis	O
showed	O
56%	O
of	O
the	O
detected	O
patients	O
to	O
be	O
compound	O
heterozygotes	O
for	O
the	O
A985G	B-DNAMutation
and	O
a	O
second	O
mutation	O
.	O

This	O
is	O
in	O
contrast	O
to	O
clinical	O
retrospective	O
studies	O
which	O
have	O
found	O
only	O
20%	O
to	O
be	O
compound	O
heterozygotes	O
.	O

We	O
have	O
identified	O
two	O
of	O
the	O
other	O
mutations	O
including	O
a	O
novel	O
mutation	O
(	O
DG91/C92	B-DNAMutation
,	I-DNAMutation
6-bp	I-DNAMutation
deletion	I-DNAMutation
)	O
in	O
one	O
of	O
our	O
patients	O
by	O
using	O
single-stranded	O
conformation	O
polymorphism	O
(SSCP)	O
and	O
sequence	O
analysis	O
of	O
conformers	O
.	O

Our	O
results	O
confirm	O
that	O
MCAD	O
is	O
one	O
of	O
the	O
more	O
common	O
inborn	O
errors	O
of	O
metabolism	O
.	O

The	O
different	O
mutation	O
frequencies	O
observed	O
between	O
retrospective	O
clinical	O
studies	O
and	O
our	O
prospective	O
newborn	O
screening	O
study	O
suggest	O
that	O
clinical	O
ascertainment	O
may	O
lead	O
to	O
preferential	O
identification	O
of	O
the	O
A985G	B-DNAMutation
mutation	O
.	O

p75	O
neurotrophin	O
receptor	O
is	O
a	O
clock	B-DNAMutation
gene	O
that	O
regulates	O
oscillatory	O
components	O
of	O
circadian	O
and	O
metabolic	O
networks	O
.	O

The	O
p75	B-DNAMutation
neurotrophin	I-DNAMutation
receptor	I-DNAMutation
p75(NTR)	B-DNAMutation
is	O
a	O
member	O
of	O
the	O
tumor	O
necrosis	O
factor	O
receptor	O
superfamily	O
with	O
a	O
widespread	O
pattern	O
of	O
expression	O
in	O
tissues	O
such	O
as	O
the	O
brain	O
,	O
liver	O
,	O
lung	O
,	O
and	O
muscle	O
.	O

The	O
mechanisms	O
that	O
regulate	O
p75(NTR)	B-DNAMutation
transcription	O
in	O
the	O
nervous	O
system	O
and	O
its	O
expression	O
in	O
other	O
tissues	O
remain	O
largely	O
unknown	O
.	O

Here	O
we	O
show	O
that	O
p75(NTR)	B-DNAMutation
is	O
an	O
oscillating	O
gene	O
regulated	O
by	O
the	O
helix-loop-helix	O
transcription	O
factors	O
CLOCK	B-DNAMutation
and	O
BMAL1	B-DNAMutation
.	O

The	O
p75(NTR)	B-DNAMutation
promoter	O
contains	O
evolutionarily	O
conserved	O
noncanonical	O
E-box	O
enhancers	O
.	O

Deletion	O
mutagenesis	O
of	O
the	O
p75(NTR)-luciferase	B-DNAMutation
reporter	O
identified	O
the	O
-1039	O
conserved	O
E-box	O
necessary	O
for	O
the	O
regulation	O
of	O
p75(NTR)	B-DNAMutation
by	O
CLOCK	B-DNAMutation
and	O
BMAL1	B-DNAMutation
.	O

Accordingly	O
,	O
gel-shift	O
assays	O
confirmed	O
the	O
binding	O
of	O
CLOCK	B-DNAMutation
and	O
BMAL1	B-DNAMutation
to	O
the	O
p75(NTR-)1039	B-DNAMutation
E-box	O
.	O

Studies	O
in	O
mice	O
revealed	O
that	O
p75(NTR)	B-DNAMutation
transcription	O
oscillates	O
during	O
dark	O
and	O
light	O
cycles	O
not	O
only	O
in	O
the	O
suprachiasmatic	O
nucleus	O
(SCN)	O
,	O
but	O
also	O
in	O
peripheral	O
tissues	O
including	O
the	O
liver	O
.	O

Oscillation	O
of	O
p75(NTR)	B-DNAMutation
is	O
disrupted	O
in	O
Clock-deficient	B-DNAMutation
and	O
mutant	O
mice	O
,	O
is	O
E-box	O
dependent	O
,	O
and	O
is	O
in	O
phase	O
with	O
clock	B-DNAMutation
genes	O
,	O
such	O
as	O
Per1	B-DNAMutation
and	O
Per2	B-DNAMutation
.	O

Intriguingly	O
,	O
p75(NTR)	B-DNAMutation
is	O
required	O
for	O
circadian	O
clock	B-DNAMutation
oscillation	O
,	O
since	O
loss	O
of	O
p75(NTR)	B-DNAMutation
alters	O
the	O
circadian	O
oscillation	O
of	O
clock	B-DNAMutation
genes	O
in	O
the	O
SCN	O
,	O
liver	O
,	O
and	O
fibroblasts	O
.	O

Consistent	O
with	O
this	O
,	O
Per2::Luc/p75(NTR-/-)	B-DNAMutation
liver	O
explants	O
showed	O
reduced	O
circadian	O
oscillation	O
amplitude	O
compared	O
with	O
those	O
of	O
Per2::Luc/p75(NTR+/+)	B-DNAMutation
.	O

Moreover	O
,	O
deletion	B-DNAMutation
of	I-DNAMutation
p75(NTR)	I-DNAMutation
also	O
alters	O
the	O
circadian	O
oscillation	O
of	O
glucose	O
and	O
lipid	O
homeostasis	O
genes	O
.	O

Overall	O
,	O
our	O
findings	O
reveal	O
that	O
the	O
transcriptional	O
activation	O
of	O
p75(NTR)	B-DNAMutation
is	O
under	O
circadian	O
regulation	O
in	O
the	O
nervous	O
system	O
and	O
peripheral	O
tissues	O
,	O
and	O
plays	O
an	O
important	O
role	O
in	O
the	O
maintenance	O
of	O
clock	B-DNAMutation
and	O
metabolic	O
gene	O
oscillation	O
.	O

Mechanism	O
for	O
nucleocytoplasmic	O
shuttling	O
of	O
histone	B-DNAMutation
deacetylase	I-DNAMutation
7	I-DNAMutation
.	O

Here	O
we	O
show	O
that	O
HDAC7	B-DNAMutation
,	O
a	O
member	O
of	O
the	O
class	O
II	O
histone	O
deacetylases	O
,	O
specifically	O
targets	O
several	O
members	O
of	O
myocyte	O
enhancer	O
factors	O
,	O
MEF2A	B-DNAMutation
,	I-DNAMutation
-2C	I-DNAMutation
,	O
and	O
-2D	O
,	O
and	O
inhibits	O
their	O
transcriptional	O
activity	O
.	O

Furthermore	O
,	O
we	O
demonstrate	O
that	O
DNA-bound	O
MEF2C	B-DNAMutation
is	O
capable	O
of	O
recruiting	O
HDAC7	B-DNAMutation
,	O
demonstrating	O
that	O
the	O
HDAC7-dependent	B-DNAMutation
repression	O
of	O
transcription	O
is	O
not	O
due	O
to	O
the	O
inhibition	O
of	O
the	O
MEF2	O
DNA	O
binding	O
activity	O
.	O

The	O
data	O
also	O
suggest	O
that	O
the	O
promoter	O
bound	O
MEF2	O
is	O
potentially	O
capable	O
of	O
remodeling	O
adjacent	O
nucleosomes	O
via	O
the	O
recruitment	O
of	O
HDAC7	B-DNAMutation
.	O

We	O
have	O
also	O
observed	O
a	O
nucleocytoplasmic	O
shuttling	O
of	O
HDAC7	B-DNAMutation
and	O
dissected	O
the	O
mechanism	O
involved	O
.	O

In	O
NIH3T3	O
cells	O
,	O
HDAC7	B-DNAMutation
was	O
primarily	O
localized	O
in	O
the	O
cytoplasm	O
,	O
essentially	O
due	O
to	O
an	O
active	O
CRM1-dependent	B-DNAMutation
export	O
of	O
the	O
protein	O
from	O
the	O
nucleus	O
.	O

Interestingly	O
,	O
in	O
HeLa	O
cells	O
,	O
HDAC7	B-DNAMutation
was	O
predominantly	O
nuclear	O
.	O

In	O
these	O
cells	O
we	O
could	O
restore	O
the	O
cytoplasmic	O
localization	O
of	O
HDAC7	B-DNAMutation
by	O
expressing	O
CaMK	B-DNAMutation
I	I-DNAMutation
.	O

This	O
CaMK	B-DNAMutation
I-induced	I-DNAMutation
nuclear	O
export	O
of	O
HDAC7	B-DNAMutation
was	O
abolished	O
when	O
three	O
critical	O
serines	O
,	O
Ser-178	B-DNAMutation
,	I-DNAMutation
Ser-344	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Ser-479	I-DNAMutation
,	I-DNAMutation
of	I-DNAMutation
HDAC7	I-DNAMutation
were	I-DNAMutation
mutated	I-DNAMutation
.	O

We	O
show	O
that	O
these	O
serines	O
are	O
involved	O
in	O
the	O
direct	O
interaction	O
of	O
HDAC7	B-DNAMutation
with	O
14-3-3	O
.	O

Mutations	O
of	O
these	O
serine	O
residues	O
weakened	O
the	O
association	O
with	O
14-3-3	O
and	O
dramatically	O
enhanced	O
the	O
repression	O
activity	O
of	O
HDAC7	B-DNAMutation
in	O
NIH3T3	O
cells	O
,	O
but	O
not	O
in	O
HeLa	O
cells	O
.	O

Data	O
presented	O
in	O
this	O
work	O
clearly	O
show	O
that	O
the	O
signal	O
dependent	O
subcellular	O
localization	O
of	O
HDAC7	B-DNAMutation
is	O
essential	O
in	O
controlling	O
its	O
activities	O
.	O

The	O
data	O
also	O
show	O
that	O
the	O
cellular	O
concentration	O
of	O
factors	O
such	O
as	O
14-3-3	O
,	O
CaMK	B-DNAMutation
I	I-DNAMutation
,	O
and	O
other	O
yet	O
unknown	O
molecules	O
may	O
determine	O
the	O
subcellular	O
localization	O
of	O
an	O
individual	O
HDAC	O
member	O
in	O
a	O
cell	O
type	O
and	O
HDAC-specific	O
manner	O
.	O

A	O
novel	O
D104G	B-DNAMutation
mutation	O
in	O
the	O
adenine	O
nucleotide	O
translocator	O
1	O
gene	O
in	O
autosomal	O
dominant	O
progressive	O
external	O
ophthalmoplegia	O
patients	O
with	O
mitochondrial	O
DNA	O
with	O
multiple	O
deletions	O
.	O

Autosomal	O
dominant	O
progressive	O
external	O
ophthalmoplegia	O
is	O
a	O
mitochondrial	O
disorder	O
characterized	O
by	O
multiple	O
large	O
deletions	O
of	O
mitochondrial	O
DNA	O
.	O

A	O
recent	O
study	O
showed	O
pathogenic	O
heterozygous	O
missense	O
mutations	O
in	O
the	O
heart/skeletal	O
muscle	O
isoform	O
of	O
the	O
adenine	O
nucleotide	O
translocator	O
1	O
gene	O
in	O
autosomal	O
dominant	O
progressive	O
external	O
ophthalmoplegia	O
patients	O
.	O

In	O
one	O
Japanese	O
autosomal	O
dominant	O
progressive	O
external	O
ophthalmoplegia	O
family	O
,	O
we	O
found	O
a	O
novel	O
A-to-G	B-DNAMutation
heterozygous	I-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
311	I-DNAMutation
of	O
the	O
adenine	O
nucleotide	O
translocator	O
1	O
gene	O
,	O
which	O
segregated	O
with	O
affected	O
individuals	O
and	O
could	O
not	O
be	O
detected	O
in	O
the	O
genomic	O
DNA	O
sequence	O
of	O
120	O
normal	O
controls	O
.	O

This	O
mutation	O
converted	O
a	O
highly	O
conserved	O
aspartic	B-DNAMutation
acid	I-DNAMutation
into	I-DNAMutation
a	I-DNAMutation
glycine	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
104	I-DNAMutation
.	O

Polymerase	O
chain	O
reaction	O
analysis	O
of	O
single	O
muscle	O
fibers	O
showed	O
the	O
presence	O
of	O
one	O
type	O
of	O
deletion	O
in	O
each	O
fiber	O
,	O
suggesting	O
clonal	O
expansion	O
of	O
mitochondrial	O
DNA	O
with	O
deletions	O
.	O

These	O
findings	O
support	O
the	O
pathogenesis	O
of	O
the	O
adenine	O
nucleotide	O
translocator	O
1	O
gene	O
mutation	O
in	O
human	O
disease	O
.	O

Leukotriene	B-DNAMutation
A4	I-DNAMutation
hydrolase	I-DNAMutation
:	O
determination	O
of	O
the	O
three	O
zinc-binding	O
ligands	O
by	O
site-directed	O
mutagenesis	O
and	O
zinc	O
analysis	O
.	O

Three	O
mutants	O
of	O
recombinant	O
mouse	O
leukotriene	O
A4	O
(LTA4)	O
hydrolase	O
(3.3.2.6)	O
were	O
produced	O
by	O
site-directed	O
mutagenesis	O
on	O
cDNA	O
.	O

The	O
codons	O
corresponding	O
to	O
His-295	B-DNAMutation
,	I-DNAMutation
His-299	I-DNAMutation
,	I-DNAMutation
or	I-DNAMutation
Glu-318	I-DNAMutation
were	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
codons	I-DNAMutation
encoding	I-DNAMutation
tyrosine	I-DNAMutation
,	I-DNAMutation
tyrosine	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
glutamine	I-DNAMutation
,	O
respectively	O
.	O

The	O
mutated	O
cDNAs	O
were	O
expressed	O
in	O
Escherichia	O
coli	O
,	O
and	O
the	O
three	O
mutated	O
proteins	O
were	O
purified	O
to	O
apparent	O
homogeneity	O
.	O

None	O
of	O
these	O
mutants	O
contained	O
significant	O
amounts	O
of	O
zinc	O
,	O
as	O
determined	O
by	O
atomic	O
absorption	O
spectrometry	O
,	O
and	O
all	O
of	O
them	O
were	O
practically	O
devoid	O
of	O
both	O
LTA4	O
hydrolase	O
and	O
peptidase	O
enzyme	O
activities	O
.	O

Nevertheless	O
,	O
the	O
mutated	O
proteins	O
could	O
be	O
positively	O
identified	O
by	O
their	O
immunoreactivities	O
with	O
an	O
antiserum	O
for	O
human	O
LTA4	O
hydrolase	O
in	O
immunoblot	O
analysis	O
.	O

Site-directed	O
mutagenesis	O
was	O
also	O
carried	O
out	O
on	O
human	O
LTA4	O
hydrolase	O
cDNA	O
.	O

Codons	B-DNAMutation
encoding	I-DNAMutation
His-295	I-DNAMutation
,	I-DNAMutation
His-299	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Glu-318	I-DNAMutation
were	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
ones	I-DNAMutation
encoding	I-DNAMutation
tyrosine	I-DNAMutation
,	I-DNAMutation
leucine	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
alanine	I-DNAMutation
,	O
respectively	O
,	O
and	O
the	O
three	O
mutants	O
were	O
expressed	O
in	O
E	O
.	O

coli	O
.	O

The	O
LTA4	O
hydrolase	O
activities	O
of	O
the	O
total	O
soluble	O
proteins	O
produced	O
in	O
these	O
expressions	O
were	O
less	O
than	O
10%	O
of	O
that	O
obtained	O
for	O
bacteria	O
harboring	O
nonmutated	O
cDNA	O
.	O

In	O
agreement	O
with	O
earlier	O
predictions	O
,	O
our	O
experimental	O
data	O
demonstrate	O
that	O
His-295	O
,	O
His-299	O
,	O
and	O
Glu-318	O
constitute	O
the	O
three	O
ligands	O
of	O
the	O
intrinsic	O
zinc	O
atom	O
in	O
LTA4	O
hydrolase	O
.	O

Additionally	O
,	O
the	O
combined	O
loss	O
of	O
enzyme	O
activities	O
and	O
zinc	O
content	O
in	O
the	O
purified	O
mutated	O
mouse	O
proteins	O
,	O
emphasizes	O
the	O
critical	O
role	O
of	O
the	O
zinc	O
atom	O
for	O
catalysis	O
,	O
whereas	O
the	O
virtually	O
identical	O
chromatographic	O
behaviors	O
of	O
the	O
mutated	O
and	O
nonmutated	O
mouse	O
LTA4	O
hydrolase	O
proteins	O
suggest	O
that	O
the	O
metal	O
is	O
of	O
limited	O
importance	O
for	O
the	O
maintenance	O
of	O
the	O
enzyme	O
tertiary	O
structure	O
.	O

Two	O
naturally	O
occurring	O
amino	O
acid	O
substitutions	O
in	O
the	O
human	O
5-HT1A	B-DNAMutation
receptor	I-DNAMutation
:	O
glycine	B-DNAMutation
22	I-DNAMutation
to	I-DNAMutation
serine	I-DNAMutation
22	I-DNAMutation
and	O
isoleucine	B-DNAMutation
28	I-DNAMutation
to	I-DNAMutation
valine	I-DNAMutation
28	I-DNAMutation
.	O

The	O
human	O
5-HT1A	B-DNAMutation
receptor	I-DNAMutation
was	O
screened	O
for	O
naturally	O
occurring	O
mutations	O
.	O

The	O
PCR	O
product	O
of	O
the	O
5-HT1A	B-DNAMutation
receptor	I-DNAMutation
gene	O
was	O
digested	O
with	O
several	O
restriction	O
enzymes	O
and	O
evaluated	O
by	O
single-strand	O
conformational	O
polymorphism	O
(SSCP)	O
analysis	O
.	O

Comparison	O
of	O
the	O
SSCP	O
electrophoretic	O
pattern	O
with	O
a	O
restriction	O
map	O
of	O
the	O
5-HT1A	B-DNAMutation
receptor	I-DNAMutation
allowed	O
localization	O
of	O
the	O
polymorphic	O
sites	O
facilitating	O
their	O
identification	O
by	O
sequence	O
analysis	O
.	O

Two	O
polymorphisms	O
were	O
identified	O
in	O
the	O
human	O
5-HT1A	B-DNAMutation
receptor	I-DNAMutation
gene	O
that	O
altered	O
amino	O
acid	O
composition	O
.	O

The	O
polymorphisms	O
encode	O
amino	O
acid	O
substitutions	O
in	O
the	O
5-HT1A	B-DNAMutation
receptor	I-DNAMutation
of	O
a	O
glycine	B-DNAMutation
to	I-DNAMutation
serine	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
22	I-DNAMutation
and	O
an	B-DNAMutation
isoleucine	I-DNAMutation
to	I-DNAMutation
valine	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
28	I-DNAMutation
,	O
respectively	O
.	O

Both	O
polymorphisms	O
alter	O
the	O
extracellular	O
amino	O
terminal	O
domain	O
of	O
the	O
5-HT1A	B-DNAMutation
receptor	I-DNAMutation
.	O

The	O
polymorphic	O
5-HT1A	O
alleles	O
have	O
been	O
found	O
in	O
American	O
and	O
Finnish	O
Caucasians	O
and	O
in	O
native	O
American	O
Indians	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
a	O
polymorphism	O
in	O
the	O
human	O
5-HT1A	B-DNAMutation
receptor	I-DNAMutation
gene	O
that	O
alters	O
the	O
structure	O
of	O
the	O
5-HT1A	B-DNAMutation
receptor	I-DNAMutation
protein	O
composition	O
.	O

Amelogenin	O
signal	O
peptide	O
mutation	O
:	O
correlation	O
between	O
mutations	O
in	O
the	O
amelogenin	B-DNAMutation
gene	I-DNAMutation
AMGX	B-DNAMutation
and	O
manifestations	O
of	O
X-linked	O
amelogenesis	O
imperfecta	O
.	O

Formation	O
of	O
tooth	O
enamel	O
is	O
a	O
poorly	O
understood	O
biological	O
process	O
.	O

In	O
this	O
study	O
we	O
describe	O
a	O
9-bp	B-DNAMutation
deletion	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
2	I-DNAMutation
of	O
the	O
amelogenin	B-DNAMutation
gene	I-DNAMutation
AMGX	B-DNAMutation
causing	O
X-linked	O
hypoplastic	O
amelogenesis	O
imperfecta	O
,	O
a	O
disease	O
characterized	O
by	O
defective	O
enamel	O
.	O

The	O
mutation	B-DNAMutation
results	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
loss	I-DNAMutation
of	I-DNAMutation
3	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
and	O
exchange	B-DNAMutation
of	I-DNAMutation
1	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
signal	I-DNAMutation
peptide	I-DNAMutation
of	O
the	O
amelogenin	B-DNAMutation
protein	I-DNAMutation
.	O

This	O
deletion	O
in	O
the	O
signal	O
peptide	O
probably	O
interferes	O
with	O
translocation	O
of	O
the	O
amelogenin	B-DNAMutation
protein	I-DNAMutation
during	O
synthesis	O
,	O
resulting	O
in	O
the	O
thin	O
enamel	O
observed	O
in	O
affected	O
members	O
of	O
the	O
family	O
.	O

We	O
compare	O
this	O
mutation	O
to	O
a	O
previously	O
reported	O
mutation	O
in	O
the	O
amelogenin	B-DNAMutation
gene	I-DNAMutation
that	O
causes	O
a	O
different	O
disease	O
phenotype	O
.	O

The	O
study	O
illustrates	O
that	O
molecular	O
analysis	O
can	O
help	O
explain	O
the	O
various	O
manifestations	O
of	O
a	O
tooth	O
disorder	O
and	O
thereby	O
provide	O
insights	O
into	O
the	O
mechanisms	O
of	O
tooth	O
enamel	O
formation	O
.	O

Phosphorylation-dependent	O
regulation	O
of	O
the	O
interaction	O
of	O
amyloid	O
precursor	O
protein	O
with	O
Fe65	O
affects	O
the	O
production	O
of	O
beta-amyloid	O
.	O

Neuronal	O
Fe65	O
is	O
an	O
adapter	O
protein	O
that	O
interacts	O
with	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
beta-amyloid	B-DNAMutation
precursor	I-DNAMutation
protein	I-DNAMutation
(APP)	O
.	O

Although	O
the	O
interaction	O
has	O
been	O
reported	O
to	O
occur	O
between	O
the	O
second	O
phosphotyrosine	O
interaction	O
domain	O
of	O
Fe65	O
and	O
the	O
YENPTY	O
motif	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
APP	O
,	O
the	O
regulatory	O
mechanism	O
and	O
biological	O
function	O
of	O
this	O
interaction	O
remain	O
unknown	O
.	O

We	O
report	O
here	O
that	O
(i)	O
a	O
single	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
Thr-668	I-DNAMutation
residue	I-DNAMutation
of	I-DNAMutation
APP695	I-DNAMutation
,	I-DNAMutation
located	I-DNAMutation
14	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
toward	I-DNAMutation
the	I-DNAMutation
amino-terminal	I-DNAMutation
end	I-DNAMutation
from	I-DNAMutation
the	I-DNAMutation
(682)YENPTY(687)	I-DNAMutation
motif	I-DNAMutation
,	O
reduced	O
the	O
interaction	O
between	O
members	O
of	O
the	O
Fe65	O
family	O
of	O
proteins	O
and	O
APP	O
,	O
whereas	O
interaction	O
of	O
APP	O
with	O
the	O
phosphotyrosine	O
interaction	O
domain	O
of	O
other	O
APP	O
binders	O
such	O
as	O
X11-like	O
and	O
mammalian	O
disabled-1	O
was	O
not	O
influenced	O
by	O
this	O
mutation	O
;	O
(ii)	O
the	O
phosphorylation	O
of	O
APP	O
at	O
Thr-668	O
diminished	O
the	O
interaction	O
of	O
APP	O
with	O
Fe65	O
by	O
causing	O
a	O
conformational	O
change	O
in	O
the	O
cytoplasmic	O
domain	O
that	O
contains	O
the	O
Fe65-binding	O
motif	O
,	O
YENPTY	O
;	O
and	O
(iii)	O
the	O
expression	O
of	O
Fe65	O
slightly	O
suppressed	O
maturation	O
of	O
APP	O
and	O
decreased	O
production	O
of	O
beta-amyloid	O
Abeta	B-DNAMutation
.	O

Mutation	B-DNAMutation
at	I-DNAMutation
Thr-668	I-DNAMutation
of	O
APP	O
abolished	O
the	O
effect	O
of	O
Fe65	O
on	O
APP	O
maturation	O
.	O

This	O
mutation	O
blocked	O
the	O
Fe65-dependent	O
suppression	O
of	O
Abeta	B-DNAMutation
production	O
and	O
resulted	O
in	O
the	O
release	O
of	O
increased	O
levels	O
of	O
Abeta	B-DNAMutation
in	O
the	O
presence	O
of	O
Fe65	O
.	O

We	O
previously	O
reported	O
that	O
during	O
maturation	O
of	O
APP	O
in	O
neurons	O
,	O
the	O
protein	O
is	O
specifically	O
phosphorylated	O
at	O
Thr-668	O
and	O
undergoes	O
O-glycosylation	O
.	O

The	O
present	O
results	O
suggest	O
that	O
the	O
phosphorylation	O
of	O
O-glycosylated	O
mature	O
APP	O
at	O
Thr-668	O
causes	O
a	O
conformational	O
change	O
in	O
its	O
cytoplasmic	O
domain	O
that	O
prevents	O
binding	O
of	O
Fe65	O
in	O
neurons	O
and	O
may	O
lead	O
to	O
an	O
alteration	O
in	O
the	O
production	O
of	O
Abeta	B-DNAMutation
.	O

The	I-DNAMutation
multiple	I-DNAMutation
cases	I-DNAMutation
of	I-DNAMutation
Fabry	O
disease	O
in	O
a	O
Russian	O
family	O
caused	O
by	O
an	O
E341K	B-DNAMutation
amino	O
acid	O
substitution	O
in	O
the	O
alpha-galactosidase	O
A	O
.	O

A	O
large	O
Russian	O
family	O
with	O
multiple	O
cases	O
of	O
Fabry	O
disease	O
in	O
several	O
generations	O
is	O
presented	O
.	O

Fourteen	O
family	O
members	O
were	O
clinico-biochemically	O
examined	O
.	O

Among	O
12	O
adult	O
children	O
(	O
19-32	O
years	O
old	O
)	O
of	O
one	O
couple	O
,	O
five	O
sons	O
manifested	O
angiokeratotic	O
skin	O
lesions	O
and	O
other	O
Fabry	O
symptoms	O
.	O

Biochemical	O
studies	O
including	O
an	O
enzyme	O
assay	O
,	O
the	O
analysis	O
of	O
glycosphingolipid	O
excretion	O
and	O
isoelectric	O
focusing	O
of	O
a	O
patient	O
leukocyte	O
extract	O
allowed	O
us	O
to	O
identify	O
Fabry	O
disease	O
in	O
four	O
affected	O
brothers	O
and	O
to	O
establish	O
the	O
heterozygous	O
status	O
of	O
their	O
mother	O
.	O

The	O
analysis	O
of	O
genomic	O
DNA	O
of	O
four	O
patients	O
and	O
their	O
mother	O
revealed	O
a	O
novel	O
E341K	B-DNAMutation
missense	O
mutation	O
caused	O
by	O
a	O
G	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
transition	I-DNAMutation
(	I-DNAMutation
codon	I-DNAMutation
341	I-DNAMutation
GAA-AAA	I-DNAMutation
)	O
in	O
the	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
.	O

Mouse	O
glutaredoxin	B-DNAMutation
-	O
cDNA	O
cloning	O
,	O
high	O
level	O
expression	O
in	O
E	O
.	O

coli	O
and	O
its	O
possible	O
implication	O
in	O
redox	O
regulation	O
of	O
the	O
DNA	O
binding	O
activity	O
in	O
transcription	O
factor	O
PEBP2	O
.	O

We	O
have	O
isolated	O
a	O
cDNA	O
encoding	O
glutaredoxin	B-DNAMutation
(GRX)	O
from	O
a	O
mouse	O
splenic	O
cDNA	O
library	O
.	O

This	O
cDNA	O
encoded	O
a	O
protein	O
of	O
107	O
amino	O
acids	O
with	O
a	O
calculated	O
molecular	O
weight	O
of	O
11.9	O
kDa	O
.	O

The	O
deduced	O
amino	O
acid	O
sequence	O
of	O
glutaredoxin	B-DNAMutation
in	O
mouse	O
was	O
highly	O
homologous	O
with	O
that	O
in	O
other	O
mammals	O
(81-89%)	O
,	O
containing	O
a	O
putative	O
active	O
sequence	O
of	O
-Cys-Pro-Try-Cys-	O
.	O

Recombinant	O
mouse	O
glutaredoxin	B-DNAMutation
expressed	O
in	O
E	O
.	O

coli	O
showed	O
glutathione-disulfide	O
oxidoreductase	O
activity	O
with	O
beta-hydroxyethyl	O
disulfide	O
as	O
its	O
substrate	O
,	O
whereas	O
mutant	O
glutaredoxin	O
(	O
Cys	B-DNAMutation
22	I-DNAMutation
,	I-DNAMutation
Cys	I-DNAMutation
25	I-DNAMutation
to	I-DNAMutation
Ser	I-DNAMutation
)	O
showed	O
no	O
activity	O
.	O

In	O
electrophoretic	O
mobility	O
shift	O
assay	O
,	O
we	O
proved	O
that	O
wild	O
type	O
GRX	O
,	O
not	O
mutant	O
one	O
,	O
recovered	O
the	O
DNA-binding	O
activity	O
of	O
a	O
transcription	O
factor	O
,	O
PEBP2	B-DNAMutation
,	O
oxidized	O
by	O
diamide	O
.	O

This	O
showed	O
that	O
GRX	O
may	O
be	O
involved	O
in	O
the	O
redox	O
regulation	O
of	O
the	O
DNA-binding	O
activity	O
of	O
PEBP2	B-DNAMutation
as	O
is	O
the	O
case	O
with	O
thioredoxin	B-DNAMutation
.	O

Arl13b-regulated	B-DNAMutation
cilia	O
activities	O
are	O
essential	O
for	O
polarized	O
radial	O
glial	O
scaffold	O
formation	O
.	O

The	O
construction	O
of	O
cerebral	O
cortex	O
begins	O
with	O
the	O
formation	O
of	O
radial	O
glia	O
.	O

Once	O
formed	O
,	O
polarized	O
radial	O
glial	O
cells	O
divide	O
either	O
symmetrically	O
or	O
asymmetrically	O
to	O
balance	O
appropriate	O
production	O
of	O
progenitor	O
cells	O
and	O
neurons	O
.	O

Following	O
birth	O
,	O
neurons	O
use	O
the	O
processes	O
of	O
radial	O
glia	O
as	O
scaffolding	O
for	O
oriented	O
migration	O
.	O

Radial	O
glia	O
therefore	O
provide	O
an	O
instructive	O
structural	O
matrix	O
to	O
coordinate	O
the	O
generation	O
and	O
placement	O
of	O
distinct	O
groups	O
of	O
cortical	O
neurons	O
in	O
the	O
developing	O
cerebral	O
cortex	O
.	O

We	O
found	O
that	O
Arl13b	B-DNAMutation
,	O
a	O
cilia-enriched	O
small	O
GTPase	O
that	O
is	O
mutated	O
in	O
Joubert	O
syndrome	O
,	O
was	O
critical	O
for	O
the	O
initial	O
formation	O
of	O
the	O
polarized	O
radial	O
progenitor	O
scaffold	O
.	O

Using	O
developmental	O
stage-specific	O
deletion	B-DNAMutation
of	I-DNAMutation
Arl13b	B-DNAMutation
in	O
mouse	O
cortical	O
progenitors	O
,	O
we	O
found	O
that	O
early	O
neuroepithelial	O
deletion	B-DNAMutation
of	I-DNAMutation
ciliary	O
Arl13b	B-DNAMutation
led	O
to	O
a	O
reversal	O
of	O
the	O
apical-basal	O
polarity	O
of	O
radial	O
progenitors	O
and	O
aberrant	O
neuronal	O
placement	O
.	O

Arl13b	B-DNAMutation
modulated	O
ciliary	O
signaling	O
necessary	O
for	O
radial	O
glial	O
polarity	O
.	O

Our	O
findings	O
indicate	O
that	O
Arl13b	B-DNAMutation
signaling	O
in	O
primary	O
cilia	O
is	O
crucial	O
for	O
the	O
initial	O
formation	O
of	O
a	O
polarized	O
radial	O
glial	O
scaffold	O
and	O
suggest	O
that	O
disruption	O
of	O
this	O
process	O
may	O
contribute	O
to	O
aberrant	O
neurodevelopment	O
and	O
brain	O
abnormalities	O
in	O
Joubert	O
syndrome-related	O
ciliopathies	O
.	O

ASXL1	B-DNAMutation
represses	O
retinoic	O
acid	O
receptor-mediated	O
transcription	O
through	O
associating	O
with	O
HP1	O
and	O
LSD1	B-DNAMutation
.	O

We	O
previously	O
suggested	O
that	O
ASXL1	B-DNAMutation
(	O
additional	B-DNAMutation
sex	I-DNAMutation
comb-like	I-DNAMutation
1	I-DNAMutation
)	O
functions	O
as	O
either	O
a	O
coactivator	O
or	O
corepressor	O
for	O
the	O
retinoid	O
receptors	O
retinoic	O
acid	O
receptor	O
(RAR)	O
and	O
retinoid	O
X	B-DNAMutation
receptor	I-DNAMutation
in	O
a	O
cell	O
type-specific	O
manner	O
.	O

Here	O
,	O
we	O
provide	O
clues	O
toward	O
the	O
mechanism	O
underlying	O
ASXL1-mediated	B-DNAMutation
repression	O
.	O

Transfection	O
assays	O
in	O
HEK293	O
or	O
H1299	O
cells	O
indicated	O
that	O
ASXL1	B-DNAMutation
alone	O
possessing	O
autonomous	O
transcriptional	O
repression	O
activity	O
significantly	O
represses	O
RAR-	O
or	O
retinoid	O
X	B-DNAMutation
receptor-dependent	I-DNAMutation
transcriptional	O
activation	O
,	O
and	O
the	O
N-terminal	O
portion	O
of	O
ASXL1	B-DNAMutation
is	O
responsible	O
for	O
the	O
repression	O
.	O

Amino	O
acid	O
sequence	O
analysis	O
identified	O
a	O
consensus	O
HP1	O
(	O
heterochromatin	O
protein	O
1)-binding	O
site	O
(	O
HP1	O
box	O
,	O
PXVXL	O
)	O
in	O
that	O
region	O
.	O

Systematic	O
in	O
vitro	O
and	O
in	O
vivo	O
assays	O
revealed	O
that	O
the	O
HP1	O
box	O
in	O
ASXL1	B-DNAMutation
is	O
critical	O
for	O
the	O
interaction	O
with	O
the	O
chromoshadow	O
domain	O
of	O
HP1	O
.	O

Transcription	O
assays	O
with	O
HP1	B-DNAMutation
box	I-DNAMutation
deletion	I-DNAMutation
or	O
HP1alpha	B-DNAMutation
knockdown	B-DNAMutation
indicated	O
that	O
HP1alpha	B-DNAMutation
is	O
required	O
for	O
ASXL1-mediated	B-DNAMutation
repression	O
.	O

Furthermore	O
,	O
we	O
found	O
a	O
direct	O
interaction	O
of	O
ASXL1	B-DNAMutation
with	O
histone	O
H3	O
demethylase	O
LSD1	B-DNAMutation
through	O
the	O
N-terminal	O
region	O
nearby	O
the	O
HP1-binding	O
site	O
.	O

ASXL1	B-DNAMutation
binding	O
to	O
LSD1	B-DNAMutation
was	O
greatly	O
increased	O
by	O
HP1alpha	B-DNAMutation
,	O
resulting	O
in	O
the	O
formation	O
of	O
a	O
ternary	O
complex	O
.	O

LSD1	B-DNAMutation
cooperates	O
with	O
ASXL1	B-DNAMutation
in	O
transcriptional	O
repression	O
,	O
presumably	O
by	O
removing	O
H3K4	O
methylation	O
,	O
an	O
active	O
histone	O
mark	O
,	O
but	O
not	O
H3K9	O
methylation	O
,	O
a	O
repressive	O
histone	O
mark	O
recognized	O
by	O
HP1	O
.	O

This	O
possibility	O
was	O
supported	O
by	O
chromatin	O
immunoprecipitation	O
assays	O
followed	O
by	O
ASXL1	B-DNAMutation
overexpression	O
or	O
knockdown	B-DNAMutation
.	O

Overall	O
,	O
this	O
study	O
provides	O
the	O
first	O
evidence	O
that	O
ASXL1	B-DNAMutation
cooperates	O
with	O
HP1	O
to	O
modulate	O
LSD1	B-DNAMutation
activity	O
,	O
leading	O
to	O
a	O
change	O
in	O
histone	O
H3	O
methylation	O
and	O
thereby	O
RAR	O
repression	O
.	O

Characterization	O
of	O
a	O
novel	O
variant	O
S145C/L311V	B-DNAMutation
of	O
3alpha-hydroxysteroid/dihydrodiol	O
dehydrogenase	O
in	O
human	O
liver	O
.	O

Human	O
liver	O
3alpha-hydroxysteroid/dihydrodiol	O
dehydrogenase	O
(DD)	O
is	O
involved	O
in	O
the	O
metabolism	O
of	O
steroid	O
hormones	O
and	O
polycyclic	O
aromatic	O
hydrocarbons	O
,	O
and	O
is	O
also	O
responsible	O
for	O
the	O
reduction	O
of	O
ketone-containing	O
drugs	O
.	O

To	O
account	O
for	O
the	O
interindividual	O
difference	O
in	O
the	O
activity	O
,	O
we	O
isolated	O
and	O
characterized	O
clones	O
for	O
the	O
human	O
liver	O
enzymes	O
.	O

The	O
sequence	O
of	O
the	O
cDNA	O
clone	O
coding	O
for	O
the	O
variant	O
differed	O
from	O
that	O
coding	O
for	O
the	O
wild-type	O
DD	O
by	O
two	O
nucleotides	O
(	O
substitutions	B-DNAMutation
of	I-DNAMutation
C	I-DNAMutation
with	I-DNAMutation
G	I-DNAMutation
at	I-DNAMutation
positions	I-DNAMutation
434	I-DNAMutation
and	I-DNAMutation
931	I-DNAMutation
)	O
which	O
caused	O
two	O
amino	O
acid	O
replacements	O
,	O
Ser145	B-DNAMutation
to	I-DNAMutation
Cys	I-DNAMutation
(S145C)	I-DNAMutation
and	O
Leu311	B-DNAMutation
to	I-DNAMutation
Val	I-DNAMutation
L311V	B-DNAMutation
.	O

The	O
heterologous	O
expression	O
of	O
the	O
variant	O
mRNA	O
was	O
confirmed	O
in	O
four	O
of	O
31	O
liver	O
samples	O
from	O
Japanese	O
by	O
an	O
allele-specific	O
polymerase	O
chain	O
reaction	O
.	O

The	O
effects	O
of	O
the	O
mutations	O
on	O
the	O
catalytic	O
properties	O
were	O
examined	O
with	O
the	O
recombinant	O
enzymes	O
expressed	O
in	O
Escherichia	O
coli	O
.	O

The	O
introduction	O
of	O
S145C/L311V	B-DNAMutation
double	O
mutations	O
resulted	O
in	O
three-	O
to	O
five-fold	O
decreased	O
activities	O
for	O
xenobiotic	O
and	O
steroidal	O
substrates	O
,	O
whereas	O
no	O
significant	O
change	O
was	O
observed	O
by	O
an	O
introduction	O
of	O
the	O
S145C	B-DNAMutation
mutation	O
alone	O
.	O

The	O
results	O
substantiate	O
the	O
existence	O
of	O
polymorphic	O
forms	O
for	O
human	O
liver	O
DD	O
,	O
and	O
also	O
suggest	O
the	O
importance	O
of	O
the	O
residue	O
at	O
position	O
311	O
for	O
substrate	O
binding	O
to	O
the	O
enzyme	O
.	O

Hsp90	O
and	O
a	O
tyrosine	O
embedded	O
in	O
the	O
Hsp90	O
recognition	O
loop	O
are	O
required	O
for	O
the	O
Fer	O
tyrosine	O
kinase	O
activity	O
.	O

Hsp90	O
is	O
a	O
key	O
regulator	O
of	O
tyrosine	O
kinases	O
activity	O
and	O
is	O
therefore	O
considered	O
as	O
a	O
promising	O
target	O
for	O
intervention	O
with	O
deregulated	O
signaling	O
pathways	O
in	O
malignant	O
cells	O
.	O

Here	O
we	O
describe	O
a	O
novel	O
Hsp90	O
client	O
-	O
the	O
intracellular	O
tyrosine	O
kinase	O
,	O
Fer	O
,	O
which	O
is	O
subjected	O
to	O
a	O
unique	O
regulatory	O
regime	O
by	O
this	O
chaperone	O
.	O

Inhibition	O
of	O
Hsp90	O
activity	O
led	O
to	O
proteasomal	O
degradation	O
of	O
the	O
Fer	O
enzyme	O
.	O

However	O
,	O
circumventing	O
the	O
dependence	O
of	O
Fer	O
accumulation	O
on	O
Hsp90	O
,	O
revealed	O
the	O
dependence	O
of	O
the	O
Fer	O
kinase	O
activity	O
and	O
its	O
ability	O
to	O
phosphorylate	O
Stat3	B-DNAMutation
on	O
the	O
chaperone	O
,	O
expressing	O
the	O
necessity	O
of	O
Hsp90	O
for	O
its	O
function	O
.	O

Mutation	O
analysis	O
unveiled	O
a	O
tyrosine	O
(Tyr(616))	O
embedded	O
in	O
the	O
Hsp90	O
recognition	O
loop	O
,	O
which	O
is	O
required	O
for	O
the	O
kinase	O
activity	O
of	O
Fer	O
.	O

Replacement	B-DNAMutation
of	I-DNAMutation
this	I-DNAMutation
tyrosine	I-DNAMutation
by	I-DNAMutation
phenylalanine	I-DNAMutation
Y616F	B-DNAMutation
disabled	O
the	O
auto-phosphorylation	O
activity	O
of	O
Fer	O
and	O
abolished	O
its	O
ability	O
to	O
phosphorylate	O
Stat3	B-DNAMutation
.	O

Notably	O
,	O
surrounding	O
the	O
replaced	O
Y616F	B-DNAMutation
with	O
subtle	O
mutations	O
restored	O
the	O
auto	O
and	O
trans-phosphorylation	O
activities	O
of	O
Fer	O
suggesting	O
that	O
Y(616)	O
is	O
not	O
itself	O
an	O
essential	O
auto-phosphorylation	O
site	O
of	O
the	O
kinase	O
.	O

Taken	O
together	O
,	O
our	O
results	O
portray	O
Hsp90	O
and	O
its	O
recognition	O
loop	O
as	O
novel	O
positive	O
regulators	O
of	O
the	O
Fer	O
tyrosine	O
kinase	O
stability	O
and	O
activity	O
.	O

A	O
novel	O
gene	O
encoding	O
an	O
integral	O
membrane	O
protein	O
is	O
mutated	O
in	O
nephropathic	O
cystinosis	O
.	O

Nephropathic	O
cystinosis	O
,	O
an	O
autosomal	O
recessive	O
disorder	O
resulting	O
from	O
defective	O
lysosomal	O
transport	O
of	O
cystine	O
,	O
is	O
the	O
most	O
common	O
inherited	O
cause	O
of	O
renal	O
Fanconi	O
syndrome	O
.	O

The	O
cystinosis	O
gene	O
has	O
been	O
mapped	O
to	O
chromosome	O
17p13	O
.	O

We	O
found	O
that	O
the	O
locus	O
D17S829	B-DNAMutation
was	O
homozygously	O
deleted	O
in	O
23	O
out	O
of	O
70	O
patients	O
,	O
and	O
identified	O
a	O
novel	O
gene	O
,	O
CTNS	B-DNAMutation
,	O
which	O
mapped	O
to	O
the	O
deletion	O
interval	O
.	O

CTNS	B-DNAMutation
encodes	O
an	O
integral	O
membrane	O
protein	O
,	O
cystinosin	B-DNAMutation
,	O
with	O
features	O
of	O
a	O
lysosomal	O
membrane	O
protein	O
.	O

Eleven	O
different	O
mutations	O
,	O
all	O
predicted	O
to	O
cause	O
loss	O
of	O
function	O
of	O
the	O
protein	O
,	O
were	O
found	O
to	O
segregate	O
with	O
the	O
disorder	O
.	O

Comparison	O
of	O
crystal	O
structures	O
of	O
human	O
type	O
3	O
3alpha-hydroxysteroid	O
dehydrogenase	O
reveals	O
an	O
"induced-fit"	O
mechanism	O
and	O
a	O
conserved	O
basic	O
motif	O
involved	O
in	O
the	O
binding	O
of	O
androgen	O
.	O

The	O
aldo-keto	O
reductase	O
(AKR)	O
human	O
type	O
3	O
3alpha-hydroxysteroid	O
dehydrogenase	O
(	O
h3alpha-HSD3	O
,	O
AKR1C2	B-DNAMutation
)	O
plays	O
a	O
crucial	O
role	O
in	O
the	O
regulation	O
of	O
the	O
intracellular	O
concentrations	O
of	O
testosterone	O
and	O
5alpha-dihydrotestosterone	O
(5alpha-DHT)	O
,	O
two	O
steroids	O
directly	O
linked	O
to	O
the	O
etiology	O
and	O
the	O
progression	O
of	O
many	O
prostate	O
diseases	O
and	O
cancer	O
.	O

This	O
enzyme	O
also	O
binds	O
many	O
structurally	O
different	O
molecules	O
such	O
as	O
4-hydroxynonenal	O
,	O
polycyclic	O
aromatic	O
hydrocarbons	O
,	O
and	O
indanone	O
.	O

To	O
understand	O
the	O
mechanism	O
underlying	O
the	O
plasticity	O
of	O
its	O
substrate-binding	O
site	O
,	O
we	O
solved	O
the	O
binary	O
complex	O
structure	O
of	O
h3alpha-HSD3-NADP(H)	O
at	O
1.9	O
A	O
resolution	O
.	O

During	O
the	O
refinement	O
process	O
,	O
we	O
found	O
acetate	O
and	O
citrate	O
molecules	O
deeply	O
engulfed	O
in	O
the	O
steroid-binding	O
cavity	O
.	O

Superimposition	O
of	O
this	O
structure	O
with	O
the	O
h3alpha-HSD3-NADP(H)-testosterone/acetate	O
ternary	O
complex	O
structure	O
reveals	O
that	O
one	O
of	O
the	O
mobile	O
loops	O
forming	O
the	O
binding	O
cavity	O
operates	O
a	O
slight	O
contraction	O
movement	O
against	O
the	O
citrate	O
molecule	O
while	O
the	O
side	O
chains	O
of	O
many	O
residues	O
undergo	O
numerous	O
conformational	O
changes	O
,	O
probably	O
to	O
create	O
an	O
optimal	O
binding	O
site	O
for	O
the	O
citrate	O
.	O

These	O
structural	O
changes	O
,	O
which	O
altogether	O
cause	O
a	O
reduction	O
of	O
the	O
substrate-binding	O
cavity	O
volume	O
(	O
from	O
776	O
A(3)	O
in	O
the	O
presence	O
of	O
testosterone/acetate	O
to	O
704	O
A(3)	O
in	O
the	O
acetate/citrate	O
complex	O
)	O
,	O
are	O
reminiscent	O
of	O
the	O
"induced-fit"	O
mechanism	O
previously	O
proposed	O
for	O
the	O
aldose	O
reductase	O
,	O
another	O
member	O
of	O
the	O
AKR	O
superfamily	O
.	O

We	O
also	O
found	O
that	O
the	O
replacement	B-DNAMutation
of	I-DNAMutation
residues	I-DNAMutation
Arg(301)	I-DNAMutation
and	I-DNAMutation
Arg(304)	I-DNAMutation
,	O
localized	O
near	O
the	O
steroid-binding	O
cavity	O
,	O
significantly	O
affects	O
the	O
3alpha-HSD	O
activity	O
of	O
this	O
enzyme	O
toward	O
5alpha-DHT	O
and	O
completely	O
abolishes	O
its	O
17beta-HSD	O
activity	O
on	O
4-dione	O
.	O

All	O
these	O
results	O
have	O
thus	O
been	O
used	O
to	O
reevaluate	O
the	O
binding	O
mode	O
of	O
this	O
enzyme	O
for	O
androgens	O
.	O

Acetylation	O
stabilizes	O
ATP-citrate	B-DNAMutation
lyase	I-DNAMutation
to	O
promote	O
lipid	O
biosynthesis	O
and	O
tumor	O
growth	O
.	O

Increased	O
fatty	O
acid	O
synthesis	O
is	O
required	O
to	O
meet	O
the	O
demand	O
for	O
membrane	O
expansion	O
of	O
rapidly	O
growing	O
cells	O
.	O

ATP-citrate	B-DNAMutation
lyase	I-DNAMutation
ACLY	B-DNAMutation
is	O
upregulated	O
or	O
activated	O
in	O
several	O
types	O
of	O
cancer	O
,	O
and	O
inhibition	O
of	O
ACLY	B-DNAMutation
arrests	O
proliferation	O
of	O
cancer	O
cells	O
.	O

Here	O
we	O
show	O
that	O
ACLY	B-DNAMutation
is	O
acetylated	O
at	O
lysine	O
residues	O
540	O
,	O
546	O
,	O
and	O
554	O
(3K)	O
.	O

Acetylation	O
at	O
these	O
three	O
lysine	O
residues	O
is	O
stimulated	O
by	O
P300/calcium-binding	O
protein	O
(CBP)-associated	O
factor	O
PCAF	B-DNAMutation
acetyltransferase	O
under	O
high	O
glucose	O
and	O
increases	O
ACLY	B-DNAMutation
stability	O
by	O
blocking	O
its	O
ubiquitylation	O
and	O
degradation	O
.	O

Conversely	O
,	O
the	O
protein	O
deacetylase	O
sirtuin	B-DNAMutation
2	I-DNAMutation
SIRT2	B-DNAMutation
deacetylates	O
and	O
destabilizes	O
ACLY	B-DNAMutation
.	O

Substitution	B-DNAMutation
of	I-DNAMutation
3K	I-DNAMutation
abolishes	O
ACLY	B-DNAMutation
ubiquitylation	O
and	O
promotes	O
de	O
novo	O
lipid	O
synthesis	O
,	O
cell	O
proliferation	O
,	O
and	O
tumor	O
growth	O
.	O

Importantly	O
,	O
3K	O
acetylation	O
of	O
ACLY	B-DNAMutation
is	O
increased	O
in	O
human	O
lung	O
cancers	O
.	O

Our	O
study	O
reveals	O
a	O
crosstalk	O
between	O
acetylation	O
and	O
ubiquitylation	O
by	O
competing	O
for	O
the	O
same	O
lysine	O
residues	O
in	O
the	O
regulation	O
of	O
fatty	O
acid	O
synthesis	O
and	O
cell	O
growth	O
in	O
response	O
to	O
glucose	O
.	O

The	O
neuroendocrine	O
precursor	O
7B2	B-DNAMutation
is	O
a	O
sulfated	O
protein	O
proteolytically	O
processed	O
by	O
a	O
ubiquitous	O
furin-like	B-DNAMutation
convertase	O
.	O

The	O
neuroendocrine	O
granule-associated	O
protein	O
7B2	B-DNAMutation
,	O
unlike	O
many	O
other	O
neuroendocrine	O
precursor	O
proteins	O
stored	O
in	O
secretory	O
granules	O
,	O
carries	O
in	O
its	O
primary	O
structure	O
the	O
Arg-Xaa-Arg/Lys-Arg	O
processing	O
site	O
usually	O
found	O
in	O
constitutively	O
secreted	O
precursor	O
proteins	O
and	O
recognized	O
by	O
the	O
ubiquitously	O
expressed	O
convertase	O
,	O
furin	B-DNAMutation
.	O

pro7B2	O
(	O
30	O
kDa	O
)	O
,	O
when	O
expressed	O
in	O
endocrine	O
(	O
AtT-20	O
,	O
PC12	O
,	O
and	O
GH4C1	O
)	O
or	O
non-endocrine	O
(Ltk-)	O
cell	O
lines	O
using	O
recombinant	O
vaccinia	O
viruses	O
,	O
was	O
converted	O
to	O
a	O
23-kDa	O
form	O
.	O

Mutation	O
of	O
the	O
P4	B-DNAMutation
Arg	I-DNAMutation
to	I-DNAMutation
Gly	I-DNAMutation
completely	O
prevented	O
this	O
conversion	O
.	O

When	O
excess	O
pro7B2	O
was	O
coexpressed	O
with	O
the	O
pro-protein	O
convertases	O
PC1	B-DNAMutation
,	O
PC2	B-DNAMutation
,	O
or	O
furin	B-DNAMutation
,	O
only	O
furin	B-DNAMutation
could	O
induce	O
complete	O
processing	O
.	O

In	O
addition	O
,	O
coexpression	O
of	O
pro7B2	O
in	O
LoVo	O
cells	O
,	O
which	O
are	O
devoid	O
of	O
endogenous	O
furin	B-DNAMutation
activity	O
,	O
with	O
each	O
one	O
of	O
the	O
three	O
convertases	O
,	O
showed	O
that	O
only	O
furin	B-DNAMutation
was	O
able	O
to	O
induce	O
processing	O
of	O
this	O
precursor	O
.	O

pro7B2	O
processing	O
in	O
AtT-20	O
was	O
completely	O
abolished	O
when	O
protein	O
transport	O
into	O
Golgi	O
compartments	O
was	O
blocked	O
by	O
cell	O
incubation	O
at	O
either	O
15	O
or	O
37	O
degrees	O
C	O
in	O
the	O
presence	O
of	O
monensin	O
or	O
brefeldin	O
A	O
.	O

Furthermore	O
,	O
pulse-chase	O
experiments	O
in	O
the	O
presence	O
of	O
Na2[35S]SO4	O
showed	O
that	O
pro7B2	O
is	O
Tyr-sulfated	O
in	O
the	O
trans-Golgi	O
network	O
before	O
it	O
is	O
processed	O
.	O

These	O
results	O
demonstrate	O
that	O
pro7B2	O
is	O
first	O
processed	O
by	O
a	O
furin-like	O
enzyme	O
within	O
the	O
trans-Golgi	O
network	O
into	O
a	O
23-kDa	O
form	O
that	O
is	O
then	O
sequestered	O
into	O
secretory	O
granules	O
.	O

Protein	O
kinase	O
C	O
phosphorylates	O
protein	O
kinase	O
D	O
activation	O
loop	O
Ser744	O
and	O
Ser748	O
and	O
releases	O
autoinhibition	O
by	O
the	O
pleckstrin	O
homology	O
domain	O
.	O

Persistent	O
activation	O
of	O
protein	O
kinase	O
D	O
PKD	B-DNAMutation
via	O
protein	O
kinase	O
C	O
(PKC)-mediated	B-DNAMutation
signal	O
transduction	O
is	O
accompanied	O
by	O
phosphorylation	O
at	O
Ser(744)	O
and	O
Ser(748)	O
located	O
in	O
the	O
catalytic	O
domain	O
activation	O
loop	O
,	O
but	O
whether	O
PKC	B-DNAMutation
isoforms	O
directly	O
phosphorylate	O
these	O
residues	O
,	O
induce	O
PKD	B-DNAMutation
autophosphorylation	O
,	O
or	O
recruit	O
intermediate	O
upstream	O
kinase(s)	O
is	O
unclear	O
.	O

Here	O
,	O
we	O
explore	O
the	O
mechanism	O
whereby	O
PKC	B-DNAMutation
activates	O
PKD	B-DNAMutation
in	O
response	O
to	O
cellular	O
stimuli	O
.	O

We	O
first	O
assessed	O
in	O
vitro	O
PKC-PKD	B-DNAMutation
transphosphorylation	O
and	O
PKD	B-DNAMutation
activation	O
.	O

A	O
PKD738-753	O
activation	O
loop	O
peptide	O
was	O
well	O
phosphorylated	O
by	O
immunoprecipitated	O
PKC	B-DNAMutation
isoforms	O
,	O
consistent	O
with	O
similarities	O
between	O
the	O
loop	O
and	O
their	O
known	O
substrate	O
specificities	O
.	O

A	O
similar	O
peptide	O
with	O
glutamic	B-DNAMutation
acid	I-DNAMutation
replacing	I-DNAMutation
Ser(748)	I-DNAMutation
was	O
preferentially	O
phosphorylated	O
by	O
PKCepsilon	B-DNAMutation
,	O
suggesting	O
that	O
PKD	B-DNAMutation
containing	O
phosphate	O
at	O
Ser(748)	O
is	O
rapidly	O
targeted	O
by	O
this	O
isoform	O
at	O
Ser(744)	O
.	O

When	O
incubated	O
in	O
the	O
presence	O
of	O
phosphatidylserine	O
,	O
phorbol	O
12,13-dibutyrate	O
and	O
ATP	O
,	O
intact	O
PKD	B-DNAMutation
slowly	O
autophosphorylated	O
in	O
the	O
activation	O
loop	O
but	O
only	O
at	O
Ser(748)	O
.	O

In	O
contrast	O
,	O
addition	O
of	O
purified	O
PKCepsilon	B-DNAMutation
to	O
the	O
incubation	O
mixture	O
induced	O
rapid	O
Ser(744)	O
and	O
Ser(748)	O
phosphorylation	O
,	O
concomitant	O
with	O
persistent	O
2-3-fold	O
increases	O
in	O
PKD	B-DNAMutation
activity	O
,	O
measured	O
using	O
reimmunoprecipitated	O
PKD	B-DNAMutation
to	O
phosphorylate	O
an	O
exogenous	O
peptide	O
,	O
syntide-2	O
.	O

We	O
also	O
further	O
examined	O
pleckstrin	O
homology	O
domain-mediated	O
PKD	B-DNAMutation
regulation	O
to	O
determine	O
its	O
relationship	O
with	O
activation	O
loop	O
phosphorylation	O
.	O

The	O
high	O
constitutive	O
activity	O
of	O
the	O
pleckstrin	O
homology	O
(PH)	O
domain	O
deletion	O
mutant	O
PKD-deltaPH	B-DNAMutation
was	O
not	O
abrogated	O
by	O
mutation	B-DNAMutation
of	I-DNAMutation
Ser(744)	I-DNAMutation
and	O
Ser(748)	B-DNAMutation
to	I-DNAMutation
alanines	I-DNAMutation
,	O
suggesting	O
that	O
one	O
function	O
of	O
activation	O
loop	O
phosphorylation	O
in	O
the	O
PKD	B-DNAMutation
activation	O
mechanism	O
is	O
to	O
relieve	O
autoinhibition	O
by	O
the	O
PH	O
domain	O
.	O

These	O
studies	O
provide	O
evidence	O
of	O
a	O
direct	O
PKCepsilon-PKD	B-DNAMutation
phosphorylation	O
cascade	O
and	O
provide	O
additional	O
insight	O
into	O
the	O
activation	O
mechanism	O
.	O

The	O
human	O
serotonin	B-DNAMutation
7	I-DNAMutation
5-HT7	B-DNAMutation
receptor	O
gene	O
:	O
genomic	O
organization	O
and	O
systematic	O
mutation	O
screening	O
in	O
schizophrenia	O
and	O
bipolar	O
affective	O
disorder	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
evaluated	O
the	O
possible	O
contribution	O
of	O
genetic	O
variation	O
of	O
the	O
serotonin	O
5-HT7	B-DNAMutation
receptor	O
to	O
the	O
development	O
of	O
schizophrenia	O
and	O
bipolar	O
affective	O
disorder	O
.	O

Cloning	O
and	O
characterization	O
of	O
exon-flanking	O
intronic	O
sequences	O
enabled	O
us	O
to	O
investigate	O
the	O
whole	O
coding	O
region	O
and	O
the	O
exon-intron	O
boundaries	O
of	O
the	O
human	O
5-HT7	B-DNAMutation
receptor	O
gene	O
.	O

Using	O
single-strand	O
conformational	O
analysis	O
,	O
we	O
screened	O
for	O
presence	O
of	O
DNA	O
sequence	O
variation	O
in	O
a	O
sample	O
of	O
137	O
unrelated	O
individuals	O
including	O
45	O
schizophrenic	O
and	O
46	O
bipolar	O
affective	O
patients	O
,	O
as	O
well	O
as	O
46	O
healthy	O
controls	O
.	O

We	O
detected	O
two	O
rare	O
naturally	O
occurring	O
receptor	O
variants	O
(	O
Pro-279-Leu	B-DNAMutation
,	O
Thr-92-Lys	B-DNAMutation
)	O
and	O
a	O
silent	O
nucleotide	O
substitution	O
A-->G	B-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
+1233	I-DNAMutation
.	O

The	O
occurrence	O
of	O
the	O
Pro-279-Leu	B-DNAMutation
and	O
Thr-92-Lys	B-DNAMutation
substitutions	O
was	O
studied	O
in	O
an	O
extended	O
sample	O
of	O
patients	O
(	O
n	O
=	O
462	O
)	O
and	O
controls	O
(	O
n	O
=	O
335	O
)	O
.	O

The	O
Leu-279	O
variant	O
was	O
found	O
in	O
similar	O
frequency	O
in	O
all	O
groups	O
,	O
indicating	O
that	O
presence	O
of	O
this	O
variant	O
is	O
not	O
causally	O
related	O
to	O
the	O
development	O
of	O
schizophrenia	O
or	O
bipolar	O
affective	O
disorder	O
.	O

The	O
Lys-92	O
variant	O
was	O
found	O
in	O
a	O
single	O
individual	O
who	O
suffered	O
from	O
bipolar	O
affective	O
disorder	O
.	O

Investigation	O
of	O
the	O
patient's	O
family	O
revealed	O
independent	O
segregation	O
between	O
the	O
Lys-92	O
variant	O
and	O
psychiatric	O
illness	O
.	O

Our	O
data	O
suggests	O
that	O
genetic	O
variation	O
of	O
the	O
5-HT7	B-DNAMutation
receptor	O
does	O
not	O
play	O
a	O
major	O
role	O
in	O
the	O
development	O
of	O
bipolar	O
affective	O
disorder	O
and	O
schizophrenia	O
.	O

Presenile	O
Alzheimer	O
dementia	O
characterized	O
by	O
amyloid	O
angiopathy	O
and	O
large	O
amyloid	O
core	O
type	O
senile	O
plaques	O
in	O
the	O
APP	O
692Ala-->Gly	B-DNAMutation
mutation	O
.	O

Mutations	B-DNAMutation
at	I-DNAMutation
codons	I-DNAMutation
717	I-DNAMutation
and	O
670/671	B-DNAMutation
in	O
the	O
amyloid	O
precursor	O
protein	O
(APP)	O
are	O
rare	O
genetic	O
causes	O
of	O
familial	O
Alzheimer's	O
disease	O
(AD)	O
.	O

A	O
mutation	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
693	I-DNAMutation
of	O
APP	O
has	O
also	O
been	O
described	O
as	O
the	O
genetic	O
defect	O
in	O
hereditary	O
cerebral	O
hemorrhage	O
with	O
amyloidosis	O
of	O
the	O
Dutch	O
type	O
(HCHWA-D)	O
.	O

We	O
have	O
reported	O
a	O
APP692Ala-->Gly	B-DNAMutation
(Flemish)	O
mutation	O
as	O
a	O
cause	O
of	O
intracerebral	O
hemorrhage	O
and	O
presenile	O
dementia	O
diagnosed	O
as	O
probable	O
AD	O
in	O
a	O
Dutch	O
family	O
.	O

We	O
now	O
describe	O
the	O
post-mortem	O
examination	O
of	O
two	O
demented	O
patients	O
with	O
the	O
APP692	O
mutation	O
.	O

The	O
neuropathological	O
findings	O
support	O
the	O
diagnosis	O
of	O
AD	O
.	O

Leptomeningial	O
and	O
parenchymal	O
vessels	O
showed	O
extensive	O
deposition	O
of	O
Abeta	B-DNAMutation
amyloid	O
protein	O
.	O

Numerous	O
senile	O
plaques	O
consisted	O
of	O
large	O
Abeta	B-DNAMutation
amyloid	O
cores	O
,	O
often	O
measuring	O
more	O
than	O
30	O
microm	O
in	O
diameter	O
and	O
were	O
surrounded	O
by	O
a	O
fine	O
meshwork	O
of	O
dystrophic	O
neurites	O
.	O

In	O
addition	O
,	O
there	O
were	O
a	O
large	O
number	O
of	O
paired	O
helical	O
filaments	O
in	O
pyramidal	O
neurons	O
and	O
dystrophic	O
neurites	O
.	O

Our	O
findings	O
show	O
that	O
the	O
APP692	O
mutation	O
leads	O
to	O
morphological	O
abnormalities	O
that	O
are	O
similar	O
to	O
AD	O
,	O
but	O
the	O
morphology	O
of	O
senile	O
plaques	O
is	O
clearly	O
distinct	O
from	O
that	O
described	O
in	O
sporadic	O
and	O
chromosome	O
14-linked	O
AD	O
patients	O
,	O
in	O
patients	O
with	O
APP717	O
mutations	O
causing	O
familial	O
,	O
presenile	O
AD	O
and	O
in	O
patients	O
with	O
the	O
APP693	O
mutation	O
causing	O
HCHWA-D	O
.	O

Molecular	O
basis	O
of	O
Japanese	O
variants	O
of	O
pyrimidine	O
5'-nucleotidase	O
deficiency	O
.	O

The	O
type-I	O
isoform	O
of	O
pyrimidine	O
5'-nucleotidase	O
P5N-I	B-DNAMutation
has	O
an	O
important	O
role	O
in	O
the	O
catabolism	O
of	O
pyrimidine	O
mononucleotides	O
during	O
erythroid	O
maturation	O
.	O

Two	O
alternatively	O
spliced	O
forms	O
of	O
P5N-I	B-DNAMutation
mRNA	O
have	O
been	O
identified	O
,	O
and	O
we	O
found	O
another	O
alternatively	O
spliced	O
form	O
in	O
reticulocytes	O
,	O
which	O
included	O
an	O
additional	O
87-bp	O
sequence	O
.	O

The	O
sequence	O
is	O
located	O
6.2-kb	O
downstream	O
of	O
the	O
exon	O
2	O
and	O
2.7-kb	O
upstream	O
of	O
the	O
exon	O
3	O
sequence	O
;	O
consequently	O
,	O
the	O
P5N-I	B-DNAMutation
gene	O
encodes	O
11	O
exons	O
,	O
which	O
span	O
approximately	O
48	O
kb	O
.	O

We	O
identified	O
five	O
novel	O
mutations	O
in	O
nine	O
families	O
with	O
P5N-I	B-DNAMutation
deficiency	O
:	O
two	B-DNAMutation
missense	I-DNAMutation
mutations	I-DNAMutation
(	I-DNAMutation
425C	I-DNAMutation
,	I-DNAMutation
721C	I-DNAMutation
)	I-DNAMutation
,	O
one	B-DNAMutation
splice	I-DNAMutation
mutation	I-DNAMutation
(339C)	I-DNAMutation
,	O
one	B-DNAMutation
1-bp	I-DNAMutation
insertion	I-DNAMutation
(251-insA-252)	I-DNAMutation
and	O
one	O
9-bp	B-DNAMutation
deletion	I-DNAMutation
(	I-DNAMutation
del	I-DNAMutation
192-200	I-DNAMutation
)	O
.	O

All	O
patients	O
were	O
homozygous	O
for	O
each	O
mutation	O
.	O

The	O
mutant	O
P5N-I	B-DNAMutation
with	O
721C	O
G241R	B-DNAMutation
had	O
lower	O
affinity	O
for	O
cytidine	O
monophosphate	O
,	O
suggesting	O
that	O
Gly241	O
is	O
important	O
for	O
substrate	O
binding	O
.	O

Haplotype	O
analysis	O
showed	O
that	O
721C	O
,	O
which	O
had	O
been	O
identified	O
in	O
five	O
unrelated	O
families	O
,	O
was	O
a	O
founder	O
mutation	O
.	O

The	O
mutant	O
P5N	B-DNAMutation
was	O
then	O
expressed	O
in	O
Cos-7	O
.	O

The	O
degradation	O
of	O
P5N	B-DNAMutation
with	O
425C	O
L142P	B-DNAMutation
was	O
significantly	O
faster	O
than	O
a	O
wild-type	O
control	O
,	O
and	O
proteasome	O
inhibitors	O
restored	O
the	O
stability	O
of	O
L142P	B-DNAMutation
.	O

These	O
data	O
suggest	O
that	O
L142P	B-DNAMutation
increases	O
susceptibility	O
to	O
the	O
degradation	O
by	O
the	O
ubiquitin-proteasome	O
pathway	O
.	O

SUMOylation	O
target	O
sites	O
at	O
the	O
C	O
terminus	O
protect	O
Axin	B-DNAMutation
from	O
ubiquitination	O
and	O
confer	O
protein	O
stability	O
.	O

Axin	B-DNAMutation
is	O
a	O
scaffold	O
protein	O
for	O
the	O
beta-catenin	O
destruction	O
complex	O
,	O
and	O
a	O
negative	O
regulator	O
of	O
canonical	O
Wnt	O
signaling	O
.	O

Previous	O
studies	O
implicated	O
the	O
six	O
C-terminal	O
amino	O
acids	O
(	O
C6	O
motif	O
)	O
in	O
the	O
ability	O
of	O
Axin	B-DNAMutation
to	O
activate	O
c-Jun	O
N-terminal	O
kinase	O
,	O
and	O
identified	O
them	O
as	O
a	O
SUMOylation	O
target	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
C6	I-DNAMutation
motif	I-DNAMutation
of	O
mouse	O
Axin	B-DNAMutation
in	O
vivo	O
reduced	O
the	O
steady-state	O
protein	O
level	O
,	O
which	O
caused	O
embryonic	O
lethality	O
.	O

Here	O
,	O
we	O
report	O
that	O
this	O
deletion	O
Axin-DeltaC6	B-DNAMutation
causes	O
a	O
reduced	O
half-life	O
in	O
mouse	O
embryonic	O
fibroblasts	O
and	O
an	O
increased	O
susceptibility	O
to	O
ubiquitination	O
in	O
HEK	O
293T	O
cells	O
.	O

We	O
confirmed	O
the	O
C6	O
motif	O
as	O
a	O
SUMOylation	O
target	O
in	O
vitro	O
,	O
and	O
found	O
that	O
mutating	O
the	O
C-terminal	O
SUMOylation	O
target	O
residues	O
increased	O
the	O
susceptibility	O
of	O
Axin	B-DNAMutation
to	O
polyubiquitination	O
and	O
reduced	O
its	O
steady-state	O
level	O
.	O

Heterologous	O
SUMOylation	O
target	O
sites	O
could	O
replace	O
C6	O
in	O
providing	O
this	O
protective	O
effect	O
.	O

These	O
findings	O
suggest	O
that	O
SUMOylation	O
of	O
the	O
C6	O
motif	O
may	O
prevent	O
polyubiquitination	O
,	O
thus	O
increasing	O
the	O
stability	O
of	O
Axin	B-DNAMutation
.	O

Although	O
C6	B-DNAMutation
deletion	I-DNAMutation
also	O
caused	O
increased	O
association	O
of	O
Axin	B-DNAMutation
with	O
Dvl-1	B-DNAMutation
,	O
this	O
interaction	O
was	O
not	O
altered	O
by	O
mutating	B-DNAMutation
the	I-DNAMutation
lysine	I-DNAMutation
residues	I-DNAMutation
in	I-DNAMutation
C6	I-DNAMutation
,	O
nor	O
could	O
heterologous	O
SUMOylation	O
motifs	O
replace	O
the	O
C6	O
motif	O
in	O
this	O
assay	O
.	O

Therefore	O
,	O
some	O
other	O
specific	O
property	O
of	O
the	O
C6	O
motif	O
seems	O
to	O
reduce	O
the	O
interaction	O
of	O
Axin	B-DNAMutation
with	O
Dvl-1	B-DNAMutation
.	O

SADB	O
phosphorylation	O
of	O
gamma-tubulin	O
regulates	O
centrosome	O
duplication	O
.	O

Symmetrical	O
cell	O
division	O
requires	O
duplication	O
of	O
DNA	O
and	O
protein	O
content	O
to	O
generate	O
two	O
daughter	O
cells	O
.	O

Centrosomes	O
also	O
duplicate	O
during	O
cell	O
division	O
,	O
but	O
the	O
mechanism	O
controlling	O
this	O
process	O
is	O
incompletely	O
understood	O
.	O

We	O
describe	O
an	O
alternative	O
splice	O
form	O
of	O
SadB	O
encoding	O
a	O
short	O
SADB	O
Ser/Thr	O
kinase	O
whose	O
activity	O
fluctuates	O
during	O
the	O
cell	O
cycle	O
,	O
localizes	O
to	O
centrosomes	O
,	O
and	O
controls	O
centrosome	O
duplication	O
.	O

Reduction	O
of	O
endogenous	O
SADB	O
levels	O
diminished	O
centrosome	O
numbers	O
,	O
whereas	O
enhanced	O
SADB	O
expression	O
induced	O
centrosome	O
amplification	O
.	O

SADB	O
exerted	O
this	O
action	O
through	O
phosphorylation	O
of	O
gamma-tubulin	O
on	O
Ser	O
131	O
,	O
as	O
expression	O
of	O
a	O
phosphomimetic	O
Ser	B-DNAMutation
131-to-Asp	I-DNAMutation
gamma-tubulin	O
mutant	O
alone	O
increased	O
centrosome	O
numbers	O
,	O
whereas	O
non-phosphorylatable	O
Ala	O
131-gamma-tubulin	O
impaired	O
centrosome	O
duplication	O
.	O

We	O
propose	O
that	O
SADB	O
kinase	O
activity	O
controls	O
centrosome	O
homeostasis	O
by	O
regulating	O
phosphorylation	O
of	O
gamma-tubulin	O
.	O

The	O
Purkinje	B-DNAMutation
cell	I-DNAMutation
degeneration	I-DNAMutation
5J	O
mutation	O
is	O
a	O
single	O
amino	O
acid	O
insertion	O
that	O
destabilizes	O
Nna1	B-DNAMutation
protein	O
.	O

In	O
the	O
mouse	O
,	O
Purkinje	B-DNAMutation
cell	I-DNAMutation
degeneration	I-DNAMutation
pcd	B-DNAMutation
is	O
a	O
recessive	O
mutation	O
characterized	O
by	O
degeneration	O
of	O
cerebellar	O
Purkinje	O
cells	O
,	O
retinal	O
photoreceptors	O
,	O
olfactory	O
bulb	O
mitral	O
neurons	O
,	O
and	O
certain	O
thalamic	O
neurons	O
,	O
and	O
is	O
accompanied	O
by	O
defective	O
spermatogenesis	O
.	O

Previous	O
studies	O
of	O
pcd	B-DNAMutation
have	O
led	O
to	O
the	O
identification	O
of	O
Nna1	B-DNAMutation
as	O
the	O
causal	O
gene	O
;	O
however	O
,	O
how	O
loss	O
of	O
Nna1	B-DNAMutation
function	O
results	O
in	O
neurodegeneration	O
remains	O
unresolved	O
.	O

One	O
useful	O
approach	O
for	O
establishing	O
which	O
functional	O
domains	O
of	O
a	O
protein	O
underlie	O
a	O
recessive	O
phenotype	O
has	O
been	O
to	O
determine	O
the	O
genetic	O
basis	O
of	O
the	O
various	O
alleles	O
at	O
the	O
locus	O
of	O
interest	O
.	O

Because	O
none	O
of	O
the	O
pcd	B-DNAMutation
alleles	O
analyzed	O
at	O
the	O
time	O
of	O
the	O
identification	O
of	O
Nna1	B-DNAMutation
provided	O
insight	O
into	O
the	O
molecular	O
basis	O
of	O
Nna1	B-DNAMutation
loss-of-function	O
,	O
we	O
obtained	O
a	O
recent	O
pcd	B-DNAMutation
remutation--pcd5J	O
,	O
and	O
after	O
determining	O
that	O
its	O
phenotype	O
is	O
comparable	O
to	O
existing	O
pcd	B-DNAMutation
severe	O
alleles	O
,	O
we	O
sought	O
its	O
genetic	O
basis	O
by	O
sequencing	O
Nna1	B-DNAMutation
.	O

In	O
this	O
article	O
we	O
report	O
that	O
pcd5J	O
results	O
from	O
the	O
insertion	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
single	I-DNAMutation
GAC	I-DNAMutation
triplet	I-DNAMutation
encoding	I-DNAMutation
an	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
residue	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
775	I-DNAMutation
of	O
Nna1	B-DNAMutation
.	O

Although	O
this	O
insertion	O
does	O
not	O
affect	O
Nna1	B-DNAMutation
expression	O
at	O
the	O
RNA	O
level	O
,	O
Nna1pcd-5J	O
protein	O
expression	O
is	O
markedly	O
decreased	O
.	O

Pulse-chase	O
experiments	O
reveal	O
that	O
the	O
aspartic	O
acid	O
insertion	O
dramatically	O
destabilizes	O
Nna1pcd-5J	O
protein	O
,	O
accounting	O
for	O
the	O
observation	O
that	O
pcd5J	O
is	O
a	O
severe	O
allele	O
.	O

The	O
presence	O
of	O
a	O
readily	O
detectable	O
genetic	O
mutation	O
in	O
pcd5J	O
confirms	O
that	O
Nna1	B-DNAMutation
loss-of-function	O
alone	O
underlies	O
the	O
broad	O
pcd	B-DNAMutation
phenotype	O
and	O
will	O
facilitate	O
further	O
studies	O
of	O
how	O
Nna1	B-DNAMutation
loss-of-function	O
produces	O
neurodegeneration	O
and	O
defective	O
spermatogenesis	O
in	O
pcd	B-DNAMutation
mice	O
.	O

Molecular	O
and	O
cellular	O
analysis	O
of	O
the	O
DNA	O
repair	O
defect	O
in	O
a	O
patient	O
in	O
xeroderma	O
pigmentosum	O
complementation	O
group	O
D	O
who	O
has	O
the	O
clinical	O
features	O
of	O
xeroderma	O
pigmentosum	O
and	O
Cockayne	O
syndrome	O
.	O

Xeroderma	O
pigmentosum	O
(XP)	O
and	O
Cockayne	O
syndrome	O
(CS)	O
are	O
quite	O
distinct	O
genetic	O
disorders	O
that	O
are	O
associated	O
with	O
defects	O
in	O
excision	O
repair	O
of	O
UV-induced	O
DNA	O
damage	O
.	O

A	O
few	O
patients	O
have	O
been	O
described	O
previously	O
with	O
the	O
clinical	O
features	O
of	O
both	O
disorders	O
.	O

In	O
this	O
paper	O
we	O
describe	O
an	O
individual	O
in	O
this	O
category	O
who	O
has	O
unusual	O
cellular	O
responses	O
to	O
UV	O
light	O
.	O

We	O
show	O
that	O
his	O
cultured	O
fibroblasts	O
and	O
lymphocytes	O
are	O
extremely	O
sensitive	O
to	O
irradiation	O
with	O
UV-C	O
,	O
despite	O
a	O
level	O
of	O
nucleotide	O
excision	O
repair	O
that	O
is	O
30%-40%	O
that	O
of	O
normal	O
cells	O
.	O

The	O
deficiency	O
is	O
assigned	O
to	O
the	O
XP-D	O
complementation	O
group	O
,	O
and	O
we	O
have	O
identified	O
two	O
causative	O
mutations	O
in	O
the	O
XPD	B-DNAMutation
gene	O
:	O
a	B-DNAMutation
gly-->arg	I-DNAMutation
change	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
675	I-DNAMutation
in	O
the	O
allele	O
inherited	O
from	O
the	O
patient's	O
mother	O
and	O
a	O
-1	B-DNAMutation
frameshift	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
669	I-DNAMutation
in	O
the	O
allele	O
inherited	O
from	O
his	O
father	O
.	O

These	O
mutations	O
are	O
in	O
the	O
C-terminal	O
20%	O
of	O
the	O
760-amino-acid	O
XPD	B-DNAMutation
protein	O
,	O
in	O
a	O
region	O
where	O
we	O
have	O
recently	O
identified	O
several	O
mutations	O
in	O
patients	O
with	O
trichothiodystrophy	O
.	O

Identification	O
of	O
an	O
INSM1-binding	B-DNAMutation
site	O
in	O
the	O
insulin	B-DNAMutation
promoter	O
:	O
negative	O
regulation	O
of	O
the	O
insulin	B-DNAMutation
gene	O
transcription	O
.	O

In	O
this	O
study	O
,	O
an	O
insulinoma-associated	B-DNAMutation
antigen-1	I-DNAMutation
(INSM1)-binding	B-DNAMutation
site	O
in	O
the	O
proximal	O
promoter	O
sequence	O
of	O
the	O
insulin	B-DNAMutation
gene	O
was	O
identified	O
.	O

The	O
co-transfection	O
of	O
INSM1	B-DNAMutation
with	O
rat	B-DNAMutation
insulin	B-DNAMutation
I/II	I-DNAMutation
promoter-driven	O
reporter	O
genes	O
exhibited	O
a	O
40-50%	O
inhibitory	O
effect	O
on	O
the	O
reporter	O
activity	O
.	O

Mutational	O
experiments	O
were	O
performed	O
by	O
introducing	B-DNAMutation
a	I-DNAMutation
substitution	I-DNAMutation
,	I-DNAMutation
GG	I-DNAMutation
to	I-DNAMutation
AT	I-DNAMutation
,	I-DNAMutation
into	I-DNAMutation
the	I-DNAMutation
INSM1	I-DNAMutation
core	I-DNAMutation
binding	O
site	O
of	O
the	O
rat	B-DNAMutation
insulin	B-DNAMutation
I/II	I-DNAMutation
promoters	O
.	O

The	O
mutated	O
insulin	B-DNAMutation
promoter	O
exhibited	O
a	O
three-	O
to	O
20-fold	O
increase	O
in	O
the	O
promoter	O
activity	O
over	O
the	O
wild-type	O
promoter	O
in	O
several	O
insulinoma	O
cell	O
lines	O
.	O

Moreover	O
,	O
INSM1	B-DNAMutation
overexpression	O
exhibited	O
no	O
inhibitory	O
effect	O
on	O
the	O
mutated	O
insulin	B-DNAMutation
promoter	O
.	O

Chromatin	O
immunoprecipitation	O
assays	O
using	O
beta	O
TC-1	O
,	O
mouse	O
fetal	O
pancreas	O
,	O
and	O
Ad-INSM1-transduced	B-DNAMutation
human	O
islets	O
demonstrated	O
that	O
INSM1	B-DNAMutation
occupies	O
the	O
endogenous	O
insulin	B-DNAMutation
promoter	O
sequence	O
containing	O
the	O
INSM1-binding	B-DNAMutation
site	O
in	O
vivo	O
.	O

The	O
binding	O
of	O
the	O
INSM1	B-DNAMutation
to	O
the	O
insulin	B-DNAMutation
promoter	O
could	O
suppress	O
approximately	O
50%	O
of	O
insulin	B-DNAMutation
message	O
in	O
human	O
islets	O
.	O

The	O
mechanism	O
for	O
transcriptional	O
repression	O
of	O
the	O
insulin	B-DNAMutation
gene	O
by	O
INSM1	B-DNAMutation
is	O
mediated	O
through	O
the	O
recruitment	O
of	O
cyclin	B-DNAMutation
D1	I-DNAMutation
and	O
histone	B-DNAMutation
deacetylase-3	I-DNAMutation
to	O
the	O
insulin	B-DNAMutation
promoter	O
.	O

Anti-INSM1	B-DNAMutation
or	O
anti-cyclin	O
D1	O
morpholino	O
treatment	O
of	O
fetal	O
mouse	O
pancreas	O
enhances	O
the	O
insulin	B-DNAMutation
promoter	O
activity	O
.	O

These	O
data	O
strongly	O
support	O
the	O
view	O
that	O
INSM1	B-DNAMutation
is	O
a	O
new	O
zinc-finger	O
transcription	O
factor	O
that	O
modulates	O
insulin	B-DNAMutation
gene	O
transcription	O
during	O
early	O
pancreas	O
development	O
.	O

Prolyl	O
4-hydroxylation	O
regulates	O
Argonaute	B-DNAMutation
2	I-DNAMutation
stability	O
.	O

Human	O
Argonaute	O
(Ago)	O
proteins	O
are	O
essential	O
components	O
of	O
the	O
RNA-induced	O
silencing	O
complexes	O
(RISCs)	O
.	O

Argonaute	B-DNAMutation
2	I-DNAMutation
Ago2	B-DNAMutation
has	O
a	O
P-element-induced	O
wimpy	O
testis	O
(PIWI)	O
domain	O
,	O
which	O
folds	O
like	O
RNase	O
H	O
and	O
is	O
responsible	O
for	O
target	O
RNA	O
cleavage	O
in	O
RNA	O
interference	O
.	O

Proteins	O
such	O
as	O
Dicer	O
,	O
TRBP	B-DNAMutation
,	O
MOV10	B-DNAMutation
,	O
RHA	B-DNAMutation
,	O
RCK/p54	B-DNAMutation
and	O
KIAA1093	O
associate	O
with	O
Ago	O
proteins	O
and	O
participate	O
in	O
small	O
RNA	O
processing	O
,	O
RISC	B-DNAMutation
loading	O
and	O
localization	O
of	O
Ago	O
proteins	O
in	O
the	O
cytoplasmic	O
messenger	O
RNA	O
processing	O
bodies	O
.	O

However	O
,	O
mechanisms	O
that	O
regulate	O
RNA	O
interference	O
remain	O
obscure	O
.	O

Here	O
we	O
report	O
physical	O
interactions	O
between	O
Ago2	B-DNAMutation
and	O
the	O
alpha-(P4H-alpha(I))	B-DNAMutation
and	O
beta-(P4H-beta)	B-DNAMutation
subunits	O
of	O
the	O
type	O
I	O
collagen	O
prolyl-4-hydroxylase	B-DNAMutation
C-P4H(I)	B-DNAMutation
.	O

Mass	O
spectrometric	O
analysis	O
identified	O
hydroxylation	O
of	O
the	O
endogenous	O
Ago2	B-DNAMutation
at	O
proline	O
700	O
.	O

In	O
vitro	O
,	O
both	O
Ago2	B-DNAMutation
and	O
Ago4	B-DNAMutation
seem	O
to	O
be	O
more	O
efficiently	O
hydroxylated	O
than	O
Ago1	B-DNAMutation
and	O
Ago3	B-DNAMutation
by	O
recombinant	O
human	O
C-P4H(I)	B-DNAMutation
.	O

Importantly	O
,	O
human	O
cells	O
depleted	O
of	O
P4H-alpha(I)	B-DNAMutation
or	O
P4H-beta	B-DNAMutation
by	O
short	O
hairpin	O
RNA	O
and	O
P4H-alpha(I)	B-DNAMutation
null	O
mouse	O
embryonic	O
fibroblast	O
cells	O
showed	O
reduced	O
stability	O
of	O
Ago2	B-DNAMutation
and	O
impaired	O
short	O
interfering	O
RNA	O
programmed	O
RISC	B-DNAMutation
activity	O
.	O

Furthermore	O
,	O
mutation	B-DNAMutation
of	I-DNAMutation
proline	I-DNAMutation
700	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
also	O
resulted	O
in	O
destabilization	O
of	O
Ago2	B-DNAMutation
,	O
thus	O
linking	O
Ago2	B-DNAMutation
P700	O
and	O
hydroxylation	O
at	O
this	O
residue	O
to	O
its	O
stability	O
regulation	O
.	O

These	O
findings	O
identify	O
hydroxylation	O
as	O
a	O
post-translational	O
modification	O
important	O
for	O
Ago2	B-DNAMutation
stability	O
and	O
effective	O
RNA	O
interference	O
.	O

Four	O
new	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
mutations	O
,	O
altering	O
a	O
zinc-binding	O
histidine	O
,	O
two	O
conserved	O
alanines	O
,	O
and	O
a	O
5'	O
splice	O
site	O
.	O

Three	O
new	O
missense	O
mutations	O
(	O
H15D	B-DNAMutation
,	O
A83D	B-DNAMutation
,	O
and	O
A179D	B-DNAMutation
)	O
and	O
a	O
new	O
splicing	O
defect	O
(	O
573	B-DNAMutation
+	I-DNAMutation
IG-->A	I-DNAMutation
)	O
in	O
the	O
5'	O
splice	O
site	O
of	O
intron	O
5	O
were	O
among	O
six	O
mutant	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
ADA	B-DNAMutation
alleles	O
found	O
in	O
three	O
unrelated	O
patients	O
with	O
severe	O
combined	O
immunodeficiency	O
disease	O
,	O
the	O
most	O
common	O
phenotype	O
associated	O
with	O
ADA	B-DNAMutation
deficiency	O
.	O

When	O
expressed	O
in	O
vitro	O
,	O
the	O
H15D	B-DNAMutation
,	O
A83D	B-DNAMutation
,	O
and	O
A179D	B-DNAMutation
proteins	O
lacked	O
detectable	O
ADA	B-DNAMutation
activity	O
.	O

The	O
splicing	O
defect	O
caused	O
skipping	B-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
5	I-DNAMutation
,	O
resulting	O
in	O
premature	O
termination	O
of	O
translation	O
and	O
a	O
reduced	O
level	O
of	O
mRNA	O
.	O

H15D	B-DNAMutation
is	O
the	O
first	O
naturally	O
occurring	O
mutation	O
of	O
a	O
residue	O
that	O
coordinates	O
directly	O
with	O
the	O
enzyme-associated	O
zinc	O
ion	O
.	O

Molecular	O
modeling	O
based	O
on	O
the	O
atomic	O
coordinates	O
of	O
murine	O
ADA	B-DNAMutation
suggests	O
that	O
the	O
D15	O
mutation	O
would	O
create	O
a	O
cavity	O
or	O
gap	O
between	O
the	O
zinc	O
ion	O
and	O
the	O
side	O
chain	O
carboxylate	O
of	O
D15	O
.	O

This	O
could	O
alter	O
the	O
ability	O
of	O
zinc	O
to	O
activate	O
a	O
water	O
molecule	O
postulated	O
to	O
play	O
a	O
role	O
in	O
the	O
catalytic	O
mechanism	O
.	O

A83	O
and	O
A179	O
are	O
not	O
directly	O
involved	O
in	O
the	O
active	O
site	O
,	O
but	O
are	O
conserved	O
residues	O
located	O
respectively	O
in	O
alpha	O
helix	O
4	O
and	O
beta	O
strand	O
4	O
of	O
the	O
alpha/beta	O
barrel	O
.	O

Replacement	B-DNAMutation
of	I-DNAMutation
these	I-DNAMutation
small	I-DNAMutation
hydrophobic	I-DNAMutation
Ala	I-DNAMutation
residues	I-DNAMutation
with	I-DNAMutation
the	I-DNAMutation
charged	I-DNAMutation
,	I-DNAMutation
more	I-DNAMutation
bulky	I-DNAMutation
Asp	I-DNAMutation
side	I-DNAMutation
chain	I-DNAMutation
may	O
distort	O
ADA	B-DNAMutation
structure	O
and	O
affect	O
enzyme	O
stability	O
or	O
folding	O
.	O

Identification	O
of	O
genetic	O
variation	O
in	O
the	O
human	O
serotonin	B-DNAMutation
1D	I-DNAMutation
beta	I-DNAMutation
receptor	I-DNAMutation
gene	O
.	O

Disturbances	O
of	O
serotonergic	O
pathways	O
have	O
been	O
implicated	O
in	O
a	O
wide	O
variety	O
of	O
neuropsychiatric	O
disorders	O
such	O
as	O
depression	O
,	O
anxiety	O
,	O
migraine	O
,	O
and	O
substance	O
abuse	O
.	O

Genetic	O
variation	O
in	O
genes	O
coding	O
for	O
serotonin	O
receptor	O
proteins	O
might	O
well	O
be	O
involved	O
in	O
the	O
genetic	O
predisposition	O
to	O
these	O
diseases	O
and/or	O
of	O
pharmacogenetic	O
relevance	O
.	O

Genomic	O
samples	O
from	O
46	O
unrelated	O
healthy	O
subjects	O
were	O
investigated	O
by	O
single-strand	O
conformation	O
analysis	O
(SSCA)	O
to	O
screen	O
for	O
genetic	O
variation	O
in	O
the	O
human	O
serotonin	O
1D	O
beta	O
(	O
5-HT1D	B-DNAMutation
beta	I-DNAMutation
)	O
receptor	O
gene	O
.	O

Overlapping	O
PCR	O
(	O
polymerase	O
chain	O
reaction	O
)	O
fragments	O
covered	O
the	O
whole	O
coding	O
sequence	O
as	O
well	O
as	O
5'	O
untranslated	O
regions	O
of	O
the	O
5-HT1D	B-DNAMutation
beta	I-DNAMutation
gene	O
.	O

Four	O
nucleotide	O
sequence	O
variants	O
were	O
found	O
:	O
a	O
coding	B-DNAMutation
mutation	I-DNAMutation
in	I-DNAMutation
nucleotide	I-DNAMutation
position	I-DNAMutation
371	I-DNAMutation
which	O
leads	O
to	O
an	O
amino	B-DNAMutation
acid	I-DNAMutation
exchange	I-DNAMutation
(Phe-->Cys)	I-DNAMutation
in	I-DNAMutation
position	I-DNAMutation
124	I-DNAMutation
of	O
the	O
receptor	O
protein	O
and	O
three	O
mutations	O
in	O
the	O
5'	O
flanking	O
region	O
.	O

For	O
all	O
mutations	O
specific	O
PCR-based	O
assays	O
were	O
developed	O
which	O
allow	O
rapid	O
genotyping	O
in	O
populations	O
and	O
families	O
.	O

To	O
our	O
knowledge	O
,	O
the	O
Phe-124-Cys	B-DNAMutation
substitution	O
is	O
the	O
first	O
natural	O
occurring	O
molecular	O
variant	O
which	O
has	O
been	O
identified	O
for	O
the	O
5-HT1D	B-DNAMutation
beta	I-DNAMutation
receptor	O
so	O
far	O
.	O

Contrasting	O
,	O
species-dependent	O
modulation	O
of	O
copper-mediated	O
neurotoxicity	O
by	O
the	O
Alzheimer's	O
disease	O
amyloid	O
precursor	O
protein	O
.	O

The	O
amyloid	O
precursor	O
protein	O
(APP)	O
of	O
Alzheimer's	O
disease	O
(AD)	O
has	O
a	O
copper	O
binding	O
domain	O
(CuBD)	O
located	O
in	O
the	O
N-terminal	O
cysteine-rich	O
region	O
that	O
can	O
strongly	O
bind	O
copper(II)	O
and	O
reduce	O
it	O
to	O
Cu(I)	O
in	O
vitro	O
.	O

The	O
CuBD	O
sequence	O
is	O
similar	O
among	O
the	O
APP	O
family	O
paralogs	O
[	O
amyloid	O
precursor-like	O
proteins	O
(	O
APLP1	O
and	O
APLP2)	O
]	O
and	O
its	O
orthologs	O
(	O
including	O
Drosophila	O
melanogaster	O
,	O
Xenopus	O
laevis	O
,	O
and	O
Caenorhabditis	O
elegans	O
)	O
,	O
suggesting	O
an	O
overall	O
conservation	O
in	O
its	O
function	O
or	O
activity	O
.	O

The	O
APP	O
CuBD	O
is	O
involved	O
in	O
modulating	O
Cu	O
homeostasis	O
and	O
amyloid	O
beta	O
peptide	O
production	O
.	O

In	O
this	O
paper	O
,	O
we	O
demonstrate	O
for	O
the	O
first	O
time	O
that	O
Cu-metallated	O
full-length	O
APP	O
ectodomain	O
induces	O
neuronal	O
cell	O
death	O
in	O
vitro	O
.	O

APP	O
Cu	O
neurotoxicity	O
can	O
be	O
induced	O
directly	O
or	O
potentiated	O
through	O
Cu(I)-mediated	O
oxidation	O
of	O
low-density	O
lipoprotein	O
,	O
a	O
finding	O
that	O
may	O
have	O
important	O
implications	O
for	O
the	O
role	O
of	O
lipoproteins	O
and	O
membrane	O
cholesterol	O
composition	O
in	O
AD	O
.	O

Cu	O
toxicity	O
induced	O
by	O
human	O
APP	O
,	O
Xenopus	O
APP	O
,	O
and	O
APLP2	B-DNAMutation
CuBDs	O
is	O
dependent	O
on	O
conservation	O
of	O
histidine	O
residues	O
at	O
positions	O
corresponding	O
to	O
147	O
and	O
151	O
of	O
human	O
APP	O
.	O

Intriguingly	O
,	O
APP	O
orthologs	O
with	O
different	O
amino	O
acid	O
residues	O
at	O
these	O
positions	O
had	O
dramatically	O
altered	O
Cu	O
phenotypes	O
.	O

The	O
corresponding	O
C	O
.	O

elegans	O
APL-1	O
CuBD	O
,	O
which	O
has	O
tyrosine	O
and	O
lysine	O
residues	O
at	O
positions	O
147	O
and	O
151	O
,	O
respectively	O
,	O
strongly	O
protected	O
against	O
Cu-mediated	O
lipid	O
peroxidation	O
and	O
neurotoxicity	O
in	O
vitro	O
.	O

Replacement	B-DNAMutation
of	I-DNAMutation
histidines	I-DNAMutation
147	I-DNAMutation
and	I-DNAMutation
151	I-DNAMutation
with	I-DNAMutation
tyrosine	I-DNAMutation
and	I-DNAMutation
lysine	I-DNAMutation
residues	I-DNAMutation
conferred	O
this	O
neuroprotective	O
Cu	O
phenotype	O
to	O
human	O
APP	O
,	O
APLP2	B-DNAMutation
,	O
and	O
Xenopus	O
APP	O
CuBD	O
peptides	O
.	O

Moreover	O
,	O
we	O
show	O
that	O
the	O
toxic	O
and	O
protective	O
CuBD	O
phenotypes	O
are	O
associated	O
with	O
differences	O
in	O
Cu	O
binding	O
and	O
reduction	O
.	O

These	O
studies	O
identify	O
a	O
significant	O
evolutionary	O
change	O
in	O
the	O
function	O
of	O
the	O
CuBD	O
in	O
modulating	O
Cu	O
metabolism	O
.	O

Our	O
findings	O
also	O
suggest	O
that	O
targeting	O
of	O
inhibitors	O
to	O
histidine	O
residues	O
at	O
positions	O
147	O
and	O
151	O
of	O
APP	O
could	O
significantly	O
alter	O
the	O
oxidative	O
potential	O
of	O
APP	O
.	O

The	O
eighth	O
component	O
of	O
human	B-DNAMutation
complement	O
:	O
molecular	O
basis	O
of	O
C8A	B-DNAMutation
(C81)	O
polymorphism	O
.	O

Using	O
an	O
exon-specific	O
polymerase	O
chain	O
reaction	O
(PCR)	O
followed	O
by	O
direct	O
DNA	O
sequence	O
analysis	O
we	O
have	O
analyzed	O
the	O
polymorphism	O
of	O
the	O
alpha-chain	B-DNAMutation
of	O
the	O
eighth	O
component	O
of	O
human	B-DNAMutation
complement	O
(C8)	O
at	O
the	O
DNA	O
level	O
.	O

We	O
found	O
that	O
two	O
common	O
alleles	O
,	O
C8A*A	B-DNAMutation
and	O
C8A*B	B-DNAMutation
,	O
are	O
characterized	O
by	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
single	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
(	I-DNAMutation
Gln	I-DNAMutation
to	I-DNAMutation
Lys	I-DNAMutation
)	I-DNAMutation
,	I-DNAMutation
which	I-DNAMutation
is	I-DNAMutation
caused	I-DNAMutation
by	I-DNAMutation
a	I-DNAMutation
point	I-DNAMutation
mutation	I-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
single	I-DNAMutation
nucleotide	I-DNAMutation
(	I-DNAMutation
C	I-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
)	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
3	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
187	I-DNAMutation
of	O
the	O
mature	O
C8	B-DNAMutation
alpha	I-DNAMutation
cDNA	O
sequence	O
.	O

Based	O
on	O
this	O
mutation	O
,	O
an	O
allele-specific	O
PCR	O
was	O
designed	O
detecting	O
the	O
two	O
alleles	O
of	O
C8A	B-DNAMutation
.	O

We	O
applied	O
this	O
method	O
to	O
type	O
the	O
C8A	B-DNAMutation
polymorphism	O
using	O
DNA	O
samples	O
from	O
a	O
Chinese	O
Han	O
population	O
.	O

The	O
comparison	O
with	O
the	O
data	O
of	O
protein	O
typing	O
of	O
the	O
same	O
samples	O
proved	O
that	O
the	O
described	O
method	O
is	O
efficient	O
and	O
reliable	O
for	O
the	O
identification	O
of	O
C8A	B-DNAMutation
genotypes	O
and	O
may	O
be	O
valuable	O
for	O
further	O
application	O
in	O
population	O
studies	O
and	O
forensic	O
science	O
.	O

Single	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
(482)	I-DNAMutation
variants	I-DNAMutation
of	O
the	O
ABCG2	B-DNAMutation
multidrug	O
transporter	O
:	O
major	O
differences	O
in	O
transport	O
capacity	O
and	O
substrate	O
recognition	O
.	O

The	O
human	O
ABCG2	B-DNAMutation
protein	O
is	O
an	O
ATP	O
binding	O
cassette	O
half-transporter	O
,	O
which	O
protects	O
our	O
cells	O
and	O
tissues	O
against	O
various	O
xenobiotics	O
,	O
while	O
overexpression	O
of	O
ABCG2	B-DNAMutation
in	O
tumor	O
cells	O
confers	O
multidrug	O
resistance	O
.	O

It	O
has	O
been	O
documented	O
that	O
single	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
changes	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
482	I-DNAMutation
resulted	O
in	O
altered	O
drug	O
resistance	O
and	O
transport	O
capacity	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
generated	O
nine	O
Arg-482	B-DNAMutation
mutants	I-DNAMutation
(	I-DNAMutation
G	I-DNAMutation
,	I-DNAMutation
I	I-DNAMutation
,	I-DNAMutation
M	I-DNAMutation
,	I-DNAMutation
S	I-DNAMutation
,	I-DNAMutation
T	I-DNAMutation
,	I-DNAMutation
D	I-DNAMutation
,	I-DNAMutation
N	I-DNAMutation
,	I-DNAMutation
K	I-DNAMutation
,	I-DNAMutation
Y	I-DNAMutation
)	O
of	O
ABCG2	B-DNAMutation
,	O
and	O
expressed	O
them	O
in	O
insect	O
cells	O
.	O

All	O
ABCG2	B-DNAMutation
variants	O
showed	O
cell	O
surface	O
expression	O
and	O
,	O
in	O
isolated	O
membranes	O
,	O
an	O
ABCG2-specific	B-DNAMutation
ATPase	O
activity	O
.	O

When	O
methotrexate	O
accumulation	O
was	O
measured	O
in	O
inside-out	O
membrane	O
vesicles	O
,	O
this	O
transport	O
was	O
supported	O
only	O
by	O
the	O
wild-type	O
ABCG2	B-DNAMutation
.	O

In	O
intact	O
cells	O
,	O
mitoxantrone	O
was	O
transported	O
by	O
all	O
ABCG2	B-DNAMutation
variants	O
,	O
except	O
by	O
R482K	B-DNAMutation
.	O

Rhodamine	O
123	O
was	O
extruded	O
by	O
most	O
of	O
the	O
mutants	O
,	O
except	O
by	O
R482K	B-DNAMutation
,	I-DNAMutation
Y	I-DNAMutation
and	O
by	O
wild-type	O
ABCG2	B-DNAMutation
.	O

Hoechst	O
33342	O
was	O
pumped	O
out	O
from	O
cells	O
expressing	O
the	O
wild-type	O
and	O
all	O
Arg-482	B-DNAMutation
variants	I-DNAMutation
,	O
but	O
not	O
from	O
those	O
expressing	O
R482K	B-DNAMutation
and	I-DNAMutation
Y	I-DNAMutation
.	O

Our	O
study	O
demonstrates	O
that	O
the	O
substrate	O
specificity	O
of	O
the	O
Arg	O
(wild-type)	O
form	O
is	O
unique	O
and	O
that	O
amino	O
acid	O
replacements	B-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
482	I-DNAMutation
induce	O
major	O
alterations	O
in	O
both	O
the	O
transport	O
activity	O
and	O
substrate	O
specificity	O
of	O
this	O
protein	O
.	O

Post-translational	O
modifications	O
of	O
the	O
gamma-subunit	O
affect	O
intracellular	O
trafficking	O
and	O
complex	O
assembly	O
of	O
GlcNAc-1-phosphotransferase	O
.	O

GlcNAc-1-phosphotransferase	O
plays	O
a	O
key	O
role	O
in	O
the	O
generation	O
of	O
mannose	O
6-phosphate	O
,	O
a	O
recognition	O
marker	O
essential	O
for	O
efficient	O
transport	O
of	O
lysosomal	O
hydrolases	O
to	O
lysosomes	O
.	O

The	O
enzyme	O
complex	O
is	O
composed	O
of	O
six	O
subunits	O
(Î±(2)Î²(2)Î³(2))	O
.	O

The	O
Î±-	O
and	O
Î²-subunits	O
are	O
catalytically	O
active	O
,	O
whereas	O
the	O
function	O
of	O
the	O
Î³-subunit	O
is	O
still	O
unclear	O
.	O

We	O
have	O
investigated	O
structural	O
properties	O
,	O
localization	O
,	O
and	O
intracellular	O
transport	O
of	O
the	O
human	O
and	O
mouse	O
Î³-subunits	O
and	O
the	O
molecular	O
requirements	O
for	O
the	O
assembly	O
of	O
the	O
phosphotransferase	O
complex	O
.	O

The	O
results	O
showed	O
that	O
endogenous	O
and	O
overexpressed	O
Î³-subunits	O
were	O
localized	O
in	O
the	O
cis-Golgi	O
apparatus	O
.	O

Secreted	O
forms	O
of	O
Î³-subunits	O
were	O
detectable	O
in	O
media	O
of	O
cultured	O
cells	O
as	O
well	O
as	O
in	O
human	O
serum	O
.	O

The	O
Î³-subunit	O
contains	O
two	O
in	O
vivo	O
used	O
N-glycosylation	O
sites	O
at	O
positions	O
88	O
and	O
115	O
,	O
equipped	O
with	O
high	O
mannose-type	O
oligosaccharides	O
.	O

(35)S	O
pulse-chase	O
experiments	O
and	O
size	O
exclusion	O
chromatography	O
revealed	O
that	O
the	O
majority	O
of	O
non-glycosylated	O
Î³-subunit	O
mutants	O
were	O
integrated	O
in	O
high	O
molecular	O
mass	O
complexes	O
,	O
failed	O
to	O
exit	O
the	O
endoplasmic	O
reticulum	O
(ER)	O
,	O
and	O
were	O
rapidly	O
degraded	B-DNAMutation
.	I-DNAMutation
The	I-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
cysteine	O
245	O
involved	O
in	O
dimerization	O
of	O
Î³-subunits	O
impaired	O
neither	O
ER	O
exit	O
nor	O
trafficking	O
through	O
the	O
secretory	O
pathway	O
.	O

Monomeric	O
Î³-subunits	O
failed	O
,	O
however	O
,	O
to	O
associate	O
with	O
other	O
GlcNAc-1-phosphotransferase	O
subunits	O
.	O

The	O
data	O
provide	O
evidence	O
that	O
assembly	O
of	O
the	O
GlcNAc-1-phosphotransferase	O
complex	O
takes	O
place	O
in	O
the	O
ER	O
and	O
requires	O
dimerization	O
of	O
the	O
Î³-subunits	O
.	O

A	O
novel	O
mutation	O
of	O
the	O
TGFBI	O
gene	O
found	O
in	O
a	O
Vietnamese	O
family	O
with	O
atypical	O
granular	O
corneal	O
dystrophy	O
.	O

BACKGROUND	O
:	O
Mutation	O
of	O
the	O
human	O
transforming	O
growth	O
factor	O
beta-induced	O
(TGFBI)	O
gene	O
causes	O
granular	O
corneal	O
dystrophy	O
(GCD)	O
in	O
various	O
ethnic	O
groups	O
.	O

In	O
this	O
report	O
,	O
we	O
identify	O
the	O
genetic	O
defect	O
on	O
the	O
TGFBI	O
gene	O
in	O
a	O
Vietnamese	O
family	O
with	O
atypical	O
GCD	O
.	O

CASES	O
:	O
The	O
patient	O
and	O
her	O
relatives	O
were	O
examined	O
clinically	O
.	O

Genomic	O
DNA	O
was	O
extracted	O
from	O
blood	O
leukocytes	O
.	O

Fifty	O
normal	O
Vietnamese	O
were	O
used	O
as	O
controls	O
.	O

Analysis	O
of	O
the	O
TGFBI	O
gene	O
was	O
performed	O
using	O
polymerase	O
chain	O
reaction	O
and	O
direct	O
sequencing	O
.	O

OBSERVATIONS	O
:	O
The	O
42-year-old	O
proband	O
clinically	O
showed	O
multiple	O
white	O
dot-like	O
opacities	O
scattered	O
in	O
the	O
anterior	O
and	O
mid-stroma	O
of	O
the	O
central	O
cornea	O
.	O

Unlike	O
GCD	O
,	O
these	O
deposits	O
were	O
smaller	O
,	O
localized	O
deeper	O
and	O
less	O
severe	O
.	O

DNA	O
analysis	O
revealed	O
a	O
nucleotide	O
transversion	O
at	O
codon	B-DNAMutation
123	I-DNAMutation
(	I-DNAMutation
GAC	I-DNAMutation
-->	I-DNAMutation
CAC	I-DNAMutation
)	I-DNAMutation
,	O
causing	O
Asp	O
-->	O
His	O
substitution	O
D123H	B-DNAMutation
.	O

This	O
mutation	O
was	O
also	O
detected	O
in	O
3	O
out	O
of	O
5	O
unaffected	O
family	O
members	O
,	O
but	O
was	O
absent	O
in	O
the	O
50	O
normal	O
controls	O
.	O

CONCLUSIONS	O
:	O
The	O
novel	O
D123H	B-DNAMutation
mutation	O
of	O
the	O
TGFBI	O
gene	O
was	O
not	O
co-segregated	O
with	O
GCD	O
in	O
the	O
family	O
studied	O
,	O
and	O
did	O
not	O
exist	O
in	O
the	O
control	O
population	O
.	O

It	O
probably	O
was	O
a	O
disease-causing	O
mutation	O
,	O
thus	O
expected	O
to	O
cause	O
a	O
novel	O
variant	O
of	O
GCD	O
in	O
the	O
proband	O
.	O

The	O
detection	O
of	O
the	O
D123H	B-DNAMutation
mutation	O
in	O
three	O
unaffected	O
family	O
members	O
indicates	O
that	O
it	O
has	O
low	O
penetrance	O
for	O
GCD	O
.	O

Sequence	O
data	O
of	O
the	O
rare	O
deficient	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
variant	O
PI	B-DNAMutation
Zaugsburg	I-DNAMutation
.	O

Weidinger	O
et	O
al	O
.	O

recognized	O
a	O
rare	O
deficient	O
PI-variant	O
,	O
named	O
PI	B-DNAMutation
Zaugsburg	I-DNAMutation
(	O
PI	B-DNAMutation
Zaug	I-DNAMutation
)	O
,	O
by	O
using	O
isoelectric	O
focusing	O
with	O
a	O
narrow	O
pH	O
gradient	O
.	O

The	O
serum	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
(	O
alpha	O
1AT	O
)	O
level	O
determined	O
quantitatively	O
in	O
an	O
individual	O
carrying	O
the	O
phenotype	O
PI	O
M1Zaug	O
revealed	O
a	O
value	O
of	O
50%-60%	O
of	O
the	O
normal	O
range	O
.	O

The	O
frequency	O
of	O
the	O
deficient	O
PI*Zaug	B-DNAMutation
allele	O
is	O
still	O
unknown	O
.	O

Haplotyping	O
the	O
Zaug-affected	B-DNAMutation
chromosome	O
,	O
we	O
found	O
a	O
pattern	O
different	O
from	O
the	O
common	O
PI*Z	O
allele	O
described	O
by	O
Cox	O
et	O
al	O
.	O

Therefore	O
,	O
we	O
directly	O
sequenced	O
the	O
coding	O
exons	O
of	O
both	O
genes	O
(	O
M1	B-DNAMutation
and	O
Zaug	B-DNAMutation
)	O
after	O
PCR	O
amplification	O
.	O

Zaug	B-DNAMutation
sequence	O
data	O
analysis	O
showed	O
the	O
presence	O
of	O
the	O
common	O
PI*Z	O
allele-specific	O
mutation	O
(	O
M1	B-DNAMutation
Glu342	I-DNAMutation
GAG	I-DNAMutation
to	I-DNAMutation
Z	I-DNAMutation
Lys342	I-DNAMutation
AAG	I-DNAMutation
)	O
surprisingly	O
occurring	O
in	O
an	O
M2	O
ancestral	O
gene	O
.	O

This	O
is	O
not	O
consistent	O
with	O
the	O
heretofore	O
common	O
finding	O
,	O
by	O
Nukiwa	O
et	O
al	O
.	O

and	O
others	O
,	O
that	O
this	O
mutation	O
is	O
derived	O
from	O
an	O
M1	B-DNAMutation
(Ala213)	I-DNAMutation
background	O
gene	O
.	O

No	O
further	O
mutations	O
were	O
found	O
in	O
the	O
PI	B-DNAMutation
Zaug	I-DNAMutation
gene	O
.	O

Adiponectin	B-DNAMutation
multimerization	O
is	O
dependent	O
on	O
conserved	O
lysines	O
in	O
the	O
collagenous	O
domain	O
:	O
evidence	O
for	O
regulation	O
of	O
multimerization	O
by	O
alterations	O
in	O
posttranslational	O
modifications	O
.	O

Adiponectin	B-DNAMutation
is	O
a	O
secreted	O
,	O
multimeric	O
protein	O
with	O
insulin-sensitizing	B-DNAMutation
,	O
antiatherogenic	O
,	O
and	O
antiinflammatory	O
properties	O
.	O

Serum	O
adiponectin	B-DNAMutation
consists	O
of	O
trimer	O
,	O
hexamer	O
,	O
and	O
larger	O
high-molecular-weight	O
(HMW)	O
multimers	O
,	O
and	O
these	O
HMW	O
multimers	O
appear	O
to	O
be	O
the	O
more	O
bioactive	O
forms	O
.	O

Multimer	O
composition	O
of	O
adiponectin	B-DNAMutation
appears	O
to	O
be	O
regulated	O
;	O
however	O
,	O
the	O
molecular	O
mechanisms	O
involved	O
are	O
unknown	O
.	O

We	O
hypothesize	O
that	O
regulation	O
of	O
adiponectin	B-DNAMutation
multimerization	O
and	O
secretion	O
occurs	O
via	O
changes	O
in	O
posttranslational	O
modifications	O
(PTMs)	O
.	O

Although	O
a	O
structural	O
role	O
for	O
intertrimer	O
disulfide	O
bonds	O
in	O
the	O
formation	O
of	O
hexamers	O
and	O
HMW	O
multimers	O
is	O
established	O
,	O
the	O
role	O
of	O
other	O
PTMs	O
is	O
unknown	O
.	O

PTMs	O
identified	O
in	O
murine	O
and	O
bovine	O
adiponectin	B-DNAMutation
include	O
hydroxylation	O
of	O
multiple	O
conserved	O
proline	O
and	O
lysine	O
residues	O
and	O
glycosylation	O
of	O
hydroxylysines	O
.	O

By	O
mass	O
spectrometry	O
,	O
we	O
confirmed	O
the	O
presence	O
of	O
these	O
PTMs	O
in	O
human	O
adiponectin	B-DNAMutation
and	O
identified	O
three	O
additional	O
hydroxylations	O
on	O
Pro71	O
,	O
Pro76	O
,	O
and	O
Pro95	O
.	O

We	O
also	O
investigated	O
the	O
role	O
of	O
the	O
five	O
modified	O
lysines	O
in	O
multimer	O
formation	O
and	O
secretion	O
of	O
recombinant	O
human	O
adiponectin	B-DNAMutation
expressed	O
in	O
mammalian	O
cell	O
lines	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
modified	I-DNAMutation
lysines	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
collagenous	I-DNAMutation
domain	I-DNAMutation
prevented	O
formation	O
of	O
HMW	O
multimers	O
,	O
whereas	O
a	O
pharmacological	O
inhibitor	O
of	O
prolyl-	O
and	O
lysyl-hydroxylases	O
,	O
2,2'-dipyridyl	O
,	O
inhibited	O
formation	O
of	O
hexamers	O
and	O
HMW	O
multimers	O
.	O

Bacterially	O
expressed	O
human	O
adiponectin	B-DNAMutation
displayed	O
a	O
complete	O
lack	O
of	O
differentially	O
modified	O
isoforms	O
and	O
failed	O
to	O
form	O
bona	O
fide	O
trimers	O
and	O
larger	O
multimers	O
.	O

Finally	O
,	O
glucose-induced	O
increases	O
in	O
HMW	O
multimer	O
production	O
from	O
human	O
adipose	O
explants	O
correlated	O
with	O
changes	O
in	O
the	O
two-dimensional	O
electrophoresis	O
profile	O
of	O
adiponectin	B-DNAMutation
isoforms	O
.	O

Collectively	O
,	O
these	O
data	O
suggest	O
that	O
adiponectin	B-DNAMutation
multimer	O
composition	O
is	O
affected	O
by	O
changes	O
in	O
PTM	O
in	O
response	O
to	O
physiological	O
factors	O
.	O

Familial	O
focal	O
segmental	O
glomerulosclerosis	O
associated	O
with	O
an	O
ACTN4	B-DNAMutation
mutation	O
and	O
paternal	O
germline	O
mosaicism	O
.	O

Mutations	O
in	O
the	O
ACTN4	B-DNAMutation
gene	O
cause	O
focal	O
segmental	O
glomerulosclerosis	O
(FSGS)	O
,	O
which	O
shows	O
autosomal	O
dominant	O
inheritance	O
(	O
Online	O
Mendelian	O
Inheritance	O
in	O
Man	O
No	O
.	O

603278	O
,	O
FSGS1	O
)	O
.	O

Most	O
patients	O
with	O
a	O
diagnosis	O
of	O
FSGS1	O
show	O
a	O
mild	O
to	O
moderate	O
degree	O
of	O
proteinuria	O
during	O
adolescence	O
or	O
later	O
,	O
and	O
some	O
patients	O
gradually	O
progress	O
to	O
end-stage	O
renal	O
disease	O
.	O

Here	O
,	O
we	O
report	O
a	O
familial	O
case	O
of	O
FSGS1	O
in	O
which	O
2	O
affected	O
siblings	O
showed	O
unusual	O
clinical	O
,	O
pathological	O
,	O
and	O
genetic	O
features	O
.	O

Both	O
patients	O
presented	O
with	O
full-blown	O
rapidly	O
progressing	O
nephrotic	O
syndrome	O
in	O
early	O
childhood	O
.	O

Renal	O
pathological	O
findings	O
were	O
of	O
an	O
FSGS	O
collapsing	O
variant	O
and	O
FSGS	O
not	O
otherwise	O
specified	O
.	O

A	O
novel	O
ACTN4	B-DNAMutation
mutation	O
,	O
p.Ser262Phe	B-DNAMutation
,	O
was	O
detected	O
in	O
the	O
patients	O
,	O
and	O
their	O
father	O
was	O
found	O
to	O
have	O
a	O
germline	O
mosaicism	O
for	O
the	O
mutation	O
.	O

In	O
addition	O
,	O
these	O
siblings	O
also	O
had	O
a	O
heterozygous	O
p.Thr5Met	B-DNAMutation
substitution	O
in	O
NPHS1	B-DNAMutation
,	O
which	O
encodes	O
nephrin	O
,	O
although	O
the	O
functional	O
significance	O
of	O
this	O
substitution	O
is	O
unclear	O
.	O

This	O
is	O
the	O
third	O
clinical	O
report	O
of	O
FSGS1	O
and	O
the	O
first	O
case	O
report	O
of	O
germline	O
mosaicism	O
confirmed	O
in	O
patients	O
with	O
hereditary	O
podocyte	O
disorders	O
.	O

FSGS1	O
may	O
have	O
widely	O
variable	O
clinical	O
and	O
pathological	O
phenotypes	O
and	O
therefore	O
should	O
be	O
considered	O
in	O
young	O
children	O
with	O
full-blown	O
and	O
rapidly	O
progressing	O
nephrotic	O
syndrome	O
.	O

The	O
possibility	O
of	O
germline	O
mosaicism	O
makes	O
interpretation	O
of	O
molecular	O
diagnoses	O
and	O
genetic	O
counseling	O
more	O
difficult	O
.	O

The	O
second	O
member	O
of	O
the	O
human	O
and	O
murine	O
bubblegum	O
family	O
is	O
a	O
testis-	O
and	O
brainstem-specific	O
acyl-CoA	O
synthetase	O
.	O

Acyl-CoA	O
synthetases	O
that	O
activate	O
fatty	O
acids	O
to	O
their	O
CoA	O
derivatives	O
play	O
a	O
central	O
role	O
in	O
fatty	O
acid	O
metabolism	O
.	O

ACSBG1	O
,	O
an	O
acyl-CoA	O
synthetase	O
originally	O
identified	O
in	O
the	O
fruit	O
fly	O
mutant	O
bubblegum	O
,	O
was	O
hypothesized	O
to	O
contribute	O
to	O
the	O
biochemical	O
pathology	O
of	O
X-linked	O
adrenoleukodystrophy	O
.	O

We	O
looked	O
for	O
homologous	O
proteins	O
and	O
identified	O
ACSBG2	B-DNAMutation
in	O
humans	O
,	O
mice	O
,	O
and	O
rats	O
.	O

Human	O
ACSBG1	B-DNAMutation
and	O
ACSBG2	B-DNAMutation
amino	O
acid	O
sequences	O
are	O
50%	O
identical	O
.	O

ACSBG2	B-DNAMutation
expression	O
was	O
confined	O
to	O
the	O
testis	O
and	O
brainstem	O
.	O

Immunohistochemistry	O
and	O
in	O
situ	O
hybridization	O
studies	O
further	O
localized	O
ACSBG2	B-DNAMutation
expression	O
to	O
testicular	O
Sertoli	O
cells	O
and	O
large	O
motoneurons	O
in	O
the	O
medulla	O
oblongata	O
and	O
cervical	O
spinal	O
cord	O
.	O

Full-length	O
cDNA	O
encoding	O
human	O
and	O
mouse	O
ACSBG2	B-DNAMutation
was	O
cloned	O
.	O

In	O
transfected	O
COS-1	O
cells	O
,	O
both	O
human	O
and	O
murine	O
ACSBG2	B-DNAMutation
were	O
detected	O
as	O
75-	O
to	O
80-kDa	O
proteins	O
by	O
Western	O
blot	O
.	O

Cells	O
overexpressing	O
ACSBG2	B-DNAMutation
had	O
increased	O
ability	O
to	O
activate	O
oleic	O
acid	O
(C18:1omega9)	O
and	O
linoleic	O
acid	O
(C18:2omega6)	O
but	O
not	O
other	O
fatty	O
acid	O
substrates	O
tested	O
.	O

Within	B-DNAMutation
a	I-DNAMutation
highly	I-DNAMutation
conserved	I-DNAMutation
motif	I-DNAMutation
known	I-DNAMutation
to	I-DNAMutation
be	I-DNAMutation
important	I-DNAMutation
for	I-DNAMutation
catalysis	I-DNAMutation
,	I-DNAMutation
human	I-DNAMutation
ACSBG2	I-DNAMutation
contains	I-DNAMutation
a	I-DNAMutation
histidine	I-DNAMutation
residue	I-DNAMutation
where	O
all	B-DNAMutation
other	I-DNAMutation
known	I-DNAMutation
acyl-CoA	I-DNAMutation
synthetases	I-DNAMutation
,	I-DNAMutation
including	I-DNAMutation
mouse	I-DNAMutation
and	I-DNAMutation
rat	I-DNAMutation
ACSBG2	I-DNAMutation
,	I-DNAMutation
contain	I-DNAMutation
an	I-DNAMutation
arginine	I-DNAMutation
.	O

This	O
substitution	O
resulted	O
in	O
a	O
shift	O
of	O
the	O
human	O
ACSBG2	B-DNAMutation
pH	O
optimum	O
to	O
a	O
more	O
acidic	O
pH	O
.	O

Mutation	O
of	O
this	O
histidine	O
to	O
arginine	O
improved	O
catalytic	O
function	O
at	O
neutral	O
pH	O
by	O
shifting	O
the	O
pH	O
profile	O
without	O
affecting	O
substrate	O
specificity	O
.	O

Although	O
the	O
role	O
of	O
ACSBG2	B-DNAMutation
in	O
testicular	O
and	O
neuronal	O
lipid	O
metabolism	O
remains	O
unclear	O
,	O
the	O
limited	O
tissue	O
expression	O
pattern	O
and	O
limited	O
substrate	O
specificity	O
rule	O
out	O
a	O
likely	O
role	O
for	O
this	O
enzyme	O
in	O
X-linked	O
adrenoleukodystrophy	O
pathology	O
.	O

Abnormal	O
messenger	O
RNA	O
expression	O
and	O
a	O
missense	O
mutation	O
in	O
patients	O
with	O
X-linked	O
adrenoleukodystrophy	O
.	O

A	O
candidate	O
gene	O
for	O
X-linked	O
adrenoleukodystrophy	O
(ALD)	O
has	O
been	O
identified	O
via	O
positional	O
cloning	O
strategies	O
.	O

We	O
now	O
report	O
messenger	O
RNA	O
expression	O
in	O
fibroblasts	O
from	O
6	O
unrelated	O
ALD	O
patients	O
.	O

Four	O
patients	O
lacked	O
the	O
normal	O
4.2	O
kb	O
transcript	O
,	O
three	O
of	O
them	O
having	O
deletions	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
ALD	I-DNAMutation
gene	I-DNAMutation
.	O

A	O
fifth	O
patient	O
with	O
a	O
deletion	B-DNAMutation
of	I-DNAMutation
1.6	I-DNAMutation
kb	I-DNAMutation
had	O
a	O
smaller	O
4.0	O
kb	O
transcript	O
.	O

The	O
last	O
patient	O
had	O
a	O
normal	O
sized	O
transcript	O
and	O
a	O
missense	O
mutation	B-DNAMutation
at	I-DNAMutation
base	I-DNAMutation
1258	I-DNAMutation
leading	O
to	O
Glu-291-Lys	B-DNAMutation
substitution	O
in	O
a	O
region	O
of	O
the	O
candidate	O
gene	O
protein	O
which	O
is	O
conserved	O
in	O
the	O
70	O
kD	O
peroxisomal	O
membrane	O
protein	O
.	O

These	O
results	O
provide	O
further	O
evidence	O
that	O
this	O
candidate	O
gene	O
is	O
indeed	O
the	O
ALD	O
gene	O
.	O

Functional	O
roles	O
of	O
charged	O
residues	O
in	O
the	O
putative	O
voltage	O
sensor	O
of	O
the	O
HCN2	O
pacemaker	O
channel	O
.	O

Hyperpolarization-activated	O
,	O
cyclic	O
nucleotide-gated	O
(HCN)	O
channels	O
contribute	O
to	O
pacemaking	O
activity	O
in	O
specialized	O
neurons	O
and	O
cardiac	O
myocytes	O
.	O

HCN	O
channels	O
have	O
a	O
structure	O
similar	O
to	O
voltage-gated	O
K(+)	O
channels	O
but	O
have	O
a	O
much	O
larger	O
putative	O
S4	O
transmembrane	O
domain	O
and	O
open	O
in	O
response	O
to	O
membrane	O
hyperpolarization	O
instead	O
of	O
depolarization	O
.	O

As	O
an	O
initial	O
attempt	O
to	O
define	O
the	O
structural	O
basis	O
of	O
HCN	O
channel	O
gating	O
,	O
we	O
have	O
characterized	O
the	O
functional	O
roles	O
of	O
the	O
charged	O
residues	O
in	O
the	O
S2	O
,	O
S3	O
,	O
and	O
S4	O
transmembrane	O
domains	O
.	O

The	O
nine	B-DNAMutation
basic	I-DNAMutation
residues	I-DNAMutation
and	I-DNAMutation
a	I-DNAMutation
single	I-DNAMutation
Ser	I-DNAMutation
in	I-DNAMutation
S4	I-DNAMutation
were	I-DNAMutation
mutated	I-DNAMutation
individually	I-DNAMutation
to	I-DNAMutation
Gln	I-DNAMutation
,	O
and	O
the	O
function	O
of	O
mutant	O
channels	O
was	O
analyzed	O
in	O
Xenopus	O
oocytes	O
using	O
two-microelectrode	O
voltage	O
clamp	O
techniques	O
.	O

Surface	O
membrane	O
expression	O
of	O
hemagglutinin-epitope-tagged	O
channel	O
proteins	O
was	O
examined	O
by	O
chemiluminescence	O
.	O

Our	O
results	O
suggest	O
that	O
1	O
)	O
Lys-291	O
,	O
Arg-294	O
,	O
Arg-297	O
,	O
and	O
Arg-300	O
contribute	O
to	O
the	O
voltage	O
dependence	O
of	O
gating	O
but	O
not	O
to	O
channel	O
folding	O
or	O
trafficking	O
to	O
the	O
surface	O
membrane	O
;	O
2	O
)	O
Lys-303	O
and	O
Ser-306	O
are	O
essential	O
for	O
gating	O
,	O
but	O
not	O
for	O
channel	O
folding/trafficking	O
;	O
3	O
)	O
Arg-312	O
is	O
important	O
for	O
folding	O
but	O
not	O
gating	O
;	O
and	O
4	O
)	O
Arg-309	O
,	O
Arg-315	O
,	O
and	O
Arg-318	O
are	O
crucial	O
for	O
normal	O
protein	O
folding/trafficking	O
and	O
may	O
charge-pair	O
with	O
Asp	O
residues	O
located	O
in	O
the	O
S2	O
and	O
S3	O
domains	O
.	O

Identification	O
and	O
characterization	O
of	O
novel	O
mutations	O
of	O
the	O
aspartoacylase	B-DNAMutation
gene	O
in	O
non-Jewish	O
patients	O
with	O
Canavan	O
disease	O
.	O

Canavan	O
disease	O
,	O
an	O
inherited	O
leukodystrophy	O
,	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
aspartoacylase	B-DNAMutation
ASPA	B-DNAMutation
gene	O
.	O

It	O
is	O
most	O
common	O
among	O
children	O
of	O
Ashkenazi	O
Jewish	O
descent	O
but	O
has	O
been	O
diagnosed	O
in	O
many	O
diverse	O
ethnic	O
groups	O
.	O

Two	O
mutations	O
comprise	O
the	O
majority	O
of	O
mutant	O
alleles	O
in	O
Jewish	O
patients	O
,	O
while	O
mutations	O
in	O
the	O
ASPA	B-DNAMutation
gene	O
among	O
non-Jewish	O
patients	O
are	O
different	O
and	O
more	O
diverse	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
ASPA	B-DNAMutation
gene	O
was	O
analysed	O
in	O
22	O
unrelated	O
non-Jewish	O
patients	O
with	O
Canavan	O
disease	O
,	O
and	O
24	O
different	O
mutations	O
were	O
found	O
.	O

Of	O
these	O
,	O
14	O
are	O
novel	O
,	O
including	O
five	O
missense	O
mutations	O
(	O
E24G	B-DNAMutation
,	O
D68A	B-DNAMutation
,	O
D249V	B-DNAMutation
,	O
C152W	B-DNAMutation
,	O
H244R	B-DNAMutation
)	O
,	O
two	O
nonsense	O
mutations	O
(	O
Q184X	B-DNAMutation
,	O
E214X	B-DNAMutation
)	O
,	O
three	O
deletions	O
(	O
923delT	B-DNAMutation
,	O
33del13	B-DNAMutation
,	O
244delA	B-DNAMutation
)	O
,	O
one	B-DNAMutation
insertion	I-DNAMutation
mutation	I-DNAMutation
(698insC)	I-DNAMutation
,	O
two	O
sequence	O
variations	O
in	O
one	O
allele	O
(	O
[	O
10T>G	B-DNAMutation
;	I-DNAMutation
11insG]	I-DNAMutation
)	O
,	O
an	O
elimination	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
stop	I-DNAMutation
codon	I-DNAMutation
(	I-DNAMutation
941A>G	I-DNAMutation
,	I-DNAMutation
TAG-->TGG	I-DNAMutation
,	O
X314W	B-DNAMutation
)	O
,	O
and	O
one	O
splice	O
acceptor	O
site	O
mutation	O
(	O
IVS1	B-DNAMutation
-	I-DNAMutation
2A>T	I-DNAMutation
)	O
.	O

The	O
E24G	B-DNAMutation
mutation	O
resulted	O
in	O
substitution	O
of	O
an	O
invariable	O
amino	O
acid	O
residue	O
(Glu)	O
in	O
the	O
first	O
esterase	O
catalytic	O
domain	O
consensus	O
sequence	O
.	O

The	O
IVS1	B-DNAMutation
-	I-DNAMutation
2A>T	I-DNAMutation
mutation	O
caused	O
the	O
retention	B-DNAMutation
of	I-DNAMutation
40	I-DNAMutation
nucleotides	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
1	I-DNAMutation
upstream	I-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
2	I-DNAMutation
.	O

The	O
results	O
of	O
transient	O
expression	O
of	O
the	O
mutant	O
ASPA	B-DNAMutation
cDNA	O
containing	O
these	O
mutations	O
in	O
COS-7	O
cells	O
and	O
assays	O
for	O
ASPA	B-DNAMutation
activity	O
of	O
patient	O
fibroblasts	O
indicated	O
that	O
these	O
mutations	O
were	O
responsible	O
for	O
the	O
enzyme	O
deficiency	O
.	O

In	O
addition	O
,	O
patients	O
with	O
the	O
novel	O
D249V	B-DNAMutation
mutation	O
manifested	O
clinically	O
at	O
birth	O
and	O
died	O
early	O
.	O

Also	O
,	O
patients	O
with	O
certain	O
other	O
novel	O
mutations	O
,	O
including	O
C152W	B-DNAMutation
,	O
E214X	B-DNAMutation
,	O
X314W	B-DNAMutation
,	O
and	O
frame	O
shift	O
mutations	O
in	O
both	O
alleles	O
,	O
developed	O
clinical	O
manifestations	O
at	O
an	O
earlier	O
age	O
than	O
in	O
classical	O
Canavan	O
disease	O
.	O

Mechanism	O
of	O
activation	O
of	O
protein	O
kinase	O
B	O
by	O
insulin	O
and	O
IGF-1	B-DNAMutation
.	O

Insulin	O
activated	O
endogenous	O
protein	B-DNAMutation
kinase	I-DNAMutation
B	I-DNAMutation
alpha	I-DNAMutation
(	O
also	O
known	O
as	O
RAC/Akt	O
kinase	O
)	O
activity	O
12-fold	O
in	O
L6	O
myotubes	O
,	O
while	O
after	O
transfection	O
into	O
293	O
cells	O
PKBalpha	B-DNAMutation
was	O
activated	O
20-	O
and	O
50-fold	O
in	O
response	O
to	O
insulin	O
and	O
IGF-1	B-DNAMutation
respectively	O
.	O

In	O
both	O
cells	O
,	O
the	O
activation	O
of	O
PKBalpha	B-DNAMutation
was	O
accompanied	O
by	O
its	O
phosphorylation	O
at	O
Thr308	O
and	O
Ser473	O
and	O
,	O
like	O
activation	O
,	O
phosphorylation	O
of	O
both	O
of	O
these	O
residues	O
was	O
prevented	O
by	O
the	O
phosphatidylinositol	O
3-kinase	O
inhibitor	O
wortmannin	O
.	O

Thr308	B-DNAMutation
and/or	I-DNAMutation
Ser473	I-DNAMutation
were	I-DNAMutation
mutated	I-DNAMutation
to	I-DNAMutation
Ala	I-DNAMutation
or	I-DNAMutation
Asp	I-DNAMutation
and	O
activities	O
of	O
mutant	O
PKBalpha	B-DNAMutation
molecules	O
were	O
analysed	O
after	O
transfection	O
into	O
293	O
cells	O
.	O

The	O
activity	O
of	O
wild-type	O
and	O
mutant	O
PKBalpha	B-DNAMutation
was	O
also	O
measured	O
in	O
vitro	O
after	O
stoichiometric	O
phosphorylation	O
of	O
Ser473	O
by	O
MAPKAP	B-DNAMutation
kinase-2	I-DNAMutation
.	O

These	O
experiments	O
demonstrated	O
that	O
activation	O
of	O
PKBalpha	B-DNAMutation
by	O
insulin	O
or	O
insulin-like	B-DNAMutation
growth	I-DNAMutation
factor-1	I-DNAMutation
IGF-1	B-DNAMutation
results	O
from	O
phosphorylation	O
of	O
both	O
Thr308	O
and	O
Ser473	O
,	O
that	O
phosphorylation	O
of	O
both	O
residues	O
is	O
critical	O
to	O
generate	O
a	O
high	O
level	O
of	O
PKBalpha	B-DNAMutation
activity	O
and	O
that	O
the	O
phosphorylation	O
of	O
Thr308	O
in	O
vivo	O
is	O
not	O
dependent	O
on	O
phosphorylation	O
of	O
Ser473	O
or	O
vice	O
versa	O
.	O

We	O
propose	O
a	O
model	O
whereby	O
PKBalpha	B-DNAMutation
becomes	O
phosphorylated	O
and	O
activated	O
in	O
insulin/IGF-1-stimulated	B-DNAMutation
cells	O
by	O
an	O
upstream	O
kinase(s)	O
.	O

The	O
structure	O
and	O
expression	O
of	O
genes	O
encoding	O
serologically	O
undetected	O
HLA-C	O
locus	O
antigens	O
.	O

Approximately	O
20	O
to	O
50%	O
individuals	O
in	O
every	O
race	O
are	O
untypable	O
by	O
human	O
alloantisera	O
for	O
at	O
least	O
one	O
allele	O
of	O
HLA-C	O
locus	O
and	O
the	O
surface	O
expression	O
of	O
HLA-C	O
locus	O
Ag	O
in	O
such	O
an	O
individual	O
(	O
HLA-C	O
blank	O
Ag	O
)	O
remains	O
unknown	O
.	O

To	O
investigate	O
the	O
structure	O
and	O
the	O
surface	O
expression	O
of	O
HLA-C	O
blank	O
Ag	O
,	O
two	O
genes	O
(	O
Cb-1	B-DNAMutation
and	O
Cb-2	B-DNAMutation
)	O
encoding	O
HLA-C	O
blank	O
Ag	O
were	O
cloned	O
and	O
their	O
primary	O
structures	O
were	O
determined	O
and	O
compared	O
with	O
other	O
HLA-C	O
locus	O
genes	O
.	O

The	O
similarity	O
of	O
amino	O
acids	O
between	O
Cb-1	B-DNAMutation
and	O
Cw1	B-DNAMutation
was	O
the	O
highest	O
among	O
HLA-C	O
locus	O
genes	O
previously	O
published	O
.	O

Five	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
substitutions	I-DNAMutation
between	I-DNAMutation
these	I-DNAMutation
molecules	I-DNAMutation
were	I-DNAMutation
shown	I-DNAMutation
to	I-DNAMutation
be	I-DNAMutation
located	I-DNAMutation
on	I-DNAMutation
the	I-DNAMutation
beta-strand	I-DNAMutation
of	I-DNAMutation
alpha	I-DNAMutation
1	I-DNAMutation
and	I-DNAMutation
alpha	I-DNAMutation
2	I-DNAMutation
domains	I-DNAMutation
,	O
suggesting	O
that	O
they	O
might	O
change	O
the	O
conformational	O
allodeterminants	O
on	O
the	O
alpha-helical	O
region	O
of	O
Cw1	B-DNAMutation
which	O
were	O
recognized	O
by	O
antibodies	O
.	O

On	O
the	O
other	O
hand	O
,	O
Cb-2	B-DNAMutation
was	O
the	O
closest	O
to	O
Cw2.2	O
.	O

Six	B-DNAMutation
of	I-DNAMutation
nine	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
substitutions	I-DNAMutation
between	I-DNAMutation
these	I-DNAMutation
molecules	I-DNAMutation
were	I-DNAMutation
observed	I-DNAMutation
on	I-DNAMutation
alpha	I-DNAMutation
1	I-DNAMutation
and	I-DNAMutation
alpha	I-DNAMutation
2	I-DNAMutation
domains	I-DNAMutation
,	O
whereas	O
three	O
other	O
substitutions	B-DNAMutation
were	I-DNAMutation
located	I-DNAMutation
on	I-DNAMutation
the	I-DNAMutation
leader	I-DNAMutation
peptide	I-DNAMutation
,	I-DNAMutation
the	I-DNAMutation
alpha	I-DNAMutation
3	I-DNAMutation
domain	I-DNAMutation
and	I-DNAMutation
the	I-DNAMutation
transmembrane	I-DNAMutation
.	O

Two	B-DNAMutation
substitutions	I-DNAMutation
(	I-DNAMutation
residues	I-DNAMutation
73	I-DNAMutation
and	I-DNAMutation
163	I-DNAMutation
)	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
alpha-helical	I-DNAMutation
region	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
alpha	I-DNAMutation
1	I-DNAMutation
and	I-DNAMutation
alpha	I-DNAMutation
2	I-DNAMutation
domains	I-DNAMutation
and	O
one	O
(	O
residue	O
16	O
)	O
of	O
exposed	O
loop	O
may	O
make	O
new	O
allodeterminants	O
which	O
are	O
not	O
recognized	O
by	O
anti-Cw2	O
sera	O
as	O
well	O
as	O
other	O
alloantisera	O
.	O

The	O
surface	O
expression	O
of	O
these	O
genes	O
was	O
examined	O
on	O
transfected	O
mouse	O
L	O
cells	O
and	O
human	O
B	O
cell	O
line	O
.	O

Both	O
gene	O
products	O
were	O
expressed	O
stably	O
on	O
the	O
surface	O
of	O
these	O
cells	O
.	O

These	O
results	O
suggest	O
that	O
HLA-C	O
blank	O
Ag	O
are	O
most	O
probably	O
expressed	O
on	O
cells	O
in	O
HLA-C	O
blank	O
individuals	O
and	O
that	O
the	O
primary	O
structures	O
of	O
these	O
Ag	O
,	O
which	O
were	O
not	O
detectable	O
by	O
the	O
available	O
alloantisera	O
,	O
may	O
be	O
incapable	O
of	O
generating	O
corresponding	O
alloantibodies	O
.	O

Absence	O
of	O
PPP2R1B	B-DNAMutation
gene	O
alterations	O
in	O
primary	O
ovarian	O
cancers	O
.	O

The	O
PPP2R1B	B-DNAMutation
gene	O
has	O
recently	O
been	O
implicated	O
as	O
a	O
tumor	O
suppressor	O
based	O
on	O
the	O
finding	O
of	O
somatic	O
alterations	O
in	O
lung	O
and	O
colon	O
cancers	O
.	O

PPP2R1B	B-DNAMutation
is	O
located	O
on	O
chromosome	O
11q22-24	O
which	O
coincides	O
with	O
the	O
site	O
of	O
frequent	O
loss	O
of	O
heterozygosity	O
(LOH)	O
in	O
ovarian	O
cancer	O
.	O

We	O
investigated	O
if	O
the	O
PPP2R1B	B-DNAMutation
gene	O
was	O
inactivated	O
in	O
ovarian	O
cancer	O
by	O
single	O
strand	O
conformational	O
polymorphism	O
(SSCP)	O
and	O
heteroduplex	O
(HD)	O
analysis	O
of	O
99%	O
of	O
the	O
coding	O
region	O
.	O

LOH	O
at	O
the	O
PPP2R1B	B-DNAMutation
locus	O
was	O
detected	O
in	O
32%	O
of	O
the	O
malignant	O
tumors	O
but	O
no	O
somatic	O
alterations	O
were	O
detected	O
in	O
any	O
of	O
65	O
malignant	O
,	O
five	O
borderline	O
or	O
six	O
benign	O
tumors	O
.	O

A	O
germline	O
G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
transition	I-DNAMutation
(	I-DNAMutation
GGC	I-DNAMutation
>	I-DNAMutation
GAC	I-DNAMutation
)	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
90	I-DNAMutation
was	O
detected	O
in	O
4/76	O
tumors	O
.	O

This	O
alteration	O
has	O
previously	O
been	O
described	O
as	O
a	O
mutation	O
but	O
on	O
further	O
investigation	O
we	O
found	O
that	O
the	O
frequency	O
of	O
this	O
variant	O
among	O
167	O
ovarian	O
cancers	O
(4.2%)	O
was	O
not	O
statistically	O
significantly	O
different	O
from	O
that	O
observed	O
in	O
247	O
non-cancer	O
random	O
controls	O
(2.4%)	O
.	O

We	O
conclude	O
that	O
the	O
PPP2R1B	B-DNAMutation
gene	O
is	O
not	O
involved	O
in	O
the	O
pathogenesis	O
of	O
ovarian	O
cancer	O
.	O

The	O
codon	B-DNAMutation
90	I-DNAMutation
Gly	I-DNAMutation
>	I-DNAMutation
Asp	I-DNAMutation
alteration	O
may	O
represent	O
a	O
non-pathological	O
polymorphism	O
and	O
consequently	O
the	O
mutation	O
frequency	O
reported	O
in	O
lung	O
cancers	O
may	O
have	O
been	O
overstated	O
and	O
the	O
designation	O
of	O
PPP2R1B	B-DNAMutation
as	O
a	O
tumor	O
suppressor	O
gene	O
should	O
be	O
regarded	O
with	O
caution	O
.	O

Foxp3	B-DNAMutation
processing	O
by	O
proprotein	O
convertases	O
and	O
control	O
of	O
regulatory	O
T	O
cell	O
function	O
.	O

Foxp3	B-DNAMutation
is	O
a	O
47-kDa	O
transcription	O
factor	O
central	O
to	O
regulatory	O
T	O
cell	O
(Treg)	O
function	O
.	O

The	O
importance	O
of	O
Foxp3(+)	B-DNAMutation
Tregs	O
in	O
controlling	O
self-reactive	O
T	O
cells	O
and	O
preventing	O
autoimmunity	O
is	O
well	O
established	O
.	O

Our	O
analysis	O
of	O
Foxp3	B-DNAMutation
expression	O
in	O
natural	O
Tregs	O
led	O
to	O
identification	O
of	O
a	O
shorter	O
41-kDa	O
Foxp3	B-DNAMutation
species	O
in	O
activated	O
Tregs	O
,	O
indicating	O
that	O
Foxp3	B-DNAMutation
may	O
be	O
processed	O
by	O
proteolytic	O
cleavage	O
upon	O
cell	O
activation	O
.	O

Searches	O
of	O
murine	O
and	O
human	O
Foxp3	B-DNAMutation
sequences	O
for	O
potential	O
cleavage	O
sites	O
responsible	O
for	O
the	O
generation	O
of	O
the	O
short	O
Foxp3	B-DNAMutation
species	O
revealed	O
the	O
presence	O
of	O
two	O
RXXR	O
proprotein	O
convertase	O
(PC)	O
motifs	O
,	O
(48)RDLR(51)	O
and	O
(414)RKKR(417)	O
,	O
located	O
near	O
the	O
N-	O
and	O
C-terminal	O
ends	O
,	O
respectively	O
.	O

We	O
show	O
,	O
using	O
retroviral	O
expression	O
of	O
Foxp3	B-DNAMutation
in	O
CD4(+)	O
T	O
cells	O
,	O
that	O
Foxp3	B-DNAMutation
is	O
cleaved	O
at	O
both	O
the	O
N-	O
and	O
C-terminal	O
RXXR	O
sites	O
and	O
that	O
mutagenesis	O
of	O
the	O
RXXR	O
motif	O
prevents	O
cleavage	O
.	O

The	O
cleaved	O
forms	O
of	O
Foxp3	B-DNAMutation
are	O
found	O
in	O
the	O
chromatin	O
fraction	O
but	O
not	O
in	O
nuclear	O
or	O
cytoplasmic	O
extracts	O
.	O

CD4(+)	O
T	O
cells	O
expressing	O
Foxp3	B-DNAMutation
species	O
engineered	O
to	O
mimic	O
N-terminally	O
,	O
C-terminally	O
,	O
or	O
N-	O
and	O
C-terminally	O
cleaved	O
Foxp3	B-DNAMutation
forms	O
are	O
functionally	O
distinct	O
,	O
as	O
indicated	O
by	O
differences	O
in	O
expression	O
of	O
key	O
Treg	O
genes	O
,	O
such	O
as	O
interleukin-10	B-DNAMutation
and	O
cytotoxic	B-DNAMutation
T-lymphocyte	I-DNAMutation
antigen	I-DNAMutation
4	I-DNAMutation
CTLA-4	B-DNAMutation
.	O

In	O
addition	O
,	O
CD4(+)	B-DNAMutation
cells	O
expressing	O
C-cleaved	O
Foxp3	B-DNAMutation
are	O
superior	O
to	O
those	O
that	O
express	O
WT	O
Foxp3	B-DNAMutation
in	O
preventing	O
experimental	O
colitis	O
.	O

Coexpression	O
of	O
Foxp3	B-DNAMutation
with	O
PC1	B-DNAMutation
or	O
PC7	B-DNAMutation
results	O
in	O
cleavage	O
of	O
the	O
Foxp3	B-DNAMutation
C	O
terminus	O
.	O

The	O
mechanism	O
by	O
which	O
Foxp3	B-DNAMutation
is	O
processed	O
likely	O
extends	O
to	O
other	O
members	O
of	O
the	O
FoxP	O
subfamily	O
,	O
because	O
Foxp1	B-DNAMutation
and	O
Foxp2	B-DNAMutation
also	O
have	O
N-terminal	O
RXXR	O
proteolytic	O
cleavage	O
motifs	O
at	O
similar	O
locations	O
to	O
Foxp3	B-DNAMutation
.	O

Our	O
results	O
indicate	O
that	O
the	O
generation	O
of	O
fully	O
functionally	O
competent	O
Tregs	O
is	O
complex	O
and	O
dependent	O
on	O
the	O
generation	O
of	O
multiple	O
forms	O
of	O
Foxp3	B-DNAMutation
that	O
have	O
differing	O
effects	O
on	O
Treg	O
cytokine	O
production	O
and	O
suppressive	O
function	O
.	O

Molecular	O
dissection	O
of	O
2B4	B-DNAMutation
signaling	O
:	O
implications	O
for	O
signal	O
transduction	O
by	O
SLAM-related	O
receptors	O
.	O

2B4	B-DNAMutation
is	O
a	O
SLAM-related	O
receptor	O
expressed	O
on	O
natural	O
killer	O
(NK)	O
cells	O
and	O
cytotoxic	O
T	O
cells	O
.	O

It	O
can	O
regulate	O
killing	O
and	O
gamma	O
interferon	O
secretion	O
by	O
NK	O
cells	O
,	O
as	O
well	O
as	O
T-cell-mediated	O
cytotoxicity	O
.	O

There	O
are	O
conflicting	O
data	O
regarding	O
the	O
mechanism	O
of	O
action	O
of	O
2B4	B-DNAMutation
.	O

In	O
these	O
studies	O
,	O
we	O
attempted	O
to	O
understand	O
better	O
the	O
nature	O
and	O
basis	O
of	O
2B4	B-DNAMutation
signaling	O
.	O

Our	O
studies	O
showed	O
that	O
engagement	O
of	O
2B4	B-DNAMutation
on	O
NK	O
cells	O
triggered	O
a	O
tyrosine	O
phosphorylation	O
signal	O
implicating	O
2B4	B-DNAMutation
,	O
Vav-1	B-DNAMutation
,	O
and	O
,	O
to	O
a	O
lesser	O
extent	O
,	O
SHIP-1	B-DNAMutation
and	O
c-Cbl	B-DNAMutation
.	O

Structure-function	O
analyses	O
demonstrated	O
that	O
this	O
response	O
was	O
defined	O
by	O
a	O
series	O
of	O
tyrosine-based	O
motifs	O
in	O
the	O
cytoplasmic	O
region	O
of	O
2B4	B-DNAMutation
and	O
was	O
not	O
influenced	O
by	O
the	O
extracellular	O
or	O
transmembrane	O
segment	O
of	O
2B4	B-DNAMutation
.	O

In	O
addition	O
,	O
the	O
2B4-induced	B-DNAMutation
signal	O
was	O
absolutely	O
dependent	O
on	O
coexpression	O
of	O
SAP	O
,	O
a	O
Src	O
homology	O
2	O
(SH2)	O
domain-containing	O
adaptor	O
associating	O
with	O
SLAM-related	O
receptors	O
and	O
mutated	O
in	O
X-linked	O
lymphoproliferative	O
disease	O
.	O

It	O
was	O
also	O
observed	O
that	O
2B4	B-DNAMutation
was	O
detectably	O
associated	O
with	O
the	O
Src-related	O
protein	O
tyrosine	O
kinase	O
FynT	O
in	O
an	O
immortalized	O
NK	O
cell	O
line	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
arginine	I-DNAMutation
78	I-DNAMutation
of	O
SAP	O
,	O
a	O
residue	O
critical	O
for	O
binding	O
of	O
SAP	O
to	O
FynT	O
,	O
eliminated	O
2B4-mediated	B-DNAMutation
protein	O
tyrosine	O
phosphorylation	O
,	O
implying	O
that	O
SAP	O
promotes	O
2B4	B-DNAMutation
signaling	O
most	O
probably	O
by	O
recruiting	O
FynT	O
.	O

Finally	O
,	O
despite	O
the	O
similarities	O
in	O
the	O
signaling	O
modalities	O
of	O
2B4	B-DNAMutation
and	O
its	O
relative	O
SLAM	B-DNAMutation
,	O
the	O
natures	O
of	O
the	O
tyrosine	O
phosphorylation	O
signals	O
induced	O
by	O
these	O
two	O
receptors	O
were	O
found	O
to	O
be	O
different	O
.	O

These	O
differences	O
were	O
not	O
caused	O
by	O
variations	O
in	O
the	O
extent	O
of	O
binding	O
to	O
SAP	O
but	O
rather	O
were	O
dictated	O
by	O
the	O
tyrosine-based	O
sequences	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
receptors	O
.	O

Taken	O
together	O
,	O
these	O
data	O
lead	O
to	O
a	O
better	O
understanding	O
of	O
2B4	B-DNAMutation
signaling	O
.	O

Furthermore	O
,	O
they	O
provide	O
firm	O
evidence	O
that	O
the	O
signals	O
transduced	O
by	O
the	O
various	O
SLAM-related	O
receptors	O
are	O
unique	O
and	O
that	O
the	O
specificity	O
of	O
these	O
signals	O
is	O
defined	O
by	O
the	O
distinctive	O
arrays	O
of	O
intracytoplasmic	O
tyrosines	O
in	O
the	O
receptors	O
.	O

Anti-lipolytic	O
action	O
of	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
in	O
rodent	O
adipocytes	O
.	O

Despite	O
its	O
importance	O
in	O
terms	O
of	O
energy	O
homeostasis	O
,	O
the	O
role	O
of	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
in	O
adipose	O
tissue	O
remains	O
controversial	O
.	O

Initial	O
studies	O
have	O
described	O
an	O
anti-lipolytic	O
role	O
for	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
,	O
whereas	O
more	O
recent	O
studies	O
have	O
suggested	O
the	O
converse	O
.	O

Thus	O
we	O
have	O
addressed	O
the	O
role	O
of	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
in	O
adipose	O
tissue	O
by	O
modulating	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
activity	O
in	O
primary	O
rodent	O
adipocytes	O
using	O
pharmacological	O
activators	O
or	O
by	O
adenoviral	O
expression	O
of	O
dominant	O
negative	O
or	O
constitutively	O
active	O
forms	O
of	O
the	O
kinase	O
.	O

We	O
then	O
studied	O
the	O
effects	O
of	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
activity	O
modulation	O
on	O
lipolytic	O
mechanisms	O
.	O

Finally	O
,	O
we	O
analyzed	O
the	O
consequences	O
of	O
a	O
genetic	O
deletion	B-DNAMutation
of	I-DNAMutation
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
in	O
mouse	O
adipocytes	O
.	O

AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
activity	O
in	O
adipocytes	O
is	O
represented	O
mainly	O
by	O
the	O
alpha(1)	O
isoform	O
and	O
is	O
induced	O
by	O
all	O
of	O
the	O
stimuli	O
that	O
increase	O
cAMP	O
in	O
adipocytes	O
,	O
including	O
fasting	O
.	O

When	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
activity	O
is	O
increased	O
by	O
5-aminoimidazole-4-carboxamide-riboside	O
,	O
phenformin	O
,	O
or	O
by	O
the	O
expression	O
of	O
a	O
constitutively	O
active	O
form	O
,	O
isoproterenol-induced	O
lipolysis	O
is	O
strongly	O
reduced	O
.	O

Conversely	O
,	O
when	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
activity	O
is	O
decreased	O
either	O
by	O
a	O
dominant	O
negative	O
form	O
or	O
in	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
alpha(1)	O
knock-out	B-DNAMutation
mice	O
,	O
lipolysis	O
is	O
increased	O
.	O

We	O
present	O
data	O
suggesting	O
that	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
acts	O
on	O
hormone-sensitive	O
lipase	O
by	O
blocking	O
its	O
translocation	O
to	O
the	O
lipid	O
droplet	O
.	O

We	O
conclude	O
that	O
,	O
in	O
mature	O
adipocytes	O
,	O
AMP-activated	B-DNAMutation
protein	I-DNAMutation
kinase	I-DNAMutation
activation	O
has	O
a	O
clear	O
anti-lipolytic	O
effect	O
.	O

Phosphorylation	O
of	O
p90	B-DNAMutation
ribosomal	O
S6	O
kinase	O
(RSK)	O
regulates	O
extracellular	O
signal-regulated	O
kinase	O
docking	O
and	O
RSK	O
activity	O
.	O

Stimulation	O
of	O
the	O
Ras/extracellular	B-DNAMutation
signal-regulated	I-DNAMutation
kinase	I-DNAMutation
ERK	B-DNAMutation
pathway	O
can	O
modulate	O
cell	O
growth	O
,	O
proliferation	O
,	O
survival	O
,	O
and	O
motility	O
.	O

The	O
p90	O
ribosomal	O
S6	O
kinases	O
(RSKs)	O
comprise	O
a	O
family	O
of	O
serine/threonine	O
kinases	O
that	O
lie	O
at	O
the	O
terminus	O
of	O
the	O
ERK	B-DNAMutation
pathway	O
.	O

Efficient	O
RSK	O
activation	O
by	O
ERK	B-DNAMutation
requires	O
its	O
interaction	O
through	O
a	O
docking	O
site	O
located	O
near	O
the	O
C	O
terminus	O
of	O
RSK	O
,	O
but	O
the	O
regulation	O
of	O
this	O
interaction	O
remains	O
unknown	O
.	O

In	O
this	O
report	O
we	O
show	O
that	O
RSK1	B-DNAMutation
and	O
ERK1/2	B-DNAMutation
form	O
a	O
complex	O
in	O
quiescent	O
HEK293	O
cells	O
that	O
transiently	O
dissociates	O
upon	O
mitogen	O
stimulation	O
.	O

Complex	O
dissociation	O
requires	O
phosphorylation	B-DNAMutation
of	I-DNAMutation
RSK1	I-DNAMutation
serine	I-DNAMutation
749	I-DNAMutation
,	O
which	O
is	O
a	O
mitogen-regulated	O
phosphorylation	O
site	O
located	O
near	O
the	O
ERK	B-DNAMutation
docking	O
site	O
.	O

Using	O
recombinant	O
RSK1	B-DNAMutation
proteins	O
,	O
we	O
find	O
that	O
serine	B-DNAMutation
749	I-DNAMutation
is	I-DNAMutation
phosphorylated	I-DNAMutation
by	O
the	O
N-terminal	O
kinase	O
domain	O
of	O
RSK1	B-DNAMutation
in	O
vitro	O
,	O
suggesting	O
that	O
ERK1/2	B-DNAMutation
dissociation	O
is	O
mediated	O
through	O
RSK1	B-DNAMutation
autophosphorylation	O
of	O
this	O
residue	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
we	O
find	O
that	O
inactivating	O
mutations	O
in	O
the	O
RSK1	B-DNAMutation
kinase	O
domains	O
disrupted	O
the	O
mitogen-regulated	O
dissociation	O
of	O
ERK1/2	B-DNAMutation
in	O
vivo	O
.	O

Analysis	O
of	O
different	O
RSK	O
isoforms	O
revealed	O
that	O
RSK1	B-DNAMutation
and	O
RSK2	B-DNAMutation
readily	O
dissociate	O
from	O
ERK1/2	B-DNAMutation
following	O
mitogen	O
stimulation	O
but	O
that	O
RSK3	B-DNAMutation
remains	O
associated	O
with	O
active	O
ERK1/2	B-DNAMutation
.	O

RSK	O
activity	O
assays	O
revealed	O
that	O
RSK3	B-DNAMutation
also	O
remains	O
active	O
longer	O
than	O
RSK1	B-DNAMutation
and	O
RSK2	B-DNAMutation
,	O
suggesting	O
that	O
prolonged	O
ERK	B-DNAMutation
association	O
increased	O
the	O
duration	O
of	O
RSK3	B-DNAMutation
activation	O
.	O

These	O
results	O
provide	O
new	O
evidence	O
for	O
the	O
regulated	O
nature	O
of	O
ERK	B-DNAMutation
docking	O
interactions	O
and	O
reveal	O
important	O
differences	O
among	O
the	O
closely	O
related	O
RSK	O
family	O
members	O
.	O

Mutations	O
in	O
the	O
sulonylurea	O
receptor	O
gene	O
are	O
associated	O
with	O
familial	O
hyperinsulinism	O
in	O
Ashkenazi	O
Jews	O
.	O

Familial	O
hyperinsulinism	O
(HI)	O
is	O
a	O
disorder	O
of	O
pancreatic	O
beta-cell	O
function	O
characterized	O
by	O
persistent	O
hyperinsulinism	O
despite	O
severe	O
hypoglycemia	O
.	O

To	O
define	O
the	O
molecular	O
genetic	O
basis	O
of	O
HI	O
in	O
Ashkenazi	O
Jews	O
,	O
25	O
probands	O
were	O
screened	O
for	O
mutations	O
in	O
the	O
sulfonylurea	O
receptor	O
SUR1	B-DNAMutation
gene	O
by	O
single-strand	O
conformation	O
polymorphism	O
(SSCP)	O
analysis	O
of	O
genomic	O
DNA	O
and	O
subsequent	O
nucleotide	O
sequence	O
analyses	O
.	O

Two	O
common	O
mutations	O
were	O
identified	O
:	O
(I)	O
a	O
novel	O
in-frame	B-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
three	I-DNAMutation
nucleotides	I-DNAMutation
(nt)	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
34	I-DNAMutation
,	O
resulting	B-DNAMutation
in	I-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
codon	I-DNAMutation
for	I-DNAMutation
F1388	I-DNAMutation
(	I-DNAMutation
delta	I-DNAMutation
F1388	I-DNAMutation
)	O
and	O
(II)	O
a	O
previously	O
described	O
g-->a	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
position-9	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
3'	I-DNAMutation
splice	I-DNAMutation
site	I-DNAMutation
of	I-DNAMutation
intron	I-DNAMutation
32	I-DNAMutation
(	I-DNAMutation
designated	I-DNAMutation
3992-9g-->a	I-DNAMutation
)	O
.	O

Together	O
,	O
these	O
mutations	O
are	O
associated	O
with	O
88%	O
of	O
the	O
HI	O
chromosomes	O
of	O
the	O
patients	O
studied	O
.	O

86Rb+	O
efflux	O
measurements	O
of	O
COSm6	O
cells	O
co-expressing	O
Kir6.2	B-DNAMutation
and	O
either	O
wild-type	O
or	O
delta	B-DNAMutation
F1388	I-DNAMutation
SUR1	B-DNAMutation
revealed	O
that	O
the	O
F1388	O
mutation	O
abolished	O
ATP-sensitive	O
potassium	O
channel	O
(KATP)	O
activity	O
in	O
intact	O
cells	O
.	O

Extended	O
haplotype	O
analyses	O
indicated	O
that	O
the	O
delta	B-DNAMutation
F1388	I-DNAMutation
mutation	O
was	O
associated	O
with	O
a	O
single	O
specific	O
haplotype	O
whereas	O
the	O
3992-9g-->a	B-DNAMutation
mutation	I-DNAMutation
was	O
primarily	O
associated	O
with	O
a	O
single	O
haplotype	O
but	O
also	O
occurred	O
in	O
the	O
context	O
of	O
several	O
other	O
different	O
haplotypes	O
.	O

These	O
data	O
suggest	O
that	O
HI	O
in	O
Ashkenazi	O
Jews	O
is	O
predominantly	O
associated	O
with	O
mutations	O
in	O
the	O
SUR1	B-DNAMutation
gene	O
and	O
provide	O
evidence	O
for	O
the	O
existence	O
of	O
at	O
least	O
two	O
founder	O
HI	O
chromosomes	O
in	O
this	O
population	O
.	O

Alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
Wbethesda	O
:	O
molecular	O
basis	O
of	O
an	O
unusual	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
deficiency	O
variant	O
.	O

Molecular	O
analysis	O
of	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
(	O
alpha	B-DNAMutation
1AT	I-DNAMutation
)	O
Wbethesda	O
revealed	O
that	O
it	O
differs	O
from	O
the	O
normal	O
M1	O
Ala213	B-DNAMutation
allele	I-DNAMutation
by	I-DNAMutation
a	I-DNAMutation
single	I-DNAMutation
base	I-DNAMutation
mutation	I-DNAMutation
causing	I-DNAMutation
an	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
substitution	I-DNAMutation
Ala336	I-DNAMutation
GCT----Thr	I-DNAMutation
ACT	I-DNAMutation
.	O

Evaluation	O
of	O
alpha	B-DNAMutation
1AT	I-DNAMutation
biosynthesis	O
directed	O
by	O
the	O
Wbethesda	O
allele	O
showed	O
that	O
although	O
Wbethesda	O
alpha	B-DNAMutation
1AT	I-DNAMutation
mRNA	O
was	O
translated	O
normally	O
in	O
vitro	O
,	O
transfection	O
of	O
the	O
Wbethesda	O
cDNA	O
into	O
COS-I	O
cells	O
was	O
associated	O
with	O
human	O
alpha	B-DNAMutation
1AT	I-DNAMutation
secretion	O
of	O
50%	O
that	O
of	O
cells	O
transfected	O
with	O
a	O
normal	O
alpha	B-DNAMutation
1AT	I-DNAMutation
cDNA	O
.	O

The	O
pattern	O
of	O
alpha	B-DNAMutation
1AT	I-DNAMutation
biosynthesis	O
was	O
not	O
intracellular	O
accumulation	O
as	O
observed	O
with	O
the	O
common	O
Z	O
alpha	B-DNAMutation
1AT	I-DNAMutation
deficiency	O
allele	O
,	O
but	O
reduced	O
intracellular	O
alpha	B-DNAMutation
1AT	I-DNAMutation
,	O
suggesting	O
intracellular	O
degradation	O
of	O
the	O
newly	O
synthesized	O
Wbethesda	O
molecule	O
.	O

Together	O
these	O
observations	O
suggest	O
that	O
in	O
heterozygous	O
combination	O
with	O
a	O
Z	O
or	O
Null	O
alpha	B-DNAMutation
1AT	I-DNAMutation
allele	O
,	O
the	O
Wbethesda	O
variant	O
causes	O
"alpha	B-DNAMutation
1AT	I-DNAMutation
deficiency"	O
,	O
thus	O
classifying	O
it	O
as	O
an	O
alpha	B-DNAMutation
1AT	I-DNAMutation
"at	O
risk"	O
allele	O
for	O
emphysema	O
.	O

Mutations	O
in	O
ABCR	B-DNAMutation
ABCA4	B-DNAMutation
in	O
patients	O
with	O
Stargardt	O
macular	O
degeneration	O
or	O
cone-rod	B-DNAMutation
degeneration	I-DNAMutation
.	O

PURPOSE	O
:	O
To	O
determine	O
the	O
spectrum	O
of	O
ABCR	B-DNAMutation
mutations	O
associated	O
with	O
Stargardt	O
macular	O
degeneration	O
and	O
cone-rod	B-DNAMutation
degeneration	I-DNAMutation
CRD	B-DNAMutation
.	O

METHODS	O
:	O
One	O
hundred	O
eighteen	O
unrelated	O
patients	O
with	O
recessive	O
Stargardt	O
macular	O
degeneration	O
and	O
eight	O
with	O
recessive	O
CRD	B-DNAMutation
were	O
screened	O
for	O
mutations	O
in	O
ABCR	B-DNAMutation
ABCA4	B-DNAMutation
by	O
single-strand	O
conformation	O
polymorphism	O
analysis	O
.	O

Variants	O
were	O
characterized	O
by	O
direct	O
genomic	O
sequencing	O
.	O

Segregation	O
analysis	O
was	O
performed	O
on	O
the	O
families	O
of	O
20	O
patients	O
in	O
whom	O
at	O
least	O
two	O
or	O
more	O
likely	O
pathogenic	O
sequence	O
changes	O
were	O
identified	O
.	O

RESULTS	O
:	O
The	O
authors	O
found	O
77	O
sequence	O
changes	O
likely	O
to	O
be	O
pathogenic	O
:	O
21	O
null	O
mutations	O
(	O
15	O
novel	O
)	O
,	O
55	O
missense	O
changes	O
(	O
26	O
novel	O
)	O
,	O
and	O
one	O
deletion	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
consensus	I-DNAMutation
glycosylation	I-DNAMutation
site	I-DNAMutation
(	O
also	O
novel	O
)	O
.	O

Fifty-two	O
patients	O
with	O
Stargardt	O
macular	O
degeneration	O
(	O
44%	O
of	O
those	O
screened	O
)	O
and	O
five	O
with	O
CRD	B-DNAMutation
each	O
had	O
two	O
of	O
these	O
sequence	O
changes	O
or	O
were	O
homozygous	O
for	O
one	O
of	O
them	O
.	O

Segregation	O
analyses	O
in	O
the	O
families	O
of	O
19	O
of	O
these	O
patients	O
were	O
informative	O
and	O
revealed	O
that	O
the	O
index	O
cases	O
and	O
all	O
available	O
affected	O
siblings	O
were	O
compound	O
heterozygotes	O
or	O
homozygotes	O
.	O

The	O
authors	O
found	O
one	O
instance	O
of	O
an	O
apparently	O
de	O
novo	O
mutation	O
,	O
Ile824Thr	B-DNAMutation
,	O
in	O
a	O
patient	O
.	O

Thirty-seven	O
(31%)	O
of	O
the	O
118	O
patients	O
with	O
Stargardt	O
disease	O
and	O
one	O
with	O
CRD	B-DNAMutation
had	O
only	O
one	O
likely	O
pathogenic	O
sequence	O
change	O
.	O

Twenty-nine	O
patients	O
with	O
Stargardt	O
disease	O
(25%)	O
and	O
two	O
with	O
CRD	B-DNAMutation
had	O
no	O
identified	O
sequence	O
changes	O
.	O

CONCLUSIONS	O
:	O
This	O
report	O
of	O
42	O
novel	O
mutations	O
brings	O
the	O
growing	O
number	O
of	O
identified	O
likely	O
pathogenic	O
sequence	O
changes	O
in	O
ABCR	B-DNAMutation
to	O
approximately	O
250	O
.	O

Mutation	O
spectra	O
of	O
ABCC8	B-DNAMutation
gene	O
in	O
Spanish	O
patients	O
with	O
Hyperinsulinism	O
of	O
Infancy	O
(HI)	O
.	O

Hyperinsulinism	O
of	O
Infancy	O
(HI)	O
is	O
a	O
clinical	O
disorder	O
characterized	O
by	O
deregulation	O
of	O
insulin	O
secretion	O
that	O
leads	O
to	O
profound	O
hypoglycemia	O
.	O

Mutations	O
in	O
genes	O
encoding	O
the	O
ATP-regulated	O
potassium	O
channels	O
of	O
the	O
pancreatic	O
beta-cell	O
,	O
namely	O
ABCC8	B-DNAMutation
(SUR1)	O
and	O
KCNJ11	B-DNAMutation
(Kir6.2)	O
,	O
are	O
the	O
major	O
genetic	O
known	O
cause	O
of	O
the	O
disease	O
.	O

To	O
elucidate	O
the	O
genetic	O
etiology	O
of	O
HI	O
in	O
the	O
uncharacterized	O
Spanish	O
population	O
,	O
we	O
conducted	O
extensive	O
sequencing	O
analysis	O
of	O
the	O
ABCC8	B-DNAMutation
(83.5Kb)	O
and	O
KCNJ11	B-DNAMutation
(1.7Kb)	O
genes	O
in	O
34	O
Spanish	O
HI	O
patients	O
.	O

Mutations	O
in	O
ABCC8	B-DNAMutation
were	O
detected	O
for	O
both	O
alleles	O
in	O
13	O
patients	O
,	O
while	O
ten	O
patients	O
carried	O
only	O
one	O
mutation	O
in	O
one	O
of	O
the	O
ABCC8	B-DNAMutation
alleles	O
.	O

We	O
have	O
detected	O
22	O
novel	O
and	O
seven	O
previously	O
described	O
mutations	O
in	O
ABCC8	B-DNAMutation
,	O
approximately	O
60%	O
of	O
them	O
lead	O
to	O
a	O
premature	O
termination	O
signal	O
,	O
which	O
would	O
result	O
in	O
truncated	O
SUR1	O
proteins	O
.	O

No	O
mutations	O
were	O
found	O
in	O
the	O
KCNJ11	B-DNAMutation
gene	O
.	O

In	O
addition	O
,	O
we	O
report	O
for	O
the	O
first	O
time	O
a	O
3914bp	O
macrodeletion	O
associated	O
with	O
the	O
HI	O
disorder	O
.	O

The	O
potential	O
pathogenicity	O
of	O
several	O
additional	O
variants	O
is	O
discussed	O
.	O

The	O
spatial	O
pattern	O
of	O
three	O
pathological	O
mutations	O
suggests	O
possible	O
geographical	O
founder	O
effects	O
.	O

This	O
work	O
reveals	O
for	O
first	O
time	O
the	O
involvement	O
of	O
KATP	O
channels	O
in	O
the	O
pathogenesis	O
of	O
an	O
important	O
proportion	O
(	O
approximately	O
68%	O
)	O
of	O
Spanish	O
HI	O
patients	O
.	O

The	O
spectrum	O
of	O
mutations	O
in	O
Spanish	O
HI	O
patients	O
provides	O
an	O
important	O
tool	O
for	O
diagnosis	O
and	O
prognosis	O
of	O
HI	O
patients	O
in	O
the	O
Spanish	O
population	O
,	O
as	O
well	O
as	O
for	O
genetic	O
counseling	O
of	O
HI	O
families	O
.	O

A	O
valid	O
mouse	O
model	O
of	O
AGRIN-associated	B-DNAMutation
congenital	O
myasthenic	O
syndrome	O
.	O

Congenital	O
myasthenic	O
syndromes	O
(CMS)	O
are	O
inherited	O
diseases	O
affecting	O
the	O
neuromuscular	O
junction	O
(NMJ)	O
.	O

Mutations	O
in	O
AGRIN	B-DNAMutation
AGRN	B-DNAMutation
and	O
other	O
genes	O
in	O
the	O
AGRIN	B-DNAMutation
signaling	O
pathway	O
cause	O
CMS	O
,	O
and	O
gene	O
targeting	O
studies	O
in	O
mice	O
confirm	O
the	O
importance	O
of	O
this	O
pathway	O
for	O
NMJ	O
formation	O
.	O

However	O
,	O
these	O
mouse	O
mutations	O
are	O
complete	O
loss-of-function	O
alleles	O
that	O
result	O
in	O
an	O
embryonic	O
failure	O
of	O
NMJ	O
formation	O
,	O
and	O
homozygous	O
mice	O
do	O
not	O
survive	O
postpartum	O
.	O

Therefore	O
,	O
mouse	O
models	O
of	O
AGRIN-related	B-DNAMutation
CMS	O
that	O
would	O
allow	O
preclinical	O
testing	O
or	O
studies	O
of	O
postnatal	O
disease	O
progression	O
are	O
lacking	O
.	O

Using	O
chemical	O
mutagenesis	O
in	O
mice	O
,	O
we	O
identified	O
a	O
point	O
mutation	O
in	O
Agrn	B-DNAMutation
that	O
results	O
in	O
a	O
partial	O
loss-of-function	O
allele	O
,	O
creating	O
a	O
valid	O
model	O
of	O
CMS	O
.	O

The	O
mutation	O
changes	O
phenylalanine	B-DNAMutation
1061	I-DNAMutation
to	I-DNAMutation
serine	I-DNAMutation
in	O
the	O
SEA	O
domain	O
of	O
AGRIN	B-DNAMutation
,	O
a	O
poorly	O
characterized	O
motif	O
shared	O
by	O
other	O
extracellular	O
proteoglycans	O
.	O

NMJs	O
in	O
homozygous	O
mice	O
progressively	O
degrade	O
postnataly	O
.	O

Severity	O
differs	O
with	O
genetic	O
background	O
,	O
in	O
different	O
muscles	O
,	O
and	O
in	O
different	O
regions	O
within	O
a	O
muscle	O
in	O
a	O
pattern	O
matching	O
mouse	O
models	O
of	O
motor	O
neuron	O
disease	O
.	O

Mutant	O
NMJs	O
have	O
decreased	O
acetylcholine	O
receptor	O
density	O
and	O
an	O
increased	O
subsynaptic	O
reticulum	O
,	O
evident	O
by	O
electron	O
microscopy	O
.	O

Synapses	O
eventually	O
denervate	O
and	O
the	O
muscles	O
atrophy	O
.	O

Molecularly	O
,	O
several	O
factors	O
contribute	O
to	O
the	O
partial	O
loss	O
of	O
AGRIN's	B-DNAMutation
function	O
.	O

The	O
mutant	O
protein	O
is	O
found	O
at	O
NMJs	O
,	O
but	O
is	O
processed	O
differently	O
than	O
wild-type	O
,	O
with	O
decreased	O
glycosylation	O
,	O
changes	O
in	O
sensitivity	O
to	O
the	O
protease	O
neurotrypsin	B-DNAMutation
and	O
other	O
proteolysis	O
,	O
and	O
less	O
efficient	O
externalization	O
and	O
secretion	O
.	O

Therefore	O
,	O
the	O
Agrn	B-DNAMutation
point	O
mutation	O
is	O
a	O
model	O
for	O
CMS	O
caused	O
by	O
Agrn	B-DNAMutation
mutations	O
and	O
potentially	O
other	O
related	O
neuromuscular	O
diseases	O
.	O

Characterization	O
of	O
the	O
gene	O
and	O
protein	O
of	O
the	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
"deficiency"	O
allele	O
Mprocida	O
.	O

The	O
"deficiency"	O
group	O
of	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
(	O
alpha	B-DNAMutation
1AT	I-DNAMutation
)	O
alleles	O
is	O
characterized	O
by	O
alpha	B-DNAMutation
1AT	I-DNAMutation
genes	O
that	O
code	O
for	O
alpha	B-DNAMutation
1AT	I-DNAMutation
present	O
in	O
serum	O
but	O
in	O
amounts	O
insufficient	O
to	O
protect	O
the	O
lower	O
respiratory	O
tract	O
from	O
progressive	O
destruction	O
by	O
its	O
burden	O
of	O
neutrophil	O
elastase	O
.	O

Mprocida	O
,	O
a	O
rare	O
alpha	B-DNAMutation
1AT	I-DNAMutation
allele	O
associated	O
with	O
alpha	B-DNAMutation
1AT	I-DNAMutation
serum	O
levels	O
less	O
than	O
10	O
mg/dl	O
(	O
normal	O
150-350	O
mg/dl	O
)	O
,	O
codes	O
for	O
an	O
alpha	B-DNAMutation
1AT	I-DNAMutation
molecule	O
that	O
focuses	O
on	O
immobilized	O
pH	O
gradient	O
isoelectric	O
gels	O
slightly	O
cathodal	O
to	O
the	O
common	O
normal	O
M1	O
(Val213)	O
protein	O
.	O

On	O
a	O
per	O
molecule	O
basis	O
,	O
Mprocida	O
has	O
a	O
mildly	O
reduced	O
function	O
as	O
an	O
inhibitor	O
,	O
with	O
an	O
association	O
rate	O
constant	O
for	O
human	O
neutrophil	O
elastase	O
of	O
7.0	O
+/-	O
0.1	O
x	O
10(6)	O
M-1	O
s-1	O
(	O
normal	O
M1	O
(Val213)	O
9.3	O
+/-	O
0.8	O
x	O
10(6)	O
,	O
p	O
less	O
than	O
0.01	O
)	O
.	O

The	O
Mprocida	O
molecule	O
behaves	O
normally	O
in	O
vivo	O
with	O
a	O
half-life	O
similar	O
to	O
normal	O
M1	O
alpha	B-DNAMutation
1AT	I-DNAMutation
molecules	O
.	O

Restriction	O
endonuclease	O
mapping	O
demonstrates	O
that	O
the	O
cloned	O
Mprocida	O
gene	O
was	O
grossly	O
intact	O
.	O

Sequencing	O
of	O
all	O
the	O
exons	O
,	O
exon-intron	O
junctions	O
,	O
and	O
the	O
major	O
promoter	O
region	O
demonstrated	O
Mprocida	O
to	O
be	O
identical	O
to	O
the	O
M1	B-DNAMutation
(Val213)	I-DNAMutation
gene	I-DNAMutation
except	I-DNAMutation
for	I-DNAMutation
a	I-DNAMutation
single	I-DNAMutation
base	I-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
II	I-DNAMutation
coding	I-DNAMutation
for	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
41	I-DNAMutation
of	O
the	O
mature	O
protein	O
(	B-DNAMutation
M1	I-DNAMutation
(Val213)	I-DNAMutation
Leu41	I-DNAMutation
CTG----Mprocida	I-DNAMutation
Pro41	I-DNAMutation
CCG	I-DNAMutation
)	O
.	O

Usefully	O
,	O
the	O
coding	O
sequence	O
of	O
the	O
alpha	B-DNAMutation
1AT	I-DNAMutation
residues	O
40-41	O
is	O
recognized	O
by	O
the	O
restriction	O
endonuclease	O
PvuII	O
so	O
that	O
using	O
a	O
probe	O
corresponding	O
to	O
this	O
region	O
of	O
exon	O
II	O
,	O
the	O
Mprocida	O
mutation	O
can	O
be	O
rapidly	O
identified	O
by	O
Southern	O
analysis	O
.	O

Evaluation	O
of	O
the	O
crystallographic	O
structure	O
of	O
alpha	B-DNAMutation
1AT	I-DNAMutation
suggests	O
the	O
Leu41	B-DNAMutation
to	I-DNAMutation
Pro41	I-DNAMutation
mutation	O
may	O
disrupt	O
alpha-helix	O
A	O
in	O
the	O
region	O
of	O
Pro21-Ser45	B-DNAMutation
,	O
suggesting	O
the	O
possibility	O
that	O
the	O
alpha	B-DNAMutation
1AT	I-DNAMutation
Mprocida	O
molecule	O
is	O
unstable	O
and	O
degraded	O
intracellularly	O
prior	O
to	O
secretion	O
.	O

A	O
point	O
mutation	O
inactivating	O
the	O
sulfonylurea	O
receptor	O
causes	O
the	O
severe	O
form	O
of	O
persistent	O
hyperinsulinemic	O
hypoglycemia	O
of	O
infancy	O
in	O
Finland	O
.	O

Mutations	O
in	O
genes	O
encoding	O
the	O
ATP-regulated	O
potassium	O
(K(ATP))	O
channels	O
of	O
the	O
pancreatic	O
beta-cell	O
(	O
SUR1	B-DNAMutation
and	O
Kir6.2	B-DNAMutation
)	O
are	O
the	O
major	O
known	O
cause	O
of	O
persistent	O
hyperinsulinemic	O
hypoglycemia	O
of	O
infancy	O
(PHHI)	O
.	O

We	O
collected	O
all	O
cases	O
of	O
PHHI	O
diagnosed	O
in	O
Finland	O
between	O
1983	O
and	O
1997	O
(	O
n	O
=	O
24	O
)	O
.	O

The	O
overall	O
incidence	O
was	O
1:40,400	O
,	O
but	O
in	O
one	O
area	O
of	O
Central	O
Finland	O
it	O
was	O
as	O
high	O
as	O
1:3,200	O
.	O

Haplotype	O
analysis	O
using	O
polymorphic	O
markers	O
spanning	O
the	O
SUR1/Kir6.2	B-DNAMutation
gene	O
cluster	O
confirmed	O
linkage	O
to	O
the	O
11p	O
region	O
.	O

Sequence	O
analysis	O
revealed	O
a	O
novel	O
point	O
mutation	O
in	O
exon	O
4	O
of	O
SUR1	B-DNAMutation
,	O
predicting	O
a	O
valine	B-DNAMutation
to	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
change	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
187	I-DNAMutation
(V187D)	I-DNAMutation
.	O

Of	O
the	O
total	O
cases	O
,	O
15	O
affected	O
individuals	O
harbored	O
this	O
mutation	O
in	O
heterozygous	O
or	O
homozygous	O
form	O
,	O
and	O
all	O
of	O
these	O
had	O
severe	O
hyperinsulinemia	O
that	O
responded	O
poorly	O
to	O
medical	O
treatment	O
and	O
required	O
subtotal	O
pancreatectomy	O
.	O

No	O
K(ATP)	O
channel	O
activity	O
was	O
observed	O
in	O
beta-cells	O
isolated	O
from	O
a	O
homozygous	O
patient	O
or	O
after	O
coexpression	O
of	O
recombinant	O
Kir6.2	B-DNAMutation
and	O
SUR1	B-DNAMutation
carrying	O
the	O
V187D	B-DNAMutation
mutation	O
.	O

Thus	O
,	O
the	O
mutation	O
produces	O
a	O
nonfunctional	O
channel	O
and	O
,	O
thereby	O
,	O
continuous	O
insulin	B-DNAMutation
secretion	O
.	O

This	O
unique	O
SUR1	B-DNAMutation
mutation	O
explains	O
the	O
majority	O
of	O
PHHI	O
cases	O
in	O
Finland	O
and	O
is	O
strongly	O
associated	O
with	O
a	O
severe	O
form	O
of	O
the	O
disease	O
.	O

These	O
findings	O
provide	O
diagnostic	O
and	O
prognostic	O
utility	O
for	O
suspected	O
PHHI	O
patients	O
.	O

Erythropoietin	B-DNAMutation
induces	O
association	O
of	O
the	O
JAK2	B-DNAMutation
protein	O
tyrosine	O
kinase	O
with	O
the	O
erythropoietin	B-DNAMutation
receptor	I-DNAMutation
in	O
vivo	O
.	O

Protein	O
tyrosine	O
phosphorylation	O
has	O
been	O
hypothesized	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
growth	O
signaling	O
induced	O
by	O
erythropoietin	B-DNAMutation
Epo	B-DNAMutation
,	O
although	O
the	O
Epo	B-DNAMutation
receptor	I-DNAMutation
EpoR	B-DNAMutation
,	O
a	O
member	O
of	O
the	O
cytokine	O
receptor	O
superfamily	O
,	O
lacks	O
a	O
tyrosine	O
kinase	O
domain	O
.	O

Recently	O
,	O
the	O
JAK2	B-DNAMutation
tyrosine	O
kinase	O
was	O
shown	O
to	O
be	O
activated	O
on	O
Epo	B-DNAMutation
stimulation	O
and	O
to	O
bind	O
to	O
the	O
cytoplasmic	O
domain	O
of	O
EpoR	B-DNAMutation
in	O
vitro	O
.	O

To	O
further	O
explore	O
the	O
mechanisms	O
of	O
activation	O
of	O
JAK2	B-DNAMutation
in	O
EpoR-mediated	B-DNAMutation
signal	O
transduction	O
,	O
we	O
assessed	O
the	O
conditions	O
for	O
association	O
of	O
JAK2	B-DNAMutation
with	O
EpoR	B-DNAMutation
in	O
vivo	O
.	O

Epo	B-DNAMutation
stimulation	O
rapidly	O
induced	O
association	O
of	O
JAK2	B-DNAMutation
with	O
the	O
EpoR	B-DNAMutation
in	O
an	O
interleukin	B-DNAMutation
3	I-DNAMutation
(IL-3)-dependent	I-DNAMutation
cell	O
line	O
transfected	O
with	O
the	O
wild-type	O
EpoR	B-DNAMutation
.	O

On	O
Epo	B-DNAMutation
stimulation	O
JAK2	B-DNAMutation
also	O
associated	O
with	O
a	O
truncated	O
mutant	O
EpoR	B-DNAMutation
(H-mutant)	O
,	O
which	O
is	O
mitogenetically	O
active	O
but	O
not	O
tyrosine	O
phosphorylated	O
,	O
indicating	O
that	O
association	O
does	O
not	O
require	O
receptor	O
phosphorylation	O
and	O
occurs	O
in	O
the	O
membrane	O
proximal	O
region	O
.	O

However	O
,	O
association	O
was	O
not	O
detected	O
with	O
mutant	O
receptors	O
inactivated	O
by	O
an	O
internal	O
deletion	O
or	O
a	O
point	O
mutation	O
,	O
Trp282	B-DNAMutation
to	I-DNAMutation
Arg	I-DNAMutation
,	O
in	O
a	O
membrane-proximal	O
cytoplasmic	O
region	O
(	O
PB	O
or	O
PM4	O
mutant	O
,	O
respectively	O
)	O
.	O

Immune	O
complex	O
kinase	O
assays	O
of	O
anti-EpoR	B-DNAMutation
immunoprecipitates	O
also	O
revealed	O
that	O
activated	O
JAK2	B-DNAMutation
associates	O
with	O
the	O
EpoR	B-DNAMutation
in	O
Epo-stimulated	B-DNAMutation
cells	O
.	O

By	O
this	O
approach	O
,	O
association	O
also	O
occurred	O
with	O
the	O
mitogenically	O
active	O
H	O
mutant	O
but	O
not	O
with	O
the	O
mitogenically	O
inactive	O
PB	O
or	O
PM4	O
mutants	O
.	O

In	O
the	O
immune	O
complex	O
kinases	O
assays	O
,	O
EpoR	B-DNAMutation
,	O
JAK2	B-DNAMutation
,	O
and	O
a	O
150-kD	O
protein	O
were	O
phosphorylated	O
on	O
tyrosine	O
.	O

Taken	O
together	O
,	O
the	O
results	O
further	O
support	O
the	O
hypothesis	O
that	O
,	O
on	O
Epo	B-DNAMutation
stimulation	O
,	O
JAK2	B-DNAMutation
associates	O
with	O
the	O
membrane-proximal	O
cytoplasmic	O
region	O
of	O
the	O
EpoR	B-DNAMutation
to	O
be	O
activated	O
and	O
induces	O
tyrosine	O
phosphorylation	O
of	O
cellular	O
substrates	O
,	O
including	O
the	O
EpoR	B-DNAMutation
,	O
to	O
transduce	O
a	O
growth	O
signal	O
.	O

Role	O
of	O
arginine	O
115	O
in	O
fatty	O
acid	O
activation	O
and	O
formaldehyde	O
dehydrogenase	O
activity	O
of	O
human	O
class	O
III	O
alcohol	O
dehydrogenase	O
.	O

Modification	O
of	O
class	O
III	O
alcohol	O
dehydrogenase	O
(	O
chi	O
chi-ADH	O
)	O
with	O
phenylglyoxal	O
eliminates	O
fatty	O
acid	O
activation	O
by	O
pentanoate	O
and	O
octanoate	O
and	O
concomitantly	O
increases	O
specific	O
activity	O
toward	O
ethanol	O
and	O
3-methylcrotyl	O
alcohol	O
2-3-fold	O
.	O

In	O
contrast	O
,	O
chemical	O
modification	O
decreases	O
activity	O
toward	O
S-(hydroxymethyl)glutathione	O
(	O
FDH	B-DNAMutation
activity	O
)	O
and	O
12-hydroxydodecanoic	O
acid	O
by	O
increasing	O
Km	O
,	O
pointing	O
to	O
a	O
role	O
for	O
arginine	O
in	O
binding	O
anionic	O
substrates	O
.	O

Modification	O
with	O
[7-14C]phenylglyoxal	O
indicates	O
that	O
only	O
one	O
arginine	O
residue	O
per	O
subunit	O
is	O
modified	O
.	O

Sequence	O
analysis	O
of	O
tryptic	O
peptides	O
indicates	O
that	O
Arg-115	B-DNAMutation
is	I-DNAMutation
modified	I-DNAMutation
.	O

Site-directed	O
mutation	O
of	O
this	O
residue	O
to	O
alanine	O
eliminates	O
both	O
fatty	O
acid	O
activation	O
and	O
FDH	B-DNAMutation
activity	O
,	O
thus	O
confirming	O
the	O
identity	O
of	O
the	O
modified	O
residue	O
and	O
its	O
function	O
.	O

These	O
results	O
account	O
in	O
part	O
for	O
the	O
unique	O
specificity	O
of	O
chi	O
chi-ADH	O
relative	O
to	O
other	O
human	O
ADH	O
isozymes	O
.	O

Genome-wide	O
association	O
study	O
identifies	O
genetic	O
variants	O
in	O
GOT1	B-DNAMutation
determining	O
serum	O
aspartate	O
aminotransferase	O
levels	O
.	O

We	O
carried	O
out	O
a	O
genome-wide	O
association	O
study	O
of	O
serum	O
aspartate	O
aminotransferase	O
(AST)	O
activity	O
in	O
866	O
Amish	O
participants	O
of	O
the	O
Heredity	O
and	O
Phenotype	O
Intervention	O
Heart	O
Study	O
and	O
identified	O
significant	O
association	O
of	O
AST	O
activity	O
with	O
a	O
cluster	O
of	O
single	O
nucleotide	O
polymorphisms	O
located	O
on	O
chromosome	O
10q24.1	O
(	O
peak	O
association	O
was	O
rs17109512	B-DNAMutation
;	O
P=2.80E-14	O
)	O
,	O
in	O
the	O
vicinity	O
of	O
GOT1	B-DNAMutation
,	O
the	O
gene	O
encoding	O
cytosolic	B-DNAMutation
AST	I-DNAMutation
(cAST)	I-DNAMutation
.	O

Sequencing	O
of	O
GOT1	B-DNAMutation
revealed	O
an	O
in-frame	B-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
three	I-DNAMutation
nucleic	I-DNAMutation
acids	I-DNAMutation
encoding	I-DNAMutation
asparagine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
389	I-DNAMutation
c.1165_1167delAAC	B-DNAMutation
p.Asn389del	B-DNAMutation
in	O
the	O
gene	O
.	O

Deletion	O
carriers	O
had	O
significantly	O
lower	O
AST	O
activity	O
levels	O
compared	O
with	O
homozygotes	O
for	O
the	O
common	O
allele	O
(	O
meanÂ±s.d.	O
:	O
10.0Â±2.8	O
versus	O
18.8Â±5.2âUâl(-1)	O
;	O
P=2.80E-14	O
)	O
.	O

Further	O
genotyping	O
of	O
the	O
deletion	O
in	O
other	O
Amish	O
samples	O
(n=1932)	O
identified	O
an	O
additional	O
20	O
carriers	O
(	O
minor	O
allele	O
frequency	O
(	O
MAF)=0.0052	O
)	O
.	O

The	O
deletion	O
was	O
not	O
detected	O
in	O
647	O
outbred	O
Caucasians	O
.	O

Asn	O
at	O
codon	O
389	O
is	O
conserved	O
among	O
known	O
mammalian	O
cASTs	O
.	O

In	O
vitro	O
transient	O
transfection	O
of	O
wild-type	O
and	O
mutant	I-DNAMutation
cAST	O
indicated	O
that	O
mutant	I-DNAMutation
cAST	O
protein	O
was	O
barely	O
detectable	O
in	O
the	O
cells	O
.	O

Furthermore	O
,	O
even	O
after	O
correction	B-DNAMutation
for	O
cAST	O
expression	O
,	B-DNAMutation
mutant	I-DNAMutation
cAST	O
had	O
markedly	O
diminished	O
enzymatic	O
activity	O
.	O

Remarkably	O
,	O
we	O
did	O
not	O
find	O
any	O
association	O
between	O
the	O
deletion	O
and	O
metabolic	O
traits	O
including	O
serum	O
fasting	O
glucose	B-DNAMutation
or	I-DNAMutation
insulin	O
,	O
fasting	O
and	O
post-meal	O
lipids	O
,	O
inflammatory	O
markers	O
,	O
or	O
sub-clinical	O
markers	O
of	O
cardiovascular	O
disease	O
.	O

In	O
conclusion	O
,	O
we	O
discovered	O
a	O
rare	O
in-frame	O
deletion	B-DNAMutation
in	O
GOT1	O
gene	O
,	O
which	O
inactivates	B-DNAMutation
cAST	O
enzyme	O
in	O
the	O
Old	O
Order	O
Amish	O
.	O

This	O
finding	O
will	O
help	O
us	O
to	O
understand	O
structure	O
and	O
function	O
of	O
the	O
enzyme	O
and	O
would	O
be	O
useful	O
for	O
predicting	O
serum	O
AST	O
levels	O
.	O

Sequence	O
variation	O
in	O
the	O
human	O
angiotensin	B-DNAMutation
converting	I-DNAMutation
enzyme	I-DNAMutation
.	O

Angiotensin	B-DNAMutation
converting	I-DNAMutation
enzyme	I-DNAMutation
(	O
encoded	O
by	O
the	O
gene	O
DCP1	B-DNAMutation
,	O
also	O
known	O
as	O
ACE	B-DNAMutation
)	O
catalyses	O
the	O
conversion	O
of	O
angiotensin	O
I	O
to	O
the	O
physiologically	O
active	O
peptide	O
angiotensin	B-DNAMutation
II	I-DNAMutation
,	O
which	O
controls	O
fluid-electrolyte	O
balance	O
and	O
systemic	O
blood	O
pressure	O
.	O

Because	O
of	O
its	O
key	O
function	O
in	O
the	O
renin-angiotensin	O
system	O
,	O
many	O
association	O
studies	O
have	O
been	O
performed	O
with	O
DCP1	B-DNAMutation
.	O

Nearly	O
all	O
studies	O
have	O
associated	O
the	O
presence	O
(	B-DNAMutation
insertion	I-DNAMutation
,	I-DNAMutation
I	I-DNAMutation
)	I-DNAMutation
or	I-DNAMutation
absence	I-DNAMutation
(	I-DNAMutation
deletion	I-DNAMutation
,	I-DNAMutation
D	I-DNAMutation
)	I-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
287-bp	I-DNAMutation
Alu	I-DNAMutation
repeat	I-DNAMutation
element	I-DNAMutation
in	I-DNAMutation
intron	I-DNAMutation
16	I-DNAMutation
with	O
the	O
levels	O
of	O
circulating	O
enzyme	O
or	O
cardiovascular	O
pathophysiologies	O
.	O

Many	O
epidemiological	O
studies	O
suggest	O
that	O
the	O
DCP1*D	B-DNAMutation
allele	O
confers	O
increased	O
susceptibility	O
to	O
cardiovascular	O
disease	O
;	O
however	O
,	O
other	O
reports	O
have	O
found	O
no	O
such	O
association	O
or	O
even	O
a	O
beneficial	O
effect	O
.	O

We	O
present	O
here	O
the	O
complete	O
genomic	O
sequence	O
of	O
DCP1	B-DNAMutation
from	O
11	O
individuals	O
,	O
representing	O
the	O
longest	O
contiguous	O
scan	O
(	O
24	O
kb	O
)	O
for	O
sequence	O
variation	O
in	O
human	O
DNA	O
.	O

We	O
identified	O
78	O
varying	O
sites	O
in	O
22	O
chromosomes	O
that	O
resolved	O
into	O
13	O
distinct	O
haplotypes	O
.	O

Of	O
the	O
variant	O
sites	O
,	O
17	O
were	O
in	O
absolute	O
linkage	O
disequilibrium	O
with	O
the	O
commonly	O
typed	O
Alu	O
insertion/deletion	O
polymorphism	O
,	O
producing	O
two	O
distinct	O
and	O
distantly	O
related	O
clades	O
.	O

We	O
also	O
identified	O
a	O
major	O
subdivision	O
in	O
the	O
Alu	O
deletion	O
clade	O
that	O
enables	O
further	O
analysis	O
of	O
the	O
traits	O
associated	O
with	O
this	O
gene	O
.	O

The	O
diversity	O
uncovered	O
in	O
DCP1	B-DNAMutation
is	O
comparable	O
to	O
that	O
described	O
for	O
other	O
regions	O
in	O
the	O
human	O
genome	O
.	O

The	O
highly	O
correlated	O
structure	O
in	O
DCP1	B-DNAMutation
raises	O
important	O
issues	O
for	O
the	O
determination	O
of	O
functional	O
DNA	O
variants	O
within	O
genes	O
and	O
genetic	O
studies	O
in	O
humans	O
based	O
on	O
marker	O
association	O
.	O

Eukaryote-specific	O
insertion	O
elements	O
control	O
human	O
ARGONAUTE	O
slicer	O
activity	O
.	O

We	O
have	O
solved	O
the	O
crystal	O
structure	O
of	O
human	B-DNAMutation
ARGONAUTE1	I-DNAMutation
hAGO1	B-DNAMutation
bound	O
to	O
endogenous	O
5'-phosphorylated	O
guide	O
RNAs	O
.	O

To	O
identify	O
changes	O
that	O
evolutionarily	O
rendered	O
hAGO1	B-DNAMutation
inactive	O
,	O
we	O
compared	O
our	O
structure	O
with	O
guide-RNA-containing	O
and	O
cleavage-active	O
hAGO2	B-DNAMutation
.	O

Aside	O
from	O
mutation	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
catalytic	I-DNAMutation
tetrad	I-DNAMutation
residue	I-DNAMutation
,	O
proline	B-DNAMutation
residues	I-DNAMutation
at	I-DNAMutation
positions	I-DNAMutation
670	I-DNAMutation
and	I-DNAMutation
675	I-DNAMutation
in	O
hAGO1	B-DNAMutation
introduce	O
a	O
kink	O
in	O
the	O
cS7	O
loop	O
,	O
forming	O
a	O
convex	O
surface	O
within	O
the	O
hAGO1	O
nucleic-acid-binding	O
channel	O
near	O
the	O
inactive	O
catalytic	O
site	O
.	O

We	O
predicted	O
that	O
even	O
upon	O
restoration	O
of	O
the	O
catalytic	O
tetrad	O
,	O
hAGO1-cS7	B-DNAMutation
sterically	O
hinders	O
the	O
placement	O
of	O
a	O
fully	O
paired	O
guide-target	O
RNA	O
duplex	O
into	O
the	O
endonuclease	O
active	O
site	O
.	O

Consistent	O
with	O
this	O
hypothesis	O
,	O
reconstitution	O
of	O
the	O
catalytic	O
tetrad	O
with	O
R805H	B-DNAMutation
led	O
to	O
low-level	O
hAGO1	B-DNAMutation
cleavage	O
activity	O
,	O
whereas	O
combining	O
R805H	B-DNAMutation
with	O
cS7	O
substitutions	O
P670S	B-DNAMutation
and	O
P675Q	B-DNAMutation
substantially	O
augmented	O
hAGO1	B-DNAMutation
activity	O
.	O

Evolutionary	O
amino	O
acid	O
changes	O
to	O
hAGO1	B-DNAMutation
were	O
readily	O
reversible	O
,	O
suggesting	O
that	O
loading	O
of	O
guide	O
RNA	O
and	O
pairing	O
of	O
seed-based	O
miRNA	O
and	O
target	O
RNA	O
constrain	O
its	O
sequence	O
drift	O
.	O

Palmitoylation	O
of	O
p59fyn	B-DNAMutation
is	O
reversible	O
and	O
sufficient	O
for	O
plasma	O
membrane	O
association	O
.	O

Members	O
of	O
the	O
Src	O
family	O
of	O
protein	O
tyrosine	O
kinases	O
are	O
localized	O
to	O
subspecialized	O
regions	O
of	O
the	O
plasma	O
membrane	O
.	O

Herein	O
we	O
show	O
that	O
the	O
N-terminal	O
SH4	O
region	O
of	O
the	O
Src	O
family	O
member	O
p59fyn	B-DNAMutation
Fyn	B-DNAMutation
is	O
both	O
necessary	O
and	O
sufficient	O
for	O
targeting	O
of	O
Fyn	B-DNAMutation
and	O
heterologous	O
proteins	O
to	O
the	O
plasma	O
membrane	O
and	O
detergent-insoluble	O
subdomains	O
.	O

Attachment	O
of	O
the	O
first	O
16	O
amino	O
acids	O
of	O
Fyn	B-DNAMutation
to	O
a	O
normally	O
cytosolic	O
protein	O
,	O
beta-galactosidase	B-DNAMutation
,	O
resulted	O
in	O
distinct	O
plasma	O
membrane	O
localization	O
of	O
the	O
chimeric	O
protein	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
palmitoylation	I-DNAMutation
site	I-DNAMutation
(cysteine-3)	I-DNAMutation
within	O
Fyn16-beta-galactosidase	B-DNAMutation
or	O
wild-type	O
Fyn	B-DNAMutation
abrogated	O
plasma	O
membrane	O
localization	O
,	O
resulting	O
in	O
redistribution	O
of	O
the	O
mutant	O
proteins	O
into	O
intracellular	O
membranes	O
.	O

Substitution	O
of	O
the	O
SH4	O
motif	O
within	O
Fyn	B-DNAMutation
with	O
heterologous	O
sequences	O
from	O
other	O
palmitoylated	O
proteins	O
(	O
G	O
alpha	O
o	O
and	O
GAP43	B-DNAMutation
)	O
revealed	O
that	O
the	O
presence	O
of	O
palmitate	O
is	O
sufficient	O
to	O
direct	O
plasma	O
membrane	O
localization	O
independent	O
of	O
surrounding	O
amino	O
acid	O
sequences	O
and	O
myristate	O
.	O

Palmitoylated	O
Fyn	B-DNAMutation
chimeras	O
were	O
also	O
enriched	O
in	O
the	O
Triton	O
X-100-resistant	O
matrix	O
,	O
whereas	O
nonpalmitoylated	O
forms	O
of	O
these	O
proteins	O
were	O
detected	O
in	O
the	O
detergent-soluble	O
fraction	O
.	O

The	O
palmitate	O
moiety	O
on	O
Fyn	B-DNAMutation
exhibited	O
a	O
half-life	O
of	O
1.5-2	O
h	O
.	O

In	O
contrast	O
,	O
the	O
half-life	O
of	O
the	O
polypeptide	O
backbone	O
was	O
8	O
h	O
,	O
indicating	O
that	O
palmitoylation	O
is	O
a	O
reversible	O
modification	O
.	O

These	O
studies	O
establish	O
that	O
the	O
palmitoylated	O
SH4	O
sequence	O
of	O
Fyn	B-DNAMutation
can	O
be	O
used	O
to	O
specifically	O
target	O
proteins	O
to	O
the	O
plasma	O
membrane	O
in	O
a	O
reversible	O
manner	O
.	O

Polymorphisms	O
of	O
human	O
aryl	B-DNAMutation
hydrocarbon	I-DNAMutation
receptor	I-DNAMutation
AhR	B-DNAMutation
gene	O
in	O
a	O
French	O
population	O
:	O
relationship	O
with	O
CYP1A1	B-DNAMutation
inducibility	O
and	O
lung	O
cancer	O
.	O

The	O
Ah	B-DNAMutation
receptor	I-DNAMutation
AhR	B-DNAMutation
is	O
a	O
ligand-dependent	O
transcription	O
factor	O
that	O
positively	O
regulates	O
the	O
expression	O
of	O
the	O
CYP1A1	B-DNAMutation
gene	O
.	O

We	O
investigated	O
the	O
genetic	O
polymorphisms	O
of	O
the	O
AhR	B-DNAMutation
gene	O
including	O
the	O
promoter	O
,	O
and	O
examined	O
the	O
link	O
between	O
these	O
polymorphisms	O
,	O
CYP1A1	B-DNAMutation
inducibility	O
and	O
the	O
lung	O
cancer	O
incidence	O
.	O

The	O
AhR	O
promoter	O
region	O
and	O
the	O
11	O
exons	O
of	O
30	O
subjects	O
were	O
screened	O
.	O

Among	O
the	O
three	O
polymorphisms	O
found	O
,	O
two	O
[	O
(	B-DNAMutation
2417)(A/G	I-DNAMutation
)	O
(	B-DNAMutation
(	I-DNAMutation
157)G/A	I-DNAMutation
)	O
]	O
have	O
never	O
been	O
described	O
previously	O
.	O

The	O
1721)(G/A	B-DNAMutation
and	O
2417)(A/G	B-DNAMutation
are	O
localized	O
in	O
exon	O
10	O
and	O
lead	O
to	O
Arg(554)Lys	B-DNAMutation
and	O
Met(786)Val	B-DNAMutation
substitutions	O
,	O
respectively	O
.	O

The	O
other	O
polymorphism	O
was	O
found	O
in	O
the	O
5'-untranslated	O
region	O
,	O
resulting	O
in	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
G	I-DNAMutation
by	I-DNAMutation
an	I-DNAMutation
A	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
157	I-DNAMutation
157)(G/A	B-DNAMutation
.	O

To	O
evaluate	O
the	O
frequency	O
of	O
this	O
allelic	O
variant	O
found	O
,	O
a	O
DNA	O
library	O
of	O
a	O
case-control	O
study	O
of	O
lung	O
cancer	O
(	O
162	O
controls	O
and	O
177	O
patients	O
)	O
was	O
studied	O
.	O

There	O
is	O
no	O
significant	O
association	O
between	O
1721)(G/A	B-DNAMutation
,	O
157)(G/A	B-DNAMutation
and	O
lung	O
cancer	O
:	O
1721)(G/A	B-DNAMutation
and	O
157)(G/A	B-DNAMutation
were	O
detected	O
at	O
the	O
same	O
allele	O
frequency	O
of	O
0.086	O
and	O
0.25	O
,	O
respectively	O
in	O
both	O
controls	O
and	O
patients	O
.	O

2417)(A/G	B-DNAMutation
was	O
found	O
in	O
only	O
one	O
control	O
of	O
100	O
(	O
allele	O
frequency	O
0.005	O
)	O
.	O

Statistical	O
analysis	O
did	O
not	O
show	O
any	O
relationship	O
between	O
both	O
1721)(G/A	B-DNAMutation
and	O
157)(G/A	B-DNAMutation
polymorphisms	O
found	O
and	O
CYP1A1	B-DNAMutation
inducibility	O
.	O

Considering	O
the	O
rareness	O
of	O
the	O
2417)(A/G	B-DNAMutation
allelic	O
variant	O
we	O
were	O
not	O
able	O
to	O
evaluate	O
its	O
association	O
with	O
inducibility	O
.	O

In	O
conclusion	O
,	O
none	O
of	O
the	O
polymorphisms	O
were	O
found	O
to	O
play	O
a	O
key	O
role	O
in	O
the	O
CYP1A1	B-DNAMutation
inducibility	O
or	O
in	O
the	O
susceptibility	O
to	O
develop	O
lung	O
cancer	O
.	O

The	O
mutant	O
leucine-zipper	O
domain	O
impairs	O
both	O
dimerization	O
and	O
suppressive	O
function	O
of	O
Foxp3	B-DNAMutation
in	O
T	O
cells	O
.	O

Regulatory	O
T	O
cells	O
that	O
express	O
the	O
Foxp3	B-DNAMutation
transcription	O
factor	O
play	O
important	O
roles	O
in	O
preventing	O
autoimmune	O
diseases	O
.	O

Although	O
several	O
studies	O
have	O
demonstrated	O
that	O
the	O
lack	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
forkhead	I-DNAMutation
DNA-binding	I-DNAMutation
domain	I-DNAMutation
of	O
Foxp3	B-DNAMutation
caused	O
severe	O
autoimmune	O
disease	O
in	O
scurfy	O
mutant	O
mice	O
,	O
the	O
other	O
functional	O
domains	O
of	O
Foxp3	B-DNAMutation
are	O
less	O
well	O
characterized	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
deletion	O
of	O
glutamic	O
acid	O
DeltaE250	B-DNAMutation
in	O
the	O
leucine-zipper	O
domain	O
of	O
Foxp3	B-DNAMutation
causes	O
a	O
loss	O
of	O
hyporesponsiveness	O
when	O
compared	O
with	O
wild-type	O
Foxp3	B-DNAMutation
upon	O
antigenic	O
stimulation	O
.	O

CD4	O
T	O
cells	O
that	O
ectopically	O
express	O
the	O
glutamic	O
acid	O
mutant	O
show	O
significant	O
losses	O
of	O
suppressor	O
activity	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
.	O

We	O
also	O
demonstrate	O
that	O
regulation	O
of	O
both	O
Th1-	B-DNAMutation
and	O
Th2-type	B-DNAMutation
cytokine	O
secretion	O
in	O
CD4	O
T	O
cells	O
that	O
express	O
wild-type	O
Foxp3	B-DNAMutation
is	O
significantly	O
altered	O
by	O
the	O
deletion	O
of	O
glutamic	O
acid	O
.	O

Defects	O
are	O
also	O
observed	O
in	O
the	O
expression	O
of	O
adhesion	O
molecules	O
,	O
such	O
as	O
l-selectin	B-DNAMutation
CD62L	B-DNAMutation
and	O
CD103	B-DNAMutation
,	O
suggesting	O
an	O
important	O
role	O
of	O
glutamic	O
acid	O
in	O
the	O
migratory	O
behavior	O
of	O
regulatory	O
T	O
cells	O
.	O

Finally	O
,	O
this	O
mutation	O
reduces	O
transcriptional	O
repressor	O
activity	O
and	O
impairs	O
the	O
homodimerization	O
of	O
Foxp3	B-DNAMutation
.	O

Taken	O
together	O
,	O
our	O
results	O
provide	O
insight	O
into	O
the	O
mechanism	O
that	O
controls	O
autoimmune	O
diseases	O
via	O
the	O
deletion	B-DNAMutation
of	I-DNAMutation
this	I-DNAMutation
single	I-DNAMutation
glutamic	I-DNAMutation
acid	I-DNAMutation
residue	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
leucine-zipper	I-DNAMutation
domain	I-DNAMutation
of	O
Foxp3	B-DNAMutation
.	O

N-Linked	O
glycosylation	O
of	O
the	O
human	O
ABC	O
transporter	O
ABCG2	B-DNAMutation
on	O
asparagine	O
596	O
is	O
not	O
essential	O
for	O
expression	O
,	O
transport	O
activity	O
,	O
or	O
trafficking	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
human	O
ATP-binding	O
cassette	O
half-transporter	O
ABCG2	B-DNAMutation
is	O
a	O
72	O
kDa	O
plasma	O
membrane	O
protein	O
that	O
can	O
confer	O
multidrug	O
resistance	O
to	O
cells	O
in	O
culture	O
when	O
overexpressed	O
.	O

Both	O
transiently	O
and	O
stably	O
expressed	O
ABCG2	B-DNAMutation
are	O
glycosylated	O
,	O
and	O
treatment	O
with	O
peptide	O
N-glycosidase	O
F	O
reduces	O
the	O
apparent	O
molecular	O
mass	O
on	O
SDS-PAGE	O
gels	O
to	O
approximately	O
60	O
kDa	O
.	O

Sequence	O
analysis	O
revealed	O
three	O
potential	O
N-linked	O
glycosylation	O
sites	O
in	O
human	O
ABCG2	B-DNAMutation
at	O
amino	O
acids	O
418	O
,	O
557	O
,	O
and	O
596	O
.	O

Site-directed	O
mutagenesis	O
experiments	O
,	O
in	O
which	O
each	B-DNAMutation
Asn	I-DNAMutation
was	I-DNAMutation
changed	I-DNAMutation
to	I-DNAMutation
Gln	I-DNAMutation
independently	O
,	O
revealed	O
that	O
only	O
asparagine	O
596	O
is	O
N-linked	O
glycosylated	O
.	O

These	O
data	O
provide	O
the	O
first	O
direct	O
identification	O
of	O
the	O
modified	O
residue	O
in	O
ABCG2	B-DNAMutation
and	O
evidence	O
for	O
the	O
localization	O
of	O
loop	O
5	O
to	O
the	O
extracellular	O
space	O
,	O
previously	O
only	O
predicted	O
from	O
hydropathy	O
analysis	O
.	O

Immunoblot	O
and	O
pulse-chase	O
analyses	O
revealed	O
that	O
the	O
glycosylation-deficient	O
ABCG2	B-DNAMutation
N596Q	B-DNAMutation
variant	O
and	O
the	O
glycosylated	O
parent	O
transporter	O
are	O
expressed	O
equivalently	O
at	O
steady	O
state	O
and	O
have	O
similar	O
half-lives	O
.	O

Cell	O
surface	O
analysis	O
of	O
ABCG2	B-DNAMutation
expression	O
showed	O
comparable	O
amounts	O
of	O
the	O
N596Q	B-DNAMutation
variant	O
present	O
at	O
the	O
plasma	O
membrane	O
compared	O
to	O
the	O
glycosylated	O
ABCG2	B-DNAMutation
protein	O
.	O

The	O
ABCG2	B-DNAMutation
N596Q	B-DNAMutation
variant	O
is	O
also	O
functional	O
,	O
demonstrating	O
rhodamine	O
123	O
transport	O
in	O
intact	O
cells	O
comparable	O
to	O
that	O
in	O
cells	O
expressing	O
glycosylated	O
ABCG2	B-DNAMutation
.	O

Furthermore	O
,	O
in	O
crude	O
membrane	O
preparations	O
,	O
neither	O
the	O
basal	O
nor	O
the	O
prazosin-stimulated	O
(	O
approximately	O
2-fold	O
)	O
ATPase	O
activities	O
of	O
ABCG2	B-DNAMutation
(N596Q)	O
were	O
affected	O
compared	O
to	O
glycosylated	O
ABCG2	B-DNAMutation
.	O

Although	O
subtle	O
defects	O
in	O
transporter	O
trafficking	O
and	O
function	O
may	O
exist	O
,	O
these	O
data	O
taken	O
together	O
suggest	O
that	O
N-glycosylation	O
at	O
arginine	O
596	O
is	O
not	O
essential	O
for	O
the	O
expression	O
,	O
trafficking	O
to	O
the	O
plasma	O
membrane	O
,	O
or	O
the	O
overall	O
function	O
of	O
ABCG2	B-DNAMutation
.	O

A	O
SNP	O
in	O
the	O
ABCC11	B-DNAMutation
gene	O
is	O
the	O
determinant	O
of	O
human	O
earwax	O
type	O
.	O

Human	O
earwax	O
consists	O
of	O
wet	O
and	O
dry	O
types	O
.	O

Dry	O
earwax	O
is	O
frequent	O
in	O
East	O
Asians	O
,	O
whereas	O
wet	O
earwax	O
is	O
common	O
in	O
other	O
populations	O
.	O

Here	O
we	O
show	O
that	O
a	O
SNP	O
,	O
538G	B-DNAMutation
-->	I-DNAMutation
A	I-DNAMutation
rs17822931	B-DNAMutation
,	O
in	O
the	O
ABCC11	B-DNAMutation
gene	O
is	O
responsible	O
for	O
determination	O
of	O
earwax	O
type	O
.	O

The	O
AA	O
genotype	O
corresponds	O
to	O
dry	O
earwax	O
,	O
and	O
GA	O
and	O
GG	O
to	O
wet	O
type	O
.	O

A	O
27-bp	B-DNAMutation
deletion	I-DNAMutation
in	I-DNAMutation
ABCC11	I-DNAMutation
exon	I-DNAMutation
29	I-DNAMutation
was	O
also	O
found	O
in	O
a	O
few	O
individuals	O
of	O
Asian	O
ancestry	O
.	O

A	O
functional	O
assay	O
demonstrated	O
that	O
cells	O
with	O
allele	O
A	O
show	O
a	O
lower	O
excretory	O
activity	O
for	O
cGMP	O
than	O
those	O
with	O
allele	O
G	O
.	O

The	O
allele	O
A	O
frequency	O
shows	O
a	O
north-south	O
and	O
east-west	O
downward	O
geographical	O
gradient	O
;	O
worldwide	O
,	O
it	O
is	O
highest	O
in	O
Chinese	O
and	O
Koreans	O
,	O
and	O
a	O
common	O
dry-type	O
haplotype	O
is	O
retained	O
among	O
various	O
ethnic	O
populations	O
.	O

These	O
suggest	O
that	O
the	O
allele	O
A	O
arose	O
in	O
northeast	O
Asia	O
and	O
thereafter	O
spread	O
through	O
the	O
world	O
.	O

The	O
538G	B-DNAMutation
-->	I-DNAMutation
A	I-DNAMutation
SNP	O
is	O
the	O
first	O
example	O
of	O
DNA	O
polymorphism	O
determining	O
a	O
visible	O
genetic	O
trait	O
.	O

CYP11B1	B-DNAMutation
mutations	O
causing	O
non-classic	O
adrenal	O
hyperplasia	O
due	O
to	O
11	O
beta-hydroxylase	O
deficiency	O
.	O

Steroid	O
11	O
beta-hydroxylase	O
deficiency	O
is	O
the	O
second	O
most	O
common	O
cause	O
of	O
congenital	O
adrenal	O
hyperplasia	O
,	O
the	O
inherited	O
inability	O
to	O
synthesize	O
cortisol	O
.	O

Severely	O
affected	O
patients	O
carry	O
mutations	O
in	O
the	O
CYB11B1	O
gene	O
that	O
destroy	O
enzymatic	O
activity	O
.	O

Such	O
patients	O
have	O
signs	O
of	O
androgen	O
excess	O
and	O
usually	O
have	O
hypertension	O
.	O

Mild	O
or	O
non-classic	O
11	O
beta-hydroxylase	O
deficiency	O
has	O
been	O
reported	O
previously	O
but	O
not	O
studied	O
genetically	O
.	O

In	O
this	O
study	O
we	O
report	O
analysis	O
of	O
the	O
CYP11B1	B-DNAMutation
genes	O
of	O
three	O
patients	O
thought	O
to	O
suffer	O
from	O
non-classic	O
11	O
beta-hydroxylase	O
deficiency	O
.	O

Mutations	O
were	O
detected	O
in	O
the	O
CYP11B1	B-DNAMutation
genes	O
of	O
two	O
patients	O
.	O

One	O
was	O
a	O
compound	O
heterozygote	O
for	O
missense	O
mutations	O
N133H	B-DNAMutation
and	O
T319M	B-DNAMutation
,	O
whereas	O
the	O
other	O
carried	O
a	O
nonsense	O
mutation	O
Y423X	B-DNAMutation
on	O
one	O
allele	O
and	O
a	O
missense	O
mutation	O
P42S	B-DNAMutation
on	O
the	O
other	O
.	O

All	O
three	O
missense	O
mutations	O
affected	O
enzymatic	O
activity	O
when	O
expressed	O
in	O
vitro	O
.	O

No	O
mutations	O
were	O
detected	O
in	O
the	O
coding	O
regions	O
or	O
intron-exon	O
boundaries	O
of	O
the	O
CYP11B1	B-DNAMutation
genes	O
of	O
the	O
other	O
putative	O
non-classic	O
patient	O
.	O

In	O
addition	O
,	O
we	O
were	O
unable	O
to	O
detect	O
CYP11B1	B-DNAMutation
mutations	O
in	O
two	O
hirsute	O
women	O
with	O
mildly	O
elevated	O
levels	O
of	O
11	O
beta-hydroxylase	O
precursors	O
who	O
had	O
previously	O
been	O
identified	O
in	O
a	O
screening	O
study	O
of	O
patients	O
in	O
a	O
reproductive	O
endocrinology	O
clinic	O
.	O

We	O
conclude	O
that	O
nonclassic	O
11	O
beta-hydroxylase	O
deficiency	O
is	O
a	O
rare	O
disorder	O
.	O

It	O
is	O
not	O
a	O
significant	O
cause	O
of	O
hyperandrogenism	O
in	O
women	O
and	O
relatively	O
stringent	O
criteria	O
should	O
be	O
used	O
to	O
prevent	O
its	O
misdiagnosis	O
.	O

The	O
UIM	O
domain	O
of	O
Hrs	O
couples	O
receptor	O
sorting	O
to	O
vesicle	O
formation	O
.	O

Hepatocyte	O
growth	O
factor	O
regulated	O
tyrosine	O
kinase	O
substrate	O
(Hrs)	O
,	O
a	O
main	O
component	O
of	O
the	O
'bilayered'	O
clathrin	O
coat	O
on	O
sorting	O
endosomes	O
,	O
was	O
originally	O
identified	O
as	O
a	O
substrate	O
of	O
activated	O
tyrosine	O
kinase	O
receptors	O
.	O

We	O
have	O
analysed	O
Hrs	O
phosphorylation	O
in	O
response	O
to	O
epidermal	O
growth	O
factor	O
(EGF)	O
stimulation	O
and	O
show	O
that	O
the	O
evolutionary	O
conserved	O
tyrosines	O
Y329	O
and	O
Y334	O
provide	O
the	O
principal	O
phosphorylation	O
sites	O
.	O

Hrs	O
is	O
proposed	O
to	O
concentrate	O
ubiquitinated	O
receptors	O
within	O
clathrin-coated	O
regions	O
via	O
direct	O
interaction	O
with	O
its	O
UIM	O
(	O
ubiquitin	O
interaction	O
motif	O
)	O
domain	O
.	O

We	O
show	O
that	O
the	O
same	O
UIM	O
domain	O
is	O
necessary	O
for	O
EGF-stimulated	O
tyrosine	O
phosphorylation	O
of	O
Hrs	O
.	O

Over-expression	O
of	O
wild-type	O
Hrs	O
or	O
a	O
double	O
mutant	O
,	O
Y329/334F	B-DNAMutation
,	O
defective	O
in	O
EGF-dependent	O
phosphorylation	O
,	O
both	O
substantially	O
retard	O
EGF	B-DNAMutation
receptor	I-DNAMutation
EGFR	B-DNAMutation
degradation	O
by	O
inhibiting	O
internal	O
vesicle	O
formation	O
and	O
thereby	O
preventing	O
EGFR	B-DNAMutation
incorporation	O
into	O
lumenal	O
vesicles	O
of	O
the	O
multivesicular	O
bodies	O
.	O

In	O
contrast	O
,	O
mutation	B-DNAMutation
or	I-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
Hrs-UIM	I-DNAMutation
domain	I-DNAMutation
strongly	O
suppresses	O
this	O
effect	O
.	O

In	O
addition	O
the	O
UIM-deletion	B-DNAMutation
and	O
point	O
mutants	O
are	O
also	O
observed	O
on	O
internal	O
membranes	O
,	O
indicating	O
a	O
failure	O
to	O
dissociate	O
from	O
the	O
endosomal	O
membrane	O
prior	O
to	O
incorporation	O
of	O
the	O
receptor	O
complex	O
into	O
lumenal	O
vesicles	O
.	O

Our	O
data	O
suggest	O
a	O
role	O
for	O
the	O
UIM-domain	O
of	O
Hrs	O
in	O
actively	O
retaining	O
EGFR	B-DNAMutation
at	O
the	O
limiting	O
membrane	O
of	O
endosomes	O
as	O
a	O
prelude	O
to	O
lumenal	O
vesicle	O
formation	O
.	O

Functional	O
analysis	O
of	O
the	O
Ala67Thr	B-DNAMutation
polymorphism	O
in	O
agouti	O
related	O
protein	O
associated	O
with	O
anorexia	O
nervosa	O
and	O
leanness	O
.	O

AgRP	B-DNAMutation
is	O
a	O
neuropeptide	O
that	O
stimulates	O
food	O
intake	O
through	O
inhibition	O
of	O
central	O
melanocortin	O
receptors	O
(MCRs)	O
.	O

In	O
humans	O
,	O
the	O
non-conservative	B-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
substitution	I-DNAMutation
Alanine	I-DNAMutation
(Ala)	I-DNAMutation
67	I-DNAMutation
Threonine	I-DNAMutation
(Thr)	I-DNAMutation
has	O
been	O
associated	O
with	O
Anorexia	O
Nervosa	O
and	O
with	O
leanness	O
.	O

In	O
the	O
present	O
study	O
,	O
the	O
cellular	O
distribution	O
,	O
processing	O
and	O
in	O
vitro	O
and	O
in	O
vivo	O
activities	O
of	O
Ala67	O
and	O
Thr67	O
AgRP	B-DNAMutation
were	O
investigated	O
.	O

Western	O
blots	O
of	O
media	O
and	O
lysates	O
of	O
BHK	O
cells	O
stably	O
transfected	O
with	O
Ala67	O
or	O
Thr67	O
expression	O
constructs	O
showed	O
identical	O
AgRP	B-DNAMutation
bands	O
.	O

Both	O
Ala67	O
and	O
Thr67	O
AgRP	O
colocalised	O
with	O
the	O
Golgi	O
apparatus	O
,	O
but	O
not	O
with	O
the	O
ER	O
or	O
lysosomes	O
when	O
expressed	O
in	O
Att20	B-DNAMutation
D16V	I-DNAMutation
cells	O
.	O

Also	O
,	O
no	O
differences	O
were	O
observed	O
between	O
the	O
potencies	O
of	O
bacterially	O
expressed	O
Ala67	O
and	O
Thr67	O
AgRP	O
to	O
stimulate	O
MC4R	B-DNAMutation
in	O
a	O
reporter	O
gene	O
assay	O
or	O
inhibit	O
food	O
intake	O
in	O
rats	O
.	O

Taken	O
together	O
,	O
no	O
evidence	O
was	O
found	O
for	O
a	O
functional	O
defect	O
of	O
Thr67	O
AgRP	B-DNAMutation
related	O
to	O
MC4R	B-DNAMutation
interactions	O
.	O

Long	O
sleep	O
and	O
short	O
sleep	O
mice	O
differ	O
in	O
nicotine-stimulated	O
86Rb+	O
efflux	O
and	O
alpha4	O
nicotinic	O
receptor	O
subunit	O
cDNA	O
sequence	O
.	O

In	O
a	O
recent	O
study	O
,	O
we	O
reported	O
that	O
a	O
restriction	O
fragment	O
length	O
polymorphism	O
associated	O
with	O
the	O
alpha4	O
nicotinic	O
receptor	O
gene	O
Chrna4	B-DNAMutation
may	O
play	O
a	O
role	O
in	O
regulating	O
differential	O
sensitivity	O
of	O
LS	O
and	O
SS	O
mouse	O
lines	O
to	O
the	O
seizure-inducing	O
effects	O
of	O
nicotine	O
.	O

Since	O
the	O
alpha4	O
subunit	O
CHRNA4	B-DNAMutation
is	O
often	O
found	O
as	O
a	O
heteromer	O
with	O
the	O
beta2	O
subunit	O
CHRNB2	B-DNAMutation
,	O
alpha4	O
and	O
beta2	O
cDNAs	O
from	O
the	O
LS	O
and	O
SS	O
mice	O
were	O
cloned	O
and	O
sequenced	O
.	O

A	O
polymorphism	O
in	O
the	O
coding	O
portion	O
of	O
the	O
alpha4	O
gene	O
was	O
found	O
(	O
1587A	B-DNAMutation
to	I-DNAMutation
G	I-DNAMutation
)	O
which	O
should	O
result	O
in	O
a	O
threonine/alanine	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
529	I-DNAMutation
T529A	B-DNAMutation
.	O

The	O
LS	O
and	O
SS	O
beta2	O
nicotinic	O
receptor	O
subunit	O
cDNAs	O
were	O
identical	O
.	O

The	O
potential	O
consequences	O
of	O
the	O
alpha4	O
polymorphism	O
were	O
evaluated	O
using	O
an	O
ion	O
(86Rb+)	O
flux	O
assay	O
that	O
likely	O
measures	O
the	O
function	O
of	O
alpha4beta2-type	O
receptors	O
.	O

LS-SS	O
differences	O
in	O
maximal	O
nicotine-stimulated	O
ion	O
flux	O
were	O
seen	O
when	O
bovine	B-DNAMutation
serum	I-DNAMutation
albumin	I-DNAMutation
(BSA)	O
was	O
not	O
included	O
but	O
this	O
difference	O
was	O
not	O
seen	O
when	O
BSA	O
was	O
included	O
in	O
the	O
perfusion	O
buffer	O
.	O

Current	O
evidence	O
suggests	O
that	O
BSA	O
may	O
alter	O
the	O
ratio	O
of	O
nicotinic	O
receptors	O
that	O
are	O
in	O
the	O
ground	O
state	O
and	O
desensitized	O
forms	O
.	O

Thus	O
,	O
it	O
may	O
be	O
that	O
the	O
Chrna4	B-DNAMutation
T529A	B-DNAMutation
substitution	O
leads	O
to	O
a	O
difference	O
in	O
the	O
ratio	O
of	O
the	O
two	O
receptor	O
forms	O
which	O
then	O
promotes	O
differences	O
in	O
receptor	O
function	O
,	O
as	O
well	O
as	O
differential	O
behavioural	O
sensitivity	O
to	O
nicotine	O
.	O

Structural	O
diversity	O
in	O
the	O
HLA-A10	O
family	O
of	O
alleles	O
:	O
correlations	O
with	O
serology	O
.	O

The	O
HLA-A10	O
crossreacting	O
group	O
consists	O
of	O
the	O
A25	B-DNAMutation
,	O
A26	B-DNAMutation
,	O
A34	O
,	O
A43	O
and	O
A66	O
antigens	O
.	O

Here	O
,	O
we	O
report	O
allelic	O
sequences	O
for	O
A43	O
and	O
for	O
2	O
subtypes	O
of	O
both	O
A26	B-DNAMutation
and	O
A34	O
.	O

Combining	O
these	O
results	O
with	O
previously	O
determined	O
sequences	O
for	O
A25	B-DNAMutation
,	O
A26	B-DNAMutation
and	O
A66	O
enables	O
molecular	O
comparison	O
of	O
all	O
the	O
serologically	O
defined	O
A10	B-DNAMutation
antigens	O
.	O

They	O
form	O
a	O
closely	O
related	O
and	O
well-defined	O
group	O
of	O
alleles	O
which	O
may	O
have	O
originated	O
with	O
A*2601	O
.	O

Patterns	O
of	O
serological	O
crossreactivity	O
are	O
correlated	O
with	O
sequence	O
and	O
a	O
public	O
epitope	O
shared	O
by	O
A33	O
and	O
members	O
of	O
the	O
A10	B-DNAMutation
family	O
is	O
localized	O
to	O
residues	O
R62	O
and	O
N63	O
.	O

The	O
A*2501	O
,	O
A*4301	O
and	O
A*6601	O
alleles	O
appear	O
to	O
have	O
derived	O
from	O
A*2601	O
by	O
single	O
gene	O
conversion	O
events	O
with	O
other	O
HLA-A	B-DNAMutation
alleles	O
.	O

In	O
the	O
case	O
of	O
A*4301	O
,	O
the	O
donor	O
allele	O
was	O
probably	O
an	O
A29	B-DNAMutation
allele	O
as	O
A*4301	O
has	O
a	O
small	O
element	O
of	O
sequence	O
in	O
the	O
alpha	O
1	O
helix	O
(	O
residues	O
L62	O
and	O
Q63	O
)	O
uniquely	O
shared	O
with	O
A29	B-DNAMutation
.	O

The	O
chimaeric	O
structure	O
of	O
A43	O
explains	O
the	O
reactivity	O
of	O
A43	O
molecules	O
with	O
both	O
A10	B-DNAMutation
and	O
A29	B-DNAMutation
alloantisera	O
.	O

The	O
rare	O
Oriental	O
variant	O
of	O
A26	B-DNAMutation
(A26v*)	O
is	O
encoded	O
by	O
an	O
allele	O
(A*2602)	O
that	O
differs	O
from	O
A*2601	O
by	O
a	O
unique	O
nucleotide	O
substitution	O
which	O
changes	O
aspartate	B-DNAMutation
to	I-DNAMutation
asparagine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
116	I-DNAMutation
in	O
the	O
floor	O
of	O
the	O
peptide	O
binding	O
groove	O
.	O

Thus	O
A*2602	O
is	O
a	O
functionally	O
distinct	O
allele	O
that	O
originated	O
by	O
a	O
point	O
mutation	O
.	O

Alleles	O
encoding	O
A34	O
and	O
A66	O
antigens	O
are	O
found	O
to	O
have	O
very	O
similar	O
structures	O
,	O
explaining	O
the	O
difficulty	O
in	O
their	O
serological	O
definition.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Molecular	O
characterisation	O
of	O
two	O
alpha-1-antitrypsin	B-DNAMutation
deficiency	O
variants	O
:	O
proteinase	O
inhibitor	O
(Pi)	O
Null(Newport)	O
Gly115----Ser	B-DNAMutation
and	O
(Pi)	O
Z	O
Wrexham	O
Ser-19----Leu	B-DNAMutation
.	O

Two	O
single	O
point	O
mutations	O
in	O
the	O
alpha-1-antitrypsin	B-DNAMutation
gene	O
,	O
resulting	O
in	O
AAT	O
deficiency	O
,	O
have	O
been	O
characterised	O
in	O
heterozygotes	O
by	O
DNA	O
amplification	O
and	O
direct	O
sequencing	O
.	O

The	O
mutations	O
result	O
in	O
amino	O
acid	O
substitutions	O
,	O
Gly115----Ser	B-DNAMutation
and	O
Ser-19----Leu	B-DNAMutation
,	O
in	O
the	O
leader	O
sequence	O
,	O
respectively	O
,	O
and	O
have	O
been	O
designated	O
Pi	O
Null(Newport)	O
and	O
Pi	O
Z	O
Wrexham	O
.	O

In	O
the	O
two	O
families	O
studied	O
the	O
mutations	O
occur	O
on	O
chromosomes	O
which	O
also	O
carry	O
the	O
common	O
mutation	O
causing	O
Z	O
deficiency	O
.	O

Individuals	O
with	O
such	O
a	O
deficiency	O
are	O
,	O
therefore	O
,	O
compound	O
heterozygotes	O
.	O

It	O
is	O
not	O
known	O
if	O
these	O
particular	O
mutations	O
would	O
only	O
cause	O
a	O
mild	O
form	O
of	O
AAT	O
deficiency	O
in	O
the	O
absence	O
of	O
the	O
Z	O
mutation	O
as	O
they	O
do	O
not	O
appear	O
to	O
cause	O
predictable	O
folding	O
abnormalities	O
.	O

They	O
do	O
,	O
however	O
,	O
result	O
in	O
severe	O
deficiency	O
when	O
the	O
Z	O
mutation	O
occurs	O
in	O
the	O
same	O
gene	O
.	O

Human	O
glutamate	O
pyruvate	O
transaminase	O
GPT	B-DNAMutation
:	O
localization	O
to	O
8q24.3	O
,	O
cDNA	O
and	O
genomic	O
sequences	O
,	O
and	O
polymorphic	O
sites	O
.	O

Two	I-DNAMutation
frequent	O
protein	O
variants	O
of	O
glutamate	O
pyruvate	O
transminase	O
GPT	B-DNAMutation
(E.C.2.6.1.2)	O
have	O
been	O
used	O
as	O
genetic	O
markers	O
in	O
humans	O
for	O
more	O
than	O
two	O
decades	O
,	O
although	O
chromosomal	O
mapping	O
of	O
the	O
GPT	B-DNAMutation
locus	O
in	O
the	O
1980s	O
produced	O
conflicting	O
results	O
.	O

To	O
resolve	O
this	O
conflict	O
and	O
develop	O
useful	O
DNA	O
markers	O
for	O
this	O
gene	O
,	O
we	O
isolated	O
and	O
characterized	O
cDNA	O
and	O
genomic	O
clones	O
of	O
GPT	B-DNAMutation
.	O

We	O
have	O
definitively	O
mapped	O
human	O
GPT	B-DNAMutation
to	O
the	O
terminus	O
of	O
8q	O
using	O
several	O
methods	O
.	O

First	O
,	O
two	O
cosmids	O
shown	O
to	O
contain	O
the	O
GPT	B-DNAMutation
sequence	O
were	O
derived	O
from	O
a	O
chromosome	O
8-specific	O
library	O
.	O

Second	O
,	O
by	O
fluorescence	O
in	O
situ	O
hybridization	O
,	O
we	O
mapped	O
the	O
cosmid	O
containing	O
the	O
human	O
GPT	B-DNAMutation
gene	O
to	O
chromosome	O
band	O
8q24.3	O
.	O

Third	O
,	O
we	O
mapped	O
the	O
rat	O
gpt	O
cDNA	O
to	O
the	O
syntenic	O
region	O
of	O
rat	O
chromosome	O
7	O
.	O

Finally	O
,	O
PCR	O
primers	O
specific	O
to	O
human	O
GPT	B-DNAMutation
amplify	O
sequences	O
contained	O
within	O
a	O
"half-YAC"	O
from	O
the	O
long	O
arm	O
of	O
chromosome	O
8	O
,	O
that	O
is	O
,	O
a	O
YAC	O
containing	O
the	O
8q	O
telomere	O
.	O

The	O
human	O
GPT	B-DNAMutation
genomic	O
sequence	O
spans	O
2,7	O
kb	O
and	O
consists	O
of	O
11	O
exons	O
,	O
ranging	O
in	O
size	O
from	O
79	O
to	O
243	O
bp	O
.	O

The	O
exonic	O
sequence	O
encodes	O
a	O
protein	O
of	O
495	O
amino	O
acids	O
that	O
is	O
nearly	O
identical	O
to	O
the	O
previously	O
reported	O
protein	O
sequence	O
of	O
human	O
GPT-1	B-DNAMutation
.	O

The	O
two	O
polymorphic	O
GPT	B-DNAMutation
isozymes	O
are	O
the	O
results	O
of	O
a	O
nucleotide	B-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
14	I-DNAMutation
,	I-DNAMutation
coding	I-DNAMutation
for	I-DNAMutation
a	I-DNAMutation
histidine	I-DNAMutation
in	I-DNAMutation
GPT-1	I-DNAMutation
and	I-DNAMutation
an	I-DNAMutation
asparagine	I-DNAMutation
in	I-DNAMutation
GPT-2	I-DNAMutation
,	O
which	O
causes	O
a	O
gain	O
or	O
loss	O
of	O
an	O
NlaIII	O
restriction	O
site	O
.	O

In	O
addition	O
,	O
a	O
cosmid	O
containing	O
the	O
GPT	B-DNAMutation
sequence	O
also	O
contains	O
a	O
previously	O
unmapped	O
,	O
polymorphic	O
microsatellite	O
sequence	O
,	O
D8S421	O
.	O

The	O
cloned	O
GPT	B-DNAMutation
gene	O
and	O
associated	O
polymorphisms	O
will	O
be	O
useful	O
for	O
linkage	O
and	O
physical	O
mapping	O
of	O
disease	O
loci	O
that	O
map	O
to	O
the	O
terminus	O
of	O
8q	O
,	O
including	O
atypical	O
vitelliform	O
macular	O
dystrophy	O
VMD1	B-DNAMutation
and	O
epidermolysis	O
bullosa	O
simplex	O
,	O
type	O
Ogna	O
EBS1	B-DNAMutation
.	O

In	O
addition	O
,	O
this	O
will	O
be	O
a	O
useful	O
system	O
for	O
characterizing	O
the	O
telomeric	O
region	O
of	O
8q	O
.	O

Finally	O
,	O
determination	O
of	O
the	O
molecular	O
basis	O
of	O
the	O
GPT	B-DNAMutation
isozyme	O
variants	O
will	O
permit	O
PCR-based	O
detection	O
of	O
this	O
world-wide	O
polymorphism	O
.	O

Mitochondrial	O
aldehyde	O
dehydrogenase	O
polymorphism	O
in	O
Asian	O
and	O
American	O
Indian	O
populations	O
:	O
detection	O
of	O
new	O
ALDH2	B-DNAMutation
alleles	O
.	O

Genetic	O
deficiency	O
of	O
the	O
mitochondrial	O
aldehyde	O
dehydrogenase	O
ALDH2	B-DNAMutation
is	O
frequent	O
in	O
Asian	O
peoples	O
where	O
it	O
is	O
an	O
important	O
factor	O
negatively	O
regulating	O
drinking	O
behavior	O
.	O

To	O
obtain	O
additional	O
information	O
on	O
gene	O
geography	O
of	O
known	O
ALDH2	B-DNAMutation
alleles	O
,	O
and	O
look	O
for	O
new	O
variants	O
,	O
ALDH2	B-DNAMutation
genes	O
were	O
evaluated	O
in	O
a	O
Chinese	O
population	O
from	O
Taiwan	O
,	O
a	O
Yakut	O
population	O
of	O
Siberia	O
,	O
and	O
in	O
five	O
North	O
American	O
Indian	O
populations	O
.	O

A	O
novel	O
approach	O
based	O
on	O
a	O
single-strand	O
conformation	O
polymorphism	O
assay	O
,	O
and	O
polymerase	O
chain	O
reaction-directed	O
mutagenesis	O
was	O
developed	O
for	O
genotyping	O
.	O

In	O
the	O
Taiwan	O
Chinese	O
population	O
,	O
the	O
ALDH2(2)	B-DNAMutation
allele	O
frequency	O
was	O
0.319	O
+/-	O
0.025	O
,	O
and	O
this	O
allele	O
was	O
not	O
detected	O
in	O
the	O
Yakut	O
population	O
nor	O
in	O
the	O
five	O
North	O
American	O
Indian	O
populations	O
.	O

However	O
,	O
a	O
new	O
allele	O
,	O
ALDH2(3)	B-DNAMutation
,	O
was	O
detected	O
in	O
Pima	O
Indians	O
at	O
a	O
frequency	O
of	O
0.044	O
+/-	O
0.022	O
,	O
and	O
this	O
allele	O
was	O
also	O
observed	O
in	O
1	O
of	O
49	O
Pueblo	O
samples	O
.	O

ALDH2(3)	B-DNAMutation
is	O
a	O
silent	O
transition	O
1464	B-DNAMutation
G-->A	I-DNAMutation
,	O
and	O
it	O
possibly	O
has	O
a	O
wide	O
distribution	O
among	O
North	O
American	O
Indians	O
.	O

A	O
new	O
subtype	O
of	O
the	O
ALDH2(2)	B-DNAMutation
allele	O
,	O
designated	O
as	O
ALDH2(2Taiwan)	B-DNAMutation
,	O
was	O
found	O
in	O
1	O
of	O
174	O
Chinese	O
from	O
Taiwan	O
.	O

ALDH2(2Taiwan)	B-DNAMutation
is	O
characterized	O
by	O
two	B-DNAMutation
G-->A	I-DNAMutation
transitions	I-DNAMutation
at	I-DNAMutation
bases	I-DNAMutation
1486	I-DNAMutation
and	I-DNAMutation
1510	I-DNAMutation
,	O
resulting	O
in	O
Glu-->Lys	B-DNAMutation
substitutions	I-DNAMutation
at	I-DNAMutation
both	I-DNAMutation
the	I-DNAMutation
479	I-DNAMutation
and	I-DNAMutation
487	I-DNAMutation
positions	I-DNAMutation
.	O

Thus	O
,	O
this	O
second	O
nonconservative	O
ALDH2	B-DNAMutation
substitution	O
occurs	O
within	O
the	O
sequence	O
of	O
the	O
already	O
inactive	O
ALDH2(2)	B-DNAMutation
allele	O
.	O

The	O
after-hours	O
mutant	O
reveals	O
a	O
role	O
for	O
Fbxl3	B-DNAMutation
in	O
determining	O
mammalian	O
circadian	O
period	O
.	O

By	O
screening	O
N-ethyl-N-nitrosourea-mutagenized	O
animals	O
for	O
alterations	O
in	O
rhythms	O
of	O
wheel-running	O
activity	O
,	O
we	O
identified	O
a	O
mouse	O
mutation	O
,	O
after	O
hours	O
(Afh)	O
.	O

The	O
mutation	O
,	O
a	O
Cys(358)Ser	B-DNAMutation
substitution	O
in	O
Fbxl3	B-DNAMutation
,	O
an	O
F-box	O
protein	O
with	O
leucine-rich	O
repeats	O
,	O
results	O
in	O
long	O
free-running	O
rhythms	O
of	O
about	O
27	O
hours	O
in	O
homozygotes	O
.	O

Circadian	O
transcriptional	O
and	O
translational	O
oscillations	O
are	O
attenuated	O
in	O
Afh	O
mice	O
.	O

The	O
Afh	O
allele	O
significantly	O
affected	O
Per2	B-DNAMutation
expression	O
and	O
delayed	O
the	O
rate	O
of	O
Cry	O
protein	O
degradation	O
in	O
Per2::Luciferase	B-DNAMutation
tissue	O
slices	O
.	O

Our	O
in	O
vivo	O
and	O
in	O
vitro	O
studies	O
reveal	O
a	O
central	O
role	O
for	O
Fbxl3	B-DNAMutation
in	O
mammalian	O
circadian	O
timekeeping	O
.	O

Structural	O
definition	O
of	O
the	O
A*74	O
group	O
:	O
implications	O
for	O
matching	O
in	O
bone	O
marrow	O
transplantation	O
with	O
alternative	O
donors	O
.	O

We	O
have	O
identified	O
two	O
new	O
A*74	O
alleles	O
(	O
A*7402	O
and	O
7403	O
)	O
in	O
two	O
unrelated	O
individuals	O
.	O

A*7402	O
differs	O
from	O
A*7401	O
by	O
a	O
single	O
amino	O
acid	O
substitution	O
in	O
the	O
signal	O
peptide	O
and	O
may	O
be	O
the	O
result	O
of	O
a	O
gene	O
conversion	O
event	O
at	O
the	O
3'	O
end	O
of	O
exon	O
1	O
.	O

A*7403	O
differs	O
from	O
A*7401	O
by	O
a	O
single	O
amino	O
acid	O
exchange	O
in	O
the	O
alpha	O
1	O
domain	O
and	O
is	O
most	O
likely	O
due	O
to	O
a	O
point	O
mutation	O
in	O
exon	O
2	O
,	O
since	O
no	O
HLA	O
class	O
I	O
donor	O
allele	O
has	O
been	O
found	O
.	O

Since	O
A*7402	O
appears	O
to	O
be	O
the	O
ancestor	O
of	O
the	O
other	O
two	O
A*74	O
alleles	O
,	O
it	O
is	O
possible	O
that	O
A*7401	O
and	O
7403	O
have	O
been	O
created	O
by	O
successive	O
point	O
mutations	O
.	O

The	O
sequences	O
of	O
the	O
expressed	O
proteins	O
of	O
A*7401	O
and	O
7402	O
are	O
identical	O
.	O

The	O
heavy	O
chain	O
sequence	O
of	O
A*7403	O
differs	B-DNAMutation
from	I-DNAMutation
these	I-DNAMutation
alleles	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
crucial	I-DNAMutation
residue	I-DNAMutation
79	I-DNAMutation
which	O
is	O
located	O
in	O
the	O
sequence	O
stretch	O
of	O
the	O
alpha	O
1	O
alpha-Helix	O
where	O
the	O
Bw4/Bw6	B-DNAMutation
determinants	O
have	O
been	O
identified	O
and	O
which	O
probably	O
affects	O
TCR	O
interaction	O
.	O

This	O
variation	O
can	O
therefore	O
be	O
expected	O
to	O
stimulate	O
alloreactive	O
T	O
cells	O
,	O
graft	O
rejection	O
and	O
graft	O
versus	O
host	O
disease	O
emphasizing	O
the	O
relevance	O
for	O
matching	O
in	O
bone	O
marrow	O
transplantation	O
with	O
alternative	O
donors	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
mouse	O
Col2a1	B-DNAMutation
gene	O
causes	O
spondyloepiphyseal	O
dysplasia	O
congenita	O
,	O
hearing	O
loss	O
,	O
and	O
retinoschisis	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
mouse	O
Col2a1	B-DNAMutation
gene	O
has	O
been	O
discovered	O
,	O
resulting	O
in	O
a	O
mouse	O
phenotype	O
with	O
similarities	O
to	O
human	O
spondyloepiphyseal	O
dysplasia	O
(SED)	O
congenita	O
.	O

In	O
addition	O
,	O
SED	O
patients	O
have	O
been	O
identified	O
with	O
a	O
similar	O
molecular	O
mutation	O
in	O
human	O
COL2A1	B-DNAMutation
.	O

This	O
mouse	O
model	O
offers	O
a	O
useful	O
tool	O
for	O
molecular	O
and	O
biological	O
studies	O
of	O
bone	O
development	O
and	O
pathology	O
.	O

INTRODUCTION	O
:	O
A	O
new	O
mouse	O
autosomal	O
recessive	O
mutation	O
has	O
been	O
discovered	O
and	O
named	O
spondyloepiphyseal	O
dysplasia	O
congenita	O
(	O
gene	O
symbol	O
sedc	O
)	O
.	O

MATERIALS	O
AND	O
METHODS	O
:	O
Homozygous	O
sedc	O
mice	O
can	O
be	O
identified	O
at	O
birth	O
by	O
their	O
small	O
size	O
and	O
shortened	O
trunk	O
.	O

Adults	O
have	O
shortened	O
noses	O
,	O
dysplastic	O
vertebrae	O
,	O
femora	O
,	O
and	O
tibias	O
,	O
plus	O
retinoschisis	O
and	O
hearing	O
loss	O
.	O

The	O
mutation	O
was	O
mapped	O
to	O
Chr15	O
,	O
and	O
Col2a1	B-DNAMutation
was	O
identified	O
as	O
a	O
candidate	O
gene	O
.	O

RESULTS	O
:	O
Sequence	O
analyses	O
revealed	O
that	O
the	O
affected	O
gene	O
is	O
Col2a1	B-DNAMutation
,	O
which	O
has	O
a	O
missense	O
mutation	O
at	O
exon	O
48	O
causing	O
an	O
amino	B-DNAMutation
acid	I-DNAMutation
change	I-DNAMutation
of	I-DNAMutation
arginine	I-DNAMutation
to	I-DNAMutation
cysteine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
1417	I-DNAMutation
.	O

Two	O
human	O
patients	O
with	O
spondyloepiphyseal	O
dysplasia	O
(SED)	O
congenita	O
have	O
been	O
reported	O
with	O
the	O
same	O
amino	B-DNAMutation
acid	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
789	I-DNAMutation
in	O
the	O
human	O
COL2A1	B-DNAMutation
gene	O
.	O

CONCLUSIONS	O
:	O
Thus	O
,	O
sedc/sedc	O
mice	O
provide	O
a	O
valuable	O
model	O
of	O
human	O
SED	O
congenita	O
with	O
molecular	O
and	O
phenotypic	O
homology	O
.	O

Further	O
biochemical	O
analyses	O
,	O
molecular	O
modeling	O
,	O
and	O
cell	O
culture	O
studies	O
using	O
sedc/sedc	O
mice	O
could	O
provide	O
insight	O
into	O
mechanisms	O
of	O
skeletal	O
development	O
dependent	O
on	O
Col2a1	B-DNAMutation
and	O
its	O
role	O
in	O
fibril	O
formation	O
and	O
cartilage	O
template	O
organization	O
.	O

Human	B-DNAMutation
aldolase	B-DNAMutation
A	I-DNAMutation
of	O
a	O
hemolytic	O
anemia	O
patient	O
with	O
Asp-128----Gly	B-DNAMutation
substitution	O
:	O
characteristics	O
of	O
an	O
enzyme	O
generated	O
in	O
E	B-DNAMutation
.	I-DNAMutation
coli	I-DNAMutation
transfected	O
with	O
the	O
expression	O
plasmid	O
pHAAD128G	B-DNAMutation
.	O

Aldolase	B-DNAMutation
A	I-DNAMutation
derived	O
from	O
a	O
hemolytic	O
anemia	O
patient	O
with	O
aldolase	B-DNAMutation
A	I-DNAMutation
deficiency	O
was	O
shown	O
to	O
have	O
an	O
amino	O
acid	O
substitution	O
of	O
glycine	B-DNAMutation
for	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
128th	I-DNAMutation
position	I-DNAMutation
(Asp-128)	O
in	O
the	O
enzyme	O
[	O
Kishi	O
et	O
al	O
.	O

(1987)	O
Proc	O
.	O

Natl	O
.	O

Acad	O
.	O

Sci	O
.	O

U.S.A	O
.	O

84	O
,	O
8623-8627	O
]	O
.	O

We	O
constructed	O
an	O
Escherichia	B-DNAMutation
coli	I-DNAMutation
expression	O
plasmid	O
,	O
pHAAD128G	B-DNAMutation
,	O
which	O
carries	O
the	O
mutant	O
aldolase	B-DNAMutation
A	I-DNAMutation
[	O
aldolase	B-DNAMutation
A(D-G)	I-DNAMutation
]	O
cDNA	O
,	O
and	O
the	O
enzyme	O
generated	O
in	O
E	B-DNAMutation
.	I-DNAMutation
coli	I-DNAMutation
transfected	O
with	O
the	O
expression	O
plasmid	O
was	O
purified	O
and	O
characterized	O
.	O

Conversion	O
of	O
Asp	B-DNAMutation
to	I-DNAMutation
Gly	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
128th	I-DNAMutation
position	I-DNAMutation
in	O
the	O
enzyme	O
rendered	O
the	O
enzyme	O
thermolabile	O
and	O
susceptible	O
to	O
tryptic	O
digestion	O
.	O

CD	O
spectra	O
analysis	O
also	O
revealed	O
that	O
the	O
mutant	O
enzyme	O
had	O
a	O
remarkable	O
conformation	O
change	O
with	O
a	O
decrease	O
of	O
regular	O
form	O
in	O
the	O
molecule	O
.	O

Addition	O
of	O
glycerol	O
or	O
some	O
other	O
polyalcohols	O
during	O
thermal	O
treatment	O
protected	O
this	O
altered	O
enzyme	O
(	O
but	O
not	O
the	O
normal	O
enzyme	O
)	O
against	O
denaturation	O
and	O
activity	O
decrease	O
.	O

In	O
order	O
to	O
determine	O
the	O
function	O
of	O
the	O
amino	O
acid	O
residue	O
at	O
the	O
128th	O
position	O
,	O
two	O
artificial	O
mutant	O
enzymes	O
with	O
the	O
substitutions	O
of	O
Glu	O
for	O
Asp	O
[	O
aldolase	B-DNAMutation
A(D-E)	I-DNAMutation
]	O
and	O
Ser	O
for	O
Asp	O
[	O
aldolase	B-DNAMutation
A(D-S)	I-DNAMutation
]	O
,	O
respectively	O
,	O
at	O
the	O
position	O
were	O
constructed	O
by	O
site-directed	O
mutagenesis	O
and	O
characterized	O
.	O

These	O
analyses	O
demonstrated	O
the	O
necessity	O
for	O
Asp	O
to	O
be	O
present	O
at	O
the	O
128th	O
residue	O
in	O
order	O
for	O
this	O
enzyme	O
to	O
be	O
thermally	O
stable	O
.	O

Mutation	O
causing	O
severe	O
myasthenia	O
reveals	O
functional	O
asymmetry	O
of	O
AChR	O
signature	O
cystine	O
loops	O
in	O
agonist	O
binding	O
and	O
gating	O
.	O

We	O
describe	O
a	O
highly	O
disabling	O
congenital	O
myasthenic	O
syndrome	O
(CMS)	O
associated	O
with	O
rapidly	O
decaying	O
,	O
low-amplitude	O
synaptic	O
currents	O
,	O
and	O
trace	O
its	O
cause	O
to	O
a	O
valine	B-DNAMutation
to	I-DNAMutation
leucine	I-DNAMutation
mutation	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
signature	I-DNAMutation
cystine	I-DNAMutation
loop	I-DNAMutation
(cys-loop)	I-DNAMutation
of	O
the	O
AChR	B-DNAMutation
alpha	I-DNAMutation
subunit	O
.	O

The	O
recently	O
solved	O
crystal	O
structure	O
of	O
an	O
ACh-binding	O
protein	O
places	O
the	O
cys-loop	O
at	O
the	O
junction	O
between	O
the	O
extracellular	O
ligand-binding	O
and	O
transmembrane	O
domains	O
where	O
it	O
may	O
couple	O
agonist	O
binding	O
to	O
channel	O
gating	O
.	O

We	O
therefore	O
analyzed	O
the	O
kinetics	O
of	O
ACh-induced	O
single-channel	O
currents	O
to	O
identify	O
elementary	O
steps	O
in	O
the	O
receptor	O
activation	O
mechanism	O
altered	O
by	O
the	O
alphaV132L	B-DNAMutation
mutation	O
.	O

The	O
analysis	O
reveals	O
that	O
alphaV132L	B-DNAMutation
markedly	O
impairs	O
ACh	O
binding	O
to	O
receptors	O
in	O
the	O
resting	O
closed	O
state	O
,	O
decreasing	O
binding	O
affinity	O
for	O
the	O
second	O
binding	O
step	O
30-fold	O
,	O
but	O
attenuates	O
gating	O
efficiency	O
only	O
about	O
twofold	O
.	O

By	O
contrast	O
,	O
mutation	O
of	O
the	O
equivalent	O
valine	O
residue	O
in	O
the	O
delta	O
subunit	O
impairs	O
channel	O
gating	O
approximately	O
fourfold	O
with	O
little	O
effect	O
on	O
ACh	O
binding	O
,	O
while	O
corresponding	O
mutations	O
in	O
the	O
beta	O
and	O
epsilon	O
subunits	O
are	O
without	O
effect	O
.	O

The	O
unique	O
functional	O
contribution	O
of	O
the	O
alpha	O
subunit	O
cys-loop	O
likely	O
owes	O
to	O
its	O
direct	O
connection	O
via	O
a	O
beta	O
strand	O
to	O
alphaW149	O
at	O
the	O
center	O
of	O
the	O
ligand-binding	O
domain	O
.	O

The	O
overall	O
findings	O
reveal	O
functional	O
asymmetry	O
between	O
cys-loops	O
of	O
the	O
different	O
AChR	O
subunits	O
in	O
contributing	O
to	O
ACh	O
binding	O
and	O
channel	O
gating	O
.	O

Identification	O
of	O
zinc-finger	O
BED	O
domain-containing	O
3	O
(Zbed3)	O
as	O
a	O
novel	O
Axin-interacting	O
protein	O
that	O
activates	O
Wnt/beta-catenin	O
signaling	O
.	O

Axin	O
,	O
a	O
key	O
modulator	O
of	O
the	O
Wnt/beta-catenin	O
pathway	O
,	O
acts	O
as	O
a	O
scaffold	O
protein	O
in	O
phosphorylating	O
and	O
degrading	O
cytoplasmic	O
beta-catenin	O
.	O

Canonical	O
Wnt	O
proteins	O
appear	O
to	O
stabilize	O
beta-catenin	O
by	O
inducing	O
the	O
interaction	O
of	O
LRP5/6	O
with	O
Axin	O
.	O

This	O
interaction	O
requires	O
the	O
phosphorylation	O
of	O
the	O
Ser	O
or	O
Thr	O
residues	O
in	O
the	O
PPPP(S/T)PX(T/S)	O
motifs	O
at	O
the	O
intracellular	O
domain	O
of	O
LRP5/6	O
.	O

In	O
this	O
work	O
,	O
we	O
identified	O
a	O
novel	O
Axin-interacting	O
protein	O
,	O
zinc-finger	O
BED	O
domain-containing	O
3	O
(Zbed3)	O
,	O
by	O
yeast	O
two-hybrid	O
screening	O
.	O

The	O
interaction	O
was	O
confirmed	O
in	O
co-immunoprecipitation	O
experiment	O
in	O
mammalian	O
cells	O
and	O
in	O
vitro	O
pulldown	O
assays	O
.	O

Moreover	O
,	O
we	O
found	O
Zbed3	O
also	O
contains	O
a	O
PPPPSPT	O
motif	O
,	O
which	O
is	O
crucial	O
to	O
its	O
binding	O
to	O
Axin	O
.	O

The	O
Ser	O
and	O
Thr	O
residues	O
in	O
the	O
motif	O
appear	O
to	O
be	O
also	O
phosphorylated	O
by	O
glycogen	O
synthase	O
kinase	O
3beta	O
(GSK3beta)	O
and	O
the	O
CKI	O
family	O
kinases	O
,	O
as	O
GSK3beta	O
and	O
CKIepsilon	O
could	O
enhance	O
the	O
interaction	O
of	O
Zbed3	O
with	O
Axin	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
Ser	I-DNAMutation
(SA)	I-DNAMutation
or	I-DNAMutation
Thr	I-DNAMutation
(TA)	I-DNAMutation
residue	I-DNAMutation
to	I-DNAMutation
Ala	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
motif	I-DNAMutation
markedly	O
impaired	O
its	O
ability	O
to	O
interact	O
with	O
Axin	O
.	O

Expressing	O
Zbed3	O
,	O
but	O
not	O
these	O
mutants	O
,	O
led	O
to	O
inhibition	O
of	O
GSK3beta-mediated	O
beta-catenin	O
phosphorylation	O
,	O
cytoplasmic	O
beta-catenin	O
accumulation	O
,	O
and	O
activation	O
of	O
lymphoid	O
enhancer	O
binding	O
factor-1-dependent	O
reporter	O
gene	O
transcription	O
.	O

Furthermore	O
,	O
knockdown	B-DNAMutation
of	O
Zbed3	O
with	O
RNA	O
interference	O
attenuated	O
Wnt-induced	O
beta-catenin	O
accumulation	O
,	O
lymphoid	O
enhancer	O
binding	O
factor-1-dependent	O
luciferase	O
reporter	O
activity	O
,	O
and	O
the	O
Wnt	O
target	O
gene	O
expression	O
.	O

These	O
results	O
together	O
indicate	O
that	O
Zbed3	O
is	O
a	O
novel	O
Axin-binding	O
protein	O
that	O
is	O
involved	O
in	O
Wnt/beta-catenin	O
signaling	O
modulation	O
.	O

Molecular	O
basis	O
of	O
transient	O
outward	O
K+	O
current	O
diversity	O
in	O
mouse	O
ventricular	O
myocytes	O
.	O

1	O
.	O

Two	O
kinetically	O
and	O
pharmacologically	O
distinct	O
transient	O
outward	O
K+	O
currents	O
,	O
referred	O
to	O
as	O
Ito,f	O
and	O
Ito,s	O
,	O
have	O
been	O
distinguished	O
in	O
mouse	O
left	O
ventricular	O
myocytes	O
.	O

Ito,f	O
is	O
present	O
in	O
all	O
left	O
ventricular	O
apex	O
cells	O
and	O
in	O
most	O
left	O
ventricular	O
septum	O
cells	O
,	O
whereas	O
Ito,s	O
is	O
identified	O
exclusively	O
in	O
left	O
ventricular	O
septum	O
cells	O
.	O

2	O
.	O

Electrophysiological	O
recordings	O
from	O
ventricular	O
myocytes	O
isolated	O
from	O
animals	O
with	O
a	O
targeted	O
deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
Kv1.4	I-DNAMutation
gene	O
(	O
Kv1.4-/-	B-DNAMutation
mice	O
)	O
reveal	O
that	O
Ito,s	O
is	O
undetectable	O
in	O
cells	O
isolated	O
from	O
the	O
left	O
ventricular	O
septum	O
(	O
n	O
=	O
26	O
)	O
.	O

Ito,f	O
density	O
in	O
both	O
apex	O
and	O
septum	O
cells	O
,	O
in	O
contrast	O
,	O
is	O
not	O
affected	O
by	O
deletion	B-DNAMutation
of	I-DNAMutation
Kv1.4	I-DNAMutation
.	O

3	O
.	O

Neither	O
the	O
4-AP-sensitive	O
,	O
slowly	O
inactivating	O
K+	O
current	O
,	O
IK,slow	O
,	O
nor	O
the	O
steady-state	O
non-inactivating	O
K+	O
current	O
,	O
ISS	O
,	O
is	O
affected	O
in	O
Kv1.4-/-	B-DNAMutation
mouse	O
left	O
ventricular	O
cells	O
.	O

4	O
.	O

In	O
myocytes	O
isolated	O
from	O
transgenic	O
mice	O
expressing	O
a	O
dominant	O
negative	O
Kv4.2	B-DNAMutation
alpha	O
subunit	O
,	O
Kv4.2W362F	B-DNAMutation
,	O
Ito,f	O
is	O
eliminated	O
in	O
both	O
left	O
ventricular	O
apex	O
and	O
septum	O
cells	O
.	O

In	O
addition	O
,	O
a	O
slowly	O
inactivating	O
transient	O
outward	O
K+	O
current	O
similar	O
to	O
Ito,s	O
in	O
wild-type	O
septum	O
cells	O
is	O
evident	O
in	O
myocytes	O
isolated	O
from	O
left	O
ventricular	O
apex	O
of	O
Kv4.2W362F-expressing	B-DNAMutation
transgenics	O
.	O

The	O
density	O
of	O
Ito,s	O
in	O
septum	O
cells	O
,	O
however	O
,	O
is	O
unaffected	O
by	O
Kv4.2W362F	B-DNAMutation
expression	O
.	O

5	O
.	O

Western	O
blots	O
of	O
fractionated	O
mouse	O
ventricular	O
membrane	O
proteins	O
reveal	O
a	O
significant	O
increase	O
in	O
Kv1.4	B-DNAMutation
protein	O
level	O
in	O
Kv4.2W362F-expressing	B-DNAMutation
transgenic	O
mice	O
.	O

The	O
protein	O
levels	O
of	O
other	O
Kv	O
alpha	O
subunits	O
,	O
Kv1.2	B-DNAMutation
and	O
Kv2.1	B-DNAMutation
,	O
in	O
contrast	O
,	O
are	O
not	O
affected	O
by	O
the	O
expression	O
of	O
the	O
Kv4.2W362F	B-DNAMutation
transgene	O
.	O

6	O
.	O

The	O
results	O
presented	O
here	O
demonstrate	O
that	O
the	O
molecular	O
correlates	O
of	O
Ito,f	O
and	O
Ito,s	O
in	O
adult	O
mouse	O
ventricle	O
are	O
distinct	O
.	O

Kv1.4	B-DNAMutation
underlies	O
mouse	O
ventricular	O
septum	O
Ito,s	O
,	O
whereas	O
Kv	O
alpha	O
subunits	O
of	O
the	O
Kv4	O
subfamily	O
underlie	O
mouse	O
ventricular	O
apex	O
and	O
septum	O
Ito	O
,	O
f	O
.	O

The	O
appearance	O
of	O
the	O
slow	O
transient	O
outward	O
K+	O
current	O
in	O
Kv4	B-DNAMutation
.	I-DNAMutation
2W362F-expressing	I-DNAMutation
left	O
ventricular	O
apex	O
cells	O
with	O
properties	O
indistinguishable	O
from	O
Ito,s	O
in	O
wild-type	O
cells	O
is	O
accompanied	O
by	O
an	O
increase	O
in	O
Kv1.4	B-DNAMutation
protein	O
expression	O
,	O
suggesting	O
that	O
the	O
upregulation	O
of	O
Kv1.4	B-DNAMutation
underlies	O
the	O
observed	O
electrical	O
remodeling	O
in	O
Kv4.2W362F-expressing	B-DNAMutation
transgenics	O
.	O

In	O
vivo	O
identification	O
of	O
genes	O
that	O
modify	O
ether-a-go-go-related	O
gene	O
activity	O
in	O
Caenorhabditis	O
elegans	O
may	O
also	O
affect	O
human	O
cardiac	O
arrhythmia	O
.	O

Human	B-DNAMutation
ether-a-go-go-related	I-DNAMutation
gene	I-DNAMutation
HERG	B-DNAMutation
encodes	O
the	O
pore-forming	O
subunit	O
of	O
I(Kr)	O
,	O
a	O
cardiac	O
K(+)	O
channel	O
.	O

Although	O
many	O
commonly	O
used	O
drugs	O
block	O
I(Kr)	O
,	O
in	O
certain	O
individuals	O
,	O
this	O
action	O
evokes	O
a	O
paradoxical	O
life-threatening	O
cardiac	O
rhythm	O
disturbance	O
,	O
known	O
as	O
the	O
acquired	O
long	O
QT	O
syndrome	O
(aLQTS)	O
.	O

Although	O
aLQTS	O
has	O
become	O
the	O
leading	O
cause	O
of	O
drug	O
withdrawal	O
by	O
the	O
U.S	O
.	O

Food	O
and	O
Drug	O
Administration	O
,	O
DNA	O
sequencing	O
in	O
aLQTS	O
patients	O
has	O
revealed	O
HERG	B-DNAMutation
mutations	O
only	O
in	O
rare	O
cases	O
,	O
suggesting	O
that	O
unknown	O
HERG	B-DNAMutation
modulators	O
are	O
often	O
responsible	O
.	O

By	O
using	O
the	O
worm	O
Caenorhabditis	O
elegans	O
,	O
we	O
have	O
developed	O
in	O
vivo	O
behavioral	O
assays	O
that	O
identify	O
candidate	O
modulators	O
of	O
unc-103	B-DNAMutation
,	O
the	O
worm	O
HERG	O
orthologue	O
.	O

By	O
using	O
RNA-interference	O
methods	O
,	O
we	O
have	O
shown	O
that	O
worm	O
homologues	O
of	O
two	O
HERG-interacting	O
proteins	O
,	O
Hyperkinetic	O
and	O
K	B-DNAMutation
channel	I-DNAMutation
regulator	I-DNAMutation
1	I-DNAMutation
KCR1	B-DNAMutation
,	O
modify	O
unc-103	O
function	O
.	O

Examination	O
of	O
the	O
human	O
KCR1	B-DNAMutation
sequence	O
in	O
patients	O
with	O
drug-induced	O
cardiac	O
repolarization	O
defects	O
revealed	O
a	O
sequence	O
variation	O
(	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
isoleucine	I-DNAMutation
447	I-DNAMutation
by	I-DNAMutation
valine	I-DNAMutation
,	O
I447V	B-DNAMutation
)	O
that	O
occurs	O
at	O
a	O
reduced	O
frequency	O
(1.1%)	O
relative	O
to	O
a	O
matched	O
control	O
population	O
(7.0%)	O
,	O
suggesting	O
that	O
I447V	B-DNAMutation
may	O
be	O
an	O
allele	O
for	O
reduced	O
aLQTS	O
susceptibility	O
.	O

This	O
clinical	O
result	O
is	O
supported	O
by	O
in	O
vitro	O
studies	O
of	O
HERG	B-DNAMutation
dofetilide	O
sensitivity	O
by	O
using	O
coexpression	O
of	O
HERG	B-DNAMutation
with	O
wild-type	O
and	O
I447V	B-DNAMutation
KCR1	B-DNAMutation
cDNAs	O
.	O

Our	O
studies	O
demonstrate	O
the	O
feasibility	O
of	O
using	O
C	O
.	O

elegans	O
to	O
assay	O
and	O
potentially	O
identify	O
aLQTS	O
candidate	O
genes	O
.	O

Site-directed	O
mutagenesis	B-DNAMutation
of	I-DNAMutation
histidine	I-DNAMutation
238	I-DNAMutation
in	O
mouse	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
:	O
substitution	B-DNAMutation
of	I-DNAMutation
histidine	I-DNAMutation
238	I-DNAMutation
does	O
not	O
impede	O
hydroxylate	O
formation	O
.	O

His	O
238	O
,	O
a	O
conserved	O
amino	O
acid	O
located	O
in	O
hydrogen-bonding	O
distance	O
from	O
C-6	O
of	O
the	O
substrate	O
in	O
the	O
active	O
site	O
of	O
murine	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
mADA	B-DNAMutation
and	O
postulated	O
to	O
play	O
an	O
important	O
role	O
in	O
catalysis	O
,	O
was	B-DNAMutation
altered	I-DNAMutation
into	I-DNAMutation
an	I-DNAMutation
alanine	I-DNAMutation
,	I-DNAMutation
a	I-DNAMutation
glutamate	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
an	I-DNAMutation
arginine	I-DNAMutation
using	O
site-directed	O
mutagenesis	O
.	O

The	O
Ala	O
and	O
Glu	O
substitutions	O
did	O
not	O
result	O
in	O
changes	O
of	O
the	O
secondary	O
or	O
tertiary	O
structure	O
,	O
while	O
the	O
Arg	O
mutation	O
caused	O
local	O
perturbations	O
in	O
tertiary	O
structure	O
and	O
quenched	O
the	O
emission	O
of	O
one	O
or	O
more	O
enzyme	O
tryptophans	O
.	O

Neither	O
the	O
Glu	O
or	O
Arg	O
mutations	O
affected	O
substrate	O
binding	O
affinity	O
.	O

By	O
contrast	O
,	O
the	O
Ala	O
mutation	O
enhanced	O
substrate	O
and	O
inhibitor	O
binding	O
by	O
20-fold	O
.	O

The	O
most	O
inactive	O
of	O
the	O
mutants	O
,	O
Glu	O
238	O
,	O
had	O
a	O
kcat/K(m)	O
4	O
x	O
10(-6)	O
lower	O
than	O
the	O
wild-type	O
value	O
,	O
suggesting	O
that	O
a	O
positive	O
charge	O
on	O
His	O
238	O
is	O
important	O
for	O
proper	O
catalytic	O
function	O
.	O

The	O
Ala	B-DNAMutation
238	I-DNAMutation
mutant	I-DNAMutation
was	O
the	O
most	O
active	O
ADA	B-DNAMutation
,	O
with	O
a	O
kcat/K(m)	O
2	O
x	O
10(-3)	O
lower	O
than	O
the	O
wild-type	O
value	O
.	O

NMR	O
spectroscopy	O
and	O
crystallography	O
revealed	O
that	O
this	O
mutant	O
is	O
able	O
to	O
catalyze	O
hydration	O
of	O
purine	O
riboside	O
,	O
a	O
ground-state	O
analog	O
of	O
the	O
reaction	O
.	O

These	O
results	O
collectively	O
show	O
that	O
His	O
238	O
is	O
not	O
required	O
for	O
formation	O
of	O
the	O
hydroxylate	O
used	O
in	O
the	O
deamination	O
and	O
may	O
instead	O
have	O
an	O
important	O
electrostatic	O
role	O
.	O

Site-directed	O
mutagenesis	O
studies	O
on	O
a	O
putative	O
fifth	O
iron	O
ligand	O
of	O
mouse	O
8S-lipoxygenase	B-DNAMutation
:	O
retention	O
of	O
catalytic	O
activity	O
on	O
mutation	O
of	O
serine-558	B-DNAMutation
to	I-DNAMutation
asparagine	I-DNAMutation
,	I-DNAMutation
histidine	I-DNAMutation
,	I-DNAMutation
or	I-DNAMutation
alanine	I-DNAMutation
.	O

The	O
reported	O
crystal	O
structures	O
of	O
plant	O
and	O
animal	O
lipoxygenases	O
(LOX)	O
show	O
that	O
the	O
nonheme	O
iron	O
in	O
the	O
catalytic	O
domain	O
is	O
ligated	O
by	O
three	O
histidines	O
,	O
the	O
C-terminal	O
isoleucine	O
,	O
and	O
in	O
certain	O
structures	O
also	O
by	O
a	O
fifth	O
iron	O
ligand	O
,	O
an	O
asparagine	O
or	O
histidine	O
residue	O
.	O

Mouse	O
8-LOX	B-DNAMutation
and	O
its	O
homologues	O
(	O
e.g.	O
,	O
human	O
15-LOX-2	B-DNAMutation
)	O
are	O
unique	O
in	O
having	O
a	O
serine	B-DNAMutation
in	I-DNAMutation
place	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
usual	I-DNAMutation
Asn	I-DNAMutation
or	I-DNAMutation
His	I-DNAMutation
in	I-DNAMutation
this	I-DNAMutation
fifth	I-DNAMutation
position	I-DNAMutation
.	O

To	O
investigate	O
the	O
importance	O
of	O
the	O
residue	O
in	O
mouse	O
8-LOX	B-DNAMutation
structure-function	O
,	O
the	O
serine-558	B-DNAMutation
was	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
asparagine	I-DNAMutation
,	I-DNAMutation
histidine	I-DNAMutation
,	I-DNAMutation
or	I-DNAMutation
alanine	I-DNAMutation
using	O
oligonucleotide-directed	O
mutagenesis	O
.	O

Wild-type	O
mouse	O
8-LOX	B-DNAMutation
and	O
the	O
mutant	O
cDNAs	O
were	O
expressed	O
in	O
HeLa	O
cells	O
infected	O
with	O
vaccinia	O
virus	O
encoding	O
T7	O
RNA	O
polymerase	O
and	O
their	O
relative	O
lipoxygenase	O
activities	O
assessed	O
by	O
incubation	O
with	O
[14C]arachidonic	O
acid	O
or	O
[14C]linoleic	O
acid	O
followed	O
by	O
HPLC	O
analysis	O
of	O
the	O
products	O
.	O

The	O
Ser558Asn	B-DNAMutation
and	O
Ser558His	B-DNAMutation
mutants	O
had	O
equivalent	O
or	O
greater	O
activity	O
than	O
wild-type	O
8-LOX	B-DNAMutation
.	O

They	O
also	O
exhibited	O
some	O
15-LOX	O
activity	O
,	O
indicating	O
that	O
small	O
structural	O
perturbations	O
(	O
in	O
this	O
case	O
to	O
a	O
residue	O
identical	O
in	O
mouse	O
8-LOX	B-DNAMutation
and	O
its	O
15-LOX-2	B-DNAMutation
homologues	O
)	O
can	O
interchange	O
the	O
positional	O
specificity	O
of	O
these	O
closely	O
related	O
enzymes	O
.	O

Remarkably	O
,	O
the	O
Ser558Ala	B-DNAMutation
mutant	O
exhibited	O
significant	O
8-LOX	B-DNAMutation
activity	O
,	O
indicating	O
that	O
this	O
position	O
is	O
not	O
an	O
essential	O
iron	O
ligand	O
in	O
the	O
enzyme	O
.	O

We	O
conclude	O
that	O
mouse	O
8-LOX	B-DNAMutation
is	O
catalytically	O
competent	O
with	O
only	O
four	O
amino	O
acid	O
iron	O
ligands	O
,	O
and	O
that	O
Ser-558	O
of	O
the	O
wild-type	O
enzyme	O
does	O
not	O
play	O
an	O
essential	O
role	O
in	O
catalysis	O
.	O

The	O
primary	O
structure	O
of	O
genetic	O
variants	O
of	O
mouse	O
hemoglobin	O
.	O

The	O
primary	O
structures	O
of	O
the	O
alpha	O
globins	O
from	O
CE/J	O
,	O
DBA/2J	O
,	O
and	O
a	O
stock	O
of	O
Potter's	O
mice	O
were	O
determined	O
to	O
identify	O
the	O
amino	O
acid	O
substitutions	O
associated	O
with	O
the	O
unique	O
isoelectric	O
focusing	O
patterns	O
of	O
these	O
hemoglobins	O
.	O

In	O
addition	O
,	O
the	O
primary	O
structures	O
of	O
the	O
alpha	O
globins	O
from	O
MOL	O
III	O
and	O
PERU	O
mice	O
were	O
studied	O
in	O
search	O
of	O
amino	O
acid	O
substitutions	O
that	O
may	O
not	O
be	O
detected	O
by	O
isoelectric	O
focusing	O
.	O

CE/J	O
hemoglobin	O
contains	O
a	O
unique	O
kind	O
of	O
alpha	O
globin	O
called	O
chain	O
5	O
.	O

It	O
differs	O
from	O
the	O
single	O
kind	O
of	O
alpha	O
globin	O
(	O
chain	O
1	O
)	O
in	O
C57BL/6	O
by	O
having	B-DNAMutation
alanine	I-DNAMutation
rather	I-DNAMutation
than	I-DNAMutation
glycine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
78	I-DNAMutation
.	O

DBA/2J	O
hemoglobin	O
has	O
two	O
kinds	O
of	O
alpha	O
globins	O
:	O
one	O
half	O
is	O
like	O
chain	O
5	O
and	O
the	O
other	O
half	O
is	O
like	O
chain	O
1	O
.	O

The	O
hemoglobin	O
from	O
Potter's	O
stock	O
of	O
Mus	O
musculus	O
molossinus	O
also	O
contains	O
chains	O
1	O
and	O
5	O
,	O
but	O
they	O
are	O
expressed	O
at	O
different	O
levels	O
i.e.	O
,	O
80%	O
chain	O
1	O
and	O
20%	O
chain	O
5	O
.	O

MOL	O
III	O
hemoglobin	O
has	O
a	O
single	O
kind	O
of	O
a	O
alpha	O
globin	O
identical	O
to	O
that	O
in	O
C57BL/6	O
,	O
and	O
PERU	O
hemoglobin	O
contains	O
approximately	O
40%	O
chain	O
1	O
and	O
60%	O
chain	O
4	O
.	O

Chains	O
1	O
and	O
4	O
have	B-DNAMutation
different	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
at	I-DNAMutation
positions	I-DNAMutation
25	I-DNAMutation
,	I-DNAMutation
62	I-DNAMutation
and	I-DNAMutation
68	I-DNAMutation
.	O

These	O
studies	O
confirm	O
that	O
mouse	O
hemoglobins	O
separable	O
by	O
isoelectric	O
focusing	O
,	O
but	O
not	O
by	O
other	O
means	O
of	O
electrophoresis	O
,	O
have	O
substitutions	O
of	O
neutrally	O
charged	O
amino	O
acids	O
in	O
their	O
alpha	O
chains	O
.	O

Identification	O
of	O
a	O
novel	O
mutation	O
in	O
patients	O
with	O
medium-chain	O
acyl-CoA	O
dehydrogenase	O
deficiency	O
.	O

A	O
novel	O
mutation	O
was	O
identified	O
in	O
two	O
unrelated	O
patients	O
with	O
medium-chain	O
acyl-CoA	O
dehydrogenase	O
deficiency	O
.	O

First	O
,	O
a	O
19-year-old	O
Caucasian	O
female	O
presented	O
with	O
a	O
devastating	O
illness	O
,	O
resulting	O
in	O
sudden	O
death	O
in	O
adulthood	O
which	O
is	O
unusual	O
.	O

The	O
second	O
patient	O
,	O
now	O
a	O
3.5-year-old	O
male	O
,	O
presented	O
at	O
17	O
months	O
of	O
age	O
with	O
a	O
hypoglycemic	O
seizure	O
and	O
dehydration	O
.	O

Sequence	O
analysis	O
revealed	O
a	O
novel	O
mutation	O
G617T	B-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
8	I-DNAMutation
resulting	O
in	O
an	O
arginine	B-DNAMutation
to	I-DNAMutation
leucine	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
206	I-DNAMutation
(R206L)	I-DNAMutation
.	O

Both	O
patients	O
were	O
compound	O
heterozygous	O
for	O
this	O
G617T	B-DNAMutation
and	O
the	O
common	O
mutation	O
A985G	B-DNAMutation
.	O

Synthesis	O
in	O
yeast	O
of	O
a	O
functional	O
oxidation-resistant	O
mutant	O
of	O
human	O
alpha-antitrypsin	O
.	O

Cumulative	O
damage	O
to	O
lung	O
tissue	O
by	O
leukocyte	O
elastase	O
is	O
thought	O
to	O
be	O
responsible	O
for	O
the	O
development	O
of	O
pulmonary	O
emphysema	O
,	O
an	O
irreversible	O
lung	O
disease	O
characterized	O
by	O
loss	O
of	O
lung	O
elasticity	O
.	O

It	O
is	O
also	O
thought	O
to	O
be	O
involved	O
in	O
the	O
rapidly	O
developing	O
and	O
usually	O
fatal	O
adult	O
respiratory	O
distress	O
syndrome	O
.	O

The	O
primary	O
defence	O
against	O
elastase	O
damage	O
is	O
the	O
anti-protease	O
known	O
as	O
alpha	O
1-antitrypsin	O
,	O
a	O
glycosylated	O
serum	O
protein	O
of	O
394	O
amino	O
acids	O
.	O

Oxidation	O
of	O
the	O
methionine	O
358	O
residue	O
located	O
at	O
the	O
active	O
centre	O
of	O
alpha	O
1-antitrypsin	O
results	O
in	O
a	O
dramatic	O
decrease	O
in	O
inhibitory	O
activity	O
towards	O
elastase	O
which	O
effectively	O
inactivates	O
the	O
protective	O
function	O
.	O

It	O
has	O
been	O
suggested	O
that	O
this	O
oxidation	O
sensitivity	O
has	O
a	O
regulatory	O
function	O
and	O
allows	O
tissue	O
breakdown	O
at	O
sites	O
of	O
inflammation	O
by	O
inactivation	O
of	O
alpha	O
1-antitrypsin	O
by	O
oxygen	O
radicals	O
released	O
by	O
phagocytes	O
.	O

In	O
the	O
above	O
diseases	O
,	O
however	O
,	O
the	O
oxidative	O
inactivation	O
of	O
alpha	O
1-antitrypsin	O
is	O
probably	O
of	O
major	O
importance	O
in	O
allowing	O
lung	O
damage	O
by	O
elastase	O
.	O

An	O
oxidation-resistant	O
alpha	O
1-antitrypsin	O
required	O
for	O
emphysemics	O
and	O
provide	O
treatment	O
for	O
acute	O
inflammatory	O
respiratory	O
conditions	O
.	O

To	O
further	O
the	O
possibility	O
of	O
therapy	O
for	O
the	O
above	O
conditions	O
,	O
we	O
describe	O
here	O
the	O
synthesis	O
in	O
yeast	O
of	O
active	O
,	O
non-glycosylated	O
,	O
human	O
alpha	O
1-antitrypsin	O
.	O

Site-directed	O
mutagenesis	O
has	O
been	O
used	O
to	O
construct	O
an	O
active	O
,	O
oxidation-resistant	O
derivative	O
containing	O
a	O
single	B-DNAMutation
methionine	I-DNAMutation
to	I-DNAMutation
valine	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
active	I-DNAMutation
centre	I-DNAMutation
.	O

This	O
demonstrates	O
the	O
potential	O
of	O
engineered	O
modifications	O
to	O
protein	O
molecules	O
designed	O
to	O
improve	O
their	O
physiological	O
function	O
.	O

Palmitoylation	O
of	O
the	O
human	O
beta	B-DNAMutation
2-adrenergic	I-DNAMutation
receptor	I-DNAMutation
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
Cys341	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
carboxyl	I-DNAMutation
tail	I-DNAMutation
leads	O
to	O
an	O
uncoupled	O
nonpalmitoylated	O
form	O
of	O
the	O
receptor	O
.	O

We	O
report	O
that	O
a	O
cysteine	O
residue	O
in	O
the	O
human	O
beta	B-DNAMutation
2-adrenergic	I-DNAMutation
receptor	I-DNAMutation
(	O
beta	B-DNAMutation
2AR	I-DNAMutation
)	O
is	O
covalently	O
modified	O
by	O
thioesterification	O
with	O
palmitic	O
acid	O
.	O

By	O
site-directed	O
mutagenesis	O
of	O
the	O
receptor	O
,	O
we	O
have	O
identified	O
Cys341	O
in	O
the	O
carboxyl	O
tail	O
of	O
the	O
protein	O
as	O
the	O
most	O
likely	O
site	O
of	O
palmitoylation	O
.	O

Mutation	O
of	O
Cys341	B-DNAMutation
to	I-DNAMutation
glycine	I-DNAMutation
results	O
in	O
a	O
nonpalmitoylated	O
form	O
of	O
the	O
receptor	O
that	O
exhibits	O
a	O
drastically	O
reduced	O
ability	O
to	O
mediate	O
isoproterenol	O
stimulation	O
of	O
adenylyl	O
cyclase	O
.	O

The	O
functional	O
impairment	O
of	O
this	O
mutated	O
beta	B-DNAMutation
2AR	I-DNAMutation
is	O
also	O
reflected	O
in	O
a	O
markedly	O
reduced	O
ability	O
to	O
form	O
a	O
guanyl	O
nucleotide-sensitive	O
high	O
affinity	O
state	O
for	O
agonists	O
,	O
characteristic	O
of	O
wild-type	O
receptor	O
.	O

These	O
results	O
indicate	O
that	O
post-translational	O
modification	O
by	O
palmitate	O
of	O
beta	B-DNAMutation
2AR	I-DNAMutation
may	O
play	O
a	O
crucial	O
role	O
in	O
the	O
normal	O
coupling	O
of	O
the	O
receptor	O
to	O
the	O
adenylyl	O
cyclase	O
signal	O
transduction	O
system	O
.	O

Novel	O
delta	O
subunit	O
mutation	O
in	O
slow-channel	O
syndrome	O
causes	O
severe	O
weakness	O
by	O
novel	O
mechanisms	O
.	O

We	O
investigated	O
the	O
basis	O
for	O
a	O
novel	O
form	O
of	O
the	O
slow-channel	O
congenital	O
myasthenic	O
syndrome	O
presenting	O
in	O
infancy	O
in	O
a	O
single	O
individual	O
as	O
progressive	O
weakness	O
and	O
impaired	O
neuromuscular	O
transmission	O
without	O
overt	O
degeneration	O
of	O
the	O
motor	O
endplate	O
.	O

Prolonged	O
low-amplitude	O
synaptic	O
currents	O
in	O
biopsied	O
anconeus	O
muscle	O
at	O
9	O
years	O
of	O
age	O
suggested	O
a	O
kinetic	O
disorder	O
of	O
the	O
muscle	O
acetylcholine	O
receptor	O
.	O

Ultrastructural	O
studies	O
at	O
16	O
months	O
,	O
at	O
9	O
years	O
,	O
and	O
at	O
15	O
years	O
of	O
age	O
showed	O
none	O
of	O
the	O
typical	O
degenerative	O
changes	O
of	O
the	O
endplate	O
associated	O
with	O
the	O
slow-channel	O
congenital	O
myasthenic	O
syndrome	O
,	O
and	O
acetylcholine	O
receptor	O
numbers	O
were	O
not	O
significantly	O
reduced	O
.	O

We	O
identified	O
a	O
novel	O
C-to-T	B-DNAMutation
substitution	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
8	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
delta-subunit	I-DNAMutation
that	O
results	O
in	O
a	O
serine	B-DNAMutation
to	I-DNAMutation
phenylalanine	I-DNAMutation
mutation	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
region	I-DNAMutation
encoding	I-DNAMutation
the	I-DNAMutation
second	I-DNAMutation
transmembrane	I-DNAMutation
domain	I-DNAMutation
that	I-DNAMutation
lines	I-DNAMutation
the	I-DNAMutation
ion	I-DNAMutation
channel	I-DNAMutation
.	O

Using	O
Xenopus	O
oocyte	O
in	O
vitro	O
expression	O
studies	O
we	O
confirmed	O
that	O
the	O
deltaS268F	B-DNAMutation
mutation	O
,	O
as	O
with	O
other	O
slow-channel	O
congenital	O
myasthenic	O
syndrome	O
mutations	O
,	O
causes	O
delayed	O
closure	O
of	O
acetylcholine	O
receptor	O
ion	O
channels	O
.	O

In	O
addition	O
,	O
unlike	O
other	O
mutations	O
in	O
slow-channel	O
congenital	O
myasthenic	O
syndrome	O
,	O
this	O
mutation	O
also	O
causes	O
delayed	O
opening	O
of	O
the	O
channel	O
,	O
a	O
finding	O
that	O
readily	O
explains	O
the	O
marked	O
congenital	O
weakness	O
in	O
the	O
absence	O
of	O
endplate	O
degeneration	O
.	O

Finally	O
,	O
we	O
used	O
serial	O
morphometric	O
analysis	O
of	O
electron	O
micrographs	O
to	O
explore	O
the	O
basis	O
for	O
the	O
progressive	O
weakness	O
and	O
decline	O
of	O
amplitude	O
of	O
endplate	O
currents	O
over	O
a	O
period	O
of	O
14	O
years	O
.	O

We	O
demonstrated	O
a	O
progressive	O
widening	O
and	O
accumulation	O
of	O
debris	O
in	O
the	O
synaptic	O
cleft	O
,	O
resulting	O
in	O
loss	O
of	O
efficacy	O
of	O
released	O
neurotransmitter	O
and	O
reduced	O
safety	O
factor	O
.	O

These	O
studies	O
demonstrate	O
the	O
role	O
of	O
previously	O
unrecognized	O
mechanisms	O
of	O
impairment	O
of	O
synaptic	O
transmission	O
caused	O
by	O
a	O
novel	O
mutation	O
and	O
show	O
the	O
importance	O
of	O
serial	O
in	O
vitro	O
studies	O
to	O
elucidate	O
novel	O
disease	O
mechanisms	O
.	O

Serine	O
residue	O
115	O
of	O
MAPK-activated	O
protein	O
kinase	O
MK5	B-DNAMutation
is	O
crucial	O
for	O
its	O
PKA-regulated	O
nuclear	O
export	O
and	O
biological	O
function	O
.	O

The	O
mitogen-activated	B-DNAMutation
protein	I-DNAMutation
kinase-activated	I-DNAMutation
protein	I-DNAMutation
kinase-5	I-DNAMutation
MK5	B-DNAMutation
resides	O
predominantly	O
in	O
the	O
nucleus	O
of	O
resting	O
cells	O
,	O
but	O
p38(MAPK)	B-DNAMutation
,	O
extracellular	O
signal-regulated	O
kinases-3	O
and	O
-4	O
(	O
ERK3	B-DNAMutation
and	O
ERK4	B-DNAMutation
)	O
,	O
and	O
protein	O
kinase	O
A	O
(PKA)	O
induce	O
nucleocytoplasmic	O
redistribution	O
of	O
MK5	B-DNAMutation
.	O

The	O
mechanism	O
by	O
which	O
PKA	O
causes	O
nuclear	O
export	O
remains	O
unsolved	O
.	O

In	O
the	O
study	O
reported	O
here	O
we	O
demonstrated	O
that	O
Ser-115	O
is	O
an	O
in	O
vitro	O
PKA	O
phosphoacceptor	O
site	O
,	O
and	O
that	O
PKA	O
,	O
but	O
not	O
p38(MAPK)	B-DNAMutation
,	O
ERK3	B-DNAMutation
or	O
ERK4	B-DNAMutation
,	O
is	O
unable	O
to	O
redistribute	O
MK5	B-DNAMutation
S115A	B-DNAMutation
to	O
the	O
cytoplasm	O
.	O

However	O
,	O
the	O
phospho-mimicking	O
MK5	B-DNAMutation
S115D	B-DNAMutation
mutant	O
resides	O
in	O
the	O
cytoplasm	O
in	O
untreated	O
cells	O
.	O

While	O
p38(MAPK)	B-DNAMutation
,	O
ERK3	B-DNAMutation
and	O
ERK4	B-DNAMutation
fail	O
to	O
trigger	O
nuclear	O
export	O
of	O
the	O
kinase	O
dead	O
T182A	B-DNAMutation
and	O
K51E	B-DNAMutation
MK5	B-DNAMutation
mutants	O
,	O
S115D/T182A	B-DNAMutation
and	O
K51E/S115D	B-DNAMutation
mutants	O
were	O
able	O
to	O
enter	O
the	O
cytoplasm	O
of	O
resting	O
cells	O
.	O

Finally	O
,	O
we	O
demonstrated	O
that	O
mutations	O
in	O
Ser-115	O
affect	O
the	O
biological	O
properties	O
of	O
MK5	B-DNAMutation
.	O

Taken	O
together	O
,	O
our	O
results	O
suggest	O
that	O
Ser-115	O
plays	O
an	O
essential	O
role	O
in	O
PKA-regulated	O
nuclear	O
export	O
of	O
MK5	B-DNAMutation
,	O
and	O
that	O
it	O
also	O
may	O
regulate	O
the	O
biological	O
functions	O
of	O
MK5	B-DNAMutation
.	O

Neurodegeneration	O
in	O
Lurcher	B-DNAMutation
mice	O
caused	O
by	O
mutation	O
in	O
delta2	O
glutamate	O
receptor	O
gene	O
.	O

Lurcher	B-DNAMutation
(Lc)	O
is	O
a	O
spontaneous	O
,	O
semidominant	O
mouse	O
neurological	O
mutation	O
.	O

Heterozygous	O
Lurcher	B-DNAMutation
mice	O
(Lc/+)	O
display	O
ataxia	O
as	O
a	O
result	O
of	O
a	O
selective	O
,	O
cell-autonomous	O
and	O
apoptotic	O
death	O
of	O
cerebellar	O
Purkinje	O
cells	O
during	O
postnatal	O
development	O
.	O

Homozygous	O
Lurcher	B-DNAMutation
mice	O
(Lc/Lc)	O
die	O
shortly	O
after	O
birth	O
because	O
of	O
a	O
massive	O
loss	O
of	O
mid-	O
and	O
hindbrain	O
neurons	O
during	O
late	O
embryogenesis	O
.	O

We	O
have	O
used	O
positional	O
cloning	O
to	O
identify	O
the	O
mutations	O
responsible	O
for	O
neurodegeneration	O
in	O
two	O
independent	O
Lc	O
alleles	O
as	O
G-to-A	B-DNAMutation
transitions	I-DNAMutation
that	I-DNAMutation
change	I-DNAMutation
a	I-DNAMutation
highly	I-DNAMutation
conserved	I-DNAMutation
alanine	I-DNAMutation
to	I-DNAMutation
a	I-DNAMutation
threonine	I-DNAMutation
residue	I-DNAMutation
in	I-DNAMutation
transmembrane	I-DNAMutation
domain	I-DNAMutation
III	I-DNAMutation
of	O
the	O
mouse	O
delta2	O
glutamate	O
receptor	O
gene	O
(	O
GluR	B-DNAMutation
delta2	I-DNAMutation
)	O
.	O

Lc/+	O
Purkinje	O
cells	O
have	O
a	O
very	O
high	O
membrane	O
conductance	O
and	O
a	O
depolarized	O
resting	O
potential	O
,	O
indicating	O
the	O
presence	O
of	O
a	O
large	O
,	O
constitutive	O
inward	O
current	O
.	O

Expression	O
of	O
the	O
mutant	O
GluR	O
delta2(Lc)	O
protein	O
in	O
Xenopus	O
oocytes	O
confirmed	O
these	O
results	O
,	O
demonstrating	O
that	O
Lc	O
is	O
inherited	O
as	O
a	O
neurodegenerative	O
disorder	O
resulting	O
from	O
a	O
gain-of-function	O
mutation	O
in	O
a	O
glutamate	O
receptor	O
gene	O
.	O

Thus	O
the	O
activation	O
of	O
apoptotic	O
neuronal	O
death	O
in	O
Lurcher	B-DNAMutation
mice	O
may	O
provide	O
a	O
physiologically	O
relevant	O
model	O
for	O
excitotoxic	O
cell	O
death	O
.	O

An	O
Asp8Asn	B-DNAMutation
substitution	O
results	O
in	O
the	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
ADA	B-DNAMutation
genetic	O
polymorphism	O
(	O
ADA	B-DNAMutation
2	I-DNAMutation
allozyme	O
)	O
:	O
occurrence	O
on	O
different	O
chromosomal	O
backgrounds	O
and	O
apparent	O
intragenic	O
crossover	O
.	O

We	O
have	O
now	O
determined	O
the	O
molecular	O
genetic	O
basis	O
for	O
the	O
common	O
biochemical	O
polymorphism	O
at	O
the	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
ADA	B-DNAMutation
locus	O
.	O

The	O
ADA*2	B-DNAMutation
allele	O
contains	O
a	O
G	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nt22	I-DNAMutation
(	O
relative	O
to	O
the	O
ATG	O
)	O
that	O
results	O
in	O
substitution	O
of	O
asparagine	B-DNAMutation
for	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
8	I-DNAMutation
Asp8Asn	B-DNAMutation
.	O

Introduction	O
of	O
the	O
nucleotide	O
substitution	O
into	O
an	O
ADA	B-DNAMutation
1	I-DNAMutation
cDNA	O
and	O
transfection	O
into	O
monkey	O
kidney	O
(Cos)	O
cells	O
confirmed	O
that	O
the	O
mutation	O
resulted	O
in	O
expression	O
of	O
an	O
enzyme	O
that	O
comigrated	O
with	O
the	O
naturally	O
occurring	O
ADA	B-DNAMutation
2	I-DNAMutation
allozyme	O
.	O

The	O
substitution	B-DNAMutation
of	I-DNAMutation
neutral	I-DNAMutation
asparagine	I-DNAMutation
for	I-DNAMutation
anionic	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
is	O
consistent	O
with	O
the	O
more	O
cathodal	O
electrophoretic	O
migration	O
of	O
ADA	B-DNAMutation
2	I-DNAMutation
as	O
compared	O
with	O
ADA	B-DNAMutation
1	I-DNAMutation
.	O

The	O
nucleotide	O
substitution	O
was	O
found	O
on	O
at	O
least	O
two	O
different	O
genetic	O
backgrounds	O
,	O
suggesting	O
independent	O
recurrence	O
of	O
the	O
mutation	O
.	O

Consistent	O
with	O
independent	O
recurrence	O
,	O
the	O
G	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
transition	I-DNAMutation
is	I-DNAMutation
at	I-DNAMutation
a	I-DNAMutation
CpG	I-DNAMutation
dinucleotide	I-DNAMutation
and	O
represents	O
a	O
type	O
of	O
mutation	O
that	O
occurs	O
with	O
high	O
frequency	O
.	O

We	O
have	O
also	O
unexpectedly	O
identified	O
a	O
probable	O
intragenic	O
crossover	O
in	O
the	O
very	O
large	O
first	O
intron	O
that	O
is	O
rich	O
in	O
repetitive	O
DNA	O
sequences	O
.	O

Three	O
novel	O
IGFALS	B-DNAMutation
gene	O
mutations	O
resulting	O
in	O
total	O
ALS	O
and	O
severe	O
circulating	O
IGF-I/IGFBP-3	B-DNAMutation
deficiency	O
in	O
children	O
of	O
different	O
ethnic	O
origins	O
.	O

BACKGROUND/AIMS	O
:	O
To	O
date	O
,	O
four	O
mutations	O
in	O
the	O
IGFALS	B-DNAMutation
gene	O
have	O
been	O
reported	O
.	O

We	O
now	O
describe	O
two	O
children	O
of	O
different	O
ethnic	O
background	O
with	O
total	O
acid-labile	O
subunit	O
(ALS)	O
and	O
severe	O
circulating	O
IGF-I/IGFBP-3	B-DNAMutation
deficiencies	O
resulting	O
from	O
three	O
novel	O
mutations	O
in	O
the	O
IGFALS	B-DNAMutation
gene	O
.	O

PATIENTS/METHODS	O
:	O
Serum	O
and	O
DNA	O
of	O
patients	O
were	O
analyzed	O
.	O

RESULTS	O
:	O
Case	O
1	O
is	O
a	O
12-year-old	O
boy	O
of	O
Mayan	O
origin	O
.	O

Case	O
2	O
is	O
a	O
5-year-old	O
girl	O
of	O
Jewish/Eastern	O
European	O
(	O
Polish	O
,	O
Russian	O
,	O
Austrian-Hungarian)/Icelandic/European	O
(	O
French	O
,	O
English	O
)	O
ancestry	O
.	O

The	O
reported	O
cases	O
had	O
moderate	O
short	O
stature	O
(	O
-2.91	O
and	O
-2.14	O
SDS	O
,	O
respectively	O
)	O
,	O
nondetectable	O
serum	O
ALS	O
and	O
extremely	O
low	O
serum	O
concentrations	O
of	O
IGF-I	B-DNAMutation
and	O
IGFBP-3	B-DNAMutation
.	O

Case	O
1	O
harbored	O
a	O
novel	O
homozygous	O
1308_1316	B-DNAMutation
dup9	I-DNAMutation
mutation	I-DNAMutation
in	I-DNAMutation
a	I-DNAMutation
highly	I-DNAMutation
conserved	I-DNAMutation
leucine-rich	I-DNAMutation
repeat	I-DNAMutation
(LRR)	I-DNAMutation
17	I-DNAMutation
motif	I-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
2	I-DNAMutation
,	O
representing	O
an	O
in-frame	B-DNAMutation
insertion	I-DNAMutation
of	I-DNAMutation
3	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
,	O
LEL	O
.	O

Case	O
2	O
harbored	O
a	O
novel	O
heterozygous	O
C60S/L244F	B-DNAMutation
mutation	O
in	O
exon	O
2	O
,	O
located	O
within	O
a	O
highly	O
conserved	O
LRR	O
1	O
and	O
LRR	O
9	O
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
identification	O
of	O
additional	O
novel	O
IGFALS	B-DNAMutation
mutations	O
,	O
resulting	O
in	O
severe	O
IGF-I/IGFBP-3	B-DNAMutation
and	O
ALS	O
deficiencies	O
,	O
supports	O
IGFALS	B-DNAMutation
as	O
a	O
candidate	O
gene	O
of	O
the	O
GH/IGF	O
system	O
,	O
implicated	O
in	O
the	O
pathogenesis	O
of	O
primary	O
IGF	O
deficiency	O
,	O
and	O
represents	O
an	O
important	O
part	O
of	O
its	O
differential	O
diagnosis	O
.	O

Mutations	O
in	O
ATP-cassette	O
binding	O
proteins	O
G5	O
ABCG5	B-DNAMutation
and	O
G8	O
ABCG8	B-DNAMutation
causing	O
sitosterolemia	O
.	O

Sitosterolemia	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
caused	O
by	O
mutations	O
in	O
two	O
adjacent	O
genes	O
encoding	O
coordinately	O
regulated	O
ATP	O
binding	O
cassette	O
(ABC)	O
half	O
transporters	O
(	O
ABCG5	B-DNAMutation
and	O
ABCG8	B-DNAMutation
)	O
.	O

In	O
this	O
paper	O
we	O
describe	O
three	O
novel	O
mutations	O
causing	O
sitosterolemia	O
:	O
1	O
)	O
a	O
frameshift	O
mutation	O
c.336-337insA	B-DNAMutation
in	O
ABCG5	B-DNAMutation
that	O
results	O
in	O
premature	B-DNAMutation
termination	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
protein	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
197	I-DNAMutation
;	O
2	O
)	O
a	O
missense	O
mutation	O
that	O
changes	O
a	O
conserved	O
residue	O
c.1311C>G	B-DNAMutation
;	O
N437K	B-DNAMutation
)	O
in	O
ABCG5	B-DNAMutation
and	I-DNAMutation
3	I-DNAMutation
)	O
a	O
splice	O
site	O
mutation	O
in	O
ABCG8	B-DNAMutation
IVS1-2A>G	B-DNAMutation
.	O

This	O
study	O
expands	O
the	O
spectrum	O
of	O
the	O
ABCG5	B-DNAMutation
and	O
ABCG8	B-DNAMutation
mutations	O
that	O
cause	O
sitosterolemia	O
.	O

Nine	O
nonsynonymous	O
polymorphisms	O
are	O
also	O
reported	O
:	O
I523V	B-DNAMutation
,	O
C600Y	B-DNAMutation
,	O
Q604E	B-DNAMutation
,	O
and	O
M622V	B-DNAMutation
in	O
ABCG5	B-DNAMutation
;	O
and	O
D19H	B-DNAMutation
,	O
Y54C	B-DNAMutation
,	O
T400K	B-DNAMutation
,	O
A632V	B-DNAMutation
,	O
and	O
Y641F	B-DNAMutation
in	O
ABCG8	B-DNAMutation
.	O

Identification	O
of	O
a	O
PDZ	O
domain	O
containing	O
Golgi	O
protein	O
,	O
GOPC	B-DNAMutation
,	O
as	O
an	O
interaction	O
partner	O
of	O
frizzled	O
.	O

The	O
frizzled	O
gene	O
is	O
evolutionally	O
conserved	O
in	O
a	O
wide	O
variety	O
of	O
organisms	O
including	O
mammals	O
,	O
and	O
in	O
Drosophila	O
,	O
frizzled	B-DNAMutation
is	O
implicated	O
in	O
the	O
development	O
of	O
planar	O
polarity	O
.	O

We	O
describe	O
here	O
the	O
isolation	O
and	O
characterization	O
of	O
a	O
Golgi	O
protein	O
,	O
GOPC	B-DNAMutation
,	O
as	O
a	O
frizzled	O
interacting	O
protein	O
.	O

GOPC	B-DNAMutation
comprises	O
one	O
PDZ	O
domain	O
,	O
two	O
coiled-coil	O
motifs	O
and	O
two	O
evolutionally	O
conserved	O
regions	O
.	O

Immunofluorescence	O
studies	O
indicated	O
that	O
a	O
significant	O
fraction	O
of	O
GOPC	B-DNAMutation
protein	O
was	O
localized	O
in	O
the	O
Golgi	O
apparatus	O
.	O

Using	O
a	O
series	O
of	O
deletion	O
mutants	O
,	O
we	O
show	O
that	O
both	O
coiled-coil	O
motifs	O
and	O
a	O
C-terminal	O
conserved	O
region	O
were	O
required	O
for	O
its	O
Golgi	O
localization	O
.	O

Interestingly	O
,	O
deletion	B-DNAMutation
mutants	I-DNAMutation
that	I-DNAMutation
lack	I-DNAMutation
a	I-DNAMutation
N-terminal	I-DNAMutation
conserved	O
region	O
or	O
coiled-coil	O
motifs	O
formed	O
aggresome-like	O
perinuclear	O
structure	O
.	O

Interaction	O
of	O
GOPC	B-DNAMutation
and	O
frizzled	O
was	O
observed	O
both	O
in	O
vivo	O
and	O
in	O
vitro	O
,	O
and	O
the	O
PDZ	O
domain	O
of	O
GOPC	B-DNAMutation
and	O
the	O
C-terminal	O
Ser/Thr-X-Val	O
motif	O
of	O
frizzled	O
were	O
required	O
for	O
their	O
interaction	O
.	O

Immunofluorescence	O
studies	O
indicated	O
that	O
,	O
although	O
frizzled	O
was	O
a	O
membrane	O
protein	O
,	O
it	O
was	O
localized	O
at	O
the	O
Golgi	O
apparatus	O
as	O
well	O
,	O
and	O
colocalization	O
of	O
GOPC	B-DNAMutation
and	O
frizzled	O
at	O
the	O
Golgi	O
apparatus	O
was	O
observed	O
.	O

Furthermore	O
,	O
when	O
GOPC	B-DNAMutation
was	O
coexpressed	O
with	O
frizzled	O
,	O
translocation	O
of	O
GOPC	B-DNAMutation
to	O
the	O
plasma	O
membrane	O
was	O
observed	O
.	O

Importantly	O
,	O
brefeldin	O
A	O
interrupted	O
not	O
only	O
the	O
localization	O
of	O
GOPC	B-DNAMutation
to	O
the	O
Golgi	O
apparatus	O
but	O
also	O
the	O
translocation	O
of	O
frizzled	O
to	O
the	O
plasma	O
membrane	O
,	O
indicating	O
that	O
the	O
Golgi	O
structure	O
was	O
required	O
for	O
the	O
proper	O
subcellular	O
localization	O
of	O
frizzled	O
.	O

Taken	O
together	O
,	O
these	O
results	O
indicate	O
that	O
GOPC	B-DNAMutation
may	O
play	O
a	O
role	O
in	O
the	O
vesicle	O
transport	O
of	O
frizzled	O
from	O
the	O
Golgi	O
apparatus	O
to	O
the	O
plasma	O
membrane	O
.	O

Identification	O
of	O
a	O
point	O
mutation	O
in	O
the	O
cDNA	O
of	O
the	O
catalytic	O
subunit	O
of	O
DNA	O
polymerase	O
alpha	O
from	O
a	O
temperature-sensitive	O
mouse	O
FM3A	O
cell	O
line	O
.	O

DNA	O
polymerase	O
alpha	O
is	O
a	O
key	O
enzyme	O
in	O
eukaryotic	O
chromosomal	O
DNA	O
replication	O
.	O

tsFT20	O
is	O
a	O
temperature-sensitive	O
mutant	O
cell	O
line	O
derived	O
from	O
mouse	O
mammary	O
carcinoma	O
FM3A	O
cells	O
,	O
and	O
the	O
cells	O
contain	O
heat-labile	O
DNA	O
polymerase	O
alpha	O
and	O
are	O
arrested	O
at	O
the	O
S	O
phase	O
at	O
the	O
nonpermissive	O
temperature	O
.	O

We	O
isolated	O
cDNA	O
of	O
the	O
catalytic	O
subunit	O
of	O
DNA	O
polymerase	O
alpha	O
from	O
tsFT20	O
cells	O
.	O

DNA	O
sequence	O
analysis	O
revealed	O
that	O
the	O
cDNA	O
from	O
tsFT20	O
has	O
a	O
single	O
mutation	O
,	O
a	O
cytosine	B-DNAMutation
to	I-DNAMutation
thymine	I-DNAMutation
substitution	I-DNAMutation
that	I-DNAMutation
changes	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
1180	I-DNAMutation
from	I-DNAMutation
serine	I-DNAMutation
to	I-DNAMutation
phenylalanine	I-DNAMutation
.	O

We	O
have	O
also	O
shown	O
that	O
tsFT20	O
cells	O
could	O
be	O
rescued	O
by	O
transfection	O
with	O
the	O
wild-type	O
cDNA	O
.	O

These	O
results	O
demonstrate	O
that	O
the	O
point	O
mutation	O
in	O
the	O
gene	O
of	O
DNA	B-DNAMutation
polymerase	I-DNAMutation
alpha	I-DNAMutation
causes	O
the	O
temperature-sensitive	O
phenotype	O
of	O
tsFT20	O
cells	O
and	O
provide	O
additional	O
evidence	O
that	O
DNA	B-DNAMutation
polymerase	I-DNAMutation
alpha	I-DNAMutation
is	O
essential	O
for	O
chromosomal	O
replication	O
in	O
mammalian	O
cells	O
.	O

We	O
also	O
detected	O
mutation	O
sites	O
in	O
one	O
spontaneous	O
and	O
six	O
N-methyl-N'-nitro-N-nitrosoguanidine-induced	O
growth	O
revertants	O
of	O
tsFT20	O
cells	O
by	O
single	O
strand	O
conformation	O
polymorphism	O
analyses	O
and	O
direct	O
sequencing	O
.	O

All	O
revertant	O
cell	O
lines	O
had	O
a	O
second	O
point	O
mutation	O
adjacent	O
to	O
the	O
first	O
mutation	O
site	O
in	O
tsFT20	O
cells	O
.	O

The	O
gamma	O
1	O
and	O
gamma	B-DNAMutation
2	I-DNAMutation
subunits	O
of	O
human	O
liver	O
alcohol	O
dehydrogenase	O
.	O

cDNA	O
structures	O
,	O
two	O
amino	O
acid	O
replacements	O
,	O
and	O
compatibility	O
with	O
changes	O
in	O
the	O
enzymatic	O
properties	O
.	O

cDNA	O
clones	O
corresponding	O
to	O
two	O
alleles	O
of	O
the	O
ADH3	B-DNAMutation
locus	O
were	O
identified	O
by	O
hybridization	O
with	O
synthetic	O
oligodeoxyribonucleotides	O
specific	O
for	O
class	O
I	O
human	O
liver	O
alcohol	O
dehydrogenase	O
.	O

Sequences	O
were	O
determined	O
for	O
a	O
1457-nucleotide	O
cDNA	O
,	O
covering	O
the	O
whole	O
gamma	B-DNAMutation
2-coding	I-DNAMutation
region	O
,	O
and	O
a	O
1224-nucleotide	O
cDNA	O
,	O
including	O
the	O
region	O
coding	O
for	O
amino	O
acid	O
residues	O
53-374	O
of	O
the	O
gamma	O
1	O
subunit	O
.	O

Two	O
amino	O
acid	O
replacements	O
between	O
the	O
gamma	B-DNAMutation
1	I-DNAMutation
and	I-DNAMutation
gamma	I-DNAMutation
2	I-DNAMutation
subunits	O
were	O
identified	O
.	O

At	B-DNAMutation
position	I-DNAMutation
349	I-DNAMutation
,	I-DNAMutation
isoleucine	I-DNAMutation
in	I-DNAMutation
gamma	I-DNAMutation
1	I-DNAMutation
instead	I-DNAMutation
of	I-DNAMutation
valine	I-DNAMutation
in	I-DNAMutation
gamma	I-DNAMutation
2	I-DNAMutation
is	O
a	O
conservative	O
exchange	O
of	O
a	O
superficial	O
residue	O
which	O
has	O
been	O
ascribed	O
no	O
special	O
importance	O
.	O

The	O
other	O
exchange	O
,	O
at	B-DNAMutation
position	I-DNAMutation
271	I-DNAMutation
,	I-DNAMutation
arginine	I-DNAMutation
in	I-DNAMutation
gamma	I-DNAMutation
1	I-DNAMutation
and	I-DNAMutation
glutamine	I-DNAMutation
in	I-DNAMutation
gamma	I-DNAMutation
2	I-DNAMutation
,	O
explains	O
differences	O
in	O
enzyme	O
properties	O
.	O

Electrophoretically	O
,	O
it	O
is	O
consistent	O
with	O
the	O
less	O
cathodic	O
mobility	O
of	O
the	O
gamma	B-DNAMutation
2	I-DNAMutation
subunit	O
.	O

Functionally	O
,	O
the	O
location	O
of	O
the	O
exchange	O
at	O
the	O
surface	O
of	O
the	O
coenzyme-binding	O
pocket	O
may	O
influence	O
the	O
dissociation	O
of	O
the	O
reduced	O
coenzyme	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
Tyr697	I-DNAMutation
,	I-DNAMutation
a	I-DNAMutation
GRB2-binding	I-DNAMutation
site	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Tyr721	I-DNAMutation
,	O
a	O
PI	O
3-kinase	O
binding	O
site	O
,	O
abrogates	O
signal	O
transduction	O
by	O
the	O
murine	O
CSF-1	B-DNAMutation
receptor	I-DNAMutation
expressed	O
in	O
Rat-2	O
fibroblasts	O
.	O

The	O
receptor	O
for	O
the	O
myeloid	O
cell	O
growth	O
factor	O
colony	O
stimulating	O
factor	O
1	O
CSF-1	B-DNAMutation
is	O
a	O
protein	O
tyrosine	O
kinase	O
that	O
is	O
closely	O
related	O
to	O
the	O
PDGF	O
receptor	O
.	O

Ligand	O
binding	O
results	O
in	O
kinase	O
activation	O
and	O
autophosphorylation	O
.	O

Three	O
autophosphorylation	O
sites	O
,	O
Tyr697	O
,	O
Tyr706	O
and	O
Tyr721	O
,	O
have	O
been	O
mapped	O
to	O
the	O
kinase	O
insert	O
domain	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
entire	I-DNAMutation
kinase	I-DNAMutation
insert	I-DNAMutation
domain	I-DNAMutation
completely	O
abrogates	O
signal	O
transduction	O
by	O
the	O
CSF-1	B-DNAMutation
receptor	I-DNAMutation
expressed	O
in	O
Rat-2	O
fibroblasts	O
.	O

To	O
investigate	O
the	O
function	O
of	O
individual	O
phosphorylation	O
sites	O
present	O
in	O
the	O
CSF-1	O
receptor	O
kinase	O
insert	O
domain	O
,	O
a	O
number	O
of	O
phosphorylation	O
site	O
mutants	O
were	O
expressed	O
in	O
Rat-2	O
fibroblasts	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
either	I-DNAMutation
Tyr697	I-DNAMutation
or	I-DNAMutation
Tyr721	I-DNAMutation
compromised	O
signal	O
transduction	O
by	O
the	O
CSF-1	B-DNAMutation
receptor	I-DNAMutation
.	O

A	O
mutant	O
receptor	O
,	O
in	O
which	O
both	O
Tyr697	B-DNAMutation
and	I-DNAMutation
Tyr721	I-DNAMutation
were	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
phenylalanine	I-DNAMutation
,	O
has	O
lost	O
all	O
ability	O
to	O
induce	O
changes	O
in	O
morphology	O
or	O
to	O
increase	O
cell	O
growth	O
rate	O
in	O
response	O
to	O
CSF-1	B-DNAMutation
.	O

Tyr721	O
has	O
been	O
identified	O
recently	O
as	O
the	O
binding	O
site	O
for	O
PI	O
3-kinase	O
.	O

Here	O
we	O
report	O
that	O
GRB2	B-DNAMutation
associates	O
with	O
the	O
CSF-1	B-DNAMutation
receptor	I-DNAMutation
upon	O
ligand	O
binding	O
.	O

The	O
phosphorylation	O
on	O
tyrosine	O
of	O
SHC	O
and	O
several	O
other	O
GRB2-associated	B-DNAMutation
proteins	O
increased	O
upon	O
stimulation	O
with	O
CSF-1	B-DNAMutation
.	O

Tyr697	O
was	O
identified	O
as	O
a	O
binding	O
site	O
for	O
GRB2	B-DNAMutation
.	O

We	O
suggest	O
that	O
PI	O
3-kinase	O
,	O
GRB2	B-DNAMutation
and	O
some	O
of	O
the	O
GRB2-associated	B-DNAMutation
proteins	O
could	O
play	O
an	O
important	O
role	O
in	O
signal	O
transduction	O
by	O
the	O
CSF-1	B-DNAMutation
receptor	I-DNAMutation
.	O

Mutations	O
associated	O
with	O
SjÃ¶gren-Larsson	O
syndrome	O
.	O

SjÃ¶gren-Larsson	O
syndrome	O
(SLS)	O
,	O
a	O
rare	O
autosomal	O
disorder	O
characterized	O
by	O
ichthyosis	O
,	O
spastic	O
neurological	O
disorders	O
and	O
oligophrenia	O
,	O
is	O
associated	O
with	O
deficiency	O
of	B-DNAMutation
fatty	I-DNAMutation
aldehyde	I-DNAMutation
dehydrogenase	I-DNAMutation
encoded	O
by	O
a	O
gene	O
on	O
chromosome	O
17q11.2	O
.	O

Mutations	O
of	O
the	O
gene	O
(	O
GDB	O
symbol	B-DNAMutation
ALDH10	I-DNAMutation
)	O
were	O
recently	O
identified	O
in	O
three	O
SLS	O
patients	O
.	O

Another	O
aldehyde	O
dehydrogenase	O
isozyme	B-DNAMutation
.	I-DNAMutation
ALDH3	I-DNAMutation
,	O
also	O
has	O
a	O
high	O
activity	O
for	O
fatty	O
aldehyde	O
oxidation	O
,	O
and	O
is	O
encoded	O
by	O
a	O
gene	O
in	O
chromosome	O
17q11.2	O
.	O

Abnormality	O
of	O
the	B-DNAMutation
ALDH3	I-DNAMutation
gene	O
could	O
also	O
cause	O
a	O
similar	O
syndrome	O
.	O

The	O
examination	O
of	O
the	B-DNAMutation
ALDH3	I-DNAMutation
locus	O
of	O
three	O
additional	O
SLS	O
patients	O
showed	O
that	O
two	O
are	B-DNAMutation
heterozygous	I-DNAMutation
with	I-DNAMutation
C-->G	I-DNAMutation
at	I-DNAMutation
nt	I-DNAMutation
985	O
(	I-DNAMutation
Pro-->Ala	I-DNAMutation
at	I-DNAMutation
protein	I-DNAMutation
position	I-DNAMutation
329	O
)	O
.	O

However	O
,	O
the	O
mutation	O
was	O
found	O
to	O
be	O
common	O
(	O
frequency	O
of	O
the	O
atypical	O
allele	O
is	O
about	O
0.25	O
)	O
in	O
normal	O
subjects	O
,	O
and	O
not	O
related	O
to	O
SLS	O
.	O

Isoelectric	O
focusing	O
analysis	O
indicated	O
that	B-DNAMutation
ALDH3	I-DNAMutation
is	O
hardly	O
expressed	O
in	O
normal	O
as	O
well	O
as	O
patients'	O
fibroblast	O
cells	O
,	O
while	B-DNAMutation
ALDH10	I-DNAMutation
expressed	O
in	O
the	O
normal	O
cells	O
is	O
diminished	O
in	O
the	O
three	O
patients'	O
cells	O
.	O

The	O
level	O
of	B-DNAMutation
ALDH10	I-DNAMutation
mRNA	O
is	O
also	O
low	O
in	O
the	O
patients'	O
cells	O
.	O

The	O
examination	O
of	O
the	B-DNAMutation
ALDH10	I-DNAMutation
locus	O
revealed	O
the	O
existence	O
of	O
a	I-DNAMutation
3	I-DNAMutation
base	I-DNAMutation
deletion	I-DNAMutation
coupled	I-DNAMutation
with	I-DNAMutation
a	I-DNAMutation
21	I-DNAMutation
base	I-DNAMutation
insertion	I-DNAMutation
at	I-DNAMutation
intron	I-DNAMutation
6/exon	I-DNAMutation
7	O
junction	O
in	O
one	O
patient	O
.	O

This	O
abnormality	O
is	O
the	O
same	O
as	O
that	O
found	O
in	O
the	O
patient	O
previously	O
reported	O
by	O
other	O
investigators	O
.	O

One	O
patient	O
is	O
associated	O
with	O
a	I-DNAMutation
2	I-DNAMutation
base	I-DNAMutation
deletion	I-DNAMutation
at	I-DNAMutation
nt	I-DNAMutation
1297	I-DNAMutation
and	B-DNAMutation
consequent	I-DNAMutation
premature	I-DNAMutation
chain	I-DNAMutation
termination	I-DNAMutation
at	I-DNAMutation
protein	I-DNAMutation
position	I-DNAMutation
434	O
.	O

Another	O
patient	O
is	O
a	O
compound	O
heterozygote	O
for	O
the	O
same	B-DNAMutation
2	I-DNAMutation
base	I-DNAMutation
deletion	I-DNAMutation
at	I-DNAMutation
nt	I-DNAMutation
1297	I-DNAMutation
and	O
a	I-DNAMutation
5	I-DNAMutation
base	I-DNAMutation
insertion	I-DNAMutation
at	I-DNAMutation
nt	I-DNAMutation
1311	I-DNAMutation
and	B-DNAMutation
premature	I-DNAMutation
chain	I-DNAMutation
termination	I-DNAMutation
at	I-DNAMutation
protein	I-DNAMutation
position	I-DNAMutation
457	O
.	O

Unique	O
characteristics	O
of	O
the	O
SLS	O
mutations	O
are	O
pointed	O
out	O
.	O

Congenital	O
myasthenic	O
syndromes	O
due	O
to	O
heteroallelic	O
nonsense/missense	O
mutations	O
in	O
the	O
acetylcholine	B-DNAMutation
receptor	I-DNAMutation
epsilon	I-DNAMutation
subunit	O
gene	O
:	O
identification	O
and	O
functional	O
characterization	O
of	O
six	O
new	O
mutations	O
.	O

We	O
describe	O
and	O
functionally	O
characterize	O
six	O
mutations	O
of	O
the	O
acetylcholine	B-DNAMutation
receptor	I-DNAMutation
(AChR)	I-DNAMutation
epsilon	I-DNAMutation
subunit	I-DNAMutation
gene	O
in	O
three	O
congenital	O
myasthenic	O
syndrome	O
patients	O
.	O

Endplate	O
studies	O
demonstrated	O
severe	O
endplate	O
AChR	O
deficiency	O
,	O
dispersed	O
endplate	O
regions	O
and	O
well	O
preserved	O
junctional	O
folds	O
in	O
all	O
three	O
patients	O
.	O

Electrophysiologic	O
studies	O
were	O
consistent	O
with	O
expression	O
of	O
the	O
fetal	O
gamma-AChR	O
at	O
the	O
endplates	O
in	O
one	O
patient	O
,	O
prolongation	O
of	O
some	O
channel	O
events	O
in	O
another	O
and	O
gamma-AChR	O
expression	O
as	O
well	O
as	O
some	O
shorter	O
than	O
normal	O
channel	O
events	O
in	O
still	O
another	O
.	O

Genetic	O
analysis	O
revealed	O
two	O
recessive	O
and	O
heteroallelic	B-DNAMutation
epsilon	I-DNAMutation
subunit	O
gene	O
mutations	O
in	O
each	O
patient	O
.	O

One	O
mutation	O
in	O
each	O
(	O
epsilonC190T	B-DNAMutation
[	O
epsilon	B-DNAMutation
R64X	B-DNAMutation
]	O
,	O
epsilon	B-DNAMutation
127ins5	B-DNAMutation
and	O
epsilon	B-DNAMutation
553del	B-DNAMutation
7	I-DNAMutation
)	O
generates	O
a	O
nonsense	O
codon	O
that	O
predicts	O
truncation	O
of	O
the	O
epsilon	B-DNAMutation
subunit	O
in	O
its	O
N-terminal	O
,	O
extracellular	O
domain	O
;	O
and	O
one	O
mutation	O
in	O
each	O
generates	O
a	O
missense	O
codon	O
(	O
epsilon	B-DNAMutation
R147L	B-DNAMutation
,	O
epsilon	B-DNAMutation
P245L	B-DNAMutation
and	O
epsilon	B-DNAMutation
R311W	B-DNAMutation
)	O
.	O

None	O
of	O
the	O
mutations	O
was	O
detected	O
in	O
100	O
controls	O
.	O

Expression	O
studies	O
in	O
HEK	O
cells	O
indicate	O
that	O
the	O
three	O
nonsense	O
mutations	O
are	O
null	O
mutations	O
and	O
that	O
surface	O
expression	O
of	O
AChRs	O
harboring	O
the	O
missense	O
mutations	O
is	O
significantly	O
reduced	O
.	O

Kinetic	O
analysis	O
of	O
AChRs	O
harboring	O
the	O
missense	O
mutations	O
show	O
that	O
epsilon	B-DNAMutation
R147L	B-DNAMutation
is	O
kinetically	O
benign	O
,	O
epsilon	B-DNAMutation
P245L	B-DNAMutation
prolongs	O
burst	O
open	O
duration	O
2-fold	O
by	O
slowing	O
the	O
rate	O
of	O
channel	O
closing	O
and	O
epsilon	B-DNAMutation
R311W	B-DNAMutation
shortens	O
burst	O
duration	O
2-fold	O
by	O
slowing	O
the	O
rate	O
of	O
channel	O
opening	O
and	O
speeding	O
the	O
rate	O
of	O
ACh	O
dissociation	O
.	O

The	O
modest	O
changes	O
in	O
activation	O
kinetics	O
are	O
probably	O
overshadowed	O
by	O
reduced	O
expression	O
of	O
the	O
missense	O
mutations	O
.	O

The	O
consequences	O
of	O
the	O
endplate	O
AChR	O
deficiency	O
are	O
mitigated	O
by	O
persistent	O
expression	O
of	O
gamma-AChR	O
,	O
changes	O
in	O
the	O
release	O
of	O
transmitter	O
quanta	O
and	O
appearance	O
of	O
multiple	O
endplate	O
regions	O
on	O
the	O
muscle	O
fiber	O
.	O

Population	O
genetic	O
studies	O
of	O
the	O
Philippine	O
Negritos	O
.	O

III	O
.	O

Identification	O
of	O
the	O
carbonic	O
anhydrase-1	O
variant	O
with	O
CA1	O
Guam	O
.	O

Investigation	O
of	O
blood	O
samples	O
from	O
277	O
Mamanwas	O
of	O
northeastern	O
Mindanao	O
,	O
Philippines	O
,	O
confirmed	O
the	O
concentration	O
of	O
the	O
variant	O
carbonic	O
anhydrase-1	O
(	O
CA1	O
3N	O
)	O
in	O
this	O
group	O
.	O

The	O
frequency	O
for	O
the	O
variant	O
allele	O
was	O
estimated	O
at	O
.217	O
+/-	O
.017	O
.	O

It	O
occurs	O
also	O
in	O
the	O
Manobos	O
,	O
the	O
Mongoloid	O
indigenous	O
inhabitants	O
of	O
the	O
same	O
district	O
,	O
although	O
the	O
frequency	O
is	O
low	O
(	O
.019	O
+/-	O
.008	O
)	O
.	O

Survey	O
of	O
samples	O
from	O
other	O
Philippine	O
populations	O
,	O
including	O
the	O
Aeta	O
and	O
the	O
Ifugao	O
of	O
Luzon	O
,	O
failed	O
to	O
find	O
variants	O
.	O

This	O
findings	O
suggests	O
different	O
origins	O
of	O
the	O
Aeta	O
and	O
the	O
Mamanwa	O
,	O
although	O
both	O
are	O
usually	O
referred	O
to	O
as	O
Negritos	O
.	O

The	O
Ca1	O
3N	O
protein	O
was	O
purified	O
by	O
affinity	O
chromatography	O
using	O
azosulfonamide	O
and	O
rechromatography	O
on	O
a	O
DEAE-Sephadex	O
column	O
.	O

The	O
tryptic	O
peptide	O
pattern	O
of	O
CA1	O
3N	O
was	O
similar	O
to	O
that	O
of	O
CA1	O
Guam	O
already	O
reported	O
.	O

Furthermore	O
,	O
amino	O
acid	O
analyses	O
of	O
the	O
tryptic	O
peptides	O
indicated	O
that	O
CA1	O
3N	O
is	O
characterized	O
by	O
the	O
substitution	B-DNAMutation
253	I-DNAMutation
Gly	I-DNAMutation
leads	I-DNAMutation
to	I-DNAMutation
Arg	I-DNAMutation
,	O
confirming	O
the	O
identity	O
of	O
this	O
variant	O
with	O
CA1	O
Guam	O
.	O

The	O
widespread	O
occurrence	O
of	O
CA1	O
3	O
variants	O
in	O
the	O
Western	O
Pacific	O
suggests	O
that	O
this	O
variant	O
was	O
once	O
common	O
in	O
an	O
aboriginal	O
population	O
of	O
this	O
region	O
,	O
from	O
which	O
it	O
was	O
scattered	O
by	O
gene	O
flow	O
.	O

A	O
novel	O
ANT1	B-DNAMutation
gene	O
mutation	O
with	O
probable	O
germline	O
mosaicism	O
in	O
autosomal	O
dominant	O
progressive	B-DNAMutation
external	I-DNAMutation
ophthalmoplegia	I-DNAMutation
.	O

Only	O
four	O
different	O
mutations	O
in	O
the	O
adenine	B-DNAMutation
nucleotide	I-DNAMutation
translocator	I-DNAMutation
1	I-DNAMutation
ANT1	B-DNAMutation
gene	O
have	O
been	O
found	O
in	O
families	O
with	O
progressive	B-DNAMutation
external	I-DNAMutation
ophthalmoplegia	I-DNAMutation
PEO	B-DNAMutation
.	O

We	O
report	O
a	O
novel	O
heterozygous	O
C	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
transversion	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
269	I-DNAMutation
in	O
the	O
ANT1	B-DNAMutation
gene	O
in	O
a	O
German	O
family	O
with	O
PEO	B-DNAMutation
,	O
predicted	O
to	O
convert	O
a	O
highly	O
conserved	O
alanine	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
90	I-DNAMutation
to	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
.	O

The	O
mutation	O
was	O
identified	O
in	O
three	O
siblings	O
with	O
PEO	B-DNAMutation
,	O
one	O
of	O
them	O
additionally	O
suffered	O
from	O
schizoaffective	O
disorder	O
.	O

Microsatellite	O
analysis	O
showed	O
that	O
the	O
mutation	O
was	O
dominant	O
and	O
inherited	O
from	O
the	O
mother	O
who	O
did	O
not	O
carry	O
the	O
mutation	O
in	O
blood	O
,	O
indicating	O
germ-line	O
mosaicism	O
.	O

Impaired	O
multimerization	O
of	O
human	O
adiponectin	B-DNAMutation
mutants	O
associated	O
with	O
diabetes	O
.	O

Molecular	O
structure	O
and	O
multimer	O
formation	O
of	O
adiponectin	B-DNAMutation
.	O

Adiponectin	B-DNAMutation
is	O
an	O
adipocyte-derived	O
hormone	O
,	O
which	O
has	O
been	O
shown	O
to	O
play	O
important	O
roles	O
in	O
the	O
regulation	O
of	O
glucose	O
and	O
lipid	O
metabolism	O
.	O

Eight	O
mutations	O
in	O
human	O
adiponectin	B-DNAMutation
have	O
been	O
reported	O
,	O
some	O
of	O
which	O
were	O
significantly	O
related	O
to	O
diabetes	O
and	O
hypoadiponectinemia	O
,	O
but	O
the	O
molecular	O
mechanisms	O
of	O
decreased	O
plasma	O
levels	O
and	O
impaired	O
action	O
of	O
adiponectin	B-DNAMutation
mutants	O
were	O
not	O
clarified	O
.	O

Adiponectin	B-DNAMutation
structurally	O
belongs	O
to	O
the	O
complement	O
1q	O
family	O
and	O
is	O
known	O
to	O
form	O
a	O
characteristic	O
homomultimer	O
.	O

Herein	O
,	O
we	O
demonstrated	O
that	O
simple	O
SDS-PAGE	O
under	O
non-reducing	O
and	O
non-heat-denaturing	O
conditions	O
clearly	O
separates	O
multimer	O
species	O
of	O
adiponectin	B-DNAMutation
.	O

Adiponectin	B-DNAMutation
in	O
human	O
or	O
mouse	O
serum	O
and	O
adiponectin	B-DNAMutation
expressed	O
in	O
NIH-3T3	O
or	O
Escherichia	O
coli	O
formed	O
a	O
wide	O
range	O
of	O
multimers	O
from	O
trimers	O
to	O
high	O
molecular	O
weight	O
(HMW)	O
multimers	O
.	O

A	O
disulfide	O
bond	O
through	O
an	O
amino-terminal	O
cysteine	O
was	O
required	O
for	O
the	O
formation	O
of	O
multimers	O
larger	O
than	O
a	O
trimer	O
.	O

An	O
amino-terminal	B-DNAMutation
Cys-Ser	I-DNAMutation
mutation	I-DNAMutation
,	O
which	O
could	O
not	O
form	O
multimers	O
larger	O
than	O
a	O
trimer	O
,	O
abrogated	O
the	O
effect	O
of	O
adiponectin	B-DNAMutation
on	O
the	O
AMP-activated	O
protein	O
kinase	O
pathway	O
in	O
hepatocytes	O
.	O

Among	O
human	O
adiponectin	B-DNAMutation
mutations	O
,	O
G84R	B-DNAMutation
and	O
G90S	B-DNAMutation
mutants	O
,	O
which	O
are	O
associated	O
with	O
diabetes	O
and	O
hypoadiponectinemia	O
,	O
did	O
not	O
form	O
HMW	O
multimers	O
.	O

R112C	B-DNAMutation
and	O
I164T	B-DNAMutation
mutants	O
,	O
which	O
are	O
associated	O
with	O
hypoadiponectinemia	O
,	O
did	O
not	O
assemble	O
into	O
trimers	O
,	O
resulting	O
in	O
impaired	O
secretion	O
from	O
the	O
cell	O
.	O

These	O
data	O
suggested	O
impaired	O
multimerization	O
and/or	O
the	O
consequent	O
impaired	O
secretion	O
to	O
be	O
among	O
the	O
causes	O
of	O
a	O
diabetic	O
phenotype	O
or	O
hypoadiponectinemia	O
in	O
subjects	O
having	O
these	O
mutations	O
.	O

In	O
conclusion	O
,	O
not	O
only	O
total	O
concentrations	O
,	O
but	O
also	O
multimer	O
distribution	O
should	O
always	O
be	O
considered	O
in	O
the	O
interpretation	O
of	O
plasma	O
adiponectin	B-DNAMutation
levels	O
in	O
health	O
as	O
well	O
as	O
various	O
disease	O
states	O
.	O

Familial	O
Alzheimer's	O
disease-linked	O
mutations	O
at	O
Val717	O
of	O
amyloid	O
precursor	O
protein	O
are	O
specific	O
for	O
the	O
increased	O
secretion	O
of	O
A	B-DNAMutation
beta	I-DNAMutation
42(43)	O
.	O

In	O
some	O
pedigrees	O
of	O
familial	O
Alzheimer's	O
disease	O
(FAD)	O
,	O
three	O
mutations	O
of	O
beta	O
amyloid	O
precursor	O
protein	O
(APP)	O
have	O
been	O
found	O
at	O
the	O
Val717	B-DNAMutation
residue	I-DNAMutation
(	I-DNAMutation
to	I-DNAMutation
Ile	I-DNAMutation
,	I-DNAMutation
Phe	I-DNAMutation
,	I-DNAMutation
or	I-DNAMutation
Cly	I-DNAMutation
)	O
and	O
these	O
mutations	O
increase	O
the	O
secretion	O
of	O
A	B-DNAMutation
beta	I-DNAMutation
42(43)	O
.	O

To	O
study	O
the	O
specificity	O
of	O
the	O
effects	O
of	O
these	O
mutations	O
on	O
APP	O
processing	O
,	O
we	O
transiently	O
expressed	O
APP	O
genes	O
with	O
mutations	O
of	O
Val717	B-DNAMutation
to	I-DNAMutation
Lys	I-DNAMutation
,	I-DNAMutation
Ser	I-DNAMutation
,	I-DNAMutation
Glu	I-DNAMutation
,	I-DNAMutation
or	I-DNAMutation
Cys	I-DNAMutation
in	O
COS	O
cells	O
.	O

The	O
three	O
familial	O
AD-linked	O
mutations	O
increased	O
the	O
levels	O
or	O
ratios	O
of	O
A	B-DNAMutation
beta	I-DNAMutation
42(43)	O
,	O
whereas	O
the	O
secretion	O
of	O
A	B-DNAMutation
beta	I-DNAMutation
40	O
was	O
decreased	O
.	O

Other	O
mutations	O
irrelevant	O
to	O
FAD	O
except	O
Val717	B-DNAMutation
to	I-DNAMutation
Lys	I-DNAMutation
had	O
little	O
effect	O
on	O
the	O
ratio	O
of	O
A	B-DNAMutation
beta	I-DNAMutation
42(43)	O
.	O

Substitution	B-DNAMutation
to	I-DNAMutation
Lys	I-DNAMutation
decreased	O
the	O
secretion	O
of	O
A	B-DNAMutation
beta	I-DNAMutation
42(43)	O
;	O
substitution	B-DNAMutation
to	I-DNAMutation
Glu	I-DNAMutation
or	I-DNAMutation
Gly	I-DNAMutation
decreased	O
the	O
amount	O
of	O
intracellular	O
C-terminal	O
fragment	O
produced	O
by	O
alpha-secretase	O
,	O
whereas	O
it	O
was	O
increased	O
by	O
mutations	B-DNAMutation
to	I-DNAMutation
Phe	I-DNAMutation
,	I-DNAMutation
Cys	I-DNAMutation
,	I-DNAMutation
or	I-DNAMutation
Lys	I-DNAMutation
.	O

However	O
,	O
the	O
levels	O
of	O
secretion	O
of	O
soluble	O
APP	O
were	O
constant	O
,	O
but	O
a	O
substitution	B-DNAMutation
to	I-DNAMutation
Glu	I-DNAMutation
reduced	O
it	O
.	O

These	O
results	O
suggest	O
a	O
specific	O
role	O
of	O
the	O
Val717	O
residue	O
in	O
APP	O
processing	O
and	O
,	O
especially	O
,	O
in	O
gamma-cleavage	O
.	O

The	O
transcriptional	O
activation	O
function	O
of	O
the	O
HIF-like	O
factor	O
requires	O
phosphorylation	O
at	O
a	O
conserved	O
threonine	O
.	O

The	O
hypoxia-inducible	O
factor	O
(HIF)-1alpha	O
and	O
the	O
HIF-like	O
factor	O
(HLF)	O
transcription	O
factors	O
are	O
regulated	O
at	O
multiple	O
levels	O
including	O
protein	O
stabilization	O
,	O
nuclear	O
import	O
,	O
and	O
activation	O
of	O
transactivation	O
,	O
resulting	O
in	O
recruitment	O
of	O
coactivators	O
such	O
as	O
the	O
cAMP-response	O
element-binding	O
protein	O
(CREB)-binding	O
protein	O
(CBP)/p300	B-DNAMutation
and	O
SRC-1	B-DNAMutation
.	O

During	O
low	O
oxygen	O
tension	O
these	O
proteins	O
modulate	O
a	O
network	O
of	O
genes	O
that	O
are	O
necessary	O
for	O
angiogenesis	O
,	O
erythropopoiesis	O
,	O
and	O
glycolysis	O
.	O

We	O
report	O
here	O
that	O
the	O
C-terminal	O
transactivation	O
domain	O
of	O
HLF	O
is	O
phosphorylated	O
on	O
multiple	O
sites	O
and	O
that	O
phosphorylation	O
on	O
threonine	O
844	O
of	O
HLF	O
is	O
necessary	O
for	O
the	O
transcriptional	O
activation	O
function	O
of	O
the	O
protein	O
independently	O
of	O
the	O
hypoxia	O
condition	O
.	O

Importantly	O
,	O
using	O
the	O
mammalian	O
two-hybrid	O
system	O
we	O
demonstrate	O
that	O
a	O
substitution	B-DNAMutation
of	I-DNAMutation
threonine	I-DNAMutation
844	I-DNAMutation
to	I-DNAMutation
an	I-DNAMutation
alanine	I-DNAMutation
decreased	O
the	O
enhanced	O
transcriptional	O
activation	O
function	O
mediated	O
by	O
CBP/p300	B-DNAMutation
.	O

A	O
missense	O
mutation	O
in	O
the	O
FALDH	B-DNAMutation
gene	O
identified	O
in	O
SjÃ¶gren-Larsson	O
syndrome	O
patients	O
originating	O
from	O
the	O
northern	O
part	O
of	O
Sweden	O
.	O

SjÃ¶gren-Larsson	O
syndrome	O
(SLS)	O
is	O
an	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
congenital	O
ichthyosis	O
,	O
spastic	O
di-	O
or	O
tetraplegia	O
,	O
and	O
mental	O
retardation	O
.	O

SLS	O
has	O
been	O
reported	O
to	O
occur	O
in	O
many	O
populations	O
but	O
the	O
highest	O
incidence	O
is	O
in	O
the	O
north	O
of	O
Sweden	O
.	O

The	O
gene	O
causing	O
SLS	O
encodes	O
a	I-DNAMutation
fatty	I-DNAMutation
aldehyde	I-DNAMutation
dehydrogenase	I-DNAMutation
(FALDH)	I-DNAMutation
.	O

In	O
the	O
present	O
study	O
,	O
a	O
point	O
mutation	O
in	O
exon	O
7	O
of	O
the	B-DNAMutation
FALDH	I-DNAMutation
gene	O
was	O
found	O
in	O
SLS	O
patients	O
of	O
northern	O
Swedish	O
origin	O
.	O

The	O
mutation	O
consists	O
of	O
a	I-DNAMutation
C-to-T	I-DNAMutation
exchange	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
position	I-DNAMutation
943	O
in	O
the	O
cDNA	O
.	O

As	O
a	O
consequence	O
,	O
a	O
highly	O
conserved	O
proline	O
is	O
replaced	O
by	O
a	O
serine	O
.	O

The	O
mutation	O
was	O
found	O
in	O
49	O
out	O
of	O
58	O
affected	O
chromosomes	O
and	O
could	O
be	O
the	O
most	O
widely	O
spread	O
SLS	O
mutation	O
in	O
the	O
world	O
.	O

Compound	O
heterozygous	O
mutations	O
including	O
a	O
de	O
novo	O
missense	O
mutation	O
in	O
ABCA12	B-DNAMutation
led	O
to	O
a	O
case	O
of	O
harlequin	O
ichthyosis	O
with	O
moderate	O
clinical	O
severity	O
.	O

Harlequin	O
ichthyosis	O
(HI)	O
is	O
one	O
of	O
the	O
most	O
devastating	O
genodermatoses	O
.	O

Recently	O
,	O
ABCA12	B-DNAMutation
mutations	O
were	O
identified	O
as	O
the	O
cause	O
of	O
HI	O
.	O

A	O
newborn	O
Japanese	O
male	O
demonstrated	O
the	O
typical	O
features	O
of	O
HI	O
.	O

The	O
patient	O
was	O
treated	O
with	O
oral	O
etretinate	O
and	O
his	O
general	O
condition	O
has	O
been	O
good	O
(	O
now	O
aged	O
1.5	O
years	O
)	O
.	O

This	O
patient	O
with	O
moderate	O
clinical	O
severity	O
was	O
compound	O
heterozygous	O
for	O
a	O
novel	O
de	O
novo	O
missense	O
mutation	O
1160G	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
(S387N)	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
10	I-DNAMutation
and	O
a	O
maternal	O
deletion	B-DNAMutation
mutation	I-DNAMutation
4158_4160delTAC	I-DNAMutation
(T1387del)	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
28	I-DNAMutation
of	O
ABCA12	B-DNAMutation
.	O

T1387del	B-DNAMutation
was	O
a	O
deletion	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
highly	I-DNAMutation
conserved	I-DNAMutation
threonine	I-DNAMutation
residue	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
first	I-DNAMutation
adenosine	I-DNAMutation
5'	I-DNAMutation
triphosphate-binding	I-DNAMutation
domain	I-DNAMutation
and	O
is	O
thought	O
to	O
seriously	O
affect	O
the	O
function	O
of	O
the	O
ABCA12	B-DNAMutation
protein	O
.	O

Conversely	O
,	O
the	O
residue	O
387	O
is	O
located	O
outside	O
the	O
known	O
active	O
sites	O
of	O
ABCA12	B-DNAMutation
and	O
S387N	B-DNAMutation
is	O
predicted	O
not	O
to	O
lead	O
to	O
a	O
serious	O
functional	O
deficiency	O
in	O
ABCA12	B-DNAMutation
.	O

Electron	O
microscopy	O
revealed	O
abnormal	O
lamellar	O
granules	O
in	O
the	O
granular	O
layer	O
cells	O
and	O
a	O
moderate	O
number	O
of	O
lipid	O
vacuoles	O
in	O
the	O
cornified	O
cells	O
.	O

Disturbed	O
glucosylceramide	O
transport	O
was	O
confirmed	O
in	O
the	O
cultured	O
keratinocytes	O
from	O
the	O
patient	O
.	O

No	O
de	O
novo	O
mutation	O
in	O
ABCA12	B-DNAMutation
has	O
yet	O
been	O
reported	O
either	O
in	O
HI	O
or	O
lamellar	O
ichthyosis	O
.	O

The	O
present	O
case	O
suggested	O
that	O
a	O
de	O
novo	O
ABCA12	B-DNAMutation
mutation	O
might	O
underlie	O
HI	O
.	O

Mutations	O
in	O
SDHD	B-DNAMutation
lead	O
to	O
autosomal	O
recessive	O
encephalomyopathy	O
and	O
isolated	O
mitochondrial	O
complex	O
II	O
deficiency	O
.	O

BACKGROUND	O
:	O
Defects	O
of	O
the	O
mitochondrial	O
respiratory	O
chain	O
complex	O
II	O
(	O
succinate	O
dehydrogenase	O
(SDH)	O
complex	O
)	O
are	O
extremely	O
rare	O
.	O

Of	O
the	O
four	O
nuclear	O
encoded	O
proteins	O
composing	O
complex	O
II	O
,	O
only	O
mutations	O
in	O
the	O
70	O
kDa	O
flavoprotein	O
(SDHA)	O
and	O
the	O
recently	O
identified	O
complex	O
II	O
assembly	O
factor	O
(SDHAF1)	O
have	O
been	O
found	O
to	O
be	O
causative	O
for	O
mitochondrial	O
respiratory	O
chain	O
diseases	O
.	O

Mutations	O
in	O
the	O
other	O
three	O
subunits	O
(	O
SDHB	B-DNAMutation
,	O
SDHC	B-DNAMutation
,	O
SDHD	B-DNAMutation
)	O
and	O
the	O
second	O
assembly	O
factor	O
SDHAF2	B-DNAMutation
have	O
so	O
far	O
only	O
been	O
associated	O
with	O
hereditary	O
paragangliomas	O
and	O
phaeochromocytomas	O
.	O

Recessive	O
germline	O
mutations	O
in	O
SDHB	B-DNAMutation
have	O
recently	O
been	O
associated	O
with	O
complex	O
II	O
deficiency	O
and	O
leukodystrophy	O
in	O
one	O
patient	O
.	O

METHODS	O
AND	O
RESULTS	O
:	O
We	O
present	O
the	O
clinical	O
and	O
molecular	O
investigations	O
of	O
the	O
first	O
patient	O
with	O
biochemical	O
evidence	O
of	O
a	O
severe	O
isolated	O
complex	O
II	O
deficiency	O
due	O
to	O
compound	O
heterozygous	O
SDHD	B-DNAMutation
gene	O
mutations	O
.	O

The	O
patient	O
presented	O
with	O
early	O
progressive	O
encephalomyopathy	O
due	O
to	O
compound	O
heterozygous	O
p.E69	B-DNAMutation
K	I-DNAMutation
and	O
p.*164Lext*3	B-DNAMutation
SDHD	B-DNAMutation
mutations	O
.	O

Native	O
polyacrylamide	O
gel	O
electrophoresis	O
and	O
western	O
blotting	O
demonstrated	O
an	O
impaired	O
complex	O
II	O
assembly	O
.	O

Complementation	O
of	O
a	O
patient	O
cell	O
line	O
additionally	O
supported	O
the	O
pathogenicity	O
of	O
the	O
novel	O
identified	O
mutations	O
in	O
SDHD	B-DNAMutation
.	O

CONCLUSIONS	O
:	O
This	O
report	O
describes	O
the	O
first	O
case	O
of	O
isolated	O
complex	O
II	O
deficiency	O
due	O
to	O
recessive	O
SDHD	B-DNAMutation
germline	O
mutations	O
.	O

We	O
therefore	O
recommend	O
screening	O
for	O
all	O
SDH	O
genes	O
in	O
isolated	O
complex	O
II	O
deficiencies	O
.	O

It	O
further	O
emphasises	O
the	O
importance	O
of	O
appropriate	O
genetic	O
counselling	O
to	O
the	O
family	O
with	O
regard	O
to	O
SDHD	B-DNAMutation
mutations	O
and	O
their	O
role	O
in	O
tumorigenesis	O
.	O

Large	O
deletion	O
of	O
the	O
peroxisomal	O
acyl-CoA	O
oxidase	O
gene	O
in	O
pseudoneonatal	O
adrenoleukodystrophy	O
.	O

We	O
have	O
cloned	O
the	O
cDNA	O
encoding	O
human	O
peroxisomal	O
acyl-CoA	O
oxidase	O
,	O
the	O
first	O
enzyme	O
in	O
the	O
peroxisomal	O
beta-oxidation	O
of	O
very	O
long	O
chain	O
fatty	O
acids	O
.	O

Its	O
nucleotide	O
sequence	O
was	O
found	O
to	O
be	O
highly	O
homologous	O
(85%)	O
to	O
the	O
rat	O
cDNA	O
counterpart	O
.	O

An	O
88%	O
homology	O
between	O
rat	O
and	O
human	O
was	O
found	O
in	O
the	O
COOH-terminal	O
end	O
of	O
the	O
cDNA	O
which	O
includes	O
the	O
Ser-Lys-Leu	O
peroxisomal	O
targeting	O
signal	O
common	O
to	O
many	O
peroxisomal	O
proteins	O
.	O

The	O
gene	O
spans	O
approximately	O
30-40	O
kb	O
and	O
is	O
poorly	O
polymorphic	O
.	O

Southern	O
blot	O
analyses	O
were	O
performed	O
in	O
two	O
previously	O
reported	O
siblings	O
with	O
an	O
isolated	O
peroxisomal	O
acyl-CoA	O
oxidase	O
deficiency	O
(	O
pseudoneonatal	O
adrenoleukodystrophy	O
)	O
.	O

A	O
deletion	B-DNAMutation
of	I-DNAMutation
at	I-DNAMutation
least	I-DNAMutation
17	I-DNAMutation
kb	I-DNAMutation
,	I-DNAMutation
starting	I-DNAMutation
down-stream	I-DNAMutation
from	I-DNAMutation
exon	I-DNAMutation
2	I-DNAMutation
and	I-DNAMutation
extending	I-DNAMutation
beyond	I-DNAMutation
the	I-DNAMutation
3'	I-DNAMutation
end	I-DNAMutation
of	O
the	O
gene	O
,	O
was	O
observed	O
in	O
the	O
two	O
patients	O
.	O

These	O
observations	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
observed	O
acyl-CoA	O
oxidase	O
deficiency	O
in	O
our	O
family	O
.	O

In	O
addition	O
,	O
our	O
study	O
will	O
enable	O
the	O
characterization	O
of	O
the	O
genetic	O
defect	O
in	O
unrelated	O
families	O
with	O
suspected	O
acyl-CoA	O
oxidase	O
disorders	O
.	O

Dioxin	O
binding	O
activities	O
of	O
polymorphic	O
forms	O
of	O
mouse	O
and	O
human	O
arylhydrocarbon	O
receptors	O
.	O

The	O
genetic	O
difference	O
in	O
the	O
susceptibility	O
of	O
mice	O
to	O
environmental	O
toxicities	O
induced	O
by	O
dioxin	O
and	O
related	O
chemicals	O
is	O
governed	O
by	O
polymorphism	O
of	O
the	O
arylhydrocarbon	O
receptor	O
(AhR)	O
(	O
Poland	O
,	O
A.	O
,	O
and	O
Knutson	O
,	O
C	O
.	O

(1982)	O
Annu	O
.	O

Rev	O
.	O

Pharmacol	O
.	O

Toxicol	O
.	O

22	O
,	O
517-554	O
)	O
.	O

cDNA	O
cloning	O
of	O
AhR	O
cDNA	O
from	O
responder	O
(C57BL/6)	O
and	O
non-responder	O
(DBA/2J)	O
mice	O
allowed	O
us	O
to	O
analyze	O
the	O
structure	O
and	O
function	O
of	O
these	O
AhRs	O
.	O

Both	O
of	O
the	O
AhRs	O
,	O
which	O
were	O
expressed	O
in	O
COS-7	O
cells	O
transfected	O
with	O
their	O
expression	O
plasmids	O
,	O
showed	O
a	O
clear	O
9	O
S	O
complex	O
with	O
2,3,7,8-[3H]tetrachlorodibenzo-p-dioxin	O
(TCDD)	O
in	O
a	O
linear	O
glycerol	O
gradient	O
centrifugation	O
,	O
consistent	O
with	O
the	O
result	O
of	O
the	O
endogenously	O
expressed	O
AhR	O
in	O
Hepa-1	O
cells	O
.	O

This	O
result	O
provides	O
the	O
first	O
direct	O
evidence	O
that	O
the	O
cDNA-encoded	O
protein	O
binds	O
the	O
ligand	O
specifically	O
.	O

Scatchard	O
plot	O
analysis	O
revealed	O
that	O
the	O
dissociation	O
constant	O
(Kd)	O
of	O
C57BL	O
AhR	O
for	O
TCDD	O
is	O
0.27	O
nM	O
,	O
while	O
that	O
of	O
DBA	O
AhR	O
is	O
elevated	O
up	O
to	O
six	O
times	O
that	O
high	O
.	O

Chimeric	O
plasmids	O
between	O
the	O
two	O
cDNAs	O
and	O
site-directed	O
mutagenesis	O
revealed	O
two	O
critical	O
alterations	O
responsible	O
for	O
the	O
reduced	O
ligand	O
binding	O
activity	O
:	O
an	O
Ala375	B-DNAMutation
to	I-DNAMutation
Val	I-DNAMutation
alteration	O
and	O
an	O
elongated	O
carboxyl-terminal	O
sequence	O
due	O
to	O
a	O
T	B-DNAMutation
to	I-DNAMutation
C	I-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
first	I-DNAMutation
letter	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
termination	I-DNAMutation
codon	I-DNAMutation
of	O
C57BL	O
AhR	O
.	O

Two	O
variants	O
with	O
reduced	O
and	O
intermediate	O
ligand	O
binding	O
activity	O
were	O
also	O
found	O
in	O
human	O
AhRs	O
with	O
amino	O
acid	O
alterations	O
equivalent	O
to	O
those	O
of	O
the	O
DBA	O
AhR	O
.	O

Importance	O
of	O
the	O
amino	O
acid	O
at	O
position	O
381	O
of	O
human	O
AhR	O
(	O
equivalent	O
to	O
position	O
375	O
of	O
mouse	O
AhR	O
)	O
in	O
the	O
ligand	O
binding	O
was	O
confirmed	O
by	O
the	O
fact	O
that	O
the	O
mutation	O
of	O
Val381	B-DNAMutation
to	I-DNAMutation
Asp	I-DNAMutation
completely	O
abolished	O
the	O
ligand	O
binding	O
activity	O
of	O
human	O
AhR	O
.	O

Phosphorylation	O
at	O
Tyr-838	O
in	O
the	O
kinase	O
domain	O
of	O
EphA8	B-DNAMutation
modulates	O
Fyn	B-DNAMutation
binding	O
to	O
the	O
Tyr-615	O
site	O
by	O
enhancing	O
tyrosine	O
kinase	O
activity	O
.	O

Eph-related	O
receptors	O
and	O
their	O
ephrin	O
ligands	O
are	O
highly	O
conserved	O
protein	O
families	O
which	O
play	O
important	O
roles	O
in	O
targeting	O
axons	O
and	O
migrating	O
cells	O
.	O

In	O
this	O
study	O
we	O
have	O
examined	O
the	O
functional	O
roles	O
of	O
two	O
major	O
autophosphorylation	O
sites	O
,	O
Tyr-615	O
and	O
Tyr-838	O
,	O
in	O
the	O
EphA8	B-DNAMutation
receptor	O
.	O

Two-dimensional	O
phosphopeptide	O
mapping	O
analysis	O
demonstrated	O
that	O
Tyr-615	O
and	O
Tyr-838	O
constitute	O
major	O
autophosphorylation	O
sites	O
in	O
EphA8	B-DNAMutation
.	O

Tyr-615	O
was	O
phosphorylated	O
to	O
the	O
highest	O
stoichiometry	O
,	O
suggesting	O
that	O
phosphorylation	O
at	O
this	O
site	O
may	O
have	O
a	O
physiologically	O
important	O
role	O
.	O

Upon	O
conservative	O
mutation	B-DNAMutation
of	I-DNAMutation
Tyr-838	I-DNAMutation
located	O
in	O
the	O
tyrosine	O
kinase	O
domain	O
,	O
the	O
catalytic	O
activity	O
of	O
EphA8	B-DNAMutation
was	O
strikingly	O
reduced	O
both	O
in	O
vitro	O
and	O
in	O
vivo	O
,	O
whereas	O
a	O
mutation	B-DNAMutation
at	I-DNAMutation
Tyr-615	I-DNAMutation
in	O
the	O
juxtamembrane	O
domain	O
did	O
not	O
impair	O
the	O
tyrosine	O
kinase	O
activity	O
.	O

In	O
vitro	O
binding	O
experiments	O
revealed	O
that	O
phosphorylation	O
at	O
Tyr-615	O
in	O
EphA8	B-DNAMutation
mediates	O
the	O
preferential	O
binding	O
to	O
Fyn-SH2	B-DNAMutation
domain	O
rather	O
than	O
Src	O
and	O
Ras	O
GTPase-activating	O
protein	O
(	O
Ras	O
GAP)-SH2	O
domains	O
.	O

Additionally	O
,	O
a	O
high	O
level	O
of	O
EphA8	B-DNAMutation
was	O
detected	O
in	O
Fyn	B-DNAMutation
immunoprecipitates	O
in	O
intact	O
cells	O
,	O
indicating	O
that	O
EphA8	B-DNAMutation
and	O
Fyn	B-DNAMutation
can	O
physically	O
associate	O
in	O
vivo	O
.	O

In	O
contrast	O
,	O
the	O
association	O
of	O
full-length	O
Fyn	B-DNAMutation
to	O
EphA8	B-DNAMutation
containing	O
mutation	B-DNAMutation
at	I-DNAMutation
either	I-DNAMutation
Tyr-615	I-DNAMutation
or	I-DNAMutation
Tyr-838	I-DNAMutation
was	O
greatly	O
reduced	O
.	O

These	O
data	O
indicate	O
that	O
phosphorylation	O
of	O
Tyr-615	O
is	O
critical	O
for	O
determining	O
the	O
association	O
with	O
Fyn	B-DNAMutation
whereas	O
the	O
integrity	O
of	O
Tyr-838	O
phosphorylation	O
is	O
required	O
for	O
efficient	O
phosphorylation	O
at	O
Tyr-615	O
as	O
well	O
as	O
other	O
major	O
sites	O
.	O

Finally	O
,	O
it	O
was	O
observed	O
that	O
cell	O
attachment	O
responses	O
are	O
attenuated	O
by	O
overexpression	O
of	O
wild	O
type	O
EphA8	B-DNAMutation
receptor	O
but	O
to	O
much	O
less	O
extent	O
by	O
EphA8	B-DNAMutation
mutants	O
lacking	O
phosphorylation	O
at	O
either	O
Tyr-615	O
or	O
Tyr-838	O
.	O

Furthermore	O
,	O
transient	O
expression	O
of	O
kinase-inactive	O
Fyn	B-DNAMutation
in	O
EphA8-overexpressing	B-DNAMutation
cells	O
blocked	O
cell	O
attachment	O
responses	O
attenuated	O
by	O
the	O
EphA8	B-DNAMutation
signaling	O
.	O

We	O
therefore	O
propose	O
that	O
Fyn	B-DNAMutation
kinase	O
is	O
one	O
of	O
the	O
major	O
downstream	O
targets	O
for	O
the	O
EphA8	B-DNAMutation
signaling	O
pathway	O
leading	O
to	O
a	O
modification	O
of	O
cell	O
adhesion	O
,	O
and	O
that	O
autophosphorylation	O
at	O
Tyr-838	O
is	O
critical	O
for	O
positively	O
regulating	O
the	O
EphA8	B-DNAMutation
signaling	O
event	O
.	O

Endopeptidase	O
cleavage	O
generates	O
a	O
functionally	O
distinct	O
isoform	O
of	O
C1q/tumor	B-DNAMutation
necrosis	I-DNAMutation
factor-related	I-DNAMutation
protein-12	I-DNAMutation
CTRP12	B-DNAMutation
with	O
an	O
altered	O
oligomeric	O
state	O
and	O
signaling	O
specificity	O
.	O

Adipose	O
tissue-derived	O
adipokines	O
are	O
an	O
important	O
class	O
of	O
secreted	O
metabolic	O
regulators	O
that	O
mediate	O
tissue	O
cross-talk	O
to	O
control	O
systemic	O
energy	O
balance	O
.	O

We	O
recently	O
described	O
C1q/TNF-related	B-DNAMutation
protein-12	I-DNAMutation
CTRP12	B-DNAMutation
,	O
a	O
novel	O
insulin-sensitizing	O
adipokine	O
that	O
regulates	O
glucose	O
metabolism	O
in	O
liver	O
and	O
adipose	O
tissue	O
.	O

However	O
,	O
the	O
biochemical	O
properties	O
of	O
CTRP12	B-DNAMutation
and	O
its	O
naturally	O
occurring	O
cleaved	O
isoform	O
have	O
not	O
been	O
characterized	O
.	O

Here	O
,	O
we	O
show	O
that	O
CTRP12	B-DNAMutation
is	O
a	O
secreted	O
hormone	O
subjected	O
to	O
multiple	O
functionally	O
relevant	O
posttranslational	O
modifications	O
at	O
highly	O
conserved	O
residues	O
.	O

For	O
example	O
,	O
Asn(39)	O
is	O
glycosylated	O
,	O
whereas	O
Cys(85)	O
mediates	O
the	O
assembly	O
of	O
higher	O
order	O
oligomeric	O
structure	O
.	O

Endopeptidase	O
cleavage	O
at	O
Lys(91)	O
generates	O
a	O
cleaved	O
globular	O
gCTRP12	O
isoform	O
,	O
the	O
expression	O
of	O
which	O
is	O
increased	O
by	O
insulin	B-DNAMutation
.	O

PCSK3/furin	B-DNAMutation
was	O
identified	O
as	O
the	O
major	O
proprotein	O
convertase	O
expressed	O
by	O
adipocytes	O
that	O
mediates	O
the	O
endogenous	O
cleavage	O
of	O
CTRP12	B-DNAMutation
.	O

Cleavage	O
at	O
Lys(91)	O
is	O
context-dependent	O
:	O
mutation	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
charged	I-DNAMutation
Arg(93)	I-DNAMutation
to	I-DNAMutation
Ala	I-DNAMutation
on	I-DNAMutation
the	I-DNAMutation
P2'	I-DNAMutation
position	I-DNAMutation
enhanced	O
cleavage	O
,	O
and	O
triple	O
mutations	O
K90A/K91A/R93A	B-DNAMutation
abolished	O
cleavage	O
.	O

Importantly	O
,	O
the	O
two	O
isoforms	O
of	O
CTRP12	B-DNAMutation
differ	O
in	O
oligomeric	O
structures	O
and	O
are	O
functionally	O
distinct	O
.	O

The	O
full-length	O
protein	O
forms	O
trimers	O
and	O
larger	O
complexes	O
,	O
and	O
the	O
cleaved	O
isoform	O
consisted	O
of	O
predominantly	O
dimers	O
.	O

Whereas	O
full-length	O
fCTRP12	O
strongly	O
activated	O
Akt	O
signaling	O
in	O
H4IIE	O
hepatocytes	O
and	O
3T3-L1	O
adipocytes	O
,	O
gCTRP12	O
preferentially	O
activated	O
MAP	O
kinase	O
(	O
ERK1/2	B-DNAMutation
and	O
p38	O
MAPK	O
)	O
signaling	O
.	O

Further	O
,	O
only	O
fCTRP12	O
improved	O
insulin-stimulated	B-DNAMutation
glucose	O
uptake	O
in	O
adipocytes	O
.	O

These	O
results	O
reveal	O
a	O
novel	O
mechanism	O
controlling	O
signaling	O
specificity	O
and	O
function	O
of	O
a	O
hormone	O
via	O
cleavage-dependent	O
alteration	O
in	O
oligomeric	O
state	O
.	O

Disease-causing	O
mutations	O
in	O
exon	O
11	O
of	O
the	O
medium-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
gene	O
.	O

Medium-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
MCAD	B-DNAMutation
deficiency	O
is	O
the	O
most	O
commonly	O
recognized	O
defect	O
of	O
the	O
mitochondrial	O
beta-oxidation	O
in	O
humans	O
.	O

It	O
is	O
a	O
potentially	O
fatal	O
,	O
autosomal	O
recessive	O
inherited	O
defect	O
.	O

Most	O
patients	O
with	O
MCAD	B-DNAMutation
deficiency	O
are	O
homozygous	O
for	O
a	O
single	O
disease-causing	O
mutation	O
G985	B-DNAMutation
,	O
causing	O
a	O
change	B-DNAMutation
from	I-DNAMutation
lysine	I-DNAMutation
to	I-DNAMutation
glutamate	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
304	I-DNAMutation
(K304E)	I-DNAMutation
in	O
the	O
mature	O
MCAD	B-DNAMutation
.	O

Only	O
seven	O
non-G985	B-DNAMutation
mutations	O
,	O
all	O
of	O
which	O
are	O
rare	O
,	O
have	O
been	O
reported	O
.	O

Because	O
the	O
G985	B-DNAMutation
mutation	I-DNAMutation
and	O
three	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
non-G985	I-DNAMutation
mutations	I-DNAMutation
are	I-DNAMutation
located	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
11	I-DNAMutation
,	O
it	O
has	O
been	O
suggested	O
that	O
this	O
exon	O
may	O
be	O
a	O
mutational	O
hot	O
spot	O
.	O

Here	O
we	O
describe	O
the	O
results	O
from	O
sequence	O
analysis	O
of	O
exon	O
11	O
and	O
part	O
of	O
the	O
flanking	O
introns	O
from	O
36	O
compound	O
heterozygous	O
patients	O
with	O
MCAD	B-DNAMutation
deficiency	O
.	O

We	O
have	O
identified	O
four	O
previously	O
unknown	O
disease-causing	O
mutations	O
(	O
M301T	B-DNAMutation
,	O
S311R	B-DNAMutation
,	O
R324X	B-DNAMutation
,	O
and	O
E359X	B-DNAMutation
)	O
and	O
two	O
silent	O
mutations	O
in	O
exon	O
11	O
.	O

Our	O
results	O
show	O
that	O
exon	O
11	O
is	O
not	O
especially	O
mutation	O
prone	O
.	O

We	O
demonstrate	O
that	O
two	O
of	O
the	O
identified	O
disease-causing	O
mutations	O
can	O
be	O
detected	O
by	O
restriction	O
enzyme	O
digestion	O
of	O
the	O
PCR	O
product	O
from	O
the	O
assay	O
for	O
the	O
G985	B-DNAMutation
mutation	O
,	O
a	O
discovery	O
that	O
makes	O
this	O
assay	O
even	O
more	O
useful	O
than	O
before	O
.	O

On	O
the	O
basis	O
of	O
expression	O
of	O
wild-type	O
and	O
mutant	O
MCAD	B-DNAMutation
protein	O
in	O
COS-7	O
cells	O
,	O
we	O
show	O
that	O
the	O
identified	O
mutations	O
abolish	O
MCAD	B-DNAMutation
enzyme	O
activity	O
and	O
that	O
they	O
therefore	O
must	O
be	O
disease	O
causing	O
.	O

The	O
M301T	B-DNAMutation
,	O
S311R	B-DNAMutation
,	O
and	O
K304E	B-DNAMutation
mutations	O
are	O
located	O
in	O
helix	O
H	O
,	O
which	O
makes	O
up	O
part	O
of	O
the	O
dimer-dimer	O
interface	O
of	O
the	O
MCAD	B-DNAMutation
tetramer	O
.	O

On	O
the	O
basis	O
of	O
the	O
three-dimensional	O
structure	O
of	O
MCAD	B-DNAMutation
and	O
the	O
results	O
from	O
the	O
COS-7	O
expression	O
experiments	O
,	O
we	O
speculate	O
that	O
the	O
primary	O
effect	O
of	O
the	O
M301T	B-DNAMutation
and	O
S311R	B-DNAMutation
mutations	O
is	O
on	O
correct	O
folding/tetramer	O
assembly	O
,	O
as	O
it	O
has	O
previously	O
been	O
observed	O
for	O
the	O
K304E	B-DNAMutation
mutation	O
.	O

Molecular	O
basis	O
of	O
congenital	O
adrenal	O
hyperplasia	O
due	O
to	O
3	B-DNAMutation
beta-hydroxysteroid	I-DNAMutation
dehydrogenase	I-DNAMutation
deficiency	O
.	O

Congenital	O
adrenal	O
hyperplasia	O
is	O
the	O
most	O
frequent	O
cause	O
of	O
adrenal	O
insufficiency	O
and	O
ambiguous	O
genitalia	O
in	O
newborn	O
children	O
.	O

In	O
contrast	O
to	O
congenital	O
adrenal	O
hyperplasia	O
due	O
to	O
21-hydroxylase	O
and	O
11	O
beta-hydroxylase	O
deficiencies	O
,	O
which	O
impair	O
steroid	O
formation	O
in	O
the	O
adrenal	O
cortex	O
,	O
exclusively	O
,	O
classical	O
3	B-DNAMutation
beta-hydroxysteroid	I-DNAMutation
dehydrogenase	I-DNAMutation
(	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
)	O
deficiency	O
affects	O
steroid	O
biosynthesis	O
in	O
the	O
gonads	O
as	O
well	O
as	O
in	O
the	O
adrenals	O
.	O

The	O
structures	O
of	O
the	O
highly	O
homologous	O
type	O
I	O
and	O
II	B-DNAMutation
3	I-DNAMutation
beta-HSD	I-DNAMutation
genes	O
have	O
been	O
analyzed	O
in	O
three	O
male	O
pseudohermaphrodite	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
deficient	O
patients	O
from	O
unrelated	O
families	O
in	O
order	O
to	O
elucidate	O
the	O
molecular	O
basis	O
of	O
classical	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
deficiency	O
from	O
patients	O
exhibiting	O
various	O
degrees	O
of	O
severity	O
of	O
salt	O
losing	O
.	O

The	O
nucleotide	O
sequence	O
of	O
DNA	O
fragments	O
generated	O
by	O
selective	O
polymerase	O
chain	O
reaction	O
amplification	O
that	O
span	O
the	O
four	O
exons	O
,	O
the	O
exon-intron	O
boundaries	O
,	O
as	O
well	O
as	O
the	O
5'-flanking	O
region	O
of	O
each	O
of	O
the	O
two	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
genes	O
have	O
been	O
determined	O
in	O
the	O
three	O
male	O
patients	O
.	O

The	O
five	O
point	O
mutations	O
characterized	O
were	O
all	O
detected	O
in	O
the	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta-HSD	I-DNAMutation
gene	O
,	O
which	O
is	O
the	O
gene	O
predominantly	O
expressed	O
in	O
the	O
adrenals	O
and	O
gonads	O
,	O
while	O
no	O
mutation	O
was	O
detected	O
in	O
the	O
type	O
I	B-DNAMutation
3	I-DNAMutation
beta-HSD	I-DNAMutation
gene	O
,	O
predominantly	O
expressed	O
in	O
the	O
placenta	O
and	O
peripheral	O
tissues	O
.	O

The	O
two	O
male	O
patients	O
suffering	O
from	O
severe	O
salt-losing	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
deficiency	O
are	O
compound	O
heterozygotes	O
,	O
one	O
bearing	O
the	O
frame-shift	O
mutation	O
186/insC/187	B-DNAMutation
and	O
the	O
missense	O
mutation	O
Y253N	B-DNAMutation
,	O
while	O
the	O
other	O
bears	O
the	O
nonsense	O
mutation	O
W171X	B-DNAMutation
and	O
the	O
missense	O
mutation	O
E142K	B-DNAMutation
.	O

The	O
influence	O
of	O
the	O
detected	O
missense	O
mutations	O
on	O
enzymatic	O
activity	O
was	O
assessed	O
by	O
in	O
vitro	O
expression	O
analysis	O
of	O
mutant	O
recombinant	O
enzymes	O
generated	O
by	O
site-directed	O
mutagenesis	O
in	O
heterologous	O
mammalian	O
cells	O
.	O

Recombinant	O
mutant	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta-HSD	I-DNAMutation
enzymes	O
carrying	O
Y253N	B-DNAMutation
or	O
E142K	B-DNAMutation
substitutions	O
exhibit	O
no	O
detectable	O
activity	O
.	O

On	O
the	O
other	O
hand	O
,	O
the	O
nonsalt-losing	O
patient	O
is	O
homozygous	O
for	O
the	O
missense	O
mutation	O
A245P	B-DNAMutation
.	O

This	O
mutation	O
decreases	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
activity	O
by	O
approximately	O
90%	O
.	O

The	O
present	O
findings	O
,	O
describing	O
the	O
first	O
missense	O
mutations	O
in	O
the	O
human	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta-HSD	I-DNAMutation
gene	O
,	O
provide	O
unique	O
information	O
on	O
the	O
structure-activity	O
relationships	O
of	O
the	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
superfamily	O
.	O

Moreover	O
,	O
the	O
present	O
findings	O
provide	O
a	O
molecular	O
explanation	O
for	O
the	O
enzymatic	O
heterogeneity	O
responsible	O
for	O
the	O
severe	O
salt-losing	O
form	O
to	O
the	O
clinically	O
inapparent	O
salt-wasting	O
form	O
of	O
classical	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
deficiency.(ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
mouse	O
homolog	O
of	O
bacterial	O
ClpX	B-DNAMutation
,	O
a	O
novel	O
mammalian	O
class	O
II	O
member	O
of	O
the	O
Hsp100/Clp	O
chaperone	O
family	O
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
the	O
molecular	O
cloning	O
and	O
characterization	O
of	O
a	O
murine	O
homolog	O
of	O
the	O
Escherichia	O
coli	O
chaperone	O
ClpX	O
.	O

Murine	O
ClpX	B-DNAMutation
shares	O
38%	O
amino	O
acid	O
sequence	O
identity	O
with	O
the	O
E	O
.	O

coli	O
homolog	O
and	O
is	O
a	O
novel	O
member	O
of	O
the	O
Hsp100/Clp	O
family	O
of	O
molecular	O
chaperones	O
.	O

ClpX	B-DNAMutation
localizes	O
to	O
human	O
chromosome	O
15q22.2-22.3	O
and	O
in	O
mouse	O
is	O
expressed	O
tissue-specifically	O
as	O
one	O
transcript	O
of	O
approximately	O
2.9	O
kilobases	O
(kb)	O
predominantly	O
within	O
the	O
liver	O
and	O
as	O
two	O
isoforms	O
of	O
approximately	O
2.6	O
and	O
approximately	O
2.9	O
kb	O
within	O
the	O
testes	O
.	O

Purified	O
recombinant	O
ClpX	B-DNAMutation
displays	O
intrinsic	O
ATPase	O
activity	O
,	O
with	O
a	O
Km	O
of	O
approximately	O
25	O
microM	O
and	O
a	O
Vmax	O
of	O
approximately	O
660	O
pmol	O
min-1	O
microgram-1	O
,	O
which	O
is	O
active	O
over	O
a	O
broad	O
range	O
of	O
pH	O
,	O
temperature	O
,	O
ethanol	O
,	O
and	O
salt	O
parameters	O
.	O

Substitution	B-DNAMutation
of	I-DNAMutation
lysine	I-DNAMutation
300	I-DNAMutation
with	I-DNAMutation
alanine	I-DNAMutation
in	O
the	O
ATPase	O
domain	O
P-loop	O
abolishes	O
both	O
ATP	O
hydrolysis	O
and	O
binding	O
.	O

Recombinant	O
ClpX	B-DNAMutation
can	O
also	O
interact	O
with	O
its	O
putative	O
partner	O
protease	O
subunit	O
ClpP	B-DNAMutation
in	O
overexpression	O
experiments	O
in	O
293T	O
cells	O
.	O

Subcellular	O
studies	O
by	O
confocal	O
laser	O
scanning	O
microscopy	O
localized	O
murine	O
ClpX	B-DNAMutation
green	O
fluorescent	O
protein	O
fusions	O
to	O
the	O
mitochondria	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
N-terminal	I-DNAMutation
mitochondrial	O
targeting	O
sequence	O
abolished	O
mitochondrial	O
compartmentalization	O
.	O

Our	O
results	O
thus	O
suggest	O
that	O
murine	O
ClpX	B-DNAMutation
acts	O
as	O
a	O
tissue-specific	O
mammalian	O
mitochondrial	O
chaperone	O
that	O
may	O
play	O
a	O
role	O
in	O
mitochondrial	O
protein	O
homeostasis	O
.	O

Double	O
deletions	O
and	O
missense	O
mutations	O
in	O
the	O
first	O
nucleotide-binding	O
fold	O
of	O
the	O
ATP-binding	B-DNAMutation
cassette	I-DNAMutation
transporter	I-DNAMutation
A1	I-DNAMutation
(	O
ABCA1	B-DNAMutation
)	O
gene	O
in	O
Japanese	O
patients	O
with	O
Tangier	O
disease	O
Tangier	O
disease	O
(TD)	O
is	O
a	O
rare	O
autosomal	O
recessive	O
disease	O
characterized	O
by	O
plasma	O
high-density	O
lipoprotein	O
deficiency	O
caused	O
by	O
an	O
ATP-binding	B-DNAMutation
cassette	I-DNAMutation
transporter	I-DNAMutation
A1	I-DNAMutation
(	O
ABCA1	B-DNAMutation
)	I-DNAMutation
gene	O
mutation	O
.	O

We	O
describe	O
three	O
different	O
mutations	O
in	O
Japanese	O
patients	O
with	O
TD	O
.	O

The	O
first	O
patient	O
was	O
homozygous	O
for	O
double	O
deletions	O
of	O
1221	B-DNAMutation
bp	I-DNAMutation
between	I-DNAMutation
intron	I-DNAMutation
12	I-DNAMutation
and	I-DNAMutation
14	I-DNAMutation
and	I-DNAMutation
19.9	B-DNAMutation
kb	I-DNAMutation
between	I-DNAMutation
intron	I-DNAMutation
16	I-DNAMutation
and	I-DNAMutation
31	I-DNAMutation
.	I-DNAMutation
The	O
breakpoint	O
sequence	O
analyses	O
suggest	O
that	O
it	O
is	O
a	O
simultaneous	O
event	O
caused	O
by	O
double-loop	O
formation	O
through	O
multiple	O
Alu	O
.	O

The	O
second	O
patient	O
was	O
homozygous	O
for	O
a	O
novel	B-DNAMutation
mutation	I-DNAMutation
of	I-DNAMutation
A3198C	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
19	I-DNAMutation
,	I-DNAMutation
resulting	O
in	O
Asn935His	B-DNAMutation
.	I-DNAMutation
The	O
third	O
patient	O
was	O
homozygous	O
for	O
A3199G	B-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
19	I-DNAMutation
that	I-DNAMutation
leads	O
to	O
Asn935Ser	B-DNAMutation
,	I-DNAMutation
which	O
is	O
the	O
same	O
mutation	O
found	O
in	O
German	O
and	O
Spanish	O
families	O
.	O

Both	O
Asn	O
mutations	O
involved	O
Walker	O
A	O
motif	O
of	O
the	O
first	O
nucleotide-binding	O
fold	O
.	O

Eps8	B-DNAMutation
regulates	O
axonal	O
filopodia	O
in	O
hippocampal	O
neurons	O
in	O
response	O
to	O
brain-derived	B-DNAMutation
neurotrophic	I-DNAMutation
factor	I-DNAMutation
BDNF	B-DNAMutation
.	O

The	O
regulation	O
of	O
filopodia	O
plays	O
a	O
crucial	O
role	O
during	O
neuronal	O
development	O
and	O
synaptogenesis	O
.	O

Axonal	O
filopodia	O
,	O
which	O
are	O
known	O
to	O
originate	O
presynaptic	O
specializations	O
,	O
are	O
regulated	O
in	O
response	O
to	O
neurotrophic	O
factors	O
.	O

The	O
structural	O
components	O
of	O
filopodia	O
are	O
actin	O
filaments	O
,	O
whose	O
dynamics	O
and	O
organization	O
are	O
controlled	O
by	O
ensembles	O
of	O
actin-binding	O
proteins	O
.	O

How	O
neurotrophic	O
factors	O
regulate	O
these	O
latter	O
proteins	O
remains	O
,	O
however	O
,	O
poorly	O
defined	O
.	O

Here	O
,	O
using	O
a	O
combination	O
of	O
mouse	O
genetic	O
,	O
biochemical	O
,	O
and	O
cell	O
biological	O
assays	O
,	O
we	O
show	O
that	O
genetic	O
removal	B-DNAMutation
of	I-DNAMutation
Eps8	B-DNAMutation
,	O
an	O
actin-binding	O
and	O
regulatory	O
protein	O
enriched	O
in	O
the	O
growth	O
cones	O
and	O
developing	O
processes	O
of	O
neurons	O
,	O
significantly	O
augments	O
the	O
number	O
and	O
density	O
of	O
vasodilator-stimulated	O
phosphoprotein	O
(VASP)-dependent	O
axonal	O
filopodia	O
.	O

The	O
reintroduction	O
of	O
Eps8	B-DNAMutation
wild	O
type	O
(WT)	O
,	O
but	O
not	O
an	O
Eps8	B-DNAMutation
capping-defective	O
mutant	O
,	O
into	O
primary	O
hippocampal	O
neurons	O
restored	O
axonal	O
filopodia	O
to	O
WT	O
levels	O
.	O

We	O
further	O
show	O
that	O
the	O
actin	O
barbed-end	O
capping	O
activity	O
of	O
Eps8	B-DNAMutation
is	O
inhibited	O
by	O
brain-derived	B-DNAMutation
neurotrophic	I-DNAMutation
factor	I-DNAMutation
BDNF	B-DNAMutation
treatment	O
through	O
MAPK-dependent	O
phosphorylation	O
of	O
Eps8	B-DNAMutation
residues	O
S624	O
and	O
T628	O
.	O

Additionally	O
,	O
an	O
Eps8	B-DNAMutation
mutant	O
,	O
impaired	O
in	O
the	O
MAPK	O
target	O
sites	O
S624A/T628A	B-DNAMutation
,	O
displays	O
increased	O
association	O
to	O
actin-rich	O
structures	O
,	O
is	O
resistant	O
to	O
BDNF-mediated	B-DNAMutation
release	O
from	O
microfilaments	O
,	O
and	O
inhibits	O
BDNF-induced	B-DNAMutation
filopodia	O
.	O

The	O
opposite	O
is	O
observed	O
for	O
a	O
phosphomimetic	O
Eps8	B-DNAMutation
S624E/T628E	B-DNAMutation
mutant	O
.	O

Thus	O
,	O
collectively	O
,	O
our	O
data	O
identify	O
Eps8	B-DNAMutation
as	O
a	O
critical	O
capping	O
protein	O
in	O
the	O
regulation	O
of	O
axonal	O
filopodia	O
and	O
delineate	O
a	O
molecular	O
pathway	O
by	O
which	O
BDNF	B-DNAMutation
,	O
through	O
MAPK-dependent	O
phosphorylation	O
of	O
Eps8	B-DNAMutation
,	O
stimulates	O
axonal	O
filopodia	O
formation	O
,	O
a	O
process	O
with	O
crucial	O
impacts	O
on	O
neuronal	O
development	O
and	O
synapse	O
formation	O
.	O

Functional	O
characterization	O
of	O
the	O
novel	O
L108W	B-DNAMutation
and	O
P186L	B-DNAMutation
mutations	O
detected	O
in	O
the	O
type	B-DNAMutation
II	I-DNAMutation
3	I-DNAMutation
beta-hydroxysteroid	I-DNAMutation
dehydrogenase	I-DNAMutation
gene	O
of	O
a	O
male	O
pseudohermaphrodite	O
with	O
congenital	O
adrenal	O
hyperplasia	O
.	O

Two	O
isoenzymes	O
are	O
responsible	O
for	O
3	B-DNAMutation
beta-hydroxysteroid	I-DNAMutation
dehydrogenase/delta	I-DNAMutation
5-delta	I-DNAMutation
4-isomerase	I-DNAMutation
(	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
)	O
activity	O
in	O
humans	O
.	O

We	O
analyzed	O
the	O
structure	O
of	O
types	O
I	O
and	O
II	B-DNAMutation
3	I-DNAMutation
beta-HSD	I-DNAMutation
genes	O
in	O
a	O
male	O
pseudohermaphrodite	O
suffering	O
from	O
a	O
severe	O
salt-losing	O
form	O
of	O
congenital	O
adrenal	O
hyperplasia	O
.	O

We	O
did	O
not	O
detect	O
any	O
mutation	O
in	O
the	O
type	O
I	B-DNAMutation
3	I-DNAMutation
beta-HSD	I-DNAMutation
gene	O
,	O
but	O
we	O
found	O
two	O
different	O
missense	O
mutations	O
in	O
exon	O
IV	O
of	O
the	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta-HSD	I-DNAMutation
gene	O
of	O
the	O
patient	O
;	O
a	O
conversion	O
of	O
codon	O
Leu108	B-DNAMutation
into	I-DNAMutation
a	I-DNAMutation
Trp	I-DNAMutation
L108W	B-DNAMutation
inherited	O
from	O
his	O
mother	O
and	O
a	O
conversion	O
of	O
codon	O
Pro186	B-DNAMutation
into	I-DNAMutation
a	I-DNAMutation
Leu	I-DNAMutation
P186L	B-DNAMutation
inherited	O
from	O
his	O
father	O
.	O

We	O
assessed	O
the	O
effect	O
of	O
the	O
L108W	B-DNAMutation
and	O
P186L	B-DNAMutation
mutations	O
on	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
activity	O
by	O
in	O
vitro	O
analysis	O
of	O
mutant	O
enzymes	O
expressed	O
in	O
heterologous	O
COS-1	O
cells	O
.	O

Using	O
homogenates	O
from	O
transfected	O
cells	O
,	O
the	O
Km	O
values	O
for	O
PREG	O
were	O
7	O
+/-	O
2	O
and	O
8	O
+/-	O
2	O
microM	O
for	O
the	O
recombinant	O
L108W	B-DNAMutation
and	O
P186L	B-DNAMutation
enzymes	O
,	O
respectively	O
,	O
compared	O
with	O
2.2	O
+/-	O
0.2	O
microM	O
for	O
the	O
normal	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta-HSD	I-DNAMutation
enzyme	O
.	O

Moreover	O
,	O
Km	O
values	O
for	O
NAD+	O
were	O
much	O
higher	O
for	O
the	O
L108W	B-DNAMutation
and	O
P186L	B-DNAMutation
proteins	O
,	O
being	O
678	O
+/-	O
166	O
and	O
920	O
+/-	O
351	O
microM	O
,	O
respectively	O
,	O
compared	O
with	O
24	O
+/-	O
3	O
microM	O
for	O
the	O
normal	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta-HSD	I-DNAMutation
enzyme	O
.	O

Vmax	O
values	O
for	O
PREG	O
and	O
NAD+	O
were	O
lower	O
for	O
both	O
mutant	O
enzymes	O
;	O
thus	O
,	O
the	O
in	O
vitro	O
overall	O
efficiency	O
,	O
relative	O
to	O
the	O
normal	O
enzyme	O
,	O
is	O
approximate	O
as	O
0.3%	O
and	O
0.2%	O
for	O
the	O
L108W	B-DNAMutation
and	O
P186L	B-DNAMutation
enzymes	O
,	O
respectively.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Analysis	O
of	O
multiple	O
mutations	O
in	O
the	O
hALG6	B-DNAMutation
gene	O
in	O
a	O
patient	O
with	O
congenital	O
disorder	O
of	O
glycosylation	O
Ic	O
.	O

Congenital	O
disorder	O
of	O
glycosylation	O
Ic	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
hALG6	B-DNAMutation
gene	O
that	O
encodes	O
an	O
alpha-1,3	O
glucosyltransferase	O
.	O

This	O
enzyme	O
is	O
required	O
for	O
the	O
addition	O
of	O
the	O
first	O
glucose	O
residue	O
to	O
the	O
lipid-linked	O
oligosaccharide	O
precursor	O
for	O
N-linked	O
glycosylation	O
.	O

Here	O
we	O
describe	O
the	O
biochemical	O
and	O
molecular	O
analysis	O
of	O
a	O
patient	O
with	O
three	O
mutations	O
in	O
the	O
hALG6	B-DNAMutation
gene	O
.	O

The	O
maternal	O
allele	O
has	O
an	O
intronic	B-DNAMutation
G	I-DNAMutation
-->	I-DNAMutation
A	I-DNAMutation
mutation	O
resulting	O
in	O
skipping	B-DNAMutation
of	I-DNAMutation
exon3	I-DNAMutation
(	O
IVS3	B-DNAMutation
+	I-DNAMutation
5G	I-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
)	O
.	O

This	O
produces	O
a	O
nonfunctional	O
enzyme	O
as	O
shown	O
by	O
its	O
inability	O
to	O
restore	O
normal	O
glycosylation	O
in	O
a	O
Saccharomyces	O
cerevisiae	O
strain	O
lacking	O
a	O
functional	O
ALG6	B-DNAMutation
.	O

The	O
paternal	O
allele	O
has	O
two	O
mutations	O
.	O

One	O
is	O
a	O
deletion	B-DNAMutation
of	I-DNAMutation
three	I-DNAMutation
bases	I-DNAMutation
895-897delATA	B-DNAMutation
leading	O
to	O
an	O
in-frame	B-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
isoleucine	I-DNAMutation
299	I-DNAMutation
delI299	B-DNAMutation
located	O
in	O
a	O
transmembrane	O
domain	O
.	O

The	O
second	O
mutation	O
on	O
the	O
same	O
allele	O
911T	B-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
causes	O
a	O
F304S	B-DNAMutation
change	O
.	O

When	O
expressed	O
in	O
the	O
ALG6	B-DNAMutation
deficient	O
yeast	O
strain	O
,	O
this	O
allele	O
restores	O
glycosylation	O
but	O
the	O
mRNA	O
is	O
unstable	O
or	O
inefficiently	O
transcribed	O
,	O
contributing	O
to	O
the	O
impaired	O
glycosylation	O
in	O
the	O
patient	O
.	O

In-frame	O
single	O
codon	O
deletion	O
in	O
the	O
Mmalton	O
deficiency	O
allele	O
of	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
.	O

A	O
deficiency	O
of	O
the	O
plasma	O
protease	O
inhibitor	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
(	O
alpha	B-DNAMutation
1AT	I-DNAMutation
)	O
is	O
usually	O
a	O
consequence	O
of	O
the	O
PI*Z	O
allele	O
.	O

Mmalton	O
is	O
another	O
deficiency	O
allele	O
which	O
,	O
like	O
Z	O
alpha	B-DNAMutation
1AT	I-DNAMutation
,	O
is	O
associated	O
with	O
hepatocyte	O
inclusions	O
and	O
impaired	O
secretion	O
.	O

We	O
report	O
here	O
the	O
sequence	O
of	O
the	O
PI	O
Mmalton	O
allele	O
,	O
which	O
contains	O
a	O
3-bp	B-DNAMutation
deletion	I-DNAMutation
coding	I-DNAMutation
for	I-DNAMutation
one	I-DNAMutation
of	I-DNAMutation
two	I-DNAMutation
adjacent	I-DNAMutation
phenylalanine	I-DNAMutation
residues	I-DNAMutation
(	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
51	I-DNAMutation
or	I-DNAMutation
52	I-DNAMutation
of	O
the	O
mature	O
protein	O
)	O
.	O

Using	O
oligonucleotide	O
hybridization	O
of	O
polymerase	O
chain	O
reaction-amplified	O
DNA	O
,	O
we	O
have	O
demonstrated	O
cosegregation	O
of	O
the	O
PI	O
Mmalton	O
protein	O
and	O
the	O
3-bp	O
deletion	O
in	O
the	O
family	O
in	O
which	O
this	O
allele	O
was	O
originally	O
described	O
and	O
in	O
three	O
other	O
,	O
unrelated	O
kindreds	O
.	O

This	O
deletion	O
is	O
found	O
exclusively	O
in	O
PI	O
Mmalton	O
alleles	O
and	O
not	O
in	O
the	O
normal	O
M2	O
alleles	O
from	O
which	O
,	O
to	O
judge	O
on	O
the	O
basis	O
of	O
haplotype	O
data	O
,	O
the	O
Mmalton	O
mutation	O
must	O
have	O
been	O
derived	O
.	O

In	O
polyacrylamide	O
isoelectric	O
focusing	O
(PIEF)	O
gels	O
,	O
the	O
isoelectric	O
point	O
of	O
Mmalton	O
is	O
only	O
slightly	O
more	O
cathodal	O
than	O
M2	O
,	O
a	O
finding	O
consistent	O
with	O
the	O
loss	O
of	O
a	O
single	O
uncharged	O
amino	O
acid	O
.	O

To	O
judge	O
on	O
the	O
basis	O
of	O
X-ray	O
crystallography	O
data	O
for	O
the	O
normal	O
alpha	B-DNAMutation
1AT	I-DNAMutation
protein	O
,	O
the	O
deletion	B-DNAMutation
of	I-DNAMutation
aa	I-DNAMutation
51/52	I-DNAMutation
would	O
shorten	O
one	O
strand	O
of	O
the	O
beta	O
sheet	O
,	O
B6	O
,	O
apparently	O
preventing	O
normal	O
processing	O
and	O
secretion	O
.	O

Evidence	O
for	O
in	O
vivo	O
phosphorylation	O
of	O
the	O
Grb2	O
SH2-domain	O
binding	O
site	O
on	O
focal	O
adhesion	O
kinase	O
by	O
Src-family	O
protein-tyrosine	O
kinases	O
.	O

Focal	O
adhesion	O
kinase	O
(FAK)	O
is	O
a	O
nonreceptor	O
protein-tyrosine	O
kinase	O
(PTK)	O
that	O
associates	O
with	O
integrin	O
receptors	O
and	O
participates	O
in	O
extracellular	O
matrix-mediated	O
signal	O
transduction	O
events	O
.	O

We	O
showed	O
previously	O
that	O
the	O
c-Src	B-DNAMutation
nonreceptor	O
PTK	O
and	O
the	O
Grb2	B-DNAMutation
SH2/SH3	I-DNAMutation
adaptor	I-DNAMutation
protein	O
bound	O
directly	O
to	O
FAK	O
after	O
fibronectin	O
stimulation	O
(	O
D	O
.	O

D	O
.	O

Schlaepfer	O
,	O
S.K	O
.	O

Hanks	O
,	O
T	O
.	O

Hunter	O
,	O
and	O
P	O
.	O

van	B-DNAMutation
der	O
Geer	O
,	O
Nature	O
[London]	O
372:786-791	O
,	O
1994	O
)	O
.	O

Here	O
,	O
we	O
present	O
evidence	O
that	O
c-Src	B-DNAMutation
association	O
with	O
FAK	O
is	O
required	O
for	O
Grb2	B-DNAMutation
binding	O
to	O
FAK	O
.	O

Using	O
a	O
tryptic	O
phosphopeptide	O
mapping	O
approach	O
,	O
the	O
in	O
vivo	O
phosphorylation	O
of	O
the	O
Grb2	O
binding	O
site	O
on	O
FAK	O
(Tyr-925)	O
was	O
detected	O
after	O
fibronectin	O
stimulation	O
of	O
NIH	O
3T3	O
cells	O
and	O
was	O
constitutively	O
phosphorylated	O
in	O
v-Src-transformed	O
NIH	O
3T3	O
cells	O
.	O

In	O
vitro	O
,	O
c-Src	B-DNAMutation
phosphorylated	O
FAK	O
Tyr-925	O
in	O
a	O
glutathione	O
S-transferase-FAK	O
C-terminal	O
domain	O
fusion	O
protein	O
,	O
whereas	O
FAK	O
did	O
not	O
.	O

Using	O
epitope-tagged	O
FAK	O
constructs	O
,	O
transiently	O
expressed	O
in	O
human	O
293	O
cells	O
,	O
we	O
determined	O
the	O
effect	O
of	O
site-directed	O
mutations	O
on	O
c-Src	B-DNAMutation
and	O
Grb2	B-DNAMutation
binding	O
to	O
FAK	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
FAK	I-DNAMutation
Tyr-925	I-DNAMutation
disrupted	O
Grb2	B-DNAMutation
binding	O
,	O
whereas	O
mutation	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
c-Src	I-DNAMutation
binding	I-DNAMutation
site	I-DNAMutation
on	I-DNAMutation
FAK	I-DNAMutation
(Tyr-397)	I-DNAMutation
disrupted	O
both	O
c-Src	B-DNAMutation
and	O
Grb2	B-DNAMutation
binding	O
to	O
FAK	O
in	O
vivo	O
.	O

These	O
results	O
support	O
a	O
model	O
whereby	O
Src-family	O
PTKs	O
are	O
recruited	O
to	O
FAK	O
and	O
focal	O
adhesions	O
following	O
integrin-induced	O
autophosphorylation	O
and	O
exposure	O
of	O
FAK	O
Tyr-397	O
.	O

Src-family	O
binding	O
and	O
phosphorylation	O
of	O
FAK	O
at	O
Tyr-925	O
creates	O
a	O
Grb2	O
SH2-domain	O
binding	O
site	O
and	O
provides	O
a	O
link	O
to	O
the	O
activation	O
of	O
the	O
Ras	O
signal	O
transduction	O
pathway	O
.	O

In	O
Src-transformed	O
cells	O
,	O
this	O
pathway	O
may	O
be	O
constitutively	O
activated	O
as	O
a	O
result	O
of	O
FAK	O
Tyr-925	O
phosphorylation	O
in	O
the	O
absence	O
of	O
integrin	O
stimulation	O
.	O

Hereditary	O
alpha	O
2-plasmin	O
inhibitor	O
deficiency	O
caused	O
by	O
a	O
transport-deficient	O
mutation	O
(	O
alpha	O
2-PI-Okinawa	O
)	O
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
Glu137	I-DNAMutation
by	I-DNAMutation
a	I-DNAMutation
trinucleotide	I-DNAMutation
deletion	I-DNAMutation
blocks	O
intracellular	O
transport	O
.	O

alpha	O
2-Plasmin	O
inhibitor	O
is	O
the	O
most	O
important	O
physiological	O
inhibitor	O
of	O
fibrinolysis	O
;	O
hence	O
,	O
its	O
deficiency	O
results	O
in	O
a	O
severe	O
hemorrhagic	O
diathesis	O
.	O

We	O
have	O
cloned	O
and	O
characterized	O
a	O
mutant	O
alpha	O
2-plasmin	O
inhibitor	O
gene	O
from	O
an	O
individual	O
homozygous	O
for	O
the	O
deficiency	O
.	O

By	O
sequencing	O
all	O
the	O
coding	O
exons	O
and	O
exon-intron	O
boundaries	O
of	O
the	O
gene	O
,	O
a	B-DNAMutation
trinucleotide	I-DNAMutation
deletion	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
VII	I-DNAMutation
that	I-DNAMutation
results	I-DNAMutation
in	I-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
Glu137	I-DNAMutation
was	O
identified	O
.	O

We	O
have	O
designated	O
this	O
variant	O
as	O
alpha	O
2-plasmin	O
inhibitor	O
Okinawa	O
.	O

Using	O
DNA	O
samples	O
amplified	O
with	O
the	O
polymerase	O
chain	O
reaction	O
,	O
hybridization	O
analysis	O
by	O
oligonucleotide	O
probes	O
confirmed	O
the	O
presence	O
of	O
this	O
mutation	O
in	O
all	O
the	O
affected	O
family	O
members	O
,	O
including	O
both	O
parents	O
.	O

To	O
elucidate	O
the	O
mechanism	O
by	O
which	O
this	O
mutation	O
leads	O
to	O
the	O
deficiency	O
,	O
a	O
eukaryotic	O
expression	O
plasmid	O
for	O
alpha	O
2-plasmin	O
inhibitor	O
containing	O
this	O
mutation	O
was	O
constructed	O
and	O
transfected	O
into	O
COS-7	O
cells	O
for	O
transient	O
expression	O
analysis	O
.	O

Immunoprecipitation	O
analysis	O
and	O
enzyme-linked	O
immunosorbent	O
assay	O
revealed	O
that	O
the	O
mutant	O
alpha	O
2-plasmin	O
inhibitor	O
synthesized	O
is	O
mostly	O
retained	O
within	O
the	O
cells	O
as	O
an	O
endoglycosidase	O
H-sensitive	O
form	O
,	O
and	O
only	O
a	O
small	O
portion	O
of	O
it	O
is	O
secreted	O
into	O
the	O
medium	O
as	O
a	O
neuraminidase-sensitive	O
form	O
.	O

These	O
results	O
suggest	O
that	O
the	O
Glu137	B-DNAMutation
deletion	I-DNAMutation
leads	O
to	O
the	O
alpha	O
2-plasmin	O
inhibitor	O
deficiency	O
by	O
causing	O
a	O
block	O
in	O
its	O
intracellular	O
transport	O
from	O
the	O
endoplasmic	O
reticulum	O
to	O
the	O
Golgi	O
complex	O
.	O

E-cadherin	B-DNAMutation
gene	O
variants	O
in	O
gastric	O
cancer	O
families	O
whose	O
probands	O
are	O
diagnosed	O
with	O
diffuse	O
gastric	O
cancer	O
.	O

To	O
identify	O
germline	O
E-cadherin	B-DNAMutation
mutations	O
responsible	O
for	O
the	O
predisposition	O
to	O
diffuse	O
gastric	O
cancer	O
(DGC)	O
among	O
the	O
Japanese	O
,	O
we	O
screened	O
17	O
patients	O
with	O
familial	O
aggregation	O
of	O
gastric	O
cancer	O
by	O
sequencing	O
analysis	O
.	O

All	O
the	O
patients	O
were	O
diagnosed	O
with	O
DGC	O
and	O
had	O
at	O
least	O
1	O
sibling	O
with	O
gastric	O
cancer	O
.	O

Two	O
novel	O
E-cadherin	B-DNAMutation
gene	O
variants	O
were	O
detected	O
.	O

One	O
was	O
detected	O
in	O
1	O
patient	O
only	O
and	O
associated	O
with	O
an	O
amino	O
acid	O
substitution	O
Val/Met	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
832	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
region	I-DNAMutation
essential	O
for	O
binding	O
to	O
beta-catenin	B-DNAMutation
.	O

The	O
M832	O
variant	O
was	O
detected	O
not	O
only	O
in	O
the	O
proband	O
but	O
also	O
in	O
2	O
other	O
gastric	O
cancer	O
patients	O
in	O
the	O
family	O
.	O

Immunohistochemical	O
analysis	O
of	O
gastric	O
cancer	O
tissue	O
from	O
the	O
proband	O
revealed	O
that	O
E-cadherin	B-DNAMutation
expression	O
was	O
markedly	O
reduced	O
and	O
beta-catenin	B-DNAMutation
expression	O
was	O
also	O
reduced	O
in	O
cancer	O
cells	O
.	O

However	O
,	O
no	O
significant	O
difference	O
in	O
the	O
activity	O
of	O
beta-catenin	B-DNAMutation
binding	O
was	O
detected	O
between	O
the	O
M832	O
variant	O
and	O
V832	O
wild-type	O
E-cadherin	B-DNAMutation
in	O
immunofluorescence	O
and	O
immunoprecipitation/Western	O
blot	O
analyses	O
.	O

The	O
other	O
was	O
detected	O
in	O
5	O
patients	O
and	O
was	O
located	O
in	O
the	O
splice	O
donor	O
site	O
IVS1+6T/C	B-DNAMutation
;	O
however	O
,	O
RT-PCR	O
analysis	O
indicated	O
that	O
the	O
IVS+6C	O
variant	O
did	O
not	O
cause	O
an	O
aberrant	O
splicing	O
.	O

Thus	O
,	O
the	O
M832	O
variant	O
could	O
be	O
a	O
germline	O
mutation	O
causative	O
of	O
familial	O
aggregation	O
of	O
DGC	O
,	O
although	O
further	O
functional	O
studies	O
are	O
needed	O
to	O
understand	O
the	O
pathogenic	O
significance	O
of	O
this	O
variant	O
.	O

Identification	O
,	O
expression	O
,	O
and	O
pharmacology	O
of	O
a	O
Cys23-Ser23	B-DNAMutation
substitution	I-DNAMutation
in	O
the	O
human	O
5-HT2c	O
receptor	O
gene	O
HTR2C	B-DNAMutation
.	O

The	O
function	O
of	O
brain	O
serotonin-2C	O
5-HT2C	B-DNAMutation
receptors	O
,	O
including	O
behavioral	O
and	O
neurochemical	O
responses	O
to	O
5-HT2C	B-DNAMutation
agonist	O
challenge	O
,	O
has	O
been	O
suggested	O
to	O
be	O
abnormal	O
in	O
individuals	O
with	O
neuropsychiatric	O
disorders	O
.	O

Thus	O
,	O
it	O
is	O
important	O
to	O
identify	O
polymorphisms	O
and	O
functional	O
variants	O
within	O
this	O
gene	O
.	O

Using	O
SSCP	O
analysis	O
,	O
we	O
identified	O
a	O
Cys23-Ser23	B-DNAMutation
substitution	I-DNAMutation
(	O
designated	O
5-HT2Ccys	O
and	O
5-HT2Cser	O
)	O
in	O
the	O
first	O
hydrophobic	O
region	O
of	O
the	O
human	O
5-HT2C	B-DNAMutation
receptor	O
.	O

Allele	O
frequencies	O
in	O
unrelated	O
Caucasians	O
were	O
0.13	O
and	O
0.87	O
for	O
5-HT2Cser	O
and	O
5-HT2Ccys	O
,	O
respectively	O
.	O

DNAs	O
from	O
informative	O
CEPH	O
families	O
were	O
typed	O
for	O
this	O
polymorphism	O
and	O
analyzed	O
with	O
respect	O
to	O
20	O
linked	O
markers	O
on	O
the	O
X	O
chromosome	O
.	O

Linkage	O
analysis	O
placed	O
the	O
5-HT2C	B-DNAMutation
receptor	O
gene	O
HTR2C	B-DNAMutation
on	O
Xq24	O
.	O

To	O
evaluate	O
whether	O
this	O
amino	O
acid	O
substitution	O
causes	O
a	O
variant	O
function	O
of	O
this	O
receptor	O
,	O
recombinant	O
human	O
5-HT2Ccys	O
and	O
5-HT2Cser	O
receptors	O
were	O
expressed	O
in	O
Xenopus	O
oocytes	O
and	O
tested	O
for	O
responses	O
to	O
5-HT	O
using	O
electrophysiological	O
techniques	O
.	O

Concentration-response	O
curves	O
for	O
5-HT	O
were	O
not	O
significantly	O
different	O
in	O
oocytes	O
expressing	O
either	O
form	O
of	O
the	O
receptor	O
,	O
suggesting	O
that	O
the	O
5-HT2Ccys	O
and	O
5-HT2Cser	O
receptor	O
proteins	O
may	O
not	O
differ	O
in	O
their	O
responses	O
to	O
serotonin	O
under	O
baseline	O
physiological	O
conditions	O
.	O

Functional	O
implications	O
of	O
a	O
novel	O
EA2	O
mutation	O
in	O
the	O
P/Q-type	O
calcium	O
channel	O
.	O

Episodic	O
ataxia	O
type	O
2	O
(EA2)	O
is	O
an	O
autosomal	O
dominant	O
condition	O
characterized	O
by	O
paroxysmal	O
attacks	O
of	O
ataxia	O
,	O
vertigo	O
,	O
and	O
nausea	O
,	O
typically	O
lasting	O
minutes	O
to	O
days	O
in	O
duration	O
.	O

These	O
symptoms	O
can	O
be	O
prevented	O
or	O
significantly	O
attenuated	O
by	O
the	O
oral	O
administration	O
of	O
acetazolamide	O
;	O
however	O
,	O
the	O
mechanism	O
by	O
which	O
acetazolamide	O
ameliorates	O
EA2	O
symptoms	O
is	O
unknown	O
.	O

EA2	O
typically	O
results	O
from	O
nonsense	O
mutations	O
in	O
the	O
CACNA1A	B-DNAMutation
gene	O
that	O
encodes	O
the	O
alpha1A	O
Cav2.1	B-DNAMutation
subunit	O
of	O
the	O
P/Q-type	O
calcium	O
(Ca2+)	O
channel	O
.	O

We	O
have	O
identified	O
a	O
novel	O
H1736L	B-DNAMutation
missense	O
mutation	O
in	O
the	O
CACNA1A	B-DNAMutation
gene	O
associated	O
with	O
the	O
EA2	O
phenotype	O
.	O

This	O
mutation	O
is	O
localized	O
near	O
the	O
pore-forming	O
region	O
of	O
the	O
P/Q-type	O
Ca2+	O
channel	O
.	O

Functional	O
analysis	O
of	O
P/Q-type	O
channels	O
containing	O
the	O
mutation	O
show	O
that	O
the	O
H1736L	B-DNAMutation
alteration	O
affects	O
several	O
channel	O
properties	O
,	O
including	O
reduced	O
current	O
density	O
,	O
increased	O
rate	O
of	O
inactivation	O
,	O
and	O
a	O
shift	O
in	O
the	O
voltage	O
dependence	O
of	O
activation	O
to	O
more	O
positive	O
values	O
.	O

Although	O
these	O
findings	O
are	O
consistent	O
with	O
an	O
overall	O
loss	O
of	O
P/Q-type	O
channel	O
function	O
,	O
the	O
mutation	O
also	O
caused	O
some	O
biophysical	O
changes	O
consistent	O
with	O
a	O
gain	O
of	O
function	O
.	O

We	O
also	O
tested	O
the	O
direct	O
effect	O
of	O
acetazolamide	O
on	O
both	O
wild-type	O
and	O
H1736L	B-DNAMutation
mutated	O
P/Q-type	O
channels	O
and	O
did	O
not	O
observe	O
any	O
direct	O
action	O
on	O
channel	O
properties	O
of	O
this	O
pharmacological	O
agent	O
used	O
to	O
treat	O
EA2	O
patients	O
.	O

Functional	O
and	O
molecular	O
modelling	O
studies	O
of	O
two	O
hereditary	O
fructose	O
intolerance-causing	O
mutations	B-DNAMutation
at	I-DNAMutation
arginine	I-DNAMutation
303	I-DNAMutation
in	O
human	O
liver	O
aldolase	O
.	O

We	O
have	O
identified	O
a	O
novel	O
hereditary	O
fructose	O
intolerance	O
mutation	O
in	O
the	O
aldolase	O
B	O
gene	O
(	O
i.e	O
.	O

liver	O
aldolase	O
)	O
that	O
causes	O
an	O
arginine-to-glutamine	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
residue	I-DNAMutation
303	I-DNAMutation
Arg(303)-->Gln	B-DNAMutation
.	O

We	O
previously	O
described	O
another	O
mutation	O
Arg(303)-->Trp	B-DNAMutation
at	O
the	O
same	O
residue	O
.	O

We	O
have	O
expressed	O
the	O
wild-type	O
protein	O
and	O
the	O
two	O
mutated	O
proteins	O
and	O
characterized	O
their	O
kinetic	O
properties	O
.	O

The	O
catalytic	O
efficiency	O
of	O
protein	O
Gln(303)	O
is	O
approx	O
.	O

1/100	O
that	O
of	O
the	O
wild-type	O
for	O
substrates	O
fructose	O
1,6-bisphosphate	O
and	O
fructose	O
1-phosphate	O
.	O

The	O
Trp(303)	O
enzyme	O
has	O
a	O
catalytic	O
efficiency	O
approx	O
.	O

1/4800	O
that	O
of	O
the	O
wild-type	O
for	O
fructose	O
1,6-bisphosphate	O
;	O
no	O
activity	O
was	O
detected	O
with	O
fructose	O
1-phosphate	O
.	O

The	O
mutation	O
Arg(303)-->Trp	B-DNAMutation
thus	O
substitution	O
impairs	O
enzyme	O
activity	O
more	O
than	O
Arg(303)-->Gln	B-DNAMutation
.	O

Three-dimensional	O
models	O
of	O
wild-type	O
,	O
Trp(303)	O
and	O
Gln(303)	O
aldolase	O
B	O
generated	O
by	O
homology-modelling	O
techniques	O
suggest	O
that	O
,	O
because	O
of	O
its	O
larger	O
size	O
,	O
tryptophan	O
exerts	O
a	O
greater	O
deranging	O
effect	O
than	O
glutamine	O
on	O
the	O
enzyme's	O
three-dimensional	O
structure	O
.	O

Our	O
results	O
show	O
that	O
the	O
Arg(303)-->Gln	B-DNAMutation
substitution	O
is	O
a	O
novel	O
mutation	O
causing	O
hereditary	O
fructose	O
intolerance	O
and	O
provide	O
a	O
functional	O
demonstration	O
that	O
Arg(303)	O
,	O
a	O
conserved	O
residue	O
in	O
all	O
vertebrate	O
aldolases	O
,	O
has	O
a	O
dominant	O
role	O
in	O
substrate	O
binding	O
during	O
enzyme	O
catalysis	O
.	O

Identification	O
and	O
characterization	O
of	O
novel	O
members	O
of	O
the	O
CREG	O
family	O
,	O
putative	O
secreted	O
glycoproteins	O
expressed	O
specifically	O
in	O
brain	O
.	O

The	O
cellular	O
repressor	O
of	O
E1A-stimulated	O
genes	O
,	O
CREG	O
,	O
is	O
a	O
secreted	O
glycoprotein	O
that	O
enhances	O
differentiation	O
of	O
pluripotent	O
stem	O
cells	O
.	O

Here	O
we	O
report	O
two	O
novel	O
members	O
of	O
the	O
CREG	O
family	O
,	O
human	O
CREG2	B-DNAMutation
and	O
mouse	O
Creg2	B-DNAMutation
cDNAs	O
.	O

The	O
predicted	O
human	O
and	O
mouse	O
protein	O
sequences	O
exhibit	O
35%	O
identity	O
with	O
CREG	O
protein	O
.	O

Northern	O
blot	O
analyses	O
demonstrate	O
specific	O
CREG2	B-DNAMutation
and	O
Creg2	B-DNAMutation
transcription	O
in	O
brain-in	O
the	O
case	O
of	O
CREG2	B-DNAMutation
,	O
mainly	O
in	O
the	O
limbic	O
system	O
of	O
the	O
brain	O
.	O

Both	O
mouse	O
and	O
human	O
CREG2	B-DNAMutation
fused	O
to	O
the	O
carboxy	O
terminus	O
of	O
EGFP	O
in	O
NIH3T3	O
cells	O
localize	O
to	O
the	O
perinuclear	O
region	O
,	O
which	O
demonstrates	O
implicit	O
endoplasmic	O
reticulum	O
and	O
Golgi	O
localization	O
.	O

Human	O
and	O
mouse	O
CREG2	B-DNAMutation
are	O
N-glycosylated	O
in	O
HeLa	O
cells	O
and	O
deletion	B-DNAMutation
of	I-DNAMutation
amino-terminal	I-DNAMutation
sequences	I-DNAMutation
completely	O
abolishes	O
N-glycosylation	O
,	O
indicating	O
that	O
the	O
N	O
termini	O
of	O
both	O
proteins	O
may	O
function	O
as	O
signal	O
sequences	O
.	O

Thus	O
,	O
human	O
and	O
mouse	O
CREG2	B-DNAMutation
are	O
putative	O
secreted	O
glycoproteins	O
and	O
may	O
be	O
novel	O
neuronal	O
extracellular	O
molecules	O
.	O

A	O
point	O
mutation	O
in	O
the	O
seventh	O
hydrophobic	O
domain	O
of	O
the	O
alpha	O
2	O
adrenergic	O
receptor	O
increases	O
its	O
affinity	O
for	O
a	O
family	O
of	O
beta	O
receptor	O
antagonists	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
differences	O
in	O
subtype-specific	O
ligand	O
binding	O
between	O
alpha	O
2	O
and	O
beta	O
2	O
adrenergic	O
receptors	O
are	O
largely	O
determined	O
by	O
the	O
seventh	O
hydrophobic	O
domain	O
.	O

Here	O
,	O
we	O
report	O
that	O
a	O
single	O
amino	O
acid	O
substitution	O
Phe412----Asn	B-DNAMutation
in	O
the	O
seventh	O
hydrophobic	O
domain	O
of	O
the	O
alpha	O
2	O
adrenergic	O
receptor	O
reduces	O
affinity	O
for	O
the	O
alpha	O
2	O
antagonist	O
yohimbine	O
by	O
350-fold	O
and	O
increases	O
affinity	O
for	O
beta	O
antagonist	O
alprenolol	O
by	O
3000-fold	O
.	O

The	O
affinity	O
of	O
this	O
mutant	O
receptor	O
alpha	O
2F----N	O
for	O
several	O
alpha	O
and	O
beta	O
adrenergic	O
receptor	O
agonists	O
and	O
antagonists	O
was	O
determined	O
.	O

Beta	O
adrenergic	O
receptor	O
antagonists	O
containing	O
an	O
oxygen	O
atom	O
linking	O
the	O
amino	O
side	O
chain	O
with	O
the	O
aromatic	O
ring	O
bound	O
to	O
alpha	O
2F----N	O
with	O
high	O
affinity	O
,	O
while	O
the	O
beta	O
receptor	O
antagonist	O
sotalol	O
,	O
which	O
lacks	O
this	O
oxygen	O
,	O
bound	O
with	O
low	O
affinity	O
.	O

These	O
data	O
suggest	O
that	O
the	O
Asn	O
residue	O
is	O
involved	O
in	O
conferring	O
specificity	O
for	O
binding	O
to	O
a	O
specific	O
class	O
of	O
beta	O
receptor	O
antagonists	O
.	O

Detection	O
of	O
a	O
new	O
mutant	O
alpha-1-antichymotrypsin	B-DNAMutation
in	O
patients	O
with	O
occlusive-cerebrovascular	O
disease	O
.	O

A	O
new	O
mutant	O
alpha-1-antichymotrypsin	B-DNAMutation
(	O
variant	O
ACT	O
)	O
was	O
found	O
by	O
direct	O
sequencing	O
and	O
PCR-single	O
strand	O
conformation	O
polymorphism	O
(PCR-SSCP)	O
.	O

This	O
variant	O
ACT	O
was	O
a	O
point	O
mutation	O
of	O
exon	B-DNAMutation
V	I-DNAMutation
of	I-DNAMutation
ACT	I-DNAMutation
,	I-DNAMutation
with	I-DNAMutation
the	I-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
Met	I-DNAMutation
by	I-DNAMutation
Val	I-DNAMutation
.	O

Four	O
out	O
of	O
six	O
individuals	O
with	O
this	O
variant	O
ACT	O
had	O
occlusive-cerebrovascular	O
disease	O
,	O
leading	O
to	O
one	O
hypothesis	O
that	O
there	O
might	O
be	O
an	O
association	O
between	O
this	O
mutation	O
and	O
occlusive-cerebrovascular	O
disease	O
.	O

Biological	O
and	O
structural	O
features	O
of	O
murine	B-DNAMutation
angiogenin-4	I-DNAMutation
,	O
an	O
angiogenic	O
protein	O
.	O

Murine	B-DNAMutation
angiogenin-4	I-DNAMutation
mAng-4	B-DNAMutation
is	O
a	O
member	O
of	O
the	O
pancreatic	O
ribonuclease	O
superfamily	O
that	O
is	O
expressed	O
in	O
some	O
endodermally	O
derived	O
organs	O
.	O

We	O
now	O
show	O
that	O
mAng-4	B-DNAMutation
is	O
angiogenic	O
using	O
a	O
thoracic	O
aorta	O
assay	O
never	O
before	O
applied	O
to	O
the	O
angiogenins	O
.	O

mAng-4	B-DNAMutation
,	O
human	O
angiogenin	O
hAng	B-DNAMutation
,	O
and	O
murine	O
angiogenin-1	O
mAng-1	B-DNAMutation
stimulate	O
the	O
proliferation	O
of	O
IGR1	O
melanoma	O
cells	O
but	O
do	O
not	O
stimulate	O
the	O
proliferation	O
or	O
migration	O
of	O
bovine	O
corneal	O
endothelial	O
cells	O
or	O
primary	O
mouse	O
embryonic	O
fibroblasts	O
.	O

In	O
addition	O
,	O
we	O
report	O
the	O
3-D	O
structure	O
of	O
mAng-4	B-DNAMutation
at	O
2.02-A	O
resolution	O
.	O

The	O
structure	O
shows	O
that	O
the	O
residues	O
forming	O
the	O
putative	O
B1	O
,	O
P1	O
,	O
and	O
B2	O
RNA-binding	O
subsites	O
occupy	O
positions	O
similar	O
to	O
their	O
hAng	B-DNAMutation
counterparts	O
.	O

The	O
B1	O
subsite	O
is	O
obstructed	O
by	O
Glu115	O
and	O
Ile118	O
.	O

The	O
obstruction	O
is	O
stabilized	O
by	O
a	O
novel	O
salt	O
bridge	O
between	O
the	O
C-terminal	O
carboxyl	O
group	O
and	O
the	O
side	O
chain	O
of	O
Arg99	B-DNAMutation
.	O

Through	O
mutational	O
studies	O
,	O
we	O
identify	O
residues	O
critical	O
to	O
the	O
angiogenic	O
function	O
of	O
mAng-4	B-DNAMutation
.	O

The	O
effect	O
of	O
H12A	B-DNAMutation
and	O
H112A	B-DNAMutation
mutations	O
in	O
the	O
catalytic	O
site	O
indicates	O
that	O
ribonucleolytic	O
activity	O
is	O
essential	O
to	O
angiogenesis	O
.	O

The	O
consequences	O
of	O
a	O
nearby	O
E115A	B-DNAMutation
mutation	O
are	O
consistent	O
with	O
a	O
significant	O
role	O
for	O
Glu115	O
in	O
the	O
attenuation	O
of	O
enzymatic	O
activity	O
but	O
also	O
suggest	O
that	O
sufficient	O
suppression	O
of	O
catalysis	O
is	O
necessary	O
for	O
angiogenesis	O
.	O

The	O
effect	O
of	O
an	O
R32A	B-DNAMutation
mutation	O
in	O
the	O
putative	O
nuclear	O
localization	O
sequence	O
indicates	O
that	O
this	O
residue	O
is	O
crucial	O
for	O
angiogenesis	O
.	O

In	O
the	O
putative	O
cell-binding	O
segment	O
,	O
the	O
replacement	B-DNAMutation
of	I-DNAMutation
Lys59	I-DNAMutation
with	I-DNAMutation
Asn	I-DNAMutation
(	O
its	O
counterpart	O
at	O
position	O
61	O
of	O
hAng	B-DNAMutation
)	O
does	O
not	O
abrogate	O
enzymatic	O
activity	O
but	O
abolishes	O
angiogenic	O
activity	O
,	O
the	O
reason	O
for	O
which	O
is	O
unclear	O
.	O

Palmitylation	O
of	O
an	O
amino-terminal	O
cysteine	O
motif	O
of	O
protein	O
tyrosine	O
kinases	O
p56lck	B-DNAMutation
and	O
p59fyn	B-DNAMutation
mediates	O
interaction	O
with	O
glycosyl-phosphatidylinositol-anchored	O
proteins	O
.	O

Cross-linking	O
of	O
glycosyl-phosphatidylinositol	O
(GPI)-anchored	O
membrane	O
proteins	O
on	O
T	O
cells	O
can	O
trigger	O
cell	O
activation	O
.	O

We	O
and	O
others	O
have	O
shown	O
an	O
association	O
between	O
GPI-anchored	O
proteins	O
and	O
the	O
protein	O
tyrosine	O
kinases	O
(PTKs)	O
p56lck	B-DNAMutation
and	O
p59fyn	B-DNAMutation
,	O
suggesting	O
a	O
pathway	O
for	O
signaling	O
through	O
GPI-anchored	O
proteins	O
.	O

Studies	O
of	O
decay-accelerating	O
factor	O
(DAF)	O
or	O
CD59	B-DNAMutation
in	O
either	O
the	O
C32	O
cell	O
line	O
or	O
the	O
HeLa	O
cell	O
line	O
transfected	O
with	O
PTK	O
cDNA	O
demonstrated	O
that	O
the	O
GPI-anchored	O
proteins	O
associated	O
noncovalently	O
with	O
p56lck	B-DNAMutation
and	O
p59fyn	B-DNAMutation
but	O
not	O
with	O
p60src	B-DNAMutation
.	O

Nonmyristylated	O
versions	O
of	O
p56lck	B-DNAMutation
and	O
p59fyn	B-DNAMutation
also	O
failed	O
to	O
associate	O
with	O
the	O
GPI-anchored	O
proteins	O
.	O

Mutational	O
analysis	O
of	O
the	O
PTK	O
demonstrated	O
that	O
the	O
association	O
with	O
the	O
GPI-anchored	O
proteins	O
mapped	O
to	O
the	O
unique	O
amino-terminal	O
domains	O
of	O
the	O
PTK	O
.	O

A	O
chimeric	O
PTK	O
consisting	O
of	O
the	O
10	O
amino-terminal	O
residues	O
of	O
p56lck	B-DNAMutation
or	O
p59fyn	B-DNAMutation
replacing	O
the	O
corresponding	O
amino	O
acids	O
in	O
p60src	B-DNAMutation
was	O
sufficient	O
for	O
association	O
with	O
DAF	O
,	O
but	O
the	O
converse	O
constructs	O
containing	O
the	O
first	O
10	O
amino	O
acids	O
of	O
p60src	B-DNAMutation
plus	O
the	O
remainder	O
of	O
p56lck	B-DNAMutation
or	O
p59fyn	B-DNAMutation
did	O
not	O
associate	O
with	O
DAF	O
.	O

Mutation	O
of	O
cysteine	B-DNAMutation
to	I-DNAMutation
serine	I-DNAMutation
at	I-DNAMutation
positions	I-DNAMutation
3	I-DNAMutation
and	I-DNAMutation
6	I-DNAMutation
in	O
p59fyn	B-DNAMutation
or	O
positions	O
3	O
and	O
5	O
in	O
p56lck	B-DNAMutation
abolished	O
the	O
association	O
of	O
these	O
kinases	O
with	O
DAF	O
.	O

Mutation	O
of	O
serine	B-DNAMutation
to	I-DNAMutation
cysteine	I-DNAMutation
at	I-DNAMutation
positions	I-DNAMutation
3	I-DNAMutation
and	I-DNAMutation
6	I-DNAMutation
in	O
p60src	B-DNAMutation
conferred	O
on	O
p60src	B-DNAMutation
the	O
ability	O
to	O
associate	O
with	O
DAF	O
.	O

Direct	O
labeling	O
with	O
[3H]palmitate	O
demonstrated	O
palmitylation	O
of	O
this	O
amino-terminal	O
cysteine	O
motif	O
in	O
p56lck	B-DNAMutation
.	O

Thus	O
,	O
palmitylation	O
of	O
the	O
amino-terminal	O
cysteine	O
residue(s)	O
together	O
with	O
myristylation	O
of	O
the	O
amino-terminal	O
glycine	O
residue	O
defines	O
important	O
motifs	O
for	O
the	O
association	O
of	O
PTKs	O
with	O
GPI-anchored	O
proteins	O
.	O

Mutation	O
of	O
a	O
putative	O
mitochondrial	O
iron	O
transporter	O
gene	O
(ABC7)	O
in	O
X-linked	O
sideroblastic	O
anemia	O
and	O
ataxia	O
(XLSA/A)	O
.	O

X-linked	O
sideroblastic	O
anemia	O
and	O
ataxia	O
(XLSA/A)	O
is	O
a	O
recessive	O
disorder	O
characterized	O
by	O
an	O
infantile	O
to	O
early	O
childhood	O
onset	O
of	O
non-progressive	O
cerebellar	O
ataxia	O
and	O
mild	O
anemia	O
with	O
hypochromia	O
and	O
microcytosis	O
.	O

A	O
gene	O
encoding	O
an	O
ATP-binding	O
cassette	O
(ABC)	O
transporter	O
was	O
mapped	O
to	O
Xq13	O
,	O
a	O
region	O
previously	O
shown	O
by	O
linkage	O
analysis	O
to	O
harbor	O
the	O
XLSA/A	O
gene	O
.	O

This	O
gene	O
,	O
ABC7	O
,	O
is	O
an	O
ortholog	O
of	O
the	O
yeast	O
ATM1	B-DNAMutation
gene	O
whose	O
product	O
localizes	O
to	O
the	O
mitochondrial	O
inner	O
membrane	O
and	O
is	O
involved	O
in	O
iron	O
homeostasis	O
.	O

The	O
full-length	O
ABC7	O
cDNA	O
was	O
cloned	O
and	O
the	O
entire	O
coding	O
region	O
screened	O
for	O
mutations	O
in	O
a	O
kindred	O
in	O
which	O
five	O
male	O
members	O
manifested	O
XLSA/A	O
.	O

An	O
I400M	B-DNAMutation
variant	O
was	O
identified	O
in	O
a	O
predicted	O
transmembrane	O
segment	O
of	O
the	O
ABC7	B-DNAMutation
gene	O
in	O
patients	O
with	O
XLSA/A	B-DNAMutation
.	O

The	O
mutation	O
was	O
shown	O
to	O
segregate	O
with	O
the	O
disease	O
in	O
the	O
family	O
and	O
was	O
not	O
detected	O
in	O
at	O
least	O
600	O
chromosomes	O
of	O
general	O
population	O
controls	O
.	O

Introduction	O
of	O
the	O
corresponding	O
mutation	O
into	O
the	O
Saccharomyces	O
cerevisiae	O
ATM1	B-DNAMutation
gene	O
resulted	O
in	O
a	O
partial	O
loss	O
of	O
function	O
of	O
the	O
yeast	O
Atm1	B-DNAMutation
protein	O
.	O

In	O
addition	O
,	O
the	O
human	O
wild-type	O
ABC7	B-DNAMutation
protein	O
was	O
able	O
to	O
complement	O
ATM1	B-DNAMutation
deletion	I-DNAMutation
in	O
yeast	O
.	O

These	O
data	O
indicate	O
that	O
ABC7	O
is	O
the	O
causal	O
gene	O
of	O
XLSA/A	O
and	O
that	O
XLSA/A	O
is	O
a	O
mitochondrial	O
disease	O
caused	O
by	O
a	O
mutation	O
in	O
the	O
nuclear	O
genome	O
.	O

Homogeneous	O
assay	O
based	O
on	O
52	O
primer	O
sets	O
to	O
scan	O
for	O
mutations	O
of	O
the	O
ABCA1	B-DNAMutation
gene	O
and	O
its	O
application	O
in	O
genetic	O
analysis	O
of	O
a	O
new	O
patient	O
with	O
familial	O
high-density	O
lipoprotein	O
deficiency	O
syndrome	O
.	O

Familial	O
high-density	O
lipoprotein	O
(HDL)-deficiency	O
syndromes	O
are	O
caused	O
by	O
mutations	O
of	O
the	O
ABCA1	B-DNAMutation
gene	O
,	O
coding	O
for	O
the	O
ATP-binding	O
cassette	O
transporter	O
1	O
.	O

We	O
have	O
developed	O
a	O
homogeneous	O
assay	O
based	O
on	O
52	O
primer	O
sets	O
to	O
amplify	O
all	O
50	O
ABCA1	B-DNAMutation
exons	O
and	O
approximately	O
1	O
kb	O
of	O
its	O
promoter	O
.	O

The	O
assay	O
allows	O
for	O
convenient	O
amplification	O
of	O
the	O
gene	O
from	O
genomic	O
DNA	O
and	O
easy	O
mutational	O
analysis	O
through	O
automatic	O
sequencing	O
.	O

It	O
obviates	O
the	O
need	O
to	O
use	O
mRNA	O
preparations	O
,	O
which	O
were	O
difficult	O
to	O
handle	O
and	O
posed	O
a	O
risk	O
to	O
miss	O
splice	O
junction	O
or	O
promoter	O
mutations	O
.	O

The	O
application	O
of	O
the	O
test	O
to	O
the	O
molecular	O
analysis	O
of	O
a	O
new	O
patient	O
with	O
familial	O
HDL-deficiency	O
(	O
Tangier	O
disease	O
)	O
led	O
to	O
a	O
discovery	O
of	O
two	O
novel	O
ABCA1	B-DNAMutation
mutations	O
:	O
C2665del	B-DNAMutation
and	O
C4457T	B-DNAMutation
.	O

A	O
juxtamembrane	O
tyrosine	O
in	O
the	O
colony	B-DNAMutation
stimulating	I-DNAMutation
factor-1	I-DNAMutation
receptor	I-DNAMutation
regulates	O
ligand-induced	O
Src	O
association	O
,	O
receptor	O
kinase	O
function	O
,	O
and	O
down-regulation	O
.	O

Recent	O
literature	O
implicates	O
a	O
regulatory	O
function	O
of	O
the	O
juxtamembrane	O
domain	O
(JMD)	O
in	O
receptor	O
tyrosine	O
kinases	O
.	O

Mutations	O
in	O
the	O
JMD	O
of	O
c-Kit	B-DNAMutation
and	O
Flt3	B-DNAMutation
are	O
associated	O
with	O
gastrointestinal	O
stromal	O
tumors	O
and	O
acute	O
myeloid	O
leukemias	O
,	O
respectively	O
.	O

Additionally	O
,	O
autophosphorylated	O
Tyr559	O
in	O
the	O
JMD	O
of	O
the	O
colony	B-DNAMutation
stimulating	I-DNAMutation
factor-1	I-DNAMutation
CSF-1	B-DNAMutation
receptor	I-DNAMutation
CSF-1R	B-DNAMutation
binds	O
to	O
Src	O
family	O
kinases	O
(SFKs)	O
.	O

To	O
investigate	O
SFK	O
function	O
in	O
CSF-1	B-DNAMutation
signaling	O
we	O
established	O
stable	O
32D	O
myeloid	O
cell	O
lines	O
expressing	O
CSF-1Rs	O
with	O
mutated	O
SFK	O
binding	O
sites	O
(Tyr559-TFI)	O
.	O

Whereas	O
binding	O
to	O
I562S	B-DNAMutation
was	O
not	O
significantly	O
perturbed	O
,	O
Y559F	B-DNAMutation
and	O
Y559D	B-DNAMutation
exhibited	O
markedly	O
decreased	O
CSF-1-dependent	B-DNAMutation
SFK	O
association	O
.	O

All	O
JMD	O
mutants	O
retained	O
intrinsic	O
kinase	O
activity	O
,	O
but	O
Y559F	B-DNAMutation
,	O
and	O
less	O
so	O
Y559D	B-DNAMutation
,	O
showed	O
dramatically	O
reduced	O
CSF-1-induced	B-DNAMutation
autophosphorylation	O
.	O

CSF-1-mediated	B-DNAMutation
wild-type	O
(WT)-CSF-1R	B-DNAMutation
phosphorylation	O
was	O
not	O
markedly	O
affected	O
by	O
SFK	O
inhibition	O
,	O
indicating	O
that	O
lack	O
of	O
SFK	O
binding	O
is	O
not	O
responsible	O
for	O
diminished	O
Y559F	B-DNAMutation
phosphorylation	O
.	O

Unexpectedly	O
,	O
cells	O
expressing	O
Y559F	B-DNAMutation
were	O
hyperproliferative	O
in	O
response	O
to	O
CSF-1	B-DNAMutation
.	O

Hyperproliferation	O
correlated	O
with	O
prolonged	O
activation	O
of	O
Akt	B-DNAMutation
,	O
ERK	O
,	O
and	O
Stat5	B-DNAMutation
in	O
the	O
Y559F	B-DNAMutation
mutant	O
.	O

Consistent	O
with	O
a	O
defect	O
in	O
receptor	O
negative	O
regulation	O
,	O
c-Cbl	B-DNAMutation
tyrosine	O
phosphorylation	O
and	O
CSF-1R/c-Cbl	B-DNAMutation
co-association	O
were	O
almost	O
undetectable	O
in	O
the	O
Y559F	B-DNAMutation
mutant	O
.	O

Furthermore	O
,	O
Y559F	B-DNAMutation
underwent	O
reduced	O
multiubiquitination	O
and	O
delayed	O
receptor	O
internalization	O
and	O
degradation	O
.	O

In	O
conclusion	O
,	O
we	O
propose	O
that	O
Tyr559	O
is	O
a	O
switch	O
residue	O
that	O
functions	O
in	O
kinase	O
regulation	O
,	O
signal	O
transduction	O
and	O
,	O
indirectly	O
,	O
receptor	O
down-regulation	O
.	O

These	O
findings	O
may	O
have	O
implications	O
for	O
the	O
oncogenic	O
conversion	O
of	O
c-Kit	B-DNAMutation
and	O
Flt3	B-DNAMutation
with	O
JMD	O
mutations	O
.	O

Tyrosine	O
569	O
in	O
the	O
c-Fms	O
juxtamembrane	O
domain	O
is	O
essential	O
for	O
kinase	O
activity	O
and	O
macrophage	B-DNAMutation
colony-stimulating	I-DNAMutation
factor-dependent	I-DNAMutation
internalization	O
.	O

The	O
receptor	O
Fms	B-DNAMutation
for	O
macrophage	B-DNAMutation
colony-stimulating	I-DNAMutation
factor	I-DNAMutation
M-CSF	B-DNAMutation
is	O
a	O
member	O
of	O
the	O
tyrosine	O
kinase	O
class	O
of	O
growth	O
factor	O
receptors	O
.	O

It	O
maintains	O
survival	O
,	O
stimulates	O
growth	O
,	O
and	O
drives	O
differentiation	O
of	O
the	O
macrophage	O
lineage	O
of	O
hematopoietic	O
cells	O
.	O

Fms	B-DNAMutation
accumulates	O
on	O
the	O
cell	O
surface	O
and	O
becomes	O
activated	O
for	O
signal	O
transduction	O
after	O
M-CSF	B-DNAMutation
binding	O
and	O
is	O
then	O
internalized	O
via	O
endocytosis	O
for	O
eventual	O
degradation	O
in	O
lysosomes	O
.	O

We	O
have	O
investigated	O
the	O
mechanism	O
of	O
endocytosis	O
as	O
part	O
of	O
the	O
overall	O
signaling	O
process	O
of	O
this	O
receptor	O
and	O
have	O
identified	O
an	O
amino	O
acid	O
segment	O
near	O
the	O
cytoplasmic	O
juxtamembrane	O
region	O
surrounding	O
tyrosine	O
569	O
that	O
is	O
important	O
for	O
internalization	O
.	O

Mutation	O
of	O
tyrosine	B-DNAMutation
569	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
Y569A	B-DNAMutation
eliminates	O
ligand-induced	O
rapid	O
endocytosis	O
of	O
receptor	O
molecules	O
.	O

The	O
mutant	O
Fms	B-DNAMutation
Y569A	B-DNAMutation
also	O
lacks	O
tyrosine	O
kinase	O
activity	O
;	O
however	O
,	O
tyrosine	O
kinase	O
activity	O
is	O
not	O
essential	O
for	O
endocytosis	O
because	O
the	O
kinase	O
inactive	O
receptor	O
Fms	B-DNAMutation
K614A	B-DNAMutation
does	O
undergo	O
ligand-induced	O
endocytosis	O
,	O
albeit	O
at	O
a	O
reduced	O
rate	O
.	O

Mutation	O
of	O
tyrosine	B-DNAMutation
569	I-DNAMutation
to	I-DNAMutation
phenylalanine	I-DNAMutation
had	O
no	O
effect	O
on	O
the	O
M-CSF-induced	B-DNAMutation
endocytosis	O
of	O
Fms	B-DNAMutation
,	O
and	O
a	O
four-amino-acid	O
sequence	O
containing	O
Y-569	O
could	O
support	O
endocytosis	O
when	O
transferred	O
into	O
the	O
cytoplasmic	O
juxtamembrane	O
region	O
of	O
a	O
glycophorin	B-DNAMutation
A	I-DNAMutation
construct	O
.	O

These	O
results	O
indicate	O
that	O
tyrosine	O
569	O
within	O
the	O
juxtamembrane	O
region	O
of	O
Fms	B-DNAMutation
is	O
part	O
of	O
a	O
signal	O
recognition	O
sequence	O
for	O
endocytosis	O
that	O
does	O
not	O
require	O
tyrosine	O
phosphorylation	O
at	O
this	O
site	O
and	O
that	O
this	O
domain	O
also	O
influences	O
the	O
kinase	O
activity	O
of	O
the	O
receptor	O
.	O

These	O
results	O
are	O
consistent	O
with	O
a	O
ligand-dependent	O
step	O
in	O
recognition	O
of	O
the	O
potential	O
cryptic	O
internalization	O
signal	O
.	O

Molecular	O
definition	O
of	O
a	O
polymorphic	O
antigen	O
(LA45)	O
of	O
free	O
HLA-A	B-DNAMutation
and	I-DNAMutation
-B	I-DNAMutation
heavy	O
chains	O
found	O
on	O
the	O
surfaces	O
of	O
activated	O
B	O
and	O
T	O
cells	O
.	O

A	O
monomoprhic	O
monoclonal	O
antibody	O
(	O
LA45	O
antibody	O
)	O
reactive	O
with	O
"a	O
new	O
activation-induced	O
surface	O
structure	O
on	O
human	O
T	O
lymphocytes"	O
(	O
LA45	O
antigen	O
)	O
that	O
resembled	O
free	O
class	O
I	O
heavy	O
chains	O
has	O
recently	O
been	O
described	O
(	O
Schnabl	O
,	O
E.	O
,	O
H	O
.	O

Stockinger	O
,	O
O	O
.	O

Majdic	O
,	O
H	O
.	O

Gaugitsch	O
,	O
I.J.D	O
.	O

Lindley	O
,	O
D	O
.	O

Maurer	O
,	O
A	O
.	O

Hajek-Rosenmayr	O
,	O
and	O
W	O
.	O

Knapp	O
.	O

1990	O
.	O

J	O
.	O

Exp	B-DNAMutation
.	O

Med	O
.	O

171:1431	O
)	O
.	O

This	O
antibody	O
was	O
used	O
to	O
clone	O
a	O
class	O
I-like	O
heavy	O
chain	O
(	O
LA45	O
gene	O
)	O
from	O
the	O
HUT	O
102	O
tumor	O
cell	O
,	O
which	O
paradoxically	O
did	O
not	O
give	O
rise	O
to	O
the	O
LA45	O
antigen	O
on	O
transfection	O
into	O
monkey	O
COS	O
cells	O
.	O

We	O
show	O
here	O
that	O
the	O
LA45	O
gene	O
is	O
HLA-Aw66.2	O
,	O
a	O
previously	O
uncharacterized	O
allele	O
of	O
the	O
HLA-A	O
locus	O
.	O

The	O
previously	O
determined	O
LA45	O
sequence	O
differs	O
from	O
that	O
of	O
HLA-Aw66.2	O
,	O
from	O
HUT	O
102	O
,	O
and	O
the	O
CR-B	O
B	O
cell	O
line	O
derived	O
from	O
the	O
same	O
individual	O
as	O
HUT	O
102	O
by	O
substitution	O
of	O
tryptophan	B-DNAMutation
for	I-DNAMutation
serine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
4	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
alpha	I-DNAMutation
1	I-DNAMutation
domain	I-DNAMutation
.	O

Transfection	O
of	O
HLA-Aw66.2	O
,	O
and	O
of	O
a	O
mutant	O
of	O
this	O
gene	O
with	O
serine	B-DNAMutation
4	I-DNAMutation
substituted	I-DNAMutation
for	I-DNAMutation
tryptophan	I-DNAMutation
,	O
into	O
a	O
human	O
B	O
cell	O
line	O
(C1R)	O
both	O
resulted	O
in	O
expression	O
of	O
the	O
LA45	O
epitope	O
.	O

Furthermore	O
,	O
we	O
find	O
expression	O
of	O
the	O
LA45	O
epitope	O
on	O
Epstein	O
Barr	O
virus-transformed	O
B	O
cell	O
lines	O
as	O
well	O
as	O
lectin-activated	O
T	O
cells	O
,	O
but	O
not	O
on	O
long-term	O
T	O
cell	O
lines	O
or	O
unstimulated	O
peripheral	O
blood	O
T	O
cells	O
.	O

The	O
specificity	O
of	O
the	O
LA45	O
antibody	O
is	O
polymorphic	O
and	O
the	O
presence	O
of	O
the	O
LA45	O
epitope	O
is	O
precisely	O
correlated	O
with	O
the	O
sequence	O
arginine	O
,	O
asparagine	O
(RN)	O
at	O
residues	O
62	O
and	O
63	O
of	O
the	O
helix	O
of	O
the	O
alpha	O
1	O
domain	O
.	O

The	O
LA45	O
epitope	O
is	O
broadly	O
distributed	O
,	O
being	O
associated	O
with	O
half	O
the	O
alleles	O
of	O
both	O
HLA-A	B-DNAMutation
and	I-DNAMutation
-B	I-DNAMutation
loci	O
but	O
none	O
of	O
the	O
HLA-C	O
locus	O
.	O

All	O
the	O
results	O
are	O
consistent	O
with	O
the	O
presence	O
of	O
pools	O
of	O
free	O
HLA-A	B-DNAMutation
and	I-DNAMutation
-B	I-DNAMutation
heavy	O
chains	O
at	O
the	O
surfaces	O
of	O
certain	O
cell	O
types	O
but	O
not	O
others	O
.	O

Such	O
molecules	O
are	O
probably	O
responsible	O
for	O
the	O
HLA-associated	O
class	O
I	O
alloantigens	O
of	O
lectin-activated	O
T	O
cells	O
.	O

We	O
hypothesize	O
the	O
free	O
heavy	O
chains	O
result	O
from	O
dissociation	O
of	O
beta	B-DNAMutation
2-microglobulin	I-DNAMutation
from	O
subpopulations	O
of	O
empty	O
HLA-A,B	B-DNAMutation
molecules	O
,	O
or	O
molecules	O
with	O
weakly	O
bound	O
peptides	O
,	O
that	O
vary	O
in	O
size	O
depending	O
on	O
cellular	O
activation	O
and	O
peptide	O
supply	O
.	O

Mutation	O
detection	O
in	O
the	O
aspartoacylase	B-DNAMutation
gene	O
in	O
17	O
patients	O
with	O
Canavan	O
disease	O
:	O
four	O
new	O
mutations	O
in	O
the	O
non-Jewish	O
population	O
.	O

Canavan	O
disease	O
is	O
a	O
severe	O
progressive	O
autosomal	O
recessive	O
disorder	O
,	O
which	O
is	O
characterised	O
by	O
spongy	O
degeneration	O
of	O
the	O
brain	O
.	O

The	O
disease	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
aspartoacylase	B-DNAMutation
gene	O
.	O

Two	O
different	O
mutations	O
were	O
reported	O
on	O
98%	O
of	O
the	O
alleles	O
of	O
Ashkenazi	O
Jewish	O
patients	O
,	O
in	O
which	O
population	O
the	O
disease	O
is	O
highly	O
prevalent	O
.	O

In	O
non-Jewish	O
patients	O
of	O
European	O
origin	O
,	O
one	O
mutation	O
(	O
914C	B-DNAMutation
>	I-DNAMutation
A	I-DNAMutation
)	O
is	O
found	O
in	O
50%	O
of	O
the	O
alleles	O
,	O
the	O
other	O
alleles	O
representing	O
all	O
kinds	O
of	O
different	O
mutations	O
.	O

We	O
here	O
describe	O
the	O
results	O
of	O
the	O
mutation	O
analysis	O
in	O
17	O
European	O
,	O
non-Jewish	O
patients	O
.	O

Ten	O
different	O
mutations	O
were	O
found	O
,	O
of	O
which	O
four	O
had	O
not	O
been	O
described	O
before	O
(	O
H21P	B-DNAMutation
,	O
A57T	B-DNAMutation
,	O
R168H	B-DNAMutation
,	O
P181T	B-DNAMutation
)	O
.	O

A	O
deletion	B-DNAMutation
of	I-DNAMutation
exon4	I-DNAMutation
,	O
which	O
until	O
now	O
had	O
only	O
been	O
described	O
once	O
,	O
was	O
revealed	O
in	O
all	O
five	O
alleles	O
of	O
Turkish	O
origin	O
tested	O
,	O
indicating	O
that	O
this	O
is	O
a	O
founder	O
effect	O
in	O
the	O
Turkish	O
population	O
.	O

A	O
human	O
skeletal	O
overgrowth	O
mutation	O
increases	O
maximal	O
velocity	O
and	O
blocks	O
desensitization	O
of	O
guanylyl	O
cyclase-B	O
.	O

C-type	B-DNAMutation
natriuretic	I-DNAMutation
peptide	I-DNAMutation
(CNP)	O
increases	O
long	O
bone	O
growth	O
by	O
stimulating	O
guanylyl	B-DNAMutation
cyclase	I-DNAMutation
(GC)-B/NPR-B/NPR2	I-DNAMutation
.	O

Recently	O
,	O
a	O
Val	B-DNAMutation
to	I-DNAMutation
Met	I-DNAMutation
missense	I-DNAMutation
mutation	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
883	I-DNAMutation
in	O
the	O
catalytic	O
domain	O
of	O
GC-B	B-DNAMutation
was	O
identified	O
in	O
humans	O
with	O
increased	O
blood	O
cGMP	O
levels	O
that	O
cause	O
abnormally	O
long	O
bones	O
.	O

Here	O
,	O
we	O
determined	O
how	O
this	O
mutation	O
activates	O
GC-B	B-DNAMutation
.	O

In	O
the	O
absence	O
of	O
CNP	O
,	O
cGMP	O
levels	O
in	O
cells	O
expressing	O
V883M-GC-B	B-DNAMutation
were	O
increased	O
more	O
than	O
20	O
fold	O
compared	O
to	O
cells	O
expressing	O
wild-type	O
(WT)-GC-B	B-DNAMutation
,	O
and	O
the	O
addition	O
of	O
CNP	O
only	O
further	O
increased	O
cGMP	O
levels	O
2-fold	O
.	O

In	O
the	O
absence	O
of	O
CNP	O
,	O
maximal	O
enzymatic	O
activity	O
(Vmax)	O
of	O
V883M-GC-B	B-DNAMutation
was	O
increased	O
15-fold	O
compared	O
to	O
WT-GC-B	B-DNAMutation
but	O
the	O
affinity	O
of	O
the	O
enzymes	O
for	O
substrate	O
as	O
revealed	O
by	O
the	O
Michaelis	O
constant	O
(Km)	O
was	O
unaffected	O
.	O

Surprisingly	O
,	O
CNP	O
decreased	O
the	O
Km	O
of	O
V883M-GC-B	B-DNAMutation
10-fold	O
in	O
a	O
concentration-dependent	O
manner	O
without	O
increasing	O
Vmax	O
.	O

Unlike	O
the	O
WT	O
enzyme	O
the	O
Km	O
reduction	O
of	O
V883M-GC-B	B-DNAMutation
did	O
not	O
require	O
ATP	O
.	O

Unexpectedly	O
,	O
V883M-GC-B	B-DNAMutation
,	O
but	O
not	O
WT-GC-B	B-DNAMutation
,	O
failed	O
to	O
inactivate	O
with	O
time	O
.	O

Phosphorylation	O
elevated	O
but	O
was	O
not	O
required	O
for	O
the	O
activity	O
increase	O
associated	O
with	O
the	O
mutation	O
because	O
the	O
Val	B-DNAMutation
to	I-DNAMutation
Met	I-DNAMutation
substitution	I-DNAMutation
also	O
activated	O
a	O
GC-B	B-DNAMutation
mutant	O
lacking	O
all	O
known	O
phosphorylation	O
sites	O
.	O

We	O
conclude	O
that	O
the	O
V883M	B-DNAMutation
mutation	O
increases	O
maximal	O
velocity	O
in	O
the	O
absence	O
of	O
CNP	O
,	O
eliminates	O
the	O
requirement	O
for	O
ATP	O
in	O
the	O
CNP-dependent	O
Km	O
reduction	O
,	O
and	O
disrupts	O
the	O
normal	O
inactivation	O
process	O
.	O

A	O
mutation	B-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
717	I-DNAMutation
of	O
the	O
amyloid	O
precursor	O
protein	O
gene	O
in	O
an	O
Australian	O
family	O
with	O
Alzheimer's	O
disease	O
.	O

DNA	O
from	O
the	O
probands	O
of	O
seven	O
Australian	O
families	O
with	O
hereditary	O
Alzheimer's	O
disease	O
was	O
screened	O
for	O
the	O
presence	O
of	O
known	O
mutations	O
in	O
the	O
amyloid	O
precursor	O
protein	O
(APP)	O
gene	O
on	O
chromosome	O
21	O
using	O
single	O
stranded	O
conformational	O
polymorphism	O
(SSCP)	O
analysis	O
[14]	O
.	O

One	O
subject	O
was	O
found	O
to	O
have	O
a	O
mutation	O
causing	O
a	O
Val-->Ile	B-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
717	I-DNAMutation
.	O

This	O
was	O
confirmed	O
by	O
restriction	O
enzyme	O
digestion	O
and	O
sequencing	O
.	O

The	O
mutation	O
has	O
been	O
found	O
in	O
both	O
the	O
other	O
affected	O
family	O
members	O
available	O
for	O
study	O
and	O
in	O
two	O
at-risk	O
relatives	O
.	O

It	O
was	O
not	O
present	O
in	O
the	O
only	O
living	O
unaffected	O
relative	O
who	O
has	O
passed	O
the	O
usual	O
age	O
of	O
onset	O
in	O
this	O
family	O
.	O

There	O
is	O
so	O
far	O
no	O
evidence	O
that	O
apolipoprotein	O
E	O
(APOE)	O
genotype	O
influences	O
age	O
of	O
onset	O
in	O
this	O
family	O
,	O
though	O
numbers	O
are	O
small	O
.	O

Two	O
other	O
families	O
with	O
autopsy	O
confirmation	O
and	O
age	O
of	O
onset	O
in	O
the	O
fifth	O
decade	O
had	O
no	O
APP	O
mutation	O
and	O
are	O
thought	O
likely	O
to	O
have	O
a	O
mutation	O
on	O
chromosome	O
14	O
on	O
the	O
basis	O
of	O
their	O
earlier	O
onset	O
age	O
.	O

Molecular	O
analysis	O
of	O
aldolase	O
B	O
genes	O
in	O
hereditary	O
fructose	O
intolerance	O
.	O

The	O
molecular	O
basis	O
of	O
hereditary	O
fructose	O
intolerance	O
(HFI)	O
was	O
studied	O
in	O
50	O
subjects	O
(	O
41	O
pedigrees	O
,	O
82	O
apparently	O
independent	O
mutant	O
alleles	O
of	O
aldolase	O
B	O
)	O
by	O
direct	O
analysis	O
of	O
aldolase	O
B	O
genes	O
amplified	O
by	O
means	O
of	O
the	O
polymerase	O
chain	O
reaction	O
.	O

The	O
mutation	O
A149P	B-DNAMutation
(	O
ala	B-DNAMutation
149----pro	I-DNAMutation
)	O
was	O
found	O
in	O
67%	O
of	O
alleles	O
but	O
was	O
significantly	O
more	O
common	O
in	O
patients	O
from	O
northern	O
than	O
from	O
southern	O
Europe	O
.	O

Two	O
other	O
point	O
mutations	O
of	O
aldolase	O
B	O
were	O
identified	O
.	O

A174D	B-DNAMutation
(	O
C----A	B-DNAMutation
;	O
ala	B-DNAMutation
174----asp	I-DNAMutation
)	O
was	O
found	O
in	O
subjects	O
from	O
Italy	O
,	O
Switzerland	O
,	O
and	O
Yugoslavia	O
(	O
overall	O
frequency	O
16%	O
)	O
but	O
not	O
in	O
those	O
from	O
the	O
United	O
Kingdom	O
,	O
France	O
,	O
or	O
the	O
United	O
States	O
.	O

L288	O
delta	O
C	O
carried	O
a	O
single	B-DNAMutation
base-pair	I-DNAMutation
deletion	I-DNAMutation
causing	I-DNAMutation
frameshift	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
288	I-DNAMutation
and	O
was	O
restricted	O
to	O
Sicilian	O
subjects	O
.	O

By	O
testing	O
for	O
these	O
mutations	O
in	O
amplified	O
DNA	O
with	O
a	O
limited	O
panel	O
of	O
allele-specific	O
oligonucleotides	O
,	O
more	O
than	O
95%	O
of	O
HFI	O
patients	O
will	O
be	O
susceptible	O
to	O
genetic	O
diagnosis	O
.	O

Mutations	O
in	O
the	O
gene	O
encoding	O
for	O
the	O
beta	B-DNAMutation
2-adrenergic	I-DNAMutation
receptor	I-DNAMutation
in	O
normal	O
and	O
asthmatic	O
subjects	O
.	O

It	O
has	O
long	O
been	O
hypothesized	O
that	O
a	O
defective	O
beta	B-DNAMutation
2-adrenergic	I-DNAMutation
receptor	I-DNAMutation
(	O
beta	B-DNAMutation
2AR	I-DNAMutation
)	O
may	O
be	O
a	O
pathogenic	O
factor	O
in	O
bronchial	O
asthma	O
.	O

We	O
examined	O
the	O
gene	O
encoding	O
the	O
beta	B-DNAMutation
2AR	I-DNAMutation
to	O
assess	O
the	O
frequency	O
of	O
polymorphisms	O
in	O
51	O
patients	O
with	O
moderate	O
to	O
severe	O
asthma	O
and	O
56	O
normal	O
subjects	O
.	O

Nine	B-DNAMutation
different	I-DNAMutation
point	I-DNAMutation
mutations	I-DNAMutation
were	I-DNAMutation
found	I-DNAMutation
in	I-DNAMutation
both	I-DNAMutation
heterozygous	I-DNAMutation
and	I-DNAMutation
homozygous	I-DNAMutation
forms	I-DNAMutation
at	I-DNAMutation
nucleic	I-DNAMutation
acid	I-DNAMutation
residues	I-DNAMutation
46	I-DNAMutation
,	I-DNAMutation
79	I-DNAMutation
,	I-DNAMutation
100	I-DNAMutation
,	I-DNAMutation
252	I-DNAMutation
,	I-DNAMutation
491	I-DNAMutation
,	I-DNAMutation
523	I-DNAMutation
,	I-DNAMutation
1053	I-DNAMutation
,	I-DNAMutation
1098	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
1239	I-DNAMutation
.	O

No	O
mutations	O
resulting	O
in	O
large	O
deletions	O
or	O
frame	O
shifts	O
were	O
detected	O
.	O

Of	O
these	O
nine	O
polymorphisms	O
,	O
four	O
were	O
found	O
to	O
cause	B-DNAMutation
changes	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
encoded	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
at	I-DNAMutation
residues	I-DNAMutation
16	I-DNAMutation
,	I-DNAMutation
27	I-DNAMutation
,	I-DNAMutation
34	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
164	I-DNAMutation
.	O

The	O
most	O
frequent	O
polymorphisms	O
were	O
arginine	B-DNAMutation
16	I-DNAMutation
to	I-DNAMutation
glycine	I-DNAMutation
Arg16-->Gly	B-DNAMutation
and	O
glutamine	B-DNAMutation
27	I-DNAMutation
to	I-DNAMutation
glutamic	I-DNAMutation
acid	I-DNAMutation
Gln27-->Glu	B-DNAMutation
.	O

The	O
other	O
two	O
polymorphisms	O
,	O
valine	B-DNAMutation
34	I-DNAMutation
to	I-DNAMutation
methionine	I-DNAMutation
,	O
and	O
threonine	B-DNAMutation
164	I-DNAMutation
to	I-DNAMutation
isoleucine	I-DNAMutation
,	O
occurred	O
in	O
only	O
four	O
subjects	O
.	O

The	O
incidence	O
of	O
beta	B-DNAMutation
2AR	I-DNAMutation
homozygous	O
polymorphisms	O
was	O
no	O
greater	O
in	O
asthmatic	O
patients	O
as	O
compared	O
with	O
controls	O
(	O
Arg16-->Gly	B-DNAMutation
:	O
53%	O
versus	O
59%	O
,	O
Gln27-->Glu	B-DNAMutation
:	O
24%	O
versus	O
29%	O
,	O
respectively	O
;	O
P	O
=	O
NS	O
)	O
.	O

Some	O
subjects	O
were	O
found	O
to	O
have	O
both	O
of	O
these	O
polymorphisms	O
simultaneously	O
,	O
but	O
there	O
was	O
no	O
difference	O
in	O
incidence	O
between	O
the	O
two	O
groups	O
,	O
with	O
23%	O
of	O
asthmatics	O
and	O
28%	O
of	O
normal	O
subjects	O
being	O
homozygous	O
for	O
both	O
polymorphisms	O
.	O

The	O
apparently	O
normal	O
subjects	O
with	O
both	O
polymorphisms	O
did	O
not	O
have	O
subclinical	O
hyperreactive	O
airways	O
disease	O
as	O
determined	O
by	O
methacholine	O
challenge	O
testing	O
.	O

In	O
the	O
asthma	O
group	O
,	O
one	O
mutation	O
Arg16-->Gly	B-DNAMutation
identified	O
a	O
subset	O
of	O
patients	O
with	O
a	O
distinct	O
clinical	O
profile.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Eight	O
novel	O
ABCD1	B-DNAMutation
gene	O
mutations	O
and	O
three	O
polymorphisms	O
in	O
patients	O
with	O
X-linked	O
adrenoleukodystrophy	O
:	O
The	O
first	O
polymorphism	O
causing	O
an	O
amino	O
acid	O
exchange	O
.	O

X-ALD	O
is	O
a	O
neurological	O
disorder	O
associated	O
with	O
inherited	O
defects	O
in	O
the	O
ABCD1	B-DNAMutation
(ALD)	O
gene	O
located	O
on	O
Xq28	O
and	O
with	O
impaired	O
peroxisomal	O
very	O
long-chain	O
fatty	O
acid	O
beta-oxidation	O
.	O

We	O
examined	O
the	O
ABCD1	B-DNAMutation
gene	O
in	O
probands	O
from	O
11	O
unrelated	O
X-ALD	O
Czech	O
and	O
Slovak	O
families	O
by	O
the	O
direct	O
sequencing	O
of	O
cDNA	O
or	O
genomic	O
PCR	O
products	O
.	O

In	O
10	O
families	O
there	O
were	O
10	O
different	O
mutations	O
,	O
eight	O
of	O
which	O
were	O
novel	O
.	O

The	O
spectrum	O
of	O
mutations	O
consists	O
of	O
six	O
point	O
mutations	O
,	O
three	O
microdeletions	O
(	O
1bp	O
,	O
2bp	O
,	O
4	O
bp	O
)	O
,	O
and	O
one	O
large	O
deletion	O
(229bp)	O
.	O

In	O
the	O
11th	O
family	O
we	O
detected	O
two	O
novel	O
single-base	O
pair	O
substitutions	O
in	O
exon	O
1	O
(	O
c.38	B-DNAMutation
A>C	I-DNAMutation
and	O
c.649	B-DNAMutation
A>G	I-DNAMutation
)	O
,	O
both	O
causing	O
amino	O
acid	O
exchanges	O
(	O
N13T	B-DNAMutation
and	O
K217E	B-DNAMutation
)	O
.	O

Expression	O
studies	O
revealed	O
that	O
only	O
K217E	B-DNAMutation
is	O
a	O
deleterious	O
mutation	O
,	O
because	O
a	O
plasmid	O
encoding	O
ALDP	B-DNAMutation
with	O
K217E	B-DNAMutation
was	O
ineffective	O
in	O
the	O
restoration	O
of	O
defective	O
beta-oxidation	O
in	O
X-ALD	O
fibroblasts	O
.	O

The	O
N13T	B-DNAMutation
amino	O
acid	O
exchange	O
,	O
on	O
the	O
other	O
hand	O
,	O
did	O
not	O
affect	O
ALDP	B-DNAMutation
function	O
.	O

Thus	O
,	O
N13T	B-DNAMutation
represents	O
the	O
first	O
polymorphism	O
causing	O
an	O
amino	O
acid	O
exchange	O
in	O
the	O
ABCD1	B-DNAMutation
gene	O
.	O

As	O
this	O
polymorphism	O
was	O
observed	O
neither	O
in	O
100	O
control	O
alleles	O
nor	O
in	O
300	O
X-ALD	O
patients	O
who	O
have	O
been	O
sequenced	O
so	O
far	O
world-wide	O
,	O
it	O
seems	O
to	O
be	O
very	O
rare	O
or	O
unique	O
.	O

Two	O
additional	O
novel	O
polymorphisms	O
were	O
found	O
by	O
the	O
sequencing	O
of	O
the	O
ABCD1	B-DNAMutation
gene	O
from	O
our	O
patients	O
:	O
c.-59	B-DNAMutation
C/T	I-DNAMutation
in	O
the	O
5'untranslated	O
region	O
and	O
c.2019	B-DNAMutation
C/T	I-DNAMutation
F673F	B-DNAMutation
in	O
exon	O
10	O
.	O

The	O
frequencies	O
of	O
these	O
two	O
polymorphisms	O
,	O
were	O
11/150	O
and	O
2/150	O
control	O
alleles	O
,	O
respectively	O
.	O

Distinct	O
C/EBPalpha	O
motifs	O
regulate	O
lipogenic	O
and	O
gluconeogenic	O
gene	O
expression	O
in	O
vivo	O
.	O

The	O
C/EBPalpha	O
transcription	O
factor	O
regulates	O
hepatic	O
nitrogen	O
,	O
glucose	O
,	O
lipid	O
and	O
iron	O
metabolism	O
.	O

However	O
,	O
how	O
it	O
is	O
able	O
to	O
independently	O
control	O
these	O
processes	O
is	O
not	O
known	O
.	O

Here	O
,	O
we	O
use	O
mouse	O
knock-in	O
mutagenesis	O
to	O
identify	O
C/EBPalpha	O
domains	O
that	O
specifically	O
regulate	O
hepatic	O
gluconeogenesis	O
and	O
lipogenesis	O
.	O

In	O
vivo	O
deletion	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
proline-histidine	I-DNAMutation
rich	I-DNAMutation
domain	I-DNAMutation
(PHR)	I-DNAMutation
,	O
dephosphorylated	O
at	O
S193	O
by	O
insulin	O
signaling	O
,	O
dysregulated	O
genes	O
involved	O
in	O
the	O
generation	O
of	O
acetyl-CoA	O
and	O
NADPH	B-DNAMutation
for	O
triglyceride	O
synthesis	O
and	O
led	O
to	O
increased	O
hepatic	O
lipogenesis	O
.	O

These	O
promoters	O
bound	O
SREBP-1	B-DNAMutation
as	O
well	O
as	O
C/EBPalpha	O
,	O
and	O
the	O
PHR	O
was	O
required	O
for	O
C/EBPalpha-SREBP	O
transcriptional	O
synergy	O
.	O

In	O
contrast	O
,	O
the	O
highly	O
conserved	O
C/EBPalpha	O
CR4	O
domain	O
was	O
found	O
to	O
undergo	O
liver-specific	O
dephosphorylation	O
of	O
residues	O
T222	B-DNAMutation
and	I-DNAMutation
T226	I-DNAMutation
upon	I-DNAMutation
fasting	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
alanine	I-DNAMutation
mutation	I-DNAMutation
of	I-DNAMutation
these	I-DNAMutation
residues	I-DNAMutation
upregulated	O
the	O
hepatic	O
expression	O
of	O
the	O
gluconeogenic	O
G6Pase	B-DNAMutation
and	O
PEPCK	B-DNAMutation
mRNAs	O
,	O
but	O
not	O
PGC-1alpha	B-DNAMutation
,	O
leading	O
to	O
glucose	O
intolerance	O
.	O

Our	O
results	O
show	O
that	O
pathway-specific	O
metabolic	O
regulation	O
can	O
be	O
achieved	O
through	O
a	O
single	O
transcription	O
factor	O
containing	O
context-sensitive	O
regulatory	O
domains	O
,	O
and	O
indicate	O
C/EBPalpha	O
phosphorylation	O
as	O
a	O
PGC-1alpha-independent	B-DNAMutation
mechanism	O
for	O
regulating	O
hepatic	O
gluconeogenesis	O
.	O

Erythropoietin	B-DNAMutation
induces	O
activation	O
of	O
Stat5	B-DNAMutation
through	O
association	O
with	O
specific	O
tyrosines	O
on	O
the	O
receptor	O
that	O
are	O
not	O
required	O
for	O
a	O
mitogenic	O
response	O
.	O

The	O
cytoplasmic	O
domain	O
of	O
the	O
erythropoietin	B-DNAMutation
receptor	I-DNAMutation
EpoR	B-DNAMutation
contains	O
a	O
membrane-distal	O
region	O
that	O
is	O
dispensable	O
for	O
mitogenesis	O
but	O
is	O
required	O
for	O
the	O
recruitment	O
and	O
tyrosine	O
phosphorylation	O
of	O
a	O
variety	O
of	O
signaling	O
proteins	O
.	O

The	O
membrane-proximal	O
region	O
of	O
96	O
amino	O
acids	O
is	O
necessary	O
and	O
sufficient	O
for	O
mitogenesis	O
as	O
well	O
as	O
Jak2	B-DNAMutation
activation	O
,	O
induction	O
of	O
c-fos	B-DNAMutation
,	O
c-myc	B-DNAMutation
,	O
cis	O
,	O
the	O
T-cell	B-DNAMutation
receptor	I-DNAMutation
gamma	I-DNAMutation
locus	I-DNAMutation
(TCR-gamma)	I-DNAMutation
,	O
and	O
c-pim-1	O
.	O

The	O
studies	O
presented	O
here	O
demonstrate	O
that	O
this	O
region	O
is	O
also	O
necessary	O
and	O
sufficient	O
for	O
the	O
activation	O
of	O
Stat5A	B-DNAMutation
and	O
Stat5B	B-DNAMutation
.	O

The	O
membrane-proximal	O
domain	O
contains	O
a	O
single	O
tyrosine	O
,	O
Y-343	B-DNAMutation
,	I-DNAMutation
which	I-DNAMutation
when	I-DNAMutation
mutated	I-DNAMutation
eliminates	O
the	O
ability	O
of	O
the	O
receptor	O
to	O
couple	O
Epo	O
binding	O
to	O
the	O
activation	O
of	O
Stat5	B-DNAMutation
.	O

Furthermore	O
,	O
peptide	O
competitions	O
demonstrate	O
that	O
this	O
site	O
,	O
when	O
phosphorylated	O
,	O
can	O
disrupt	O
Stat5	B-DNAMutation
DNA	O
binding	O
activity	O
,	O
consistent	O
with	O
a	O
role	O
of	O
Y-343	O
as	O
a	O
site	O
of	O
recruitment	O
to	O
the	O
receptor	O
.	O

Cells	O
expressing	O
the	O
truncated	O
,	O
Y343F	B-DNAMutation
mutant	O
(	O
a	O
mutant	O
with	O
a	O
Y-to-F	B-DNAMutation
alteration	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
343	I-DNAMutation
)	O
proliferate	O
in	O
response	O
to	O
Epo	O
in	O
a	O
manner	O
comparable	O
to	O
that	O
of	O
the	O
controls	O
.	O

However	O
,	O
in	O
these	O
cells	O
,	O
Epo	O
stimulation	O
does	O
not	O
induce	O
the	O
appearance	O
of	O
transcripts	O
for	O
cis	O
,	O
TCR-gamma	O
,	O
or	O
c-fos	B-DNAMutation
,	O
suggesting	O
a	O
role	O
for	O
Stat5	B-DNAMutation
in	O
their	O
regulation	O
.	O

Sirtuin	B-DNAMutation
3	I-DNAMutation
SIRT3	B-DNAMutation
protein	O
regulates	O
long-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
by	O
deacetylating	O
conserved	O
lysines	O
near	O
the	O
active	O
site	O
.	O

Long-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
LCAD	B-DNAMutation
is	O
a	O
key	O
mitochondrial	O
fatty	O
acid	O
oxidation	O
enzyme	O
.	O

We	O
previously	O
demonstrated	O
increased	O
LCAD	B-DNAMutation
lysine	O
acetylation	O
in	O
SIRT3	B-DNAMutation
knockout	B-DNAMutation
mice	O
concomitant	O
with	O
reduced	O
LCAD	B-DNAMutation
activity	O
and	O
reduced	O
fatty	O
acid	O
oxidation	O
.	O

To	O
study	O
the	O
effects	O
of	O
acetylation	O
on	O
LCAD	B-DNAMutation
and	O
determine	O
sirtuin	B-DNAMutation
3	I-DNAMutation
SIRT3	B-DNAMutation
target	O
sites	O
,	O
we	O
chemically	O
acetylated	O
recombinant	O
LCAD	B-DNAMutation
.	O

Acetylation	O
impeded	O
substrate	O
binding	O
and	O
reduced	O
catalytic	O
efficiency	O
.	O

Deacetylation	O
with	O
recombinant	O
SIRT3	B-DNAMutation
partially	O
restored	O
activity	O
.	O

Residues	O
Lys-318	O
and	O
Lys-322	O
were	O
identified	O
as	O
SIRT3-targeted	B-DNAMutation
lysines	O
.	O

Arginine	B-DNAMutation
substitutions	I-DNAMutation
at	I-DNAMutation
Lys-318	I-DNAMutation
and	I-DNAMutation
Lys-322	I-DNAMutation
prevented	O
the	O
acetylation-induced	O
activity	O
loss	O
.	O

Lys-318	O
and	O
Lys-322	O
flank	O
residues	O
Arg-317	O
and	O
Phe-320	O
,	O
which	O
are	O
conserved	O
among	O
all	O
acyl-CoA	O
dehydrogenases	O
and	O
coordinate	O
the	O
enzyme-bound	O
FAD	O
cofactor	O
in	O
the	O
active	O
site	O
.	O

We	O
propose	O
that	O
acetylation	O
at	O
Lys-318/Lys-322	O
causes	O
a	O
conformational	O
change	O
which	O
reduces	O
hydride	O
transfer	O
from	O
substrate	O
to	O
FAD	O
.	O

Medium-chain	O
acyl-CoA	O
dehydrogenase	O
and	O
acyl-CoA	O
dehydrogenase	O
9	O
,	O
two	O
related	O
enzymes	O
with	O
lysines	O
at	O
positions	O
equivalent	O
to	O
Lys-318/Lys-322	O
,	O
were	O
also	O
efficiently	O
deacetylated	O
by	O
SIRT3	B-DNAMutation
following	O
chemical	O
acetylation	O
.	O

These	O
results	O
suggest	O
that	O
acetylation/deacetylation	O
at	O
Lys-318/Lys-322	O
is	O
a	O
mode	O
of	O
regulating	O
fatty	O
acid	O
oxidation	O
.	O

The	O
same	O
mechanism	O
may	O
regulate	O
other	O
acyl-CoA	O
dehydrogenases	O
.	O

Identification	O
and	O
characterization	O
of	O
the	O
fifth	O
membrane-type	O
matrix	O
metalloproteinase	O
MT5-MMP	B-DNAMutation
.	O

A	O
new	O
member	O
of	O
the	O
membrane-type	O
matrix	O
metalloproteinase	O
(MT-MMP)	O
subfamily	O
tentatively	O
named	O
MT5-MMP	B-DNAMutation
was	O
isolated	O
from	O
mouse	O
brain	O
cDNA	O
library	O
.	O

It	O
is	O
predicted	O
to	O
contain	O
(i)	O
a	O
candidate	O
signal	O
sequence	O
,	O
(ii)	O
a	O
propeptide	O
region	O
with	O
the	O
highly	O
conserved	O
PRCGVPD	O
sequence	O
,	O
(iii)	O
a	O
potential	O
furin	O
recognition	O
motif	O
RRRRNKR	O
,	O
(iv)	O
a	O
zinc-binding	O
catalytic	O
domain	O
,	O
(v)	O
a	O
hemopexin-like	O
domain	O
,	O
(vi)	O
a	O
24-residue	O
hydrophobic	O
domain	O
as	O
a	O
potential	O
transmembrane	O
domain	O
,	O
and	O
(vii)	O
a	O
short	O
cytosolic	O
domain	O
.	O

Reverse	O
transcriptase-polymerase	O
chain	O
reaction	O
analysis	O
of	O
its	O
transcripts	O
indicates	O
that	O
MT5-MMP	B-DNAMutation
is	O
expressed	O
in	O
a	O
brain-specific	O
manner	O
consistent	O
with	O
the	O
origin	O
of	O
its	O
EST	O
clone	O
from	O
cerebellum	O
.	O

It	O
is	O
also	O
highly	O
expressed	O
during	O
embryonic	O
development	O
at	O
stages	O
day	O
11	O
and	O
15	O
.	O

Like	O
other	O
MT-MMPs	O
,	O
MT5-MMP	B-DNAMutation
specifically	O
activates	O
progelatinase	O
A	O
when	O
co-expressed	O
in	O
Madin-Darby	O
canine	O
kidney	O
cells	O
.	O

Its	O
ability	O
to	O
activate	O
progelatinase	O
A	O
is	O
dependent	O
on	O
its	O
proteolytic	O
activity	O
since	O
a	O
mutation	B-DNAMutation
converting	I-DNAMutation
Glu	I-DNAMutation
to	I-DNAMutation
Ala	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
zinc	I-DNAMutation
binding	I-DNAMutation
motif	I-DNAMutation
HE255LGH	I-DNAMutation
renders	O
MT5-MMP	B-DNAMutation
inactive	O
against	O
progelatinase	O
A	O
.	O

In	O
contrast	O
to	O
other	O
MT-MMPs	O
,	O
MT5-MMP	B-DNAMutation
tends	O
to	O
shed	O
from	O
cell	O
surface	O
as	O
soluble	O
proteinases	O
,	O
thus	O
offering	O
flexibility	O
as	O
both	O
a	O
cell	O
bound	O
and	O
soluble	O
proteinase	O
for	O
extracellular	O
matrix	O
remodeling	O
processes	O
.	O

Taken	O
together	O
,	O
these	O
properties	O
serve	O
to	O
distinguish	O
MT5-MMP	B-DNAMutation
as	O
a	O
versatile	O
MT-MMP	O
playing	O
an	O
important	O
role	O
in	O
extracellular	O
matrix	O
remodeling	O
events	O
in	O
the	O
brain	O
and	O
during	O
embryonic	O
development	O
.	O

Siiyama	O
(	O
serine	B-DNAMutation
53	I-DNAMutation
(TCC)	I-DNAMutation
to	I-DNAMutation
phenylalanine	I-DNAMutation
53	I-DNAMutation
(	I-DNAMutation
TTC	I-DNAMutation
)	O
)	O
.	O

A	O
new	O
alpha	O
1-antitrypsin-deficient	O
variant	O
with	O
mutation	O
on	O
a	O
predicted	O
conserved	O
residue	O
of	O
the	O
serpin	O
backbone	O
.	O

alpha	O
1-antitrypsin	O
(	O
alpha	B-DNAMutation
1AT	I-DNAMutation
)	O
,	O
a	O
plasma	O
serine	O
protease	O
inhibitor	O
,	O
increases	O
the	O
risk	O
of	O
precocious	O
pulmonary	O
emphysema	O
in	O
individuals	O
when	O
deficient	O
.	O

Although	O
more	O
than	O
25	O
years	O
have	O
passed	O
since	O
a	O
deficiency	O
in	O
the	O
serum	O
level	O
of	O
alpha	B-DNAMutation
1AT	I-DNAMutation
was	O
reported	O
,	O
it	O
is	O
only	O
recently	O
that	O
the	O
consequence	O
of	O
the	O
amino	O
acid	O
replacement	O
which	O
leads	O
to	O
the	O
deficient	O
state	O
has	O
been	O
discussed	O
in	O
terms	O
of	O
the	O
crystallographic	O
structure	O
of	O
alpha	B-DNAMutation
1AT	I-DNAMutation
and	O
the	O
amino	O
acid	O
residues	O
conserved	O
in	O
the	O
superfamily	O
to	O
which	O
it	O
belongs	O
.	O

Our	O
case	O
involved	O
a	O
38-year-old	O
Japanese	O
male	O
with	O
alpha	B-DNAMutation
1AT	I-DNAMutation
deficiency	O
which	O
was	O
analyzed	O
and	O
identified	O
as	O
a	O
new	O
deficient	O
variant	O
.	O

The	O
serum	O
alpha	B-DNAMutation
1AT	I-DNAMutation
of	O
the	O
proband	O
migrated	O
to	O
the	O
S	O
position	O
of	O
the	O
reference	O
serum	O
which	O
is	O
more	O
cathodal	O
than	O
M1	O
,	O
the	O
predominant	O
normal	O
variant	O
,	O
when	O
isoelectric	O
focusing	O
(	O
pH	O
4.2-4.9	O
)	O
is	O
performed	O
by	O
a	O
combination	O
of	O
Western	O
blotting	O
and	O
crossed	O
immunoelectrophoresis	O
.	O

The	O
new	O
deficient	O
variant	O
is	O
designated	O
as	O
Siiyama	O
after	O
his	O
birthplace	O
.	O

Although	O
liver	O
biopsy	O
specimen	O
showed	O
no	O
apparent	O
pathological	O
findings	O
,	O
PAS-positive	O
with	O
diastase-resistant	O
inclusion	O
bodies	O
and	O
immunoreactive	O
aggregates	O
were	O
detected	O
in	O
several	O
hepatocytes	O
.	O

In	O
addition	O
,	O
similar	O
alpha	B-DNAMutation
1AT	I-DNAMutation
mRNA	O
transcript	O
levels	O
were	O
observed	O
in	O
peripheral	O
blood	O
leukocytes	O
from	O
the	O
proband	O
and	O
healthy	O
subjects	O
by	O
Northern	O
analysis	O
.	O

All	O
the	O
coding	O
exons	O
(	O
exon	O
Ic	O
,	O
II	O
,	O
III	O
,	O
IV	O
,	O
and	O
V	O
)	O
of	O
the	O
alpha	B-DNAMutation
1AT	I-DNAMutation
gene	O
of	O
the	O
proband	O
and	O
his	O
family	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
followed	O
by	O
direct	O
sequencing	O
.	O

A	O
single	O
missense	O
mutation	O
,	O
Ser53	B-DNAMutation
(TCC)	I-DNAMutation
to	I-DNAMutation
Phe53	I-DNAMutation
(	O
TTC	O
was	O
identified	O
in	O
exon	O
II	O
of	O
the	O
proband's	O
alpha	B-DNAMutation
1AT	I-DNAMutation
gene	O
.	O

All	O
his	O
family	O
examined	O
were	O
heterozygous	O
at	O
this	O
base	O
.	O

Ser53	O
is	O
one	O
of	O
the	O
most	O
conserved	O
residues	O
as	O
predicted	O
by	O
Huber	O
and	O
Carrell	O
(	O
Huber	O
,	O
R.	O
,	O
and	O
Carrell	O
,	O
R	O
.	O

W	O
.	O

(1989)	O
Biochemistry	O
28	O
,	O
8951-8966	O
)	O
and	O
is	O
thought	O
to	O
contribute	O
to	O
the	O
organization	O
of	O
the	O
internal	O
core	O
element	O
of	O
the	O
alpha	B-DNAMutation
1AT	I-DNAMutation
molecule	O
.	O

The	O
mutational	O
matrix	O
number	O
of	O
Ser	O
to	O
Phe	O
substitution	O
is	O
-3	O
,	O
indicating	O
that	O
this	O
change	O
is	O
evolutionally	O
rare	O
.	O

In	O
this	O
regard	O
,	O
a	O
possible	O
explanation	O
for	O
the	O
deficient	O
state	O
in	O
alpha	B-DNAMutation
1AT	I-DNAMutation
Siiyama	O
is	O
that	O
the	O
change	O
from	O
an	O
uncharged	O
polar	O
to	O
a	O
nonpolar	O
amino	O
acid	O
imposed	O
on	O
the	O
conserved	O
serpin	O
backbone	O
exerts	O
severe	O
effects	O
on	O
the	O
integrity	O
of	O
the	O
molecule	O
,	O
and	O
hence	O
alters	O
the	O
intracellular	O
processing	O
of	O
alpha	B-DNAMutation
1AT	I-DNAMutation
.	O

A	O
point	O
mutation	O
in	O
ABC1	B-DNAMutation
gene	O
in	O
a	O
patient	O
with	O
severe	O
premature	O
coronary	O
heart	O
disease	O
and	O
mild	O
clinical	O
phenotype	O
of	O
Tangier	O
disease	O
.	O

The	O
proband	O
is	O
a	O
50	O
year-old	O
woman	O
born	O
from	O
a	O
consanguineous	O
marriage	O
.	O

She	O
has	O
been	O
suffering	O
from	O
angina	O
pectoris	O
since	O
the	O
age	O
of	O
38	O
and	O
underwent	O
coronary	O
bypass	O
surgery	O
for	O
three-vessel	O
disease	O
at	O
48	O
.	O

The	O
presence	O
of	O
low	O
plasma	O
levels	O
of	O
total	O
cholesterol	O
and	O
high	O
density	O
lipoprotein	O
(HDL)	O
cholesterol	O
(	O
2.4	O
and	O
0.1	O
mmol/l	O
)	O
and	O
apo	O
AI	O
(	O
<15	O
mg/dl	O
)	O
,	O
associated	O
with	O
corneal	O
lesions	O
and	O
a	O
mild	O
splenomegaly	O
suggested	O
the	O
diagnosis	O
of	O
Tangier	O
disease	O
.	O

However	O
,	O
none	O
of	O
the	O
other	O
features	O
of	O
Tangier	O
disease	O
,	O
including	O
hepatomegaly	O
,	O
anemia	O
and	O
peripheral	O
neuropathy	O
,	O
were	O
present	O
.	O

The	O
analysis	O
of	O
the	O
dinucleotide	O
microsatellites	O
located	O
in	O
chromosome	O
9q31	O
region	O
demonstrated	O
that	O
the	O
proband	O
was	O
homozygous	O
for	O
the	O
alleles	O
of	O
D9S53	O
,	O
D9S1784	O
and	O
D9S1832	O
.	O

The	O
mother	O
and	O
son	O
of	O
the	O
proband	O
,	O
both	O
with	O
low	O
levels	O
of	O
HDL	O
cholesterol	O
,	O
shared	O
one	O
of	O
the	O
proband's	O
haplotypes	O
,	O
whereas	O
neither	O
of	O
these	O
haplotypes	O
was	O
present	O
in	O
the	O
normolipidemic	O
proband's	O
sister	O
.	O

The	O
sequence	O
of	O
ATP-binding	O
cassette	O
transporter	O
1	O
(ABC1-1)	O
cDNA	O
obtained	O
by	O
reverse	O
transcription-PCR	O
(RT-PCR)	O
of	O
total	O
RNA	O
isolated	O
from	O
cultured	O
fibroblasts	O
showed	O
that	O
the	O
proband	O
was	O
homozygous	O
for	O
a	O
C>T	B-DNAMutation
transition	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
13	I-DNAMutation
,	O
which	B-DNAMutation
caused	I-DNAMutation
a	I-DNAMutation
tryptophane	I-DNAMutation
for	I-DNAMutation
arginine	I-DNAMutation
substitution	O
R527W	B-DNAMutation
.	O

This	O
mutation	O
was	O
confirmed	O
by	O
direct	O
sequencing	O
of	O
exon	O
13	O
amplified	O
from	O
genomic	O
DNA	O
.	O

It	O
can	O
be	O
easily	O
screened	O
,	O
as	O
the	O
nucleotide	O
change	O
introduces	O
a	O
restriction	O
site	O
for	O
the	O
enzyme	O
Afl	O
III	O
.	O

R527W	B-DNAMutation
substitution	O
occurs	O
in	O
a	O
highly	O
conserved	O
region	O
of	O
the	O
NH2	O
cytoplasmic	O
domain	O
of	O
ABC1	B-DNAMutation
protein	O
.	O

R527W	B-DNAMutation
co-segregates	O
with	O
the	O
low	O
HDL	O
phenotype	O
in	O
the	O
family	O
and	O
was	O
not	O
found	O
in	O
200	O
chromosomes	O
from	O
normolipidemic	O
individuals	O
.	O

Shedding	O
of	O
membrane	B-DNAMutation
type	I-DNAMutation
matrix	I-DNAMutation
metalloproteinase	I-DNAMutation
5	I-DNAMutation
by	O
a	O
furin-type	B-DNAMutation
convertase	O
:	O
a	O
potential	O
mechanism	O
for	O
down-regulation	O
.	O

The	O
shedding	O
of	O
membrane-associated	O
proteins	O
has	O
been	O
recognized	O
as	O
a	O
regulatory	O
mechanism	O
to	O
either	O
up-regulate	O
or	O
down-regulate	O
cellular	O
functions	O
by	O
releasing	O
membrane-bound	O
growth	O
factors	O
or	O
removing	O
ectodomains	O
of	O
adhesion	O
molecules	O
and	O
receptors	O
.	O

We	O
have	O
reported	O
previously	O
that	O
the	O
ectoenzyme	O
of	O
membrane	B-DNAMutation
type	I-DNAMutation
matrix	I-DNAMutation
metalloproteinase	I-DNAMutation
5	I-DNAMutation
MT5-MMP	B-DNAMutation
is	O
shed	O
into	O
extracellular	O
milieu	O
(	O
Pei	O
,	O
D	O
.	O

(1999)	O
J	O
.	O

Biol	O
.	O

Chem	O
.	O

274	O
,	O
8925-8932	O
)	O
.	O

Here	O
we	O
present	O
evidence	O
that	O
MT5-MMP	B-DNAMutation
is	O
shed	O
by	O
a	O
furin-type	B-DNAMutation
convertase	O
activity	O
in	O
the	O
trans-Golgi	O
network	O
.	O

Among	O
proteinase	O
inhibitors	O
screened	O
,	O
only	O
decanoyl-Arg-Val-Lys-Arg-chloromethylketone	O
,	O
a	O
known	O
inhibitor	O
for	O
furin-type	B-DNAMutation
convertases	O
,	O
blocked	O
the	O
shedding	O
of	O
MT5-MMP	B-DNAMutation
in	O
a	O
dose-dependent	O
manner	O
.	O

As	O
expected	O
,	O
decanoyl-Arg-Val-Lys-Arg-chloromethylketone	O
also	O
prevented	O
the	O
activation	O
of	O
MT5-MMP	B-DNAMutation
,	O
raising	O
the	O
possibility	O
that	O
the	O
observed	O
shedding	O
could	O
be	O
autolytic	O
.	O

However	O
,	O
an	O
active	O
site	O
mutant	O
devoid	O
of	O
any	O
catalytic	O
activity	O
,	O
is	O
also	O
shed	O
efficiently	O
,	O
thus	O
ruling	O
out	O
the	O
autolytic	O
pathway	O
.	O

The	O
shedding	O
cleavage	O
was	O
subsequently	O
mapped	O
to	O
the	O
stem	O
region	O
immediately	O
upstream	O
of	O
the	O
transmembrane	O
domain	O
,	O
where	O
a	O
cryptic	O
furin	O
recognition	O
site	O
,	O
(545)RRKERR	O
,	O
was	O
recognized	O
.	O

Indeed	O
,	O
MT5-MMP	B-DNAMutation
and	O
furin	B-DNAMutation
are	O
co-localized	O
in	O
the	O
trans-Golgi	O
network	O
and	O
the	O
shed	O
species	O
could	O
be	O
detected	O
inside	O
the	O
cells	O
.	O

Furthermore	O
,	O
deletion	O
mutations	O
removing	O
this	O
cryptic	O
site	O
prevented	O
MT5-MMP	B-DNAMutation
from	O
shedding	O
.	O

The	O
resulting	O
mutants	O
express	O
a	O
gain-of-function	O
phenotype	O
by	O
mediating	O
more	O
robust	O
activation	O
of	O
proMMP-2	O
than	O
the	O
wild	O
type	O
molecule	O
.	O

Thus	O
,	O
shedding	O
provides	O
a	O
potential	O
mechanism	O
to	O
regulate	O
proteolytic	O
activity	O
of	O
membrane-bound	O
MMPs	O
.	O

A	O
frequent	O
mild	O
mutation	O
in	O
ALG6	B-DNAMutation
may	O
exacerbate	O
the	O
clinical	O
severity	O
of	O
patients	O
with	O
congenital	O
disorder	O
of	O
glycosylation	O
Ia	O
(CDG-Ia)	O
caused	O
by	O
phosphomannomutase	O
deficiency	O
.	O

Single	O
nucleotide	O
polymorphisms	O
occur	O
throughout	O
the	O
human	O
genome	O
.	O

A	O
gene	O
that	O
causes	O
one	O
of	O
the	O
congenital	O
disorders	O
of	O
glycosylation	O
(CDG)	O
has	O
a	O
mutation	O
(	O
911T-->C	B-DNAMutation
)	O
that	O
changes	O
a	O
phenylalanine	B-DNAMutation
to	I-DNAMutation
serine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
304	I-DNAMutation
(F304S)	O
of	O
the	O
alpha	O
1,3	O
glucosyl	O
transferase	O
.	O

We	O
show	O
that	O
this	O
change	O
reduces	O
the	O
ability	O
of	O
the	O
gene	O
product	O
to	O
rescue	O
defective	O
glycosylation	O
of	O
an	O
alg6-deficient	B-DNAMutation
strain	O
of	O
Saccharomyces	O
cerevisiae	O
during	O
rapid	O
growth	O
.	O

This	O
finding	O
suggested	O
that	O
the	O
mutation	O
might	O
affect	O
glycosylation	O
in	O
humans	O
.	O

We	O
therefore	O
compared	O
the	O
frequency	O
of	O
this	O
variant	O
in	O
301	O
controls	O
and	O
in	O
101	O
CDG	O
patients	O
who	O
carry	O
known	O
mutations	O
in	O
other	O
genes	O
involved	O
in	O
CDG	O
,	O
i.e	O
.	O

PMM2	B-DNAMutation
(	O
CDG-Ia	O
;	O
91	O
patients	O
)	O
and	O
MPI	B-DNAMutation
(	O
CDG-Ib	O
;	O
10	O
patients	O
)	O
.	O

The	O
variant	O
allele	O
frequency	O
is	O
identical	O
in	O
both	O
CDG	O
patients	O
(0.30)	O
and	O
controls	O
(0.28)	O
.	O

Importantly	O
,	O
the	O
F304S	B-DNAMutation
genotype	O
frequency	O
in	O
55	O
CDG-Ia	O
patients	O
classified	O
as	O
mild/moderate	O
(	O
n	O
=	O
28	O
)	O
,	O
or	O
severe	O
(	O
n	O
=	O
27	O
)	O
was	O
significantly	O
higher	O
in	O
severely	O
affected	O
patients	O
(0.41)	O
than	O
in	O
mild/moderately	O
affected	O
patients	O
(0.21)	O
.	O

Mortality	O
(	O
n	O
=	O
9	O
)	O
was	O
higher	O
when	O
F304S	B-DNAMutation
was	O
present	O
(	O
n	O
=	O
6	O
)	O
.	O

Severely	O
affected	O
patients	O
with	O
the	O
PMM2	B-DNAMutation
mutations	O
F119L/R141H	B-DNAMutation
(	O
n	O
=	O
22	O
)	O
carry	O
the	O
F304S	B-DNAMutation
mutation	O
more	O
often	O
(0.36)	O
than	O
mildly	O
affected	O
patients	O
(	O
0.18	O
,	O
n	O
=	O
11	O
)	O
with	O
this	O
mutation	O
.	O

Clinical	O
severity	O
of	O
mildly	O
affected	O
sibs	O
with	O
the	O
same	O
PMM2	B-DNAMutation
mutations	O
did	O
not	O
correlate	O
with	O
F304S	B-DNAMutation
genotype	O
.	O

Thus	O
,	O
the	O
presence	O
of	O
the	O
F304S	B-DNAMutation
allele	O
may	O
exacerbate	O
the	O
clinical	O
outcome	O
,	O
especially	O
in	O
severely	O
affected	O
CDG	O
patients	O
.	O

We	O
speculate	O
that	O
this	O
type	O
of	O
variant	O
may	O
be	O
implicated	O
in	O
other	O
multi-factorial	O
disorders	O
that	O
involve	O
N-glycosylation	O
.	O

O-linked	O
N-acetylglucosamine	O
modification	O
on	O
CCAAT	B-DNAMutation
enhancer-binding	I-DNAMutation
protein	I-DNAMutation
beta	I-DNAMutation
:	O
role	O
during	O
adipocyte	O
differentiation	O
.	O

CCAAT	O
enhancer-binding	O
protein	O
(C/EBP)beta	B-DNAMutation
is	O
a	O
basic	O
leucine	O
zipper	O
transcription	O
factor	O
family	O
member	O
,	O
and	O
can	O
be	O
phosphorylated	O
,	O
acetylated	O
,	O
and	O
sumoylated	O
.	O

C/EBPbeta	B-DNAMutation
undergoes	O
sequential	O
phosphorylation	O
during	O
3T3-L1	O
adipocyte	O
differentiation	O
.	O

Phosphorylation	O
on	O
Thr(188)	O
by	O
MAPK	O
or	O
cyclin	B-DNAMutation
A/cdk2	I-DNAMutation
primes	O
the	O
phosphorylations	O
on	O
Ser(184)/Thr(179)	O
by	O
GSK3beta	B-DNAMutation
,	O
and	O
these	O
phosphorylations	O
are	O
required	O
for	O
the	O
acquisition	O
of	O
DNA	O
binding	O
activity	O
of	O
C/EBPbeta	B-DNAMutation
.	O

Here	O
we	O
show	O
that	O
C/EBPbeta	B-DNAMutation
is	O
modified	O
by	O
O-GlcNAc	O
,	O
a	O
dynamic	O
single	O
sugar	O
modification	O
found	O
on	O
nucleocytoplasmic	O
proteins	O
.	O

The	O
GlcNAcylation	O
sites	O
are	O
Ser(180)	O
and	O
Ser(181)	O
,	O
which	O
are	O
in	O
the	O
regulation	O
domain	O
and	O
are	O
very	O
close	O
to	O
the	O
phosphorylation	O
sites	O
(	O
Thr(188	O
)	O
,	O
Ser(184)	O
,	O
and	O
Thr(179)	O
)	O
required	O
for	O
the	O
gain	O
of	O
DNA	O
binding	O
activity	O
.	O

Both	O
in	O
vitro	O
and	O
ex	O
vivo	O
experiments	O
demonstrate	O
that	O
GlcNAcylation	O
on	O
Ser(180)	O
and	O
Ser(181)	O
prevents	O
phosphorylation	O
on	O
Thr(188)	O
,	O
Ser(184)	O
,	O
and	O
Thr(179)	O
,	O
as	O
indicated	O
by	O
the	O
decreased	O
relative	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
C/EBPbeta	B-DNAMutation
delayed	O
the	O
adipocyte	O
differentiation	O
program	O
.	O

Mutation	O
of	O
both	O
Ser(180)	B-DNAMutation
and	I-DNAMutation
Ser(181)	I-DNAMutation
to	I-DNAMutation
Ala	I-DNAMutation
significantly	O
increase	O
the	O
transcriptional	O
activity	O
of	O
C/EBPbeta	B-DNAMutation
.	O

These	O
data	O
suggest	O
that	O
GlcNAcylation	O
regulates	O
both	O
the	O
phosphorylation	O
and	O
DNA	O
binding	O
activity	O
of	O
C/EBPbeta	B-DNAMutation
.	O

A	O
novel	O
GJA3	B-DNAMutation
mutation	O
associated	O
with	O
congenital	O
nuclear	O
pulverulent	O
and	O
posterior	O
polar	O
cataract	O
in	O
a	O
Chinese	O
family	O
.	O

Congenital	O
cataract	O
(CC)	O
is	O
the	O
leading	O
cause	O
of	O
visual	O
disability	O
in	O
children	O
.	O

To	O
date	O
,	O
mutations	O
in	O
many	O
genes	O
have	O
been	O
linked	O
to	O
CC	O
.	O

In	O
a	O
four-generation	O
Chinese	O
family	O
with	O
congenital	O
nuclear	O
pulverulent	O
and	O
posterior	O
polar	O
cataracts	O
,	O
we	O
detected	O
a	O
heterozygous	O
c.5G>A	B-DNAMutation
transition	O
in	O
the	O
second	O
exon	O
of	O
GJA3	B-DNAMutation
,	O
resulting	O
in	O
the	O
substitution	O
of	O
a	O
highly	O
conserved	O
glycine	O
with	O
aspartic	O
acid	O
p.G2D	B-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
N-terminus	I-DNAMutation
of	O
the	O
connexin46	B-DNAMutation
Cx46	B-DNAMutation
protein	O
.	O

Wild	O
type	O
(wt)	O
and	O
mutant	O
Cx46	B-DNAMutation
plasmids	O
were	O
transfected	O
into	O
HeLa	O
cells	O
to	O
examine	O
the	O
molecular	O
basis	O
of	O
cataract	O
formation	O
.	O

Unlike	O
wt	O
Cx46	B-DNAMutation
,	O
Cx46G2D	B-DNAMutation
mutant	O
formed	O
gap	O
junction	O
plaques	O
inefficiently	O
,	O
changed	O
hemichannel	O
permeability	O
,	O
and	O
caused	O
apoptosis	O
.	O

These	O
results	O
suggest	O
that	O
the	O
glycine	O
residue	O
at	O
the	O
second	O
position	O
of	O
the	O
N-terminus	O
is	O
important	O
for	O
gap	O
junction	O
plaque	O
formation	O
and	O
hemichannel	O
function	O
.	O

Mutations	O
alter	O
secretion	O
of	O
fukutin-related	B-DNAMutation
protein	I-DNAMutation
.	O

Mutations	O
in	O
the	O
fukutin-related	B-DNAMutation
protein	I-DNAMutation
FKRP	B-DNAMutation
gene	O
cause	O
limb-girdle	O
muscular	O
dystrophy	O
type	O
2I	O
LGMD2I	B-DNAMutation
as	O
well	O
as	O
other	O
severe	O
muscle	O
disorders	O
,	O
including	O
Walker-Warburg	O
syndrome	O
,	O
muscle-eye-brain	O
disease	O
,	O
and	O
congenital	O
muscular	O
dystrophy	O
type	O
1C	O
.	O

The	O
FKRP	B-DNAMutation
gene	O
encodes	O
a	O
putative	O
glycosyltransferase	O
,	O
but	O
its	O
precise	O
localization	O
and	O
functions	O
have	O
yet	O
to	O
be	O
determined	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
demonstrated	O
that	O
normal	O
FKRP	B-DNAMutation
is	O
secreted	O
into	O
culture	O
medium	O
and	O
mutations	O
alter	O
the	O
pattern	O
of	O
secretion	O
in	O
CHO	O
cells	O
.	O

L276I	B-DNAMutation
mutation	O
associated	O
with	O
mild	O
disease	O
phenotype	O
was	O
shown	O
to	O
reduce	O
the	O
level	O
of	O
secretion	O
whereas	O
P448L	B-DNAMutation
and	O
C318Y	B-DNAMutation
mutations	O
associated	O
with	O
severe	O
disease	O
phenotype	O
almost	O
abolished	O
the	O
secretion	O
.	O

However	O
,	O
a	O
truncated	O
FKRP	B-DNAMutation
mutant	O
protein	O
lacking	B-DNAMutation
the	I-DNAMutation
entire	I-DNAMutation
C-terminal	I-DNAMutation
185	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
due	O
to	O
the	O
E310X	B-DNAMutation
nonsense	O
mutation	O
was	O
able	O
to	O
secrete	O
as	O
efficiently	O
as	O
the	O
normal	O
FKRP	B-DNAMutation
.	O

The	O
N-terminal	O
signal	O
peptide	O
sequence	O
is	O
apparently	O
cleaved	O
from	O
the	O
secreted	O
FKRP	B-DNAMutation
proteins	O
.	O

Alteration	O
of	O
the	O
secretion	O
pathway	O
by	O
different	O
mutations	O
and	O
spontaneous	O
read-through	O
of	O
nonsense	O
mutation	O
may	O
contribute	O
to	O
wide	O
variations	O
in	O
phenotypes	O
associated	O
with	O
FKRP-related	B-DNAMutation
diseases	O
.	O

Deficiency	O
of	O
GDP-Man:GlcNAc2-PP-dolichol	O
mannosyltransferase	O
causes	O
congenital	O
disorder	O
of	O
glycosylation	O
type	O
Ik	O
.	O

The	O
molecular	O
nature	O
of	O
a	O
severe	O
multisystemic	O
disorder	O
with	O
a	O
recurrent	O
nonimmune	O
hydrops	O
fetalis	O
was	O
identified	O
as	O
deficiency	O
of	O
GDP-Man:GlcNAc(2)-PP-dolichol	O
mannosyltransferase	O
,	O
the	O
human	O
orthologue	O
of	O
the	O
yeast	O
ALG1	O
gene	O
(	O
MIM	O
605907	O
)	O
.	O

The	O
disease	O
belongs	O
to	O
the	O
group	O
of	O
congenital	O
disorders	O
of	O
glycosylation	O
(CDG)	O
and	O
is	O
designated	O
as	O
subtype	O
CDG-Ik	O
.	O

In	O
patient-derived	O
serum	O
,	O
the	O
total	O
amount	O
of	O
the	O
glycoprotein	O
transferrin	O
was	O
reduced	O
.	O

Moreover	O
,	O
a	O
partial	O
loss	O
of	O
N-glycan	O
chains	O
was	O
observed	O
,	O
a	O
characteristic	O
feature	O
of	O
CDG	O
type	O
I	O
forms	O
.	O

Metabolic	O
labeling	O
with	O
[6-(3)H]glucosamine	O
revealed	O
an	O
accumulation	O
of	O
GlcNAc(2)-PP-dolichol	O
and	O
GlcNAc(1)-PP-dolichol	O
in	O
skin	O
fibroblasts	O
of	O
the	O
patient	O
.	O

Incubation	O
of	O
fibroblast	O
extracts	O
with	O
[(14)C]GlcNAc(2)-PP-dolichol	O
and	O
GDP-mannose	O
indicated	O
a	O
severely	O
reduced	O
activity	O
of	O
the	O
beta	B-DNAMutation
1,4-mannosyltransferase	I-DNAMutation
,	O
elongating	O
GlcNAc(2)-PP-dolichol	O
to	O
Man(1)GlcNAc(2)-PP-dolichol	O
at	O
the	O
cytosolic	O
side	O
of	O
the	O
endoplasmic	O
reticulum	O
.	O

Genetic	O
analysis	O
of	O
the	O
patient's	O
hALG1	O
gene	O
identified	O
a	O
homozygous	O
mutation	O
leading	O
to	O
the	O
exchange	O
of	O
a	O
serine	B-DNAMutation
residue	I-DNAMutation
to	I-DNAMutation
leucine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
258	I-DNAMutation
in	O
the	O
hALG1	O
protein	O
.	O

The	O
disease-causing	O
nature	O
of	O
the	O
hALG1	O
mutation	O
for	O
the	O
glycosylation	O
defect	O
was	O
verified	O
by	O
a	O
retroviral	O
complementation	O
approach	O
in	O
patient-derived	O
primary	O
fibroblasts	O
and	O
was	O
confirmed	O
by	O
the	O
expression	O
of	O
wild-type	O
and	O
mutant	O
hALG1	O
in	O
the	O
Saccharomyces	O
cerevisiae	O
alg1-1	B-DNAMutation
strain	O
.	O

Characterization	O
of	O
beta-glucan	O
recognition	O
site	O
on	O
C-type	O
lectin	O
,	O
dectin	B-DNAMutation
1	I-DNAMutation
.	O

Dectin	B-DNAMutation
1	I-DNAMutation
is	O
a	O
mammalian	O
cell	O
surface	O
receptor	O
for	O
(1-->3)-beta-d-glucans	O
.	O

Since	O
(1-->3)-beta-d-glucans	O
are	O
commonly	O
present	O
on	O
fungal	O
cell	O
walls	O
,	O
it	O
has	O
been	O
suggested	O
that	O
dectin	B-DNAMutation
1	I-DNAMutation
is	O
important	O
for	O
recognizing	O
fungal	O
invasion	O
.	O

In	O
this	O
study	O
we	O
tried	O
to	O
deduce	O
the	O
amino	O
acid	O
residues	O
in	O
dectin	B-DNAMutation
1	I-DNAMutation
responsible	O
for	O
beta-glucan	O
recognition	O
.	O

HEK293	O
cells	O
transfected	O
with	O
mouse	O
dectin	B-DNAMutation
1	I-DNAMutation
cDNA	O
could	O
bind	O
to	O
a	O
gel-forming	O
(1-->3)-beta-d-glucan	O
,	O
schizophyllan	O
(SPG)	O
.	O

The	O
binding	O
of	O
SPG	B-DNAMutation
to	O
a	O
dectin	B-DNAMutation
1	I-DNAMutation
transfectant	O
was	O
inhibited	O
by	O
pretreatment	O
with	O
other	O
beta-glucans	O
having	O
a	O
(1-->3)-beta-d-glucosyl	O
linkage	O
but	O
not	O
by	O
pretreatment	O
with	O
alpha-glucans	O
.	O

Dectin	B-DNAMutation
1	I-DNAMutation
has	O
a	O
carbohydrate	O
recognition	O
domain	O
(CRD)	O
consisting	O
of	O
six	O
cysteine	O
residues	O
that	O
are	O
highly	O
conserved	O
in	O
C-type	O
lectins	O
.	O

We	O
prepared	O
32	O
point	O
mutants	O
with	O
mutations	O
in	O
the	O
CRD	O
and	O
analyzed	O
their	O
binding	O
to	O
SPG	B-DNAMutation
.	O

Mutations	B-DNAMutation
at	I-DNAMutation
Trp(221)	I-DNAMutation
and	I-DNAMutation
His(223)	I-DNAMutation
resulted	O
in	O
decreased	O
binding	O
to	O
beta-glucan	O
.	O

Monoclonal	O
antibody	O
4B2	O
,	O
a	O
dectin-	O
1	O
monoclonal	O
antibody	O
which	O
had	O
a	O
blocking	O
effect	O
on	O
the	O
beta-glucan	O
interaction	O
,	O
completely	O
failed	O
to	O
bind	O
the	O
dectin-1	B-DNAMutation
mutant	O
W221A	B-DNAMutation
.	O

A	O
mutant	O
with	O
mutations	B-DNAMutation
in	I-DNAMutation
Trp(221)	I-DNAMutation
and	I-DNAMutation
His(223)	I-DNAMutation
did	O
not	O
have	O
a	O
collaborative	O
effect	O
on	O
Toll-like	B-DNAMutation
receptor	I-DNAMutation
2-mediated	I-DNAMutation
cellular	O
activation	O
in	O
response	O
to	O
zymosan	O
.	O

These	O
amino	O
acid	O
residues	O
are	O
distinct	O
from	O
residues	O
in	O
other	O
sugar-recognizing	O
peptide	O
sequences	O
of	O
typical	O
C-type	O
lectins	O
.	O

These	O
results	O
suggest	O
that	O
the	O
amino	O
acid	O
sequence	O
W221-I222-H223	O
is	O
critical	O
for	O
formation	O
of	O
a	O
beta-glucan	O
binding	O
site	O
in	O
the	O
CRD	O
of	O
dectin	B-DNAMutation
1	I-DNAMutation
.	O

Site-directed	O
mutagenesis	O
and	O
continuous	O
expression	O
of	O
human	O
beta-adrenergic	O
receptors	O
.	O

Identification	O
of	O
a	O
conserved	O
aspartate	O
residue	O
involved	O
in	O
agonist	O
binding	O
and	O
receptor	O
activation	O
.	O

Using	O
a	O
new	O
expression	O
vector	O
that	O
allows	O
stable	O
and	O
steroid	O
inducible	O
expression	O
of	O
the	O
human	O
beta	B-DNAMutation
2-adrenergic	I-DNAMutation
receptor	I-DNAMutation
in	O
mouse	O
L	O
cells	O
,	O
we	O
have	O
examined	O
the	O
functional	O
significance	O
of	O
the	O
highly	O
conserved	O
aspartate	O
residue	O
in	O
the	O
putative	O
second	O
transmembrane	O
region	O
of	O
the	O
receptor	O
.	O

Substitution	B-DNAMutation
of	I-DNAMutation
aspartate	I-DNAMutation
79	I-DNAMutation
with	I-DNAMutation
asparagine	I-DNAMutation
produced	O
a	O
mutant	O
receptor	O
that	O
displays	O
the	O
expected	O
affinity	O
and	O
stereoselectivity	O
for	O
antagonists	O
but	O
a	O
40-	O
,	O
140-	O
,	O
and	O
240-fold	O
reduction	O
in	O
its	O
affinity	O
for	O
isoproterenol	O
,	O
epinephrine	O
,	O
and	O
norepinephrine	O
,	O
respectively	O
.	O

This	O
receptor	O
mutant	O
does	O
not	O
display	O
guanine	O
nucleotide-sensitive	O
high	O
affinity	O
binding	O
of	O
agonists	O
.	O

Addition	O
of	O
saturating	O
concentrations	O
of	O
isoproterenol	O
to	O
cell	O
cultures	O
expressing	O
the	O
mutant	O
receptor	O
produces	O
a	O
slight	O
,	O
albeit	O
significant	O
,	O
increase	O
in	O
intracellular	O
levels	O
of	O
cyclic	O
AMP	B-DNAMutation
as	O
compared	O
to	O
cells	O
expressing	O
wild	O
type	O
receptor	O
.	O

These	O
observations	O
demonstrate	O
that	O
substitution	B-DNAMutation
of	I-DNAMutation
aspartate	I-DNAMutation
with	I-DNAMutation
asparagine	I-DNAMutation
at	I-DNAMutation
residue	I-DNAMutation
79	I-DNAMutation
in	O
the	O
human	O
beta-adrenergic	B-DNAMutation
receptor	I-DNAMutation
differentially	O
affects	O
the	O
binding	O
of	O
catecholamines	O
and	O
produces	O
a	O
functional	O
uncoupling	O
of	O
receptors	O
and	O
stimulatory	O
guanine	O
nucleotide	O
regulatory	O
proteins	O
(Gs)	O
.	O

These	O
data	O
are	O
consistent	O
with	O
a	O
role	O
for	O
aspartate	O
79	O
as	O
a	O
counterion	O
to	O
the	O
amine	O
in	O
catecholamines	O
and	O
in	O
agonist-induced	O
activation	O
of	O
the	O
beta-adrenergic	B-DNAMutation
receptor	I-DNAMutation
associated	O
with	O
high	O
affinity	O
ligand	O
binding	O
,	O
Gs	O
coupling	O
,	O
and	O
adenylate	O
cyclase	O
stimulation	O
.	O

Activation	O
of	O
signalling	O
by	O
the	O
activin	B-DNAMutation
receptor	I-DNAMutation
complex	O
.	O

Activin	O
exerts	O
its	O
effects	O
by	O
simultaneously	O
binding	O
to	O
two	O
types	O
of	O
p	O
rotein	O
serine/threonine	O
kinase	O
receptors	O
,	O
each	O
type	O
existing	O
in	O
various	O
isoforms	O
.	O

Using	O
the	O
ActR-IB	B-DNAMutation
and	O
ActR-IIB	B-DNAMutation
receptor	O
isoforms	O
,	O
we	O
have	O
investigated	O
the	O
mechanism	O
of	O
activin	B-DNAMutation
receptor	I-DNAMutation
activation	O
.	O

ActR-IIB	B-DNAMutation
are	O
phosphoproteins	O
with	O
demonstrable	O
affinity	O
for	O
each	O
other	O
.	O

However	O
,	O
activin	B-DNAMutation
addition	O
strongly	O
promotes	O
an	O
interaction	O
between	O
these	O
two	O
proteins	O
.	O

Activin	B-DNAMutation
binds	O
directly	O
to	O
ActR-IIB	B-DNAMutation
,	O
and	O
this	O
complex	O
associates	O
with	O
ActR-IB	B-DNAMutation
,	O
which	O
does	O
not	O
bind	O
ligand	O
on	O
its	O
own	O
.	O

In	O
the	O
resulting	O
complex	O
,	O
ActR-IB	B-DNAMutation
becomes	O
hyperphosphorylated	O
,	O
and	O
this	O
requires	O
the	O
kinase	O
activity	O
of	O
ActR-IIB	B-DNAMutation
.	O

Mutation	O
of	O
conserved	O
serines	O
and	O
threonines	O
in	O
the	O
GS	O
domain	O
,	O
a	O
region	O
just	O
upstream	O
of	O
the	O
kinase	O
domain	O
in	O
ActR-IB	B-DNAMutation
,	O
abrogates	O
both	O
phosphorylation	O
and	O
signal	O
propagation	O
,	O
suggesting	O
that	O
this	O
domain	O
contains	O
phosphorylation	O
sites	O
required	O
for	O
signalling	O
.	O

ActR-IB	B-DNAMutation
activation	O
can	O
be	O
mimicked	O
by	O
mutation	B-DNAMutation
of	I-DNAMutation
Thr-206	I-DNAMutation
to	I-DNAMutation
aspartic	I-DNAMutation
acid	I-DNAMutation
,	O
which	O
yields	O
a	O
construct	O
,	O
ActR-IB(T206D)	B-DNAMutation
,	O
that	O
signals	O
in	O
the	O
absence	O
of	O
ligand	O
.	O

Furthermore	O
,	O
the	O
signalling	O
activity	O
of	O
this	O
mutant	O
construct	O
is	O
undisturbed	O
by	O
overexpression	O
of	O
a	O
dominant	O
negative	O
kinase-defective	O
ActR-IIB	B-DNAMutation
construct	O
,	O
indicating	O
that	O
ActR-IB(T206D)	B-DNAMutation
can	O
signal	O
independently	O
of	O
ActR-IIB	B-DNAMutation
.	O

The	O
evidence	O
suggests	O
that	O
ActR-IIB	B-DNAMutation
acts	O
as	O
a	O
primary	O
activin	B-DNAMutation
receptor	I-DNAMutation
and	O
ActR-IB	B-DNAMutation
acts	O
as	O
a	O
downstream	O
transducer	O
of	O
activin	B-DNAMutation
signals	O
.	O

Mutation	O
of	O
tyrosine-141	O
inhibits	O
insulin-promoted	B-DNAMutation
tyrosine	O
phosphorylation	O
and	O
increased	O
responsiveness	O
of	O
the	O
human	O
beta	B-DNAMutation
2-adrenergic	I-DNAMutation
receptor	I-DNAMutation
.	O

The	O
ability	O
of	O
insulin	B-DNAMutation
to	O
promote	O
phosphorylation	O
of	O
the	O
human	O
beta	B-DNAMutation
2-adrenergic	I-DNAMutation
receptor	I-DNAMutation
(	O
beta	B-DNAMutation
2AR	I-DNAMutation
)	O
was	O
assessed	O
in	O
Chinese	O
hamster	O
fibroblasts	O
transfected	O
with	O
beta	O
2AR	O
cDNA	O
.	O

Phosphotyrosine	O
residues	O
were	O
detected	O
in	O
purified	O
beta	B-DNAMutation
2AR	I-DNAMutation
using	O
a	O
polyclonal	O
anti-phosphotyrosine	O
antibody	O
and	O
by	O
phosphoamino	O
acid	O
analysis	O
following	O
metabolic	O
labelling	O
with	O
inorganic	O
32P	O
.	O

Treatment	O
of	O
the	O
cells	O
with	O
insulin	B-DNAMutation
induced	O
a	O
2.4-fold	O
increase	O
in	O
the	O
phosphotyrosine	O
content	O
of	O
the	O
receptor	O
.	O

The	O
insulin-promoted	B-DNAMutation
phosphorylation	O
of	O
the	O
beta	B-DNAMutation
2AR	I-DNAMutation
was	O
accompanied	O
by	O
an	O
increase	O
in	O
the	O
beta-adrenergic-stimulated	O
adenyl	O
cyclase	O
activity	O
.	O

Substitution	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
phenylalanine	I-DNAMutation
residue	I-DNAMutation
for	I-DNAMutation
tyrosine-141	I-DNAMutation
completely	O
prevented	O
both	O
the	O
increased	O
tyrosine	O
phosphorylation	O
and	O
the	O
enhanced	O
responsiveness	O
of	O
the	O
beta	B-DNAMutation
2AR	I-DNAMutation
promoted	O
by	O
insulin	B-DNAMutation
treatment	O
.	O

Mutation	O
of	O
three	O
other	O
tyrosines	O
located	O
in	O
the	O
cytoplasmic	O
domain	O
of	O
the	O
receptor	O
,	O
tyrosine-366	O
,	O
tyrosine-350	O
and	O
tyrosine-354	O
,	O
did	O
not	O
abolish	O
the	O
insulin-promoted	B-DNAMutation
tyrosine	O
phosphorylation	O
.	O

Taken	O
together	O
,	O
these	O
results	O
suggest	O
that	O
insulin	B-DNAMutation
promotes	O
phosphorylation	O
of	O
the	O
beta	B-DNAMutation
2AR	I-DNAMutation
on	O
tyrosine-141	O
and	O
that	O
such	O
phosphorylation	O
leads	O
to	O
a	O
supersensitization	O
of	O
the	O
receptor	O
.	O

Demonstration	O
by	O
transfection	O
studies	O
that	O
mutations	O
in	O
the	O
adrenocorticotropin	B-DNAMutation
receptor	I-DNAMutation
gene	O
are	O
one	O
cause	O
of	O
the	O
hereditary	O
syndrome	O
of	O
glucocorticoid	O
deficiency	O
.	O

The	O
hereditary	O
syndrome	O
of	O
unresponsiveness	O
to	O
ACTH	B-DNAMutation
is	O
a	O
rare	O
autosomal	O
recessive	O
disorder	O
characterized	O
by	O
low	O
levels	O
of	O
serum	O
cortisol	O
and	O
high	O
levels	O
of	O
plasma	O
ACTH	B-DNAMutation
.	O

There	O
is	O
no	O
cortisol	O
response	O
to	O
exogenous	O
ACTH	B-DNAMutation
.	O

Recent	O
cloning	O
of	O
the	O
human	O
ACTH	B-DNAMutation
receptor	I-DNAMutation
gene	O
has	O
enabled	O
us	O
to	O
study	O
this	O
gene	O
in	O
patients	O
with	O
glucocorticoid	O
deficiency	O
.	O

By	O
using	O
the	O
PCR	O
to	O
amplify	O
the	O
coding	O
sequence	O
of	O
the	O
ACTH	B-DNAMutation
receptor	I-DNAMutation
gene	O
,	O
we	O
identified	O
three	O
mutations	O
in	O
two	O
unrelated	O
patients	O
.	O

One	O
mutation	O
present	O
in	O
homozygous	O
form	O
converted	B-DNAMutation
the	I-DNAMutation
negatively	I-DNAMutation
charged	I-DNAMutation
Asp107	I-DNAMutation
,	I-DNAMutation
located	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
third	I-DNAMutation
transmembrane	I-DNAMutation
domain	I-DNAMutation
,	I-DNAMutation
to	I-DNAMutation
an	I-DNAMutation
uncharged	I-DNAMutation
Asn	I-DNAMutation
residue	I-DNAMutation
.	O

The	O
second	O
patient	O
was	O
a	O
compound	O
heterozygote	O
:	O
the	O
paternal	O
allele	O
contained	O
a	O
one-nucleotide	O
insertion	O
leading	O
to	O
a	O
stop	O
codon	O
within	O
the	O
third	O
extracellular	O
loop	O
,	O
and	O
the	O
maternal	B-DNAMutation
allele	I-DNAMutation
contained	I-DNAMutation
a	I-DNAMutation
point	I-DNAMutation
mutation	I-DNAMutation
converting	I-DNAMutation
Cys251	I-DNAMutation
to	I-DNAMutation
Phe	I-DNAMutation
,	O
also	O
in	O
the	O
third	O
extracellular	O
loop	O
.	O

Normal	O
and	O
mutant	O
ACTH	B-DNAMutation
receptor	I-DNAMutation
genes	O
were	O
expressed	O
in	O
the	O
M3	O
cell	O
line	O
,	O
and	O
intracellular	O
cAMP	O
production	O
in	O
response	O
to	O
ACTH	B-DNAMutation
was	O
measured	O
.	O

For	O
the	O
mutant	O
receptors	O
,	O
no	O
response	O
to	O
physiological	O
ACTH	B-DNAMutation
concentrations	O
was	O
detected	O
,	O
suggesting	O
an	O
impaired	O
binding	O
of	O
ACTH	B-DNAMutation
to	O
the	O
receptors	O
and/or	O
an	O
altered	O
coupling	O
to	O
the	O
adenylate	O
cyclase	O
effector	O
.	O

Identification	O
of	O
a	O
mutation	O
in	O
the	O
MP19	B-DNAMutation
gene	O
,	O
Lim2	B-DNAMutation
,	O
in	O
the	O
cataractous	O
mouse	O
mutant	O
To3	B-DNAMutation
.	O

PURPOSE	O
:	O
Lim2	B-DNAMutation
,	O
the	O
gene	O
encoding	O
the	O
second	O
most	O
abundant	O
lens	O
specific	O
integral	O
membrane	O
protein	O
,	O
MP19	B-DNAMutation
,	O
has	O
recently	O
been	O
proposed	O
as	O
an	O
ideal	O
candidate	O
gene	O
for	O
the	O
cataractous	O
mouse	O
mutant	O
,	O
To3	B-DNAMutation
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
screen	O
the	O
Lim2	B-DNAMutation
gene	O
in	O
the	O
To3	B-DNAMutation
mutant	O
for	O
a	O
genetic	O
lesion	O
that	O
was	O
correlated	O
and	O
consistent	O
with	O
the	O
mutant	O
phenotype	O
.	O

METHODS	O
:	O
Genomic	O
DNA	O
was	O
isolated	O
from	O
both	O
normal	O
mouse	O
parental	O
strains	O
as	O
well	O
as	O
the	O
heterozygous	O
and	O
homozygous	O
To3	B-DNAMutation
cataract	O
mutant	O
.	O

PCR	O
was	O
used	O
to	O
generate	O
overlapping	O
fragments	O
of	O
the	O
entire	O
Lim2	B-DNAMutation
gene	O
from	O
these	O
DNAs	O
.	O

The	O
coding	O
regions	O
,	O
including	O
splice	O
junctions	O
and	O
the	O
translational	O
termination	O
site	O
,	O
of	O
these	O
fragments	O
were	O
then	O
sequenced	O
.	O

RESULTS	O
:	O
A	O
single	O
G	B-DNAMutation
->	I-DNAMutation
T	I-DNAMutation
transversion	I-DNAMutation
was	I-DNAMutation
identified	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
first	I-DNAMutation
coding	I-DNAMutation
exon	I-DNAMutation
of	O
the	O
Lim2	B-DNAMutation
gene	O
in	O
the	O
To3	B-DNAMutation
mutant	O
DNA	O
.	O

This	O
DNA	O
change	O
results	O
in	O
the	O
nonconservative	B-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
valine	I-DNAMutation
for	I-DNAMutation
the	I-DNAMutation
normally	I-DNAMutation
encoded	I-DNAMutation
glycine	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
15	I-DNAMutation
of	O
the	O
MP19	B-DNAMutation
polypeptide	O
.	O

CONCLUSIONS	O
:	O
The	O
identified	O
genetic	O
lesion	O
in	O
the	O
Lim2	B-DNAMutation
gene	O
of	O
the	O
cataractous	O
mouse	O
mutant	O
,	O
To3	B-DNAMutation
,	O
confirms	O
Lim2	B-DNAMutation
as	O
an	O
ideal	O
candidate	O
gene	O
.	O

Future	O
transgenic	O
experiments	O
should	O
provide	O
proof	O
or	O
disproof	O
of	O
a	O
causative	O
relationship	O
between	O
the	O
identified	O
mutation	O
and	O
the	O
cataractous	O
phenotype	O
.	O

These	O
studies	O
indicate	O
that	O
MP19	B-DNAMutation
may	O
play	O
an	O
important	O
role	O
in	O
both	O
normal	O
lens	O
development	O
and	O
cataractogenesis	O
,	O
and	O
warrants	O
more	O
intense	O
investigation	O
of	O
its	O
role	O
within	O
the	O
ocular	O
lens	O
.	O

Disruption	O
of	O
Toxoplasma	O
gondii	O
parasitophorous	O
vacuoles	O
by	O
the	O
mouse	O
p47-resistance	B-DNAMutation
GTPases	O
.	O

The	O
p47	O
GTPases	O
are	O
essential	O
for	O
interferon-gamma-induced	O
cell-autonomous	O
immunity	O
against	O
the	O
protozoan	O
parasite	O
,	O
Toxoplasma	O
gondii	O
,	O
in	O
mice	O
,	O
but	O
the	O
mechanism	O
of	O
resistance	O
is	O
poorly	O
understood	O
.	O

We	O
show	O
that	O
the	O
p47	O
GTPases	O
,	O
including	O
IIGP1	O
,	O
accumulate	O
at	O
vacuoles	O
containing	O
T	O
.	O

gondii	O
.	O

The	O
accumulation	O
is	O
GTP-dependent	O
and	O
requires	O
live	O
parasites	O
.	O

Vacuolar	O
IIGP1	O
accumulations	O
undergo	O
a	O
maturation-like	O
process	O
accompanied	O
by	O
vesiculation	O
of	O
the	O
parasitophorous	O
vacuole	O
membrane	O
.	O

This	O
culminates	O
in	O
disruption	O
of	O
the	O
parasitophorous	O
vacuole	O
and	O
finally	O
of	O
the	O
parasite	O
itself	O
.	O

Over-expression	O
of	O
IIGP1	O
leads	O
to	O
accelerated	O
vacuolar	O
disruption	O
whereas	O
a	O
dominant	O
negative	O
form	O
of	O
IIGP1	O
interferes	O
with	O
interferon-gamma-mediated	O
killing	O
of	O
intracellular	O
parasites	O
.	O

Targeted	O
deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
IIGP1	O
gene	O
results	O
in	O
partial	O
loss	O
of	O
the	O
IFN-gamma-mediated	O
T	O
.	O

gondii	O
growth	O
restriction	O
in	O
mouse	O
astrocytes	O
.	O

A	O
mutation	O
in	O
the	O
human	O
ortholog	O
of	O
the	O
Saccharomyces	O
cerevisiae	O
ALG6	B-DNAMutation
gene	O
causes	O
carbohydrate-deficient	O
glycoprotein	O
syndrome	O
type-Ic	O
.	O

Carbohydrate-deficient	O
glycoprotein	O
syndrome	O
(CDGS)	O
represents	O
a	O
class	O
of	O
genetic	O
diseases	O
characterized	O
by	O
abnormal	O
N-linked	O
glycosylation	O
.	O

CDGS	O
patients	O
show	O
a	O
large	O
number	O
of	O
glycoprotein	O
abnormalities	O
resulting	O
in	O
dysmorphy	O
,	O
encephalopathy	O
,	O
and	O
other	O
organ	O
disorders	O
.	O

The	O
majority	O
of	O
CDGSs	O
described	O
to	O
date	O
are	O
related	O
to	O
an	O
impaired	O
biosynthesis	O
of	O
dolichyl	O
pyrophosphate-linked	O
Glc3Man9GlcNAc2	O
in	O
the	O
endoplasmic	O
reticulum	O
.	O

Recently	O
,	O
we	O
identified	O
in	O
four	O
related	O
patients	O
a	O
novel	O
type	O
of	O
CDGS	O
characterized	O
by	O
an	O
accumulation	O
of	O
dolichyl	O
pyrophosphate-linked	O
Man9GlcNAc2	O
.	O

Elaborating	O
on	O
the	O
analogy	O
of	O
this	O
finding	O
with	O
the	O
phenotype	O
of	O
alg5	B-DNAMutation
and	O
alg6	B-DNAMutation
Saccharomyces	O
cerevisiae	O
strains	O
,	O
we	O
have	O
cloned	O
and	O
analyzed	O
the	O
human	O
orthologs	O
to	O
the	O
ALG5	O
dolichyl	O
phosphate	O
glucosyltransferase	O
and	O
ALG6	B-DNAMutation
dolichyl	O
pyrophosphate	O
Man9GlcNAc2	O
alpha1,3-glucosyltransferase	O
in	O
four	O
novel	O
CDGS	O
patients	O
.	O

Although	O
ALG5	B-DNAMutation
was	O
not	O
altered	O
in	O
the	O
patients	O
,	O
a	O
C-->T	B-DNAMutation
transition	I-DNAMutation
was	O
detected	O
in	O
ALG6	B-DNAMutation
cDNA	O
of	O
all	O
four	O
CDGS	O
patients	O
.	O

The	O
mutation	O
cosegregated	O
with	O
the	O
disease	O
in	O
a	O
Mendelian	O
recessive	O
manner	O
.	O

Expression	O
of	O
the	O
human	O
ALG5	B-DNAMutation
and	O
ALG6	B-DNAMutation
cDNA	O
could	O
partially	O
complement	O
the	O
respective	O
S	O
.	O

cerevisiae	O
alg5	B-DNAMutation
and	O
alg6	B-DNAMutation
deficiency	O
.	O

By	O
contrast	O
,	O
the	O
mutant	O
ALG6	B-DNAMutation
cDNA	O
of	O
CDGS	O
patients	O
failed	O
to	O
revert	O
the	O
hypoglycosylation	O
observed	O
in	O
alg6	B-DNAMutation
yeasts	O
,	O
thereby	O
proving	O
a	O
functional	O
relationship	O
between	O
the	O
alanine	B-DNAMutation
to	I-DNAMutation
valine	I-DNAMutation
substitution	I-DNAMutation
introduced	O
by	O
the	O
C-->T	B-DNAMutation
transition	I-DNAMutation
and	O
the	O
CDGS	O
phenotype	O
.	O

The	O
mutation	O
in	O
the	O
ALG6	B-DNAMutation
alpha1,3-glucosyltransferase	I-DNAMutation
gene	O
defines	O
an	O
additional	O
type	O
of	O
CDGS	O
,	O
which	O
we	O
propose	O
to	O
refer	O
to	O
as	O
CDGS	O
type-Ic	O
.	O

Clinical	O
characteristics	O
in	O
a	O
kindred	O
with	O
early-onset	O
Alzheimer's	O
disease	O
and	O
their	O
linkage	O
to	O
a	O
G-->T	B-DNAMutation
change	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2149	I-DNAMutation
of	O
the	O
amyloid	O
precursor	O
protein	O
gene	O
.	O

Patients	O
from	O
five	O
generations	O
of	O
a	O
family	O
developed	O
presenile	O
Alzheimer's	O
disease	O
(AD)	O
early	O
in	O
the	O
fifth	O
decade	O
.	O

Recent	O
memory	O
,	O
information-processing	O
speed	O
,	O
sequential	O
tracking	O
,	O
and	O
conceptual	O
reasoning	O
were	O
the	O
earliest	O
cognitive	O
functions	O
affected	O
.	O

Language	O
and	O
visuoperceptual	O
skills	O
were	O
largely	O
spared	O
early	O
in	O
the	O
course	O
of	O
the	O
disease	O
.	O

Later	O
,	O
there	O
were	O
progressive	O
cognitive	O
deficits	O
and	O
inability	O
to	O
perform	O
the	O
activities	O
of	O
daily	O
living	O
.	O

Death	O
occurred	O
,	O
on	O
average	O
,	O
6	O
years	O
after	O
onset	O
.	O

Three	O
autopsies	O
in	O
affected	O
members	O
revealed	O
cerebral	O
amyloid	O
deposits	O
and	O
neurofibrillary	O
tangles	O
.	O

Clinical	O
and	O
pathologic	O
features	O
were	O
typical	O
for	O
familial	O
AD	O
.	O

Direct	O
DNA	O
sequencing	O
revealed	O
a	O
G-->T	B-DNAMutation
change	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
2149	I-DNAMutation
of	O
the	O
amyloid	B-DNAMutation
precursor	I-DNAMutation
protein	I-DNAMutation
(APP)	I-DNAMutation
gene	O
that	O
resulted	O
in	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
phenylalanine	I-DNAMutation
for	I-DNAMutation
valine	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
transmembrane	I-DNAMutation
domain	I-DNAMutation
of	O
the	O
mature	O
protein	O
.	O

This	O
mutation	O
was	O
present	O
in	O
DNA	O
from	O
all	O
four	O
examined	O
affected	O
individuals	O
and	O
linked	O
to	O
the	O
disease	O
with	O
a	O
lod	O
score	O
of	O
3.25	O
,	O
and	O
was	O
the	O
most	O
probable	O
cause	O
of	O
AD	O
in	O
this	O
family	O
.	O

Molecular	O
basis	O
of	O
congenital	O
adrenal	O
hyperplasia	O
in	O
two	O
siblings	O
with	O
classical	O
nonsalt-losing	O
3	O
beta-hydroxysteroid	O
dehydrogenase	O
deficiency	O
.	O

We	O
report	O
mutations	O
of	O
the	O
type	B-DNAMutation
II	I-DNAMutation
3	I-DNAMutation
beta-hydroxysteroid	I-DNAMutation
dehydrogenase	I-DNAMutation
(	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
)	O
gene	O
in	O
two	O
siblings	O
,	O
male	O
and	O
female	O
,	O
with	O
congenital	O
adrenal	O
hyperplasia	O
caused	O
by	O
classical	O
nonsalt-losing	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
deficiency	O
.	O

During	O
childhood	O
,	O
the	O
male	O
sibling	O
,	O
born	O
with	O
ambiguous	O
genitalia	O
,	O
and	O
the	O
female	O
sibling	O
,	O
born	O
with	O
normal	O
genitalia	O
,	O
both	O
manifested	O
symptoms	O
of	O
mild	O
androgen	O
excess	O
;	O
both	O
apparently	O
had	O
normal	O
zona	O
glomerulosa	O
function	O
.	O

Gonadal	O
dynamic	O
study	O
at	O
puberty	O
showed	O
the	O
presence	O
of	O
partial	O
gonadal	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
deficiency	O
in	O
both	O
siblings	O
despite	O
their	O
spontaneous	O
pubertal	O
maturation	O
.	O

The	O
5'-region	O
as	O
well	O
as	O
exons	O
I-II	O
,	O
III	O
,	O
and	O
IV	O
and	O
portions	O
of	O
the	O
adjacent	O
introns	O
of	O
the	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
gene	O
were	O
amplified	O
by	O
polymerase	O
chain	O
reaction	O
and	O
sequenced	O
.	O

In	O
both	O
siblings	O
and	O
their	O
mother	O
,	O
an	O
identical	O
single	O
nucleotide	O
substitution	O
mutation	O
in	O
intron	O
III	O
,	O
six	O
bases	O
up-stream	O
from	O
exon	O
IV	O
,	O
was	O
identified	O
in	O
one	O
allele	O
.	O

This	O
mutation	O
,	O
G	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
6651	I-DNAMutation
,	O
may	O
create	O
a	O
new	O
splicing	O
junction	O
and	O
affect	O
the	O
normal	O
splicing	O
of	O
the	O
messenger	O
ribonucleic	O
acid	O
.	O

In	O
the	O
other	O
allele	O
of	O
both	O
siblings	O
,	O
a	O
missense	O
mutation	O
from	O
GGG	B-DNAMutation
(Gly)	I-DNAMutation
to	I-DNAMutation
AGG	I-DNAMutation
(Arg)	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
129	I-DNAMutation
G129R	B-DNAMutation
in	O
exon	O
IV	O
was	O
found	O
.	O

We	O
assessed	O
the	O
effect	O
of	O
the	O
G129R	B-DNAMutation
missense	O
mutation	O
on	O
enzymatic	O
activity	O
by	O
in	O
vitro	O
analysis	O
of	O
the	O
mutant	O
recombinant	O
enzyme	O
generated	O
by	O
site-directed	O
mutagenesis	O
after	O
its	O
transient	O
expression	O
in	O
COS-1	O
cells	O
.	O

Using	O
homogenates	O
from	O
transfected	O
cells	O
,	O
the	O
G129R	B-DNAMutation
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
enzyme	O
showed	O
a	O
Km	O
value	O
for	O
pregnenolone	O
of	O
10	O
+/-	O
2	O
mumol/L	O
compared	O
with	O
1.00	O
+/-	O
0.03	O
mumol/L	O
for	O
the	O
wild-type	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
enzyme	O
.	O

When	O
dehydroepiandrosterone	O
was	O
used	O
as	O
substrate	O
,	O
the	O
Km	O
value	O
for	O
G129R3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
was	O
14	O
+/-	O
2	O
mumol/L	O
compared	O
with	O
2.1	O
+/-	O
0.2	O
mumol/L	O
for	O
the	O
wild-type	O
II	B-DNAMutation
3	I-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
enzyme	O
.	O

In	O
addition	O
to	O
an	O
apparent	O
decrease	O
in	O
affinity	O
,	O
the	O
G129R	B-DNAMutation
mutation	O
caused	O
a	O
marked	O
decrease	O
in	O
the	O
apparent	O
relative	O
specific	O
activity	O
,	O
thus	O
leading	O
to	O
apparent	O
relative	O
specific	O
efficiencies	O
(	O
relative	O
specific	O
activity/Km	O
)	O
of	O
2.0%	O
and	O
4.7%	O
that	O
of	O
the	O
normal	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
using	O
pregnenolone	O
or	O
dehydroepiandrosterone	O
as	O
substrate	O
,	O
respectively	O
.	O

It	O
appears	O
likely	O
that	O
this	O
low	O
level	O
of	O
activity	O
is	O
sufficient	O
to	O
prevent	O
salt	O
loss	O
,	O
but	O
it	O
is	O
also	O
possible	O
that	O
part	O
of	O
the	O
enzymatic	O
activity	O
comes	O
from	O
the	O
putative	O
remaining	O
percentage	O
of	O
correctly	O
spliced	O
n6651	O
allele	O
in	O
these	O
patients	O
.	O

Identification	O
of	O
a	O
functional	O
binding	O
site	O
for	O
activin	O
on	O
the	O
type	O
I	O
receptor	O
ALK4	B-DNAMutation
.	O

Activins	O
,	O
like	O
other	O
members	O
of	O
the	O
transforming	O
growth	O
factor-beta	O
(TGF-beta)	O
superfamily	O
,	O
initiate	O
signaling	O
by	O
assembling	O
a	O
complex	O
of	O
two	O
types	O
of	O
transmembrane	O
serine/threonine	O
receptor	O
kinases	O
classified	O
as	O
type	O
II	O
(	O
ActRII	O
or	O
ActRIIB	B-DNAMutation
)	O
and	O
type	O
I	O
ALK4	B-DNAMutation
.	O

A	O
kinase-deleted	B-DNAMutation
version	O
of	O
ALK4	B-DNAMutation
can	O
form	O
an	O
inactive	O
complex	O
with	O
activin	O
and	O
ActRII/IIB	O
and	O
thereby	O
acts	O
in	O
a	O
dominant	O
negative	O
manner	O
to	O
block	O
activin	O
signaling	O
.	O

Using	O
the	O
complex	O
structure	O
of	O
bone	B-DNAMutation
morphogenetic	I-DNAMutation
protein-2	I-DNAMutation
bound	O
to	O
its	O
type	O
I	O
receptor	O
ALK3	B-DNAMutation
as	O
a	O
guide	O
,	O
we	O
introduced	O
extracellular	O
domain	O
mutations	O
in	O
the	O
context	O
of	O
the	O
truncated	O
ALK4	B-DNAMutation
ALK4-trunc	B-DNAMutation
construct	O
and	O
assessed	O
the	O
ability	O
of	O
the	O
mutants	O
to	O
inhibit	O
activin	O
function	O
.	O

We	O
have	O
identified	O
five	O
hydrophobic	O
amino	O
acid	O
residues	O
on	O
the	O
ALK4	O
extracellular	O
domain	O
(	B-DNAMutation
Leu40	I-DNAMutation
,	I-DNAMutation
Ile70	I-DNAMutation
,	I-DNAMutation
Val73	I-DNAMutation
,	I-DNAMutation
Leu75	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
Pro77	I-DNAMutation
)	I-DNAMutation
that	I-DNAMutation
,	I-DNAMutation
when	I-DNAMutation
mutated	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
,	O
have	O
substantial	O
effects	O
on	O
ALK4-trunc	B-DNAMutation
dominant	O
negative	O
activity	O
.	O

In	O
addition	O
,	O
eleven	O
mutants	O
partially	O
affected	O
activin	O
binding	O
to	O
ALK4	B-DNAMutation
.	O

Together	O
,	O
these	O
residues	O
likely	O
constitute	O
the	O
binding	O
surface	O
for	O
activin	O
on	O
ALK4	B-DNAMutation
.	O

Cross-linking	O
studies	O
measuring	O
binding	O
of	O
125I-activin-A	O
to	O
the	O
ALK4-trunc	B-DNAMutation
mutants	O
in	O
the	O
presence	O
of	O
ActRII	O
implicated	O
the	O
same	O
residues	O
.	O

Our	O
results	O
indicate	O
that	O
there	O
is	O
only	O
a	O
partial	O
overlap	O
of	O
the	O
binding	O
sites	O
on	O
ALK4	B-DNAMutation
and	O
ALK3	B-DNAMutation
for	O
activin-A	O
and	O
bone	B-DNAMutation
morphogenetic	I-DNAMutation
protein-2	I-DNAMutation
,	O
respectively	O
.	O

In	O
addition	O
three	O
of	O
the	O
residues	O
required	O
for	O
activin	O
binding	O
to	O
ALK4	B-DNAMutation
are	O
conserved	O
on	O
the	O
type	O
I	O
TGF-beta	O
receptor	O
ALK5	B-DNAMutation
,	O
suggesting	O
the	O
corresponding	O
region	O
on	O
ALK5	B-DNAMutation
may	O
be	O
important	O
for	O
TGF-beta	O
binding	O
.	O

A	O
novel	O
splice	O
variant	O
of	O
GLI1	B-DNAMutation
that	O
promotes	O
glioblastoma	O
cell	O
migration	O
and	O
invasion	O
.	O

The	O
family	O
of	O
GLI	O
zinc	O
finger	O
transcription	O
factors	O
regulates	O
the	O
expression	O
of	O
genes	O
involved	O
in	O
many	O
important	O
cellular	O
processes	O
,	O
notably	O
embryonal	O
development	O
and	O
cellular	O
differentiation	O
.	O

The	O
glioma-associated	O
oncogene	O
homologue	O
1	O
GLI1	B-DNAMutation
isoform	O
,	O
in	O
particular	O
,	O
has	O
attracted	O
much	O
attention	O
because	O
of	O
its	O
frequent	O
activation	O
in	O
many	O
human	O
cancers	O
and	O
its	O
interactions	O
with	O
other	O
signaling	O
pathways	O
,	O
such	O
as	O
those	O
mediated	O
by	O
K-RAS	B-DNAMutation
,	O
transforming	O
growth	O
factor-beta	O
,	O
epidermal	B-DNAMutation
growth	I-DNAMutation
factor	I-DNAMutation
receptor	I-DNAMutation
,	O
and	O
protein	O
kinase	O
A	O
.	O

Here	O
,	O
we	O
report	O
the	O
identification	O
of	O
a	O
novel	O
truncated	O
GLI1	B-DNAMutation
splice	O
variant	O
,	O
tGLI1	O
,	O
with	O
an	O
in-frame	B-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
123	I-DNAMutation
bases	I-DNAMutation
(	I-DNAMutation
41	I-DNAMutation
codons	I-DNAMutation
)	I-DNAMutation
spanning	I-DNAMutation
the	I-DNAMutation
entire	I-DNAMutation
exon	I-DNAMutation
3	I-DNAMutation
and	I-DNAMutation
part	I-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
4	I-DNAMutation
of	O
the	O
GLI1	B-DNAMutation
gene	O
.	O

Expression	O
of	O
tGLI1	O
is	O
undetectable	O
in	O
normal	O
cells	O
but	O
is	O
high	O
in	O
glioblastoma	O
multiforme	O
(GBM)	O
and	O
other	O
cancer	O
cells	O
.	O

Although	O
tGLI1	O
undergoes	O
nuclear	O
translocalization	O
and	O
transactivates	O
GLI1-binding	B-DNAMutation
sites	O
similar	O
to	O
GLI1	B-DNAMutation
,	O
unlike	O
GLI1	B-DNAMutation
,	O
it	O
is	O
associated	O
with	O
increased	O
motility	O
and	O
invasiveness	O
of	O
GBM	O
cells	O
.	O

Using	O
microarray	O
analysis	O
,	O
we	O
showed	O
>100	O
genes	O
to	O
be	O
differentially	O
expressed	O
in	O
tGLI1-expressing	O
compared	O
with	O
GLI1-expressing	B-DNAMutation
GBM	O
cells	O
,	O
although	O
both	O
cell	O
types	O
expressed	O
equal	O
levels	O
of	O
known	O
GLI1-regulated	B-DNAMutation
genes	O
,	O
such	O
as	O
PTCH1	O
.	O

We	O
further	O
showed	O
one	O
of	O
the	O
tGLI1	O
up-regulated	O
genes	O
,	O
CD24	O
,	O
an	O
invasion-associated	O
gene	O
,	O
to	O
be	O
required	O
for	O
the	O
migratory	O
and	O
invasive	O
phenotype	O
of	O
GBM	O
cells	O
.	O

These	O
data	O
provide	O
conclusive	O
evidence	O
for	O
a	O
novel	O
gain-of-function	O
GLI1	B-DNAMutation
splice	O
variant	O
that	O
promotes	O
migration	O
and	O
invasiveness	O
of	O
GBM	O
cells	O
and	O
open	O
up	O
a	O
new	O
research	O
paradigm	O
on	O
the	O
role	O
of	O
the	O
GLI1	B-DNAMutation
pathway	O
in	O
malignancy	O
.	O

Dual	O
modification	O
of	O
BMAL1	B-DNAMutation
by	O
SUMO2/3	B-DNAMutation
and	O
ubiquitin	O
promotes	O
circadian	O
activation	O
of	O
the	O
CLOCK/BMAL1	B-DNAMutation
complex	O
.	O

Heterodimers	O
of	O
BMAL1	B-DNAMutation
and	O
CLOCK	B-DNAMutation
drive	O
rhythmic	O
expression	O
of	O
clock-controlled	B-DNAMutation
genes	O
,	O
thereby	O
generating	O
circadian	O
physiology	O
and	O
behavior	O
.	O

Posttranslational	O
modifications	O
of	O
BMAL1	B-DNAMutation
play	O
a	O
key	O
role	O
in	O
modulating	O
the	O
transcriptional	O
activity	O
of	O
the	O
CLOCK/BMAL1	B-DNAMutation
complex	O
during	O
the	O
circadian	O
cycle	O
.	O

Recently	O
,	O
we	O
demonstrated	O
that	O
circadian	O
activation	O
of	O
the	O
heterodimeric	O
transcription	O
factor	O
is	O
accompanied	O
by	O
ubiquitin-dependent	O
proteolysis	O
of	O
BMAL1	B-DNAMutation
.	O

Here	O
we	O
show	O
that	O
modification	O
by	O
SUMO	O
localizes	O
BMAL1	B-DNAMutation
exclusively	O
to	O
the	O
promyelocytic	O
leukemia	O
nuclear	O
body	O
(NB)	O
and	O
simultaneously	O
promotes	O
its	O
transactivation	O
and	O
ubiquitin-dependent	O
degradation	O
.	O

Under	O
physiological	O
conditions	O
,	O
BMAL1	B-DNAMutation
was	O
predominantly	O
conjugated	O
to	O
poly-SUMO2/3	B-DNAMutation
rather	O
than	O
SUMO1	B-DNAMutation
,	O
and	O
the	O
level	O
of	O
these	O
conjugates	O
underwent	O
rhythmic	O
variation	O
,	O
peaking	O
at	O
times	O
of	O
maximum	O
E-box-mediated	O
circadian	O
transcription	O
.	O

Interestingly	O
,	O
mutation	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
sumoylation	I-DNAMutation
site	I-DNAMutation
(Lys(259))	I-DNAMutation
of	O
BMAL1	B-DNAMutation
markedly	O
inhibited	O
both	O
its	O
ubiquitination	O
and	O
its	O
proteasome-mediated	O
proteolysis	O
,	O
and	O
these	O
effects	O
were	O
reversed	O
by	O
covalent	O
attachment	O
of	O
SUMO3	B-DNAMutation
to	O
the	O
C	O
terminus	O
of	O
the	O
mutant	O
BMAL1	B-DNAMutation
.	O

Consistent	O
with	O
this	O
,	O
SUSP1	B-DNAMutation
,	O
a	O
SUMO	O
protease	O
highly	O
specific	O
for	O
SUMO2/3	B-DNAMutation
,	O
abolished	O
ubiquitination	O
,	O
as	O
well	O
as	O
sumoylation	O
of	O
BMAL1	B-DNAMutation
,	O
while	O
the	O
ubiquitin	O
protease	O
UBP41	B-DNAMutation
blocked	O
BMAL1	B-DNAMutation
ubiquitination	O
but	O
induced	O
accumulation	O
of	O
polysumoylated	O
BMAL1	B-DNAMutation
and	O
its	O
localization	O
to	O
the	O
NB	O
.	O

Furthermore	O
,	O
inhibition	O
of	O
proteasome	O
with	O
MG132	O
elicited	O
robust	O
nuclear	O
accumulation	O
of	O
SUMO2/3-	B-DNAMutation
and	O
ubiquitin-modified	O
BMAL1	B-DNAMutation
that	O
was	O
restricted	O
to	O
the	O
transcriptionally	O
active	O
stage	O
of	O
the	O
circadian	O
cycle	O
.	O

These	O
results	O
indicate	O
that	O
dual	O
modification	O
of	O
BMAL1	B-DNAMutation
by	O
SUMO2/3	B-DNAMutation
and	O
ubiquitin	O
is	O
essential	O
for	O
circadian	O
activation	O
and	O
degradation	O
of	O
the	O
CLOCK/BMAL1	B-DNAMutation
complex	O
.	O

Reversed	O
functional	O
organization	O
of	O
mouse	O
and	O
human	O
APOBEC3	O
cytidine	O
deaminase	O
domains	O
.	O

APOBEC3	O
proteins	O
comprise	O
a	O
multigene	O
family	O
of	O
antiviral	O
cytidine	O
deaminases	O
that	O
are	O
active	O
against	O
human	O
immunodeficiency	O
virus	O
,	O
simian	O
immunodeficiency	O
virus	O
,	O
endogenous	O
retroelements	O
.	O

The	O
Vif	O
protein	O
of	O
lentiviruses	O
binds	O
to	O
specific	O
APOBEC3	O
proteins	O
,	O
notably	O
A3F	B-DNAMutation
and	O
A3G	B-DNAMutation
,	O
to	O
induce	O
their	O
degradation	O
by	O
proteasomes	O
.	O

APOBEC3	O
proteins	O
are	O
of	O
two	O
types	O
,	O
those	O
with	O
a	O
single	O
deaminase	O
domain	O
such	O
as	O
human	O
(h)A3A	O
and	O
hA3C	B-DNAMutation
and	O
those	O
with	O
two	O
cytidine	O
deaminase	O
domains	O
(CDD)	O
such	O
as	O
hA3G	B-DNAMutation
,	O
hA3F	B-DNAMutation
,	O
hA3B	B-DNAMutation
and	O
the	O
mouse	O
APOBEC3	O
,	O
mA3	B-DNAMutation
.	O

In	O
hA3G	B-DNAMutation
,	O
both	O
active	O
sites	O
are	O
required	O
for	O
antiviral	O
function	O
but	O
serve	O
separate	O
functions	O
.	O

CDD2	O
mediates	O
the	O
C	O
to	O
U	O
deamination	O
of	O
the	O
human	O
immunodeficiency	O
virus	O
type	O
1	O
genome	O
,	O
whereas	O
CDD1	O
binds	O
the	O
viral	O
RNA	O
to	O
allow	O
for	O
virion	O
packaging	O
.	O

Here	O
we	O
analyzed	O
the	O
role	O
of	O
the	O
two	O
domains	O
in	O
additional	O
APOBEC3	O
family	O
members	O
.	O

We	O
analyzed	O
APOBEC3	O
proteins	O
in	O
which	O
either	O
the	O
critical	O
glutamic	O
acid	O
residue	O
or	O
the	O
Zn(2+)	O
coordination	O
amino	O
acid	O
residues	O
in	O
the	O
active	O
sites	O
were	O
mutated	O
.	O

The	O
separation	O
of	O
function	O
of	O
the	O
domains	O
is	O
maintained	O
in	O
hA3B	B-DNAMutation
and	O
hA3F	B-DNAMutation
,	O
but	O
in	O
the	O
mouse	O
protein	O
mA3	B-DNAMutation
,	O
the	O
roles	O
of	O
the	O
two	O
domains	O
are	O
reversed	O
.	O

Deamination	O
is	O
mediated	O
by	O
CDD1	O
,	O
whereas	O
encapsidation	O
and	O
dimerization	O
are	O
mediated	O
by	O
CDD2	O
.	O

Antiviral	O
function	O
of	O
each	O
of	O
the	O
APOBEC3	O
proteins	O
was	O
largely	O
attributable	O
to	O
deaminase	O
activity	O
.	O

Deaminase-independent	O
antiviral	O
activity	O
of	O
the	O
active	O
site	O
mutants	O
was	O
minor	O
.	O

These	O
findings	O
suggest	O
that	O
the	O
two	O
active	O
sites	O
have	O
different	O
functions	O
but	O
that	O
these	O
functions	O
can	O
be	O
interchanged	O
in	O
different	O
APOBEC3	O
family	O
members	O
.	O

Interaction	O
with	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator-associated	O
ligand	O
CAL	B-DNAMutation
inhibits	O
beta1-adrenergic	B-DNAMutation
receptor	I-DNAMutation
surface	O
expression	O
.	O

G	O
protein-coupled	O
receptors	O
such	O
as	O
the	O
beta1-adrenergic	B-DNAMutation
receptor	I-DNAMutation
beta1AR	B-DNAMutation
must	O
be	O
trafficked	O
to	O
the	O
plasma	O
membrane	O
in	O
order	O
to	O
bind	O
with	O
their	O
extracellular	O
ligands	O
and	O
regulate	O
cellular	O
physiology	O
.	O

By	O
using	O
glutathione	O
S-transferase	O
pull-down	O
techniques	O
,	O
we	O
found	O
that	O
the	O
beta1AR	B-DNAMutation
carboxyl	O
terminus	O
directly	O
interacts	O
with	O
the	O
cystic	O
fibrosis	O
transmembrane	O
conductance	O
regulator-associated	O
ligand	O
(	O
CAL	B-DNAMutation
;	O
also	O
known	O
as	O
PIST	B-DNAMutation
,	O
GOPC	B-DNAMutation
,	O
and	O
FIG	O
)	O
,	O
a	O
protein	O
known	O
to	O
be	O
primarily	O
localized	O
to	O
the	O
Golgi	O
apparatus	O
.	O

CAL	B-DNAMutation
contains	O
two	O
predicted	O
coiled-coil	O
domains	O
and	O
one	O
PSD-95/Discs-large/ZO-1	B-DNAMutation
homology	O
(PDZ)	O
domain	O
.	O

The	O
beta1AR	B-DNAMutation
carboxyl	O
terminus	O
(CT)	O
binds	O
to	O
the	O
PDZ	O
domain	O
of	O
CAL	B-DNAMutation
,	O
with	O
the	O
last	O
few	O
amino	O
acids	O
(ESKV)	O
of	O
the	O
beta1AR-CT	B-DNAMutation
being	O
the	O
key	O
determinants	O
for	O
the	O
interaction	O
.	O

Mutation	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
terminal	I-DNAMutation
valine	I-DNAMutation
residue	I-DNAMutation
resulted	O
in	O
markedly	O
reduced	O
association	O
of	O
the	O
beta1AR-CT	B-DNAMutation
with	O
CAL	B-DNAMutation
.	O

Numerous	O
other	O
mutations	O
to	O
the	O
ESKV	O
motif	O
also	O
impaired	O
the	O
beta1AR-CT/CAL	B-DNAMutation
interaction	O
,	O
suggesting	O
that	O
this	O
motif	O
is	O
close	O
to	O
optimal	O
for	O
association	O
with	O
the	O
CAL	O
PDZ	O
domain	O
.	O

In	O
cells	O
,	O
full-length	O
beta1AR	B-DNAMutation
robustly	O
associates	O
with	O
CAL	B-DNAMutation
,	O
and	O
this	O
interaction	O
is	O
abolished	O
by	O
mutation	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
terminal	I-DNAMutation
valine	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
of	O
the	O
receptor	O
V477A	B-DNAMutation
,	O
as	O
determined	O
by	O
co-immunoprecipitation	O
experiments	O
and	O
immunofluorescence	O
co-localization	O
studies	O
.	O

Consistent	O
with	O
observations	O
that	O
CAL	B-DNAMutation
is	O
a	O
Golgi-associated	O
protein	O
,	O
overexpression	O
of	O
CAL	B-DNAMutation
reduces	O
surface	O
expression	O
of	O
beta1AR	B-DNAMutation
.	O

Interaction	O
with	O
CAL	B-DNAMutation
promotes	O
retention	O
of	O
beta1AR	B-DNAMutation
within	O
the	O
cell	O
,	O
whereas	O
PSD-95	B-DNAMutation
,	O
another	O
beta1AR-associated	O
PDZ	O
domain-containing	O
protein	O
,	O
competitively	O
blocks	O
beta1AR	B-DNAMutation
association	O
with	O
CAL	B-DNAMutation
and	O
promotes	O
receptor	O
trafficking	O
to	O
the	O
cell	O
surface	O
.	O

These	O
data	O
reveal	O
that	O
CAL	B-DNAMutation
,	O
a	O
novel	O
beta1AR-binding	B-DNAMutation
partner	O
,	O
modulates	O
beta1AR	B-DNAMutation
intracellular	O
trafficking	O
,	O
thereby	O
revealing	O
a	O
new	O
mechanism	O
of	O
regulation	O
for	O
beta1AR	B-DNAMutation
anterograde	O
trafficking	O
through	O
the	O
endoplasmic	O
reticulum-Golgi	O
complex	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
molecular	O
basis	O
of	O
canavan	O
(	O
aspartoacylase	B-DNAMutation
deficiency	O
)	O
disease	O
in	O
European	O
non-Jewish	O
patients	O
.	O

Canavan	O
disease	O
is	O
an	O
infantile	O
neurodegenerative	O
disease	O
that	O
is	O
due	O
to	O
aspartoacylase	B-DNAMutation
deficiency	O
.	O

The	O
disease	O
has	O
been	O
reported	O
mainly	O
in	O
Ashkenazi	O
Jews	O
but	O
also	O
occurs	O
in	O
other	O
ethnic	O
groups	O
.	O

Determination	O
of	O
enzymatic	O
activity	O
for	O
carrier	O
detection	O
and	O
prenatal	O
diagnosis	O
is	O
considered	O
unreliable	O
.	O

In	O
the	O
present	O
study	O
,	O
nine	O
mutations	O
were	O
found	O
in	O
the	O
aspartoacylase	B-DNAMutation
gene	O
of	O
19	O
non-Jewish	O
patients	O
.	O

These	O
included	O
four	O
point	O
mutations	O
(	O
A305E	B-DNAMutation
[	O
39.5%	O
of	O
the	O
mutated	O
alleles	O
]	O
,	O
C218X	B-DNAMutation
[15.8%]	O
,	O
F295S	B-DNAMutation
[2.6%]	O
,	O
and	O
G274R	B-DNAMutation
[	O
5.3%	O
]	O
)	O
;	O
four	O
deletion	O
mutations	O
(	O
827delGT	B-DNAMutation
[5.3%]	O
,	O
870del4	B-DNAMutation
[2.6%]	O
,	O
566del7	B-DNAMutation
[2.6%]	O
,	O
and	O
527del6	B-DNAMutation
[	O
2.6%	O
]	O
)	O
;	O
and	O
one	O
exon	O
skip	O
(	O
527del108	B-DNAMutation
[	O
5.3%	O
]	O
)	O
.	O

The	O
A305E	B-DNAMutation
mutation	O
is	O
pan-European	O
and	O
probably	O
the	O
most	O
ancient	O
mutation	O
,	O
identified	O
in	O
patients	O
of	O
Greek	O
,	O
Polish	O
,	O
Danish	O
,	O
French	O
,	O
Spanish	O
,	O
Italian	O
,	O
and	O
British	O
origin	O
.	O

In	O
contrast	O
,	O
the	O
G274R	B-DNAMutation
and	O
527del108	B-DNAMutation
mutations	O
were	O
found	O
only	O
in	O
patients	O
of	O
Turkish	O
origin	O
,	O
and	O
the	O
C218X	B-DNAMutation
mutation	O
was	O
identified	O
only	O
in	O
patients	O
of	O
Gypsy	O
origin	O
.	O

Homozygosity	O
for	O
the	O
A305E	B-DNAMutation
mutation	O
was	O
identified	O
in	O
patients	O
with	O
both	O
the	O
severe	O
and	O
the	O
mild	O
forms	O
of	O
Canavan	O
disease	O
.	O

Mutations	O
were	O
identified	O
in	O
31	O
of	O
the	O
38	O
alleles	O
,	O
resulting	O
in	O
an	O
overall	O
detection	O
rate	O
of	O
81.6%	O
.	O

All	O
nine	O
mutations	O
identified	O
in	O
non-Jewish	O
patients	O
reside	O
in	O
exons	O
4-6	O
of	O
the	O
aspartoacylase	B-DNAMutation
gene	O
.	O

The	O
results	O
would	O
enable	O
accurate	O
genetic	O
counseling	O
in	O
the	O
families	O
of	O
13	O
(68.4%)	O
of	O
19	O
patients	O
,	O
in	O
whom	O
two	O
mutations	O
were	O
identified	O
in	O
the	O
aspartoacylase	B-DNAMutation
cDNA	O
.	O

Diverse	O
polymorphism	O
within	O
a	O
short	O
coding	O
region	O
of	O
the	O
human	O
aldehyde	O
dehydrogenase-5	O
(ALDH5)	O
gene	O
.	O

Human	O
aldehyde	O
dehydrogenase-5	O
gene	O
(	O
originally	O
named	O
as	O
ALDHX	O
)	O
is	O
expressed	O
in	O
liver	O
and	O
testis	O
.	O

The	O
ALDH5	O
does	O
not	O
contain	O
introns	O
in	O
the	O
coding	O
sequence	O
for	O
517	O
amino	O
acid	O
residues	O
.	O

Within	O
a	O
short	O
nucleotide	O
region	O
of	O
the	O
gene	O
,	O
the	O
following	O
three	O
nucleotide	O
changes	O
were	O
found	O
in	O
high	O
frequencies	O
,	O
i.e.	O
,	O
a	O
silent	O
C<-->T	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
(nt)	I-DNAMutation
183	I-DNAMutation
,	O
C<-->T	B-DNAMutation
at	I-DNAMutation
nt	I-DNAMutation
257	I-DNAMutation
associated	I-DNAMutation
with	O
a	O
Val<-->Ala	B-DNAMutation
substitution	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
T<-->G	B-DNAMutation
at	I-DNAMutation
nt	I-DNAMutation
320	I-DNAMutation
associated	I-DNAMutation
with	O
a	O
Arg<-->Leu	B-DNAMutation
substitution	I-DNAMutation
.	I-DNAMutation
The	I-DNAMutation
frequency	I-DNAMutation
of	O
C	O
at	O
nt	O
183	O
is	O
81%	O
in	O
Caucasians	O
and	O
65%	O
in	O
Japanese	O
,	O
and	O
the	O
difference	O
is	O
statistically	O
not	O
significant	O
.	O

The	O
frequency	O
of	O
C	O
at	O
nt	O
257	O
is	O
76%	O
in	O
Caucasians	O
and	O
55%	O
in	O
Japanese	O
,	O
and	O
the	O
difference	O
is	O
statistically	O
significant	O
(	O
P	O
=	O
0.02	O
)	O
.	O

The	O
frequency	O
of	O
T	O
at	O
nt	O
320	O
is	O
71%	O
in	O
Caucasians	O
,	O
while	O
it	O
is	O
only	O
27%	O
in	O
Japanese	O
.	O

The	O
racial	O
difference	O
at	O
nt	O
320	O
is	O
highly	O
significant	O
(	O
P	O
<	O
0.001	O
)	O
.	O

No	O
significant	O
difference	O
was	O
found	O
in	O
the	O
genotypes	O
of	O
the	O
three	O
nucleotide	O
positions	O
between	O
alcoholic	O
and	O
nonalcoholic	O
Caucasians	O
within	O
the	O
limited	O
numbers	O
of	O
subjects	O
examined	O
.	O

Fatal	O
hypertrophic	O
cardiomyopathy	O
and	O
nemaline	O
myopathy	O
associated	O
with	O
ACTA1	B-DNAMutation
K336E	B-DNAMutation
mutation	O
.	O

We	O
report	O
on	O
a	O
2-year-old	O
male	O
child	O
with	O
both	O
nemaline	O
myopathy	O
and	O
hypertrophic	O
cardiomyopathy	O
(HCM)	O
.	O

Sequencing	O
of	O
the	O
ACTA1	B-DNAMutation
gene	O
showed	O
a	O
"de	B-DNAMutation
novo"	I-DNAMutation
missense	I-DNAMutation
heterozygous	I-DNAMutation
mutation	I-DNAMutation
a>g	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
7	I-DNAMutation
Lys336Glu	B-DNAMutation
.	O

Two-dimensional	O
electrophoresis	O
showed	O
28%	O
mutant	O
actin	O
present	O
in	O
his	O
muscle	O
biopsy	O
.	O

Actin	O
was	O
isolated	O
from	O
the	O
muscle	O
biopsy	O
and	O
examined	O
by	O
in	O
vitro	O
motility	O
assay	O
.	O

The	O
sliding	O
speed	O
was	O
13+/-3%	O
less	O
than	O
normal	O
and	O
the	O
affinity	O
of	O
actin	O
for	O
the	O
Z-line	O
protein	O
alpha-actinin	O
was	O
reduced	O
10	O
fold	O
.	O

This	O
is	O
the	O
first	O
report	O
on	O
a	O
hypertrophic	O
cardiomyopathy	O
associated	O
with	O
nemaline	O
myopathy	O
and	O
an	O
ACTA1	B-DNAMutation
mutation	O
.	O

PKA-mediated	O
phosphorylation	O
regulates	O
the	O
function	O
of	O
activation-induced	B-DNAMutation
deaminase	I-DNAMutation
AID	B-DNAMutation
in	O
B	O
cells	O
.	O

During	O
humoral	O
immune	O
responses	O
,	O
two	O
distinct	O
genetic	O
modification	O
events	O
diversify	O
the	O
Ig	O
genes	O
in	O
germinal	O
center	O
(GC)	O
B	O
cells	O
:	O
somatic	O
hypermutation	O
and	O
class	B-DNAMutation
switch	I-DNAMutation
recombination	I-DNAMutation
CSR	B-DNAMutation
.	O

Both	O
processes	O
require	O
the	O
activity	O
of	O
activation-induced	B-DNAMutation
cytidine	I-DNAMutation
deaminase	I-DNAMutation
AID	B-DNAMutation
,	O
an	O
enzyme	O
expressed	O
specifically	O
in	O
GC	O
B	O
cells	O
.	O

However	O
,	O
the	O
mechanisms	O
that	O
regulate	O
AID	B-DNAMutation
activity	O
are	O
largely	O
unknown	O
.	O

Here	O
we	O
report	O
that	O
protein	O
kinase	O
A	O
(PKA)	O
phosphorylates	O
AID	B-DNAMutation
and	O
regulates	O
its	O
activity	O
in	O
GC	O
B	O
cells	O
.	O

AID	B-DNAMutation
physically	O
interacts	O
with	O
the	O
PKA	O
holoenzyme	O
in	O
the	O
cytoplasm	O
and	O
is	O
phosphorylated	O
by	O
the	O
PKA	O
catalytic	O
subunit	O
at	O
specific	O
residues	O
.	O

AID	B-DNAMutation
phosphorylation	O
is	O
required	O
for	O
CSR	B-DNAMutation
,	O
because	O
substitution	O
of	O
the	O
two	O
phosphorylation	O
targets	O
impairs	O
its	O
ability	O
to	O
rescue	O
CSR	B-DNAMutation
in	O
AID-deficient	O
B	O
cells	O
.	O

Pharmacologic	O
inhibition	O
of	O
PKA	O
prevents	O
isotype	O
class	O
switching	O
in	O
a	O
murine	O
B-cell	O
lymphoma	O
cell	O
line	O
;	O
conversely	O
,	O
B	O
cells	O
from	O
mice	O
where	O
PKA	O
activity	O
is	O
made	O
constitutive	O
by	O
conditional	B-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
PKA	I-DNAMutation
regulatory	I-DNAMutation
subunit	I-DNAMutation
gene	O
display	O
enhanced	O
CSR	B-DNAMutation
.	O

These	O
findings	O
implicate	O
PKA	O
in	O
the	O
regulation	O
of	O
AID	B-DNAMutation
function	O
and	O
suggest	O
that	O
the	O
control	O
of	O
T	O
cell-dependent	O
immune	O
responses	O
may	O
be	O
modulated	O
,	O
via	O
AID	B-DNAMutation
,	O
by	O
signals	O
that	O
activate	O
PKA	O
.	O

Molecular	O
characterization	O
of	O
inherited	O
medium-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
deficiency	O
.	O

Deficiency	O
of	O
medium-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
MCAD	B-DNAMutation
is	O
a	O
common	O
inherited	O
defect	O
in	O
energy	O
metabolism	O
.	O

Characterization	O
of	O
the	O
mRNA	O
encoding	O
MCAD	B-DNAMutation
in	O
a	O
Dutch	O
MCAD-deficient	B-DNAMutation
patient	O
revealed	O
an	O
A----G	B-DNAMutation
change	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
position	I-DNAMutation
985	I-DNAMutation
of	O
the	O
MCAD	B-DNAMutation
mRNA	O
coding	O
region	O
.	O

This	O
point	O
mutation	O
results	O
in	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
glutamic	I-DNAMutation
acid	I-DNAMutation
for	I-DNAMutation
a	I-DNAMutation
lysine	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
position	I-DNAMutation
304	I-DNAMutation
of	O
the	O
mature	O
protein	O
.	O

The	O
single	O
base	O
change	O
was	O
not	O
found	O
in	O
any	O
wild-type	O
MCAD	B-DNAMutation
mRNAs	O
.	O

A	O
mutant	O
allele-specific	O
oligonucleotide	O
probe	O
was	O
used	O
in	O
a	O
hybridization	O
analysis	O
of	O
amplified	O
genomic	O
DNA	O
of	O
MCAD-deficient	B-DNAMutation
family	O
members	O
,	O
a	O
carrier	O
,	O
and	O
normal	O
individuals	O
.	O

The	O
hybridization	O
analysis	O
specifically	O
identified	O
individuals	O
who	O
were	O
heterozygotes	O
or	O
homozygotes	O
.	O

In	O
addition	O
to	O
the	O
point	O
mutation	O
,	O
a	O
significant	O
proportion	O
of	O
the	O
index	O
patient's	O
MCAD	B-DNAMutation
mRNA	O
contained	O
a	O
variety	O
of	O
deletions	O
and	O
insertions	O
as	O
a	O
result	O
of	O
exon	O
skipping	O
and	O
intron	O
retention	O
.	O

The	O
missplicing	O
occurred	O
in	O
multiple	O
regions	O
throughout	O
the	O
MCAD	B-DNAMutation
mRNA	O
.	O

Analysis	O
of	O
the	O
patient's	O
MCAD	B-DNAMutation
gene	O
in	O
the	O
regions	O
where	O
the	O
missplicing	O
occurred	O
most	O
frequently	O
did	O
not	O
reveal	O
a	O
mutation	O
in	O
the	O
splicing	O
acceptor	O
or	O
donor	O
sites	O
.	O

Therefore	O
,	O
the	O
molecular	O
characterization	O
of	O
this	O
family	O
revealed	O
a	O
crucial	O
point	O
mutation	O
in	O
the	O
MCAD	B-DNAMutation
gene	O
and	O
an	O
unusual	O
abnormality	O
in	O
MCAD	B-DNAMutation
pre-mRNA	O
splicing	O
.	O

Identification	O
of	O
domains	O
in	O
apobec-1	B-DNAMutation
complementation	I-DNAMutation
factor	I-DNAMutation
required	O
for	O
RNA	O
binding	O
and	O
apolipoprotein-B	B-DNAMutation
mRNA	O
editing	O
.	O

The	O
C-to-U	O
editing	O
of	O
apolipoprotein-B	B-DNAMutation
apo-B	B-DNAMutation
mRNA	O
is	O
catalyzed	O
by	O
an	O
enzyme	O
complex	O
that	O
recognizes	O
an	O
11-nt	O
mooring	O
sequence	O
downstream	O
of	O
the	O
editing	O
site	O
.	O

A	O
minimal	O
holoenzyme	O
that	O
edits	O
apo-B	B-DNAMutation
mRNA	O
in	O
vitro	O
has	O
been	O
defined	O
.	O

This	O
complex	O
contains	O
apobec-1	B-DNAMutation
,	O
the	O
catalytic	O
subunit	O
,	O
and	O
apobec-1	B-DNAMutation
complementation	I-DNAMutation
factor	I-DNAMutation
(ACF)	O
,	O
the	O
RNA-binding	O
subunit	O
that	O
binds	O
to	O
the	O
mooring	O
sequence	O
.	O

Here	O
,	O
we	O
show	O
that	O
ACF	O
binds	O
with	O
high	O
affinity	O
to	O
single-stranded	O
but	O
not	O
double-stranded	O
apo-B	B-DNAMutation
mRNA	O
.	O

ACF	O
contains	O
three	O
nonidentical	O
RNA	O
recognition	O
motifs	O
(RRM)	O
and	O
a	O
unique	O
C-terminal	O
auxiliary	O
domain	O
.	O

In	O
many	O
multi-RRM	O
proteins	O
,	O
the	O
RRMs	O
mediate	O
RNA	O
binding	O
and	O
an	O
auxiliary	O
domain	O
functions	O
in	O
protein-protein	O
interactions	O
.	O

Here	O
we	O
show	O
that	O
ACF	O
does	O
not	O
fit	O
this	O
simple	O
model	O
.	O

Based	O
on	O
deletion	O
mutagenesis	O
,	O
the	O
RRMs	O
in	O
ACF	O
are	O
necessary	O
but	O
not	O
sufficient	O
for	O
binding	O
to	O
apo-B	B-DNAMutation
mRNA	O
.	O

Amino	O
acids	O
in	O
the	O
pre-RRM	O
region	O
are	O
required	O
for	O
complementing	O
activity	O
and	O
RNA	O
binding	O
,	O
but	O
not	O
for	O
interaction	O
with	O
apobec-1	B-DNAMutation
.	O

The	O
C-terminal	O
196	O
amino	O
acids	O
are	O
not	O
absolutely	O
essential	O
for	O
function	O
.	O

However	O
,	O
further	O
deletion	O
of	O
an	O
RG-rich	O
region	O
from	O
the	O
auxiliary	O
domain	O
abolished	O
complementing	O
activity	O
,	O
RNA	O
binding	O
,	O
and	O
apobec-1	B-DNAMutation
interaction	O
.	O

The	O
auxiliary	O
domain	O
alone	O
did	O
not	O
bind	O
apobec-1	B-DNAMutation
.	O

Although	O
all	O
three	O
RRMs	O
are	O
required	O
for	O
complementing	O
activity	O
and	O
apobec-1	B-DNAMutation
interaction	O
,	O
the	O
individual	O
motifs	O
contribute	O
differently	O
to	O
RNA	O
binding	O
.	O

Point	O
mutations	O
in	O
RRM1	O
or	O
RRM2	O
decreased	O
the	O
Kd	O
for	O
apo-B	B-DNAMutation
mRNA	O
by	O
two	O
orders	O
of	O
magnitude	O
whereas	O
mutations	O
in	O
RRM3	O
reduced	O
binding	O
affinity	O
13-fold	O
.	O

The	O
pairwise	O
expression	O
of	O
RRM1	O
with	O
RRM2	O
or	O
RRM3	O
resulted	O
in	O
moderate	O
affinity	O
binding	O
.	O

The	O
717Val----Ile	B-DNAMutation
substitution	O
in	O
amyloid	O
precursor	O
protein	O
is	O
associated	O
with	O
familial	O
Alzheimer's	O
disease	O
regardless	O
of	O
ethnic	O
groups	O
.	O

Alzheimer's	O
disease	O
(AD)	O
is	O
a	O
devastating	O
neurological	O
disorder	O
and	O
the	O
leading	O
cause	O
of	O
dementia	O
among	O
aged	O
individuals	O
.	O

The	O
human	O
amyloid	O
beta	O
protein	O
,	O
which	O
is	O
a	O
cleavage	O
product	O
of	O
amyloid	O
precursor	O
protein	O
(APP)	O
,	O
is	O
a	O
major	O
component	O
of	O
the	O
amyloid	O
deposited	O
in	O
the	O
brain	O
of	O
patients	O
with	O
AD	O
.	O

By	O
using	O
PCR	O
direct	O
sequencing	O
of	O
exon	O
17	O
(	O
encoding	O
part	O
of	O
the	O
beta	O
protein	O
)	O
of	O
the	O
APP	O
gene	O
,	O
we	O
have	O
found	O
that	O
a	O
Japanese	O
AD	O
patient	O
harbours	O
a	O
C	B-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
substitution	I-DNAMutation
,	O
responsible	B-DNAMutation
for	I-DNAMutation
a	I-DNAMutation
valine	I-DNAMutation
to	I-DNAMutation
isoleucine	I-DNAMutation
change	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
717	I-DNAMutation
,	O
heterogeneously	O
.	O

The	O
mutation	O
is	O
exactly	O
the	O
same	O
as	O
that	O
found	O
in	O
a	O
Caucasian	O
AD	O
family	O
by	O
Goate	O
et	O
al	O
.	O

(1)	O
.	O

Furthermore	O
,	O
the	O
mutation	O
was	O
shown	O
to	O
co-segregate	O
with	O
AD	O
in	O
his	O
family	O
.	O

These	O
results	O
suggest	O
that	O
the	O
Val----Ile	B-DNAMutation
change	I-DNAMutation
in	O
the	O
APP	O
causes	O
AD	O
,	O
regardless	O
of	O
ethnic	O
background	O
.	O

The	O
impact	O
of	O
Glu102Lys	B-DNAMutation
on	O
the	O
factor	O
X	O
function	O
in	O
a	O
patient	O
with	O
a	O
doubly	O
homozygous	O
factor	O
X	O
deficiency	O
(	O
Gla14Lys	B-DNAMutation
and	O
Glu102Lys	B-DNAMutation
)	O
.	O

Two	O
homozygous	O
point	O
mutations	O
were	O
found	O
in	O
a	O
patient	O
with	O
factor	O
X	O
(FX)	O
deficiency	O
;	O
One	O
results	O
in	O
substitution	O
of	O
Lys	B-DNAMutation
for	I-DNAMutation
Gla+	I-DNAMutation
14	I-DNAMutation
and	O
the	O
second	O
causes	O
a	O
Lys	B-DNAMutation
substitution	I-DNAMutation
for	I-DNAMutation
Glu102	I-DNAMutation
.	O

The	O
proposita	O
has	O
a	O
severely	O
reduced	O
FX	O
coagulant	O
activity	O
in	O
the	O
extrinsic	O
(	O
<1%	O
of	O
normal	O
)	O
and	O
in	O
the	O
intrinsic	O
(	O
30%	O
of	O
normal	O
)	O
system	O
of	O
coagulation	O
and	O
after	O
activation	O
with	O
Russel's	O
viper	O
venom	O
(	O
18%	O
of	O
normal	O
)	O
.	O

The	O
FX	O
antigen	O
is	O
reduced	O
in	O
this	O
patient	O
to	O
20%	O
of	O
normal	O
.	O

The	O
substitution	B-DNAMutation
of	I-DNAMutation
Lys	I-DNAMutation
for	I-DNAMutation
Glu102	I-DNAMutation
in	O
FX	O
deficiency	O
has	O
been	O
reported	O
previously	O
in	O
a	O
heterozygous	O
state	O
in	O
conjunction	O
with	O
a	O
Lys	B-DNAMutation
for	I-DNAMutation
Gla+14	I-DNAMutation
substitution	O
and	O
with	O
a	O
Pro	B-DNAMutation
for	I-DNAMutation
Ser334	I-DNAMutation
substitution	O
.	O

The	O
contribution	O
of	O
the	O
Lys	B-DNAMutation
for	I-DNAMutation
Glu102	I-DNAMutation
substitution	O
in	O
the	O
observed	O
combined	O
FX	O
defect	O
in	O
these	O
patients	O
was	O
unclear	O
.	O

The	O
mutation	O
causing	O
the	O
Glu102Lys	B-DNAMutation
substitution	O
was	O
introduced	O
by	O
site	O
directed	O
mutagenesis	O
into	O
a	O
wild-type	O
FX	O
cDNA	O
,	O
and	O
recombinant	O
protein	O
was	O
expressed	O
in	O
HEK	O
293	O
cells	O
.	O

Compared	O
to	O
the	O
wild-type	O
FX	O
cDNA	O
,	O
the	O
mutant	O
construct	O
had	O
a	O
67%	O
activity	O
upon	O
activation	O
in	O
the	O
extrinsic	O
system	O
,	O
93%	O
activity	O
upon	O
activation	O
in	O
the	O
intrinsic	O
system	O
and	O
72%	O
after	O
activation	O
with	O
RVV	O
.	O

The	O
data	O
presented	O
show	O
that	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
Lys	I-DNAMutation
for	I-DNAMutation
Glu102	I-DNAMutation
results	O
in	O
a	O
minor	O
functional	O
defect	O
of	O
the	O
FX	O
molecule	O
.	O

Changes	O
at	O
P183	O
of	O
emerin	B-DNAMutation
weaken	O
its	O
protein-protein	O
interactions	O
resulting	O
in	O
X-linked	O
Emery-Dreifuss	O
muscular	O
dystrophy	O
.	O

Emery-Dreifuss	O
muscular	O
dystrophy	O
(EDMD)	O
is	O
an	O
X-linked	O
recessive	O
muscular	O
dystrophy	O
characterized	O
by	O
early	O
contractures	O
of	O
the	O
elbows	O
,	O
Achilles	O
tendons	O
and	O
spine	O
,	O
slowly	O
progressive	O
muscle	O
wasting	O
and	O
weakness	O
,	O
and	O
cardiomyopathy	O
associated	O
with	O
cardiac	O
conduction	O
defects	O
.	O

The	O
emerin	B-DNAMutation
gene	O
has	O
been	O
mapped	O
to	O
Xq28	O
and	O
encodes	O
a	O
34-kDa	O
serine-rich	O
protein	O
,	O
emerin	B-DNAMutation
,	O
which	O
has	O
been	O
localized	O
to	O
the	O
nuclear	O
envelope	O
in	O
a	O
wide	O
variety	O
of	O
tissues	O
,	O
including	O
skeletal	O
and	O
cardiac	O
muscle	O
.	O

Mutations	O
spanning	O
the	O
emerin	B-DNAMutation
gene	O
have	O
been	O
identified	O
in	O
patients	O
with	O
EDMD	O
.	O

We	O
present	O
here	O
the	O
effect	O
,	O
on	O
emerin	B-DNAMutation
protein	O
expression	O
,	O
of	O
two	O
missense	O
mutations	O
identified	O
in	O
unrelated	O
EDMD	O
patients	O
.	O

These	O
alterations	O
predict	O
the	O
replacement	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
proline	I-DNAMutation
residue	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
183	I-DNAMutation
with	O
either	O
a	O
histidine	O
or	O
a	O
threonine	O
.	O

Biochemical	O
analysis	O
has	O
demonstrated	O
that	O
the	O
mobility	O
and	O
expression	O
levels	O
of	O
the	O
mutant	O
forms	O
of	O
emerin	B-DNAMutation
are	O
indistinguishable	O
from	O
that	O
of	O
wild-type	O
emerin	B-DNAMutation
,	O
but	O
that	O
they	O
have	O
weakened	O
interactions	O
with	O
nuclear	O
lamina	O
components	O
.	O

In	O
comparison	O
with	O
the	O
usual	O
EDMD	O
phenotype	O
,	O
patients	O
with	O
P183	O
missense	O
mutations	O
have	O
a	O
later	O
age	O
at	O
onset	O
of	O
first	O
symptoms	O
,	O
elbow	O
contractures	O
,	O
ankle	O
contractures	O
,	O
upper	O
limb	O
weakness	O
and	O
lower	O
limb	O
weakness	O
,	O
but	O
there	O
is	O
no	O
difference	O
for	O
the	O
age	O
at	O
onset	O
of	O
cardiac	O
involvement	O
.	O

This	O
is	O
the	O
first	O
report	O
of	O
protein	O
studies	O
on	O
patients	O
with	O
missense	O
mutations	O
resulting	O
in	O
the	O
clinical	O
features	O
of	O
EDMD	O
.	O

These	O
studies	O
demonstrate	O
the	O
importance	O
of	O
proline	O
183	O
for	O
the	O
proper	O
structure/function	O
of	O
emerin	B-DNAMutation
.	O

Mutagenesis	O
of	O
human	O
acetylcholinesterase	B-DNAMutation
.	O

Identification	O
of	O
residues	O
involved	O
in	O
catalytic	O
activity	O
and	O
in	O
polypeptide	O
folding	O
.	O

Evidence	O
for	O
the	O
involvement	O
of	O
Ser-203	B-DNAMutation
,	O
His-447	B-DNAMutation
,	O
and	O
Glu-334	B-DNAMutation
in	O
the	O
catalytic	O
triad	O
of	O
human	O
acetylcholinesterase	B-DNAMutation
was	O
provided	O
by	O
substitution	B-DNAMutation
of	I-DNAMutation
these	I-DNAMutation
amino	I-DNAMutation
acids	I-DNAMutation
by	I-DNAMutation
alanine	I-DNAMutation
residues	O
.	O

Of	O
20	O
amino	O
acid	O
positions	O
mutated	O
so	O
far	O
in	O
human	O
acetylcholinesterase	B-DNAMutation
(AChE)	I-DNAMutation
,	O
these	O
three	O
were	O
unique	O
in	O
abolishing	O
detectable	O
enzymatic	O
activity	O
(	O
less	O
than	O
0.0003	O
of	O
wild	O
type	O
)	O
,	O
yet	O
allowing	O
proper	O
production	O
,	O
folding	O
,	O
and	O
secretion	O
.	O

This	O
is	O
the	O
first	O
biochemical	O
evidence	O
for	O
the	O
involvement	O
of	O
a	O
glutamate	O
in	O
a	O
hydrolase	O
triad	O
(	O
Schrag	O
,	O
J.D.	O
,	O
Li	O
,	O
Y.	O
,	O
Wu	O
,	O
M.	O
,	O
and	O
Cygler	O
,	O
M	O
.	O

(1991)	O
Nature	O
351	O
,	O
761-764	O
)	O
,	O
supporting	O
the	O
x-ray	O
crystal	O
structure	O
data	O
of	O
the	O
Torpedo	O
californica	O
acetylcholinesterase	B-DNAMutation
(	O
Sussman	O
,	O
J.L.	O
,	O
Harel	O
,	O
M.	O
,	O
Frolow	O
,	O
F.	O
,	O
Oefner	O
,	O
C.	O
,	O
Goldman	O
,	O
A.	O
,	O
Toker	O
,	O
L	O
.	O

and	O
Silman	O
,	O
I	O
.	O

(1991)	O
Science	O
253	O
,	O
872-879	O
)	O
.	O

Attempts	O
to	O
convert	B-DNAMutation
the	I-DNAMutation
AChE	I-DNAMutation
triad	I-DNAMutation
into	I-DNAMutation
a	I-DNAMutation
Cys-His-Glu	I-DNAMutation
or	I-DNAMutation
Ser-His-Asp	I-DNAMutation
configuration	I-DNAMutation
by	I-DNAMutation
site-directed	I-DNAMutation
mutagenesis	I-DNAMutation
did	O
not	O
yield	O
effective	O
AChE	O
activity	O
.	O

Another	O
type	O
of	O
substitution	O
,	O
that	O
of	O
Asp-74	B-DNAMutation
by	I-DNAMutation
Gly	I-DNAMutation
or	I-DNAMutation
Asn	I-DNAMutation
,	O
generated	O
an	O
active	O
enzyme	O
with	O
increased	O
resistance	O
to	O
succinylcholine	O
and	O
dibucaine	O
;	O
thus	O
mimicking	O
in	O
an	O
AChE	O
molecule	O
the	O
phenotype	O
of	O
the	O
atypical	O
butyrylcholinesterase	B-DNAMutation
natural	O
variant	O
(	O
D70G	B-DNAMutation
mutation	O
)	O
.	O

Mutations	O
of	O
other	O
carboxylic	O
residues	O
Glu-84	B-DNAMutation
,	O
Asp-95	B-DNAMutation
,	O
Asp-333	B-DNAMutation
,	O
and	O
Asp-349	B-DNAMutation
,	O
all	O
conserved	O
among	O
cholinesterases	O
,	O
did	O
not	O
result	O
in	O
detectable	O
alteration	O
in	O
the	O
recombinant	O
AChE	O
,	O
although	O
polypeptide	O
productivity	O
of	O
the	O
D95N	B-DNAMutation
mutant	O
was	O
considerably	O
lower	O
.	O

In	O
contrast	O
,	O
complete	O
absence	O
of	O
secreted	O
human	O
AChE	O
polypeptide	O
was	O
observed	O
when	O
Asp-175	B-DNAMutation
or	I-DNAMutation
Asp-404	I-DNAMutation
were	I-DNAMutation
substituted	I-DNAMutation
by	I-DNAMutation
Asn	I-DNAMutation
.	O

These	O
two	O
aspartates	O
are	O
conserved	O
in	O
the	O
entire	O
cholinesterase/thyroglobulin	O
family	O
and	O
appear	O
to	O
play	O
a	O
role	O
in	O
generating	O
and/or	O
maintaining	O
the	O
folded	O
state	O
of	O
the	O
polypeptide	O
.	O

The	O
x-ray	O
structure	O
of	O
the	O
Torpedo	O
acetylcholinesterase	B-DNAMutation
supports	O
this	O
assumption	O
by	O
revealing	O
the	O
participation	O
of	O
these	O
residues	O
in	O
salt	O
bridges	O
between	O
neighboring	O
secondary	O
structure	O
elements	O
.	O

Serine	O
phosphorylation	O
of	O
mCRY1	B-DNAMutation
and	O
mCRY2	B-DNAMutation
by	O
mitogen-activated	O
protein	O
kinase	O
.	O

The	O
circadian	O
oscillator	O
is	O
composed	O
of	O
a	O
transcription/translation-based	O
autoregulatory	O
feedback	O
loop	O
in	O
which	O
Cryptochromes	O
and	O
Periods	O
function	O
as	O
negative	O
regulators	O
for	O
their	O
own	O
gene	O
expression	O
.	O

Although	O
post-translational	O
modifications	O
such	O
as	O
phosphorylation	O
of	O
these	O
regulators	O
appear	O
crucial	O
for	O
circadian	O
time-keeping	O
mechanism	O
,	O
less	O
is	O
known	O
about	O
responsible	O
protein	O
kinases	O
and	O
their	O
contribution	O
to	O
the	O
function	O
of	O
the	O
regulators	O
.	O

We	O
found	O
that	O
mitogen-activated	O
protein	O
kinase	O
(MAPK)	O
associates	O
with	O
and	O
phosphorylates	O
mouse	O
Cryptochromes	O
(	O
mCRY1	B-DNAMutation
and	O
mCRY2	B-DNAMutation
)	O
.	O

Mass	O
spectrometry	O
analysis	O
identified	O
Ser265	O
and	O
Ser557	O
of	O
mCRY2	B-DNAMutation
to	O
be	O
in	O
vitro	O
phospho-acceptor	O
residues	O
.	O

Mutations	B-DNAMutation
of	I-DNAMutation
both	I-DNAMutation
the	I-DNAMutation
Ser	I-DNAMutation
residues	I-DNAMutation
to	I-DNAMutation
Ala	I-DNAMutation
completely	O
abolished	O
MAPK-mediated	O
mCRY2	B-DNAMutation
phosphorylation	O
,	O
suggesting	O
that	O
the	O
two	O
residues	O
are	O
the	O
principal	O
phosphorylation	O
sites	O
in	O
mCRY2	B-DNAMutation
.	O

Similarly	O
,	O
MAPK	O
phosphorylates	O
mCRY1	B-DNAMutation
at	O
Ser247	O
,	O
a	O
site	O
corresponding	O
to	O
Ser265	O
of	O
mCRY2	B-DNAMutation
.	O

An	O
effect	O
of	O
the	O
Ser	O
phosphorylation	O
was	O
investigated	O
by	O
mutating	B-DNAMutation
Ser247	I-DNAMutation
of	O
mCRY1	B-DNAMutation
and	O
Ser265	O
of	O
mCRY2	B-DNAMutation
to	O
Asp	O
,	O
which	O
resulted	O
in	O
attenuation	O
of	O
each	O
mCRYs'	O
ability	O
to	O
inhibit	O
BMAL1	B-DNAMutation
:	O
CLOCK-mediated	B-DNAMutation
transcription	O
,	O
whereas	O
a	O
similar	O
mutation	B-DNAMutation
at	I-DNAMutation
Ser557	I-DNAMutation
of	O
mCRY2	B-DNAMutation
induced	O
no	O
measurable	O
change	O
in	O
its	O
activity	O
.	O

These	O
results	O
illustrate	O
a	O
model	O
of	O
MAPK-mediated	O
negative	O
regulation	O
of	O
mCRY	O
function	O
by	O
phosphorylation	O
at	O
the	O
specific	O
Ser	O
residue	O
.	O

TRESK	O
two-pore-domain	O
K+	O
channels	O
constitute	O
a	O
significant	O
component	O
of	O
background	O
potassium	O
currents	O
in	O
murine	O
dorsal	O
root	O
ganglion	O
neurones	O
.	O

TRESK	B-DNAMutation
(	O
TWIK-related	B-DNAMutation
spinal	I-DNAMutation
cord	I-DNAMutation
K(+)	I-DNAMutation
channel	I-DNAMutation
)	O
is	O
the	O
most	O
recently	O
identified	O
member	O
of	O
the	O
two-pore-domain	O
potassium	O
channel	O
(K(2P))	O
family	O
,	O
the	O
molecular	O
source	O
of	O
background	O
potassium	O
currents	O
.	O

Human	O
TRESK	B-DNAMutation
channels	O
are	O
not	O
affected	O
by	O
external	O
acidification	O
.	O

However	O
,	O
the	O
mouse	O
orthologue	O
displays	O
moderate	O
pH	O
dependence	O
isolated	O
to	O
a	O
single	O
histidine	O
residue	O
adjacent	O
to	O
the	O
GYG	O
selectivity	O
filter	O
.	O

In	O
the	O
human	O
protein	O
,	O
sequence	B-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
tyrosine	I-DNAMutation
by	I-DNAMutation
histidine	I-DNAMutation
at	I-DNAMutation
this	I-DNAMutation
critical	I-DNAMutation
position	I-DNAMutation
generated	O
a	O
mutant	O
that	O
displays	O
almost	O
identical	O
proton	O
sensitivity	O
compared	O
with	O
mouse	B-DNAMutation
TRESK	I-DNAMutation
.	O

In	O
contrast	O
to	O
human	O
TRESK	B-DNAMutation
,	O
which	O
is	O
specifically	O
located	O
in	O
spinal	O
cord	O
,	O
we	O
detected	O
mouse	B-DNAMutation
TRESK	I-DNAMutation
mTRESK	B-DNAMutation
mRNA	O
in	O
several	O
epithelial	O
and	O
neuronal	O
tissues	O
including	O
lung	O
,	O
liver	O
,	O
kidney	O
,	O
brain	O
and	O
spinal	O
cord	O
.	O

As	O
revealed	O
by	O
endpoint	O
and	O
quantitative	O
RT-PCR	O
,	O
mTRESK	B-DNAMutation
channels	O
are	O
mainly	O
expressed	O
in	O
dorsal	O
root	O
ganglia	O
(DRG)	O
and	O
on	O
the	O
transcript	O
level	O
represent	O
the	O
most	O
important	O
background	O
potassium	O
channel	O
in	O
this	O
tissue	O
.	O

DRG	O
neurones	O
of	O
all	O
sizes	O
were	O
labelled	O
by	O
in	O
situ	O
hybridizations	O
with	O
TRESK-specific	B-DNAMutation
probes	O
.	O

In	O
DRG	O
neurones	O
of	O
TRESK[G339R]	B-DNAMutation
functional	O
knock-out	O
(KO)	O
mice	O
the	O
standing	O
outward	O
current	O
IK(so)	O
was	O
significantly	O
reduced	O
compared	O
with	O
TRESK	B-DNAMutation
wild-type	O
(WT)	O
littermates	O
.	O

Different	O
responses	O
to	O
K(2P)	O
channel	O
regulators	O
such	O
as	O
bupivacaine	O
,	O
extracellular	O
protons	O
and	O
quinidine	O
corroborated	O
the	O
finding	O
that	O
approximately	O
20%	O
of	O
IK(so)	O
is	O
carried	O
by	O
TRESK	B-DNAMutation
channels	O
.	O

Unexpectedly	O
,	O
we	O
found	O
no	O
difference	O
in	O
resting	O
membrane	O
potential	O
between	O
DRG	O
neurones	O
of	O
TRESK[WT]	B-DNAMutation
and	O
TRESK[G339R]	B-DNAMutation
functional	O
KO	O
mice	O
.	O

However	O
,	O
in	O
current-clamp	O
recordings	O
we	O
observed	O
significant	O
changes	O
in	O
action	O
potential	O
duration	O
and	O
amplitude	O
of	O
after-hyperpolarization	O
.	O

Most	O
strikingly	O
,	O
cellular	O
excitability	O
of	O
DRG	O
neurones	O
from	O
functional	O
KO	O
mice	O
was	O
significantly	O
augmented	O
as	O
revealed	O
by	O
reduced	O
rheobase	O
current	O
to	O
elicit	O
action	O
potentials	O
.	O

Ten	O
nucleotide	O
differences	O
,	O
five	O
of	O
which	O
cause	O
amino	O
acid	O
changes	O
,	O
are	O
associated	O
with	O
the	O
Ah	B-DNAMutation
receptor	I-DNAMutation
locus	O
polymorphism	O
of	O
C57BL/6	O
and	O
DBA/2	O
mice	O
.	O

We	O
have	O
analysed	O
by	O
heteroduplex	O
formation	O
(HF)	O
,	O
single	O
stranded	O
conformational	O
polymorphism	O
(SSCP)	O
,	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(DGGE)	O
,	O
and	O
nucleotide	O
sequencing	O
the	O
cDNAs	O
of	O
the	O
Ahrb-1	O
and	O
Ahrd	O
allelic	O
forms	O
of	O
the	O
aromatic	B-DNAMutation
hydrocarbon	I-DNAMutation
receptor	I-DNAMutation
AhR	B-DNAMutation
present	O
in	O
inbred	O
strains	O
of	O
mice	O
.	O

The	O
Ahrb-1	O
allele	O
,	O
found	O
in	O
the	O
C57BL	O
and	O
C57BR	O
strains	O
,	O
encodes	O
a	O
95	O
kDa	O
receptor	O
with	O
an	O
affinity	O
for	O
ligand	O
15-20	O
times	O
higher	O
than	O
the	O
affinity	O
of	O
the	O
104	O
kDa	O
receptor	O
encoded	O
by	O
the	O
Ahrd	O
allele	O
,	O
found	O
in	O
the	O
DBA/2	O
strain	O
.	O

Five	O
overlapping	O
fragments	O
of	O
the	O
AhR	B-DNAMutation
coding	O
sequence	O
were	O
obtained	O
from	O
liver	O
RNA	O
by	O
reverse	O
transcriptase	O
synthesis	O
of	O
a	O
cDNA	O
first	O
strand	O
,	O
followed	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
these	O
cDNA	O
sequences	O
(RT-PCR)	O
.	O

Analysis	O
by	O
HF	O
and	O
SSCP	O
revealed	O
the	O
presence	O
of	O
sequence	O
differences	O
in	O
three	O
of	O
the	O
five	O
fragments	O
.	O

When	O
the	O
complete	O
nucleotide	O
sequence	O
of	O
the	O
coding	O
regions	O
was	O
determined	O
by	O
PCR	O
sequencing	O
,	O
we	O
found	O
a	O
total	O
of	O
ten	O
nucleotide	O
differences	O
between	O
the	O
two	O
alleles	O
,	O
nine	O
of	O
which	O
localized	O
to	O
the	O
three	O
fragments	O
where	O
differences	O
were	O
detected	O
by	O
HF	O
and	O
SSCP	O
.	O

Five	O
of	O
the	O
differences	O
are	O
silent	O
.	O

Of	O
the	O
other	O
five	O
,	O
one	O
changes	O
the	O
opal	B-DNAMutation
termination	I-DNAMutation
codon	I-DNAMutation
in	I-DNAMutation
Ahrb-1	I-DNAMutation
to	I-DNAMutation
the	I-DNAMutation
codon	I-DNAMutation
for	I-DNAMutation
Arg	I-DNAMutation
in	O
Ahrd	O
,	O
extending	O
translation	O
of	O
the	O
mRNA	O
by	O
43	O
amino	O
acids	O
and	O
accounting	O
for	O
the	O
larger	O
size	O
of	O
the	O
AhR	B-DNAMutation
peptide	O
in	O
DBA/2	O
mice	O
.	O

One	O
of	O
the	O
four	O
remaining	O
differences	O
causes	O
the	O
replacement	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
leucine	I-DNAMutation
residue	I-DNAMutation
in	I-DNAMutation
Ahrb-1	I-DNAMutation
by	I-DNAMutation
a	I-DNAMutation
proline	I-DNAMutation
residue	I-DNAMutation
in	I-DNAMutation
Ahrd	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
breaks	I-DNAMutation
a	I-DNAMutation
potential	I-DNAMutation
alpha-helix	I-DNAMutation
near	I-DNAMutation
the	I-DNAMutation
AhR	I-DNAMutation
Q-rich	I-DNAMutation
region	I-DNAMutation
;	O
it	O
is	O
likely	O
that	O
structural	O
changes	O
associated	O
with	O
this	O
amino	O
acid	O
change	O
are	O
responsible	O
for	O
the	O
differences	O
in	O
agonist	O
affinity	O
observed	O
between	O
the	O
Ah	O
receptors	O
of	O
these	O
two	O
strains	O
of	O
mice	O
.	O

Presenile	O
dementia	O
and	O
cerebral	O
haemorrhage	O
linked	O
to	O
a	O
mutation	B-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
692	I-DNAMutation
of	O
the	O
beta-amyloid	B-DNAMutation
precursor	I-DNAMutation
protein	I-DNAMutation
gene	O
.	O

Several	O
families	O
with	O
an	O
early-onset	O
form	O
of	O
familial	O
Alzheimer's	O
disease	O
have	O
been	O
found	O
to	O
harbour	O
mutations	B-DNAMutation
at	I-DNAMutation
a	I-DNAMutation
specific	I-DNAMutation
codon	I-DNAMutation
(717)	I-DNAMutation
of	O
the	O
gene	O
for	O
the	O
beta-amyloid	B-DNAMutation
precursor	I-DNAMutation
protein	I-DNAMutation
APP	B-DNAMutation
on	O
chromosome	O
21	O
.	O

We	O
now	O
report	O
,	O
a	O
novel	O
base	O
mutation	O
in	O
the	O
same	O
exon	O
of	O
the	O
APP	B-DNAMutation
gene	O
which	O
co-segregates	O
in	O
one	O
family	O
with	O
presenile	O
dementia	O
and	O
cerebral	O
haemorrhage	O
due	O
to	O
cerebral	O
amyloid	O
angiopathy	O
.	O

The	O
mutation	O
results	O
in	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
alanine	I-DNAMutation
into	I-DNAMutation
glycine	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
692	I-DNAMutation
.	O

These	O
results	O
suggest	O
that	O
the	O
clinically	O
distinct	O
entities	O
,	O
presenile	O
dementia	O
and	O
cerebral	O
amyloid	O
angiopathy	O
,	O
can	O
be	O
caused	O
by	O
the	O
same	O
mutation	O
in	O
the	O
APP	B-DNAMutation
gene	O
.	O

B56Î´-related	O
protein	O
phosphatase	O
2A	O
dysfunction	O
identified	O
in	O
patients	O
with	O
intellectual	O
disability	O
.	O

Here	O
we	O
report	O
inherited	O
dysregulation	O
of	O
protein	O
phosphatase	O
activity	O
as	O
a	O
cause	O
of	O
intellectual	O
disability	O
(ID)	O
.	O

De	O
novo	O
missense	O
mutations	O
in	O
2	O
subunits	O
of	O
serine/threonine	O
(Ser/Thr)	O
protein	O
phosphatase	O
2A	O
(PP2A)	I-DNAMutation
were	O
identified	O
in	O
16	O
individuals	O
with	O
mild	O
to	O
severe	O
ID	O
,	O
long-lasting	O
hypotonia	O
,	O
epileptic	O
susceptibility	O
,	O
frontal	O
bossing	O
,	O
mild	O
hypertelorism	O
,	O
and	O
downslanting	O
palpebral	O
fissures	O
.	I-DNAMutation
PP2A	I-DNAMutation
comprises	O
catalytic	O
(C)	O
,	O
scaffolding	O
(A)	O
,	O
and	O
regulatory	O
(B)	O
subunits	O
that	O
determine	O
subcellular	O
anchoring	O
,	O
substrate	O
specificity	O
,	O
and	O
physiological	O
function	O
.	O

Ten	O
patients	O
had	O
mutations	O
within	O
a	O
highly	O
conserved	O
acidic	O
loop	O
of	O
the	B-DNAMutation
PPP2R5D-encoded	I-DNAMutation
B56Î´	O
regulatory	O
subunit	O
,	O
with	O
the	O
same	B-DNAMutation
E198K	I-DNAMutation
mutation	O
present	O
in	O
6	O
individuals	O
.	O

Five	O
patients	O
had	O
mutations	O
in	O
the	B-DNAMutation
PPP2R1A-encoded	I-DNAMutation
scaffolding	O
AÎ±	O
subunit	O
,	O
with	O
the	O
same	B-DNAMutation
R182W	I-DNAMutation
mutation	O
in	O
3	O
individuals	O
.	O

Some	O
AÎ±	O
cases	O
presented	O
with	O
large	O
ventricles	O
,	O
causing	O
macrocephaly	O
and	O
hydrocephalus	O
suspicion	O
,	O
and	O
all	O
cases	O
exhibited	O
partial	O
or	O
complete	O
corpus	O
callosum	O
agenesis	O
.	O

Functional	O
evaluation	O
revealed	O
that	O
mutant	O
A	O
and	O
B	O
subunits	O
were	O
stable	O
and	O
uncoupled	O
from	O
phosphatase	O
activity	O
.	O

Mutant	O
B56Î´	O
was	O
A	O
and	O
C	O
binding-deficient	O
,	O
while	O
mutant	O
AÎ±	O
subunits	O
bound	O
B56Î´	O
well	O
but	O
were	O
unable	O
to	O
bind	O
C	O
or	O
bound	O
a	O
catalytically	O
impaired	O
C	O
,	O
suggesting	O
a	O
dominant-negative	O
effect	O
where	O
mutant	O
subunits	O
hinder	O
dephosphorylation	O
of	O
B56Î´-anchored	O
substrates	O
.	O

Moreover	O
,	O
mutant	O
subunit	O
overexpression	O
resulted	O
in	O
hyperphosphorylation	B-DNAMutation
of	O
GSK3Î²	O
,	O
a	O
B56Î´-regulated	O
substrate	O
.	O

This	O
effect	O
was	O
in	O
line	O
with	O
clinical	O
observations	O
,	O
supporting	O
a	O
correlation	O
between	O
the	O
ID	O
degree	O
and	O
biochemical	O
disturbance	O
.	O

Characterization	O
of	O
the	O
normal	O
alpha	B-DNAMutation
1-antitrypsin	I-DNAMutation
allele	O
Vmunich	O
:	O
a	O
variant	O
associated	O
with	O
a	O
unique	O
protein	O
isoelectric	O
focusing	O
pattern	O
.	O

alpha	B-DNAMutation
1-Antitrypsin	I-DNAMutation
(	O
alpha	B-DNAMutation
1AT	I-DNAMutation
)	O
,	O
the	O
major	O
serum	O
inhibitor	O
of	O
neutrophil	O
elastase	O
,	O
is	O
a	O
highly	O
polymorphic	O
protein	O
associated	O
with	O
isoelectric	O
focusing	O
(IEF)	O
patterns	O
typical	O
for	O
each	O
variant	O
.	O

alpha	B-DNAMutation
1AT	I-DNAMutation
Vmunich	O
,	O
a	O
previously	O
unreported	O
normal	O
alpha	B-DNAMutation
1AT	I-DNAMutation
variant	O
,	O
has	O
a	O
unique	O
IEF	O
banding	O
pattern	O
in	O
which	O
the	O
7	O
and	O
8	O
alpha	B-DNAMutation
1AT	I-DNAMutation
protein	O
bands	O
focus	O
with	O
the	O
normal	O
M-type	O
7	O
and	O
8	O
bands	O
,	O
despite	O
the	O
fact	O
that	O
the	O
major	O
fraction	O
of	O
the	O
Vmunich	O
protein	O
focuses	O
in	O
the	O
"V"	O
region	O
of	O
the	O
IEF	O
gel	O
.	O

To	O
characterize	O
the	O
molecular	O
basis	O
of	O
this	O
variant	O
and	O
its	O
unique	O
IEF	O
pattern	O
,	O
DNA	O
sequence	O
analysis	O
of	O
the	O
coding	O
exons	O
of	O
the	O
Vmunich	O
alpha	B-DNAMutation
1AT	I-DNAMutation
gene	O
was	O
carried	O
out	O
using	O
the	O
polymerase	O
chain	O
reaction	O
.	O

The	O
Vmunich	O
allele	O
differed	O
from	O
the	O
common	O
normal	O
M1(Val213)	B-DNAMutation
alpha	I-DNAMutation
1AT	I-DNAMutation
allele	I-DNAMutation
by	I-DNAMutation
a	I-DNAMutation
single	I-DNAMutation
nucleotide	I-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
cytosine	I-DNAMutation
for	I-DNAMutation
adenosine	I-DNAMutation
,	O
with	O
the	O
resultant	O
amino	B-DNAMutation
acid	I-DNAMutation
change	I-DNAMutation
Asp2	I-DNAMutation
GAT----Ala	I-DNAMutation
GCT	I-DNAMutation
.	O

Inheritance	O
of	O
the	O
allele	O
was	O
confirmed	O
by	O
family	O
analysis	O
using	O
allele-specific	O
amplification	O
with	O
the	O
polymerase	O
chain	O
reaction	O
.	O

The	O
Asp2----Ala	B-DNAMutation
mutation	I-DNAMutation
explains	O
the	O
cathodal	O
position	O
of	O
the	O
Vmunich	O
protein	O
on	O
IEF	O
,	O
as	O
there	O
is	O
a	O
substitution	O
of	O
a	O
negatively	O
charged	O
amino	O
acid	O
by	O
a	O
neutral	O
one.(ABSTRACT	O
TRUNCATED	O
AT	O
250	O
WORDS	O
)	O
Novel	O
mutation	O
in	O
the	O
gene	O
encoding	O
c-Abl-binding	O
protein	O
SH3BP2	B-DNAMutation
causes	O
cherubism	O
.	O

Cherubism	O
is	O
a	O
rare	O
autosomal	O
dominant	O
inherited	O
condition	O
caused	O
by	O
mutations	O
in	O
the	O
c-Abl-binding	O
protein	O
SH3BP2	B-DNAMutation
.	O

It	O
is	O
characterized	O
by	O
multiple	O
cystic	O
giant	O
cell	O
lesions	O
of	O
the	O
jaw	O
appearing	O
in	O
early	O
childhood	O
with	O
stabilization	O
and	O
remission	O
after	O
puberty	O
.	O

In	O
the	O
present	O
study	O
,	O
we	O
used	O
direct	O
sequence	O
analysis	O
of	O
the	O
SH3BP2	B-DNAMutation
gene	O
of	O
several	O
individuals	O
from	O
a	O
family	O
with	O
cherubism	O
to	O
search	O
for	O
additional	O
SH3BP2	B-DNAMutation
mutations	O
resulting	O
in	O
cherubism	O
.	O

In	O
affected	O
relatives	O
,	O
we	O
found	O
a	O
previously	O
unreported	O
G	B-DNAMutation
to	I-DNAMutation
A	I-DNAMutation
transition	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
9	I-DNAMutation
leading	I-DNAMutation
to	I-DNAMutation
a	I-DNAMutation
Gly	I-DNAMutation
to	I-DNAMutation
Arg	I-DNAMutation
substitution	I-DNAMutation
at	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
position	I-DNAMutation
420	I-DNAMutation
.	O

G420R	B-DNAMutation
has	O
been	O
reported	O
previously	O
with	O
a	O
G	B-DNAMutation
to	I-DNAMutation
C	I-DNAMutation
transversion	I-DNAMutation
.	O

To	O
date	O
there	O
have	O
been	O
no	O
disease	O
causing	O
mutations	O
outside	O
exon	O
9	O
.	O

Therefore	O
,	O
the	O
amino	O
acid	O
sequence	O
from	O
positions	O
415	O
to	O
420	O
may	O
represent	O
a	O
specific	O
protein	O
domain	O
which	O
,	O
when	O
disrupted	O
,	O
leads	O
to	O
the	O
cherubism	O
phenotype	O
.	O

Mutation	O
in	O
the	O
human	O
gene	O
for	O
3	B-DNAMutation
beta-hydroxysteroid	I-DNAMutation
dehydrogenase	I-DNAMutation
type	O
II	O
leading	O
to	O
male	O
pseudohermaphroditism	O
without	O
salt	O
loss	O
.	O

A	I-DNAMutation
5-year-old	O
XY	O
pseudohermaphrodite	O
was	O
found	O
to	O
have	O
a	O
defect	O
of	O
steroid	O
biosynthesis	O
consistent	O
with	O
a	O
partial	O
deficiency	O
of	O
the	O
enzyme	O
3	B-DNAMutation
beta-hydroxysteroid	I-DNAMutation
dehydrogenase	I-DNAMutation
(	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
)	O
.	O

Circulating	O
concentrations	O
of	O
delta	O
5	O
steroids	O
and	O
delta	O
5	O
urinary	O
steroid	O
metabolites	O
were	O
elevated	O
and	O
remained	O
elevated	O
after	O
orchidectomy	O
.	O

There	O
was	O
no	O
evidence	O
of	O
salt	O
loss	O
,	O
plasma	O
renin	O
being	O
within	O
normal	O
limits	O
,	O
and	O
no	O
detectable	O
glucocorticoid	O
abnormality	O
.	O

The	O
coding	O
sequences	O
of	O
the	O
genes	O
for	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
types	O
I	O
and	O
II	O
were	O
amplified	O
by	O
PCR	O
and	O
screened	O
for	O
mutations	O
by	O
denaturing	O
gradient	O
gel	O
electrophoresis	O
(DGGE)	O
and	O
manual	O
and	O
automatic	O
DNA	O
sequencing	O
.	O

A	O
mutation	O
in	O
the	O
gene	O
for	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
type	O
II	O
was	O
observed	O
at	O
codon	B-DNAMutation
173	I-DNAMutation
(CTA-->CGA)	I-DNAMutation
,	O
leading	O
in	O
the	O
affected	O
patient	O
to	O
a	O
homozygous	O
substitution	O
in	O
which	O
the	O
leucine	B-DNAMutation
at	I-DNAMutation
residue	I-DNAMutation
173	I-DNAMutation
was	I-DNAMutation
altered	I-DNAMutation
to	I-DNAMutation
an	I-DNAMutation
arginine	I-DNAMutation
L173R	B-DNAMutation
.	O

The	O
propositus's	O
2-year-old	O
XX	O
sister	O
was	O
also	O
homozygous	O
for	O
L173R	B-DNAMutation
and	O
showed	O
the	O
biochemical	O
characteristics	O
of	O
partial	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
deficiency	O
without	O
clinical	O
symptoms	O
or	O
signs	O
.	O

The	O
mutation	O
segregated	O
as	O
an	O
autosomal	O
recessive	O
.	O

Three	O
related	O
heterozygous	O
adult	O
females	O
showed	O
evidence	O
of	O
a	O
small	O
over-production	O
of	O
delta	O
5	O
steroids	O
and	O
steroid	O
metabolites	O
and	O
a	O
variable	O
reduction	O
in	O
ovarian	O
function	O
.	O

Concentrations	O
of	O
delta	O
5	O
steroids	O
and	O
steroid	O
metabolites	O
in	O
the	O
heterozygous	O
father	O
of	O
the	O
propositus	O
were	O
within	O
the	O
normal	O
range	O
.	O

These	O
data	O
are	O
discussed	O
in	O
relation	O
to	O
the	O
endocrine	O
causes	O
of	O
pseudohermaphroditism	O
and	O
hirsutism	O
.	O

Evidence	O
for	O
tight	O
linkage	O
between	O
the	O
genes	O
for	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
types	O
I	O
and	O
II	O
was	O
obtained	O
using	O
a	O
microsatellite	O
polymorphism	O
in	O
the	O
third	O
intron	O
of	O
the	O
gene	O
for	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
type	O
II	O
and	O
synonymous	O
and	O
non-synonymous	O
mutations	O
and	O
polymorphisms	O
in	O
the	O
gene	O
for	O
3	B-DNAMutation
beta-HSD	I-DNAMutation
type	O
I	O
.	O

The	O
latter	O
polymorphisms	B-DNAMutation
were	I-DNAMutation
located	I-DNAMutation
88	I-DNAMutation
bp	I-DNAMutation
apart	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
3'	I-DNAMutation
end	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
type	I-DNAMutation
I	I-DNAMutation
coding	I-DNAMutation
sequence	I-DNAMutation
and	O
could	O
be	O
physically	O
resolved	O
as	O
haplotypes	O
using	O
DGGE	O
.	O

The	O
application	O
of	O
DGGE	O
to	O
the	O
analysis	O
of	O
mutations	O
in	O
members	O
of	O
a	O
multigene	O
family	O
is	O
discussed	O
.	O

Secretion	O
and	O
lysophospholipase	O
D	O
activity	O
of	O
autotaxin	B-DNAMutation
by	O
adipocytes	O
are	O
controlled	O
by	O
N-glycosylation	O
and	O
signal	O
peptidase	O
.	O

Autotaxin	B-DNAMutation
ATX	B-DNAMutation
is	O
a	O
lysophospholipase	O
D	O
involved	O
in	O
synthesis	O
of	O
lysophosphatidic	O
acid	O
(LPA)	O
.	O

ATX	B-DNAMutation
is	O
secreted	O
by	O
adipocytes	O
and	O
is	O
associated	O
with	O
adipogenesis	O
and	O
obesity-associated	O
diabetes	O
.	O

Here	O
we	O
have	O
studied	O
the	O
mechanisms	O
involved	O
in	O
biosynthesis	O
and	O
secretion	O
of	O
ATX	B-DNAMutation
by	O
mouse	O
3T3-F442A	B-DNAMutation
adipocytes	O
.	O

We	O
found	O
that	O
inhibition	O
of	O
N-glycosylation	O
with	O
tunicamycin	O
or	O
by	O
double	O
point	O
deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
amino-acids	I-DNAMutation
N53	I-DNAMutation
and	I-DNAMutation
N410	I-DNAMutation
of	O
ATX	B-DNAMutation
inhibit	O
its	O
secretion	O
.	O

In	O
addition	O
,	O
N-glycosidase	O
treatment	O
and	O
point	O
deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
amino-acid	I-DNAMutation
N410	I-DNAMutation
inhibits	O
the	O
lysophospholipase	O
D	O
activity	O
of	O
ATX	B-DNAMutation
.	O

Analysis	O
of	O
the	O
amino-acid	O
sequence	O
of	O
mouse	O
ATX	B-DNAMutation
shows	O
the	O
presence	O
of	O
a	O
N-terminal	O
signal	O
peptide	O
.	O

Treatment	O
with	O
the	O
signal	O
peptidase	O
inhibitor	O
globomycin	O
inhibits	O
ATX	B-DNAMutation
secretion	O
by	O
adipocytes	O
.	O

Transfection	O
in	O
Cos-7	O
cells	O
of	O
site-directed	O
deleted	O
ATX	B-DNAMutation
shows	O
that	O
ATX	B-DNAMutation
secretion	O
is	O
dependent	O
on	O
the	O
hydrophobic	O
core	O
sequence	O
of	O
the	O
signal	O
peptide	O
,	O
not	O
on	O
the	O
putative	O
signal	O
peptidase	O
cleavage	O
site	O
sequence	O
.	O

Analysis	O
of	O
the	O
amino-acid	O
sequence	O
of	O
mouse	O
ATX	B-DNAMutation
also	O
reveals	O
the	O
presence	O
of	O
a	O
putative	O
cleavage	O
site	O
by	O
the	O
protein	O
convertase	O
furin	B-DNAMutation
.	O

Treatment	O
of	O
adipocytes	O
with	O
the	O
furin	B-DNAMutation
inhibitor	O
decanoyl-Arg-Val-Lys-Arg-chloromethylketone	O
does	O
not	O
modified	O
secretion	O
or	O
lysophospholipase	O
D	O
activity	O
of	O
ATX	B-DNAMutation
.	O

Transfection	O
in	O
Cos-7	O
cells	O
of	O
site-directed	O
deleted	O
ATX	B-DNAMutation
shows	O
that	O
the	O
furin	B-DNAMutation
recognition	O
site	O
is	O
not	O
required	O
for	O
secretion	O
or	O
lysophospholipase	O
D	O
activity	O
of	O
ATX	B-DNAMutation
.	O

In	O
conclusion	O
,	O
the	O
present	O
work	O
demonstrates	O
the	O
crucial	O
role	O
of	O
N-glycosylation	O
in	O
secretion	O
and	O
activity	O
of	O
ATX	B-DNAMutation
.	O

The	O
present	O
work	O
also	O
confirms	O
the	O
crucial	O
role	O
signal	O
peptidase	O
in	O
secretion	O
of	O
ATX	B-DNAMutation
by	O
adipocytes	O
.	O

Pias1	B-DNAMutation
interaction	O
and	O
sumoylation	O
of	O
metabotropic	O
glutamate	O
receptor	O
8	O
.	O

Group	O
III	O
presynaptic	O
metabotropic	O
glutamate	O
receptors	O
(mGluRs)	O
play	O
a	O
central	O
role	O
in	O
regulating	O
presynaptic	O
activity	O
through	O
G-protein	O
effects	O
on	O
ion	O
channels	O
and	O
signal	O
transducing	O
enzymes	O
.	O

Like	O
all	O
Class	O
C	O
G-protein-coupled	O
receptors	O
,	O
mGluR8	B-DNAMutation
has	O
an	O
extended	O
intracellular	O
C-terminal	O
domain	O
(CTD)	O
presumed	O
to	O
allow	O
for	O
modulation	O
of	O
downstream	O
signaling	O
.	O

In	O
a	O
yeast	O
two-hybrid	O
screen	O
of	O
an	O
adult	O
rat	O
brain	O
cDNA	O
library	O
with	O
the	O
CTDs	O
of	O
mGluR8a	O
and	O
8b	O
mGluR8-C	B-DNAMutation
as	O
baits	O
,	O
we	O
identified	O
sumo1	B-DNAMutation
and	O
four	O
different	O
components	O
of	O
the	O
sumoylation	O
cascade	O
(	O
ube2a	B-DNAMutation
,	O
Pias1	O
,	O
Piasgamma	O
,	O
Piasxbeta	O
)	O
as	O
interacting	O
proteins	O
.	O

Binding	O
assays	O
using	O
recombinant	O
GST	O
fusion	O
proteins	O
confirmed	O
that	O
Pias1	B-DNAMutation
interacts	O
not	O
only	O
with	O
mGluR8-C	B-DNAMutation
but	O
also	O
with	O
all	O
group	O
III	O
mGluR	O
CTDs	O
.	O

Pias1	B-DNAMutation
binding	O
to	O
mGluR8-C	B-DNAMutation
required	O
a	O
region	O
N-terminal	O
to	O
a	O
consensus	O
sumoylation	O
motif	O
and	O
was	O
not	O
affected	O
by	O
arginine	B-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
conserved	I-DNAMutation
lysine	I-DNAMutation
882	I-DNAMutation
within	O
this	O
motif	O
.	O

Co-transfection	O
of	O
fluorescently	O
tagged	O
mGluR8a-C	O
,	O
sumo1	B-DNAMutation
,	O
and	O
enzymes	O
of	O
the	O
sumoylation	O
cascade	O
into	O
HEK293	O
cells	O
showed	O
that	O
mGluR8a-C	O
can	O
be	O
sumoylated	O
in	O
vivo	O
.	O

Arginine	B-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
lysine	I-DNAMutation
882	I-DNAMutation
within	O
the	O
consensus	O
sumoylation	O
motif	O
,	O
but	O
not	O
other	O
conserved	O
lysines	O
within	O
the	O
CTD	O
,	O
abolished	O
in	O
vivo	O
sumoylation	O
.	O

Our	O
results	O
are	O
consistent	O
with	O
post-translational	O
sumoylation	O
providing	O
a	O
novel	O
mechanism	O
of	O
group	O
III	O
mGluR	O
regulation	O
.	O

Linkage	O
and	O
mutational	O
analysis	O
of	O
familial	O
Alzheimer	O
disease	O
kindreds	O
for	O
the	O
APP	O
gene	O
region	O
.	O

A	O
large	O
number	O
of	O
familial	O
Alzheimer	O
disease	O
(FAD)	O
kindreds	O
were	O
examined	O
to	O
determine	O
whether	O
mutations	O
in	O
the	O
amyloid	B-DNAMutation
precursor	I-DNAMutation
protein	I-DNAMutation
(APP)	O
gene	O
could	O
be	O
responsible	O
for	O
the	O
disease	O
.	O

Previous	O
studies	O
have	O
identified	O
three	O
mutations	B-DNAMutation
at	I-DNAMutation
APP	I-DNAMutation
codon	I-DNAMutation
717	I-DNAMutation
which	O
are	O
pathogenic	O
for	O
Alzheimer	O
disease	O
(AD)	O
.	O

Samples	O
from	O
affected	O
subjects	O
were	O
examined	O
for	O
mutations	O
in	O
exons	O
16	O
and	O
17	O
of	O
the	O
APP	O
gene	O
.	O

A	O
combination	O
of	O
direct	O
sequencing	O
and	O
single-strand	O
conformational	O
polymorphism	O
analysis	O
was	O
used	O
.	O

Sporadic	O
AD	O
and	O
normal	O
controls	O
were	O
also	O
examined	O
by	O
the	O
same	O
methods	O
.	O

Five	O
sequence	O
variants	O
were	O
identified	O
.	O

One	O
variant	O
at	O
APP	O
codon	B-DNAMutation
693	I-DNAMutation
resulted	I-DNAMutation
in	I-DNAMutation
a	I-DNAMutation
Glu-->Gly	I-DNAMutation
change	I-DNAMutation
.	O

This	O
is	O
the	O
same	O
codon	O
as	O
the	O
hereditary	O
cerebral	O
hemorrhage	O
with	O
amyloidosis-Dutch	O
type	O
Glu-->Gln	O
mutation	O
.	O

Another	O
single-base	B-DNAMutation
change	I-DNAMutation
at	I-DNAMutation
APP	I-DNAMutation
codon	I-DNAMutation
708	I-DNAMutation
did	O
not	O
alter	O
the	O
amino	O
acid	O
encoded	O
at	O
this	O
site	O
.	O

Two	O
point	O
mutations	O
and	O
a	O
6-bp	B-DNAMutation
deletion	I-DNAMutation
were	I-DNAMutation
identified	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
intronic	I-DNAMutation
sequences	I-DNAMutation
surrounding	I-DNAMutation
exon	I-DNAMutation
17	I-DNAMutation
.	O

None	O
of	O
the	O
variants	O
could	O
be	O
unambiguously	O
determined	O
to	O
be	O
responsible	O
for	O
FAD	O
.	O

The	O
larger	O
families	O
were	O
also	O
analyzed	O
by	O
testing	O
for	O
linkage	O
of	O
FAD	O
to	O
a	O
highly	O
polymorphic	O
short	O
tandem	O
repeat	O
marker	O
(D21S210)	O
that	O
is	O
tightly	O
linked	O
to	O
APP	O
.	O

Highly	O
negative	O
LOD	O
scores	O
were	O
obtained	O
for	O
the	O
family	O
groups	O
tested	O
,	O
and	O
linkage	O
was	O
formally	O
excluded	O
beyond	O
theta	O
=	O
.10	O
for	O
the	O
Volga	O
German	O
kindreds	O
,	O
theta	O
=	O
.20	O
for	O
early-onset	O
non-Volga	O
Germans	O
,	O
and	O
theta	O
=	O
.10	O
for	O
late-onset	O
families	O
.	O

LOD	O
scores	O
for	O
linkage	O
of	O
FAD	O
to	O
markers	O
centromeric	O
to	O
APP	O
(	O
D21S1/S11	O
,	O
D21S13	O
,	O
and	O
D21S215	O
)	O
were	O
also	O
negative	O
in	O
the	O
three	O
family	O
groups	O
.	O

These	O
studies	O
show	O
that	O
APP	O
mutations	O
account	O
for	O
AD	O
in	O
only	O
a	O
small	O
fraction	O
of	O
FAD	O
kindreds	O
.	O

ADAMTS-1	B-DNAMutation
is	O
an	O
active	O
metalloproteinase	O
associated	O
with	O
the	O
extracellular	O
matrix	O
.	O

Cellular	O
disintegrin	O
and	O
metalloproteinases	O
(ADAMs)	O
are	O
a	O
family	O
of	O
genes	O
with	O
a	O
sequence	O
similar	O
to	O
the	O
snake	O
venom	O
metalloproteinases	O
and	O
disintegrins	O
.	O

ADAMTS-1	B-DNAMutation
is	O
a	O
unique	O
ADAM	O
family	O
protein	O
with	O
respect	O
to	O
the	O
presence	O
of	O
thrombospondin	O
type	O
I	O
motifs	O
and	O
the	O
capacity	O
to	O
bind	O
to	O
the	O
extracellular	O
matrix	O
.	O

Because	O
ADAMTS-1	B-DNAMutation
has	O
a	O
potential	O
zinc-binding	O
motif	O
in	O
the	O
metalloproteinase	O
domain	O
,	O
we	O
examined	O
in	O
this	O
study	O
whether	O
ADAMTS-1	B-DNAMutation
is	O
an	O
active	O
metalloproteinase	O
by	O
means	O
of	O
the	O
proteinase	O
trapping	O
mechanism	O
of	O
alpha2-macroglobulin	B-DNAMutation
.	O

We	O
found	O
that	O
the	O
soluble	O
type	O
of	O
ADAMTS-1	B-DNAMutation
protein	O
is	O
able	O
to	O
form	O
a	O
covalent-binding	O
complex	O
with	O
alpha2-macroglobulin	B-DNAMutation
.	O

Furthermore	O
,	O
the	O
point	O
mutation	O
within	O
the	O
zinc-binding	O
motif	O
of	O
ADAMTS-1	B-DNAMutation
protein	O
eliminates	O
its	O
capacity	O
to	O
bind	O
to	O
alpha2-macroglobulin	B-DNAMutation
.	O

These	O
data	O
demonstrate	O
that	O
the	O
metalloproteinase	O
domain	O
of	O
ADAMTS-1	B-DNAMutation
is	O
catalytically	O
active	O
.	O

In	O
addition	O
,	O
we	O
showed	O
that	O
the	O
removal	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
pro-domain	I-DNAMutation
from	O
the	O
ADAMTS-1	B-DNAMutation
precursor	O
is	O
impaired	O
in	O
the	O
furin-deficient	B-DNAMutation
cell	O
line	O
,	O
LoVo	O
,	O
and	O
that	O
the	O
processing	O
ability	O
of	O
the	O
cells	O
is	O
restored	O
by	O
the	O
co-expression	O
of	O
the	O
furin	B-DNAMutation
cDNA	O
.	O

These	O
data	O
provide	O
evidence	O
that	O
the	O
ADAMTS-1	B-DNAMutation
precursor	O
is	O
processed	O
in	O
vivo	O
by	O
furin	B-DNAMutation
endopeptidase	O
in	O
the	O
secretory	O
pathway	O
.	O

Consequently	O
,	O
ADAMTS-1	B-DNAMutation
is	O
an	O
active	O
metalloprotease	O
that	O
is	O
associated	O
with	O
the	O
extracellular	O
matrix	O
.	O

This	O
study	O
strongly	O
suggests	O
that	O
ADAMTS-1	B-DNAMutation
may	O
play	O
a	O
role	O
in	O
the	O
inflammatory	O
process	O
through	O
its	O
protease	O
activity	O
.	O

Constitutively	O
active	O
AMP	O
kinase	O
mutations	O
cause	O
glycogen	O
storage	O
disease	O
mimicking	O
hypertrophic	O
cardiomyopathy	O
.	O

Mutations	O
in	O
PRKAG2	B-DNAMutation
,	O
the	O
gene	O
for	O
the	O
gamma	O
2	O
regulatory	O
subunit	O
of	O
AMP-activated	O
protein	O
kinase	O
,	O
cause	O
cardiac	O
hypertrophy	O
and	O
electrophysiologic	O
abnormalities	O
,	O
particularly	O
preexcitation	O
(	O
Wolff-Parkinson-White	O
syndrome	O
)	O
and	O
atrioventricular	O
conduction	O
block	O
.	O

To	O
understand	O
the	O
mechanisms	O
by	O
which	O
PRKAG2	O
defects	O
cause	O
disease	O
,	O
we	O
defined	O
novel	O
mutations	O
,	O
characterized	O
the	O
associated	O
cardiac	O
histopathology	O
,	O
and	O
studied	O
the	O
consequences	O
of	O
introducing	O
these	O
mutations	O
into	O
the	O
yeast	O
homologue	O
of	O
PRKAG2	O
,	O
Snf4	B-DNAMutation
.	O

Although	O
the	O
cardiac	O
pathology	O
caused	O
by	O
PRKAG2	B-DNAMutation
mutations	O
Arg302Gln	B-DNAMutation
,	O
Thr400Asn	B-DNAMutation
,	O
and	O
Asn488Ile	B-DNAMutation
include	O
myocyte	O
enlargement	O
and	O
minimal	O
interstitial	O
fibrosis	O
,	O
these	O
mutations	O
were	O
not	O
associated	O
with	O
myocyte	O
and	O
myofibrillar	O
disarray	O
,	O
the	O
pathognomonic	O
features	O
of	O
hypertrophic	O
cardiomyopathy	O
caused	O
by	O
sarcomere	O
protein	O
mutations	O
.	O

Instead	O
PRKAG2	B-DNAMutation
mutations	O
caused	O
pronounced	O
vacuole	O
formation	O
within	O
myocytes	O
.	O

Several	O
lines	O
of	O
evidence	O
indicated	O
these	O
vacuoles	O
were	O
filled	O
with	O
glycogen-associated	O
granules	O
.	O

Analyses	O
of	O
the	O
effects	O
of	O
human	O
PRKAG2	B-DNAMutation
mutations	O
on	O
Snf1/Snf4	O
kinase	O
function	O
demonstrated	O
constitutive	O
activity	O
,	O
which	O
could	O
foster	O
glycogen	O
accumulation	O
.	O

Taken	O
together	O
,	O
our	O
data	O
indicate	O
that	O
PRKAG2	B-DNAMutation
mutations	O
do	O
not	O
cause	O
hypertrophic	O
cardiomyopathy	O
but	O
rather	O
lead	O
to	O
a	O
novel	O
myocardial	O
metabolic	O
storage	O
disease	O
,	O
in	O
which	O
hypertrophy	O
,	O
ventricular	O
pre-excitation	O
and	O
conduction	O
system	O
defects	O
coexist	O
.	O

Functional	O
significance	O
of	O
the	O
conserved	O
residues	O
for	O
the	O
23-residue	O
module	O
among	O
MTH1	B-DNAMutation
and	O
MutT	O
family	O
proteins	O
.	O

Human	O
MTH1	B-DNAMutation
and	O
Escherichia	O
coli	O
MutT	O
proteins	O
hydrolyze	O
7	O
,	O
8-dihydro-8-oxo-dGTP	O
(8-oxo-dGTP)	O
to	O
monophosphate	O
,	O
thus	O
avoiding	O
the	O
incorporation	O
of	O
8-oxo-7,8-dihydroguanine	O
into	O
nascent	O
DNA	O
.	O

Although	O
only	O
30	O
amino	O
acid	O
residues	O
(23%)	O
are	O
identical	O
between	O
MTH1	B-DNAMutation
and	O
MutT	O
,	O
there	O
is	O
a	O
highly	O
conserved	O
region	O
consisting	O
of	O
23	O
residues	O
(	O
MTH1	B-DNAMutation
,	O
Gly(36)-Gly(58)	O
)	O
with	O
14	O
identical	O
residues	O
.	O

A	O
chimeric	O
protein	O
MTH1-Ec	B-DNAMutation
,	O
in	O
which	O
the	O
23-residue	B-DNAMutation
sequence	I-DNAMutation
of	I-DNAMutation
MTH1	I-DNAMutation
was	I-DNAMutation
replaced	I-DNAMutation
with	I-DNAMutation
that	I-DNAMutation
of	I-DNAMutation
MutT	I-DNAMutation
,	O
retains	O
its	O
capability	O
to	O
hydrolyze	O
8-oxo-dGTP	O
,	O
thereby	O
indicating	O
that	O
the	O
23-residue	O
sequences	O
of	O
MTH1	B-DNAMutation
and	O
MutT	O
are	O
functionally	O
and	O
structurally	O
equivalent	O
and	O
constitute	O
functional	O
modules	O
.	O

By	O
saturation	O
mutagenesis	O
of	O
the	O
module	O
in	O
MTH1	B-DNAMutation
,	O
14	O
of	O
the	O
23	O
residues	O
proved	O
to	O
be	O
essential	O
to	O
exert	O
8-oxo-dGTPase	O
activity	O
.	O

For	O
the	O
other	O
9	O
residues	O
(	O
40	O
,	O
42	O
,	O
44	O
,	O
46	O
,	O
47	O
,	O
49	O
,	O
50	O
,	O
54	O
,	O
and	O
58	O
)	O
,	O
positive	O
mutants	O
were	O
obtained	O
,	O
and	O
Arg(50)	B-DNAMutation
can	I-DNAMutation
be	I-DNAMutation
replaced	I-DNAMutation
with	I-DNAMutation
hydrophobic	I-DNAMutation
residues	I-DNAMutation
(	I-DNAMutation
Val	I-DNAMutation
,	I-DNAMutation
Leu	I-DNAMutation
,	I-DNAMutation
or	I-DNAMutation
Ile	I-DNAMutation
)	O
,	O
with	O
a	O
greater	O
stability	O
and	O
higher	O
specific	O
activity	O
of	O
the	O
enzyme	O
.	O

Indispensabilities	O
of	O
Val(39)	O
,	O
Ile(45)	O
,	O
and	O
Leu(53)	O
indicate	O
that	O
an	O
amphipathic	O
property	O
of	O
alpha-helix	O
I	O
consisting	O
of	O
14	O
residues	O
of	O
the	O
module	O
(Thr(44)-Gly(58))	O
is	O
essential	O
to	O
maintain	O
the	O
stable	O
catalytic	O
surface	O
for	O
8-oxo-dGTPase	O
.	O

Hierarchical	O
regulation	O
of	O
CTLA-4	B-DNAMutation
dimer-based	O
lattice	O
formation	O
and	O
its	O
biological	O
relevance	O
for	O
T	O
cell	O
inactivation	O
.	O

CTLA-4	B-DNAMutation
is	O
an	O
activation-induced	O
,	O
homodimeric	O
inhibitory	O
receptor	O
in	O
T	O
cells	O
.	O

Recent	O
crystallographic	O
reports	O
have	O
suggested	O
that	O
it	O
may	O
form	O
lattice-like	O
arrays	O
on	O
the	O
cell	O
surface	O
upon	O
binding	O
B7.1/B7.2	B-DNAMutation
(	O
CD80	B-DNAMutation
,	O
CD86	B-DNAMutation
)	O
molecules	O
.	O

To	O
test	O
the	O
biological	O
relevance	O
of	O
these	O
CTLA-4-B7	B-DNAMutation
lattices	O
,	O
we	O
introduced	O
a	O
C122A	B-DNAMutation
point	O
mutation	O
in	O
human	O
CTLA-4	B-DNAMutation
,	O
because	O
this	O
residue	O
was	O
shown	O
to	O
be	O
essential	O
for	O
dimerization	O
in	O
solution	O
.	O

Surprisingly	O
,	O
we	O
found	O
that	O
up	O
to	O
35%	O
of	O
C122A	B-DNAMutation
CTLA-4	B-DNAMutation
dimerized	O
in	O
human	O
T	O
lymphocytes	O
.	O

Moreover	O
,	O
C122A	B-DNAMutation
CTLA-4	B-DNAMutation
partitioned	O
within	O
lipid	O
rafts	O
,	O
colocalized	O
with	O
the	O
TCR	O
in	O
the	O
immunological	O
synapse	O
,	O
and	O
inhibited	O
T	O
cell	O
activation	O
.	O

C122-independent	O
dimerization	O
of	O
CTLA-4	B-DNAMutation
involved	O
N-glycosylation	O
,	O
because	O
further	O
mutation	O
of	O
the	O
N78	O
and	O
N110	O
glycosylation	O
sites	O
abrogated	O
dimerization	O
.	O

Despite	O
being	O
monomeric	O
,	O
the	O
N78A/N110A/C122A	B-DNAMutation
triple	O
mutant	O
CTLA-4	B-DNAMutation
localized	O
in	O
the	O
immunological	O
synapse	O
and	O
inhibited	O
T	O
cell	O
activation	O
.	O

Such	O
functionality	O
correlated	O
with	O
B7-induced	O
dimerization	O
of	O
these	O
mutant	O
molecules	O
.	O

Based	O
on	O
these	O
data	O
,	O
we	O
propose	O
a	O
model	O
of	O
hierarchical	O
regulation	O
of	O
CTLA-4	B-DNAMutation
oligomerization	O
by	O
which	O
B7	O
binding	O
ultimately	O
determines	O
the	O
formation	O
of	O
dimer-dependent	O
CTLA-4	B-DNAMutation
lattices	O
that	O
may	O
be	O
necessary	O
for	O
triggering	O
B7-dependent	O
T	O
cell	O
inactivation	O
.	O

Molecular	O
localization	O
of	O
ion	O
selectivity	O
sites	O
within	O
the	O
pore	O
of	O
a	O
human	B-DNAMutation
L-type	O
cardiac	B-DNAMutation
calcium	I-DNAMutation
channel	I-DNAMutation
.	O

A	O
highly	O
conserved	O
position	O
of	O
negatively	O
charged	O
amino	O
acids	O
is	O
present	O
in	O
the	O
SS2	B-DNAMutation
segments	O
of	O
the	O
S5-S6	O
linker	O
regions	O
among	O
calcium	O
channels	O
.	O

We	O
report	O
here	O
that	O
replacing	O
Glu	O
residues	O
at	O
this	O
position	O
alters	O
the	O
ion	O
selectivity	O
of	O
the	O
human	B-DNAMutation
cardiac	B-DNAMutation
calcium	I-DNAMutation
channel	I-DNAMutation
.	O

Substituting	B-DNAMutation
Glu334	I-DNAMutation
in	I-DNAMutation
motif	I-DNAMutation
I	I-DNAMutation
or	I-DNAMutation
Glu1086	I-DNAMutation
in	I-DNAMutation
motif	I-DNAMutation
III	I-DNAMutation
with	I-DNAMutation
Lys	I-DNAMutation
produced	O
mutant	O
calcium	O
channels	O
that	O
permeated	O
sodium	O
ions	O
10-fold	O
more	O
effectively	O
than	O
barium	O
ions	O
.	O

More	O
conservative	O
changes	O
such	O
as	O
substitution	B-DNAMutation
of	I-DNAMutation
Glu1086	I-DNAMutation
with	I-DNAMutation
Gln	I-DNAMutation
or	O
substitution	B-DNAMutation
of	I-DNAMutation
Glu1387	I-DNAMutation
with	I-DNAMutation
Ala	I-DNAMutation
also	O
increased	O
sodium	O
permeation	O
through	O
the	O
mutant	O
calcium	O
channels	O
.	O

Sodium	O
currents	O
through	O
the	O
mutant	O
calcium	O
channels	O
could	O
be	O
modulated	O
by	O
dihydropyridines	O
and	O
blocked	O
by	O
external	O
divalent	O
cations	O
.	O

These	O
results	O
suggest	O
that	O
Glu334	O
,	O
Glu1086	O
,	O
and	O
Glu1387	O
are	O
part	O
of	O
a	O
ring	O
of	O
glutamate	O
residues	O
formed	O
in	O
the	O
pore-lining	O
SS1-SS2	O
region	O
and	O
are	O
critical	O
in	O
determining	O
ion	O
selectively	O
and	O
permeability	O
of	O
a	O
human	B-DNAMutation
cardiac	B-DNAMutation
calcium	I-DNAMutation
channel	I-DNAMutation
.	O

Genotypes	O
of	O
the	O
pancreatic	O
beta-cell	O
K-ATP	O
channel	O
and	O
clinical	O
phenotypes	O
of	O
Japanese	O
patients	O
with	O
persistent	O
hyperinsulinaemic	O
hypoglycaemia	O
of	O
infancy	O
.	O

OBJECTIVE	O
:	O
Persistent	O
hyperinsulinaemic	O
hypoglycaemia	O
of	O
infancy	O
(PHHI)	O
is	O
a	O
disorder	O
of	O
glucose	O
metabolism	O
that	O
is	O
characterized	O
by	O
dysregulated	O
secretion	O
of	O
insulin	B-DNAMutation
from	O
pancreatic	O
beta-cells	O
.	O

This	O
disease	O
has	O
been	O
reported	O
to	O
be	O
associated	O
with	O
mutations	O
of	O
the	O
sulfonylurea	O
receptor	O
SUR1	B-DNAMutation
ABCC8	B-DNAMutation
or	O
the	O
inward-rectifying	O
potassium	O
channel	O
Kir6.2	B-DNAMutation
KCNJ11	B-DNAMutation
,	O
which	O
are	O
two	O
subunits	O
of	O
the	O
pancreatic	O
beta-cell	O
ATP-sensitive	O
potassium	O
channel	O
.	O

PATIENTS	O
AND	O
METHODS	O
:	O
In	O
14	O
Japanese	O
PHHI	O
patients	O
,	O
all	O
exons	O
of	O
SUR1	B-DNAMutation
and	O
Kir6.2	B-DNAMutation
genes	O
were	O
analysed	O
by	O
polymerase	O
chain	O
reaction	O
(PCR)	O
and	O
direct	O
sequencing	O
.	O

Four	O
patients	O
responded	O
to	O
diazoxide	O
,	O
and	O
nine	O
patients	O
underwent	O
a	O
subtotal	O
pancreatectomy	O
.	O

Histologically	O
,	O
seven	O
patients	O
were	O
diagnosed	O
to	O
have	O
a	O
focal	O
form	O
and	O
two	O
a	O
diffuse	O
form	O
of	O
the	O
disease	O
.	O

RESULTS	O
:	O
We	O
found	O
nine	O
novel	O
mutations	O
in	O
the	O
SUR1	B-DNAMutation
gene	O
and	O
two	O
in	O
the	O
Kir6.2	B-DNAMutation
gene	O
.	O

In	O
the	O
SUR1	B-DNAMutation
gene	O
mutations	O
,	O
three	O
were	O
nonsense	O
mutations	O
(	O
Y512X	B-DNAMutation
,	O
Y1354X	B-DNAMutation
and	O
G1469X	B-DNAMutation
)	O
,	O
one	O
was	O
a	O
one-base	O
deletion	O
in	O
exon	O
7	O
,	O
and	O
two	O
were	O
missense	O
mutations	O
in	O
the	O
nucleotide-binding	O
domain	O
2	O
(	O
K1385Q	B-DNAMutation
,	O
R1487K	B-DNAMutation
)	O
.	O

The	O
other	O
three	O
mutations	O
occurred	O
in	O
introns	O
14	O
,	O
29	O
and	O
36	O
,	O
which	O
might	O
cause	O
aberrant	O
splicing	O
of	O
RNA	O
.	O

Two	O
siblings	O
in	O
one	O
family	O
were	O
heterozygotes	O
for	O
a	O
missense	O
mutation	O
,	O
K1385Q	B-DNAMutation
,	O
which	O
was	O
maternally	O
inherited	O
.	O

In	O
Kir6.2	B-DNAMutation
gene	O
screening	O
,	O
one	O
patient	O
was	O
found	O
to	O
be	O
a	O
compound	O
heterozygote	O
of	O
a	O
missense	O
mutation	O
R34H	B-DNAMutation
and	O
a	O
one-base	B-DNAMutation
deletion	I-DNAMutation
(C344fs/ter)	I-DNAMutation
.	O

CONCLUSION	O
:	O
The	O
novel	O
mutations	O
reported	O
here	O
could	O
be	O
pathological	O
candidates	O
for	O
PHHI	O
in	O
Japan	O
.	O

They	O
also	O
reveal	O
that	O
SUR1	B-DNAMutation
and	O
Kir6.2	B-DNAMutation
mutations	O
in	O
the	O
Japanese	O
population	O
exhibit	O
heterogeneity	O
and	O
that	O
they	O
occurred	O
at	O
a	O
frequency	O
similar	O
to	O
other	O
genetic	O
populations	O
.	O

Phosphorylation	O
directly	O
regulates	O
the	O
intrinsic	O
DNA	O
cytidine	O
deaminase	O
activity	O
of	O
activation-induced	B-DNAMutation
deaminase	I-DNAMutation
and	O
APOBEC3G	B-DNAMutation
protein	O
.	O

The	O
beneficial	O
effects	O
of	O
DNA	O
cytidine	O
deamination	O
by	O
activation-induced	B-DNAMutation
deaminase	I-DNAMutation
(	O
AID	B-DNAMutation
;	O
antibody	O
gene	O
diversification	O
)	O
and	O
APOBEC3G	B-DNAMutation
(	O
retrovirus	O
restriction	O
)	O
are	O
tempered	O
by	O
probable	O
contributions	O
to	O
carcinogenesis	O
.	O

Multiple	O
regulatory	O
mechanisms	O
serve	O
to	O
minimize	O
this	O
detrimental	O
outcome	O
.	O

Here	O
,	O
we	O
show	O
that	O
phosphorylation	O
of	O
a	O
conserved	O
threonine	O
attenuates	O
the	O
intrinsic	O
activity	O
of	O
activation-induced	B-DNAMutation
deaminase	I-DNAMutation
(Thr-27)	O
and	O
APOBEC3G	B-DNAMutation
(Thr-218)	O
.	O

Phospho-null	O
alanine	O
mutants	O
maintain	O
intrinsic	O
DNA	O
deaminase	O
activity	O
,	O
whereas	O
phospho-mimetic	O
glutamate	O
mutants	O
are	O
inactive	O
.	O

The	O
phospho-mimetic	O
variants	O
fail	O
to	O
mediate	O
isotype	O
switching	O
in	O
activated	O
mouse	O
splenic	O
B	O
lymphocytes	O
or	O
suppress	O
HIV-1	O
replication	O
in	O
human	O
T	O
cells	O
.	O

Our	O
data	O
combine	O
to	O
suggest	O
a	O
model	O
in	O
which	O
this	O
critical	O
threonine	O
acts	O
as	O
a	O
phospho-switch	O
that	O
fine-tunes	O
the	O
adaptive	O
and	O
innate	O
immune	O
responses	O
and	O
helps	O
protect	O
mammalian	O
genomic	O
DNA	O
from	O
procarcinogenic	O
lesions	O
.	O

Phosphorylation	O
of	O
the	O
Ca2+-binding	O
protein	O
CaBP4	B-DNAMutation
by	O
protein	B-DNAMutation
kinase	I-DNAMutation
C	I-DNAMutation
zeta	I-DNAMutation
in	O
photoreceptors	O
.	O

CaBP4	B-DNAMutation
is	O
a	O
calmodulin-like	O
neuronal	O
calcium-binding	O
protein	O
that	O
is	O
crucial	O
for	O
the	O
development	O
and/or	O
maintenance	O
of	O
the	O
cone	O
and	O
rod	O
photoreceptor	O
synapse	O
.	O

Previously	O
,	O
we	O
showed	O
that	O
CaBP4	B-DNAMutation
directly	O
regulates	O
Ca(v)1	O
L-type	O
Ca2+	O
channels	O
,	O
which	O
are	O
essential	O
for	O
normal	O
photoreceptor	O
synaptic	O
transmission	O
.	O

Here	O
,	O
we	O
show	O
that	O
the	O
function	O
of	O
CaBP4	B-DNAMutation
is	O
regulated	O
by	O
phosphorylation	O
.	O

CaBP4	B-DNAMutation
is	O
phosphorylated	O
by	O
protein	B-DNAMutation
kinase	I-DNAMutation
C	I-DNAMutation
zeta	I-DNAMutation
(PKCzeta)	O
at	O
serine	O
37	O
both	O
in	O
vitro	O
and	O
in	O
the	O
retina	O
and	O
colocalizes	O
with	O
PKCzeta	O
in	O
photoreceptors	O
.	O

CaBP4	B-DNAMutation
phosphorylation	O
is	O
greater	O
in	O
light-adapted	O
than	O
dark-adapted	O
mouse	O
retinas	O
.	O

In	O
electrophysiological	O
recordings	O
of	O
cells	O
transfected	O
with	O
Ca(v)1.3	O
and	O
CaBP4	B-DNAMutation
,	O
mutation	O
of	O
the	O
serine	B-DNAMutation
37	I-DNAMutation
to	I-DNAMutation
alanine	I-DNAMutation
abolished	O
the	O
effect	O
of	O
CaBP4	B-DNAMutation
in	O
prolonging	O
the	O
Ca2+	O
current	O
through	O
Ca(v)1.3	O
channel	O
,	O
whereas	O
inactivating	O
mutations	O
in	O
the	O
CaBP4	B-DNAMutation
Ca2+-binding	O
sites	O
strengthened	O
Ca(v)1.3	O
modulation	O
.	O

These	O
findings	O
demonstrate	O
how	O
light-stimulated	O
changes	O
in	O
CaBP4	B-DNAMutation
phosphorylation	O
and	O
Ca2+	O
binding	O
may	O
regulate	O
presynaptic	O
Ca2+	O
signals	O
in	O
photoreceptors	O
.	O

A	O
gene	O
encoding	O
a	O
liver-specific	O
ABC	O
transporter	O
is	O
mutated	O
in	O
progressive	O
familial	O
intrahepatic	O
cholestasis	O
.	O

The	O
progressive	O
familial	O
intrahepatic	O
cholestases	O
(PFIC)	O
are	O
a	O
group	O
of	O
inherited	O
disorders	O
with	O
severe	O
cholestatic	O
liver	O
disease	O
from	O
early	O
infancy	O
.	O

A	O
subgroup	O
characterized	O
by	O
normal	O
serum	O
cholesterol	O
and	O
gamma-glutamyltranspeptidase	O
(gammaGT)	O
levels	O
is	O
genetically	O
heterogeneous	O
with	O
loci	O
on	O
chromosomes	O
2q	O
(PFIC2)	O
and	O
18q	O
.	O

The	O
phenotype	O
of	O
the	O
PFIC2-linked	O
group	O
is	O
consistent	O
with	O
defective	O
bile	O
acid	O
transport	O
at	O
the	O
hepatocyte	O
canalicular	O
membrane	O
.	O

The	O
PFIC2	O
gene	O
has	O
now	O
been	O
identified	O
by	O
mutations	O
in	O
a	O
positional	O
candidate	O
,	O
BSEP	O
,	O
which	O
encodes	O
a	O
liver-specific	O
ATP-binding	O
cassette	O
(ABC)	O
transporter	O
,	O
sister	O
of	O
p-glycoprotein	O
(SPGP)	O
.	O

The	O
product	O
of	O
the	O
orthologous	O
rat	O
gene	O
has	O
been	O
shown	O
to	O
be	O
an	O
effective	O
bile	O
acid	O
transporter	O
in	O
vitro	O
.	O

These	O
data	O
provide	O
evidence	O
that	O
SPGP	O
is	O
the	O
human	O
bile	O
salt	O
export	O
pump	O
(BSEP)	O
.	O

Enzymatic	O
activity	O
and	O
substrate	O
specificity	O
of	O
mitogen-activated	O
protein	O
kinase	O
p38alpha	B-DNAMutation
in	O
different	O
phosphorylation	O
states	O
.	O

The	O
mitogen-activated	O
protein	O
(MAP)	O
kinases	O
are	O
essential	O
signaling	O
molecules	O
that	O
mediate	O
many	O
cellular	O
effects	O
of	O
growth	O
factors	O
,	O
cytokines	O
,	O
and	O
stress	O
stimuli	O
.	O

Full	O
activation	O
of	O
the	O
MAP	O
kinases	O
requires	O
dual	O
phosphorylation	O
of	O
the	O
Thr	O
and	O
Tyr	O
residues	O
in	O
the	O
TXY	O
motif	O
of	O
the	O
activation	O
loop	O
by	O
MAP	O
kinase	O
kinases	O
.	O

Down-regulation	O
of	O
MAP	O
kinase	O
activity	O
can	O
be	O
initiated	O
by	O
multiple	O
serine/threonine	O
phosphatases	O
,	O
tyrosine-specific	O
phosphatases	O
,	O
and	O
dual	O
specificity	O
phosphatases	O
(	O
MAP	O
kinase	O
phosphatases	O
)	O
.	O

This	O
would	O
inevitably	O
lead	O
to	O
the	O
formation	O
of	O
monophosphorylated	O
MAP	O
kinases	O
.	O

However	O
,	O
the	O
biological	O
functions	O
of	O
these	O
monophosphorylated	O
MAP	O
kinases	O
are	O
currently	O
not	O
clear	O
.	O

In	O
this	O
study	O
,	O
we	O
have	O
prepared	O
MAP	O
kinase	O
p38alpha	B-DNAMutation
,	O
a	O
member	O
of	O
the	O
MAP	O
kinase	O
family	O
,	O
in	O
all	O
phosphorylated	O
forms	O
and	O
characterized	O
their	O
biochemical	O
properties	O
.	O

Our	O
results	O
indicated	O
the	O
following	O
:	O
(i)	O
p38alpha	B-DNAMutation
phosphorylated	O
at	O
both	O
Thr-180	O
and	O
Tyr-182	O
was	O
10-20-fold	O
more	O
active	O
than	O
p38alpha	B-DNAMutation
phosphorylated	O
at	O
Thr-180	O
only	O
,	O
whereas	O
p38alpha	B-DNAMutation
phosphorylated	O
at	O
Tyr-182	O
alone	O
was	O
inactive	O
;	O
(ii)	O
the	O
dual-specific	O
MKP5	B-DNAMutation
,	O
the	O
tyrosine-specific	O
hematopoietic	O
protein-tyrosine	O
phosphatase	O
,	O
and	O
the	O
serine/threonine-specific	O
PP2Calpha	B-DNAMutation
are	O
all	O
highly	O
specific	O
for	O
the	O
dephosphorylation	O
of	O
p38alpha	B-DNAMutation
,	O
and	O
the	O
dephosphorylation	O
rates	O
were	O
significantly	O
affected	O
by	O
different	O
phosphorylated	O
states	O
of	O
p38alpha	B-DNAMutation
;	O
(iii)	O
the	O
N-terminal	O
domain	O
of	O
MPK5	O
has	O
no	O
effect	O
on	O
enzyme	O
catalysis	O
,	O
whereas	O
deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
MAP	I-DNAMutation
kinase-binding	I-DNAMutation
domain	I-DNAMutation
in	O
MKP5	B-DNAMutation
leads	O
to	O
a	O
370-fold	O
decrease	O
in	O
k(cat)/K(m)	O
for	O
the	O
dephosphorylation	O
of	O
p38alpha	B-DNAMutation
.	O

This	O
study	O
has	O
thus	O
revealed	O
the	O
quantitative	O
contributions	O
of	O
phosphorylation	O
of	O
Thr	O
,	O
Tyr	O
,	O
or	O
both	O
to	O
the	O
activation	O
of	O
p38alpha	B-DNAMutation
and	O
to	O
the	O
substrate	O
specificity	O
for	O
various	O
phosphatases	O
.	O

Glucocorticoid-stimulated	O
preadipocyte	O
differentiation	O
is	O
mediated	O
through	O
acetylation	O
of	O
C/EBPbeta	B-DNAMutation
by	O
GCN5	B-DNAMutation
.	O

Preadipocyte	O
differentiation	O
in	O
culture	O
is	O
driven	O
by	O
an	O
insulin	B-DNAMutation
and	O
cAMP	B-DNAMutation
dependant	O
transcriptional	O
cascade	O
which	O
induces	O
the	O
bzip	O
transcription	O
factors	O
C/EBPbeta	B-DNAMutation
and	O
C/EBPdelta	B-DNAMutation
.	O

We	O
have	O
previously	O
shown	O
that	O
glucocorticoid	O
treatment	O
,	O
which	O
strongly	O
potentiates	O
this	O
differentiation	O
pathway	O
,	O
stimulates	O
the	O
titration	O
of	O
the	O
corepressor	O
histone	B-DNAMutation
deacetylase	I-DNAMutation
1	I-DNAMutation
HDAC1	B-DNAMutation
from	O
C/EBPbeta	B-DNAMutation
.	O

This	O
results	O
in	O
a	O
dramatic	O
enhancement	O
of	O
C/EBPbeta-dependent	B-DNAMutation
transcription	O
from	O
the	O
C/EBPalpha	B-DNAMutation
promoter	O
,	O
concomitant	O
with	O
potentiation	O
of	O
preadipocyte	O
differentiation	O
.	O

Here	O
,	O
we	O
show	O
that	O
C/EBPbeta	B-DNAMutation
is	O
acetylated	O
by	O
GCN5	B-DNAMutation
and	O
PCAF	B-DNAMutation
within	O
a	O
cluster	O
of	O
lysine	O
residues	O
between	O
amino	O
acids	O
98-102	O
and	O
that	O
this	O
acetylation	O
is	O
strongly	O
induced	O
by	O
glucocorticoid	O
treatment	O
.	O

Arginine	B-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
lysine	I-DNAMutation
residues	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
acetylation	I-DNAMutation
motif	I-DNAMutation
of	O
C/EBPbeta	B-DNAMutation
prevented	O
acetylation	O
and	O
blocked	O
the	O
ability	O
of	O
glucocorticoids	O
to	O
enhance	O
C/EBPbeta-directed	B-DNAMutation
transcription	O
and	O
to	O
potentiate	O
C/EBPbeta-dependent	B-DNAMutation
preadipocyte	O
differentiation	O
.	O

Moreover	O
,	O
acetylation	O
of	O
C/EBPbeta	B-DNAMutation
appeared	O
to	O
directly	O
interfere	O
with	O
the	O
interaction	O
of	O
HDAC1	B-DNAMutation
with	O
C/EBPbeta	B-DNAMutation
,	O
suggesting	O
that	O
PCAF/GCN5-dependent	B-DNAMutation
acetylation	O
of	O
C/EBPbeta	B-DNAMutation
serves	O
as	O
an	O
important	O
molecular	O
switch	O
in	O
determining	O
the	O
transcriptional	O
regulatory	O
potential	O
of	O
this	O
transcription	O
factor	O
.	O

Human	O
ABCA1	B-DNAMutation
contains	O
a	O
large	O
amino-terminal	O
extracellular	O
domain	O
homologous	O
to	O
an	O
epitope	O
of	O
SjÃ¶gren's	O
Syndrome	O
.	O

ABCA1	B-DNAMutation
has	O
been	O
suggested	O
to	O
play	O
a	O
key	O
role	O
in	O
cellular	O
lipid	O
release	O
from	O
peripheral	O
cells	O
.	O

In	O
order	O
to	O
study	O
structure-function	O
relationship	O
of	O
this	O
protein	O
,	O
the	O
protein	O
product	O
of	O
a	O
full-length	O
human	B-DNAMutation
ABCA1	I-DNAMutation
cDNA	O
was	O
examined	O
for	O
its	O
functions	O
and	O
topological	O
orientation	O
.	O

The	O
electrophoretic	O
mobilities	O
of	O
human	B-DNAMutation
ABCA1	I-DNAMutation
expressed	O
in	O
transfected	O
cells	O
increased	O
when	O
treated	O
with	O
N-glycosidase	O
F	O
,	O
suggesting	O
that	B-DNAMutation
ABCA1	I-DNAMutation
is	O
highly	O
glycosylated	O
.	O

The	B-DNAMutation
ABCA1	I-DNAMutation
was	O
photoaffinity-labeled	O
with	O
ATP	O
and	O
mediated	O
the	B-DNAMutation
apoA-I-dependent-release	I-DNAMutation
of	O
cholesterol	O
and	O
phospholipid	O
.	I-DNAMutation
The	I-DNAMutation
influenza	I-DNAMutation
hemagglutinin	I-DNAMutation
(HA)	I-DNAMutation
epitope	I-DNAMutation
was	I-DNAMutation
introduced	I-DNAMutation
into	I-DNAMutation
the	I-DNAMutation
amino-terminus	I-DNAMutation
(N-HA)	I-DNAMutation
or	B-DNAMutation
between	I-DNAMutation
the	I-DNAMutation
residues	I-DNAMutation
207	I-DNAMutation
and	I-DNAMutation
208	I-DNAMutation
(207-HA)	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
protein	I-DNAMutation
.	O

While	O
an	O
antibody	O
against	O
the	O
C-terminus	O
peptide	O
of	B-DNAMutation
ABCA1	I-DNAMutation
detected	O
both	O
fusion	O
proteins	O
,	O
an	O
anti-HA	O
antibody	O
did	O
not	O
react	O
with	O
the	O
N-HA	O
fusion	O
protein	O
.	O

Confocal	O
microscopy	O
demonstrated	O
strong	O
cell	O
surface	O
signal	O
with	O
the	O
anti-HA	O
antibody	O
of	O
nonpermeabilized	O
HEK293	O
cells	O
expressing	O
the	O
207-HA	O
fusion	O
protein	O
.	O

The	O
results	O
suggested	O
that	O
the	O
signal	O
peptide	O
in	O
the	O
amino-terminal	O
region	O
is	O
cleaved	O
off	O
in	O
its	O
mature	O
form	O
and	O
that	O
the	O
following	O
large	O
hydrophilic	O
region	O
is	O
exposed	O
to	O
outside	O
of	O
cells	O
unlike	O
previously	O
proposed	O
models	O
.	O

We	O
found	O
that	O
this	O
amino-terminal	O
extracellular	O
domain	O
contains	O
a	O
segment	O
homologous	O
to	O
the	O
autoantigen	O
SS-N	O
,	O
an	O
epitope	O
of	O
SjÃ¶gren's	O
syndrome	O
,	O
and	O
further	O
identified	O
that	B-DNAMutation
ABCA7	I-DNAMutation
codes	O
for	O
the	O
autoantigen	O
SS-N	O
.	O

Activated	O
Cdc42-associated	O
kinase	O
1	O
is	O
a	O
component	O
of	O
EGF	B-DNAMutation
receptor	I-DNAMutation
signaling	O
complex	O
and	O
regulates	O
EGF	B-DNAMutation
receptor	I-DNAMutation
degradation	O
.	O

Cdc42-associated	B-DNAMutation
tyrosine	I-DNAMutation
kinase	I-DNAMutation
1	I-DNAMutation
ACK1	B-DNAMutation
is	O
a	O
specific	O
down-stream	O
effector	O
of	O
Cdc42	O
,	O
a	O
Rho	O
family	O
small	O
G-protein	O
.	O

Previous	O
studies	O
have	O
shown	O
that	O
ACK1	B-DNAMutation
interacts	O
with	O
clathrin	B-DNAMutation
heavy	I-DNAMutation
chain	I-DNAMutation
and	O
is	O
involved	O
in	O
clathrin-coated	O
vesicle	O
endocytosis	O
.	O

Here	O
we	O
report	O
that	O
ACK1	B-DNAMutation
interacted	O
with	O
epidermal	B-DNAMutation
growth	I-DNAMutation
factor	I-DNAMutation
receptor	I-DNAMutation
EGFR	B-DNAMutation
upon	O
EGF	O
stimulation	O
via	O
a	O
region	O
at	O
carboxy	O
terminus	O
that	O
is	O
highly	O
homologous	O
to	O
Gene-33/Mig-6/RALT	B-DNAMutation
.	O

The	O
interaction	O
of	O
ACK1	B-DNAMutation
with	O
EGFR	B-DNAMutation
was	O
dependent	O
on	O
the	O
kinase	O
activity	O
or	O
tyrosine	O
phosphorylation	O
of	O
EGFR	B-DNAMutation
.	O

Immunofluorescent	O
staining	O
using	O
anti-EGFR	B-DNAMutation
and	O
GFP-ACK1	B-DNAMutation
indicates	O
that	O
ACK1	B-DNAMutation
was	O
colocalized	O
with	O
EGFR	B-DNAMutation
on	O
EEA-1	B-DNAMutation
positive	O
vesicles	O
upon	O
EGF	O
stimulation	O
.	O

Suppression	O
of	O
the	O
expression	O
of	O
ACK1	B-DNAMutation
by	O
ACK-RNAi	O
inhibited	O
ligand-induced	O
degradation	O
of	O
EGFR	B-DNAMutation
upon	O
EGF	O
stimulation	O
,	O
suggesting	O
that	O
ACK1	B-DNAMutation
plays	O
an	O
important	O
role	O
in	O
regulation	O
of	O
EGFR	B-DNAMutation
degradation	O
in	O
cells	O
.	O

Furthermore	O
,	O
we	O
identified	O
ACK1	B-DNAMutation
as	O
an	O
ubiquitin-binding	O
protein	O
.	O

Through	O
an	O
ubiquitin-association	O
(Uba)	O
domain	O
at	O
the	O
carboxy	O
terminus	O
,	O
ACK1	B-DNAMutation
binds	O
to	O
both	O
poly-	O
and	O
mono-ubiquitin	O
.	O

Overexpression	O
of	O
the	O
Uba	B-DNAMutation
domain-deletion	I-DNAMutation
mutant	O
of	O
ACK1	B-DNAMutation
blocked	O
the	O
ligand-dependent	O
degradation	O
of	O
EGFR	B-DNAMutation
,	O
suggesting	O
that	O
ACK1	B-DNAMutation
regulates	O
EGFR	B-DNAMutation
degradation	O
via	O
its	O
Uba	O
domain	O
.	O

Taken	O
together	O
,	O
our	O
studies	O
suggest	O
that	O
ACK1	B-DNAMutation
senses	O
signal	O
of	O
EGF	O
and	O
regulates	O
ligand-induced	O
degradation	O
of	O
EGFR	B-DNAMutation
.	O

Analysis	O
of	O
the	O
glucocerebrosidase	B-DNAMutation
gene	I-DNAMutation
and	O
mutation	O
profile	O
in	O
144	O
Italian	O
gaucher	O
patients	O
.	O

Gaucher	O
disease	O
(GD)	O
,	O
the	O
most	O
prevalent	O
lysosomal	O
storage	O
disease	O
characterized	O
by	O
a	O
remarkable	O
degree	O
of	O
clinical	O
variability	O
,	O
results	O
from	O
deleterious	O
mutations	O
in	O
the	O
glucocerebrosidase	B-DNAMutation
gene	I-DNAMutation
GBA	B-DNAMutation
.	O

In	O
this	O
paper	O
we	O
report	O
the	O
molecular	O
characterization	O
of	O
144	O
unrelated	O
Italian	O
GD	O
patients	O
with	O
the	O
three	O
types	O
of	O
the	O
disease	O
.	O

The	O
allelic	O
frequencies	O
of	O
Italians	O
are	O
reported	O
and	O
the	O
mutation	O
profile	O
is	O
analyzed	O
.	O

Besides	O
the	O
common	O
N370S	B-DNAMutation
,	O
L444P	B-DNAMutation
,	O
RecNciI	B-DNAMutation
,	O
G202R	B-DNAMutation
,	O
IVS2+1G>A	B-DNAMutation
,	O
D409H	B-DNAMutation
,	O
F213I	B-DNAMutation
mutations	O
,	O
the	O
different	O
molecular	O
strategies	O
,	O
used	O
for	O
the	O
mutation	O
detection	O
,	O
identified	O
the	O
rare	O
N107L	B-DNAMutation
,	O
R131C	B-DNAMutation
,	O
R170C	B-DNAMutation
,	O
R170P	B-DNAMutation
,	O
N188S	B-DNAMutation
,	O
S196P	B-DNAMutation
,	O
R285C	B-DNAMutation
,	O
R285H	B-DNAMutation
,	O
W312C	B-DNAMutation
,	O
D399N	B-DNAMutation
,	O
A446P	B-DNAMutation
,	O
IVS10-1G>A	B-DNAMutation
,	O
RecDelta55	B-DNAMutation
,	O
total	B-DNAMutation
gene	I-DNAMutation
deletion	I-DNAMutation
,	O
as	O
well	O
as	O
12	O
mutant	O
alleles	O
that	O
were	O
exclusively	O
present	O
in	O
the	O
Italian	O
population	O
until	O
now	O
:	O
the	O
previously	O
reported	O
R353G	B-DNAMutation
,	O
N370S+S488P	B-DNAMutation
mosaicism	O
,	O
IVS8(-11delC)-14T>A	B-DNAMutation
)	O
,	O
Rec	B-DNAMutation
I	I-DNAMutation
,	O
Y418C	B-DNAMutation
,	O
and	O
the	O
seven	O
novel	O
alleles	O
D127X	B-DNAMutation
,	O
P159T	B-DNAMutation
,	O
V214X	B-DNAMutation
,	O
T231R	B-DNAMutation
,	O
L354X	B-DNAMutation
,	O
H451R	B-DNAMutation
,	O
and	O
G202R+M361I	B-DNAMutation
.	O

The	O
wide	O
phenotypic	O
differences	O
observed	O
within	O
the	O
genotypic	O
groups	O
as	O
well	O
as	O
between	O
siblings	O
implicate	O
a	O
significant	O
contribution	O
of	O
other	O
modifying	O
genetic	O
and/or	O
non-genetic	O
factors	O
and	O
claim	O
a	O
comprehensive	O
valuation	O
of	O
the	O
patient	O
including	O
clinical.	O
,	O
biochemical	O
and	O
molecular	O
investigations	O
for	O
prognosis	O
,	O
appropriate	O
interventive	O
therapy	O
and	O
reliable	O
genetic	O
counseling	O
.	O

Regulation	O
of	O
RasGRP	B-DNAMutation
via	O
a	O
phorbol	O
ester-responsive	O
C1	O
domain	O
.	O

As	O
part	O
of	O
a	O
cDNA	O
library	O
screen	O
for	O
clones	O
that	O
induce	O
transformation	O
of	O
NIH	O
3T3	O
fibroblasts	O
,	O
we	O
have	O
isolated	O
a	O
cDNA	O
encoding	O
the	O
murine	O
homolog	O
of	O
the	O
guanine	O
nucleotide	O
exchange	O
factor	O
RasGRP	B-DNAMutation
.	O

A	O
point	O
mutation	O
predicted	O
to	O
prevent	O
interaction	O
with	O
Ras	O
abolished	O
the	O
ability	O
of	O
murine	B-DNAMutation
RasGRP	I-DNAMutation
mRasGRP	B-DNAMutation
to	O
transform	O
fibroblasts	O
and	O
to	O
activate	O
mitogen-activated	O
protein	O
kinases	O
(	O
MAP	O
kinases	O
)	O
.	O

MAP	O
kinase	O
activation	O
via	O
mRasGRP	B-DNAMutation
was	O
enhanced	O
by	O
coexpression	O
of	O
H-	O
,	O
K-	O
,	O
and	O
N-Ras	B-DNAMutation
and	O
was	O
partially	O
suppressed	O
by	O
coexpression	O
of	O
dominant	O
negative	O
forms	O
of	O
H-	O
and	O
K-Ras	B-DNAMutation
.	O

The	O
C	O
terminus	O
of	O
mRasGRP	B-DNAMutation
contains	O
a	O
pair	O
of	O
EF	O
hands	O
and	O
a	O
C1	O
domain	O
which	O
is	O
very	O
similar	O
to	O
the	O
phorbol	O
ester-	O
and	O
diacylglycerol-binding	O
C1	O
domains	O
of	O
protein	O
kinase	O
Cs	O
.	O

The	O
EF	O
hands	O
could	O
be	O
deleted	O
without	O
affecting	O
the	O
ability	O
of	O
mRasGRP	B-DNAMutation
to	O
transform	O
NIH	O
3T3	O
cells	O
.	O

In	O
contrast	O
,	O
deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
C1	I-DNAMutation
domain	I-DNAMutation
or	O
an	O
adjacent	O
cluster	O
of	O
basic	O
amino	O
acids	O
eliminated	O
the	O
transforming	O
activity	O
of	O
mRasGRP	B-DNAMutation
.	O

Transformation	O
and	O
MAP	O
kinase	O
activation	O
via	O
mRasGRP	B-DNAMutation
were	O
restored	O
if	O
the	O
deleted	B-DNAMutation
C1	I-DNAMutation
domain	I-DNAMutation
was	O
replaced	O
either	O
by	O
a	O
membrane-localizing	O
prenylation	O
signal	O
or	O
by	O
a	O
diacylglycerol-	O
and	O
phorbol	O
ester-binding	O
C1	O
domain	O
of	O
protein	O
kinase	O
C	O
.	O

The	O
transforming	O
activity	O
of	O
mRasGRP	B-DNAMutation
could	O
be	O
regulated	O
by	O
phorbol	O
ester	O
when	O
serum	O
concentrations	O
were	O
low	O
,	O
and	O
this	O
effect	O
of	O
phorbol	O
ester	O
was	O
dependent	O
on	O
the	O
C1	O
domain	O
of	O
mRasGRP	B-DNAMutation
.	O

The	O
C1	O
domain	O
could	O
also	O
confer	O
phorbol	O
myristate	O
acetate-regulated	O
transforming	O
activity	O
on	O
a	O
prenylation-defective	O
mutant	O
of	O
K-Ras	B-DNAMutation
.	O

The	O
C1	O
domain	O
mediated	O
the	O
translocation	O
of	O
mRasGRP	B-DNAMutation
to	O
cell	O
membranes	O
in	O
response	O
to	O
either	O
phorbol	O
ester	O
or	O
serum	O
stimulation	O
.	O

These	O
results	O
suggest	O
that	O
the	O
primary	O
mechanism	O
of	O
activation	O
of	O
mRasGRP	B-DNAMutation
in	O
fibroblasts	O
is	O
through	O
its	O
recruitment	O
to	O
diacylglycerol-enriched	O
membranes	O
.	O

mRasGRP	B-DNAMutation
is	O
expressed	O
in	O
lymphoid	O
tissues	O
and	O
the	O
brain	O
,	O
as	O
well	O
as	O
in	O
some	O
lymphoid	O
cell	O
lines	O
.	O

In	O
these	O
cells	O
,	O
RasGRP	B-DNAMutation
has	O
the	O
potential	O
to	O
serve	O
as	O
a	O
direct	O
link	O
between	O
receptors	O
which	O
stimulate	O
diacylglycerol-generating	O
phospholipase	O
Cs	O
and	O
the	O
activation	O
of	O
Ras	O
.	O

Nature	O
and	O
frequency	O
of	O
mutations	O
in	O
the	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
that	O
cause	O
Fabry	O
disease	O
.	O

Fabry	O
disease	O
,	O
an	O
X-linked	O
inborn	O
error	O
of	O
glycosphingolipid	O
catabolism	O
,	O
results	O
from	O
mutations	O
in	O
the	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
(	O
alpha-Gal	B-DNAMutation
A	I-DNAMutation
)	O
gene	O
at	O
Xq22.1	O
.	O

To	O
determine	O
the	O
nature	O
and	O
frequency	O
of	O
the	O
molecular	O
lesions	O
causing	O
the	O
classical	O
and	O
milder-variant	O
Fabry	O
phenotypes	O
,	O
and	O
for	O
precise	O
carrier	O
detection	O
in	O
Fabry	O
families	O
,	O
the	O
alpha-Gal	O
A	O
transcripts	O
or	O
genomic	O
sequences	O
from	O
unrelated	O
Fabry	O
hemizygotes	O
were	O
analyzed	O
.	O

In	O
patients	O
with	O
the	O
classical	O
phenotype	O
,	O
18	O
new	O
mutations	O
were	O
identified	O
:	O
N34S	B-DNAMutation
,	O
C56G	B-DNAMutation
,	O
W162R	B-DNAMutation
,	O
R227Q	B-DNAMutation
,	O
R227X	B-DNAMutation
,	O
D264V	B-DNAMutation
,	O
D266V	B-DNAMutation
,	O
S297F	B-DNAMutation
,	O
D313Y	B-DNAMutation
,	O
G328A	B-DNAMutation
,	O
W340X	B-DNAMutation
,	O
E398X	B-DNAMutation
,	O
IVS2+2	B-DNAMutation
,	O
IVS5	B-DNAMutation
delta-2,3	I-DNAMutation
,	O
773	B-DNAMutation
delta	I-DNAMutation
2	I-DNAMutation
,	O
954	B-DNAMutation
delta	I-DNAMutation
5	I-DNAMutation
,	O
1016	B-DNAMutation
delta	I-DNAMutation
11	I-DNAMutation
,	O
and	O
1123	B-DNAMutation
delta	I-DNAMutation
53	I-DNAMutation
.	O

Unrelated	O
asymptomatic	O
or	O
mildly	O
affected	O
patients	O
with	O
symptoms	O
confined	O
to	O
the	O
heart	O
had	O
a	O
missense	O
mutation	O
,	O
N215S	B-DNAMutation
,	O
that	O
expressed	O
residual	O
enzymatic	O
activity	O
.	O

Related	O
,	O
moderately	O
affected	O
patients	O
with	O
late-onset	O
cardiac	O
and	O
pulmonary	O
manifestations	O
had	O
a	O
small	O
deletion	O
,	O
1208	B-DNAMutation
delta	I-DNAMutation
3	I-DNAMutation
,	O
that	O
predicted	O
the	O
in-frame	B-DNAMutation
deletion	I-DNAMutation
of	I-DNAMutation
arginine	I-DNAMutation
404	I-DNAMutation
near	I-DNAMutation
the	I-DNAMutation
terminus	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
429	I-DNAMutation
residue	I-DNAMutation
enzyme	O
polypeptide	O
.	O

In	O
addition	O
,	O
five	O
small	O
gene	O
rearrangements	O
involving	O
exonic	O
sequences	O
were	O
identified	O
in	O
unrelated	O
classically	O
affected	O
patients	O
.	O

Two	O
small	O
deletions	O
and	O
one	O
small	O
duplication	O
had	O
short	O
direct	O
repeats	O
at	O
their	O
respective	O
breakpoint	O
junctions	O
and	O
presumably	O
resulted	O
from	O
slipped	O
mispairing	O
.	O

A	O
deletion	B-DNAMutation
occurred	I-DNAMutation
at	I-DNAMutation
a	I-DNAMutation
potential	I-DNAMutation
polymerase	I-DNAMutation
alpha	I-DNAMutation
arrest	I-DNAMutation
site	I-DNAMutation
,	O
while	O
the	O
breakpoints	O
of	O
another	O
deletion	B-DNAMutation
occurred	I-DNAMutation
at	I-DNAMutation
an	I-DNAMutation
inverted	I-DNAMutation
tetranucleotide	I-DNAMutation
repeat	I-DNAMutation
.	O

Screening	O
of	O
unrelated	O
Fabry	O
patients	O
with	O
allele-specific	O
oligonucleotides	O
for	O
seven	O
mutations	O
revealed	O
that	O
these	O
were	O
private	O
,	O
with	O
the	O
notable	O
exception	O
of	O
N215S	B-DNAMutation
,	O
R227Q	B-DNAMutation
,	O
and	O
R227X	B-DNAMutation
,	O
which	O
were	O
each	O
found	O
in	O
several	O
unrelated	O
families	O
from	O
different	O
ethnic	O
backgrounds	O
.	O

The	O
CpG	B-DNAMutation
dinucleotide	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
227	I-DNAMutation
was	I-DNAMutation
the	I-DNAMutation
most	I-DNAMutation
common	I-DNAMutation
site	I-DNAMutation
of	I-DNAMutation
mutation	I-DNAMutation
,	O
having	O
been	O
altered	O
in	O
5%	O
of	O
the	O
148	O
unrelated	O
Fabry	O
alleles	O
.	O

These	O
studies	O
revealed	O
that	O
most	O
alpha-Gal	B-DNAMutation
A	I-DNAMutation
lesions	O
were	O
private	O
,	O
that	O
codon	B-DNAMutation
227	I-DNAMutation
was	I-DNAMutation
a	I-DNAMutation
mutational	I-DNAMutation
hot	I-DNAMutation
spot	I-DNAMutation
,	O
and	O
that	O
certain	O
mutations	O
predicted	O
a	O
milder	O
disease	O
phenotype	O
.	O

Fundamental	O
gating	O
mechanism	O
of	O
nicotinic	O
receptor	O
channel	O
revealed	O
by	O
mutation	O
causing	O
a	O
congenital	O
myasthenic	O
syndrome	O
.	O

We	O
describe	O
the	O
genetic	O
and	O
kinetic	O
defects	O
in	O
a	O
congenital	O
myasthenic	O
syndrome	O
due	O
to	O
the	O
mutation	B-DNAMutation
epsilonA411P	I-DNAMutation
in	O
the	O
amphipathic	O
helix	O
of	O
the	O
acetylcholine	O
receptor	O
AChR	B-DNAMutation
epsilon	O
subunit	O
.	O

Myasthenic	O
patients	O
from	O
three	O
unrelated	O
families	O
are	O
either	O
homozygous	O
for	O
epsilonA411P	B-DNAMutation
or	O
are	O
heterozygous	O
and	O
harbor	O
a	O
null	O
mutation	O
in	O
the	O
second	O
epsilon	O
allele	O
,	O
indicating	O
that	O
epsilonA411P	B-DNAMutation
is	O
recessive	O
.	O

We	O
expressed	O
human	O
AChRs	B-DNAMutation
containing	O
wild-type	O
or	O
A411P	B-DNAMutation
epsilon	O
subunits	O
in	O
293HEK	O
cells	O
,	O
recorded	O
single	O
channel	O
currents	O
at	O
high	O
bandwidth	O
,	O
and	O
determined	O
microscopic	O
rate	O
constants	O
for	O
individual	O
channels	O
using	O
hidden	O
Markov	O
modeling	O
.	O

For	O
individual	O
wild-type	O
and	O
mutant	O
channels	O
,	O
each	O
rate	O
constant	O
distributes	O
as	O
a	O
Gaussian	O
function	O
,	O
but	O
the	O
spread	O
in	O
the	O
distributions	O
for	O
channel	O
opening	O
and	O
closing	O
rate	O
constants	O
is	O
greatly	O
expanded	O
by	O
epsilonA411P	B-DNAMutation
.	O

Prolines	B-DNAMutation
engineered	I-DNAMutation
into	I-DNAMutation
positions	I-DNAMutation
flanking	I-DNAMutation
residue	I-DNAMutation
411	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
epsilon	I-DNAMutation
subunit	I-DNAMutation
greatly	O
increase	O
the	O
range	O
of	O
activation	O
kinetics	O
similar	O
to	O
epsilonA411P	B-DNAMutation
,	O
whereas	O
prolines	B-DNAMutation
engineered	I-DNAMutation
into	I-DNAMutation
positions	I-DNAMutation
equivalent	I-DNAMutation
to	I-DNAMutation
epsilonA411	I-DNAMutation
in	I-DNAMutation
beta	I-DNAMutation
and	I-DNAMutation
delta	I-DNAMutation
subunits	I-DNAMutation
are	O
without	O
effect	O
.	O

Thus	O
,	O
the	O
amphipathic	O
helix	O
of	O
the	O
epsilon	O
subunit	O
stabilizes	O
the	O
channel	O
,	O
minimizing	O
the	O
number	O
and	O
range	O
of	O
kinetic	O
modes	O
accessible	O
to	O
individual	O
AChRs	B-DNAMutation
.	O

The	O
findings	O
suggest	O
that	O
analogous	O
stabilizing	O
structures	O
are	O
present	O
in	O
other	O
ion	O
channels	O
,	O
and	O
possibly	O
allosteric	O
proteins	O
in	O
general	O
,	O
and	O
that	O
they	O
evolved	O
to	O
maintain	O
uniformity	O
of	O
activation	O
episodes	O
.	O

The	O
findings	O
further	O
suggest	O
that	O
the	O
fundamental	O
gating	O
mechanism	O
of	O
the	O
AChR	B-DNAMutation
channel	O
can	O
be	O
explained	O
by	O
a	O
corrugated	O
energy	O
landscape	O
superimposed	O
on	O
a	O
steeply	O
sloped	O
energy	O
well	O
.	O

A	O
missense	O
mutation	O
in	O
the	O
neuronal	B-DNAMutation
nicotinic	I-DNAMutation
acetylcholine	I-DNAMutation
receptor	I-DNAMutation
alpha	I-DNAMutation
4	I-DNAMutation
subunit	I-DNAMutation
is	O
associated	O
with	O
autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
.	O

Epilepsy	O
affects	O
at	O
least	O
2%	O
of	O
the	O
population	O
at	O
some	O
time	O
in	O
their	O
lives	O
.	O

The	O
epilepsies	O
are	O
a	O
heterogeneous	O
group	O
of	O
disorders	O
,	O
many	O
with	O
an	O
inherited	O
component	O
.	O

Although	O
specific	O
genes	O
have	O
been	O
identified	O
in	O
a	O
few	O
rare	O
diseases	O
causing	O
seizures	O
as	O
part	O
of	O
a	O
more	O
diffuse	O
brain	O
disorder	O
,	O
the	O
molecular	O
pathology	O
of	O
the	O
common	O
idiopathic	O
epilepsies	O
is	O
still	O
unknown	O
.	O

Linkage	O
has	O
been	O
reported	O
for	O
some	O
generalised	O
epilepsy	O
syndromes	O
,	O
but	O
only	O
very	O
recently	O
for	O
familial	O
partial	O
epilepsy	O
syndromes	O
.	O

Autosomal	O
dominant	O
nocturnal	O
frontal	O
lobe	O
epilepsy	O
(ADNFLE)	O
is	O
a	O
partial	O
epilepsy	O
causing	O
frequent	O
,	O
violent	O
,	O
brief	O
seizures	O
at	O
night	O
,	O
usually	O
beginning	O
in	O
childhood	O
.	O

The	O
gene	O
for	O
ADNFLE	O
maps	O
to	O
chromosome	O
20q13.2-q13.3	O
in	O
one	O
large	O
Australian	O
kindred	O
.	O

The	O
neuronal	B-DNAMutation
nicotinic	I-DNAMutation
acetylcholine	I-DNAMutation
receptor	I-DNAMutation
alpha	I-DNAMutation
4	I-DNAMutation
subunit	I-DNAMutation
CHRNA4	B-DNAMutation
maps	O
to	O
the	O
same	O
region	O
of	O
20q	O
(	O
ref	O
.	O

12	O
)	O
and	O
the	O
gene	O
is	O
expressed	O
in	O
all	O
layers	O
of	O
the	O
frontal	O
cortex	O
.	O

We	O
screened	O
affected	O
family	O
members	O
for	O
mutations	O
within	O
CHRNA4	B-DNAMutation
and	O
found	O
a	O
missense	B-DNAMutation
mutation	I-DNAMutation
that	I-DNAMutation
replaces	I-DNAMutation
serine	I-DNAMutation
with	I-DNAMutation
phenylalanine	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
248	I-DNAMutation
,	O
a	O
strongly	O
conserved	O
amino	O
acid	O
residue	O
in	O
the	O
second	O
transmembrane	O
domain	O
.	O

The	O
mutation	O
is	O
present	O
in	O
all	O
21	O
available	O
affected	O
family	O
members	O
and	O
in	O
four	O
obligate	O
carriers	O
,	O
but	O
not	O
in	O
333	O
healthy	O
control	O
subjects	O
.	O

Human	O
ABC7	B-DNAMutation
transporter	O
:	O
gene	O
structure	O
and	O
mutation	O
causing	O
X-linked	O
sideroblastic	O
anemia	O
with	O
ataxia	O
with	O
disruption	O
of	O
cytosolic	O
iron-sulfur	O
protein	O
maturation	O
.	O

The	O
human	O
protein	O
ABC7	B-DNAMutation
belongs	O
to	O
the	O
adenosine	O
triphosphate-binding	O
cassette	O
transporter	O
superfamily	O
,	O
and	O
its	O
yeast	O
orthologue	O
,	O
Atm1p	O
,	O
plays	O
a	O
central	O
role	O
in	O
the	O
maturation	O
of	O
cytosolic	O
iron-sulfur	O
(Fe/S)	O
cluster-containing	O
proteins	O
.	O

Previously	O
,	O
a	O
missense	O
mutation	O
in	O
the	O
human	O
ABC7	B-DNAMutation
gene	O
was	O
shown	O
to	O
be	O
the	O
defect	O
in	O
members	O
of	O
a	O
family	O
affected	O
with	O
X-linked	O
sideroblastic	O
anemia	O
with	O
cerebellar	O
ataxia	O
XLSA/A	B-DNAMutation
.	O

Here	O
,	O
the	O
promoter	O
region	O
and	O
the	O
intron/exon	O
structure	O
of	O
the	O
human	O
ABC7	B-DNAMutation
gene	O
were	O
characterized	O
,	O
and	O
the	O
function	O
of	O
wild-type	O
and	O
mutant	O
ABC7	B-DNAMutation
in	O
cytosolic	O
Fe/S	O
protein	O
maturation	O
was	O
analyzed	O
.	O

The	O
gene	O
contains	O
16	O
exons	O
,	O
all	O
with	O
intron/exon	O
boundaries	O
following	O
the	O
AG/GT	O
rule	O
.	O

A	O
single	B-DNAMutation
missense	I-DNAMutation
mutation	I-DNAMutation
was	I-DNAMutation
found	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
10	I-DNAMutation
of	O
the	O
ABC7	B-DNAMutation
gene	O
in	O
2	O
affected	O
brothers	O
with	O
XLSA/A	B-DNAMutation
.	O

The	O
mutation	O
was	O
a	O
G-to-A	B-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
1305	I-DNAMutation
of	O
the	O
full-length	O
cDNA	O
,	O
resulting	O
in	O
a	O
charge	O
inversion	O
caused	O
by	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
lysine	I-DNAMutation
for	I-DNAMutation
glutamate	I-DNAMutation
at	I-DNAMutation
residue	I-DNAMutation
433	I-DNAMutation
C-terminal	I-DNAMutation
to	I-DNAMutation
the	I-DNAMutation
putative	I-DNAMutation
sixth	I-DNAMutation
transmembrane	I-DNAMutation
domain	I-DNAMutation
of	O
ABC7	B-DNAMutation
.	O

Expression	O
of	O
normal	O
ABC7	O
almost	O
fully	O
complemented	O
the	O
defect	O
in	O
the	O
maturation	O
of	O
cytosolic	O
Fe/S	O
proteins	O
in	O
a	O
yeast	O
strain	O
in	O
which	O
the	O
ATM1	B-DNAMutation
gene	I-DNAMutation
had	I-DNAMutation
been	I-DNAMutation
deleted	I-DNAMutation
(	O
Deltaatm1	O
cells	O
)	O
.	O

Thus	O
,	O
ABC7	B-DNAMutation
is	O
a	O
functional	O
orthologue	O
of	O
Atm1p	B-DNAMutation
.	O

In	O
contrast	O
,	O
the	O
expression	O
of	O
mutated	O
ABC7	B-DNAMutation
E433K	B-DNAMutation
or	O
Atm1p	B-DNAMutation
D398K	B-DNAMutation
proteins	O
in	O
Deltaatm1	O
cells	O
led	O
to	O
a	O
low	O
efficiency	O
of	O
cytosolic	O
Fe/S	O
protein	O
maturation	O
.	O

These	O
data	O
demonstrate	O
that	O
both	O
the	O
molecular	O
defect	O
in	O
XLSA/A	B-DNAMutation
and	O
the	O
impaired	O
maturation	O
of	O
a	O
cytosolic	O
Fe/S	O
protein	O
result	O
from	O
an	O
ABC7	B-DNAMutation
mutation	O
in	O
the	O
reported	O
family	O
.	O

The	O
linkage	O
of	O
Kennedy's	O
neuron	O
disease	O
to	O
ARA24	B-DNAMutation
,	O
the	O
first	O
identified	O
androgen	B-DNAMutation
receptor	I-DNAMutation
polyglutamine	O
region-associated	O
coactivator	O
.	O

Although	O
the	O
linkage	O
of	O
polyglutamine	O
(poly-Q)	O
repeat	O
expansion	O
in	O
the	O
androgen	B-DNAMutation
receptor	I-DNAMutation
AR	B-DNAMutation
to	O
Kennedy's	O
disease	O
(	O
X-linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophy	O
)	O
was	O
a	O
major	O
step	O
forward	O
,	O
the	O
detailed	O
molecular	O
mechanism	O
of	O
how	O
the	O
change	O
in	O
poly-Q	O
length	O
contributes	O
to	O
the	O
disease	O
remains	O
unclear	O
.	O

Here	O
we	O
report	O
the	O
identification	O
of	O
a	O
nuclear	O
G-protein	O
,	O
Ras-related	O
nuclear	O
protein/ARA24	B-DNAMutation
,	O
as	O
the	O
first	O
AR	B-DNAMutation
coactivator	O
that	O
can	O
bind	O
differentially	O
with	O
different	O
lengths	O
of	O
poly-Q	O
within	O
AR	B-DNAMutation
.	O

In	O
the	O
yeast	B-DNAMutation
and	O
mammalian	O
reciprocal	O
interacting	O
assays	O
,	O
our	O
data	O
suggested	O
the	O
interaction	O
of	O
AR	B-DNAMutation
N-terminal	O
domain	O
with	O
ARA24	B-DNAMutation
diminishes	O
as	O
the	O
poly-Q	O
length	O
increases	O
.	O

The	O
coactivation	O
of	O
ARA24	B-DNAMutation
also	O
diminishes	O
with	O
the	O
poly-Q	O
expansion	O
within	O
AR	B-DNAMutation
.	O

Deletion	B-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
acidic	I-DNAMutation
hexapeptide	I-DNAMutation
(DEDDDL)	I-DNAMutation
at	I-DNAMutation
the	I-DNAMutation
C	I-DNAMutation
terminus	I-DNAMutation
of	O
ARA24	B-DNAMutation
further	O
enhances	O
its	O
AR	B-DNAMutation
coactivation	O
.	O

Together	O
,	O
our	O
data	O
suggest	O
that	O
poor	O
interaction	O
and	O
weaker	O
coactivation	O
of	O
ARA24	B-DNAMutation
to	O
the	O
longer	O
poly-Q	O
AR	B-DNAMutation
in	O
the	O
X-linked	O
spinal	O
and	O
bulbar	O
muscular	O
atrophied	O
AR	B-DNAMutation
could	O
contribute	O
to	O
the	O
weaker	O
transactivation	O
of	O
AR	B-DNAMutation
.	O

The	O
consequence	O
of	O
poor	O
interaction	O
and	O
weak	O
coactivation	O
may	O
eventually	O
lead	O
to	O
the	O
partial	O
androgen	O
insensitivity	O
during	O
the	O
development	O
of	O
Kennedy's	O
disease	O
.	O

X-linked	O
adrenoleukodystrophy	O
:	O
ABCD1	B-DNAMutation
de	O
novo	O
mutations	O
and	O
mosaicism	O
.	O

X-linked	O
adrenoleukodystrophy	O
(X-ALD)	O
is	O
a	O
progressive	O
peroxisomal	O
disorder	O
affecting	O
adrenal	O
glands	O
,	O
testes	O
and	O
myelin	O
stability	O
that	O
is	O
caused	O
by	O
mutations	O
in	O
the	O
ABCD1	B-DNAMutation
(NM_000033)	O
gene	O
.	O

Males	O
with	O
X-ALD	O
may	O
be	O
diagnosed	O
by	O
the	O
demonstration	O
of	O
elevated	O
very	O
long	O
chain	O
fatty	O
acid	O
(VLCFA)	O
levels	O
in	O
plasma	O
.	O

In	O
contrast	O
,	O
only	O
80%	O
of	O
female	O
carriers	O
have	O
elevated	O
plasma	O
VLCFA	O
;	O
therefore	O
targeted	O
mutation	O
analysis	O
is	O
the	O
most	O
effective	O
means	O
for	O
carrier	O
detection	O
.	O

Amongst	O
489	O
X-ALD	O
families	O
tested	O
at	O
Kennedy	O
Krieger	O
Institute	O
,	O
we	O
identified	O
20	O
cases	O
in	O
which	O
the	O
ABCD1	B-DNAMutation
mutation	O
was	O
de	O
novo	O
in	O
the	O
index	O
case	O
,	O
indicating	O
that	O
the	O
mutation	O
arose	O
in	O
the	O
maternal	O
germ	O
line	O
and	O
supporting	O
a	O
new	O
mutation	O
rate	O
of	O
at	O
least	O
4.1%	O
for	O
this	O
group	O
.	O

In	O
addition	O
,	O
we	O
identified	O
10	O
cases	O
in	O
which	O
a	O
de	O
novo	O
mutation	O
arose	O
in	O
the	O
mother	O
or	O
the	O
grandmother	O
of	O
the	O
index	O
case	O
.	O

In	O
two	O
of	O
these	O
cases	O
studies	O
indicated	O
that	O
the	O
mothers	O
were	O
low	O
level	O
gonosomal	O
mosaics	O
.	O

In	O
a	O
third	O
case	O
biochemical	O
,	O
molecular	O
and	O
pedigree	O
analysis	O
indicated	O
the	O
mother	O
was	O
a	O
gonadal	O
mosaic	O
.	O

To	O
the	O
best	O
of	O
our	O
knowledge	O
mosaicism	O
has	O
not	O
been	O
previously	O
reported	O
in	O
X-ALD	O
.	O

In	O
addition	O
,	O
we	O
identified	O
one	O
pedigree	O
in	O
which	O
the	O
maternal	O
grandfather	O
was	O
mosaic	O
for	O
the	O
familial	O
ABCD1	B-DNAMutation
mutation	O
.	O

Less	O
than	O
1%	O
of	O
our	O
patient	O
population	O
had	O
evidence	O
of	O
gonadal	O
or	O
gonosomal	O
mosaicism	O
,	O
suggesting	O
it	O
is	O
a	O
rare	O
occurrence	O
for	O
this	O
gene	O
and	O
its	O
associated	O
disorders	O
.	O

However	O
,	O
the	O
residual	O
maternal	O
risk	O
for	O
having	O
additional	O
ovum	O
carrying	O
the	O
mutant	O
allele	O
identified	O
in	O
an	O
index	O
case	O
that	O
appears	O
to	O
have	O
a	O
de	O
novo	O
mutation	O
is	O
at	O
least	O
13%	O
.	O

Identification	O
of	O
a	O
point	O
mutation	O
in	O
the	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
gene	O
responsible	O
for	O
immunodeficiency	O
.	O

Deficiency	O
of	O
adenosine	B-DNAMutation
deaminase	I-DNAMutation
ADA	B-DNAMutation
is	O
the	O
cause	O
of	O
an	O
autosomal	O
recessive	O
form	O
of	O
immunodeficiency	O
.	O

We	O
sought	O
to	O
define	O
,	O
at	O
a	O
molecular	O
level	O
,	O
the	O
mutations	O
responsible	O
for	O
ADA	B-DNAMutation
deficiency	O
in	O
the	O
cell	O
line	O
GM-1715	O
,	O
derived	O
from	O
an	O
immunodeficient	O
patient	O
.	O

Full-length	O
complementary	O
DNA	O
(cDNA)	O
for	O
ADA	B-DNAMutation
was	O
synthesized	O
and	O
cloned	O
from	O
the	O
cell	O
line	O
.	O

Sequence	O
analysis	O
of	O
the	O
clones	O
revealed	O
a	O
point	O
mutation	O
in	O
codon	B-DNAMutation
101	I-DNAMutation
(	I-DNAMutation
CGG	I-DNAMutation
to	I-DNAMutation
CAG	I-DNAMutation
)	O
that	O
predicts	O
an	O
amino	O
acid	O
change	B-DNAMutation
from	I-DNAMutation
arginine	I-DNAMutation
to	I-DNAMutation
glutamine	I-DNAMutation
.	O

Southern	O
blot	O
analysis	O
,	O
based	O
on	O
silent	O
polymorphisms	O
in	O
the	O
cDNA	O
sequence	O
,	O
indicated	O
that	O
only	O
one	O
of	O
the	O
defective	O
alleles	O
of	O
the	O
GM-1715	O
line	O
had	O
been	O
sequenced	O
.	O

The	O
mutation	O
that	O
was	O
identified	O
appears	O
to	O
be	O
responsible	O
for	O
the	O
loss	O
of	O
function	O
in	O
this	O
allele	O
,	O
since	O
the	O
predicted	O
primary	O
structure	O
of	O
the	O
enzyme	O
is	O
otherwise	O
entirely	O
normal	O
.	O

Nonsalt-losing	O
male	O
pseudohermaphroditism	O
due	O
to	O
the	O
novel	O
homozygous	O
N100S	B-DNAMutation
mutation	O
in	O
the	O
type	B-DNAMutation
II	I-DNAMutation
3	I-DNAMutation
beta-hydroxysteroid	I-DNAMutation
dehydrogenase	I-DNAMutation
gene	O
.	O

Recently	O
,	O
the	O
structure	O
of	O
two	O
genes	O
encoding	O
isoenzymes	O
responsible	O
for	O
3	B-DNAMutation
beta-hydroxysteroid	I-DNAMutation
dehydrogenase/delta	I-DNAMutation
5-delta	I-DNAMutation
4-isomerase	I-DNAMutation
(	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
)	O
activity	O
in	O
the	O
human	O
was	O
elucidated	O
.	O

This	O
activity	O
is	O
an	O
essential	O
step	O
in	O
the	O
biosynthesis	O
of	O
all	O
classes	O
of	O
steroid	O
hormones	O
.	O

In	O
the	O
classic	O
severe	O
form	O
of	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
deficiency	O
,	O
patients	O
present	O
with	O
adrenal	O
insufficiency	O
,	O
various	O
degrees	O
of	O
salt	O
loss	O
,	O
and	O
incomplete	O
masculinization	O
in	O
males	O
.	O

Here	O
we	O
report	O
the	O
characterization	O
of	O
the	O
molecular	O
basis	O
of	O
congenital	O
adrenal	O
hyperplasia	O
due	O
to	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
deficiency	O
in	O
a	O
male	O
pseudohermaphrodite	O
born	O
from	O
consanguineous	O
parents	O
and	O
having	O
no	O
clinical	O
salt	O
loss	O
.	O

To	O
analyze	O
the	O
structure	O
of	O
the	O
type	O
I	O
and	O
II	B-DNAMutation
3	I-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
genes	O
of	O
the	O
patient	O
,	O
DNA	O
fragments	O
,	O
generated	O
by	O
polymerase	O
chain	O
reaction	O
amplification	O
of	O
the	O
four	O
exons	O
and	O
the	O
exon-intron	O
boundaries	O
of	O
these	O
genes	O
,	O
were	O
directly	O
sequenced	O
.	O

The	O
patients	O
carried	O
a	O
homozygous	O
missense	O
mutation	O
converting	O
Asn100	B-DNAMutation
to	I-DNAMutation
Ser	I-DNAMutation
in	O
exon	O
3	O
of	O
his	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
gene	O
.	O

His	O
parents	O
were	O
heterozygous	O
for	O
the	O
same	O
point	O
mutation	O
.	O

The	O
absence	O
of	O
clinical	O
salt	O
loss	O
associated	O
with	O
a	O
male	O
pseudohermaphroditism	O
suggested	O
that	O
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
activity	O
was	O
impaired	O
to	O
different	O
levels	O
in	O
the	O
testes	O
and	O
adrenal	O
.	O

To	O
elucidate	O
whether	O
this	O
N100S	B-DNAMutation
missense	O
mutation	O
affected	O
preferentially	O
a	O
steroidogenic	O
pathway	O
,	O
enzymatic	O
activity	O
was	O
analyzed	O
by	O
in	O
vitro	O
analysis	O
of	O
mutant	O
recombinant	O
enzyme	O
generated	O
by	O
site-directed	O
mutagenesis	O
after	O
its	O
transient	O
expression	O
in	O
COS-1	O
cells	O
.	O

Using	O
homogenates	O
from	O
transfected	O
cells	O
,	O
the	O
N100S	B-DNAMutation
3	B-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
enzyme	O
showed	O
a	O
Km	O
value	O
for	O
pregnenolone	O
of	O
25	O
+/-	O
3	O
mumol/L	O
compared	O
with	O
3.5	O
+/-	O
0.2	O
mumol/L	O
for	O
the	O
normal	O
human	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
enzyme	O
.	O

Similar	O
results	O
were	O
obtained	O
using	O
dehydroepiandrosterone	O
as	O
substrate	O
.	O

In	O
addition	O
to	O
decreasing	O
apparent	O
affinity	O
,	O
the	O
N100S	B-DNAMutation
mutation	O
decreased	O
the	O
relative	O
specific	O
activity	O
(Vmax)	O
,	O
leading	O
to	O
a	O
relative	O
specificity	O
(	O
relative	O
Vmax/Km	O
)	O
2.7%	O
and	O
11%	O
that	O
of	O
normal	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
using	O
pregnenolone	O
or	O
dehydroepiandrosterone	O
as	O
substrate	O
,	O
respectively	O
.	O

Moreover	O
,	O
the	O
mutant	O
N100S	B-DNAMutation
protein	O
had	O
an	O
apparent	O
decreased	O
affinity	O
for	O
NAD+	O
,	O
with	O
a	O
Km	O
value	O
of	O
650	O
+/-	O
66	O
mumol/L	O
compared	O
with	O
20	O
+/-	O
2	O
mumol/L	O
for	O
normal	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
.	O

Except	O
for	O
the	O
hypothetical	O
effect	O
of	O
local	O
factors	O
,	O
these	O
findings	O
suggest	O
that	O
a	O
very	O
weak	O
residual	O
activity	O
of	O
the	O
normal	O
type	O
II	B-DNAMutation
3	I-DNAMutation
beta	I-DNAMutation
HSD	I-DNAMutation
enzyme	O
could	O
prevent	O
salt	O
loss	O
,	O
but	O
it	O
was	O
insufficient	O
for	O
normal	O
male	O
sex	O
differentiation.(ABSTRACT	O
TRUNCATED	O
AT	O
400	O
WORDS	O
)	O
Variation	O
of	O
clinical	O
expression	O
in	O
patients	O
with	O
Stargardt	O
dystrophy	O
and	O
sequence	O
variations	O
in	O
the	O
ABCR	B-DNAMutation
gene	O
.	O

OBJECTIVE	O
:	O
To	O
report	O
the	O
spectrum	O
of	O
ophthalmic	O
findings	O
in	O
patients	O
with	O
Stargardt	O
dystrophy	O
or	O
fundus	O
flavimaculatus	O
who	O
have	O
a	O
specific	O
sequence	O
variation	O
in	O
the	O
ABCR	B-DNAMutation
gene	O
.	O

PATIENTS	O
:	O
Twenty-nine	O
patients	O
with	O
Stargardt	O
dystrophy	O
or	O
fundus	O
flavimaculatus	O
from	O
different	O
pedigrees	O
were	O
identified	O
with	O
possible	O
disease-causing	O
sequence	O
variations	O
in	O
the	O
ABCR	B-DNAMutation
gene	O
from	O
a	O
group	O
of	O
66	O
patients	O
who	O
were	O
screened	O
for	O
sequence	O
variations	O
in	O
this	O
gene	O
.	O

METHODS	O
:	O
Patients	O
underwent	O
a	O
routine	O
ocular	O
examination	O
,	O
including	O
slitlamp	O
biomicroscopy	O
and	O
a	O
dilated	O
fundus	O
examination	O
.	O

Fluorescein	O
angiography	O
was	O
performed	O
on	O
22	O
patients	O
,	O
and	O
electroretinographic	O
measurements	O
were	O
obtained	O
on	O
24	O
of	O
29	O
patients	O
.	O

Kinetic	O
visual	O
fields	O
were	O
measured	O
with	O
a	O
Goldmann	O
perimeter	O
in	O
26	O
patients	O
.	O

Single-strand	O
conformation	O
polymorphism	O
analysis	O
and	O
DNA	O
sequencing	O
were	O
used	O
to	O
identify	O
variations	O
in	O
coding	O
sequences	O
of	O
the	O
ABCR	B-DNAMutation
gene	O
.	O

RESULTS	O
:	O
Three	O
clinical	O
phenotypes	O
were	O
observed	O
among	O
these	O
29	O
patients	O
.	O

In	O
phenotype	O
I	O
,	O
9	O
of	O
12	O
patients	O
had	O
a	O
sequence	O
change	O
in	B-DNAMutation
exon	I-DNAMutation
42	I-DNAMutation
of	I-DNAMutation
the	I-DNAMutation
ABCR	I-DNAMutation
gene	I-DNAMutation
in	I-DNAMutation
which	I-DNAMutation
the	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
glutamic	I-DNAMutation
acid	I-DNAMutation
was	I-DNAMutation
substituted	I-DNAMutation
for	I-DNAMutation
glycine	I-DNAMutation
Gly1961Glu	B-DNAMutation
.	O

In	O
only	O
4	O
of	O
these	O
9	O
patients	O
was	O
a	O
second	O
possible	O
disease-causing	O
mutation	O
found	O
on	O
the	O
other	O
ABCR	B-DNAMutation
allele	O
.	O

In	O
addition	O
to	O
an	O
atrophic-appearing	O
macular	O
lesion	O
,	O
phenotype	O
I	O
was	O
characterized	O
by	O
localized	O
perifoveal	O
yellowish	O
white	O
flecks	O
,	O
the	O
absence	O
of	O
a	O
dark	O
choroid	O
,	O
and	O
normal	O
electroretinographic	O
amplitudes	O
.	O

Phenotype	O
II	O
consisted	O
of	O
10	O
patients	O
who	O
showed	O
a	O
dark	O
choroid	O
and	O
more	O
diffuse	O
yellowish	O
white	O
flecks	O
in	O
the	O
fundus	O
.	O

None	O
exhibited	O
the	O
Gly1961Glu	B-DNAMutation
change	O
.	O

Phenotype	O
III	O
consisted	O
of	O
7	O
patients	O
who	O
showed	O
extensive	O
atrophic-appearing	O
changes	O
of	O
the	O
retinal	O
pigment	O
epithelium	O
.	O

Electroretinographic	O
cone	O
and	O
rod	O
amplitudes	O
were	O
reduced	O
.	O

One	O
patient	O
showed	O
the	O
Gly1961Glu	B-DNAMutation
change	O
.	O

CONCLUSIONS	O
:	O
A	O
wide	O
variation	O
in	O
clinical	O
phenotype	O
can	O
occur	O
in	O
patients	O
with	O
sequence	O
changes	O
in	O
the	O
ABCR	B-DNAMutation
gene	O
.	O

In	O
individual	O
patients	O
,	O
a	O
certain	O
phenotype	O
seems	O
to	O
be	O
associated	O
with	O
the	O
presence	O
of	O
a	O
Gly1961Glu	B-DNAMutation
change	O
in	O
exon	O
42	O
of	O
the	O
ABCR	B-DNAMutation
gene	O
.	O

CLINICAL	O
RELEVANCE	O
:	O
The	O
identification	O
of	O
correlations	O
between	O
specific	O
mutations	O
in	O
the	O
ABCR	B-DNAMutation
gene	O
and	O
clinical	O
phenotypes	O
will	O
better	O
facilitate	O
the	O
counseling	O
of	O
patients	O
on	O
their	O
visual	O
prognosis	O
.	O

This	O
information	O
will	O
also	O
likely	O
be	O
important	O
for	O
future	O
therapeutic	O
trials	O
in	O
patients	O
with	O
Stargardt	O
dystrophy	O
.	O

Fabry	O
disease	O
:	O
six	O
gene	O
rearrangements	O
and	O
an	O
exonic	O
point	O
mutation	O
in	O
the	O
alpha-galactosidase	O
gene	O
.	O

Fabry	O
disease	O
,	O
an	O
X-linked	O
recessive	O
disorder	O
of	O
glycosphingolipid	O
catabolism	O
,	O
results	O
from	O
the	O
deficient	O
activity	O
of	O
the	O
lysosomal	O
hydrolase	O
,	O
alpha-galactosidase	O
.	O

Southern	O
hybridization	O
analysis	O
of	O
the	O
alpha-galactosidase	O
gene	O
in	O
affected	O
hemizygous	O
males	O
from	O
130	O
unrelated	O
families	O
with	O
Fabry	O
disease	O
revealed	O
six	O
with	O
different	O
gene	O
rearrangements	O
and	O
one	O
with	O
an	O
exonic	O
point	O
mutation	O
resulting	O
in	O
the	O
obliteration	B-DNAMutation
of	I-DNAMutation
an	I-DNAMutation
Msp	I-DNAMutation
I	I-DNAMutation
restriction	I-DNAMutation
site	I-DNAMutation
.	O

Five	O
partial	O
gene	O
deletions	O
were	O
detected	O
ranging	O
in	O
size	O
from	O
0.4	O
to	O
greater	O
than	O
5.5	O
kb	O
.	O

Four	O
of	O
these	O
deletions	B-DNAMutation
had	I-DNAMutation
breakpoints	I-DNAMutation
in	I-DNAMutation
intron	I-DNAMutation
2	I-DNAMutation
,	O
a	O
region	O
in	O
the	O
gene	O
containing	O
multiple	O
Alu	O
repeat	O
sequences	O
.	O

A	O
sixth	O
genomic	O
rearrangement	O
was	O
identified	O
in	O
which	O
a	O
region	B-DNAMutation
of	I-DNAMutation
about	I-DNAMutation
8	I-DNAMutation
kb	I-DNAMutation
,	I-DNAMutation
containing	I-DNAMutation
exons	I-DNAMutation
2	I-DNAMutation
through	I-DNAMutation
6	I-DNAMutation
,	I-DNAMutation
was	I-DNAMutation
duplicated	I-DNAMutation
by	O
a	O
homologous	O
,	O
but	O
unequal	O
crossover	O
event	O
.	O

The	O
Msp	B-DNAMutation
I	I-DNAMutation
site	I-DNAMutation
obliteration	I-DNAMutation
,	I-DNAMutation
which	I-DNAMutation
mapped	I-DNAMutation
to	I-DNAMutation
exon	I-DNAMutation
7	I-DNAMutation
,	O
was	O
detected	O
in	O
an	O
affected	O
hemizygote	O
who	O
had	O
residual	O
enzyme	O
activity	O
.	O

Genomic	O
amplification	O
by	O
the	O
polymerase	O
chain	O
reaction	O
and	O
sequencing	O
revealed	O
that	O
the	O
obliteration	O
resulted	O
from	O
a	O
C	B-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
transition	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
1066	I-DNAMutation
in	O
the	O
coding	O
sequence	O
.	O

This	O
point	O
mutation	O
,	O
the	O
first	O
identified	O
in	O
Fabry	O
disease	O
,	O
resulted	O
in	O
an	O
arginine356	B-DNAMutation
to	I-DNAMutation
tryptophan356	I-DNAMutation
substitution	O
which	O
altered	O
the	O
enzyme's	O
kinetic	O
and	O
stability	O
properties	O
.	O

The	O
detection	O
of	O
these	O
abnormalities	O
provided	O
for	O
the	O
precise	O
identification	O
of	O
Fabry	O
heterozygotes	O
,	O
thereby	O
permitting	O
molecular	O
pedigree	O
analysis	O
in	O
these	O
families	O
which	O
revealed	O
paternity	O
exclusions	O
and	O
the	O
first	O
documented	O
new	O
mutations	O
in	O
this	O
disease	O
.	O

A	O
molecular	O
basis	O
for	O
the	O
selective	O
recognition	O
of	O
2-hydroxy-dATP	O
and	O
8-oxo-dGTP	O
by	O
human	O
MTH1	B-DNAMutation
.	O

MTH1	B-DNAMutation
hydrolyzes	O
oxidized	O
purine	O
nucleoside	O
triphosphates	O
such	O
as	O
8-oxo-dGTP	O
,	O
8-oxo-dATP	O
,	O
2-hydroxy-dATP	O
,	O
and	O
2-hydroxy	O
rATP	O
to	O
monophosphates	O
,	O
and	O
thus	O
avoids	O
errors	O
caused	O
by	O
their	O
misincorporation	O
during	O
DNA	O
replication	O
or	O
transcription	O
,	O
which	O
may	O
result	O
in	O
carcinogenesis	O
or	O
neurodegeneration	O
.	O

This	O
substrate	O
specificity	O
for	O
oxidized	O
purine	O
nucleoside	O
triphosphates	O
was	O
investigated	O
by	O
mutation	O
analyses	O
based	O
on	O
the	O
sequence	O
comparison	O
with	O
the	O
Escherichia	O
coli	O
homolog	O
,	O
MutT	O
,	O
which	O
hydrolyzes	O
only	O
8-oxo-dGTP	O
and	O
8-oxo-rGTP	O
but	O
not	O
oxidized	O
forms	O
of	O
dATP	O
or	O
ATP	O
.	O

Neither	O
a	O
replacement	O
of	O
the	O
phosphohydrolase	O
module	O
of	O
MTH1	B-DNAMutation
with	O
that	O
of	O
MutT	O
nor	O
deletions	O
of	O
the	O
C-terminal	O
region	O
of	O
MTH1	B-DNAMutation
,	O
which	O
is	O
unique	O
for	O
MTH1	B-DNAMutation
,	O
altered	O
the	O
substrate	O
specificity	O
of	O
MTH1	B-DNAMutation
.	O

In	O
contrast	O
,	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
residues	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
Trp-117	I-DNAMutation
and	O
Asp-119	B-DNAMutation
of	O
MTH1	B-DNAMutation
,	O
which	O
showed	O
apparent	O
chemical	O
shift	O
perturbations	O
with	O
8-oxo-dGDP	O
in	O
NMR	O
analyses	O
but	O
are	O
not	O
conserved	O
in	O
MutT	O
,	O
affected	O
the	O
substrate	O
specificity	O
.	O

Trp-117	B-DNAMutation
is	O
essential	O
for	O
MTH1	B-DNAMutation
to	O
recognize	O
both	O
8-oxo-dGTP	O
and	O
2-hydroxy-dATP	O
,	O
whereas	O
Asp-119	B-DNAMutation
is	O
only	O
essential	O
for	O
recognizing	O
2-hydroxy-dATP	O
,	O
thus	O
suggesting	O
that	O
origins	O
of	O
the	O
substrate-binding	O
pockets	O
for	O
MTH1	B-DNAMutation
and	O
MutT	O
are	O
different	O
.	O

Novel	O
mutations	O
of	O
the	O
ACTH	B-DNAMutation
receptor	I-DNAMutation
gene	O
in	O
a	O
female	O
adult	O
patient	O
with	O
adrenal	O
unresponsiveness	O
to	O
ACTH	B-DNAMutation
.	O

We	O
report	O
a	O
30-year-old	O
female	O
with	O
adrenal	O
unresponsiveness	O
to	O
ACTH	B-DNAMutation
.	O

Her	O
clinical	O
features	O
included	O
no	O
adrenal	O
crisis	O
despite	O
poor	O
drug	O
compliance	O
,	O
poor	O
pubic	O
hair	O
development	O
(	O
Tanner	O
stage	O
2	O
)	O
,	O
well-developed	O
breasts	O
(	O
Tanner	O
stage	O
5	O
)	O
,	O
and	O
regular	O
menstrual	O
cycles	O
.	O

Endocrinological	O
data	O
included	O
blood	O
ACTH	B-DNAMutation
1500	O
pmol/l	O
,	O
cortisol	O
18	O
nmol/l	O
,	O
dehydroepiandrosterone	O
sulphate	O
below	O
0.26	O
micromol/l	O
,	O
activated	O
renin	B-DNAMutation
0.37	O
pmol/l	O
,	O
and	O
aldosterone	O
3.4	O
nmol/l	O
.	O

Direct	O
sequencing	O
and	O
allele-specific	O
amplification	O
revealed	O
two	O
novel	O
mutations	O
in	O
the	O
ACTH	B-DNAMutation
receptor	I-DNAMutation
gene	O
.	O

One	O
was	O
transition	B-DNAMutation
from	I-DNAMutation
guanine	I-DNAMutation
to	I-DNAMutation
adenine	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
position	I-DNAMutation
1002	I-DNAMutation
,	O
resulting	O
in	O
substitution	B-DNAMutation
of	I-DNAMutation
aspartate	I-DNAMutation
for	I-DNAMutation
asparagine	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
103	I-DNAMutation
,	O
and	O
the	O
other	O
was	O
transition	B-DNAMutation
from	I-DNAMutation
cytosine	I-DNAMutation
to	I-DNAMutation
thymine	I-DNAMutation
at	I-DNAMutation
nucleotide	I-DNAMutation
1104	I-DNAMutation
,	O
leading	B-DNAMutation
to	I-DNAMutation
substitution	I-DNAMutation
of	I-DNAMutation
arginine	I-DNAMutation
for	I-DNAMutation
tryptophan	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
137	I-DNAMutation
.	O

The	O
present	O
findings	O
lend	O
additional	O
credence	O
to	O
the	O
notions	O
that	O
adrenal	O
androgens	O
play	O
an	O
important	O
role	O
in	O
female	O
pubic	O
hair	O
development	O
and	O
that	O
ovarian	O
development	O
takes	O
place	O
independently	O
of	O
adrenarche	O
.	O

Topological	O
mapping	O
of	O
BRIL	B-DNAMutation
reveals	O
a	O
type	O
II	O
orientation	O
and	O
effects	O
of	O
osteogenesis	O
imperfecta	O
mutations	O
on	O
its	O
cellular	O
destination	O
.	O

BRIL/IFITM5	B-DNAMutation
is	O
a	O
membrane	O
protein	O
present	O
almost	O
exclusively	O
in	O
osteoblasts	O
,	O
which	O
is	O
believed	O
to	O
adopt	O
a	O
type	O
III	O
(N-out/C-out)	O
topology	O
.	O

Mutations	O
in	O
IFITM5	O
cause	O
OI	O
type	O
V	O
,	O
but	O
the	O
characteristics	O
of	O
the	O
mutant	O
protein	O
and	O
the	O
mechanism	O
involved	O
are	O
still	O
unknown	O
.	O

The	O
purpose	O
of	O
the	O
current	O
study	O
was	O
to	O
re-assess	O
the	O
topology	O
,	O
localization	O
,	O
and	O
biochemical	O
properties	O
of	O
BRIL	B-DNAMutation
and	O
compare	O
it	O
to	O
the	O
OI	O
type	O
V	O
mutant	O
in	O
MC3T3	O
osteoblasts	O
.	O

Immunofluorescence	O
labeling	O
was	O
performed	O
with	O
antibodies	O
directed	O
against	O
BRIL	B-DNAMutation
N-	O
or	O
C-terminus	O
.	O

In	O
intact	O
cells	O
,	O
BRIL	B-DNAMutation
labeling	O
was	O
conspicuously	O
detected	O
at	O
the	O
plasma	O
membrane	O
only	O
with	O
the	O
anti-C	O
antibody	O
.	O

Detection	O
of	O
BRIL	B-DNAMutation
N-terminus	O
was	O
only	O
possible	O
after	O
cell	O
permeabilization	O
,	O
revealing	O
both	O
plasma	O
membrane	O
and	O
Golgi	O
labeling	O
.	O

Trypsinization	O
of	O
live	O
cells	O
expressing	O
BRIL	B-DNAMutation
only	O
cleaved	O
off	O
the	O
C-terminus	O
,	O
confirming	O
that	O
it	O
is	O
a	O
type	O
II	O
protein	O
and	O
that	O
its	O
N-terminus	O
is	O
intracellular	O
.	O

A	O
truncated	O
form	O
of	O
BRIL	B-DNAMutation
lacking	B-DNAMutation
the	I-DNAMutation
last	I-DNAMutation
18	I-DNAMutation
residues	I-DNAMutation
did	O
not	O
appear	O
to	O
affect	O
localization	O
,	O
whereas	O
mutation	B-DNAMutation
of	I-DNAMutation
a	I-DNAMutation
single	I-DNAMutation
leucine	I-DNAMutation
to	I-DNAMutation
arginine	I-DNAMutation
within	I-DNAMutation
the	I-DNAMutation
transmembrane	I-DNAMutation
segment	I-DNAMutation
abolished	O
plasma	O
membrane	O
targeting	O
.	O

BRIL	B-DNAMutation
is	O
first	O
targeted	O
to	O
the	O
endoplasmic	O
reticulum	O
as	O
the	O
entry	O
point	O
to	O
the	O
secretory	O
pathway	O
and	O
rapidly	O
traffics	O
to	O
the	O
Golgi	O
via	O
a	O
COPII-dependent	O
pathway	O
.	O

BRIL	B-DNAMutation
was	O
found	O
to	O
be	O
palmitoylated	O
and	O
two	O
conserved	O
cysteine	O
residues	O
(	O
C52	O
and	O
C53	O
)	O
were	O
critical	O
for	O
targeting	O
to	O
the	O
plasma	O
membrane	O
.	O

The	O
OI	O
type	O
V	O
mutant	O
BRIL	B-DNAMutation
,	O
having	O
a	O
five	B-DNAMutation
residue	I-DNAMutation
extension	I-DNAMutation
(MALEP)	I-DNAMutation
at	I-DNAMutation
its	I-DNAMutation
N-terminus	I-DNAMutation
,	O
presented	O
with	O
exactly	O
the	O
same	O
topological	O
and	O
biochemical	O
characteristics	O
as	O
wild	O
type	O
BRIL	B-DNAMutation
.	O

In	O
contrast	O
,	O
the	O
S42â>âL	I-DNAMutation
mutant	B-DNAMutation
BRIL	O
was	O
trapped	O
intracellularly	O
in	O
the	O
Golgi	B-DNAMutation
.	O

BRIL	O
proteins	O
and	O
transcripts	O
were	O
equally	O
detected	O
in	O
bone	O
from	O
a	O
patient	O
with	O
OI	O
type	O
V	O
,	O
suggesting	O
that	O
the	O
cause	O
of	O
the	O
disease	O
is	O
a	O
gain	O
of	O
function	O
mediated	O
by	O
a	O
faulty	O
intracellular	O
activity	O
of	O
the	O
mutant	B-DNAMutation
BRIL	O
.	O

CHRND	B-DNAMutation
mutation	O
causes	O
a	O
congenital	O
myasthenic	O
syndrome	O
by	O
impairing	O
co-clustering	O
of	O
the	O
acetylcholine	O
receptor	O
with	O
rapsyn	B-DNAMutation
.	O

The	O
objective	O
of	O
this	O
study	O
was	O
to	O
analyse	O
the	O
mutations	O
of	O
the	O
acetylcholine	O
receptor	O
(AChR)	O
delta	B-DNAMutation
subunit	O
gene	O
CHRND	B-DNAMutation
in	O
a	O
patient	O
with	O
sporadic	O
congenital	O
myasthenic	O
syndrome	O
(CMS)	O
.	O

Mutations	O
in	O
various	O
genes	O
encoding	O
proteins	O
expressed	O
at	O
the	O
neuromuscular	O
junction	O
may	O
cause	O
CMS	O
.	O

Mutations	O
of	O
AChR	O
subunit	O
genes	O
lead	O
to	O
end-plate	O
AChR	O
deficiency	O
or	O
to	O
altered	O
kinetic	O
properties	O
of	O
the	O
receptor	O
.	O

Mutations	O
in	O
the	O
alpha	O
,	O
beta	O
and	O
delta	O
subunits	O
of	O
the	O
AChR	O
are	O
less	O
frequent	O
than	O
mutations	O
of	O
the	O
epsilon	O
subunit	O
;	O
mutations	O
in	O
these	O
subunits	O
leading	O
to	O
AChR	O
deficiency	O
are	O
often	O
associated	O
with	O
a	O
severe	O
phenotype	O
.	O

A	O
sporadic	O
patient	O
from	O
Germany	O
was	O
studied	O
,	O
who	O
presented	O
with	O
an	O
early	O
onset	O
CMS	O
associated	O
with	O
feeding	O
difficulties	O
,	O
ptosis	O
,	O
a	O
moderate	O
general	O
weakness	O
responsive	O
to	O
anticholinesterase	O
treatment	O
and	O
recurrent	O
episodes	O
of	O
respiratory	O
insufficiency	O
provoked	O
by	O
infections	O
.	O

The	O
CHRND	B-DNAMutation
gene	O
was	O
screened	O
for	O
mutations	O
by	O
RFLP	O
,	O
long-range	O
PCR	O
and	O
sequence	O
analysis	O
.	O

Subsequently	O
,	O
we	O
conducted	O
functional	O
studies	O
of	O
AChR	O
mutants	O
co-transfected	O
with	O
rapsyn	B-DNAMutation
in	O
HEK	O
293	O
cells	O
.	O

Heterozygously	O
to	O
a	O
2.2	O
kb	O
microdeletion	O
disrupting	O
the	O
CHRND	B-DNAMutation
gene	O
,	O
we	O
identified	O
a	O
novel	O
point	O
mutation	O
in	O
the	O
long	O
cytoplasmic	O
loop	O
,	O
CHRND	B-DNAMutation
E381K	B-DNAMutation
.	O

The	O
cytoplasmic	O
loop	O
of	O
the	O
AChR	O
subunits	O
is	O
known	O
to	O
be	O
essential	O
for	O
AChR-rapsyn	B-DNAMutation
co-clustering	O
.	O

We	O
therefore	O
studied	O
the	O
interaction	O
of	O
AChR	O
containing	O
the	O
CHRND	B-DNAMutation
E381K	B-DNAMutation
mutation	O
with	O
rapsyn	B-DNAMutation
by	O
evaluating	O
expression	O
and	O
co-localization	O
of	O
rapsyn	B-DNAMutation
and	O
mutated	O
AChR	O
subunits	O
in	O
co-transfected	O
HEK	O
293	O
cells	O
.	O

Interestingly	O
,	O
the	O
mutated	O
receptor	O
showed	O
severely	O
reduced	O
cluster	O
formation	O
compared	O
with	O
the	O
wild-type	O
receptor	O
.	O

In	O
contrast	O
,	O
the	O
corresponding	O
amino	O
acid	O
substitution	O
in	O
the	O
cytoplasmic	O
loop	O
of	O
the	O
AChR	O
epsilon	O
(	O
CHRNE	B-DNAMutation
E376K	B-DNAMutation
)	O
as	O
well	O
as	O
a	O
recently	O
reported	O
CMS	O
mutation	O
affecting	O
this	O
domain	O
(	O
CHRNE	B-DNAMutation
N436del	B-DNAMutation
)	O
had	O
no	O
impact	O
on	O
cluster	O
formation	O
.	O

CHRND	B-DNAMutation
mutations	O
are	O
a	O
rare	O
cause	O
for	O
CMS	O
but	O
should	O
be	O
considered	O
in	O
patients	O
with	O
a	O
severe	O
,	O
early	O
onset	O
disease	O
form	O
,	O
clinically	O
resembling	O
a	O
rapsyn	B-DNAMutation
phenotype	O
with	O
recurrent	O
episodic	O
apnoeas	O
.	O

Our	O
results	O
suggest	O
that	O
impairment	O
of	O
AChR-rapsyn	B-DNAMutation
co-clustering--a	O
well-known	O
molecular	O
mechanism	O
for	O
rapsyn	B-DNAMutation
mutations--could	O
also	O
result	O
from	O
mutations	O
in	O
the	O
delta	O
subunit	O
.	O

Introduction	O
of	O
the	O
same	O
mutation	O
in	O
the	O
epsilon	O
subunit	O
had	O
no	O
effect	O
on	O
AChR	O
clustering	O
indicating	O
a	O
special	O
role	O
of	O
the	O
delta	B-DNAMutation
subunit	O
in	O
AChR-rapsyn	B-DNAMutation
interactions	O
.	O

In	O
silico	O
structural	O
,	O
functional	O
and	O
pathogenicity	O
evaluation	O
of	O
a	O
novel	O
mutation	O
:	O
an	O
overview	O
of	O
HSD3B2	B-DNAMutation
gene	O
mutations	O
.	O

Mutations	O
of	O
3	O
beta	O
hydroxysteroid	O
dehydrogenase	O
type	O
II	O
HSD3B2	B-DNAMutation
gene	O
result	O
in	O
different	O
clinical	O
consequences	O
.	O

We	O
explain	O
a	O
patient	O
who	O
demonstrated	O
a	O
salt	O
wasting	O
form	O
of	O
3Î²HSD	O
deficiency	O
in	O
infancy	O
.	O

Signs	O
of	O
hyponatremia	O
and	O
hyperkalemia	O
were	O
recognized	O
in	O
the	O
infant	O
with	O
ambiguous	O
genitalia	O
and	O
perineal	O
hypospadias	O
.	O

The	O
46,XY	O
male	O
was	O
genotyped	O
by	O
direct	O
sequencing	O
of	B-DNAMutation
HSD3B2	I-DNAMutation
gene	O
.	O

Steroid	O
profiles	O
showed	O
elevated	O
concentration	O
of	O
17	O
hydroxyprogesterone	O
,	O
and	O
decrease	O
in	O
concentration	O
of	O
cortisol	O
,	O
and	O
testosterone	O
.	O

Dehydroepiandrotone	O
(DHEA)	O
to	O
androstenedione	O
ratio	O
had	O
6	O
fold	O
increases	O
.	O

Direct	O
sequencing	O
of	O
the	O
patient	O
revealed	O
homozygous	O
missense	B-DNAMutation
A82P	I-DNAMutation
mutation	O
in	O
exon	O
3	O
.	O

This	O
mutation	O
was	O
confirmed	O
by	O
segregation	O
analysis	O
of	O
the	O
parents	O
.	O

Bioinformatic	O
tools	O
were	O
used	O
for	O
in	O
silico	O
structural	O
and	O
functional	O
analyses	O
.	O

Also	O
,	O
the	O
pathological	O
effect	O
of	O
the	O
mutation	O
was	O
validated	O
by	O
different	O
software	O
.	O

Alanine	O
is	O
a	O
conserved	O
amino	O
acid	O
in	O
the	O
membrane	O
binding	O
domain	O
of	O
the	O
enzyme	O
and	O
proline	O
substitution	O
was	O
predicted	O
to	O
destabilize	O
the	O
protein	O
.	O

This	O
report	O
may	O
highlight	O
the	O
importance	O
of	O
the	O
screening	O
programs	O
of	O
the	O
disorder	O
in	O
Iran	O
.	O

Impaired	O
expression	O
and	O
function	O
of	O
the	O
bile	O
salt	O
export	O
pump	O
due	O
to	O
three	O
novel	O
ABCB11	B-DNAMutation
mutations	O
in	O
intrahepatic	O
cholestasis	O
.	O

BACKGROUND/AIMS	O
:	O
Inherited	O
dysfunction	O
of	O
the	O
bile	O
salt	O
export	O
pump	O
BSEP	B-DNAMutation
ABCB11	B-DNAMutation
causes	O
a	O
progressive	O
and	O
a	O
benign	O
form	O
of	O
familial	O
intrahepatic	O
cholestasis	O
,	O
denominated	O
as	O
PFIC2	B-DNAMutation
and	O
BRIC2	B-DNAMutation
,	O
respectively	O
.	O

We	O
functionally	O
characterized	O
novel	O
ABCB11	B-DNAMutation
mutations	O
encountered	O
in	O
two	O
patients	O
with	O
a	O
PFIC2	B-DNAMutation
and	O
a	O
BRIC2	B-DNAMutation
phenotype	O
,	O
respectively	O
.	O

METHODS	O
:	O
BSEP	B-DNAMutation
expression	O
was	O
determined	O
in	O
liver	O
biopsies	O
by	O
immunohistochemistry	O
.	O

ABCB11	B-DNAMutation
mutations	O
were	O
functionally	O
characterized	O
by	O
taurocholate	O
transport	O
in	O
SF9	O
cells	O
transfected	O
with	O
human	O
ABCB11	B-DNAMutation
.	O

RESULTS	O
:	O
The	O
PFIC2	B-DNAMutation
patient	O
was	O
compound	O
heterozygous	O
for	O
a	O
splicing	O
mutation	O
in	O
intron	B-DNAMutation
4	I-DNAMutation
(	I-DNAMutation
(+3)A	I-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
)	O
combined	O
with	O
an	O
early	B-DNAMutation
stop	I-DNAMutation
codon	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
930	I-DNAMutation
R930X	B-DNAMutation
,	O
while	O
the	O
BRIC2	B-DNAMutation
patient	O
was	O
compound	O
heterozygous	O
for	O
two	O
nonsynonymous	O
mutations	O
in	O
exon	O
9	O
E297G	B-DNAMutation
and	O
exon	O
12	O
R432T	B-DNAMutation
,	O
respectively	O
.	O

Hepatic	O
BSEP	B-DNAMutation
expression	O
was	O
absent	O
in	O
PFIC2	B-DNAMutation
and	O
preserved	O
in	O
BRIC2	B-DNAMutation
.	O

In	O
BRIC2	B-DNAMutation
,	O
taurocholate	O
transport	O
was	O
decreased	O
to	O
13%	O
and	O
20%	O
of	O
reference	O
levels	O
for	O
R432T	B-DNAMutation
and	O
E297G	B-DNAMutation
,	O
respectively	O
.	O

CONCLUSIONS	O
:	O
The	O
intron	B-DNAMutation
4	I-DNAMutation
(+3)A	I-DNAMutation
>	I-DNAMutation
C	I-DNAMutation
,	O
R930X	B-DNAMutation
and	O
R432T	B-DNAMutation
represent	O
previously	O
undescribed	O
mutations	O
of	O
the	O
ABCB11	B-DNAMutation
gene	O
that	O
confer	O
a	O
PFIC2	B-DNAMutation
and	O
a	O
BRIC2	B-DNAMutation
phenotype	O
,	O
respectively	O
.	O

By	O
combining	O
functional	O
in-vitro	O
characterization	O
with	O
immunohistochemical	O
detection	O
of	O
variant	O
BSEP	B-DNAMutation
we	O
provide	O
direct	O
evidence	O
for	O
the	O
role	O
of	O
ABCB11	B-DNAMutation
mutations	O
in	O
the	O
pathogenesis	O
of	O
different	O
forms	O
of	O
intrahepatic	O
cholestasis	O
.	O

Characterisation	O
of	O
the	O
alpha-1-antitrypsin	B-DNAMutation
M3	O
gene	O
,	O
a	O
normal	O
variant	O
.	O

By	O
sequence	O
analysis	O
of	O
the	O
complete	O
protein-coding	O
region	O
of	O
the	O
human	O
alpha-1-antitrypsin	B-DNAMutation
gene	O
using	O
polymerase	O
chain	O
reaction	O
techniques	O
,	O
we	O
have	O
characterised	O
one	O
of	O
the	O
normal	O
variants	O
,	O
M3	O
.	O

We	O
have	O
identified	O
a	O
single	B-DNAMutation
point	I-DNAMutation
mutation	I-DNAMutation
between	I-DNAMutation
M1	I-DNAMutation
Val213	I-DNAMutation
and	I-DNAMutation
M3	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
position	I-DNAMutation
376	I-DNAMutation
which	I-DNAMutation
is	I-DNAMutation
a	I-DNAMutation
GAA(Glu)	I-DNAMutation
to	I-DNAMutation
GAC(Asp)	I-DNAMutation
transversion	I-DNAMutation
.	O

A	O
novel	O
missense	O
adenine	B-DNAMutation
nucleotide	I-DNAMutation
translocator-1	I-DNAMutation
gene	O
mutation	O
in	O
a	O
Greek	O
adPEO	O
family	O
.	O

Autosomal	O
dominant	O
progressive	O
external	O
ophthalmoplegia	O
(adPEO)	O
is	O
caused	O
by	O
mutations	O
in	O
at	O
least	O
three	O
different	O
genes	O
:	O
ANT1	B-DNAMutation
(	O
chromosome	O
4q34-35	O
)	O
,	O
TWINKLE	O
,	O
and	O
POLG	B-DNAMutation
.	O

The	O
ANT1	B-DNAMutation
gene	O
encodes	O
the	O
adenine	B-DNAMutation
nucleotide	I-DNAMutation
translocator-1	I-DNAMutation
ANT1	B-DNAMutation
.	O

We	O
identified	O
a	O
heterozygous	O
T293C	B-DNAMutation
mutation	O
of	O
the	O
ANT1	B-DNAMutation
gene	O
in	O
a	O
Greek	O
family	O
with	O
adPEO	O
.	O

The	O
resulting	B-DNAMutation
leucine	I-DNAMutation
to	I-DNAMutation
proline	I-DNAMutation
substitution	I-DNAMutation
likely	O
modifies	O
the	O
secondary	O
structure	O
of	O
the	O
ANT1	B-DNAMutation
protein	O
.	O

ANT1	B-DNAMutation
gene	O
mutations	O
may	O
account	O
for	O
adPEO	O
in	O
families	O
with	O
different	O
ethnic	O
backgrounds	O
.	O

The	O
human	O
beta	O
3	O
alcohol	O
dehydrogenase	O
subunit	O
differs	O
from	O
beta	O
1	O
by	O
a	O
Cys	B-DNAMutation
for	I-DNAMutation
Arg-369	I-DNAMutation
substitution	O
which	O
decreases	O
NAD(H)	O
binding	O
.	O

The	O
beta	O
3	O
beta	O
3	O
(	O
formerly	O
called	O
beta	O
Indianapolis	O
)	O
and	O
beta	O
1	O
beta	O
1	O
isoenzymes	O
of	O
human	O
alcohol	O
dehydrogenase	O
differ	O
substantially	O
in	O
their	O
catalytic	O
properties	O
.	O

Specifically	O
,	O
the	O
KM	O
value	O
for	O
NAD+	O
of	O
beta	O
3	O
beta	O
3	O
is	O
70	O
times	O
greater	O
than	O
that	O
of	O
beta	O
1	O
beta	O
1	O
,	O
and	O
the	O
Ki	O
value	O
for	O
NADH	O
is	O
35	O
times	O
greater	O
than	O
that	O
of	O
beta	O
1	O
beta	O
1	O
.	O

To	O
identify	O
the	O
structural	O
basis	O
of	O
these	O
catalytic	O
differences	O
,	O
we	O
sequenced	O
regions	O
of	O
the	O
beta	O
3	O
subunit	O
and	O
the	O
beta	O
3	O
gene	O
.	O

beta	O
3	O
differs	O
from	O
beta	O
1	O
by	O
the	O
substitution	B-DNAMutation
of	I-DNAMutation
Cys	I-DNAMutation
for	I-DNAMutation
Arg-369	I-DNAMutation
.	O

Based	O
on	O
x-ray	O
crystallography	O
of	O
horse	O
ADH	O
,	O
Arg-369	O
should	O
interact	O
with	O
the	O
nicotinamide	O
phosphate	O
moiety	O
of	O
NAD(H)	O
.	O

The	O
Cys	B-DNAMutation
for	I-DNAMutation
Arg-369	I-DNAMutation
substitution	O
would	O
decrease	O
the	O
enzyme's	O
affinity	O
for	O
coenzyme	O
and	O
,	O
thus	O
,	O
account	O
for	O
the	O
observed	O
kinetic	O
differences	O
between	O
beta	O
3	O
beta	O
3	O
and	O
beta	O
1	O
beta	O
1	O
.	O

Probing	O
the	O
active	O
site	O
of	O
human	O
aldose	O
reductase	O
.	O

Site-directed	O
mutagenesis	B-DNAMutation
of	I-DNAMutation
Asp-43	I-DNAMutation
,	I-DNAMutation
Tyr-48	I-DNAMutation
,	I-DNAMutation
Lys-77	I-DNAMutation
,	I-DNAMutation
and	I-DNAMutation
His-110	I-DNAMutation
.	O

Structural	O
models	O
of	O
human	O
aldose	O
reductase	O
complexed	O
with	O
NADPH	B-DNAMutation
have	O
revealed	O
the	O
apposition	O
of	O
C4	O
of	O
the	O
nicotinamide	O
ring	O
with	O
tyrosine	O
48	O
and	O
histidine	O
110	O
,	O
suggesting	O
that	O
either	O
of	O
these	O
residues	O
could	O
function	O
as	O
the	O
proton	O
donor	O
in	O
the	O
reaction	O
mechanism	O
.	O

Tyrosine	O
48	O
is	O
also	O
part	O
of	O
a	O
hydrogen-bonding	O
network	O
that	O
includes	O
lysine	O
77	O
and	O
aspartate	O
43	O
.	O

In	O
order	O
to	O
study	O
the	O
potential	O
catalytic	O
roles	O
of	O
these	O
4	O
residues	O
,	O
we	O
evaluated	O
the	O
kinetic	O
properties	O
of	O
mutants	O
containing	O
structurally	O
conservative	O
replacements	O
at	O
these	O
sites	O
.	O

Enzymatic	O
activity	O
was	O
undetectable	O
when	O
Tyr-48	B-DNAMutation
was	I-DNAMutation
mutated	I-DNAMutation
to	I-DNAMutation
phenylalanine	I-DNAMutation
Y48F	B-DNAMutation
although	O
affinity	O
for	O
NADPH	B-DNAMutation
was	O
unchanged	O
.	O

In	O
contrast	O
,	O
a	O
mutant	O
containing	O
asparagine	B-DNAMutation
substituted	I-DNAMutation
for	I-DNAMutation
His-110	I-DNAMutation
H110N	B-DNAMutation
was	O
characterized	O
by	O
an	O
almost	O
80,000-fold	O
increase	O
in	O
Km	O
,	O
but	O
only	O
about	O
a	O
14-fold	O
reduction	O
in	O
kcat	O
measured	O
with	O
D-glyceraldehyde	O
.	O

Modest	O
changes	O
in	O
catalytic	O
properties	O
were	O
observed	O
in	O
the	O
mutant	O
containing	O
aspartate	B-DNAMutation
43	I-DNAMutation
substituted	I-DNAMutation
with	I-DNAMutation
asparagine	I-DNAMutation
D43N	B-DNAMutation
:	O
Km	O
for	O
aldehyde	O
substrates	O
was	O
elevated	O
up	O
to	O
17-fold	O
,	O
and	O
kcat	O
decreased	O
less	O
than	O
16-fold	O
.	O

However	O
,	O
the	O
Kd(NADP)	O
values	O
for	O
D43N	B-DNAMutation
were	O
about	O
5	O
times	O
higher	O
than	O
those	O
for	O
wild	O
type	O
.	O

Mutant	O
enzyme	O
containing	O
methionine	B-DNAMutation
substituted	I-DNAMutation
for	I-DNAMutation
lysine	I-DNAMutation
77	I-DNAMutation
K77M	B-DNAMutation
was	O
up	O
to	O
1,460-fold	O
less	O
active	O
than	O
the	O
wild	O
type	O
.	O

These	O
results	O
are	O
consistent	O
with	O
Tyr-48	O
acting	O
as	O
the	O
acid-base	O
catalyst	O
in	O
human	O
aldose	O
reductase	O
and	O
confirm	O
the	O
importance	O
of	O
Asp-43	O
,	O
Lys-77	O
,	O
and	O
His-110	O
to	O
the	O
structure	O
and	O
function	O
of	O
the	O
active	O
site	O
.	O

Liver	O
tumors	O
escape	O
negative	O
control	O
of	O
proliferation	O
via	O
PI3K/Akt-mediated	O
block	O
of	O
C/EBP	B-DNAMutation
alpha	I-DNAMutation
growth	O
inhibitory	O
activity	O
.	O

Liver	O
tumor	O
cells	O
arise	O
from	O
normal	O
hepatocytes	O
that	O
escape	O
negative	O
control	O
of	O
proliferation	O
.	O

The	O
transcription	O
factor	O
C/EBPalpha	B-DNAMutation
maintains	O
quiescence	O
of	O
hepatocytes	O
through	O
two	O
pathways	O
:	O
inhibition	O
of	O
cdks	O
and	O
repression	O
of	O
E2F	O
.	O

Nevertheless	O
,	O
liver	O
tumors	O
and	O
cultured	O
hepatoma	O
cell	O
lines	O
proliferate	O
in	O
the	O
presence	O
of	O
C/EBPalpha	B-DNAMutation
.	O

In	O
this	O
paper	O
,	O
we	O
present	O
evidence	O
that	O
the	O
activation	O
of	O
the	O
PI3K/Akt	O
pathway	O
in	O
liver	O
tumor	O
cells	O
blocks	O
the	O
growth	O
inhibitory	O
activity	O
of	O
C/EBPalpha	B-DNAMutation
through	O
the	O
PP2A-mediated	B-DNAMutation
dephosphorylation	O
of	O
C/EBPalpha	B-DNAMutation
on	O
Ser	O
193	O
,	O
leading	O
to	O
a	O
failure	O
of	O
C/EBPalpha	B-DNAMutation
to	O
interact	O
with	O
and	O
inhibit	O
cdks	O
and	O
E2F	O
.	O

Mutation	O
of	O
Ser	B-DNAMutation
193	I-DNAMutation
to	I-DNAMutation
Ala	I-DNAMutation
also	O
abolishes	O
the	O
ability	O
of	O
C/EBPalpha	B-DNAMutation
to	O
cause	O
growth	O
arrest	O
because	O
of	O
a	O
lack	O
of	O
interactions	O
with	O
cdk2	B-DNAMutation
and	O
E2F-Rb	O
complexes	O
.	O

These	O
data	O
provide	O
a	O
molecular	O
basis	O
for	O
the	O
development	O
of	O
liver	O
tumors	O
in	O
which	O
the	O
activation	O
of	O
PI3K/Akt	O
pathway	O
neutralizes	O
C/EBPalpha	B-DNAMutation
growth	O
inhibitory	O
activity	O
.	O

Biochemical	O
characterization	O
of	O
a	O
variant	O
human	O
medium-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
with	O
a	O
disease-associated	O
mutation	O
localized	O
in	O
the	O
active	O
site	O
.	O

Medium-chain	B-DNAMutation
acyl-CoA	I-DNAMutation
dehydrogenase	I-DNAMutation
MCADH	B-DNAMutation
deficiency	O
,	O
an	O
autosomal	O
recessive	O
inherited	O
disorder	O
,	O
is	O
the	O
most	O
common	O
genetic	O
disorder	O
in	O
mitochondrial	O
beta-oxidation	O
in	O
humans	O
.	O

In	O
addition	O
to	O
one	O
prevalent	O
disease-causing	O
mutation	O
K304E	B-DNAMutation
,	O
a	O
series	O
of	O
rarer	O
mutations	O
has	O
been	O
reported	O
,	O
but	O
none	O
of	O
these	O
has	O
yet	O
been	O
characterized	O
in	O
detail	O
.	O

We	O
report	O
here	O
on	O
the	O
biochemical	O
characterization	O
of	O
the	O
purified	O
recombinant	O
mutant	O
protein	O
in	O
which	O
threonine	B-DNAMutation
is	I-DNAMutation
replaced	I-DNAMutation
by	I-DNAMutation
alanine	I-DNAMutation
at	I-DNAMutation
position	I-DNAMutation
168	I-DNAMutation
of	O
the	O
mature	O
protein	O
T168A-MCADH	B-DNAMutation
.	O

It	O
is	O
the	O
first	O
mutation	O
to	O
be	O
found	O
in	O
patients	O
that	O
is	O
located	O
in	O
the	O
active	O
site	O
of	O
the	O
enzyme	O
.	O

Thr-168	O
is	O
hydrogen-bonded	O
to	O
the	O
flavin	O
N(5)	O
of	O
the	O
cofactor	O
FAD	O
.	O

The	O
thermostability	O
of	O
T168A-MCADH	B-DNAMutation
is	O
markedly	O
decreased	O
compared	O
with	O
human	O
wild-type	O
MCADH	B-DNAMutation
hwt-MCADH	B-DNAMutation
.	O

Catalytic	O
activity	O
with	O
ferricenium	O
as	O
acceptor	O
is	O
lowered	O
by	O
80%	O
and	O
with	O
the	O
natural	O
acceptor	O
electron-transferring	O
flavoprotein	O
by	O
over	O
90%	O
compared	O
with	O
hwt-MCADH	B-DNAMutation
.	O

In	O
the	O
mutant	O
the	O
extent	O
of	O
flavin	O
semiquinone	O
formed	O
on	O
reduction	O
is	O
approx	O
.	O

50%	O
that	O
of	O
hwt-MCADH	B-DNAMutation
.	O

The	O
pK	O
reflected	O
by	O
the	O
pH-dependence	O
of	O
Vmax	O
is	O
shifted	O
from	O
approx	O
.	O

8.2	O
hwt-MCADH	B-DNAMutation
to	O
approx	O
.	O

7	O
T168A-MCADH	B-DNAMutation
and	O
the	O
rates	O
of	O
enzyme	O
flavin	O
reduction	O
(	O
stopped-flow	O
measurements	O
)	O
are	O
only	O
approx	O
.	O

1/10	O
those	O
of	O
the	O
parent	O
enzyme	O
.	O

These	O
properties	O
are	O
discussed	O
in	O
the	O
light	O
of	O
the	O
possible	O
mechanisms	O
leading	O
to	O
disease	O
in	O
humans	O
.	O

Mutation	B-DNAMutation
in	I-DNAMutation
codon	I-DNAMutation
713	I-DNAMutation
of	O
the	O
beta	B-DNAMutation
amyloid	I-DNAMutation
precursor	I-DNAMutation
protein	O
gene	O
presenting	O
with	O
schizophrenia	O
.	O

Following	O
reports	O
of	O
mutations	B-DNAMutation
of	I-DNAMutation
codon	I-DNAMutation
717	I-DNAMutation
in	I-DNAMutation
exon	I-DNAMutation
17	I-DNAMutation
of	O
the	O
amyloid	B-DNAMutation
precursor	I-DNAMutation
protein	I-DNAMutation
APP	B-DNAMutation
gene	O
in	O
early-onset	O
familial	O
Alzheimer's	O
disease	O
,	O
we	O
screened	O
exon	O
17	O
for	O
new	O
mutations	O
in	O
presenile	O
dementia	O
.	O

The	O
majority	O
of	O
the	O
105	O
patients	O
screened	O
had	O
definite	O
or	O
probable	O
Alzheimer's	O
disease	O
,	O
but	O
we	O
also	O
included	O
atypical	O
cases	O
and	O
some	O
chronic	O
schizophrenics	O
.	O

We	O
identified	O
a	O
single	O
abnormal	O
case--a	O
chronic	O
schizophrenic	O
with	O
cognitive	O
defects	O
.	O

Sequencing	O
revealed	O
a	O
C	B-DNAMutation
to	I-DNAMutation
T	I-DNAMutation
nucleotide	I-DNAMutation
substitution	I-DNAMutation
which	I-DNAMutation
produces	I-DNAMutation
an	I-DNAMutation
alanine	I-DNAMutation
to	I-DNAMutation
valine	I-DNAMutation
change	I-DNAMutation
at	I-DNAMutation
codon	I-DNAMutation
713	I-DNAMutation
.	O

We	O
were	O
unable	O
to	O
detect	O
the	O
mutation	O
in	O
the	O
remaining	O
members	O
of	O
the	O
original	O
cohort	O
nor	O
in	O
a	O
further	O
100	O
chronic	O
schizophrenics	O
and	O
100	O
non-demented	O
controls	O
.	O

Nonetheless	O
,	O
the	O
position	O
of	O
the	O
mutation	O
in	O
a	O
critical	O
portion	O
of	O
the	O
APP	B-DNAMutation
gene	O
suggests	O
that	O
it	O
may	O
well	O
prove	O
to	O
be	O
pathogenic	O
.	O

Identification	O
of	O
a	O
novel	O
point	O
mutation	O
S65T	B-DNAMutation
in	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
in	O
Chinese	O
patients	O
with	O
Fabry	O
disease	O
.	O

Mutations	O
in	O
brief	O
no	O
.	O

169	O
.	O

Online	O
.	O

Fabry	O
disease	O
is	O
an	O
X-linked	O
inborn	O
error	O
of	O
sphingolipid	O
catabolism	O
resulting	O
from	O
deficient	O
enzyme	O
activity	O
of	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
.	O

The	O
molecular	O
defects	O
of	O
human	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
causing	O
Fabry	O
disease	O
have	O
been	O
characterized	O
,	O
including	O
gene	O
rearrangement	O
and	O
point	O
mutations	O
,	O
which	O
show	O
the	O
genetic	O
heterogeneity	O
in	O
Fabry	O
disease	O
.	O

To	O
characterize	O
the	O
molecular	O
defects	O
of	O
these	O
patients	O
,	O
each	O
exon	O
of	O
alpha-galactosidase	B-DNAMutation
A	I-DNAMutation
gene	O
including	O
intron-exon	O
junctions	O
were	O
PCR	O
amplified	O
using	O
biotin-labelled	O
primer	O
and	O
sequenced	O
using	O
magnetic	O
beads	O
solid-phase	O
sequencing	O
.	O

A	O
G	B-DNAMutation
to	I-DNAMutation
C	I-DNAMutation
transversion	I-DNAMutation
was	I-DNAMutation
identified	I-DNAMutation
in	I-DNAMutation
the	I-DNAMutation
last	I-DNAMutation
nucleotide	I-DNAMutation
of	I-DNAMutation
exon	I-DNAMutation
1	I-DNAMutation
in	O
two	O
unrelated	O
Chinese	O
patients	O
.	O

This	O
mutation	O
obliterates	O
an	O
EcoN1	O
restriction	O
site	O
.	O

Family	O
studies	O
show	O
close	O
linkage	O
with	O
the	O
affected	O
family	O
members	O
.	O

Screening	O
of	O
100	O
alleles	O
(	O
22	O
males	O
,	O
39	O
females	O
)	O
of	O
unrelated	O
normal	O
Chinese	O
can	O
not	O
find	O
this	O
mutation	O
.	O

This	B-DNAMutation
mutation	I-DNAMutation
not	I-DNAMutation
only	I-DNAMutation
changes	I-DNAMutation
the	I-DNAMutation
amino	I-DNAMutation
acid	I-DNAMutation
from	I-DNAMutation
serine	I-DNAMutation
to	I-DNAMutation
threonine	I-DNAMutation
,	O
but	O
also	O
likely	O
cause	O
splicing	O
defects	O
.	O

To	O
our	O
knowledge	O
,	O
this	O
is	O
the	O
first	O
report	O
of	O
mutation	O
in	O
Chinese	O
patients	O
with	O
Fabry	O
disease	O
,	O
and	O
a	O
novel	O
mutation	O
causing	O
Fabry	O
disease	O
not	O
reported	O
in	O
literature	O
previously	O
.	O

Isobutyryl-CoA	O
dehydrogenase	O
deficiency	O
:	O
isobutyrylglycinuria	O
and	O
ACAD8	B-DNAMutation
gene	O
mutations	O
in	O
two	O
infants	O
.	O

Isobutyryl-CoA	O
dehydrogenase	O
(IBD)	O
is	O
an	O
enzyme	O
involved	O
in	O
the	O
catabolism	O
of	O
the	O
branched-chain	O
amino	O
acid	O
valine	O
.	O

We	O
report	O
a	O
third	O
and	O
a	O
fourth	O
child	O
with	O
IBD	O
deficiency	O
who	O
were	O
both	O
detected	O
during	O
newborn	O
screening	O
with	O
tandem	O
mass	O
spectrometry	O
and	O
so	O
far	O
do	O
not	O
receive	O
any	O
treatment	O
.	O

The	O
diagnosis	O
was	O
confirmed	O
by	O
biochemical	O
and	O
molecular	O
studies	O
.	O

One	O
of	O
the	O
children	O
is	O
homozygous	O
for	O
the	O
mutation	O
M128I	B-DNAMutation
in	O
the	O
ACAD8	B-DNAMutation
gene	O
,	O
which	O
is	O
predicted	O
to	O
affect	O
the	O
substrate	O
binding	O
cavity	O
.	O

The	O
other	O
child	O
is	O
compound	O
heterozygous	O
for	O
a	O
frameshift	O
mutation	O
F33fsins	B-DNAMutation
and	O
a	O
missense	O
mutation	O
V203I	B-DNAMutation
.	O

It	O
is	O
as	O
yet	O
uncertain	O
whether	O
IBD	O
deficiency	O
may	O
cause	O
significant	O
morbidity	O
in	O
affected	O
children	O
and	O
whether	O
treatment	O
is	O
necessary	O
.	O

In	O
view	O
of	O
the	O
limited	O
experience	O
worldwide	O
,	O
careful	O
monitoring	O
of	O
the	O
children	O
is	O
recommended	O
.	O